diff --git a/parsed_sections/prospectus_summary/1996/ANF_abercrombi_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/ANF_abercrombi_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..7ab1b78e17da42ab9382d664798032e2048408c7
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/ANF_abercrombi_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a summary of certain information contained elsewhere in this Prospectus. Reference is made to, and this summary is qualified in its entirety by, the more detailed information contained in this Prospectus. As used herein, unless the context otherwise requires, the "Company" or "Abercrombie & Fitch" means Abercrombie & Fitch Co. and its subsidiaries (which, prior to the formation of the Company on June 26, 1996, are referred to herein as the "Abercrombie & Fitch Business"), and "The Limited" means The Limited, Inc. and its subsidiaries (other than the Company). Unless indicated otherwise, the information contained in this Prospectus assumes that the Underwriters do not exercise their over-allotment options. Except as otherwise specified, references herein to years are to the Company's fiscal year, which ends on the Saturday closest to January 31 in the following calendar year. For example, "1995" refers to the fiscal year ended February 3, 1996. All fiscal years for which financial information is included in this Prospectus had 52 weeks, except 1995 which had 53 weeks. All references to "dollars" or "$" are to U.S. dollars. Unless otherwise defined herein, capitalized terms used in this summary have the meanings ascribed to them elsewhere in this Prospectus. Prospective investors should carefully consider the information set forth under the heading "Risk Factors". THE COMPANY Abercrombie & Fitch is a rapidly growing specialty retailer of high-quality, casual apparel for men and women approximately 15 to 50 years of age. The Company's net sales have increased from $85.3 million in 1992 to $235.7 million in 1995, representing a compound annual growth rate of 40.3%. During this time, operating income has improved from an operating loss of $10.2 million in 1992 to operating income of $23.8 million in 1995, while the number of Abercrombie & Fitch stores in operation more than doubled, increasing from 40 at the end of 1992 to 100 at the end of 1995. The Company plans to continue this new store expansion program by opening 29 new stores in 1996 and by increasing the number of stores in operation by approximately 20% annually for the next several years thereafter. The Abercrombie & Fitch brand was established in 1892 and became well known as a supplier of rugged, high-quality outdoor gear. Famous for outfitting the safaris of Teddy Roosevelt and Ernest Hemingway and the expeditions of Admiral Byrd to the North and South Poles, Abercrombie & Fitch goods were renowned for their durability and dependability--and Abercrombie & Fitch placed a premium on complete customer satisfaction with each item sold. In 1992, a new management team began repositioning Abercrombie & Fitch as a more fashion-oriented casual apparel business directed at men and women with a youthful lifestyle. In reestablishing the Abercrombie & Fitch brand, the Company combined its historical image for quality with a new emphasis on casual American style and youthfulness. The Company believes that this strategic decision has contributed to the strong growth and improved profitability it has experienced since 1992. BUSINESS STRENGTHS The Company believes that certain business strengths have contributed to its success in the past and will enable it to continue growing profitably. ESTABLISHED AND DIFFERENTIATED LIFESTYLE BRAND. Abercrombie & Fitch has created a focused and differentiated brand image based on quality, youthfulness and classic American style. This image is consistently communicated through all aspects of the Company's business, including merchandise assortments, in-store marketing and print advertising. The Company believes that the strength of the Abercrombie & Fitch brand provides opportunities for increased penetration of current merchandise categories and entry into new product categories. BROAD AND GROWING APPEAL. The Company's merchandise assortment appeals to a broad range of customers with varying ages and income levels. The Company believes that both men and women interested in casual, classic American fashion are attracted to the Abercrombie & Fitch lifestyle image. The Company also believes that the brand's broad appeal has been augmented by, and should continue to benefit from, the current trend in fashion toward casual apparel. PROVEN MANAGEMENT TEAM. Since the current management team assumed responsibility in 1992, the Company has increased the level of brand awareness and consistently reported improved financial results. In addition, the Company's senior management has significant experience, with an aggregate of over one hundred years in the retail business. The Company believes that management's substantial experience and demonstrated track record of highly profitable growth strongly positions the Company for the future. CONSISTENT STORE LEVEL EXECUTION. Abercrombie & Fitch believes that a major element of its success is the consistent store level execution of its brand strategy. Store presentation is tightly controlled by the Company and is based on a detailed and comprehensive store plan regarding visual merchandising, marketing and fixtures to ensure that all stores provide a consistent portrayal of the brand. Store associates are trained as "brand representatives" who convey and reinforce the brand image through their attitude and enthusiasm. QUALITY. Since its founding over 100 years ago, Abercrombie & Fitch has maintained a strong reputation for quality. This reputation has been enhanced in recent years as management has made quality a defining element of the brand. The Company sources high quality natural fabrics from around the world and uses distinctive trim details and specialized washes to achieve a unique style and comfort in its products. As part of this focus on quality, the Company establishes on-going relationships with key factories to ensure reliability and consistency in production. INTERNAL DESIGN AND MERCHANDISING CAPABILITIES. The cornerstone of the Company's business is its ability to design products which embody the Abercrombie & Fitch image. Abercrombie & Fitch develops substantially all of its merchandise line through its own design group, which allows it to develop exclusive merchandise and offer a consistent assortment within a season and from year to year. In addition, because the Company's merchandise is sold exclusively in its own stores, Abercrombie & Fitch is able to control the presentation and pricing of its merchandise, provide a higher level of customer service and closely monitor retail sell-through, which provides competitive advantages over other brand manufacturers that market their goods through department stores. RELATIONSHIP WITH THE LIMITED. Unlike most high growth, specialty apparel retailers, Abercrombie & Fitch directly benefits from the resources and expertise of a major retailer such as The Limited. Abercrombie & Fitch has been able to concentrate the efforts of its management team and associates on strengthening its brand image by taking advantage of The Limited's capabilities in the areas of real estate negotiation and acquisition, central distribution, sourcing, store design and construction and general corporate services. The Company will continue to receive such services after the Offerings pursuant to agreements to be entered into with The Limited. See "Relationship with The Limited". GROWTH STRATEGY The Company has implemented a growth strategy designed to permit Abercrombie & Fitch to capitalize on its business strengths. The Company plans to continue its store expansion program by opening 29 new stores in 1996 and increasing the number of stores in operation by approximately 20% annually for the next several years thereafter. While substantially all stores to be opened in 1996 will be in regional shopping malls, the Company believes that selected street locations in university and high-traffic urban settings also provide attractive expansion opportunities. In addition, Abercrombie & Fitch believes that there are opportunities to expand its customer base and enhance the productivity of its stores through further penetration of existing merchandise categories and the introduction of new classifications and categories. Products which are being introduced or expanded in 1996 include men's and women's underwear and outerwear, fragrances, sunglasses and decorative home accessories. The Company believes that its internal design capability will enable it to continue to develop new merchandise which reflects the Abercrombie & Fitch lifestyle. See "Business--Growth Strategy".
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CALM_cal-maine_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CALM_cal-maine_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..88c87aa1f83b942486e4674d2fbbb16fd81acf3e
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CALM_cal-maine_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. UNLESS OTHERWISE INDICATED, INFORMATION IN THIS PROSPECTUS (I) ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION AND (II) IS ADJUSTED TO REFLECT A RECENT RECAPITALIZATION, WHICH RESULTED IN THE CREATION OF THE COMMON STOCK AND THE CLASS A COMMON STOCK, AND A 1,200-FOR-1 STOCK SPLIT OF THE CAPITAL STOCK, EFFECTIVE AS OF OCTOBER 3, 1996. SEE "CAPITALIZATION -- RECAPITALIZATION AND STOCK SPLIT." THE COMPANY GENERAL The Company is primarily engaged in the production, cleaning, grading, packing and sale of fresh shell eggs and the manufacture and sale of egg products. Shell eggs accounted for approximately 92% and egg products approximately 6% of the Company's net sales in fiscal 1996. The Company currently is the largest producer and distributor of fresh shell eggs in the United States, with fiscal 1996 sales of approximately 384.4 million dozen shell eggs, representing approximately 7.5% of all shell eggs sold in the United States. Cal-Maine primarily markets its shell eggs and egg products in 26 states, chiefly in the southwestern, southeastern, mid-western and mid-Atlantic regions of the United States. The Company's operations are fully integrated. It owns facilities to hatch chicks, grow pullets, manufacture feed and produce, process, manufacture and distribute shell eggs and egg products. Company-owned facilities accounted for approximately 60% of total egg production in fiscal 1996, with the balance attributable to contract producers used by the Company. Approximately 95% of the feed for Company-owned farms and contract producers is manufactured by the Company, from purchased ingredients, in feed mills that it owns and operates. Shell eggs are sold directly by the Company primarily to national and regional supermarket chains. Egg products are sold both on a direct basis and through egg product brokers to institutional users, including manufacturers of baked goods, mayonnaise and confections. GROWTH STRATEGY During the past eight years the Company has pursued an aggressive growth strategy, including the acquisition of existing shell egg production and processing facilities, as well as the construction of new and more efficient facilities. Since the beginning of fiscal 1989, the Company has consummated six acquisitions, adding an aggregate of 13.7 million layers to its capacity, and built four new "in-line" shell egg production and processing facilities and one pullet growing facility, adding 4 million layers and 950,000 pullets to its capacity. The increases in capacity have been offset by the retirement of older and less efficient facilities and a reduction in eggs produced by contract producers. As a result of the Company's growth strategy, its total flock, including pullets, layers and breeders, has increased from approximately 6.8 million at May 28, 1988 to an average of approximately 17.4 million for each of the past five fiscal years. Also, there has been a three-fold increase in the number of dozens of shell eggs sold, from approximately 117 million in the fiscal year ended May 28, 1988 to an average of approximately 394 million in each of the past five fiscal years. Net sales amounted to approximately $282.8 million in fiscal 1996, approximately four times net sales of approximately $70.0 million in fiscal 1988. The Company expects to continue to pursue its growth strategy and to use a portion of its net proceeds from this offering to acquire additional shell egg production and processing facilities and feed mills. However, it has no understandings or agreements in that regard at this time. The Company's new "in-line" facilities result in the gathering, cleaning, grading and packaging of shell eggs by less labor-intensive, more efficient, mechanical means. The increased use of in-line facilities has generated significant cost savings. The cost of eggs produced at these facilities was lower by 1.0cents, 1.5cents, 2.1cents, 2.3cents and 3.1cents per dozen in fiscal 1992, 1993, 1994, 1995 and 1996, respectively, than the cost to the Company of eggs produced from non-in-line facilities. Also, the Company produces a higher percentage of grade A eggs, which sell at higher prices, at its in-line facilities. The percentage of the total number of layers housed in the Company's in-line facilities increased from 25% in fiscal 1992 to 55% in fiscal 1996. The Company's acquisitions and construction of larger facilities, described in the tables below, reflect the continuing concentration of shell egg production in the United States in a decreasing number of shell egg producers. The Company believes that a continuation of that concentration trend may result in the reduced cyclicality of shell egg prices, but no assurance can be given in that regard. ACQUISITIONS OF EGG PRODUCTION AND PROCESSING FACILITIES
LAYERS PURCHASE FISCAL YEAR(1) SELLER LOCATION ACQUIRED PRICE - -------------- ---------------------------------------- --------------- -------------- ----------- 1989 Egg City, Inc........................... Arkansas 1,300,000 $ 6,716,000 1990 Sunny Fresh Foods, Inc.................. (2) 7,500,000 21,629,000 1991 Sunnyside Eggs, Inc..................... North Carolina 1,800,000 6,000,000 1994 Wayne Detling Farms..................... Ohio 1,500,000 12,194,000 1995 A&G Farms(3)............................ Kentucky 1,000,000 2,883,000 1997 Sunbest Farms(4)........................ Arkansas 600,000 1,302,000 ---------- ----------- Total..................................................... 13,700,000 $50,724,000 ========== ===========
CONSTRUCTION OF EGG PRODUCTION, PULLET GROWING AND PROCESSING FACILITIES(5) FISCAL YEAR LAYER PULLET APPROXIMATE COMPLETED LOCATION CAPACITY CAPACITY COST - ----------- -------------------------------------------------- --------- -------- ----------- 1990 Mississippi....................................... 1,000,000 200,000 $10,000,000 1992 Louisiana......................................... 1,000,000 -- 10,000,000 1992 Mississippi....................................... -- 500,000 3,500,000 1994 Mississippi....................................... 1,000,000 -- 9,200,000 1996 Texas............................................. 1,000,000 250,000 14,000,000 --------- ------- ----------- Total............................................. 4,000,000 950,000 $46,700,000 ========= ======= ===========
- --------------- (1) The Company's fiscal year ends on the Saturday closest to May 31. (2) New Mexico, Kansas, Texas, Alabama, Oklahoma, Arkansas and North Carolina. (3) In connection with the purchase, the Company leased substantially all facilities and certain equipment of the business under an operating lease with monthly rentals of $79,000. See "Business -- Growth Strategy." (4) Acquired subsequent to quarter ended August 31, 1996. (5) Does not include (i) current construction in Chase, Kansas, expected to be completed in fiscal 1999 at an estimated cost of approximately $16,000,000, adding approximately 1,000,000 layer and 250,000 pullet capacity, and a feed mill and grain storage; or (ii) proposed construction in Waelder, Texas, expected to commence in fiscal 1997, and to be completed in fiscal 2000 at an estimated cost of approximately $13,900,000, adding approximately 1,000,000 layer and 250,000 pullet capacity. The Company was incorporated under Delaware law in 1969. Its principal executive offices are located at 3320 Woodrow Wilson Drive, Jackson, Mississippi 39209, and its telephone number is (601) 948-6813. Except as otherwise indicated by the context, references in this Prospectus to the "Company" or "Cal-Maine" include all subsidiaries of the Company. THE OFFERING Common Stock being offered.......... 1,700,000 shares by the Company and 800,000 shares by the Selling Stockholder(1) Common Stock to be outstanding after the offering...................... 12,006,800 shares(1)(2) Use of Proceeds..................... To provide additional funds for possible future acquisitions, increase working capital, and for general corporate purposes. Proposed NASDAQ National Market trading symbol...................... CALM - --------------- (1) Assumes no exercise of the Underwriters' over-allotment option. See "Underwriting." (2) Excludes shares reserved under the Company's 1993 Stock Option Plan. See "Management -- 1993 Stock Option Plan." SUMMARY CONSOLIDATED FINANCIAL AND OPERATING DATA (DOLLAR AND SHARE AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA) FISCAL YEAR ENDED 13 WEEKS ENDED ----------------------------------------------------------- -------------------- MAY 30, MAY 29, MAY 28, JUNE 3, JUNE 1, SEPT. 2, AUG. 31, 1992 1993 1994 1995 1996 1995 1996 -------- ----------- -------- -------- -------- -------- -------- (UNAUDITED) STATEMENTS OF OPERATIONS DATA: Net sales.............................. $234,767 $ 235,908 $254,713 $242,649 $282,844 $56,219 $65,563 Net income (loss)...................... (2,192) 3,103 224 (8,685) 10,925 (1,635) 1,097 Net income (loss) per common share(1)............................. $ (.18) $ .26 $ .02 $ (.74) $ .94 $ (.14) $ .10 Weighted average shares outstanding(1)....................... 11,921 11,821 11,760 11,700 11,584 11,647 11,509 OPERATING DATA: Total flock size (thousands)(2)........ 16,839 17,439 17,697 18,014 17,209 17,819 17,375 Total shell eggs sold (millions of dozens).............................. 381.2 379.8 403.9 421.8 384.4 94.8 89.4 AUGUST 31, 1996 ----------------------- (UNAUDITED) AS ACTUAL ADJUSTED(3) -------- ----------- BALANCE SHEET DATA: Working capital........................ $ 28,229 $ 40,286 Total assets........................... 150,351 162,408 Total long-term debt (including current portion and capitalized lease obligations)......................... 62,866 62,866 Total stockholders' equity............. 48,976 61,033
- --------------- (1) Reflects the 1,200-for-1 stock split effective October 3, 1996 as if the split had occurred in the earliest period presented. (2) Includes pullets (young female chickens, usually under 20 weeks of age), layers (mature female chickens), and breeders (male or female birds used to produce fertile eggs to be hatched for egg production flocks). (3) Adjusted to give effect to (i) the sale of 1,700,000 shares of Common Stock offered by the Company (at an assumed initial public offering price of $7.00 per share and after deduction of the underwriting discount and estimated offering expenses payable by the Company) and the addition of the net proceeds thereof to working capital, and (ii) an increase in stockholders' equity resulting from the payment of a note payable to the Company by its principal stockholder. See "Use of Proceeds" and "Capitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000004317_sento-corp_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000004317_sento-corp_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..ebe30cff0e4cb75ce5fadc469cf3867f598b7d66
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000004317_sento-corp_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS (INCLUDING THE NOTES THERETO) APPEARING ELSEWHERE IN THIS PROSPECTUS. THE COMPANY Sento Technical Innovations Corporation ("Sento" or the "Company") develops, configures, markets and distributes industry-leading hardware and software computing solutions, combined with consulting, training and support services, to business, government and educational organizations world-wide through direct sales and marketing, channel distribution, and industry partners. The Company, through its four wholly-owned subsidiaries, Spire Technologies, Inc. ("Spire Technologies"), Spire Systems Incorporated ("Spire Systems"), DewPoint Distributed Solutions Incorporated ("DewPoint") and Centerpost Innovations Pty. Ltd., develops and implements system management and office automation solutions for open and proprietary computing environments, acts as a "service and value-added reseller" and distributor of software developed by third parties, resells Digital Equipment Corporation ("Digital") network computer systems and components on a value-added basis and manages value-added reseller and distribution channels in the Americas, Europe, and Southeast Asia. The Company offers a wide range of desktop, workstation, client/server and centralized computing software, systems and peripheral equipment, as well as channel management and support services for both domestic and international clientele in a wide variety of industries and computing environments, including UNIX, Windows NT and Digital Open VMS. In September 1996, the Company obtained an option to acquire the assets (including all intellectual property) of Australian Software Innovations (Services) Pty. Ltd. ("ASI"), a developer of UNIX-based management and performance monitoring software and provider of software education and consulting services based in Sydney, Australia. ASI develops and markets performance monitoring software and provides related technical consulting services to customers located in Asia, Europe, the United Kingdom and the United States. See "Recent Developments--Australian Software Innovations" and "Business-- Products--Software." Unless the context requires otherwise, all references to the "Company" in this Prospectus refer to the Company and each of its subsidiaries. The Company's principal executive offices are located at 311 North State Street, Orem, Utah 84057, and its telephone number is (801) 226-3355. THE OFFERING Common Stock offered by the Selling Shareholders................................ 1,096,214 shares Common Stock outstanding prior to and after this offering............................... 4,347,914 shares(1) Use of Proceeds.............................. The proceeds of the offering will be received by the Selling Shareholders. See "Use of Proceeds." Over-the-counter Bulletin Board symbol....... STIC(2)
- ------------------------ (1) As of October 31, 1996, and excluding 879,209 shares issuable upon the exercise of outstanding stock options and warrants granted by the Company. (2) The National Association of Securities Dealers has approved the Company's application for quotation of the Common Stock on the NASDAQ Small Cap Market under the symbol "SNTO." SUMMARY FINANCIAL DATA (1) THREE MONTHS ENDED YEAR ENDED APRIL 30, JUNE 30, ---------------------------------------------------------- -------------------- 1996 1995 1994 1993 1992 1996 (2) 1995 ---------- --------- --------- ----------- ----------- --------- --------- (UNAUDITED) (UNAUDITED) STATEMENTS OF INCOME DATA: Total revenues....................... $13,873,401 $9,674,683 $6,043,411 $5,949,072 $4,164,044 $4,518,439 $3,302,858 Gross profit......................... 5,421,358 3,060,608 2,076,382 1,875,527 1,437,778 1,568,834 1,385,743 Operating income..................... 547,928 133,527 43,869 27,691 11,884 64,020 250,980 Net income........................... 339,555 98,735 18,233 10,951 (8,109) 51,975 153,462 Net income per common share (3)...... .08 .03 -- -- -- .01 .04 Weighted average common shares outstanding (3).................... 3,992,768 3,346,274 3,612,328 3,547,861 3,547,861 4,269,140 3,949,750
APRIL 30, JUNE 30, 1996 1996 ------------- ------------- (UNAUDITED) BALANCE SHEET DATA: Cash and Cash Equivalents........................................................... $ 2,459,938 $ 1,552,806 Working Capital..................................................................... 2,692,590 943,332 Total Assets........................................................................ 6,755,007 4,544,825 Total Long-term Debt................................................................ 222,169 223,412 Total stockholders' equity.......................................................... 3,103,490 1,480,907
- ------------------------------ (1) The consolidated financial statements of the Company as of and for the year ended April 30, 1996 include the financial statements of the Company and the three subsidiaries of the Company owned during such year (Spire Technologies, Spire Systems and DewPoint). The financial statements of the Company as of April 30, 1995, and for each of the years in the two-year period then ended are the combined financial statements of Spire Technologies and Spire Systems prior to the consummation of the share exchange transaction completed by the Company in April 1996. See "Recent Developments--Share Exchange." All significant intercompany balances and transactions have been eliminated in consolidation or combination. (2) In June 1996, the Company changed its fiscal year end from April 30 to March 31 of each year, commencing with the fiscal year ending March 31, 1997. The consolidated financial statements set forth in this Prospectus are based upon the Company's former fiscal year end of April 30. (3) Per share amounts are computed by dividing net income by the weighted average number of common shares and common share equivalents resulting from options outstanding. There were 3,992,768, 3,346,274 and 3,612,328 weighted average common shares and common share equivalents outstanding for the years ended April 30, 1996, 1995 and 1994, respectively, and there were 3,547,861 weighted average common shares and common share equivalents outstanding for the years ended April 30, 1993 and 1992, respectively. Income per share for the 1995 and prior fiscal years has been restated to give effect to the share exchange completed by the Company in April 1996. See "Recent Developments--Share Exchange."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000005588_american_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000005588_american_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..e923911e96851e5c7fd37904fcbbf50ded304c11
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000005588_american_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by more detailed information and financial statements and notes thereto included elsewhere in this Prospectus. Unless otherwise stated, the information contained in this Prospectus (i) assumes no exercise of the U.S. Underwriters' over-allotment option, (ii) reflects a 8.1192-for-one stock split of the existing Common Stock and Common Stock equivalents and (iii) reflects the conversion of all shares of preferred stock and preferred stock equivalents into shares of Common Stock and Common Stock equivalents, respectively. See "The Recapitalization." Unless otherwise stated in this Prospectus, references to (a) the "Company" shall mean American Pad & Paper Company, its consolidated subsidiaries and their respective predecessors; (b) "Williamhouse" shall mean the operations of Williamhouse--Regency of Delaware, Inc. prior to its acquisition by the Company on October 31, 1995 (the "Acquisition"); and (c) "Ampad" shall mean Ampad Corporation, the former operating subsidiary of the Company, prior to Ampad's merger with and into Williamhouse immediately prior to the Acquisition. On May 29, 1996, the Company executed a definitive agreement to purchase the Niagara Envelope Company, Inc. ("Niagara"). Financial data presented herein on a pro forma basis for the year ended December 31, 1995 gives effect to the Acquisition, the other transactions related thereto, the acquisition of Niagara and the Offering as if such transactions occurred on January 1, 1995. See "Unaudited Pro Forma Financial Data." THE COMPANY The Company is one of the largest manufacturers and marketers of paper-based office products (excluding computer forms and copy paper) in the $60 billion to $70 billion North American office products industry. The Company offers a broad product line including nationally branded and private label writing pads, file folders, envelopes and other office products. Through its Ampad division, the Company is among the largest and most important suppliers of pads and other paper-based writing products, filing supplies and envelopes to many of the largest and fastest growing office products distributors. Acquired in October 1995, the Company's Williamhouse division is the leading supplier of mill branded, specialty and commodity envelopes to paper merchants/distributors. The Company's strategy is to grow by focusing on the largest and fastest growing office product distribution channels, making acquisitions, introducing new product lines, broadening product distribution across its channels and maintaining its position among the lowest-cost manufacturers in the industry. As a result of this strategy, the Company's sales have grown at a compound annual rate of approximately 34% from 1992 to 1995. For the year ended December 31, 1995, the Company had net sales of $617.2 million and income from operations of $57.3 million on the pro forma basis described herein. See "Unaudited Pro Forma Financial Data." Since the mid-1980s, the office products industry has experienced significant changes in the channels through which office products are distributed such as the emergence of new channels, including national office products superstores, national contract stationers and mass merchandisers, and consolidation within these and other channels. As a result of these changes, approximately 6,800 office product distributors existed in 1994 compared with approximately 13,300 in 1987. The channels through which office products are distributed from the manufacturer to the end-user include retail channels such as national office products superstores, mass merchandisers and warehouse clubs; commercial channels such as national contract stationers; paper merchants/distributors; and other channels such as regional distributors, school campuses and direct mail. The Company believes that sales of office products through retail channels are approximately $20 billion to $25 billion. The three dominant national superstores (Office Depot, OfficeMax and Staples) have experienced significant growth over the past three years and currently account for approximately 17% of retail office products sales and approximately 6% of total office products sales. The Company believes that sales of office products through commercial channels are approximately $25 billion to $30 billion. Principally through the acquisition of smaller, regional contract stationers, national contract stationers (including Boise Cascade Office Products, BT Office Products, Corporate Express, U.S. Office Products and the contract stationer divisions of Office Depot and Staples) have grown more rapidly than other commercial channels. These national contract stationers now account for approximately 25% of commercial office products sales and approximately 11% of total office products sales. Certain office products, particularly envelopes, are sold predominantly through paper merchants/distributors or directly to end users. Paper merchants/distributors currently account for approximately 30% of the envelope market. The three largest paper merchants (ResourceNet, Unisource and Zellerbach) have experienced significant growth primarily through consolidation. The Company has targeted and will continue to target those customers driving consolidation in the retail, commercial and paper merchant distribution channels and believes that it is uniquely positioned to meet the special requirements of these customers. These customers seek suppliers, such as the Company, who are able to offer broad product lines, higher value-added innovative products, national distribution capabilities, low costs and reliable service. Furthermore, as these customers continue to grow and as they consolidate their supplier bases, the Company's ability to meet their special requirements becomes an increasingly important competitive advantage. Recognizing Ampad's potential for growth through the changing distribution channels, Bain Capital, Inc. ("Bain Capital") and management formed the Company and purchased Ampad from Mead Corporation ("Mead") in 1992. Since that time, management has enhanced the Company's scale, broadened its product line, expanded upon its national presence and strengthened its distribution capabilities through acquisition and innovation while simultaneously delivering higher customer service levels. As a result, the Company's net sales through the most rapidly growing retail and commercial channels increased from $8.8 million in 1992 to $134.8 million ($164.5 million on a pro forma basis) in 1995. COMPETITIVE STRENGTHS The combination of the Company's products, customers and national scale distinguishes it as a leading manufacturer and marketer of paper-based office products (excluding computer forms and copy paper) in North America. The Company attributes this position and its continued opportunities for growth and profitability to the following competitive strengths: . Market Leader. The Company has achieved market leadership in core products sold to customers in the largest and fastest growing office products channels by offering one of the broadest assortments of high quality products in the industry. Furthermore, the Company enjoys national brand awareness in many of its product lines, including Ampad, Century, Embassy, Evidence, Gold Fibre, Huxley, Karolton, Kent, Peel & Seel, SCM, Williamhouse and World Fibre. . Well-Positioned and Diversified Customer Base. The Company has substantial opportunities for growth within several distribution channels of the office products industry. The Company has focused on the largest and fastest growing office products channels. Several of the Company's largest customers, such as Boise Cascade Office Products, BT Office Products, Corporate Express, Office Depot, OfficeMax and Staples, are expected by industry analysts to experience annual revenue growth of 15% to 35% over the next five years. The Company's Williamhouse division maintains particularly strong relationships with the largest and fastest growing paper merchants/distributors in the market, including ResourceNet, Unisource and Zellerbach. The Company also maintains strong customer relationships across all of the other office products distribution channels, including mass merchandisers, warehouse clubs, office products wholesalers and independent dealers. . National Scale and Service Capability. The Company's extensive product line, multiple brands and broad price point coverage provide significant advantages and economies of scale in selling to and servicing its customers. The Company has become an increasingly important strategic partner to its customers as they seek higher value-added products, simplify their purchasing organizations and consolidate their relationships among selected national suppliers. The Company's national presence and network of 22 strategically located facilities have enabled it to maintain rapid and efficient order fulfillment standards. In addition, the Company's advanced electronic data interchange ("EDI") capabilities enable it to meet its customers' EDI requirements, executing automated transactions rapidly, efficiently and accurately. . Innovation/New Products. The Company has introduced several innovative products as part of its marketing strategy to differentiate itself from other suppliers and enhance profitability. Recent examples include Gold Fibre classic and designer notebooks, Papers with a Purpose, World Fibre ground- wood writing pads and Peel & Seel envelopes. Products introduced since 1992 accounted for over $70 million of the Company's 1995 net sales. The Company's brand recognition and presence with its national customers allows it to more easily introduce new or acquired product lines to those customers. . Low-Cost Manufacturer. The Company believes it is among the lowest-cost manufacturers of paper-based office products in the industry. The Company ensures its low-cost manufacturing position through its paper purchasing and distribution advantages as well as its maintenance of modern and efficient manufacturing technology and a high quality workforce. The Company has been successful in reducing costs with each of its acquisitions in the last three years by continually streamlining its manufacturing processes and overhead structure. From 1992 to 1995, the Company reduced its fixed manufacturing costs from 7.4% to 5.2% of net sales and its selling, general and administrative expenses from 10.5% to 7.2% of net sales. See "Management's Discussion and Analysis of Financial Condition and Results of Operations-- Overview." . Purchasing Advantages. The Company has strong relationships with most of the country's largest paper mills, many of which have been conducting business with the Company for more than 30 years. The Company is one of the largest purchasers of the principal paper grades used in its manufacturing operations. In addition, the Company has the largest number of designated mill relationships which involve some of the largest and most recognized paper mill brands such as Hammermill, Hopper, Neenah and Strathmore. These relationships afford the Company certain paper purchasing advantages, including stable supply and favorable pricing arrangements. . Proven Management Team With Successful Track Record. The Company's senior operating management team averages over 25 years each in the paper products industry. Management has succeeded in increasing sales and operating profitability by recognizing and acting on the transition to the fastest growing distribution channels, introducing higher value-added products, acquiring complementary product lines (Karolton in December 1993, SCM Office Supplies, Inc. ("SCM") in July 1994 and certain product lines of Huxley and Globe-Weis in July 1994 and August 1995, respectively), improving manufacturing processes and reducing overhead and administrative costs. Upon completion of the Offering, the Company's senior management team (Messrs. Hanson, Gard and Benson) will collectively own 865,516 shares of Common Stock (438,427 shares if the U.S. Underwriters' over-allotment option is exercised in full) and hold currently exercisable options to purchase an additional 2,156,000 shares of Common Stock. Assuming an initial public offering price of $16.00 per share, these holdings represent on a fully-diluted basis approximately 10.3% of the outstanding Common Stock (8.9% if the U.S. Underwriters' over-allotment option is exercised in full). See "Principal and Selling Stockholders." GROWTH STRATEGY The Company's strategy is to maintain and strengthen its leadership position by focusing on the following: . Focus on Rapidly Growing Customers. The Company serves many of the largest and best positioned customers in the office products market segment including national office products superstores, mass merchandisers and warehouse clubs, national contract stationers and national paper merchants/distributors. For 1995 on a pro forma basis, approximately 15.3% of the Company's net sales were to national office product superstores, 7.8% to mass merchandisers and warehouse clubs, 9.1% to national contract stationers and 19.7% to the three largest national paper merchants/distributors. Anticipating further consolidation in the office products industry, the Company expects that its national scope and broad product line will be increasingly important in meeting the needs of its customers. The Company will continue to target those customers driving consolidation in the office products industry. . Continue to Introduce New Products. New, higher value-added products give the Company a greater selection to offer its customers and improve product line profitability for both the Company and its customers. The Company plans to differentiate itself from other suppliers and improve profitability through product innovation, differentiation and line extensions. . Pursue Complementary Product Line and Strategic Acquisitions. The office products industry is highly fragmented despite continuing consolidation among its manufacturers. The Company is leading consolidation among manufacturers of writing products, filing supplies and envelopes. The SCM and Williamhouse acquisitions broadened the Company's product line to include filing products and envelopes and enhanced its presence in the growing distribution channels. The Globe-Weis acquisition and the Company's agreement to acquire Niagara demonstrate its commitment to strengthening its competitive and strategic position within its markets. The Company believes that there are significant opportunities to acquire companies in both its existing and complementary product lines. In addition, the Company intends to enter new office products markets through acquisitions of established companies in those markets. . Broaden Product Distribution. The Company's market presence and distribution strengths uniquely position it to sell new or acquired product lines across its distribution channels, including national office products superstores, national contract stationers, office product wholesalers and mass merchandisers. As an important part of its growth strategy, for example, the Company has successfully introduced the envelope product lines acquired in the Acquisition, previously distributed primarily through paper merchants/distributors, to the Ampad division's distribution channels under the Ampad and private label names. The Company estimates that this market opportunity is approximately $350 million in annual net sales. . Continue to Reduce Costs. The Company has identified and is in the process of implementing cost reductions in connection with the Acquisition that are expected to result in approximately $7.4 million of annualized cost savings. In addition, management plans to implement further identified cost reductions beyond 1996. RECENT TRANSACTIONS On May 29, 1996, the Company executed a definitive agreement to acquire Niagara for an aggregate purchase price of approximately $50 million, plus $5.0 million to be paid under a one-year consulting services agreement (the "Niagara Acquisition"). Niagara supplies mill branded, specialty and commodity envelopes to paper merchants/distributors through four manufacturing facilities located near Buffalo, Chicago, Dallas and Denver. Niagara had 1995 net sales of approximately $106 million and operating income of approximately $8.5 million. The Company expects the Niagara Acquisition to be completed by the middle of July 1996. The Company believes that the Niagara Acquisition will strengthen the Company's distribution capabilities in the Midwest, provide additional manufacturing capacity and provide opportunities to achieve operating improvements through the consolidation of Niagara's operations with those of the Company. The completion of the Niagara Acquisition is subject to certain conditions. In October 1995, the Company acquired Williamhouse for an aggregate purchase price (including assumption of debt of approximately $152.9 million) of approximately $300 million, plus reimbursement of certain expenses. In connection with the Acquisition, the Company (i) refinanced an aggregate of approximately $119.1 million of combined indebtedness of the Company and Williamhouse, (ii) purchased for $109.0 million in cash all of the outstanding 11 1/2% Senior Subordinated Debentures due 2005 of Williamhouse (the "Old Debentures"), together with accrued interest thereon of $5.3 million, (iii) declared a stock dividend of $200 million in aggregate liquidation value of preferred stock and preferred stock equivalents (collectively, the "Preferred Stock") and subsequently redeemed approximately $70.6 million of such Preferred Stock and declared a $4.5 million cash dividend on its Class P Common Stock, (iv) paid approximately $34.2 million in related fees and expenses and (v) used approximately $3.4 million for working capital purposes. To finance the Acquisition and these related transactions, the Company's principal operating subsidiary (i) incurred borrowings under a credit agreement (the "Bank Credit Agreement") of approximately $245 million, (ii) issued $200 million in aggregate principal amount of senior subordinated notes due 2005 (the "Notes"), and (iii) received approximately $45 million from the establishment of a new non-recourse, off-balance sheet accounts receivable securitization program (the "Accounts Receivable Facility"). The Acquisition, the other transactions entered into in connection therewith, and the financing thereof are collectively referred to herein as the "Transactions." The Company's management identified the personalizing business division of Williamhouse (the "Personalizing Division") as a nonstrategic asset following the Acquisition and has decided to pursue a sale of the Personalizing Division. As a result, the financial statements of the Company included elsewhere in this Prospectus reflect the Personalizing Division as "Assets held for Sale" as of December 31, 1995 and March 31, 1996. On June 6, 1996, the Company signed a definitive agreement with a potential buyer to sell the Personalizing Division. Under the terms of the agreement, the Company will receive approximately $60 million in gross proceeds (subject to certain closing adjustments) from the sale of the Personalizing Division, which it expects to complete by the end of June 1996. The sales agreement is subject to certain conditions, some of which are outside the control of the Company. As a result, no assurance can be given that the proposed sale will be completed or, if completed, will be on the terms outlined herein. See "Management's Discussion and Analysis of Financial Condition and Results of Operations-- Overview." Although the Company regularly engages in discussions with companies regarding potential acquisitions, it currently does not have any agreements or understandings relating to acquisitions other than the Niagara Acquisition. THE OFFERING(1) Common Stock offered by The Company........... 12,500,000 shares The Selling 3,125,000 shares Stockholders......... Total............... 15,625,000 shares Common Stock offered U. S. Offering........ 12,500,000 shares International 3,125,000 shares Offering............. Total............... 15,625,000 shares Common Stock to be outstanding after the Offering............... 26,925,272 shares(2) Use of proceeds......... The net proceeds to be received by the Company from the Offering will be used to repay certain outstanding bank indebtedness and to redeem a portion of the Notes issued by the Company's principal operating subsidiary and to pay certain fees. The Company will not receive any proceeds from the sale of shares by the Selling Stockholders. See "Use of Proceeds." Proposed NYSE symbol.... AGP
- -------- (1) Does not include the Underwriters' over-allotment option granted by the Selling Stockholders for an aggregate of 2,343,750 shares of Common Stock. (2) Does not include 2,156,000 shares of Common Stock reserved for issuance upon the exercise of options outstanding as of June 5, 1996 and granted to members of management pursuant to the Company's 1992 Key Employees Stock Option Plan (the "1992 Stock Plan") or 2,100,000 shares of Common Stock reserved for issuance under the Company's 1996 Key Employees Stock Incentive Plan (the "1996 Stock Plan"), the Non-Employee Director Stock Option Plan (the "Non-Employee Director Plan") and the Management Stock Purchase Plan. See "Management--Stock Options." SUMMARY FINANCIAL DATA The summary historical consolidated financial data set forth below for the years ended December 31, 1993, 1994 and 1995 have been derived from, and are qualified by reference to, the audited consolidated financial statements of the Company included elsewhere in this Prospectus. The summary historical consolidated financial data set forth below for the three months ended March 31, 1995 and 1996 have been derived from the unaudited consolidated financial statements of the Company, which, in the opinion of the Company, reflect all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation. Results for the three months ended March 31, 1996 are not necessarily indicative of results for the full year. The summary historical consolidated and unaudited pro forma financial data set forth below should be read in conjunction with, and are qualified by reference to, "Selected Historical Consolidated Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Unaudited Pro Forma Financial Data" and the audited consolidated financial statements and accompanying notes thereto included elsewhere in this Prospectus. YEAR ENDED DECEMBER 31, THREE MONTHS ENDED MARCH 31, ----------------------------------------- ----------------------------------- HISTORICAL HISTORICAL ------------------------------ ----------------- PRO FORMA PRO FORMA 1993 1994 1995 1995(1) 1995 1996 1996(2) -------- -------- -------- --------- ------- -------- --------- (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED) INCOME STATEMENT DATA(3)(4)(5): Net sales............... $104,277 $120,443 $259,341 $617,167 $47,691 $121,418 $149,735 Cost of sales(6)........ 88,491 113,394 211,814 481,804 42,394 97,889 121,245 -------- -------- -------- -------- ------- -------- -------- Gross profit............ 15,786 7,049(6) 47,527 135,363 5,297 23,529 28,490 Selling, general and administrative expenses............... 10,765 10,615 18,545 74,678(7) 2,749 11,026 14,493(7) Non-recurring compensation charge(8).............. -- -- 27,632 3,367 -- -- -------- -------- -------- -------- ------- -------- -------- Income (loss) from operations............. 5,021 (3,566) 1,350 57,318 2,548 12,503 13,997 Interest expense........ 3,320 4,560 13,657 30,953 1,656 12,542 7,738 Other (income) expense.. (167) (90) (735) (642) (65) (269) (265) -------- -------- -------- -------- ------- -------- -------- Income (loss) before income taxes........... 1,868 (8,036) (11,572) 27,007 957 230 6,524 Provision for (benefit from) income taxes..... 64 (488) (6,538) 9,814 366 102 2,596 -------- -------- -------- -------- ------- -------- -------- Income (loss) before extraordinary item..... 1,804 (7,548) (5,034) 17,193 591 128 3,928 Extraordinary loss from extinguishment of debt, net of income tax benefit................ -- -- (9,652) -- -- -- -- -------- -------- -------- -------- ------- -------- -------- Net income (loss)....... $ 1,804 $ (7,548) $(14,686) $ 17,193 $ 591 $ 128 $ 3,928 ======== ======== ======== ======== ======= ======== ======== Pro forma earnings (loss) per share(9).... $ (.95) $ .59 $ .01 $ .14 ======== ======== ======== ======== Pro forma weighted average number of common shares and common share equivalents outstanding(9)......... 15,540 29,063 16,562 29,063 ======== ======== ======== ======== OTHER DATA: Depreciation and amortization........... $ 159 $ 942 $ 4,248 $ 17,982 $ 528 $ 3,020 $ 3,803 Capital expenditures.... 1,656 942 5,640 13,688 2,530 2,321 3,087
MARCH 31, 1996 ------------------------- PRO FORMA ACTUAL AS ADJUSTED(10) -------- --------------- BALANCE SHEET DATA: Working capital...................................... $109,238 $114,799 Total assets......................................... 500,794 541,933 Long-term debt, less current maturities(11).......... 440,453 319,295 Stockholders' equity (deficit)(12)................... (66,293) 100,650
(footnotes on next page) (1) The summary unaudited pro forma income statement and other data for the year ended December 31, 1995 give pro forma effect, in the manner described under "Unaudited Pro Forma Financial Data" and the notes thereto, to: (i) the Transactions, (ii) the Globe-Weis Acquisition (as defined), (iii) the pending disposal of the Personalizing Division, (iv) the transactions described under "The Recapitalization," (v) refinancing of the Bank Credit Agreement, (vi) the Niagara Acquisition and (vii) the Offering (assuming an initial public offering price of $16.00 per share) and the application of the net proceeds therefrom as described under "Use of Proceeds," as if each had occurred on January 1, 1995. The summary pro forma income statement data and other data do not (i) purport to represent what the Company's results of operations actually would have been if the foregoing transactions had actually occurred as of such date or what such results will be for any future periods or (ii) give effect to certain non- recurring charges expected to result from items (i), (v) and (vii) above, including certain non-cash compensation charges directly related to the Acquisition and an extraordinary charge for the write-off of deferred financing fees and direct expenses to retire and refinance existing Company debt. The final allocation of purchase price and the resulting amortization expense in the income statement data may differ somewhat from the preliminary estimates for the reasons described in more detail in "Unaudited Pro Forma Financial Data" and in Note 3 of the Notes to Consolidated Financial Statements of the Company. (2) The summary unaudited pro forma income statement and other data for the three months ended March 31, 1996 give pro forma effect, in the manner described under "Unaudited Pro Forma Financial Data" and the notes thereto, to: (i) the pending disposal of the Personalizing Division, (ii) the transactions described under "The Recapitalization," (iii) refinancing of the Bank Credit Agreement, (iv) the Niagara Acquisition and (v) the Offering (assuming an initial public offering price of $16.00 per share) and the application of the net proceeds therefrom as described under "Use of Proceeds," as if each had occurred on January 1, 1996. (3) Effective July 5, 1994, the Company acquired the assets and assumed certain liabilities of SCM Office Supplies, Inc. (the "SCM Acquisition"). The acquisition has been accounted for under the purchase method of accounting and, accordingly, the operating results have been included with the Company's results since the date of acquisition. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Note 3 of the Notes to Consolidated Financial Statements of the Company included herein. (4) Effective August 16, 1995, the Company acquired the inventories and certain equipment of the file folder and hanging file product lines of the Globe-Weis office products division ("Globe-Weis") of Atapco (as defined) (the "Globe-Weis Acquisition"). The acquisition has been accounted for under the purchase method of accounting and, accordingly, the operating results have been included in the Company's results since the date of acquisition. See "Management's Discussion and Analysis of Financial Condition and Results of Operations," Note 3 of the Notes to Consolidated Financial Statements of the Company and the audited statements of Net Sales and Cost of Sales of Globe-Weis included herein. (5) Effective October 31, 1995, the Company acquired Williamhouse in the Acquisition. The Acquisition has been accounted for under the purchase method of accounting and accordingly, the operating results of Williamhouse, except for the Personalizing Division, for the two-month period ended December 31, 1995 have been included in the Company's results for the year ended December 31, 1995. The Personalizing Division was held for sale at December 31, 1995 and March 31, 1996. As such, the operating results of the Personalizing Division are excluded from the results of operations for the two-month period ended December 31, 1995 (period subsequent to the Acquisition) and the three months ended March 31, 1996. See "Management's Discussion and Analysis of Financial Condition and Results of Operations," Note 3 of the Notes of Consolidated Financial Statements of the Company and the audited financial statements of Williamhouse included herein. (6) Inventory cost is determined using the last-in, first-out ("LIFO") method of valuation. Gross profit in the fourth quarter of 1994 was adversely impacted by a significant increase in paper prices, resulting in a $5.4 million charge for LIFO in advance of the Company's raising selling prices in the first quarter of 1995. Beginning in January 1995, the Company adopted new pricing policies enabling it to set product prices consistent with the Company's cost of paper at the time of shipment. The Company believes that it is now able to price its products so as to minimize the impact of price volatility on dollar margins. See "Management's Discussion and Analysis of Financial Condition and Results of Operations--Overview." (7) Includes charges under a one-year consulting services agreement to be entered into in connection with the Niagara Acquisition of $5.0 million and $1.25 million for the year ended December 31, 1995 and the three months ended March 31, 1996, respectively. (8) Includes non-cash stock option compensation charges of $24.3 million directly related to the Acquisition as well as other non-recurring cash and non-cash charges aggregating $3.3 million. See Note 9 of Notes to Consolidated Financial Statements of the Company included herein. (9) Pro forma earnings (loss) per common share and pro forma weighted average number of shares and share equivalents outstanding have been adjusted to give effect to (i) a 8.1192-for-one stock split of all existing Common Stock and Common Stock equivalents and (ii) the conversion of all shares of Preferred Stock and Preferred Stock equivalents into shares of Common Stock and Common Stock equivalents at the assumed offering price per share to the public. Common Stock equivalents were determined using the treasury stock method. (10) The unaudited "Pro Forma As Adjusted" balance sheet data at March 31, 1996 gives pro forma effect to (i) the transactions described under "The Recapitalization," (ii) the refinancing of the Bank Credit Agreement, (iii) the Niagara Acquisition and (iv) the sale by the Company of 12,500,000 shares of Common Stock pursuant to the Offering, assuming an initial public offering price of $16.00 per share and the application of the estimated net proceeds to the Company therefrom as described under "Use of Proceeds," as if each had occurred on such date. See "Unaudited Pro Forma Financial Data." (11) Does not reflect the expected repayment of debt from the estimated proceeds from the sale of the Personalizing Division. (12) Includes $4.5 million to pay the liquidation preference, including the return of original cost, of the Company's Class P Common Stock and $70.6 million to redeem a portion of its Preferred Stock. See "Dividend Policy."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000006885_stage_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000006885_stage_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..ecacc83ac476bc0bd73f3ac6e24254d53b369b68
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000006885_stage_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by reference to the more detailed information and financial statements, including the notes thereto, appearing elsewhere in this Prospectus. References in this Prospectus to the Company shall, as the context requires, refer to Stage Stores, Inc. ("Stage Stores"), which was previously known as Apparel Retailers, Inc., together with its wholly-owned subsidiaries, including Specialty Retailers, Inc. ("SRI"). References to a particular year are to the Company's fiscal year which is the 52 or 53 week period ending on the Saturday closest to January 31 of the following calendar year (e.g., a reference to "1995" is a reference to the fiscal year ended February 3, 1996). The term pro forma refers to the basis described under "Unaudited Pro Forma Combined Financial Data." In addition, unless otherwise indicated, (i) the information in this Prospectus reflects a .94727 for 1 reverse stock split of the common stock to be consummated prior to the Offering and (ii) the information contained herein assumes that the Underwriters' over-allotment option is not exercised. See "Underwriting." The Company The Company operates the store of choice for well known, national brand name family apparel in over 200 small towns and communities across the central United States. The Company has recognized the high level of brand awareness and demand for fashionable, quality apparel by consumers in small markets and has identified these markets as a profitable and underserved niche. The Company has developed a unique franchise focused on small markets, differentiating itself from the competition by offering a broad range of merchandise with a high level of customer service in convenient locations. The Company currently operates 314 stores through its "Stage", "Bealls" and "Palais Royal" trade names in 20 states throughout the central United States. Approximately 77% of these stores are located in small markets and communities with as few as 4,000 people. The Company's store format (averaging approximately 18,000 total selling square feet) and merchandising capabilities enable the Company to operate profitably in small markets. The remainder of the Company's stores operate in metropolitan areas, primarily in suburban Houston. For the twelve months ended February 3, 1996, the Company would have had pro forma sales and income before extraordinary item of $742.4 million and $20.7 million, respectively. Stage Stores' merchandise offerings include a carefully edited but broad selection of branded, moderately priced, fashion apparel, accessories, fragrances and cosmetics and footwear for women, men and children. Over 85% of 1995 sales consisted of branded merchandise, including nationally recognized brands such as Levi Strauss, Liz Claiborne, Chaps/Ralph Lauren, Calvin Klein, Guess, Hanes, Nike, Reebok and Haggar Apparel. In recent years, the Company has undertaken several initiatives to realize the full potential of its unique franchise in small markets, including (i) recruiting a new senior management team, (ii) embarking on a store expansion program to capitalize on available opportunities in new markets through new store openings and strategic acquisitions, (iii) continuing to refine the Company's retailing concept and (iv) closing unprofitable stores. As a result of these initiatives, the lower operating costs of small market stores, the benefits of economies of scale, and its highly automated facilities and sophisticated information systems, the Company has among the highest operating income margins in the apparel retailing industry. Competitively Well Positioned As a result of its small market focus, Stage Stores generally faces less competition for brand name apparel because consumers in small markets generally have only been able to shop for branded merchandise in distant regional malls. In those small markets where the Company does compete for brand name apparel sales, such competition generally comes from local retailers, small regional chains and, to a lesser extent, national department stores. The Company believes it has a competitive advantage over local retailers and smaller regional chains due to its (i) economies of scale, (ii) strong vendor relationships, (iii) proprietary credit card program and (iv) sophisticated operating systems. The Company believes it has a competitive advantage in small markets over national department stores due to its (i) experience with smaller markets, (ii) ability to effectively manage merchandise assortments in a small store format and (iii) established operating systems designed for efficient management within small markets. In addition, due to minimal merchandise overlap, Stage Stores generally does not directly compete for branded apparel sales with national discounters such as Wal-Mart. Key Strengths The following factors serve as the Company's key strengths and distinguishing characteristics: Ability to Operate Profitably in Smaller Markets. In targeting small markets, the Company has developed a store format, generally ranging in size from 12,000 to 30,000 square feet, which is smaller than typical department stores yet large enough to offer a well edited, but broad selection of merchandise. This format, together with economies of scale in buying and merchandising, information systems, distribution and advertising, has enabled the Company to operate profitably in small markets. In 1995, the Company's small market stores open for at least one year generated a store contribution (operating profit before allocation of corporate overhead) as a percentage of sales of 18%, as compared to 12% for its larger market stores. Benefits of Strong Vendor Relationships. The Company's large store base offers major vendors a unique vehicle for accessing multiple small markets in a cost effective manner. The proliferation of media combined with the significant marketing efforts of these vendors has created significant demand for branded merchandise. However, the financial and other limitations of many local retailers have left vendors of large national brands with limited access to such markets. Further, these vendors, in order to preserve brand image, generally do not sell to national discounters. As a result, the Company is able to carry branded merchandise frequently not carried by local competitors. Additionally, the Company continuously seeks to expand its vendor base and has recently added nationally recognized brand names such as Polo, Dockers for Women, and Oshkosh, and fragrances by Elizabeth Arden, Liz Claiborne and Perry Ellis. In addition, the Company has successfully increased the participation by key vendors in joint marketing programs to a level that the Company believes exceeds the standard programs provided to its smaller, regional competitors. Effective Merchandising Strategy. The Company's merchandising strategy is based on an in-depth understanding of its customers and is designed to accommodate the particular demographic profile of each store. Store layouts and visual merchandising displays are designed to create a friendly, modern, department store environment, which is frequently not found in small markets. The Company's strategy focuses on moderately priced merchandise categories of women's, men's and children's apparel, accessories, fragrances, cosmetics and footwear, which have traditionally experienced attractive margins. The Company utilizes a sophisticated merchandise allocation and transfer system which is designed to maximize in-stock positions, increase sales and reduce markdowns. The Company believes that the combination of the size and experience of its buyer group, strong vendor relationships, effective merchandising systems and participation in the Associated Merchandising Corporation ("AMC") cooperative buying service enable it to compete effectively on both price and selection in its markets. Focused Marketing Strategy. The Company's primary target customers are women between the ages of 20 and 55 with household incomes over $25,000 who are the primary decision makers for family clothing purchases. The Company uses a multi-media advertising approach to position its stores as the local destination for fashionable, brand name merchandise. In addition, the Company heavily promotes its proprietary credit card in order to create customer loyalty and to effectively identify its core customers. The Company believes it has a high level of customer awareness due to the small size of its markets, its aggressive advertising strategy and well developed corporate programs designed to encourage a high level of customer interaction and employee participation in local community activities. Benefits of Proprietary Credit Card Program. The Company aggressively promotes its proprietary credit card and, as a result, the Company believes it experiences a higher percentage of proprietary credit card sales (55.6% of net sales in 1995) than most retailers. The Company considers its credit card program to be a critical component of its retailing concept because it (i) enhances customer loyalty by providing a service that few local and regional competitors or discounters offer, (ii) allows the Company to identify and regularly contact its best customers and (iii) creates a comprehensive database that enables the Company to implement detailed, segmented marketing and merchandising strategies for each store. Emphasis on Customer Service. A primary corporate objective is to provide excellent customer service through stores staffed with highly trained and motivated sales associates. Each sales associate is evaluated based upon the attainment of specific customer service standards such as offering prompt assistance, suggesting complementary items, sending thank-you notes to charge customers and establishing consistent contact with customers in order to create the associate's own customer base. The Company continuously monitors the quality of its service by making over 3,000 calls each month to credit card customers who have recently made a purchase. The results of these surveys are used to determine a portion of each store manager's bonus. The Company further extends its service philosophy to the design of the store, including installing call buttons in its fitting rooms and, in its small market stores, locating the store manager on the selling floor to increase accessibility to customers. Sophisticated Operating and Information Systems. The Company supports its retail concept with highly automated and integrated systems in areas such as merchandising, distribution, sales promotions, credit, personnel management, store design and accounting. These systems have enabled the Company to effectively manage its inventory, improve sales productivity and reduce costs, and have contributed to its relatively high operating income margins. Growth Strategy In order to fully realize the potential of its unique market position and proven ability to operate profitably in small markets, the Company has initiated an aggressive growth strategy to capitalize on available opportunities in new markets through new store openings and strategic acquisitions. The Company opened 23 new stores and 45 acquired stores in 1995, has opened 25 new stores and acquired 34 stores to date in 1996, and expects to open approximately 10 additional new stores during the remainder of 1996. The Company's goal is to open at least 55 new stores in 1997. The following are the primary elements of the Company's strategy for profitable growth: New Store Openings in Smaller Markets. As part of its ongoing expansion program, the Company has identified over 600 additional markets in the central United States and contiguous states which meet its demographic and competitive criteria. All of these target markets are smaller communities, where the Company has historically experienced its highest profit margins. Strategic Acquisitions. The Company believes that it can benefit from strategic acquisitions by (i) applying its buying and merchandising capabilities, sales promotion techniques and customer service methods, (ii) introducing its proven management systems, and (iii) consolidating overhead functions. This strategy has been successfully demonstrated by the Company's acquisition of 45 stores from Beall-Ladymon, Inc. ("Beall-Ladymon") in 1994 and the subsequent reopening of the stores in the first quarter of 1995 under the Stage name. In 1993, the year prior to their acquisition, the Beall-Ladymon stores generated sales of approximately $53.4 million, whereas the newly opened Stage stores in the same locations generated sales for the twelve months ended August 3, 1996 of $95.0 million, an increase of 78%. Over the same periods, store contribution more than doubled. In June 1996, the Company acquired Uhlmans Inc. ("Uhlmans"), a privately held retailer with 34 locations in Ohio, Indiana and Michigan, where the Company previously had no stores (the "Uhlmans Acquisition"). These stores are of similar size and merchandise content to the Company's existing stores and are compatible with the Company's retailing concept and growth strategy. For 1995, Uhlmans had net sales of $59.7 million and operating income of $2.2 million. The Company believes significant opportunities are available to improve Uhlmans' financial results through the expansion of certain merchandise categories, the Company's lower merchandising costs, increased proprietary credit card-based sales, the implementation of the Company's operating systems and the elimination of duplicative central and administrative overhead. Expansion to Micromarkets. The Company recently began targeting its small market retailing concept towards communities with populations from 4,000 to 12,000 ("micromarkets"). These efforts are designed to capitalize on the Company's favorable operating experience in markets of this size. Stage Stores believes that micromarkets may offer a significant avenue for potential growth, because the Company is able to apply its existing successful store model in those micromarkets due to its ability to scale its store concept to the appropriate size (less than 12,000 gross square feet), the generally lower levels of competition and low labor and occupancy costs. The Company has identified approximately 1,200 potential micromarkets in the central United States and contiguous states which meet these criteria. The Offering Common Stock offered by: The Company (1) 10,000,000 shares Selling Stockholders 1,000,000 shares (1) Total 11,000,000 shares ============= Common Stock to be outstanding after the Offering (2) 22,520,892 shares Use of proceeds The net proceeds to be received by the Company from the Offering are estimated to be approximately $139.7 million and will be used (i) to purchase for cash up to all of the Company's outstanding 12-3/4% Senior Discount Debentures due 2005 (the "Senior Discount Debentures") in a tender offer (the "Tender Offer") and to pay a consent fee for elimination or amendment of certain covenants in the Senior Discount Debentures for an aggregate amount of approximately $135.0 million, (ii) to pay consent fees for amendments to certain covenants in the indebtedness of SRI and (iii) to pay a $2.0 million fee to terminate the Professional Services Agreement (as defined). See "Use of Proceeds" and "Certain Relationships and Related Transactions." The Company will not receive any of the proceeds from the sale of shares by the Selling Stockholders. Proposed Nasdaq National "STGE" Market symbol - ------------- (1) Assumes that the Underwriters' over-allotment option is not exercised. (2) Includes 1,351,967 shares issuable upon the conversion of non-voting Class B Common Stock, $0.01 par value per share (the "Class B Common Stock"), which are convertible into Common Stock on a share-for-share basis, subject to certain restrictions. See "Description of Capital Stock." Excludes 1,511,523 shares that may be issued upon the exercise of options granted pursuant to the 1993 Stock Option Plan (as defined). See "Management--1993 Stock Option Plan." Prospective purchasers of the Common Stock offered hereby should carefully consider the "Risk Factors" immediately following this Prospectus Summary. The executive offices of the Company are located at 10201 Main Street, Houston, Texas 77025. The Company's telephone number is (713) 667-5601. Summary Consolidated Historical and Pro Forma Combined Financial and Operating Data The following table sets forth summary consolidated historical and pro forma combined financial and operating data of the Company for the periods indicated. The Company's summary consolidated historical financial data were derived from the Company's Consolidated Financial Statements. The summary pro forma combined financial data were derived from the Unaudited Pro Forma Combined Financial Data of the Company and give effect to the Uhlmans Acquisition, including the issuance of the SRPC Notes (as defined), and the Offering (including a .94727 for 1 reverse stock split of the common stock to be consummated prior to the Offering). The information in the table should be read in conjunction with "Selected Consolidated Historical Financial and Operating Data", "Management's Discussion and Analysis of Financial Condition and Results of Operations", "Unaudited Pro Forma Combined Financial Data", the Company's Consolidated Financial Statements and the Financial Statements of Uhlmans, included elsewhere in this Prospectus. Fiscal Year ----------------------------------------------------------------------------- Pro Forma 1991 1992 1993(1) 1994 1995(2) 1995 (2) ------------ ------------ ------------ ------------ ------------ ------------ (dollars in thousands, except per share and store data) Statement of operations data: Net sales $447,142 $504,401 $557,422 $581,463 $682,624 $742,373 Gross profit 135,569 154,265 172,579 182,804 214,277 229,498 Selling, general and administrative expenses 116,403 129,193 135,011 134,715 159,625 168,936 Service charge income (3) 22,840 29,670 20,003 8,515 10,523 11,374 Store opening and closure costs 255 120 199 5,647 3,689 3,689 Operating income (4) 41,751 54,622 57,372 50,957 61,486 68,247 Net interest expense 33,407 31,771 36,377 40,010 43,989 34,713 Income before extraordinary item 3,961 12,235 13,426 6,630 10,730 20,673 Pro forma earnings per common share (5) -- -- -- -- -- 0.91 Margin and other data: Gross profit margin 30.3% 30.6% 31.0% 31.4% 31.4% 30.9% Selling, general and administrative expense rate 26.0% 25.6% 24.2% 23.2% 23.4% 22.8% Operating income margin (4) 9.3% 10.8% 10.3% 8.8% 9.0% 9.2% Adjusted operating income margin (6) 8.1% 8.7% 8.4% 9.2% 9.4% 9.4% Adjusted operating income (6) $ 36,064 $ 43,680 $ 46,828 $ 53,677 $ 63,996 $ 70,036 Depreciation and amortization 10,049 9,065 9,259 9,997 12,816 13,712 Capital expenditures 4,768 7,631 8,503 19,706 28,638 -- Store data: (7) Comparable store sales growth: Bealls/Stage (8) 4.1% 5.1% 7.2% 4.8% 3.3% -- Palais Royal (2.8)% (9.8)% 0.8% 1.7% 1.4% -- Total Company (9) 2.9% 1.8% 6.3% 4.1% 0.8%(10) -- Net sales per selling square foot: Bealls/Stage (8) $ 113 $ 118 $ 129 $ 138 $ 142 -- Palais Royal 228 191 200 205 203 -- Total Company (9) 138 138 149 157 157 -- Total selling square footage(11) 3,354 3,418 3,472 3,516 4,581 -- Number of stores open at end of period(12) 159 175 180 188 256 290
Six Months Ended -------------------------------------- Pro Forma July 29, August 3, August 3, 1995 1996 1996 ------------ ------------ ------------ Statement of operations data: Net sales $296,931 $345,927 $362,443 Gross profit 92,838 108,704 112,697 Selling, general and administrative expenses 70,877 84,335 86,425 Service charge income (3) 5,124 5,902 6,171 Store opening and closure costs 1,176 301 301 Operating income (4) 25,909 29,970 32,142 Net interest expense 21,365 24,054 18,091 Income before extraordinary item 2,659 3,520 8,563 Pro forma earnings per common share (5) -- -- 0.37 Margin and other data: Gross profit margin 31.3% 31.4% 31.1% Selling, general and administrative expense rate 23.9% 24.4% 23.8% Operating income margin (4) 8.7% 8.7% 8.9% Adjusted operating income margin (6) 8.5% 7.8% 8.0% Adjusted operating income (6) $ 25,134 $ 27,128 $ 29,031 Depreciation and amortization 5,721 6,844 7,148 Capital expenditures 16,786 15,183 -- Store data: (7) Comparable store sales growth: Bealls/Stage (8) 3.8% 7.7% -- Palais Royal 0.9% 6.2% -- Total Company (9) 0.5% 7.3% -- Net sales per selling square foot: Bealls/Stage (8) -- -- -- Palais Royal -- -- -- Total Company (9) -- -- -- Total selling square footage(11) 4,365 5,361 5,361 Number of stores open at end of period(12) 242 308 308 Balance sheet data (at end of period): Working capital $181,118 $204,808 Total assets 463,240 473,534 Total long-term debt 425,353 308,354 Stockholders' (deficit) equity (68,428) 56,451(13) Notes to Summary Consolidated Historical and Pro Forma Combined Financial and Operating Data (1) During 1993, Stage Stores was formed and concurrently became the direct parent of SRI when the existing stockholders of SRI exchanged all of their common stock for common stock of Stage Stores. Concurrent with the formation of Stage Stores, the Company completed the refinancing of its existing debt and preferred stock (the "Refinancing"). As a result of the Refinancing, the Company recorded an after-tax extraordinary charge of $16.2 million. (2) 1995 includes 53 weeks. (3) Service charge income for 1993, 1994 and 1995 decreased as compared to levels achieved during 1991 and 1992 due to the sale of accounts receivable to the SRI Receivables Master Trust (the "Trust") established as part of the Refinancing in which the Company adopted an accounts receivable securitization program (the "Accounts Receivable Program"). Without giving effect to the Accounts Receivable Program, service charge income for 1993, 1994 and 1995 would have been $32.5 million, $35.2 million and $41.3 million, respectively. For a complete summary of the impact of the Company's proprietary credit card program and the Accounts Receivable Program, see Note 2 to the Company's Consolidated Financial Statements, Note 6 below and "Management's Discussion and Analysis of Financial Condition and Results of Operations--General--Accounts Receivable Program." (4) Operating income and operating income margin decreased during 1994 compared to 1993 due primarily to the impact of the adoption of the Accounts Receivable Program (See Note 2 to the Company's Consolidated Financial Statements and Note 6 below) combined with a $5.2 million provision associated with the closure of a majority of the stores operated under the Fashion Bar name (the "Store Closure Plan") (substantially all of which were underperforming). See Note 4 to the Company's Consolidated Financial Statements and "Management's Discussion and Analysis of Financial Condition and Results of Operations." (5) Pro forma earnings per common share reflects the impact of a .94727 for 1 reverse stock split of the common stock to be consummated prior to the Offering. (6) Adjusted operating income represents operating income adjusted to eliminate store opening and closure costs, and the positive impact on operating income of the Company's proprietary credit card program (including the Accounts Receivable Program). Fiscal Year ---------------------------------------------------------- Pro Forma 1991 1992 1993 1994 1995 1995 --------- --------- ------------------ --------- --------- (in thousands) Operating income $41,751 $54,622 $57,372 $50,957 $61,486 $68,247 Plus: Store opening and closure costs 255 120 199 5,647 3,689 3,689 Less: Positive impact of proprietary credit card program on operating income 5,942 11,062 10,743 2,927 1,179 1,900 --------- --------- ------------------ --------- --------- Adjusted operating income $36,064 $43,680 $46,828 $53,677 $63,996 $70,036 ========= ========= ================== ========= ========= Six Months Ended ----------------------------- July 29, August 3, Pro Forma August 3, 1995 1996 1996 --------- --------- --------- Operating income $25,909 $29,970 $32,142 Plus: Store opening and closure costs 1,176 301 301 Less: Positive impact of proprietary credit card program on operating income 1,951 3,143 3,412 --------- --------- --------- Adjusted operating income $25,134 $27,128 $29,031 ========= ========= ========= The impact of the Company's proprietary credit card program (including the Accounts Receivable Program) on operating income is calculated as: (i) the reported service charge income less (ii) the servicing and bad debt costs reflected in the Company's selling, general and administrative expenses less (iii) the gain (or plus the loss) associated with the sale of receivables to the Trust. See "Management's Discussion and Analysis of Financial Condition and Results of Operations--General--Accounts Receivable Program" and Note 7 to Selected Consolidated Historical Financial and Operating Data. Although adjusted operating income and adjusted operating income margin do not represent operating income or any other measure of financial performance under generally accepted accounting principles, the Company believes they are helpful in understanding the profitability of the Company's retailing operations prior to the impact of its credit card program, the Accounts Receivable Program and store opening and closure costs. (7) Store data exclude Bealls stores scheduled to be closed under the Bealls 1988 store closure program, except as otherwise noted in Note 12 below, and also exclude the Fashion Bar stores included in the Store Closure Plan. Comparable store sales growth and net sales per selling square foot for 1995 have been determined based on a comparable fifty-two week period. Sales are considered comparable after a store has been in operation fourteen months. Net sales per selling square foot are calculated for stores open the entire year. (8) Excludes for all the periods presented the six Bealls stores located on the border of Mexico which were adversely affected by the peso devaluation in 1994. Comparable stores sales growth and net sales per selling square foot for Bealls/Stage including these stores were: Fiscal Year ------------------------------------ Bealls/Stage 1991 1992 1993 1994 1995 ------ ------ ------ ------ ------ Comparable store sales growth 5.4% 6.7% 7.7% 4.6% 0.2% 0.3% Net sales per selling square foot $119 $125 $137 $146 $145 -- Six Months Ended ------------------------- July 29, August 3, Bealls/Stage 1995 1996 ------------ ------------ Comparable store sales growth 0.3% 7.7% Net sales per selling square foot -- -- (9) Total Company comparable store sales growth and net sales per selling square foot including the stores which were part of the Store Closure Plan were as follows: Fiscal Year ------------------------------------ Total Company 1991 1992 1993 1994 1995 ------ ------ ------ ------ ------ Comparable store sales growth 2.9% 1.8% 5.4% 3.2% 0.5% Net sales per selling square foot $138 $138 $143 $151 $150 Six Months Ended ------------------------- July 29, August 3, Total Company 1995 1996 ------------ ------------ Comparable store sales growth 0.4 6.8% Net sales per selling square foot -- -- (10) Excluding the six Bealls stores located on the border of Mexico which were adversely affected by the peso devaluation in 1994, total Company comparable store sales growth for 1995 would have been 3.0%. (11) Excludes data related to the stores which were included in the Store Closure Plan. Data is in thousands and is as of the end of the period. (12) Number of stores open at the end of each period presented also exclude stores in the Store Closure Plan. Stores open at the end of 1992 and 1993 included one and six stores, respectively, which were previously excluded under the Bealls 1988 store closure program. Such stores are only included in the Company's results of operations subsequent to their removal from the Bealls 1988 store closure program. Both the Store Closure Plan and the Bealls 1988 store closure program were substantially completed before the end of 1995. (13) Reflects non-recurring charges, net of tax, totalling approximately $14.8 million in connection with the early retirement of the Senior Discount Debentures and the write-off of related debt issue costs, the payment of consent fees for amendments to certain covenants in the indebtedness of SRI and the termination of the Professional Services Agreement (as defined).
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000007974_associates_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000007974_associates_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..020e6c58ca30afb85fda593dc06f5deb5a3dfe29
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000007974_associates_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a summary of certain information contained elsewhere in this Prospectus. Reference is made to, and this summary is qualified in its entirety by, the more detailed information and supplemental combined financial statements, including the notes thereto, appearing elsewhere in this Prospectus. Unless the context otherwise requires, (i) the "Company" means Associates First Capital Corporation and its consolidated subsidiaries after giving effect to the recontribution by Ford of certain non-U.S. subsidiaries described below under "The Company", (ii) "ACONA" means Associates Corporation of North America, the Company's principal operating subsidiary, (iii) "Ford" means Ford Motor Company and its consolidated subsidiaries (other than the Company) and (iv) the information contained in this Prospectus assumes that the Class A Common Stock offered hereby will be sold in the Offerings at $26.50 per share (the mid-point of the range set forth on the cover page of this Prospectus) and that the Underwriters' over-allotment options are not exercised. Unless otherwise defined herein, capitalized terms used in this summary have the respective meanings ascribed to them elsewhere in this Prospectus. For a description of certain terms and phrases in this Prospectus, see "Glossary" at the end of this Prospectus. Terms and phrases set forth in the Glossary are printed in bold face type the first time they appear in this Prospectus. PROSPECTIVE INVESTORS SHOULD CAREFULLY CONSIDER THE INFORMATION SET FORTH UNDER THE HEADING "RISK FACTORS". THE COMPANY The Company is a leading, diversified consumer and commercial finance organization which provides finance, leasing and related services to approximately 9.4 million individual consumers and 143,000 businesses in the United States and internationally. At or for the year ended December 31, 1995, the Company had aggregate NET FINANCE RECEIVABLES of $39.7 billion, total assets of $41.3 billion, net earnings of $723.1 million and stockholder's equity of $4.8 billion. The Company, through its predecessors, commenced operations in 1918 and was acquired by Ford in 1989. The Company believes that it is the second largest INDEPENDENT FINANCE COMPANY in the United States based on aggregate net finance receivables outstanding. The Company's operations outside the United States are conducted principally in Japan ($2.1 billion of net finance receivables) and are also conducted in, among other places, the United Kingdom and Canada. The current credit ratings for the long-term debt of ACONA, through which the Company conducts substantially all of its funding activities, are Aa3 and AA- as determined by MOODY'S and STANDARD & POOR'S, respectively, and those of the Company are A1 and A+. Through various economic conditions and interest rate environments, the Company has produced growth in pre-tax earnings for twenty-one consecutive years. As the following graph depicts, over this period, pre-tax earnings have grown at a compound annual rate in excess of 22% to $1.2 billion for the year ended December 31, 1995. Such growth resulted principally from internal expansion (through, among other things, branch openings, new lines of business and geographic expansion) as well as selective acquisitions. PRE-TAX EARNINGS TREND(1) (DOLLARS IN MILLIONS) [GRAPH] (1) 1990 and 1991 pre-tax earnings exclude non-recurring interest expense. See the immediately following financial information and note (4) thereto. The table below sets forth certain financial information (dollars in millions): YEAR ENDED OR AT DECEMBER 31(1) --------------------------------------------------------- 1995 1994 1993 1992 1991 ---------- ---------- ---------- ---------- --------- CONSUMER NET FINANCE RECEIVABLES: Home equity lending.............. $ 14,386.2 $ 12,349.9 $ 10,619.7 $ 9,630.1 $ 8,249.1 Personal lending and retail sales finance....................... 6,117.6 5,304.2 4,354.2 3,640.2 3,224.2 Credit card...................... 4,818.6 3,915.5 3,104.8 2,614.6 2,668.4 COMMERCIAL NET FINANCE RECEIVABLES: Truck and truck trailer.......... $ 7,648.4 $ 6,681.5 $ 5,540.0 $ 4,350.7 $ 4,000.3 Equipment........................ 3,827.2 2,987.4 2,464.5 2,290.6 2,157.9 Manufactured housing(2).......... 2,034.1 1,669.2 1,290.2 983.9 697.2 Other(3)......................... 416.3 336.5 345.3 324.7 269.8 TOTAL NET FINANCE RECEIVABLES...... 39,702.5 33,685.7 28,294.7 24,371.0 21,672.8 TOTAL ASSETS....................... 41,303.9 35,283.5 30,039.6 25,996.3 23,523.5 STOCKHOLDER'S EQUITY............... 4,801.1 4,436.8 3,774.3 3,231.1 3,061.0 NET EARNINGS(4).................... 723.1 603.3 494.0 410.1 311.9 RETURN ON AVERAGE ASSETS(4)........ 1.89% 1.85% 1.76% 1.66% 1.40% RETURN ON AVERAGE EQUITY(4)........ 15.66 14.70 14.10 13.04 12.49 RETURN ON AVERAGE TANGIBLE EQUITY(4)........................ 21.90 21.71 22.31 22.15 24.59
- --------------- (1) Amounts in this table reflect the inclusion of certain non-U.S. subsidiaries of Ford which are expected to be recontributed to the Company prior to the completion of the Offerings. Such subsidiaries were owned by the Company prior to its acquisition by Ford and have been continuously managed by the Company since such acquisition. These subsidiaries had total assets of $4.1 billion at December 31, 1995. See "-- Relationship with Ford" and "The Company". (2) Manufactured housing operations are discussed in this Prospectus as part of the Company's commercial activities because the marketing and management of manufactured housing products are more closely related to commercial finance products. See "Business -- Commercial Finance". Except as otherwise indicated, the dollar amount of manufactured housing receivables is included in the dollar amount of total consumer net finance receivables throughout this Prospectus, because the credit and related risks of the manufactured housing business are similar to those of the Company's consumer finance business. Similarly, manufactured housing receivables are included with consumer net finance receivables in determining the percentage of total net finance receivables which are consumer net finance receivables. (3) Includes auto fleet leasing and management, small business administration lending, relocation services and auto club and roadside assistance services. See "Business -- Commercial Finance -- Other Commercial Activities". (4) In 1991, certain debt related to Ford's acquisition of the Company's operation in Japan was converted to equity. Non-recurring interest expense related to such debt was $39.2 million and $54.2 million in 1991 and 1990, respectively. If 1991 results treated the converted debt as equity and excluded the related non-recurring interest expense consistent with subsequent years, net earnings would have been $351.1 million and the return on average assets, average equity and average tangible equity would have been 1.58%, 12.29% and 21.56%, respectively. In addition, if 1990 results excluded the related non-recurring interest expense, pre-tax earnings would have been $493.7 million. CONSUMER FINANCE The Company's consumer finance business represents approximately $27.6 billion, or 70%, of its 1995 year-end net finance receivables. HOME EQUITY LOANS account for the largest share, or 52%, of the Company's consumer finance portfolio based on outstanding net finance receivables at December 31, 1995. In addition, the Company offers secured and unsecured personal loans and purchases retail sales finance contracts from consumer goods retailers. The Company also provides REVOLVING CREDIT through its VISA(R) and MasterCard(R) bankcard and PRIVATE LABEL CREDIT CARD businesses. In addition, the Company sells a variety of credit-related and other specialized insurance products to its consumer finance customers. At December 31, 1995, the Company had approximately 9.4 million individual consumer finance customers spanning a wide range of income levels, age groups and credit histories. The Company markets its consumer finance products through a number of different channels of distribution, including its network of over 1,400 domestic branch offices and 400 international branch offices as well as its centralized lending operations. The Company believes that its domestic branch system is the largest consumer finance branch system in the United States. In Japan, the Company's branch system and net finance receivables have been growing in recent years at rates in excess of the Company's overall rates of growth, and the Company believes that its international markets offer significant opportunities for future growth. The Company believes that its domestic and international branches enable it to attract, service and retain customers through personal relationships with branch employees. COMMERCIAL FINANCE The Company's commercial finance business, which represents $12.1 billion, or 30%, of its 1995 year-end net finance receivables, consists of a variety of retail and WHOLESALE FINANCING and leasing products and services for heavy-duty (Class 8) and medium-duty (Classes 3 through 7) trucks and truck trailers, construction and material handling equipment and other industrial equipment. The Company believes that it is the leading independent source of financing for heavy-duty trucks, truck trailers and heavy construction equipment in the United States. The Company also engages in a number of other commercial activities, including auto fleet leasing and management, small business administration lending, relocation services and auto club and roadside assistance services. In addition, the Company's commercial operations' staff manages its $2.0 billion portfolio of MANUFACTURED HOUSING receivables (which for financial reporting purposes are treated as consumer receivables). The Company also sells a variety of credit-related and other specialized insurance products to its commercial finance customers. At December 31, 1995, the Company had approximately 143,000 commercial finance customers ranging from large corporate customers to small, individually-owned businesses. The Company provides truck and truck trailer financing and leasing services from 39 branch offices in the United States and Canada, and provides equipment financing and leasing services through 19 branch offices in the United States, Mexico and the United Kingdom and, in the case of material handling and certain other equipment, from two centralized lending and service operations. Manufactured housing financing is provided from five regional offices and 14 sales purchase offices, and fee-based services are provided from centralized locations. STRATEGY The Company believes that its consistent growth in profits has resulted from the balanced pursuit of asset and revenue growth and risk and expense control. The Company believes that the following operating disciplines have been key to its success: (i) focusing employees on growth and profitability through incentives, (ii) maintaining strict credit underwriting standards and collection policies to reduce losses, (iii) controlling operating expenses and (iv) sourcing funds on a cost effective basis. The Company believes that adherence to these disciplines has created a receivables portfolio that is diversified by market, geography, customer, maturity and product. As a result, the Company believes that it has been able to reduce its exposure to adverse economic developments in any particular market or region. The Company's business objective is to continue to achieve consistent profitable growth based upon the foregoing operating disciplines, regardless of economic conditions and interest rate environments. The Company seeks to achieve this goal by (i) expanding its existing businesses by developing new product lines in its core businesses and expanding its flexible delivery systems, (ii) identifying and entering new markets with strong profit potential, (iii) providing superior customer service through building long-term relationships and maintaining an intimate knowledge of its business segments, (iv) employing proven technology to reduce costs and enhance product delivery and portfolio management and (v) pursuing selective acquisitions designed to leverage operating costs, increase market share, introduce new product lines and fuel growth. The Company believes that its strong, experienced management team has developed a disciplined operating philosophy and has defined and implemented a distinct business strategy in each of the Company's diverse business units. Management believes that employees' commitment to a distinct culture and set of core values distinguishes the Company from its competitors. The Company seeks to reinforce its culture and core values to all employees through extensive training, incentive programs and operating controls at every level. The Company believes that maintaining its distinct culture, core values and strong management at every level will continue to be a key element of the Company's future strategy. THE OFFERINGS Class A Common Stock Offered(1): United States Offering........ 51,000,000 shares International Offering........ 9,000,000 shares Total................. 60,000,000 shares Common Stock Outstanding After the Offerings(1)(2): Class A Common Stock.......... 85,883,019 shares Class B Common Stock.......... 253,601,830 shares Total................. 339,484,849 shares Use of Proceeds................. The net proceeds to the Company from the offering made hereby in the United States (the "U.S. Offering") and the concurrent international offering (the "International Offering" and, together with the U.S. Offering, the "Offerings"), are estimated to be $1.51 billion ($1.74 billion if the Underwriters' over-allotment options are exercised in full), all of which is expected to be used to reduce short-term indebtedness of the Company. See "Use of Proceeds". New York Stock Exchange Symbol for Class A Common Stock...... AFS Dividends; Voting Rights; Conversion.................... The holders of CLASS A COMMON STOCK and CLASS B COMMON STOCK (collectively, "Common Stock") share ratably on a per share basis in all dividends and other distributions declared by the board of directors; however, the holders of Class A Common Stock are entitled to one vote per share and holders of Class B Common Stock are entitled to five votes per share. See "Description of Capital Stock -- Common Stock -- Voting Rights". Under certain circumstances, shares of Class B Common Stock convert or are convertible into an equivalent number of shares of Class A Common Stock. See "-- Relationship with Ford" and "Description of Capital Stock -- Common Stock -- Conversion". Controlling Stockholder......... For information regarding the Company's controlling stockholder, see "-- Relationship with Ford" below.
- --------------- (1) Excludes up to 7,650,000 shares and 1,350,000 shares subject to over-allotment options granted by the Company to the U.S. Underwriters and the International Underwriters, respectively. See "Underwriting". (2) Excludes 204,200 shares of Class A Common Stock reserved for issuance pursuant to certain employee benefit plans. See "Management -- Additional Material Employee Compensation Plans and Agreements -- Long-Term Equity Compensation Plan". DIVIDEND POLICY The Company's board of directors currently intends to declare quarterly dividends on both the Class A Common Stock and Class B Common Stock. It is expected that the first quarterly dividend payment will be $0.10 per share (a rate of $0.40 annually), with the initial dividend to be declared and paid in the third quarter of 1996. The declaration and payment of dividends by the Company are subject to the discretion of its board of directors. Any determination as to the payment of dividends will depend upon, among other things, general business conditions, the Company's financial results, contractual, legal and regulatory restrictions regarding the payment of dividends by the Company's subsidiaries, the credit ratings of the Company and ACONA and such other factors as the board of directors may consider to be relevant. See "Risk Factors -- Limitations Upon Liquidity and Capital Raising -- Limitations upon the payment of dividends" and "-- Holding Company Structure". The Company paid cash dividends to Ford of $226.0 million, $288.1 million and $318.0 million during the years ended December 31, 1993, 1994 and 1995, respectively. The Company paid a dividend of $1.75 billion to its immediate parent, Ford FSG, Inc., an indirect, wholly-owned subsidiary of Ford ("FFSG"), on February 8, 1996 in the form of an intercompany note (which the Company paid on April 2, 1996), and also paid a cash dividend of $100.0 million to FFSG on March 29, 1996. In 1993, 1994 and 1995, Ford made cash capital contributions to the Company of $200.0 million, $215.1 million and $200.0 million, respectively. Thus, the dividends historically paid by the Company are not indicative of its future dividend policy. RELATIONSHIP WITH FORD The Company is an indirect, wholly-owned subsidiary of Ford. Upon completion of the Offerings, Ford will beneficially own 30.1% of the outstanding Class A Common Stock (27.3% if the Underwriters' over-allotment options are exercised in full) and 100% of the outstanding Class B Common Stock. Accordingly, Ford will beneficially own Common Stock representing in the aggregate 95.6% of the combined voting power of all of the outstanding Common Stock (94.9% if the Underwriters' over-allotment options are exercised in full) and will continue to have the ability to direct the election of members of the board of directors of the Company and exercise a controlling influence over the business and affairs of the Company. Ford has advised the Company that its current intent is to continue to hold all of the Common Stock beneficially owned by it following the Offerings. However, Ford is not subject to any contractual obligation to retain its controlling interest, except that Ford has agreed not to sell or otherwise dispose of any shares of Common Stock of the Company for a period of 180 days after the date of this Prospectus without the prior written consent of Goldman, Sachs & Co. See "Underwriting". As a result, there can be no assurance concerning the period of time during which Ford will maintain its beneficial ownership of Common Stock owned by it following the Offerings. See "Risk Factors -- Control by and Relationship with Ford", "-- Possible Future Sales of Common Stock by Ford" and "Relationship with Ford". From time to time the Company and Ford have entered into, and can be expected to continue to enter into, certain agreements and business transactions in the ordinary course of their respective businesses, and the Company's Restated Certificate of Incorporation includes certain provisions relating to the Company's relationship with Ford. See "Relationship with Ford" and "Description of Capital Stock -- Certain Certificate of Incorporation and By-law Provisions -- Corporate Opportunities". The Company was acquired by Ford and became part of its Financial Services Group in 1989. In connection with this acquisition, the Company's operations in Japan, the United Kingdom, Canada and Puerto Rico were transferred to certain non-U.S. subsidiaries of Ford, but the Company continued to manage such operations. Prior to completion of the Offerings, Ford is expected to recontribute the operations of Ford's non-U.S. subsidiaries managed by the Company (principally subsidiaries in Japan, the United Kingdom, Canada, Puerto Rico and Mexico, the "Foreign Subsidiaries"). In connection with this transaction, Ford will receive an estimated 25,883,019 shares of Class A Common Stock and an estimated 28,113,208 shares of Class B Common Stock (assuming an initial public offering price of $26.50 per share, the mid-point of the range set forth on the cover page of this Prospectus). These share amounts have been used in determining the number of shares of Class A Common Stock and Class B Common Stock to be outstanding upon completion of the Offerings and the percentages of economic and voting interests in the Company to be held by Ford and the other holders of the Class A Common Stock upon completion of the Offerings. The number of shares of Class A Common Stock and Class B Common Stock to be received by Ford in connection with the contribution of the Foreign Subsidiaries will be determined by dividing the aggregate fair market value of such subsidiaries by the initial public offering price per share of Class A Common Stock. The Foreign Subsidiaries had aggregate total assets at December 31, 1995 of $4.1 billion, and the financial and other information with respect to the Foreign Subsidiaries have been retroactively included in the financial and other information of the Company contained herein. See "The Company". SUMMARY SUPPLEMENTAL COMBINED FINANCIAL DATA The summary supplemental combined financial data of the Company presented below presents financial information of the Company giving supplemental combined effect to the expected recontribution by Ford to the Company of the Foreign Subsidiaries. See "The Company". The summary supplemental combined results of operations and balance sheet data presented below as of December 31, 1995 and 1994 and for each of the years in the three-year period ended December 31, 1995 was derived from the supplemental combined financial statements of the Company and the notes thereto set forth herein. The summary supplemental combined results of operations and balance sheet data presented below as of December 31, 1993, 1992 and 1991 and for each of the years in the two-year period ended December 31, 1992 was derived from supplemental combined financial statements and the related notes thereto not presented herein. The data presented below should be read in conjunction with the supplemental combined financial statements and the related notes thereto set forth herein (dollars in millions, except per share data): YEAR ENDED OR AT DECEMBER 31 --------------------------------------------------------------- 1995 1994 1993 1992 1991 --------- --------- --------- --------- --------- RESULTS OF OPERATIONS Total revenue....................................... $ 6,107.2 $ 4,925.8 $ 4,114.8 $ 3,696.2 $ 3,495.8 Finance charge revenue.............................. 5,560.8 4,445.2 3,709.7 3,330.7 3,117.9 Interest expense.................................... 2,177.9 1,657.3 1,421.7 1,352.1 1,452.8 Net interest margin................................. 3,382.9 2,787.9 2,288.0 1,978.6 1,665.1 Operating expenses.................................. 1,754.7 1,456.1 1,216.8 1,007.2 911.7 Provision for losses................................ 834.0 647.1 536.1 568.6 494.3 Insurance benefits paid............................. 142.5 147.9 118.9 103.7 99.9 Earnings before provision for income taxes and cumulative effect of changes in accounting principles........................................ 1,198.1 1,017.4 821.3 664.6 537.1 Provision for income taxes.......................... 475.0 414.1 327.3 254.5 225.2 Net earnings(1)..................................... 723.1 603.3 494.0 410.1 311.9 Pro forma net earnings per share(2)(3).............. 2.13 BALANCE SHEET DATA Net finance receivables: Consumer.......................................... 27,575.3 23,627.8 19,912.4 17,412.7 15,275.9 Commercial........................................ 12,127.2 10,057.9 8,382.3 6,958.3 6,396.9 --------- --------- --------- --------- --------- Total............................................. 39,702.5 33,685.7 28,294.7 24,371.0 21,672.8 ========= ========= ========= ========= ========= Allowance for losses................................ (1,268.6) (1,061.6) (892.3) (764.7) (649.7) Total assets........................................ 41,303.9 35,283.5 30,039.6 25,996.3 23,523.5 Short-term debt (notes payable)..................... 13,747.3 12,431.9 10,385.9 9,086.4 8,632.4 Long-term debt(4)................................... 21,372.6 17,306.2 14,826.8 12,846.5 11,022.3 Stockholder's equity................................ 4,801.1 4,436.8 3,774.3 3,231.1 3,061.0 Pro forma stockholder's equity per share(2)(3)...... 14.14 SELECTED DATA AND RATIOS Net interest margin as a percentage of average net finance receivables............................... 9.22% 9.00% 8.69% 8.59% 8.25% Earnings to fixed charges........................... 1.55x 1.61x 1.57x 1.49x 1.37x Total debt to equity................................ 7.2:1 6.6:1 6.6:1 6.7:1 6.4:1 Total debt to tangible equity....................... 9.9:1 9.6:1 10.1:1 11.1:1 11.2:1 Return on average assets(1)......................... 1.89% 1.85% 1.76% 1.66% 1.40% Return on average equity(1)......................... 15.66 14.70 14.10 13.04 12.49 Return on average tangible equity(1)................ 21.90 21.71 22.31 22.15 24.59 60+days contractual delinquency..................... 1.71 1.35 1.43 1.85 2.56 Net credit losses to average net finance receivables....................................... 1.70 1.64 1.68 2.04 2.17 Allowance for losses to net finance receivables..... 3.20 3.15 3.15 3.14 3.00 Allowance for losses to net credit losses........... 2.03x 2.09x 2.02x 1.63x 1.49x Number of employees................................. 16,647 15,318 13,933 12,430 11,142 Number of consumer and commercial branch offices Domestic.......................................... 1,543 1,472 1,378 1,133 892 International..................................... 404 329 278 256 240 Total............................................. 1,947 1,801 1,656 1,389 1,132
- --------------- (1) In 1991, certain debt related to Ford's acquisition of the Company's operation in Japan was converted to equity, and 1991 results therefore include $39.2 million of non-recurring interest expense related to the converted debt. If 1991 results treated the converted debt as equity and excluded the related non-recurring interest expense consistent with subsequent years, net earnings would have been $351.1 million and the return on average assets, average equity and average tangible equity would have been 1.58%, 12.29% and 21.56%, respectively. (2) Based on 339,484,849 shares to be outstanding after the Offerings. Excludes up to 7,650,000 shares and 1,350,000 shares subject to over-allotment options granted by the Company to the U.S. Underwriters and the International Underwriters, respectively. See "Underwriting". If such options are exercised in full, pro forma net earnings per share and pro forma stockholder's equity per share would be $2.08 and $13.78, respectively. (3) Due to the change in the Company's capital structure, historical share and per share data will not be comparable to, or meaningful in the context of, future periods. See "Capitalization".
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000011913_beverly_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000011913_beverly_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..9e87ff718621be5d95ddd513dbc4f2bf06146be8
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000011913_beverly_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND CONSOLIDATED FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. UNLESS OTHERWISE INDICATED, THE INFORMATION CONTAINED IN THIS PROSPECTUS (I) ASSUMES THE REINCORPORATION OF BEVERLY BANCORPORATION, INC., AN ILLINOIS CORPORATION ("BEVERLY ILLINOIS"), AS A DELAWARE CORPORATION, WHICH TOOK PLACE ON AUGUST 16, 1996 (THE "REINCORPORATION"), (II) GIVES EFFECT TO THE ISSUANCE OF FIVE SHARES OF COMMON STOCK OF THE COMPANY FOR EACH SHARE OF COMMON STOCK OF BEVERLY ILLINOIS IN CONNECTION WITH THE REINCORPORATION AND ALL STOCK DIVIDENDS PAID THROUGH THE DATE HEREOF, AND (III) ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION. PROSPECTIVE INVESTORS SHOULD CAREFULLY CONSIDER THE MATTERS SET FORTH IN "RISK FACTORS." THE COMPANY Beverly Bancorporation, Inc. (the "Company") is a community-based financial services holding company headquartered in Chicago, Illinois. Through its subsidiaries, the Company provides a full range of banking services and also provides personal and corporate trust services. The Company's principal operating subsidiaries are Beverly Bank, Beverly Bank Matteson, First National Bank of Wilmington ("Wilmington") and Beverly Bank Lockport (collectively, the "Banks"), and Beverly Trust Company ("Beverly Trust"). The Banks are chartered as Illinois state banks, with the exception of Wilmington, which was federally chartered in 1863 and is the second oldest active national bank in Illinois. The Banks are community-oriented, full-service commercial banks, providing a full range of banking services to individuals, small-to-medium-sized businesses, and not-for-profit organizations. The Banks operate out of 12 full-service locations in the south and southwest parts of the Chicago metropolitan area, a business development office located in downtown Chicago and a mortgage origination office located in Naperville, Illinois. Through Wilmington, the Company also operates a full-service insurance agency and a residential mortgage brokerage business and offers a broad range of annuities and mutual funds through a relationship with a securities firm. Beverly Trust provides a wide array of trust services for individuals and corporations. As of June 30, 1996, Beverly Trust managed $277.1 million in assets, primarily in the areas of personal living trusts and corporate employee benefit plans, and administered more than 3,000 land trusts. As of December 31, 1995, the Company's total assets were $591.2 million and net income for the year ended December 31, 1995 was $6.2 million, with a return on average assets of 1.09% and a return on average equity of 13.37% for the year then ended. As of June 30, 1996, the Company's total assets had grown to $614.6 million, with net income of $3.0 million for the six months then ended, an increase in net income of 5.4% from the six months ended June 30, 1995. The Company's strategy is to continue to increase its core banking business through its commercial community banking presence and its retail product sales and distribution system. The Company will also pursue an increased market share in personal and corporate trust services and intends to further develop its securities sales and insurance activities. Where opportunities arise, the Company may seek to augment its internal growth through the establishment of additional branches and offices, as well as acquisitions or joint ventures in both banking and non-banking areas. In 1996, Wilmington formed a joint venture, currently in its initial stages, with a prominent realtor for the purpose of increasing its mortgage origination business. The Company was incorporated in Delaware on June 13, 1996 as a wholly-owned subsidiary of Beverly Bancorporation, Inc., an Illinois corporation ("Beverly Illinois"). Beverly Illinois was organized in 1969 and prior to the Reincorporation owned all of the outstanding capital stock of the Banks and Beverly Trust. Pursuant to the Reincorporation, which took place on August 16, 1996, Beverly Illinois was merged with and into the Company and the Company is the surviving corporation. As a result of the Reincorporation, the Company owns all of the outstanding capital stock of the Banks and Beverly Trust. In connection with the Reincorporation, each outstanding share of common stock of Beverly Illinois was converted into five shares of Common Stock of the Company. The Company intends to merge Beverly Bank, Beverly Bank Matteson and Beverly Bank Lockport with and into Wilmington by year-end 1996. Pursuant to the merger, Wilmington will be renamed Beverly National Bank and will remain a nationally chartered bank. The anticipated result of the merger, assuming all regulatory approvals are received, will be to consolidate the operations of the Banks and to reduce the administrative costs under which the Banks presently operate. The Company's principal executive offices are located at 1357 West 103rd Street, Chicago, Illinois 60643, and its telephone number is (312) 881-2214. Except where the context otherwise requires, when used herein the term "Company" refers to Beverly Bancorporation, Inc., a Delaware corporation, its predecessor and its subsidiaries. THE OFFERING Common Stock offered.............. 1,000,000 shares Common Stock to be outstanding after the offering (1)........... 4,974,942 shares Nasdaq symbol..................... BEVB Use of Proceeds................... The Company will use a portion of the net proceeds from the sale of shares of Common Stock offered hereby to repay outstanding short-term borrowings of $9.0 million. The remaining net proceeds will be used for general corporate purposes including, if and when opportunities arise, establishing additional branches and offices and acquiring businesses complementary to those of the Company. See "Use of Proceeds."
- ------------------------ (1) Based on the number of shares of Common Stock outstanding as of June 30, 1996 and excluding 7,159 shares of Common Stock issued on July 15, 1996 pursuant to the reinvestment of dividends and the payment of directors' fees and 1,100 shares of Common Stock issued on July 23, 1996 pursuant to the exercise of options. In addition, as of June 30, 1996, 532,945 shares of Common Stock were reserved for issuance under the Company's stock option plan pursuant to which options to purchase 418,040 shares of Common Stock were outstanding, 146,610 of which were exercisable. SUMMARY CONSOLIDATED FINANCIAL DATA SIX MONTHS ENDED JUNE 30, (1) YEAR ENDED DECEMBER 31, -------------------- ----------------------------------------------------- 1996 1995 1995 1994 1993 1992 1991 --------- --------- --------- --------- --------- --------- --------- (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF INCOME DATA: Total interest income................... $ 20,778 $ 19,512 $ 39,970 $ 35,206 $ 33,468 $ 36,583 $ 42,328 Total interest expense.................. 9,649 8,335 17,184 12,949 12,805 15,256 20,858 --------- --------- --------- --------- --------- --------- --------- Net interest income..................... 11,129 11,177 22,786 22,257 20,663 21,327 21,470 Provision for loan losses............... 75 103 159 311 1,299 3,577 2,923 Other income............................ 4,149 3,762 7,870 8,017 9,820 11,300 9,048 Operating expenses...................... 10,879 10,727 21,416 20,875 22,169 23,127 22,513 Income tax expense...................... 1,317 1,257 2,877 2,672 2,143 1,519 1,036 Cumulative effect of change in accounting principle................... -- -- -- -- 374 -- -- --------- --------- --------- --------- --------- --------- --------- Net income.............................. $ 3,007 $ 2,852 $ 6,204 $ 6,416 $ 5,246 $ 4,404 $ 4,046 --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- PER SHARE DATA (2): Income before cumulative effect of change in accounting principle......... $ .74 $ .58 $ 1.26 $ 1.34 $ 1.05 $ .96 $ .89 Net income.............................. .74 .58 1.26 1.34 1.13 .96 .89 Cash dividends declared................. .10 .10 .19 .18 .17 .17 .12 Book value at end of period............. 10.19 9.87 10.35 8.44 8.58 7.72 6.94 Net tangible book value at end of period................................. 9.92 9.57 10.02 8.11 8.14 7.18 6.29 Stock dividends declared................ 5.00% 5.00% 5.00% 5.00% 5.00% -- -- SELECTED FINANCIAL RATIOS: Return on average assets................ 1.00% 1.02% 1.09% 1.20% 1.03% .90% .85% Return on average equity................ 14.58 13.03 13.37 16.10 13.33 12.61 12.95 Dividend payout ratio (dividends declared per share to net income per share)................................. 13.51 17.24 15.08 13.43 15.04 17.71 13.48 Average equity to average assets........ 6.86 7.84 8.17 7.47 7.72 7.17 6.53 Net interest margin (tax equivalent).... 4.18 4.49 4.49 4.66 4.52 5.05 5.27 Allowance for loan losses to total loans at end of period....................... 1.21 1.24 1.13 1.37 1.51 1.79 1.51 Non-performing loans to total loans at end of period.......................... .55 .57 .57 .82 1.05 1.76 2.70 Net loans charged off (recoveries) to average loans.......................... (.11) .06 .21 .13 .70 1.23 2.02
JUNE 30, DECEMBER 31, -------------------- ----------------------------------------------------- 1996 1995 1995 1994 1993 1992 1991 --------- --------- --------- --------- --------- --------- --------- (IN THOUSANDS) SELECTED BALANCE SHEET DATA: Total assets..................... $ 614,569 $ 567,312 $ 591,203 $ 561,339 $ 519,635 $ 510,642 $ 467,287 Total earning assets............. 566,425 524,183 539,842 505,307 477,196 462,549 422,185 Loans............................ 324,573 314,572 312,160 291,042 267,517 251,062 279,511 Total deposits................... 553,792 507,946 527,131 504,445 459,132 454,917 418,134 Short-term borrowings............ 14,770 7,678 17,292 11,414 13,346 15,795 12,884 Long-term obligations............ 596 -- -- -- -- -- -- Total stockholders' equity....... 40,587 47,951 40,961 40,808 40,055 35,253 31,266 Net tangible book value.......... 39,426 46,510 39,660 39,202 38,017 32,784 28,365
- ------------------------------ (1) Ratios for interim periods are stated on an annualized basis. However, interim operating results and ratios for the six months ended June 30, 1996 are not necessarily indicative of results that may be experienced for the full year. (2) All per share amounts have been adjusted to give effect to the issuance of five shares of Common Stock of the Company for each share of common stock of Beverly Illinois in connection with the Reincorporation and all stock dividends paid through the date hereof.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000014637_bns_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000014637_bns_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..c085c2542b1d3d81389b0f6dc77fb9997dec4927
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000014637_bns_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by reference to the more detailed information and the Consolidated Financial Statements and Notes thereto appearing elsewhere in this Prospectus. As used in this Prospectus, the terms "Brown & Sharpe" and the "Company" refer to Brown & Sharpe Manufacturing Company and its subsidiaries. Except as otherwise noted, all information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. See "Underwriting." THE COMPANY Brown & Sharpe, which was founded in 1833, is a leading designer, manufacturer and marketer of metrology products worldwide under numerous internationally recognized brand names. Metrology is the science of the physical measurement of objects using various precision instruments and equipment. The Company's high precision products measure physical dimensions of, and inspect and verify conformance to specifications of, components and products and are used in manufacturing, quality control and product development operations. The Company's product line ranges from hand tools and instruments to customized computer-controlled metrology systems which integrate hardware and software and are augmented by service, training and aftermarket support. The Company markets its metrology products and services in North America, Europe, Asia, South America and the Middle East. Important end user markets for the Company's products include the automotive, aerospace, industrial machinery, electronics and computer industries, and the Company's customers include Ford Motor Co., Daimler Benz, Toyota, Chrysler, BMW, Boeing Co., Eastman Kodak Co. Inc., International Business Machines Corp., Hewlett-Packard Co., General Electric Co., Caterpillar Inc., United Technologies Corp., Motorola Inc., Phillips, Samsung and Xerox Corp. For the twelve months ended June 30, 1996, the Company recorded net sales of $335.8 million, approximately two-thirds of which were sales to customers located outside of the United States. Manufacturers depend upon metrology hardware and software products to monitor consistent product conformance to their exacting specifications, thereby improving the reliability, fit and finish of their products. In addition to these quality and performance benefits, metrology products help manufacturers lower costs by reducing errors, scrap, rework and warranty expense, improving the manufacturing process, lowering throughput time, increasing capacity and reducing work-in-progress inventories. In recent years, manufacturers have accelerated the integration of quality control functions directly into the production process by incorporating the use of metrology products on the factory floor. In addition, manufacturers are demanding more precise, capable and flexible metrology systems as their products become smaller, more complex and/or must meet more stringent quality and safety standards. Their exacting product specifications often require measurement to an accuracy of less than one micron (one millionth of a meter or approximately 1/100th of the thickness of a human hair) or, in some special cases, measurement of nanometers (one billionth of a meter or the unit of measurement for the wavelength of light). Increasingly, metrology systems must incorporate a mix of traditional contact and newer non-contact technologies because of reduced part sizes and the diversity of new materials used in manufactured products. Metrology systems are purchased by customers regardless of their need for additional production capacity because of ever-increasing quality requirements and the need to reduce product costs. The price points of metrology products range from $100 for a caliper to over $1.5 million for a sophisticated coordinate measuring machine ("CMM") system. The Company's operations are conducted through three management units: Measuring Systems, Precision Measuring Instruments and Custom Metrology. The Measuring Systems Group (the "MS Group"), which accounted for approximately 67% of the Company's net sales in 1995, manufactures and markets a wide range of manual and computer-controlled, high precision CMMs including "in-process" measuring systems under the Brown & Sharpe, DEA and Leitz brand names. The Company believes it is the worldwide market leader for CMMs as measured by net sales and installed base. The Company believes it has an installed base of over 18,000 CMMs worldwide, creating a significant opportunity for aftermarket sales and services. The Precision Measuring Instruments Division (the "PMI Division"), which accounted for approximately 30% of the Company's net sales in 1995, manufactures a wide range of mechanical and electronic measuring and inspection tools (including height gauges, calipers, dial indicators, micrometers and gauge blocks) which are marketed under the Brown & Sharpe, Tesa, Etalon, Interapid, Standard Gage, Select Gauge, Mauser, Mercer and Roch brand names through more than 450 distributors and catalog houses worldwide. The Custom Metrology Division (the "CM Division") designs and engineers, under the Tesa brand name, specialty products and systems that provide customized solutions for unique measurement or inspection problems primarily utilizing non-contact technology. Technologies and custom applications developed by the CM Division with customer funding have been directly applied to the design of standard products or systems distributed by the MS Group or the PMI Division. REPOSITIONING INITIATIVES Over the past several years, the Company has undertaken a series of divestitures, acquisitions and other strategic initiatives which have repositioned the Company from its historical origins as a machine tool manufacturer into a leader in the field of metrology. These repositioning initiatives included: . Divestiture of Non-Core Operations. The divestiture of non-strategic operations including the machine tool, pump and hydraulics businesses enabled the Company to focus on its core metrology technologies and market distribution strengths. . Strategic Metrology Acquisitions. Strategic metrology acquisitions enabled the Company to increase greatly the breadth of its metrology product offering and the strength of its distribution system. These acquisitions included the 1994 acquisitions of DEA S.p.A. ("DEA"), the Italy-based metrology business of Finmeccanica S.p.A. ("Finmeccanica"), Ets. Pierre Roch S.A. and its German affiliate, Mauser Prazisions- Messmittel GmbH ("Mauser") (together, "Roch") and certain intellectual property and assets of Metronic Engineering Limited ("Metronic Ltd."). . Rationalization and Consolidation of Operations. Lowering the Company's overhead cost structure by reducing duplicative functions and associated headcount and by consolidating and rationalizing the Company's manufacturing facilities and operations enabled the Company to increase productivity and efficiency. As a result of these repositioning initiatives, the Company's net sales increased from $162.5 million in fiscal 1992 to $328.0 million in fiscal 1995, while its gross profit margin increased from 28.5% to 32.4% and selling, general and administrative expenses, excluding foreign currency transaction gains and losses, as a percentage of net sales decreased from 34.0% to 29.1% during the same period. See "Selected Consolidated Financial Data." NEW LEADERSHIP AND BUSINESS STRATEGY Following completion of the Company's repositioning initiatives, the Company sought to recruit new management leadership to enhance the Company's leading market positions, improve its global competitiveness and continue to improve its financial performance. To that end, the Company recruited Frank T. Curtin as its new President and Chief Executive Officer in May 1995, who then restructured the senior management team and recruited additional senior managers for key management roles. The current ten-member senior management team has over 296 years of combined experience in highly competitive industrial businesses and global manufacturing organizations. This team is focused on enhancing the financial performance of the Company, motivated in part by an equity-based incentive compensation system, and has made significant progress in realigning the structure and culture of the Company towards a more focused and integrated metrology business. As a result of the repositioning of the Company and the focus of the current management team on enhancing financial performance, the Company has achieved positive net income in each of its fiscal quarters since Mr. Curtin joined the Company. In addition, management believes that its focus on cost reduction during Mr. Curtin's tenure has resulted in a decrease in selling, general and administrative expenses, excluding foreign currency transaction gains or losses, as a percentage of net sales from 30.7% in the first half of 1995 to 26.7% in the first half of 1996. See "Selected Consolidated Financial Data." The Company is implementing its strategy based on the following elements: . Continue Cost Improvements. The Company intends to continue to implement measures designed to reduce its product costs through: (i) standardizing product designs worldwide; (ii) increasing the cost-effectiveness of product designs; (iii) outsourcing components and products; (iv) increasing supplier partnering; and (v) focusing on core manufacturing processes. The Company also intends to streamline its sales, marketing and general and administrative processes in an effort to reduce selling, general and administrative expenses as a percentage of sales. . Develop New Products and End User Markets. The Company's goal is to increase net sales by expanding penetration of served industrial end user markets and by capitalizing on high growth end user markets such as the electronics, computer and medical industries where metrology needs are growing rapidly. To expand in these high growth industries, the Company intends to focus on development of software and emerging non- contact metrology technologies through continued internal development and through strategic acquisitions and technical partnerships (such as the acquisition of certain intellectual property and assets of Metronic Ltd. and the Automation Software Incorporated joint venture, of which the Company owns 50% of the voting securities ("ASI")). To expand its penetration of served industrial end user markets, the Company expects to continue the introduction of new metrology systems utilizing both contact and non-contact technologies, and to develop sensors and other sophisticated products that can be imbedded in a variety of manufacturing processes. The Company plans to form technical and commercial alliances with manufacturers of process equipment to provide enhanced combined manufacturing systems utilizing the Company's sensors and other products. . Enhance Existing and Develop New Software. The Company intends to emphasize research and development of software systems and applications designed to meet the evolving metrology needs of its end users. To that end, the Company intends to leverage off its software development team of approximately 320 software and applications engineers and technicians (including 50 engineers of ASI) in the following four areas: (i) metrology software for inspection and verification of piece-part integrity and conformance to design specifications; (ii) process control software designed to detect and correct drifts in part tolerances before the manufacturing process produces scrap or improperly configured components; (iii) enhanced management information systems that report statistical and quality information from the manufacturing process; and (iv) new software that will link the Company's CMMs and, therefore, the manufacturing process with computer-aided engineering and manufacturing systems that will provide the means for real-time feedback, analysis and, ultimately, control of manufacturing to design specifications. The Company believes that its existing library of metrology software, together with newly developed software, should enable it to respond to the growing demand in manufacturing for on-line inspection and verification. The Company also believes that its experience with CMM software and manufacturing processes are critical to the successful development of software that is linked with computer-aided engineering systems. . Leverage Worldwide Distribution Capability. Through the acquisitions of DEA and Roch, Brown & Sharpe expanded its product lines and strengthened its marketing and distribution capabilities in Europe, South America, the Middle East, India and China. The Company plans to continue to strengthen and expand its worldwide distribution capability, principally by continuing to rationalize its existing distribution network and by opening new demonstration centers and adding direct sales capacity and distributors where cost effective. The Company also intends to capitalize on the strength of its global distribution network by increasing the number of Company-designed and third-party sourced products sold through its distribution channels in an effort to increase gross profit without a corresponding increase in selling, general and administrative expenses. . Increase Aftermarket Sales and Services. The Company intends to increase its focus on higher margin aftermarket sales and services, including calibration and rebuilding of CMMs, software upgrades and parts sales. The Company believes that the worldwide installed base of CMMs, estimated at over 60,000 (including 18,000 of the Company's CMMs), creates a significant demand for such aftermarket services. The Company believes that the level of customer service it provides, as measured by third-party surveys of its customers, is superior to that of its principal competitors, and expects to further strengthen its customer relationships through enhanced aftermarket support and increased partnering efforts. The Company's net sales attributable to aftermarket sales and service in 1995 were estimated to be approximately 25% of MS Group net sales for the same period. For a discussion of certain risk factors which the Company may face in implementing this strategy, see "Risk Factors--Achievement of Strategic Plan." The Company was founded in 1833, incorporated in Rhode Island in 1868 and reincorporated in Delaware in 1969. The Company's principal executive offices are located at Precision Park, 200 Frenchtown Road, North Kingstown, Rhode Island, 02852, and its telephone number is (401) 886-2000. THE OFFERING Class A Common Stock offered(1): By the Company........ 4,000,000 shares By the Selling Stockholders......... 3,286,000 shares Total............... 7,286,000 shares Common Stock outstanding after the Offering(2): Class A Common Stock(3)............. 12,199,989 shares Class B Common Stock(3)............. 519,436 shares Total............... 12,719,425 shares Use of proceeds......... Approximately $35.1 million of the net proceeds to the Company from the Offering will be used to repay $31.9 million of outstanding short-term indebtedness and $3.2 million of the current portion of long-term indebtedness. The remaining net proceeds to the Company of $10.5 million will be used for working capital and general corporate purposes. See "Use of Proceeds." New York Stock Exchange Symbol................. BNS
- -------------------- (1) Pursuant to the Rights Plan adopted in 1988, each purchaser of shares of Class A Common Stock offered pursuant to the Offering will receive three quarters of a preferred stock purchase right (the "Rights") for each share of Class A Common Stock purchased. No additional consideration will be payable with respect to the Rights and, prior to the occurrence of specified events, the Rights will not be exercisable or evidenced separately from the Class A Common Stock. See "Description of Capital Stock--Rights Plan." (2) Excludes 864,283 shares of Class A Common Stock reserved for issuance under the 1989 Equity Incentive Plan, the Amended 1973 Stock Option Plan and the Employee Stock Ownership and Profit Participation Plan. See "Management-- Executive Compensation." Excludes 50,000 shares of Class A Common Stock reserved for issuance upon certain specified events under the Stock Purchase and Transfer Agreement dated March 24, 1994 between the Company and Diehl GmbH & Co. See "Certain Transactions." (3) Assumes no conversions of Class B Common Stock into Class A Common Stock after August 31, 1996. SUMMARY CONSOLIDATED FINANCIAL INFORMATION During the periods presented below, the Company has undertaken a number of divestitures and acquisitions, including the 1994 acquisitions of DEA and Roch. Consequently, the summary consolidated financial information set forth in the table below may not be comparable for all periods presented. The following data should be read in conjunction with the Company's Consolidated Financial Statements and the Notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this Prospectus. SIX MONTHS ENDED FISCAL YEAR ENDED DECEMBER (1) JUNE 30, -------------------------------- ---------------------- 1993 1994 1995 1995 1996 (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF OPERATIONS DATA: Net sales............... $ 159,518 $ 209,369 $ 328,031 $ 158,349 $ 166,113 Cost of sales........... 110,841 142,776 221,729 108,174 113,693 Selling, general and administrative expense(2)............. 48,073 68,473 94,902 46,580 45,104 Restructuring charges(3)............. -- 4,169 336 247 -- --------- --------- ---------- ---------- ---------- Operating profit (loss)................. 604 (6,049) 11,064 3,348 7,316 Interest expense........ 5,100 6,575 9,129 3,948 4,553 Other income, net....... 2,880 689 688 390 169 --------- --------- ---------- ---------- ---------- Income (loss) before taxes.................. (1,616) (11,935) 2,623 (210) 2,932 Income tax provision.... 800 2,400 697 200 528 --------- --------- ---------- ---------- ---------- Net income (loss)....... $ (2,416) $ (14,335) $ 1,926 $ (410) $ 2,404 ========= ========= ========== ========== ========== Net income (loss) per share.................. $ (0.49) $ (2.37) $ 0.22 $ (0.05) $ 0.27 ========= ========= ========== ========== ========== Weighted average number of shares outstanding and common stock equivalents............ 4,969,543 6,057,090 8,772,748 8,691,487 8,884,156 OTHER DATA: Gross profit margin(4).. 30.5% 31.8% 32.4% 31.7% 31.6% Selling, general, and administrative expense, excluding foreign currency transaction gains or losses, as a percent of net sales... 30.2% 33.2% 29.1% 30.7% 26.7% Net sales per employee(5)............ $ 104 $ 114 $ 138 NM NM PRO FORMA FINANCIAL DATA(6): Interest expense........ $ 5,733 $ 2,875 $ 2,768 Net income.............. 5,294 759 3,741 Net income per share.... $ 0.41 $ 0.06 $ 0.29 Weighted average number of shares outstanding and common stock equivalents............ 12,773,000 12,692,000 12,884,000
AS OF JUNE 30, 1996 -------------------- AS ACTUAL ADJUSTED(7) BALANCE SHEET DATA: Cash and cash equivalents.................................. $ 4,226 $ 14,686 Working capital............................................ 97,845 143,405 Total assets............................................... 302,652 313,112 Total debt................................................. 106,512 71,412 Total stockholders' equity................................. 84,870 130,430
- -------------------- (1) Fiscal years presented ended December 31, except the Company's 1993 fiscal year which ended on December 25. (2) During fiscal 1994, selling, general and administrative expenses included duplicative costs associated with the DEA and Roch operations which were consolidated during 1994 and 1995. Includes foreign currency transaction gains of $0.2 million, $1.1 million, $0.6 million and $2.0 million in 1993, 1994, 1995 and the first half of 1995, respectively, and $0.7 million of transaction losses in the first half of 1996. (3) Restructuring charges are principally attributable to the payment of employee severance and the closing of sales offices associated with integrating the Company's existing operations with those of DEA and Roch. (4) Data for the first half of the year may not be indicative of data for the full year due to seasonal factors and the frequent impact of product mix variations quarter to quarter. (5) During fiscal 1994, DEA employees have been accounted for by annualizing the number of employees for the period. (6) Pro forma to reflect the sale of the shares of Class A Common Stock offered by the Company hereby, at an assumed public offering price of $12.25 per share, and repayment of all short-term indebtedness and current portions of long-term debt outstanding during the pro forma periods, not exceeding $31.9 million and $3.2 million, respectively, as if such transactions had occurred on the first day of the relevant period. The unaudited pro forma financial information does not purport to be indicative of the financial position or operating results which would have been achieved had the Offering taken place at the dates indicated and should not be construed as representative of the Company's financial position or results of operations for any future period or date. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000018827_ekco_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000018827_ekco_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..e6acb2cf369d8c8ce4258b985554435a9fbd788c
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000018827_ekco_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety and should be read in conjunction with the more detailed information and financial statements, including the notes thereto, included elsewhere in this Prospectus. As used in this Prospectus, unless the context requires otherwise, "Ekco" refers to Ekco Group, Inc. and "Company" refers to Ekco and its subsidiaries. References to "fiscal years" refer to the Company's fiscal years ended on the Sunday closest to December 31 of the referenced year. THE COMPANY The Company is a leading U.S. manufacturer and marketer of multiple categories of branded houseware products for everyday home use. The Company believes it is the leading U.S. supplier of metal bakeware, kitchen tools and gadgets and non-toxic pest control products. In addition, the Company believes it is a leading U.S. supplier of plastic storage products (including crates, containers, baskets and office organizers), cleaning products (primarily brushes, brooms and mops) and small animal care and control products. The Ekco(R) brand ranked eighth in a recent survey of the 300 most widely recognized brand names in home furnishings. The Company markets its products primarily in the U.S. through substantially all distribution channels that sell houseware products for everyday home use, including mass merchandisers, supermarkets, and hardware, drug and specialty stores. The Company has a significant presence among mass merchandisers, selling to each of the 30 largest discount department store chains, and in supermarkets where it occupies space in over 90% of the approximately 38,000 U.S. supermarkets. The Company's sales have increased in each of the last five years as a result of internal growth and acquisitions. The Company's net revenues increased from $166.7 million in Fiscal 1991 to $278.0 million in Fiscal 1995, a compound annual growth rate of 13.6%. The Company's EBITDA (as defined) increased from $31.0 million in Fiscal 1991 to $50.1 million in Fiscal 1995, a compound annual growth rate of 12.7%. The following table summarizes the Company's principal product lines, brand names and net revenues by product category for Fiscal 1995 (in millions): FISCAL 1995 NET PRODUCT CATEGORY PRINCIPAL PRODUCT LINES PRINCIPAL BRAND NAMES REVENUES ---------------- ----------------------- --------------------- -------- Bakeware Non-stick and uncoated cookie Ekco(R), Baker's Secret(R) $ 81.3 sheets, muffin tins, brownie pans and loaf pans Kitchenware Tools including spoons, spatulas, Ekco(R), Ekco Pro(TM) 73.0 serving forks, ladles and specialty cooking accessories Gadgets including peelers, corkscrews, whisks and can and bottle openers Cleaning products Brushes, brooms and mops Ekco(R), Wright-Bernet(TM) 55.2 Pest control and Spring action rodent traps, glue-based Victor(R), Havahart(R) 34.0 small animal care rodent and insect traps and live animal and control traps products Molded plastic Crates, bins, baskets, organizers, carts Ekco(R) 31.0 products and caddies for storage, laundry and the office VIA! Upscale bakeware, kitchen tools and VIA!(TM) 3.5 gadgets, and tea kettles $278.0 ======
- 4 - 7 THE EKCO INTEGRATION Since the fourth quarter of Fiscal 1993, Ekco has taken a series of actions to position the Company for long-term growth (the "Ekco Integration"). The Ekco Integration included (i) the combination of four of the Company's principal business units into a single operating division and (ii) the introduction of a new branding strategy to capitalize on the strength of the Ekco(R) brand name. The Ekco Integration combined the management and operations of the Company's bakeware, kitchenware, cleaning products and molded plastic products businesses, which sell through common channels of distribution and accounted for over 75% of the Company's net revenues in Fiscal 1995. The newly created single organization combines and coordinates the sales, marketing, manufacturing, distribution, administrative and financial activities for the four product categories. The Company also consolidated a large portion of the distribution of bakeware and kitchenware products as well as certain cleaning products into its new distribution facility in Bolingbrook, Illinois from four separate warehousing and distribution locations. These steps have improved customer service, created more effective sales and marketing programs, reduced costs and resulted in distribution efficiencies. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Notes to the Consolidated Financial Statements included elsewhere in this Prospectus. As part of the Ekco Integration, in January 1996 the Company introduced its new branding strategy in which the Ekco(R) brand name is used to market most of the products in these four categories. The new strategy enables the Company to capitalize on the strength of the Ekco(R) brand name by improving the brand identification of these products by consumers and increasing promotional opportunities for retailers. In addition, management believes that the new branding strategy enhances the effectiveness of the Company's newly combined sales and marketing effort by facilitating cross-marketing of the Company's products to retail customers under Ekco(R), one of the strongest brand names in the housewares industry. COMPETITIVE STRENGTHS The Company believes its competitive strengths include: - LEADING MARKET POSITIONS. More than 50% of the Company's sales are from metal bakeware and kitchen tools and gadgets, categories in which the Company believes it is the industry leader. The Company has achieved primary vendor status with many of its retail customers in certain product categories, including bakeware, kitchenware, cleaning products and non-toxic pest control products. - WIDELY RECOGNIZED BRAND NAMES. In 1995, the Ekco(R) brand ranked eighth in Home Furnishing News' survey of the 300 most widely recognized brand names in home furnishings. Ekco(R) and the Company's other brand names, including Baker's Secret(R) bakeware, Wright-Bernet(TM) cleaning products, Victor(R) pest control products and Havahart(R) small animal care and control products, are recognized by consumers and retailers for quality, value, design and functionality. - BROAD MARKET PENETRATION. Management believes that the Company has one of the broadest distribution networks of any company in the housewares industry. The Company has a significant presence in mass merchandisers (including Wal-Mart, Kmart and Target) and supermarkets (including Winn-Dixie, Kroger and Albertson's). - MULTIPLE CATEGORY SUPPLIER. The Company serves as a single source for a wide range of products at a variety of price points in several categories, enabling the Company to be a more efficient and attractive vendor to the retail industry, which is consolidating its supply base. - EFFICIENT DISTRIBUTION SYSTEM. The Company's distribution facilities and processes enable the Company to effectively pick, pack and deliver customer orders from its inventory, resulting in greater on-time deliveries, higher order fill rates, optimal use of full-truckload shipments and short purchase order lead times. - CUSTOMER SERVICE. The Company offers retailers an integrated program of productivity enhancing services which are designed to reduce their operating costs and working capital and to increase their sales volume of the Company's products. - 5 - 8 BUSINESS STRATEGY The Company's business strategy has four primary components: (i) leverage Ekco's brand names, (ii) focus on customer sales and service, (iii) increase market and customer penetration and (iv) pursue growth through acquisitions. - LEVERAGE EKCO'S BRAND NAMES: The Company intends to leverage the Ekco(R) brand name to (i) further increase brand recognition and reputation among both retailers and consumers, (ii) expand sales through cross-marketing of the Company's product lines to existing customers and (iii) become the sole or primary vendor to existing and future customers across multiple product categories. As part of the Ekco Integration, in January 1996 the Company introduced its new branding strategy in which the Ekco(R) brand name is used to market most of the Company's bakeware, kitchenware, cleaning products and molded plastic products. The Company continues to promote its Baker's Secret(R), Wright-Bernet(TM), Victor(R) and Havahart(R) brand names and to enhance them with the Ekco(R)signature. - FOCUS ON CUSTOMER SALES AND SERVICE: The Ekco Integration has enabled the Company to shift the focus of its sales and marketing strategy from individual product categories to the broader needs of each of its customers. Each of the Company's customers now has one Ekco sales person responsible for selling and marketing most of the Company's products. The combined marketing staff now coordinates most of the Company's market research, advertising and other marketing related functions. This coordination augments the Company's efforts to leverage the Ekco(R) brand name, to increase market and customer penetration and to provide superior service to its customers. - INCREASE MARKET AND CUSTOMER PENETRATION: The Company strives to expand its retail space at existing customers and to gain new customers by (i) offering differentiated product lines, (ii) developing new and proprietary products, (iii) cross-marketing existing product lines to existing customers who do not currently purchase such product lines and (iv) cross-merchandising combinations of products from different product categories with a uniform Ekco(R) message. The Company offers products which are differentiated by price, quality, value, color, design, packaging and functionality. The Company strives to be a full-line supplier and to be the first to market with new product introductions to increase sales of each of its product lines. - PURSUE GROWTH THROUGH ACQUISITIONS: The Company's growth has been enhanced by acquisitions. The Company's acquisition strategy is focused on long life-cycle consumer products related to the Company's current product portfolio which can benefit from (i) integration into the Company's existing manufacturing, warehousing and distribution systems, (ii) if appropriate, inclusion under the Ekco(R) brand name and (iii) the Company's broad distribution network. Management believes that there are and will continue to be opportunities to acquire additional consumer product lines and businesses due to, among other things, the large number of consumer product companies and the increased pressure on such companies from retailers to provide greater and more costly levels of service and support. The Company's principal executive offices are located at 98 Spit Brook Road, Nashua, New Hampshire 03062 and its telephone number is (603) 888-1212. THE EXCHANGE OFFER Registration Rights Agreement.............. The Old Senior Notes were sold by the Company on March 25, 1996, to Bear, Stearns & Co. Inc. and Smith Barney Inc. (the "Initial Purchasers"), who placed the Old Senior Notes with institutional investors. In connection therewith, the Company and the Guarantors executed and delivered for the benefit of the Holders of the Old Senior Notes a registration rights agreement (the "Registration Rights Agreement") providing, among other things, for the Exchange Offer. - 6 - 9 The Exchange Offer......................... New Senior Notes are being offered in exchange for a like face amount of Old Senior Notes. As of the date hereof, $125,000,000 aggregate face amount of Old Senior Notes are outstanding. The Company will issue the New Senior Notes to Holders promptly following the Expiration Date. See "Risk Factors - Consequences of Failure to Exchange." Expiration Date............................ 5:00 p.m., New York City time, on August 7, 1996, unless the Exchange Offer is extended, in which case the term "Expiration Date" means the latest date and time to which the Exchange Offer is extended. Accrued Interest on the New Senior Notes and the Old Senior Notes................. Each New Senior Note will bear interest from its issuance date. Holders of Old Senior Notes that are accepted for exchange will receive, in cash, accrued interest thereon to, but not including, the issuance date of the New Senior Notes. Such interest will be paid with the first interest payment on the New Senior Notes. Interest on the Old Senior Notes accepted for exchange will cease to accrue upon issuance of the New Senior Notes. Conditions to the Exchange Offer........... The Exchange Offer is subject to certain customary conditions, which may be waived by the Company. See "The Exchange Offer - Conditions." Procedures for Tendering Old Senior Notes.................................... Each Holder of Old Senior Notes wishing to accept the Exchange Offer must complete, sign and date the Letter of Transmittal, or a facsimile thereof, in accordance with the instructions contained herein and therein, and mail or otherwise deliver such Letter of Transmittal, or such facsimile, together with the Old Senior Notes and any other required documentation to the exchange agent (the "Exchange Agent") at the address set forth herein. By executing the Letter of Transmittal, each Holder will represent to the Company, among other things, that (i) the New Senior Notes acquired pursuant to the Exchange Offer by the Holder and any beneficial owners of Old Senior Notes are being obtained in the ordinary course of business of the person receiving such New Senior Notes, (ii) neither the Holder nor such beneficial owner is participating in, intends to participate in or has an arrangement or understanding with any person to participate in the distribution of such New Senior Notes and (iii) neither the Holder nor such beneficial owner is an "affiliate," as defined under Rule 405 of the Securities Act, of the Company. Each broker-dealer that receives New Senior Notes for its own account in exchange for Old Senior Notes, where such Old Senior Notes were acquired by such broker or dealer as a result of market-making activities or other trading activities (other than Old Senior Notes acquired directly from the Company), may participate in the Exchange Offer but may be deemed an "underwriter" under the Securities Act and, therefore, must acknowledge in the Letter of Transmittal that it will deliver a prospectus in connection with any resale of such New Senior Notes. The Letter of Transmittal states that by so acknowledging and by delivering a prospectus, a broker or dealer will not be deemed to admit that it is an "underwriter" within the meaning of the Securities Act. See "The Exchange Offer - Procedures for Tendering" and "Plan of Description." - 7 - 10 Special Procedures for Beneficial Owners........................ Any beneficial owner whose Old Senior Notes are registered in the name of a broker, dealer, commercial bank, trust company or other nominee and who wishes to tender should contact such registered Holder promptly and instruct such registered Holder to tender on such beneficial owner's behalf. If such beneficial owner wishes to tender on such owner's own behalf, such owner must, prior to completing and executing the Letter of Transmittal and delivering its Old Senior Notes, either make appropriate arrangements to register ownership of the Old Senior Notes in such owner's name or obtain a properly completed bond power from the registered Holder. The transfer of registered ownership may take considerable time. See "The Exchange Offer - Procedures for Tendering." Guaranteed Delivery Procedures............. Holders of Old Senior Notes who wish to tender their Old Senior Notes and whose Old Senior Notes are not immediately available or who cannot deliver their Old Senior Notes, the Letter of Transmittal or any other documents required by the Letter of Transmittal to the Exchange Agent prior to the Expiration Date must tender their Old Senior Notes according to the guaranteed delivery procedures set forth in "The Exchange Offer - Guaranteed Delivery Procedures." Withdrawal Rights.......................... Tenders may be withdrawn at any time prior to 5:00 p.m., New York City time, on the Expiration Date. See "The Exchange Offer - Withdrawal of Tenders." Acceptance of Old Senior Notes and Delivery of New Senior Notes............. The Company will accept for exchange any and all Old Senior Notes which are properly tendered in the Exchange Offer prior to 5:00 p.m., New York City time, on the Expiration Date. The New Senior Notes issued pursuant to the Exchange Offer will be delivered promptly following the Expiration Date. See "The Exchange Offer - Terms of the Exchange Offer." Exchange Agent............................. Fleet National Bank is serving as Exchange Agent in connection with the Exchange Offer. See "The Exchange Offer - Exchange Agent." SUMMARY DESCRIPTION OF THE NEW SENIOR NOTES The Exchange Offer applies to $125,000,000 aggregate face amount of Old Senior Notes. The terms of the New Senior Notes are identical in all material respects to the Old Senior Notes, except that the New Senior Notes have been registered under the Securities Act and, therefore, will not bear legends restricting their transfer and will not contain certain provisions providing for an increase in the interest rate on the Old Senior Notes under certain circumstances relating to the timing of the Exchange Offer, which rights will terminate when the Exchange Offer is consummated. The New Senior Notes will evidence the same debt as the Old Senior Notes and will be entitled to the benefits of the Indenture, under which both the Old Senior Notes were, and the New Senior Notes will be, issued. See "Description of the Notes." The New Senior Notes....................... $125,000,000 principal amount of 9 1/4% New Senior Notes due 2006. Maturity Date.............................. April 1, 2006. Interest Payment Dates..................... April 1 and October 1, commencing October 1, 1996. Guarantees................................. The New Senior Notes will be fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by substantially all of Ekco's existing and future domestic - 8 - 11 subsidiaries (collectively, the "Guarantors"). See "Description of Senior Notes--General." Ranking.................................... The New Senior Notes will be senior unsecured obligations of Ekco and will rank pari passu in right of payment with all existing and future Senior Indebtedness of Ekco and senior in right of payment to all existing and future Subordinated Indebtedness of Ekco. The Guarantees will be senior unsecured obligations of the Guarantors and will rank pari passu in right of payment with all existing and future Senior Indebtedness of the Guarantors and senior in right of payment to all existing and future Subordinated Indebtedness of the Guarantors. The indebtedness under the Revolving Credit Facility is secured by substantially all of the assets of the Company. As a result, the Senior Notes will effectively be subordinated to the Revolving Credit Facility. At March 31, 1996 the Company's only outstanding indebtedness was its $124.1 million of Senior Notes. The Company had no outstanding Subordinated Indebtedness or indebtedness under the Revolving Credit Facility as of such date. Mandatory Redemption....................... None. Optional Redemption........................ The New Senior Notes will be redeemable for cash at the option of Ekco, in whole or in part, on or after April 1, 2001, at the redemption prices set forth herein, together with accrued and unpaid interest and Liquidated Damages, if any, to the redemption date. See "Description of Senior Notes-- Redemption." Change of Control.......................... Upon the occurrence of a Change of Control, each holder of New Senior Notes will have the option to require Ekco to repurchase such holder's New Senior Notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, to the date of repurchase. Ekco's ability to repurchase the New Senior Notes following a Change of Control will be dependent upon it having sufficient cash therefor and the terms of its then outstanding Senior Indebtedness, including the Revolving Credit Facility. See "Description of Senior Notes--Certain Covenants--Repurchase of Senior Notes at the Option of the Holder Upon a Change of Control." Certain Covenants.......................... The indenture under which the New Senior Notes will be issued (the "Indenture") contains certain restrictive covenants that, among other things, limit the ability of Ekco and its Subsidiaries to incur additional Indebtedness (as defined) and issue preferred stock, create liens, pay dividends, repurchase capital stock and make certain other Restricted Payments (as defined), sell assets, engage in transactions with affiliates, enter into sale and leaseback transactions, conduct unrelated lines of business and consummate mergers or consolidations. The term "Subsidiaries" is defined in the Indenture to exclude "Unrestricted Subsidiaries." See "Description of Senior Notes- -Certain Covenants." - 9 - 12 Use of Proceeds............................ The Exchange Offer is intended to satisfy certain of Ekco and the Guarantors' obligations under the Registration Rights Agreement. Ekco will not receive any cash proceeds from the issuance of the New Senior Notes in the Exchange Offer. The net proceeds from the issuance of the Old Senior Notes were used by the Company to (i) repurchase all of the outstanding 12.70% Senior Subordinated Notes due 1998 (the "12.70% Notes") of Ekco Housewares, Inc., (ii) repurchase its outstanding 7.0% Subordinated Convertible Note due 2002 (the "7.0% Note") and (iii) repay amounts outstanding under the Revolving Credit Facility. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000025757_crompton_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000025757_crompton_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..a923c543d2c5bdcbc3cfa80894497809e03e330b
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000025757_crompton_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a summary of certain information contained elsewhere in this Prospectus. This summary is not intended to be complete and is qualified in its entirety by the more detailed information and financial statements appearing elsewhere in this Prospectus. Prospective investors are urged to read and consider carefully all of the information contained in this Prospectus. As used herein, the terms "Crompton" and "the Company" refer to Crompton & Knowles Corporation and its consolidated subsidiaries, unless the context otherwise requires. THE COMPANY Crompton is engaged in the manufacture and sale of specialty chemicals and specialty process equipment and controls which are marketed throughout the world. Crompton's line of specialty value-added chemicals includes textile and industrial dyes and auxiliary chemicals, reaction flavors, specialty sweeteners, food colors and inactive pharmaceutical additives and coatings. Crompton's specialty process equipment and controls business consists primarily of the manufacture and sale of plastics and rubber extrusion equipment and integrated extrusion systems, industrial blow molding equipment and electronic controls. The principal executive offices of Crompton are located at One Station Place, Metro Center, Stamford, Connecticut 06902, and its telephone number is (203) 353-5400. See "The Company." RECENT DEVELOPMENTS Pursuant to an Agreement and Plan of Merger, dated as of April 30, 1996 (the "Merger Agreement"), Crompton has agreed to the merger (the "Merger") of Tiger Merger Corp., a Delaware corporation and a wholly owned subsidiary of Crompton ("Subcorp"), with and into Uniroyal Chemical Corporation, a Delaware corporation ("Uniroyal"), subject to the approval of the transaction by the stockholders of each of Uniroyal and Crompton at special meetings thereof currently scheduled to be held on August 21, 1996. The Board of Directors of Crompton has fixed the close of business on July 9, 1996, as the record date for determination of holders of Crompton Common Stock entitled to notice of and to vote at such meeting of Crompton stockholders. Accordingly, purchasers of the shares of Crompton Common Stock offered hereby will not be entitled to vote such shares at such special meeting. The Merger will be consummated on the terms and subject to the conditions set forth in the Merger Agreement (which was filed by Crompton with the Commission as an exhibit to Crompton's Quarterly Report on Form 10-Q for the quarter ended March 30, 1996), pursuant to which, among other things, (i) Subcorp will be merged with and into Uniroyal as a result of which Uniroyal will become a wholly owned subsidiary of Crompton, (ii) each issued and outstanding share (other than shares, if any, held in the treasury of Uniroyal or held by Crompton or any of its subsidiaries, which will be cancelled) of common stock, $0.01 par value per share (together with the attached preferred stock purchase rights, "Uniroyal Common Stock"), of Uniroyal will be converted into 0.9577 shares of Crompton Common Stock (with cash in lieu of fractional shares), and (iii) each issued and outstanding share (other than shares, if any, held in the treasury of Uniroyal or held by Crompton or any of its subsidiaries, which will be cancelled, and other than shares as to which dissenters' appraisal rights have been perfected) of Series A Cumulative Redeemable Preferred Stock, par value $0.01 per share ("Series A Preferred Stock"), of Uniroyal and of Series B Preferred Stock, par value $0.01 per share ("Series B Preferred Stock," and together with the Series A Preferred Stock, "Uniroyal Preferred Stock"), of Uniroyal will be converted into 6.3850 shares of Crompton Common Stock (with cash in lieu of fractional shares). It is currently anticipated that the Merger will be consummated shortly after the special meetings of Crompton and Uniroyal stockholders, assuming the Merger Agreement and the Merger are approved at such meetings and all other conditions to the Merger have been satisfied or waived. Uniroyal, through its subsidiaries, is a major multinational manufacturer of a wide variety of specialty chemical products, including specialty elastomers, rubber chemicals, crop protection chemicals and additives for the plastics and lubricants industries. Uniroyal produces high value added products which are currently marketed in approximately 120 countries. Crompton does not currently AVAILABLE INFORMATION Crompton is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the "Exchange Act"), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the "Commission"). Such reports, proxy statements and other information filed by Crompton with the Commission can be inspected and copied at the public reference facilities maintained by the Commission at its principal office at 450 Fifth Street, N.W., Room 1024, Washington, D.C. 20549, and at the following Regional Offices of the Commission: New York Regional Office, 7 World Trade Center, 13th Floor, New York, New York 10048, and Chicago Regional Office, Citicorp Center, 500 West Madison, Suite 1400, Chicago, Illinois 60661. Copies of such material can also be obtained from the Public Reference Section of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed rates, or through the World Wide Web (http://www.sec.gov). Crompton Common Stock is listed on the NYSE, and such reports, proxy statements and other information concerning Crompton are available for inspection and copying at the offices of the NYSE, 20 Broad Street, New York, New York 10005. Crompton has filed with the Commission a Registration Statement on Form S-1 under the Securities Act of 1933, as amended (together with the rules and regulations promulgated thereunder, the "Securities Act"), with respect to the shares of Crompton Common Stock to be offered hereby (the "Registration Statement"). This Prospectus does not contain all of the information set forth in the Registration Statement, certain parts of which are omitted in accordance with the rules and regulations of the Commission. Reference is hereby made to the Registration Statement and related exhibits for further information with respect to Crompton and the securities offered hereby. Statements contained herein concerning the provisions of any document are necessarily summaries of such documents and not complete, and in each instance, reference is made to the copy of such document attached hereto or filed as an exhibit to the Registration Statement or otherwise filed with the Commission. Each such statement is qualified in its entirety by such reference. intend to make any material changes to the general operating activities of Uniroyal following consummation of the Merger. The principal executive offices of Uniroyal are located at Benson Road, Middlebury, Connecticut 06749, and its telephone number is (203) 573-2000. Uniroyal is subject to the informational requirements of the Exchange Act, and in accordance therewith files reports, proxy statements and other information with the Commission. Prospective investors are urged to read and consider carefully such reports, proxy statements and other information. Uniroyal Common Stock is quoted on the Nasdaq National Market (the "NASDAQ/NM"). Crompton is effecting the Offering in order for the Merger to qualify as a pooling-of-interests for accounting and financial reporting purposes. See "Recent Developments." THE OFFERING Common Stock offered by Crompton............. 1,000,000 shares Common Stock to be outstanding immediately after the Offering........................... 49,039,309 shares(1) NYSE Symbol.................................. CNK Use of Proceeds.............................. The net proceeds to Crompton from the Offering will be used to partially offset the estimated merger costs discussed elsewhere herein. See "Use of Proceeds." Risk Factors................................. See "Risk Factors."
- ------------ (1) Calculated based on 48,039,309 shares of Common Stock outstanding on July 30, 1996, and not giving effect to the up to approximately 26,089,206 shares of Common Stock expected to be issued in connection with the Merger. SELECTED HISTORICAL AND UNAUDITED PRO FORMA COMBINED FINANCIAL DATA Selected Historical Financial Data The selected financial data presented below for Crompton as of December 31, 1994 and December 30, 1995 and for the years ended December 25, 1993, December 31, 1994 and December 30, 1995, and Uniroyal as of October 2, 1994 and October 1, 1995 and for the three years ended September 30, 1993, October 2, 1994 and October 1, 1995, have been derived from and are qualified in their entirety by, and should be read in conjunction with, the respective audited financial statements and notes thereto contained herein. See "Index to Financial Statements." Crompton's statement of operations data for the years ended December 28, 1991 and December 26, 1992 and the balance sheet data as of December 28, 1991, December 26, 1992 and December 25, 1993 are derived from audited Crompton consolidated financial statements that are neither included nor incorporated by reference herein. Uniroyal's statement of operations data for the fiscal years ended September 30, 1991 and 1992 and the balance sheet data as of September 30, 1991, 1992 and 1993 are derived from audited Uniroyal financial statements which are neither included nor incorporated by reference herein. The unaudited financial data presented below for the interim periods ended July 1, 1995 and June 29, 1996, and July 2, 1995 and June 30, 1996, are derived from the unaudited consolidated financial statements of Crompton and Uniroyal, respectively, that are contained herein. In the opinion of Crompton, such unaudited financial data have been prepared on the same basis as the audited financial statements contained herein or otherwise filed with the Commission and include all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the information set forth herein. Operating results for the interim periods ended June 29, 1996 and June 30, 1996 are not necessarily indicative of the results that may be expected for the year or for any other interim period. YEARS ENDED SIX MONTHS ENDED ------------------------------------------------------------------------ ------------------- DECEMBER 28, DECEMBER 26, DECEMBER 25, DECEMBER 31, DECEMBER 30, JULY 1, JUNE 29, 1991 1992 1993 1994 1995 1995 1996 ------------ ------------ ------------ ------------ ------------ -------- -------- (IN THOUSANDS, EXCEPT PER SHARE DATA) Crompton & Knowles Corporation CONSOLIDATED STATEMENT OF OPERATIONS DATA: Net sales.................. $450,228 517,718 558,348 589,757 665,513 343,810 332,410 Income before extraordinary charges and cumulative effect of accounting changes.................... $ 35,941 43,265 51,958 50,916 40,493 25,254 19,180 Net income................. $ 35,941 34,465 51,958 50,916 40,493 25,254 19,180 Income per common share before extraordinary charges and cumulative effect of accounting changes.................... $ 0.73 0.87 1.00 1.00 0.84 0.52 0.40 Net income per common share...................... $ 0.73 0.69 1.00 1.00 0.84 0.52 0.40 Weighted average number of shares outstanding......... 49,317 49,967 52,176 51,152 48,448 48,569 48,499 CONSOLIDATED BALANCE SHEET DATA: Total assets............... $308,562 350,715 363,246 432,328 484,138 537,369 Long-term debt............. $ 76,118 24,000 14,000 54,000 64,000 79,000 Cash dividends declared per common share............... $ 0.25 0.31 0.38 0.46 0.525 0.255 0.27
YEARS ENDED NINE MONTHS ENDED ------------------------------------------------------------------------- --------------------- SEPTEMBER 30, SEPTEMBER 30, SEPTEMBER 30, OCTOBER 2, OCTOBER 1, JULY 2, JUNE 30, 1991 1992 1993 1994 1995 1995 1996 ------------- ------------- ------------- ---------- ---------- ------- --------- (IN THOUSANDS, EXCEPT PER SHARE DATA) Uniroyal Chemical Corporation CONSOLIDATED STATEMENT OF OPERATIONS DATA: Net sales............ $ 832,302 856,591 907,862 946,454 1,079,321 784,567 829,171 Income (loss) before extraordinary charges and cumulative effect of accounting changes... $ (23,648) (27,790) (24,792) (213,843)(3) 99,429(4) 95,694(4) 17,982 Net income (loss).... $ (23,648) (27,790) (236,733) (213,843)(3) 91,150(4) 87,415(4) 17,541 Income (loss) per common share before extraordinary charges and cumulative effect of accounting changes (1)(2)............... $ (2.15) (2.54) (2.31) (20.31)(3) 5.37(4) 5.80(4) 0.72 Net income (loss) per common share (1)(2).. $ (2.15) (2.54) (21.85) (20.31)(3) 4.92(4) 5.30(4) 0.70 Weighted average number of shares outstanding(2)....... 11,167 11,038 10,847 10,543 18,461 16,436 24,582 CONSOLIDATED BALANCE SHEET DATA (5): Total assets......... $ 1,253,370 1,228,569 1,225,438 1,056,017 1,171,707 1,161,047 Long-term debt....... $ 854,619 880,343 1,034,799 1,048,225 910,156 888,856
- ------------ (1) Calculated based on income (loss) available to common shareholders after preferred dividends earned of $375, $262, $267, $292, $395, $298 and $313 for the years ended September 30, 1991, 1992 and 1993, October 2, 1994, and October 1, 1995, and the nine-month periods ended July 2, 1995 and June 30, 1996, respectively. (2) During the second quarter of fiscal 1995, Uniroyal completed an initial public offering. Upon consummation of the offering, certain redeemable common stock owned by Uniroyal management was converted into a single class of common stock. Weighted average number of shares outstanding reflects the conversion on a retroactive basis for all periods presented. (3) Includes an after-tax write-off of $163 million for impairment of certain intangible assets. (4) Includes a gain of $78.9 million related to a deferred tax asset reserve. (See note 10 under "Unaudited Pro Forma Combined Financial Information--Notes To Unaudited Pro Forma Combined Financial Information.") (5) Uniroyal has not declared any dividends on its common stock during the periods indicated above. UNAUDITED SELECTED PRO FORMA COMBINED FINANCIAL DATA The unaudited selected pro forma combined financial data shown below gives effect to the Merger using the pooling-of-interests basis of accounting. The pro forma statement of operations data reflects the combination of statement of operations data of Crompton for each of the years ended December 25, 1993, December 31, 1994 and December 30, 1995, and the six-month periods ended July 1, 1995 and June 29, 1996, with statement of operations data of Uniroyal for each of the years ended September 30, 1993, October 2, 1994 and October 1, 1995, and the six-month periods ended July 2, 1995 and June 30, 1996. The pro forma balance sheet data reflects the combination of balance sheet data of Crompton as of December 25, 1993, December 31, 1994, December 30, 1995 and June 29, 1996 with balance sheet data of Uniroyal as of September 30, 1993, October 2, 1994, October 1, 1995 and June 30, 1996. The selected pro forma combined financial data should be read in conjunction with the unaudited pro forma combined financial information and notes thereto, which are included elsewhere in this Prospectus. These pro forma data do not purport to be indicative of the results that would have actually been obtained if the Merger had been in effect for the above-mentioned periods and on the dates indicated or that may be obtained in the future. SIX MONTHS YEARS ENDED ENDED --------------------------------------------- --------------------- DECEMBER 25, DECEMBER 31, DECEMBER 30, JULY 1, JUNE 29, 1993 AND 1994 AND 1995 AND 1995 AND 1996 AND SEPTEMBER 30, OCTOBER 2, OCTOBER 1, JULY 2, JUNE 30, 1993 1994 1995 1995 1996(4) ------------- ------------ ------------ -------- --------- (IN THOUSANDS, EXCEPT PER SHARE DATA) PRO FORMA STATEMENT OF OPERATIONS DATA: (2) Net sales................ $ 1,466,210 1,536,211 1,744,834 916,736 930,101 Operating profit........ $ 187,372 1,417(5) 218,122 139,986 131,756 Income (loss) before extraordinary charges and cumulative effect of accounting changes.................. $ 27,166 (162,927)(5) 139,922(6) 131,484(6) 45,530 Income (loss) per common share before extraordinary charges and cumulative effect of accounting changes (1)...................... $ 0.43 (2.65)(5) 2.11(6) 1.96(6) 0.63(7) Weighted average number of shares outstanding (1)...................... 63,689 61,515 66,394 67,109 72,405 PRO FORMA BALANCE SHEET DATA: Total assets............. $ 1,588,684 1,488,345 1,655,845 1,698,416 Long-term debt........... $ 1,048,799 1,102,225 974,156 1,007,906(3) Cash dividends declared per common share (8)..... $ 0.38 0.46 0.525 0.255 0.27
- ------------ (1) Common and common equivalent shares outstanding were calculated assuming a conversion rate of 0.9577 shares of Crompton Common Stock for each share of Uniroyal Common Stock, and 6.3850 shares of Crompton Common Stock for each share of Uniroyal Preferred Stock as provided for in the Merger Agreement. (2) The Pro Forma Statement of Operations Data does not include an estimated $55 million of after tax costs associated with the Merger, as such costs are non-recurring and will be reflected in the statement of operations of the combined company in its first reporting period. (3) Long-term debt includes the financing of the estimated costs of the Merger (see notes 1, 2 and 6 under "Historical and Unaudited Pro Forma Combined Capitalization--Notes to Historical and Unaudited Pro Forma Combined Capitalization"), net of proceeds from the issuance from treasury stock of 1,000,000 shares of Crompton Common Stock to be issued in an offering to take place prior to the consummation of the Merger. (4) After the consummation of the Merger, Uniroyal will change its fiscal year-end to conform with that of Crompton. Results of operations for Uniroyal's quarter ended December 31, 1995 were a net loss of $8.4 million which will be reflected as a one-time adjustment to stockholders' equity in the combined company's 1996 financial statements. (5) Includes an after-tax write-off of $163 million for impairment of certain intangible assets. (6) Includes a gain of $78.9 million related to a deferred tax asset reserve. (See note 10 under "Unaudited Pro Forma Combined Financial Information--Notes To Unaudited Pro Forma Combined Financial Information.") (7) The calculation of pro forma income (loss) per common share before extraordinary charges and cumulative effect of accounting changes does not reflect as outstanding 1,000,000 shares of Crompton Common Stock to be issued in an offering prior to the consummation of the Merger, as such amounts are not reflective of historical trends for the combined company. Assuming the issuance of 1,000,000 shares of treasury stock (see note 3 above) had taken place at the beginning of the year, income per common share before extraordinary charges and cumulative effect of accounting changes for the six months ended 1996 would have been $0.62. (8) Represents Crompton's historical dividends per share. Uniroyal has not declared any dividends on its common stock during the periods presented.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000028630_drs_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000028630_drs_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..42ba164f85f9a0102ea5b32dd1c31641a3c8b027
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000028630_drs_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements (including the notes thereto) appearing elsewhere in this Prospectus. Unless the context otherwise requires, all references herein to the "Company" include Diagnos- tic/Retrieval Systems, Inc. and its consolidated subsidiaries. THE COMPANY Diagnostic/Retrieval Systems,Inc. ("DRS" or the "Company") designs, manufactures and markets high-technology computer workstations for the United States (the "U.S.") Department of Defense, electro-optical targeting systems for military customers and image and data storage products for both military and commer- cial customers. In response to a 1992 mandate by the Joint Chiefs of Staff, the Company focuses on "commercial-off-the- shelf" ("COTS") product designs, whereby commercial electronic components are adapted, upgraded and "ruggedized" for application in harsh military environments. The Company believes that military expenditures on electronic systems and equipment will grow in coming years as the nature of modern warfare dictates increasing reliance on real-time, accurate battlefield informa- tion and the electronic content and sophistication of defense systems increases. During its last three fiscal years, the Company has restruc- tured its management team and implemented strategies to exploit the changing nature of military procurement programs brought on by the end of the cold war, military budget constraints and the COTS mandate. The Company's strategies include: * expanding and diversifying the Company's technol- ogy and product base into complementary military and commercial markets primarily through acquisi- tions and the forging of strategic relationships; * increasing revenue opportunities through the de- sign and adaptation of products for use by all branches of the military; and * enhancing financial performance through specific cost reduction measures and increased manufactur- ing efficiencies. To effect these strategies, the Company has (i) acquired several businesses with complementary military and commercial products and technologies over the last three years; (ii) forged strategic relationships with other defense suppliers such as Lockheed-Martin Tactical Defense Systems (formerly, Loral Corpo- ration) and Westinghouse Electric Corporation, among others; (iii) emphasized the development of COTS-based products as well as products and systems that are easily adapted to similar weapons platforms for use by all branches of the military; and (iv) implemented cost reduction programs to reduce its fixed-cost base, allow for growth and maintain the flexibility of its operations. The implementation of these strategies has resulted in increasing revenues and profits over the last three fiscal years. Although the Company experienced operating losses in fiscal 1990 through 1992, primarily due to cost overruns on a single fixed- price development contract, a shift over the last several years in the nature of military development contracting from fixed- price to cost-type contracts has reduced the Company's exposure in this area. For the fiscal year ended March 31, 1995, the Company had revenues of $69.9 million, net income of $2.6 million and earnings per share of $.50, representing increases of 20.9%, 61.2% and 66.7%, respectively, compared with the year ended March 31, 1994. For the nine months ended December 31, 1995 the Company had revenues of $65.6 million, net income of $2.5 million and fully diluted earnings per share of $.44, representing increases of 38.4%, 45.7% and 29.4%, respectively, compared with the same nine-month period ended December 31, 1994. SUMMARY FINANCIAL INFORMATION Nine Months Year Ended March 31, Ended December 31, _____________________________________________________________ _____________________ 1995 1994 1993 1992 1991 1995 1994 ____ ____ ____ ____ ____ ____ ____ SUMMARY OF OPERATIONS DATA: Revenues . . . . . . . . $ 69,930,000 $ 57,820,000 $ 47,772,000 $ 28,925,000 $ 47,762,000 $ 65,628,000 $ 47,404,000 Costs and Expenses 64,836,000 54,372,000 45,461,000 37,032,000 52,812,000 60,289,000 44,143,000 Operating Income (Loss) 5,094,000 3,448,000 2,311,000 (8,107,000) (5,050,000) 5,339,000 3,261,000 Interest and Related Expenses (1,372,000) (1,574,000) (1,735,000) (2,198,000) (2,362,000) (1,675,000) (1,020,000) Other Income, Net 534,000 834,000 1,224,000 944,000 1,677,000 425,000 613,000 Earnings (Loss) before Income Taxes (Benefit) 4,256,000 2,708,000 1,800,000 (9,361,000) (5,735,000) 4,089,000 2,854,000 Income Taxes (Benefit) 1,652,000 1,093,000 715,000 (4,006,000) (1,488,000) 1,594,000 1,142,000 Net Earnings (Loss) $ 2,604,000 $ 1,615,000 $ 1,085,000 $ (5,355,000) $ (4,247,000) $ 2,495,000 $ 1,712,000 Net Earnings (Loss) per share of Class A and Class B Common Stock(1)(2) $ .50 $ .30 $ .20 $ (1.01) $ (.79) $ .44 $ .34 December 31, 1995 BALANCE SHEET DATA: Working Capital $ 40,585,000 Net Property, Plant and Equipment $ 14,728,000 Total Assets $ 90,770,000 Long-Term Debt, Excluding Current Installments $ 35,319,000 Net Stockholders' Equity $ 24,907,000 ___________________________ (1) No cash dividends have been distributed during any of the years in the five-year period ended March 31, 1995 or the nine months ended December 31, 1995. (2) Does not give effect to the Reclassification (as hereinafter defined). On April 1, 1996, the Reclassification became effective pursuant to which each share of the Class A Common Stock (as hereinafter defined) and each share of the Class B Common Stock (as hereinafter defined) was reclassified into one share of the Common Stock. See "The Offering--Reclassification" and "Description of Capital Stock."
THE OFFERING Common Stock Offered . . . . 885,924 shares Common Stock to be outstanding after the offering . . . . . . . 5,467,632 shares(1) Reclassification . . . . . . On February 7, 1996, the Board of Directors of the Company approved and recommended for submission to the stockholders of the Company by a majority vote the consideration and approval of an Amended and Restated Certificate of Incor- poration (the "Restated Cer- tificate"), which amended and restated the Company's certif- icate to (i) effect a reclas- sification (the "Reclassifica- tion") of each share of Class A Common Stock, $.01 par value per share (the "Class A Common Stock"), and each share of Class B Common Stock, $.01 par value per share (the "Class B Common Stock"), into one share of Common Stock of the Compa- ny, (ii) provide that action by the stockholders may be taken only at a duly called annual or special meeting, and not by written consent, and (iii) provide that the stock- holders of the Company would have the right to make, adopt, alter, amend, change or repeal the by-laws of the Company only upon the affirmative vote of not less than 66-2/3 % of the outstanding capital stock of the Company entitled to vote thereon. On March 26, 1996, the stockholders approved the Restated Certificate. The Restated Certificate was filed with the Secretary of State of the State of Delaware and became effective on April 1, 1996. As a result of the Reclassification, the Company's 9% Senior Subordi- nated Convertible Debentures due October 1, 2003 (the "De- bentures") and the 81/2% Con- vertible Subordinated Deben- tures due August 1, 1998 (the "1998 Debentures") are con- vertible into shares of Common Stock. In addition, each option issued or issuable pursuant to the Company's stock option plan is now exer- cisable for an equal number of shares of the Common Stock. The purpose of the Reclassifi- cation was to simplify the Company's capital structure, streamline the Company's vot- ing procedures and enhance the marketability and liquidity of and maximize investor interest in the Company's capital stock. In addition, the Com- pany believes that, as a re- sult of the Reclassification, the Company is in a more flex- ible position to raise capital and effect mergers and acqui- sitions using its common stock. However, there can be no assurance that the Reclas- sification will have such effects. Voting Rights . . . . . . . . Holders of Common Stock are entitled to one vote per share on all matters submitted for approval of stockholders. See "Description of Capital Stock." AMEX symbol for Common Stock . . "DRS" Registration Rights . . . . . Pursuant to a registration rights agreement (the "Regis- tration Rights Agreement") between the Company and Pali- sade Capital Management L.L.C. ("Palisade"), acting as in- vestment adviser to the Sell- ing Stockholders, the Company has agreed to file a shelf registration statement (the "Shelf Registration State- ment") relating to the shares of Common Stock offered here- by. The Company has agreed to use its reasonable best ef- forts to maintain the effec- tiveness of the Shelf Regis- tration Statement until the earlier of the disposition of the shares offered hereby or the third anniversary of the effective date of the Shelf Registration Statement, except that it will be permitted to suspend the use of the Shelf Registration Statement during certain periods under certain circumstances. Use of Proceeds . . . . . . . The Company will not receive any proceeds from the sale of shares of Common Stock offered pursuant to this Prospectus. The Selling Stockholders will receive all of the net pro- ceeds from any sale of shares of Common Stock offered here- by. See "Use of Proceeds" and "Selling Stockholders." (1) Based upon 5,467,632 shares of Common Stock outstanding as of May 23, 1996 (exclusive of 498,434 shares held in treasury).
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000030302_alco_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000030302_alco_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..e4617716fa58dd6df675530316d544ddf77629f6
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000030302_alco_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements and notes thereto appearing elsewhere in this Prospectus. Except as otherwise noted, all information in this Prospectus assumes the Underwriters' over-allotment option has not been exercised (see ``Underwriting''). The Company operates on a fiscal year basis which ends on the Sunday which falls most closely to January 31 of each year. The Company is currently operating in fiscal 1997. This Prospectus contains forward-looking statements that involve risks and uncertainties. The Company's actual results may differ materially from those discussed in the forward-looking statements. Factors that might cause such a disparity include, but are not limited to, those discussed in ``Risk Factors.'' Prospective investors should carefully consider the information set forth under the heading ``Risk Factors.'' THE COMPANY Duckwall-ALCO Stores, Inc. (the ``Company''), which was established in 1901, is a regional retailer operating, as of September 4, 1996, 173 stores in 16 states in the central United States. Under the names ``ALCO'' and ``Duckwall,'' the Company's strategy is to target smaller markets not served by other regional or national retail discount chains and provide the most convenient access to retail shopping within each market. The Company's ALCO discount stores offer a full line of merchandise consisting of approximately 35,000 items, including automotive, candy, crafts, domestics, electronics, fabrics, furniture, hardware, health and beauty aids, housewares, jewelry, ladies', men's and children's apparel and shoes, pre-recorded music and video, sporting goods, seasonal items, stationery and toys. The Company's smaller Duckwall variety stores offer a more limited selection of merchandise. Of the Company's 121 ALCO discount stores, 77 stores are located in communities which do not have another full service discounter. The Company intends to continue its strategy of opening ALCO stores in markets that do not have other discount retailers and where the opening of an ALCO store would significantly reduce the likelihood of the entry by other competitors in the market. The ALCO stores accounted for approximately 95% of the Company's fiscal 1996 net sales. While the current ALCO stores average approximately 23,300 square feet of selling space, the Company's store expansion program is primarily directed toward stores with a design prototype of approximately 18,000 square feet of selling space, which, based on the Company's experience, has been a design that maximizes return on investment for newly-constructed stores (referred to as ``Class 18 Stores''). The Company's 52 Duckwall variety stores are primarily located in communities of less than 2,500 residents and are designed to act as the primary convenience retailer in these smaller communities. These stores, which accounted for the remaining 5% of the Company's fiscal 1996 net sales, average approximately 4,800 square feet of selling space and offer approximately 12,000 items. Operating Duckwall stores offers the Company the opportunity to serve the needs of a community that would not support a full service retail discount store with a reduced investment per store and a higher return on investment than the Company's average. The Company believes that its strong operating performance and improved financial condition over the last four fiscal years and the first twenty-six weeks of the current fiscal year is the result of the focused execution of a business strategy that includes the following key components: Markets: The Company intends to open ALCO stores in towns with populations of typically less than 5,000 which are in trade areas with populations of less than 16,000 where: (1) there is no direct competition from national or regional discount retailers; (2) economic and demographic criteria indicate the market is able to commercially support a discount retailer; and (3) the opening of an ALCO store would significantly reduce the likelihood of the entry into such market by another discount retailer. This strategy has guided the Company in both its opening of new stores and in the closing of existing stores. Market Selection: The Company has a detailed process which it uses to analyze under-served markets which includes examining factors such as distance from competition, trade area, disposable income and retail sales levels. Markets that are determined to be sizable enough to support an ALCO or a Duckwall store, and that have no direct competition from another discount retailer, are examined closely and eventually selected or passed over by the Company's experienced management team. As of September 4, 1996, the Company's management had approximately 166 markets which it had identified for possible ALCO stores and was in the site selection or development process in 34 of those markets. Store Expansion: The Company's expansion program for ALCO stores is designed around the prototype Class 18 Store. This prototype details for each new store plans for shelf space, merchandise presentation, store items to be offered, parking, storage, as well as other store design considerations. The 18,000 square feet of selling space is large enough to permit a full line of the Company's merchandise, while minimizing capital expenditures, required labor costs and general overhead costs. Generally, the Company has expanded its ALCO stores through internal development efforts on a location-by-location basis. Recently, however, the Company entered into a definitive agreement to assume 14 leases and purchase the related fixtures for ALCO stores in eastern Indiana and western Ohio (the ``Real Estate Transaction''). The Company's expansion strategy for the Duckwall variety store is based on opportunities presented to the Company in and by those communities where there is demand and where existing premises are available for lease at a relatively low cost and with limited financial commitment. Technology: The Company is continually improving its management information technologies in order to reduce costs, improve customer service, and enhance general business planning. The Company's accounting and information systems and merchandise and inventory planning systems have recently been enhanced and are in the process of being implemented. The Company has undertaken a $2.3 million project to upgrade the back office equipment and software being used at the ALCO stores for sales processing. This project is expected to extend the life of the current point-of-sale equipment, as well as to improve efficiencies in training and operations and is expected to be completed in fiscal 1998. In conjunction with the project, the ALCO stores will be equipped with radio frequency hand held devices to allow for additional efficiencies in processing inventory receipts and counts. Advertising and Promotion: The Company utilizes full-color photography advertising circulars of 8 to 20 pages distributed by insertion into newspapers or direct mail where newspaper service is inadequate. These circulars are distributed approximately 41 times per year in ALCO markets. In its Duckwall markets, the Company advertises approximately 12 times a year during seasonal promotions. The Company's marketing program is designed to create an awareness, on the part of its identified target customer base, of the Company's comprehensive selection of merchandise and its competitive pricing. Store Environment: The Company's stores are open, clean, bright and offer a pleasant atmosphere with disciplined product presentation, attractive displays and efficient check-out procedures. The Company strives to staff its stores with courteous, highly motivated, knowledgeable store associates in order to provide a convenient, friendly and enjoyable shopping experience. The Company's growth strategy is to increase sales and profitability at existing stores by continually refining the merchandising mix and improving operating efficiencies, and to open new stores in under-served markets in the central United States. The Company plans to open a total of 15 ALCO stores and 15 Duckwall stores and close 1 ALCO store in the current fiscal year, and open 25 ALCO stores (including the 14 locations involved with the Real Estate Transaction) and at least 15 Duckwall stores during fiscal year 1998, and a minimum of 16 ALCO stores and 15 Duckwall stores during fiscal year 1999. THE OFFERING Common Stock offered: By the Company.............................. 1,000,000 shares By the Selling Stockholders................. 400,000 shares Total................................... 1,400,000 shares Common Stock outstanding after the offering..... 5,000,523 shares Use of proceeds................................. The Company intends to use the net proceeds of the offering to fund the opening of new stores. Pending such use, the Company intends to use the net proceeds to repay indebtedness under its revolving loan credit facility. Nasdaq National Market symbol................... DUCK - -------- Excludes 188,325 Shares of Common Stock for which options have been granted under the Company's Incentive Stock Option Plan and includes 1,013 Shares of Common Stock issued in August and September of 1996 pursuant to options exercised by former employees of the Company.
SUMMARY CONSOLIDATED FINANCIAL DATA (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) TWENTY-SIX WEEKS FISCAL YEAR ENDED ENDED ------------------------------------------------------------------- --------------------- FEBRUARY 2, JANUARY 31, JANUARY 30, JANUARY 29, JANUARY 28, JULY 30, JULY 28, 1992 1993 1994 1995 1996 1995 1996 ----------- ----------- ----------- ----------- ----------- --------- --------- (UNAUDITED) STATEMENTS OF OPERATIONS DATA: Net sales......................... $210,812 $217,236 $225,903 $242,144 $256,454 $117,532 $127,774 Gross margin...................... 66,181 68,402 71,686 78,964 83,158 38,393 41,962 Income from operations............ 5,561 7,038 8,304 10,207 11,047 4,012 4,715 Interest expense.................. 5,197 4,284 4,091 3,390 2,958 1,417 1,592 Net earnings (loss)............... $ (794) $ 1,559 $ 2,260 $ 4,130 $ 5,130 $ 1,609 $ 1,927 Earnings (loss) per common and common equivalent share................... $ (.50) $ .57 $ .80 $ 1.51 $ 1.28 $ .40 $ .48 Weighted average common and common equivalent shares outstanding................. 1,575,813 2,006,250 2,006,250 2,737,620 4,014,351 4,007,909 4,033,522 OPERATING DATA: Stores open at period-end......... 104 110 121 138 156 146 170 Stores in noncompetitive markets at period-end............... 48 57 72 91 110 100 123 Percentage of total stores in non-competitive markets..... 46.2% 51.8% 59.5% 65.9% 70.5% 68.4% 72.4% Net sales of stores in non- competitive markets......... $ 84,835 $ 96,243 $112,590 $132,743 $151,733 $ 69,252 $ 80,793 Percentage of net sales from stores in non-competitive markets..................... 40.2% 44.3% 49.8% 54.8% 59.2% 58.9% 63.2% Comparable store sales for all stores...................... (4.2%) (0.3%) 0.0% 1.1% (3.2%) (4.2%) (1.5%) Comparable store sales for stores in non-competitive markets................. 0.0% 2.7% 4.0% 2.7% (1.0%) (1.4%) 0.2% JULY 28, 1996 --------------------------- ACTUAL AS ADJUSTED -------- --------------- BALANCE SHEET DATA: Working capital............................................................. $ 56,786 $ 56,786 Total assets................................................................ 123,072 123,072 Total debt (includes capital lease obligation and current maturities)....... 35,719 23,572 Stockholders' equity........................................................ 55,614 67,761 - --------- Net loss and the related loss per share amounts for the fiscal year ended February 2, 1992 as presented above exclude an extraordinary gain from discharge of indebtedness of $43,101 related to the Company's 1991 Reorganization. The extraordinary gain has been excluded from the above table because it is not relevant to ongoing operations. Earnings per common and common equivalent share for fiscal 1993 and 1994 includes the dilutive effect of accretion in the carrying value of a redeemable common stock purchase warrant of $408 and $645, respectively. See Note 1(i) of Notes to Consolidated Financial Statements. Pro forma earnings (loss) per common and common equivalent share for fiscal 1992, 1993 and 1994 amounted to $(.41), $.66 and $.96, respectively, based on pro forma weighted average common and common equivalent shares outstanding of 1,925,813, 2,356,250 and 2,356,250, respectively. See Note 1(i) of Notes to Consolidated Financial Statements. ``Non-competitive'' markets refer to those markets where there is not a national or regional discount store located in the primary market served by the Company. The Company's stores in such non-competitive markets nevertheless face competition from various sources. See ``Business--Competition.'' Percentages reflect the increase or decrease based upon a comparison of the applicable fiscal year with the immediately preceding fiscal year for stores open during the entirety of both years. Adjusted to reflect the issuance of 1,000,000 shares of Common Stock offered by the Company hereby, based on an assumed offering price of $13.25 per share, less the underwriting discount and estimated offering expenses, and the application of the net proceeds therefrom. See ``Use of Proceeds'' and ``Capitalization.''
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000043837_noodle_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000043837_noodle_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..8393dbc720bb1e5b61f0c5bc34c277fe95636f73
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000043837_noodle_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements, including the notes thereto, appearing elsewhere and incorporated by reference in this Prospectus. Unless the context otherwise requires, all references herein to the "Company" include Noodle Kidoodle, Inc. and its subsidiaries. The Company's fiscal year ends on the Saturday closest to January 31 of that year. For example, references to fiscal 1995 refer to the fiscal year ended January 28, 1995. Unless otherwise indicated, the information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. THE COMPANY Noodle Kidoodle, Inc. is a specialty retailer of a broad assortment of educationally oriented, creative and non-violent children's products, including toys, books, games, video and audio tapes, computer software, crafts and other learning products. The Noodle Kidoodle concept offers something new to parents and children by combining the attractive pricing and larger size of traditional toy stores with the more creative product selection and superior customer service of smaller boutiques, while providing an entertaining shopping environment through interactive play areas and daily in-store events. The Company's prototype store is approximately 12,000 square feet and offers customers a warm and inviting shopping environment with brightly lit spaces, colorful walls, ceilings and carpets, wide aisles for strollers and kid-level seating and product shelving. Each store typically carries approximately 25,000 stock-keeping units ("SKUs"), conveniently displayed in separate merchandise departments, such as "Science & Nature" and "Arts & Crafts," which are identified by eye-catching signs that are visual as well as verbal so that children can understand them. All of the products carried in Noodle Kidoodle stores conform to the Company's creative, non-violent and educational merchandising strategy. The Company generally does not carry mass market television advertised toys. However, in certain product categories, the Company does carry brand name products which fit the Noodle Kidoodle philosophy, such as Crayola, Lego, Playmobil, the full line of Walt Disney video titles and the Goosebumps line of books. The Company currently operates 18 Noodle Kidoodle stores in New York, New Jersey, Connecticut and the Chicago metropolitan area, and plans to open approximately 15 more stores in fiscal 1997 in new and existing markets. The Company's near-term plan is to cluster its stores in the Northeastern United States and several Midwestern markets, in order to leverage the Company's advertising programs as well as optimize the capabilities of its strategically located distribution center. The Company believes that there are opportunities for nationwide expansion over the longer term beyond fiscal 1997. The Company's strategy is to become the leading national retailer of educationally oriented children's products. Key components of the Company's business strategy are: . Interactive Shopping Environment--Each Noodle Kidoodle store is designed with children in mind. Each store has designated play areas where children and their parents are encouraged to explore toys and games in keeping with the Company's "try before you buy" philosophy. Among the key interactive features of each store are the Computer Center, "Kidoodle Theater" and Electronic Learning Center. . Broad Assortment of Imaginative Products--Noodle Kidoodle stores offer a broad assortment of products designed to stimulate a child's imagination and contribute to his or her growth and development consistent with the Company's slogan that "Kids learn best when they're having fun." The Company believes that within its targeted age group of infant to twelve years, it offers in a single location one of the broadest available assortments of educationally oriented, creative and non-violent children's products. To keep its merchandise mix fresh and exciting, the Company continually seeks innovative new products. . Daily In-Store Events--The Company provides without charge daily in-store events such as personal appearances by authors and children's television personalities, arts and crafts workshops and readings from selected books to provide entertainment to its customers, increase store traffic and position Noodle Kidoodle as a destination store. . Superior Customer Service--By providing knowledgeable and friendly customer service and selecting enthusiastic employees who enjoy working with children, the Company believes that it has a competitive advantage over lower-service superstores and mass merchandisers. . Targeted Marketing--The Company has created the Noodle Kidoodle Club in order to establish customer loyalty and track repeat customers. The club provides its members advance notice of sale events and special promotions, a bi-monthly newsletter and events calendar, birthday cards sent to children and similar special privileges. The Company is also establishing a targeted direct mail marketing program and is in the process of expanding its customer database for this purpose. . Competitive Pricing--Noodle Kidoodle offers everyday competitive pricing. Many products are regularly discounted and prices in general are believed to be competitive with those featured by superstores carrying the same lines of merchandise. The Company was founded in 1946 and, doing business under its former name Greenman Bros. Inc., historically was engaged in the retail toy business as well as the wholesale distribution of general merchandise, with an emphasis on toys, stationery and housewares. During the 1980s, the Company operated a number of retail toy stores, including a chain of 330 stores under the Circus World name located principally in shopping malls in approximately 30 states. The Company sold the Circus World stores in fiscal 1991 but continued to operate a number of retail toy stores under the Playworld name. The Company opened its first Noodle Kidoodle store in November 1993, and opened three additional Noodle Kidoodle stores in fiscal 1995. During fiscal 1996, management determined, based in large part on the success of its early Noodle Kidoodle stores, that the Company should focus exclusively on its retail business by expanding and developing the Noodle Kidoodle retail concept. Accordingly, in August 1995, the Company adopted a new business plan and ceased operating its wholesale division, which generated net sales of $113.2 million in fiscal 1995. The Company recently changed its name from Greenman Bros. Inc. to Noodle Kidoodle, Inc. and its jurisdiction of incorporation to Delaware. The Company's executive offices are located at 105 Price Parkway, Farmingdale, New York 11735. Its telephone number is (516) 293-5300. RECENT DEVELOPMENT For the nine-week period ended December 30, 1995, during which the Company added three additional Noodle Kidoodle stores, the Company recorded net sales of $15.9 million and gross profit of $6.3 million. The Company was satisfied with its holiday season especially in light of the generally weak retail environment and the severe weather conditions in its major markets, particularly during the week prior to Christmas. THE OFFERING Common Stock Offered by the Company....................... 2,000,000 shares Common Stock to be Outstanding after the Offering......... 7,369,890 shares (1) Use of Proceeds........................................... Primarily to finance new store openings, as well as for general corporate purposes. See "Use of Proceeds" and "Business--Expansion Strategy." Nasdaq National Market Symbol............................. NKID
- ------------ (1) Excludes as of February 8, 1996 (i) 587,984 shares of Common Stock issuable upon exercise of outstanding options at exercise prices ranging from $3.50 to $13.13 per share and (ii) 279,250 shares of Common Stock reserved for issuance pursuant to options issuable under the Company's stock option plans. SUMMARY FINANCIAL INFORMATION AND STORE DATA(A) (IN THOUSANDS, EXCEPT PER SHARE AND STORE DATA) THIRTY-NINE WEEKS FISCAL YEARS ENDED ENDED ---------------------------------------------------- ----------------------- FEB. 2, FEB. 1, JAN. 30, JAN. 29, JAN. 28, OCT. 29, OCT. 28, 1991 1992 1993 1994 1995 1994 1995 -------- -------- -------- -------- -------- ----------- -------- (UNAUDITED) STATEMENT OF OPERATIONS DATA: Net sales......................... $ 11,022 $ 12,850 $ 18,250 $ 20,712 $ 23,308 $12,042 $ 13,508 Gross profit...................... 3,885 4,794 5,471 6,143 7,116 3,828 4,724 Selling and administrative expenses........................ 5,078 5,813 6,645 8,401 10,790 6,937 10,563 Provision for restructured operations(b)................... -- -- -- -- 3,900 3,500 500 Operating loss.................... (1,193) (1,019) (1,174) (2,258) (7,574) (6,609) (6,339) Net income (loss): Continuing operations........... (2,622) (1,141) (425) (1,180) (4,490) (3,819) (5,870) Discontinued operations(c)...... (12,305) 5,069 2,226 1,889 1,096 22 (9,059) Extraordinary item(d)........... 325 (263) -- -- -- -- -- -------- -------- -------- -------- -------- ----------- -------- Net income (loss)............. $(14,602) $ 3,665 $ 1,801 $ 709 $ (3,394) $(3,797) $(14,929) -------- -------- -------- -------- -------- ----------- -------- -------- -------- -------- -------- -------- ----------- -------- Net income (loss) per share: Continuing operations........... $ (.44) $ (.21) $ (.08) $ (.22) $ (.86) $ (.73) $ (1.11) Discontinued operations(c)...... (2.07) .92 .40 .35 .21 -- (1.71) Extraordinary item(d)........... .06 (.05) -- -- -- -- -- -------- -------- -------- -------- -------- ----------- -------- Net income (loss) per share... $ (2.45) $ .66 $ .32 $ .13 $ (.65) $ (.73) $ (2.82) -------- -------- -------- -------- -------- ----------- -------- -------- -------- -------- -------- -------- ----------- -------- Weighted average shares outstanding....................... 5,949 5,540 5,575 5,338 5,220 5,207 5,302 OTHER FINANCIAL DATA: Net sales: Noodle Kidoodle................. $ -- $ -- $ -- $ 1,168 $ 6,414 $ 2,544 $ 11,042 Other Retail(e)................. 11,022 12,850 18,250 19,544 16,894 9,498 2,466 -------- -------- -------- -------- -------- ----------- -------- Total net sales............... 11,022 12,850 18,250 20,712 23,308 12,042 13,508 Discontinued operations:(c) Net sales....................... $198,890 $151,718 $136,488 $122,138 $113,194 $80,729 $ 50,635 Gross profit.................... 52,753 33,475 31,035 26,711 24,604 17,069 9,164 Operating income (loss)......... (8,666) 5,576 3,633 3,171 1,781 37 (1,914) Provision for discontinued operations.................... 5,712 -- -- -- -- -- 7,145 -------- -------- -------- -------- -------- ----------- -------- Net income (loss)............... (12,305) 5,069 2,226 1,889 1,096 22 (9,059) STORE DATA (AT END OF PERIOD): Number of stores: Noodle Kidoodle................. -- -- -- 1 4 3 15 Other Retail(e)................. 6 8 10 10 4 10 4 -------- -------- -------- -------- -------- ----------- -------- Total......................... 6 8 10 11 8 13 19 Gross square footage: Noodle Kidoodle................. -- -- -- 10,450 39,700 29,700 160,130 Other Retail(e)................. 56,570 68,870 86,400 86,400 31,500 86,400 31,500 -------- -------- -------- -------- -------- ----------- -------- Total......................... 56,570 68,870 86,400 96,850 71,200 116,100 191,630
OCTOBER 28, 1995 ------------------------- ACTUAL AS ADJUSTED(F) ------- -------------- BALANCE SHEET DATA: Working capital............................................................... $14,772 $ 28,911 Net assets of discontinued operations(c)...................................... 6,327 6,327 Total assets.................................................................. 38,872 53,011 Total debt.................................................................... -- -- Total liabilities............................................................. 12,428 12,428 Stockholders' equity.......................................................... 26,444 40,583
- ------------ (a) As a result of recent strategic changes, period-to-period comparisons of financial results are not meaningful. See "Management's Discussion and Analysis of Financial Condition and Results of Operations."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000052532_mercury_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000052532_mercury_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..39c41b22a5a10333ff089249e02064852fcb11e1
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000052532_mercury_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS NOT INTENDED TO BE COMPLETE AND SHOULD BE READ IN CONJUNCTION WITH, AND IS QUALIFIED IN ITS ENTIRETY BY, THE MORE DETAILED INFORMATION AND CONSOLIDATED FINANCIAL STATEMENTS (INCLUDING THE NOTES THERETO) APPEARING ELSEWHERE IN THIS PROSPECTUS. EACH PROSPECTIVE INVESTOR IS URGED TO READ THIS PROSPECTUS IN ITS ENTIRETY. UNLESS OTHERWISE INDICATED, ALL INFORMATION HEREIN ASSUMES THAT THE UNDERWRITERS' OVER-ALLOTMENT OPTION IS NOT EXERCISED. ALL PER SHARE AND OTHER SHAREHOLDER INFORMATION HAS BEEN ADJUSTED TO REFLECT THE EFFECT OF A JUNE 16, 1995 TEN PERCENT STOCK DIVIDEND. EXCEPT AS OTHERWISE NOTED, REFERENCES IN THIS PROSPECTUS TO "MERCURY" OR THE "COMPANY" REFER TO MERCURY AIR GROUP, INC. AND ITS SUBSIDIARIES. THE DEBENTURES OFFERED HEREBY ARE OBLIGATIONS OF MERCURY AIR GROUP, INC., THE PARENT HOLDING COMPANY, AND NOT ITS SUBSIDIARIES, AND REFERENCES TO "MERCURY" OR THE "COMPANY" RELATING TO THE DEBENTURES REFER ONLY TO THE PARENT HOLDING COMPANY. THE COMPANY Mercury provides a broad range of services to the aviation industry. These services include fuel sales and fuel delivery to commercial, private and military aircraft (collectively, "fuel sales and services"); cargo handling, space brokerage and general cargo sales agent services (collectively, "cargo operations"); fixed base operations for commercial, private and other aircraft, including fuel sales, fuel delivery services ("into-plane services"), ground support services and tie-down facilities (collectively, "FBOs"); and the operation of government-owned fuel depots and the performance of aircraft and other services at U.S. military bases (collectively, "government contract services"). Mercury's customers in one or more of these categories include domestic and international airlines; regional and commuter air carriers; operators of cargo, corporate and private aircraft; and the U.S. government. FUEL SALES AND SERVICES. Mercury's fuel sales and services consist primarily of aviation fuel sales; comprehensive fuel management services, which allow customers to reduce administrative expenses; into-plane services; and the brokering of non-aviation fuel. Through its extensive network of third-party delivery and supply relationships, Mercury conducts its fuel sales business at over 100 airports primarily in the United States, as well as throughout the world. At most of these locations, Mercury contracts with third parties for into-plane services, thereby minimizing its fixed costs and capital requirements. Mercury believes that its status as a volume purchaser and its creditworthiness enable it to purchase fuel on more favorable pricing and credit terms than most of its customers could obtain independently. Mercury's fuel sales and services strategy is to expand its business with existing customers and attract new customers by further enhancing its customer services and by continuing to offer favorable credit terms and competitive fuel prices. CARGO OPERATIONS. Mercury's cargo operations are conducted primarily at Los Angeles International Airport ("LAX") where it maintains approximately 90,000 square feet of warehouse facilities. Mercury also leases a 45,000 square foot warehouse facility near the San Francisco International Airport which it uses for cargo handling operations. In September 1995, Mercury acquired the operating and other assets of certain providers of cargo handling services at airport facilities in Toronto and Montreal, Canada. See "Business -- Recent Developments - -- Excel Cargo." Mercury's strategy is to continue to expand its cargo handling operations by securing additional warehouse facilities on favorable economic terms and to obtain additional customers to fully utilize existing warehouse facilities. Space brokerage, a significant part of Mercury's cargo operations, consists of contracting with domestic and international airlines for cargo space and reselling the cargo space to customers with shipping needs. This allows airlines to increase cargo capacity utilization by using Mercury's marketing capabilities. Mercury's strategy is to expand its space brokerage operations by establishing relationships with additional shipping agents and by contracting for additional cargo space. In conducting its general cargo sales agent services, another important component of Mercury's cargo operations, Mercury acts as an agent for airlines in the Far East, Mexico, Central and South America and the United States. In this capacity, Mercury earns a commission from the airlines for selling air cargo space. Mercury's strategy is to expand its revenues and operating income from general cargo sales agent services by obtaining new sales territories for airlines with which it has an existing relationship and by entering into arrangements with additional airlines. FBOS. Mercury's FBO services are performed at leased facilities located at LAX and at airports in Reno, Nevada; Bakersfield, California; Burbank, California; and Santa Barbara, California. At each FBO, Mercury maintains administrative offices, conducts fuel sales and refueling operations, provides catering and other ground support services and provides tie-down space for its customers. Mercury's strategy is to acquire additional FBOs on favorable economic terms and to expand its business at existing FBOs. GOVERNMENT CONTRACT SERVICES. Mercury conducts its government contract services at 14 military bases throughout the United States and at three military bases outside the United States, one in Greece and two in Japan. The majority of these contracts entail providing equipment and manpower to fuel aircraft, but do not include the sale of fuel, the procurement of which is handled by the military. The Company's government contracts have terms of one to four years. Mercury has recently lost several government contracts due to base closures and other reasons. Mercury's strategy in the government contract services area is to retain existing contracts and cost effectively bid for new refueling contracts. Mercury also intends to expand the types of outsourcing services provided to the U.S. government beyond the Company's core military refueling business. Potential areas of expansion include engineering services, base operating services and maintenance and operations services. Mercury believes its expansion efforts in this area will be facilitated by its familiarity with military base operations and government contract requirements. Mercury's principal executive offices are located at 5456 McConnell Avenue, Los Angeles, California 90066, and its telephone number is (310) 827-2737. The Company was incorporated in New York in April 1956. THE OFFERING Securities Offered................. $25,000,000 aggregate principal amount of % Convertible Subordinated Debentures due 2006. Maturity Date...................... February , 2006. Interest Payment Dates............. Interest payable semi-annually on August and February of each year, commencing August , 1996. The first interest payment will represent interest from the date of original issuance to and including August , 1996. Denominations...................... $1,000 and any integral multiple thereof. Conversion Rights.................. The Debentures are convertible at the option of the holder at any time prior to maturity, unless previously redeemed or repurchased, at a conversion rate of shares of Common Stock per $1,000 principal amount of Debentures (equivalent to a conversion price of approximately $ per share), subject to adjustment in certain circumstances as described herein. No accrued interest will be paid upon conversion, except that Debentures called for redemption which are held on a record date respecting any interest payment date shall be paid accrued interest to the earlier of the date of conversion or through the end of the related semi-annual interest payment period. See "Description of Debentures -- Conversion Rights."
Optional Redemption................ The Debentures are redeemable on or after February , 1999, in whole or in part, at any time, at the option of Mercury, at the declining redemption prices set forth herein plus accrued and unpaid interest to the date of redemption. In addition, Mercury may redeem the Debentures between February , 1998 and February , 1999, if the closing price of the Common Stock has been at least 140% of the Conversion Price (as defined herein) for at least 20 trading days within a period of 30 consecutive trading days ending not more than five trading days prior to the date of the redemption notice. See "Description of Debentures -- Optional Redemption." Sinking Fund....................... None. Redemption Option Upon Death of Holder.................. Debentures tendered by an authorized representative or the surviving joint tenant, tenant by the entirety or tenant in common of a deceased holder will be redeemable, in whole or in part, within 60 days of tender, at 100% of the principal amount plus accrued and unpaid interest to and including the date of redemption, subject to a maximum principal amount of $100,000 per deceased holder and a maximum aggregate principal amount for all deceased holders of $500,000 during each calendar year. See "Description of Debentures -- Repurchase of Debentures Upon Death of Holder." Repurchase at Option of Holder After Certain Changes of Control.......................... After a Change of Control and a Rating Downgrade, each holder will have the right, subject to certain conditions, to require Mercury to repurchase all or part of such holder's Debentures at 100% of the principal amount thereof, plus accrued and unpaid interest to the date of repurchase. See "Risk Factors -- Limitations on Repurchase of Debentures" and "Description of Debentures -- Repurchase of Debentures at the Option of the Holder After Certain Changes of Control." Subordination...................... The Debentures are unsecured obligations of Mercury and are subordinated in the right of payment to all existing and future Senior Indebtedness (as defined herein) of Mercury. As of September 30, 1995, assuming application of the net proceeds of this offering in the manner described herein, Senior Indebtedness would have been approximately $10.9 million. The Indenture does not restrict the incurrence of additional Senior Indebtedness or other indebtedness by Mercury or any subsidiary. See "Risk Factors -- Subordination" and "Description of Debentures -- Subordination." Rating............................. The Debentures are rated "B-" by Standard & Poor's Corporation. See "Rating of Debentures." Listing............................ The Debentures have been approved for listing on the AMEX under the symbol MAX.A. Application has also been
made to list the Debentures on the PSE. The Common Stock is listed on the AMEX and traded under the symbol "MAX." See "Price Range of Common Stock and Dividend Policy." Use of Proceeds.................... Mercury intends to use the net proceeds of this offering to repay the outstanding balance under the Revolver (as defined herein); to fund expansion and growth, both internally and through acquisitions; and for general corporate purposes. See "Use of Proceeds."
SUMMARY CONSOLIDATED FINANCIAL DATA THREE MONTHS ENDED FISCAL YEAR ENDED JUNE 30, SEPTEMBER 30, ----------------------------------------------------------- ---------------------- 1991 1992 1993 1994 1995 1994 1995 ---------- ---------- ----------- ---------- ---------- ---------- ---------- (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF OPERATIONS DATA: Sales and revenues.................... $ 73,498 $ 71,746 $ 84,543 $ 103,069 $ 183,000 $ 35,554 $ 51,880 Operating income...................... 7,909 6,492 8,903 12,665 16,573 3,851 4,597 Income before income taxes............ 1,634 616 3,363(1) 5,169 7,312 1,724 2,076 Net income............................ 944 359 1,950 2,995 4,307 1,002 1,232 PER SHARE DATA: (2) Net income per common share on a fully diluted basis....................... $ 0.38 $ 0.01 $ 0.39 $ 0.59 $ 0.76 $ 0.18 $ 0.22 Weighted average common shares outstanding......................... 2,377,821 2,394,151 2,431,549 3,719,884 5,420,158 5,354,000 5,415,000 SUPPLEMENTAL DATA: EBITDA (3)............................ $ 4,474 $ 2,761 $ 5,024 $ 8,404 $ 11,210 $ 2,661 $ 3,124 Ratio of earnings to fixed charges (4)................................. 1.82x 1.36x 2.73 x 3.82x 4.16x 4.34x 4.11x Dividends per share (5)............... -- -- -- -- $ 0.02 -- $ 0.01
SEPTEMBER 30, 1995 -------------------------- ACTUAL AS ADJUSTED (6) --------- --------------- (IN THOUSANDS) BALANCE SHEET DATA: Working capital......................................................................... $ 20,488 $ 31,991 Total assets............................................................................ 59,491 72,544 Long-term debt (net of current maturities).............................................. 20,011 33,064 Total liabilities....................................................................... 40,756 53,809 Shareholders' equity.................................................................... 18,735 18,735
- --------------- (1) Includes a pre-tax gain from a legal judgment in the amount of $1,060,000. (2) Shares outstanding and earnings per share have been adjusted retroactively to reflect the payment of a ten percent stock dividend on June 16, 1995. (3) EBITDA as used herein means earnings before interest expense, interest income, taxes, depreciation and amortization, and excludes minority interest and the pre-tax gain from a legal judgment in fiscal 1993. (4) For purposes of calculating this ratio, earnings consist of income before income taxes and fixed charges. Fixed charges consist of interest expense and one-third of rental expense, representative of that portion of the rental expense attributable to interest. The pro forma ratio, adjusted to reflect the issuance of the Debentures offered hereby and the application of the net proceeds therefrom to repay the Revolver, with the balance invested at short-term market rates, would be 2.70x and 2.96x for the year ended June 30, 1995 and the three months ended September 30, 1995, respectively. (5) In December 1994, Mercury's Board of Directors adopted a quarterly dividend plan of $.01 per share of common stock. Dividends in the aggregate amounts of $50,000, $50,000, $55,000 and $54,000 were paid on February 1, 1995, May 1, 1995, September 1, 1995 and November 1, 1995, respectively. (6) Adjusted to reflect the issuance of the Debentures offered hereby and the application of a portion of the net proceeds therefrom to repay the Revolver in full. As of December 31, 1995, the amount of the Revolver was $13.2 million. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000055698_first_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000055698_first_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..cb40f74d3c22e8a5db3c5e7de7fc37c2921aacda
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000055698_first_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and Financial Statements and Notes thereto appearing elsewhere in this Prospectus. Except as otherwise indicated, the information in this Prospectus assumes the Underwriters' over allotment option is not exercised. All information reflects the two-for-one, three-for-one, and two-for-one stock splits effected on June 14, 1991, December 15, 1992 and December 29, 1995, respectively. The First Years Inc. is a leading developer and worldwide marketer of a broad line of innovative, high-quality, value-priced, developmentally-sound products for infants and toddlers. Since 1973, the Company has sold products under its well-known brand name and principal trademark, THE FIRST YEARS. In the last three years, the Company has entered into licensing agreements with The Walt Disney Companies to feature Winnie the Pooh characters on a variety of its products in various countries. The Company's product line now contains approximately 300 items and is divided into five categories -- Feeding & Soothing, Care & Safety, Play & Discover, Gifts & Sets and Winnie the Pooh. Retail prices for the Company's products range from approximately $0.99 to $69.99. Major channels through which the Company sells its products include mass merchants, supermarkets, drug stores, department stores, wholesale clubs, convenience stores, specialty stores, mail-order catalogs and catalog showrooms. The Company currently has over 1,000 customers in over 40 countries. Major customers include Wal*Mart, Toys "R" Us, Target, Kmart, J. C. Penney, Kroger and Baby Superstore. The Company believes that a number of recent demographic trends in the United States have had a favorable impact on the market for juvenile products in general and the appeal of the Company's product line in particular. In the U.S. and many other developed countries, children are being born to dual-income parents and parents are having children at later ages. The Company also believes that parents in general, and especially older parents, are now more aware of the developmental importance of a child's early years and more concerned about safety, quality and value in juvenile products and that they are also more willing and able to pay for products that embody these qualities. Capitalizing on its reputation for parenting expertise and product quality, its development of products that are based on Ideas Inspired by Parents and its longstanding relationship with Dr. T. Berry Brazelton and the Child Development Unit at Boston's Children's Hospital, the Company believes it is well positioned to produce new and innovative products that meet the requirements of today's parents. The Company believes that its growth will result in large part from the continued expansion of its existing product line for infants and toddlers up to three years of age and the development of products for children from three to six years of age. The Company introduced 45 new products in 1994, 90 new products in 1995 and intends to introduce over 60 new products in 1996. Among the 1995 items were initial entries into product segments that were new to the Company. Those entries included several higher-priced furnishings, such as bath seats, booster seats and step stools; higher-priced boxed toys; electronic products for the nursery, including a nursery monitor and crib tape player/night light; travel-related products such as diaper bags and child carriers; and 25 products featuring Winnie the Pooh characters. In 1996, the Company is expanding each of its product categories, including the introduction of 26 new products featuring Winnie the Pooh characters. During this period of rapid product development, net sales have increased from approximately $46.1 million in 1993 to $75.8 million in 1995. The Company believes that its future growth will also come from the expansion of its distribution in both domestic and international markets. The Company's strategy in the United States is to increase its penetration in all of its major channels of distribution. Internationally, the Company has expanded its sales in Europe with the opening of a sales office in the United Kingdom in 1992 and has increased distribution of its products in the past few years in Canada, Central and South America, the Middle East and the Pacific Rim. The Company believes that its products have been well received by international consumers and that the number of births and rising income levels in international markets present significant opportunities for growth. The Company was incorporated in 1952 in Massachusetts under the name Kiddie Products, Inc. The Company changed its name to The First Years Inc. in May 1995. The Company's headquarters are located at One Kiddie Drive, Avon, Massachusetts 02322, and its telephone number is (508) 588-1220. [THE FIRST YEARS] IFC [Child on parent's shoulders with Company logo superimosed.] THE FIRST YEARS(R), Ideas Inspired by Parents(R), TumbleMates(R), Firstronics(R) and Washables(R) are registered trademarks of The First Years Inc. Simplicity(TM), Sure(TM), Choice(TM), Clip'n Go(TM), Neats(TM), PackMates(TM), Nurserytronics(TM), Step-by-Step(TM) and First Gifts(TM) are trademarks of The First Years Inc. 3M(R) and SCOTCHGARD(R) are registered trademarks of Minnesota Mining and Manufacturing Company. WINNIE THE POOH(R), POOH(R), DISNEY BABIES(R), and 101 DALMATIANS(R) are registered trademarks of Disney Enterprises, Inc. ------------------------ IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVERALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OF THE COMPANY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. ------------------------ IN CONNECTION WITH THIS OFFERING, CERTAIN UNDERWRITERS AND SELLING GROUP MEMBERS AND THEIR AFFILIATES MAY ENGAGE IN PASSIVE MARKET MAKING TRANSACTIONS IN THE COMMON STOCK OF THE COMPANY ON THE NASDAQ NATIONAL MARKET IN ACCORDANCE WITH RULE 10B-6A UNDER THE SECURITIES EXCHANGE ACT OF 1934. SEE "UNDERWRITING." THE OFFERING Common Stock offered by: The Company............................................. 400,000 shares The Selling Stockholders................................ 1,200,000 shares Total.............................................. 1,600,000 shares Common Stock to be outstanding after completion of this Offering(1)................................................ 4,935,570 shares Use of proceeds.............................................. Debt repayment and working capital. See "Use of Proceeds." Nasdaq National Market symbol................................ KIDD
- --------------- (1) Based on shares outstanding at June 3, 1996. Does not include 453,662 shares issuable upon the exercise of outstanding options under the Company's stock plans. SUMMARY FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS YEAR ENDED DECEMBER 31, ENDED MARCH 31, ----------------------------------------------- ----------------- 1991 1992 1993 1994 1995 1995 1996 ------- ------- ------- ------- ------- ------- ------- STATEMENT OF INCOME DATA: Net sales........................ $37,993 $45,267 $46,124 $53,233 $75,757 $15,802 $23,009 Cost of products sold............ 20,199 23,645 26,654 29,498 45,109 9,256 13,947 Selling, general, and administrative expenses........ 14,776 18,430 17,857 18,916 23,961 5,158 6,926 Income before income taxes....... 3,306 3,315 1,278 4,861 6,207 1,383 1,972 Net income....................... 1,916 1,930 796 2,989 3,724 830 1,187 Earnings per share(1)............ $ 0.43 $ 0.43 $ 0.18 $ 0.66 $ 0.80 $ 0.18 $ 0.25 Weighted average number of shares outstanding.................... 4,497 4,497 4,497 4,497 4,663 4,662 4,689
SUMMARY BALANCE SHEET AT MARCH 31, 1996: AS ACTUAL ADJUSTED(2) ------- ----------- Current assets........ $37,242 $$37,242 Property, plant, and equipment - net..... 6,708 6,708 ------- ----------- $43,950 $43,950 ======= =========
AS ACTUAL ADJUSTED(2) ------- ----------- Current liabilities... $16,272 $ 9,863 Long term liabilities......... 715 715 Stockholders' equity.............. 26,963 33,372 ------- ----------- $43,950 $43,950 ======= =========
- --------------- (1) The net proceeds from the sale of approximately 387,000 of the shares of Common Stock offered by the Company hereby will be used to repay certain indebtedness. Assuming these shares had been issued and the indebtedness repaid as of January 1, 1995, pro forma earnings per share for 1995 would have been $0.76. (2) Adjusted to reflect the sale of the 400,000 shares of Common Stock offered by the Company hereby at an assumed public offering price of $17.25 per share (the last reported sale price on June 3, 1996) and after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company related to the Offering, and the application of the net proceeds therefrom. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000060064_loehmanns_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000060064_loehmanns_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..f9a3931dc69770d0dcbe35eccf52342f8deea050
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000060064_loehmanns_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and consolidated financial statements appearing elsewhere in this Prospectus. Unless otherwise indicated, all information in this Prospectus, including the share and per share information, (i) gives effect to the Recapitalization Transactions as defined under "The Company" and (ii) assumes no exercise of the Underwriters' over-allotment option. As used in this Prospectus, references to a fiscal year refer to Loehmann's, Inc.'s fiscal year ended or ending on the Saturday closest to January 31 of the following year. Certain statements in this Prospectus (including this Prospectus Summary) constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). See "Special Note Regarding Forward-Looking Statements." THE COMPANY Loehmann's, Inc. ("Loehmann's" or the "Company"), founded in 1921 as the "Original Designer Outlet," is a leading specialty retailer of well known designer and brand name women's fashion apparel, accessories and shoes offered at prices that are typically 25% to 50% below department store prices. The Company believes it has developed a unique franchise as the largest national upscale off-price specialty retailer--one that differentiates itself from finer department stores by offering similar merchandise at significantly lower prices, and from other off-price apparel retailers by offering a broad range of designer and bridge merchandise. The Company currently operates 73 stores in major metropolitan markets located in 23 states. The Company has embarked on an expansion strategy to capitalize on the strength of its franchise and well-recognized name. The following factors serve as the Company's key strengths and distinguishing characteristics: . The Company, like finer department stores, is known for carrying designer and bridge labels by prominent designers such as Donna Karan, Calvin Klein, Ralph Lauren, Adrienne Vittadini, Tahari, Dana Buchman, Andrea Jovine and Emanuel Ungaro, among others. However, unlike finer department stores, the Company offers such merchandise for sale at a substantial discount. . Loehmann's high quality image and affluent customer base uniquely position the Company as a principal choice for well known designers who believe their prestige will be preserved by having their merchandise offered by Loehmann's as opposed to other off-price retailers. . The Company provides in-season high quality merchandise to its stores on a daily basis as a result of its flexible purchasing strategy, low-price, cyclical markdown policy and efficient inventory management systems. . The Company has a low-cost operating structure as a result of its no-frills store format, lean corporate overhead and disciplined real estate strategy. In recent years, the Company has sought to broaden its appeal and to increase margins through the addition of new product categories such as shoes and a broader range of accessories and intimate apparel. Since the introduction or expansion of these categories starting in fiscal 1992, gross margins have increased from 26.4% for fiscal 1992 to 31.1% for fiscal 1995 and to 31.7% for the first six months of fiscal 1996. In addition, to prepare for its store expansion program, the Company has made significant investments in merchandising, planning, allocation and MIS infrastructure and has continued to refine its store format. To capitalize on its unique franchise, the Company has embarked on a new store expansion program under which it intends to open seven stores in fiscal 1996 and seven to ten stores in each of the next two fiscal years. Four of the seven stores planned for fiscal 1996 already have been opened. Based on its historical operating experience, the Company believes that its larger stores typically experience enhanced operating performance with increased inventory turns, higher margins and increased profitability. The Company's eight stores which exceed 23,000 square feet averaged $11.7 million in net sales in fiscal 1995 as compared to $4.7 million for the balance of the Company's stores which were open for the entire year in fiscal 1995. These eight stores generated store contribution as a percentage of net sales of 15.1% as compared to 13.3% for the balance of the Company's stores. To take advantage of the favorable economics associated with its larger stores, the Company's prototype for its new stores is 25,000 to 35,000 square feet compared to the Company-wide average of approximately 16,000 square feet. The Company's planned store openings for fiscal 1996 will be located in existing markets where the Loehmann's franchise is well established and in central business districts which have appealing demographics, such as New York and Boston. As part of its store opening program, the Company intends to open a new 60,000 square foot flagship store in downtown Manhattan at the site that recently housed Barneys' Seventh Avenue Men's Store in October 1996. RECENT DEVELOPMENTS Since February 1996, the Company has opened four of the seven stores planned for fiscal 1996, one each in Merrick, New York, Houston, Texas, San Diego, California and Paramus, New Jersey. These new stores reflect the Company's new, larger store format and average approximately 26,000 square feet compared to the Company-wide average of approximately 16,000 square feet. Two of the new stores being opened in fiscal 1996 are replacing existing, smaller format stores. The Company has signed leases for its three remaining stores planned for fiscal 1996. Two of these stores are scheduled to open during the third quarter, including the Company's new 60,000 square foot flagship store in downtown Manhattan and a new central business district store in Boston, Massachusetts. The third store, a replacement store in Brooklyn, New York, is scheduled to open in November 1996. These new stores, other than the Company's Manhattan store, will each be approximately 30,000 square feet. The Company has also signed four leases associated with stores to be opened in fiscal 1997 including locations in Seattle, Washington, Ft. Lauderdale, Florida, Tustin, California, and Westbury, New York. The Company is currently in lease negotiations for several other store locations for fiscal 1997 openings. Combined sales of the Company for the months of August and September 1996 rose 12.0% to $73.2 million from $65.4 million in the comparable period in 1995, and combined comparable store sales of the Company for August and September 1996 were up 3.4% from the comparable period in 1995. THE OFFERING Common Stock offered by the Selling Stockholders..... 1,970,000 shares Common Stock to be outstanding after the Offering.... 8,385,638 shares (1) Nasdaq National Market symbol........................ LOEH
- ------------ (1) Excludes (i) 958,664 shares of Common Stock, par value $0.01 per share, of the Company (the "Common Stock") which, upon consummation of the Offering, will be issuable upon the exercise of outstanding stock options at a weighted average exercise price of approximately $7.08 per share, 365,963 of which will be exercisable immediately and (ii) 469,237 shares of Class B Common Stock, which are convertible after November 6, 1996 into 469,237 shares of Common Stock. SUMMARY CONSOLIDATED FINANCIAL AND OPERATING DATA (IN THOUSANDS, EXCEPT OPERATING AND PER SHARE DATA) FISCAL YEAR SIX MONTHS ENDED ------------------------------------------------ ----------------------------- JULY 29, AUGUST 3, 1991 1992 1993 1994 1995 1995 1996 -------- -------- -------- -------- -------- ------------- -------------- STATEMENT OF OPERATIONS DATA: ]Net sales........................ $389,183 $389,330 $373,443 $392,606 $386,090 $ 186,932 $194,772 Gross profit...................... 92,310 102,691 98,452 114,208 120,201 57,705 61,834 Store contribution (1)............ 39,384 45,948 39,180 49,192 52,159 25,240 28,402 Depreciation and amortization..... 12,462 11,492 14,334 11,955 12,120 6,062 6,046 Charge for store closings and impairment of assets (2)......... -- -- -- -- 15,300 15,300 -- Operating income (loss)........... 11,146 16,233 8,654 16,613 3,296 (6,116) 11,101 Interest expense, net............. 17,663 16,889 17,299 18,085 18,153 8,955 7,990 Income (loss) before extraordinary items............................. (6,472) (783) (8,724) (1,506) (14,963) (15,179) 3,051 Extraordinary items (3)........... -- -- 3,507 -- -- -- 7,101 Net loss (4)...................... (6,472) (783) (12,231) (1,506) (14,963) (15,179) (4,050) Stock dividends on and normal and accelerated accretion of preferred stock (5).............. 1,181 1,335 1,496 1,802 2,056 922 5,668 Net loss applicable to common stock (4)......................... (7,653) (2,118) (13,727) (3,308) (17,019) (16,101) (9,718) Net loss per share applicable to common stock before extraordinary items............................. $(1.78) $(0.49) $(2.18) $(0.63) $(3.12) $(3.07) $(0.38) Net loss per share applicable to common stock after extraordinary items............................. (1.78) (0.49) (2.93) (0.63) (3.12) (3.07) (1.40) Weighted average common shares outstanding (6)................... 4,297 4,299 4,680 5,228 5,463 5,247 6,934
SIX MONTHS ENDED ------------------------------- JULY 29, AUGUST 3, 1995 1996 ------------- -------------- PRO FORMA STATEMENT OF OPERATIONS DATA (7): Net sales........................................................... $ 186,932 $194,772 Store contribution (1).............................................. 25,240 28,402 Depreciation and amortization....................................... 5,722 5,895 Operating income (loss)............................................. (5,776)* 11,253 Interest expense, net............................................... 5,800 5,499 Net income (loss)................................................... (7,061)* 3,510 Earnings (loss) per share........................................... $ (0.79)* $ 0.37 Weighted average common shares and common share equivalents outstanding......................................................... 8,946 9,503
- ------------ * Includes a charge to operating income (loss) and net income (loss) of $15.3 million, related to the closure of 11 stores in August 1995 and the impairment of certain primarily intangible assets, which had a negative impact of $1.03 per share (after tax effect) on earnings per share. FISCAL YEAR SIX MONTHS ENDED ------------------------------------------------ ----------------------------- JULY 29, AUGUST 3, 1991 1992 1993 1994 1995 1995 1996 -------- -------- -------- -------- -------- ------------- -------------- SELECTED OPERATING DATA: Number of stores open at end of period............................ 81 85 81 80 69 69 71 Average net sales per gross square foot (8).......................... $350 $333 $320 $337 $327 -- -- Inventory turnover (9)............ 5.4x 5.4x 5.1x 5.7x 5.4x -- --
AUGUST 3, 1996 --------- BALANCE SHEET DATA: Working capital.................................................................... $ 12,985 Total assets....................................................................... 155,667 Total debt......................................................................... 100,543 Common stockholders' equity........................................................ 16,721
- ------------ (1) Computed as gross profit less store operating expenses and pre-opening costs. (2) In fiscal 1995, the Company recorded charges related to the closure of 11 stores in August and the impairment of certain primarily intangible assets of $10.35 million and $4.95 million, respectively. Of the total $15.3 million charge, $10.45 million represents non-cash items. See Notes 5 and 6 to the Consolidated Financial Statements of the Company. (3) The extraordinary loss recorded in the first six months of fiscal 1996 related to the prepayment of the Company's 10 1/2% Senior Secured Notes ($52.5 million face amount), 13 3/4% Senior Subordinated Notes ($77.6 million face amount), 11 7/8% Senior Notes ($5.0 million face amount) along with the write-off of related deferred financing amounts of $2.2 million. The extraordinary loss in fiscal 1993 related to the repurchase of $30.0 million principal amount 13 3/4% Senior Subordinated Notes and the payment of $12.0 million on the remaining balance of a term loan in October 1993. The loss includes a $2.0 million premium paid on the repurchase of the 13 3/4% Senior Subordinated Notes and a $1.5 million write-off of the deferred financing costs attributed to the term loan. (4) At February 3, 1996, the Company had a net operating loss carryforward of $27.0 million which is available to reduce taxes payable on future taxable income. The Company's ability to utilize its net operating loss carryforward will be dependent on the Company generating taxable income in future years and will be subject to certain limitations on its ability to use all of the net operating loss carryforward in any single fiscal year pursuant to Section 382 of the Internal Revenue Code. (5) Represents stock dividends on and normal and accelerated accretion of the Company's Series A Preferred Stock to its liquidation price of $0.56 per share. All shares of Series A Preferred Stock were redeemed in connection with the Company's debt and equity offerings completed in May 1996 (see "The Company"). (6) Excludes for fiscal years 1991 to 1995 and for the six months ended July 29, 1995, 453,317 shares of Common Stock issuable as of August 3, 1996 upon the exercise of outstanding stock options at a weighted average exercise price of approximately $1.60 per share, 416,587 of which are exercisable within 60 days following such date, as inclusion of such options in weighted average shares would have been antidilutive. Excludes for the six months ended August 3, 1996, 877,884 shares of Common Stock issuable as of August 3, 1996 upon the exercise of outstanding stock options at a weighted average exercise price of approximately $3.77 per share, 416,587 of which are exercisable within 60 days following such date, as inclusion of such options in weighted average shares would have been antidilutive. Includes 469,237 shares of Class B Common Stock, convertible after November 6, 1996 into 469,237 shares of Common Stock. (7) Pro forma to reflect the effects of the Company's debt and equity offerings completed in May 1996 (see "The Company") and an assumed effective tax rate of 39%, as if such transactions had been completed immediately prior to the commencement of the respective periods. (8) Average net sales per gross square foot is determined by dividing total net sales by the weighted average gross square footage of stores open during the period indicated. (9) Inventory turnover is determined by dividing cost of sales by monthly average inventory valued at cost.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000061442_ascent_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000061442_ascent_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..fed49347b798410dfc68317c9f87d877f58b9937
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000061442_ascent_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION, INCLUDING "RISK FACTORS" AND THE CONSOLIDATED FINANCIAL STATEMENTS AND NOTES THERETO INCLUDED ELSEWHERE IN THIS PROSPECTUS. UNLESS OTHERWISE INDICATED, THE INFORMATION IN THIS PROSPECTUS ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION. UNLESS THE CONTEXT OTHERWISE REQUIRES, REFERENCES IN THIS PROSPECTUS TO THE COMPANY OR TODD-AO INCLUDE THE TODD-AO CORPORATION AND ITS SUBSIDIARIES. THE COMPANY Todd-AO provides sound, video and ancillary post production and distribution services to the motion picture and television industries in the United States and Europe. The Company believes that it is one of the largest independent providers of combined sound studio and video services in the world with facilities located in Los Angeles, New York, London and Atlanta. Sound services include music recording, sound editing and enhancement and the mixing of dialogue, music and sound effects. Todd-AO's principal video services include film-to-video transfer (telecine), mastering and duplication of professional videotape formats, transmission for satellite broadcast, videotape editing, audio post production, and visual effects and graphics. Todd-AO provides these sound and video services to over 500 clients, including the major motion picture studios and television production companies such as The Walt Disney Company ("Disney"), Paramount Pictures Corporation ("Paramount"), Turner Broadcasting System, Inc. ("Turner"), Sony Pictures Entertainment ("Sony"), Warner Bros. Studios Inc. ("Warner Bros.") and Spelling Entertainment Group, Inc. ("Spelling"). The Company believes that its principal strengths include the depth and continuity of its creative and artistic talent, the quality and scope of its facilities, a tradition of providing quality services to its clients and a history of technological innovation. Since its inception in 1952, the Company and its employees have been nominated for 31 Academy Awards-Registered Trademark- and have won 18. Demand for the Company's services and facilities is principally derived from the production of new motion pictures, television programs and television commercials, as well as the distribution of previously released motion pictures and television programming through distribution channels such as television syndication, home video, cable and satellite. Historically, its clients have outsourced, and are expected by the Company to continue to outsource, many services required for production, post production, and distribution of film and television programming. The Company believes that trends toward digitalization and globalization in the entertainment and media industries are increasing the quality, variety and number of post production services required by customers. The Company believes that the worldwide market penetration of distribution channels such as home video and digital satellite broadcast is contributing to a growing demand for original and reissued programming, American product in particular, which in turn should increase demand for the Company's services. The Company's objective is to be the leading worldwide independent provider of sound and video post production services. Since 1994, the Company has implemented a strategy to achieve this objective and to capitalize on the movement towards digitalization and globalization in the motion picture and television industries by expanding its range of services through strategic acquisitions, internal growth and strategic alliances. The Company believes that in the future, U.S. and international entertainment and media companies will demand a broader range of sound and video post production services and are likely to prefer a single-source service provider. This strategy was formulated by the Company and is being executed under the leadership of Salah M. Hassanein, who became President in 1994. Mr. Hassanein has spent his entire career in the entertainment and media industry and has garnered both international experience and mergers and acquisitions expertise with United Artists Theatre Circuit, Inc. and Time Warner International Theatres, where he was responsible for development and expansion of Warner Bros.' overseas theater operations. To implement its strategy, the Company has assembled a senior management team experienced in the industry. The Company entered the video services business in 1994 through its acquisition of Film Video Masters, renamed Todd-AO Video Services. In 1995, the Company expanded its sound studio business through the acquisition of Skywalker Sound South, renamed Todd-AO Studios West, with sound studios and facilities located in the West Los Angeles area. Also in 1995, the Company expanded its operations into Europe through the acquisition of Chrysalis Television Facilities, Ltd. ("Chrysalis"), which augmented the Company's video services capabilities to include the collation of television programming for satellite broadcast. The purchase of Filmatic Laboratories ("Filmatic") in 1996 enlarged Todd-AO's video services capabilities in London and added film processing capability. In August 1996, the Company acquired Edit Acquisition LLC ("Editworks"), located in Atlanta, Georgia, which specializes in providing video services to the advertising industry. As a result of these transactions, the Company has expanded its client base, increased its range of services and broadened its global market coverage. Largely as a result of efforts implementing its strategy, the Company's annual sales have grown in the past three years at an annual compounded rate of 32% from $27.4 million in fiscal 1993 to $62.9 million in fiscal 1996. Net income has grown in the same period at an annual compounded rate of 62% from $1.14 million in fiscal 1993 to $4.84 million in fiscal 1996. THE OFFERING Common Stock Offered................................ 2,500,000 shares of Class A Common Stock Common Stock Outstanding After the Offering......... 9,055,640 shares of Class A Common Stock and 1,747,181 shares of Class B Common Stock (1) Use of Proceeds..................................... For possible future acquisitions, temporary repayment of amounts under credit facility, working capital requirements and general corporate purposes. See "Use of Proceeds." Nasdaq National Market Symbol....................... "TODDA"
- ------------------------ (1) Excludes 660,000, 330,000 and 770,000 shares of Class A Common Stock reserved for issuance under the Company's 1986 Stock Option Plan, 1994 Stock Option Plan, and 1995 Stock Option Plan (the "Stock Option Plans"), respectively, of which options for an aggregate of 1,008,645 shares of Class A Common Stock were issued and outstanding as of August 31, 1996 and options for an aggregate of 514,677 shares of Class A Common Stock were exercisable as of August 31, 1996. See "Management--Stock Options." SUMMARY CONSOLIDATED FINANCIAL DATA YEARS ENDED AUGUST 31, NINE MONTHS ENDED MAY 31, -------------------------------------------- --------------------------------- 1995 1996 ---------------------- ---------------------- PRO PRO 1993 1994 ACTUAL FORMA(1) 1995 ACTUAL FORMA(1) --------- --------- --------- ----------- --------- --------- ----------- (IN THOUSANDS, EXCEPT PER SHARE DATA) CONSOLIDATED INCOME STATEMENT DATA: Revenues............................. $ 27,402 $ 32,892 $ 50,003 $ 53,194 $ 37,125 $ 48,140 $ 51,445 --------- --------- --------- ----------- --------- --------- ----------- Costs and expenses: Operating costs and other expenses......................... 22,641 27,021 39,867 42,126 29,405 37,231 39,345 Depreciation and amortization...... 2,412 2,603 3,917 4,526 3,014 3,967 4,480 Interest expense................... 17 24 581 874 320 531 780 Equipment lease expense, net....... -- -- 593 593 371 415 415 Other (income) expense, net........ (483) (773) (290) (315) (223) (554) (600) --------- --------- --------- ----------- --------- --------- ----------- Total costs and expenses......... 24,587 28,875 44,668 47,804 32,887 41,590 44,420 --------- --------- --------- ----------- --------- --------- ----------- Income before loss from joint venture and provision for income taxes..... 2,815 4,017 5,335 5,390 4,238 6,550 7,025 Loss from joint venture.............. (1,014) (1,215) (249) (249) (167) (117) (117) --------- --------- --------- ----------- --------- --------- ----------- Income before provision for income taxes.............................. 1,801 2,802 5,086 5,141 4,071 6,433 6,908 Provision for income taxes........... 664 1,022 1,711 1,731 1,452 2,371 2,542 --------- --------- --------- ----------- --------- --------- ----------- Net income........................... $ 1,137 $ 1,780 $ 3,375 $ 3,410 $ 2,619 $ 4,062 $ 4,366 --------- --------- --------- ----------- --------- --------- ----------- --------- --------- --------- ----------- --------- --------- ----------- Net income per common share and common share equivalents(2)........ $ 0.14 $ 0.22 $ 0.40 $ 0.40 $ 0.31 $ 0.46 $ 0.49 --------- --------- --------- ----------- --------- --------- ----------- --------- --------- --------- ----------- --------- --------- ----------- Weighted average shares outstanding(2)..................... 8,279 8,196 8,399 8,466 8,352 8,805 8,872 --------- --------- --------- ----------- --------- --------- ----------- --------- --------- --------- ----------- --------- --------- ----------- OTHER FINANCIAL DATA: Capital expenditures................. $ 393 $ 1,404 $ 3,345 $ 3,848 $ 2,638 $ 3,317 $ 3,950 EBITDA(3)............................ 5,244 6,644 9,833 10,790 7,572 11,048 12,285
MAY 31, 1996 ----------------------------------- PRO FORMA PRO AS ACTUAL FORMA(4) ADJUSTED(5) --------- ----------- ----------- (IN THOUSANDS) CONSOLIDATED BALANCE SHEET DATA: Cash and cash equivalents...................................................... $ 3,263 $ 3,274 $ 18,556 Working capital................................................................ 11,181 11,012 26,294 Total assets................................................................... 57,684 64,469 79,751 Long-term debt, net of current portion......................................... 6,065 10,945 2,315 Stockholders' equity........................................................... 34,594 35,564 59,476
(FOOTNOTES BEGIN ON NEXT PAGE) (1) The Company purchased substantially all of the assets and certain liabilities of Editworks for cash and the Company's Class A Common Stock as of August 15, 1996. The pro forma summary financial data gives effect to the acquisition of Editworks as if it had occurred as of September 1, 1994. Such pro forma consolidated financial information is not necessarily indicative of the financial position or results of operations as they may be in the future or as they might have been had the acquisition been effected on the assumed date. See "Unaudited Pro Forma Condensed Consolidated Information." (2) Such amounts represent net income per common share and common share equivalents, pro forma, to give effect to the 66,863 shares of the Company's Class A Common Stock issued as part of the purchase of Editworks. The net income per common share and common share equivalent is computed based upon the weighted average number of shares of common stock and common stock equivalents, including the number of shares of common stock issued in connection with the purchase of Editworks, and includes common share equivalents arising from the assumed conversion of any outstanding dilutive stock options. All share and per share data has been adjusted to give effect to the 10% stock dividends paid in August 1995. (3) EBITDA, defined as earnings before interest expense, income taxes, depreciation and amortization and loss from joint venture, is not intended to represent an alternative to net income (as determined in accordance with generally accepted accounting principles) as a measure of performance and is also not intended to represent an alternative to cash flow from operating activities as a measure of liquidity. Rather, it is included herein because management believes that it provides an important additional perspective on the Company's operating results and the Company's ability to service its long-term debt and to fund the Company's continuing operations. (4) Adjusted to give effect to the Editworks acquisition, consummated in the fourth quarter of 1996, as if the acquisition was consummated as of May 31, 1996. (5) Adjusted to give effect to (i) the sale of 2,500,000 shares of Class A Common Stock offered hereby by the Company at an assumed offering price to the public of $10.50 per share, net of underwriting discounts and commission and estimated expenses of the offering, (ii) the Editworks acquisition as if it occurred as of May 31, 1996, and (iii) the anticipated use of the estimated net proceeds of the offering. See "Unaudited Pro Forma Condensed Consolidated Information" and "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000072575_nai_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000072575_nai_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..c631b67f9611ad44c845e542f45f403628553912
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000072575_nai_prospectus_summary.txt
@@ -0,0 +1 @@
+SUMMARY The following is a brief summary of certain information contained elsewhere in this Prospectus. This summary is not intended to be complete and is qualified in its entirety by the more detailed information appearing elsewhere in this Prospectus and in the documents referred to herein, all of which should be carefully reviewed. Capitalized terms used herein are defined on the pages of this Prospectus referred to in the Glossary found on page 91. The Company NAI Technologies, Inc., through its wholly-owned subsidiaries (the "Company"), designs, manufactures and markets rugged computer systems, advanced peripheral products, intelligent terminals, high performance work stations, TEMPEST computer systems (which suppress certain radiation to prevent external detectors from reading the data being transcribed) and telecommunications test equipment and transmission products. The Company operates in two distinct operating segments: an Electronic Systems segment and a Telecommunications segment. The Electronic Systems segment, comprised of three subsidiaries, Codar Technology, Inc. ("Codar"), NAI Technologies-Systems Division Corporation ("Systems"), and Lynwood Scientific Developments Limited ("Lynwood"), and all of the Company's defense, military and government-related businesses, provides rugged computer products specifically designed for deployment in harsh environments that require special attention to system configurations. This segment's customer base includes United States and foreign armed services and intelligence agencies. The Telecommunications segment consists of one company, Wilcom, Inc. ("Wilcom"), which provides transmission enhancement products and rugged, hand-held test equipment for analog, digital and fiber-optic communications and data-interchange networks. This segment has developed and is marketing a product which enables telephone companies to enhance the capacity of copper lines for improved voice and data transmission. This segment's customer base includes the Regional Bell Operating Companies ("RBOCs") and independent telephone companies. The Company sells its products directly to these customers and serves as a subcontractor to larger prime contractors serving the same customer base. The Company was incorporated in the State of New York in 1954. The Company's principal executive office is located at 2405 Trade Centre Avenue, Longmont, Colorado 80503, and its telephone number is (303) 776-5674. The Offering Securities Offered $6,342,000 aggregate principal amount of Notes 4,119,700 Warrants to Purchase Common Stock 8,904,336 shares of Common Stock See "DESCRIPTION OF SECURITIES." Terms of the Notes: Maturity Date January 15, 2001. Interest Rate 12% per annum. In the event of a Chapter 11 or Chapter 7 bankruptcy case in which the Company is the debtor, the Notes will bear interest from the date of commencement of the case at a default rate per annum equal to the lesser of 18% or the highest such rate allowable by law. Interest Payment Dates January 15, April 15, July 15 and October 15 of each year, commencing April 15, 1996. Conversion Each Note is convertible into shares of Common Stock at the option of the holder, at any time in whole or in part at a conversion price equal to $2.00 per share, subject to adjustment in certain events (the "Conversion Price"). The Conversion Price will be adjusted to $1.50 or $1.00, respectively, if earnings before interest, taxes, depreciation and amortization ("EBITDA") of the Company fall below $6,000,000 or $4,750,000 in 1996. Should the Company sell the stock or assets of a subsidiary in 1996, such amounts will be reduced by certain agreed amounts, depending on the time of sale. The Conversion Price and the number of shares of Common Stock to be received upon conversion are subject to adjustment upon the occurrence of certain events. See "DESCRIPTION OF SECURITIES--The Notes." The Company may at its option require the conversion of the Notes, at any time prior to maturity, provided that the closing bid price for the Common Stock exceeds $6.00 per share for the 30 consecutive trading days prior to the giving of notice of conversion. Prepayment The Notes are subject to prepayment, in whole and not in part, at the option of the Company, at any time after the third anniversary of the date of issuance, without premium or penalty. Upon the occurrence of a "change in control" of the Company, each holder of the Notes will have the right to require that the Company repurchase such holder's Notes in whole and not in part, without premium or penalty, at a purchase price in cash in an amount equal to 100% of the principal amount thereof, together with accrued and unpaid interest, if any, to the date of purchase, pursuant to an offer made in accordance with the procedures described in the Notes. Subordination; Sinking Fund The indebtedness evidenced by the Notes is subordinated to all existing and future Senior Indebtedness (as hereinafter defined) of the Company. The Notes do not provide for a sinking fund. Certain Covenants The Notes contain certain covenants prohibiting the Company from: (i) creating any liens on its assets, (ii) incurring or assuming any indebtedness other than certain specific indebtedness including the Senior Indebtedness and all extensions, renewals and refundings thereof, (iii) making any investments, (iv) paying dividends on its capital stock, (v) disposing of certain assets, (vi) engaging in certain affiliated party transactions, and (vii) merging or consolidating. Events of Default "Events of Default" under the Notes include the failure to pay principal when due or the failure to pay interest for a period of 10 days after such payment becomes due, the failure to pay other indebtedness for borrowed money in excess of $500,000 when due or the acceleration of such indebtedness, the failure to pay any judgment in excess of $500,000 when due or stayed, and the voluntary or involuntary bankruptcy of the Company. Terms of the Warrants: Exercise and Terms Each Warrant entitles the holder to purchase 250 shares of Common Stock at any time and from time to time on or before February 15, 2002, at an exercise price equal to $2.50 per share of Common Stock, subject to adjustment in certain events (the "Exercise Price"). The Exercise Price will be adjusted to $2.00 or $1.50, respectively, if the Company's EBITDA falls below $6,000,000 or $4,750,000 in 1996. Should the Company sell the stock or assets of a subsidiary in 1996, such amounts will be reduced by certain agreed amounts, depending on the time of sale. The Exercise Price and the number of shares of Common Stock to be received upon exercise are subject to adjustment upon the occurrence of certain events. Warrants will be exercisable, at any time and from time to time, on or before 5:30 p.m., local time, on or before February 15, 2002 (the "Expiration Date") by delivery of an exercise notice duly completed and tendering of the aggregate Exercise Price. Each Warrant may be exercised in whole or in part so long as any exercise in part would not involve the issuance of fractional shares of Common Stock. See "DESCRIPTION OF SECURITIES--The Warrants." Terms of the Common Stock: Terms Holders of shares of Common Stock are entitled to one vote for each share of Common Stock held. The holders of Common Stock are not entitled to preemptive or subscription rights. Upon liquidation, dissolution or winding up of the Company, the holders of the Common Stock are entitled to share ratably in all assets available for distribution after payment in full of creditors and after the preferential rights of holders of shares of Preferred Stock then outstanding, if any, have been satisfied. The affirmative vote of the holders of 80% of all Common Stock of the Company is required for the adoption or authorization of certain extraordinary matters. See "DESCRIPTION OF SECURITIES-- Common Stock." Trading The Common Stock is traded on Nasdaq under the symbol NATL. Offering Period From time to time after the date hereof. Use of Proceeds The Company will not receive any proceeds from the sale of the Securities by the Selling Securityholders. Risk Factors Reference is made to "RISK FACTORS" which contains material information that should be considered in connection with the Securities being offered hereby. Summary Financial Data The summary financial data set forth below for the fiscal years 1991 through 1995 are derived from the consolidated financial statements of the Company which financial statements have been audited by KPMG Peat Marwick LLP, independent certified public accountants, whose report on the Company's consolidated financial statements for the three years ended December 31, 1995 is included elsewhere in this Prospectus. The selected financial data for the six months ended July 1, 1995 and June 29, 1996 have been derived from the Company's unaudited consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 29, 1996. Such unaudited consolidated financial statements in the opinion of the Company's management reflect all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of interim data. Year Ended December 31, Six Months Ended ----------------------- ---------------- 1991 1992 1993 1994 1995 July 1, June 29, ---- ---- ---- ---- ---- ------- -------- (in thousands except share and per share data and 1995 1996 ratios) ---- ---- (unaudited) Statement of Operations Data Net sales $ 59,412 $ 67,315 $ 81,024 $ 54,520 $ 60,008 $ 26,771 $ 33,857 Operating earnings (loss)(1) 6,308 8,407 8,960 (14,589) (8,875) (5,826) 1,789 Net earnings (loss)(1) 3,900 5,051 5,455 (11,591) (11,619) (6,899) 365 Per share data: Net earnings (loss)(2) .63 .80 .80 (1.69) (1.57) (0.94) 0.05 Cash dividends(3) -- -- -- -- -- -- -- Ratio of earnings to fixed charges 8.14 13.88 11.55 * * * 1.36 Balance Sheet Data (at end of period) Working capital $ 14,134 $ 17,094 $ 19,105 $ 16,665 $ 10,044 $ -- $ 14,255 Total assets at end of period 33,817 43,704 60,715 53,720 48,012 -- 48,891 Long-term debt 5,017 7,158 10,797 13,990 15,573 -- 15,951 Shareholders' equity 18,897 23,911 30,593 20,296 10,086 -- 13,515 Average market price per common share at end of period 4-9/16 8-3/16 6-1/4 2-11/16 1-1/2 3-1/4 3-5/8 Weighted average common shares outstanding(2) 6,222 6,309 6,843 6,580 7,382 7,459 8,459
(1) Includes $7,321 in restructuring costs in 1994. (2) Prior year per share data has been restated to reflect 4% stock dividends declared in February 1992, 1993 and 1994 and a three-for-two stock split declared in August 1993. (3) There have been no cash dividends paid during the above five fiscal years. * Earnings are inadequate to cover fixed charges. The coverage deficiency is $15,983 for 1994, $11,242 for 1995, and $6,789,000 for July 1, 1995.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000073822_strategic_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000073822_strategic_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..e2227d12c841258e610055e3b577a457b0fc1e65
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000073822_strategic_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a summary of certain information contained elsewhere in this Prospectus and is qualified in its entirety by the more detailed information and financial statements, and notes thereto, contained elsewhere in this Prospectus. Unless otherwise indicated, the information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. Prospective investors are urged to read this Prospectus in its entirety. Unless otherwise indicated, all information in this Prospectus gives effect to the three percent (3%) Common Stock dividend paid on December 29, 1995 to stockholders of record on December 18, 1995. THE COMPANY The Company provides proprietary industrial supply procurement solutions to industrial sites, primarily through its In-Plant Store(R) program. The Company sells a broad range of industrial supplies, which include maintenance, repair and operations ("MRO") items, replacement parts and selected classes of production materials. Industrial supplies are generally items which are low in price, but are critical to the production process and have historically been characterized by high procurement costs due to inherent inefficiencies in traditional industrial supply distribution methods. The Company's In-Plant Store(R) program, in which large industrial sites outsource the procurement of industrial supplies to the Company, substantially eliminates these inefficiencies by reducing both the process and product costs associated with industrial supply procurement. The Company's In-Plant Store(R) program also helps customers achieve operational improvements, such as reduced plant down-time resulting from unavailable parts and manufacturing process improvements due to better tracking of critical parts. The Company believes that its In-Plant Store(R) program is superior to both traditional and other alternative methods of industrial supply distribution. The Company believes that increased recognition of the inefficiencies associated with the traditional industrial supply distribution process has rapidly increased the demand for the Company's In-Plant Store(R) program in recent years. From January 1994 to April 1996, the number of In-Plant Store(R) sites operated by the Company increased from 13 to 44. Twenty of these sites were added from March 1995 to April 1996. In addition, the Company recently announced the signing of an agreement with a single customer to implement eight additional In-Plant Store(R) facilities during 1996. The In-Plant Store(R) program is a comprehensive outsourcing service through which the Company manages all aspects of industrial supply procurement at a customer's industrial site. Prior to the implementation of an In-Plant Store(R), the industrial site would typically obtain industrial supplies from as many as 500 traditional industrial distributors. Through the In-Plant Store(R) program, the Company becomes responsible for servicing all of its customer's industrial supply needs by establishing a dedicated, fully integrated store within the customer's plant. The customer, in turn, purchases virtually all of its industrial supplies from the In-Plant Store(R). The Company staffs the In-Plant Store(R) with its own highly trained industrial procurement professionals, installs proprietary software designed specifically for industrial procurement and helps determine optimal inventory levels based on the supply needs of each site. Upon implementation, the In-Plant Store(R) purchases, receives, inventories and issues industrial supplies directly to plant personnel, delivers ongoing technical support and provides the customer with a comprehensive invoice twice per month thereby reducing the administrative burden of traditional industrial supply. The In-Plant Store(R) generates system-wide savings generally ranging from 15% to 25% of customers' annual industrial supply purchase costs. The total United States market for the categories of industrial supplies offered by the Company is estimated to be approximately $225 billion annually. Of this total, it is estimated that approximately $20 billion to $30 billion of industrial supplies are purchased annually by the 15,000 largest industrial plants in the United States. These plants represent potential customers for the Company's In-Plant Store(R) program. The Company believes that very few of these 15,000 plants have outsourced their 4 industrial supply procurement. The Company's In-Plant Store(R) customers span a broad range of industries, including the automotive, chemicals, construction, food processing, power generation and natural resource extraction industries, and the In-Plant Store(R) program is suitable for virtually any industry that uses industrial supplies. The Company's existing customers include Allied Signal Inc., The Black and Decker Corporation, Bridgestone/Firestone, Inc., Onan Corporation, Homelite Inc., Hoechst Celanese Corporation, NACCO Materials Handling Group Inc. and Westinghouse Electric Corporation. In addition to its In-Plant Store(R) program, the Company offers several other proprietary industrial supply procurement solutions aimed at specific types of customers. Through its Value Managed SupplySM program, the Company is able to provide some of the features of the In-Plant Store(R) to customers which are too small to support an In-Plant Store(R) or are not prepared to outsource completely their industrial supply procurement. For industrial activities such as construction projects and plant turnarounds, the Company offers its proprietary On-Site StoreSM program in which customers temporarily outsource the management of industrial supply procurement to the Company. The Company offers its Value Managed SupplySM and On-Site StoreSM programs through its network of branches which also provide traditional industrial supply services to customers in markets that have historically been underserved by other industrial supply distributors. The Company also offers other selected outsourcing services for industrial customers, including the management of industrial laundry, process control maintenance and plant logistics. The Company delivers the Value Managed SupplySM program, the On-Site StoreSM program, other outsourcing services and traditional distribution to over 19,000 customers through a network of 32 branches and ten sales and service offices located throughout the United States and in Mexico. The Company's principal executive offices are located at 12136 West Bayaud, Suite 320, Lakewood, Colorado 80228, and the Company's telephone number is (303) 234-1419. 5 THE OFFERING Common Stock offered by the Company.......... 7,000,000 shares Common Stock offered by the Selling Stockholders............................... 1,200,000 shares(1) Total.................................. 8,200,000 shares Common Stock to be outstanding after the Offering................................... 28,765,957 shares(2) Use of Proceeds.............................. To repay bank indebtedness, for working capital, including the opening of In-Plant Store(R) facilities, for general corporate purposes and for the possible acquisition of companies engaged in the business of providing industrial supply services. See "Use of Proceeds." Nasdaq Symbol................................ STRD
------------ (1) Does not include up to 600,000 shares of Common Stock which may be offered by a stockholder of the Company upon exercise of the Underwriters' over-allotment option. See "Principal and Selling Stockholders" and "Underwriting." (2) Excludes (i) 2,976,093 shares of Common Stock at March 31, 1996 which were reserved for issuance under the Company's 1990 Incentive Stock Option Plan and certain other stock option agreements, 1,727,188 of which were subject to currently exercisable options and 429,983 of which were subject to options that were not currently exercisable, and (ii) warrants to purchase 38,625 shares of Common Stock outstanding at March 31, 1996. See Note 14 of Notes to the Company's Financial Statements included elsewhere in this Prospectus. 6 SUMMARY FINANCIAL AND OPERATING DATA The following summary consolidated financial and operating data should be read in conjunction with the Consolidated Financial Statements and Notes thereto of the Company and the other selected historical and pro forma consolidated financial data set forth elsewhere in this Prospectus. THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, --------------------------------------------------- ----------------------- PRO FORMA(1) 1993 1994 1995 1995 1995 1996 ---------- ---------- ---------- ------------ ---------- ---------- (IN THOUSANDS, EXCEPT PER SHARE AND OTHER DATA) STATEMENT OF OPERATIONS DATA: Revenues................... $37,098 $77,613 $117,493 $120,265 $25,396 $33,316 Income (loss) from continuing operations.... 202 2,235 1,004 429 540 (1,966)(2) Income from discontinued operations(3)............ 100 -- -- -- -- -- Net income (loss).......... 302 2,235 1,004 429 540 (1,966)(2) PER SHARE DATA: Primary: Income (loss) from continuing operations.. 0.02 0.13 0.05 0.02 0.02 (0.09)(2) Income from discontinued operations(3).......... -- -- -- -- -- -- Net income (loss)........ 0.02 0.13 0.05 0.02 0.02 (0.09)(2) Fully diluted-- Net income (loss)........ 0.02 0.13 0.04 0.02 0.02 (0.09)(2) AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING.. 12,684,911 16,993,971 21,689,653 21,689,653 21,661,222 21,740,823 OTHER DATA: Number of operational In-Plant Store(R) FACILITIES(4)............. -- 17 31 31 24 37 NUMBER OF IN-PLANT STORE(R) CUSTOMERS(4)............. -- 12 21 21 14 23 NUMBER OF BRANCHES(4)...... 23 26 32 32 26 32 REVENUES FROM IN-PLANT STORE(R) FACILITIES...... -- $31,931 $ 53,895 $ 53,895 $ 11,126 $ 16,805 REVENUES FROM BRANCHES(5).............. $37,098 $45,682 $ 63,598 $ 66,370 $ 14,270 $ 16,511
MARCH 31, 1996 ---------------------- DECEMBER 31, AS 1995 ACTUAL ADJUSTED(6) ------------ ------- ----------- BALANCE SHEET DATA: Working capital.................................... $ 23,599 $19,650 $66,190 Total assets....................................... 48,051 48,881 95,421 Long-term debt obligations......................... 5,903 4,162 1,452 Stockholders' equity............................... 27,391 25,518 74,768
------------ (1) Includes the applicable pro forma effect of adjustments in 1995 for the acquisition of American Technical Services Group, Inc. ("ATSG") as if such acquisition occurred on January 1 , 1995. See Pro Forma Statement of Income for the year ended December 31, 1995 set forth in the Company's Financial Statements included elsewhere in this Prospectus. (2) Includes a restructuring charge of $920,000. (3) Relates to the Company's discontinuance of its information services business, which constituted the Company's business prior to July 1, 1990. (4) As of the end of the period. (5) Includes all revenues other than those from the Company's In-Plant Store(R) PROGRAM. (6) Adjusted to give effect to the sale by the Company of the Shares offered by the Company hereby (based upon an assumed offering price of $7.50 per share) and the application of the net proceeds therefrom as described under "Use of Proceeds." 7
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000080816_providence_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000080816_providence_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..a21a475ae8d83f1c06993670584e25d07e248104
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000080816_providence_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements, including the notes thereto, appearing elsewhere in this Prospectus. Unless the context otherwise requires, all references to the "Company" are to The Providence Journal Company and its consolidated subsidiaries, as successor to Providence Journal Company ("Old PJC") after giving effect to the transactions described herein under "The Company -- Background; Reorganization". Unless otherwise indicated, all market rank, station rank in market and station audience rating and share data contained herein have been obtained from the Nielsen Station Index dated May 1996 and all "effective buying income" ("EBI"), market population, household growth and retail sales data contained herein have been obtained from Investing in Television, 1996 Market Report, published by BIA Publications, Inc. ("BIA"). Unless otherwise indicated, the information in this Prospectus (i) assumes no exercise of the over-allotment option granted to the Underwriters, (ii) assumes that 450,000 shares of Class A Common Stock will be issued in the Direct Placement and (iii) gives effect to a 450-for-1 stock split (the "Stock Split") of the Common Stock effected on June 18, 1996. THE COMPANY GENERAL The Company owns and operates nine network-affiliated television stations (the "Stations") and provides or will provide programming and marketing services to three television stations (the "LMA Stations") under local marketing agreements ("LMAs") in geographically diverse markets throughout the United States (the "Broadcasting Business"), publishes the largest daily newspaper in the Rhode Island and southeastern Massachusetts market (the "Publishing Business"), and produces diversified programming and interactive electronic media services (the "Programming and Electronic Media Business"). The Company's television broadcasting group reaches 5.6 million households, or 6% of all U.S. television households; its newspaper is the leading newspaper in its market in terms of advertising and circulation; and certain of its programming and electronic media businesses, such as the Television Food Network, serve subscribers and viewers nationwide. Important factors in the success of the Company's broadcasting and publishing businesses have been its strong local news focus, targeted local advertising sales efforts, investment in advanced technology and emphasis on cost control. The resulting strength of its media franchises presents attractive opportunities for future growth and for realization of operating efficiencies. In addition to increasing the reach of its broadcasting operations and cable and satellite television networks through acquisitions and internal growth, the Company intends to develop new revenue sources that build on the existing strength of its brands and expertise and have broad regional or national appeal. See "Business". The Company's broadcasting operations are located in markets ranging from the 12th to the 127th largest Designated Market Areas (defined by A. C. Nielsen Co. ("Nielsen") as geographic markets for the sale of national "spot" and local advertising time) in the United States ("DMAs"), with five such Stations and one LMA Station in the 50 largest DMAs. Five of the Stations are network affiliates of the National Broadcasting Company Incorporated ("NBC") television network, two are network affiliates of the Fox Broadcasting Network ("Fox"), one is a network affiliate of the American Broadcasting Company ("ABC") and one is a network affiliate of CBS, Inc. ("CBS"). In 1995, EBITDA (as defined herein) of the Broadcasting Business represented approximately 81% of the Company's EBITDA excluding programming and electronic media and corporate expenses. Eight of these nine Stations are VHF (as defined herein) television stations. Two of the LMA Stations are affiliated with the United Paramount Network ("UPN"). See "Business -- Broadcasting". The Company publishes the leading newspaper in terms of advertising and circulation in its market of Rhode Island and southeastern Massachusetts, the Providence Journal-Bulletin Monday through Saturday and The Providence Sunday Journal (collectively the "Providence Journal"). Average daily circulation levels for the three months ended March 31, 1996 following the consolidation of the morning and afternoon newspapers in June 1995 (see "Business -- Publishing") were approximately 169,500 for Monday through - ------------------------------------------------------------------------------ INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE. SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS DATED JUNE 21, 1996 PROSPECTUS - ---------- 7,125,000 SHARES THE PROVIDENCE [LOGO] JOURNAL COMPANY CLASS A COMMON STOCK ($1.00 PAR VALUE) --------------- All of the 7,125,000 shares of Class A Common Stock, $1.00 par value (the "Class A Common Stock"), offered hereby (the "Underwritten Offering") are being offered by The Providence Journal Company (the "Company"). In addition to the Underwritten Offering contemplated hereby, the Company is also offering an additional 450,000 shares of Class A Common Stock to eligible employees of the Company and its subsidiaries (the "Direct Placement" and, together with the Underwritten Offering, the "Offerings") at a price per share equal to the initial public offering price per share for the Class A Common Stock less an amount equal to the underwriting discount per share. Prior to the Offerings, there has been no public market for the Class A Common Stock. It is currently anticipated that the initial public offering price for the Class A Common Stock will be between $15.00 and $17.00 per share. See "Underwriting" for information relating to the determination of the initial public offering price. Upon consummation of the Offerings, the Company's authorized and outstanding capital stock will consist of Class A Common Stock and Class B Common Stock, $1.00 par value (the "Class B Common Stock" and together with the Class A Common Stock, the "Common Stock"). The rights of the holders of the Common Stock are identical, except that each share of Class B Common Stock entitles the holder to four votes per share, while each share of Class A Common Stock entitles the holder to one vote per share. The Class A Common Stock and Class B Common Stock vote as a single class on substantially all matters, except as otherwise required by law. The Class B Common Stock is convertible at any time at the election of the holder on a share-for-share basis into Class A Common Stock, and automatically converts into Class A Common Stock under certain circumstances involving a transfer. See "Description of Capital Stock". The shares of Class A Common Stock have been approved for listing on the New York Stock Exchange, subject to official notice of issuance, under the symbol "PRJ". SEE "RISK FACTORS" BEGINNING ON PAGE 12 FOR A DISCUSSION OF CERTAIN FACTORS THAT SHOULD BE CONSIDERED BY PROSPECTIVE PURCHASERS OF THE CLASS A COMMON STOCK OFFERED HEREBY. --------------- THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. ================================================================================ PRICE TO UNDERWRITING PROCEEDS TO PUBLIC DISCOUNT(1) COMPANY(2) - -------------------------------------------------------------------------------- Per Share............. $ $ $ - -------------------------------------------------------------------------------- Total(3).............. $ $ $ ================================================================================ - ----------- (1) The Company has agreed to indemnify the several Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). See "Underwriting". (2) Before deducting expenses estimated at $1,400,000 payable by the Company. (3) The Company has granted the Underwriters an option, exercisable within 30 days after the date hereof, to purchase up to an aggregate of 1,068,750 additional shares of Class A Common Stock, at the initial price to public per share, less the underwriting discount, solely to cover over-allotments, if any. If such option is exercised in full, the total Price to Public, Underwriting Discount and Proceeds to Company will be $ , $ and $ , respectively. See "Underwriting".
--------------- The shares of Class A Common Stock are being offered by the several Underwriters, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of certain legal matters by counsel for the Underwriters and certain other conditions. The Underwriters reserve the right to withdraw, cancel or modify such offer and to reject orders in whole or in part. It is expected that delivery of certificates for the shares of Class A Common Stock will be made in New York, New York on or about ,1996. --------------- MERRILL LYNCH & CO. BEAR, STEARNS & CO. INC. DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION --------------- The date of this Prospectus is , 1996. - -------------------------------------------------------------------------------- Saturday and 251,300 for Sunday. The Company, which was founded in 1820, believes that the Providence Journal, published daily since 1829, is the oldest continuously published daily newspaper in the United States. See "Business -- Publishing". The Company produces cable and satellite television programming and interactive and on-line electronic media services through its management role or ownership interests in a variety of content-driven entertainment and information businesses. The Company owns a 46% interest in and participates in the management of Television Food Network, a cable television network that is distributed to approximately 16.5 million subscribers throughout the United States. The Company controls America's Health Network with a 65% ownership interest, and owns all of the equity interest in NorthWest Cable News, both recently launched development stage cable programming network services. The Company also owns equity interests in a variety of interactive, on-line, and broadcast programming businesses. See "Business -- Programming and Electronic Media". BROADCASTING GENERAL. The Stations generally are in markets that the Company believes will experience above-average economic growth in retail sales, EBI and population. The Stations are typically located in the largest cities or state capitals of the states in which they operate. The Company's Stations and the LMA Stations are in geographically diverse regions of the United States, which reduces the Company's exposure to regional economic fluctuations. The following table sets forth general information for each of the Stations and the LMA Stations and the markets they serve, based on the Nielsen Station Index as of May 1996. In February 1992, the Company acquired a 50% joint venture interest (the "King Acquisition") in King Holding Corp. ("KHC"), which indirectly owned Stations KING (Seattle), KGW (Portland), KHNL (Honolulu), KREM (Spokane) and KTVB (Boise) (the "King Stations"). The Company has operated the King Stations since such acquisition and in 1995 acquired 100% of the ownership of the King Stations in the Kelso Buyout (as defined herein). The Stations are listed in order of the ranking of their DMA. NUMBER OF COMMERCIAL TELEVISION NETWORK CHANNEL/ DMA STATIONS RANK IN STATION MARKET AREA(1) STATION(1) STATUS AFFILIATION FREQUENCY(2) RANK(3) IN MARKET(4) MARKET(5) SHARE(6) - --------------- ------- -------- ----------- --------- ------- ------------ --------- -------- Seattle, WA KING Owned NBC 5/VHF 12 8 1 19% KONG(8) LMA N/A N/A 12 8 -- -- Portland, OR KGW Owned NBC 8/VHF 24 8 1 17 Charlotte, NC WCNC Owned NBC 36/UHF 28 8 3 10 Albuquerque/ KASA Owned Fox 2/VHF 48 6 4 7 Santa Fe, NM Louisville, KY WHAS Owned ABC 11/VHF 50 6 1 23 Honolulu, HI KHNL Owned NBC 13/VHF 70 8 1 19 KFVE LMA UPN 5/VHF 70 8 -- -- Spokane, WA KREM Owned CBS 2/VHF 74 4 2 18 Tucson, AZ KMSB Owned Fox 11/VHF 80 6 4 10 KTTU LMA UPN 18/UHF 80 6 -- -- Boise, ID KTVB Owned NBC 7/VHF 127 5 1 30 1995 MARKET REVENUE(7) --------------------- STATION $ (IN MARKET AREA SHARE MILLIONS) - --------------- ------- --------- Seattle, WA 25% $ 269.0 -- 269.0 Portland, OR 22 144.9 Charlotte, NC 11 118.1 Albuquerque/ 16 79.0 Santa Fe, NM Louisville, KY 31 82.3 Honolulu, HI 19 63.7 -- 63.7 Spokane, WA 27 42.8 Tucson, AZ 21 52.2 -- 52.2 Boise, ID 40 26.0 - --------------- (1) As used in this Prospectus, the following "call letters" refer, as the context may require, either to the corporate owner of the station indicated or to the station itself: "KING" refers to KING-TV, Seattle, Washington; "KONG" refers to KONG-TV, Seattle, Washington; "KGW" refers to KGW(TV), Portland, Oregon; "WCNC" refers to WCNC-TV, Charlotte, North Carolina; "KASA" refers to KASA-TV, Albuquerque/Santa Fe, New Mexico; "WHAS" refers to WHAS-TV, Louisville, Kentucky; "KHNL" refers to KHNL(TV), Honolulu, Hawaii; "KFVE" refers to KFVE(TV), Honolulu, Hawaii; "KREM" refers to KREM-TV, Spokane, Washington; "KMSB" refers to KMSB-TV, Tucson, Arizona; "KTTU" refers to KTTU(TV), Tucson, Arizona; and "KTVB" refers to KTVB(TV), Boise, Idaho.
- -------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- (2) As used in this Prospectus, "VHF" refers to the very high frequency band (channels 2-13) of the spectrum and "UHF" refers to the ultra-high frequency band (channels above 13) of the spectrum. (3) Ranking of DMA served by the Station among all DMAs, measured by the number of television households for the 1995-1996 broadcast year. (4) Represents the number of television stations ("reportable stations") designated by Nielsen as "local" to the DMA, excluding public television stations and stations that do not meet minimum Nielsen reporting standards (weekly cumulative audience of less than 2.5%) for reporting in the Sunday through Saturday, 6:00 a.m. to 2:00 a.m. period ("sign-on to sign-off"). Does not include national cable channels or satellite stations. The number of reportable stations may change for each reporting period. (5) Station's rank relative to other reportable stations, based upon the DMA rating as reported by Nielsen, 6:00 a.m. to 2:00 a.m., during the May 1996 measuring period. Data for KHNL and KMSB include KFVE and KTTU, respectively. Data for KING does not include KONG because the LMA for such LMA Station was entered into on May 14, 1996 and the station is not yet operational. (6) Represents the number of television households tuned to the Station as a percentage of the number of television households with sets in use for Sunday-Saturday 6:00 a.m. to 2:00 a.m. from the May 1996 Nielsen Station Index. Data for KHNL and KMSB include KFVE and KTTU, respectively. Data for KING does not include KONG because the LMA for such LMA Station was entered into on May 14, 1996 and the station is not yet operational. (7) Represents gross national, local, regional and political advertising revenues, excluding network and barter revenues (defined as the revenue resulting from the exchange of unsold advertising time for products or services, typically including programming, merchandise, fixed assets, other media advertising privileges, travel and hotel arrangements, and entertainment), for all commercial television stations in the DMA, based on actual local market reporting, as estimated by BIA. Station share of 1995 market revenue for KHNL and KMSB includes revenues of KFVE and KTTU, respectively. Data for KING does not include KONG because the LMA for such LMA Station was entered into on May 14, 1996 and the station is not yet operational. (8) Data for KONG is not available because the station is not yet operational. BROADCASTING BUSINESS AND OPERATING STRATEGY. The Company's strategy in the Broadcasting Business is to increase viewership, advertising revenue and EBITDA primarily by capitalizing on its strong local news franchises, targeted marketing and local sales efforts, high quality, non-network programming and strict cost controls. This strategy has contributed to average compound annual growth in the Company's net revenues and EBITDA in the Broadcasting Business, calculated on a combined basis as herein described, of 9.5% and 23.9%, respectively, from 1991 to 1995. In addition, EBITDA as a percentage of net revenues, calculated on a combined basis, has increased from 21.6% in 1991 to 35.7% in 1995. The components of the Company's Broadcasting Business strategy include the following: ENHANCE STRONG LOCAL NEWS FRANCHISES. Most of the Stations lead their markets in terms of ratings for local news and number of hours of local news that are broadcast per week. The Company has focused on enhancing each Station's local market news programming franchise as the foundation to build significant audience share in such market. Local news programming is commercially valuable because of its high viewership level, the attractiveness to advertisers of the demographic characteristics of the typical news audience (allowing stations generally to charge higher rates for advertising time) and the enhanced ratings of programming in time periods adjacent to the news. In addition, the Company believes that its strong local news programming has helped to differentiate the Stations from cable programming competitors, which generally do not provide such programming. LEVERAGE LOCAL MARKET STRENGTH WITH ADDITIONAL LMAS. The Company plans to pursue opportunities to enter into LMAs in the DMAs in which the Company's Stations operate. The Company believes that LMAs enable the Company to increase revenue and broadcast cash flow by taking advantage of the economies of scale derived from being a television station group owner. The Company also believes that there are benefits in terms of increased advertising revenue from LMA arrangements. MATCH ADVERTISERS TO AUDIENCES THROUGH TARGETED LOCAL SALES. The Company seeks to leverage its strong local presence to increase its advertising revenues and broadcast cash flow by expanding relationships with local and national advertisers and attracting new advertisers through targeted marketing techniques and carefully tailored programming. Each of the Company's Stations has developed high quality programming of local interest and sponsored community events to attract audiences with demographic characteristics desirable to advertisers. In addition, the Company works closely with - ------------------------------------------------------------------------------- advertisers to develop campaigns that match specifically targeted audience segments with the advertisers' overall marketing strategies. MAXIMIZE VIEWER SHARE THROUGH HIGH QUALITY, NON-NETWORK PROGRAMMING. Each of the Company's Stations is focused on improving its syndicated and locally produced non-network programming to attract audiences with favorable demographic characteristics. The Company believes that through a cooperative approach to programming, it can generate incremental revenue by adjusting its programming mix to capture viewers of certain targeted demographic segments that meet the needs of valued advertisers. MAINTAIN EFFECTIVE COST CONTROLS AND LEVERAGE ECONOMIES OF SCALE. Each Station emphasizes strict control of its programming and operating costs as an essential factor in increasing broadcast cash flow. In addition, the Company, as a television station group owner, believes that it has the ability to enter into advantageous group programming contracts. As the provider of NBC network programming in five markets, the Company believes that its ability to enter into stable and favorable affiliation agreements with NBC is enhanced. Through strategic planning and annual budget processes, the Company continually seeks to identify and implement cost-saving opportunities at each of the Stations. CREATE OPERATING EFFICIENCIES THROUGH INVESTING IN TECHNOLOGY. The Company invests selectively in technology to increase operating efficiency, reduce Station operating expenses, or gain a local market competitive advantage. Areas of focus include digital news production, editing and library systems, advanced weather radar equipment, and robotic cameras. The Company has entered into an agreement with AVID Technology, Inc. ("AVID") to test and deploy advanced digital editing, production and server technology that is intended to create a more efficient video production environment. The Company believes that the use of AVID or other digital equipment will result in cost savings and operating efficiencies when fully deployed at the Stations. BROADCASTING ACQUISITION STRATEGY. The Company plans to pursue favorable acquisition opportunities as they become available. The Company's acquisition strategy is to target network-affiliated television stations where it believes it can successfully apply its operating strategy and where such stations can be acquired on attractive terms. The Company generally intends to review acquisition opportunities in growth markets, typically in the 75 largest DMAs in the nation, with what the Company believes to be advantageous business climates. In assessing acquisitions, the Company targets stations for which it has identified specific expense reductions and proposals for revenue enhancement that can be implemented upon acquisition. The Company does not presently have any agreements or understandings to acquire or sell any television stations. See "Business -- Broadcasting -- Business and Operating Strategy". PUBLISHING GENERAL. The Providence Journal is the leading newspaper in terms of advertising and circulation in its market of Rhode Island and southeastern Massachusetts. Average daily circulation levels for the three months ended March 31, 1996 following the consolidation of the morning and afternoon newspapers in June 1995 (as described below) were approximately 169,500 for circulation Monday through Saturday and 251,300 for circulation on Sunday. According to a Belden Associates study, an average of approximately 58% and 69% of the 929,000 total adults in the market surveyed in the fourth quarter of 1995 read the daily Providence Journal-Bulletin and The Providence Sunday Journal, respectively, on a daily basis. In addition, according to this study, an average of approximately 77% and 87% of adults in the market who read any newspaper read the daily Providence Journal-Bulletin and The Providence Sunday Journal, respectively, on a daily basis. The Providence Journal has received numerous awards over the years for its local and national coverage, including its fourth Pulitzer Prize in 1994. BUSINESS AND OPERATING STRATEGY. The Company's publishing strategy is to leverage the Providence Journal's comprehensive regional and local news coverage to generate increased readership, local advertising sales, and new revenue sources based on its strong brand recognition. The Company believes that the recent consolidation of its daily newspapers, reorganization of its staff, and effective cost controls will help contribute to improved operating results. The Company's business and operating strategy for the Publishing Business includes the following key elements: ENHANCE STRONG LOCAL NEWS PRESENCE. The Company has the largest local news gathering resources in its Rhode Island and southeastern Massachusetts market. In 1995, the Company intensified its commitment to local news by reallocating resources to the Providence Journal's regional sections that target readers in seven geographic zones of its market. As a result of the Company's strategies to emphasize regionally-zoned news and information sections and to control costs, on June 5, 1995, the Company consolidated the morning and afternoon newspapers in order to reallocate resources to the regional editions and to reduce operating costs (the "Newspaper Consolidation"). A portion of the total annual savings from this consolidation is being used to enhance local news coverage. REORGANIZE SALES FORCE TO INCREASE CUSTOMER FOCUS. The Company emphasizes a targeted approach to its advertisers and has recently begun the reorganization of its sales force to enhance its effectiveness in attracting advertisers. The Company also intends to institute a new performance-based incentive compensation plan for its salespeople that rewards employees based on their contribution to EBITDA rather than to revenues. The Company believes that this reorganization will enable its sales force to better identify sales opportunities, be more responsive to advertiser needs, and operate more cost effectively. REDUCE OPERATING COSTS. Expenses of the Company's Publishing Business are closely monitored in an effort to control costs without sacrificing revenue opportunities. The Company seeks to reduce labor costs through investment in modern production equipment and the consolidation of operations and administrative activities. The Company has recently reduced operating costs through the Newspaper Consolidation and the Newspaper Restructuring (as defined herein), which together have resulted in an estimated $10 million in annual savings. The Company has also made efforts to reduce its newsprint costs through a variety of methods, including reducing the page width of the newspaper and strict control of newspaper waste. INCREASE REVENUES THROUGH RELATED PRODUCTS. The Company has introduced new informational products and services to generate revenue from sources other than newspaper publishing. These products and services seek to exploit the strong local brand recognition of the Providence Journal and include fax-on-demand products, voice information services, a news wire service, and telemarketing services. See "Business -- Publishing -- Business and Operating Strategy" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". PROGRAMMING AND ELECTRONIC MEDIA GENERAL; BUSINESS AND OPERATING STRATEGY. The Company produces cable television and satellite network programming and interactive and on-line electronic media services through its management role or ownership interests in a variety of content-driven entertainment and information businesses. The Company's approach to development of programming and interactive opportunities is to invest in or manage businesses that are extensions of its experience in the production of programming content or that build on existing media franchises. The Company's programming and electronic media strategy consists of the following key elements: LEVERAGE EXISTING EXPERTISE IN PROGRAMMING AND OTHER CONTENT DEVELOPMENT. The Company has invested in and operates certain businesses, such as the Television Food Network, America's Health Network and NorthWest Cable News, that capitalize on the Company's experience in television broadcasting and newspaper publishing. As additional opportunities arise, the Company expects to pursue such opportunities that best exploit or extend the capabilities of existing talent and resources. EMPHASIZE PROGRAMMING TOPICS WITH BROAD APPEAL. The Company's strategy in its programming businesses is to develop cable and satellite programming networks, such as the Television Food Network, America's Health Network and NorthWest Cable News, based on issues of interest to potential viewers such as food, health and local news. As the Company reviews additional opportunities, it plans to invest in such ventures that it believes have broad audience appeal. EXTEND AND ENHANCE EXISTING BRANDS AND CONTENT. The Company's strategy in developing cable network programming and interactive and on-line electronic media products has been to create products that are closely related to the Company's existing brands and franchises. For example, NorthWest Cable News builds on the leading local news franchises of the Stations in Washington, Oregon and Idaho, and Rhode Island Horizons, an on-line service, presents news, features and advertising displayed in the Providence Journal. The Company also believes that the success of these ventures will serve to enhance the Company's existing broadcast and newspaper properties. MINIMIZE RISK THROUGH STAGED INVESTMENTS IN NEW OPPORTUNITIES. The Company attempts to take a staged approach to investing in start-up ventures by committing financial and managerial resources upon reaching certain milestones in the businesses' development. Such milestones are dependent on the nature of the start-up business, but include identifying promising concepts, commissioning market research, establishing strategic relationships with other investors, negotiating contractual arrangements with key suppliers and evaluating early-stage financial results of specific projects. See "Business -- Programming and Electronic Media -- Business and Operating Strategy". THE OFFERINGS Class A Common Stock offered in the Underwritten Offering............... 7,125,000 shares(1) Class A Common Stock offered in the Direct Placement.................... 450,000 shares Common Stock to be outstanding after the Offerings: Class A Common Stock................ 24,911,700 shares(2)(3) Class B Common Stock................ 21,067,650 shares Total....................... 45,979,350 shares Use of Proceeds....................... The net proceeds from the Offerings will be used to repay a portion of the indebtedness outstanding under the Company's revolving credit facility. See "Use of Proceeds". Voting and Conversion Rights.......... The rights of the holders of the Common Stock are identical, except that each share of Class B Common Stock entitles the holder to four votes per share, while each share of Class A Common Stock entitles the holder to one vote per share. The Class A Common Stock and Class B Common Stock vote as a single class on substantially all matters, except as otherwise required by law. The Class B Common Stock is convertible at any time at the election of the holder on a share-for-share basis into Class A Common Stock, and automatically converts into Class A Common Stock under certain circumstances involving a transfer. See "Description of Capital Stock".
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000083402_resource_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000083402_resource_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..668ac17246b856008901149ca3c97c00672e843e
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000083402_resource_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements and notes thereto appearing elsewhere in this Prospectus. Unless otherwise indicated, all information set forth herein (i) assumes that the Underwriters' overallotment option is not exercised, and (ii) gives effect to 6% stock dividends paid in January 1996 and April 1996 and a five-for-two stock split (effected in the form of a 150% stock dividend) in May 1996. References to the "Company" in this Prospectus include the Company and its consolidated subsidiaries, unless the context otherwise requires. THE COMPANY GENERAL The Company is a specialty finance company engaged in three lines of business: the acquisition and resolution of commercial real estate loans, "small ticket" commercial equipment leasing, and energy operations, including natural gas and oil production. For approximately 25 years prior to 1991, the Company was principally involved in the energy industry. Following the acquisition of a significant ownership position in the Company by new stockholders in 1988 and the appointment of new senior management (including the current Chairman, who has been a senior officer of banking and other financial institutions for the past 30 years), the Company evaluated alternative strategies to expand and diversify its operations (particularly in light of the declining attractiveness of the energy business to small investors following the 1986 changes to the federal tax law). Since 1991, the Company's business strategy has focused on locating and developing niche finance businesses in which the Company can realize attractive returns by targeting well-defined financial services markets and by developing specialized skills to service those markets on a cost-effective basis. To date, the Company has developed two business lines (asset acquisition and resolution, and equipment leasing) that it believes meet these criteria. The Company was organized in 1947. Its executive offices are located at 1521 Locust Street, Philadelphia, Pennsylvania 19102, and its telephone number is (215) 546-5005. ASSET ACQUISITION AND RESOLUTION The Company's asset acquisition and resolution business involves the purchase at a discount of relatively small (generally $1 million to $5 million in purchase price) troubled commercial real estate loans from private market sellers (primarily financial institutions), and the restructuring and refinancing of those loans. These loans typically involve legal and other disputes among the lender, the borrower and/or other parties in interest, and generally are secured by properties which are unable to produce sufficient cash flow to fully service the loans in accordance with the original lender's loan terms. Since entering this business in 1991, the Company's loan portfolio has increased to $100.5 million (before discounts) at September 30, 1996. During the fiscal years ended September 30, 1994, 1995 and 1996, the Company's yield on its net investment in loans acquired (including gains on refinancings and sales of participations) equalled 30.8%, 34.6% and 36.2%, respectively, while its gross profits from its loan activities (that is, revenues from loan activities minus costs attributable thereto and less depreciation, depletion and amortization, but without allocation of corporate overhead) for fiscal 1994, 1995 and 1996 were $2.3 million, $5.3 million and $6.7 million, respectively. The Company seeks to reduce the amount of its own capital invested in loans after their acquisition, and to enhance its returns, through prompt refinancing of the properties underlying its loans, or through sale at a profit of senior participations in its loans (typically on a recourse basis). At September 30, 1996, senior lenders held outstanding obligations of $38.7 million secured by properties with an aggregate appraised value of $68.2 million, resulting in a ratio of senior lien obligations-to-appraised value of property of 56.7%. Currently, the operating cash flow coverage on the required debt service on refinancings and participations (exclusive of proceeds from such refinancings or participations) is 160.8%. The balance of operating cash flow is, pursuant to agreements with the borrowers, retained by the Company as debt service on the outstanding balance of the Company's loans. See "Business -- Asset Acquisition and Resolution: Loan Status." EQUIPMENT LEASING In September 1995, the Company entered the commercial leasing business through its acquisition of the leasing subsidiary of a regional insurance company. This acquisition provided the Company with a servicing portfolio of approximately 520 individual leases held by six leasing partnerships which provided the Company with a servicing revenue stream of $1.1 million during fiscal 1996. More importantly, through this acquisition the Company acquired an infrastructure of operating systems, computer hardware and proprietary software (generally referred to as a "platform"), as well as personnel, which the Company is utilizing to develop a commercial leasing business for its own account. In order to develop this business, in early 1996 the Company hired a team of four experienced leasing executives, including the former chief executive officer of the U.S. leasing subsidiary of Tokai Bank, a major Japanese banking institution. The Company's strategy in developing its leasing business is to focus on leases with equipment costs of between $5,000 to $100,000 (with a targeted average transaction of approximately $15,000 per lease) ("small ticket" leasing) and to market its equipment leasing product through vendor programs with equipment manufacturers likely to generate $10 million or less annually in equipment leases, regional distributors and other vendors. The Company has currently entered into vendor program relationships with five vendors: Minolta Corporation (copiers), Celsis Incorporated (microbial testing systems), American Marabacom Communications (Teleco) (telephone systems), CSi (test equipment) and ATI Communications (telephone systems). The Company believes that this market is under-served by equipment lessors, banks and other financial institutions, affording the Company a niche market with significant growth potential. From the inception of leasing activity for its own account in June 1996 through September 30, 1996, the Company has received 271 lease proposals involving equipment with an aggregate cost of $6.5 million, approved 118 such proposals involving equipment with an aggregate cost of $2.5 million, entered into 39 transactions involving equipment with an aggregate cost of $711,000 and had 21 such proposals pending involving equipment with an aggregate cost of $1.3 million. According to the Equipment Leasing Association of America ("ELA"), a leading industry trade association, approximately 80% of all United States businesses lease some portion of their equipment. Leasing enables a company to obtain the equipment it needs, while preserving cash flow and often receiving favorable accounting and tax treatment. The Company believes that small businesses are becoming more aware of the economic benefits offered by equipment leasing, and that small business leasing will therefore become an increasingly important segment of the leasing market. ENERGY OPERATIONS The Company produces natural gas and, to a lesser extent, oil from locations principally in Ohio, Pennsylvania and New York. At September 30, 1996, the Company had a net investment of $11.3 million in its energy operations, including interests in 769 individual wells owned directly by the Company or through 52 partnerships and joint ventures managed by the Company. While the Company has focused its business development efforts on its specialty finance operations over the past several years, its energy operations historically have provided a steady source of revenues and tax benefits. THE OFFERING Common Stock offered....... 1,200,000 shares(1) Common Stock to be outstanding after the Offering................... 3,094,761 shares(1)(2) Use of Proceeds............ For general corporate purposes, including the acquisition of additional commercial real estate loans for the Company's portfolio and expansion of the Company's equipment leasing operations. See "Use of Proceeds." Nasdaq National Market Symbol..................... REXI Risk Factors............... An investment in the shares of Common Stock offered hereby involves a high degree of risk. See "Risk Factors" beginning on page 8 hereof for information that should be considered by prospective purchasers of the Common Stock offered hereby. - --------------- (1) Assumes that the Underwriters' over-allotment option to purchase up to 180,000 shares of Common Stock is not exercised. (2) Does not give effect to any future exercise of outstanding warrants to purchase up to 983,150 shares of Common Stock or employee stock options to purchase up to 348,316 shares of Common Stock. See "Description of Capital Stock -- Warrants" and "Security Ownership of Certain Beneficial Owners and Management."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000095626_centire_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000095626_centire_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..368193bd7afc6ac4f06341514c15339aeb4da0cb
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000095626_centire_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY This Prospectus contains certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Prospective investors are cautioned that such statements are only predictions and that actual events may differ materially. In evaluating such statements, prospective investors should specifically consider the various factors identified in this Prospectus, including the matters set forth under the caption "Risk Factors," which would cause actual results to differ materially from those indicated by such forward-looking statements. The following summary is qualified in its entirety by the more detailed information, including "Risk Factors" and the Consolidated Financial Statements and notes thereto, appearing elsewhere in this Prospectus. THE OFFERING Securities........ 1,000,000 shares of Common Stock, $.001 par value per share, offered by the Selling Shareholders. Use of Proceeds... The Company will not receive any proceeds from this offering. Risk Factors...... Investment in the Company involves certain risks. See "Risk Factors." NASDAQ symbol Common Stock ........ ASIA The Company's Common Stock is quoted on the NASDAQ National Market.
THE COMPANY Sunbase Asia, Inc., a Nevada corporation (the "Company," which term shall include, unless the context so requires, its subsidiaries and affiliates), is engaged in the design, manufacture and distribution of a broad range of bearing products in the People's Republic of China ("China" or the "PRC"), and the United States ("US"). The Company also distributes its bearing products in Europe, Asia, South America and Africa. The Company's subsidiary in China, Harbin Bearing Company, Ltd. ("Harbin Bearing"), employs approximately 13,000 employees. Harbin Bearing is the largest precision bearing manufacturer and the third largest bearing manufacturer overall in China. Harbin Bearing produces a wide variety of precision and commercial-grade rolling-element bearings in sizes ranging from 10mm to 1000mm (internal diameter). Rolling-element bearings use small metal balls or cylinders to facilitate rotation with minimal friction and are typically used in vehicles, aircraft, appliances, machine tools, general machinery and virtually any other product that contains rotating or revolving parts. Precision bearings are bearings that are produced to more exacting dimensional tolerances and to higher performance characteristics than standard commercial bearings. The manufacturing process for precision bearings generally requires the labor of highly-skilled machinists and the use of sophisticated machine tools. On January 16, 1996 (effective December 29, 1995), the Company acquired Smith Acquisition Company, Inc., d/b/a Southwest Products Company ("Southwest Products"), an engineering-intensive company located in Southern California, that produces precision spherical bearings for US, European and Asian aerospace and high tech commercial applications and the US military. Over 90% of Harbin Bearing's sales are made to the OEM and replacement markets in China. Based on low production costs in China and the on-going world-wide demand for bearings, management intends to create a substantial export business to complement the Company's strong domestic position in the Chinese markets. Historically, Harbin Bearing export sales have been made through trade intermediaries and by receiving customer orders that are placed directly to its offices in China. Southwest Products has commenced providing and will provide engineering and technical support, and has commenced to and will market and distribute Harbin Bearing products internationally, focusing on exports of the products to the US. In addition, Southwest Products has begun to and will assist Harbin Bearing in implementing US manufacturing methods, improving quality control procedures and in developing new products at Harbin Bearing's facilities in China. The Company's principal executive offices are located at 19/F First Pacific Bank Centre, 51-57 Gloucester Road, Wanchai, Hong Kong, telephone (852) 2865-1511. The following is a chart of the Company's organizational structure. [Chart Appears Here] SUMMARY CONSOLIDATED FINANCIAL INFORMATION The following summary financial data (expressed in thousands) have been derived from the audited financial statements of Harbin Bearing General Factory (the predecessor operating company to Harbin Bearing) for the year ended December 31, 1993 and the audited financial statements of the Company for the years ended December 31, 1994 and 1995, and the unaudited financial statements of the Company for the nine month periods ended September 30, 1995 and 1996. All U.S. dollar amounts have been converted from Renminbi based on the exchange rate on September 30, 1996 of $1.00 US to each Rmb 8.3 as quoted at the People's Bank of China. Due to the reorganization of the Harbin Bearing General Factory on January 1, 1994, the 1993 financial information was prepared on a pro-forma basis as if the acquisition of China Bearing and Harbin Bearing had occurred on January 1, 1993. (See the discussion after the table under the caption "Selected Consolidated Financial Information"). OPERATIONS DATA Twelve Months Ended December 31 Nine Months Ended September 30 --------------------------------------------------- --------------------------------- (UNAUDITED) 1993 1994 1995 1995 1995 1996 1996 RMB RMB RMB US$ RMB RMB US$ PROFORMA Net sales 687,064 719,842 672,359 80,812 651,070 724,960 87,345 Cost of sales (439,417) (441,854) (381,377) (45,838) (397,584) (444,750) (53,584) Gross profit 247,647 277,988 290,982 34,974 253,486 280,210 33,761 Selling, general and administrative expense. (91,197) (95,218) (113,002) (13,582) (77,804) (91,731) (11,052) Interest expense, net (40,638) (43,446) (48,446) (5,822) (36,060) (46,047) (5,548) Foreign exchange gain/loss- - 725 - - - Reorganization expenses (7,307) (7,307) - - - - Income before income taxes 108,505 132,742 129,534 15,570 139,622 142,432 17,161 Provision for income taxes (16,700) (22,687) (20,472) (2,461) (21,497) (23,590) (2,842) Income before minority interests 91,805 110,055 109,062 13,109 118,125 118,842 14,319 Minority interests (50,495) (58,447) (54,967) (6,607) (59,168) (64,926) (7,823) Net income 41,310 51,608 54,095 6,502 58,957 53,916 6,496 BALANCE SHEET DATA AT SEPTEMBER 30, 1996 ------------------------------ RMB US$ Current Assets 1,224,827 147,571 Working Capital 488,671 58,876 Long-Term Debt 262,002 31,567 Minority Interests 408,068 49,165 Shareholders' Equity 419,880 50,587 Total Assets 1,826,106 220,014
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000098618_alanco_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000098618_alanco_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..7ac552c301f0174eae3bfe298fedc263892ace94
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000098618_alanco_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information, including "
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000202930_printpack_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000202930_printpack_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..c433468fd7e34728081e6f2eff3d6a10a5df7a12
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000202930_printpack_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary information is qualified in its entirety by, and should be read in conjunction with the more detailed information and Financial Statements, and the notes thereto contained elsewhere in this Prospectus. As used herein, "Printpack" or the "Company" refers to the Company and its subsidiaries unless the context otherwise requires. The Company's fiscal year ends on the last Saturday in June, and references to particular fiscal years of the Company refer to the 12 months ended on the last Saturday of June of the year indicated. See the Financial Statements and Notes thereto. THE COMPANY Printpack is one of the largest domestic manufacturers and converters of flexible packaging products used by leading salted snacks, confectionery, cookies/crackers, cereal, beverage and other food and consumer product companies. Management estimates, based in part upon trade and Flexible Packaging Association ("FPA") data as of 1995, that, prior to the Acquisition (as defined herein), the Company had the leading market share in several major end use categories of flexible packaging, including salted snack foods (approximately 30% market share), which includes packaging for such products as Lays(R) and Ruffles(R) potato chips; confectionery products (approximately 30% market share), which includes packaging for such products as Reese's(R) and Hershey's(R) candy bars; and cookies/crackers (approximately 17% market share), which includes packaging for such products as Fig Newtons(R) and Famous Amos(R) cookies. The Company's customer base, prior to the Acquisition included nationally recognized, brand-name food companies such as Frito-Lay, General Mills, Hershey, Mars, Nabisco, Nestle, Quaker Oats and Ralston. Printpack, founded in 1956, is headquartered in Atlanta, Georgia and is owned and managed by the founding family together with several long-term members of management. The Company manufactures a wide variety of high value-added flexible packaging products, including laminates made of various layers of plastic film, aluminum foil, metallized films, paper and specialized coatings, as well as cast and blown monolayer and co-extruded films. Printpack's sales and EBITDA (as defined herein and before certain charges) for fiscal year 1996 were $442.9 million and $60.0 million, respectively. Over the last five fiscal years ending June 1996, the Company has experienced compound annual growth of sales and EBITDA before certain charges of 5.2% and 8.9%, respectively, exclusively through internal growth. Printpack management estimates, based in part upon data prepared by the FPA and other trade and industry information, that the U.S. end use markets for the types of flexible packaging products produced by the Company (the "flexible packaging industry") had annual sales of approximately $7.5 billion in 1995 and has one of the highest historical growth rates in the packaging industry, generally. According to this data, the eight largest flexible packaging companies accounted for approximately 50% of total 1995 sales in the flexible packaging industry, with the balance shared by several hundred other competitors. Management believes recent industry growth has been and will continue to be driven principally by (i) the shift from rigid containers (paperboard, glass and plastic) to lower cost and lighter weight flexible packaging, (ii) changing demographic trends which have increased the demand for more convenient forms of packaging, including single servings and packaging that extends product shelf life, (iii) the growth in several major end use market segments (such as snack foods), (iv) the growth of low-fat and non-fat foods which require more complex packaging barriers, (v) concerns over waste and resource reduction, and (vi) increasing demands for specialized packaging with enhanced barrier properties and distinctive graphics. On August 22, 1996, Printpack closed (the "Closing") the transactions contemplated in an asset purchase agreement dated as of April 10, 1996, as amended (the "Acquisition Agreement"), with James River and acquired substantially all of the assets of JR Flexible. JR Flexible was also one of the largest domestic manufacturers and converters of flexible packaging products to leading food and consumer products companies, as well as a major supplier of high performance films to other converters. The Acquisition has further increased Printpack's leading position in the flexible packaging industry, and as a result, the Company has total annual combined sales of approximately $900 million, which is approximately 12% of total 1995 industry sales. INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "COMMISSION OR THE "SEC"). THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE. SUBJECT TO COMPLETION, DATED DECEMBER 18, 1996 PROSPECTUS (LOGO) PRINTPACK INC. OFFER TO EXCHANGE ITS 9 7/8% SENIOR NOTES DUE 2004, SERIES B WHICH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 FOR ANY AND ALL OUTSTANDING 9 7/8% SENIOR NOTES DUE 2004, SERIES A AND 10 5/8% SENIOR SUBORDINATED NOTES DUE 2006, SERIES B WHICH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 FOR ANY AND ALL OUTSTANDING 10 5/8% SENIOR SUBORDINATED NOTES DUE 2006, SERIES A --------------------- EACH EXCHANGE OFFER WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON , 1996, UNLESS EXTENDED BY THE COMPANY IN ITS SOLE DISCRETION (THE "EXPIRATION DATE"). Printpack, Inc., a Georgia corporation (the "Company"), hereby offers (the "Exchange Offer"), upon the terms and subject to the conditions set forth in this Prospectus (the "Prospectus") and the accompanying Letters of Transmittal (the "Letters of Transmittal"), to exchange up to $100,000,000 aggregate principal amount of its 9 7/8% Series B Senior Notes due 2004 (the "Exchange Senior Notes") and $200,000,000 aggregate principal amount of its 10 5/8% Series B Senior Subordinated Notes due 2006 (the "Exchange Senior Subordinated Notes" and, collectively with the Exchange Senior Notes, the "Exchange Notes") for equal principal amounts of its outstanding 9 7/8% Series A Senior Notes due 2004 (the "Senior Notes") and 10 5/8% Series A Senior Subordinated Notes due 2006 (the "Senior Subordinated Notes" and, collectively with the Senior Notes, the "Notes"), respectively. The Exchange Notes are substantially identical (including principal amount, interest rate, maturity and redemption rights) to the Notes for which they may be exchanged pursuant to this offer, except that (i) the offering and sale of the Exchange Notes will have been registered under the Securities Act of 1933, as amended (the "Securities Act"), and (ii) holders of Exchange Notes will not be entitled to certain rights of holders under a Registration Rights Agreement of the Company dated as of August 22, 1996 (the "Registration Rights Agreement"). The Senior Notes have been, and the Exchange Senior Notes will be, issued under an Indenture dated as of August 22, 1996 (the "Senior Note Indenture"), between the Company and Fleet National Bank, as trustee (the "Senior Note Trustee"). The Senior Subordinated Notes have been, and the Exchange Senior Subordinated Notes will be, issued under an Indenture dated as of August 22, 1996 (the "Senior Subordinated Note Indenture" and, collectively with the Senior Note Indenture, the "Indentures"), between the Company and Fleet National Bank, as trustee (the "Senior Subordinated Note Trustee" and, collectively with its capacity as the Senior Note Trustee, the "Trustee"). The Company will not receive any proceeds from this Exchange Offer; however, pursuant to the Registration Rights Agreement, the Company will bear certain offering expenses. See "Description of Exchange Notes -- Registration Rights; Liquidated Damages." The Exchange Notes will bear interest at the same rate and on the same terms as the Notes. Consequently, interest on the Exchange Notes will be payable semi-annually in arrears on February 15 and August 15 of each year, commencing February 15, 1997. The Exchange Senior Notes will mature on August 15, 2004, and may be redeemed at the option of the Company, in whole or in part, at any time on or after August 15, 2000. The Exchange Senior Subordinated Notes will mature on August 15, 2006, and may be redeemed at the option of the Company, in whole or in part, at any time on or after August 15, 2001. See "Description of Exchange Notes." The Exchange Senior Notes will be general unsecured obligations of the Company ranking senior to all subordinated Indebtedness (as defined herein) of the Company, including the Exchange Senior Subordinated Notes, and pari passu with all existing and future senior Indebtedness of the Company, including borrowings under the New Credit Agreement. However, borrowings under the New Credit Agreement are secured by Liens (as defined herein) on substantially all of the assets of the Company and will, therefore, effectively rank senior to the Exchange Senior Notes. As of September 28, 1996, as a result of the Transactions (as defined herein) approximately $210.4 million principal amount of outstanding Indebtedness of the Company will be, by its terms, subordinated to the Exchange Senior Notes. The Exchange Senior Subordinated Notes will be general unsecured obligations of the Company and will be subordinated in right of payment to Senior Debt (as defined herein). As of September 28, 1996, as a result of the Transactions (as defined herein), and excluding receivables sold pursuant to the Receivables Securitization Facility (as defined herein) $318.0 million of Senior Debt was outstanding, $218.0 million of which was secured Indebtedness under the New Credit Agreement. The Indentures (as defined herein) will permit the Company and its subsidiaries to incur additional Indebtedness subject to certain limitations. See "Risk Factors -- Effective Subordination of Exchange Senior Notes" and "Description of Exchange Notes -- Certain Covenants." (Continued on inside front cover) The Company will accept for exchange any and all Notes validly tendered by eligible holders and not withdrawn prior to 5:00 P.M. Eastern time on , 1996, unless extended by the Company in its sole discretion (the "Expiration Date"). Tenders of Notes may be withdrawn at any time prior to the Expiration Date. The Exchange Offer is subject to certain customary conditions. The Notes may be tendered only in integral multiples of $1,000. See "The Exchange Offer." SEE "RISK FACTORS" BEGINNING ON PAGE 18 FOR A DISCUSSION OF CERTAIN FACTORS THAT SHOULD BE CONSIDERED BY INVESTORS WITH RESPECT TO THE NOTES AND THE EXCHANGE NOTES. ON A PRO FORMA COMBINED BASIS FOR ITS LATEST FISCAL YEAR ENDED JUNE 30, 1996, THE COMPANY'S EARNINGS WERE INADEQUATE TO COVER ITS FIXED CHARGES BY APPROXIMATELY $10.3 MILLION. FOR THE COMPANY'S FIRST FISCAL QUARTER ENDED SEPTEMBER 28, 1996, EARNINGS WERE APPROXIMATELY $5.1 MILLION LESS THAN FIXED CHARGES FOR THAT THREE-MONTH PERIOD. THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The date of this Prospectus is , 1996. "underwriter" within the meaning of the Securities Act. Such broker-dealer will also be deemed to represent and warrant to the Company that it is not participating in, and has no intent to participate in, any distribution of Exchange Notes, and has not entered into any arrangement or understanding with any person to distribute the Exchange Notes. In the event that any holder of Notes is prohibited by law or any policy of the Commission from participating in the Exchange Offer or any holder may not resell the Exchange Notes without delivering a prospectus and the Prospectus contained in this Registration Statement is inappropriate or unavailable for such resales by such holder or if such holder is a broker-dealer and holds Notes acquired directly from the Company or one of its affiliates, and such holder satisfies certain other requirements, the Company has agreed, pursuant to the Registration Rights Agreement, to file a registration statement in respect of such Exchange Notes and Notes pursuant to Rule 415 under the Securities Act. See "Prospectus Summary -- The Exchange Offer;" "The Exchange Offer;" and "Plan of Distribution." Any Notes not tendered and accepted in the Exchange Offer will remain outstanding. To the extent any Notes are tendered and accepted in the Exchange Offer, a holder's ability to sell untendered and unregistered Notes could be adversely affected. Following consummation of the Exchange Offer, the holders of Notes will continue to be subject to the existing restrictions upon transfer thereof and the Company will have fulfilled one of its obligations under the Registration Rights Agreement. Holders of Notes who do not tender their Notes generally will not have any further registration rights under the Registration Rights Agreement or otherwise. See "The Exchange Offer -- Consequences Of Failure To Exchange." The Company expects that similar to the Notes, and except as specifically requested by a holder on the Letter of Transmittal, the Exchange Notes will be issued only in the form of a Global Note (as defined herein), which will be deposited with, or on behalf of, The Depository Trust Company (the "Depository") and registered in its name or in the name of the Depository's nominee, Cede & Co. Beneficial interests in the Global Note representing the Exchange Notes will be shown on, and transfers thereof will be effected through, records maintained by the Depository and its participants. After the initial issuance of the Global Note, Exchange Notes in certificated form may be issued in exchange for the Global Note on the terms and conditions set forth in the Indentures. See "Description of Exchange Notes -- Book-Entry, Delivery and Form." The Company is not currently subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). As a result of the offering of the Exchange Notes, the Company will become subject to the informational requirements of the Exchange Act. So long as the Company is subject to the periodic reporting requirements of the Exchange Act, it is required to furnish the information required to be filed with the Commission to the Trustee and the holders of the Notes and the Exchange Notes. The Company has agreed that, even if it is not required under the Exchange Act to furnish such information to the Commission, it will nonetheless continue to furnish information that would be required to be furnished by the Company by Section 13 of the Exchange Act to the Trustee and the holders of the Notes or Exchange Notes as if it were subject to such periodic reporting requirements. "See "Available Information." In addition, the Company has agreed that, for so long as any of the Notes remain outstanding, it will make available to any prospective purchaser of the Notes or beneficial owner of the Notes in connection with any sale thereof the information required by Rule 144A(d)(4) under the Securities Act, until such time as the Company has either exchanged the Notes for the Exchange Notes or until such time as the holders thereof have disposed of such Notes pursuant to an effective registration statement filed by the Company. AVAILABLE INFORMATION The Company has filed with the Securities and Exchange Commission a registration statement on Form S-1 (together with all amendments and exhibits thereto, the "Registration Statement") under the Securities Act with respect to the securities offered hereby. This Prospectus does not contain all of the information set forth in the Registration Statement and the exhibits and schedules thereto, as permitted by the rules and regulations of the Commission. For further information with respect to the Company, the Notes and JR Flexible, headquartered in Milford, Ohio, had leading market shares in various flexible packaging end use markets, including bakery, cookies/crackers, cereal, ream wrap (wrapping for reams of office paper), tissue/towel overwrap, coffee serving packs and dentifrice (plastic laminate materials for tooth paste tubes and other personal care products). JR Flexible manufactured many of the same product lines and materials as those manufactured by Printpack. JR Flexible's customer base also included many of the same brand name food companies as Printpack (General Mills, Nabisco, Nestle and Quaker Oats), as well as other major consumer products companies, such as Flowers, Kellogg, Kraft and James River. The Acquisition is expected to broaden Printpack's sales to certain existing customers, as well as provide new customer relationships and products. In recent years, JR Flexible has been an underperforming business; however, in late 1995, James River and JR Flexible management began various profitability improvement measures, including shedding certain lower margin businesses, reducing waste and related costs, improving product mixes and production processes and negotiating more favorable long-term raw materials contracts, especially for resins. As a result of these initiatives, JR Flexible's unaudited EBITDA for the 26 weeks ended June 30, 1996 was $15.9 million, compared to $3.8 million for the same period in 1995. JR Flexible's unaudited sales and EBITDA before certain charges for the latest 12 months ended June 30, 1996 were $467.0 million and $21.8 million, respectively. The Company's principal executive offices are located at 4335 Wendell Drive, S.W., Atlanta, Georgia 30336, and its telephone number is (404) 691-5830. BUSINESS STRATEGY Printpack focuses its sales and marketing efforts, technical development initiatives, and manufacturing capabilities on targeted end use markets for flexible packaging, with the goals of achieving critical mass and leading market shares. Printpack has achieved leadership positions in these markets by (i) making customer service its first priority, (ii) achieving economies of scale and manufacturing efficiencies to remain a low cost producer, (iii) investing in state-of-the-art equipment, and technological and production innovation, and (iv) providing high value-added flexible packaging structures and enhanced graphics. By focusing its equipment and facilities on specific market segments and product structures, the Company has been able to provide high quality products and service and realize production efficiencies. The Company leverages its strong customer relationships, market leadership and economies of scale to earn additional business from existing customers and to attract new customers. Printpack has developed mutually beneficial relationships with large food and consumer product companies and has benefited from the expanding market shares of such customers. The Company expects to continue this strategy. REASONS FOR THE ACQUISITION Printpack's management believes that the JR Flexible Acquisition is a significant strategic opportunity, consistent with the Company's long-term business strategy. The combination of Printpack (approximately 6% market share) and JR Flexible (approximately 6% market share) has created one of the largest U.S. companies focused on film-based flexible packaging products, with combined sales of approximately 12% of the industry's $7.5 billion of total 1995 sales. The Acquisition increased Printpack's leadership in several end use categories, extends its product lines with existing and new customers, helped diversify its customer base and created significant opportunities for cost savings and economies of scale. INDUSTRY LEADERSHIP Printpack management believes that as a result of the Acquisition, it has increased its leading share of the estimated $1.2 billion market for flexible packaging sales to the snack food industry to approximately 30%. Printpack also expects to increase its already leading shares of flexible packaging sales for each of the salted snack, confectionery and cookies/crackers products. Printpack also believes it obtained JR Flexible's leading market shares in several other products that use flexible packaging, including ream wrap, dentifrice, tissue/towel overwrap and bread bags. the Exchange Notes reference is hereby made to the Registration Statement, including the exhibits and schedules filed or incorporated as a part thereof. Statements contained herein concerning the provisions of any document are not necessarily complete and in each instance reference is made to the copy of the document filed as an exhibit or schedule to the Registration Statement. Each such statement is qualified in its entirety by reference to the copy of the applicable documents filed with the Commission. In addition, after effectiveness of the Registration Statement, the Company will file periodic reports and other information with the Commission under the Exchange Act, relating to the Company's business, financial statements and other matters. The Registration Statement, including the exhibits and schedules thereto, and the periodic reports and other information filed in connection therewith, may be inspected and copied at the public reference facilities maintained by the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549, and at the following Regional Offices of the Commission: Seven World Trade Center, New York, New York 10048 and Northwest Atrium Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661-2511. In addition, the Commission maintains a site on the World Wide Web at http://www.sec.gov that contains reports, information statements and other information regarding Printpack, Inc. and other registrants that file electronically with the Commission. SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Certain of the matters discussed under the captions "Prospectus Summary;" "Risk Factors;" "Summary Unaudited Pro Forma Condensed Combined Financial Data" (including EBITDA and EBITDA before certain charges); "Unaudited Pro Forma Condensed Combined Statement of Operations" (including EBITDA and EBITDA before certain charges); "Printpack Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations;" "Business" and elsewhere in this Prospectus may constitute forward-looking statements, and as such may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause the actual results, performance or achievements of the Company to differ materially from the Company's expectations are disclosed in this Prospectus ("Cautionary Statements"), including, without limitation, those statements made in conjunction with the forward-looking statements included under "Risk Factors" and otherwise herein. All written or oral forward-looking statements attributable to the Company are expressly qualified in their entirety by the Cautionary Statements. EXTENSION OF PRODUCT LINES AND CUSTOMERS Management believes that the Acquisition provides Printpack with a wider range of flexible packaging capabilities and further diversification of its product offerings, enabling Printpack to better serve customers. The Acquisition is expected to increase Printpack's business with various existing major customers, including General Mills, Mars, Nabisco, Nestle, Quaker Oats and Ralston. In addition, Printpack's new customers include Flowers, Kellogg, Kraft and James River. COST SAVINGS AND ECONOMIES OF SCALE The Acquisition is expected to produce significant cost savings through the elimination of redundant corporate overhead and the reduction of personnel at JR Flexible's headquarters and plants. Printpack management expects to realize significant cost savings through the consolidation and rationalization of JR Flexible's manufacturing operations with Printpack's manufacturing facilities, including the conversion of JR Flexible's plants to Printpack's production strategy. Printpack has announced the closing of two former JR Flexible plants, one in San Leandro, California and one in Dayton, Ohio, which closures presently are expected to be completed by the end of the Company's fiscal year 1997. In addition, after the Acquisition, Printpack is now one of the largest domestic purchasers of certain key materials used for flexible packaging manufacturing such as extrusion grade resin, oriented polypropylene ("OPP") film and other types of plastic film, paper and foil, and its enhanced purchasing power is expected to result in greater cost savings and technical development support from its key raw materials suppliers. See "Printpack, Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." THE ACQUISITION, FINANCING AND RELATED TRANSACTIONS THE ACQUISITION AND RELATED FINANCING The Company acquired JR Flexible for approximately $380 million (including the repayment of approximately $2.4 million of JR Flexible indebtedness on revenue bonds), subject to certain adjustments based upon, among other things, an audited closing date balance sheet that has not yet been completed. The initial offering of the Notes (the "Offering"), the refinancing pursuant to the New Credit Agreement and the transactions contemplated in the Acquisition Agreement were completed contemporaneously on August 22, 1996. The Acquisition, the Offering and the New Credit Agreement are referred to collectively herein as the "Transactions." The First National Bank of Chicago ("First Chicago"), together with a syndicate of lenders, has provided the Company with the New Credit Facilities, including a revolving credit facility (the "Revolving Credit Facility") of $155 million reduced pro rata by sales of accounts receivable pursuant to the Receivables Securitization Facility (as defined below) and a term loan (the "Term Loan") of $170 million. At Closing, the entire amount of the Term Loan and approximately $53.7 million of the Revolving Credit Facility was funded. A portion of the borrowings under the New Credit Facilities, together with the net proceeds to the Company from the Offering of the Notes, were applied against the purchase price of JR Flexible. Approximately $171.2 million of the New Credit Facilities were used at Closing to repay existing credit facilities and to pay prepayment penalties, fees and expenses associated with the Transactions. Approximately $51.3 million remained available under the New Credit Facilities for general corporate purposes, including working capital. See "Description of Certain Indebtedness" and "Receivables Securitization Facility." In addition, the Company entered into an asset-backed accounts receivable financing arrangement through a new special purpose, bankruptcy remote subsidiary of the Company, "Flexible Funding Corp." ("Receivables Funding"), a Delaware corporation. A special purpose bankruptcy remote subsidiary is a corporation which has been formed for a single purpose of (e.g. in the case of Receivables Funding, buying and selling receivables originated by the Company), which operates separately from its parent and other affiliated companies, and which has special charter provisions to assure its corporate separateness from its affiliates in an effort to avoid substantive consolidation in a bankruptcy proceeding involving its parent corporation or other affiliates. Receivables Funding has acquired and will continue to acquire accounts receivable generated by the Company, and sell them to Falcon Asset Securitization Corporation ("Falcon"), an asset-backed commercial paper conduit issuer sponsored by First Chicago, and to First Chicago and other investors. The receivables securitization facility (the "Receivables Securitization Facility") was established in an amount of up to approximately $50 million and, at the Closing, Printpack received approximately $23 million of proceeds from the initial sale of receivables under the Receivables Securitization Facility. See "Receivables Securitization Facility." SOURCES AND USES OF PROCEEDS Presented below are the sources and uses of funds in connection with the Acquisition and the other Transactions: SOURCES OF FUNDS AMOUNT ------------------------------------------------------------------- ---------------------- (DOLLARS IN MILLIONS) New Credit Agreement: Revolving Credit Facility........................................ $ 53.7 Term Loan........................................................ 170.0 Receivables Securitization Facility................................ 23.0 9 7/8% Senior Notes due 2004....................................... 100.0 10 5/8% Senior Subordinated Notes due 2006......................... 200.0 ------ Total Sources of Funds................................... $546.7 ====== USES OF FUNDS JR Flexible purchase price......................................... $372.5 Repay existing Printpack debt...................................... 146.8 Estimated prepayment penalties, fees and transaction expenses...... 24.4 Working Capital.................................................... 3.0 ------ Total Uses of Funds...................................... $546.7 ======
THE REORGANIZATION The Company was reorganized to facilitate the Acquisition and its financing. Previously, the Company was owned and operated together with Printpack Enterprises, Inc. ("Enterprises"), a Georgia corporation that had elected to be taxed as a Subchapter S corporation under the Internal Revenue Code of 1986, as amended (the "Code"). Printpack and Enterprises were affiliated by common ownership and management. Following the Company's 1996 fiscal year, Printpack and Enterprises were reorganized into a holding company structure (the "Reorganization"). Printpack Holdings, Inc. ("Holdings"), a new Delaware corporation, was formed, and Enterprises contributed substantially all its assets and liabilities to Printpack. Following the Reorganization, Enterprises owns approximately 100% of the Company and Holdings owns approximately 97% of Enterprises. The remaining minority interests are held by members of the Love family and certain members of the Company's senior management who were not eligible to participate in the Reorganization. Prior to the Reorganization, Printpack and Enterprises had acquired and jointly owned approximately 95% of certain separately chartered flexible packaging operations ("Printpack Europe") located in the United Kingdom ("U.K."). Following the Reorganization, Holdings and Enterprises became holding companies that jointly own Printpack Europe, which is operated separately from the Company, except as permitted under the Indentures. See "-- United Kingdom Affiliates" and "Description of Exchange Notes." The Company has acquired all of JR Flexible's business and will conduct all North American operations previously carried on by the Company, Enterprises and JR Flexible, including the operations of various wholly-owned Mexican subsidiaries of the Company and JR Flexible. The Company also owns 100% of Printpack Illinois, Inc. ("Printpack Illinois"), which has been formed to own and operate Printpack's Elgin, Illinois plant, and the Company's patents, trademarks, trade secrets, knowhow and other intellectual property. See "Business -- Patents and Trademarks." UNITED KINGDOM AFFILIATES Printpack Europe began with the purchase of a separate U.K. company from a management and investor group in 1993, which previously had acquired such operations in a management buyout. In 1994, Printpack Europe acquired another U.K. flexible packaging company to become a larger competitor in the U.K. and Continental Europe. The U.K. operations were combined in an effort to assimilate and expand Printpack's European operations, which created one of the three largest flexible packaging companies in the U.K. After Printpack's purchases, Printpack Europe continued to be operated independently by its management, which was responsible for Printpack Europe's policies, operations and day-to-day management, including financial controls. In 1996, it became apparent to the Company that Printpack Europe management was not timely and appropriately recognizing expenses and rebates, and was capitalizing certain expenses, leading to the recognition of approximately $32.5 million of special charges in May 1996, of which approximately $10 million related to fiscal year 1995. As a result of these special charges and increased raw material costs and competition, Printpack Europe had net losses in fiscal years 1995 and 1996. In May 1996, certain former senior managers of Printpack Europe were terminated, and Mr. James J. Greco, a long-time senior Company manager, was sent to the U.K. to manage this unit. Improvements in financial controls and reports also have been made at Printpack Europe. Former credit agreements in existence prior to the effective time of the Acquisition pertaining to approximately $146.7 million of Company debt outstanding at June 29, 1996 contained various covenants related to the Company and Printpack Europe that were not amended to reflect the Reorganization, but these credit agreements were terminated as a result of the Transactions consummated on August 22, 1996. The Company has agreed not to merge, consolidate or otherwise acquire Printpack Europe's operations as a subsidiary of the Company, except as permitted under the Indentures. See "Risk Factors -- Foreign Operations; Losses incurred by Printpack Europe;" "Printpack, Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations;" "Description of Exchange Notes -- Certain Covenants -- Transaction with Affiliates;" and "Management;" and Note 5 to the Printpack Financial Statements. THE EXCHANGE OFFER Securities Offered......... $100,000,000 aggregate principal amount of 9 7/8% Exchange Senior Notes due August 15, 2004. $200,000,000 aggregate principal amount of 10 5/8% Exchange Senior Subordinated Notes due August 15, 2006. The Exchange Offer......... $1,000 principal amount of the Exchange Senior Notes in exchange for each $1,000 principal amount of Senior Notes and $1,000 principal amount of the Exchange Senior Subordinated Notes in exchange for each $1,000 principal amount of Senior Subordinated Notes. As of the date hereof, all of the aggregate principal amount of Senior Notes and Senior Subordinated Notes are outstanding. The Company will issue the Exchange Notes to eligible holders on or promptly after the Expiration Date of the Exchange Offer. Based on interpretations by the staff of the SEC set forth in no-action letters issued to third parties, the Company believes that Exchange Notes issued pursuant to the Exchange Offer in exchange for Notes may be offered for resale, resold and otherwise transferred by any holder thereof (other than any holder which is a broker-dealer that holds Notes acquired for its own account as a result of market-making or other trading activities, or any such holder which is an "affiliate" of the Company within the meaning of Rule 405 under the Securities Act) without compliance with the registration and prospectus delivery provisions of the Securities Act, provided that such Exchange Notes are acquired in the ordinary course of such holder's business and that such holder does not intend to participate and has no arrangement or understanding with any person to participate in a distribution of such Exchange Notes. Each broker-dealer that receives Exchange Notes for its own account pursuant to the Exchange Offer may be a statutory underwriter and must acknowledge that it will deliver a prospectus in connection with any resale of such Exchange Notes. The Letters of Transmittal state that by so acknowledging and by delivering a prospectus, a broker-dealer will not be deemed to admit that it is an "underwriter" within the meaning of the Securities Act. This Prospectus, as it may be amended or supplemented from time to time, may be used for 180 days after the Expiration Date by a broker-dealer in connection with resales of Exchange Notes received in exchange for Notes where such Notes were acquired by such broker-dealer as a result of market-making activities or other trading activities. The Company has agreed that for a period of 180 days after the Expiration Date, it will make this Prospectus available to any broker-dealer for use in connection with any such resale. See "Plan of Distribution." Any holder who is an affiliate of the Company, and any person who intends to, or is participating in a distribution of the Exchange Notes, will not be able to rely on the position of the staff of the SEC enunciated in Exxon Capital Holdings Corporation (available May 13, 1988), Morgan Stanley & Co., Inc. (available June 5, 1991), and Shearman & Sterling (available July 2, 1993) or similar no-action letters and, in the absence of an exemption therefrom, must comply with the registration and prospectus delivery requirements of the Securities Act in connection with the resale of the Exchange Notes. Failure to comply with such requirements in such instance may result in such holder incurring liability under the Securities Act for which the holder will not be indemnified by the Company. Expiration Date............ 5:00 p.m., Eastern Time, on , 1996, unless the Exchange Offer is extended by the Company in its sole discretion, in which case the term "Expiration Date" means the latest date and time to which the Exchange Offer is extended. Interest on the Exchange Notes and the Notes........ The Exchange Notes will bear interest from August 15, 1996, the date of issuance of the Notes that are tendered in exchange for the Exchange Notes (or the most recent Interest Payment Date (as defined herein) to which interest on such Notes has been paid). Accordingly, holders of Notes that are accepted for exchange will not receive interest on the Notes that is accrued but unpaid at the time of tender, but such interest will be payable on the Exchange Notes issued therefor on the first Interest Payment Date after the Expiration Date. Conditions to the Exchange Offer.................... The Exchange Offer is subject to certain customary conditions, which may be waived, to the extent permitted by law, by the Company. See "The Exchange Offer -- Conditions" and "-- Procedures for Tendering." Procedures for Tendering Notes.................... Each eligible holder of Notes wishing to accept the Exchange Offer must complete, sign and date the accompanying Letter of Transmittal, or a facsimile thereof, in accordance with the instructions contained herein and therein, and mail or otherwise deliver such Letter of Transmittal, or such facsimile, together with the Notes and any other required documentation to the Exchange Agent (as defined herein) at the address set forth in the Letter of Transmittal. The blue Letter of Transmittal should be used to tender Senior Notes and the yellow Letter of Transmittal should be used to tender Senior Subordinated Notes. By executing the Letter of Transmittal, each holder will represent to the Company that, among other things, the holder or the person receiving such Exchange Notes, whether or not such person is the holder, is acquiring the Exchange Notes in the ordinary course of business and that neither the holder nor any such other person has any arrangement or understanding with any person to participate in the distribution of such Exchange Notes, that neither the holder nor any such person is an "affiliate" (as defined under Rule 405 of the Securities Act) of the Company, and if such holder is a broker-dealer that holds the Notes as a result of market-making or other trading activities, it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resales of the Exchange Notes. In lieu of physical delivery of the certificates representing Notes, tendering holders may transfer Notes pursuant to the procedure for book-entry transfer as set forth under "The Exchange Offer -- Procedures for Tendering." Special Procedures for Beneficial Owners.......... Any beneficial owner whose Notes are held in book-entry form or are registered in the name of a broker, dealer, commercial bank, trust company or other nominee and who wishes to exchange such Notes for the Exchange Notes should contact such registered holder promptly and instruct such registered holder to tender the Notes for exchange on such beneficial owner's behalf. See "The Exchange Offer -- Procedures for Tendering." Guaranteed Delivery Procedures............... Holders of Notes who wish to tender their Notes and whose Notes are not immediately available or who cannot deliver their Notes, the Letter of Transmittal or any other documents required by the Letter of Transmittal to the Exchange Agent (or comply with the procedures for book-entry transfer) prior to the Expiration Date must tender their Notes according to the guaranteed delivery procedures set forth in "The Exchange Offer -- Guaranteed Delivery Procedures." Withdrawal Rights.......... Tenders may be withdrawn at any time prior to 5:00 P.M., Eastern Time, on the Expiration Date pursuant to the procedures described under "The Exchange Offer -- Withdrawals of Tenders." Acceptance of Notes and Delivery of Exchange Notes.................... The Company will accept for exchange any and all Notes that are properly tendered in the Exchange Offer, and not withdrawn, prior to 5:00 P.M., Eastern Time, on the Expiration Date. The Exchange Notes issued pursuant to the Exchange Offer will be delivered on the earliest practicable date following the Expiration Date. See "The Exchange Offer -- Terms of the Exchange Offer." Federal Income Tax Consequences............. The issuance of the Exchange Notes to holders of the Notes pursuant to the terms set forth in this Prospectus will not constitute an exchange for federal income tax purposes. Consequently, no gain or loss will be recognized by holders of the Notes upon receipt of the Exchange Notes. See "The Exchange Offer -- Certain Federal Income Tax Consequences of the Exchange Offer." Effect on holders of the Notes...................... As a result of the making of this Exchange Offer, the Company will have fulfilled certain of its obligations under the Registration Rights Agreement, and holders of Notes who do not tender their Notes will generally not have any further registration rights under the Registration Rights Agreement or otherwise. Such holders will continue to hold the untendered Notes and will be entitled to all the rights and subject to all the limitations, including, without limitation, transfer restrictions, applicable thereto under the Indentures, except to the extent such rights or limitations, by their terms, terminate or cease to have further effectiveness as a result of the Exchange Offer. Accordingly, if any Notes are tendered and accepted in the Exchange Offer, the trading market, if any, for the untendered Notes could be adversely affected. Exchange Agent............. Fleet National Bank is serving as exchange agent (the "Exchange Agent") with respect to the Senior Notes and the Senior Subordinated Notes. SUMMARY OF TERMS OF EXCHANGE NOTES The form and terms of the Exchange Notes are substantially identical to the form and terms of the Notes which they replace except that (i) the Exchange Notes have been registered under the Securities Act and, therefore, will not bear legends restricting the transfer thereof and (ii) the holders of Exchange Notes generally will not be entitled to further registration rights under the Registration Rights Agreement, which rights generally will have been satisfied when the Exchange Offer is consummated. The Exchange Notes will evidence the same indebtedness as the Notes which they replace and will be issued under, and be entitled to the benefits of the Indentures. See "Description of Exchange Notes." Maturity........................ The Exchange Senior Notes will mature on August 15, 2004 and the Exchange Senior Subordinated Notes will mature on August 15, 2006. Interest........................ Interest on the Exchange Senior Notes will accrue at the rate of 9 7/8% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, commencing on February 15, 1997. Interest on the Exchange Senior Subordinated Notes will accrue at the rate of 10 5/8% per annum, payable semiannually in arrears on February 15 and August 15 of each year, commencing on February 15, 1997. Optional Redemption............. The Exchange Senior Notes may be redeemed at the option of the Company, in whole or in part, at any time on or after August 15, 2000, at the redemption prices set forth herein, plus accrued and unpaid interest and Liquidated Damages (as defined herein), if any, thereon to the applicable redemption date. In addition, in the event of an Initial Public Offering (as defined herein) by the Company on or before August 15, 1999, the Company may use the proceeds from such Initial Public Offering to redeem up to 25% of the aggregate principal amount of Exchange Senior Notes originally issued at a redemption price equal to 108 7/8% of the principal amount thereof, plus accrued and unpaid interest and Liquidated Damages, if any, thereon to the date of redemption; provided, however, that at least $75.0 million in aggregate principal amount of Exchange Senior Notes remains outstanding following such redemption and, provided further, that such redemption occurs within 60 days of the closing of such Initial Public Offering. The Exchange Senior Subordinated Notes may be redeemed at the option of the Company, in whole or in part, at any time on or after August 15, 2001, at the redemption prices set forth herein, plus accrued and unpaid interest and Liquidated Damages, if any, thereon to the applicable redemption date. In addition, in the event of an Initial Public Offering of the Company on or before August 15, 1999, the Company may use the proceeds from such Initial Public Offering to redeem up to 35% of the aggregate principal amount of Exchange Senior Subordinated Notes originally issued at a redemption price equal to 109 5/8% of the principal amount thereof, plus accrued and unpaid interest and Liquidated Damages, if any, thereon to the date of redemption; provided, however, that at least $100.0 million in aggregate principal amount of Exchange Senior Subordinated Notes remains outstanding following such redemption and, provided further, that such redemption occurs within 60 days of the closing of such Initial Public Offering. Mandatory Redemption............ The Company will not be required to make any mandatory redemption or sinking fund payments with respect to the Exchange Notes. Change of Control............... Upon the occurrence of a Change of Control (as defined herein), each holder of Exchange Notes will have the right to require the Company to purchase all or any part (equal to $1,000 or an integral multiple thereof) of such holder's Notes at a price in cash equal to 101% of the aggregate principal amount thereof, plus accrued and unpaid interest and Liquidated Damages, if any, thereon to the date of purchase. See, however, "Risk Factors -- Possible Inability to Repurchase Exchange Notes upon a Change of Control." Ranking......................... The Exchange Senior Notes will be general unsecured obligations of the Company, ranking senior to all subordinated Indebtedness of the Company, including the Exchange Senior Subordinated Notes, and pari passu with all existing and future senior Indebtedness of the Company, including borrowings under the New Credit Agreement. However, borrowings under the New Credit Agreement will be secured by Liens on substantially all of the assets of the Company and will, therefore, effectively rank senior to the Exchange Senior Notes. The Exchange Senior Subordinated Notes will be general unsecured obligations of the Company and will be subordinated in right of payment to Senior Debt. As of September 28, 1996, as a result of the Transactions and excluding receivables sold pursuant to the Receivables Securitization Facility, there was approximately $318.0 million of Senior Debt outstanding, $218.0 million of which was secured Indebtedness under the New Credit Agreement. See "Risk Factors -- Subordination of Exchange Senior Subordinated Notes" and "-- Effective Subordination of Exchange Senior Notes." Certain Covenants............... The Indentures contain certain covenants that, among other things, limit the ability of the Company and its subsidiaries to incur additional Indebtedness, to issue preferred stock, pay dividends or make other distributions, repurchase Equity Interests (as defined herein) or subordinated Indebtedness, engage in sale and leaseback transactions, create certain liens, enter into certain transactions with affiliates, sell assets of the Company or its subsidiaries, issue or sell Equity Interests of the Company's subsidiaries or enter into certain mergers and consolidations. In addition, under certain circumstances, the Company will be required to offer to purchase Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest and Liquidated Damages, if any, thereon to the date of purchase, with the proceeds of certain Asset Sales (as defined herein). See "Description of Exchange Notes." Exchange Offer; Registration Rights.......................... If (i) the Exchange Offer is not permitted by applicable law or (ii) any holder of Transfer Restricted Securities (as defined herein) notifies the Company that (A) it is prohibited by law or Commission policy from participating in the Exchange Offer, (B) that it may not resell the Exchange Notes acquired by it in the Exchange Offer to the public without delivering a prospectus and the Prospectus is not appropriate or available for such resales or (C) that it is a broker-dealer and holds Notes acquired directly from the Company or an affiliate of the Company, and such holders timely notify the Company of such facts, the Company will be required to provide a shelf registration statement (the "Shelf Registration Statement") to cover resales of the Notes by the holders thereof. If the Company fails to satisfy these registration obligations, it will be required to pay liquidated damages ("Liquidated Damages") to such holders of Notes under certain circumstances. See "The Exchange Offer -- Registration Rights and Effect of Exchange Offer." PRINTPACK, INC. AND SUBSIDIARIES THE FLEXIBLE PACKAGING GROUP OF JAMES RIVER CORPORATION SUMMARY UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL DATA The following table presents summary unaudited pro forma condensed combined financial information derived from the Unaudited Pro Forma Condensed Combined Financial Statements included elsewhere in this Prospectus. The summary pro forma condensed combined financial information gives effect to the Transactions as if they had occurred as of July 1, 1995 for purposes of the pro forma condensed combined statements of operations data and other financial data. The Unaudited Pro Forma Condensed Combined Financial Statements do not purport to present the actual financial position or results of operations of the Company or JR Flexible had the Transactions and events assumed therein in fact occurred on the dates specified, nor are they necessarily indicative of the results of the operations that may be achieved in the future. The Unaudited Pro Forma Condensed Combined Financial Statements are based on certain assumptions and adjustments described in the notes to the Unaudited Pro Forma Condensed Combined Financial Statements and should be read in conjunction therewith and with the historical financial statements of the Company, the historical combined financial statements of The Flexible Packaging Group of James River Corporation ("JR Flexible Combined Financial Statements"), and the related notes thereto; and the "Printpack, Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations." HISTORICAL PRO FORMA ----------------------------------- COMBINED PRINTPACK JR FLEXIBLE LATEST 12 LATEST 12 LATEST 12 MONTHS ENDED MONTHS ENDED MONTHS ENDED JUNE 30, JUNE 29, 1996(1) JUNE 30, 1996(2) 1996 ---------------- ---------------- ------------ (DOLLARS IN THOUSANDS) STATEMENT OF INCOME DATA: Net sales........................................... $442,931 $467,023 $909,954 Gross margin........................................ 79,840 34,197 113,327 Selling, administrative and research and development expenses.......................................... 44,581 37,799 57,965 Restructuring charges............................... -- 894 894 Amortization of intangible assets................... 169 732 5,993 Severance expense................................... 7,870 1,200 9,070 Write-off of equity investment...................... 200 -- 200 Income (loss) from operations....................... 27,189 (6,428) 39,205 Interest expense(3)(4).............................. 10,814 244 49,867 Income (loss) before provision for income taxes..... 16,316 (6,112) (9,992) (Provision) benefit for income taxes................ (3,080) 2,219 -- Net income (loss)................................... 13,236 (3,893) (9,992) BALANCE SHEET DATA: Working capital..................................... $ 9,086 $ 57,021 $ 86,477 Total assets........................................ 231,269 346,119 650,037 Total debt.......................................... 157,138 2,392 534,038 Shareholders' equity................................ 13,460 247,249 12,160 OTHER FINANCIAL DATA: EBITDA(3)(5)........................................ $ 52,033 $ 20,310(6) $ 96,758 EBITDA before certain charges(3)(7)................. 59,993 21,844 106,922 Capital expenditures................................ 25,786 29,454 55,240 Depreciation and amortization....................... 24,903 26,178 56,883
HISTORICAL PRO FORMA ----------------------------------- COMBINED PRINTPACK JR FLEXIBLE LATEST 12 LATEST 12 LATEST 12 MONTHS ENDED MONTHS ENDED MONTHS ENDED JUNE 30, JUNE 29, 1996(1) JUNE 30, 1996(2) 1996 -------- -------- -------- (DOLLARS IN THOUSANDS) RATIOS: Ratio of EBITDA to interest expense(3)(5)........... 1.9x Ratio of EBITDA before certain charges to interest expense(3)(7)..................................... 2.1x Ratio of total debt to EBITDA before certain charges(3)(7)..................................... 5.0x Net income (loss)................................... $ 13,236 $ (3,893) $ (9,992) Ratio of earnings to fixed charges(3)(8)............ 2.2x -- 0.8x Earnings greater (less) than fixed charges.......... 16,013 (6,112) (10,295)
- --------------- (1) Results of operations are for the 53 weeks ended June 29, 1996. (2) Results of operations are for the 53 weeks ended June 30, 1996. The results of operations for this 53 week period were calculated by adding the six months ended June 30, 1996 to the year ended December 31, 1995 and deducting the results for the six months ended June 30, 1995. (3) Interest expense, EBITDA and the ratio of earnings to fixed charges for JR Flexible are not necessarily indicative of JR Flexible on a stand-alone basis. See Note 2 to the JR Flexible Combined Financial Statements. (4) Pro forma interest expense has been calculated based upon various assumed interest rates on the Notes and under the New Credit Agreement. (5) EBITDA represents net income (loss) before interest expense, taxes, depreciation and amortization, but after deduction for restructuring charges, severance expense and write-off of equity investments. While EBITDA should not be construed as a substitute for operating income or a better indicator of liquidity than cash flows from operating activities, which are determined in accordance with generally accepted accounting principles, it is included herein to provide additional information with respect to the ability of the Company to meet its future debt service, capital expenditures and working capital requirements. EBITDA is not necessarily a measure of the Company's ability to fund its cash needs. EBITDA is included herein because management believes that it will be useful in measuring the Company's ability to service its debt consistent with the terms of such debt. (6) This includes resin price decreases beginning March 1, 1996, the shedding by JR Flexible of certain low margin business, reduction in waste and cost reduction efforts. (7) Pro forma combined EBITDA before certain charges, which adds back restructuring charges, severance expense and write-off of equity investment, would have been $106.9 million, and is provided, in part, because similar measures are included in the terms of the Indentures and the New Credit Agreement. Printpack management estimates that additional savings (not reflected in the pro forma combined statements of operations or other pro forma data) aggregating approximately $22.8 million can be achieved as a result of the following: (A) $7.8 million in anticipated additional savings as a result of the voluntary retirement program completed by Printpack in fiscal 1996 in which approximately 160 employees participated and which savings are not reflected in the Printpack Financial Statements. Total annual savings are expected to be $9.0 million. (B) $5.8 million in anticipated additional savings as a result of below market raw material contracts acquired by Printpack in conjunction with the Acquisition based on current 1996 volumes, and which savings are not reflected in the JR Flexible Combined Financial Statements or in the Printpack Financial Statements. Total annual savings are expected to be $7.6 million. See "Risk Factors -- Exposure to Fluctuations in Raw Material Prices." (C) $9.2 million in anticipated annual savings estimated as a result of the reduction of approximately 150 JR Flexible salaried plant personnel expected to occur shortly after the Closing of the Acquisition. If the above items had occurred at the beginning of Printpack's fiscal 1996, Printpack management estimates that the Company's pro forma combined EBITDA before certain charges would have been approximately $129.7. Accordingly, the pro forma ratio of EBITDA before certain charges to interest expense would have been approximately 2.5x and the ratio of total debt to EBITDA before certain charges would have been approximately 4.1x. See "Printpack, Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations -- Certain Effects of the Acquisition," for a discussion of certain of these costs savings and certain charges related to the Acquisition. (8) The ratio of earnings to fixed charges is computed by dividing earnings by fixed charges. For this purpose, "earnings" include operating income (loss) before income taxes, extraordinary items and cumulative effect of accounting change plus fixed charges. Fixed charges include interest, whether expensed or capitalized, amortization of debt expense and discount or premium relating to any indebtedness, whether expensed or capitalized and the portion of rental expense that is representative of the interest factor in these rentals. HISTORICAL ----------------------------- PRO FORMA PRINTPACK(1) JR FLEXIBLE(2) COMBINED 3 MONTHS 53 DAYS 3 MONTHS ENDED ENDED ENDED SEPTEMBER AUGUST 22, SEPTEMBER 28, 1996 1996 28, 1996 ------------ -------------- --------- (DOLLARS IN THOUSANDS) STATEMENT OF INCOME DATA: Net Sales................................................. $ 150,787 $ 62,942 $ 213,729 Gross margin.............................................. 16,958 1,052 21,573 Selling, administrative and research and development expenses................................................ (15,202) (4,817) (16,474) Amortization of intangible assets......................... (307) (76) (1,101) --------- -------- --------- Income (loss) from operations............................. 1,449 (3,841) 3,998 Interest expense(3)(4).................................... (6,279) (31) (12,317) Loss before provision for income taxes.................... (4,837) (3,754) (8,208) (Provision) benefit for income taxes...................... (1,906) 1,404 (1,925) Income (loss) before extraordinary item................... (6,743) (2,350) (10,133) Extraordinary item -- loss on early extinguishment of debt (net of tax benefit of $999)............................ (1,631) -- (1,631) Net (loss)(7)............................................. $ (8,374) $ (2,350) $ (11,763) --------- -------- --------- OTHER FINANCIAL DATA: EBITDA(3)(5).............................................. 9,115 57 16,366 EBITDA before certain charges(3)(6)....................... 10,746 57 17,997 Capital expenditures...................................... 375,724 2,668 378,392 Depreciation and amortization............................. 9,304 3,780 13,887 RATIOS: Ratio of EBITDA to interest expense(3)(5)................. 1.3x Ratio of EBITDA before certain charges to interest expense(6).............................................. 1.5x Ratio of total debt to EBITDA before certain charges(6)... 30.6x Net income (loss)(7)...................................... $ (8,374) $ (2,350) $ (11,763) Ratio of earnings to fixed charges(3)(7).................. 0.3x 0.4x Earnings less than fixed charges.......................... (5,112) (3,754) (8,251)
- --------------- (1) Results of operations are for the 13 weeks ended September 28, 1996. (2) Results of operations are for the 53 days ended August 22, 1996, the Closing Date of the Acquisition. (3) Interest expense, EBITDA and the ratio of earnings to fixed charges for JR Flexible are not necessarily indicative of JR Flexible on a stand-alone basis. See Note 2 to the JR Flexible Combined Financial Statements. (4) Pro forma interest expense has been calculated based upon various assumed interest rates on the Notes and under the New Credit Agreement. (5) EBITDA represents net income (loss) before interest expense, taxes, depreciation and amortization, but after deduction for restructuring charges and severance expense. While EBITDA should not be construed as a substitute for operating income or a better indicator of liquidity than cash flows from operating activities, which are determined in accordance with generally accepted accounting principles, it is included herein to provide additional information with respect to the ability of the Company to meet its future debt service, capital expenditures and working capital requirements. EBITDA is not necessarily a measure of the Company's ability to fund its cash needs. EBITDA is included herein because management believes that it will be useful in measuring the Company's ability to service its debt consistent with the terms of such debt. (6) Pro forma combined EBITDA before certain charges, which adds back restructuring charges, severance expense and write-off of equity investment, as well as extraordinary items such as the $1.6 million loss on early extinguishment of debt, would have been $18.0 million, and is provided primarily because similar earnings measures are included in the terms of the Indentures and the New Credit Agreement. Printpack management estimates that additional savings (not reflected in the pro forma combined statements of operations or other pro forma data) aggregating approximately $3.4 million for similar periods can be achieved as a result of the following: (A) Approximately $2.2 million in savings related to the voluntary retirement program completed by Printpack in fiscal 1996 in which approximately 160 employees participated have been reflected in the Printpack Financial Statements. Total annual savings are expected to be $9.0 million. (B) Approximately $1.1 million in anticipated additional savings as a result of below market raw material contracts acquired by Printpack in conjunction with the Acquisition based on 1996 volumes, and which savings are not reflected in the JR Flexible Combined Financial Statements. Total annual savings are expected to be $7.6 million. See "Risk Factors -- Exposure to Fluctuations in Raw Material Prices." (C) Approximately $2.3 million in anticipated additional savings estimated as a result of the reduction of approximately 150 JR Flexible salaried plant personnel which occurred after the Closing of the Acquisition. If the above items had occurred at the beginning of Printpack's fiscal 1997 on June 30, 1996, Printpack management estimates that the Company's pro forma combined EBITDA before certain charges would have been approximately $21.4. Accordingly, the pro forma ratio of EBITDA before certain charges to interest expense would have been approximately 1.7 and the ratio of total debt to EBITDA before certain charges would have been approximately 25.8. See "Printpack, Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations -- Certain Effects of the Acquisition," for a discussion of certain of these costs savings and certain charges related to the Acquisition. (7) The ratio of earnings to fixed charges is computed by dividing earnings by fixed charges. For this purpose, "earnings" include operating income (loss) before income taxes, extraordinary items and cumulative effect of accounting change plus fixed charges. Fixed charges include interest, whether expensed or capitalized, amortization of debt expense and discount or premium relating to any indebtedness, whether expensed or capitalized and the portion of rental expense that is representative of the interest factor in these rentals. PRINTPACK, INC. AND SUBSIDIARIES THE FLEXIBLE PACKAGING GROUP OF JAMES RIVER CORPORATION SUMMARY HISTORICAL FINANCIAL DATA The summary historical financial data presented in the table below have been derived from the Printpack Financial Statements and the related notes thereto and the JR Flexible Combined Financial Statements and the related notes thereto included elsewhere in this Prospectus and should be read in conjunction therewith. Printpack's historical financial data for the three months ended September 23, 1995 and September 28, 1996 are unaudited, but have been prepared on the same basis as the audited financial statements and, in the opinion of Printpack management, include all adjustments, consisting only of normal recurring entries (except as resulted from the Transactions), necessary for the fair presentation of such statements. JR Flexible's historical financial data for the six months ended June 25, 1995 and June 30, 1996 are unaudited, but have been prepared on the same basis as the audited financial statements and, in the opinion of James River management, include all adjustments, consisting only of normal recurring entries, necessary for the fair presentation of such statements. See "Unaudited Pro Forma Condensed Combined Financial Statements;" and "Printpack, Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000277028_homegold_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000277028_homegold_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..7d5e8a544d9c86bd2f9bf2a35e3812a59bc42ed7
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000277028_homegold_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and the Consolidated Financial Statements and Notes thereto appearing elsewhere herein. Unless otherwise indicated, all information in this Prospectus has been adjusted to reflect a one-for-three reverse stock split of the Common Stock effective June 9, 1995 and a two-for-one stock split effected in the form of a 100% stock dividend on the Common Stock effective March 1, 1996. Unless otherwise indicated, the information in this Prospectus assumes that the Underwriters' over-allotment option is not exercised. Unless the context requires otherwise, all references to the Company shall include the Company and all of its subsidiaries. Prospective investors should carefully consider the information set forth under the heading "Risk Factors." THE COMPANY Emergent Group, Inc. is a diversified financial services company headquartered in Greenville, South Carolina, that originates, services and sells residential mortgage loans ("Mortgage Loans"), small business loans ("Small Business Loans") and used automobile loans ("Auto Loans"). The Company makes substantially all of its loans to borrowers who have limited access to credit or who may be considered credit-impaired by conventional lending standards ("non-prime borrowers"). The Company commenced its lending operations in 1991 and has experienced significant loan growth over the past several years. During the years 1993, 1994 and 1995, the Company originated $63.6 million, $150.0 million and $249.5 million in loans, respectively. During the six months ended June 30, 1996, the Company originated $194.4 million in loans. Of the Company's loan originations in the first six months of 1996, $153.8 million were Mortgage Loans, $30.6 million were Small Business Loans and $10.0 million were Auto Loans. For the years ended December 31, 1993, 1994 and 1995, the Company's pre-tax income from continuing operations was $663,000, $2.4 million and $4.9 million, respectively. For the six months ended June 30, 1996, the Company's pre-tax income from continuing operations was $3.6 million. MORTGAGE LOAN DIVISION The Company's Mortgage Loan operation (the "Mortgage Loan Division") makes Mortgage Loans primarily to owners of single family residences who use the loan proceeds for such purposes as debt consolidation, home improvements and educational expenditures. Approximately 93% of the Company's Mortgage Loans are secured by first mortgages, with the balance being secured by second mortgages. The Mortgage Loans generally have initial principal balances ranging from $25,000 to $100,000 (with an average initial principal balance in the first six months of 1996 of approximately $41,500) and fixed rates of interest ranging from 9% to 16% per annum (with an average interest rate earned in the first six months of 1996 of 12.2%). The Mortgage Loan Division has experienced significant growth over the past several years. During 1993, 1994 and 1995, Mortgage Loan originations totaled $20.5 million, $99.4 million and $192.8 million, respectively. During the six months ended June 30, 1996, Mortgage Loan originations totaled $153.8 million. A majority of the Mortgage Loans are sold on a non-recourse basis to institutional investors. The Mortgage Loan Division originates Mortgage Loans on both a retail basis through regional offices and a wholesale basis through independent mortgage brokers and mortgage bankers (collectively, the "Mortgage Bankers"). The Company's retail lending operations were established in the second quarter of 1996, and currently operate through offices in Indianapolis, IN, Baton Rouge, LA and New Orleans, LA. The Company expects to open retail lending operations in Greenville, SC and Phoenix, AZ during the fourth quarter of 1996 and five new retail lending offices during the first quarter of 1997. Through its retail offices, the Company targets Mortgage Loan borrowers through a variety of marketing methods. During August and September 1996, retail originations totaled $5.0 million and $8.4 million, respectively. The Company also originates Mortgage Loans on a wholesale basis through approximately 225 Mortgage Bankers in approximately 12 states. The Company has established strategic alliance agreements with certain Mortgage Bankers (the "Strategic Alliance Mortgage Bankers"), which require the Strategic Alliance Mortgage Bankers to refer to the Company all of their loans up to specified levels which meet the Company's underwriting criteria, in exchange for delegated underwriting, administrative support and expedited funding. The Company currently has four Strategic Alliance Mortgage Bankers (one of which was added in October 1996) and plans to add two more during the remainder of 1996 and the first quarter of 1997. The Company has a minority equity interest in certain of the Strategic Alliance Mortgage Bankers. The Company believes that its use of retail and wholesale origination and strategic alliances is a unique strategy which enables the Company to penetrate the non-prime mortgage loan market through multiple channels. In the first six months of 1996, approximately 53% (or approximately $15 million per month) of the Company's Mortgage Loans by principal amount were originated through one Strategic Alliance Mortgage Banker, First Greensboro Home Equity, Inc. ("First Greensboro"). On June 1, 1996, First Greensboro terminated its agreement with the Company in connection with its sale to a third party. As a result of such termination, First Greensboro paid the Company $7.3 million in September 1996. Although First Greensboro generated a large percentage of the Company's Mortgage Loan originations, the Company believes that it will be able to replace such originations through its retail lending operations and through additional Strategic Alliance Mortgage Bankers, two of which entered into strategic alliance agreements with the Company in the second and third quarters of 1996. During August and September 1996, Mortgage Loan originations through these additional sources totaled $6.2 million and $9.9 million, respectively. SMALL BUSINESS LOAN DIVISION The Company's Small Business Loan operation (the "Small Business Loan Division") makes loans to small businesses primarily for the acquisition or refinancing of property, plant and equipment and working capital. During 1993, 1994 and 1995, Small Business Loan originations totaled $37.9 million, $43.1 million and $39.6 million, respectively. During the six months ended June 30, 1996, Small Business Loan originations totaled $30.6 million. A substantial portion of the Company's Small Business Loans are loans ("SBA Loans") which are guaranteed by the U.S. Small Business Administration (the "SBA"). The SBA Loans are secured by real or personal property and have initial principal balances ranging from $250,000 to $1.5 million (with an average initial principal balance in the first six months of 1996 of $650,000) and variable interest rates limited to a maximum of 2.75% over the prime rate. The SBA guarantees approximately 75% of the original principal amount of the SBA Loans, up to a maximum guarantee amount of $750,000. The Company sells participations representing the SBA-guaranteed portion of its SBA Loans (the "SBA Loan Participations") in the secondary market. In connection with such sales, the Company receives, in addition to excess servicing revenue, cash premiums of approximately 10% of the guaranteed portion being sold. SBA Loans are originated directly by the Company's loan officers in its six branch offices and are primarily generated through referral sources such as commercial loan and real estate brokers ("Commercial Loan Brokers") located in its market areas. Approximately 75% of the SBA Loans originated in the first six months of 1996 were originated through Commercial Loan Brokers. The Company believes that it was among the ten largest SBA Loan lenders in the United States, by principal amount of SBA Loans approved, for the SBA's fiscal year ended September 30, 1995. The Small Business Loan Division also provides working capital loans secured by accounts receivable, inventory and equipment to small- to medium-sized businesses in the southeastern United States ("Asset-based Small Business Loans"). The Company began its asset-based lending operation in April 1996 in Atlanta, GA. For the six months ended June 30, 1996, Asset-based Small Business Loans originated by the Small Business Loan Division totaled approximately $4.6 million. AUTO LOAN DIVISION The Company's Auto Loan operation (the "Auto Loan Division") makes loans to non-prime borrowers for the purchase of used automobiles. Substantially all of the Auto Loans are made directly by the Company to purchasers of automobiles who are referred to the Company by automobile dealers ("Dealers"). Less than 20% of the Auto Loans made in the first six months of 1996 were indirect loans purchased from Dealers. The Auto Loans generally have initial principal balances ranging from $3,000 to $10,000 (with an average initial principal balance in the first six months of 1996 of approximately $5,000), terms ranging from 24 to 48 months, and fixed interest rates ranging from 18% to 46% per annum (with an average yield in the first six months of 1996 of 27.4%). The Auto Loan Division operates through eight locations and originates Auto Loans in connection with approximately 200 Dealers. During 1993, 1994 and 1995, Auto Loan originations totaled $5.2 million, $7.5 million and $17.1 million, respectively. During the six months ended June 30, 1996, Auto Loan originations totaled $10.0 million. LOAN PORTFOLIO/LOAN SALES AND SECURITIZATIONS The Company's loan receivables held for investment at December 31, 1993, 1994 and 1995 totaled $66.3 million, $91.7 million, and $103.9 million, respectively. At June 30, 1996, loan receivables totaled $87.8 million, of which $55.0 million were Mortgage Loans, $24.0 million were Small Business Loans and $8.8 million were Auto Loans. Consistent with the Company's "high velocity" capital strategy described below, the Company has sold a substantial majority of the loans it has originated through whole Mortgage Loan sales, sales of SBA Loan participations and through the securitization of approximately $17.1 million of the unguaranteed portion of SBA Loans in June 1995 and $16.1 million of Auto Loans in March 1996. The Company plans to continue to pursue securitizations in the future, including the securitization of a majority of its Mortgage Loans beginning in 1997, principally because the Company believes that securitization is potentially more profitable than loan sales. BUSINESS AND GROWTH STRATEGY The Company's business strategy is to be a diversified financial services company that meets the credit needs of borrowers in what the Company believes to be under-served credit markets. Key elements of the Company's business strategy are to: -- Maintain a "high velocity" capital strategy whereby loans are generally sold within 10 to 40 days of origination, thereby enabling the Company to recognize cash gains on the sales of its loans and quickly redeploy its capital, as well as reduce its interest rate risk, default risk and borrowing costs. In addition, the Company plans to continue to pursue securitization transactions for all of its loan divisions in the future. -- Respond quickly to customer credit requests by utilizing a decentralized loan approval process, while ensuring consistent credit quality through uniform underwriting guidelines and procedures. -- Utilize a proactive underwriting process whereby the Company may restructure credit requests in order to cause them to meet the Company's underwriting criteria. -- Achieve profitability goals by maximizing interest margins and emphasizing effective monitoring and collection of loans. The Company's growth strategy is to continue to expand all areas of its lending operations, emphasizing profitability, rather than asset growth. Key elements of the Company's growth strategy are to: -- Increase Mortgage Loan originations by expanding its retail lending operations where the Company lends directly to the customer without using a Mortgage Banker. -- Increase wholesale Mortgage Loan originations from the Strategic Alliance Mortgage Bankers and enter into additional strategic alliances with other Mortgage Bankers, as well as increase the number of relationships with other referral sources such as Commercial Loan Brokers and Dealers. -- Expand its Small Business Loan operations by utilizing its "Preferred Lender" status with the SBA to minimize response time and maximize Small Business Loan production. -- Increase its penetration in existing markets and expand geographically by opening additional offices. -- Pursue the acquisition of businesses in the financial services industry (although no agreements or understandings relating to any acquisitions are presently pending). The Company was incorporated in 1968 and until 1990 engaged principally in railroad-related operations. Prior to 1990, the Company incurred significant losses which resulted in net operating losses. In December 1990, current management acquired control of the Company and implemented a strategic plan to acquire profitable businesses which could utilize such net operating losses. Pursuant to such strategy, the Company acquired certain financial services companies in 1991 and an apparel manufacturer in 1993. In 1994, the Company made a strategic decision to divest all non-financial operations and to focus exclusively on the financial services industry. In accordance with such strategy, the Company has completed its divestiture of its apparel-related and transportation-related operations. THE OFFERING Common Stock offered by the Company.......... 2,119,031 shares Common Stock offered by the Selling Shareholders....................... 880,969 shares Common Stock to be outstanding after the Offering............................... 8,741,130 shares(1) Use of proceeds.............................. To repay indebtedness under the Company's existing credit facilities(2). See "Use of Proceeds." Proposed Nasdaq National Market symbol....... EMER
- --------------- (1) Excludes (i) 226,708 shares of Common Stock issuable upon the exercise of options granted pursuant to the Company's existing stock option plans, (ii) 102,167 shares of Common Stock issuable upon the exercise of outstanding warrants and (iii) 10,500 shares of Common Stock issuable pursuant to stock grants made pursuant to the Company's Restricted Stock Agreement Plan. See "Management." (2) At September 30, 1996, such indebtedness totaled $29.7 million. SUMMARY CONSOLIDATED FINANCIAL AND OPERATING DATA AT AND FOR THE SIX MONTHS AT AND FOR THE FISCAL YEAR ENDED DECEMBER 31, ENDED JUNE 30, ----------------------------------------------------------- -------------------------- 1991 1992 1993 1994 1995 1995 1996 -------- -------- --------- --------- --------- --------- ----------- (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF INCOME DATA: Revenues: Interest and servicing revenue....................... $ 4,064 $ 6,980 $ 7,983 $ 10,903 $ 15,639 $ 7,307 $ 9,937 Gain on sale of loans(1)........ -- 1,686 3,605 6,450 9,169 4,355 7,468 Other revenues.................. 96 342 458 842 1,470 692 904 -------- -------- --------- --------- --------- --------- ----------- Total revenues.............. 4,160 9,008 12,046 18,195 26,278 12,354 18,309 Expenses: Interest expense................ 2,399 4,315 5,073 5,879 8,527 3,780 5,576 Provision for credit losses(2)..................... 83 349 686 2,510 2,480 1,240 1,532 General and administrative expenses...................... 2,265 4,698 5,624 7,359 10,419 4,514 7,622 -------- -------- --------- --------- --------- --------- ----------- Total expenses.............. 4,747 9,362 11,383 15,748 21,426 9,534 14,730 Income (loss) from continuing operations(3)(4)................ (595) (249) 937 1,792 4,581 2,696 3,436 Income (loss) from discontinued operations(3)................... 344 685 260 546 (3,924) (751) -- -------- -------- --------- --------- --------- --------- ----------- Net income (loss)(3).............. $ (251) $ 436 $ 1,197 $ 2,338 $ 657 $ 1,945 $ 3,436 ========== ========== =========== =========== =========== =========== ============== Income (loss) per share from continuing operations(3)(4)..... $ (0.11) $ (0.04) $ 0.14 $ 0.27 $ 0.69 $ 0.40 $ 0.51 Income (loss) per share from discontinued operations(3)...... 0.06 0.12 0.04 0.08 (0.59) (0.11) -- -------- -------- --------- --------- --------- --------- ----------- Net income (loss) per share(3).... $ (0.05) $ 0.08 $ 0.18 $ 0.35 $ 0.10 $ 0.29 $ 0.51 ========== ========== =========== =========== =========== =========== ============== Weighted average outstanding equivalent shares (in thousands)...................... 5,660 5,639 6,552 6,689 6,668 6,691 6,728 Supplemental net income per share:(3)(5) Income per share from continuing operations.................... $ 0.52 $ 0.39 Income (loss) from discontinued operations.................... (0.45) -- --------- ----------- Net income per share............ $ 0.07 $ 0.39 =========== ============== OPERATING DATA: Total loans originated or purchased....................... $ 18,361 $ 57,282 $ 63,633 $ 150,044 $ 249,507 $ 104,977 $ 194,437 Total loans sold.................. -- 10,827 31,052 85,772 153,055 58,494 159,886 Total loans securitized........... -- -- -- -- 17,063 17,063 16,107 Total loans serviced (period end)(6)......................... 41,250 68,489 106,898 157,443 214,534 185,118 217,982 Total loans receivable (period end)............................ 39,870 56,785 66,279 95,398 126,458 98,969 103,265 Weighted average interest rate earned.......................... 14.23% 14.19% 12.83% 13.43% 13.94% 15.02% 15.76% Weighted average interest rate paid............................ 7.69 7.74 7.24 6.94 7.57 7.40 8.64 Loans receivable held for investment...................... $ 39,870 $ 56,785 $ 66,279 $ 91,736 $ 103,865 $ 88,842 $ 87,835 Allowance for credit losses as a % of loans receivable held for investment...................... 2.35% 1.92% 1.60% 2.07% 2.02% 1.59% 2.67% Allowance for credit losses as a % of nonperforming loans held for investment...................... 490.05 16.39 45.12 92.17 51.83 52.32 62.84 Allowance for credit losses as a % of nonperforming loans serviced for others(6)................... -- -- -- -- (8) (8) 308.94 Allowance for credit losses as a % of serviced loans (period end)(6)......................... 2.35 1.92 1.60 1.98 2.03 2.07 2.83 Net charge-offs as a % of average serviced loans(2)(6)............ 0.83 0.68 1.29 2.36 1.43 0.90 0.96 General and administrative expenses as a % of average serviced loans(6)............... 8.24 8.56 6.41 5.57 5.60 5.39 6.66
AT JUNE 30, 1996 ------------------------ AS ACTUAL ADJUSTED(7) --------- ----------- BALANCE SHEET DATA: Loans receivable................................................................................. $ 87,835 $ 87,835 Mortgage loans held for sale..................................................................... 15,430 15,430 Total assets..................................................................................... 146,657 149,787 Total indebtedness............................................................................... 128,334 108,073 Total shareholders' equity....................................................................... 13,535 36,925
- --------------- (1) These amounts represent gains recorded on the sale of Mortgage Loans and SBA Loan Participations. (2) Approximately 90% of the amount in 1994 relates to the writedown to market of certain foreclosed properties associated with speculative construction loans made by the Mortgage Loan Division prior to its acquisition by the Company. Speculative construction loans are no longer being made by the Company. (3) Includes the impact of the utilization of the Company's net operating loss carryforward, which totaled approximately $23 million and $18 million at December 31, 1995 and June 30, 1996, respectively. Absent the utilization of the NOL, for the year ended December 31, 1995 and the six months ended June 30, 1996 (i) income (loss) from continuing operations would have been $2.9 million and $2.2 million, respectively; (ii) income (loss) from discontinued operations would have been ($2.5 million) and $0, respectively; and (iii) the net income (loss) would have been approximately $448,000 and $2.2 million, respectively. (4) The amount set forth with respect to the year ended December 31, 1993 includes $113,000 ($0.01 per share) which reflects the cumulative effect of a change in the method of accounting for income taxes. (5) Supplemental net income per share (as adjusted) reflects the issuance of the 2,119,031 shares of Common Stock offered by the Company hereby, the proceeds of which are to be used to repay approximately $22 million in Company debt. These amounts were calculated based on total weighted average shares of 8,787,222 at December 31, 1995 and 8,846,704 shares at June 30, 1996. (6) Serviced loans includes all portfolio Mortgage Loans and Auto Loans, all securitized loans, and the Small Business Loans, but solely for purposes of calculating the allowance ratio and net charge-off ratio, excludes the guaranteed portion of the SBA Loans. Operating data stated as a percentage of serviced loans (except period end data) for the six month periods ended June 30, 1995 and 1996 have been annualized. (7) Adjusted to reflect the sale by the Company of 2,119,031 shares at an assumed public offering price of $12.00, the receipt by the Company of $242,000 in connection with the exercise of warrants by certain Selling Shareholders and the application of the estimated net proceeds thereof as described under "Use of Proceeds." (8) Allowance for credit losses on non-portfolio loans totaled $773,000 and $669,000 for December 31, 1995 and June 30, 1995, respectively, and there were no nonperforming loans serviced for others at these dates. RECENT DEVELOPMENTS The following table sets forth certain recent unaudited financial data of the Company on a consolidated basis. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the financial position and results of operations for such unaudited periods have been included. The financial position and results of operations for the three and nine month periods ended September 30, 1996, are not necessarily indicative of operations which may be expected for the entire year. FOR THE THREE AT AND FOR THE MONTHS NINE MONTHS ENDED SEPTEMBER 30, ENDED SEPTEMBER 30, ------------------- --------------------- 1995 1996 1995 1996 ------- ------- -------- -------- (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF INCOME DATA: Revenues: Interest and servicing revenue.................. $ 3,909 $ 5,143 $ 11,216 $ 15,081 Gain on sale of loans........................... 2,224 7,870 6,579 15,338 Other revenues.................................. 526 1,557 1,218 2,459 ------- ------- -------- -------- Total revenues.......................... 6,659 14,570 19,013 32,878 Expenses: Interest expense................................ 2,161 2,603 5,941 8,181 Provision for credit losses..................... 380 1,569 1,620 3,101 General and administrative expenses............. 2,620 6,058 7,134 13,680 ------- ------- -------- -------- Total expenses.......................... 5,161 10,230 14,695 24,962 Income from continuing operations................. 1,376 4,301 4,072 7,736 Income (loss) from discontinued operations........ (2,728) -- (3,479) -- ------- ------- -------- -------- Net income (loss)(1).............................. $(1,352) $ 4,301 $ 593 $ 7,736 ======= ======= ======== ======== Net income (loss) per share....................... $ (0.20) $ 0.63 $ 0.09 $ 1.14 ======= ======= ======== ======== Weighted average outstanding equivalent shares (in thousands)...................................... 6,706 6,777 6,706 6,774 OPERATING DATA: Total loans originated or purchased............. $63,290 $89,043 $168,268 $283,480 Total loans sold................................ 38,694 52,146 94,597 211,913 Total loans securitized......................... -- -- 17,063 16,107 Total loans serviced (period end)............... 197,512 238,737 Allowance for credit losses as a % of serviced loans (period end)(2)........................ 1.97% 2.81% Net charge-offs as a % of average serviced loans(2)..................................... 0.74 1.43 Total serviced loans past due 90 days or more as a % of total serviced loans(2)............... 2.10 4.03 BALANCE SHEET DATA: Loans receivable................................ $ 93,405 $105,700 Mortgage Loans held for sale.................... 14,348 23,111 Total assets.................................... 124,283 165,106 Total indebtedness.............................. 111,031 142,060 Total shareholders' equity...................... 9,743 17,834
- --------------- (1) Absent the utilization of the NOL, for the three months and nine months ended September 30, 1996, the net income (loss) would have been approximately $2.8 million and $5.0 million, respectively. (2) Serviced loans includes all portfolio Mortgage Loans and Auto Loans, all securitized loans, and the Small Business Loans, but solely for purposes of calculating the allowance ratio, net charge-off ratio, and delinquency ratio, excludes the guaranteed portion of the SBA Loans. Operating data stated as a percentage of average serviced loans (except period end data) for the periods indicated have been annualized. Revenues increased $7.9 million, or 118%, from $6.7 million for the three months ended September 30, 1995, to $14.6 million for the three months ended September 30, 1996. This increase in revenues was due principally to increases in interest and servicing revenue, gain on sale of loans, and loan fee income. Interest and servicing revenue increased $1.2 million, or 31%, from $3.9 million for the three months ended September 30, 1995, to $5.1 million for the same period in 1996. The increase in interest and servicing revenue was due principally to the increase in loan originations of $25.7 million, or 41%, from $63.3 million for the three months ended September 30, 1995, to $89.0 million for the same period in 1996. Gain on sale of loans increased $5.7 million, or 259%, from $2.2 million for the three months ended September 30, 1995, to $7.9 million for the same period in 1996. The increase in gain on sale of loans was principally from the recoupment by the Company of previously shared premiums received in connection with the settlement with First Greensboro. Other revenues, including loan fee income, increased $1.1 million, or 220%, from $500,000 for the three month period ended September 30, 1995, to $1.6 million for the same period in 1996. The increase in other revenues was due principally to increased loan-fee income generated by the Company's retail mortgage operation. Interest expense increased $400,000, or 18%, from $2.2 million for the three month period ended September 30, 1995, to $2.6 million for the same period in 1996. Interest expense increased due to the increased borrowings to fund the growth in loan originations. Provision for credit losses increased $1.2 million, or 300%, from $400,000 for the three months ended September 30, 1995, to $1.6 million for the same period in 1996. With this increased provision, the allowance for credit losses increased from 1.97% of average unguaranteed serviced loans at September 30, 1995, to 2.81% of average unguaranteed serviced loans at September 30, 1996. While total serviced loans past due 90 days or more as a percent of total serviced loans increased from 2.10% at September 30, 1995 to 4.03% at September 30, 1996, overall delinquencies of 30 days and greater decreased from 12.46% at September 30, 1995 to 11.37% at September 30, 1996. The increase in total serviced loans past due 90 days or more was principally due to the increase in loans past due 90 days or more in the Small Business Loan Division from .25% at September 30, 1995 to 4.65% at September 30, 1996. Management believes that the allowance for credit losses is adequate to cover possible losses. General and administrative expense increased $3.5 million, or 135%, from $2.6 million for the three months ended September 30, 1995, to $6.1 million for the same period in 1996. The increase in general and administrative expenses was due primarily to increased personnel, facilities, advertising, and operating costs related to new retail mortgage operations in Indianapolis and Baton Rouge, as well as increased loan servicing facilities and personnel to handle additional lending activities. Income from continuing operations for the three month period ended September 30, 1996, increased $2.9 million, or 207%, from $1.4 million for the three month period ended September 30, 1995, to $4.3 million for the three month period ended September 30, 1996. Absent the utilization of the NOL, income from continuing operations for the three month periods ending September 30, 1995 and 1996 would have been approximately $894,000 and $2.8 million, respectively. In October 1996, AmeriFund Group, Inc. ("AmeriFund"), a Strategic Alliance Mortgage Banker, terminated its strategic alliance agreement with the Company. During 1995 and the first nine months of 1996, approximately 7.0% and 14.5%, respectively, of the Company's total loans were originated through AmeriFund. For July, August and September 1996, AmeriFund originated $6.4 million, $2.6 million and $2.0 million in Mortgage Loans, respectively. Because of the Company's agreement with AmeriFund to share certain production costs, the Company's arrangement with AmeriFund was not as profitable for the Company as other Strategic Alliance Mortgage Bankers. For the nine months ended September 30, 1996, approximately $550,000 of the Company's pre-tax income resulted from its relationship with AmeriFund. The Company currently does not have any other arrangements with Strategic Alliance Mortgage Bankers which provide for shared production costs.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000312840_empire-of_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000312840_empire-of_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..f794b67fcad0bded3f780a38e6fa950ecd3061b9
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000312840_empire-of_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements, including the notes thereto, appearing elsewhere in this Prospectus. Unless otherwise indicated, all information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. See "Underwriting." THE COMPANY Empire of Carolina, Inc. designs, manufactures and markets a broad variety of toys and plastic decorative holiday products. The Company manages its business through four strategic business units ("SBUs") which are accountable for specific product categories: (i) ride-on products including Big Wheel(R) and Power Driver(R) brands; (ii) outdoor activities and games such as Snow Works(TM) winter sleds and Water Works(TM) water slides and pools (including Crocodile Mile(R) water slides); (iii) girls and boys toys featuring Buddy L(R) cars, trucks and other vehicles and Grand Champions(R) collectible horses; and (iv) holiday products featuring plastic decorative holiday display items, including the recently introduced Light Toppers(TM) outdoor lighting add-ons. The Company believes that it is the market share leader in non-powered ride-ons and in plastic water slides, winter sleds, collectible horses and outdoor decorative holiday products. Empire has been a toy manufacturer for approximately 40 years. The Company's business experienced significant change in 1993 when substantial non-toy operations were sold, and since mid-1994 the Company has undergone a change of control and management, established a new business strategy, and effected two acquisitions which added established core toy product lines to the Company's business. Following the divestitures of non-toy businesses, Empire's operations were focused on its toy business, including the Big Wheel(R) non-powered ride-on product line which has been sold throughout the United States since 1970, and its plastic decorative holiday products business. In the third quarter of 1994, current principal stockholders of the Company, led by Steven Geller, the current Chairman and Chief Executive Officer of the Company, acquired control of Empire as a base from which to build a diversified toy and plastic products manufacturing company. In October 1994, Empire acquired Marchon, Inc., a toy designer, marketer and manufacturer founded and managed by Marvin Smollar, the current President and Chief Operating Officer of the Company. Marchon's core toy products included Grand Champions(R) collectible horses and Crocodile Mile(R) water slides. In July 1995, Empire acquired the toy business and certain related liabilities of Buddy L Inc., one of the oldest toy brands in the United States whose core toy products included plastic and metal toy cars, trucks and other vehicles and battery-operated ride-ons. As a result of these recent transactions, the Company believes it is well-positioned to become a leading U.S. toy manufacturer. The Company's net sales were $41.4 million, $58.0 million and $153.7 million, respectively, for the years ended December 31, 1993, 1994 and 1995, and net sales from toy products contributed 51%, 57% and 79%, respectively, of the Company's consolidated net sales. The Company's goal is to become a leading supplier of toy and plastic decorative holiday products to retailers throughout the world. The Company believes it has distinct competitive advantages including: (i) a team of managers that, with one exception, has joined the Company since July 1994, and has extensive experience in the toy industry; (ii) a balanced line of stable core products with long histories of consumer appeal; (iii) manufacturing and sourcing flexibility through use of the Company's 1.2 million square foot facility in Tarboro, North Carolina and foreign sourcing expertise; and (iv) its decorative holiday product line, which has broad consumer appeal, has provided the Company with a consistent source of revenue while reducing the Company's dependence on major toy retailers and can be manufactured during off-peak periods throughout the year in anticipation of seasonal demand. According to the Toy Manufacturers' Association, total domestic shipments of toys, excluding video games, were approximately $13.4 billion in 1995. Management believes changing industry dynamics favor larger toy companies that can offer a broad selection of popular toy products, supported by consistent, high quality marketing programs to an increasingly concentrated distribution channel. Management also believes that there is significant potential for the Company to leverage its existing relationships with major retailers because many of such retailers are seeking to expand their relationships with suppliers like the Company in order to avoid becoming overly dependent on products from the largest domestic toy companies and to help EXHIBIT NUMBER DESCRIPTION - ------ ------------------------------------------------------------------------------------ 10.31 Asset Purchase Agreement, dated as of March 3, 1995, by and among the Company, Buddy L and Buddy L (Hong Kong) Limited.(14) 10.32 Bid Protection Agreement, dated as of March 3, 1995, between the Company and Buddy L.(14) 10.33 Assignment and Assumption Agreement dated as of June 21, 1995 between the Company and EAC.(4) 10.34 Assignment dated as of May 22, 1995 between the Company and Carnichi Limited.(4) 10.35 Lease dated July 7, 1995 between Buddy L and EAC.(4) 10.36 Access Agreement dated as of July 7, 1995 between Buddy L, BLHK, SLM, and Buddy L Canada Inc., and EAC.(4) 10.37 Access Agreement dated as of July 7, 1995 between Buddy L, BLHK, SLM, and Buddy L Canada Inc., and EAC.(4) 10.38 Assignment and Assumption of Lease dated as of July 7, 1995 between Buddy L and EAC.(4) 10.39 Loan and Security Agreement dated as of June 30, 1995 between LaSalle National Bank, N. A. ("LaSalle") and EAC.(4) 10.40 Guaranty dated as of June 30, 1995 between LaSalle and the Company.(4) 10.41 Subordination Agreement dated as of June 30, 1995 between LaSalle and the Company.(4) 10.42 $7,580,000 Senior/Subordinated Term Loan Agreement dated July 7, 1995 among the Company as Borrower and the Lenders Listed therein ("Lenders").(4) 10.43 Form of the Company's 12% Senior/Subordinated Note due July 7, 1998.(4) 10.44 Form of Warrant to Purchase Common Stock of the Company issued to the Lenders.(4) 10.45 Amended and Restated Intercreditor Agreement dated July 7, 1995 by and among the Company, EII, Wachovia, the Lenders and the holders of certain debentures dated December 22, 1994 issued by the Company.(4) 10.46 Registration Rights Agreement dated July 7, 1995 by and between the Company and the Lenders.(4) 10.47 Form of Subscription Agreement executed in connection with subscription of Common Stock and Preferred Stock by WPG Corporate Development Associates IV (Overseas), L.P., Westpool Investment Trust PLC, Glenbrook Partners, L.P., and WPG Corporate Development Associates IV, L.P.(4) 10.48 Shareholders' agreement ("Shareholders' Agreement") dated December 22, 1994 among WPG Corporate Development Associates IV, L.P., WPG Corporate Development Associates IV (Overseas), Ltd., Weiss, Peck & Greer, as Trustee of Craig S. Whiting IRA, Peter Pfister, Weiss, Peck & Greer, as Trustee of Nora E. Kerppola IRA Westpool Investment Trust, PLC, Glenbrook Partners, L. P., Steve Geller, Neil Saul, Marvin Smollar and Champ Enterprises Limited Partnership.(17) 10.49 Amendment No. 2 to Shareholders Agreement dated as of June 29, 1995 among WPG Corporate Development Associates IV, L.P., WPG Corporate Development Associates IV (Overseas), Ltd., as the exempt transferee of WPG Corporate Development Associates IV (Overseas), Ltd., certain persons identified on Schedule I of Amendment No. 2 to the Shareholders' Agreement, Steven E. Geller ("Geller"), Neil B. Saul ("Saul") and The Autumn Glory Trust, a Cook Islands Registered International Trust ("Trust") as the permitted transferee of Champ Enterprises Limited Partnership.(4) 10.50 Registration Rights Agreement ("Registration Rights Agreement") dated as of December 22, 1994 by and between Empire of Carolina, Inc., WPG Corporate Development Associates IV, L.P. WPG Corporate Development Associates IV (Overseas), Ltd., Weiss Peck & Greer, as Trustee under Craig Whiting IRA, Peter B. Pfister, Weiss, Peck & Greer, as Trustee under Nora Kerppola IRA, Westpool Investment Trust PLC and Glenbrook Partners, L. P.(17) 10.51 Amendment No. 1 to Registration Rights Agreement.(4)
assure that reliable supplies of quality products may be obtained at competitive prices. The following are the major elements of the Company's growth strategy: - Focus on core brands with long histories of broad consumer appeal, such as the Big Wheel(R) and Buddy L(R) product lines, which provide the Company with a base from which to build a diversified toy and plastic products manufacturing company. - Leverage existing manufacturing capabilities by upgrading the equipment, increasing the capacity and integrating all of the domestic manufacturing operations of the Buddy L product line at its manufacturing facility in Tarboro, North Carolina. - Offer value to toy retailers and consumers by utilizing the Company's diverse manufacturing capabilities and stable core product lines to offer high quality products and customer support at prices which enable the retailer to realize attractive gross margins. - Expand international presence, especially in Western Europe and Japan, which present significant growth opportunities for the Company. - Acquire new product lines and deepen and expand its core product lines with new licensing arrangements. - Extend core product lines through product innovation resulting from increased investment in research and development. - Develop additional countercyclical product lines to, in part, counterbalance the seasonality generally present in the toy industry and take advantage of additional manufacturing capacity available during off-peak production periods. THE OFFERING Common Stock Offered by the Company................. 1,400,000 shares Common Stock Offered by the Selling Stockholders (1)............................................... 1,723,908 shares Common Stock to be Outstanding Immediately After the Offering (2)...................................... 6,961,300 shares Use of Proceeds to the Company...................... To prepay senior subordinated notes, repay bank debt and for general corporate purposes. See "Use of Proceeds." American Stock Exchange Symbol...................... EMP
- ------------------------------ (1) Includes 315,833 outstanding shares obtainable upon exercise of an option being sold to the Underwriters by a Selling Stockholder. See "Principal and Selling Stockholders." (2) Includes 356,100 shares of Common Stock to be issued upon the exercise by certain Selling Stockholders of stock options and warrants concurrently with this Offering, but does not include an aggregate of 6,849,224 shares (758,000 of which are subject to warrants which will lapse upon the application of the net proceeds to the Company from this Offering) comprised of (i) 1,397,500 shares issuable upon the exercise of stock options outstanding on the date of this Prospectus, (ii) 1,962,900 shares issuable upon the exercise of warrants outstanding on the date of this Prospectus, of which warrants for the purchase of 758,000 shares will lapse upon the application of the net proceeds to the Company from this Offering as described in "Use of Proceeds," (iii) 442,264 shares issuable upon the conversion of the Series A cumulative convertible preferred stock upon the affirmative vote of a majority of the shares represented at the Company's 1996 Annual Meeting of Stockholders, (iv) 2,000,000 shares issuable upon the conversion of the convertible subordinated debentures, (v) up to 454,000 shares which may be issuable as a contingent payment obligation in connection with the Buddy L acquisition in certain circumstances and (vi) 592,560 shares available for future grants under the Company's 1994 Employee Stock Option Plan. See "Use of Proceeds" and "Certain Transactions." Empire of Carolina, Inc. was incorporated in Delaware in 1979. Unless the context indicates otherwise, all references to "Empire" or the "Company" refer to Empire of Carolina, Inc. and its subsidiaries. The Company's principal executive offices are located at 5150 Linton Boulevard, Delray Beach, Florida 33484, and its telephone number is (407) 498-4000. EXHIBIT NUMBER DESCRIPTION - ------ ------------------------------------------------------------------------------------ 10.52 Settlement and Termination Agreement with Neil Saul.(18) 10.53 Extension to Financing Agreement, dated February 12, 1996 between Empire and Wachovia.(18) 10.54+ Loan and Security Agreement between LaSalle National Bank and BT Commercial Corporation to Empire Industries, Inc., with exhibits and security instruments. 21+ Subsidiaries of the Company 23.1 Consent of Deloitte & Touche LLP 23.2+ Consent of Coopers & Lybrand LLP 23.3+ Consent of Wong Brothers & Co. 23.4+ Consent of Schwartz & Freeman (to be included in Exhibit 5.1) 24.1+ Powers of Attorney (included on signature page) 99.1+ Letter dated June 17, 1996 from Wong Brothers & Co. to the Members of Marchon Toys Limited
- ------------------------------ + Previously filed (1) Previously filed as an exhibit to the Company's Registration Statement on Form S-1 (File No. 2-73208), dated July 13, 1981 and incorporated by reference herein. (2) Previously filed as an exhibit to Clabir's Current Report on Form 8-K, dated December 23, 1988 (File No. 1-7769) and incorporated by reference herein. (3) Previously filed as an exhibit to the Company's Registration Statement on Form S-4 (File No. 33-32186), dated November 17, 1989 and incorporated by reference herein. (4) Previously filed as an Exhibit to the Company's Current Report on Form 8-K dated July 21, 1995, and incorporated by reference herein. (5) Previously filed as an exhibit to the Company's Current Report on Form 8-K, dated October 6, 1992 and incorporated by reference herein. (6) Previously filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 1992 and incorporated by reference herein. (7) Previously filed as an exhibit to the Company's Current Report on Form 8-K, dated February 1, 1993 and incorporated by reference herein. (8) Previously filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 1993 and incorporated by reference herein. (9) Previously filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 1993 and incorporated by reference herein. (10) Previously filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 1994 and incorporated by reference herein. (11) Previously filed as an exhibit to the Company's Current Report on Form 8-K for September 30, 1994 and incorporated by reference herein. (12) Previously filed as an exhibit to the Company's Current Report on Form 8-K for December 22, 1994 and incorporated by reference herein. (13) Previously filed as an exhibit to Amendment No. 1 to Schedule 13D filed by the WPG Group, dated December 23, 1994 and incorporated by reference herein. (14) Previously filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 1994 and incorporated by reference herein. (15) Previously filed as an exhibit to Amendment No. 1 to the Company's Annual Report on Form 10-K for the year ended December 31, 1994. SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, ---------------------------------------------------------- ------------------ 1991(1)(2) 1992(1)(2) 1993(2) 1994(3) 1995(4) 1995 1996 ---------- ---------- ------- ------- -------- ------- ------- STATEMENT OF OPERATIONS DATA: Net sales...................... $ 41,253 $ 42,882 $41,354 $57,964 $153,744 $19,088 $22,186 Gross profit................... 13,936 13,439 11,621 17,407 41,839 6,151 5,969 Nonrecurring restructuring and relocation charges........... -- -- -- -- 7,550 150 -- Operating income (loss)........ 983 1,267 (3,465) 965 (1,894) (803) (1,329) Interest expense............... 13,549 10,314 2,937 1,407 5,996 667 2,132 After-tax income (loss) from continuing operations before extraordinary items and cumulative effect of an accounting change............ (6,318) (2,696) (1,516) 589 (4,501) (1,006) (2,156) Net income (loss).............. 8,756 11,098 24,327 589 (4,501) (1,006) (2,156) Weighted average shares outstanding -- primary(5).... 10,536 10,537 14,670 12,159 4,681 4,191 5,201 Income (loss) per common share from continuing operations -- primary(5)................... $ (.60) $ (.26) $ (.10) $ .05 $ (.96) $ (.24) $ (.41)
MARCH 31, 1996 -------------------------- ACTUAL AS ADJUSTED(6) -------- -------------- BALANCE SHEET DATA: Working capital............................................................ $ 5,978 $ 23,295 Total assets............................................................... 127,467 131,404 Total debt................................................................. 68,581 54,633 Stockholders' equity....................................................... 28,371 46,256
- ------------------------------ (1) Prior to 1992, the Company owned a minority interest in The Deltona Corporation, a real estate development corporation based in Florida. Income from continuing operations includes equity loss of The Deltona Corporation for 1991 of $1,613. Income from continuing operations for 1992 includes the gain on sale of common stock of, and notes receivable from, The Deltona Corporation of $2,000. (2) On October 6, 1992, the Company sold all of the stock of Wilbur Chocolate Co., Inc. In February 1993, the Company sold the assets used in the businesses of The Isaly Klondike Company and Popsicle Industries, Inc. These businesses had been acquired in 1989. As a result of the sale of these businesses, the results of operations and gains on sale from Wilbur, Isaly Klondike, and Popsicle have been included in income from discontinued operations. See Note 15 of Notes to Consolidated Financial Statements and "Management's Discussion and Analysis of Financial Condition and Results of Operations." (3) The results of operations for 1994 reflect the results of operations of Marchon Inc. since its acquisition by the Company on October 13, 1994. See Note 3 of Notes to Consolidated Financial Statements and "Management's Discussion and Analysis of Financial Condition and Results of Operations." (4) The results of operations for 1995 reflect the results of operations of substantially all of the toy business of Buddy L Inc. and its Hong Kong subsidiary since its acquisition by the Company on July 7, 1995. See Notes 3 and 14 of Notes to Consolidated Financial Statements and "Management's Discussion and Analysis of Financial Condition and Results of Operations." (5) Fully diluted income (loss) per common share from continuing operations was $(.28), $(.06), $(.07), $.05 and $(.96), respectively, during the five years ending December 31, 1995 based on weighted average shares outstanding of 16,296, 16,297, 16,295, 12,159 and 4,681, respectively. Fully diluted loss per common share from continuing operations was $(.24) and $(.41) for the three month period ended March 31, 1995 and 1996, respectively, based on weighted average shares outstanding of 4,191 and 5,201, respectively. During September 1994, the Company repurchased approximately 11,800 shares in a treasury stock transaction. Weighted average shares outstanding in 1995 reflects 454 shares which may become issuable as a contingent payment obligation with respect to the acquisition of Buddy L in July 1995. See Notes 2, 3 and 11 of Notes to Consolidated Financial Statements. (6) Adjusted to give effect to (i) the sale by the Company of 1,400 shares of Common Stock offered (at the public offering price per share of $12.00) and the application of the net proceeds therefrom and (ii) the exercise by certain Selling Stockholders of stock options and warrants concurrently with this Offering to purchase an aggregate of 356 shares of Common Stock. See "Use of Proceeds" and "Capitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000314733_host_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000314733_host_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..d44bc7ca562bf1c6fc9e72a1be5babab99b11780
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000314733_host_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements appearing elsewhere in this Prospectus. Unless the context otherwise requires, the term "Company" refers to Host Marriott Corporation and its subsidiaries and their combined operations. Unless otherwise indicated, the information in this Prospectus does not give effect to the exercise of the over-allotment option described in "Underwriting." References herein to "Smith Travel Research" are to industry data provided by Smith Travel Research. References herein to "Coopers & Lybrand" refer to the January 1996 Hospitality Directions Quarterly Research Journal published by Coopers & Lybrand LLP. THE COMPANY The Company is one of the largest owners of hotels in the world with 90 lodging properties as of December 29, 1995, primarily located in the United States. These properties generally are operated under Marriott brands and managed by Marriott International, Inc. ("Marriott International"), formerly a wholly owned subsidiary of the Company. The Marriott brand name is among the most respected and widely recognized brand names in the lodging industry. The Company's primary focus is on the acquisition of full-service lodging properties. During 1994 and 1995, the Company added 27 full-service hotels with approximately 11,300 rooms for an aggregate of approximately $915 million, bringing the Company's total full-service hotels to 55 at December 29, 1995. Based on data provided by Smith Travel Research, the Company believes that its full-service hotels consistently outperform the industry's average occupancy rate by a significant margin and averaged 75.5% occupancy for 1995 compared to 68.2% average occupancy for the upscale full-service segment of the lodging industry (the segment which is most representative of the Company's full- service hotels). The lodging industry as a whole, and the full-service hotel segment in particular, is benefiting from an improved supply and demand relationship in the United States. Management believes that recent demand increases have resulted primarily from an improved economic environment and a corresponding increase in business travel. In spite of increased demand for rooms, the room supply growth rate in the full-service segment has greatly diminished. Management believes that this decrease in the supply growth rate in the full- service segment is attributable to many factors including the limited availability of attractive building sites for full-service hotels, the lack of available financing for new full-service hotel construction and the availability of existing full-service properties for sale at a discount to their replacement value. Due to the relatively high occupancy rates of the Company's hotels, the limited supply of new rooms and the recent increase in business travel, the managers of the Company's hotels have increased average daily room rates by primarily replacing certain discounted group business with higher-rated group and transient business and by selectively increasing room rates. As a result, on a comparable basis, room revenues per available room ("REVPAR") for full-service properties increased approximately 7% for 1995 over the comparable period for the prior year. Furthermore, because lodging property operations have a high fixed cost component, increases in REVPAR generally yield greater percentage increases in operating profit. Accordingly, the approximate 7% increase in REVPAR resulted in a 25% increase in comparable full-service hotel operating profit for 1995. The Company expects this supply/demand imbalance, particularly in the upscale full-service segment, to continue, which should result in improved REVPAR and operating profits at its hotel properties in the near term. BUSINESS STRATEGY The Company's business strategy continues to focus on opportunistic acquisitions of full-service urban, convention and resort hotels primarily in the United States. The Company believes that the full-service segment of the market offers numerous opportunities to acquire assets at attractive multiples of cash flow and at substantial discounts to replacement value, including underperforming hotels which can be improved by conversion to the Marriott brand. The Company believes this segment is very promising because: . There is virtually no new supply of upscale full-service hotel rooms currently under construction. According to Smith Travel Research, from 1988 to 1990, upscale full-service room supply increased an average of approximately 5% annually, which resulted in an oversupply of rooms in the industry. However, this growth slowed to an average of approximately 1.7% from 1990 to 1995. Management believes that the lead time from conception to completion of a full-service hotel is generally five years or more in the types of markets the Company is principally pursuing, which will contribute to the continued low growth of supply. According to Coopers & Lybrand, hotel supply in the upscale full-service segment is expected to grow annually at 1.8% to 1.9% through 1998. Furthermore, because of the prolonged lead time for construction of new full-service hotels, management believes that growth in the full-service segment will continue to be limited at least through 2000. . Many desirable hotel properties are held by inadvertent owners such as banks, insurance companies and other financial institutions which are motivated and willing sellers. The Company has acquired several properties from these inadvertent owners at significant discounts to replacement cost. . Management believes that there are numerous opportunities to improve the performance of acquired hotels by replacing the existing hotel manager with Marriott International and converting the hotels to the Marriott brand. Nine of the 27 full-service hotels added in 1994 and 1995 were converted to the Marriott brand following their acquisition. These conversion properties (excluding the Marriott World Trade Center which was only partially open during 1995) experienced a 66.5% average occupancy rate during 1995 compared to an average occupancy rate of 75.5% for all of the Company's full-service hotels. The Company believes these nine conversion properties will experience improved operations as a result of increases in occupancy and room rates as the properties begin to benefit from Marriott's brand recognition, reservation system and group sales organization. The Company intends to pursue additional full- service hotel acquisitions, some of which may be conversion opportunities. The Company holds minority interests and serves as general partner in various partnerships that own, as of December 29, 1995, an aggregate of 262 additional properties, 42 of which are full-service properties, managed by Marriott International. Four of the properties added by the Company in the last two years were held by a partnership in which the Company holds a minority interest. As opportunities arise, the Company intends to pursue the acquisition of additional full-service hotels currently held by such partnerships and/or additional interests in such partnerships. The Company believes it is well qualified to pursue its acquisition strategy. Management has extensive experience in acquiring and financing lodging properties and believes its industry knowledge, relationships and access to market information provide a competitive advantage with respect to evaluating and acquiring hotel assets. In addition, the Company is well positioned to convert acquired properties to the high-quality Marriott brand name due to its relationship with Marriott International. For a description of the Company's relationship with Marriott International, see "Relationship Between the Company and Marriott International." RECENT ACQUISITIONS, PENDING ACQUISITIONS AND DIVESTITURES During 1994, the Company added 18 full-service hotels with approximately 7,400 rooms (including the Springfield Radisson Hotel, a 199-room hotel subsequently sold in 1995) for approximately $525 million. In 1995, the Company acquired nine full-service hotels with approximately 3,900 rooms in separate transactions for approximately $390 million. In 1996, through the date hereof, the Company has acquired one full-service hotel (374 rooms), controlling interests in three additional properties (2,269 rooms), one of which is currently under construction and is scheduled to be completed during the third quarter of 1996, and an 83% interest in the mortgage loans secured by a 250- room full-service property. See "Business and Properties--1996 Acquisitions." The Company has also entered into agreements to purchase two full-service properties (608 rooms) for approximately $51 million and a controlling interest in one full-service property (400 rooms) for approximately $18 million (together, the "Pending Acquisitions"). See "Business and Properties--Pending Acquisitions." Consistent with its strategy of focusing on the full-service segment of the lodging industry, the Company sold 26 of its 30 Fairfield Inns and all of its 14 senior living communities in 1994. In addition, the Company sold (subject to a leaseback) 37 Courtyard by Marriott ("Courtyard") properties to an unrelated real estate investment trust (the "REIT") in 1995. In 1995, the Company also sold its remaining four Fairfield Inns and the 199-room Springfield Radisson Hotel (which was acquired as part of a portfolio of lodging properties by the Company in 1994). Management believes that all of these sales were made at valuations that were attractive to the Company. In February 1996, the Company entered into an agreement with the REIT to sell and lease back 16 Courtyard properties and 18 Residence Inns (the "Pending Dispositions") for $349 million (10% of which would be deferred). The Pending Dispositions should be completed in the first and second quarters of 1996 and the Company intends to reinvest the proceeds in the acquisition of full-service lodging properties. See "Business and Properties--Pending Dispositions." SPECIAL DIVIDEND The Company previously operated food, beverage and merchandise concessions at airports, on tollroads and at stadiums and arenas and other tourist attractions (the "Operating Group"). On December 29, 1995, the Company distributed to its shareholders through a special dividend (the "Special Dividend") all of the outstanding shares of common stock of Host Marriott Services Corporation ("HM Services"), formerly a wholly owned subsidiary of the Company, which, as of the date of the Special Dividend, owned and operated the Operating Group business. The Special Dividend provided Company shareholders with one share of common stock of HM Services for every five shares of Company Common Stock held by such shareholders on the record date of December 22, 1995. The Special Dividend was designed to separate two types of businesses with distinct financial, investment and operating characteristics and to allow each business to adopt strategies and pursue objectives appropriate to its specific needs. The Special Dividend (i) facilitates the development of employee compensation programs custom-tailored to the operations of each business, including stock-based and other incentive programs, which will more directly reward employees of each business based on the success of that business, (ii) enables the management of each company to concentrate its attention and financial resources on the core businesses of such company, and (iii) permits investors to make more focused investment decisions based on the specific attributes of each of the two businesses. THE OFFERINGS Common Stock Offered U.S. Offering.......................... 20.0 million shares International Offering................. 5.0 million shares Total................................ 25.0 million shares(1) Common Stock to be Outstanding after the Offerings............................... 184.7 million shares(1)(2) NYSE Trading Symbol...................... HMT Use of Proceeds.......................... For the acquisition of lodging properties and for general corporate purposes
- -------- (1) Assumes no exercise of the over-allotment option granted to the Underwriters by the Company. (2) Based on the number of shares of Common Stock outstanding on December 29, 1995. Does not include (i) up to 10.0 million shares of Common Stock subject to options held by current and former executive officers and certain employees of the Company, having a weighted average exercise price of $3.92 per share (certain of which options are subject to vesting requirements), (ii) up to 2.0 million shares of Common Stock held by current and former executive officers and certain employees under deferred stock incentive plans (certain of which shares are subject to vesting requirements), (iii) up to 7.5 million shares of Common Stock, issuable upon exercise of warrants having a current exercise price of $8.00 per share, issued or reserved for issuance by the Company to certain plaintiffs as part of a settlement of a class action suit, and (iv) up to 2.1 million restricted stock plan shares under the Comprehensive Stock Incentive Plan, approved by the Board of Directors in February 1996. See "Description of Capital Stock--Warrants" and "Management--Executive Officer Compensation." SUMMARY HISTORICAL AND PRO FORMA FINANCIAL DATA The following table presents summary consolidated historical and pro forma financial data of the Company for the fiscal years ended December 29, 1995 and December 30, 1994. The historical financial data provided herein is derived from the Consolidated Financial Statements of the Company included in this Prospectus and the unaudited pro forma financial data provided herein is derived from the Pro Forma Condensed Consolidated Financial Data of the Company included in this Prospectus and includes the effect of the acquisitions, dispositions, bond offerings and Special Dividend discussed in this Prospectus. The pro forma financial data set forth below may not necessarily be indicative of the results that would have been achieved had such transactions been consummated as of the dates indicated or that may be achieved in the future. The information presented below should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto, the "Selected Historical Financial Data," "Management's Discussion and Analysis of Results of Operations and Financial Condition," and the "Pro Forma Condensed Consolidated Financial Data" included elsewhere herein. The Company's fiscal year ends on the Friday closest to December 31. HISTORICAL PRO FORMA(1) ------------- -------------------------- FISCAL YEAR FISCAL YEAR 1995 1994 1995 1994 ----- ------ -------- ------ (IN MILLIONS) INCOME STATEMENT DATA: Revenues........................... $ 484 $ 380 $565 $504 Operating profit before minority interest, corporate expenses and interest.......................... 114 152 114 152 Minority interest.................. 2 1 2 1 Corporate expenses................. 36 31 36 31 Interest expense................... 178 165 209 180 Interest income.................... 27 29 28 25 Loss from continuing operations.... (62) (13) (82) (25) Net loss(2)........................ (143) (25) N/A N/A OTHER DATA: EBITDA(3).......................... $311 $ 269 $306 $258 Depreciation and amortization...... 122 113 120 111 Cash from continuing operations.... 110 75 N/A N/A Cash used in investing activities from continuing operations ....... (156) (135) N/A N/A Cash from financing activities from continuing operations............. 204 24 N/A N/A Ratio of earnings to fixed charges(4)........................ -- -- N/A N/A Deficiency of earnings to fixed charges........................... 70 12 N/A N/A AS OF DECEMBER 29, 1995 ---------------------------------- PRO PRO FORMA ACTUAL FORMA(5) AS ADJUSTED(5)(6) ------ -------- ----------------- BALANCE SHEET DATA: Cash and cash equivalents.......... $ 201 $ 387 $ 694 Total assets....................... 3,557 3,805 4,112 Total debt......................... 2,178 2,384 2,384 Shareholders' equity............... 675 675 982
(footnotes on following page) HOTEL PERFORMANCE The following table sets forth key performance statistics of the Company's properties: FISCAL YEAR -------------------------- 1995 1994 ------- ------- COMPARABLE FULL-SERVICE HOTELS(7) Number of properties............................... 25 25 Number of rooms.................................... 12,881 12,869 Average daily rate................................. $113.08 $103.53 Occupancy %........................................ 76.6% 77.9% REVPAR(8).......................................... $86.56 $80.69 REVPAR % change.................................... 7.3% -- TOTAL FULL-SERVICE HOTELS Number of properties............................... 55 41 Number of rooms.................................... 25,932 19,492 Average daily rate................................. $110.30(9) $102.82(10) Occupancy %........................................ 75.5%(9) 77.4%(10) REVPAR(8).......................................... $83.32(9) $79.61(10) REVPAR % change.................................... 4.7%(9) -- COURTYARD HOTELS (54 properties with 7,940 rooms)(11) Average daily rate................................. $73.99 $68.86 Occupancy %........................................ 80.5% 80.4% REVPAR(8).......................................... $59.54 $55.37 REVPAR % change.................................... 7.5% -- RESIDENCE INNS (18 properties with 2,178 rooms) Average daily rate................................. $85.07 $79.58 Occupancy %........................................ 86.6% 85.6% REVPAR(8).......................................... $73.69 $68.12 REVPAR % change.................................... 8.2% --
- -------- (1) Pro forma for the 1994 addition of 18 full-service properties (one of which was sold in December 1995), the 1994 sale of 14 senior living communities, the 1994 sale of 26 Fairfield Inns, the 1995 acquisition of eight full-service properties (excluding the Marriott World Trade Center), the 1995 sale/leaseback of 37 Courtyard properties, the 1995 sale of the four remaining Fairfield Inns, the May 1995 Debt Offering (as defined herein), the December 1995 Debt Offering (as defined herein), the 1996 acquisition of a controlling interest in the San Diego Marriott Hotel and Marina, the 1996 acquisition of the Toronto Delta Meadowvale, the 1996 purchase of an 83% interest in the mortgage loans secured by the Newport Beach Marriott Suites, the Pending Acquisitions and the Pending Dispositions. See "Pro Forma Condensed Consolidated Financial Data." (2) For fiscal years 1995 and 1994, the Company recorded extraordinary losses on the extinguishment of debt of $20 million and $6 million, respectively, after taxes. For fiscal years 1995 and 1994, the Company recorded a loss from discontinued operations of $61 million and $6 million, respectively, after taxes. (3) EBITDA consists of the sum of consolidated net income (loss) from continuing operations, interest expense, income taxes, depreciation and amortization and certain other noncash charges (principally noncash write- downs of lodging properties and equity in earnings of affiliates, net of distributions received). The Company considers EBITDA to be an indicative measure of the Company's operating performance due to the significance of the Company's long-lived assets and because EBITDA can be used to measure the Company's ability to service debt, fund capital expenditures and expand its business; however, such information should not be considered as an alternative to net income, operating profit, cash flows from operations, or any other operating or liquidity performance measure prescribed by generally accepted accounting principles. Cash expenditures for various long-term assets, interest expense and income taxes have been, and will be, incurred which are not reflected in the EBITDA presentation. (4) The ratio of earnings to fixed charges is computed by dividing income (loss) from continuing operations before taxes, interest expense and other fixed charges by total fixed charges, including interest expense, amortization of debt issuance costs and the portion of rent expense which represents interest. The deficiency of earnings to fixed charges is largely the result of depreciation and amortization of $122 million for fiscal year 1995, and $113 million for fiscal year 1994. (5) Pro forma for the 1996 acquisition of a controlling interest in the San Diego Marriott Hotel and Marina, the 1996 acquisition of the Toronto Delta Meadowvale, the 1996 purchase of an 83% interest in the mortgage loans secured by the Newport Beach Marriott Suites, the Pending Acquisitions and the Pending Dispositions. See "Pro Forma Condensed Consolidated Financial Data." (6) As further adjusted to give effect to the Offerings. (7) Consists of the 25 properties owned by the Company for all of 1995 and 1994, except for the 255-room Elk Grove Suites hotel, which is leased to a national hotel chain through 1997 and the Sacramento property, which is operated as an independent hotel. (8) REVPAR represents room revenues generated per available room and excludes food and beverage and other ancillary revenues generated by the property. (9) Excludes the 820-room Marriott World Trade Center acquired in the last week of 1995. (10) Excludes six properties acquired in the last two weeks of fiscal year 1994 and the Detroit Airport Marriott included in the Special Dividend. (11) Includes the 37 properties which the Company sold (subject to a leaseback) to the REIT in 1995. CORPORATE STRUCTURE The chart below presents the organizational corporate structure of Host Marriott and certain of its subsidiaries, after giving effect to the Special Dividend (including the Company's properties and other material investments as of March 15, 1996). [FLOW CHART APPEARS HERE] (1) Excludes one full-service property under construction located in Mexico City, Mexico. (2) During February 1996, the Company entered into an agreement to sell and lease back 16 of the 17 Courtyard properties and 18 Residence Inns. See "Business and Properties--Pending Dispositions."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000315272_harcor_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000315272_harcor_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..a8a285fa484aa5e706fd1fc6526350e019e40751
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000315272_harcor_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY This summary is qualified in its entirety by the more detailed information and the consolidated financial statements and notes thereto appearing elsewhere in this Prospectus. Unless otherwise indicated all information in this Prospectus assumes that the Underwriters' over-allotment option will not be exercised. Certain terms relating to the oil and gas industry are defined in the Glossary of Oil and Gas Terms included elsewhere in this Prospectus. Investors should carefully consider the information set forth in "Risk Factors." THE COMPANY GENERAL HarCor Energy, Inc. is an independent energy company engaged in the acquisition, exploitation and exploration of onshore crude oil and natural gas properties in the United States. Since 1987 when the present management group acquired control of the Company, HarCor has grown through selective acquisitions and development drilling, with estimated proved reserves increasing from 1.35 MMBOE as of January 1, 1990 to 29.9 MMBOE as of January 1, 1996, at an average replacement cost of $2.62 per BOE. The Company's operations are currently focused in the San Joaquin Basin of California, South Texas and the Permian Basin of West Texas. As of January 1, 1996, the Company's proved reserves, as estimated by the Company's independent petroleum engineers, consisted of 15.3 MMBbls of crude oil and NGLs and 87.6 Bcf of natural gas with a Pre-tax SEC 10 Value of $124.5 million, approximately 84% of which was attributable to net proved reserves located in the Lost Hills Field in the San Joaquin Basin. The Company conducts its exploration, development and production activities through strategic alliances with industry partners that are experienced and knowledgeable in the particular geologic basins of activity and that own a significant interest in the jointly owned properties. The industry partner is generally designated as the operator of the jointly owned properties, thereby allowing the Company to avoid the cost of maintaining the personnel and other resources necessary to be an operator. The Company believes, however, that its ownership of meaningful working interests in its properties, its contractual rights to approve drilling budgets or propose wells and its experienced team of oil and gas professionals allow the Company to control or significantly influence the operators' decisions affecting the magnitude and timing of exploration, development and production activities on its properties. Through geographic concentration and tight control over oil and gas operating and general and administrative expenses, the Company has maintained a relatively low cost structure. For the year ended December 31, 1995, the Company had an average production cost of $3.99 per BOE and general and administrative expenses of $1.80 per BOE. BUSINESS STRATEGY The Company's business objective is to increase its hydrocarbon reserves as economically as possible by: - Continuing to develop its San Joaquin Basin, South Texas and Permian Basin properties through additional drilling and secondary recovery activities; - Using the cash flow from its existing properties and the proceeds from the Offering to engage in exploration activities with experienced and technologically knowledgeable industry partners, initially onshore Texas and Louisiana; - Acquiring onshore oil and gas properties with significant development potential; and - Continuing to maintain relatively low production costs through geographic concentration and tight control over operating and general and administrative expenses. DEVELOPMENT ACTIVITIES San Joaquin Basin. Approximately 20.8 MMBOE, or 69.4%, of the Company's total proved reserves as of January 1, 1996 were classified as proved undeveloped by Ryder Scott Company ("Ryder Scott"). Substantially all of the Company's undeveloped reserves are located in the Lost Hills Field in the San Joaquin Basin. Bakersfield Energy Resources, Inc. ("Bakersfield Energy"), a company with extensive experience in the San Joaquin Basin, is the operator of substantially all of HarCor's oil and gas properties in the San Joaquin Basin. As of March 31, 1996, the Company had identified 173 new gross wells which it intends to drill during the next five years to fully develop the proved reserves on the properties, of which 48 are expected to be drilled in 1996. The Company also plans to commence a secondary recovery waterflood project in the fourth quarter of 1996 with respect to a portion of its properties in the Lost Hills Field. In addition, the Company has completed a horizontal well in the Lost Hills Field to test a possible extension of the current proved area of the field and to evaluate the use of horizontal wells to eliminate the need to drill certain infill vertical wells. The Company has identified 60 potential locations for future development of probable and possible reserves located on the San Joaquin Basin properties. The San Joaquin Basin properties produce a light (approximately 40() gravity), low sulfur crude oil that commands a substantial price premium to the heavier crude oils typically produced in California. The associated natural gas produced with the crude oil has a high Btu content (approximately 1,240 Btu) which yields in excess of 2 gallons of NGLs per Mcf of natural gas when processed in the Company's gas processing plant located in the San Joaquin Basin. Since acquiring the properties in June 1994, the Company has drilled 76 gross development wells on the San Joaquin Basin properties, through March 31, 1996. As a result of such drilling activity, the Company's average daily production has increased from 546 Bbls of oil and 7,195 Mcf of gas for the month ended June 30, 1994 to 1,336 Bbls of oil and 13,895 Mcf of gas based on the quarter ended March 31, 1996. The Company's net proved reserves from the San Joaquin Basin properties have increased from 14.4 MMBOE as of January 1, 1994, to 22.7 MMBOE as of January 1, 1996, at an average replacement cost of $1.65 per BOE. The Pre-tax SEC 10 Value of the Company's San Joaquin Basin properties as of January 1, 1996 was $105.2 million as estimated by Ryder Scott. In addition to the extensive development drilling program in the Lost Hills Field, the Company also plans to undertake a secondary oil recovery program to further increase reserves and production from the field. Using primary production techniques, it is estimated by Ryder Scott, as of January 1, 1996, that the Ellis Lease located in the Lost Hills Field has proved reserves net to the Company of approximately 9.0 MMBbls of crude oil. In addition to primary development, the Company intends to increase recovery rates by implementing a secondary recovery waterflood project in the Diatomite Zone on the Ellis Lease, which is similar to waterflood projects currently used by other oil and gas companies operating in the Lost Hills Field. The first phase of the Ellis Lease waterflood project is planned to be initiated in the fourth quarter of 1996, with expansion planned in 1997 and 1998 to cover the entire area currently estimated to cover proved reserves. Ryder Scott estimates that the Company's Ellis Lease will yield an additional 3.7 MMBbls of proved undeveloped secondary recovery crude oil reserves utilizing the waterflood recovery method. In addition, the Company will commence a feasibility study for waterflooding the Reef Ridge Shale and Antelope Shale formations on its San Joaquin Basin properties. During 1995, the Company and Bakersfield Energy completed a three-dimensional ("3-D") reservoir model of the Diatomite Zone on the Ellis Lease, the results of which are being used to examine various means of further optimizing its planned Ellis Lease waterflood, including the use of horizontal drilling on the property, as well as to assist the Company with additional computer simulation modeling of hot water, steam and CO(2) recovery techniques. In the fourth quarter of 1995, the Company undertook studies to evaluate the use of horizontal drilling technology on its San Joaquin Basin properties. As a result of these studies, the first of two horizontal wells planned for 1996 has been drilled and completed on the Ellis Lease in the Diatomite Zone at a vertical depth of approximately 3,450 feet with an approximate 2,000 foot lateral drilled outside of the Diatomite Zone's previous development to test a possible extension of the current proved area of the field and to evaluate the use of horizontal wells to eliminate the drilling of certain infill vertical wells on the Ellis Lease. During the five days of production tests, the well flowed at an average rate of 418 BOE per day. The second horizontal well is planned to evaluate its applicability to producing the deeper MacDonald Shale formation at a depth of AREAS OF 3-D CAEX ACTIVITY Three geological trend maps depicting cumulative natural gas production in the South Texas, West Texas and South Louisiana regions in which the Company intends to pursue its exploration prospects. THE PRODUCTION TREND MAPS DEPICT ESTIMATES OF CUMULATIVE NATURAL GAS PRODUCTION AS REPORTED BY THE OPERATORS IN THE REGIONS SHOWN. SUBSTANTIALLY ALL OF THE PRODUCTION SHOWN IN THESE REGIONS IS FROM COMPANIES OTHER THAN HARCOR ENERGY, INC. approximately 5,200 feet on the Ellis Lease. If these wells are successful, potential additional horizontal locations may be identified for future drilling on the Ellis Lease as well as in areas currently outside the proved areas of the Company's Truman and Tisdale Leases. The Company acquired its San Joaquin Basin properties from Bakersfield Energy in June 1994. Bakersfield Energy, which originally acquired these properties in 1990, retained a 25% working interest in these properties and has continued to serve as the operator. In addition, the Company entered into a joint acquisition agreement with Bakersfield Energy which gives each party the right through June 1997 to participate equally in any acquisition of oil and gas interests located within the state of California by the other party. Gas Plant. As part of the acquisition of the San Joaquin Basin properties, the Company purchased a modern, refrigeration liquid extraction facility with a rated inlet capacity of 23 MMcf of gas per day and a rated liquid fractionation capacity of 100,000 gallons of NGLs per day. Currently, the plant processes all of the gas produced from the Company's San Joaquin Basin properties as well as gas produced by third parties. The plant can deliver dry, residue gas into multiple pipeline systems allowing the Company to enter into contract and marketing arrangements that are not tied to the sometimes unfavorable and volatile California spot market. South Texas. In October 1992, the Company acquired an interest in nine gas fields located in South Texas for a total purchase price of approximately $5.3 million. Subsequent development activities have resulted in average daily production on the South Texas properties of 36 Bbls of crude oil and 4,068 Mcf of natural gas for the quarter ended March 31, 1996 and net proved reserves as estimated by Ryder Scott of 1.7 MMBOE at January 1, 1996. Approximately 51% of the Company's reserves in the South Texas properties is attributable to its interests in the Hostetter Field. The Company owns interests in 17 gross (four net) wells and owns approximately 2,525 gross (956 net) acres in the Hostetter Field. These wells are operated by Texaco Exploration and Production Company ("Texaco") and Cabot Oil and Gas Corporation ("Cabot"). The Company currently believes that there are opportunities for additional development and recompletion work in this field. Permian Basin (West Texas/New Mexico). Since 1989, the Company, in conjunction with Penroc Oil Corporation, has jointly identified and acquired interests in oil and gas properties located in the Permian Basin with total acquisition costs net to the Company of $3.4 million. Subsequent remedial work, development drilling activity and secondary recovery procedures have resulted in average daily production of 269 Bbls of crude oil and 416 Mcf of natural gas based on production in the quarter ended March 31, 1996. Ryder Scott's estimate of the Company's net proved reserves in the Permian Basin as of January 1, 1996 was 2.1 MMBOE. EXPLORATION ACTIVITIES Consistent with its core objective of increasing its reserves as economically as possible, the Company has commenced a program of identifying and developing exploratory prospects in areas where the Company or its partners have expertise. HarCor intends to manage its exploration and economic risks by (i) generating prospects with the assistance of strategic industry partners that are experienced in 3-D seismic and computer assisted exploration ("CAEX") technology, (ii) identifying and pursuing prospects with multiple potential productive zones, (iii) funding its exploration activities with proceeds from the Offering and internally generated cash flow and (iv) limiting its cash exposure to approximately $500,000 for each well. In addition, the Company intends to further manage the drilling risks associated with the exploration projects in South Texas and South Louisiana by drilling multipay prospects that combine shallower lower risk zones that have previously proven productive in the area with deeper potential target zones. In furtherance of this strategy, the Company has recently entered into an agreement with South Coast Exploration Company and its affiliated company Interactive Exploration Solutions, Inc. (collectively, "South Coast Exploration"), which have extensive experience utilizing 3-D seismic and CAEX techniques, to jointly pursue exploration projects on developed and undeveloped properties in South Texas, the Permian Basin of West Texas and South Louisiana. The Company and South Coast Exploration have jointly formed an experienced geologic team (the "GeoTeam") to work exclusively to pursue these joint projects. The following table sets forth certain information as of May 30, 1996 relating to the exploration prospects that the Company currently plans to pursue over the 18-month period ending December 31, 1997, including the estimated cost to the Company for 3-D seismic surveys, leasehold acquisitions and drilling of exploratory and development wells relating to such prospects through such date. GROSS ACREAGE OWNED OR PROSPECTIVE PROSPECTIVE ESTIMATED COST TO COMPANY(3) UNDER SQUARE MILES OF GROSS ------------------------------------- PROSPECT AREA OPTION(1) 3-D SEISMIC DATA WELLS(2) SEISMIC LAND DRILLING TOTAL - ----------------------------------------------------- ---------------- ----------- ------- ------ -------- ------- (IN THOUSANDS) South Texas (Upper Wilcox Trend)........ 23,000 83 18 $ 720 $ 640 $ 8,900 $10,260 West Texas (Permian Basin).............. 80,320 210 4 330 480 900 1,710 South Louisiana (Terrebonne Parish)..... 5,529 46 4 235 240 1,300 1,775 -- ------- ---- ------ ------ ------- ------- Total........................... 108,849 339 26 $1,285 $1,360 $11,100 $13,745 ======= ==== == ====== ====== ======= =======
- --------------- (1) Includes acreage in which the Company currently has leases, options to acquire leases, contingent lease rights or fee interests. (2) Includes 10 exploratory wells and 16 development wells. (3) The estimated cost to the Company is based on (i) preliminary estimates of seismic survey costs, leasehold acquisition costs and drilling and completion costs and (ii) assumed levels of participation by the Company in the costs thereof. Actual costs and participation levels may vary from such estimates. The following sets forth a brief summary of each exploration prospect that the Company has in progress. This discussion only includes prospects on which the Company has acquired substantial leasehold interests, options to acquire leasehold interests or other contingent lease rights and has performed or is in the process of arranging related 3-D seismic surveys. See "Risk Factors -- Risk of Exploratory Drilling Activities" for a discussion of the risks associated with these exploration prospects. South Texas (Upper Wilcox Trend). HarCor has entered into an agreement with Cabot to participate in an 83 square mile 3-D seismic survey in southeast McMullen and northwest Duval Counties, Texas. The expanded and over-pressured Upper Wilcox Trend in the survey area has significant potential for the application of 3-D seismic technology due to complex faulting in the area and stacking of multiple pay zones in both the shallow normal-pressured zones such as the Cole Sand at 1,600 feet and the over-pressured zones such as the House Sand at approximately 12,000 feet. The 3-D seismic survey in the Upper Wilcox Trend commenced in April 1996 and is expected to be completed in July 1996. The survey is designed to evaluate prospects already identified and generate new drilling prospects with both development and exploration potential in the area of the Hostetter Field and the nearby Bonne Terre Field. The survey will evaluate approximately 40 geologic formations at depths ranging between 8,500 feet and 13,000 feet for the expanded over-pressured Upper Wilcox formation and as shallow as 1,500 feet for other intervals. HarCor has joined with Cabot to acquire, or to acquire options for, leasehold interests in 23,000 gross acres inside the 3-D survey area as of May 30, 1996. Production to date in the survey area, including production from the Hostetter Field and the Bonne Terre Field, is estimated to be approximately 450 Bcf of natural gas equivalent. On May 29, 1996, HarCor assigned to South Coast Exploration and one of its affiliates 40% of its rights in its agreement with Cabot in exchange for the interest it received in the South Louisiana project described below. West Texas (Permian Basin). In May 1996, the Company entered into an agreement to participate in a 210 square mile 3-D seismic survey in Reeves County, Texas with Penwell Energy, Inc. ("Penwell") which, along with its investment partner MCN Energy, has extensive recent experience in the Permian Basin. Penwell initially derived its rights to about half of the area in the Penwell survey (74,880 fee mineral acres held by Texaco) from an agreement dated September 1995 among Texaco, Penwell and Meridian Oil Inc. Production in the field within or adjoining gross acreage in which Penwell presently owns or has contingent lease rights is estimated to be 455 Bcf of natural gas equivalents, most of which has been produced from the Silurian/Devonian Fusselman formation at depths between 10,000 feet and 17,000 feet, where the Company intends to focus. South Louisiana (Terrebonne Parish). South Coast Exploration and its affiliate have acquired an interest in a 46 square mile 3-D seismic survey to be conducted in south Terrebonne Parish, Louisiana. To date, the Lapeyrouse Field, which is located in the survey area, has produced approximately 350 Bcf of natural gas equivalents. Based upon 2-D seismic surveys and reports from independent engineers, South Coast Exploration's joint venture preliminarily has identified potential exploration sites in the area to drill an estimated four test wells in the next 18 months. Two of these potential exploration sites have been identified in the Bourg Sands between 14,500 feet and 15,500 feet and the remaining two potential exploration sites have been identified in traps associated with faulting in a series of Upper Middle Miocene Sands between 15,000 feet and 17,000 feet. South Coast Exploration and its affiliate have each assigned to HarCor a portion of their interest in this survey. SELECTIVE OPPORTUNISTIC ACQUISITIONS The Company also intends to pursue selective strategic acquisitions of attractively priced, underexploited onshore oil and gas properties in the United States. As a consequence of its working relationship with South Coast Exploration, the Company will also pursue property acquisitions where it can utilize 3-D seismic and CAEX technology to identify additional potential reserves. Management intends to continue to be active in developing acquisition opportunities rather than pursuing opportunities in the auction market. Management believes that this strategy has resulted in lower acquisition prices for its oil and gas properties. THE OFFERING Shares of Common Stock Offered: By the Company(1)........................... 5,059,059 shares By the Selling Stockholders................. 1,340,941 shares Total............................... 6,400,000 shares Shares of Common Stock Outstanding(1)(2): Before the Offering......................... 8,696,207 shares After the Offering.......................... 13,755,266 shares Use of Proceeds............................... To redeem approximately $10.9 million of principal amount of, together with accrued interest and prepayment premium on, the Company's 14 7/8% Senior Notes due 2002; and to fund 3-D seismic and leasehold acquisitions, 3-D seismic and CAEX processing and interpretation, exploratory and development drilling expenditures and other general corporate purposes. Nasdaq National Market Symbol................. "HARC"
- --------------- (1) Does not include up to 960,000 shares of Common Stock which may be sold by the Company pursuant to the Underwriters' over-allotment option. (2) Does not include (i) options to purchase 898,500 shares of Common Stock which have been granted under the Company's stock option plans and (ii) 1,697,772 shares of Common Stock issuable upon conversion of the Company's outstanding Series A, B, C and E Preferred Stock. Also does not include 2,289,791 shares of Common Stock issuable upon exercise of outstanding warrants of the Company. See "Description of Capital Stock and Other Securities." SUMMARY FINANCIAL DATA The following table presents summary historical consolidated financial data of the Company for the five years ended December 31, 1995, which have been derived from the Company's consolidated financial statements. The consolidated financial data of the Company for the three months ended March 31, 1995 and 1996 have been derived from the Company's interim consolidated financial statements which, in the opinion of management of the Company, have been prepared on the same basis as the annual consolidated financial statements and include all adjustments (consisting of only normal recurring adjustments) necessary for a fair presentation of the financial data for such periods. The information in this table should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Consolidated Financial Statements and the notes thereto included elsewhere herein. THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, ---------------------------------------------------- ------------------ 1991 1992 1993 1994 1995 1995 1996 ------- ------- ------- ------- ------- ------- ------- (IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF OPERATIONS DATA(1): Revenues: Oil and gas revenues........................ $ 5,776 $ 6,162 $ 6,507 $10,982 $16,030 $ 3,683 $ 5,956 Gas plant revenues.......................... -- -- -- 1,978 6,362 1,786 1,624 Interest income and other................... 258 504 218 253 203 15 17 ------- ------- ------- ------- ------- ------- ------- Total revenues........................ 6,034 6,666 6,725 13,213 22,595 5,484 7,597 ------- ------- ------- ------- ------- ------- ------- Costs and expenses: Production costs............................ 2,670 2,676 2,249 3,610 5,263 1,263 1,437 Gas plant costs............................. -- -- -- 1,708 3,704 1,410 956 Dry hole, impairment and abandonment costs..................................... 1,287 402 41 75 4 -- -- Engineering and geological costs............ 770 536 188 254 307 89 101 Depletion, depreciation and amortization.... 2,222 2,142 2,641 3,897 5,973 1,346 1,707 General and administrative expenses......... 2,372 2,085 2,105 2,014 2,744 666 721 Interest expense(2)......................... 872 1,048 542 2,269 6,847 1,130 2,642 Other....................................... -- -- -- 203 483 -- 261 ------- ------- ------- ------- ------- ------- ------- Total costs and expenses.............. 10,193 8,889 7,766 14,030 25,325 5,904 7,825 ------- ------- ------- ------- ------- ------- ------- Loss before minority interests................ (4,159) (2,223) (1,041) (817) (2,730) (421) (228) Loss attributable to minority interests....... 2,698 809 -- -- -- -- -- Loss attributable to early extinguishment of debt........................................ -- -- -- (122) (1,888) -- -- ------- ------- ------- ------- ------- ------- ------- Net loss...................................... (1,461) (1,414) (1,041) (939) (4,618) (421) (228) Dividends on preferred stock.................. (40) (32) (246) (795) (1,000) (335) (132) Accretion on redeemable preferred stock....... -- -- -- (156) (2,147) (81) -- ------- ------- ------- ------- ------- ------- ------- Net loss applicable to common stock........... $(1,501) $(1,446) $(1,287) $(1,890) $(7,765) $ (837) $ (360) ======= ======= ======= ======= ======= ======= ======= Net loss applicable to common stock per common and common equivalent share................. $ (0.50) $ (0.41) $ (0.23) $ (0.29) $ (0.98) $ (0.12) $ (0.04) Weighted average number of common and common equivalent shares.................... 2,973 3,512 5,492 6,447 7,904 7,226 8,685 OTHER DATA: EBITDAX(3).................................... $ 992 $ 1,906 $ 2,371 $ 5,881 $10,884 $ 2,145 $ 4,483 Capital expenditures.......................... 2,593 4,237 4,283 45,608(4) 8,953 18 9,635(5)
MARCH 31, 1996 -------------------------- ACTUAL AS ADJUSTED(6) ------- -------------- (IN THOUSANDS) BALANCE SHEET DATA: Cash and cash equivalents.............................................................. $ 3,977 $ 13,986 Total assets........................................................................... 86,770 96,007 Total debt............................................................................. 71,276 60,682 Stockholders' equity................................................................... 9,564 31,382
(1) Includes results of operations in 1991 and 1992 from HCO Energy, Ltd. ("HCO"), the Company's former Canadian affiliate. In December 1992, the Company deconsolidated HCO, and in January 1993 the Company sold all of its remaining shares of HCO common stock. (2) Interest expense includes $29,000, $42,000, $64,000, $220,000 and $709,000 in 1991, 1992, 1993, 1994 and 1995, respectively, and $117,000 and $240,000 in the three months ended March 31, 1995 and 1996, respectively, related to amortization of deferred financing costs. (3) EBITDAX represents income (loss) before provision for income tax and extraordinary items and before depletion, depreciation, amortization, interest expense, minority interests, non-recurring charges and exploration expenses. EBITDAX is presented because it is a widely accepted financial indicator of a company's ability to service and/or incur indebtedness. However, EBITDAX should not be considered as an alternative to net income as a measure of operating results or to cash flows as a measure of liquidity. (4) Includes $42 million of cash acquisition costs incurred in connection with the acquisition of the San Joaquin Basin properties. (5) Includes $8.2 million relating to drilling costs which were accrued but unpaid at December 31, 1995 resulting from the Company's 1995 drilling program. (6) As adjusted to (i) reflect an assumed public offering price of $5.125 per share (the closing price on the Nasdaq National Market on July 3, 1996) and (ii) an extraordinary charge estimated at $2,175,000 relating to early extinguishment of debt. Does not include (i) options to purchase 898,500 shares of Common Stock which have been granted under the Company's stock option plans; (ii) 1,697,772 shares of Common Stock issuable upon conversion of the Company's outstanding Series A, B, C and E Preferred Stock; and (iii) 2,289,791 shares of Common Stock issuable upon exercise of outstanding warrants of the Company. See "Description of Capital Stock and Other Securities." The Company repaid $2 million of the outstanding balance under the Credit Facility subsequent to March 31, 1996 from cash flow generated by operations. Pending the use of proceeds from the Offering to fund certain exploration expenditures, the Company will use approximately $5.5 million to repay amounts outstanding under the Credit Facility. The Company will reborrow under the Credit Facility to fund capital expenditures and operations as necessary. See "Use of Proceeds." SUMMARY OIL AND GAS RESERVE DATA The following table sets forth summary information with respect to the Company's estimated proved oil and gas reserves. The estimates of the Company's proved reserves and future net revenues were primarily derived from reports prepared by Ryder Scott. As of December 31, 1993, 1994 and 1995, the average sales prices used for estimating the proved reserves and future net revenues were $11.65, $15.86 and $17.10 per Bbl of crude oil and $2.16, $2.11 and $2.35 per Mcf of natural gas, respectively (which prices with respect to natural gas reflect the effects of the Company's hedging activities). See "Risk Factors -- Reliance on Estimates of Proved Reserves," "-- Certain Business Risks" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." A summary report of Ryder Scott is included as Annex A hereto. TOTAL PROVED RESERVES AS OF DECEMBER 31, -------------------------------- 1993 1994 1995 ------- ------- -------- (DOLLARS IN THOUSANDS) Estimated Proved Reserves: Liquids (MBbl)............................................. -- 2,908 2,979 Crude oil (MBbl)........................................... 1,724 10,581 12,358 Natural gas (MMcf)......................................... 17,169 69,802 87,637 Crude oil equivalents (MBOE)............................... 4,586 25,123 29,943 Pre-tax SEC 10 Value......................................... $20,780 $86,680 $124,498 Percent Proved Undeveloped Reserves (BOE).................... 39.8% 67.4% 69.4%
SUMMARY OPERATING DATA The following table sets forth summary information with respect to the Company's operations for the periods indicated. THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, ------------------------ ---------------- 1993 1994 1995 1995 1996 ----- ----- ------ ------ ------ Average Net Daily Production: Crude oil and plant NGLs (Bbls)................. 505 1,128 1,834 1,657 2,450 Natural gas (Mcf)............................... 5,514 9,239 14,074 12,855 19,240 Crude oil equivalents (BOE)..................... 1,424 2,668 4,180 3,800 5,657 Average Sales Price(1): Crude oil (per Bbl)............................. $16.46 $15.79 $16.49 $16.15 $17.33 Natural gas (per Mcf)........................... $ 1.77 $ 1.82 $ 1.64 $ 1.62 $ 1.86 Cost Data (per BOE)(2): Average production costs(3)..................... $ 4.41 $ 4.13 $ 3.99 $ 4.14 $ 3.22 Depletion, depreciation and amortization........ $ 5.13 $ 4.26 $ 3.60(4) $ 4.26 $ 3.60 General and administrative expense.............. $ 4.13 $ 2.32 $ 1.80 $ 2.18 $ 1.61 Total Proved Reserves to Production Ratio......... 8.8 25.8 19.6 -- -- Crude Oil and NGLs as a Percentage of Total Proved Reserve Volumes................................. 37.6% 53.7% 51.2% -- -- Producing Wells (at end of period): Gross wells..................................... 334 379 424 379 431 Net wells....................................... 104 150 183 150 187
- --------------- (1) Calculation of average selling price per barrel of crude oil and condensate excludes certain revenues attributable to hydrocarbon liquids and plant product sales. All average price data reflect the effects of the Company's fixed-price sales and hedging contracts. See Note 10 of Notes to the Consolidated Financial Statements. (2) Excludes operating costs related to the gas plant. (3) Includes production and ad valorem taxes. (4) Excludes the effect of the impairment write-down pursuant to implementation of SFAS 121 ("Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of"). See "Management's Discussion and Analysis of Financial Condition and Results of Operations."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000315547_first_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000315547_first_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..e728f2114730e309929a7aafc1a0e05cd213bf62
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000315547_first_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a selective summary of certain information contained in this Prospectus and is qualified in its entirety by the information and financial statements appearing elsewhere herein. Prospective purchasers are urged to read the entire Prospectus carefully, and to give particular attention to the section entitled "RISK FACTORS" before making any decision to purchase any of the shares offered hereby. THE COMPANY AND THE BANK First Commercial Bancorp, Inc. (the "Company") is a Sacramento, California-based bank holding company which reincorporated in Delaware in 1990 and which conducts its operations through its sole subsidiary, First Commercial Bank, a California state-chartered bank (the "Bank"). The Bank commenced operations in 1979. The Bank operates a general commercial banking business through its headquarters and 6 branch offices located in Sacramento, Roseville (2 branches), San Francisco, Concord and Campbell, California. Deposits in the Bank are insured by the Federal Deposit Insurance Corporation ("FDIC") to the maximum extent permitted by law. The Company is operating under the terms of a Memorandum of Understanding ("MOU") with the Federal Reserve Bank of San Francisco (the "FRB"). The Bank is operating under the terms of a Cease and Desist order ("FDIC Cease and Desist Order") issued by the FDIC and a second amended final order ("SBD Final Order") issued by the California State Banking Department ("SBD") (collectively, the "Orders") and also is subject to capital impairment orders dated August 3, 1994, November 3, 1994, February 17, March 13, May 15 and August 7, 1995 issued by the SBD (the "Capital Impairment Orders"). The MOU and the Orders have placed significant operating and dividend restrictions on the Company and the Bank. In addition, the FDIC notified the Bank that as of July 30, 1995, the Bank was considered "critically undercapitalized" under the Prompt Corrective Action ("PCA") provisions of the Federal Deposit Insurance Corporation Improvement Act of 1991 ("FDICIA"). However, as a result of the capital infusion represented by the First Debenture, the Bank was upgraded to "undercapitalized" as of October 31, 1995 and, as of December 31, 1995, as a result of the infusion of $1.5 million provided by First Banks' purchase of 15,000,000 shares of Common Stock and the proceeds of the Second Debenture, the Bank would be considered "adequately capitalized" under such law. The Company and the Bank remain subject to significant operating restrictions, however, including limitations on the payment of dividends. For a full description of the foregoing, see "RISK FACTORS - Failure to Meet Capital Adequacy Requirements and Regulatory Orders" and "REGULATORY AGREEMENTS AND ORDERS." The Company grew substantially during the 1980's, primarily through the acquisition of thirteen branches from California Canadian Bank and the acquisition of Citizens Bank of Roseville. Between 1988 and 1992, the Company focused its lending activities on real estate construction loans and through June of 1994, on loans to small and medium-sized businesses. For deposits, the Company focused on title insurance and escrow companies as well as on small-to-medium- sized business depositors. The focused lending and deposit-generation strategy which the Company pursued during this time period involved certain risk attributes generally not present in a more diversified lending and deposit strategy. See "RISK FACTORS - Recent Losses and Risk of Continued Losses." At December 31, 1993, the Company's assets reached $349,777,000 with $83,682,000 or 42.9% of the Company's gross loans in real estate construction and real estate secured loans, and with $86,549,000 or 26.73% of its deposits in title and escrow accounts, and $237,247,000 in all other deposits. As of December 31, 1994, the Company had consolidated total assets, deposits and stockholders' equity of $239,306,000, $233,536,000 and $4,355,000, respectively. At September 30, 1995, the Company had consolidated total assets, deposits and stockholders' equity of $172,923,000, $167,239,000 and $(1,435,000), respectively. The Company reported net losses in 1992, 1993 and 1994 of $(3,518,000), $(7,311,000) and $(18,190,000), respectively, due primarily to deterioration in its real estate lending portfolio and resultant write-downs and increased loan loss provisions. The Company reported a net loss of $(6,301,000) for the nine months ended September 30, 1995 due primarily to the continued write-down of, and other expenses associated with, real estate acquired through foreclosure or Other Real Estate Owned ("OREO"), further deterioration in the loan portfolio and the reduction in interest on loans resulting from the decrease in the amount of loans outstanding. As a result, at September 30, 1995, the Company's capital was reduced to $(1,435,000) and the Company and the Bank's Tier I leverage ratios declined to (0.83)% and 2.41%, respectively. During the second quarter of 1995, the Bank took substantial write-offs and write-downs of loans and other assets. The most significant write-off resulted from the bankruptcy of one of the Bank's largest borrowers. As a result, the Company's Tier I capital was reduced to (0.23)% at June 30, 1995, and the Bank's Tier I capital would have been reduced to 0.27%, but for the investment of $1.5 million in Bank nonvoting noncumulative preferred stock (the "Bank Preferred Stock") by James F. Dierberg, Chairman, President and Chief Executive Officer of First Banks, pursuant to the terms of the Standby Stock Purchase Agreement. See "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY." As discussed further below, Dierberg's investment was made under emergency circumstances to forestall possible closure of the Bank by its regulatory authorities. In response to these losses, the Company developed a restructuring plan to redirect the lending and deposit strategy of the Bank. The restructuring plan had six elements: (a) reduce total assets, (b) reduce operating expenses and staffing levels, (c) reduce nonperforming loans and increase reserve coverage of such loans, (d) maintain the commercial and industrial lending portfolio, but significantly reduce real estate construction lending, (e) eliminate volatile deposits and close non-strategic branch offices, and (f) maintain high levels of liquidity to facilitate the asset and deposit dispositions. Implementation of this plan began during the third quarter of 1994 and, as of September 30, 1995, has had the following results: - Total assets were reduced 51% from $349,777,000 at December 1993 to $172,923,000. - Nonperforming assets have been reduced 79% over the same period from $35,321,000 to $7,401,000 and the loan loss reserve coverage of nonperforming loans reached 90.48%. - The nonowner occupied construction loan portfolio was reduced by 86%, from $32,432,000 to $4,479,000. - Core monthly operating expenses were reduced 40% from $1,123,000 to $675,000. - Escrow and title industry deposits were reduced 99% from $86,549,000 at December 31, 1993 to $1,148,000. - Staffing has been reduced 48% from 185 to 97 employees as of September 30, 1995. By December 31, 1995, the FTE staff was reduced to 63 employees. - The Bank's liquidity ratio has been maintained above 30%. - The San Diego branch office was sold in January of 1995, and the Santa Rosa branch office was closed during April 1995. At December 31, 1995, the Company's loan portfolio was concentrated in twenty (20) loans, one (1) of which exceeded the Bank's secured and unsecured lending limit at that date. Commitments to these borrowers represent $31.2 million or 42% of the Bank's total loan portfolio at December 31, 1995. Outstanding balances to these borrowers at December 31, 1995 were $23.6 million or 32% of the Bank's loan portfolio. Four (4) of these loans, representing $7.4 million or 10% of the Bank's total loan portfolio, have been classified by the Bank as "Substandard." One (1) loan in the amount of $754,000 is on nonaccrual status. At December 31, 1995 the Bank's unsecured lending limit was approximately $2.5 million and its combined secured and unsecured lending limit was approximately $4.1 million. At December 31, 1995, the Bank had one (1) loan, representing $3.8 million, which exceeded its unsecured lending limit and one (1) loan, representing $5.5 million that exceeded the secured and unsecured lending limit. The Company intends to be able to continue to satisfy its larger customer's borrowing needs by participating loan amounts above its lending limit with other banks until such time as the Bank becomes recapitalized. On August 7, 1995, the Company entered into an Amended and Restated Stock Purchase Agreement (the "Stock Purchase Agreement") with First Banks, Inc., a Missouri corporation ("First Banks"), pursuant to which First Banks has acquired 65,000,000 shares of Common Stock of the Company at a total purchase price of $6,500,000. Previously, James F. Dierberg, Chairman, President and Chief Executive Officer of First Banks, provided interim financing for the Company's subsidiary, First Commercial Bank (the "Bank"), by purchasing $1.5 million of nonvoting, noncumulative preferred stock of the Bank (the "Bank Preferred Stock") on June 30, 1995, thus forestalling possible closure of the Bank by the FDIC. However, notwithstanding Dierberg's $1.5 million investment in Bank stock, the Bank's Tier I capital ratio at June 30, 1995 remained below 2.0% and, as a result, the Bank was classified as "critically undercapitalized" at July 30, 1995 and became subject to the FDIC's PCA regulations for critically undercapitalized institutions. The Company and the Bank thus were required by FDICIA to seek sufficient capital to bring the Bank's Tier I capital ratio above 2% or face the possible imposition of a conservatorship or receivership within 90 days. Dierberg's investment occurred pursuant to a Standby Stock Purchase Agreement entered into between the Company, the Bank, Dierberg and First Banks as of June 30, 1995 (the "Standby Stock Purchase Agreement"), which was later amended and restated to become the Stock Purchase Agreement. Subsequently, and pursuant to the Stock Purchase Agreement, on August 23, 1995, First Banks purchased 116,666,666 shares of common stock of the Bank (the "Bank Common Stock") at a price of $0.03 per share, the book value of the Bank Common Stock on August 22, 1995, for a total purchase price of $3.5 million. On August 22, 1995, Dierberg transferred to First Banks all of the shares of Bank Preferred Stock owned by him. The shares of Bank Preferred Stock and Bank Common Stock were exchanged by First Banks for 50,000,000 shares of Company Common Stock on December 28, 1995, pursuant to the terms of the Stock Purchase Agreement. The infusion by First Banks of $3.5 million on August 23, 1995 raised the Bank's Tier I capital level to 2.60%, as a result of which the Bank would have been considered "significantly undercapitalized." As described further below, at October 31, 1995, the Bank used the $1.5 million proceeds from sale of a 12% convertible debenture to raise its Tier I capital level above 3.0% and, as a result, the Bank would have been considered "undercapitalized" under the PCA regulations. Pursuant to the Stock Purchase Agreement, which was amended by the Additional Investment Agreement dated October 31, 1995 (the "Additional Investment Agreement"), First Banks has loaned to the Company a total of $6,500,000, in exchange for the issuance of two 5-year 12% convertible debentures (the "Debentures"), pursuant to which the Company agrees to issue to First Banks a total of 65,000,000 shares of Common Stock in respect of the principal amount of the Debentures and pursuant to which any unpaid and accrued interest amount is convertible into up to additional 39,000,000 shares of Common Stock at the rate of $0.10 per share. The Debentures are secured by all of the shares of Bank common stock held by the Company. The initial Debenture (the "First Debenture") was issued on October 31, 1995 and conversion of the principal and any unconverted interest amount is due on October 31, 2000. The subsequent Debenture (the "Second Debenture") was issued on December 28, 1995 and will mature on December 28, 2000, at which time conversion of the principal amount and any unconverted interest amount is due. The principal and interest amounts of each of the First and Second Debentures is payable in shares of Common Stock or cash. However, cash can be paid only when in the sole and absolute discretion of the Board of Directors of the Company, the Company has sufficient funds to make such payment of interest or principal and can make such a payment in accordance with all applicable regulatory requirements, including receipt of all necessary approvals. Management believes it is unlikely that approval for such cash payments would be received from the FRB in the foreseeable future. The Company must give First Banks 10 days prior written notice of any intention to make a payment on the Debentures. The Company contributed all but $250,000 of the proceeds of the Debentures to the Bank. On December 28, 1995, pursuant to the Stock Purchase Agreement, which was amended by the Standby Agreement dated December 28, 1995 (the "Standby Agreement," Additional Investment Agreement and the Stock Purchase Agreement, are collectively referred to herein as the "Stock Purchase Agreement"), after issuance of the Second Debenture and in order to raise the Bank's Tier I capital to the level required by the Orders, First Banks purchased 15,000,000 shares of Company Common Stock at a price of $0.10 per share, for a total of $1.5 million. As a result of First Banks' purchase of 15,000,000 shares and the issuance of the Second Debenture, at December 31, 1995, the Bank's Tier I capital level reached 6.58% and, accordingly, the Bank would continue to be considered "adequately capitalized" under the FDIC's PCA regulations. As of that date, the Bank would have been considered "well capitalized" under the PCA regulations but for the existence of the Orders, which while outstanding limit the Bank to being considered "adequately capitalized." See "SUPERVISION AND REGULATION." However, the Company and the Bank remain subject to significant operating restrictions and no assurance can be given that the Bank will not suffer future additional losses which will erode the capital condition of the Bank. The Company contributed all of the proceeds of the stock sale to the Bank. See "RISK FACTORS," "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY" and "REGULATORY AGREEMENTS AND ORDERS." As of December 31, 1995, while the Bank met the 6.5% Tier I capital requirement of the FDIC Cease and Desist Order, differences in the method of calculating capital for purposes of the SBD's regulations resulted in the Bank attaining a Tier I capital level, as calculated by the SBD, of 6.45%, thus falling short of the 7.0% capital requirement of the SBD Final Order. On a pro forma basis, at December 31, 1995, the Bank would have required approximately an additional $1,009,000 in capital in order to meet the 7.0% capital requirement of the SBD Final Order. However, the SBD has allowed the Bank to attain the 7.0% capital requirement through the proceeds of this Offering. Unless specified, the Tier I capital numbers for the Bank presented herein have been calculated in accordance with the FDIC's regulations and methodology. See "REGULATORY AGREEMENTS AND ORDERS" and "SUPERVISION AND REGULATION." As a result of the foregoing, as of the date of this Prospectus, First Banks owns 65,000,000 shares of Company Common Stock, or 93.29% of the outstanding shares. Assuming the sale to the Rights Holders and Dividend-Eligible Stockholders of all of the Underlying Shares and Dividend Exchange Shares offered hereby, First Banks would control approximately 50.25% of the outstanding shares of Common Stock of the Company and may acquire up to a total of 104,000,000 additional shares upon conversion of the principal and interest amounts subject to the Debentures. Assuming that all of the principal and interest amounts of the Debentures is converted to Company Common Stock on October 31, 2000 and December 28, 2000, and assuming the sale of all the shares offered hereby to the aforementioned purchases and no interim issuances of Common Stock by the Company, First Banks would control approximately 72.42% of the then outstanding shares of Common Stock. See "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY." Additionally, as a result of the consummation of the transactions contemplated by the Stock Purchase Agreement, as of December 31, 1995, the Tier I leverage capital levels of the Company and the Bank were 2.14% and 6.58%, respectively. As of that date, the Company and the Bank had risk-based capital levels of 4.99% and 12.66%, respectively. First Banks has agreed that, upon the conclusion of the Rights Offering and any Public Offering, First Banks will purchase, if necessary, as a Standby Purchaser and at the Subscription Price, such number of shares of Common Stock remaining unsold in the Offering as may be required to increase the Bank's Tier I capital level to 7.0%. Such issuance of Common Stock may further dilute the voting power and earnings per share, if any, of the Company's stockholders, other than First Banks. See "RISK FACTORS -- Potential Dilution of Voting Power and Earnings Per Share." However, no assurance can be given that the Bank will not experience further operating losses which will erode the capital levels of the Bank or that the Bank will be able to maintain such capital levels at any time after December 31, 1995. See "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY." As of December 31, 1995, the Company believes it has achieved substantial compliance with the requirements of the Company's MOU, the FDIC Cease and Desist Order and the SBD Final Order, except for compliance with the 7.0% Tier I capital requirement of the SBD Final Order. Further compliance with the Company's MOU and the Orders is contemplated to occur through this Offering, including any necessary participation by First Banks. As of December 31, 1995, the Bank had not complied with the Capital Impairment Orders, subjecting the Bank Common Stock to assessment. See "REGULATORY AGREEMENTS AND ORDERS." On December 27, 1995, the stockholders of the Company approved an amendment to the Company's Certificate of Incorporation authorizing an increase in the number of authorized shares of Common Stock to 250,000,000. The Company currently has 69,675,110 shares of Common Stock outstanding. If all shares of Common Stock offered pursuant to the Rights Offering, Public Offering and Dividend Exchange Offering (collectively, the "Offering") are sold, the resulting outstanding Common Stock would be 129,363,985 shares. Additionally, if the maximum number of shares are converted pursuant to the Debentures, the resulting outstanding Common Stock would be 233,363,985 shares. Stockholders other than First Banks, whether or not exercising their Stockholder Rights, may experience substantial dilution in the voting power and earnings per share, if any, of their Common Stock holdings. See "RISK FACTORS - Potential Dilution of Voting Power and Earnings Per Share" and "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY." THE OFFERING The Rights Offering General........................................... Each record holder (a "Rights Holder") of Common Stock at the close of business on October 6, 1995 (the "Rights Record Date") will receive non-transferable subscription rights (the "Stockholder Rights") to purchase shares of Common Stock. The Stockholder Rights will entitle the Rights Holder to purchase from the Company 10.695 shares of Common Stock (the "Underlying Shares") for each share of Common Stock held on the Rights Record Date, at a cash price of $0.10 per share (the "Subscription Price") on the terms and conditions of the Offering. The number of shares of Common Stock issuable upon exercise of Stockholder Rights will be rounded up to the nearest whole number. See "THE OFFERING." The ratio of 10.695 Underlying Shares per share of Common Stock (the "Rights Ratio") was determined by the Board of Directors based on the recently consummated Stock Purchase Agreement, the financial condition of the Company and the Bank, the trading history and per share book value of the Common Stock and other relevant information. See "DETERMINATION OF OFFERING PRICE." After April 12, 1996 (the "Rights Expiration Date"), the Stockholder Rights will no longer be exercisable and will have no value, unless terminated earlier or extended by the Company's Board of Directors in its sole discretion for up to two (2) consecutive periods of up to 30 days each, or until not later than June 11, 1996. Basic Subscription Privilege...................... Rights Holders are entitled to purchase, at the Subscription Price, 10.695 Underlying Shares per share of Common Stock held on the Rights Record Date, subject to reduction by the Company under certain circumstances (the "Basic Subscription Privilege"). No fractional shares will be issued in connection with the Rights Offering. See "THE OFFERING." Oversubscription Privilege........................ Each Rights Holder who elects to exercise its, his or her Basic Subscription Privilege in full may also subscribe at the Subscription Price for additional Underlying Shares (the "Excess Shares") available after satisfaction of the Basic Subscription Privilege (the "Oversubscription Privilege"), up to the greater of (a) an additional one million shares, or $100,000, or (b) an additional 10.695 shares for each share of Common Stock held on the Rights Record Date. Shares subscribed for pursuant to the Oversubscription Privilege are subject to proration and reduction by the Company under certain circumstances.
There can be no assurance that there will be Excess Shares sufficient to satisfy all exercises of the Oversubscription Privilege. If an insufficient number of Excess Shares is available to satisfy fully all exercises of the Oversubscription Privilege, then the Excess Shares will be prorated among Rights Holders who exercise their Oversubscription Privilege based upon the number of shares held on the Rights Record Date. See "THE OFFERING." Procedure For Exercising Stockholder Rights................................ The Basic Subscription Privilege and the Oversubscription Privilege may be exercised by properly completing the appropriate Subscription Right Certificate and forwarding it (or following the Guaranteed Delivery Procedures), with payment of the Subscription Price for each Underlying Share subscribed for, to the Subscription Agent, which must receive such Subscription Right Certificate or Notice of Guaranteed Delivery and payment at or prior to the Rights Expiration Date. If Subscription Right Certificates are sent by mail, Rights Holders are urged to use insured, registered mail. See "THE OFFERING - How to Subscribe." The Public Offering............................... Upon the expiration of the Rights Offering, and provided that sufficient shares of Common Stock are available, the Company may offer and sell to the public only in California at the Subscription Price up to 10,000,000 Underlying Shares not sold pursuant to the Basic or Oversubscription Privileges. The expiration date of the Public Offering is April 12, 1996, unless extended in the sole discretion of the Board of Directors of the Company for up to two (2) consecutive periods of up to 30 days each, or no later than June 11, 1996. Shares may be subscribed for in the Public Offering by properly completing the General Subscription Application and Agreement and forwarding it (or following the Guaranteed Delivery Procedures), with payment of the Subscription Price for each Underlying Share subscribed for, to the Subscription Agent, which must receive such General Subscription Application and Agreement or Notice of Guaranteed Delivery and payment at or prior to the Public Offering Expiration Date. See "THE OFFERING - How to Subscribe." Participation by First Banks...................... First Banks has committed to purchase in the Offering and at the Subscription Price, upon completion of the Rights Offering and any Public Offering, if necessary, such number of shares as would be required to raise the Bank's Tier I capital level to 7.0%, as calculated by the SBD. First Banks will only purchase such shares as a "Standby Purchaser" if the proceeds received from the Rights Offering and any Public Offering are insufficient to raise the Bank's Tier I capital level to 7.0%. Any such additional purchase by First Banks may result in substantial further dilution of the voting power and earnings per share, if any, of the Company's stockholders, other than First Banks. See "RISK FACTORS - Potential Dilution of Voting Power and Earnings Per Share." The Offering will remain open for five (5) business days after the later of the Rights Expiration Date and the Public Offering Expiration Date to allow First Banks to make any purchases as "Standby Purchaser."
The Dividend Exchange Offer Dividend Rights and Dividend Exchange Shares .................................. Each person who was a record holder of Common Stock at the close of business on June 15, 1992 or September 14, 1992 (the "Dividend Record Dates") will receive a transferable dividend subscription right (the "Dividend Right") exchangeable for shares of Common Stock valued at $0.10 per share (the "Dividend Exchange Shares"). Each Dividend Right will entitle the holder (the "Dividend Rights Holder") to receive one share of Common Stock for each $0.10 of dividend and accrued interest amount exchanged (the "Dividend Right Exchange Ratio"). In lieu of fractional shares, the number of shares issued on exercise of Dividend Rights will be rounded up to the nearest whole number. The Dividend Exchange Shares are being offered in exchange for two dividends, declared by the Board of Directors during 1992, each in the amount of $0.08 per share, which remain unpaid as of the date of this Prospectus, together with accrued interest thereon, (the "1992 Dividends"), which, on December 31, 1995, aggregated $968,887.44, or $0.2073 per share. Dividend-Eligible Stockholders may elect to receive a portion only of their Dividend Rights in the form of Dividend Exchange Shares. See "THE OFFERING - General - The Dividend Exchange Offer" and "FEDERAL INCOME TAX CONSEQUENCES." Procedure For Exercising Dividend Rights............................................ Dividend Rights may be exercised by properly completing the Exchange Offer Certificate and forwarding it (or following the Guaranteed Delivery Procedures) to the Subscription Agent, which must receive such Exchange Offer Certificate or Notice of Guaranteed Delivery at or prior to the Dividend Rights Expiration Date. If Exchange Offer Certificates are sent by mail, Dividend Rights Holders are urged to use insured, registered mail. See "THE OFFERING - How to Subscribe." General Subscription Price................................ $0.10 per share for each Underlying Share. Common Stock Outstanding prior to the Offering...................................... 69,675,110 shares at December 31, 1995.
Preferred Stock Outstanding prior to the Offering................................... None. Common Stock to be Outstanding upon Completion of the Offering................... 129,363.985 shares. Common Stock to be Outstanding upon Maximum Conversion of Debentures into Common Stock ..................... 233,363,985 shares, assuming no interim issuances of Common Stock. See "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY." Expiration Dates.................................. The Rights Expiration Date, the Dividend Rights Expiration Date and the Public Offering Expiration Date (the "Offering Expiration Date") is April 11, 1996, unless terminated or extended by the Company's Board of Directors, in its sole discretion for up to two (2) consecutive periods of up to 30 days each, or not later than June 11, 1996. See "THE OFFERING." Information Agent................................. Carpenter & Company 2600 Michelson Drive, Suite 300 Irvine, CA 92715 Attention: Edward Carpenter or John Flemming Tel: (800) 528-8580 Transfer Agent and Subscription Agent............................................. The First National Bank of Boston 435 Tasso, Suite 250 Palo Alto, CA 94301 Tel: (415) 853-0404 See "THE OFFERING -- Subscription Agent."
USE OF PROCEEDS The Company intends to use the net proceeds from the Offering to increase its regulatory capital levels and the regulatory capital levels of the Bank. Such proceeds are expected to constitute Tier I capital for Bank regulatory purposes. The Bank will use the proceeds contributed to it from the Company for general corporate purposes. See "USE OF PROCEEDS." No assurance can be given, however, that the capital of the Bank will not be eroded thereafter if the Bank continues to experience operating losses. See "RISK FACTORS." The Company intends to retain the remaining net proceeds of the Offering, if any, for general corporate purposes, including payment of operating expenses. The Company estimates that the expenses of the Offering will total $444,000. See "USE OF PROCEEDS." STOCK PURCHASE AGREEMENT; CHANGE IN CONTROL; POTENTIAL DILUTION OF VOTING POWER AND EARNINGS PER SHARE On August 7, 1995, the Company entered into the Stock Purchase Agreement pursuant to which First Banks has purchased from the Company at the Subscription Price 65,000,000 shares of Common Stock and has loaned to the Company an additional $1.5 million and $5.0 million in exchange, respectively, for issuance of two the Debentures. Certain provisions of the Stock Purchase Agreement were amended on October 31, 1995 by the Additional Investment Agreement and on December 28, 1995 by the Standby Agreement (collectively, the "Stock Purchase Agreement"). On June 30, 1995, James F. Dierberg provided emergency interim financing for the Bank pursuant to the Standby Stock Purchase Agreement through the purchase of $1.5 million in shares of Bank Preferred Stock. On August 22, 1995, First Banks received approval for a change in control of the Company and the Bank from the Federal Reserve Bank of St. Louis and the SBD. On August 22, 1995, Dierberg sold the shares of Bank Preferred Stock to First Banks. Subsequently, First Banks also purchased 116,666,666 shares, or $3.5 million, of Bank Common Stock on August 23, 1995. The terms of the Stock Purchase Agreement and the Debentures are fully described at "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY." The stockholders of the Company approved the terms of the Stock Purchase Agreement at the 1995 Special Meeting. Pursuant to the Stock Purchase Agreement, on December 28, 1995, First Banks exchanged the shares of Bank Preferred Stock originally acquired by Dierberg and the $3.5 million in shares of Bank Common Stock acquired by First Banks pursuant to the Stock Purchase Agreement for 50,000,000 shares of Company Common Stock. In addition, First Banks has loaned to the Company a total of $6,500,000 in exchange for the issuance of the Debentures. The Company may issue to First Banks a total of 65,000,000 shares of Common Stock in respect of the principal amount of the Debentures and up to an additional 39,000,000 shares of Common Stock in respect of any unpaid and accrued interest amount. The Debentures are convertible at any time at the option of First Banks into a maximum of 104,000,000 shares if the total principal and interest amounts of the Debentures are converted by First Banks into Common Stock. Finally, on December 28, 1995, First Banks purchased an additional $1,500,000 of Company Common Stock at the Subscription Price, or 15,000,000 shares, which enabled the Bank to meet the 6.5% Tier I capital requirement of the FDIC Cease and Desist Order as of December 31, 1995. For a complete description of the terms of the Stock Purchase Agreement, see "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY." The foregoing issuances of Common Stock and the Debentures to First Banks pursuant to the Stock Purchase Agreement have significantly diluted the percentage of ownership of the Company held by holders of the Company's Common Stock, other than First Banks. However, while consummation of the Stock Purchase Agreement resulted in such dilution, one purpose of this Offering is to mitigate such dilution by providing the stockholders, other than First Banks, with the opportunity to subscribe for additional shares of Common Stock. Notwithstanding this Offering, however, the voting power the Company's stockholders will be subsequently materially diluted through the issuance of between 65,000,000 and 104,000,000 additional shares of Common Stock upon conversion of the principal and/or interest amounts of the Debentures, respectively, and through the possible issuance of additional shares to First Banks acting as "Standby Purchaser." See "RISK FACTORS - Potential Dilution of Voting Power and Earnings Per Share" and "THE STOCK PURCHASE AGREEMENT AND CHANGE IN CONTROL OF THE COMPANY."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000319085_compressio_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000319085_compressio_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..31b977acbb8385e2008e836f4b3a78adc31760e9
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000319085_compressio_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information, including "Risk Factors" and the Consolidated Financial Statements and Notes thereto, appearing elsewhere in this Prospectus. The discussion in this Prospectus contains forward-looking statements that involve risk and uncertainties. The Company's actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business" as well as those discussed elsewhere in this Prospectus. THE COMPANY Compression Labs, Incorporated (the Company or CLI) is a leader in the development, manufacture and marketing of visual communication systems based on Compressed Digital Video (CDV) technology. The Company's systems use proprietary and industry standard algorithms to compress the amount of data required to transmit digital video and audio signals, thereby significantly reducing the cost of transmitting these signals over terrestrial, microwave, cable or satellite networks. The Company's strategy is to use its expertise in CDV technology to enhance its position in videoconferencing and to monitor new markets such as the desktop and personal video markets. CLI's group and desktop videoconferencing systems permit users at different locations to conduct full-color motion videoconferences ranging from two-way informal meetings between individuals to formal meetings between large groups at multiple locations. The Company's present families of videoconferencing systems include Rembrandt II/VP and Radiance videoconferencing systems, the eclipse family of mid-range videoconferencing systems, and the CLI Desktop Video family. Videoconferencing systems operate worldwide over a broad range of transmission speeds from 56 kilobits per second (kbps) to 2.048 megabits per second (mbps) for the Rembrandt and Radiance Systems, 768 kbps for the eclipse, and 384 kbps for the desktop. All of CLI's current videoconferencing systems are compliant with the International Telecommunication Union-Telecommunication (ITU-T) H.320 videoconferencing standard, and most also provide customer-selectable proprietary algorithms. The videoconferencing market has grown as a result of improvements in the price/performance of videoconferencing systems, decreases in transmission costs and increased availability of switched digital transmission services. However, there can be no assurance that this market growth will continue in the future. The Company has been a leader in video compression technology and believes that its large worldwide installed base of videoconferencing systems affords the Company significant competitive advantages. The Company's strategy is to strengthen its position as a leading supplier of a full range of high-performance quality group and desktop videoconferencing systems. CLI's development efforts are primarily directed at achieving greater levels of compression, improving picture quality and system functionality, continuing to reduce system costs, and supporting and improving industry standards. The Company's continued success in its chosen markets is dependent in part on the results of its ongoing technology and product development efforts. The Company's executive offices are located at 350 East Plumeria Drive, San Jose, California 95134, and its telephone number at that location is (408) 435-3000. PROSPECTUS 2,799,242 SHARES COMPRESSION LABS, INCORPORATED ------------------------ COMMON STOCK ------------------------ This Prospectus relates to a total of 2,799,242 shares of Common Stock (the "Shares"), with a par value of $0.001 per share (the "Common Stock") of Compression Labs, Incorporated (the "Company" or "CLI") which are being offered and sold by Infinity Investments Limited ("Infinity"), Seacrest Capital Limited ("Seacrest"), Brown Simpson LLC and Alpine Capital Partners, Inc. (collectively, the "Selling Securityholders"). Of such Shares (i) 2,424,242 shares are issuable upon the exercise of 350,000 shares of Series C Convertible Preferred Stock ("Series C Stock") which were sold by the Company to Infinity and Seacrest in a private financing pursuant to a Convertible Preferred Stock Purchase Agreement dated as of October 24, 1996 (the "Financing") and (ii) 375,000 shares are issuable pursuant to the exercise of warrants held by Selling Securityholders which were issued in connection with the Financing (the "Warrants"). The Warrants have an exercise price of $5.70 per share. The Common Stock is listed on the Nasdaq National Market under the symbol "CLIX." On November 22, 1996, the last reported sale price of the Common Stock on the Nasdaq National Market was $4.25 per share. The Shares may be offered by the Selling Securityholders from time to time in transactions on the Nasdaq National Market, in privately negotiated transactions or a combination of such methods of sale, at fixed prices that may be changed, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Selling Securityholders may effect such transactions by selling the Shares to or through broker-dealers, and such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the Selling Securityholders or the purchasers of the Shares for whom such broker-dealers may act as agent or to whom they sell as principal or both (which compensation to a particular broker-dealer might be in excess of customary commissions). See "Principal and Selling Securityholders" and "Plan of Distribution." The Company received all of the proceeds from the sale of the Series C Stock issued by the Company in the Financing and will receive any proceeds from the exercise of the Warrants if and when exercised by the Selling Securityholders but will not receive any of the proceeds from the sale of the Shares by the Selling Securityholders hereof. See "Plan of Distribution."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000319240_iris_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000319240_iris_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..3b125074905378287bebf0d1712e5a8540048916
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000319240_iris_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements, including notes thereto, appearing elsewhere in this Prospectus. Unless otherwise indicated, all figures assume no exercise of the Underwriters' over-allotment option. THE COMPANY The Company designs, develops, manufactures and markets in vitro diagnostic ("IVD") imaging systems based on its patented and proprietary "Automated Intelligent Microscopy" ("AIM") technology for automating microscopic procedures performed in clinical laboratories. AIM combines the Company's capabilities in automating specimen presentation, including its patented slideless microscope, as well as its proprietary high-speed digital processing hardware and software to rapidly capture, classify and visually present images of microscopic particles in easy-to-use displays. The Company's IVD imaging systems are designed to provide customers with consistent, more precise and timely results and labor cost-savings over manual methods of performing microscopy. The Company markets its products primarily to hospitals and clinical reference laboratories and has an installed base of over 500 customers. The Company estimates that at least three-quarters of all IVD microscopic procedures are performed manually and require trained medical specialists. Manually performed diagnostic tests are costly, labor-intensive, cumbersome, inefficient and often imprecise. Furthermore, there are pressures to reduce costs while improving operating efficiencies in hospitals and clinical reference laboratories. As a result, the Company believes there is a movement in such laboratories to automate microscopic procedures including slide presentation, testing and processing. The Company pioneered its first IVD imaging application in 1983 with the introduction of the first of The Yellow IRIS(R) workstations for urinalysis. The Company believes that it is still the only supplier of laboratory systems which fully automate a complete urinalysis, and it recently introduced its fourth generation models which incorporate significant advancements in speed, utility and ease of use. Earlier this year, the Company received clearance from the Food and Drug Administration ("FDA") and began to market the Model 900UDx(TM) urine pathology system designed especially for the high-volume testing requirements of larger laboratories. The Company is expanding into new applications of IVD imaging. The Company recently developed The White IRIS(R) leukocyte differential analyzer for the field of hematology. The FDA cleared The White IRIS(R) for marketing in May 1996, and the Company expects to initiate sales of this system in late 1996 or early 1997. The Company entered the field of genetics in July of this year with the acquisition (the "PSI Acquisition") of the IVD imaging business of Perceptive Scientific Instruments, Inc. ("PSI"), which included the PowerGene(TM) family of analyzers. PowerGene(TM), an IVD imaging system for karyotyping, DNA probe analysis and comparative genomic hybridization, has experienced average annual worldwide revenue growth of 35% over the last two fiscal years. The Company also acquired significant foreign operations from PSI which are expected to enable the Company to expand in international markets with its other IVD imaging systems and products. The Company also provides significant ongoing sales of supplies and service necessary for operation of The Yellow IRIS(R) workstations and the PowerGene(TM) analyzers and also plans to sell comparable supplies and service for The White IRIS(R). IRIS(R), The Yellow IRIS(R), The White IRIS(R), Model 900UDx(TM), PowerGene(TM), IRIStrip(TM), StatSpin(R), Cen-Slide(R) and Biovation(R) are trademarks of the Company. This Prospectus also contains trademarks and tradenames of other companies. IN CONNECTION WITH THE OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH TRANSACTIONS MAY BE EFFECTED ON THE AMEX, IN THE OVER-THE-COUNTER MARKET OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. The Company's goal is to achieve global leadership in automated IVD imaging by pursuing the following strategies: - Introducing New IVD Imaging Applications. The Company believes AIM technology has a number of potential applications in the clinical laboratory and is expanding beyond the field of urinalysis into other fields, including hematology and genetics. - Continuing Market Penetration for Current Applications of IVD Imaging Technology. The Company estimates that it has penetrated less than 20% of the potential market in the United States for The Yellow IRIS(R) urinalysis workstations and plans to continue expanding sales in this segment with its recently introduced fourth generation models of The Yellow IRIS(R) family, including the Model 900UDx(TM) urine pathology system. - Expanding in New Geographic Markets. The PSI Acquisition added significant international operations which are expected to enable the Company to expand the geographic market for its other IVD imaging systems and products. - Increasing Sales of Supplies and Service. The Company seeks to enhance the revenue stream from sales of supplies and service by installing more IVD imaging systems as well as increasing its product offering of supplies for each system. - Adding Complementary Product Lines. The Company has added several complementary lines of small instruments and supplies which appeal to smaller laboratories and respond to the desire of integrated healthcare providers to purchase products for a variety of clinical settings from one supplier. - Maintaining Technological Edge. The Company has an active research and development program to continually enhance its IVD imaging systems and explore other potential IVD imaging applications for its AIM technology. The Company's principal executive offices are located at 9162 Eton Avenue, Chatsworth, California 91311 and its telephone number is (818) 709-1244. THE OFFERING Common Stock offered by the Company.......... 3,000,000 shares Common Stock to be outstanding after the Offering................................... 8,908,392 shares(1) Use of Proceeds.............................. To repay $11.9 million of outstanding indebtedness incurred to finance the PSI Acquisition, to repurchase shares of the Company's Common Stock and warrants to purchase Common Stock, and for working capital and general corporate purposes. American Stock Exchange symbol............... IRI
- --------------- (1) Excludes an aggregate of 2,542,810 shares of Common Stock reserved for issuance upon exercise of outstanding options and warrants and an aggregate of 199,554 additional shares reserved for issuance pursuant to the Company's stock option plans and its stock purchase plan. Also excludes 469,413 shares of Common Stock and warrants to purchase an additional 250,000 shares of Common Stock to be purchased with the proceeds of the Offering. See "Use of Proceeds." SUMMARY CONSOLIDATED FINANCIAL DATA YEAR ENDED DECEMBER 31, SIX MONTHS ENDED JUNE 30, --------------------------------------------- -------------------------------- HISTORICAL PRO FORMA HISTORICAL PRO FORMA ----------------------------- --------- ------------------- --------- 1993 1994 1995 1995(2) 1995 1996 1996(2) ------- ------- ------- --------- ------- ------- --------- (IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF OPERATIONS DATA(1): Revenues Sales of IVD imaging systems.................. $ 5,029 $ 4,559 $ 4,870 $ 9,526 $ 2,150 $ 2,593 $ 5,830 Sales of supplies and service.................. 3,995 5,024 6,738 7,466 3,167 4,166 4,495 Sales of small instruments and supplies............. 3,369 2,886 3,414 3,424 1,566 2,370 2,456 ------- ------- ------- ------- ------- ------ ------- Net sales........... 12,393 12,469 15,022 20,416 6,883 9,129 12,781 Gross margin................. 6,051.. 5,970 7,661 10,702 3,445 4,634 6,827 Operating income (loss)...... 1,313 1,495 (1,549)(5) (2,743)(5) (2,696)(5) 879 520 Income (loss) before income taxes...................... 1,381 1,701 (1,171)(5) (2,717)(5) (2,491)(5) 1,042 472 Net income (loss)............ $ 1,323 $ 1,622 $ 2,357(6) $ 860(6) $(2,519) $ 867 $ 411 ======= ======= ======= ======= ======= ====== ======= Net income (loss) per share...................... $ 0.25 $ 0.28 $ 0.37 $ 0.09 $ (0.46) $ 0.13 $ 0.04 ======= ======= ======= ======= ======= ====== ======= Weighted average shares and share equivalents outstanding................ 5,355 5,699 6,419 9,419 5,486 6,915 9,915
PRO FORMA HISTORICAL PRO FORMA AS ADJUSTED --------------------- --------- ----------- DECEMBER JUNE 30, JUNE 30, JUNE 30, 1995 1996 1996(3) 1996(3)(4) -------- -------- --------- ----------- (IN THOUSANDS) BALANCE SHEET DATA(1): Cash and cash equivalents............................. $ 1,511 $ 1,229 $ 1,229 $ 7,279 Working capital....................................... 11,465 11,431 8,164 17,914 Total assets.......................................... 22,470 23,676 38,064 43,841 Total debt............................................ 311 -- 16,117 4,267 Total shareholders' equity............................ 19,172 20,366 16,726(7) 34,353(7)
- --------------- (1) On February 1, 1996, the Company acquired StatSpin, Inc. (formerly known as StatSpin Technologies) ("StatSpin"). This transaction was accounted for as a pooling of interests and, accordingly, the consolidated financial statements and summary financial data have been retroactively restated for all periods presented to include the financial position, results of operations and cash flows of StatSpin. (2) Represents the unaudited pro forma results of operations for the year ended December 31, 1995 and the six months ended June 30, 1996 giving effect to the PSI Acquisition and related financing and the sale of 3,000,000 shares of Common Stock offered hereby and the application of the net proceeds therefrom as if each were consummated at the beginning of the periods presented. See "Pro Forma Condensed Combined Financial Statements." (3) Reflects the PSI Acquisition and related financing as if each had been consummated on June 30, 1996. See "Pro Forma Condensed Combined Financial Statements." (4) Reflects the sale of 3,000,000 shares of Common Stock offered hereby and the application of the net proceeds therefrom. See "Use of Proceeds." (5) Includes a nonrecurring charge against operations of $2.9 million for 1995 and $3.2 million for the second quarter of 1995 (prior to final purchase price allocation) for the acquisition of in-process research and development for a product prototype not cleared by the FDA in connection with the Company's acquisition of LDA Systems, Inc. ("LDA"). (6) In the fourth quarter of 1995, the Company recognized a deferred tax benefit of $3.6 million resulting from a reduction in its deferred tax asset valuation allowance. See Note 8 to the Consolidated Financial Statements. (7) Includes a nonrecurring charge of $4.6 million for in-process research and development in conjunction with the PSI Acquisition which will be reflected in the Company's statement of operations for the quarter ended September 30, 1996. See "Pro Forma Condensed Combined Financial Statements."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000700892_laser_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000700892_laser_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..cfe87ddf3c2840b13be8875c9835dcdf8f04d9dc
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000700892_laser_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS APPEARING ELSEWHERE IN THIS PROSPECTUS, INCLUDING INFORMATION UNDER "RISK FACTORS". THE COMMON STOCK OFFERED HEREBY INVOLVES A HIGH DEGREE OF RISK. THE COMPANY Laser Master International, Inc. ("Laser Master" or the "Company") is a New York Corporation, incorporated on May 5, 1981, originally under the name Lasercraft Industries, Inc. Prior to said date, and in October 1980, in accordance with a specific plan or reorganization of companies under common control and exchange of stock, the Company was organized as a holding company for purposes of acquiring all the issued and outstanding Common Stock of Flexo-Craft Prints, Inc., Utmost Office Supplies, Inc., 185 Front Street Realty Corp, and Harrison Realty Corp. The Company, through its wholly-owned subsidiaries, is engaged in the use of a computerized laser system to accomplish Flexographic printing for industrial and commercial printing and engraving and counts among its customers large corporations, some of which are listed on the New York Stock Exchange. The principal process of Flexo-Craft is the use of a Zed laser in the manufacturing of its products. The Zed laser process emits a "coherent" wave length (color). A large degree of control is afforded and as a consequence, exceptionally high density of power can be delivered to a well defined area by focusing the light energy. Using a computer driven system, the laser beam makes grooves in the form of designs and patterns on to a rubber material. The rubber material is then sealed on a steel or aluminum cylinder which is then placed on a printing press. In the heat transfer printing process, the ink is injected into the grooves using a computer driven process and then the rubber coated cylinder prints on heat transfer paper. The heat transfer paper is sold to manufacturers who then seal it onto textile materials. The same process is used for gift wrap paper, except the paper itself is the final product. One of the Company's six color presses prints heat transfer paper, the Company's eight color press also prints gift wrap paper. The principal parts of the laser system are the scanning mechanism, rotating cylinders and axial scanning platform. In operation, artwork is mounted on a cylinder. As the artwork cylinder rotates, the helium neon laser scanning head reads tonal or line values of a single circumferential scan. A memory stores the data and matches it to the 360 degree rotation of the printing roller. The controlled output of the Everlase Co2 Laser is optically deflected from the laser enclosure through metal tubes to the engraving head. The collimated laser beam can be safely projected over large distances without distortion or inaccuracy. As the cylinder rotates, the scanning-engraving heads move axially between the grooves. The laser receives appropriate commands from the micro-processor insert. A control panel integrates the controls of the Co2 laser with the engraving mechanism. The patterns and designs as created and prepared by artists on multi-colored photographic film segments are fed into the computer, which is an integral part of the laser system. Colored photographic film segments are fed into the computer (this service is contracted out by the Company) and thereafter engraves, on a fully automated basis, each dedicated groove of the design simultaneously, yet separately, for each color. The Company, by this method, is able to service many diverse industries that require material in their own production. Due to the exactness of the engraving by the laser ray, the grooves of the design are so true that the impregnation of specific colored inks in the subsequent printing process produce perfect images. To the best of the Company's knowledge, there is only one major and three minor competitors in the continental United States that operate a comparable version of the laser concept and a subliflex flexographic printing press which accommodates fewer colors and produces material of a substantially narrower width. The Company acquired a new eight ink color press which was put into full operation in July 1996. The new eight color press can print on either heat transfer or gift wrap paper. The new eight color press also allows the Company to print for the wallpaper, home furnishings and carpet industries. The eight color press is three times faster than the newest six color presses. The Company receives patterns from customers and also designs its own patterns using a computerized color separating system. The Company has an extensive inventory of rubber coated cylinders and designs with engravings that can be continually reused in its process. THE OFFERING Common Stock Offered by the Company.......... 4,597,372 shares of Common Stock $.01 par value per share Common Stock to be Outstanding after the Offering................................... 10,297,028 shares(1) Use of Proceeds.............................. The Company will not receive any proceeds from the sale of Common Stock by Selling Stockholders, unless options or warrants are exercised. In the event options or warrants are exercised, the company will use the proceeds received for general working capital purposes. NASDAQ OTC Bulletin Board-Registered Trademark- Symbol......... LMTI
SUMMARY FINANCIAL DATA The summary historical consolidated financial data presented below for each of the five fiscal years in the period ended November 30, 1995 have been derived from audited Consolidated Financial Statements. The summary historical data presented below for the six months ended May 31, 1995 and May 31, 1996 were derived from Laser Master International Inc.'s Unaudited Condensed Consolidated Financial Statements which contain all accruals and adjustments (consisting only of normal recurring adjustments) which management considers necessary for a fair presentation of the financial information for such periods. The results of operations for the six months ended May 31, 1996 are not necessarily indicative of the operating results that may be expected for the full fiscal year. This financial data should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations", the Consolidated Financial Statements and Notes thereto, the Unaudited Condensed Consolidated Financial Statements and Notes thereto and the other financial information included elsewhere in this Prospectus. SIX MONTHS ENDED (UNAUDITED) ---------------------- FISCAL FISCAL FISCAL FISCAL FISCAL MAY 31, MAY 31, 1991 1992 1993 1994 1995 1995 1996 --------- --------- --------- ---------- ---------- ---------- ---------- INCOME STATEMENT DATA: Net Sales............................ $6,375,654 $7,268,413 $9,237,340 $8,158,051 $8,432,284 $4,244,770 $4,515,260 Gross Profit......................... $1,824,865 $2,000,118 $2,887,103 $2,391,675 $2,510,644 $1,325,076 $1,776,714 Net Income (loss) from Operations.... $ 633,686 $ 521,376 $ 771,837 $ 276,471 $ (178,957) $ 16,398 $ (116,604) Net Income (loss) Per Share.......... $ .111 $ .091 $ .129 $ .05 $ (.03) $ .00 $ (.01) Total Assets......................... $6,779,570 $7,269,019 $8,183,489 $14,801,853 $13,861,245 $14,826,779 $16,097,770 Total Long Term Liability............ $2,912,042 $3,028,919 $2,756,620 $8,172,928 $5,946,837 $8,134,699 $5,923,503 Total Liabilities.................... $3,745,436 $3,713,509 $3,779,141 $10,123,744 $9,359,383 $10,129,562 $8,212,512
- ------------------------ (1) Excludes 20,000,000 shares of Common Stock reserved for issuance under the Company's proposed Stock Option Plans (the "Plans"). Also, does not include an aggregate of 1,725,000 stock options exercisable at $1.00 per share awarded and or to be awarded to Messrs. Dov, Hershel and Abraham Klein under their respective employment agreements. Additionally, does not include 1,200,000 options awarded and or to be awarded to Mr. Mendel Klein, exercisable at $1.00 per share. Also, does not include a convertible debenture in the sum of $200,000 with interest payable at 5% per annum convertible into Common Stock. The debenture is convertible into shares of stock at a 30% discount to market, based upon the previous five day market average price. The debenture expires June 29, 1998. Additionally, excludes 800,000 shares of Common Stock underlying 800,000 warrants in the within offering, of which 300,000 warrants are exercisable at $1.00 per share expiring May 10, 1999, and 500,000 warrants are exercisable at $2.00 per share expiring May 10, 1999. Additionally, does not include 375,000 shares of Common Stock underlying options in the within offering, of which 100,000 options are exercisable at $1.00 per share expiring May 27, 1997; 100,000 options exercisable at $2.00 per share expiring May 27, 1998, and 175,000 options exercisable at $1.00 per share expiring May 8, 2001.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000708818_nextgen_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000708818_nextgen_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..ae297e45e73e3530716e6f3de6acf017ba50ce7e
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000708818_nextgen_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial data appearing elsewhere in this Prospectus. Unless otherwise indicated, all information in this Prospectus assumes that the Underwriters' over-allotment option is not exercised. THE COMPANY Quality Systems, Inc. ("QSI" or the "Company") develops and markets health care information systems that automate medical and dental group practices, physician hospital organizations ("PHOs"), management service organizations ("MSOs"), health maintenance organizations ("HMOs") and community health centers. In response to the growing need for more comprehensive, cost-effective information solutions for physician and dental practice management, the Company's systems provide clients with the ability to redesign patient care and other workflow processes, to improve productivity and reduce information processing and administrative costs and to provide multi-site access to patient information. The Company's proprietary software systems include general patient information and summary medical records, appointment scheduling, billing, insurance claims submission and processing, managed care implementation and referral management, treatment outcome studies, treatment planning, drug formularies, word processing and accounting. In addition to providing fully integrated information solutions to its clients, the Company provides comprehensive hardware and software installation, maintenance and support services, system training services and electronic claims submission services. The Company is also introducing patient medical records automation for medical and dental practices utilizing proprietary software developed by Clinitec International Inc. ("Clinitec"), a developer of electronic medical records software systems. The Company currently has an installed base of more than 475 operating health care information systems serving PHOs, MSOs, HMOs and other health care organizations, each of which consists of one to 120 physicians or dentists. According to Medical Data International, it is estimated that the physician practice management information systems market is currently $1.8 billion. The Company believes that as health care providers are increasingly required to reduce costs while maintaining the quality of health care, the Company will be able to capitalize on its strategy of providing fully integrated information systems and superior customer service. The Company was founded in 1974, with an early focus on providing information systems and services primarily for dental group practices. The Company's initial "turnkey" systems were designed to improve productivity while reducing information processing costs and personnel requirements. In the mid-1980's, the Company capitalized on the opportunity presented by the increasing pressure of cost containment on physicians and health care organizations and further expanded its information processing systems into the broader medical market. Today, the Company develops and provides integrated UNIX-based health care information systems for both the medical and dental markets. These systems operate on a stand-alone basis or in a networked environment and are expandable to accommodate client needs. Augmenting its practice management software, the Company added electronic medical records software to its product line in 1995 through a strategic relationship with Clinitec. The Company currently holds a 25% interest in Clinitec and a unilateral right to increase its interest to 51%, and has entered into an agreement in principle (the "Clinitec Agreement in Principle") to acquire Clinitec as a wholly-owned subsidiary. Clinitec's principal product, NextGen, permits scanning, annotation, retrieval and analysis of medical records in all formats, from documents to photographs and X-rays. NextGen has been developed using a client/server platform, a graphical user interface for compatibility with UNIX, Microsoft Windows, Windows NT and Windows 95 operating systems, and a relational database for flexibility in screen customization and logic flow. The Company is also in the process of developing an alternative client/server version of its "back office" products utilizing a graphical user interface with screens and templates similar to those in the NextGen product to enable a more seamless integration of the QSI and NextGen applications. With the addition of NextGen, the Company is able to provide its clients with a comprehensive information management solution. NextGen, in conjunction with the Company's practice management software, was first installed at a beta site in August 1995 and is currently being installed in two additional sites. General release of the combined systems is expected to occur in the quarter ending June 30, 1996. LOGO Quality Systems' health care [PHOTO] [PHOTO] information systems automate medical and dental practices and improve efficiency in such areas as billing, patient scheduling and insurance processing. These systems also permit enhanced quality of care by giving the health care professional [PHOTO] access to treatment and outcome data. The Company's health care information systems automate both medical and dental physician group practices, management services organizations ("MSOs"), physician hospital organizations ("PHOs"), health maintenance organizations ("HMOs") and community health centers with a focus on improving overall practice efficiency. These systems offer a broad range of applications for a wide variety of health care organizations. [PHOTO] QSI provides hardware and software system support to its clients seven days a week, 24 hours a day. The Company offers a selection of other client services including training, consulting and custom software development. ------------------------------ IN CONNECTION WITH THIS OFFERING, CERTAIN UNDERWRITERS AND SELLING GROUP MEMBERS (IF ANY) OR THEIR RESPECTIVE AFFILIATES MAY ENGAGE IN PASSIVE MARKET MAKING TRANSACTIONS IN THE COMPANY'S COMMON STOCK ON THE NASDAQ NATIONAL MARKET IN ACCORDANCE WITH RULE 10b-6A UNDER THE SECURITIES EXCHANGE ACT OF 1934. SEE "UNDERWRITING." IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OF THE COMPANY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. THE OFFERING Common Stock offered By the Company................................ 1,000,000 shares By the Selling Shareholders................... 500,000 shares Total...................................... 1,500,000 shares Common Stock to be outstanding after the offering................................... 5,653,491 shares(1) Use of proceeds................................. For the acquisition of an increased ownership interest in Clinitec and for general corporate purposes, including the financing of product sales growth, development of new products, working capital requirements and potential other acquisitions. See "Use of Proceeds." Nasdaq National Market symbol................... QSII
- --------------- (1) Excludes 132,125 shares of Common Stock which were subject to outstanding options as of February 12, 1996 at a weighted average exercise price of $4.61 per share under the Company's 1989 Stock Option Plan (the "1989 Plan"). See "Directors and Executive Officers -- 1989 Stock Option Plan" and Note 6 to Notes to Financial Statements. SUMMARY FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT FOR PER SHARE DATA) NINE MONTHS ENDED YEAR ENDED MARCH 31, DECEMBER 31, --------------------------- ---------------- 1993 1994 1995 1994 1995 ------- ------- ------- ------ ------- STATEMENT OF OPERATIONS: Net revenues: Sales of computer systems, upgrades and supplies................................. $ 6,274 $ 6,146 $ 5,681 $3,895 $ 7,162 Maintenance and other services............. 5,377 5,606 6,368 4,727 5,159 ------- ------- ------- ------ ------- 11,651 11,752 12,049 8,622 12,321 Cost of products and services................. 6,992 6,527 6,060 4,498 5,865 ------- ------- ------- ------ ------- Gross profit.................................. 4,659 5,225 5,989 4,124 6,456 Earnings from operations...................... 517 855 986 433 2,488 Net earnings.................................. $ 623 $ 906 $ 962 $ 524 $ 1,670 ======= ======= ======= ====== ======= Net earnings per share(1)..................... $ 0.15 $ 0.21 $ 0.21 $ 0.11 $ 0.35 ======= ======= ======= ====== ======= Weighted average shares used in computation... 4,187 4,342 4,606 4,641 4,709 ======= ======= ======= ====== =======
AT DECEMBER 31, 1995 ----------------------------------- PRO FORMA AS ADJUSTED ------------------------- 51% OF 100% OF ACTUAL CLINITEC(2) CLINITEC(3) ------- ----------- ----------- BALANCE SHEET DATA: Cash and cash equivalents and short-term investments.......... $ 7,662 $25,606 $22,210 Working capital............................................... 9,302 27,513 24,117 Total assets.................................................. 15,386 33,438 37,001 Shareholders' equity.......................................... 11,681 28,365 32,907
- --------------- (1) Net earnings per share reflects primary earnings per share for all periods indicated. Primary and fully diluted net earnings per share were the same for all periods except for the year ended March 31, 1994, for which fully diluted net earnings per share was $0.20. (2) Gives pro forma effect to the acquisition of an additional interest in Clinitec, providing the Company with a 51% ownership interest in Clinitec as if such acquisition had occurred on December 31, 1995, and adjusted to reflect the sale of 1,000,000 shares of Common Stock by the Company in the offering at an assumed public offering price of $20.75 per share and the application of the estimated net proceeds therefrom. See "Use of Proceeds." (3) Gives pro forma effect to the acquisition of all of Clinitec for $4.9 million in cash and $6.9 million in value of the Company's Common Stock as if such acquisition had occurred on December 31, 1995, and adjusted to reflect the sale of 1,000,000 shares of Common Stock by the Company in the offering at an assumed public offering price of $20.75 per share and the application of the estimated net proceeds reflect additional shares therefrom. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000715355_gulfstream_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000715355_gulfstream_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..69faff4196e8a80a4af43dfe1dd689265775b8f9
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000715355_gulfstream_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY INFORMATION IS QUALIFIED IN ITS ENTIRETY BY THE DETAILED INFORMATION AND CONSOLIDATED FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. UNLESS OTHERWISE INDICATED, ALL INFORMATION IN THIS PROSPECTUS (I) GIVES EFFECT TO THE REPURCHASE OF ALL OF THE OUTSTANDING PREFERRED STOCK AND THE EXCHANGE, REDESIGNATION AND 1.5-FOR-1 STOCK SPLIT OF THE COMPANY'S COMMON STOCK, WHICH WILL OCCUR IMMEDIATELY PRIOR TO, OR SIMULTANEOUSLY WITH, THE CLOSING OF THE OFFERINGS (COLLECTIVELY, THE "1996 RECAPITALIZATION") DESCRIBED UNDER "DESCRIPTION OF CAPITAL STOCK", (II) ASSUMES THAT THE OVER-ALLOTMENT OPTIONS GRANTED TO THE UNDERWRITERS ARE NOT EXERCISED, (III) ASSUMES THE ISSUANCE AND SALE OF COMMON STOCK IN THE OFFERINGS AT $23.00 PER SHARE (THE MID-POINT OF THE RANGE OF THE INITIAL PUBLIC OFFERING PRICES SET FORTH ON THE COVER PAGE OF THIS PROSPECTUS) AND (IV) ASSUMES THE ISSUANCE OF 1,956,520 SHARES OF COMMON STOCK BY THE COMPANY TO CERTAIN SELLING STOCKHOLDERS PURSUANT TO THE EXERCISE OF OUTSTANDING OPTIONS AND THE SALE OF SUCH SHARES IN THE OFFERINGS (WHICH AMOUNTS ARE SUBJECT TO CHANGE PENDING FINAL CONFIRMATION OF SELLING STOCKHOLDER PARTICIPATION IN THE OFFERINGS, PRIOR TO PRICING OF THE OFFERINGS). UNLESS THE CONTEXT REQUIRES OTHERWISE, REFERENCES TO THE COMPANY OR GULFSTREAM REFER TO GULFSTREAM AEROSPACE CORPORATION, ITS PREDECESSORS AND ITS SUBSIDIARIES AND REFERENCES TO "COMMON STOCK" REFER TO THE COMMON STOCK, PAR VALUE $0.01 PER SHARE, OF GULFSTREAM AEROSPACE CORPORATION AFTER GIVING EFFECT TO THE 1996 RECAPITALIZATION. REFERENCES IN THIS PROSPECTUS TO (I) MILES ARE TO NAUTICAL MILES; ONE NAUTICAL MILE IS EQUAL TO 1.15 STATUTE MILES; AND (II) FISCAL YEARS ARE TO THE FISCAL YEAR OF THE COMPANY ENDED DECEMBER 31 OF THE YEAR SPECIFIED (e.g., "FISCAL 1995" REFERS TO THE YEAR ENDED DECEMBER 31, 1995). THE COMPANY Gulfstream Aerospace Corporation is recognized worldwide as a leading designer, developer, manufacturer and marketer of the most technologically advanced intercontinental business jet aircraft. Since 1966, when the Company created the large cabin business jet category with the introduction of the Gulfstream II, the Company has dominated this market segment, capturing a cumulative market share of 60%. The Company has manufactured and sold over 950 large business aircraft since the introduction of the Gulfstream product line in 1958. Since 1990, the Company has been owned by certain partnerships formed by Forstmann Little & Co., a private investment firm ("Forstmann Little"). The Company has developed a broad range of aircraft products to meet the aviation needs of its targeted customers (which include national and multinational corporations, governments and governmental agencies, heads of state and wealthy individuals). See "Business--Customers and Marketing". The Company's current principal aircraft products are the Gulfstream IV-SP, the Gulfstream V, Gulfstream Shares-TM- (fractional ownership interests in Gulfstream IV-SPs) and pre-owned Gulfstream aircraft. As an integral part of its aircraft product offerings, the Company offers aircraft completion (exterior painting of the aircraft and installation of customer selected interiors and optional avionics) and worldwide aircraft maintenance services and technical support for all Gulfstream aircraft. In addition, the Company's financial services subsidiary, Gulfstream Financial Services Corporation, through its private label relationship with a third-party aircraft financing provider, offers customized products to finance the worldwide sale of Gulfstream aircraft. BUSINESS STRATEGY Beginning in 1993, the Company implemented a major restructuring and refocusing of its business in order to improve profitability, increase market share and build backlog. Theodore J. Forstmann, who assumed the position of Chairman of the Company in November 1993, recruited a new senior management team (including over 20 senior executives with aviation and aerospace industry experience) and established a five member Management Committee, chaired by Mr. Forstmann and comprised of four other key executives who share responsibility for strategic decisions, management and oversight of the Company's operations. In addition, Mr. Forstmann assembled both a Board of Directors and an International Advisory Board comprised of prominent business executives and senior statesmen to counsel the Company and assist in its refocused sales and operating initiatives. Under the leadership of Mr. Forstmann and the new management team, the Company (i) recapitalized its balance sheet, thereby reducing the Company's annual interest expense by approximately $38 million, (ii) reduced the Company's cost structure, yielding over $50 million in annual savings, while increasing the Company's aircraft production rate, (iii) strengthened the Company's market position and aircraft order growth, resulting in a contract backlog of approximately $3.0 billion of revenues and executed contracts with financing contingencies of approximately $295 million of potential revenues, representing total revenues and potential revenues of approximately $3.3 billion at September 30, 1996, (iv) expanded and improved the Company's product offerings and (v) increased the Company's completion order rate and expanded its worldwide service and support business. The most significant aspects of the restructuring were: RECAPITALIZATION AND SIGNIFICANT REDUCTION OF INTEREST EXPENSE In late 1993, a partnership formed by Forstmann Little exchanged approximately $469 million of the Company's subordinated debentures (including accrued interest) for preferred stock, thereby reducing the Company's annual interest expense by approximately $38 million. See "Certain Transactions -- The Acquisition; Subsequent Events". This recapitalization and the resulting increase in cash flow (together with the cost reductions and manufacturing efficiencies discussed below) enabled the Company to dedicate additional resources to significantly enhance the design of the Gulfstream V, the Company's new ultra-long range business jet. COST REDUCTIONS AND INCREASED PRODUCTION RATE The Company initiated a restructuring that significantly reduced its cost structure and product manufacturing cycle times. The restructuring program included a voluntary reduction in the Company's work force of approximately 15%, the outsourcing of certain manufacturing activities, the renegotiation of major supplier contracts and the termination of certain leases, which, in the aggregate, have yielded over $50 million in annual savings. Additionally, the Company has reduced final assembly time of an aircraft by more than 50% from over 67 days to approximately 30 days and has reduced aircraft completion time from approximately 35 weeks to approximately 21 weeks. As a result of these cycle time reductions, the use of common tooling and selected outsourcing, the Company expects to increase its production rate from an average of 2.4 aircraft per month in 1996 to an average of 3.5 to 4.0 aircraft per month in 1997. NEW MARKETING INITIATIVES AND SIGNIFICANTLY INCREASED BACKLOG The Company developed and implemented a new, proactive marketing strategy to substantially broaden the markets for its products. In addition to the Company's historical practice of targeting its existing customer base, the Company (a) initiated an aggressive marketing campaign focused on companies and individuals that have not previously owned Gulfstream aircraft, (b) significantly expanded international sales activities, (c) introduced its Gulfstream Shares-TM- program and (d) offered its customers access to customized financing to support the sale of new and pre-owned Gulfstream aircraft. The Company has also redirected its sales and marketing effort to focus on high level decision makers through increased involvement of the Company's Board of Directors, International Advisory Board and senior management in the selling process and restructured its sales commission program to more effectively support the Company's strategic goals. As a result of these new marketing initiatives, the Company has experienced strong growth in aircraft orders and backlog and believes that it has substantially strengthened its market position. At September 30, 1996, the Company had a contract backlog of approximately $3.0 billion of revenues plus executed contracts with financing contingencies of approximately $295 million of potential revenues, representing a total of 69 contracts for Gulfstream Vs and 30 contracts for Gulfstream IV-SPs. Contracts with financing contingencies are converted to backlog upon receipt of financing by the purchaser, which generally occurs within 120 days. In addition, at September 30, 1996, the Company had letters of intent with deposits for a total of 1 Gulfstream V and 4 Gulfstream IV-SPs, representing approximately $140 million of additional potential revenues. In total, approximately 50% of the Gulfstream V contracts in backlog have scheduled deliveries beyond 1997. EXPANDED PRODUCT OFFERINGS The Company expanded its product offerings to provide multiple aircraft products in contrast to its historical strategy of offering only one new aircraft model at a time. In addition, the Company began marketing its products as an integrated whole, offering completion and worldwide maintenance services and technical support for all Gulfstream aircraft. The Company's current product offerings include the following: GULFSTREAM V. The Company significantly enhanced the design and performance characteristics of the Gulfstream V, which was in the early stage of development in 1993, and accelerated the pace of its development. The Gulfstream V is targeted at the market for ultra-long range business jet aircraft (6,500 nautical miles) which is a new market segment for the business jet industry. The Gulfstream V is in the advanced stages of flight testing and is on schedule to obtain certification by the Federal Aviation Administration ("FAA") in the last quarter of 1996, at least 12 months prior to the targeted certification date of any other ultra-long range business jet aircraft. The Company believes the Gulfstream V provides the longest range, fastest cruising speed and most technologically advanced avionics of any ultra-long range business jet aircraft in operation. GULFSTREAM IV-SP. In 1993, the Company introduced the Gulfstream IV-SP, which offers significantly improved performance and upgraded avionics as compared to its predecessor, the Gulfstream IV. The Company believes that the Gulfstream IV-SP offers the best combination of large cabin size, long range (4,220 nautical miles), fast cruising speed and technologically advanced avionics of any large business jet aircraft currently available. GULFSTREAM SHARES-TM-. In 1995, the Company introduced a Gulfstream IV-SP fractional share ownership program (Gulfstream Shares-TM-) in conjunction with Executive Jet International, Inc.'s ("EJI") NetJets-Registered Trademark- Program. Gulfstream Shares-TM- provides customers with the benefits of Gulfstream aircraft ownership at a substantially lower cost than full aircraft ownership and significantly increases the Company's potential customer base. To date, the Company has contracted to deliver 16 Gulfstream IV-SPs and 2 Gulfstream Vs to EJI in connection with this program, 8 of which have been delivered and 10 of which will be delivered through 1999. EJI also has an option to purchase 5 additional Gulfstream IV-SPs in 1998. PRE-OWNED GULFSTREAM AIRCRAFT. The Company assembled a new, experienced management team for its pre-owned aircraft sales operations and introduced a number of initiatives that have enhanced the marketability of pre-owned Gulfstream aircraft. See "Business--Principal Products--Premium Pre-Owned Gulfstream Aircraft and Other Pre-Owned Aircraft". In addition, the Company has been successful in using pre-owned Gulfstream aircraft as a significant tool to expand the Company's potential market and to compete against other manufacturers of lower priced, new aircraft products. As a result of the Company's competitive success in marketing pre-owned aircraft, the Company has reduced its inventory of pre-owned aircraft available for sale to approximately $23.6 million and $35.0 million as of June 30, 1995 and 1996, respectively, as compared with approximately $125.8 million at October 31, 1993. IMPROVED COMPLETION, SERVICE AND SUPPORT The Company's new marketing strategy has resulted in substantial improvements in the Company's completion business. Gulfstream currently completes approximately 95% of all new Gulfstream aircraft sold to customers as compared to 70% in 1990. Further, the Company has significantly expanded its worldwide maintenance services and technical support for Gulfstream aircraft, including opening a new 200,000 square foot service center in 1996 to increase its ability to provide high quality service to Gulfstream customers. These service and support activities provide the Company with ongoing customer contact, which the Company believes enhances its opportunity to sell new aircraft to existing service and support customers. SUCCESSFUL CO-PRODUCTION OF GULFSTREAM V AND GULFSTREAM IV-SP AIRCRAFT The Company is currently manufacturing both the Gulfstream V and Gulfstream IV-SP. Upon FAA certification of the Gulfstream V, which is expected to occur in the last quarter of 1996, the Company will begin delivering Gulfstream V aircraft to customers. Given the Company's increased manufacturing volume and large backlog of orders, the Company expects to deliver aircraft in 1997 at rates substantially in excess of those experienced in the recent past. Assuming FAA certification in the last quarter of 1996, the Company expects to deliver approximately 46 new aircraft in 1997, including 19 Gulfstream IV-SP and 27 Gulfstream V aircraft, representing a 59% increase over the Company's expected deliveries in 1996. Certain partnerships formed by Forstmann Little (the "Forstmann Little Partnerships") own substantially all of the shares of the Company's currently outstanding common stock (87.1% of the common stock on a fully diluted basis). Shares of Common Stock to be sold pursuant to the Offerings will be sold by the Company and by the Forstmann Little Partnerships, as well as by certain other holders of the Company's common stock and certain option holders (collectively, the Forstmann Little Partnerships and such holders of common stock and options are the "Selling Stockholders"). After the consummation of the Offerings, the Forstmann Little Partnerships will beneficially own approximately 61.1% of the Common Stock (55.2% on a fully diluted basis) or 55.6% (50.6% on a fully diluted basis), assuming that the Underwriters' over-allotment options are exercised in full. See "Certain Transactions -- The Acquisition; Subsequent Events" and "Principal and Selling Stockholders". THE OFFERINGS (1) Common Stock offered by the Company: (2) United States Offering........ 3,826,100 shares International Offering........ 956,500 shares Total....................... 4,782,600 shares Common Stock offered by the Selling Stockholders: (2) United States Offering........ 18,573,900 shares International Offering........ 4,643,500 shares Total....................... 23,217,400 shares Common Stock to be outstanding after the Offerings............ 71,963,882 shares (2)(3) Use of proceeds by the Company.. Together with proceeds of $400 million from new bank borrowings, proceeds of expected stock option exercises in connection with the Offerings, and funds generated from operations, to repurchase the outstanding Series A 7% cumulative preferred stock of the Company (the "7% Cumulative Preferred Stock") at its stated value for a purchase price of $450 million, plus approximately $7.9 million of unpaid dividends, to repay outstanding indebtedness under existing credit facilities (which was $119.8 million at June 30, 1996) and to pay the fees and expenses incurred in connection with the Offerings and the refinancing of the Company's indebtedness. The Company will not receive any of the proceeds from the sale of shares by the Selling Stockholders. See "Use of Proceeds". Proposed NYSE symbol............ GAC
- -------------- (1) The offering of 22,400,000 shares of Common Stock initially being offered in the United States (the "U.S. Offering") and the offering of 5,600,000 shares of Common Stock initially being offered outside the United States (the "International Offering") are collectively referred to as the "Offerings". The underwriters for the U.S. Offering (the "U.S. Underwriters") and the underwriters for the International Offering (the "International Underwriters") are collectively referred to as the "Underwriters". (2) Assumes that the Underwriters' over-allotment options are not exercised. See "Underwriting". (3) Includes 1,956,520 shares of Common Stock to be issued simultaneously with or immediately prior to the consummation of the Offerings upon exercise of outstanding stock options, which shares will be sold in the Offerings. Does not include 7,697,124 shares issuable upon the exercise of additional outstanding stock options. See "Management -- Stock Options".
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000715428_american_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000715428_american_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..687e079bc1ce00abf5e220b07fcf5528103aebf8
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000715428_american_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the detailed information, financial statements, including the notes thereto, and other data set forth elsewhere in this Prospectus. Unless the context indicates otherwise, (i) "American Exploration" or the "Company" refers to American Exploration Company, a Delaware corporation, and its consolidated subsidiaries, (ii) all information in this Prospectus has been adjusted to reflect the one-for-ten reverse split of the Common Stock effected in June 1995 and (iii) all information in this Prospectus assumes that the Underwriters' over-allotment options will not be exercised. The pro forma information presented in this Prospectus gives effect to the acquisition by the Company of certain properties in March and September 1996 (the "March 1996 Acquisition" and "September 1996 Acquisition," respectively), the proposed sales of certain properties in connection with the liquidation of oil and gas partnerships for which the Company acts as a co-general partner (the "NYLOG Programs") and of certain related properties (collectively, the "1996 Sales") and the application of the net proceeds of the offering made by this Prospectus (the "Offering"). See "--Recent Developments and Results," "Capitalization" and the Notes to the Pro Forma Condensed Consolidated Financial Statements included elsewhere herein. For definitions of certain oil and gas terms used in this Prospectus, see "Glossary of Certain Oil and Gas Terms." THE COMPANY American Exploration is an independent company engaged in the exploration, development, acquisition and production of oil and natural gas. The Company's operations are conducted in the United States with exploration, development and acquisition activities primarily concentrated in the Gulf of Mexico, South Texas and the Smackover Trend in southwestern Arkansas. On a pro forma basis as of June 30, 1996, the Company's proved reserves totaled 13 MMBbls of oil and 145 Bcf of natural gas, or an aggregate of 37 MMBOE, with an SEC-10 Value of $225 million. Approximately 70% of these reserves are developed, and approximately 62% are attributable to properties operated by the Company. The Company also holds in excess of 200,000 net acres of undeveloped properties and owns approximately 1,300 square miles of 3-D seismic data and approximately 79,000 linear miles of 2-D seismic data. On a pro forma basis, the Company's net production for the month of September 1996 averaged 5,100 Bbls of oil and 80,100 Mcf of natural gas per day, representing a 28% increase over average daily BOE production for the second quarter of 1996. Over the past four years, the Company has implemented a series of steps that has resulted in a significant improvement in its oil and gas operating and exploration capabilities, overhead and production costs, financial position and cash operating margins. These steps include (i) hiring experienced personnel in key management and operating positions, (ii) focusing exploration and development activities in areas in which the Company believes it has competitive advantages, (iii) acquiring properties held by certain institutional oil and gas partnerships formed by the Company in the 1980s and (iv) disposing of over 250 properties, including the sale of the Company's interest in the Sawyer Field in West Texas for $64 million in July 1995. Largely as a result of these steps, the Company's operating margin has increased from $2.72 per BOE for the year ended December 31, 1992 to $6.02 per BOE for the nine months ended September 30, 1996. In addition, the Company's ratio of total debt to total capitalization has decreased from 60% at December 31, 1992 to 32% on a pro forma basis at September 30, 1996. BUSINESS STRATEGY American Exploration's strategy is to increase per share reserves, production, cash flow and earnings through exploration, development and selective acquisitions within its core operating areas. The Company's strategy is designed to capitalize on its competitive strengths, including the experience and technical expertise of its operating personnel, a substantial seismic database and a concentration of developed and undeveloped acreage in its core operating areas. The principal features of this strategy follow. GEOGRAPHIC FOCUS. The Company's exploration, development and acquisition activities are primarily focused in the Gulf of Mexico (with an emphasis on the Texas State Waters area), South Texas (with an emphasis on the Wilcox Trend) and the Smackover Trend in southwestern Arkansas. The Company believes that by focusing its operations, it can achieve cost efficiencies and enhance its ability to add new reserves. For 1996, over 90% of the Company's exploration and development budget and all of its acquisition activities have been concentrated in its core operating areas. The Company is also in the process of divesting certain properties that are not consistent with its geographic focus (see "-- Recent Developments and Results") and is reviewing the feasibility of divesting various additional non-strategic properties. ACTIVE DRILLING PROGRAM. The Company is engaged in an active drilling program and attempts to maintain a project portfolio consisting of both high risk, high potential exploration prospects and lower risk development projects. The Company's exploration activities are generally concentrated in areas where in-house geological knowledge and 2-D seismic data can be used to identify prospect leads. The Company then attempts to establish large lease positions and generally initiates or acquires 3-D seismic data to confirm prospects prior to drilling. The Company typically shares the risks associated with its exploration prospects with industry partners. In addition to internally generated exploration prospects, the Company selectively participates in exploration prospects initiated by other oil and gas companies. For 1996, the Company has budgeted approximately $40 million for exploration and development and intends to drill approximately 40 exploratory wells and 45 development wells. During the first nine months of 1996, the Company spent approximately $18 million on exploration and drilled 16 gross (7.0 net) wells, 31% of which were successfully completed. During the same period, the Company spent approximately $12 million on development and drilled 34 gross (11.7 net) wells, 85% of which were successfully completed. SELECTIVE ACQUISITIONS. The Company's acquisition strategy is to acquire producing properties within its core operating areas that enhance its competitive position, offer economies of scale and provide further development and/or exploration potential. The Company seeks to acquire properties in which it can obtain a significant ownership percentage and become the operator. Through September 1996, the Company has invested $53 million, net of interests being sold to a third party, to acquire interests in seven Gulf of Mexico fields, four of which are operated by the Company. See "-- Recent Developments and Results" and the Pro Forma Condensed Consolidated Financial Statements. ADVANCED TECHNICAL CAPABILITIES. The Company makes extensive use of advanced technologies, most notably 3-D seismic, computer-aided exploration and specialized drilling applications such as short radius horizontal wells, to better delineate or produce oil and gas reserves. The Company's experienced staff of geologists and geophysicists performs all interpretation and seismic mapping on in-house 3-D seismic workstations. FINANCIAL FLEXIBILITY. The Company is committed to maintaining financial flexibility in order to pursue its existing exploration and development projects and to take advantage of future opportunities. The Company has taken a number of steps over the past few years to reduce debt and improve its liquidity and financial flexibility. As a result, the Company's ratio of total debt to EBITDA (see Note 4 to "-- Summary Financial Data") for the prior 12 months decreased from 5.2 as of December 31, 1992 to 1.4 on a pro forma basis as of September 30, 1996. The Company intends to use the net proceeds from the Offering to reduce its outstanding bank debt. After giving effect to the proceeds from the Offering, the Company's pro forma ratio of total debt to total capitalization as of September 30, 1996 is expected to be 32%. See "Use of Proceeds," "Capitalization" and the Pro Forma Condensed Consolidated Financial Statements. RECENT DEVELOPMENTS AND RESULTS SEPTEMBER 1996 ACQUISITION. On September 27, 1996, the Company acquired interests in two blocks in the Gulf of Mexico, High Island Block 116 and East Cameron Block 328 (the "Zilkha II Properties"), for a purchase price of $39 million, net of interests being sold to a third party. The acquisition was funded through borrowings under the Company's revolving bank credit agreement (the "Credit Agreement"). The acquired properties added estimated proved reserves (as estimated by the Company as of the date of acquisition) totaling 3.6 MMBbls of oil and 16.9 Bcf of natural gas. In September 1996, production from the acquired interests was approximately 700 Bbls of oil and 17,000 Mcf of natural gas per day. The Company plans to initiate a multi-well development drilling program on East Cameron Block 328 before year-end 1996 and believes that both blocks have additional unproved reserve potential through higher primary reserve recovery and additional drilling. MARCH 1996 ACQUISITION. On March 15, 1996, the Company and a subsidiary of Dominion Resources, Inc. ("Dominion") acquired interests in five offshore blocks in the Gulf of Mexico for a purchase price of approximately $56 million. The Company's $14 million (25%) share of the March 1996 Acquisition was funded through borrowings under the Credit Agreement. The acquired properties (the "Zilkha I Properties") added estimated proved reserves (as estimated by the Company as of the date of acquisition) totaling 600 MBbls of oil and 11.3 Bcf of natural gas, net to the Company's interest. Three of the acquired properties, High Island Block 45, South Marsh Island Block 133 and East Cameron Block 129, which together represent substantially all of the proved reserve value, are operated by the Company. In September 1996, the acquired properties produced an average of approximately 670 Bbls of oil and 7,400 Mcf of natural gas per day, net to the Company's interest. During the third quarter of 1996, the Company completed the installation of production facilities on South Marsh Island Block 133 and a development well on East Cameron Block 129. The Company believes that the acquired properties have additional reserve potential through higher primary reserve recovery and the installation of gas compression. PROPOSED 1996 SALES. The Company is in the process of selling interests in approximately 70 properties, including those properties owned by the NYLOG Programs. Proved reserves and production attributable to these properties have not been included in the pro forma amounts set forth in this Prospectus. The Company intends to use the estimated $8.6 million proceeds from the proposed sales to reduce amounts outstanding under the Credit Agreement. The Company believes that these sales, which are expected to be completed by year-end 1996, will provide additional operating efficiencies. THIRD QUARTER 1996 RESULTS. For a description of the Company's results of operations for the quarter and nine months ended September 30, 1996, see "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Quarter and Nine Months Ended September 30, 1996 Compared to Quarter and Nine Months Ended September 30, 1995." PRIMARY OPERATING AREAS GULF OF MEXICO. The Gulf of Mexico is the Company's most significant area of exploration, development and acquisition activity and represents approximately 60% of the Company's 1996 exploration and development budget. On a pro forma basis, approximately 40% of total oil and gas production during September 1996 and approximately 29% of the Company's total proved reserves at June 30, 1996 were attributable to properties in the Gulf of Mexico. As of June 30, 1996, the Company held working interests in 41 offshore blocks covering 76,515 gross (28,788 net) undeveloped acres. The Company's principal offshore exploration and development focus is the Texas State Waters area. Beginning with a successful redevelopment program that increased Brazos 440 Field gross production from 5,000 Mcf of natural gas per day in February 1994 to over 25,000 Mcf of natural gas per day in October 1994, the Company has developed a large area-wide project in which it holds 29,300 gross (18,200 net) acres. In 1995, the Company participated in a 400 square mile 3-D survey covering the Brazos area and has confirmed a number of prospect leads previously identified using 2-D seismic data. Since January 1, 1994, the Company has drilled five wells on its Brazos acreage, three of which were successful, and as of September 30, 1996 it was drilling a sixth well. The Company intends to further expand its Texas State Waters acreage and participate in additional 3-D seismic surveys. SOUTH TEXAS. Approximately 30% of the Company's 1996 exploration and development budget is allocated to its South Texas operating area. On a pro forma basis, South Texas represented approximately 10% of total oil and natural gas production during September 1996 and approximately 7% of the Company's total proved reserves at June 30, 1996. American Exploration's principal exploration focus in South Texas is the Yoakum Gorge project, located in Lavaca County, where the Company controls over 55,000 acres, holds a 52.5% working interest and is nearing completion of a 152 square mile proprietary 3-D survey. The initial phase of the 3-D data has confirmed over 20 prospects in the shallow Frio and Yegua formations as well as the deeper Upper and Lower Wilcox formations. The Company plans to commence drilling 16 of these prospects in the fourth quarter of 1996. SMACKOVER TREND. American Exploration's operations in the Smackover Trend of southwestern Arkansas are focused primarily in the Midway and Buckner fields, both of which are operated by the Company. The Company's ongoing strategy in this area is to capitalize on the horizontal drilling expertise it has developed in exploiting the Midway Field by applying this technology to other Smackover fields. In 1995, the Company acquired various interests in the Buckner Field, which is located approximately 11 miles from Midway. The Buckner Field, which is geologically similar to Midway, has never been unitized and waterflooded. The Company is working to unitize the field and plans to initiate a horizontal drilling and waterflood project in 1997. OTHER OPERATING AREAS. The Company's most significant properties outside of its primary operating areas are the Bowdoin Field located in Montana, the Bradshaw Field located near the Hugoton Field in Kansas and the Henderson Canyon Field located in West Texas. During the first nine months of 1996, the Company completed 11 gross (8.7 net) development wells in the Bradshaw Field and increased net gas production by approximately 56% from an average of approximately 8,000 Mcf per day in January 1996 to approximately 12,500 Mcf per day in September 1996. In addition, the Company has a large number of development locations in the Bowdoin Field that it intends to drill as necessary to maintain production capacity at current levels. THE OFFERING Common Stock Offered: By the Company............................................ 3,000,000 shares By the Selling Stockholders............................... 579,229 shares Total............................................. 3,579,229 shares Common Stock to be Outstanding After the Offering (1)....... 14,807,741 shares Use of Proceeds............................................. To reduce amounts outstanding under the Credit Agreement. The Company will not receive any part of the proceeds from the sale of shares by the Selling Stockholders. See "Use of Proceeds." AMEX Symbol................................................. AX
- --------------- (1) Excludes (i) up to approximately 1.8 million shares issuable upon conversion of the Company's $450 Cumulative Convertible Preferred Stock, Series C, par value $1.00 per share (the "Convertible Preferred Stock"), at a conversion price of $15.00 per share, subject to adjustment in certain circumstances, (ii) approximately 1.0 million shares issuable upon exercise of stock options outstanding at September 30, 1996 at prices ranging from $11.50 to $40.00 per share at a weighted average exercise price of $13.29 per share and (iii) approximately 1.5 million shares issuable upon exercise of warrants outstanding at September 30, 1996 at a weighted average exercise price of $16.94 per share. SUMMARY FINANCIAL DATA The following table sets forth certain summary historical and pro forma financial data for the Company. The historical financial data was derived from the consolidated financial statements of the Company. The pro forma summary of operations data gives effect to the March 1996 Acquisition, the September 1996 Acquisition and the expected sale of certain assets acquired therein, the 1996 Sales and the application of the net proceeds from the Offering as if such transactions had occurred on January 1, 1995. The pro forma balance sheet data gives effect to the expected sale of certain assets acquired in the September 1996 Acquisition, the 1996 Sales and the application of the net proceeds from the Offering as if such transactions had occurred on September 30, 1996. The pro forma data for the year ended December 31, 1995 does not include results from the High Island 116 well acquired in the September 1996 Acquisition because the well did not produce during the period. Similarly, the pro forma data for the nine months ended September 30, 1996 includes only two months of results from the High Island 116 well. The well commenced production in August 1996 at a net production rate of 300 Bbls of oil per day and 17,100 Mcf of natural gas per day. The data in the following table should be read in conjunction with the Pro Forma Condensed Consolidated Financial Statements, Management's Discussion and Analysis of Financial Condition and Results of Operations and the Consolidated Financial Statements and related Notes thereto appearing elsewhere herein. PRO FORMA NINE MONTHS NINE PRO FORMA ENDED MONTHS YEAR ENDED DECEMBER 31, YEAR ENDED SEPTEMBER 30, ENDED -------------------------------- DECEMBER 31, ----------------- SEPTEMBER 30, 1993(1) 1994(2) 1995(2)(3) 1995 1995 1996 1996 -------- -------- ---------- ------------ ------- ------- ---------- (IN THOUSANDS, EXCEPT FOR PER SHARE AMOUNTS) SUMMARY OF OPERATIONS DATA: Revenues: Oil and gas sales................... $ 49,589 $ 50,033 $ 70,768 $ 65,238 $55,049 $52,263 $ 52,928 Other, net.......................... 8,569 1,326 11,166 772 10,352 912 912 -------- -------- ------- -------- ------- ------- ------- Total revenues.................. 58,158 51,359 81,934 66,010 65,401 53,175 53,840 -------- -------- ------- -------- ------- ------- ------- Costs and Expenses: Production and operating............ 15,998 21,302 24,515 19,377 19,079 15,421 14,482 Depreciation, depletion and amortization...................... 23,635 29,616 30,726 30,909 22,446 20,871 22,656 General and administrative.......... 7,413 10,035 7,472 7,528 4,683 4,450 4,450 Taxes other than income............. 4,601 5,710 5,760 4,956 4,413 4,254 3,862 Exploration......................... 7,554 2,559 4,826 4,826 3,269 9,152 9,152 Impairment.......................... 10,975 33,570 1,822 1,822 43 1,841 1,841 -------- -------- ------- -------- ------- ------- ------- Total costs and expenses........ 70,176 102,792 75,121 69,418 53,933 55,989 56,443 -------- -------- ------- -------- ------- ------- ------- Income (loss) from operations......... (12,018) (51,433) 6,813 (3,408) 11,468 (2,814) (2,603) Interest expense...................... (6,847) (6,638) (5,481) (3,336) (4,853) (2,894) (2,984) Other income (expense), net........... (321) (2,164) 145 147 (105) (63) (63) -------- -------- ------- -------- ------- ------- ------- Income (loss) before extraordinary item................................ (19,186) (60,235) 1,477 (6,597) 6,510 (5,771) (5,650) Extraordinary gain on debt extinguishment...................... -- 5,419 2,456 2,456 2,456 -- -- -------- -------- ------- -------- ------- ------- ------- Net income (loss)..................... (19,186) (54,816) 3,933 (4,141) 8,966 (5,771) (5,650) Preferred stock dividends............. (75) (1,800) (1,800) (1,800) (1,350) (1,350) (1,350) -------- -------- ------- -------- ------- ------- ------- Net income (loss) to common stock..... $(19,261) $(56,616) $ 2,133 $ (5,941) $ 7,616 $(7,121) $ (7,000) ======== ======== ======= ======== ======= ======= ======= Net income (loss) per common share: Primary and fully diluted: Loss before extraordinary item.... $ (2.77) $ (7.70) $ (0.03) $ (0.57) $ 0.43 $ (0.60) $ (0.47) Net income (loss)................. (2.77) (7.02) 0.18 (0.40) 0.64 (0.60) (0.47) OTHER FINANCIAL DATA: EBITDA(4)............................. $ 37,224 $ 10,583 $ 33,981 $ 34,588 $27,493 $28,186 $ 30,182 Operating cash flow(5)................ 26,813 4,838 27,514 29,573 21,714 24,285 25,848 Total capital expenditures (6)........ 24,167 49,889 44,215 N/A 31,229 92,116 N/A
PRO FORMA SEPTEMBER 30, SEPTEMBER 30, 1996 1996 ------------- -------------- SUMMARY OF BALANCE SHEET DATA: Working capital (deficit).......................................................... $ (1,623) $(16,007) Total assets....................................................................... 233,363 218,979 Long-term debt, excluding current obligations...................................... 105,000 56,833 Total stockholders' equity......................................................... 87,506 121,289
- --------------- (1) The Company received aggregate proceeds of approximately $35 million for the conveyance of approximately 40% of its interest in the Henderson Canyon Field in March 1993 and the sale of its Canadian assets in mid-1993. (2) The Company purchased investors' interests in certain institutional oil and gas partnerships formed by the Company in the 1980s (the "APPL Programs") in 1994 and 1995 for 4.6 million shares of Common Stock and $40.1 million in cash (the "APPL Consolidation"). (3) The Company sold its interest in the Sawyer Field for $64 million in July 1995. (4) EBITDA is defined for this purpose as net income (loss) plus interest, income taxes, depreciation, depletion and amortization, exploration expense, impairment expense and loss on sales of oil and gas properties, less gain on sales of oil and gas properties and extraordinary gain from extinguishment of debt. EBITDA should not be considered as an alternative to earnings (loss) as an indicator of the Company's financial performance or to cash flow as a measure of liquidity. See the Consolidated Statements of Operations included in the Consolidated Financial Statements appearing elsewhere herein. (5) Cash flow from operations before working capital changes and after preferred dividends. (6) Excludes the acquisition of properties in exchange for the issuance of Common Stock, principally relating to the APPL Consolidation. SUMMARY OPERATING DATA The table below sets forth certain operating information of the Company for the periods presented. NINE MONTHS YEAR ENDED DECEMBER 31, ENDED SEPTEMBER 30, ---------------------------------- ------------------- 1993(2) 1994(3) 1995(3)(4) 1995(3) 1996 ------- ------- ---------- ------- ------- AVERAGE SALES PRICE(1): Gas ($/Mcf)........................... $ 1.92 $ 1.90 $ 1.74 $ 1.70 $ 1.88 Oil ($/Bbl)........................... 16.01 15.39 16.83 16.87 16.87 BOE ($/BOE)........................... 12.99 12.67 12.30 12.05 13.17 PRODUCTION DATA: Gas (MMcf)............................ 15,336 16,241 24,450 19,866 15,772 Oil (MBbls)........................... 1,261 1,241 1,680 1,258 1,340 MBOE.................................. 3,817 3,948 5,755 4,569 3,969 UNIT DATA ($/BOE): Oil and gas sales..................... $ 12.99 $ 12.67 $ 12.30 $ 12.05 $ 13.17 Production and operating costs........ 4.19 5.40(5) 4.26 4.18 3.89 Taxes other than income............... 1.21 1.45 1.00 0.97 1.07 General and administrative expense.... 1.94 2.54(6) 1.30 1.02 1.12 Interest expense...................... 1.79 1.68 0.95 1.06 0.73 Preferred stock dividends............. 0.02 0.46 0.31 0.30 0.34 ------- ------- ------- ------- ------ Operating margin...................... $ 3.84 $ 1.14 $ 4.48 $ 4.52 $ 6.02 ======= ======= ======= ======= ======
- --------------- (1) Prices reflect impact of hedging gains and losses. (2) The Company received aggregate proceeds of approximately $35 million for the conveyance of approximately 40% of its interest in the Henderson Canyon Field in March 1993 and the sale of its Canadian assets in mid-1993. (3) The Company purchased investors' interests in the APPL Programs in 1994 and 1995 for 4.6 million shares of Common Stock and $40.1 million in cash. (4) The Company sold its interest in the Sawyer Field for $64 million in July 1995. (5) Includes $2.4 million, or $.61 per BOE, for remediation and restoration costs incurred in 1994. (6) Includes $2.0 million, or $.51 per BOE, for severance costs incurred in 1994. SUMMARY RESERVE DATA The following table sets forth summary data with respect to the estimated proved oil and gas reserves and related present value of estimated future net revenues of the Company's properties as of June 30, 1996 on a historical basis and on a pro forma basis after giving effect to the September 1996 Acquisition and the 1996 Sales. Such estimates on a historical basis are based upon (i) the quantities of reserves set forth in a reserve report prepared by Netherland, Sewell & Associates, Inc., independent petroleum engineers, as of December 31, 1995 with respect to the properties owned by the Company as of such date, (ii) adjustments to such December 31, 1995 reserves made by the Company to reflect production and drilling activity after such date, which adjustments have been audited by Netherland, Sewell & Associates, Inc. as set forth in their report dated October 8, 1996 and included in Appendix A hereto, and (iii) reserve estimates set forth in a reserve report prepared by William M. Cobb & Associates, Inc., petroleum engineering consultants, as of June 30, 1996, a copy of which is included in Appendix A hereto (the "Cobb Report"), with respect to the properties acquired in the March 1996 Acquisition. Such estimates on a pro forma basis are based on (i) the historical basis estimates as of June 30, 1996 as described above, (ii) adjustments to such June 30, 1996 estimates made by the Company to remove reserves attributable to the 1996 Sales and (iii) reserve estimates set forth in the Cobb Report with respect to the properties acquired in the September 1996 Acquisition. The estimates of the SEC-10 Value of the reserves are based upon prices as of June 30, 1996, except in those instances in which fixed and determinable gas price escalations are covered by contracts. The prices used as of June 30, 1996 averaged $18.19 per Bbl of oil and $2.25 per Mcf of natural gas. There are numerous uncertainties inherent in estimating quantities of proved oil and gas reserves and in projecting future rates of production and future net cash flows, and reserve estimates may differ significantly from the quantities of oil and gas that are ultimately recovered. See "Risk Factors -- Estimates of Reserves and Future Net Revenues" and "Business -- Reserves."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000720481_cerner_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000720481_cerner_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..e3ed4e859bab14d9fd94607eddd3056fd1c4019b
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000720481_cerner_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements, including notes thereto, appearing elsewhere in this Prospectus. Unless otherwise indicated, all financial information and share data in this Prospectus (i) have been adjusted to reflect the conversion of all outstanding shares of the Company's Series A Preferred Stock into 968,750 shares of Common Stock and all outstanding shares of the Company's Series B Preferred Stock into 3,750,000 shares of Common Stock concurrently with the consummation of this Offering, and (ii) assume no exercise of the Underwriters' over-allotment option. Investors should carefully consider the information set forth under the heading "Risk Factors." THE COMPANY Dynamic Healthcare Technologies, Inc. ("Dynamic" or the "Company") is a leading provider of enterprise-wide, patient-centered healthcare information systems. These systems enable hospitals, physician practice groups and integrated delivery networks to capture, store, archive and retrieve clinical, financial and administrative patient information. The Company's products enhance productivity, reduce costs and improve the quality of patient care by providing on-line access to patient information previously maintained on a variety of media, including paper, X-ray film, magnetic disk, and video and audio recordings. The Company's current product lines include clinical information systems for use in laboratory, radiology, anatomic pathology and anesthesiology applications, and imaging and electronic health record solutions. The Company provides support for all of its systems and provides systems integration and other consulting services. The Company currently serves over 250 customers in 44 states. Key customers include the University of California at Los Angeles Medical Center, University of Illinois at Chicago Medical Center, Methodist Hospital of Memphis, Memorial Sloan-Kettering Cancer Center, Ohio State University Hospital, Columbia/HCA, Greater Dayton Area Hospital Association, Advocate Health Care, Temple University Hospital, UniHealth and Orlando Regional Health System. Utilizing the Company's healthcare information experience, imaging technologies and customer input, the Company is focusing on a new product strategy for electronic health records. The Company's new electronic health record product, DynamicVision, provides connectivity and enabling technologies that integrate clinical and imaging information systems to create an open architecture, multi-media clinical workstation. DynamicVision provides prompt and simultaneous on-line access to information stored in various systems and data repositories located at multiple sites. This information can include documents, medical images such as X-rays, MRIs and CAT scans, and video and audio recordings. DynamicVision is currently being beta-tested and is scheduled for general availability by the end of 1996. The healthcare information industry is undergoing rapid and significant change. Cost containment pressures, industry consolidation, the movement toward managed care and rising standards of healthcare quality represent fundamental trends in today's healthcare operating environment. Increasingly, the key to effective cost control and quality management lies in the collection, availability and analysis of medical records in order to assess treatment patterns, resource utilization and outcomes. As a result, the information demands in the healthcare industry are rapidly increasing for caregivers, managers and third party payors. Total healthcare information technology spending in the United States was estimated to be $8.5 billion in 1994, and is projected to reach $13.0 billion by 1997 and $20.0 billion by 2000. The Company's new product development, including DynamicVision, employs technical designs based on open architecture at all levels of data capture, information management and workflow, application software and connectivity, which permits platform independence and plug and play capability. Dynamic's strategy to utilize open architecture leverages its own technology with capabilities of leading technology companies, enabling the Company to focus its research and development on healthcare software applications. The Company has entered into strategic relationships with several leading technology developers, including International Business Machines Corporation ("IBM"), Wang Laboratories, Inc. ("Wang") and others, to gain access to certain technologies that are integrated into the Company's systems. The Company's platform independent systems run on a variety of operating systems, including UNIX, Windows 95/NT, IBM AS/400 and other proprietary platforms. Dynamic's systems are developed using Internet/Intranet standards and protocols, are fully scaleable and preserve the customers' investment in existing systems. The Company believes its technical designs and strategic relationships enable it to respond more rapidly to changes in core technologies at a lower cost than companies utilizing proprietary information systems. The Company's objective is to be the leading provider of enterprise-wide, patient-centered healthcare information systems that enable the efficient capture, storage, archival and retrieval of electronic health information and the secure sharing of this information across the continuum of care throughout a patient's lifetime. To achieve this objective, the Company intends to employ the following strategies: (i) aggressively expand its position in the rapidly growing electronic health record market through the commercial availability of DynamicVision; (ii) focus on cross-selling additional applications and services to existing and new customers; (iii) provide solutions utilizing open architecture that offer cost-effective and flexible information solutions; (iv) maintain its technological advantage by investing in proprietary research and development for healthcare software applications while integrating state-of-the-art technology through strategic relationships with industry leading technology companies; and (v) acquire complementary businesses, products and technologies. The Company was originally incorporated in California in 1977, reincorporated in Nebraska in 1982 and subsequently reincorporated in Florida in 1996. The Company's executive offices are located at 101 Southhall Lane, Suite 210, Maitland, Florida 32751, its telephone number is (407) 875-9991 and its World Wide Web address is http://www.dht.com. THE OFFERING Common Stock Offered by the Company..................... 4,000,000 shares Common Stock Offered by the Selling Shareholders........ 1,000,000 shares Common Stock to be Outstanding after the Offering....... 15,400,536 shares(1) Use of Proceeds......................................... Repayment of indebtedness; expansion of sales, marketing and distribution; research and development; general corporate purposes, including working capital; and potential acquisitions. See "Use of Proceeds." Nasdaq Symbol........................................... DHTI
- --------------- (1) Does not include 1,908,190 shares issuable upon the exercise of outstanding options and warrants. SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) YEAR ENDED DECEMBER 31, SIX MONTHS ENDED JUNE 30, ---------------------------------------- --------------------------------- 1995 1995 1996 --------------------- ------ ------------------------ 1993 1994(1) ACTUAL PRO FORMA(2) ACTUAL ACTUAL(3) PRO FORMA(2) ------ ------- ------ ------------ ------ --------- ------------ STATEMENT OF OPERATIONS DATA: Total operating revenues... $9,688 $6,987 $8,886 $ 14,150 $4,502 $ 6,317 $7,323 Operating income (loss).... 253 (3,559) (162) (219) (503) (417) (1,537) Net earnings (loss)........ 246 (4,307) (513) (646) (706) (522) (1,632) Earnings (loss) per common share.................... $0.05 $(0.78) $(0.08) $(0.10) $(0.11) $ (0.08) $(0.25) Weighted average common shares outstanding....... 5,363 5,536 6,443 6,443 6,295 6,619 6,619
JUNE 30, 1996 ---------------------------- ACTUAL AS ADJUSTED(4) ----------- -------------- BALANCE SHEET DATA: Cash and cash equivalents........................................... $771 $ 19,950 Working capital..................................................... 122 19,301 Total assets........................................................ 11,040 30,219 Long-term obligations, net of current maturities.................... 2,922 234 Series A preferred stock............................................ 10 -- Series B preferred stock............................................ 38 -- Total shareholders' equity.......................................... 3,597 25,537
- --------------- (1) Includes the operating results and related financial information since the acquisition of Dynamic Technical Resources, Inc. on August 23, 1994, accounted for by the purchase method. (2) Gives effect to the acquisition of Dimensional Medicine, Inc. ("DMI") as if the acquisition occurred on January 1, 1995. See "Pro Forma Condensed Consolidated Statements of Operations." (3) Includes the operating results and related financial information since the acquisition of DMI on May 1, 1996, accounted for by the purchase method. (4) Adjusted to give effect to the sale of 4,000,000 shares of Common Stock offered by the Company at an assumed offering price of $6.00 per share and the application of the estimated net proceeds therefrom. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000723906_miracor_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000723906_miracor_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..6856716e822c9232f0a67e9c387347b8377b1858
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000723906_miracor_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY Unless otherwise expressly set forth herein to the contrary, all per share data in this Prospectus gives effect to the Company's 1-5 reverse stock split in September, 1981, its 1-30 reverse stock split in November, 1990, its 1-6 reverse stock split in January, 1994, and its 1-2 reverse stock split in June, 1996. In addition, unless otherwise expressly set forth herein to the contrary, all references to the Company's % Series A Cumulative Convertible Preferred Stock assumes the conversion of all 247,500 shares of the Company's Series I Convertible Preferred Stock issued in the Company's 1996 Private Placement into 247,500 shares of the Company's % Cumulative Convertible Series A Preferred Stock on a one-for-one basis on the date hereof. See "Business--Corporate History" and "The Company--Recent Financings--1996 Private Placement." THE COMPANY Medical Device Technologies, Inc. (the "Company") is a development stage company engaged in identifying, developing and bringing to market patented technologies in the medical device field. The Company's strategy is to identify technologies that it believes have commercial viability, license or acquire the technologies, complete product development, obtain regulatory clearances and initiate marketing and sales. The Company directs its efforts towards patented technologies that it believes can be commercially developed into medical devices which are innovative, represent improvements over existing products, or are responsive to a presently unfulfilled need in the market place. To date, the Company has licensed the exclusive worldwide rights to commercialize three medical devices: (1) the PERSONAL ALARM SYSTEM ("PAS"), which is designed to immediately alert healthcare professionals when their surgical gloves and garments are torn or punctured or become saturated with fluids and therefore no longer effectively provide protection from infection. The spread of the Human Immunodeficiency Virus ("HIV") that causes Acquired Immune Deficiency Syndrome ("AIDS"), and the spread of Hepatitis and other infections transmitted through bodily fluids has increased the need to protect health care workers and patients, especially in emergency and operating rooms. The Company received clearance from the Food and Drug Administration ("FDA") to sell the PAS in August of 1995, and commenced manufacturing and marketing the PAS in January of 1996; (2) the CELL RECOVERY SYSTEM ("CRS"), which is an automated biopsy brush system that collects specimen cells for cancer diagnosis, offers two distinct advantages over current techniques: it is minimally invasive and is less costly to administer. On March 20, 1996, the Company received clearance from the FDA to market the CRS for the urology market. The Company intends to launch the CRS in the fourth quarter of 1996. Prior to the market launch of the CRS, the Company intends to complete certain clinical trials for a follow-up submission to the FDA to establish that the device assists with the detection of certain urological diseases, such as bladder cancer, and at the same time commence manufacturing for the system's instrumentation and disposables; and (3) the INTRACRANIAL PRESSURE MONITORING SYSTEM ("ICP"), which is a diagnostic device that monitors pressure inside the human skull without having to drill holes in the skull. Presently, the only method by which intracranial pressure can be monitored is to drill a hole in the skull. The Company's development strategy for the ICP involves two specific versions of the device. The first generation ICP device will monitor the direction and rate of change in intracranial pressure. The second generation of the ICP will provide categories of intracranial pressure levels as well. It is presently anticipated that clinical trials for the first generation ICP device will continue through the third quarter of 1996 and clinical trials for the second generation of the device will continue through the third quarter of 1997. The Company believes there exists non-overlapping markets for each generation of the device. At present, the Company does not intend to engage in the manufacture of its products, and in January 1996, it engaged a third party to manufacture the first PAS systems. The Company is currently exploring two strategies in connection with the marketing of its medical devices. The Company will either assemble a network of independent distributors who have proven to be effective in introducing new products in the medical device field, or form an alliance with a strategic corporate partner with a strong presence in the applicable medical device market. The Company was incorporated on February 6, 1980 under the laws of the State of Utah and is located at 9171 Towne Centre Drive, Suite 355, San Diego, California 92122, telephone number (619) 455-7127. 2
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000726712_sulcus_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000726712_sulcus_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..46f721c2bf6e793f27ddfc394aa319e5f1575875
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000726712_sulcus_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS CONTAINED ELSEWHERE IN THIS PROSPECTUS. INVESTORS SHOULD CAREFULLY CONSIDER THE INFORMATION SET FORTH UNDER THE HEADING "RISK FACTORS." EXCEPT AS OTHERWISE SPECIFIED, THE INFORMATION CONTAINED IN THIS PROSPECTUS ASSUMES THAT (I) THE PREFERRED STOCK HAS NOT BEEN CONVERTED INTO SHARES OF COMMON STOCK, (II) THE WARRANTS HAVE NOT BEEN EXERCISED, AND (III) THE OVER-ALLOTMENT OPTION AND THE UNDERWRITER'S WARRANTS HAVE NOT BEEN EXERCISED. SEE "UNDERWRITING." THE COMPANY Sulcus provides automation solutions to the worldwide hospitality and tourism market and to the domestic U.S. real estate industry and legal professions. The Company develops, manufactures, markets and installs integrated microcomputer systems designed to automate the creation, handling, storage and retrieval of information and documents. The Company sells computer systems, which include a network of hardware, software and cabling as well as stand-alone turnkey systems. Sulcus sells 24-hour customer support to the hospitality industry and regular business hour support to the real estate industry and the legal profession with each new system sold. This provides a recurring revenue stream beyond the original system sale. The Company's turnkey computer systems provide all of a customers needs to automate segments of its business. Sulcus believes that this approach is critical in the vertical markets in which it competes. Some competitors can automate a specific task, most are unable to automate as broad a range of a customer's business applications as Sulcus. Customers include hotels, motels, restaurants, resorts, cruise lines, country clubs, condominiums, real estate related businesses and law offices. In 1988, the Company conceived a vision to build a leadership position in turnkey computer systems for the hospitality, and real-estate industries and developed a strategic plan to achieve that vision. The strategic plan envisioned internal growth by way of expanded research and development, as well as growth through acquisitions, mergers, joint ventures and similar alliances. In order to fulfill that vision, the Company has made numerous acquisitions, alliances and joint ventures which created additional market opportunities for existing products, created or obtained products that complement or expand existing product lines, and created additional product distribution channels. The Company has assembled a comprehensive product line that includes approximately 800 programs contained in 55 business applications with over 255 interfaces for automatic integration with third party software or hardware systems. Sulcus has built a worldwide distribution system with over 80 locations in over 20 countries and has installed its systems on all continents except Antarctica. See "Business--Historical Development." The Company was incorporated under the laws of the Commonwealth of Pennsylvania on November 5, 1979, under the name "Ragtronics, Inc." and adopted its present name in December 1982. The principal offices of Sulcus are located at Sulcus Centre, 41 N. Main Street, Greensburg, Pennsylvania 15601. Its telephone number at such address is (412) 836-2000. Unless the context indicates otherwise, all references herein to the Company or Sulcus refer to Sulcus Computer Corporation and its wholly owned subsidiaries. PROSPECTUS SUBJECT TO COMPLETION DATED OCTOBER , 1996 SULCUS COMPUTER CORPORATION 200,000 Units Each Unit Consisting of One Share of Preferred Stock and Four Class A Warrants Sulcus Computer Corporation, a Pennsylvania corporation (the" Company" or "Sulcus") hereby offers for sale 200,000 Units (the "Unit"). Each Unit consists of one share of the Company's Series A Redeemable Convertible Preferred Stock, no par value per share, (the "Preferred Stock") and four Class A Warrant (the "Warrants") to purchase Preferred Stock. The shares of Preferred Stock and Warrants included in each Unit will be immediately detachable and separately transferrable. Each share of Preferred Stock may be converted into_____________ shares of Common Stock, no par value per share, of the Company (the "Common Stock") commencing on__________________ , 1997, (six months from the date of this Prospectus). The Preferred Stock is redeemable by the Company any time commencing_________________ , 1997, (15 months from the date of this Prospectus), upon not less than thirty (30) days' notice, at a price of $_________ per share. Two Warrants will entitle the registered holder thereof to purchase one share of Preferred Stock at a price of $__________ if exercised on or before_______________ , 1996, (75 days from the date of this Prospectus). Thereafter, four Warrants shall entitle the registered holder thereof to purchase one share of Preferred Stock at a price of $_____________ , if exercised on or before______________ , 1997, (one year from the date of this Prospectus), the Warrant expiration date. See "Description of Securities" and "Risk Factors." Prior to this Offering, there has been no public market for the Preferred Stock or the Warrants and there can be no assurance that such a market will develop after the completion of this Offering or, if developed, that it will be sustained. It is currently estimated that the initial public offering price will be between $10.00 and $11.00 per Unit. For information regarding the factors considered in determining the initial public offering price of the Units and the terms of the Preferred Stock and Warrants, see "Risk Factors," "Underwriting" and "Description of Securities." The Common Stock of the Company is traded on the American Stock Exchange ("AMEX") under the symbol SUL. The closing price for the Common Stock 21/4 on October 21, 1996. See "Price Range of Common Stock." It is anticipated that the Preferred Stock and Class A Warrants will be traded on the AMEX under the symbols SULP and SULW, respectively. THE SECURITIES OFFERED HEREBY INVOLVE A HIGH DEGREE OF RISK AND IMMEDIATE SUBSTANTIAL DILUTION. SEE "RISK FACTORS" LOCATED ON PAGE 7 AND "DILUTION." THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION NOR HAS THE COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION OF THE CONTRARY IS A CRIMINAL OFFENSE. Price Underwriting Proceeds to Public Discounts(1) to Company(2) Per Unit . . . . . . . . . . . . . . . . $ $ $ Total(3) . . . . . . . . . . . . . . . $ $ $
(Footnotes appear on inside front cover.) The Units are offered by the Underwriter on a "firm commitment" basis, when as and if delivered to and accepted by the Underwriter, and subject to the right of the Underwriter to reject any order in whole or in part and to certain other conditions. It is expected that delivery of certificates representing the Preferred Stock and Warrants comprising the Units will be made at the offices of Joseph Stevens & Company, L.P., 33 Maiden Lane, New York, NY 10038 on or about ____________ , 1996. Joseph Stevens & Company, L.P. The date of this Prospectus is_____________ , 1996 INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE. THE OFFERING Securities Offered: 200,000 Units, each Unit consisting of one share of Series A Redeemable Convertible Preferred Stock ("Preferred Stock") and four Class A Warrants. Offering Price: $ 10.50 per Unit Terms of Preferred Stock: Conversion Rights. Unless previously redeemed (see below), each share of Preferred Stock is convertible into ______________shares of Common Stock, subject to adjustment in certain events, at any time after six months from the date of issuance. No fractional shares will be issued, nor will cash in lieu thereof be paid. Redemption. The Preferred Stock may be redeemed by the Company upon payment of $___________ per share at any time on or after 15 months from the date of this Prospectus, upon 30 days' prior written notice. Dividends. Payable only to the same extent as dividends are paid on the Common Stock. Liquidation Preference. In the event of any liquidation of the Company, holders of Preferred Stock are entitled to a liquidation preference of $___________ per share (the public offering price). Voting Rights. Non-voting, except with respect to matters that alter or change the powers, preferences and rights of the Preferred Stock. Terms of Class A Warrants: During the 75 day period commencing on the date of this Prospectus, two Class A Warrants entitle the holder to purchase one share of Preferred Stock for $__________. Thereafter, and prior to____________ , 1997, (one year from the date of this Prospectus), the Class A Warrant expiration date, four Class A Warrants entitle the holder to purchase one share of Preferred Stock for $____________. Warrantholders will only be entitled to exercise Class A Warrants to purchase whole shares of the Company's Preferred Stock. Common Stock Outstanding and to be Outstanding after Offering: 15,359,625 shares of Common Stock(1) Preferred Stock to be Outstanding After Offering: 200,000 shares of Preferred Stock(2) Warrants Outstanding After the Offering: 800,000 Class A Warrants Use of Proceeds: The net proceeds of the Offering will be used for working capital and general corporate purposes. Risk Factors: The Offering involves certain risks. See "Risk Factors." AMEX Symbol: Common Stock SUL Proposed AMEX Symbols: Preferred Stock SULP Class A Warrants SULW (1) Does not include (i) 2,678,631 shares reserved for issuance under the Company's stock option plans for employees; (ii) 605,000 shares reserved for issuance upon exercise of options granted to directors, consultants and advisors; (iii) 64,500 shares reserved for issuance under various "earn out" provisions in connection with recent acquisitions; (iv)____________ shares reserved for issuance upon conversion of the Preferred Stock and the conversion of the Preferred Stock issuable to the Underwriter upon exercise of the Underwriter's Warrant; and (v) 327,726 shares of Common Stock issued in connection with "earn out" provisions to the former shareholders of JBA and subsequently cancelled by the Company. See "Business--Historical Development-JBA," "The Company," "Management--Stock Option Plan," "Description of Securities," and Note 15 of Notes to Consolidated Financial Statements. (2) Does not include shares reserved for issuance upon the exercise of the Class A Warrants and the exercise of the Class A Warrants issuable to the Underwriter upon the exercise of the Underwriter's Warrant.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000737755_metromail_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000737755_metromail_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..c7a3b1b49b98dc30e7f07603209ccca0042d61b1
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000737755_metromail_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and the financial statements and pro forma information (and the notes related thereto) included elsewhere in this Prospectus. Unless otherwise indicated, all information in this Prospectus assumes no exercise of the U.S. Underwriters' over-allotment option. See "Underwriters." THE COMPANY Metromail Corporation ("Metromail" or the "Company") is a leading provider of marketing-oriented consumer information and reference services which it supplies to a wide variety of organizations engaged in direct mail, telephone and target marketing, as well as to clients who need specific reference and information services. In providing these information services, Metromail utilizes its proprietary database, which it believes is one of the most comprehensive and accurate databases in the United States, containing geographic, demographic and other marketing information on over 143 million individuals and over 90% of the households in the United States. The Company has assembled this database over almost 50 years from a wide variety of publicly available and proprietary, third-party sources and acquired databases. The markets in which the Company participates are experiencing increasing demand for high-quality consumer information. In 1995, Metromail generated net sales and earnings from operations of $237.2 million and $30.6 million, respectively. The Company offers two general categories of products and services: direct marketing services and reference services. To its direct marketing clients the Company provides: (i) targeted lists of potential customers; (ii) value-added enhancements of pre-existing customer lists; (iii) processing and mail services; and (iv) proprietary marketing database software for personal computers used to access marketing data from a client's customer database. The Company's reference services include: (1) a National Directory Assistance ("NDA") database for on-line or operator-assistance providers; (2) an on-line look-up/skip-locate service for collection agencies, consumer finance companies and credit card issuers; and (3) the Cole directories, which list households in sequence, by telephone number or address, in approximately 150 markets in the United States and Canada, delivered in printed form or on CD-ROM. Metromail's innovative marketing and distribution programs are important elements of the Company's success to date. Metromail uses a multi-channel distribution strategy to target a broad base of potential clients. The Company has its own sales force, which the Company believes to be the largest direct sales force in its industry, to call primarily on large national accounts. The Company also sells its products and services through direct mail, telemarketing and sales through third-party resellers such as advertising agencies and list brokers. In addition, the Company has invested in the development of sophisticated database marketing software applications which enable clients to create and manage their own databases as well as gain more efficient access to the data available through Metromail's proprietary database. Metromail is consolidating all of its existing databases into a single universal file through an advanced technology initiative. The Company believes that this consolidation will enable it to reduce the costs and time of updating its database and accelerate the speed at which information can be retrieved from the database. Metromail expects to benefit from continued growth in its markets resulting from the ongoing shift from "mass" marketing to "information-driven" targeted marketing, increased access to data and growth in several existing end markets and industries, as well as the emergence of new end markets. The Company believes that its competitive strengths will enable it to continue to compete effectively in its markets. These strengths include the Company's (i) comprehensive proprietary database and expertise in gathering data; (ii) ability to leverage its database into a wide range of information products and services; (iii) large base of established clients and comprehensive, multi- channel sales network; (iv) advanced technological capabilities in database management and software development; and (v) experienced management team and employees. The Company's principal strategy is to capitalize on its competitive strengths to provide high value-added information and information services to an expanding universe of clients. Key elements of the Company's strategy include: . Maintaining, integrating and expanding its proprietary database; . Developing new products and services and targeting new markets; . Developing technologies to analyze, package and distribute information more efficiently; and . Selectively acquiring data, distribution channels and businesses available as a result of ongoing consolidation in the industry. R. R. Donnelley & Sons Company ("R.R. Donnelley") is currently the sole stockholder of the Company and upon completion of the Offering will own approximately 41.7% of the outstanding Common Stock (approximately 38.4% if the over-allotment option granted by the Company to the U.S. Underwriters is exercised in full). While R.R. Donnelley in the future may reduce its ownership interest in the Company, R.R. Donnelley has advised the Company that it has no plans to do so. In connection with the Offering, R.R. Donnelley has agreed not to offer, pledge, sell or otherwise dispose of, directly or indirectly, any shares of Common Stock (or any security convertible into or exercisable or exchangeable for Common Stock) for a period of 180 days after the date of this Prospectus without the prior written consent of Morgan Stanley & Co. Incorporated. See "Relationship with R.R. Donnelley" and "Underwriters." THE OFFERING Common Stock offered by the Company: U.S. Offering.......................... 9,600,000 shares International Offering................. 2,400,000 shares Total................................ 12,000,000 shares Common Stock to be outstanding immediately after the Offering.......... 20,600,000 shares(1) Use of Proceeds.......................... The net proceeds to the Company from the Offering are estimated to be ap- proximately $219.6 million ($252.8 million if the U.S. Underwriters ex- ercise their overallotment option in full) (assuming an initial public of- fering price of $19.50 per share, af- ter deducting estimated underwriting discounts and offering expenses pay- able by the Company). The net pro- ceeds from the Offering together with, to the extent necessary, borrowings under a bank credit facil- ity to be entered into by the Company prior to consummation of the Offering will be used to repay the debt and advances owed to R.R. Donnelley and its subsidiaries, which as of March 31, 1996 totalled approximately $249.5 million. See "Use of Proceeds." NYSE Symbol.............................. ML
- -------- (1) Excludes 1,600,000 shares of Common Stock reserved for issuance under the Company's 1996 Stock Incentive Plan and 1996 Broad-Based Employee Stock Plan, including 34,000 shares of restricted Common Stock and options to purchase approximately 1,300,000 shares of Common Stock (at the initial public offering price set forth on the cover page of this Prospectus) that the Company expects to grant to employees in connection with the Offering. See "Management--Stock Plans," "Management--Employment Agreements" and Notes to Consolidated and Combined Financial Statements of Metromail. SUMMARY CONSOLIDATED AND COMBINED FINANCIAL AND OTHER DATA The following table summarizes selected historical consolidated and combined financial and other data of the Company. Statement of operations data for each of the three years in the period ended December 31, 1995 have been derived from the audited consolidated and combined financial statements of the Company contained herein. Statement of operations data for the three month periods ended March 31, 1995 and 1996, respectively, and balance sheet data as of March 31, 1996 have been derived from the unaudited consolidated and combined financial statements of the Company contained herein. Statement of operations data for each of the two years in the period ended December 31, 1992 and other data are derived from unaudited information. The information set forth below should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Unaudited Pro Forma Financial Information" and Consolidated and Combined Financial Statements of Metromail and notes thereto included elsewhere in this Prospectus. THREE MONTHS YEAR ENDED DECEMBER 31, ENDED MARCH 31, ----------------------------------------------- ---------------- 1991 1992 1993 1994(1) 1995(1) 1995 1996 -------- -------- -------- -------- -------- ------- ------- (IN THOUSANDS) STATEMENT OF OPERATIONS DATA: Direct marketing sales................. $114,871 $120,364 $127,683 $156,806 $189,713 $38,860 $41,894 Reference sales........ 30,394 33,317 36,032 38,665 47,474 10,972 12,475 -------- -------- -------- -------- -------- ------- ------- Total net sales...... 145,265 153,681 163,715 195,471 237,187 49,832 54,369 Database and production costs...... 88,945 86,184 95,016 108,806 134,361 30,279 33,606 Amortization of goodwill.............. 6,054 6,054 6,054 6,608 7,446 1,790 1,889 Selling expenses....... 26,211 26,252 29,625 37,107 45,913 10,345 11,821 General and administrative expenses.............. 15,919 13,232 12,372 14,408 16,645 3,898 4,909 Provisions for doubtful accounts..... 1,584 1,798 1,959 1,848 2,180 425 419 -------- -------- -------- -------- -------- ------- ------- Earnings from operations.......... 6,552 20,161 18,689 26,694 30,642 3,095 1,725 Interest expense-- related party......... 22,898 21,337 22,112 18,999 21,329 4,968 5,345 Interest expense....... -- -- -- -- 80 -- 60 Other expense (income)--net......... (120) (57) (138) 24 (87) (10) (5) -------- -------- -------- -------- -------- ------- ------- Earnings (loss) before income taxes. (16,226) (1,119) (3,285) 7,671 9,320 (1,863) (3,675) Income taxes........... (4,069) 2,034 1,181 5,684 6,585 (130) (788) -------- -------- -------- -------- -------- ------- ------- Net income (loss) from operations before cumulative effect of accounting change.............. (12,157) (3,153) (4,466) 1,987 2,735 (1,733) (2,887) Cumulative after-tax effect of change in accounting for post retirement benefits other than pensions... -- -- 4,388 -- -- -- -- -------- -------- -------- -------- -------- ------- ------- Net income (loss).... $(12,157) $ (3,153) $ (8,854) $ 1,987 $ 2,735 $(1,733) $(2,887) ======== ======== ======== ======== ======== ======= =======
AS OF MARCH 31, 1996 ----------------------- ACTUAL AS ADJUSTED(2) -------- -------------- (IN THOUSANDS) BALANCE SHEET DATA: Total assets.......................................... $375,678 $375,678 Total debt............................................ 253,290 34,222 Total shareholders' equity............................ 82,603 302,233
THREE MONTHS YEAR ENDED DECEMBER 31, ENDED MARCH 31, --------------------------------------- --------------- 1991 1992 1993 1994(1) 1995(1) 1995 1996 ------- ------- ------- ------- ------- ------- ------- (IN THOUSANDS, EXCEPT WHERE NOTED) OTHER DATA (FOR OR AT END OF PERIODS): Capital expenditures... $ 7,699 $ 3,117 $13,426 $ 9,940 $28,459 $ 6,877 $ 7,860 Depreciation and amortization.......... 12,780 11,596 13,143 14,781 20,851 4,774 5,437 Computer processing capacity (in MIPS).... 112 123 185 280 396 280 396 Number of individuals in database........... 132,839 130,122 138,709 146,276 146,579 143,156 143,770 Number of households in database.............. 92,268 92,362 92,859 95,130 94,958 95,465 95,770
- -------- (1) In 1994, the Company purchased Customer Insight Company for approximately $20.0 million. In 1995, an affiliate of R.R. Donnelley acquired International Communication & Data Plc for approximately $15.3 million. See Notes 1 and 14 of Notes to Consolidated and Combined Financial Statements of Metromail. (2) Adjusted to give effect to the Offering being consummated and the assumed net proceeds of the Offering together with, to the extent necessary, borrowings under a bank credit facility to be entered into by the Company prior to consummation of the Offering being applied, as of March 31, 1996, to the repayment of the debt and advances due to R.R. Donnelley and its subsidiaries. See "Use of Proceeds." SUMMARY UNAUDITED PRO FORMA CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS The unaudited pro forma consolidated and combined statements of operations for the year ended December 31, 1995 and the three months ended March 31, 1996 set forth below illustrate: (i) the effects of the historical estimated results of operations (under the Company's accounting policies) of International Communication & Data Plc ("ICD") for the period from January 1, 1995 to April 30, 1995, the date on which ICD was acquired by an affiliate of the Company; (ii) the estimated net operating effects resulting from the Company being a public entity, which include pricing of certain services the Company will provide to and receive from R.R. Donnelley after the Offering under certain intercompany agreements, as well as other incremental public company expenses; and (iii) the Offering being consummated and the assumed net proceeds therefrom together with, to the extent necessary, borrowings under a bank credit facility to be entered into by the Company prior to consummation of the Offering being used to repay the debt and advances owed to R.R. Donnelley and its subsidiaries at January 1, 1995, resulting in (a) the elimination of interest expense associated with the debt and advances owed to R.R. Donnelley and its subsidiaries and (b) additional interest expense related to borrowings under such bank credit facility described in clause (a) and to finance operating and investing activities in 1995 and in the first three months of 1996. The pro forma adjustments are based on available information and upon certain assumptions the Company believes are reasonable. The pro forma statements of operations do not purport to represent what the Company's results of operations would actually have been or to project the Company's results of operations for any future period. THREE MONTHS YEAR ENDED ENDED DECEMBER 31, 1995 MARCH 31, 1996 ------------------ ---------------- AS AS ACTUAL ADJUSTED(1) ACTUAL ADJUSTED(1) -------- -------- ------- ------- (IN THOUSANDS, EXCEPT PER SHARE DATA) Direct marketing sales.............. $189,713 $194,768 $41,894 $41,894 Reference sales..................... 47,474 47,474 12,475 12,475 -------- -------- ------- ------- Total net sales.................... 237,187 242,242 54,369 54,369 Database and production costs (2)... 134,361 135,197 33,606 33,431 Amortization of goodwill............ 7,446 7,571 1,889 1,889 Selling expenses (2)................ 45,913 47,407 11,821 11,946 General and administrative expenses (2)................................ 16,645 20,183 4,909 5,409 Provisions for doubtful accounts.... 2,180 2,281 419 419 -------- -------- ------- ------- Earnings (loss) from operations.... 30,642 29,603 1,725 1,275 Interest expense--related party..... 21,329 -- 5,345 -- Interest expense.................... 80 814 60 456 Other expense (income)--net......... (87) (87) (5) (5) -------- -------- ------- ------- Earnings (loss) before income taxes............................. 9,320 28,876 (3,675) 824 Income taxes........................ 6,585 14,485 (788) 1,030 -------- -------- ------- ------- Net income (loss).................. $ 2,735 $ 14,391 $(2,887) $ (205) ======== ======== ======= ======= Pro forma net income (loss) per share (3)......................... $ .70 $ (.01) ======== =======
- -------- (1) For a detailed description of the adjustments to these unaudited pro forma consolidated and combined statements of operations, see "Unaudited Pro Forma Financial Information."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000740622_microenerg_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000740622_microenerg_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..1a244bd200bb15837ee8d7fa276ee4be2b2187cc
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000740622_microenerg_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY This summary is qualified in its entirety by the more detailed information, financial statements and notes thereto appearing elsewhere in this Prospectus. All references herein to a number of shares of Common Stock have been adjusted to reflect the 1-for-360 reverse stock split of the Company's Common Stock on May 13, 1996. THE COMPANY MicroENERGY, Inc. ("MicroENERGY" or the "Company") has been engaged since 1984 in the business of designing and manufacturing high-frequency power supplies and DC-to-DC converters for original equipment manufacturers ("OEMs") who are engaged in the telecommunications, computer, and instrumentation segments of the electronics industry. Each of the Company's products is custom designed to meet the specific needs of a customer within a power output range of 25 watts to 2500 watts. During the Company's eleven years of operations, the Company has acquired a reputation in the marketplace for making timely deliveries of high-quality power supplies which incorporate state-of-the-art engineering. In recent years, however, the Company's growth has been stagnant, as the Company's ability to attract new customers has been hampered by the Company's high debt-to-assets ratio, which has caused some potential customers to question the Company's financial stability. Since a typical customer order anticipates deliveries over an extended period of time--often years--to meet the customer's manufacturing schedule, OEM customers avoid any supplier whose ability to deliver over the long term is in doubt. Thus, despite eleven years of timely deliveries, customer doubts about MicroENERGY's financial stability continue to hinder sales growth. During the second and third quarters of fiscal 1996, two events occurred which indicate that the Company may now enter a period of significant growth. First, the Company received pre-production orders for new product designs from eight OEM customers. While none of these orders create binding obligations on the customers, the Company expects to receive production orders from each. If all eight customers give the Company the production orders they have quoted, the eight new products will represent $10.2 Million in annual sales beginning in July, 1996. See "BUSINESS OF THE COMPANY--Marketing." The second favorable recent event was the agreement of AT&T Global Information Systems, which was the holder of $2.33 Million of the Company's long-term debt, to accept an immediate payment of $1.33 Million in satisfaction of the debt. The Company was able to effectuate that debt compromise by raising approximately $1.0 Million in debt financing and $330,000 in equity financing from the officers of the Company and the Selling Securityholders. In exchange for payment of these sums to AT&T, AT&T forgave the remaining $1 Million of the debt. See "CAPITALIZATION--Debt Compromise." The effect of the debt compromise and related financing was to reduce the Company's total debt by $1.34 Million, reduce the Company's debt-to-assets ratio from .88-to-1 as of December 31, 1995 to .68-to-1, and increase the Company's net worth by $1.3 Million, resulting in a positive shareholders equity for the first time in several years. The Company intends to use the net proceeds of this offering to finance the expansion of operations necessitated by the expected new orders and to repay some of its debt. See "USE OF PROCEEDS." Management believes that the financial improvements brought about by this offering and the anticipated sales it will finance will enable the Company to compete more effectively and facilitate a period of growth. CROSS-REFERENCE SHEET Pursuant to Item 501(b) Form S-1 Item Number and Heading Prospectus Heading - -------------------------------- ------------------ 1. Forepart of the Registration State- Front Cover of Prospec- ment and Outside Front Cover Page of tus Prospectus 2. Inside Front and Outside Back Cover Inside Front and Outside Pages of Prospectus Back Cover of Prospectus 3. Summary Information, Risk Factors, Prospectus Summary, Risk Ratio of Earnings to Fixed Charges Factors 4. Use of Proceeds Use of Proceeds 5. Determination of Offering Price Underwriting 6. Dilution Not Applicable 7. Selling Security Holders Selling Securityholders 8. Plan of Distribution Underwriting 9. Description of the Securities to be Description of the Registered Company's Securities 10. Interest of Named Experts and Counsel Legal Matters; Experts 11(a) Description of Business Business of the Company 11(b) Description of Property Business of the Company 11(c) Legal Proceedings Not Applicable 11(d) Market Price, Dividends Price Range of Common Stock, Dividends 11(e) Financial Statements Financial Statements 11(f) Selected Financial Data Selected Financial Infor- mation 11(g) Supplementary Financial Information Not Applicable 11(h) Management's Discussion Management's Discussion 11(i) Changes in and Disagreements With Accountants Not Applicable 11(j) Directors and Executive Officers Management 11(k) Executive Compensation Management 11(l) Security Ownership Principal Shareholders 11(m) Certain Relationships and Related Transactions Certain Transactions 12 Disclosure of Commission Position on Indemnification Underwriting The Company's executive offices are located at 350 Randy Road, Carol Stream, Illinois. Telephone: 708-653-5900. Capitalization............ Currently Outstanding: Common Stock: 415,143 shares; Series A Preferred Stock: 350,000 shares THE OFFERING BY THE COMPANY Securities Offered........ 494,500 shares of Series A Preferred Stock, $7.00 par value and 247,250 Class A Warrants. The Securities may be purchased separately and will be separately transferable immediately upon issuance. See "DESCRIPTION OF SECURITIES." Representative's Compensation............. I.A. Rabinowitz & Co. (the "Representative") will receive as compensation for its services in this offering a 10% discount on the purchase price of the Securities, a 3% non-accountable expense allowance and an option to purchase Securities equal to ten percent of the Securities sold in this offering. As part of the underwriting arrangements, the Company will enter into an agreement retaining the Representative as a financial consultant to the Company for a two-year period commencing as of the close of the sale of the securities offered hereby at an annual fee of $24,000, for a total of $48,000 payable in full at the closing of the Offering, and will pay an investment banking fee with respect to any transaction introduced and consummated, and a 4% warrant solicitation fee. See: "UNDERWRITING." PREFERRED STOCK Payment of Dividends...... Dividends are cumulative from the date of issue of shares of Preferred Stock and are payable semi- annually at a rate of 8% per annum. The Company may, at its sole discretion, pay each dividend either in cash or in shares of Common Stock valued at the average closing bid price for the ten days preceding the record date for the dividend or in a combination of cash and Common Stock. In addition, if the Company pays any dividend with respect to a share of its Common Stock, it will pay twice that amount as an additional dividend on each share of Preferred Stock. See "RISK FACTORS--Restrictions on Payment of Dividends." Tax Consequences of Dividends................ To the extent that Common Stock is distributed as dividends on the Preferred Stock, the amount distributed for federal income tax purposes (and consequently, subject to certain exceptions, the amount of dividend income) to the holder of the Preferred Stock would equal the fair market value of such Common Stock on the date of distribution and, accordingly, may be greater or less than the value of the dividend as calculated in the preceding section. See "RISK FACTORS--Income Tax Considerations--Distribution of Common Stock as Dividends" and "CERTAIN FEDERAL INCOME TAX CONSIDERATIONS TO INVESTORS." Redemption................ The Preferred Stock is not redeemable. Conversion................ The Preferred Stock is not convertible into any other security. Liquidation Preference.... Upon any liquidation, before distribution is made to the holders of Common Stock, holders of the Preferred Stock will be entitled to receive $7.00 per share, plus accrued and unpaid dividends to the date of distribution. Holders of the Preferred Stock will then participate with the holders of the Common Stock in the Company's net assets on a 2-to- 1 basis, such that each share of Preferred Stock will receive twice as much of the net assets as each share of Common Stock. Voting.................... The holders of Preferred Stock will be entitled to one vote per share at any meeting of the Company's shareholders. WARRANTS Terms of Class A Warrants................. Each Class A Warrant entitles the holder to purchase one share of the Company's Series A Preferred Stock at a price of $7.00, subject to adjustment, during the three year period beginning one year after the date of this Prospectus. After , 1997, the Class A Warrants are subject to redemption by the Company at any time during the exercise period on not less than 30 days' notice at $.01 per Warrant provided the average closing price of the Preferred Stock exceeds $9.00 per share for 5 consecutive trading days ending within 15 days prior to the notice. Proposed NASDAQ SmallCap Preferred Stock--MICRP; Class A Warrants--MICRW Market Symbols: Risk Factors.............. The securities are subject to a high degree of risk. See: "RISK FACTORS." SELECTED FINANCIAL INFORMATION NINE MONTHS ENDED MARCH 31 ----------------------- 1996 1995 ----------- ----------- INCOME DATA: Revenues.............................................. $10,718,611 $10,996,535 Operating Income...................................... 392,630 395,125 Net Income............................................ 1,151,869 146,170 Net Income Per Share.................................. $ 3.29 $ .46
YEARS ENDED JUNE 30 ----------------------------------- 1995 1994 1993 ----------- ----------- ----------- INCOME DATA: Revenues.................................. $14,588,844 $12,771,067 $15,886,279 Operating Income.......................... 581,685 426,419 433,280 Net Income................................ 249,894 204,845 40,806 Net Income Per Share...................... $ .79 $ .65 $ .14
AS ADJUSTED TO REFLECT: ----------------------------------- --- AT MAR. 31, 1996(1) PUBLIC OFFERING ------------------- --------------- BALANCE SHEET DATA: Working Capital/(Deficit) ........... $ (623,869)(2) $ 2,213,733(2) Total Assets......................... 7,243,714 10,081,316 Long-Term Debt, Net.................. 969,514 969,514 Stockholders Equity.................. 543,389 3,380,991
- -------- (1) Reflects the effect of $1 Million reduction in debt to AT&T and related financing transactions from January through March of 1996. See "CAPITALIZATION--Debt Compromise."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000742246_matewan_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000742246_matewan_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..f87431da06aa9317176eda89d69829bdadebe1a4
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000742246_matewan_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is not intended to be complete and is qualified in its entirety by the more detailed information and the consolidated financial statements and the related notes thereto appearing elsewhere in this Prospectus. All per share data of Matewan included in this Prospectus have been restated to reflect a 300% stock dividend paid in May 1993, a 300% stock dividend paid in May 1994 and a 10% stock dividend paid by Matewan in June 1995. Unless otherwise specified in this Prospectus, the term "Offering" as used herein refers to the Company's Offering of 600,000 shares of Convertible Preferred Stock at $25.00 per share, and does not include the exercise of the Underwriter's over-allotment option. MATEWAN BANCSHARES, INC. Matewan, a bank holding company headquartered in Williamson, West Virginia, provides through the Bank, organized in 1913, and the Thrift, organized in 1994, a broad range of financial services. Matewan has 13 offices located in southwestern West Virginia and eastern Kentucky. At September 30, 1995, Matewan had total assets of $389.5 million, total deposits of $324.0 million and total shareholders' equity of $44.5 million. Matewan ranked third in its Market based on total deposits. Matewan's strategy is to become the leading provider of financial services in its Market by offering customers innovative products through convenient delivery systems and a well-trained, sales-oriented work force. Management believes that effective employment of technology in providing financial services, coupled with a commitment to customer service, affords Matewan with a distinct competitive advantage in its Market. In implementing its strategy, management emphasizes the following: . Technology to enhance products and delivery systems. The Company uses sophisticated technology to enhance its delivery systems. Matewan offers its retail customers 24-hour banking by touch-tone phone by means of an interactive voice response system, and in 1996, Matewan will offer its retail customers the ability to access account information, transfer funds and pay certain bills via personal computer. The Company currently utilizes personal computer technology to enable its commercial customers to access cash management services via interlinks with Matewan's mainframe system. The Company also maintains an integrated PC-based server network system that provides immediate interaction among all operating functions of the Banking Subsidiaries, thereby enhancing internal communication and customer service. In addition, the Company's sophisticated credit rating and pricing models enable the Banking Subsidiaries to price their loan products to reflect credit risk more accurately. . Customer service and convenience. Through extended lobby and drive-up hours, Saturday and Sunday banking hours and alternative delivery systems, Matewan offers convenient service to customers. Because the Banking Subsidiaries have integrated consumer platforms, customers of Matewan can obtain full banking services at any branch office. All but one of the 13 branch offices of the Company are open on Saturdays, and its two supermarket branches are open 363 days a year. No other bank in its Market offers comparable extended service hours. . Dedicated, sales-oriented work force. Matewan has historically devoted significant resources to training its work force and instilling a sales- oriented culture to promote customer service and market penetration. In addition to extensive orientation and training of new employees with an emphasis on the individual's job assignment, the Company also provides regular continuing education and training to all employees. To further promote customer service, the Company emphasizes performance-based compensation, as an increasing percentage of employees have their total compensation, and all employees have at least a portion of their compensation, based on incentive programs. The Company's strategy has enabled it to enjoy a compound annual asset growth rate of 16.9% over the last decade, with assets increasing from $72.8 million on December 31, 1984, to $389.5 million at September 30, 1995. The Company's utilization of technology and commitment to cost control has resulted in an average efficiency ratio of 54.20% for the five years ended December 31, 1994. The Company's returns on average assets were 1.40% and 1.28% (annualized) for the year ended December 31, 1994, and the nine months ended September 30, 1995, respectively. PENDING ACQUISITION Matewan has entered into a stock purchase agreement (the "Purchase Agreement") with Banc One, providing for Matewan's purchase of 100% of the outstanding capital stock of Pikeville, a national bank subsidiary of Banc One, for $28.6 million in cash (the "Acquisition"). Following the Acquisition, Matewan will operate Pikeville as a separate subsidiary under the name "Matewan National Bank/Kentucky." At September 30, 1995, Pikeville had total assets of $221.0 million, total deposits of $181.5 million and total shareholder's equity of $19.4 million. The proceeds of the Offering will be used to fund approximately one-half of the $28.6 million purchase price of the Acquisition. Consummation of the Acquisition is not a condition to closing of the Offering. In the event that the Acquisition is not consummated, Matewan will use the net proceeds from the Offering for general corporate purposes. See "Use of Proceeds." REASONS FOR THE ACQUISITION The following summarizes the major reasons for the Acquisition and the benefits Matewan expects will accrue to its operations from the Acquisition: . Appeal of Pikeville Market. Management views Pikeville and Pike County, Kentucky as the most attractive segments in Matewan's Market. Pikeville, Kentucky is a regional hub of economic activity and provides the area with financial, medical, legal and retail services. Pike County has the largest population of any county in its Market. . Increased Market Share. Following the Acquisition, Matewan will increase its market share of deposits from fourth to second in Pike County and from third to first in its Market. Management believes that economic growth in its Market will continue to provide a favorable climate in which to conduct Matewan's business. . Increased Operating Efficiencies. After the Acquisition, Matewan will be able to realize operating efficiencies by consolidating certain branches, combining data processing operations and leveraging the capabilities of its existing back-office support functions. Management estimates that, within one year following the Acquisition, it can realize expense savings of $1.2 million, or 15% of Pikeville's 1994 non- interest expense, which will reduce Pikeville's efficiency ratio to levels approximating Matewan's. See "Risk Factors--Integration of Pikeville" and "Management's Discussion and Analysis of Financial Condition and Results of Operations--Anticipated Operating Effect of Acquisition on Matewan." . Revenue Enhancement Opportunities. Pikeville's profitability levels are below those being realized by Matewan. The Acquisition will provide Matewan with increased revenue enhancement opportunities through expanded customer service and convenience for Pikeville's customer base. Matewan will extend its existing alternative delivery systems and extended banking hours to Pikeville's operations. The Acquisition will also permit Matewan to apply its existing training programs to Pikeville's work force to develop a sales-oriented culture to promote customer service and further Pikeville's market penetration. For a discussion of the potential risks to Matewan inherent in the Acquisition, see "Risk Factors--Negative Effect of Acquisition on Regulatory Capital" and "--Integration of Pikeville."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000745597_interlink_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000745597_interlink_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..371e189ee8e5f7094a1422805fa545791d0b8dee
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000745597_interlink_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY This Prospectus contains certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Prospective investors are cautioned that such statements are only predictions and that actual events or results may differ materially. In evaluating such statements, prospective investors should specifically consider the various factors identified in this Prospectus, including the matters set forth under the caption "Risk Factors," which would cause actual results to differ materially from those indicated by such forward-looking statements. The following summary is qualified in its entirety by the more detailed information and financial statements, including notes thereto, appearing elsewhere in this Prospectus. Certain terms used in this Prospectus are defined in the Glossary beginning on page 61. THE COMPANY Interlink Computer Sciences, Inc. ("Interlink" or the "Company") is a supplier of high-performance solutions for enterprise networked systems management. Interlink provides software and services which enable customers to use their IBM and IBM-compatible MVS mainframes as "enterprise servers" in distributed, heterogeneous client/server network environments. The Company's products and services enable customers to transport, access and manage mission- critical data and applications across distributed network environments. The Company develops and markets network transport products which provide for enterprise server TCP/IP connectivity, fault tolerance and network file transfer. Interlink also develops and markets systems management applications for network backup, archive and restore, distribution of applications, data and software, network printing and other tools which expand the functionality of the enterprise server. Many large organizations depend on centralized mainframe computer systems to manage mission-critical software applications and to serve as the repository for essential business data. Recently, advances in hardware, software and networking technologies have led to the deployment of client/server systems, in which computing tasks are distributed throughout a network of computers. Organizations are now seeking the technology to integrate mainframe computers into client/server networks as "enterprise servers" which, like other servers on the client/server network, have a specialized purpose and function. Specifically, the enterprise server and the systems management applications associated with its use are capable of providing reliable and efficient systems management, data security, and distribution of data and applications. Improvements in the cost-effectiveness of mainframe systems have significantly increased the use of mainframe computers as enterprise servers. With almost ten years of experience in the enterprise networked systems management industry, Interlink provides networking solutions that build upon its expertise in the integration of the MVS operating system with TCP/IP and its reputation for high-performance, efficient products. Interlink's objective is to become the leading supplier of high-performance solutions for enterprise networked systems management. Key elements of the Company's strategy include: supplying a suite of products that expand the functionality of the enterprise server; capitalizing on new sales and cross-selling opportunities resulting from its recent acquisition; employing a consultative sales approach to build long-term customer relationships; differentiating its networking solutions through superior customer support; and leveraging strategic marketing and development relationships in order to provide complete solutions to its customers' evolving network systems management needs. As of June 30, 1996, the Company had approximately 1,200 customers worldwide. The Company markets and sells its software and services primarily through its direct sales organization in North America and Europe and, to a lesser extent, through resellers and international distributors. The Company's major customers include, among others, the Internal Revenue Service, MACIF, U.S. Sprint, W.R. Grace & Co. and Wells Fargo Bank. The Company recently formed a strategic relationship with Legato Systems, Inc. ("Legato") to develop products which will enable the companies to provide enterprise-class storage management solutions. Pursuant to the terms of the agreement, Interlink intends to develop a new product called HARBOR Agent for Networker (Legato's client/server storage management product) which will be distributed by Legato. Interlink will be an authorized reseller of Legato's storage management products, including HARBOR Agent for Networker. On December 29, 1995, the Company acquired New Era Systems Services Ltd. ("New Era") and its HARBOR systems management product line in exchange for cash and notes payable totaling $12.4 million and warrants to purchase 350,000 shares of its Common Stock with additional contingent earnout payments totaling up to $5.2 million due January 31, 1997 and 1998. Prior to the acquisition, the Company distributed the HARBOR products in certain countries in Europe for more than one year. Interlink was incorporated under the laws of the state of California in December 1985. The Company will reincorporate in Delaware prior to the completion of this offering. Unless the context otherwise requires, references in this Prospectus to "Interlink" and the "Company" refer to Interlink Computer Sciences, Inc., a California corporation, and its Delaware successor, together with their subsidiaries. The Company's principal executive offices are located at 47370 Fremont Boulevard, Fremont, California 94538, and its telephone number is (510) 657-9800. THE OFFERING Common Stock Offered by the Company............. 2,000,000 shares Common Stock Outstanding after the Offering..... 5,811,231 shares (1) Use of Proceeds................................. For repayment of indebtedness, capital expenditures, working capital and other general corporate purposes. Nasdaq National Market symbol................... INLK
SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) PRO FORMA FOR YEAR ENDED JUNE 30, ACQUISITION (2) ---------------------------------------- --------------- YEAR ENDED 1992 1993 1994 1995 1996 JUNE 30, 1996 ------- ------- ------- ------- ------- --------------- STATEMENTS OF OPERATIONS DATA: Revenues............... $23,326 $21,185 $21,875 $27,079 $34,002 $36,491 Gross profit........... 16,995 17,119 18,065 20,470 25,995 28,197 Purchased research and development and prod- uct amortization...... -- -- -- -- 10,479 642 Operating income (loss)................ (4,935) 2,167 844 104 (6,995) 3,757 Net income (loss)...... (5,864) 2,902 1,667 1,647 (7,616) 2,765 ======= ======= ======= ======= ======= ======= Net income (loss) per share (3)............. $ (5.47) $ 1.17 $ 0.44 $ 0.34 $ (2.44) $ 0.56 ======= ======= ======= ======= ======= ======= Shares used in per share calculation (3). 1,073 2,474 3,808 4,814 3,127 4,954 ======= ======= ======= ======= ======= =======
JUNE 30, 1996 --------------------- AS ACTUAL ADJUSTED (4) ------- ------------ BALANCE SHEET DATA: Working capital (deficit)................................ $(6,371) $14,019 Total assets............................................. 25,925 41,315 Long-term debt, less current portion..................... 2,892 2,892 Total stockholders' equity (deficit)..................... (4,585) 15,805
- ------- (1) Represents shares outstanding as of June 30, 1996. Reflects the issuance of 98,320 shares of Common Stock immediately subsequent to the offering upon the net exercise of certain outstanding warrants and excludes as of June 30, 1996: (i) options outstanding to purchase up to 1,018,503 shares of Common Stock at a weighted average exercise price of $1.82 per share under the Company's 1992 Stock Option Plan; (ii) 468,750 shares of Common Stock issuable upon exercise of warrants outstanding at a weighted average exercise price of $3.23 per share; and (iii) 870,463 shares of Common Stock reserved for issuance under the Company's 1992 Stock Option Plan. See "Management--Stock Plans," "Description of Capital Stock" and Note 7 of Notes to Consolidated Financial Statements. Also excludes 350,000 shares reserved prior to June 30, 1996 and an additional 300,000 shares reserved subsequent to June 30, 1996 for issuance under the 1992 Stock Option Plan, the 1996 Director Option Plan and the 1996 Employee Stock Purchase Plan. (2) Pro forma to give effect to the Company's acquisition of New Era Systems Services Ltd. in December 1995 as if such acquisition had taken place as of July 1, 1995. See Notes 1 and 2 of Notes to Unaudited Pro Forma Combined Condensed Consolidated Financial Statements. (3) See Note 1 of Notes to Consolidated Financial Statements for a discussion of the computation of net income (loss) per share. (4) Adjusted to reflect the sale of the 2,000,000 shares of Common Stock offered by the Company hereby at an assumed initial public offering price of $11.50 per share, and after deducting underwriting discounts and commissions and the estimated expenses of the offering, and the anticipated application of the estimated net proceeds therefrom. See "Use of Proceeds" and "Capitalization." -------------- Enterprise Print Services, SNS and the Interlink logo are registered trademarks of the Company and TCPaccess, TCPaccess Fault Tolerant, Interlink 3762 Network Controller, SNS/NFS, SNS/TCPaccess, Interlink 3700 Series Network Controller, CICS Programmers Toolkit, HARBOR and the HARBOR logo are trademarks of the Company. This Prospectus also contains trademarks and tradenames of other companies. -------------- Except as otherwise indicated, all information contained in this Prospectus (i) assumes that the Underwriters' over-allotment option is not exercised, (ii) reflects an increase in the authorized shares of Common Stock to 25,000,000 shares which will occur prior to this offering, (iii) reflects the one-for-two reverse stock split of the Company's capital stock which will occur prior to this offering, (iv) gives effect to the reincorporation of the Company from California to Delaware which will occur prior to this offering, (v) reflects the conversion of all outstanding shares of Preferred Stock into 1,229,714 shares of Common Stock, which will occur automatically upon the closing of this offering, (vi) reflects the filing, upon the closing of this offering, of the Company's Restated Certificate of Incorporation authorizing 5,000,000 shares of undesignated Preferred Stock, and (vii) reflects the issuance of 98,320 shares upon the net exercise of outstanding warrants, including the reduction of an outstanding warrant to purchase 75,000 shares to 62,500 shares, which will both occur upon the closing of this offering. See "Description of Capital Stock,"
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000751968_galoob_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000751968_galoob_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..11dac6cdf3343fb8f0b3df6efd2f653b68f42193
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000751968_galoob_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by reference to, and should be read in conjunction with, the more detailed information (including the consolidated financial statements and the notes thereto) appearing elsewhere in this Prospectus. Each prospective investor is urged to read this Prospectus in its entirety and should carefully consider the matters set forth in 'Risk Factors.' Except for the historical information contained herein, the discussion in this Prospectus contains forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled 'Risk Factors' and elsewhere in this Prospectus. Unless otherwise indicated, all information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. See 'Underwriting.' THE COMPANY Founded in 1957, the Company is a leading international toy company that designs, develops, markets and sells a variety of high-quality toy products in an expanding number of product categories. The Company believes it is a leading innovator in the toy industry as evidenced by: its award-winning Sky Dancers, the world's first flying doll, introduced in late 1994; its Double Takes line of Micro Machines transforming playsets, introduced in 1995; its line of Star Wars Action Fleet toys representing a new scale in the male action category; and Dragon Flyz, the world's first fully articulated flying male action figure. The Company's Micro Machines line, introduced in 1987, is the most comprehensive line of miniature scale play for boys in the United States, embracing traditional vehicle, military and male action play patterns. The Company's Sky Dancers line has been the number-one selling mini-doll in the United States in 1995 and 1996, and Dragon Flyz became the second best selling male action assortment in the United States within weeks of its national introduction in June. The Company's 1996 product offerings consist of six product lines: Micro Machines, Star Wars Action Fleet, Dragon Flyz, Jonny Quest, Sky Dancers, and Pound Puppies. In addition to extensions of these product lines, the Company's 1997 product offerings are expected to include new product lines based on three entertainment properties: Men In Black, a new science fiction adventure comedy film scheduled to be released by Sony in the summer of 1997; Starship Troopers, a new science fiction adventure film scheduled to be released by Sony in the summer of 1997; and Anastasia, a new animated film scheduled to be released by Fox in the fall of 1997. In connection with the scheduled re-release of the Star Wars movie trilogy in early 1997, the Company plans to introduce new Star Wars Micro Machines and Action Fleet toys. In addition, the Company intends to aggressively pursue licensing rights in connection with the release of the new Star Wars movie trilogy scheduled to start in 1999. The Company's products are sold in more than 50 countries worldwide. These products are principally sold direct to retailers in the United States and to toy distributors outside of the United States. Since 1993, the Company's revenues have grown approximately 64% from approximately $134 million in 1993 to approximately $220 million in 1995. In 1995, approximately one-third of the Company's revenues were derived from international sales which have increased by approximately 77% since 1993. Although the Company's sales have increased significantly since 1993, its market share in 1995 was only approximately one percent of the total $13.4 billion U.S. wholesale toy shipments and, therefore, management believes there is substantial opportunity for continued growth. The recent consolidations among both toy companies and toy retailers have also provided increased growth opportunities for the Company. The Company believes that the consolidation of the industry into a smaller group of larger toy companies combined with the Company's proven success in developing and marketing licensed products make the Company a relatively more attractive licensee to toy inventors and other licensors. In addition, as a result of industry concentration, the Company has become a relatively more attractive supplier to retailers that do not wish to be dependent on a few dominant toy companies. Toy retailer concentration has also been advantageous to the Company as it has reduced the need to support a large, expensive sales and distribution organization to service numerous small customers. This also enables the Company to ship product, manage account relationships and track retail sales as effectively as much larger competitors. These industry trends and developments, combined with the successful implementation of the Company's growth strategy, lead the Company to believe that it is well positioned for future growth. The key elements of the Company's growth strategy are as follows: o Build The Company's Core Brand--Micro Machines. The Company seeks to continue expanding its Micro Machines brand as the most comprehensive universe of miniature scale play for boys. The Company intends to accomplish this by extending Micro Machines into additional play patterns, such as the Micro Machines Exploration line for 1997, and to continue acquiring and exploiting new entertainment licenses to keep Micro Machines at the leading edge of boys' play. o Enter New Product Categories. The Company has entered and intends to continue to enter into new toy categories. Entering 1993, the Company competed primarily in only one category of the toy industry (excluding video games)--miniature vehicles, which generated approximately $240 million of total U.S. wholesale toy shipments in that year. Currently, the Company competes in four categories that generated approximately $2.1 billion of the total U.S. wholesale toy shipments in 1995. The Company considers entering new categories which have the following characteristics: (i) low barriers to entry such that there is no dominant competitor; and (ii) potential to create product lines that can become multi-year brands based upon collectibility and thematic extendability. o Expand Profit Margins On Rising Sales. A key goal of the Company is to expand profit margins while continuing to increase sales, thereby increasing the rate of profit growth faster than the rate of sales growth. The Company seeks to increase profit margins by: (i) increasing gross margins; (ii) achieving economies of scale on increasing sales volume, thereby reducing operating expenses as a percentage of sales; and (iii) leveraging its investments in product development, tooling and marketing over the longer life spans of its multi-year brands. o Develop Strategic Alliances With Major Content Providers. Over the past three years, the Company has developed important relationships with four major entertainment companies, Lucasfilm, Fox, Sony and Turner, which have licensed to the Company the rights to make toys based on certain of their properties. The Company intends to continue to aggressively pursue opportunities to expand its relationships with these entertainment companies and to form additional alliances with other entertainment companies in order to assure access to a continuous flow of quality entertainment properties that have potential to generate successful toy product lines. o Leverage International Distribution Networks. The Company believes it has developed a strong network of distributors in its key markets outside the United States and through such network has the ability to increase its international sales. While Europe has traditionally accounted for the highest percentage of the Company's international sales, the Company continues to build its worldwide distribution network and sees the potential for growth in new markets such as Mexico and Latin America, the Pacific Rim and the Middle East. The Company, which commenced operations in 1957, was incorporated under the laws of the State of California in 1968. The Company was reincorporated in the State of Delaware in 1987 and recently changed its name to Galoob Toys, Inc. The Company's principal executive offices are located at 500 Forbes Boulevard, South San Francisco, California 94080 and its telephone number is (415) 952-1678. THE OFFERING Common Stock Offered by the Company.......................... 2,000,000 Common Stock Offered by the Selling Stockholder...................... 392,866 shares Common Stock to be Outstanding after the Offering(1)............ 17,544,435 shares NYSE Symbol for the Common Stock... GAL Use of Proceeds to the Company..... To repay indebtedness under its short-term credit facility and the mortgage on the Company's headquarters building and to provide funds necessary to support acquisition of license rights and working capital requirements for future toy products, properties and businesses.
- ------------------ (1) Excludes (i) 1,506,250 shares of Common Stock reserved for issuance upon exercise of stock options outstanding at October 31, 1996 and (ii) 75,000 shares of Common Stock reserved for issuance upon exercise of warrants outstanding at October 31, 1996. See 'Capitalization,' 'Management' and 'Description of Capital Stock.' SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) The information set forth below should be read in conjunction with 'Selected Consolidated Financial Data,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and the Company's consolidated financial statements and related notes thereto included elsewhere in this Prospectus. NINE MONTHS ENDED YEAR ENDED DECEMBER 31, SEPTEMBER 30, -------------------------------- -------------------- 1993 1994 1995 1995 1996 -------- -------- -------- -------- -------- STATEMENTS OF OPERATIONS DATA: Net revenues............................ $134,334 $178,792 $220,044 $137,078 $175,270 Gross margin............................ 59,187 83,636 99,210 53,977 82,229 Earnings (loss) from operations......... (9,215) 9,322 12,989 723 9,407 Net proceeds from Nintendo award........ -- 12,124 -- -- -- Interest expense........................ (1,836) (2,609) (3,429) (2,357) (2,665) Earnings (loss) before income taxes..... (10,915) 19,202 9,999 (1,421) 6,927 Net earnings (loss)..................... (10,924) 18,424 9,399 (1,421) 5,541 Preferred stock dividends............... 3,127 3,127 3,127 2,345 21 Charge related to exchange of preferred stock for common...................... -- -- -- -- 24,279 Net earnings (loss) applicable to common shares................................ $(14,051) $ 15,297 $ 6,272 $ (3,766) $(18,759) -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- Common shares and common share equivalents outstanding-- average..... 9,548 10,111 10,451 10,068 13,565 Net earnings (loss) per common share(1): Primary............................... $ (1.47) $ 1.51 $ 0.60 $ (0.37) $ (1.38) -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- Fully diluted......................... $ (1.47) $ 1.41 $ 0.60 $ (0.37) $ (1.38) -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
DECEMBER 31, SEPTEMBER 30, 1996 --------------- ----------------------------- 1995 ACTUAL AS ADJUSTED(2) --------------- ----------- -------------- BALANCE SHEET DATA: Working capital.......... $ 54,670 $ 56,450 $107,616 Total assets............. 120,084 164,955 167,812 Short-term debt.......... 19,493 48,309 -- Long-term debt........... 14,000 -- -- Shareholders' equity..... 54,172 72,608 123,774
- ------------------ (1) For a discussion of the impact on net earnings of certain unusual, non-recurring items, see 'Management's Discussion and Analysis of Financial Condition and Results of Operations.' (2) Adjusted to reflect the sale of 2,000,000 shares of Common Stock offered by the Company in this offering based on an assumed offering price of $26 5/8 per share, the last reported sale price of the Common Stock on November 7, 1996 (after deducting the underwriting discounts and estimated offering expenses payable by the Company), the proceeds from the exercise of warrants by the Selling Stockholder and the anticipated application of the estimated net proceeds therefrom. See 'Use of Proceeds' and 'Capitalization.'
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000753081_raster_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000753081_raster_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..1370fd77b9edf442f139363cc651e00b8fa25d1c
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000753081_raster_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and the Consolidated Financial Statements and Notes thereto appearing elsewhere in this Prospectus. THE COMPANY Raster Graphics, Inc. ("Raster Graphics" or the "Company") develops, manufactures and markets high-performance, large format color printing systems and sells related consumables for the on-demand, large format digital printing ("LFDP") market. The LFDP market consists of color print jobs with run lengths ranging from one to 200 copies and output sizes of 20-inches by 30-inches or larger. Applications include point of purchase ("POP") signs, trade show exhibit graphics, banners, billboards, courtroom graphics and backlit signage. The primary users of the Company's products are color photo labs, reprographic houses, graphic arts service bureaus, exhibit builders, digital color printers, screen printers and in-house print shops. The Company's Digital Color Station ("DCS") printing system, consisting of the DCS Printer and PosterShop system software, allows users to print short runs of high quality color graphics on demand at substantial time and cost savings relative to traditional printing methods. According to IT Strategies, the LFDP printers and consumables market is projected to grow from annual sales of approximately $319 million in 1995 to approximately $1.9 billion in 1998. The rapid growth in this market is being driven primarily by the increasing desire and need for customized, large format color graphics, as well as significant advances in short-run printing and desktop publishing technologies. Traditional graphics printing methods, consisting of photographic, screen and offset printing, do not meet the requirements for production short-run print jobs due to the time consuming, multi-step processes and set up costs involved. As a result, digital printing was developed to fulfill the unmet demand of short-run users by allowing graphics to be printed directly from desktop publishing systems to paper. Raster Graphics offers a complete printing solution, consisting of its DCS printers, integrated image processing software and related consumables, to meet the performance, cost, versatility and quality demands of the on-demand production LFDP market. With a production printing speed of 600 to 1,000 square feet per hour, the DCS printing system can produce 50 to 60, full-color, 36- by 48-inch posters in one hour, which the Company believes is significantly faster than comparable digital printers. DCS printing systems are more cost-effective for short-run print jobs in comparison to traditional methods which have high set-up and labor costs. Using digital printing technology, DCS systems allow content to be customized on a print-by-print basis. DCS printing systems also offer two printing resolution modes, which allow the user to adjust the quality level depending on the application. The Company also markets a line of consumables, including specialized inks and print media, which the Company believes will continue to generate increasing recurring revenues to the extent that the installed base of DCS printing systems expands. Raster Graphics' objective is to build on its position as a market leader in sales of digital printing systems and related consumables and services, for the on-demand production LFDP market. In August 1995, as part of the Company's strategy to provide a complete system solution, the Company acquired Onyx Graphics Corporation ("Onyx"), a leading developer of image processing software. In addition to being used in the Company's DCS printers, Onyx's image processing software is available for printers manufactured by other companies. The Company was established in 1987 initially to develop low-cost electrostatic printers for computer aided design ("CAD") applications. In 1993, the Company identified the on-demand production LFDP market as a new opportunity to develop a product based on its proprietary high-speed print head technology. The Company introduced its initial DCS printer, the DCS 5400 in July 1994 and introduced its second generation product, the DCS 5442 in January 1996. The Company currently sells DCS products to a wide range of customers both domestically through direct and independent sales forces, original equipment manufacturers ("OEMs") and value-added resellers ("VARs") and internationally through distributors, OEMs and VARs. Raster Graphics has received five highly acclaimed industry awards for its contribution to digital printing technology, including Digital Printing and Imaging Association's 1994 Product of the Year; Top 10 New Repro Products for 1994 by Modern Reprographics; Hot Product for 1994 by Electronic Publishing; 1994 Editor's Choice from Computer Graphics World; and 1994 Industry Excellence Award by IEEE Computer Graphics and Applications. IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OF THE COMPANY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH TRANSACTIONS MAY BE EFFECTED ON THE NASDAQ NATIONAL MARKET, IN THE OVER-THE-COUNTER MARKET OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. The Raster Graphics logo, ColorStation(R) and PrimaScript(R) are registered trademarks of the Company. PosterShop(TM) and DuraPrint(TM) are trademarks of the Company. This Prospectus also contains the trademarks of other companies. THE OFFERING COMMON STOCK OFFERED BY THE COMPANY.............. 2,000,000 shares(1) COMMON STOCK OFFERED BY THE SELLING STOCKHOLDERS................................... 1,000,000 shares COMMON STOCK TO BE OUTSTANDING AFTER THE OFFERING....................................... 8,341,350 shares(2) USE OF PROCEEDS.................................. General corporate purposes including working capital, capital expenditures, research and development and potential acquisitions of businesses and technologies. See "Use of Proceeds." NASDAQ NATIONAL MARKET SYMBOL.................... RGFX
SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) YEARS ENDED SIX MONTHS ENDED ---------------------------------------------------- ------------------- DEC. 27, DEC. 25, DEC. 31, DEC. 30, DEC. 31, JUNE 30, JUNE 30, 1991 1992 1993 1994 1995 1995 1996 -------- -------- -------- -------- -------- -------- -------- STATEMENTS OF OPERATIONS DATA: Net revenues.................. $ 7,770 $ 8,525 $ 14,719 $ 13,235 $ 26,045 $ 11,652 $ 18,151 Gross profit.................. 1,659 2,410 4,777 3,531 9,447 3,951 7,165 Operating income (loss)....... (1,919) (1,725) 106 (2,229) 111 550 1,322 Net income (loss)............. $ (1,963) $ (2,061) $ 41 $ (2,128) $ 77 $ 275 $ 1,201 Net income (loss) per share(3)................... $ 0.01 $ 0.04 $ 0.16 Shares used in per share calculation................ 7,187 7,095 7,412
JUNE 30, 1996 ------------------------ ACTUAL AS ADJUSTED(4) ------- -------------- CONSOLIDATED BALANCE SHEET DATA: Cash and cash equivalents........................................... $ 1,775 $ 19,525 Total assets........................................................ 16,052 33,802 Long-term debt...................................................... 318 318 Total stockholders' equity.......................................... 7,942 25,692
- --------------- (1) Excludes up to 450,000 shares of Common Stock that may be sold by the Company pursuant to the Underwriters' over-allotment option. See "Underwriting." (2) Excludes 167,789 shares of Common Stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $2.18 per share and 1,355,652 shares of Common Stock issuable upon exercise of outstanding options at a weighted average exercise price of $2.33 per share at June 30, 1996. See "Management--Stock Options and Incentive Plans and note 7 of Notes to Consolidated Financial Statements." (3) See note 1 of Notes to Consolidated Financial Statements for an explanation of the determination of shares used in computing net income (loss) per share. (4) Adjusted to reflect the sale of shares of Common Stock offered hereby at an assumed initial public offering price of $10.00 per share and the receipt of the estimated proceeds therefrom. See "Use of Proceeds" and "Capitalization." ------------------------------------ Except as otherwise noted, all information in this Prospectus (i) assumes a 1-for-5 reverse stock split of the Common Stock and Preferred Stock to be effective prior to this offering, (ii) assumes the conversion of all outstanding shares of Preferred Stock into Common Stock upon the closing of this offering, (iii) reflects the reincorporation of the Company from California to Delaware prior to the closing of the offering and (iv) assumes no exercise of the Underwriters' over-allotment option. See "Description of Capital Stock" and "Underwriting."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000758722_paracelsus_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000758722_paracelsus_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..734089ea1de08df3fc15de84bf96bf7f2003636d
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000758722_paracelsus_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY INFORMATION IS QUALIFIED IN ITS ENTIRETY BY, AND SHOULD BE READ IN CONJUNCTION WITH, THE MORE DETAILED INFORMATION APPEARING ELSEWHERE IN THIS PROSPECTUS AND THE DOCUMENTS REFERRED TO HEREIN. UNLESS THE CONTEXT OTHERWISE REQUIRES, REFERENCES HEREIN TO "PARACELSUS" REFER TO PARACELSUS HEALTHCARE CORPORATION PRIOR TO THE MERGER OF CHAMPION HEALTHCARE CORPORATION ("CHAMPION") WITH AND INTO A WHOLLY OWNED SUBSIDIARY OF PARACELSUS (THE "MERGER"). REFERENCES TO THE "COMPANY" REFER TO PARACELSUS AFTER THE MERGER AND INCLUDE THE COMBINED OPERATIONS OF PARACELSUS AND CHAMPION. IN ADDITION, ALL REFERENCES TO PROCEEDS FROM THE NOTES OFFERING OR THE OFFERINGS (EACH AS DEFINED BELOW) AND, EXCEPT AS OTHERWISE PROVIDED, THE OTHER INFORMATION IN THIS PROSPECTUS ASSUME (I) NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION WITH RESPECT TO SHARES OF COMMON STOCK BEING OFFERED BY THE COMPANY AND (II) THE PURCHASE OF $75.0 MILLION PRINCIPAL AMOUNT OF PARACELSUS' 9 7/8% SENIOR SUBORDINATED NOTES DUE 2003 (THE "EXISTING SENIOR SUBORDINATED NOTES") IN THE DEBT TENDER OFFER (AS DEFINED BELOW). CERTAIN STATEMENTS UNDER THIS CAPTION "PROSPECTUS SUMMARY" CONSTITUTE "FORWARD-LOOKING STATEMENTS" UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT (THE "REFORM ACT"). SEE "RISK FACTORS -- FORWARD-LOOKING STATEMENTS." THE COMPANY Paracelsus is a leading healthcare company that owns and operates acute care and specialty hospitals and related healthcare businesses serving selected markets in the United States. Paracelsus currently owns and operates 18 acute care hospitals with a total of 1,685 licensed beds in California, Utah, Tennessee, Texas, Florida, Georgia and Mississippi. Paracelsus' acute care hospitals provide a broad array of general medical and surgical services on an inpatient, outpatient and emergency basis. In addition, certain hospitals and their related facilities offer rehabilitative medicine, substance abuse treatment, psychiatric care and Acquired Immune Deficiency Syndrome ("AIDS") care. In California, Paracelsus also owns and operates three psychiatric hospitals with 218 licensed beds, four skilled nursing facilities with 232 licensed beds and a 60-bed rehabilitative hospital. In addition, Paracelsus owns and operates 11 home health agencies and 16 medical office buildings adjacent to certain of its hospitals. For the 12 months ended March 31, 1996 on a pro forma basis after giving effect to acquisitions and dispositions, Paracelsus would have had total operating revenues of $516.9 million, Adjusted EBITDA (as defined below) of $55.8 million and a net loss of $3.1 million. The net loss includes an unusual charge recorded in March 1996 of $22.4 million related to the settlement of two lawsuits ($13.2 million, net of income tax benefit). On April 12, 1996, Paracelsus entered into an Agreement and Plan of Merger, as amended and restated on May 29, 1996 (the "Merger Agreement"), with Champion pursuant to which Champion will become a wholly owned subsidiary of the Company. Champion currently owns and operates five acute care hospitals with a total of 722 licensed beds in Utah, Texas and Virginia and owns a 50% interest in, and operates, a partnership that owns two additional acute care hospitals with a total of 341 licensed beds in North Dakota under the name "Dakota Heartland Health System" ("DHHS"). Champion's acute care hospitals generally offer the same types of services provided by Paracelsus' acute care hospitals. Champion also owns and operates two psychiatric hospitals with a total of 219 licensed beds in Missouri and Louisiana. For the 12 months ended March 31, 1996 on a pro forma basis after giving effect to acquisitions and dispositions, Champion would have had net revenue of $198.2 million, Adjusted EBITDA of $32.2 million and net income of $3.9 million. Following the Merger, the Company will operate 31 hospitals in 11 states, including 25 acute care hospitals with 2,748 licensed beds, five psychiatric hospitals with 437 licensed beds and a rehabilitative hospital with 60 licensed beds. On a pro forma combined basis for the 12 months ended March 31, 1996, after giving effect to the Offerings, the Company would have had total operating revenues of $714.8 million, Adjusted EBITDA of $88.1 million and a net loss of $6.9 million. The net loss includes the unusual charge related to the settlement of two lawsuits. These pro forma combined results do not give effect to any cost savings that management believes will be realized as a result of the Merger due to the combination of the corporate operations of Paracelsus and Champion and the elimination of certain corporate consulting contracts of Paracelsus. In addition, the combined entity should benefit from economies of scale in such areas as purchasing, marketing, information systems, risk management, acquisitions and development, accounting, reimbursement, corporate finance and quality assurance. The Company believes that the Merger represents a unique opportunity to integrate the operations of two companies that have a complementary portfolio of hospitals. Upon completion of the Merger, 22 of the 31 hospitals owned or operated by the Company will be located in markets where a hospital or hospital network operated by the Company is a preeminent provider. On a pro forma combined basis (excluding the PHC Salt Lake Hospital (as defined below) and the two hospitals owned by DHHS), the remaining 19 hospitals would have accounted for approximately 71% and 89% of the 28 remaining hospitals' operating revenues and Adjusted EBITDA, respectively, for the 12 months ended March 31, 1996. Following the Merger, the Company believes that it will be better positioned to implement its business strategy due to its greater scale and diversity of operations, expanded geographic presence and enhanced access to the public capital markets and other financing sources. The Company also believes that it will benefit from the addition to Paracelsus' management team of three key Champion executives who, following the Merger, will have primary responsibility for day to day management of the Company. These Champion executives have an average of 29 years of hospital industry experience and a proven track record in operating and growing publicly held hospital companies. Over the past five years, these executives grew Champion's net revenue at a compounded annual growth rate of 62.0%, from $24.3 million in 1991 to $167.5 million in 1995, while improving its Adjusted EBITDA margins from 9.4% in 1991 to 15.8% in 1995 and 19.2% for the three months ended March 31, 1996. After the Merger, the Company's principal executive offices will be located at 515 West Greens Road, Suite 800, Houston, Texas 77067. Its telephone number will be (713) 873-6623. BUSINESS STRATEGY The Company's strategic objective is to establish each of its hospitals or hospital networks as the provider of choice in its market. To accomplish this, the Company first seeks to establish a presence in geographic locations that are best suited to developing a preeminent market position. These locations primarily include small to mid-sized markets with more favorable demographics and lower levels of penetration by managed care plans and alternative niche competitors than larger metropolitan areas. Moreover, the competing hospitals in the Company's target markets frequently will be not-for-profit facilities that the Company believes have higher cost structures than its hospitals. Second, the Company focuses on implementing operating strategies developed by the Company for positioning each of its hospitals or hospital networks as providers of measurably higher quality and lower cost healthcare services than competing providers. The key elements of the Company's operating strategies are as follows: EXPAND STRATEGICALLY THROUGH SELECTED ACQUISITIONS The Company plans to continue to pursue expansion opportunities through the strategic acquisition of hospitals and complementary healthcare businesses in existing or new markets. The Company has demonstrated this strategy most recently by successfully acquiring four hospitals and a home health agency in the Salt Lake City market. The Company believes that its primary sources of acquisitions will be unaffiliated not-for-profit hospitals and facilities being divested by hospital systems for strategic, regulatory or performance reasons. INCREASE MARKET PENETRATION The Company seeks to increase the market penetration of its hospitals by offering a full range of hospital and related healthcare services and by gaining market share from local competitors by providing measurably higher quality and lower cost services. For example, this strategy has been successfully demonstrated by the addition of obstetrics programs at each of The Medical Center of Mesquite and Westwood Medical Center during the past 12 months. In addition, over the past 24 months the Company has acquired or established five home health agencies that cover 26 counties in Tennessee, providing a large referral base for the Company's four hospitals in that market. ESTABLISH A COMPETITIVE COST ADVANTAGE The Company seeks to position each of its hospitals as the low cost provider in its market by monitoring and controlling fixed and variable operating expenses. Champion's executives have demonstrated an ability to reduce costs as indicated by the improvement in Champion's Adjusted EBITDA margins from 9.4% in 1991 to 15.8% in 1995 and 19.2% for the three months ended March 31, 1996. Labor costs are a primary focus of such efforts, and Champion's executives have reduced salaries, wages and benefits as a percentage of net revenue at Champion's hospitals (including DHHS) from 38.2% in 1994 to 37.9% in 1995 and 35.4% for the three months ended March 31, 1996. The Company believes that a low cost provider is better able to succeed in the current healthcare environment by aggressively pricing its managed care contracts and direct employer arrangements and by maintaining profitability under fixed payment systems. IMPLEMENT A COMPETITIVE QUALITY ADVANTAGE The Company believes that preventing errors in the treatment process can improve quality and lower the cost of care by reducing the risk of adverse events to patients and the consequential costs of such events. For the past two years, the Company has piloted a proprietary program in four of its hospitals designed to identify and measure the incidence of patient treatment errors in 225 separate clinical categories. The Company believes the capability to quantify data regarding the quality of care in its hospitals will enable the Company to reduce the cost of care and will enhance the ability of its hospitals to win and profit from managed care contracts. DEVELOP A COMPETITIVE SERVICE ADVANTAGE The Company believes that bureaucratic and impersonalized customer service is a historical structural deficiency within the hospital industry caused by service systems, policies and procedures that are designed for the convenience of physicians and hospitals rather than patients, payors and employers. The Company is developing a proprietary customer service system that it believes will differentiate its hospitals and facilities from those of its competitors and provide a competitive advantage. REQUIRE LOCAL MANAGEMENT ACCOUNTABILITY The provision of high quality healthcare services is primarily a local business, and the Company's business strategy and operating programs emphasize local management initiative, responsibility and accountability combined with corporate support and oversight. REFINANCINGS IN CONNECTION WITH THE MERGER The Company has filed a registration statement with respect to $325,000,000 aggregate principal amount of % Senior Subordinated Notes due 2006 (the "Notes") that it plans to offer (the "Notes Offering") concurrently with the offering (the "Equity Offering" and, together with the Notes Offering, the "Offerings") of the shares of the Company's common stock, no stated value per share (the "Common Stock"), made hereby. The Company currently intends that a portion of the estimated aggregate net proceeds to the Company from the Offerings of $364.6 million (consisting of $49.8 million from the Equity Offering and $314.8 million from the Notes Offering) will be used by Champion to prepay an estimated $170.6 million of outstanding Champion indebtedness (plus $6.6 million of prepayment premiums) as of June 30, 1996. The remaining net proceeds to the Company from the Offerings will be used to reduce outstanding indebtedness under either the existing Paracelsus credit facility (the "Existing Paracelsus Credit Facility") or the new credit facility (the "New Credit Facility") that the Company intends to establish as soon as practicable at or after the effective time of the Merger (the "Effective Time"), as applicable. In addition, the Company has commenced a tender offer to purchase up to $75.0 million aggregate principal amount of outstanding Existing Senior Subordinated Notes for $1,027.50 per $1,000 principal amount of Existing Senior Subordinated Notes (the "Debt Tender Offer"). The Debt Tender Offer will expire on August 22, 1996 and, as of August 8, 1996, $66.7 million aggregate principal amount of the Existing Senior Subordinated Notes has been tendered in the Debt Tender Offer. A portion of the remaining net proceeds of the Offerings will be used to purchase Existing Senior Subordinated Notes tendered pursuant to the Debt Tender Offer and to pay consent payments of up to $1.5 million in the aggregate to be made in connection with the related consent solicitation to amend the terms of the indenture relating to the Existing Senior Subordinated Notes. Neither the Equity Offering nor the Notes Offering is contingent upon the consummation of the other. See "Risk Factors -- Significant Leverage," "The Merger and Financing" and "Use of Proceeds." The Company currently intends to refinance as soon as practicable at or after the Effective Time, through borrowings under the New Credit Facility, all amounts outstanding under the Existing Paracelsus Credit Facility (the "Credit Facility Refinancing"). The New Credit Facility will provide for borrowings of up to $400.0 million, of which $135.9 million would have been outstanding as of June 30, 1996 on a pro forma basis after giving effect to the Offerings and the Credit Facility Refinancing and the application of the net proceeds therefrom. THE EQUITY OFFERING COMMON STOCK OFFERED BY THE COMPANY (1)............. 5,200,000 shares COMMON STOCK OFFERED BY THE SELLING SHAREHOLDERS(1).................................... 229,000 shares TOTAL........................................... 5,429,000 shares COMMON STOCK OUTSTANDING AFTER THE EQUITY OFFERING(2)........................................ 54,647,167 shares USE OF PROCEEDS BY THE COMPANY...................... The aggregate net proceeds to the Com- pany from the Offerings are estimated to be $364.6 million (consisting of $49.8 million from the Equity Offering and $314.8 million from the Notes Offering). The Company intends that a portion of the net proceeds from the Offerings will be used by Champion to prepay an estimated $170.6 million of outstanding Champion indebtedness (plus $6.6 million of prepayment premiums) as of June 30, 1996. The remaining estimated net proceeds of $187.4 million will be used to purchase up to $75.0 million of Existing Senior Subordinated Notes in the Tender Offer (plus approximately $3.9 million of tender and consent fees and other related expenses) and to reduce outstanding indebtedness under the Existing Paracelsus Credit Facility or the New Credit Facility, as applicable. See "Risk Factors -- Significant Leverage," "The Merger and Financing" and "Use of Proceeds." NEW YORK STOCK EXCHANGE ("NYSE") SYMBOL............. "PLS"
- ------------------------ (1) Does not include up to 814,350 shares of Common Stock subject to the Underwriters' over-allotment option. The over-allotment option may be granted by the Selling Shareholders or the Company. (2) Does not include 7,515,740 shares of Common Stock issuable upon conversion or exercise of options, warrants, subscription rights or convertible securities outstanding as of July 10, 1996.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000765803_magicworks_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000765803_magicworks_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..bf1d2a7eeb3edf655c2b52ce6e4ac096587aad2b
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000765803_magicworks_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS, INCLUDING THE NOTES THERETO, APPEARING ELSEWHERE IN THIS PROSPECTUS. EACH PROSPECTIVE INVESTOR IS URGED TO READ THIS PROSPECTUS IN ITS ENTIRETY. UNLESS OTHERWISE NOTED, THE INFORMATION IN THIS PROSPECTUS GIVES EFFECT TO THE CONSUMMATION OF THE CONSOLIDATION AND THE MERGER DESCRIBED UNDER "CONSOLIDATION TRANSACTIONS AND S CORPORATION DISTRIBUTIONS." THE COMPANY Magicworks Entertainment Incorporated (the "Company") acquires domestic and international stage and ancillary rights to theatrical productions, produces and promotes live entertainment, manages and books performances and shows, and merchandises a broad range of products associated with its productions and performers. The Company is also involved in the management of performing arts facilities. The Company has experienced significant growth over the past several years. Revenues and pre-tax income have increased from $7.5 million and $1.0 million, respectively, in 1992 to $42.7 million and $3.7 million, respectively, in 1995. However, the Company had pre-tax income of $2,026,725 for the nine months ended September 30, 1996 compared to $4,113,332 for the nine months ended September 30, 1996. The Company's strategy has been to integrate the financing, production, booking and ancillary exploitation of live entertainment, which allows the Company to exercise control over all aspects of its productions, including theatrical production, booking, marketing and merchandising. Prior to 1992, the Company focused primarily on, and derived the majority of its profits from, the worldwide production of "The Magic of David Copperfield," as well as its management and booking agency and its merchandising business, and was not involved in other large scale productions. However, because artists and producers wishing to gauge the market's receptivity to their productions typically approached the Company in its capacity as booking agent early in a show's development process, the Company perceived an opportunity to participate in additional roles beyond its traditional management, booking agency and merchandising operations. In 1992, the Company began to act as producer and co-producer of productions for which the Company believed market demand was strong, based on the responses to its booking inquiries. In some cases, in addition to production rights, the Company obtained other rights associated with the show, such as the ability to present the show in certain venues. The Company's successful productions since 1992 have included "Ken Hill's The Phantom of the Opera" and "South Pacific," starring Robert Goulet, and its major current productions include "Jesus Christ Superstar," "The Magic of David Copperfield," "Hello, Dolly!" starring Carol Channing and "Deathtrap," starring Elliot Gould and Mariette Hartley. In addition, the Company has the rights to produce and anticipates producing "Singin' in the Rain," "Gershwin on Ice" and "The Hunchback of Notre Dame." The Company plans to continue to seek to acquire touring rights for well-established star musicals, and to utilize its management and booking division to determine the demand for live entertainment productions. Since the determination of demand is made in advance of any significant commitment by the Company, the Company believes that its success has been related in part to its ability to produce only those shows which appear prospectively to have limited risk and the potential for significant reward. After obtaining the production rights to a show, the Company typically casts the lead role with recognized talent, and then solicits commitments from promoters in various locations in which the show could be presented. The promoters guarantee the Company a minimum amount of weekly revenues (which guarantee is often secured by a letter of credit) as well as a share of any profits above the guaranteed amount. The Company frequently receives a deposit from the local promoters, the amount of which is based on the Company's past relationship with the individual promoter. For foreign productions, the deposit is generally equivalent to the total amount of the guarantee. In this manner, the Company seeks to further minimize its production risk. In addition to its production business, the Company acts as the management and booking agent for a variety of live entertainment events. As management and booking agent, the Company is retained by producers to arrange bookings for the tours of various theatrical presentations, musical acts and one person shows. The Company then markets the productions to presenters throughout the world, and is paid either a fixed fee or a percentage of proceeds for such bookings. These arrangements preclude the need for the Company to invest any of its own capital in its capacity as management and booking agent. The Company currently acts as exclusive management and booking agent for over 23 shows, including "The Magic of David Copperfield," "Nutcracker on Ice," "Jesus Christ Superstar," by Andrew Lloyd Webber and Tim Rice, "The Pointer Sisters' Ain't Misbehavin'," "Hello, Dolly!" starring Carol Channing, "Three Tall Women," "She Loves Me," "Deathtrap," "Mame" and the national touring company of "A Chorus Line;" musical acts such as the Newport Jazz All-Stars and the Preservation Hall Jazz Band; and one-person shows such as Hal Holbrook in "Mark Twain Tonight," James Whitmore in "Will Rogers USA," Amanda Plummer in "The Belle of Amherst" and Kevin McCarthy in "Give 'Em Hell Harry!" In addition, the Company has recently entered into an exclusive agreement to represent the musical "Big" for all U.S. and Canadian tour bookings (excluding New York, Los Angeles and Toronto). The Company plans to continue to exploit its experience and contacts with performers, venues, presenters and sponsors by expanding its operations, as opportunities arise, in the areas of sports, speakers' bureaus, music, movies and television. Further, the Company believes that its relationships in the entertainment industry will facilitate its expansion into other areas, particularly with respect to facility management, production and presentation opportunities. In addition, the Company perceives an opportunity to grow through the acquisition of local and regional entertainment producers, presenters, facilities owners and management companies. The Company believes that there are significant acquisition opportunities available due to the highly fragmented nature of the live entertainment industry. In keeping with its strategy to further broaden its own business by acquiring entertainment related businesses, on August 28, 1996, the Company acquired all of the issued and outstanding capital stock of Movietime Entertainment, Inc. ("Movietime") in exchange for 1,199,999 shares of Common Stock. Movietime has developed and implemented an interactive telecommunications service that provides digital telephone delivery systems to movie theaters. Movietime's digital-based delivery system replaces the analog recording machines now in use at movie theaters with an interactive digital voicemail system that provides customized, site specific theater information such as show times, ticket prices, location and travel directions. The Company believes that the Movietime system enables a theater to increase ticket sales through improved customer service by significantly increasing the number of telephone calls able to reach the theater simultaneously. If Movietime achieves significant market penetration, the Company hopes to generate revenues by selling advertising time on the recorded announcements. COMPANY BACKGROUND The Company was incorporated under the laws of the State of Utah in February 1985 under the name "Marino Investments, Inc." In April 1988, the Company changed its name to "Rattlesnake Gold, Inc." and changed its state of domicile from Utah to Delaware. In June 1995, the Company changed its name to Shadow Wood Corporation. The Company was formed for the purpose of raising capital and acquiring suitable property, assets or business by means of completing a merger with, or acquisition of, any privately-held business enterprise. The Company had no material operations until July 1996. In July 1996, Magicworks Entertainment Incorporated, a Florida corporation ("MEI"), was merged (the "Merger") into the Company and the Company changed its name to "Magicworks Entertainment Incorporated." MEI was formed in June 1996 as a holding company to facilitate the consolidation of the operations of each of Diamond Bullet Merchandising, Inc., a Florida corporation, Touring Artists Group, Inc., an Ohio corporation ("TAGO"), Touring Artists Group, Inc., a Florida corporation, Performing Arts Management of North Miami, Inc., a Florida corporation, Magic Promotions, Inc., a Florida corporation, and Magic Promotion, Inc., an Ohio corporation ("MPIO"), all of which shared common control, but which had operated previously as independent corporations (the foregoing corporations are referred to herein collectively as the "Constituent Corporations"). Concurrently with the initial closing of the Private Placement, 100% of the capital stock of each of the Constituent Corporations was acquired by the Company (the "Consolidation"). See "Consolidation Transactions and S Corporation Distributions" and "Certain Transactions." The Company was the surviving corporation in the Merger. Pursuant to the Merger, each outstanding share of common stock, $.001 par value per share, of MEI was converted into the right to receive one share of Common Stock. The Board of Directors and management of MEI were elected to corresponding positions with the Company. Simultaneously with the consummation of the Merger, the Company issued and sold 400.06 Units in connection with which it received net proceeds of $8,919,350. On September 27, 1996, the Company issued and sold an additional 14.8 Units pursuant to the Private Placement in connection with which it received additional net proceeds of $333,000. Subsequent to the Merger, on August 28, 1996, the Company acquired (the "Movietime Acquisition") all of the outstanding capital stock of Movietime, pursuant to the merger (the "Movietime Merger") of MT Acquisition Sub Inc. ("MT Sub"), a newly-formed, wholly-owned subsidiary of the Company, with and into Movietime. The Movietime Acquisition was consummated pursuant to that certain Agreement and Plan of Merger dated August 28, 1996 (the "Movietime Agreement") among the Company, MT Sub, Movietime and all of the stockholders of Movietime (the "Movietime Stockholders"). Movietime was the surviving corporation in the Movietime Merger. Pursuant to the Movietime Merger, each share of Movietime common stock, par value $1.00 per share, was converted into the right to receive 2,962.96 shares of Common Stock, rounded to the nearest whole number, resulting in the issuance of 1,199,999 shares of Common Stock to the Movietime Stockholders. Unless the context requires otherwise, all references in this Prospectus to the Company shall mean the Company as successor by merger to the business of MEI and shall include its wholly-owned subsidiaries. The Company's executive offices are located at 930 Washington Avenue, Miami Beach, Florida 33139 and its telephone number is (305) 532-1566. THE OFFERING Securities Offered.................... 26,226,465 shares of Common Stock, including 22,763,179 outstanding shares of Common Stock which may be sold by Selling Securityholders and up to 3,463,286 Note Shares, Placement Agent Warrant Shares and Redeemable Warrant Shares which may be sold by the holders, respectively, of outstanding Notes, outstanding Placement Agent Warrants and Redeemable Warrants which may be issued in the future. 1,981,643 Warrants, including 500,000 Placement Agent Warrants which may be sold by the Selling Securityholders and up to 1,481,643 Redeemable Warrants that may be issued upon the prepayment of the Notes in certain circumstances. Quotation............................ The Common Stock is listed on the OTC Bulletin Board. The Company has applied for the listing of the Common Stock on NMS. Trading Symbol....................... "MAJK" SUMMARY FINANCIAL DATA The summary financial information set forth below has been derived from the audited financial statements of the Company, giving effect to the Consolidation and the Merger, which occurred effective July 30, 1996, and to the Movietime Acquisition which occurred on August 28, 1996 and should be read in conjunction with such financial statements and the notes thereto appearing elsewhere in this Prospectus. MPIO was deemed to be the acquiring entity in the Consolidation.(1) YEAR ENDED DECEMBER 31, --------------------------------------------------- 1991 1992 1993 1994 ----------- ---------- ----------- ---------- STATEMENT OF OPERATIONS DATA: Revenues: Production .................. $ 0 $ 662,222 $18,250,149 $23,346,244 Promotion ................... 4,299,717 3,663,269 10,009,734 6,268,273 Total revenues........................ 7,284,234 7,525,156 32,167,251 33,416,193 Total operating expenses.............. 6,113 678 6,889 895 27,610,205 30,239,412 Income from operations................ 1,170,556 635,261 4,557,046 3,176,781 Net income............................ 1,295,027 1,003,866 3,020,557 2,128,198 Pro forma net income(2) .............. 789,966 612,358 1,842,540 1,298,201
DECEMBER 31, NINE MONTHS ENDED SEPTEMBER 30, -------------------------- ------------------------ ---------- 1995 1995 1995 1996 1996 ---------- ----------- ---------- ---------- ---------- STATEMENT OF OPERATIONS DATA: ACTUAL PROFORMA(3) ACTUAL ACTUAL PROFORMA(3) Revenues: Production .................. $31,638,078 $31,638,078 $20,665,310 $21,773,945 $21,773,945 Promotion ................... 6,668,672 6,668,672 4,738,992 7,412,528 7,412,528 Total revenues........................ 42,734,099 42,734,099 27,702,101 32,213,330 32,213,330 Total operating expenses.............. 38,440,260 38,596,482 23,881,534 29,936,188 30,053,354 Income from operations................ 4,293,839 4,137,617 3,820,567 2,277,142 2,159,976 Net income............................ 3,281,845 2,607,048 2,596,033 1,736,790 1,230,693 Pro forma net income(2) .............. 2,001,925 1,590,299 1,583,580 667,270 750,723
SEPTEMBER 30, 1996 ------------------ BALANCE SHEET DATA: Working capital.............. $ 6,234,223 Total assets................. 13,043,003 Total liabilities............ 8,729,999 Total shareholders' equity... 4,313,004 - ---------------------------- (1) The Consolidation complies with the requirements of Staff Accounting Bulletin No. 48 ("SAB 48") and has therefore been accounted for at the historical cost bases of the transferors. The Movietime Acquisition has been accounted for as a pooling-of-interests in accordance with APB No. 16. See Note 1 to the Historical Supplemental Pooled Financial Statements of Magic Promotion, Inc. and Movietime Entertainment, Inc. appearing elsewhere herein. (2) Reflects the effect of an adjustment for income taxes on historical statement of operations data, assuming the Constituent Corporations had been treated as C corporations for income tax purposes, and assuming an effective income tax rate of 39% for the periods presented and the income tax expense of the Company's switch in tax basis from cash to accrual in connection with the Company's S Corporation status as opposed to the C Corporation status of the Constituent Corporations. See "Consolidation Transactions and S Corporation Distributions."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000772320_gene_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000772320_gene_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..b3c2956166b15c7ea3d705b516247f8abd8bfbec
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000772320_gene_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING INFORMATION IS QUALIFIED IN ITS ENTIRETY BY THE DETAILED INFORMATION AND CONSOLIDATED FINANCIAL STATEMENTS APPEARING ELSEWHERE IN THIS PROSPECTUS, ALL OF WHICH SHOULD BE READ CAREFULLY AND THOROUGHLY. THE COMPANY The Company's focus is global natural resource development based on a strategy of applying the effective use of advanced technologies to products and services oriented toward providing efficient, cost effective and profitable solutions to global environmental and resource development challenges. Primary challenges currently being addressed include mineral resources development and water treatment in developing countries. The business activities of the Company have centered around mineral resource development. The primary focus to date has been the acquisition and exploration of precious mineral resource properties in South Africa and Zimbabwe and research and development related to minerals testing, process engineering and environmental technologies. In addition, the Company has positioned itself in the environmental industry through an investment in the preferred stock of Vector Environmental Technologies, Inc., ("VETI") a Delaware corporation, a company controlled by the Company. VETI is currently focused primarily on the development, manufacture, sale and management of water treatment equipment and facilities. Therefore, the Company and its wholly-owned and majority-owned, through voting control, subsidiaries, are considered to operate in two business segments, mining and environmental technologies, principally water treatment systems. On January 31, 1996, Casmyn Corp. (Company) acquired 100% of the shares of a group of five (5) private mining companies (the "Acquired Companies") controlled by the Muir Family in Zimbabwe through E.W.B. Properties (Private) Limited: Matabeleland Minerals (Private) Limited, Greenhorn Mines (Private) Limited, Morven Mining (Private) Limited, Motapa Minerals (Private) Limited and Turk Mines (Private) Limited. The Acquired Companies own mining claims controlling gold and silver mineral rights on properties that lie within the Bubi Greenstone Belt, which is one of the largest greenstone formations in Zimbabwe and include numerous shafts, mining equipment and mineral processing mills with a total capacity of 1,000 tonnes per day. The Company estimates that total gold resources at the Turk Mines are 5,000,000 ounces. Independent engineering studies are currently underway which may cause this estimate to change. The Company has commenced gold mining operations and is in the process of upgrading and retro-fitting various mine facilities. THE OFFERING This Prospectus relates to 2,805,791 shares of common stock that have been previously issued, 732,143 shares of common stock issuable upon the exercise of warrants and 833,333 shares of common stock issuable under a convertible debenture. The Company will not receive any of the proceeds from the sale of shares by the Selling Shareholders. SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) PRO FORMA (1) HISTORICAL -------------------------- ----------------------------------------------------- NINE YEAR MONTHS NINE MONTHS ENDED ENDED ENDED YEAR ENDED SEPTEMBER 30, SEPTEMBER JUNE JUNE 30, 30, 30, ------------------------------- -------------------- ------------- ----------- 1993 1994 1995 1995 1996 1995 1996 --------- --------- --------- --------- --------- ------------- ----------- STATEMENT OF OPERATIONS DATA: Total revenues $ 75 $ 601 $ 382 $ 375 $ 1,066 $ 2,723 $ 1,939 Loss from operations (1,566) (4,189) (6,400) (4,278) (5,139) (6,015) (4,985) Other income, net 1,272 4,879 3,325 2,067 706 3,035 895 Income (loss) from continuing operations (294) (690) (3,075) (2,211) (4,433) $ (2,980) $ (4,090) ------------- ----------- ------------- ----------- Gain (loss) from discontinued operations (292) (643) 33 32 - - --------- --------- --------- --------- --------- Net income (loss) $ (586) $ 47 $ (3,042) $ (2,179) $ (4,433) --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Income (loss) per common share: Income (loss) from continuing operations $ (0.09) $ 0.14 $ (0.40) $ (0.29) $ (0.71) $ (0.23) $ (0.38) ------------- ----------- ------------- ----------- Income (loss) from discontinued operations (0.09) (0.13) - - --------- --------- --------- --------- --------- Net income (loss) $ (0.18) $ 0.01 $ (0.40) $ (0.29) $ (0.71) --------- --------- --------- --------- --------- Weighted average common shares outstanding 3,244 4,946 7,651 7,575 6,271 12,735 10,775 --------- --------- --------- --------- --------- ------------- ----------- --------- --------- --------- --------- --------- ------------- -----------
JUNE 30, 1996 -------------------------- PRO HISTORICAL FORMA (2) ------------- ----------- BALANCE SHEET DATA: Working capital....................................................................... $ 4,652 $ 12,317 Total assets.......................................................................... 27,502 35,048 Convertible debt...................................................................... 5,000 - Stockholders' equity.................................................................. 19,572 31,995
- ------------------------ (1) Gives effect to the acquisitions of the Zimbabwe properties, 100% of the common shares of Auromar Development Corporation and a 65% interest in WestAmerica Corporation, and the issuance of common stock upon conversion of the convertible debt and the exercise of the warrants. It is assumed that these transactions took place on October 1, 1994. See "Pro Forma Consolidated Financial Statements." (2) Includes the effect of the acquisition of the Zimbabwe properties which occurred on January 31, 1996 and the acquisition of the interest in WestAmerica Corporation which occurred on May 24, 1996 and assumes the acquisitions of Auromar Development Corporation and the interest in WestAmerica Corporation and the issuance of the common stock upon conversion of the convertible debt and the exercise of the warrants occurred on June 30, 1996. Also includes reclassification of investment in Auromar shares of $204 to treasury stock. See "Pro Forma Consolidated Financial Statements." RISK FACTORS PROSPECTIVE PURCHASERS SHOULD CONSIDER CAREFULLY THE FOLLOWING FACTORS RELATING TO THE BUSINESS OF THE COMPANY AND THIS OFFERING, TOGETHER WITH THE INFORMATION AND FINANCIAL DATA SET FORTH ELSEWHERE IN THIS PROSPECTUS, PRIOR TO PURCHASING ANY SHARES OF COMMON STOCK OFFERED HEREBY. LIMITED OPERATING HISTORY UNDER CURRENT MANAGEMENT The Company has only been operating under its current management since March 1994. Since that time, it has engaged in limited business operations and is still in the process of acquiring and developing mineral properties and technologies for its business plans, and it has been operating with losses. There is no assurance that the Company will be able to generate the revenues necessary to be profitable or that it will be successful if forced to seek additional funds for further development of its current mining properties and technologies. (See "Casmyn Corp. - Business Of the Company", "Casmyn Corp. - Management Of the Company", "Certain Transactions" and "Financial Statements.") RELIANCE ON OUTSIDE FINANCING The Company's management believes that in the long term it will be able to generate revenues sufficient to fund its operations and continue with its proposed business plans. However, to complete current projects under development and should the Company expand its operations and/or make acquisitions that would require substantial sums of money, it will have to seek additional debt or equity financing. There can be no assurance that such financing would be available on terms acceptable to the Company, as and when needed. Since inception, the Company's operations have been financed, in part, through private sales of the Company's securities and private loans. (See "Certain Transactions" and "Financial Statements.") RELIANCE UPON OFFICERS AND DIRECTORS The Company is wholly dependent, at present, upon the personal efforts and abilities of its officers and directors. The loss of one or more of its officers or directors could have a material adverse effect on the Company's operating results. While the Company will solicit business through its officers and directors, there can be no assurance as to the volume of business, if any, which the Company may obtain, or that its operations will prove to be as profitable as presently anticipated. (See "Casmyn Corp. - Management Of the Company" and "Certain Transactions.") CONFLICTS OF INTEREST The Company anticipates obtaining certain of its products and services from companies of which its officers, directors and principal shareholders are officers, directors and/or principal shareholders. All such products and services will be obtained by the Company at terms competitive in the marketplace and at least as favorable to the Company as would be obtained by a third party. The Company has previously engaged, and will continue to engage in certain transactions with its officers, directors, and principal shareholders and will endeavor to insure that such transactions will be as favorable to the Company as comparable arms-length transactions would be. (See "Casmyn Corp. - Business Of the Company" and "Certain Transactions.") RECENT UNPROFITABILITY Despite the business experience of the officers, directors and principal shareholders of the Company, the Company has been operating at a loss and has not been profitable since 1994, when Mr. Dahya acquired majority ownership. There can be no assurance the Company will be productive and/or profitable in the future, or that such productivity and/or profitability, if attained, will be sufficient to permit the Company to be successful in the future or to expand or continue to operate. (See "Casmyn Corp. - Business Of the Company.") COMPETITION There is intense competition in the mineral exploration and development and environmental products industries in which the Company operates. Many of the Company's competitors have greater financial and other resources, better distribution networks and/or greater name recognition than the Company. There can be no assurance that the Company will be able to successfully compete in these industries. (See "Casmyn Corp. - Business Of the Company.") GOVERNMENTAL REGULATIONS The environmental products and mineral exploration and development activities of the Company are significantly impacted by environmental, health and import/export related government regulations and programs which the Company must comply with. If additional regulations were to be implemented, there can be no assurance that the Company would be able to comply with them without incurring substantial additional costs for compliance therewith. (See "Casmyn Corp. - Business Of the Company.") The mining operations of the Company, through its wholly-owned subsidiaries, Casmyn Mining Corporation and Casmyn Zimbabwe (Private) Ltd, are conducted primarily through its offices in South Africa and Zimbabwe. Casmyn Mining Corporation is qualified to do business in South Africa and, as such, is subject to the laws of that country, which includes permits to allow the Company to conduct exploration activities on optioned properties. COMPLIANCE WITH ENVIRONMENTAL LAWS The mining operations of the Company are directed at determining the presence of economically viable mineral resource deposits on properties under option in South Africa. It is the Company's intention, once such mineral resource deposits are discovered, to identify a joint venture partner to develop and operate the mining properties. Under the South Africa Minerals Act, 1991, the Company and/or its joint venture partner are responsible for development of an environmental impact assessment and an environmental management program for the proposed mining venture which must be approved prior to the start of exploration and/or mining operations. The cost of environmental compliance relating to mineral development is estimated by management to be immaterial as of September 30, 1995 due to the nature of the Company's exploration activities. Through January 31, 1996, the Company did not have any producing mining properties. On Janaury 31, 1996, the Company acquired various gold mining properties and processing facilities in Zimbabwe and has begun mining and processing gold at those facilities. The Company is in compliance with environmental laws of Zimbabwe. RISK OF DEVELOPMENT, CONSTRUCTION AND MINING OPERATIONS Should the Company, alone or with a joint venture partner, decide to proceed with development of a mineral resource property, the ability to meet cost estimates and construction and production time estimates cannot be assured. Technical considerations, delay in obtaining governmental approvals, inability to obtain financing or other factors could cause delays in developing mineral resource properties. The businesses of gold and/or diamond mining are subject to a variety of risks and hazards, including environmental hazards, industrial accidents, flooding and the discharge of toxic chemicals. The Company (and its joint venture partners, when identified) intend to obtain insurance in amounts the Company considers to be adequate to protect itself against certain of these risks of mining and processing. However, the Company may become subject to liability for certain hazards for which it cannot obtain insurance or which it may elect not to obtain insurance against because of premium costs or other reasons. EXPLORATION PROGRAMS A major part of the Company's business is the exploration of its existing properties and the evaluation and pursuit of potential new prospects in the exploration stage or of interests in companies which own such properties. Substantial expenditures may be incurred in an attempt to establish the economic feasibility of mining operations by identifying mineral deposits and establishing reserves through drilling and other techniques, designing facilities and planning mining operations. The economic feasibility of a project depends on numerous factors, including the cost of mining and production facilities required to extract the desired minerals, the total mineral deposits that can be mined using a given facility, the proximity of the mineral deposits to a user of the minerals, and the market price of the minerals at the time of sale. There is no assurance that existing or future exploration programs or acquisitions will result in the identification of deposits that can be mined profitably. NO CASH DIVIDENDS The Company has never paid and has no present plans to pay any cash dividends on its common stock. The Company currently intends to retain its earnings to finance the growth and development of its business. See "Price Range of Common Stock and Dividends." USE OF PROCEEDS This Prospectus relates to shares of Common Stock that may be offered and sold from time to time by the Selling Shareholders. See "Plan of Distribution." There will be no proceeds to the Company from the conversion of the convertible debenture into common stock or from previously completed private placements of common stock. The Company would receive $7,785,716 in proceeds (net of approximately $125,000 which is the estimated cost of this offering) from the exercise of warrants. Such proceeds are expected to be used for mineral property development and general corporate purposes. PRICE RANGE OF COMMON STOCK AND DIVIDENDS The shares of Common Stock of the Company are traded in the over-the-counter market in the "pink sheets" by members of the National Association of Securities Dealers, Inc. The following table identifies the high/low or bid/asked sales prices per share based upon information obtained from the National Daily Quotation Service, for each quarterly period, and the last six (6) months, since acquisition of the Company by present Management: - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- QUARTER ENDING DATE HIGH LOW - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- July 1, 1996 through September 5, 1996 $ 16.50 $ 14.50 - -------------------------------------------------------------------------------- June 30,1996 $ 18.00 $ 15.00 - -------------------------------------------------------------------------------- March 31, 1996 $ 20.00 $ 16.00 - -------------------------------------------------------------------------------- December 31, 1995 $ 21.50 $ 8.00 - -------------------------------------------------------------------------------- September 30, 1995 $ 9.00 $ 6.00 - -------------------------------------------------------------------------------- June 30, 1995 $ 8.50 $ 6.00 - -------------------------------------------------------------------------------- March 31, 1995 $ 8.00 $ 7.00 - -------------------------------------------------------------------------------- December 31, 1994 $ 9.687 $ 7.75 - -------------------------------------------------------------------------------- September 30, 1994 $ 13.50 $ 8.125 - -------------------------------------------------------------------------------- June 30, 1994 $ 13.00 $ .95 - -------------------------------------------------------------------------------- March 31, 1994 * nil nil - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- The Company has never paid and has no present plans to pay any cash dividends on its common stock. The Company currently intends to retain its earnings to finance the growth and development of its business. As of June 30, 1996, there were 7,286,992 shares of the Company's Common Stock issued and outstanding. The Company believes that as of June 30, 1996 there were approximately 100 holders of common stock of record or through nominee or street name accounts with brokers. On September 5, 1996 the last day of trading for shares of the Company's Common Stock prior to the date of this Prospectus, the closing price in the over the-counter market for the Company's Common Stock was $14.50. * Trading activity prior to March 31, 1994 was nil. CAPITALIZATION The following table sets forth as of June 30, 1996 the actual consolidated capitalization of the Company, the consolidated pro forma acquisitions capitalization to give effect to the acquisitions of the common stock of Auromar Development Corporation and WestAmerica Corporation and the consolidated pro forma as adjusted capitalization of the Company to give effect to the Offering for those shares that are being registered that are issuable upon exercise of warrants and upon conversion of a convertible debenture. This table should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Pro Forma Consolidated Financial Statements," and the Consolidated Financial Statements and Notes thereto. June 30, 1996 (in thousands) - -------------------------------------------------------------------------------- Actual Pro Forma Pro-Forma As Acquisitions(1) Adjusted(2) --------- --------------- ------------ Convertible debt $ 5,000 $ 5,000 $ - --------- --------------- ------------ Stockholders' Equity: Preferred stock, $.10 par value; 20,000 shares authorized; 2,707 shares issued and outstanding 271 271 271 Common stock, $.04 par value; 300,000 shares authorized; issued and outstanding: 7,285 shares actual; 10,199 shares pro forma acquisitions; 11,764 shares pro forma as adjusted (3) 292 409 472 Additional paid-in capital 27,854 27,823 40,301 Accumulated deficit (8,501) (8,501) (8,501) Less: treasury stock (25) (229) (229) Foreign currency translation adjustment (319) (319) (319) --------- --------------- ------------ Total stockholders' equity 19,572 19,454 31,995 --------- --------------- ------------ Total capitalization $ 24,572 $ 24,454 $ 31,995 --------- --------------- ------------ --------- --------------- ------------ - ----------- (1) Gives effect to the issuance of 2,702 shares of common stock in the acquisition of 100% of the common shares of Auromar Development Corporation, the issuance of 237 additional common shares to the holder of the convertible debentures pursuant to the Auromar acquisition. See "Pro Forma Consolidated Financial Statements" and "Business of the Company." (2) Gives effect to the common stock issued in the acquisitions discussed in (1) above, the issuance of 833 shares of common stock upon conversion of the convertible debenture, and a total of 732 shares of common stock upon the exercise of warrants. Also includes an increase in additional paid-in capital of $245 to reflect the adjustment of unamortized debt issuance costs related to convertible debt and the reclass of investment in Auromar shares of $204 to treasury stock. (3) The number of common shares issued and outstanding do not include shares of common stock issuable upon the exercise of outstanding stock options. See "Employee Stock Option Plan." SELECTED CONSOLIDATED FINANCIAL DATA (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) The selected consolidated historical financial data presented below as of and for the years ended September 30, 1993, 1994 and 1995 are derived from the Company's audited consolidated financial statements. The selected consolidated historical financial data as of June 30, 1996 and for the nine months ended June 30, 1995 and 1996 are derived from the Company's unaudited consolidated financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of the results for such interim periods, have been reflected therein. The results of operations for the nine months ended June 30, 1996 are not necessarily indicative of the results of operations that may be expected for the full fiscal year 1996. The data set forth below should be read in conjunction with the consolidated financial statements of the Company and the notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Pro Forma Consolidated Financial Statements" appearing elsewhere herein. HISTORICAL PRO FORMA (1) --------------------------------------------------------- -------------------- YEAR YEAR YEAR NINE MONTHS NINE MONTHS YEAR NINE MONTHS ENDED ENDED ENDED ENDED ENDED ENDED ENDED SEPTEMBER SEPTEMBER SEPTEMBER JUNE 30, JUNE 30, SEPTEMBER JUNE 30, 30, 1993 30, 1994 30, 1995 1995 1996 30, 1995 1996 ----------- --------- --------- ---------- ---------- --------- ---------- STATEMENT OF OPERATIONS DATA: Sales $ 75 $ 601 $ 382 $ 375 $1,066 $ 2,723 $ 1,939 Cost of goods sold 1 603 490 270 757 1,886 1,270 -------------------------------------------------------- -------------------- Gross profit (loss) 74 (2) (108) 105 309 837 669 -------------------------------------------------------- -------------------- Costs and expenses: Selling, general and administrative expense 1,077 3,225 4,998 3,296 4,695 5,364 4,830 Depreciation, depletion and amortization 80 39 99 167 101 293 172 Mineral exploration expense - - 1,010 769 448 1,010 448 Research and development 85 15 185 151 204 185 204 Write down and abandonment of assets 399 908 - - - - - -------------------------------------------------------- -------------------- Total costs and expenses 1,641 4,187 6,292 4,383 5,448 6,852 5,654 -------------------------------------------------------- -------------------- Loss from operations (1,566) (4,189) (6,400) (4,278) (5,139) (6,015) (4,985) -------------------------------------------------------- -------------------- Other income (expense): Minority interest in net loss of subsidiary 1,302 4,581 3,502 1,991 499 3,502 499 Other income (expense) (30) 298 (177) 76 207 (467) 396 -------------------------------------------------------- -------------------- Other income, net 1,272 4,879 3,325 2,067 706 3,035 895 -------------------------------------------------------- -------------------- Income (loss) from continuing operations (294) 690 (3,075) (2,211) (4,433) $(2,980) $(4,090) -------------------- -------------------- Gain (loss) from discontinued operations (292) (643) 33 32 - -------------------------------------------------------- Net income (loss) $ (586) $ 47 $(3,042) $(2,179) $(4,433) -------------------------------------------------------- -------------------------------------------------------- Income (loss) per common share: Income (loss) from continuing operations $(0.09) $ 0.14 $ (0.40) $(0.29) $ (0.71) $ (0.23) $ (0.38) -------------------- -------------------- Income (loss) from discontinued operations (0.09) (0.13) - - - -------------------------------------------------------- Net income (loss) $(0.18) $ 0.01 $ (0.40) $(0.29) $ (0.71) -------------------------------------------------------- -------------------------------------------------------- Weighted average number of common shares outstanding 3,244 4,946 7,651 7,575 6,271 12,734 10,775 -------------------------------------------------------- -------------------- -------------------------------------------------------- --------------------
PRO FORMA JUNE 30, SEPTEMBER SEPTEMBER SEPTEMBER JUNE 30, 1996, AS 30, 1993 30, 1994 30, 1995 1996 ADJUSTED (2) --------- --------- --------- --------- ------------ BALANCE SHEET DATA: Total assets $ 2,309 $3,369 $14,316 $27,504 $35,048 Long term debt 207 110 5,071 5,000 -- Stockholders' equity (deficit) (507) 2,214 8,144 19,572 31,995
(1) Gives effect to the acquisitions of the Zimbabwe properties, 100% of the common shares of Auromar Development Corporation and a 65% interest in WestAmerica Corporation, and the issuance of common stock upon conversion of the convertible debt and the exercise of the warrants. It is assumed that these transactions took place on October 1, 1994. See "Pro Forma Consolidated Financial Statements." (2) Includes the effect of the acquisition of the Zimbabwe properties which occurred on January 31, 1996 and the acquisition of the interest in WestAmerica Corporation which occurred on May 24, 1996, and assumes the acquisitions of Auromar Development Corporation and the issuance of the common stock upon conversion of the convertible debt and the exercise of the warrants occurred on March 31, 1996. Also includes reclassification of investment in Auromar shares of $204 to treasury stock. See "Pro Forma Consolidated Financial Statements." Note: The Company was inactive during the years ended September 30, 1991 and 1992, therefore consolidated financial data for those periods has been omitted. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OVERVIEW The Company's focus is global resource development based on a strategy of applying the effective use of advanced technologies to products and services oriented toward providing efficient, cost effective and profitable solutions to global environmental and resource development challenges. Primary challenges currently being addressed include mineral resources development and water treatment in developing countries. The business activities of the Company have centered around mineral resource development. The primary focus to date has been the acquisition and exploration of precious mineral resource properties in South Africa and Zimbabwe and research and development related to minerals testing, process engineering and environmental technologies through the Casmyn Mining Group. In addition, the Company has positioned itself in the environmental industry through an investment in the preferred stock of VETI. VETI is currently focused primarily on the development, manufacture, sales and management of water treatment equipment and facilities. Therefore, the Company and its wholly-owned and majority-owned, through voting control, subsidiaries, are considered to operate in two business segments, mining and environmental technologies, principally water treatment systems. See Note 2 of the Notes to the Consolidated Financial Statements for information on business segments. RESULTS OF OPERATIONS NINE MONTHS ENDED JUNE 30, 1996 COMPARED TO THE NINE MONTHS ENDED JUNE 30, 1995 Revenues for the nine months ended June 30, 1996, were $1,065,538 compared to $375,270 for the nine months ended June 30, 1995. The $690,268 increase was due to an increase of $317,512 in sales of water purification systems and $372,756 from the sale of gold produced in Zimbabwe. Overall gross profit for the nine months ended June 30, 1996 was 29% compared to 28% for the nine months ended June 30, 1995. Gross profit on water purification equipment sales was 32% for the nine month period ended June 30, 1996 compared to 28% for the nine month period ended June 30, 1995 due to lower freight charges. and lower component costs. Gross profit on gold sales was 23.4% for the nine months ended June 30, 1996, there were no gold sales in the nine month period ended June 30, 1995. Costs and expenses were $5,448,216 for the nine months ended June 30, 1996, compared to $4,383,570 for the nine months ended June 30, 1995, an increase of $1,064,646. Compensation and benefits increased $394,757 for the nine month period ended June 30, 1996 compared to the nine month period ended June 30, 1995 due primarily to the Company recording $364,560 in compensation expense related to the granting of 246,000 non-qualified stock options and increased staff levels in the nine month period ended June 30, 1996 compared to the period ended June 30, 1995. Expenses related to professional services, primarily audit and legal increased by $341,556 in the nine month period ended June 30, 1996 compared to the nine month period ended June 30, 1995. Travel related expenses increased $261,781 in the nine month period ended June 30, 1996 compared to the nine month period ended June 30, 1995 due to increased trips to Africa, India and Vietnam related to the Company's operations in those countries. Mineral exploration expense and depreciation decreased a total of $321,826 in the nine month period ended June 30, 1996 compared to the nine months ended June 30, 1995 due to start up of limited gold production at the Zimbabwe mines. This decrease was offset by a increase in research and development related expenses of $53,345. Other general and administrative costs increased $335,033 for the nine months ended June 30, 1996 compared to 1995 due primarily to higher costs related to business activities in Vietnam, increased costs related to the U.S. rollout of water purification products and expenses incurred at the Zimbabwe mining properties. Other income, exclusive of minority interest, was $207,436 for the nine month period ended June 30, 1996, compared to $76,091 for the nine months ended June 30, 1995, an increase of $131,345. This increase was due primarily to interest income earned on short term investments made by the Company offset by interest expense. Minority interest in the net loss of VETI decreased by $1,492,526 for the nine months ended June 30, 1996 due to a limitation on the amount of loss which could be absorbed by the minority shareholders. The Company anticipates that expenditures related to upgrading the newly acquired mining properties in Zimbabwe will exceed revenues derived from the sale of gold from the mines. The Company is in the process of preparing a capital improvement budget for the Zimbabwe properties. Additionally, the Company anticipates that expense levels experienced in the nine months ended June 30, 1996 relating to active exploration programs in various countries will continue for the foreseeable future. The Company charges to expense all mineral resource exploration and development costs until the mineral property to which they relate is determined to have proven reserves for which recovery is economically feasible. Costs are then capitalized until the mineral property to which they relate is placed into production, sold, abandoned or written down where there is an impairment in value. Capitalized costs are to be charged to future operations on a unit-of-production basis. The Company estimates that total gold resources at the Turk Mines are 5,000,000 ounces. Independent engineering studies are currently underway which may cause this estimate to change. The gold occurs in sulfides, oxides and old mill tailings. YEAR ENDED SEPTEMBER 30, 1995 COMPARED TO THE YEAR ENDED SEPTEMBER 30, 1994 Sales for the year ended September 30, 1995, were $382,158 compared to $600,714 for the year ended September 30, 1994. The $218,556 decrease was due primarily to a decrease of $34,383 from assaying and minerals testing services and a decrease of $184,173 from sales of water purification products. The decrease in assaying and minerals testing was due to discontinuance of those services. The decrease in sales of water purification products was the result of sales efforts being directed to market analysis and new product design and testing thereby reducing sales volume. The gross loss for the year ended September 30, 1995 was $107,431 compared to $1,964 for the year ended September 30, 1994. The increased loss was due mainly to writing off obsolete water purification inventory items. Costs and expenses were $6,292,140 for the year ended September 30, 1995, compared to $4,186,541 for the year ended September 30, 1994, an increase of $2,105,599. $1,010,334 of this increase was due to land fees and exploration costs relating to active exploration programs presently underway on various mineral properties that are under option to the Company. Selling, general and administrative expenses increased $1,773,323 to $4,997,948. Compensation and benefits increased $685,850 for the year ended September 30, 1995 compared to the year ended September 30, 1994 due primarily to the Company recording $955,100 in compensation expense related to the granting of non-qualified stock options. Advertising and marketing costs increased $260,071 for the year ended September 30, 1995 compared to the year ended September 30, 1994 due to various programs relating to the introduction of the Company's water purification systems in the U.S. and foreign markets. Other general and administrative expenses increased $204,668 for the year ended September 30, 1995 compared to the year ended September 30, 1994 due primarily to increased professional and consulting expenses. Research and development expenses for the year ended September 30, 1995 were $185,053 compared to $15,294 for the year ended September 30, 1994 due to increased projects related to the development of water purification technologies. The increase in costs and expenses in 1995 was offset by decreases in abandonment of mineral properties of $150,000 and write down of assets of $758,059 because no such transactions occurred in 1995. Other income, exclusive of minority interest, decreased by $476,325 in the fiscal year ended September 30, 1995, compared to the fiscal year ended September 30, 1994, due mainly to gains on the sale of investments in related parties of $253,218 that were realized in 1994, with a loss on sale in investments in related parties of $150,000 in 1995. Minority interest in the net loss of consolidated subsidiary decreased $1,078,293 to $3,502,401 for the fiscal year ended September 30, 1995. The Company discontinued its metal fabrication business segment in fiscal 1995 recognizing a loss from discontinued operations in the year ended September 30, 1995 of $77,354 compared to a loss of $643,767 for the year ended September 30, 1994. A gain of $109,783 was recognized on the disposal of certain metal fabrication equipment during 1995. Due to net operating loss carry forwards there was no tax provision for the fiscal year ended September 30, 1995. YEAR ENDED SEPTEMBER 30, 1994 COMPARED TO THE YEAR ENDED SEPTEMBER 30, 1993 Revenues for the year ended September 30, 1994, were $600,714 compared to $75,421 for the year ended September 30, 1993, the $525,293 increase was due primarily to sales of water purification products of $566,331, there were no sales of these products in the year ended September 30, 1993. This increase is offset by a decline in revenues recognized from ore assaying activities ($41,038), between 1994 and 1993. The Company curtailed its bulk ore assaying activities due to increasing stringent government regulations relating to the use and disposal of various substances used in the assaying process, and the increasing demands on its technical personnel for engineering and process development services for VETI. Cost and expenses were $4,186,541 in the fiscal year ended September 30, 1994, compared to $1,640,946 in the fiscal year ended September 30, 1993, an increase of $2,545,595. This increase primarily relates to an increase of $831,672 in salaries and benefits due to higher staff levels in fiscal 1994 to support domestic water purification activities and the start-up of operations in South Africa and Vietnam. General and administrative expenses increased by $1,204,864 primarily due to increased accounting, legal, consulting and mineral exploration expenses. During fiscal 1994 the Company wrote off $150,000 related to an investment in mineral properties and wrote off $758,059 in assets, while, in fiscal 1993, the Company wrote off certain assets in the amount of $209,000 and abandoned certain mineral properties totalling $190,470. Other income, exclusive of minority interest, was $298,638 in the fiscal year ended September 30, 1994 due mainly to gains realized on the sale of marketable securities of related parties to unrelated third parties. Minority interest in the net loss of consolidated subsidiary increased $3,278,890 to $4,580,694 for the fiscal year ended September 30, 1994. The Company realized a loss from its discontinued metal fabrication operations of $643,767 in the fiscal year ended September 30, 1994 compared to a loss of $291,812 in the fiscal year ended September 30, 1993. Due to net operating loss carry forwards there was no tax provision for the fiscal year. CAPITAL RESOURCES AND LIQUIDITY At June 30, 1996, the Company's working capital was $4,651,953, including $5,473,211 in cash and cash equivalents. The Company's mineral resource development business segment has acquired certain mineral properties in South Africa and on January 31, 1996 concluded the acquisition of certain mining properties and assets in Zimbabwe for $4,526,415 cash plus applicable taxes of $1,017,854 to be paid upon assessment subject to certain adjustments. In addition, the water purification business segment has begun sales and marketing programs in North America and in various third world countries. Management anticipates that the net use of cash by operations will increase during the foreseeable future due to expenditures on mineral resource development projects in South Africa, mineral exploration and facility upgrades at the Zimbabwe mining properties and development of various markets for VETI's water purification technologies. The Company will use current cash and cash equivalents to fund the on-going projects in the short term and anticipates that it will be able to secure additional debt and/or equity financing, to fund longer term projects. As evidence of the Company's ability to secure debt and/or equity financing in the nine month period ended June 30, 1996 the Company has received $8,809,862, net of commissions and other expenses related to the transaction, through issuance of 750,000 shares of restricted common stock in an exempt private transaction. During the fiscal year ended September 30, 1995, the Company completed private placements of 405,000 Common Shares and 714,286 units for total net proceeds of $7,002,859, and completed placement of a $5,000,000, 2.5%, unsecured, convertible debenture (see Note 7 to the consolidated financial statements) for net proceeds of $4,700,000. Additionally, during the year ended September 30, 1995 VETI completed private placements of 500,000 Common Shares and 1,000,000 units for total net proceeds of $3,375,000. During the fiscal year ended September 30, 1994, the Company completed a private placement of 378,055 shares of common stock for net proceeds of $1,908,000. The following is a discussion of factors that have affected the Company's financial position. NET CASH USED IN OPERATING ACTIVITIES. Net cash used in operating activities was $4,161,707 for the nine months ended June 30, 1996 compared to $4,547,789 for the nine months ended June 30, 1995. The decrease in net cash used in operations was due principally to a decrease in minority interest in the net loss of VETI of $1,492,526 offset by increases in the net loss because of active exploration programs conducted on mineral properties in fiscal 1996 and expenses related to sales of water purification systems. Net cash used in operating activities was $5,996,061, $4,476,585 and $2,196,566 for the years ended September 30, 1995, 1994 and 1993 respectively. The increase in the net cash used in operations in 1995 was due principally to the increase in the net loss because of active exploration programs conducted on mineral properties and increased costs and expenses relating to sales of water purification systems. Also contributing to the increase in the net cash used in operations was an increase in accounts receivable of $456,952 in 1995. The increase in net cash used in operations in 1994 was due primarily to losses attributed to the water purification business segment (the minority interest in net loss of VETI increased by $3,278,890 in the year ended September 30, 1994 compared to 1993). NET CASH USED IN INVESTING ACTIVITIES. Net cash used in investing activities was $10,645,707 for the nine months ended June 30, 1996 compared to net cash provided by investing activities of $605,018 for the nine months ended June 30, 1995. The increase in net cash used in investing activities was due to the purchase of certain mineral properties and assets in Zimbabwe, and purchases of equipment and improvements, primarily related to a water bottling plant under construction in Vietnam. During the year ended September 30,1995, the Company received $1,487,538 from the sale of investments and $209,324 from the sale of assets, this was offset by $650,000 which was used to purchase investments in related parties, and $239,749 that was used to purchase equipment and improvements. These transactions resulted in net cash provided by investing activities of $807,113. In the year ended September 30, 1994, proceeds from the sale of investments of $1,366,220 was the major source of cash from investing activities, offset by purchases of investments of $212,897, investments in and advances to related parties of $413,223 and purchase of equipment and improvements of $142,530. These transactions resulted in net cash provided by investing activities of $599,570. In the year ended September 30, 1993, proceeds from the sales of investments was $346,904 offset by investments in and advances to related parties of $251,302 and purchases of equipment and improvements of $147,262 resulting in net cash used in investing activities of $51,660. NET CASH PROVIDED BY FINANCING ACTIVITIES. Net cash provided by financing activities was $15,668,020 for the nine months ended June 30, 1996 compared to $2,864,398 for the nine months ended June 30, 1995. The increase is due to the Company receiving $15,791,780 from the collection of funds, net of costs, from private placements of common stock of the Company and VETI, offset by the repayment of long-term debt of $98,760 and the purchase of treasury stock of $25,000. As discussed above, during the year ended September 30, 1995, the Company received $4,700,000 (net of debt issuance costs) from the placement of a debenture and $3,060,712 from the issuance of common stock of the Company and $1,326,564 from the issuance of VETI and VVC common stock in private placements, offset by repayment of long-term debt of $42,609, resulting in net cash provided by financing activities of $9,044,667. During the year ended September 30, 1994, the Company received $1,100,000 from the issuance of common stock of the Company and $3,080,820 from the issuance of common stock of VETI and VVC, offset by repayment of long-term debt of $107,003, resulting in net cash provided by financing activities of $4,073,817. During the year ended September 30, 1993, the Company received $3,269,577 from the issuance of common stock of VVC offset by payment of long-term debt of $178,661, resulting in net cash provided by financing activities of $3,090,916. The Company is organized with a relatively small, highly trained staff and anticipates that the overall staff level will remain low in the foreseeable future because the majority of mineral resource development activities are performed by independent contractors on a project by project basis. The Company believes that these arrangements will not require a significant investment by the Company in either personnel or facilities. CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 The discussions contained in the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Casmyn Corp." sections of this Registration Statement contain various "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sections 21E of the Securities Exchange Act of 1934, as amended, which represents the Company's expectations or beliefs concerning future events, inlcuding the following: statements regarding the estimated mineral resource levels located at the Company's mining properties in Zimbabwe; the ability of the Company to secure additional debt and/or equity financing to fund future expansion and operations; statements regarding new or increased markets for the Company's water purification and water bottling business segment. In addition, statements containing expressions such as "believes," "anticipated," "plans" or "expects" used in the Company's periodic reports on Forms 10-KSB and 10-QSB filed with the SEC are intended to indentify, forward-looking statements. The Company cautions that these and similar statements included in this and in previously filed periodic reports including reports filed on Forms 10-KSB and 10-QSB are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statement, including, without limitation, the following: political and economic instability in international markets; the effect of economic conditions; the effect of regulatory and governmental actions; fluctuations in world gold prices, exchange rates, tariffs and other barriers. PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS The pro forma consolidated financial statements are presented in two steps: first, presenting the acquisitions adjustments for the acquisition of the Zimbabwe properties and 100% of the common shares of Auromar Development Corporation ("Auromar"); and a 65% interest in WestAmerica Corporation ("WestAmerica") and second, the adjustments for the issuance of shares of common stock upon conversion of the convertible debt and the exercise of the warrants. These pro forma financial statements have been prepared to show the effect of the January 31, 1996 acquisition of 100% of the shares of a group of five (5) private mining companies controlled by the Muir Family in Zimbabwe through E.W.B. Properties (Private) Limited ("EWB"), in accordance with the terms and conditions of a formal Purchase Agreement concluded in August 1995. The total consideration for this acquisition was $4,071,415 plus applicable taxes which are currently estimated at $1,017,854. The acquisition includes includes mining claims controlling gold and silver mineral rights on several producing gold mining properties covering approximately 1,200 hectares (approximately 2,965 acres) in the Bubi Greenstone Gold Belt of Zimbabwe. These properties include infrastructure, mining and milling equipment. Also on January 31, 1996, the Company purchased the assets of the Dawn Mine property in Zimbabwe from Olympus Gold Mines Limited for $455,000. The Dawn Mine is located in close proximity to the Turk mine and mill and will be operated under a mine plan which includes the Turk mine and mining properties owned by the Company. These transactions have been accounted for as purchases. These pro forma financial statements have also been adjusted to show the effect of the acquisition on May 24, 1996 of a 65% interest in WestAmerica in exchange for 606,061 common shares of the Company. This investment has been accounted for using the equity method. In addition, these pro forma financial statements have been adjusted to reflect the exchange of approximately 2,701,000 shares of the Company's common stock for approximately 7,025,000 shares (100%) of the common stock of Auromar which acquisition is anticipated to be completed in the near future. The pro forma consolidated statements of operations show what the results of the Company's operations would have been for the fiscal year ended September 30, 1995 and the nine months ended June 30, 1996 had the acquisitions been completed on October 1, 1994. The pro forma balance sheet as of June 30, 1996 includes the effect of the Zimbabwe acquisition which occured on January 31, 1996 and the WestAmerica acquisition which occurred on May 24, 1996 and assumes the other acquisitions described above occurred on June 30, 1996. The issuance of the common shares from the issuance of common stock upon conversion of the convertible debt and the exercise of warrants being registered by this offering were assumed to be on October 1, 1994 for the pro forma consolidated statements of operations and on June 30, 1996 for the pro forma consolidated balance sheet. CASMYN CORP. PRO FORMA CONSOLIDATED BALANCE SHEET JUNE 30, 1996 (IN THOUSANDS) ASSETS ACQUISITIONS PRO FORMA REGISTRATION PRO FORMA AS ACTUAL ENTRIES ACQUISITIONS ADJUSTMENTS ADJUSTED ---------------------------------------------------------------------------------- CURRENT ASSETS: CASH AND CASH EQUIVALENTS $ 5,473 $ - $ 5,473 $ 7,786 (d) $ 13,259 ACCOUNTS RECEIVABLE, NET 226 - 226 - 226 INVENTORIES 1,750 - 1,750 - 1,750 PREPAID EXPENSES AND OTHER ASSETS 135 - 135 - 135 ---------------------------------------------------------------------------------- TOTAL CURRENT ASSETS 7,584 - 7,584 7,786 15,370 ---------------------------------------------------------------------------------- INVESTMENT IN RELATED PARTY 204 (204) (b) - - - EQUIPMENT AND IMPROVEMENTS, NET 2,945 - 2,945 - 2,945 MINERAL PROPERTIES 6,712 207 (a) 6,919 - 6,919 INVESTMENT IN AFFILIATES 8,368 - 8,368 - 8,368 DUE FROM RELATED PARTIES, NET 67 - 67 - 67 OTHER ASSETS 1,624 - 1,624 (245) (e) 1,379 ---------------------------------------------------------------------------------- TOTAL ASSETS $ 27,504 $ 3 $ 27,507 $ 7,541 $ 35,048 ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITES: ACCOUNTS PAYABLE AND ACCRUED LIABILITIES $ 2,932 $ 121 (a) $ 3,053 $ - $ 3,053 ---------------------------------------------------------------------------------- CONVERTIBLE DEBT 5,000 - 5,000 (5,000) (e) - ---------------------------------------------------------------------------------- STOCKHOLDERS' EQUITY: PREFERRED STOCK, $.10 PAR VALUE 271 - 271 - 271 COMMON STOCK, $.04 PAR VALUE 292 108 (a) 409 33 (e) 472 9 (c) 30 (d) ADDITIONAL PAID-IN CAPITAL 27,854 (22) (a) 27,823 4,722 (e) 40,301 (9) (c) 7,756 (d) ACCUMULATED DEFICIT (8,501) - (8,501) - (8,501) LESS: TREASURY STOCK (25) (204) (b) (229) - (229) FOREIGN CURRENCY TRANSLATION ADJUSTMENT (319) - (319) - (319) ---------------------------------------------------------------------------------- TOTAL STOCKHOLDERS' EQUITY 19,572 (118) 19,454 12,541 31,995 ---------------------------------------------------------------------------------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 27,504 $ 3 $ 27,507 $ 7,541 $ 35,048 ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
SEE NOTES TO PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS CASMYN CORP. PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED SEPTEMBER 30, 1995 (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) ACQUISITIONS PRO FORMA REGISTRATION PRO FORMA AS ACTUAL ADJUSTMENTS ACQUISITIONS ADJUSTMENTS ADJUSTED ---------------------------------------------------------------------------------- SALES $ 382 $ 2,341 (f) $ 2,723 $ - $ 2,723 COST OF GOODS SOLD 490 1,396 (f) 1,886 - 1,886 ---------------------------------------------------------------------------------- GROSS PROFIT (LOSS) (108) 945 837 - 837 ---------------------------------------------------------------------------------- COSTS AND EXPENSES: General and administrative expense 4,998 366 (f) 5,364 - 5,364 Depreciation, depletion and amortization 99 194 (f) 293 - 293 Mineral exploration expense 1,010 - 1,010 - 1,010 Research and development 185 - 185 - 185 ---------------------------------------------------------------------------------- 6,292 560 6,852 - 6,852 ---------------------------------------------------------------------------------- INCOME (LOSS) FROM OPERATIONS (6,400) 385 (6,015) - (6,015) ---------------------------------------------------------------------------------- OTHER INCOME (EXPENSE): Minority interest in net loss of subsidiary 3,502 - 3,502 - 3,502 Equity in net loss of unconsolidated affiliate - (321) (h) (321) (321) Other (177) - (177) 31 (g) (146) ---------------------------------------------------------------------------------- Other income (expense), net 3,325 (321) 3,004 31 3,035 ---------------------------------------------------------------------------------- INCOME (LOSS) FROM CONTINUING OPERATIONS $ (3,075) $ 64 $ (3,011) $ 31 $ (2,980) ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- INCOME (LOSS) FROM CONTINUING OPERATIONS PER COMMON SHARE $ (.40) $ .13 (i) $ (.27) $ .04 (i) $ (.23) ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 7,651 3,518 11,169 1,565 12,734 ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
SEE NOTES TO PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS CASMYN CORP. PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED JUNE 30, 1996 (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) ACQUISITIONS PRO FORMA REGISTRATION PRO FORMA AS ACTUAL ADJUSTMENTS ACQUISITIONS ADJUSTMENTS ADJUSTED ---------------------------------------------------------------------------------- SALES $ 1,066 $ 873 (f) $ 1,939 $ - $ 1,939 COST OF GOODS SOLD 757 513 (f) 1,270 - 1,270 ---------------------------------------------------------------------------------- GROSS PROFIT 309 360 669 - 669 ---------------------------------------------------------------------------------- COSTS AND EXPENSES: General and administrative expense 4,695 135 (f) 4,830 - 4,830 Depreciation, depletion and amortization 101 71 (f) 172 - 172 Mineral exploration expense 448 - 448 - 448 Research and development 204 - 204 - 204 ---------------------------------------------------------------------------------- 5,448 206 5,654 - 5,654 ---------------------------------------------------------------------------------- INCOME (LOSS) FROM OPERATIONS (5,139) 154 (4,985) - (4,985) ---------------------------------------------------------------------------------- OTHER INCOME (EXPENSE): Minority interest in net loss of subsidiary 499 - 499 - 499 Equity in net income of unconsolidated affiliate - 81 (h) 81 - 81 Other 207 - 207 108 (g) 315 ---------------------------------------------------------------------------------- Other income, net 706 81 787 108 895 ---------------------------------------------------------------------------------- NET INCOME (LOSS) $ (4,433) $ 235 $ (4,198) $ 108 $ (4,090) ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- INCOME (LOSS) PER COMMON SHARE $ (.71) $ .25 (i) $ (.46) $ .08 (i) $ (.38) ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 6,271 2,939 9,210 1,565 10,775 ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
SEE NOTES TO PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS CASMYN CORP. NOTES TO PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS The pro forma adjustments and eliminations are as follows: (a) To record the issuance of 2,701,103 shares of the Company's common stock for 7,024,103 shares of the common stock of Auromar at the exchange rate of one share of the Company's common stock for each two and six tenths (2.6) shares of Auromar. The transaction has been recorded as a purchase (principally mineral properties) with the purchase price of the net assets being recorded at predecessor cost prior to their acquisition by Auromar. (b) Reclassification of the carrying value of Casmyn's 425,750 shares of Auromar common stock which are assumed exchanged for 163,750 Casmyn shares and then recorded as treasury stock. (c) Under the terms of the $5,000,000 unsecured convertible debenture with Societe Generale ("Sogen"), the Company is required to issue additional shares of its common stock upon the merger with Auromar such that Sogen would maintain its relative ownership interest in the Company. Under this provision, the Company would be required to issue 237,218 additional shares. (d) Exercise of 714,286 warrants in exchange for 357,143 common shares at $8.50 per share and exercise of 750,000 warrants in exchange for 375,000 common shares at $13.00 per share, total proceeds of $7,785,716 which is net of estimated costs of $125,000. (e) Conversion of the $5,000,000 convertible debenture to 833,333 common shares at $6.00 per share. Decrease of additional paid-in capital of $245,000 representing the reclassification of unamortized debt issuance costs relating to the convertible debenture. (f) The acquisitions adjustment and eliminations include the estimated results of operations of the Zimbabwe properties for the period October 1, 1994 through and including January 31, 1996 (date of acquisition). Revenues were computed based upon the actual gold production for the Zimbabwe properties for the period, cost of sales was computed using average cost of production per ounce obtained from local mine engineering firms. Costs and expenses were determined based upon the per ounce costs actually realized by the prior owners on a per ounce of production basis. The financial statements have been adjusted to reflect depletion expense that would have been recorded in the periods presented had the transaction occurred on October 1, 1994. The depletion expense per ounce of production was determined by dividing the total cost the Company has incurred in acquiring the gold reserves by the estimated gold reserves acquired. (g) Reduction of interest expense of $63 and $21 and amortization of debt issuance costs of $45 and $10, for the nine months ended June 30, 1996 and the year ended September 30, 1995 respectively, to reflect the assumed conversion of the convertible debenture on October 1, 1994. (h) To record the Company's equity in the income (loss) of WestAmerica for the period October 1, 1994 through and including May 24, 1996 (date of acquisition of interest). The financial statements have been adjusted to reflect depletion expense that would have been recorded in the periods presented had the transaction occurred on October 1, 1994. The depletion expense pertaining to oil and gas production was determined by dividing the excess of the purchase price of WestAmerica over the Company's portion of the net assets of WestAmerica by the estimated reserves. (i) To decrease the net loss per share to give effect to changes in net loss as described above and the issuance of additional shares. CASMYN CORP. BUSINESS OF THE COMPANY The Company was originally incorporated under the laws of the State of Colorado on December 4, 1984, as Fintech, Inc. (the "Company"). In November, 1985, the Company completed its initial public offering of securities. A total of 10,276,500 units were sold at a public offering price of $.02 per unit. The units were comprised of one Common Share and one Class A Warrant to purchase an additional Common Share of the Company at an exercise price of $.06 per share and one Class B Warrant to purchase an additional Common Share of the Company at an exercise price of $.12 per share expiring November 16, 1986 and January 16, 1987, respectively. No warrants were exercised. The Company received net proceeds of approximately $148,844 after deducting costs of $56,686 related to the offering. In 1986, the Company loaned funds obtained in the initial public offering to companies in the medical diagnostic field. The loans were subsequently written off. On November 29,1991, the Company changed its name from Fintech, Inc. to Summa Metals Corporation. In addition, on November 29, 1991, the Company's Board of Directors authorized a 1 for 400 reverse stock split, thereby decreasing the number of outstanding shares to 69,874 on that date. The Company was in the development stage from its inception until August 1994 when it purchased for approximately $150,000 all of the common stock of Casmyn USA, Inc. ("Casmyn USA"), a Nevada corporation, from Dahya Holdings, Inc., a related party. Prior to 1994, the Company's principal business was performing contract research and development services. On March 31, 1994, Amyn Dahya, an individual, acquired 2,400,000 shares (74% of the voting securities of the Company at that time) from certain officers, directors and shareholders in consideration of an agreement to loan the sellers the sum of $100,000. On September 14, 1994 the Company changed its name from Summa Metals Corporation to Casmyn Corp. On July 19, 1995 the Company placed a $5,000,000, 2.5%, unsecured Convertible Debenture, due July 31, 2000, ("Debenture") with Societe Generale, Paris, France ("Holder"). Interest is payable semi-annually commencing January 31, 1996, which, at the election of the Company, may be paid through the issuance of shares of common stock of the Company. The Debenture provides for conversion to Common Stock of the Company at $6.00 per share for the first two years after issuance, increasing to $6.50 during the third year, $7.00 during the fourth year and $7.50 during the fifth year. If the Company merges with Auromar Development Corporation. ("Auromar") on terms described below, or such other terms pursuant to which the Company issues shares of its Common Stock in exchange for a controlling interest in Auromar, then the Company is obligated to issue to the Holder, within 30 days after the effective date of such merger, a number of shares of its Common Stock, at no cost, such that upon conversion, the Holder shall be entitled to receive the number and kind of shares which, together with the shares issued to the Holder following the merger, would be equal to the same percentage of the issued and outstanding shares of Common Stock the Holder would have held if the then-outstanding Debenture had been converted immediately prior to the effective date of the merger. At June 30, 1996, the number of additional shares that the Company would be required to issue in relation to the proposed merger with Auromar would have been approximately 237,000. The net proceeds from this debenture were $4,700,000 after deducting $300,000 in costs relating to the placement. ACQUISITION OF CONTROLLING INTEREST IN VECTOR ENVIRONMENTAL TECHNOLOGIES, INC. On June 29, 1995, the Company acquired a voting controlling interest in Vector Environmental Technologies, Inc. ("VETI") through the acquisition of 3,000,000, 5%, cumulative, convertible, voting preferred shares of VETI ("preferred shares"), in exchange for approximately $2,300,000 in debts owing to the Company. On September 29, 1995, the Company purchased an additional 1,000,000 preferred shares of VETI at $2.00 per share. Each preferred share is convertible, at the Company's option, into one share of VETI common stock. Preferred shares are entitled to vote with Common Shares, with the further provision that each preferred share will be entitled to the equivalent of four (4) common share votes, with the result that the Company has effective voting control of VETI with a 56.25% voting majority. VETI is also related to the Company through certain common officers, directors and significant stockholders. As a result of the relationships between the Company and VETI, the investment in VETI has been accounted for as a combination of entities under common control, which is a method similar to a pooling of interests. Therefore, the accompanying consolidated financial statements include assets and liabilities of VETI at their historical cost and operations of VETI for all periods presented. INVESTMENT IN WESTAMERICA CORPORATION On May 24, 1996 the Company entered into a Stock Purchase Agreement to exchange shares with WestAmerica Corporation ("WACC" NASDAQ symbol - WACC), an Oklahoma corporation, whereby the Registrant received 5,680,514 common shares of WACC in exchange for 606,061 shares of the Company's common stock (approximately a 65% interest). WACC is engaged in the oil and gas exploration and production business primarily in the states of Oklahoma and Texas. WACC also engages in the securities and investment banking businesses through it's ownership of WestAmerica Investment Group, Inc. and it's subsidiary WestAmerica Investment Company, Inc. ("WIC"), a registered broker dealer. The exchange expands the Registrant's strategic interests in resource development and will be accounted for by the Registrant on the equity method. Also on May 24, 1996, the Company entered into an Agreement with WACC and Edward R. Foraker ("Foraker"), an individual and Director of WACC whereby the Company is granted the authority to nominate two of the five members of the Board of Directors of WACC. The Agreement also grants an irrevocable proxy to Foraker to vote the WACC shares held by the Company, restricts any changes in the capital structure of the companies and grants WACC a one year option to revoke the transaction whereby the Company and WestAmerica would return the shares issued under the Stock Purchase Agreement. The Company's investment in WACC, representing approximately 65% of WACC's outstanding common stock, is valued at approximately $6,970,000, representing $11.50 per share of the Company's common stock. This value reflects a discount from recent similar sized transactions to compensate for the restricted nature of the shares issued in the transaction. WACC was incorporated May 4, 1988 to consolidate oil and gas businesses, assets and operations of its predecessor corporation with those of 11 limited partnerships. Effective April 18, 1994 WACC changed its name from ECC Energy Corporation. (See "Consolidated Financial Statements of WestAmerica Corporation"). In 1994, WACC acquired the entire oil and gas leasehold interest in 7,448 contiguous acres in Washington, Nowata and Rogers counties of Northeastern Oklahoma. WACC currently holds in excess of 17,000 acres of oil and gas leases in the area, which include 119 wellbores with the potential for successful completion in coalbed formations. Production from those wellbores will qualify for tax credits under Section 29 of the IRC. During 1995, WACC completed drilling the 14 well first phase of 28 well drilling program under contract with Oklahoma Resources General Partnership, a 50% owned general partnership formed by a wholly owned subsidiary of WACC to conduct the drilling program with outside investors. All 14 of the wells found potentially productive natural gas and will be completed in one or more coalbed formations. In 1993, WACC purchased 100% of the common shares of WestAmerica Investment Group, Inc.. WestAmerica Investment Group, Inc., operates through a wholly owned subsidiary, WIC a registered broker-dealer and investment advisor business which is headquartered in Scottsdale, Arizona. PROPOSED ACQUISITION OF AUROMAR DEVELOPMENT CORPORATION Pursuant to an agreement dated March 29, 1995, amended June 30, 1996, between the Board of Directors of the Registrant and the Board of Directors of Auromar Development Corporation, a British Columbia corporation, the Registrant has offered to exchange one share of common stock of the Registrant for two and six- tenths (2.6) shares of common stock of Auromar. The Offer to Exchange (the "Offer") is applicable to all of the 7,024,103 shares of common stock of Auromar outstanding on the date of consummation of the Offer. The exchange was approved by the shareholders of Auromar at the Extraordinary General Meeting held on March 12, 1996 pursuant to Sections 276-279 of the British Columbia Company Act and has been approved by the Supreme Court of British Columbia. The Company expects to complete the proposed acquisition in the near future. The purpose of the Offer is for Registrant to acquire 100% of all the issued and outstanding shares of common stock of Auromar. Upon completion of the Offer Auromar will become a wholly-owned subsidiary of the Registrant. Auromar is related to the Registrant through common ownership of options to acquire certain mineral properties in South Africa. Auromar was incorporated under the laws of the Province of British Columbia, Canada on August 20, 1987, as Kelan Resources Inc. The name was subsequently changed to Auromar Development Corporation, pursuant to a Certificate of Amendment to the Certificate of Incorporation filed with the Registrar of Companies in the Province of British Columbia on June 22, 1992. Auromar's principal business offices are located at 800 West Pender Street, Suite 440, Vancouver, British Columbia V6C 2V6. Auromar is a mineral exploration company. However, Auromar maintains no ongoing business operations. Auromar's primary assets are options to purchase a 50% working interest in certain properties in the Schweizer-Reneke area of South Africa on which the Registrant holds options on the remaining 50% interest (See - "Casmyn Mining Corporation, South Africa."). The acquisition of Auromar will provide the Registrant with full control of the Schweizer-Reneke properties. The Company believes that such control will facilitate negotiations with major mining companies in the development of this property. OTHER TRANSACTIONS On September 14, 1994, the Company completed a private placement of 378,055 shares of common stock for net proceeds of $1,908,000. On September 29, 1995, the Company completed a private placement of 714,286 units for net proceeds of $4,750,009. Each unit consists of one share of Common Stock of the Company, plus one warrant; two warrants, plus $8.50, will entitle the holder to purchase one share of the Company's Common Stock. All warrants expire on October 1, 1997. VETI completed a private placement of 1,000,000 shares of its common stock in September, 1995 for net proceeds of $2,375,000. At September 30, 1995, $7,125,002 of these amounts was included in Common Stock subscriptions receivable. The subscriptions receivable were collected subsequent to September 30, 1995. The Company operates through the following subsidiaries: ENTITY: LOCATION BUSINESS PURPOSE - ------- -------- ---------------- MINING Casmyn Mining Corporation ("CMC") Nevada Mining operations - holding company Casmyn Mining Corporation, South Africa Nevada Mining operations - South Africa Casmyn Mining Zimbabwe [Private] Ltd. Zimbabwe Mining operations - Zimbabwe Casmyn Gold Corporation Bahamas Gold acquisition and export ENVIRONMENTAL TECHNOLOGIES Casmyn USA, Inc. * Nevada Research and development Casmyn Technologies Ltd. * Nevada Research and development of water purification technology Casmyn Desalco, Ltd. * Nevada Research and development on desalination projects Vector South Africa Ltd. * Nevada Licensed in South Africa to sell water purification systems Vector Environmental Technologies, Inc. Delaware Environmental technologies with a focus on water treatment - world wide
* Inactive or no significant activity, assets or liabilities. Other than Vector Environmental Technologies, Inc. (VETI), all of the above named companies are wholly-owned directly or indirectly, by the Company. The Company owns 100% of the outstanding Series A Preferred shares of VETI which results in a 56.25% voting majority. BUSINESS PURPOSE The Company's focus is global resource development based on a strategy of applying the effective use of advanced technologies to products and services oriented toward providing efficient, cost effective and profitable solutions to global environmental and resource development challenges. Primary challenges currently being addressed include mineral resources development and water treatment in developing countries. Subsequent to the acquisition of the majority ownership of the Company by Mr. Dahya, the business activities of the Company have centered around mineral resource development. The primary focus to date has been the acquisition and exploration of precious mineral resource properties in South Africa and Zimbabwe and research and development related to minerals testing, process engineering and environmental technologies through the Casmyn Mining Group. In addition, the Company has positioned itself in the environmental industry through an investment in the preferred stock of VETI. VETI is currently focused primarily on the development, manufacture, sales and management of water treatment equipment and facilities. Therefore, the Company and its wholly-owned and majority-owned, through voting control, subsidiaries, are considered to operate in two business segments, mining and environmental technologies, principally water treatment systems. See Note 2 of the Notes to the Consolidated Financial Statements for information on business segments. CASMYN MINING GROUP The Casmyn Mining Group ("CMG") operates principally through Casmyn Mining Company, the holding company, and its wholly owned subsidiaries Casmyn Mining Corporation, South Africa, and Casmyn Mining Zimbabwe [Private] Ltd. The primary business activities of these subsidiaries is described below. ACQUISITION OR DISPOSITION OF ASSETS On January 31, 1996, the Company acquired 100% of the shares of a group of five (5) private mining companies (the "Acquired Companies") controlled by the Muir Family in Zimbabwe through E.W.B. Properties (Private) Limited (Matabeleland Minerals (Private) Limited, Greenhorn Mines (Private) Limited, Morven Mining (Private) Limited, Motapa Minerals (Private) Limited and Turk Mines (Private) Limited. The Acquired Companies own mining claims controlling gold and silver mineral rights covering approximately 1,200 hectares (approximately 2,965 acres) on properties that lie within the Bubi Greenstone Belt, which is one of the largest greenstone formations in Zimbabwe and include numerous shafts, mining equipment and mineral processing mills with a total capacity of 1,000 tonnes per day. The Company estimates that the overall gold resources at the Turk Mines are 5,000,000 ounces. Independent engineering studies are currently underway which may cause this estimate to change. The company believes that sustainable production from the mines can be significantly increased through the application of improved mining and processing management and technologies. The Company believes that reserves will support a mine life in excess of 10 years. The total consideration for this acquisition was approximately U.S. $4,071,415 (Zim $37,986,300) cash plus applicable taxes of U.S. $1,017,854 (Zim $9,496,575) to be paid upon assessment subject to certain adjustments. The funds used to conclude this acquisition were obtained from Company bank accounts, those funds originated from a combination of private placements of Company Common Stock and from proceeds of a convertible debenture. Also on January 31, 1996, Casmyn Corp. purchased the assets of the Dawn Mine property in Zimbabwe from Olympus Gold Mines Limited for approximately U.S. $455,000 (Zim $4,250,000). The Dawn Mine is located in close proximity to the Turk mine and mill and will be operated under a mine plan which includes the Turk mine and mining properties in the area owned by the Company. The combined Muir and Dawn properties have been producing gold since the early 1900's. The Company, as part of its diamond and gold exploration activities in South Africa, regularly acquires and divests options on mineral properties. While certain of these properties may be thought to have strategic importance, none of the properties acquired during the year ended September 30, 1995, or since then to the date hereof, is considered to be financially material. In October 1994, Vector Manufacturing Corp., a second tier subsidiary of VETI, discontinued its custom metal fabrication business. MINERAL RESOURCE DEVELOPMENT INDUSTRY OVERVIEW AND CERTAIN FACTORS RELATING TO THE COMPANY'S PROPERTIES COMPETITION Competition comes from large established mining companies having substantial capabilities and greater financial and technical resources than the Company. Therefore, the Company may be unable to acquire future potential mining properties on terms it considers acceptable. The Company also competes with other mining companies in the recruitment and retention of qualified employees. The Company's smaller size and broad strategic objectives, however, may provide the Company with increased flexibility and certain strategic advantages over its competitors in developing countries. GOVERNMENT APPROVAL/REGULATIONS The mining operations of the Company, through its wholly-owned subsidiaries Casmyn Mining Corporation and Casmyn Zimbabwe [Private] Ltd., are conducted primarily through its offices located in South Africa and Zimbabwe. Casmyn Mining Corporation is qualified to do business in South Africa and, as such, is subject to the laws of that country, which includes permits to allow the Company to conduct exploration activities on optioned properties. COMPLIANCE WITH ENVIRONMENTAL LAWS The mining operations of the Company are directed at determining the presence of economically viable mineral resource deposits on properties under option in South Africa. It is the Company's intention, once such mineral resource deposits are discovered, to identify a joint venture partner to develop and operate the mining properties. Under the South Africa Minerals Act, 1991, the Company and/or its joint venture partner are responsible for development of an environmental impact assessment and an environmental management program for the proposed mining venture which must be approved prior to the start of exploration and/or mining operations. The cost of environmental compliance relating to mineral development is estimated by management to be immaterial as of September 30, 1995 due to the nature of the Company's exploration activities. At September 30, 1995, the Company was not actively involved in mining. On February 1, 1996, the Company acquired various gold mining properties and processing facilities in Zimbabwe and has begun mining and processing gold at those facilities. The Company is in compliance with environmental laws of Zimbabwe. The operations of VETI are not subject to specific governmental approval or regulation. The products of VETI are, however, significantly impacted by environmental, health and import/export related government regulations and programs. In many instances these regulations and programs provide strength to VETI's marketing efforts. VETI's water purification systems help rural communities in developing countries, as well as others, meet World Health Organization and governmental standards for drinking water quality. Anticipated costs relating to government approval and regulation, other than those encountered in the normal course of business, are considered minimal. RISK OF DEVELOPMENT, CONSTRUCTION AND MINING OPERATIONS Should the Company, alone or with a joint venture partner, decide to proceed with development of a mineral resource property, the ability to meet cost estimates and construction and production time estimates cannot be assured. Technical considerations, delay in obtaining governmental approvals, inability to obtain financing or other factors could cause delays in developing mineral resource properties. The businesses of gold and/or diamond mining are subject to a variety of risks and hazards, including environmental hazards, industrial accidents, flooding and the discharge of toxic chemicals. The Company (and its joint venture partners, when identified) intend to obtain insurance in amounts the Company considers to be adequate to protect itself against certain of these risks of mining and processing. However, the Company may become subject to liability for certain hazards for which it cannot obtain insurance or which it may elect not to obtain insurance against because of premium costs or other reasons. EXPLORATION PROGRAMS A major part of the Company's business is the exploration of its existing properties and the evaluation and pursuit of potential new prospects in the exploration stage or of interests in companies which own such properties. Substantial expenditures may be incurred in an attempt to establish the economic feasibility of mining operations by identifying mineral deposits and establishing reserves through drilling and other techniques, designing facilities and planning mining operations. The economic feasibility of a project depends on numerous factors, including the cost of mining and production facilities required to extract the desired minerals, the total mineral deposits that can be mined using a given facility, the proximity of the mineral deposits to a user of the minerals, and the market price of the minerals at the time of sale. There is no assurance that existing or future exploration programs or acquisitions will result in the identification of deposits that can be mined profitably. The Company generally acquires the rights to explore for mineral resources on various parcels of land through option payments and nomination agreements negotiated with the property owner. The agreements have a term of 1 year with the right to extend on a year to year basis. The Company is in the process of determining the potential for economically viable mineral resources on properties under option and will either renew or cancel options based upon this determination. CASMYN MINING CORPORATION, SOUTH AFRICA Casmyn Mining Corporation, South Africa is conducting mineral exploration programs in various areas of South Africa, primarily the Schweizer Property, described in more detail below. Schweizer Property The Company has acquired a 50% interest in options on certain mineral properties located in the Schweizer-Reneke area of South Africa. These options cover an area in excess of 300 square kilimeters approximately 90 miles from the Kimberly diamond mining area. Auromar owns the option to acquire the remaining 50% interest in any of the properties located in the Schweizer-Reneke region. Diamond Exploration Activities There has been significant mining of diamonds in the alluvial gravels in the area currently under option by the Company. The Company has conducted extensive research on indicator minerals that are normally found in such diamond operations. These indicator minerals suggest the potential presence of a diamondiferous kimberlite pipe or a cluster of pipes within close proximity. The Company has commenced an exploration program in this area directed at identifying potential locations of kimberlite pipes. The exploration program consists of geophysical studies which include gravity and magnetic surveys and soil sampling. To date no kimberlite pipe(s) have been discovered and there is no assurance that such pipe(s) will be discovered. Gold Mining Activities In addition to the diamond exploration activities discussed above, a core drilling gold exploration program began on a portion of the Schweizer property in which the Company holds a 50% interest in options, during March 1995. The purpose of the drilling is to test a geologic model which suggests the presence of gold bearing reefs representing an extension of the Witwatersrand Basin, an area that has produced almost 40% of the world's gold. The model, which was developed by independent experts specializing in Witwatersrand gold deposits, utilizes the interpretation of geological sequences mapped in the Schweizer area based upon local outcropping of Witwatersrand structures. Gravity surveys performed by independent consultants identified a structure consistent with the model where potential gold bearing reefs could occur at relatively shallow depths. The ultimate goal of the core drilling is to determine whether the Ventersdorp Contact Reef, which is historically a major source of gold in the Witwatersrand, is present on the Company's properties. CASMYN MINING ZIMBABWE [PRIVATE] LTD. Casmyn Mining Zimbabwe [Private] Ltd. was organized and incorporated in Zimbabwe to acquire mineral properties and mining operations as described below. ZIMBABWE GOLD PROPERTIES On January 31, 1996, the Company acquired 100% of the shares of a group of five (5) private mining companies (the "Acquired Companies") controlled by the Muir Family in Zimbabwe through E.W.B. Properties (Private) Limited (Matabeleland Minerals (Private) Limited, Greenhorn Mines (Private) Limited, Morven Mining (Private) Limited, Motapa Minerals (Private) Limited and Turk Mines (Private) Limited. The Acquired Companies own mining claims controlling gold and silver mineral rights on properties that lie within the Bubi Greenstone Belt, which is one of the largest greenstone formations in Zimbabwe and include numerous shafts, mining equipment and mineral processing mills with a total capacity of 1,000 tonnes per day. The Company estimates that the overall gold resources at the Turk Mines are 5,000,000 ounces. Independent engineering studies are currently underway which may cause this estimate to change. The company believes that sustainable production from the mines can be significantly increased through the application of improved mining and processing management and technologies. The total consideration for this acquisition was approximately U.S. $4,071,415 (Zim $37,986,300) cash plus applicable taxes of U.S. $1,017,854 (Zim $9,496,575) to be paid upon assessment of said taxes as defined in the terms of the Memorandum of Agreement. The amount of consideration is subject to certain adjustments. The funds used to conclude this acquisition were obtained from Company bank accounts, those funds originated from a combination of private placements of Company Common Stock and from proceeds of a convertible debenture. The aforementioned consideration was determined as a result of arm's length negotiations between E.W.B. Properties (Private) Limited and the Company. The principal factors considered in the determination of the consideration given for the Acquired Companies include (a) the tangible and intangible asset values of the businesses acquired including primarily gold reserves, (b) the potential for increasing gold production of the Acquired Companies and (c) the expected future operations and related contributions that the companies are expected to make to the total value of the Company. The shafts, mining equipment and mineral processing mills acquired in this transaction were used by the Acquired Companies for the purpose of mining and processing gold, it is the intention of the Company to continue such use. Also on January 31, 1996, Casmyn Corp. purchased the assets of the Dawn Mine property in Zimbabwe from Olympus Gold Mines Limited for approximately U.S. $455,000 (Zim $4,250,000). The Dawn Mine is located in close proximity to the Turk mine and mill and will be operated under a mine plan which includes the Turk mine and mining properties in the area owned by the Company. The combined Muir and Dawn properties have been producing gold since the early 1900's. On August 1, 1996 an option agreement on gold mining properties in Zimbabwe was concluded, on the "Elumba and Up To Date" properties which are within 5 kilometers of the Turk Mine and Mill and were past producers of gold and silver. CASMYN GOLD CORPORATION Casmyn Gold Corporation was organized (subsequent to September 30, 1995) and incorporated in the Bahamas to act as an agent for the purpose of converting raw gold ore to refined ore. RELIEF CANYON MINE On May 7, 1996, the Company entered into a 50:50 joint venture with Newgold Incorporated ("Newgold"), a private company based in Reno, Nevada, for the development of the Relief Canyon Mine located in Pershing County, Nevada. The Relief Canyon Mine was operated during the period 1984 to 1990 producing in excess of 130,000 ounces of gold. Newgold acquired the mine in 1995 and completed additional geological studies establishing a preliminary resource estimate of 8.6 million tons at an average grade of .022 ounces of gold per ton. Newgold has substantially completed a program to upgrade the mine and processing facilities to a capacity of 12,700 tons per day. The Company contributed or accrued approximately $1,400,000 for its 50% interest in the venture. MARKET FACTORS AND VOLATILITY Active international markets exist for both gold and diamonds, minerals which are of a commodity nature, as such the Company anticipates no barriers to the sale of these minerals. However, the marketability of natural resources which may be acquired or discovered by the Company will be affected by numerous factors beyond the control of the Company. These factors include market fluctuations and the proximity and capacity of natural resource markets and processing equipment. Prices of certain minerals have fluctuated widely, particularly in recent years, and are affected by numerous factors beyond the control of the Company. Future mineral prices cannot be accurately predicted. A decline in the price of a mineral being produced or expected to be produced by the Company could have a material adverse effect on the Company. NEED FOR ADDITIONAL FINANCING Continued exploration, development and production on the Company's mineral properties, including the purchase of additional properties, the exercise/extension of options on properties and construction of mining facilities is likely to require substantial additional financing, and there is no assurance that the Company will be able to secure such financing on acceptable terms. PATENTS, COPYRIGHTS AND LICENSES The Company holds patents on a continuous grind-leach process for gold ore grade evaluation. EMPLOYEES The Company and its subsidiaries currently have three-hundred-fifty (350) employees. These employees are primarily management and professional staff and are not subject to any collective bargaining agreements or union affiliations. Relations between management and employees are considered good. GLOSSARY OF MINING TERMS AND DEFINITIONS Presented below are the definitions of various mining terms that were gathered from Securities and Exchange Commission rules and regulations and/or mining industry literature. KIMBERLITE PIPES - geologic structures containing diamond bearing material. INDICATOR MINERALS - minerals such as garnets, ilmenites, chromites and chrome diopside that are found in soil sampling that are indicative of the presence of kimberlitic materials. MINERALIZED DEPOSIT - a mineralized body which has been physically delineated by drilling, underground work, surface trenching and other workings or drill holes to contain a sufficient amount of mineralized material with an average grade sufficient to warrant further evaluation. Such deposit does not qualify as a commercially mineable (or viable) ore body until technical, economic and legal factors have been sufficiently satisfied to classify the mineralized material as a reserve. RESOURCE - the estimated quantity and grade of mineralization that is of potential economic merit. A resource does not require specific mining, metallurgical, environmental, price, and cost data, but the nature and continuity of mineralization must be understood. WATER TREATMENT AND PURIFICATION VECTOR ENVIRONMENTAL TECHNOLOGIES, INC. The Company holds 100% of the issued and outstanding Series A Preferred shares of Vector Environmental Technologies, Inc. (VETI), which represents 56.25% of the total votes and gives the Company effective voting control. Preferred shares are entitled to vote with Common Shares with the further provision that each preferred share is entitled to the equivalent of four (4) common share votes. Preferred Shares are convertible into Common Shares at the Company's option and share equally with Common Shares with respect to dividends, results of operation and assets of VETI. Through its ownership of Preferred shares the Company holds a 24.3% equity interest in VETI. Effective June 19, 1995, VETI acquired 94% of the outstanding shares of Vector Venture Corporation (VVC), a Canadian company, through a tender offer providing for an exchange of one share of VETI for each share of VVG. The acquisition of VVG has been accounted for as a combination of entities under common control, which is a method similar to a pooling of interests. VETI's principal business is to develop or acquire leading edge environmental technologies for rapidly expanding global markets in water treatment, purification and depollution. The corporate goal is to build VETI into a major multinational corporation with a strong technical foundation, capable of providing lasting solutions which address short, medium and long-term water related environmental issues. VETI's current focus is primarily in the area of water treatment and purification. The company's Diamond Rain-TM- water purification systems are designed to purify water from rivers, lakes and other water sources using a combination of filtration, adsorption and microbial destruction processes to produce safe and healthy drinking water, with technical and economic efficiency that is required for conditions which exist in developing nations. The MCV process, used in many Diamond Rain-TM- systems, was the recipient of the NASA Invention of the Year and Commercial Invention of the Year Awards in April, 1994. During 1995, VETI's primary market focus was in Vietnam, however, the company is in the process of developing programs in India, Ghana, South Africa, Mexico and the United States. In Vietnam, VETI, through its wholly-owned subsidiary Vector Vietnam Ltd. (VVL) (as described below), is actively marketing the full range of VETI water related products and services. In India, VETI is currently in negotiations with one of the largest manufacturers of home appliances in India, which has several thousand distribution outlets across India. VETI's products have passed the testing and certification requirements for distribution in India. VETI expects to begin marketing its complete line of products in India in the fourth calendar quarter of 1996. In Ghana, VETI is currently negotiating with the Ghanaian Government on the supply of 85 Community Scale water supply plants, valued at approximately $11,000,000. Diamond Rain-TM- products have passed the testing and certification requirements of Ghana. In South Africa, at the invitation of the South African government, VETI has submitted a proposal regarding a nationwide water purification program for the supply of safe water to the rural and semi-urban townships covering the government's Reconstruction and Development Program. If negotiations are successful, the first phase of the program contemplates the sale of approximately $50,000,000 over a two year period with a subsequent five-year rollout of $250,000,000. A Community Scale Diamond Rain-TM- system installed at the Umgeni River has successfully passed on-site testing by a leading South African Water Board. In Mexico, VETI has shipped an initial order of consumer products for the Mexican market valued at approximately $40,000. In North America, prompted by growing water quality concerns, VETI plans to introduce a line of consumer-based products to combat Cryptosporidium and Giardia, as well as reduce chlorine, lead and turbidity. The Company has taken steps to penetrate this market by recently employing additional sales and marketing personnel, engaging a national sales representative organization currently covering most national mass merchandisers, retaining the services of a major national advertising agency and opening a North American sales office in Dallas, Texas. Plans for 1996 call for the expansion of the Dallas office to include a distribution and assembly center to cover NAFTA related sales. OPERATING SUBSIDIARIES OF VETI VETI currently operates through 7 (seven) subsidiaries: ENTITY LOCATION BUSINESS PURPOSE Vector Vietnam, Ltd. Vietnam Holds and manages Vietnamese operations Vector Venture Corp. * Canadian Holds certain technologies and licenses Vector India * Nevada Business development in India Vector Manufacturing, Corp. Nevada Provides purchasing and manufacturing services STOX Systems, Inc. Canadian Markets hazardous materials storage systems CGL Technologies, Inc. * Nevada Research and development water purification Alpine Water Purification, Inc. Colorado Markets consumer water treatment equipment
* Inactive or no significant activity, assets or liabilities Other than Vector Venture Corp. (VVC), all of the above named corporations are wholly-owned by the Company. The Company owns approximately 94% of the outstanding shares of VVC. VECTOR VIETNAM LTD. ("VVL") VVL markets the full range of VETI's water treatment and purification equipment, products and services throughout the country of Vietnam. The primary markets currently addressed by VVL include: the sale of personal and household water purification systems to both the retail and wholesale markets; the sale and lease of water purification systems to schools and hospitals; the sale of purified water and water products through company and operator owned retail water stores, the development and operation of water bottling plants and sale of bottled water; and the installation and management of water supply plants for rural and semi-urban communities. To date, VVL has experienced strong market demand in Vietnam for its products and services and has devoted substantial resources to the development of in-country support systems and staff. During 1995, sales growth was primarily in the sale of personal and household systems and the sale or lease of systems to schools and hospitals. VVL has installed and commissioned its first bottling plant and its first community water supply plant in April and May 1996. The installation and management of community water treatment facilities is anticipated to represent a major contributor to future results. Rural water agreements have been signed with over 50 provinces under a Build Operate and Transfer (BOT) framework. The first semi-urban water supply plant was commissioned in April 1996 with an additional 6 plants of similar size expected to be completed by September 30, 1996, with a total of 50 plants targeted for installation during calendar 1996. The scope of the BOT program requires the supply of approximately 10,000 community sized systems over a five year period. The program has the current support of the Vietnamese Government and is contingent on the substantial financial commitment and guarantee of the Government. The proposal provides that daily operations and maintenance of water plants will be performed under contract by a government owned company or companies coordinated through the Ministry of Construction, which has country wide responsibility for ground water resources. This program anticipates VETI's ability to finance between 20% to 40% of the capital cost of this program through international financial sources, however, there is no assurance that such funds will be available in the amounts necessary or under acceptable terms. Water purification systems have been installed in schools in Southern, Central, and Northern Vietnam providing safe drinking water to students on a daily basis. To date VVL has installed a total of 60 school systems. For 1996, an estimated 1,000 school installations are targeted. According to the Nationwide BOT Program, VVL has undertaken with the Vietnamese Government to install 15,000 school water purification systems over the next five years. Water purification systems have been installed in several hospitals in Southern, Central, and Northern Vietnam. For 1996, an estimated 500 hospital installations are targeted. VVL has further undertaken with the Vietnamese government to provide safe drinking and utility water to 11,000 hospitals over a five (5) year period. On October 5, 1995, VVL commissioned a Diamond Rain-TM- water purification system under a contract with Vietnam Airlines at the Hanoi Noi Bai International Airport. The system currently supplies purified water to all Vietnam Airlines local and international flights from Hanoi. Similar contracts are under negotiation for the Ho Chi Minh and Da Nang Airports. As of April 30, 1996, VVL had opened 5 Diamond Rain-TM- Water Stores in the North, Central, and Southern regions of Vietnam. These stores provide bulk purified water to customers in the urban areas, on a cash sale basis. VVL is currently working with owner-operators throughout Vietnam under a specially prepared program. Construction of the VVL's first Diamond Rain-TM- water bottling plant was completed and commissioned in May 1996 and will have an initial annual capacity of 8 million liters, with provision to increase the throughput to 16 million liters per year. VVL expects this plant to generate revenues of approximately $4 million per annum with ramp up commencing in the second calendar quarter 1996. Nationwide distribution agreements for Diamond Rain-TM- bottled water have been negotiated with a major beverage distributor in Vietnam. To date, in excess of 5,000 Diamond Rain-TM- household water purifiers had been sold in Vietnam. VECTOR MANUFACTURING CORPORATION ("VMC") VMC is a wholly owned subsidiary of VVC that provides purchasing and manufacturing services relating to VETI's water purification product lines. VMC sells water purification products to distributors as well as its subsidiary companies Alpine Water Purification, Inc. and VVL. ALPINE WATER PURIFICATION, INC. ("ALPINE") VETI markets a line of water treatment products under the Alpine name, primarily directed toward personal and household markets, involving water treatment cartridge technologies. These products are designed primarily for the North American market to improve taste. STOX SYSTEMS, INC. ("STOX") STOX has historically been involved in the design, engineering and installation of a broad range of hazardous materials storage and transportation systems. STOX has developed a diverse product line which consists primarily of prefabricated relocatable buildings or containers for storage of most classes of hazardous materials. These systems are designed to safely handle or store hazardous raw materials, reagents, explosives, products, and effluents from a broad spectrum of industries. The manufacture of these systems has been subcontracted to various other companies. There is a growing worldwide concern over the health and safety implications of improper storage and handling of hazardous materials. The market for these products has not developed to the extent anticipated. VETI remains committed to the long term viability of this product line, but has no plans to actively market this product in 1996. COMPETITION VETI's marketing strategy for water purification systems is to utilize exclusive agreements with individuals, corporations, or organizations which management believes provide contacts and expertise necessary to penetrate target markets. Initial market focus has been directed primarily to developing nations, where the need for purified drinking water is most critical and where VETI's technology and its commitment to developing the infrastructure necessary to assure long term water quality, has an advantage over competitive systems. With the exception of large infrastructure projects involving municipal systems for large cities, competition relating to water treatment equipment and services in developing countries is weak and fragmented with most competitors offering only a limited capacity in terms of technology and product diversification. VETI maintains a broad product line using a wide variety of technologies with a strategy of matching the product and technology to the problem or situation. VETI's products are competitively priced in all of its target markets. PURCHASING AND PRINCIPAL SUPPLIERS The raw materials used in VETI's products include primarily filters, filter housings, treatment media, treatment chemicals, fiberglass tanks, aluminum sheets and various plumbing supplies. Most of these components are of a standard or commodity nature and widely available. VETI maintains relationships with several principal suppliers and subcontractors due to quality considerations and in order to avail itself of volume pricing. No supplier is currently considered a sole source. Alternative suppliers with acceptable technology and quality have been identified for all critical components. PATENTS, COPYRIGHTS AND LICENSES Alpine holds a patent relating to the design of its countertop water purification cartridge. Technologies relating to water purification and treatment and hazardous material storage, while proprietary, are based on know-how and trade secrets and are not patented. VETI does not intend to patent these technologies due to the nature of the technologies and the level of public disclosure involved in the patent process. GOVERNMENT APPROVAL/REGULATIONS The operations of VETI are not subject to specific governmental approval or regulation. The products of VETI are, however, significantly impacted by environmental, health and import/export related government regulations and programs. In many instances these regulations and programs provide strength to the VETI's marketing efforts. The Diamond RainTM water purification systems help rural communities in developing countries, as well as others, meet World Health Organization and governmental standards for drinking water quality. Anticipated costs relating to government approval regulation, other than those encountered in the normal course of business, are considered minimal. RESEARCH AND DEVELOPMENT VETI is committed to ongoing research and development. The nature of environmental issues provides a constant supply of challenges and opportunities for technology based solutions. VETI estimates that it spent $185,053, $410,754 and $186,805 on research and development activities during fiscal years ended September 30, 1995 and June 30, 1994 and the three months ended September 30, 1994, respectively (these amounts are before elimination of intercompany amounts). During the past year VETI devoted substantially all of its research and development efforts toward the review and development of water purification systems and technologies. While a broad line of water purification systems has been developed, continued research and development in this area is ongoing. This research is expected to produce additional product offerings, address new problem areas, reduce the capital cost and maintenance of equipment and improve efficiency. Research and development is conducted or coordinated primarily through contracts with the Company. The Company employs qualified scientists, technologists and engineers experienced in the fields of environmental protection, water purification, treatment of effluents from mineral processing operations, and pollution control of water. The Company established its United States operations in 1991; it occupies a 6,500 square foot building that is fully equipped with offices, laboratories, pilot testing and storage areas. The Company provides research and development services to VETI to develop commercial applications for water purification technologies. In addition, the Company provides technical staff to VETI as required. The Company bills VETI for these at rates approximating cost recovery. FACILITIES The Company is located in Sparks, Nevada in office space which is currently occupied under a month-to- month lease at a cost of approximately $4,100 per month. These operations occupy a portion of a 6,500 square foot unit which includes office and laboratory facilities which are shared with certain related companies. Those companies reimburse the Company for a portion of the monthly rent. These facilities are adequate for the current level of operations and sufficient office and laboratory space is conveniently located to support future growth. Casmyn Mining Corporation, South Africa is located in Pretoria, South Africa in office space which is currently occupied on a month-to-month basis at a cost of approximately $1,700 per month. Casmyn Zimbabwe [Private] Ltd., is located near Bulawayo Zimbabwe in office space and facilities owned by Casmyn Zimbabwe [Private] Ltd. Effective December 1995, VVL occupies office space in Ho Chi Minh City and Hanoi under 36 month leases at an approximate cost of $5,000 per month. These facilities include offices, temporary living quarters and product show rooms. VVL also operates two retail water stores, one in Ho Chi Minh City and one in Hanoi. VVL has constructed a water bottling plant in the Nam Ha Province of Vietnam which began operations in June 1996. EMPLOYEES VETI and the Company currently have in excess of three-hundred-fifty (350) employees. These employees include management and professional staff and mine workers in Zimbabwe and are not subject to any collective bargaining agreements or union affiliations. Relations between management and employees are considered excellent. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE Effective December 12, 1994, the Company dismissed its prior certifying accountants, Albright, Persing & Associates, Ltd. ("Albright") and retained as its new certifying accountants, Deloitte & Touche LLP. Albright's report on the Company's financial statements during the two most recent fiscal years preceding the date hereof (periods ended September 30, 1993 and September 30, 1992) contained no adverse opinion or a disclaimer of opinion, and was not qualified as to uncertainty, audit scope or accounting principles. The decision to change accountants was approved by the Company's Board of Directors. During the last two fiscal years and the subsequent interim period to the date of this Prospectus, there were no disagreements between the Company and Albright on any matters of accounting principles or practices, financials statement disclosures, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Albright, would have caused it to make a reference to the subject matter of the disagreements in connection with its reports. MANAGEMENT The following is a list of the directors and officers of the Company: NAME AND ADDRESS POSITION(S) HELD Amyn Dahya Chairman of the Board, 1335 Greg Street #104 Chief Executive Officer and Sparks, NV 89431 President Hanif Dahya Vice Chairman of the Board of 1335 Greg Street #104 Directors Sparks, NV 89431 Vijay J. Fozdar Director, Managing Director 1335 Greg Street #104 Finance & Corporate Development Sparks, NV 89431 Sandro Kunzle Director Tenuta Aia Vecchia 58029 Sassafortino (GR) Italy Mehdi Nimjee Director, Vice President Metallurgy Unit #1 - 6645 Tomken Rd. Mississauga, Ontario Canada L5T 2C3 Douglas C. Washburn Vice-President, Treasurer and 1335 Greg Street #104 Secretary Sparks, NV 89431 Dr. Gregory J. Gosson Vice President Geology and Mining Suite 201, United Bank Bldg. Heuwel Ave / Heuwelstraat Verwoerdburg, R.S.A. Dennis E. Welling Controller 1335 Greg Street #104 Sparks, NV 89431 BACKGROUND OF OFFICERS AND DIRECTORS OF THE COMPANY AMYN S. DAHYA. Mr. Dahya has extensive international experience in project development, engineering, joint ventures, and finance. Prior to joining the Company in 1993, he has held senior positions with Davy McKee, an international engineering firm and in 1987 he founded Casmyn Group of Companies specializing in mineral and environmental engineering, which he has developed for the last seven (7) years. Mr. Dahya serves on the Board of Directors of several companies, including Diamond Fontein International, Vector Venture Corp., and VETI where he also holds executive management positions. HANIF DAHYA. Mr. Dahya is a graduate from Harvard Business School (MBA) with an undergraduate degree in (BSc) in Production Engineering from Loughborough University, UK. He has built a distinguished career on the Wall Street and has held senior positions with high profile investment banks including E F Hutton, L F Rothschild Mortgage Corp. (CEO) and Union Bank of Switzerland (managing Director -- UBS Securities). He is currently a partner at Sandler, O'Neil, a Wall Street investment bank. His experience includes multi-million dollar financings and bond issues. As an advisor to the Board of Vector, he provides strategic direction with respect to the Company's financial planning and growth, which is primarily focused on expansion of operations and acquisitions of other cash flow generating companies in the environmental industry. VIJAY J. FOZDAR. Prior to joining VETI as President, Mr. Fozdar was a founder and Managing Director of Bristol International, Ltd., a Dallas-based merchant banking firm, and the Managing Director of Bristol WorldSource, Inc. Before Bristol, he founded and was General Manager for First RepublicBank Trade. Prior to returning to the U.S. in 1978, Mr. Fozdar spent over fifteen years working with several major trading companies operating in the Far East where he helped to establish distribution systems for a number of U.S. consumer and industrial products companies. Mr. Fozdar was formerly a member of the Export Trading Company Committee of Bankers Association for Foreign Trade (BAFT) and served on the Dallas Mayor's Trade and Investment Task Force. He is currently a member of the Advisory Board for the Center for International Business Studies at Texas A & M University. In addition, Mr. Fozdar is a frequent guest lecturer on international trade issues and has addressed market intelligence, structured trade finance, international marketing, and specific country seminars and their related issues. Mr. Fozdar has served on various international trade committees in the U.S. SANDRO KUNZLE. Mr. Kunzle has over 23 years of international banking and finance experience. During his career, Mr. Kunzle has held senior positions with several Swiss banks and financial institutions. He currently holds the position of Managing Director of Witra Inc., an investment firm based in Switzerland. His expertise in international finance and venture capital adds significant experience to the Company's international business development efforts. MEHDI C. NIMJEE. Mr. Nimjee brings to the Company twenty years of project management experience in the field of analytical chemistry and its applications to exploration, mining, agriculture, hazardous materials handling and the environment. He has also had experience in designing and setting up project specific laboratories internationally. Mr. Nimjee currently holds executive and board positions with the Casmyn Canadian organization. DOUGLAS C. WASHBURN. Mr. Washburn holds a MBA/CPA and brings twenty-four (24) years of financial management experience to the Company. Prior to joining the Company in 1993 he was a principal at Washburn Partners, a financial consulting firm, from 1990 to 1993. Between 1980 and 1990, he was Vice President and Controller of Armco Financial Corporation, a $1 billion multinational merchant bank and its successor Glenfed Financial Corporation. Through his background he brings to the Company expertise in areas of international finance, planning, taxation, accounting and management information systems. DR. GREGORY G. GOSSON. Dr. Gosson is the Chief Geologist for Casmyn Mining Corporation and is overseeing the Company's exploration activities from the Pretoria, South Africa office. Dr. Gosson has been involved in the mining industry since 1977 and has managed projects in Canada, the U.S.A., the Caribbean, South East Asia, New Zealand, and most recently in South Africa. Prior to joining Casmyn, Dr. Gosson was Chief Geologist for Plexus Resources in the U.S.A. He is a graduate of Queen's University, Canada and obtained his Ph. D. in Geology from Victoria University, New Zealand. Dr. Gosson has been managing Casmyn's property acquisitions and exploration efforts in South Africa for the past three and one-half years. His experience in base and precious metal deposits, precious stones, coal, and the oil and gas industry will be instrumental in identifying and developing mining opportunities for Casmyn worldwide. DENNIS E. WELLING. Mr. Welling, a CPA, currently serves as Controller. He has twenty-four (24) years internal and external audit and controlling experience, including positions with Deloitte & Touche, Armco Steel Corporation and Glenfed Financial Corporation. He has significant management information systems experience in the mining, manufacturing and financial services sectors. EXECUTIVE COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY In 1994, upon Mr. Dahya's acquisition of a controlling interest in the Company, the organizational structure of the Company was reconstituted to implement the development of mineral resources and environmental technologies. Prior to 1995 there was no compensation paid to any of the officers or directors. On April 14, 1995, the Company hired an entirely new management team, all of whom had previously maintained consulting relationships with the Company and/or are officers of the Company's subsidiary Vector Environmental Technologies, Inc. Since the Company has no compensation committee, or other board committee performing equivalent functions, the Company's full Board of Directors participates in and approves all deliberations concerning executive officer compensation. On December 31, 1993, the Company's subsidiary, Vector Environmental Technologies, Inc., entered into a ten-year employment contract with Amyn Dahya, Chairman of the Board, President and Chief Executive Officer. Pursuant to the terms of the contract, Mr. Dahya will earn an annual base salary of $150,000, which increases by no less than 10% per year if such an increase is approved by the Board of Directors. Under this contract, Mr. Dahya also receives reimbursement for business expenses and normal group benefits available to other executives of the VETI This contract also provides Mr. Dahya with 5-year, non-qualified, stock options to purchase shares of Common Stock of the VETI at an exercise price of $1.00 per share, The issuance of these shares is not intended or anticipated to significantly dilute the equity of the Company. (See "CERTAIN TRANSACTIONS.") Under the terms of the employment contract, Mr. Dahya has been granted options to purchase shares of VETI's Common Stock pursuant to the schedule and LTIP table: NO. OF SHARES TIME OF VESTING - ------------- --------------- 250,000 Immediately upon execution of the Employment Agreement 250,000 When gross sales of VETI reach $2,500,000 250,000 When gross sales of VETI reach $5,000,000 250,000 When gross sales of VETI reach $7,500,000 The following is a Summary Compensation Table disclosing annual compensation over $100,000 paid to the executive officers of Registration and/or Option/SAR Grants during the last fiscal year: SUMMARY COMPENSATION TABLE (INCLUDES COMPENSATION PAID BY THE COMPANY AND VETI) ANNUAL COMPENSATION LONG-TERM COMPENSATION ---------------------------------------------------------------------------- AWARDS PAYOUTS - ------------------------------------------------------------------------------------------------------------ ALL FISCAL OTHER RESTRICTED OTHER NAME AND YEAR ANNUAL STOCK OPTIONS/ LTIP COMPEN- PRINCIPAL POSITION ENDING SALARY BONUS COMP. AWARD(S) SAR'S PAYOUTS SATION - ------------------------------------------------------------------------------------------------------------ Amyn Dahya, 1995 $150,000 None None 0 0 President 1994 $150,000 None None 0 0 and CEO 1993 $100,000 None None $718,750 250,000(2) None None (1) - ------------------------------------------------------------------------------------------------------------ Vijay Fozdar, 1995 $60,000* None $60,000 (4) (4) None None Managing Director (3) Finance & Corporate Development - ------------------------------------------------------------------------------------------------------------ Mehdi Nimjee, 1995 $60,000 None None (4) (4) None None Director and VP 1994 $60,000 None None 1993 $60,000 None None - ------------------------------------------------------------------------------------------------------------ Douglas Washburn, 1995 $60,000* None None (4) (4) None None VP, Treasurer and 1994 $60,000* None None Secretary 1993 $60,000* None None ----------------------------------------------------------------------------------------------------------- Dennis Welling, 1995 $60,000* None None (4) (4) None None Controller 1994 $54,162* None None 1993 $50,000* None None - ------------------------------------------------------------------------------------------------------------ Duane Dunk, 1995 $75,600* None None (4) (4) None None EVP of VETI 1994 $73,000* None None 1993 $60,000 None None - ------------------------------------------------------------------------------------------------------------ David Chase, 1995 $72,000* None None (4) (4) None None VP of VETI 1994 $72,000* None None 1993 $72,000* None None $431,250 150,000 (1) - ------------------------------------------------------------------------------------------------------------ - ------------------------------------------------------------------------------------------------------------
* Paid by VETI. (1) Calculations are based on $3.875 per share, the market value of stock on December 31, 1993 the date the Options were granted, less the option price of $1.00 per share. (2) Immediately upon execution of his employment contract, on December 31, 1993, Mr. Dahya was granted an option to purchase 250,000 shares of VETI's Common Stock at an exercise price of $1.00 per share for a period of 5 years, expiring on December 31, 1998. As of the date of this Prospectus, none of these Options have been exercised. (See "CERTAIN TRANSACTIONS.") (3) Paid to Bristol World Source ("Bristol") for international marketing and management consulting services, Mr. Fozdar is a princpal with Bristol. (4) During 1995, the Company and VETI adopted stock option plans for key officers and employees. All options granted by the Company during 1995 were granted on June 28, 1995; options to purchase 660,000 Common Shares were granted with an option price equal to the then market price of $5.00 per share and options to purchase 246,000 shares were granted at $.04 per share. All options granted during 1995 by VETI were granted on June 20, 1995 with an option price equal to the market price of $1.00 per share on the grant date. See EMPLOYEE STOCK OPTION PLANS for additional information on plans. The following tables summarize the number and value of options to purchase stock granted under these plans: THE COMPANY ---------------------------------------------------------------------------------------------- Securities underlying Restricted Stock Award (s) Options / SARs Name ($) (#) Exercisable/Unexercisable Exercisable/Unexercisable ---------------------------------------------------------------------------------------------- Amyn S. Dahya $0 / $0 0/0 Vijay Fozdar $248,000 / $0 50,000/150,000 Douglas C. Washburn $62,000 / $62,000 12,500/62,500 Dennis E. Welling $24,800 / $24,800 5,000/35,000 Duane Dunk $24,800 / $24,800 5,000/35,000 David Chase $124,000 / $124,000 25,000/75,000 ----------------------------------------------------------------------------------------------
* Options are subject to vesting period of up to four years. VETI ---------------------------------------------------------------------------------------------- Securities underlying Restricted Stock Award (s) Options / SARs Name ($) (#) Exercisable/Unexercisable Exercisable/Unexercisable ---------------------------------------------------------------------------------------------- Vijay Fozdar $49,500 / $0 99,500/100,500 Douglas C. Washburn $0 / $0 13,200/26,800 Dennis E. Welling $0 / $0 13,200/26,800 Duane Dunk $0 / $0 16,500/33,500 David Chase $0 / $0 16,500/33,500 ----------------------------------------------------------------------------------------------
* Options are subject to vesting period of up to four years. No compensation is currently paid to non-employee directors. All other executive officers of the Company listed above received a combined annual cash compensation of $156,000 for the fiscal year ended September 30, 1995. In addition, the Company pays a portion of each employee's health insurance premium. There are no employment contracts, other than with Mr. Amyn Dahya outlined below, proposed termination of employment or change-in-control arrangements between the Company and any of its directors or executive officers. The following table lists the Options granted to employees of the Company, excluding those granted to Mr. Dahya in his employment contract, during the last fiscal year: OPTION/SAR GRANTS IN LAST FISCAL YEAR THE COMPANY - ---------------------------------------------------------------------------------------------------------------------------------- POTENTIAL REALIZABLE VALUE AT ASSUMED ANNUAL RATES OF INDIVIDUAL GRANTS STOCK PRICE APPRECIATION FOR OPTION TERM - ----------------------------------------------------------------------------------------------------------------------------------- NO. OF SECURITIES % OF TOTAL UNDERLYING OPTIONS/SAR'S OPTION/SAR'S GRANTED TO EXERCISE OF NAME AND POSITION GRANTED EMPLOYEES BASE PRICE EXPIRATION IN FISCAL YEAR ($/SHARE) DATE 5% ($) 10% ($) - ----------------------------------------------------------------------------------------------------------------------------------- Vijay Fozdar, 50,000 6% $.04 6/2000 $316,518 $399,406 Director 150,000 18% $5.00 12/2003 - ----------------------------------------------------------------------------------------------------------------------------------- Mehdi Nimjee, 50,000 6% $.04 6/2001 $324,431 $419,377 Director and VP - ----------------------------------------------------------------------------------------------------------------------------------- Douglas Washburn, 25,000 3% $.04 6/2001 $162,215 $209,689 VP, Treasurer and Secretary 50,000 6% $5.00 12/2003 $20,500 $48,000 - ----------------------------------------------------------------------------------------------------------------------------------- Dennis Welling, 10,000 1% $.04 6/2001 $64,900 $83,900 Controller 30,000 4% $5.00 12/2003 $12,300 $28,800 - ----------------------------------------------------------------------------------------------------------------------------------- Duane Dunk, 10,000 1% $.04 6/2001 $64,900 $83,900 EVP of VETI 30,000 4% $5.00 12/2003 $12,300 $28,800 - ----------------------------------------------------------------------------------------------------------------------------------- David Chase, 50,000 6% $.04 6/2001 $324,431 $419,377 VP of VETI 50,000 6% $5.00 12/2003 $20,500 $48,000 - -----------------------------------------------------------------------------------------------------------------------------------
VETI - ---------------------------------------------------------------------------------------------------------------------------------- POTENTIAL REALIZABLE VALUE AT ASSUMED ANNUAL RATES OF INDIVIDUAL GRANTS STOCK PRICE APPRECIATION FOR OPTION TERM - ----------------------------------------------------------------------------------------------------------------------------------- NO. OF SECURITIES % OF TOTAL UNDERLYING OPTIONS/SAR'S OPTION/SAR'S GRANTED TO EXERCISE OF NAME AND POSITION GRANTED EMPLOYEES BASE PRICE EXPIRATION IN FISCAL YEAR ($/SHARE) DATE 5% ($) 10% ($) - ----------------------------------------------------------------------------------------------------------------------------------- Vijay Fozdar, 50,000 7% $.01 6/2000 $63,176 $79,720 Managing Director 150,000 22% $1.00 6/2001 $47,850 $108,150 Finance & Corporate Development of VETI - ----------------------------------------------------------------------------------------------------------------------------------- Mehdi Nimjee, 50,000 7% $1.00 6/2001 $15,950 $36,050 Director and VP - ----------------------------------------------------------------------------------------------------------------------------------- Douglas Washburn, 40,000 6% $1.00 6/2001 $12,760 $28,840 VP, Treasurer and Secretary - ----------------------------------------------------------------------------------------------------------------------------------- Dennis Welling, 40,000 6% $1.00 6/2001 $12,760 $28,840 Controller - ----------------------------------------------------------------------------------------------------------------------------------- Duane Dunk, 50,000 7% $1.00 6/2001 $15,950 $36,050 EVP of VETI - ----------------------------------------------------------------------------------------------------------------------------------- David Chase, 50,000 7% $1.00 6/2001 $15,950 $36,050 VP of VETI - ----------------------------------------------------------------------------------------------------------------------------------- - -----------------------------------------------------------------------------------------------------------------------------------
No other benefits, salaries, bonuses, stock options, grants, SAR's or compensation have been paid or given to executive officers during the last fiscal year and it is not anticipated that any will be in the foreseeable future. The following table lists the aggregated Option/SAR exercises during the last fiscal year by directors and officers of the Company and the fiscal year end Option/SAR values of both the exercised and unexercised Option/SAR Grants: AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION/SAR VALUES THE COMPANY - --------------------------------------------------------------------------------------------------------------------------------- - --------------------------------------------------------------------------------------------------------------------------------- Number of Securities Underlying Value of Unexercised In- Unexercised options at Sept. the-Money options 30, 1995 Exercisable / at Sept. 30, 1995 Shares Value Unexercisable Exercisable / Unexercisable Name Acquired Realized - --------------------------------------------------------------------------------------------------------------------------------- - --------------------------------------------------------------------------------------------------------------------------------- Amyn S. Dahya 0 0 0/0 $0/$0 Vijay Fozdar 0 0 50,000/150,000 $448,000/$600,000 Douglas C. Washburn 0 0 12,500/62,500 $112,000/$312,000 Dennis E. Welling 0 0 5,000/35,000 $44,800/$164,800 Duane Dunk 0 0 5,000/35,000 $44,800/$164,800 David Chase 0 0 25,000/75,000 $224,000/$424,000 - --------------------------------------------------------------------------------------------------------------------------------- - ---------------------------------------------------------------------------------------------------------------------------------
VETI - --------------------------------------------------------------------------------------------------------------------------------- - --------------------------------------------------------------------------------------------------------------------------------- Number of Securities Underlying Value of Unexercised In Unexercised options at Sept. the-Money options at Shares Value 30, 1995 Exercisable / Sept. 30, 1995 Name Acquired Realized Unexercisable Exercisable / Unexercisable - --------------------------------------------------------------------------------------------------------------------------------- - --------------------------------------------------------------------------------------------------------------------------------- Amyn S. Dahya 0 0 250,000/750,000 $437,500/$1,312,500 Vijay Fozdar 0 0 99,500/100,500 $223,625/$175,875 Douglas C. Washburn 0 0 13,200/26,800 $23,100/$46,900 Dennis E. Welling 0 0 13,200/26,800 $23,100/$46,900 Duane Dunk 0 0 16,500/33,500 $28,875/$58,625 David Chase 0 0 16,500/33,500 $28,875/$58,625 - --------------------------------------------------------------------------------------------------------------------------------- - ---------------------------------------------------------------------------------------------------------------------------------
LONG TERM INCENTIVE PLANS - AWARDS IN LAST FISCAL YEAR To date, none of the foregoing options have been exercised. None of the other directors or executive officers of the Company hold options to purchase shares of the Company's Common Stock. EMPLOYEE STOCK OPTION PLAN During 1995, the Company adopted an Incentive Stock Option Plan (ISOP) which provides that a maximum of 800,000 options to purchase the Company's common stock may be granted to officers and employees of the Company. Options granted under the ISOP are intended to qualify as incentive stock options under the Economic Recovery Tax Act of 1981 (the "1981 Act") as amended by the Tax Reform Act of 1986. The ISOP is administered by the Board of Directors through a committee presently consisting of two members of the Board (Committee). The Committee determines which persons receive options, the number of shares that may be purchased under each option, vesting provisions, option terms and exercise price. Options granted under the ISOP are require to have an exercise price equal to or greater than the market price of the Company's Common Shares at the grant date. In the event an optionee voluntarily terminates his relationship with the Company, he has the right to exercise his accrued options within 3 months of such termination. However, the Company may redeem any accrued options held by an optionee by paying the difference between the option price and the then fair market value. If an optionee's relationship is involuntarily terminated, other than because of death, he also has the right to exercise the accrued options within thirty (30) days of such termination. Upon death, his estate or heirs have one year to exercise his accrued options. Options granted under the ISOP are not transferable other than by will or by the laws of descent and distribution. The ISOP provides that the number of shares and the option price will be adjusted on a pro-rata basis for stock splits and stock dividends. Options must be granted within five (5) years from the effective date of the ISOP. As of September 30, 1995, options to purchase up to 660,000 shares of common stock were granted under the ISOP. All options granted under the ISOP are valid for a term of five (5) years from the date of vesting and vest 25% per year over a period of four years. All options granted to date under the ISOP have a exercise price of $5.00 per share which represents the market price per share on the date of grant The Company also adopted a non-qualified Stock Option Plan (SOP), which grants five year options to purchase a maximum of 250,000 shares of the Company's common stock at a price of $0.04 per share to officers and key employees of the Company. Options granted under the Plan are not-intended to qualify as incentive stock options under the Economic Recovery Tax Act of 1981 (the "1981 Act") as amended by the Tax Reform Act of 1986. The Plan is administered by the Board of Directors through a committee presently consisting of all three members of the Board which determines which persons receive options under the SOP, the number of shares that may be purchased under each option and the vesting period. The term of all options is five (5) years and all options must be granted within five (5) years from the effective date of the Plan. Options granted under the Plan are not transferable other than by will or by the laws of descent and distribution. The Option Plan provides that the number of shares and the option price will be adjusted on a pro-rata basis for stock splits and stock dividends. As of September 30, 1995, options to purchase up to 246,000 shares of common stock were granted under the SOP. With the exception of Mr. Vijay Fozdar, who's options vest 100% on the grant date, the options vest to the optionee over a one (1) year period with 50% vesting at the grant date and 50% on the first anniversary of the grant date. Options granted under the SOP are compensatory in nature and result in total compensation expense of approximately $1,220,160, of which $855,600 was recorded as compensation expense during 1995 and $364,560 will be recorded as expense for the year ended September 30, 1996. During 1995 VETI adopted a qualified Incentive Stock Option Plan (V-ISOP) which provides that a maximum of 700,000 options to purchase the VETI's common stock may be granted to officers and employees and advisors of VETI. Options granted under the V-ISOP are intended to qualify as incentive stock options under the 1981 Act. As of September 30, 1995, options to purchase up to 606,000 shares of common stock were granted under the V-ISOP. All options granted to date under the V-ISOP have a exercise price of $1.00 per share which represents the market price per share on the date of grant. The only other benefit plan offered at the present or during 1995 involves a major medical plan which is made available to all employees on a non-discriminatory basis, the Company currently maintains no other stock option plans, no plan which would termed a "Long-Term Incentive Plan" as explained in Item 402 (a)(6)(iii) of the U.S. Securities and Exchange Act, nor any benefit plan which would give rise to "Long Term Compensation" as defined in Item 402(b)(iv) of the U.S. Securities and Exchange Act, except as described above. INDEMNIFICATION OF DIRECTORS AND EXECUTIVE OFFICERS Pursuant to the By-Laws of the corporation, the Company has agreed to indemnify an officer or director who is made a party to any proceeding, including a law suit, because of his/her position, if he/she acted in good faith and in a manner he/she reasonably believed to be in the best interest of the corporation and, in certain cases, may advance expenses incurred in defending any such proceeding. To the extent that the officer or director is successful on the merits in any such proceeding as to which such person is to be indemnified, the Company must indemnify him/her against all expenses incurred, including attorney's fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officer or director is judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by Colorado law. Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to officers, directors or persons controlling the Company, pursuant to the foregoing provisions, the Company has been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in said Act and is, therefore, unenforceable. PRINCIPAL SHAREHOLDERS The following table lists the shares of Common Stock of the Company owned, directly or indirectly, by each director of the Company, and each executive officer of the Company named in the Summary Compensation Table, affiliates of the directors and executive officers, the directors and executive officers as a group, and shareholders who hold 5% or more of the Company's Common Stock at June 30, 1996: - --------------------------------------------------------------------------------------------------------------- NAME AND ADDRESS OF AMOUNT AND NATURE OF TITLE OF CLASS BENEFICIAL OWNER BENEFICIAL OWNERSHIP PERCENT OF CLASS (1) - --------------------------------------------------------------------------------------------------------------- COMMON STOCK AMYN DAHYA 1335 GREG ST. #104 (2) -- SPARKS, NV. 89431 - --------------------------------------------------------------------------------------------------------------- HANIF DAHYA NIL -- 5 BEECHWOOD ROAD ALLENDALE, NEW JERSEY 07401 - --------------------------------------------------------------------------------------------------------------- SANDRO KUNZLE NIL -- TENUTA AIA VECCHIA 58029 SASSOFORTINO (GR) ITALY - --------------------------------------------------------------------------------------------------------------- NIL -- VIJAY J. FOZDAR 1335 GREG STREET #104 SPARKS, NV 89431 - --------------------------------------------------------------------------------------------------------------- 1,807,750 (3) 19% BISMILLAH CHILDREN'S FOUNDATION LTD. 1335 GREG ST. #104 SPARKS, NV. 89431 - --------------------------------------------------------------------------------------------------------------- 877,580 8.8% SOCIETE GENERALE 17 COURS VALNEY LA DEFENSE CEDEX PARIS, FRANCE 89431 - --------------------------------------------------------------------------------------------------------------- 606,061 6.1% WESTAMERICA CORP. 4141 N. SCOTTSDALE RD. SUITE #100 SCOTTSDALE, AZ 85251 - --------------------------------------------------------------------------------------------------------------- ALL OFFICERS AND DIRECTORS OF THE -- -- COMPANY AS A GROUP - ---------------------------------------------------------------------------------------------------------------
(1) These percentages and totals are calculated based upon the total number of shares of common stock issued and outstanding as of the date of this Prospectus plus, in the case of persons holding presently exercisable options, the number of shares subject to such options. (2) At September 30, 1995, Mr. Amyn Dahya held 1,982,000 common shares of the Company, in addition 725,000 common shares of the Company were owned or controlled by Dahya Holdings, Inc., a Bahamiam corporation, of which Mr. Amyn Dahya is an officer and director. Mr. Mansoor Dahya, an uncle to Mr. Amyn Dahya, is the majority shareholder of Dahya Holdings, Inc. and holds 91% of the outstanding voting stock of Dahya Holdings, Inc. As indirect shareholders, Messrs. Amyn Dahya and Mansoor Dahya have shared voting and investment power in and to these shares. On October 3, 1995, these shares were converted into 2,707,000 Series A preferred shares and are entitled to vote with common shares with the further provision that each preferred share will be entitled to the equivalent of five (5) common share votes. (3) Bismillah Children's Foundation Ltd. is a nop-profit/charitable Nevada Corporation of which Mr. Amyn Dahya is a Trustee and Director. Bismillah is managed by a five (5) member Board of Trustees. Mr. Dahya and his wife are two of the five Trustees. A majority vote is required for the Board to take any actions on behalf of the Foundation. LEGAL PROCEEDINGS STOX has commenced an action in Ontario, Canada against Orillia Steel Works, Inc. ("OSW") entitled STOX Systems, Inc. v. Orillia Steel Works, Inc. for $550,000 Cdn ($414,094 U.S.) for breach of contract or, in the alternative, for conversion of intellectual property. OSW has defended the action and launched a counterclaim for $450,000 Cdn. ($339,623 U.S.) for breach of contract. There is also a claim for recovery of related interest and costs. STOX entered into a contract with OSW pursuant to which OSW was to fabricate a hazardous material storage facility (the "Facility"), designed by STOX. The contract included an express term regarding confidentiality (the "Confidentiality Clause"). STOX claims that OSW violated the Confidentiality Clause with respect to the intellectual property used to fabricate the facility and, as a result, STOX suffered damages. OSW claims that it did not violate the Confidentiality Clause because it actually owns the intellectual property used to fabricate the Facility. Rather, OSW alleges that STOX breached a verbal understanding that OSW would have the exclusive right to fabricate the facilities marketed and sold by STOX. AS a result of STOX's alleged breach of the verbal understanding, OSW claims that it suffered damages. STOX denies that there was any verbal understanding with OSW and, if there was, that OSW itself breached a fundamental term of that understanding and, therefore, STOX cannot be held liable. While the Company cannot yet determine the full impact of these actions, it believes that they will not have a material adverse effect on the financial condition or results of operations of the Company. The Company is not aware of any other material litigation, whether pending or threatened, to which it is or may become a party. CERTAIN TRANSACTIONS On December 31, 1993, VETI entered into a ten-year employment contract with Amyn Dahya, Chairman of the Board, President and Chief Executive Officer of Casmyn and now Chairman of the Board and CEO of VETI. Pursuant to the terms of the contract, Mr. Dahya will earn an annual base salary of $150,000, which increases by no less than 10% per year of such an increase is approved by the Board of Directors. Under this contract, Mr. Dahya also receives reimbursement for business expenses and normal group benefits available to other executives of VETI. This contract also provides Mr. Dahya with 5-year, non-qualified, stock options to purchase shares of Common Stock of VETI at an exercise price of $1 .00 per share. The issuance of these shares is not intended or anticipated to significantly dilute the equity off VETI. Under the terms of the employment contract, Mr. Dahya has been granted options to purchase shares of VETI Common Stock pursuant to the following schedule: - -------------------------------------------------------------------------------- NO. OF SHARES TIME OF VESTING - ------------- --------------- 250,000 Immediately upon execution of the Employment Agreement 250,000 When gross sales of VETI reach $2,500,000 250,000 When gross sales of VETI reach $5,000,000 250,000 When gross sales of VETI reach $7,500,000 - -------------------------------------------------------------------------------- As of the date of this Prospectus, none of the options have been exercised (See Executive Compensation of Directors and Executive Officers of the Company"). On January 31, 1994, Ace Capital Inc., a privately-held Nevada corporation of which David Chase, an executive officer of VETI, is an officer, director and shareholder, entered into a Promissory Note with VETI for the purchase of 25,000 shares of Common Stock, in the amount of $75,000, payable to VETI on demand, at 6% interest. (See "VECTOR ENVIRONMENTAL TECHNOLOGIES, Shares of Common Stock of VETI Held by Directors, Executive Officers, Affiliates and/or 5% shareholders.") On January 31, 1994, Taj Mohamed, a director of Auromar, entered into a Promissory Note with VETI for the purchase of 25,000 shares of Common Stock, in the amount of $75,000, payable to VETI on demand, at 6% interest. (See "CASMYN CORP. Shares of Common Stock of VETI Held by Directors, Executive Officers, Affiliates and/or 5% shareholders.") Amyn Dahya, an officer, director, promoter and principal shareholder of the Company was also a director of Auromar from June 29, 1993 to March 13, 1995. In connection with the acquisition of Casmyn Desalco, Ltd. from Dahya Holdings, Ltd., the Company will pay Dahya Holdings a six percent royalty on gross sales recognized from the commercial application of certain water desalination technology. In addition, the Company will issue 250,000 shares of restricted common stock upon the successful completion of a prototype desalination system. In addition, 250,000 restricted Common Shares will be issued upon the Company's achieving each of $5,000,000, $25,000,000 and $50,000,000 in gross sales from the desalination system or related technology. As of June 30, 1996, the Company had advances outstanding to Amyn Dahya of approximately $500,000 primarily relating to relocation expenses. DESCRIPTION OF THE COMPANY'S SECURITIES COMMON STOCK The Company is authorized to issue 320,000,000 shares, of which 20,000,000 are Preferred Shares, par value $.10 per share and 300,000,000 are Common Stock, par value $.04 per share. Each share of Common Stock is entitled to one vote at all meetings of shareholders. The Articles of Incorporation of the Company prohibit cumulative voting in the election of directors. All shares of Common stock are equal to each other with respect to liquidation rights and dividend rights. In the event of liquidation, dissolution or winding up of the Company, holders of the Common Stock will be entitled to receive, on a pro rata basis, all assets of the Company remaining after satisfaction of all liabilities and all liquidation preferences, if any, granted to holders of the preferred shares of the Company. There are no preemptive rights to purchase additional shares of Common Stock. Holders of shares of Common Stock are entitled to receive dividends if, as and when declared by the Board of Directors out of funds legally available therefor, subject to the dividend and liquidation rights of any preferred shares that may be issued. PREFERRED SHARES The Certificate of Incorporation of the Company authorizes issuance of a maximum of 20,000,000 preferred shares, par value $.10 per share. The Articles of Incorporation vest the Board of Directors of the Company with authority to divide the class of preferred shares into series and to fix and determine the relative rights and preferences of the shares of any such series so established to the full extent permitted by the laws of the State of Colorado and the Certificate of Incorporation with respect to, among other things: (a) the number of preferred shares to constitute such series and the distinctive designations thereof; (b) the rate and preference of dividends, if any, the time of payment of dividends, whether dividends are cumulative and the date from which any dividend shall accrue; (c) whether preferred shares may be redeemed and, if so, the redemption price and the terms and conditions of redemption; (d) the liquidation preferences payable on preferred shares in the event of involuntary of voluntary liquidation; (e) sinking fund or other provisions, if any, for redemption or purchase of preferred shares; (f) the terms and conditions by which preferred shares may be converted, if the preferred shares of any series are issued with the privilege of conversion; and (g) voting rights, if any. There are 2,707,000 Series A preferred shares issued and outstanding. Series A preferred shares have no preference with respect to dividends or liquidation and vote with Common Shares with each Series A Preferred share having a voting right equal to five Common Shares. TRANSFER AGENT AND REGISTRAR The transfer agent and registrar for the common stock is American Securities Transfer Corporation, 938 Quail Street, Suite 101, Lakewood, CO 80215-5513. PLAN OF DISTRIBUTION This Prospectus relates to 4,371,267 shares of Common Stock that may be offered and sold from time to time by certain shareholders of the Company, all of whom have been accorded certain registration rights by the Company that permit such holders to include such shares in this Prospectus. Such shares consist of (i) 2,805,791 shares of common stock that were issued in private placements, (ii) 833,333 shares of common stock issuable in connection with the conversion of a $5,000,000 convertible debenture, and (iii) 732,143 shares of common stock issuable upon the exercise of warrants. Set forth below is information, as of May 29, 1996, regarding the beneficial ownership of the Company's Common Stock by each Selling Shareholder. SHARES BENEFICIALLY OWNED SHARES BENEFICIALLY OWNED PRIOR TO OFFERING (1) NUMBER OF AFTER OFFERING (2) ------------------------------ SHARES ---------------------------- NUMBER PERCENT OFFERED NUMBER PERCENT - ---------------------------------------------------------------------------------------------------------------------------------- - ---------------------------------------------------------------------------------------------------------------------------------- SOCIETE GENERALE - ORVALOR (3) 2,144,762 22.0% 2,144,762 2,144,762 22.0% - ---------------------------------------------------------------------------------------------------------------------------------- REG "S" OFFERING (4) - ---------------------------------------------------------------------------------------------------------------------------------- CNCA/SCT BRUNDY 33,000 * 33,000 33,000 * - ---------------------------------------------------------------------------------------------------------------------------------- S.E. BANKEN LUXEMBOURGE S.A. 12,000 * 12,000 12,000 * - ---------------------------------------------------------------------------------------------------------------------------------- LA COMPAGNIE FINANCIERE 15,000 * 15,000 15,000 * (ROTHSCHILD BANQUE) - ---------------------------------------------------------------------------------------------------------------------------------- EQUITABLE LIFE ASSURANCE 450,000 3.2% 450,000 450,000 3.2% - ---------------------------------------------------------------------------------------------------------------------------------- CEDEF FINANCE 15,000 * 15,000 15,000 * TORBAY COMPANY 45,000 * 45,000 45,000 * - ---------------------------------------------------------------------------------------------------------------------------------- GFM INTERNATIONAL INVESTORS 60,000 * 60,000 60,000 * - ---------------------------------------------------------------------------------------------------------------------------------- THE PRUDENTIAL INSURANCE CO. 45,000 * 45,000 45,000 * - ---------------------------------------------------------------------------------------------------------------------------------- EXECUTRONICS LTD. 15,000 * 15,000 15,000 * - ---------------------------------------------------------------------------------------------------------------------------------- CM INVESTMENT NOMINEES LTD. 30,000 * 30,000 30,000 * - ---------------------------------------------------------------------------------------------------------------------------------- NUTRACO NOMINEES LTD. 150,000 1.1% 150,000 150,000 1.1% - ---------------------------------------------------------------------------------------------------------------------------------- WOODBRIDGE CAPITAL CORPORATION 15,000 * 15,000 15,000 * - ---------------------------------------------------------------------------------------------------------------------------------- MARTINDALE INC. 378,055 4.0% 378,055 378,055 4.0% - ---------------------------------------------------------------------------------------------------------------------------------- DIAMOND FONTEIN INTERNATIONAL, LTD. 300,000 3.2% 300,000 300,000 3.2% - ---------------------------------------------------------------------------------------------------------------------------------- COVENTRY SECURITIES, LTD. 115,000 1.2% 115,000 115,000 1.2% - ---------------------------------------------------------------------------------------------------------------------------------- NORDIC RESOURCES, CORP. 25,000 * 25,000 25,000 * - ---------------------------------------------------------------------------------------------------------------------------------- ROTH INVESTOR RELATIONS, INC. 10,000 * 10,000 10,000 * - ---------------------------------------------------------------------------------------------------------------------------------- MARSHALL AUERBACK 126,200 1.3% 126,200 126,200 1.3% - ---------------------------------------------------------------------------------------------------------------------------------- T/A PACIFIC SELECT INVESTMENTS LTD. 48,800 * 48,800 48,800 * - ---------------------------------------------------------------------------------------------------------------------------------- NABAT RAJAN 338,450 3.6% 338,450 338,450 3.6% - ---------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------
(*) Represents less than 1% of outstanding Common Stock. (1) Unless otherwise indicated, the persons named in the table have sole voting and sole investment power with respect to all shares beneficially owned subject to community property laws where applicable. (2) Assumes that all of the shares offered hereby are actually sold. (3) Consists of shares, warrants and conversion of shares under a convertible debenture. (4) Consists of shares and warrants. The Company has been advised by the Selling Shareholders that they intend to sell all or a portion of the shares of Common Stock offered by this Prospectus from time to time (I) in the over-the-counter market at prices reasonably related to the prices of the Common Stock prevailing at the time of such sales, (ii) otherwise than in the over-the-counter market in negotiated transactions (which may include the pledge or hypothecation of some of all the shares), at fixed prices which may be changed, at market prices prevailing at the time of sale or at prices reasonably related thereto or at negotiated prices, or (iii) by a combination of the foregoing methods of sale. The Selling Shareholders may effect such transactions by selling the shares of Common Stock to or through broker-dealers, and such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the Selling Shareholders and/or the purchasers of the shares of Common Stock for which such broker-dealers may act as agent or to whom they may sell as principal, or both. The Selling Shareholders and any broker, dealer or other agent executing sell orders on behalf of the Selling Shareholders may be deemed to be "underwriters" within the meaning of the Securities Act of 1933, as amended (the "1933 Act") in which event commissions received by any such broker, dealer or agent and profit on any resale of shares of Common Stock of principal may be deemed to be underwriting commissions under the 1933 Act. Such commissions received by a broker, dealer or agent may be in excess of customary compensation. Such shares of Common Stock may also be sold in accordance with Rule 144 and Rule 145 under the 1933 Act. The Company will pay all the costs, expenses and fees incident to the offering and sale of the shares to the public, other than commissions and discounts of underwriters, brokers, dealers or agents not paid by the purchasers of the shares. In addition, the Company has agreed to indemnify the Selling Shareholders against certain liabilities, including liabilities arising under the 1933 Act. EXPERTS The consolidated financial statements of the Company at September 30, 1995 and 1994 and for each of the three years in the period ended September 30, 1995, appearing in this Prospectus and Registration Statement, have been audited by Deloitte & Touche LLP, independent auditors, as set forth in their report thereon appearing elsewhere herein and in the Registration Statement, and are included in reliance upon such report given upon the authority of such firm as experts in accounting and auditing. The consolidated financial statements of WestAmerica Corporation at March 31, 1995 and 1996 and for each of the three years in the period ended March 31, 1996, appearing in this Prospectus and Registration Statement, have been audited by Tullius Taylor Sartain & Sartain, independent auditors, as set forth in their report thereon appearing elsewhere herein and in the Registration Statement, and are included in reliance upon such report given upon the authority of such firm as experts in accounting and auditing. The financial statements of WestAmerica Investment Company at March 31, 1996, and December 31, 1994 and for the fifteen month period ended March 31, 1996 and each of the two years in the period ended December 31, 1994 (not separately appearing in this Prospectus and Registration Statement), included in the consolidated financial statements of WestAmerica Corporation have been audited by George Brenner, C.P.A., independent auditor, as set forth in his report thereon appearing elsewhere herein and in the Registration Statement, and are included in the consolidated financial statements of WestAmerica Corporation in reliance upon such report given upon the authority of such firm as an expert in accounting and auditing. The financial statements of Auromar Development Corporation as of and for the years ended March 31, 1996 and 1995, appearing in this Prospectus and Registration Statement, have been audited by Deloitte & Touche, Chartered Accountants, independent auditors, as set forth in their report thereon appearing elsewhere herein and in the Registration Statement, and are included in reliance upon such report given upon the authority of such firm as experts in accounting and auditing. The financial statements of Auromar Development Corporation as of and for the year ended March 31, 1994, appearing in this Prospectus and Registration Statement, have been audited by Dennis N. Wong, Inc. Chartered Accountant, independent auditor, as set forth in his report thereon appearing elsewhere herein and in the Registration Statement, and are included in reliance upon such report given upon the authority of such firm as an expert in accounting and auditing. None of the named experts listed herein have any security interest in the Company LEGAL MATTERS The validity of the Common Stock offered hereby will be passed upon for the Selling Shareholders by Jenkens & Gilchrist, a Professional Corporation.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000774055_transaxis_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000774055_transaxis_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..fa36f15687e1cbd027e4b5a0bfe7d214bfcf0b24
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000774055_transaxis_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY This summary is qualified in its entirety by the more detailed information and financial statements and related notes appearing elsewhere in this Prospectus. See "Risk Factors" for a discussion of certain factors to be considered in evaluating the Company and its business. The Company DataMark Holding, Inc. (the "Company" or "DataMark") provides highly targeted business to consumer advertising for its clients. The medium for such targeted advertising has been direct mail and is being expanded to include an advertiser funded online network, ValuOne Online. The Company utilizes sophisticated consumer profiling techniques to target advertising to the persons most likely to purchase the specific product or service being marketed. The Company's advertising programs provide highly predictable and measurable advertising campaigns. Some of the features of the Company's services include: * Analysis - The DataMark direct advertising strategy includes an exhaustive analysis of the defining lifestyle characteristics of the client's existing customer base. The Company specifically identifies who is most likely to respond to the client's offer. * Identification - DataMark uses the results of the marketing research and analysis and performs a computerized database compilation. From this, DataMark creates a list of cluster groups or profiled individuals which match the identified demographic, socio-economic, lifestyle and behavior characteristics, and who have the highest propensity to buy the client's product. * Implementation - DataMark implements a strategically designed program of systematic advertising to the targeted potential customers on the customized database list. * Measurement - DataMark conducts a thorough analysis after each advertising campaign to understand exactly what has been accomplished and where the results are leading. This critical information allows the targeting of the marketing program to be consistently fine tuned. Systematized feedback allows accurate adjustments and targeting refinement for maximum efficiency and increased positive results. * Turn-key Services - DataMark offers a turn-key operation to which the client can outsource its entire targeted advertising including targeting, creating, producing, delivering and analyzing the campaign. Online Advertising Services The Company is completing the development of the first interactive promotional national marketing network, ValuOne Online, which is entirely advertiser funded. ValuOne Online incorporates highly successful direct mail strategies and methodologies. The strategy is to offer a leading edge advertising medium by incorporating direct advertising methodologies that can produce predictable and measurable results. ValuOne Online's primary mission is to provide, free to the consumer end-user, technologically superior, interesting, entertaining and convenient interactive promotional advertising information. ValuOne Online intends to stimulate mass use by an initial 1.5 million targeted profiled end-user households. ValuOne Online's initial 1.5 million targeted end-user households have been specifically segmented from the 9.5 million potential online households based on the lifestyle and consumer buying habits most desired by advertisers. This will create significant value and numerous benefits for advertisers who have their products on ValuOne Online. ValuOne Online consumer end-users participate in interactive, money saving, advertising messages. These end-users will be able to find products and services they want, when they want them, free of user fees. ValuOne Online will provide local telephone access for its targeted metropolitan areas through the Sprint Telnet network. This major telecommunication network is used by other major national data providers. The network will connect the end user to the ValuOne Online server in Salt Lake City, Utah. The proprietary network avoids the security risks and delays of using the Internet. National advertising is typically placed through national media representation groups, the oldest and largest of which is Katz Media Group ("Katz") (NYSE:KTZ). The Company and Katz have entered into an exclusive representation agreement whereby Katz is the exclusive agent to represent ValuOne Online to national advertisers and Katz agrees not to represent competitive online services. Katz states that it is the only full service media representative firm serving all types of media, with leading market shares in the representation of radio and television stations and cable television systems. The Company's principal executive offices are located at 488 E. Winchester Street, #100, Salt Lake City, Utah 84107. Its telephone number is 801-268-1001. The Offering Common Stock outstanding prior to offering 8,110,407 shares (1) Common Stock offered by Selling Shareholders (excluding Selling Warrantholders) 2,541,357 shares (2) Common Stock offered by Selling Warrantholders 431,125 shares Use of Proceeds The Company will not receive any proceeds from the sale of Shares by the Selling Shareholders and Selling Warrantholders. The Company may receive up to $3,497,469 in proceeds for exercise of the Warrants if all Warrants are exercised. The Company intends to use any proceeds received on exercise of the Warrants to market ValuOne Online and for working capital and general corporate purposes. See "Use of Proceeds" and "Business of the Company." Trading Symbol DTAM (OTC Bulletin Board)(3) (1) Includes 214,500 shares which have been subscribed for. Of the currently outstanding Common Stock, 7,638,811 shares are "restricted securities" which may not be readily resold into the market. Since only 471,596 shares are believed to be readily tradable, there can be no assurance that the market for the Common Stock will be sufficiently liquid to absorb the shares being offered hereby. (2) Two Selling Shareholders each beneficially own more than 5% of the Company's common stock. See "Principal Stockholders" and "Selling Shareholders." No other Selling Shareholder is an affiliate of the Company. (3) The Company has applied to Nasdaq for listing in the Nasdaq SmallCap Market. There is no assurance Nasdaq listing will be granted. - -------------------- Capitalization The following table sets forth certain information regarding the Company's equity securities outstanding prior to and after the offering: Number of Shares Capital Stock outstanding as of September 30, 1996: Common Stock: 8,110,407 Preferred Stock: 0 Capital Stock to be outstanding after Offering(1): Common Stock: 8,541,532 Preferred Stock: 0 - --------------- (1) Includes 214,500 subscribed shares which the Company has commited to issue to certain of the Selling Stockholders prior to the offering, which are also included in Capital Stock outstanding as of September 30, 1996. Assumes exercise of all Warrants. Excludes 1,047,215 shares of Common Stock which may be issued upon vesting and exercise of options outstanding at September 30, 1996 other than the Warrants, including options for 451,623 shares pursuant to the Company's Omnibus Stock Option Plan. Transactions with Related Parties There have been related party transactions between the Company and it affiliates. See "Certain Transactions with Related Parties." Summary Financial Information Summary Financial Data Set forth below are summary consolidated historical financial data for the Company as of and for the periods indicated. The following information should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Company's Consolidated Financial Statements and Notes thereto appearing elsewhere in this Prospectus. Year Ended June 30, Three Months Ended September 30, ------------------- -------------------------------- 1994 1995 1996 1995 1996 ---- ---- ---- ---- ---- Statement of Operations Data: Net sales $3,017,805 $3,443,965 $4,256,887 $1,074,559 $1,481,171 Cost of Sales Postage 1,133,710 1,360,976 1,580,484 433,766 524,499 Materials and printing 790,744 1,035,954 1,310,184 282,438 514,266 Selling expense 440,236 446,181 700,429 164,369 391,490 Research and development 89,250 560,915 1,565,718 164,350 679,447 General and administrative 456,039 268,765 1,094,375 145,965 373,463 Compensation expense - - 1,484,375 - - Net income (loss) 62,998 (264,270) (3,433,081) (120,696) (840,501) Net income (loss) per common share $ .01 $ (.06) $ (.58) $ (.02) $ (.10) Weighted average common shares outstanding 4,282,299 4,713,028 5,917,491 5,539,953 8,110,407
June 30, September 30, -------- --------- 1995 1996 1996 ---- ---- ---- (unaudited) Balance Sheet Data: Working capital $ 794,156 $12,774,113 $11,242,948 Total assets 1,631,445 16,543,253 15,447,230 Long-term debt, less current portion 25,332 - - Stockholders' equity 1,073,225 15,541,624 14,740,871
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000782145_playnet_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000782145_playnet_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..b779cd65496c489ab55f8a195fe7879ab7a9875c
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000782145_playnet_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by reference to the more detailed information and the consolidated financial statements and notes thereto appearing elsewhere in this Prospectus. Each prospective investor is urged to read this Prospectus in its entirety. Unless otherwise indicated, all share and per share data and information in this Prospectus relating to the number of shares outstanding assume no exercise of the Underwriters' over-allotment option to purchase 300,000 additional shares from the Company. See "Underwriting." THE COMPANY The Company designs and develops location-based, pay-per-play electronic game and entertainment units and music juke boxes which are networked through the Internet. The Company's products utilize the Internet to enhance traditional video game products and juke boxes through innovations such as linking multiple players in remote locations and offering competitive tournament prize play. The Company intends to initially market these products to location-based venues such as sports bars and "theme" restaurants. The Company plans to introduce three products in the next six months: the PlayNet Music juke box and the TeamNet and TouchNet electronic game systems. The Company's products are designed to utilize the Internet as a communications network and an entertainment medium in a social setting, allowing users to play networked games, compete in local or national tournaments and contests, browse the World Wide Web, participate in chat room discussions and use credit cards to purchase merchandise. The Company's business reflects the growing trend to connect people via computer networks and, as a result, to create new forms of interactive entertainment in a social setting. According to the Vending Times 1996 Census, total coin-drop revenue in the U.S. in 1995 for all amusements was $6.3 billion, and the U.S. electronic pay per play video game business (which excludes pinball and redemption machines) generated $2.0 billion of that revenue. The Company has designed an open, PC-based system architecture which blends proprietary game development, secure communications protocol, and operations software in a client/server environment. Communications take place over the Internet utilizing standard Internet protocols. This integrated system allows the Company to offer networked, location-based entertainment that can be remotely updated with the latest games or entertainment content. The Company's initial product line is expected to consist of the following location-based entertainment systems: PlayNet Music -- A juke box which will provide access to thousands of music titles via an Internet connection to the Company's music database servers, thereby providing significantly greater choices than a standard juke box. In addition to providing the ability to select songs from an extensive library, PlayNet Music will allow customers to purchase merchandise from their favorite bands. TouchNet -- A compact game system engineered to sit on a counter top and accommodate 8 to 12 different games, including trivia, parlor, strategy and action games. Touch Net allows users to choose which game to play and then to choose whether to play against the computer or against other players through an Internet connection. In addition to playing games and participating in contests and prize events, customers can choose to browse the Internet, use e-mail and participate in chat room discussions using attached telephone handsets. TeamNet -- An interactive system which allows two teams of up to four players each to compete against each other in sports simulations and other games. Both teams may be physically present in the same location, competing on the same game system, or may be in separate locations competing through an Internet connection. The TeamNet system has been specifically designed to support tournament play. The Company plans to distribute its location-based entertainment systems through a well-established network of third-party national and local distributors for resale to operators that install, operate and maintain the products, primarily in hospitality locations, including restaurants, bars and hotels, and secondarily in arcades and malls. Certain members of the Company's management have long-standing relationships with many of the major distributors in the United States and internationally. The Company anticipates that tournament play and certain other revenues will be shared among the Company, the distributor and the operator. The Company also intends to distribute its entire product line in international markets through a variety of distribution arrangements. It is contemplated that products will be localized for each territory as appropriate. Aristo is currently in the process of acquiring the rights to the libraries of various music publishers and record labels for use on its PlayNet Music system. Concurrently, the Company is negotiating to enter into sponsorship and advertising programs for its sports games, tournaments and prize contests with high-profile consumer goods and beverage companies. The Company also intends to establish various contractual arrangements, joint ventures and other mutually advantageous programs with technology providers, equipment manufacturers, distributors, major hospitality chains, consumer products companies, music-related companies, content providers and others, to develop broader, more efficient, more profitable and higher-profile products and services. STRATEGY The Company's primary strategic objective is to establish and rapidly grow an installed customer base of its location-based Internet-enabled entertainment units. The Company believes that its products and system architecture will enable it to expand the variety of content and services available beyond that which is available in existing products, as well as to increase the range of locations at which such networked entertainment units can be profitably located. The Company believes that the breadth of entertainment choices which its products will deliver, coupled with a highly diverse range of public locations, will extend the demographic universe of its potential users beyond that of adolescent males who currently dominate the coin-operated video game market. The Company's primary strategies can be summarized as follows: Enhancement of the Location-Based Entertainment Experience -- The Company intends to offer networked entertainment content with multi-player, multi-location and tournament prize play which it believes will result in significantly more compelling entertainment experiences than are possible with existing stand-alone location-based, pay-per-play machines. Unlike most competing entertainment systems, which are primarily based on proprietary hardware platforms, the Company's entertainment units will offer touch screen-operated access to a wide variety of video games including parlor, trivia, strategy and action games and prize tournament play. Additional features will include access to Internet content and thousands of music titles, the ability to purchase general entertainment and music-related merchandise, and ancillary features such as e-mail and "real-time chat" with other users of the system. Hospitality Focus and Penetration Beyond Traditional Locations -- The Company intends to focus its efforts on the hospitality sector which, according to the 1996 Vending Times Census of the Industry comprises 60% of the location-based entertainment industry. This sector primarily includes bars, restaurants and hotels and is distinguished from the remainder of the industry, which is made up of specialized game arcades and locations such as movie theaters. The Company believes that the greater variety of entertainment content offered on its products could significantly expand the number of potential locations in the hospitality sector and allow it to enter non-traditional locations such as airports, railroad stations and shopping malls. The Company intends to accelerate the distribution of its products by forming strategic alliances with major hospitality companies, both in the United States and internationally. Expansion of Potential User Base -- The Company intends to offer a range of entertainment products, including parlor, trivia, strategy and action games, expected to appeal to a broader user base than existing arcade offerings which are increasingly targeting the adolescent male demographic segment. The Company will initially target hospitality locations, especially bars and chain restaurants, for distribution of its products. Networked and prize tournaments and promotions will be aimed at a broad array of consumers who are interested in social interactive entertainment and competitive tournament prize play. The Company believes that its broad-based strategy will allow it to increase average revenue per unit and the number of potential locations for its networked machines. Product Innovation and Improvement -- The Company believes that its flexible system architecture will allow it to update and continually improve its game and entertainment offerings on a cost effective basis through remote downloads from central servers, based on customer feedback and demand. The Company expects to be able to regularly update its musical offerings on PlayNet Music based on the popularity of songs in each location. The Company also expects to augment and improve its game content and add new features on both TouchNet and TeamNet based on customer feedback. Downloading will permit TouchNet games to be updated and new games to be added to optimize choice at each unit. TeamNet sports offerings will be changed based on sport seasons and game popularity. The Company also intends to support usage through tournament prize offerings and promotions. Recurring Revenue Streams -- The Company believes that location-based entertainment product manufacturers only receive revenue from the sale of machines. The Company believes that it will be able to demonstrate that its products will result in increased coin-drop from location-based entertainment units and expects that it will be able to share in incremental revenues, thus creating recurring revenue streams for the Company. The Company intends to promote, arrange sponsorship for, and organize national and local game tournaments with cash and other prizes. The Company believes that the limited tournament features of certain existing location-based entertainment units have demonstrated an increase in machine usage and revenues, especially since such tournaments require higher game fees. Ancillary Revenue Opportunities -- Sponsorship and advertising revenue will be generated from on-screen advertisements and tournaments. The Company also expects to collect fees on merchandise sales made through its Internet-enabled entertainment units. The Company plans to re-market data collected from user polls, music selections and other similar usage to content providers, advertisers and product and service vendors. The Company's principal executive office is located at 152 West 57 Street, New York, New York 10019-3310, and its telephone number is (212) 586-2400. The Company is a Delaware corporation which is the surviving corporation of its merger with a New York corporation (see "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Overview"). References herein to the "Company" or "Aristo" are to the Company (including, for periods prior to the merger, the predecessor New York corporation) and, unless the context otherwise requires, its subsidiaries. THE OFFERING Common Stock offered......................... 2,000,000 shares Common Stock to be outstanding after the offering................................... 16,966,661 shares(1) Use of Proceeds.............................. The Company intends to use the net proceeds of this offering for system and product development, capital expenditures, product launches, software licensing and general corporate purposes. See "Use of Proceeds." Risk Factors................................. The shares offered hereby involve a high degree of risk. See "Risk Factors." Nasdaq SmallCap Market Symbol................ ATSP Proposed Nasdaq National Market Symbol.......
- --------------- (1) Does not include (i) an aggregate of 500,000 shares of Common Stock reserved for issuance pursuant to options available for grant under the Company's 1994 Stock Option Plan, of which options to purchase 395,000 shares have been granted as of the date of this Prospectus; (ii) an aggregate of 1,000,000 shares of Common Stock reserved for issuance pursuant to options available for grant under the Company's 1995 Stock Option Plan, of which options to purchase 1,000,000 shares have been granted as of the date of this Prospectus; (iii) an aggregate of 1,500,000 shares of Common Stock reserved for issuance pursuant to options available for grant under the Company's 1996 Stock Option Plan, of which options to purchase 1,425,067 shares have been granted as of the date of this Prospectus; (iv) 433,728 shares of Common Stock issuable in accordance with the terms of certain of the Company's convertible promissory notes; (v) 60,000 shares of Common Stock issuable upon exercise of certain options granted to certain lenders; and (vi) 448,101 shares of Common Stock issuable upon exercise of the Company's outstanding warrants. SUMMARY CONSOLIDATED FINANCIAL INFORMATION The following summary consolidated financial information has been derived from and should be read in conjunction with the Consolidated Financial Statements and Notes thereto included elsewhere in this Prospectus. The summary consolidated financial data set forth below should be read in conjunction with the Consolidated Financial Statements and the Notes thereto and Management's Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein. The consolidated statements of operations data set forth below with respect to the three years ended October 31, 1995 are derived from the consolidated financial statements included elsewhere in this Prospectus, which consolidated financial statements have been audited by Coopers & Lybrand L.L.P. The data as of July 31, 1996 and for the nine month periods ended July 31, 1995 and 1996 was derived from unaudited consolidated financial statements that have been prepared on the same basis as the audited financial statements and, in the opinion of management, contain all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of operations for such period. The historical results are not necessarily indicative of the results to be expected in the future. NINE MONTHS YEARS ENDED OCTOBER 31, ENDED JULY 31, ------------------------------------------------------------------- -------------------------------- 1991 1992 1993 1994 1995 1995 1996 ----------- ----------- ----------- ----------- ----------- ------------ ----------------- CONSOLIDATED OPERATIONS DATA: Total Revenue.......... $ -- $ 33,333 $ 58,334 $ 16,005 $ 157,627 $ 4,749 $ 198,349 Total Operating Expenses............. 1,462,158 1,487,728 1,659,837 2,188,605 4,281,956 2,246,438 7,499,101 Net Loss............... (1,478,158) (1,480,812) (1,636,310) (2,228,644) (4,116,457) (2,210,086 ) (7,429,529) Net Loss per Share..... $ (0.29) $ (0.23) $ (0.21) $ (0.24) $ (0.40) $ (0.23 ) $ (0.55) Weighted Average Outstanding Common Shares............... 5,122,222 6,450,298 7,723,767 9,244,593 10,388,926 9,714,981 13,554,091
JULY 31, 1996 ---------------------------------------------- ACTUAL PRO FORMA(1) AS ADJUSTED(1)(2) ----------- ------------ ----------------- CONSOLIDATED BALANCE SHEET DATA: Cash......................................................................... $ 544,104 $ 6,104,749 $22,104,749 Working Capital (Deficit).................................................... (2,152,225) 3,728,420 19,728,420 Total Assets................................................................. 10,478,933 16,039,578 32,039,578 Total Liabilities............................................................ 5,685,191 5,365,191 5,365,191 Stockholders' Equity (Deficit)............................................... 4,793,742 10,924,337 26,924,337
- --------------- (1) Reflects on a pro forma basis as at July 31, 1996 the private placements of 1,256,400 shares of Common Stock, the repayment of a $450,000 promissory note of the Company, the issuance of a $130,000 convertible promissory note and the payment in Common Stock of $250,000 of compensation to a senior executive. Assumes full conversion of shares of Astro-Stream Corporation into shares of Common Stock. (2) Also reflects on an as adjusted basis as at July 31, 1996 the sale of the 2,000,000 shares of Common Stock offered hereby and the application of the estimated net proceeds therefrom.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000787648_texas_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000787648_texas_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..b660ed006739359bad518fd8f88b492d81f959e3
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000787648_texas_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. CONTEMPORANEOUSLY WITH THE CLOSING OF THE OFFERING MADE BY THIS PROSPECTUS, THE COMPANY WILL ACQUIRE BY MERGER TWO BANKS USING A PORTION OF THE PROCEEDS OF THE OFFERING. SEE "PROPOSED MERGERS" AND "TEXAS REGIONAL BANCSHARES, INC. PRO FORMA COMBINED CONDENSED FINANCIAL INFORMATION" REGARDING THE EFFECTS ON THE COMPANY OF THE CONSUMMATION OF SUCH MERGERS. THE COMPANY Texas Regional Bancshares, Inc. ("Texas Regional" or the "Company") is a registered bank holding company whose wholly-owned subsidiary bank, Texas State Bank ("Texas State Bank" or the "Bank"), conducts a commercial banking business in the Rio Grande Valley of Texas. At March 31, 1996, Texas Regional had consolidated assets of $655.9 million, loans outstanding (net of unearned discount) of $467.1 million, total deposits of $586.0 million, and total shareholders' equity of $64.6 million. For the three months ended March 31, 1996 and 1995, the Company earned net income of $2.6 million and $2.0 million, respectively, for a return on average assets for these periods of 1.57% and 1.52%, respectively. At March 31, 1996, the Company had nonperforming assets (including loans 90 days or more past due and still accruing) of $4.9 million, representing 1.0% of period-end loans and other nonperforming assets (primarily other real estate). At December 31, 1995, Texas Regional had consolidated assets of $646.8 million, loans outstanding (net of unearned discount) of $450.9 million, total deposits of $579.7 million, and total shareholders' equity of $62.7 million. For the years ended December 31, 1995 and 1994, the Company earned net income of $8.7 million and $7.2 million, respectively, for a return on average assets for these periods of 1.51% and 1.43%, respectively. At December 31, 1995, the Company had nonperforming assets (including loans 90 days or more past due and still accruing) of $4.2 million, representing 0.9% of period-end loans and other nonperforming assets (primarily other real estate). Texas State Bank operates a total of nine full service banking locations in the Rio Grande Valley. The market area served by Texas State Bank has been recognized as among the fastest growing areas in the nation. The McAllen-Edinburg-Mission area has a projected population growth rate of 23.8% between 1994 and 2000, and the Brownsville-Harlingen area has a projected population growth rate of 16.0% during that same period. The business strategy of Texas Regional is for the Bank to provide its customers with the financial sophistication and breadth of products of a regional bank, while retaining the local appeal and service level of a community bank. Management believes that the Company is well positioned in its market due to its responsive customer service, the strong community involvement of Texas State Bank management and employees, recent trends in the Texas banking environment and the economy of the Rio Grande Valley. Management's strategy is to provide a business culture in which individual customers and small and medium sized businesses are accorded the highest priority in all aspects of the Company's operations. Management believes that individualized customer service will allow the Company to increase its market share in lending volume and deposits. As part of its operating and growth strategies, the Company is working to attract business from, and provide service to, small to medium sized businesses, and expand its operations in McAllen, Harlingen and other strategic areas in the Rio Grande Valley. Consistent with this strategy, during 1995, Texas State Bank acquired banking locations in Rio Grande City and Roma, Texas, and in January 1996 it entered into definitive agreements to acquire two banks headquartered in Mission and Hidalgo, Texas. See "The Company" and "Proposed Mergers." At March 31, 1996, Texas Regional employed 351 full time equivalent employees. The address of Texas Regional's principal executive office is Kerria Plaza, Suite 301, 3700 North 10th Street, McAllen, Texas 78501, and its telephone number is (210) 631-5400. THE MERGERS Texas State Bank has for some time sought appropriate acquisitions to permit the Bank to expand within the market areas served by Texas State Bank and into adjacent market areas in the Rio Grande Valley. In January 1996, the Company entered into definitive agreements to acquire through merger First State Bank & Trust Co., Mission, Texas ("First State Bank") and The Border Bank, Hidalgo, Texas ("Border Bank") (the "Mergers"). First State Bank and Border Bank had combined total assets of approximately $545.5 million at March 31, 1996. Assuming consummation of the Mergers, on a pro forma basis at March 31, 1996, Texas Regional would have had total assets of $1.170 billion, which would have made Texas Regional the largest bank holding company headquartered in the Rio Grande Valley. At March 31, 1996, First State Bank had total assets of $426.1 million, loans outstanding (net of unearned discount) of $192.8 million and stockholders' equity of $61.6 million. At March 31, 1996, Border Bank had total assets of $119.9 million, loans outstanding (net of unearned discount) of $51.0 million and stockholders' equity of $17.2 million. First State Bank and Border Bank had combined total assets of approximately $524.0 million at December 31, 1995. Assuming consummation of the Mergers, on a pro forma basis at December 31, 1995, Texas Regional would have had total assets of $1.143 billion. At December 31, 1995, First State Bank had total assets of $404.5 million, loans outstanding (net of unearned discount) of $188.4 million and stockholders' equity of $59.4 million. At December 31, 1995, Border Bank had total assets of $119.5 million, loans outstanding (net of unearned discount) of $47.3 million and stockholders' equity of $17.1 million. Elliot B. Bottom is the Chairman of the Board of both First State Bank and Border Bank, and the banks have substantial common ownership. The purpose of the Mergers is to further strengthen Texas State Bank's branch network and banking business in the Rio Grande Valley by adding six new banking locations in Mission, Penitas, McAllen and Hidalgo, Texas. The purchase price for the Mergers is estimated to be $99.5 million, approximately $40.0 million of which will be paid from the proceeds of the offering made hereby. The Company intends to fund the balance of the purchase price principally from liquidation of cash equivalents and, to the extent necessary, selected investment securities on a consolidated basis. See "Proposed Mergers" and "Use of Proceeds." Management of Texas State Bank believes that the Mergers will expand the Company's community banking network into contiguous markets, substantially increasing its market share and enabling the Bank to compete more effectively with other financial institutions in the Rio Grande Valley. Because of the proximity of Mission to McAllen, there is a substantial overlap in the markets served by Texas State Bank and First State Bank. For this reason and because the banks serve a similar customer base, First State Bank is considered by Texas State Bank management to be a direct competitor of Texas State Bank, particular as to loan customers. The new or expanded services to be offered to First State Bank and Border Bank customers include enhanced data processing services, additional automated teller facilities and other services now offered to Texas State Bank customers. Texas State Bank management believes that First State Bank, Border Bank and Texas State Bank customers will benefit from the expansion of Texas State Bank's branch network from nine to 15 banking locations. Texas State Bank expects to realize certain operating and administrative efficiencies as a result of the Mergers; however, because of the relatively low employee-to-asset ratio at First State Bank and Border Bank, cost savings is not a principal motivating factor for the Mergers. The operating efficiencies which are expected include the use by all banking locations of the existing Texas State Bank data processing facility, operation of a single human resources department, and economies of a combined advertising program. THE OFFERING Common Stock offered hereby................. 2,200,000 shares(1)(2) by the Company.......................... 2,180,000 shares(1) by the Selling Shareholder.............. 20,000 shares Common Stock to be outstanding after the offering.................................. 8,376,791 shares(1)(2) Use of proceeds............................. Approximately $40.0 million of the net proceeds to be received by the Company from the sale of Common Stock will be used to fund part of the consideration payable by Texas State Bank upon consummation of the Mergers. The remainder of the net proceeds, if any, will be used for general corporate purposes. See "Proposed Mergers" and "Use of Proceeds." Nasdaq National Market symbol............... TRBS
- ------------ (1) An additional 330,000 shares may be sold pursuant to an over-allotment option granted by the Company to the Underwriters. See "Underwriting." (2) The shares of Common Stock offered hereby will be sold contemporaneously with the consummation of the Mergers. TEXAS REGIONAL BANCSHARES, INC. SUMMARY CONSOLIDATED FINANCIAL INFORMATION The summary consolidated financial information under the captions "Summary of Operations" and "Period-End Balance Sheet Data" below for, and as of, each of the years in the five-year period ended December 31, 1995 has been derived from the consolidated financial statements of the Company, which financial statements have been audited by KPMG Peat Marwick LLP, independent auditors. The consolidated financial statements of the Company at December 31, 1995 and 1994 and for each of the years in the three-year period ended December 31, 1995 are included elsewhere in this Prospectus. The data presented at March 31, 1996 and 1995 and for each of the three-month periods then ended are derived from unaudited consolidated interim financial statements of the Company and include, in the opinion of management, all adjustments necessary to present fairly the data for such periods. THREE MONTHS ENDED MARCH 31, YEARS ENDED DECEMBER 31, ----------------------- ----------------------------------------------------- 1996 1995 1995 1994 1993 1992 1991 ------------ --------- --------- --------- --------- --------- --------- (DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA) SUMMARY OF OPERATIONS: Net Interest Income......... $ 7,689 $ 6,450 $ 27,540 $ 22,941 $ 19,197 $ 16,861 $ 11,773 Net Income.................. 2,554 1,987 8,725 7,185 6,011 4,519 2,824 PER SHARE DATA: Net Income.................. $ 0.41 $ 0.32 $ 1.40 $ 1.16 $ 1.16 $ 0.92 $ 0.79 Book Value.................. 10.42 9.26 10.12 9.00 7.73 6.42 5.22 Cash Dividends Declared on Common Stock.............. 0.10 0.10 0.40 0.24 -- -- -- Average Shares Outstanding (in thousands)............ 6,295 6,201 6,227 6,035 5,170 4,890 3,578 PERIOD-END BALANCE SHEET DATA: Total Assets................ $ 655,886 $ 539,005 $ 646,769 $ 531,834 $ 473,263 $ 414,331 $ 297,256 Loans....................... 467,059 354,410 450,854 339,939 290,500 252,118 179,853 Deposits.................... 585,994 475,985 579,731 472,108 429,521 375,016 271,540 Shareholders' Equity........ 64,563 57,341 62,720 55,731 39,983 34,318 19,366 PERFORMANCE RATIOS: Return on Average Assets.... 1.57% 1.52% 1.51% 1.43% 1.34% 1.23% 1.00% Return on Average Shareholders' Equity...... 16.01 14.16 14.69 14.11 16.15 15.23 15.85 ASSET QUALITY RATIOS: Nonperforming Assets to Loans and Other Nonperforming Assets...... 0.92% 0.97% 0.79% 1.41% 1.69% 2.31% 4.27% Allowance for Loan Losses as a Percentage of: Loans................... 1.05 1.13 1.01 1.03 1.18 1.16 1.42 Nonperforming Assets.... 113.12 115.33 126.62 72.96 69.39 49.43 32.44
SEE "PROPOSED MERGERS" AND "TEXAS REGIONAL BANCSHARES, INC. PRO FORMA COMBINED CONDENSED FINANCIAL INFORMATION" REGARDING THE PRO FORMA COMBINED EFFECT ON THE COMPANY ASSUMING CONSUMMATION OF THE MERGERS AT MARCH 31, 1996 AND DECEMBER 31, 1995. EXCEPT AS OTHERWISE SPECIFIED, ALL INFORMATION IN THIS PROSPECTUS ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION. SEE "UNDERWRITING."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000789853_tracker_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000789853_tracker_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..23275b344392c3cc6c7ff8868aeb31eececb2576
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000789853_tracker_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary of certain information contained in this Prospectus is not complete. This summary is qualified in its entirety by the more detailed information and financial statements appearing elsewhere in this Prospectus. Prospective investors must read the entire Prospectus. The securities offered hereby are speculative and involve a high degree of risk. See "RISK FACTORS." As used in this Prospectus, the term "Company" includes The Tracker Corporation of America, a Delaware corporation ("Tracker U.S."), and The Tracker Corporation, an Ontario, Canada corporation ("Tracker Canada"), a wholly-owned subsidiary of Tracker U.S., unless the context indicates otherwise; provided, however, that with respect to all information provided herein relating to Tracker U.S.'s Common Stock, options, warrants and other capital securities, the term "Company" means Tracker U.S., unless the context otherwise requires. All dollar amounts contained in this Prospectus are in U.S. dollars unless otherwise noted. The assets and liabilities of the Company are translated at the June 30, 1996 exchange rate while revenues, expenses and cashflows are translated at the average rates in effect for the period. THE COMPANY The Tracker Corporation of America, a Delaware corporation ("Tracker U.S."), is a development stage company which, through its wholly-owned Canadian subsidiary, The Tracker Corporation, an Ontario, Canada corporation ("Tracker Canada"), has developed and has begun to market, sell and operate a personal property identification and recovery system which uses advanced bar code and laser scanning technology to aid in the identification and recovery of lost and stolen personal possessions. The Company launched its service in a limited test market in Toronto, Canada in October 1994 and is slowly continuing to expand its service throughout Canada. The Company recently began test marketing in the United States and has begun to introduce its service to various communities in the United States through the use of diverse marketing channels. As of September 30, 1996, the Company has installed only 17 scanners in the United States. The Company's service has been endorsed by the International Association of Chiefs of Police (the "IACP"). The Company has agreed to pay the IACP a royalty fee for such endorsement. See "BUSINESS--The IACP Endorsement." To date, the Company has received very limited revenues from sales of its service. The Company offers its members special encoded labels that are attached to the members' personal possessions and contain ownership information in advanced bar code form (PDF 417 symbology). After a member's lost item has been found and then scanned, the labels are linked electronically to a central computer base. A Company service representative then notifies the member that his or her possession has been found and informs the member of the item's location. The identified item may then be picked up by the member, or delivered to the member safely and promptly by courier at the member's expense. The Company also has implemented and offers a supplemental service called the "Tracker Plus" service, which covers the full cost of returning possessions to members. The Company plans to expand its recovery service by having manufacturers of products such as computer chips, bicycles, power tools, electronic equipment, cameras and auto parts apply the Company's coding, through laser etching or other methods, directly onto or into products at the source of manufacture. The Company believes that this expansion of its service will be attractive to manufacturers because (i) it will add value to their products by showing that they care about their customers and their customers' ability to recover lost or stolen items and (ii) the coding will enhance the ability of manufacturers and distributors to combat retail and warranty fraud. Currently, however, the Company does not have a contract with any manufacturers to laser etch the Company's coding or to directly apply the Company's coding at the source of manufacture using any other method. The Company anticipates, that if such contracts are procured, the manufacturers will absorb the cost of the laser etching either directly or indirectly (i.e., through the unit price charged to the manufacturer by the Company). There can be no assurance, however, that the Company will be able to successfully expand its service in this fashion. In addition to the Company's personal property identification and recovery system, the Company has implemented and is currently offering a card registration service. The Company offers members of this program the benefit and convenience of card registration. With one phone call, a member can (a) cancel all his lost or stolen cards (whether they be debit cards, gas cards, automated bank teller cards, department THE TRACKER CORPORATION OF AMERICA 13,799,479 SHARES OF COMMON STOCK --------------------------- THE SECURITIES OFFERED HEREBY INVOLVE A HIGH DEGREE OF RISK. SEE "RISK FACTORS" AT PAGE 6 OF THIS PROSPECTUS. THESE ARE SPECULATIVE SECURITIES. --------------------------- THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. --------------------------- THE DATE OF THIS PROSPECTUS IS , 1996 ------------- --------------------------- This Prospectus relates to the public offering from time to time by certain holders thereof (the "Selling Securityholders") of up to (i) 4,709,181 issued and outstanding shares of the common stock, par value $0.001 (the "Common Stock"), of The Tracker Corporation of America, a Delaware corporation ("Tracker U.S."); (ii) 250,000 shares of Common Stock which are issuable to the holder thereof upon the exercise of Tracker U.S.'s outstanding Common Stock Purchase Warrants (the "Common Warrants"); (iii) 960,002 shares of Common Stock which are issuable to the holders of Tracker U.S.'s Convertible Subordinated Debentures in an aggregate principal amount of $1,000,000 (the "First Series Convertible Debentures") upon the conversion of such warrants into Common Stock; (iv) 728,957 shares of Common Stock which are issuable to the holders of Tracker U.S.'s Convertible Subordinated Debentures in an aggregate principal amount of $1,189,529 (individually the "Second Series Convertible Debentures" and collectively with the First Series Convertible Debentures, the "Convertible Debentures") upon the conversion of such debentures into Common Stock; (v) 5,225,339 shares of Common Stock which are issuable to the holders of Exchangeable Preference Shares (the "Exchangeable Preference Shares") issued by Tracker U.S.'s subsidiary, The Tracker Corporation, an Ontario, Canada corporation ("Tracker Canada"), and the holders of Tracker Canada's Exchangeable Preference Share Warrants (the "Exchangeable Preference Share Warrants") upon the exchange of Exchangeable Preference Shares for Common Stock; (vi) 900,000 shares of Common Stock which are issuable to the holder thereof upon the exercise of an outstanding Common Stock Purchase Option (the "Merchant Partners Option"); (vii) 326,000 shares of Common Stock which may, at the option of the Company, be issued to the Company's investor relations firm (the "CRG Shares"); (viii) 500,000 shares of Common Stock which are issuable to the holder thereof upon the exercise of outstanding options (the "CRG Options"); and (ix) 200,000 shares of Common Stock which are issuable to the holder thereof upon the exercise of an outstanding Common Stock Purchase Warrant (the "TODA Warrant"). The Common Stock offered by the Selling Securityholders hereby may be offered from time to time for the account of the Selling Securityholders. The Selling Securityholders may sell the shares of Common Stock being offered by them from time to time in transactions in the over-the-counter market, in negotiated transactions, or by a combination of these methods at market prices prevailing at the time of the sale, at prices related to such market prices or at negotiated prices. There can be no assurance, however, that the Selling Securityholders will sell any of the shares of Common Stock offered hereby. See "PLAN OF DISTRIBUTION" and "SELLING SECURITYHOLDERS." Tracker U.S. will not receive any of the proceeds from any sale of the shares of Common Stock. See "USE OF PROCEEDS." The Common Stock is traded on the over-the-counter market and is quoted on the OTC Bulletin Board under the symbol "TRKR." On August 30, 1996, the high bid price and the asked price of the Common Stock were $ 0.24 and $0.28 respectively. See "PRICE RANGE OF COMMON STOCK." store cards or credit cards), (b) request replacement cards, (c) request a change of address for all his cards, (d) receive $15,000 in travel insurance on common carrier, (e) receive $2,000 in AD&D insurance, (f) receive $500 in airline discounts and (g) be covered on fraudulent charges up to $10,000. This service includes 24 identification labels, a card registration form and an indemnification certificate. THE OFFERING Selling Securityholders may sell up to (i) 4,709,181 already issued shares of Common Stock, (ii) 250,000 shares of Common Stock which are issuable to the holder of the Common Warrants upon the exercise thereof; (iii) 960,002 shares of Common Stock which are issuable to the holders of the First Series Convertible Debentures upon the conversion of such debentures into Common Stock; (iv) 728,957 shares of Common Stock which are issuable to the holders of the Second Series Convertible Debentures upon the conversion of such debentures into Common Stock; (v) 5,225,339 shares of Common Stock which are issuable to the holders of the Exchangeable Preference Shares and Exchangeable Preference Warrants upon the exchange of Exchangeable Preference Shares for Common Stock; (vi) 900,000 shares of Common Stock which are issuable to the holder of the Merchant Partners Option upon the exercise thereof; (vii) 326,000 CRG Shares; (viii) 500,000 shares of Common Stock which are issuable to the holder of the CRG Options upon the exercise thereof; and (ix) 200,000 shares of Common Stock which are issuable to the holder of the TODA Warrant upon the exercise thereof. The Selling Securityholders may sell such shares from time to time in transactions in the over-the-counter market, in negotiated transactions, or by a combination of these methods at market prices prevailing at the time of the sale, at prices related to such market prices or at negotiated prices. There can be no assurance, however, that the Selling Securityholders will sell any of the shares of Common Stock offered hereby. COMMON STOCK CURRENTLY OUTSTANDING(1) (2) 15,921,647 COMMON STOCK TO BE OUTSTANDING AFTER THE OFFERING(1) (2) (3) 19,578,482 USE OF PROCEEDS The Company will not receive any of the proceeds of any sales. See "USE OF PROCEEDS."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000791446_trump_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000791446_trump_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..fa9223bd3557bf8d9c60810aa29eed4fb30f6641
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000791446_trump_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a summary of certain information contained elsewhere in this Prospectus and is qualified in its entirety by the more detailed information and financial statements, and notes thereto, contained elsewhere in this Prospectus. Unless otherwise indicated, (i) the term "Trump AC" as used in this Prospectus includes Trump AC and its subsidiaries and gives effect to the Merger Transaction, and (ii) the information in this Prospectus assumes no exercise of the Underwriters' over-allotment option in connection with the Stock Offering. Prospective investors are urged to read this Prospectus carefully in its entirety. This Prospectus contains forward-looking information that involves risks and uncertainties and such information is subject to the assumptions set forth in connection therewith and the information contained herein. TRUMP ATLANTIC CITY ASSOCIATES Upon consummation of the Merger Transaction, Trump Atlantic City Associates ("Trump AC"), an indirect subsidiary of Trump Hotels & Casino Resorts, Inc., will own and operate two "Four Star" Atlantic City casino hotels (the "Atlantic City Properties"): the Trump Taj Mahal Casino Resort (the "Taj Mahal") and Trump Plaza Hotel and Casino ("Trump Plaza"). The Taj Mahal is currently Atlantic City's largest casino, and Trump Plaza will have the largest casino in Atlantic City upon completion of its ongoing expansion program (the "Trump Plaza Expansion"). Through its ownership of two successful land-based casino hotels, Trump AC will have a leading presence in the growing Atlantic City market, which, in terms of gaming revenues, has demonstrated a ten-year compound annual growth rate of approximately 5.8% and a growth rate of approximately 9.5% for calendar year 1995 versus calendar year 1994. After giving effect to the Merger Transaction and the Trump Plaza Expansion, Trump AC will have approximately one-quarter of Atlantic City's casino square footage, slot machines, table games and hotel room inventory. In addition, the combination of the Taj Mahal with Trump Plaza's existing operations will also provide opportunities for operational efficiencies, economies of scale and other benefits from the expertise and experience of management at the two operating entities. Trump AC also plans to undertake an expansion program at the Taj Mahal designed to increase its hotel room inventory and casino floor space and expand its entertainment and parking facilities (the "Taj Mahal Expansion"). Management believes Trump AC will benefit from the following factors: . LEADING ATLANTIC CITY FACILITIES. Upon consummation of the Trump Plaza Expansion, Trump AC will own and operate the two largest casino hotel properties in Atlantic City, both of which are strategically located on The Boardwalk. Trump AC believes that the Atlantic City Properties' prime locations, reputations for high quality amenities and first-class customer service and targeted marketing strategies are ideally suited to capitalize on the expected continued growth in the Atlantic City gaming market. Management believes that its leading size and market share in Atlantic City following the consummation of the Merger Transaction will provide it with a competitive advantage in marketing the Atlantic City Properties, particularly to large convention groups and multi-day stay destination resort visitors. . ATLANTIC CITY PROPERTIES EXPANSION. Trump AC has nearly completed the Trump Plaza Expansion and is developing the plans for the Taj Mahal Expansion, which projects will increase the Atlantic City Properties' gaming space and hotel room capacity, allowing Trump AC to meet both existing demand and the anticipated demand from the increased number of available rooms and infrastructure improvements that are currently under development to enhance further the "vacation destination appeal" of Atlantic City. The following table profiles Trump AC's casino and hotel capacity following the planned expansions at the Atlantic City Properties: TRUMP TAJ TRUMP PLAZA TAJ MAHAL PLAZA(a) MAHAL EXPANSION(b) EXPANSION(c) TOTAL -------- ------- ------------ ------------ ------- Casino square footage... 75,395 120,000(d) 64,158 60,000 319,553 Slot machines........... 2,368 3,550 1,898 2,500 10,316 Table games............. 97 169 44 -- 310 Hotel rooms............. 555 1,250 849 800 3,454
-------------------- (a) Includes the 2,000 square foot area connecting the existing facility with Trump Plaza East (as defined) and the 75 slot machines included in this area. (b) Includes the 15,000 square foot casino with 400 slot machines and 13 table games and 326 hotel rooms which have already opened at Trump Plaza East. The remaining 14 hotel rooms and suites at Trump Plaza East are scheduled to be opened by the end of April 1996. Also reflects nine super suites scheduled to open early in 1997 and not otherwise included in the "Trump Plaza Expansion." The remaining portion of the Trump Plaza Expansion, Trump World's Fair (as defined), is scheduled to open in the second quarter of 1996. (c) Plans for the Taj Mahal Expansion, scheduled to be completed in phases from the first quarter of 1997 through early 1998, are subject to modification. (d) Excludes a 12,000 square foot poker, keno and race simulcasting room which contains 64 poker tables. . OPERATING SYNERGIES. Trump AC intends to capitalize on the opportunities for efficiencies which can be generated by integrating certain operations of the Atlantic City Properties, which previously have been operated separately. Management has identified cost savings which management estimates, by the end of the second year following the Merger Transaction, to be approximately $18-20 million on an annual basis, although no assurance may be made as to the amount which will be realized. Management believes that it will be able to consolidate certain departments at the Atlantic City Properties, reduce general and administrative expenses through possible personnel reductions and the consolidation of certain marketing efforts, and reduce operating costs through efficiencies that are expected to result from the combined purchasing power of the Atlantic City Properties. . THE "TRUMP" NAME. Trump AC capitalizes on the widespread recognition of the "Trump" name and its association with high quality amenities and first-class service. To this end, Trump AC provides a broadly diversified gaming and entertainment experience consistent with the "Trump" name and reputation for quality. ATLANTIC CITY PROPERTIES Trump Plaza. Management believes that Trump Plaza's "Four Star" Mobil Travel Guide rating and "Four Diamond" American Automobile Association rating reflect the high quality amenities and services that Trump Plaza provides to its casino patrons and hotel guests. These amenities and services include a broad selection of dining choices, headline entertainment, deluxe accommodations, tennis courts and swimming and health spa facilities. Trump Plaza Expansion. Management is seeking to enhance further Trump Plaza's position as an industry leader through the Trump Plaza Expansion, scheduled to be completed in the second quarter of 1996, which involves expanding and renovating Trump Plaza's gaming space, increasing its hotel capacity and constructing retail operations and entertainment venues. As part of the Trump Plaza Expansion, management has renovated and integrated into Trump Plaza a hotel located adjacent to Trump Plaza's main tower ("Trump Plaza East"), the grand opening for which was held on February 16, 1996, and is in the process of renovating and integrating the former Trump Regency Hotel ("Trump World's Fair"), located on The Boardwalk adjacent to the existing Atlantic City Convention Center, which is next to Trump Plaza. In February 1996, Trump Plaza East opened the 15,000 square foot Ocean View Casino and Bar, and has to date opened 326 of its 349 hotel rooms. The Ocean View Casino and Bar is the first gaming room in Atlantic City to combine a casino, bar and entertainment area and features a 70-foot long bar with 27 bar- top slot machines, live entertainment and a 58 square foot video wall. With its high ceilings and windows overlooking the Atlantic Ocean and The Boardwalk, Trump Plaza is creating a new and exciting entertainment environment for its casino patrons. Upon completion of the Trump Plaza Expansion, Trump Plaza's casino floor space will be the largest in Atlantic City, increasing from approximately 75,000 square feet to an aggregate of approximately 140,000 square feet, housing a total of approximately 4,270 slot machines and 140 table games. Trump Plaza's hotel capacity will increase to a total of 1,404 guest rooms from 555 guest rooms, making Trump Plaza's guest room inventory one of the largest in Atlantic City. Management believes the increased hotel capacity as a result of the Trump Plaza Expansion will better enable Trump Plaza to meet demand and accommodate its casino guests, as well as to host additional and larger conventions and corporate meetings. The following table details plans for the Trump Plaza Expansion: TRUMP TRUMP PLAZA TRUMP WORLD'S FACILITY(a) PLAZA EAST(b) FAIR(c) TOTAL ----------- ------------- ------- ------ Casino square footage................. 75,395 14,886 49,272 139,553 Slot machines......................... 2,368 405 1,493 4,266 Table games........................... 97 12 32 141 Hotel rooms........................... 555 349 500 1,404
- -------------------- (a) Includes the 2,000 square foot area connecting the existing facility with Trump Plaza East (as defined) and the 75 slot machines included in their area. (b) The casino and 326 hotel rooms have already opened. The remaining 14 hotel rooms and suites are scheduled to be opened by the end of April 1996. Also reflects nine super suites scheduled to open early in 1997 and not otherwise included in the "Trump Plaza Expansion." (c) Scheduled to open in the second quarter of 1996. The Trump Plaza Expansion will increase Trump Plaza's prime central frontage on The Boardwalk to nearly a quarter of a mile. Furthermore, Trump World's Fair will add approximately 50,000 square feet of casino floor space, approximately 16,000 of which will be directly accessible from The Boardwalk, and Trump Plaza has been reconfigured to provide a new entranceway to Trump Plaza directly off the Atlantic City Expressway. Management believes that the construction of a new convention center and "tourist corridor" linking the new convention center with The Boardwalk will enhance the desirability of Atlantic City generally and, as a result of Trump Plaza's central location, will benefit Trump Plaza in particular. Trump Plaza's location on The Boardwalk at the end of the main highway into Atlantic City makes it highly accessible for both "drive-in" and "walk-in" patrons. The Taj Mahal. The Taj Mahal currently has the largest casino in Atlantic City and has ranked first among all Atlantic City casinos in terms of total gaming revenues, table revenues and slot revenues since it commenced operations in 1990. The Taj Mahal capitalizes on the widespread recognition and marquee status of the "Trump" name and its association with high quality amenities and first-class service as evidenced by its "Four Star" Mobil Travel Guide rating. Management believes that the breadth and diversity of the Taj Mahal's casino, entertainment and convention facilities and its status as a "must-see" attraction will enable the Taj Mahal to benefit from the expected continued growth in the Atlantic City market. In order to enhance its status as a "must- see" attraction, the Taj Mahal has recently signed agreements for the development of Hard Rock Cafe(R), Rainforest Cafe(R) and All Star Cafe(R) themed restaurants on the property. In addition, in order to continue to attract high end players, the Taj Mahal has recently opened the Dragon Room, a new Asian themed table game area, and plans to open the Sultan's Palace, a new high-end "slots only" lounge and private club in the second quarter of 1996. The Taj Mahal Expansion. The Taj Mahal Expansion is scheduled to be completed in phases from the first quarter of 1997 through early 1998. The Taj Mahal Expansion, the plans for which are subject to modification, involves the construction of an approximately 2,000 space expansion of the Taj Mahal's existing self-parking facilities and a new 10,000 seat arena adjacent to the Taj Mahal, each scheduled to be completed in the first quarter of 1997; the conversion of the current site of the Mark Etess Arena into a new 60,000 square-foot circus-themed casino with 2,500 slot machines, scheduled to be completed in mid-1997; and the construction of an approximately 800 room hotel tower adjacent to the Taj Mahal's existing hotel tower, which is scheduled to be completed early in 1998. THE ATLANTIC CITY MARKET. The Atlantic City gaming market has demonstrated continued growth despite the recent proliferation of new gaming venues across the country. The 12 casino hotels in Atlantic City generated approximately $3.75 billion in gaming revenues in 1995, an approximately 9.5% increase over 1994 gaming revenues of approximately $3.42 billion. During 1995, all 12 casinos experienced increased gaming revenues compared to 1994. The approximately $3.75 billion of gaming revenues produced by the 12 Atlantic City casino hotels in 1995 exceeded the approximately $3.12 billion of gaming revenues produced by the 18 largest (based on net revenues) casino hotels on the Las Vegas Strip for the same period, even though the 12 Atlantic City casino hotels have less than one-quarter the number of hotel rooms of such Las Vegas Strip casino hotels. Management believes, however, that given current high occupancy levels, future casino revenue growth in the Atlantic City market will be dependent in part upon expansion in hotel capacity. Due principally to an improved regulatory environment, the general improvement of economic conditions in 1993, 1994 and 1995 and existing high occupancy rates, significant investment in the Atlantic City market has been initiated and/or announced. For example, Trump Plaza will be located at the end of the planned "tourist corridor" featuring an entertainment and retail complex that will link The Boardwalk with downtown Atlantic City. In addition, The New Jersey Casino Redevelopment Authority ("CRDA") is currently overseeing the development of a new convention center. When completed, the approximately $250 million convention center will be the largest exhibition space between New York City and Washington, D.C. The new convention center, currently scheduled to open in January 1997, will be located at the base of the Atlantic City Expressway. Trump Plaza is adjacent to the existing Atlantic City Convention Center and will also be one of the closest casino hotels to the new convention center, which as currently planned would hold approximately 500,000 square feet of exhibit and pre-function space, 45 meeting rooms, various food-service facilities and a 1,600-car underground parking garage. An additional planned infrastructure improvement is the State of New Jersey's approximately $125 million capital plan to upgrade and expand the Atlantic City International Airport. Trump AC believes that the Taj Mahal's and Trump Plaza's positions as leading Atlantic City attractions will enable them to attract a large portion of any increase in the number of potential casino hotel patrons. THE FIRST MORTGAGE NOTE OFFERING ISSUERs..................... Trump AC and Trump AC Funding as joint and several obligors. PRINCIPAL AMOUNT............ $1,100,000,000 aggregate principal amount of % First Mortgage Notes due 2006. MATURITY.................... April , 2006. INTEREST.................... % per annum, payable in cash, semi-annually in arrears, calculated on the basis of a 360-day year consisting of twelve 30-day months. INTEREST PAYMENT DATES...... April and October , commencing October , 1996. GUARANTORS.................. The First Mortgage Notes will be fully and unconditionally guaranteed on a joint and several, senior secured basis by Plaza Associates, Taj Associates, TTMC and each other present and future majority owned or controlled subsidiary (other than "unrestricted subsidiaries," a "Subsidiary") of Trump AC, other than Trump AC Funding (which is one of the Issuers). OPTIONAL REDEMPTION......... The First Mortgage Notes will be redeemable in cash at the option of the Issuers, in whole or in part, at any time on or after , 2001 at the redemption prices set forth herein, together with accrued and unpaid interest through the redemption date. In addition, the First Mortgage Notes are subject at any time to redemption in accordance with an order of a governmental authority having jurisdiction over Taj Associates or Plaza Associates' casino licenses. SINKING FUND................ None. CHANGE OF CONTROL........... Upon the occurrence of a Change in Control (as defined in "Description of the First Mortgage Notes--Certain Covenants--Repurchase of the First Mortgage Notes at the Option of the Holder Upon a Change in Control"), each holder of First Mortgage Notes may require Trump AC to repurchase such holder's First Mortgage Notes at 101% of the principal amount thereof, together with accrued and unpaid interest to the date of repurchase. SECURITY.................... The First Mortgage Notes will be secured by one or more mortgages (the "Mortgage") representing a first lien and security interest (subject to approximately $3.0 million of indebtedness secured by mortgages) on substantially all of the assets comprising Trump Plaza and the Taj Mahal, including the Specified Parcels (as defined in "--Use of Proceeds") and related facilities. The security interest held by a collateral agent on behalf of, among others, the Trustee also includes assignments of leases and rents and operating assets and encumbers furniture, fixtures, machinery and equipment. However, THCR Holdings' direct and indirect equity interests in Trump Atlantic City and its subsidiaries, including Plaza Associates and Taj Associates, will be pledged exclusively for the benefit of the holders of the 15 1/2% Senior Secured Notes due 2005 issued by THCR Holdings and its subsidiary, Trump Hotels & Casino Resorts Funding, Inc. ("THCR Funding") (the "Senior Notes"). NON-RECOURSE................ No direct or indirect stockholder, partner, employee, officer or director, as such, past, present or future, of either the Issuers, any Guarantor or any successor entity shall have any personal liability in respect of the obligations of the Issuers or any Guarantor under the indenture under which the First Mortgage Notes will be issued (the "First Mortgage Note Indenture"), the First Mortgage Notes or the guarantees thereof by reason of the status as such stockholder, partner, employee, officer or director except to the extent such party is an Issuer or Guarantor. CERTAIN COVENANTS........... The First Mortgage Note Indenture will contain certain covenants which, among other things, will (i) limit Trump AC's and its Subsidiaries' ability to incur certain indebtedness unless, among other things, Trump AC's Consolidated Coverage Ratio (as defined) for the four fiscal quarters immediately preceding such event, taken as one period, would have been at least equal to the ratios set forth in the First Mortgage Note Indenture, subject to certain exceptions; (ii) limit the making of certain dividends, distributions and other restricted payments by Trump AC and its Subsidiaries, (iii) limit the lines of business in which Trump AC and its Subsidiaries may engage to those relating to the casino hotel business in AC; (iv) limit the existence of certain liens on assets of Trump AC and its Subsidiaries; (v) restrict the use of proceeds from certain asset sales by Trump AC and its Subsidiaries; (vi) limit transactions by Trump AC and its Subsidiaries with affiliates of Trump AC (other than wholly-owned Subsidiaries); (vii) restrict Trump AC and its Subsidiaries from engaging in certain leasing activities; (viii) limit the Issuers' ability to merge, sell or consolidate; (ix) limit the obligations of Trump AC Funding to those incident to its obligations under the First Mortgage Note Indenture; (x) prohibit Trump AC and its Subsidiaries from paying services fees under a certain services agreement with a corporation wholly owned by Trump, or any expenses relating thereto, under certain circumstances, including if a Default (as defined) or an Event of Default (as defined) has occurred and is continuing; (xi) prohibit Trump AC and its Subsidiaries from paying any other amounts pursuant to other management, services or similar agreements with Trump; (xii) require the maintenance of insurance; and (xiii) limit the issuing or selling of equity interests by any of Trump AC's Subsidiaries (except to Trump AC or a wholly-owned Subsidiary thereof). EVENTS OF DEFAULT........... Events of Default will include (i) default in payment of interest when due for a period of 30 days; (ii) default in payment of principal or premium, if any, when due; (iii) default in the performance or breach of certain specified covenants, including those relating to merger, consolidation or sale of assets, failure to make or consummate a Change of Control Offer (as defined) or an Asset Sale Offer (as defined) as required; (iv) default in the performance or breach of certain other covenants of the Issuers (other than those specifically covered elsewhere in the First Mortgage Note Indenture) for 30 days after notice; (v) certain events of bankruptcy, insolvency or reorganization relating to the Issuers or significant subsidiaries, which, if involuntary, continue for 60 days, (vi) revocation, suspension or loss of certain permits resulting in a cessation of a substantial portion of the operations of Trump Plaza or the Taj Mahal for more than 90 consecutive days; (vii) acceleration prior to the maturity of certain indebtedness or the default in the payment when due of certain indebtedness of Trump AC or its subsidiaries; (viii) except as permitted by the First Mortgage Note Indenture or the First Mortgage Notes, the cessation of any guarantee in any material respect or the finding by any judicial proceeding that the guarantee is unenforceable or invalid in any material respect or the denial or disaffirmation by any Guarantor of its obligations under its guarantee; and (ix) certain events of default under the documents governing the Mortgage (as defined). An Event of Default under the First Mortgage Note Indenture could permit acceleration of the First Mortgage Notes and acceleration of certain other existing or future indebtedness of the Issuers and their affiliates under other instruments that may contain cross-acceleration or cross-default provisions. See "Risk Factors--Restrictions on Certain Activities."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000792341_unicomp_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000792341_unicomp_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..b5a08b5fc4c9130653c5795773ef15213584a092
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000792341_unicomp_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE MORE DETAILED INFORMATION APPEARING ELSEWHERE IN THIS PROSPECTUS. THIS PROSPECTUS INCLUDES FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO RISKS AND UNCERTAINTIES, AND ACTUAL RESULTS MAY DIFFER MATERIALLY. SEE "RISK FACTORS." EXCEPT AS OTHERWISE SPECIFIED, INFORMATION IN THIS PROSPECTUS ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION. THE COMPANY UniComp, Inc. ("UniComp" or the "Company") provides information technology services to businesses located primarily in the United Kingdom and platform-migration software and payment-processing systems to users in North America and Europe. The Company's strategy is to emphasize its platform- migration and payment-processing software products and to expand its services business within its existing geographic markets. The Company believes this strategy will allow it to expand profit margins and provide its high-quality information technology services to a broad and growing installed base of users of its platform-migration and payment-processing products. The worldwide information technology industry is characterized by rapid technological change, which often leads to increased costs of maintaining internal information technology resources capable of responding to such change. The Company believes that as companies strive to compete and utilize complex new technologies, more companies will move toward outsourcing their information technology requirements, thereby enhancing the Company's information technology services business. The Company believes that decreasing prices, increasing functionality in information technology products and the inherent constraints of proprietary platforms have contributed to increased market acceptance of open systems and customer demand for information technology products based on such systems. Changing to new computing platforms, however, often results in significant disruption of business operations as users are retrained and software errors are discovered and corrected. Also critical is the potential loss of data contained in existing databases that may result from a change to new applications software. The Company's platform-migration software products address these issues, enabling its customers to move more efficiently to open systems. Payment processing for commercial businesses has grown rapidly in recent years as a result of a proliferation in, and increased usage of, credit and debit cards and wider acceptance of such cards among merchants. Advances in payment-processing and telecommunications technologies have also been key factors contributing to such growth. The Company designs, develops and markets payment-processing systems that provide merchants with greater hardware independence by supporting a variety of hardware platforms, including personal computers, point-of-sale terminals and other peripheral devices. The Company's strategy in the payment-processing market is to focus its sales and marketing efforts on the relatively small number of large payment processors and hardware vendors. The Company has experienced significant growth, with total revenues growing to $22.3 million for fiscal year 1996 from $12.2 million for fiscal year 1994, a compound annual growth rate of approximately 35%. In fiscal year 1996, approximately 51% of total revenues were derived from the Company's maintenance and other technology services, with more than 80% of total revenues attributable to international operations, primarily in Northern Ireland. The Company was incorporated in Colorado in 1985. Its executive offices are located at 1800 Sandy Plains Parkway, Suite 305, Marietta, Georgia 30066 and its telephone number is (770) 424-3684. Unless the context otherwise indicates, references to "UniComp" or the "Company" include UniComp, Inc. and its wholly owned subsidiaries. THE OFFERING Common Stock offered by the Company.......... 1,500,000 shares Common Stock to be outstanding immediately after this offering........................ 7,090,245 shares (1) Use of proceeds.............................. Repayment of outstanding indebtedness, working capital and other general corporate purposes, including potential acquisitions. See "Use of Proceeds." Nasdaq National Market symbol................ UCMP
SUMMARY FINANCIAL DATA (2) (IN THOUSANDS, EXCEPT PER SHARE DATA) FISCAL YEAR ENDED SIX MONTHS ENDED ------------------------------- ------------------------ FEB. 28, FEB. 28, FEB. 29, AUGUST 31, AUGUST 31, 1994 1995 1996 1995 1996 --------- --------- --------- ----------- ----------- STATEMENT OF OPERATIONS DATA: Total revenues............................................ $ 12,206 $ 18,325 $ 22,291 $ 10,063 $ 11,620 Operating income.......................................... 1,604 2,217 2,555 1,277 1,205 Income before taxes....................................... 1,465 2,117 2,262 1,179 1,043 Provision for taxes....................................... 255 495 203 130 300 Net income................................................ 1,210 1,622 2,059 1,049 743 Net income per share...................................... $ 0.28 $ 0.34 $ 0.40 $ 0.20 $ 0.14 Weighted average shares outstanding....................... 4,344 4,710 5,188 5,186 5,483
AUGUST 31, 1996 ------------------------- AS ADJUSTED ACTUAL (3) --------- -------------- BALANCE SHEET DATA: Total assets........................................................................... $ 16,060 $ 20,200 Working capital........................................................................ 1,320 6,916 Debt, including current portion........................................................ 3,116 1,116 Total stockholders' equity............................................................. 8,418 14,558
- ------------------------ (1) Based on shares outstanding as of August 31, 1996. Excludes (i) 832,500 shares of Common Stock issuable upon exercise of outstanding stock options granted under the Company's Long Term Incentive Plan (the "LTI Plan"), (ii) 205,000 shares of Common Stock reserved for future issuance under the LTI Plan, (iii) 150,000 shares of Common Stock reserved for future issuance under the Company's 1996 Director Incentive Plan (the "Director Plan"), (iv) 150,000 shares of Common Stock issuable upon exercise of the Representative's Warrant, (v) 25,000 shares of Common Stock issuable upon exercise of an outstanding warrant to purchase shares of Common Stock at $6.90 per share issued in connection with the sale of such convertible promissory notes (the "Note Warrant"), and (vi) 87,500 shares of Common Stock issuable upon exercise of outstanding warrants to purchase shares of Common Stock at $6.00 per share and 87,500 shares of Common Stock issuable upon exercise of outstanding warrants to purchase shares of Common Stock at $7.00 per share issued to a financial advisor to the Company (together, the "Advisor Warrants"). See "Management's Discussion and Analysis of Financial Condition and Results of Operations--Liquidity and Capital Resources,"
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000799729_parexel_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000799729_parexel_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..b0b02cddc0371ded9f262238c7d22073eee08079
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000799729_parexel_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information, including Risk Factors and Consolidated Financial Statements and Notes thereto, appearing elsewhere in this Prospectus. This Prospectus contains certain "forward-looking" information, as that term is defined by (i) the Private Securities Litigation Reform Act of 1995 (the "Act") and (ii) releases made by the Securities and Exchange Commission. Such information involves risks and uncertainties. The Company's actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in "Risk Factors." Unless otherwise indicated, all information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. THE COMPANY PAREXEL International Corporation ("PAREXEL" or the "Company") is a leading contract research organization ("CRO"), providing clinical research and development services to the worldwide pharmaceutical and biotechnology industries. The Company believes it is the fourth largest CRO, based on estimated annual net revenue, and one of only a few CROs capable of providing a full range of clinical services on a global basis. The Company complements the research and development departments of pharmaceutical and biotechnology companies by offering high quality clinical research services to the client and reducing drug development time and cost. In addition, the Company's integrated services and extensive information technology capabilities, coupled with its broad experience and expertise in global drug development, provide clients with a variable cost alternative to the fixed costs associated with internal drug development. The Company offers a full complement of clinical research and development services, including designing, initiating and monitoring clinical trials, managing and analyzing clinical data and consulting on regulatory affairs. PAREXEL's integrated information systems and worldwide network of offices enable the Company to provide high-quality comprehensive services on a global basis. The Company has provided clinical research and development services in North America since 1985, in Europe since 1989, in Japan since May 1995 and in Australia since December 1995. The Company derived 61.6% and 66.2% of net revenue from its North American operations and 37.3% and 32.5% of net revenue from its European operations in the fiscal year ended June 30, 1996 and the three months ended September 30, 1996, respectively. During fiscal 1996, the Company provided services to each of the 20 largest pharmaceutical companies, as ranked by estimated worldwide 1995 research and development expenditures, and to seven of the ten largest biotechnology companies, as ranked by December 1995 market capitalization. During fiscal 1996, the Company performed services for over 250 clients, including 53 biotechnology companies, involving over 1,000 projects. The CRO industry derives substantially all of its revenue from the pharmaceutical and biotechnology industries. In 1995, the global pharmaceutical and biotechnology industries spent an estimated $33.0 billion on research and development, of which the Company estimates $15.2 billion was spent on the type of services offered by the Company. Of this amount, $2.6 billion was outsourced to CROs. The Company believes that the following trends will cause the CRO industry to continue to grow: (i) many pharmaceutical companies, in response to margin pressures, are seeking to reduce the high fixed costs associated with peak-load staffing for drug development by relying on a combination of internal resources and CROs; (ii) pharmaceutical and biotechnology companies increasingly are attempting to maximize profits from a given drug by pursuing regulatory approvals in multiple countries in parallel, rather than sequentially, by outsourcing to CROs with global capabilities; (iii) as consolidation in the pharmaceutical industry continues, many pharmaceutical companies aggressively manage costs by reducing jobs and outsourcing to variable-cost CROs in an effort to reduce the fixed costs associated with internal drug development; (iv) as regulatory requirements in many jurisdictions have become more complex, the pharmaceutical and biotechnology industries are increasingly outsourcing to certain CROs to take advantage of their data management expertise and global presence; (v) the worldwide research and development expenditures for new drugs, including amounts spent on services of the type provided by CROs, have experienced substantial growth in recent years as a result of pressures to develop new drugs for an aging population and for the treatment of life threatening diseases and chronic disorders; and (vi) the growth of the biotechnology industry has increased the demand for expertise and - -------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- services provided by outside sources, including CROs. There can be no assurance, however, that these trends will result in growth in the CRO industry. PAREXEL's objective is to maintain and enhance its position as a leading CRO by providing a full range of clinical services on a global basis. The Company addresses all aspects of clinical research and development with a flexible approach that allows its clients to use the Company's services on an individual or bundled basis. The Company believes its expertise in conducting scientifically demanding trials and its ability to coordinate complicated global trials are significant competitive strengths. PAREXEL continues to devote significant resources to developing information systems designed to allow the Company to more effectively manage its business operations and deliver services to its clients. The Company will continue to invest in improvements in information technology and consider acquisitions of complementary businesses in order to enhance its competitive position and its level of service. RECENT EVENTS In June 1996, the Company acquired Caspard Consultants, a Paris-based CRO, and in August 1996 acquired Lansal Clinical Pharmaceutics Limited, a Tel Aviv-based CRO. These acquisitions augment the Company's existing clinical operations and are in line with management's focused international expansion efforts. In June 1996, the Company acquired Sitebase Clinical Systems, Inc., a provider of remote data entry ("RDE") technology. RDE technology is expected to enhance the quality and timeliness of clinical trial data. In August 1996, the Company also acquired State and Federal Associates, Inc. ("S&FA"), a Washington D.C.-based provider of consulting services to the healthcare and pharmaceutical industries. The acquisition broadens the Company's portfolio of consulting services, specifically in the area of health economics. These acquisitions are each being accounted for as poolings of interest. The aggregate historical financial results of the acquired companies are not material to the Company's financial position and results of operations. Therefore, prior periods have not been restated and results of operations have been included since the date of acquisition. In addition, during fiscal 1996 the Company opened offices in Chicago and Madrid, Spain. THE OFFERING Common Stock Offered by the Company....................... 1,066,900 shares Common Stock Offered by the Selling Stockholders.......... 208,100 shares Common Stock Outstanding Immediately after the Offering... 9,515,868 shares(1) Use of Proceeds........................................... Working capital and general corporate purposes, including possible acquisitions. Nasdaq National Market Symbol............................. PRXL - --------------- (1) Based on shares outstanding as of October 15, 1996. Excludes 776,710 additional shares of Common Stock issuable upon exercise of stock options at a weighted average exercise price per share of $23.74. See "Capitalization" and Note 11 of Notes to Consolidated Financial Statements of the Company.
- -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- SUMMARY CONSOLIDATED FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS ENDED FOR THE YEAR ENDED JUNE 30, SEPTEMBER 30, ----------------------------------------------- ----------------- 1992 1993 1994 1995 1996 1995 1996 ------- ------- ------- ------- ------- ------- ------- STATEMENT OF OPERATIONS DATA: Net revenue........................................... $45,407 $54,000 $58,002 $58,573 $88,006 $17,973 $33,030 ------- ------- ------- ------- ------- ------- ------- Costs and expenses: Direct costs........................................ 29,772 36,106 38,244 42,140 60,141 12,465 22,821 Selling, general and administrative................. 10,164 11,831 13,631 13,294 19,027 3,834 6,617 Depreciation and amortization....................... 2,299 2,511 2,435 2,251 2,343 515 883 Facility and other restructuring charges............ -- 3,254(1) -- -- -- -- -- Impairment of long-lived assets..................... -- -- -- 11,253(2) -- -- -- ------- ------- ------- ------- ------- ------- ------- Total costs and expenses...................... 42,235 53,702 54,310 68,938 81,511 16,814 30,321 ------- ------- ------- ------- ------- ------- ------- Income (loss) from operations......................... 3,172 298 3,692 (10,365) 6,495 1,159 2,709 Other income (expense), net........................... 138 (520) (196) 55 1,157 98 364 ------- ------- ------- ------- ------- ------- ------- Income (loss) before provision for income taxes and cumulative effect of accounting change.............. 3,310 (222) 3,496 (10,310) 7,652 1,257 3,073 ======= ======= ======= ======= ======= ======= ======= Net income (loss)..................................... 1,536 (2,157) 2,423 (10,630) 4,599 742 1,936 ======= ======= ======= ======= ======= ======= ======= Net income (loss) per share........................... $ 0.33 $ (2.97) $ 0.44 $(12.61) $ 0.68 $ 0.14 $ 0.22 ======= ======= ======= ======= ======= ======= ======= PRO FORMA DATA: Income from operations (3)............................ $ 3,172 $ 3,552 $ 3,692 $ 888 $ 6,495 $ 1,159 $ 2,709 SEPTEMBER 30, 1996 --------------------------- ACTUAL AS ADJUSTED(4) -------- -------------- BALANCE SHEET DATA: Working capital.................................................. $ 54,416 $111,010 Total assets..................................................... 107,670 164,264 Long-term debt, less current maturities.......................... 304 304 Stockholders' equity............................................. 66,372 122,966 - --------------- (1) Represents a charge incurred in connection with a restructuring of operations in Germany because of a decline in net revenue from those operations. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Note 3 of Notes to Consolidated Financial Statements of the Company. (2) Represents a non-cash charge primarily due to the write-down of intangible assets of the Company's German operations. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Note 3 of Notes to Consolidated Financial Statements of the Company. (3) Excludes facility and other restructuring charges incurred in fiscal 1993 and the impairment loss from the write-down of long-lived assets incurred in fiscal 1995. (4) Adjusted to give effect to the sale of 1,066,900 shares of Common Stock by the Company in this offering at an assumed public offering price of $56.00 per share, after deducting the estimated underwriting discount and estimated offering expenses. See "Use of Proceeds," "Capitalization" and Note 10 of Notes to Consolidated Financial Statements of the Company.
- --------------------------------------------------------------------------------
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000801529_printware_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000801529_printware_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..c7def4c54452472547f40c1b8e65c03c423fba12
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000801529_printware_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY INFORMATION IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. SEE "RISK FACTORS" FOR A DISCUSSION OF CERTAIN FACTORS TO BE CONSIDERED BY PROSPECTIVE INVESTORS. EXCEPT AS OTHERWISE INDICATED, ALL INFORMATION IN THIS PROSPECTUS (I) ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION, (II) DOES NOT INCLUDE UP TO 120,000 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE REPRESENTATIVE'S WARRANT, AND (III) REFLECTS A ONE-FOR-FOUR REVERSE SPLIT OF THE COMMON STOCK EFFECTIVE APRIL 25, 1996. SEE "DESCRIPTION OF CAPITAL STOCK." THIS PROSPECTUS CONTAINS FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY FROM THE RESULTS DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. THE COMPANY Printware, Inc. ("Printware" or the "Company") designs, builds and markets "Computer-to-Plate" systems which are used by the offset printing industry to create printing plates directly from computer data. These systems replace the traditional process of typesetting, paste-up, camera work and processing film to produce a printing plate. Computer-to-Plate technology provides one-step plate making (including text, graphics and photographic halftones) directly from computer data, much as a laser printer makes printed pages directly from computer data. The key benefits of Computer-to-Plate technology are lower costs, faster turnaround times, fewer pieces of equipment and fewer environmental limitations on disposal of by-products. The key hardware element of a Computer-to-Plate system is called a Platesetter, which produces the printing plate by imaging the computer data on the physical plate material. The Company sells Platesetters, supplies for use in Platesetters and raster image processors for connecting the Platesetter to the customer's computer network. Sales of supplies accounted for approximately 55% of the Company's 1995 revenues. The Company is a leader in the development and introduction of Computer-to-Plate systems. To date the Company has sold over 300 Platesetters, which it believes is more than any other single competitor. The Company's marketing strategy is to offer a wide range of Computer-to-Plate products to the broad market of "mainstream" printers who use small format (18" wide or less) presses, typically for high-volume printing applications such as check printing, social printing (such as wedding invitations) and envelope printing. The Company's customers include leading printers such as Deluxe Corporation ("Deluxe"), Pitney Bowes, Thomson Publishing, Liberty Check Printers and Northrup-Grumman. The Company currently manufactures two lines of Platesetters in various configurations. The end-user price ranges from $75,000 to $150,000 for the Model 1440, depending on the configuration, and from $85,000 to $100,000 for the Model 3240. The Company markets the Model 1440 through its own sales force, and the Model 3240 is marketed by Mitsubishi Imaging (MC), Inc. ("Mitsubishi") under its name. Both of these Platesetter lines use patented resonant galvanometer technology which was licensed to the Company by Minnesota Mining and Manufacturing Company ("3M") when the Company was organized in 1985. The resonant galvanometer technology provides precise scanning of the laser beam which writes the digital image on the blank plate. In 1993 the Company began to focus exclusively on Computer-to-Plate products and phased out its manufacturing of laser printers and film imagers. Phasing out of these lower-margin products resulted in a reduction in revenue in 1993 and 1994. The focus on Computer-to-Plate products resulted in an improvement in profitability in 1994 and 1995 due to the higher margins provided by those products and lower research and development and sales and marketing expenditures. The Company is incorporated in Minnesota and has its principal executive office and manufacturing facility at 1270 Eagan Industrial Road, St. Paul, Minnesota 55121. Its telephone number is (612) 456-1400. THE OFFERING COMMON STOCK OFFERED BY THE COMPANY.......... 1,200,000 shares COMMON STOCK OFFERED BY THE SELLING SHAREHOLDERS................................ 400,000 shares COMMON STOCK OUTSTANDING AFTER THE OFFERING.................................... 4,829,713 shares(1) USE OF PROCEEDS.............................. Product development, sales and marketing and working capital PROPOSED NASDAQ NATIONAL MARKET SYMBOL....... PRTW
- --------------------------- (1) Does not include, as of March 30, 1996 (i) 135,567 shares issuable upon exercise of stock options held by executive officers and employees of the Company, (ii) 120,000 shares issuable upon exercise of the Representative's Warrant, and (iii) 5,000 shares issuable upon exercise of warrants held by Deluxe. RISK FACTORS AND DILUTION An investment in the Common Stock involves a high degree of risk. See "Risk Factors." Purchasers will experience immediate and substantial dilution in net tangible book value per share. See "Dilution." SUMMARY FINANCIAL DATA THREE MONTHS ENDED -------------------------- YEAR ENDED DECEMBER 31, MARCH 30, APRIL 1, ----------------------------------------- 1996 1995 1995 1994 1993 ------------ ------------ ------------ ------------ ------------- STATEMENT OF OPERATIONS DATA: Revenues................................ $ 1,832,013 $ 1,807,623 $ 8,388,148 $ 6,626,925 $ 7,296,484 Gross margin............................ 721,967 806,752 3,384,192 2,524,524 1,951,965 Income (loss) from operations........... 304,555 330,105 1,554,183 622,184 (1,213,897) Net income (loss)(1).................... 330,898 326,483 1,793,425 784,029 (1,204,707) Net income (loss) per common and common equivalent share(1).................... $.09 $.09 $.48 $.21 $(.33) Weighted average common and common equivalent shares outstanding(2)....... 3,705,403 3,705,627 3,705,627 3,685,580 3,635,226
AS OF MARCH 30, 1996 ----------------------------- ACTUAL AS ADJUSTED(3) ------------ --------------- BALANCE SHEET DATA: Cash and cash equivalents........................................................ $ 2,795,856 $ 9,695,856 Working capital.................................................................. 4,491,641 11,391,641 Total assets..................................................................... 5,396,406 12,296,406 Shareholders' equity............................................................. 4,655,666 11,555,666
- --------------------------- (1) Net income in 1994 includes an extraordinary item of $140,927, consisting of a gain on extinguishment of debt. The income per common and common equivalent share attributable to such extraordinary gain was $.04. (2) See Note 1 to Financial Statements for an explanation of the determination of weighted average common and common equivalent shares outstanding. (3) As adjusted to reflect the sale of shares offered hereby, assuming a Price to Public of $6.50 per share, and the application of the estimated net proceeds therefrom of $6.9 million. See "Use of Proceeds" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000802916_industrial_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000802916_industrial_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..adaf6b388762a71c976906fb2c5fe34899a628ca
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000802916_industrial_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a summary of certain information contained in this Prospectus and is qualified in its entirety by the detailed information and financial statements that appear elsewhere in this Prospectus.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000805574_digital_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000805574_digital_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..8034f520e094f0ce76ded10be8aea35912a69d64
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000805574_digital_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE OFFERING Securities Offered by the Company. . . . . . . . Shares of Common Stock, having an aggregate market value of $600,000 which may be issued in lieu of the Company's obligation to pay an aggregate of $600,000 in cash dividends payable on the Series A Convertible Preferred Stock for the next two years. Securities Offered by the Selling Securityholders. . . . . . . . . . . . . . . . . 54,293,591 shares of Common Stock, 750,000 shares of Series A Convertible Preferred Stock and 800,000 Warrants to purchase Common Stock. Common Stock outstanding after the Offering. . . 72,819,490 shares (1) Use of Proceeds. . . . . . . . . . . . . . . . . The Company may issue shares of Common Stock with an aggregate market value of $600,000 in lieu of its obligation to pay $600,000 in cash dividends on the Series A Convertible Preferred Stock. The Company will not receive any of the proceeds from the sale of securities by the Selling Securityholders. The Company will bear estimated expenses of registration of approximately $250,000. See "Plan of Distribution." Nasdaq SmallCap Market symbol. . . . . . . . . . RDUS SUMMARY FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) NINE MONTHS ENDED YEARS ENDED SEPTEMBER 30 (2), JUNE 30 (2), -------------------------------------------------------------- ------------------ 1995 1994(3) 1993(3) 1992(3) 1991(3) 1996 1995 ---- ------- ------- ------- ------- ---- ----- STATEMENT OF OPERATIONS DATA: Net sales. . . . . . . . . . . . $308,133 $324,805 $337,373 $284,598 $199,033 $83,261 $251,007 Income (loss) from operations. . (104,182) (80,830) (34,583) 20,483 9,485 (11,585) 3,620 Net income (loss). . . . . . . . (131,742) (77,475) (20,139) 13,032 6,204 8,849 (13,857) Net income (loss) per share. . . (8.75) (5.70) (1.56) 1.04 0.54 0.49 (0.96) Shares used to compute income (loss) per share . . . . . . 15,049 13,598 12,905 12,485 11,473 17,950 14,386 JUNE 30, 1996 (2) ------------------- BALANCE SHEET DATA: Working capital (working capital deficiency) . . . . . . . . $(49,183) Total assets . . . . . . . . . . . . . . . . . . . . . . . . 43,878 Current Liabilities. . . . . . . . . . . . . . . . . . . . . 91,444 Shareholders' equity (net capital deficiency). . . . . . . . (47,887)
- ----------------------------------- (1) Based on shares outstanding as of October 31, 1996. Excludes (i) 1,195,124 shares of Common Stock issuable upon the exercise of options outstanding under the Company's Stock Option Plans at a weighted average exercise price of $4.34 per share, (ii) 1,818,103 shares of Common Stock reserved for issuance under the Company's Stock Option Plans and Employee Stock Purchase Plan, and (iii) approximately 4,706,668 shares to be reserved for issuance under the Company's 1996 Stock Option Plan (the "1996 Plan") which the Company intends to adopt in the near future (until conversion of the Series A Convertible Preferred Stock into Common Stock, 2,865,658 shares will be reserved for issuance pursuant to the 1996 Plan). Assumes that (i) all dividends on the Series A Convertible Preferred Stock will be paid in shares of Common Stock based upon a per share price of $1 11/32, the last reported sales price of the Company's Common Stock on the Nasdaq SmallCap Market on September 16, 1996, (ii) 6,075,333 shares of Common Stock, the maximum number of shares issuable upon conversion of the Series A Convertible Preferred Stock, will be issued, (this amount of shares is only issuable in the event that the trading price of the Common Stock exceeds certain levels and the Series A Convertible Preferred Stock is not otherwise redeemed. Otherwise the Series A Preferred Stock is convertible into an aggregate of 5,523,030 shares of Common Stock) and (iii) all 800,000 shares of Common Stock issuable upon exercise of Warrants are issued. See "Description of Capital Stock -- Preferred Stock -- Series A Convertible Preferred Stock" and "-- Warrants."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000805956_cellnet_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000805956_cellnet_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..6921c588eb4f55d677a2869beda679349a462825
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000805956_cellnet_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION, INCLUDING "RISK FACTORS" AND THE CONSOLIDATED FINANCIAL STATEMENTS AND NOTES THERETO, APPEARING ELSEWHERE IN THIS PROSPECTUS. UNLESS OTHERWISE INDICATED, ALL INFORMATION IN THIS PROSPECTUS (I) ASSUMES NO EXERCISE OF THE U.S. UNDERWRITERS' OVER-ALLOTMENT OPTION, (II) REFLECTS THE AUTOMATIC CONVERSION OF ALL OUTSTANDING SHARES OF THE COMPANY'S REDEEMABLE CONVERTIBLE PREFERRED STOCK AND CONVERTIBLE PREFERRED STOCK (COLLECTIVELY, "PREFERRED STOCK") INTO COMMON STOCK EFFECTIVE UPON THE CLOSING OF THIS OFFERING, (III) ASSUMES THE EXERCISE OF WARRANTS TO PURCHASE 4,132,970 SHARES OF COMMON STOCK EFFECTIVE UPON THE CLOSING OF THIS OFFERING, (IV) GIVES EFFECT TO A 2-FOR-1 SPLIT OF THE COMMON STOCK WHICH WILL BE EFFECTED PRIOR TO THE DATE OF THIS PROSPECTUS AND (V) ASSUMES THE SALE OF 882,353, AND 533,333 AND 160,000 SHARES OF COMMON STOCK TO NSP, UE AND BEN, RESPECTIVELY, CONCURRENTLY WITH THE CLOSING OF THIS OFFERING AT AN ASSUMED PRICE OF $17.00 PER SHARE, $18.75 PER SHARE AND $18.75 PER SHARE, RESPECTIVELY. SEE "DIRECT PLACEMENTS," "DESCRIPTION OF CAPITAL STOCK" AND "UNDERWRITERS." REFERENCES HEREIN TO "CELLNET" OR THE "COMPANY" REFER TO CELLNET DATA SYSTEMS, INC. AND ITS SUBSIDIARIES. THE SHARES OFFERED HEREBY ARE SUBJECT TO A HIGH DEGREE OF RISK. SEE "RISK FACTORS." CERTAIN INFORMATION CONTAINED IN THIS SUMMARY AND ELSEWHERE IN THIS PROSPECTUS, INCLUDING INFORMATION WITH REGARD TO THE COMPANY'S EXPECTED WIRELESS DATA COMMUNICATIONS NETWORK DEPLOYMENTS AND OPERATIONS, ITS STRATEGY FOR MARKETING AND DEPLOYING SUCH NETWORKS AND RELATED FINANCING ACTIVITIES, CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THE RESULTS DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT MIGHT CAUSE SUCH A DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN "RISK FACTORS," "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" AND "BUSINESS." THE COMPANY The Company designs, builds, owns and operates innovative wireless networks capable of providing low-cost real-time status and event monitoring of up to several million fixed endpoints. The primary application of the Company's network is to provide network meter reading ("NMR") services to electric, gas and water utility companies pursuant to long-term contracts. The Company is currently building wireless networks to provide NMR services to Kansas City Power & Light Company ("KCPL") and Union Electric Company ("UE") in St. Louis covering a total of approximately 1,220,000 meters, of which more than 105,000 meters were in revenue service as of June 30, 1996. In addition, the Company has recently entered into separate services agreements with Northern States Power Company ("NSP") in Minneapolis and Puget Sound Power & Light Company ("Puget") in Washington State, pursuant to which it has contracted to build wireless networks to provide NMR services covering an aggregate of approximately 1,015,000 additional meters, including 1,000,000 meters under the NSP Services Agreement and an initial installation consisting of 15,000 meters under the Puget Services Agreement. CellNet also currently provides certain network distribution automation services to electric utility customers including monitoring and control of power distribution equipment. CellNet's network uses radio devices fitted to existing utility meters to read and report data from each meter every few minutes. Through efficient use of radio frequency spectrum, the Company's networks will have substantial additional capacity to service non-utility applications that require low-cost monitoring of fixed endpoints, such as home security and remote status monitoring of vending machines and office equipment. The Company is working with industry leaders in those markets to encourage further development of such applications. CellNet believes it has a first-to-market opportunity to offer wireless data communications services on a commercial scale for utility and selected non-utility applications. CellNet's network is distinguished by the following advantages: - infrastructure and operating costs sufficiently low to permit cost effective utility meter reading and other fixed point monitoring applications; - highly efficient use of spectrum -- the equivalent of approximately a single voice channel is needed to operate a network; - proprietary software specifically designed to manage real-time data collection from up to several million endpoints; and - open system architecture designed to allow new applications to be added to the CellNet system. PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION, INCLUDING "RISK FACTORS" AND THE CONSOLIDATED FINANCIAL STATEMENTS AND NOTES THERETO, APPEARING ELSEWHERE IN THIS PROSPECTUS. UNLESS OTHERWISE INDICATED, ALL INFORMATION IN THIS PROSPECTUS IN CONNECTION WITH THE OFFERINGS (I) ASSUMES NO EXERCISE OF THE U.S. UNDERWRITERS' OVER-ALLOTMENT OPTION, (II) REFLECTS THE AUTOMATIC CONVERSION OF ALL OUTSTANDING SHARES OF THE COMPANY'S REDEEMABLE CONVERTIBLE PREFERRED STOCK AND CONVERTIBLE PREFERRED STOCK (COLLECTIVELY, "PREFERRED STOCK") INTO COMMON STOCK EFFECTIVE UPON THE CLOSING OF THE OFFERING, (III) ASSUMES THE EXERCISE OF WARRANTS TO PURCHASE 4,132,970 SHARES OF COMMON STOCK EFFECTIVE UPON THE CLOSING OF THE OFFERING WHICH INCLUDES THE ASSUMED EXERCISE OF ALL NOTE WARRANTS ON A CASH BASIS, (IV) GIVES EFFECT TO A 2-FOR-1 SPLIT OF THE COMMON STOCK WHICH WILL BE EFFECTED PRIOR TO THE DATE OF THIS PROSPECTUS AND (V) ASSUMES THE SALE OF 882,353, 533,333 AND 160,000 SHARES OF COMMON STOCK TO NSP, UE AND BEN, RESPECTIVELY, CONCURRENTLY WITH THE CLOSING OF THE OFFERING AT AN ASSUMED PRICE OF $17.00 PER SHARE, $18.75 PER SHARE AND $18.75 PER SHARE, RESPECTIVELY. SEE "DIRECT PLACEMENTS" AND "DESCRIPTION OF CAPITAL STOCK." REFERENCES HEREIN TO "CELLNET" OR THE "COMPANY" REFER TO CELLNET DATA SYSTEMS, INC. AND ITS SUBSIDIARIES. THE NOTE WARRANT SHARES OFFERED HEREBY ARE SUBJECT TO A HIGH DEGREE OF RISK. SEE "RISK FACTORS." CERTAIN INFORMATION CONTAINED IN THIS SUMMARY AND ELSEWHERE IN THIS PROSPECTUS, INCLUDING INFORMATION WITH REGARD TO THE COMPANY'S EXPECTED WIRELESS DATA COMMUNICATIONS NETWORK DEPLOYMENTS AND OPERATIONS, ITS STRATEGY FOR MARKETING AND DEPLOYING SUCH NETWORKS AND RELATED FINANCING ACTIVITIES, CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THE RESULTS DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT MIGHT CAUSE SUCH A DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN "RISK FACTORS," "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" AND "BUSINESS." THE COMPANY The Company designs, builds, owns and operates innovative wireless networks capable of providing low-cost real-time status and event monitoring of up to several million fixed endpoints. The primary application of the Company's network is to provide network meter reading ("NMR") services to electric, gas and water utility companies pursuant to long-term contracts. The Company is currently building wireless networks to provide NMR services to Kansas City Power & Light Company ("KCPL") and Union Electric Company ("UE") in St. Louis covering a total of approximately 1,220,000 meters, of which more than 105,000 meters were in revenue service as of June 30, 1996. In addition, the Company has recently entered into separate services agreements with Northern States Power Company ("NSP") in Minneapolis and Puget Sound Power & Light Company ("Puget") in Washington State, pursuant to which it has contracted to build wireless networks to provide NMR services covering an aggregate of approximately 1,015,000 additional meters, including 1,000,000 meters under the NSP Services Agreement and an initial installation consisting of 15,000 meters under the Puget Services Agreement. CellNet also currently provides certain network distribution automation services to electric utility customers including monitoring and control of power distribution equipment. CellNet's network uses radio devices fitted to existing utility meters to read and report data from each meter every few minutes. Through efficient use of radio frequency spectrum, the Company's networks will have substantial additional capacity to service non-utility applications that require low-cost monitoring of fixed endpoints, such as home security and remote status monitoring of vending machines and office equipment. The Company is working with industry leaders in those markets to encourage further development of such applications. CellNet believes it has a first-to-market opportunity to offer wireless data communications services on a commercial scale for utility and selected non-utility applications. CellNet's network is distinguished by the following advantages: - infrastructure and operating costs sufficiently low to permit cost effective utility meter reading and other fixed point monitoring applications; - highly efficient use of spectrum -- the equivalent of approximately a single voice channel is needed to operate a network; - proprietary software specifically designed to manage real-time data collection from up to several million endpoints; and - open system architecture designed to allow new applications to be added to the CellNet system. Utilities are under increasing regulatory and competitive pressures. CellNet offers an outsourced solution which enables utilities to offer time-of-use pricing plans, peak demand monitoring, real-time response to billing inquiries, real-time power outage detection, on-demand meter reads, customized billing functions and distribution automation. The Company believes its NMR services provide utilities with an effective solution to many of the demands created by increased regulatory and competitive pressures within the utility industry. CellNet's system allows utilities to respond effectively to regulatory changes, reduce costs, defer capital spending and enhance their operating efficiencies. CellNet's strategy is to deploy and operate a series of wireless data communications networks pursuant to long-term contracts with utility company customers and to earn recurring revenues by providing NMR services to such utilities and by using the network to support a variety of non-utility applications. Principal elements of CellNet's strategy include (i) focus on utility markets, (ii) promote development of non-utility applications, (iii) form strategic alliances to enhance NMR services and offer additional services, (iv) pursue international expansion and (v) outsource a substantial portion of its manufacturing and installation activities. The Company is actively targeting those utilities which operate in the 60 largest Metropolitan Statistical Areas ("MSAs"), which represent a majority of the 225 million electric, gas and water meters in the United States. The Company believes that utilities operating in these densely populated areas will be the first to experience heightened competitive and regulatory pressures, and as such, will be most likely to benefit from the Company's services. The Company believes that these competitive and regulatory pressures have recently prompted utilities in the United States to undertake increased measures to improve their efficiency and service levels. CellNet's proprietary technology enables the Company to make extremely efficient use of spectrum. As a result, relative to other wireless services, the Company has been able to acquire frequency at a very low cost. The Company had capitalized $762,000 for license fees and related expenses as of June 30, 1996 and has acquired 50 spectrum licenses in 42 of the top 60 MSAs. The Company believes that it will be able to obtain additional spectrum at reasonable cost if required. The Company has focused its spectrum acquisition strategy on these top 60 markets. The Company believes its spectrum-efficient networks will have substantial excess capacity to service non-utility applications which require low-cost monitoring of fixed endpoints. Potential non-utility applications of the Company's systems include home security, remote status monitoring of vending machines, office equipment, parking meters and other equipment and remote control of traffic lights. The Company is working with industry leaders such as Ameritech, Hewlett-Packard, Honeywell, Inc., Real Time Data, Inc., and Interactive Technologies, Inc. to develop such applications. The Company believes that its utility networks will provide an excellent platform to position the Company as a leading wholesale provider of wireless data communications services for such non-utility applications. The Company believes that a significant international market also exists for its services with several hundred million electric, gas and water meters outside of the United States. The Company's strategy is to pursue international markets through a proposed joint venture with BEn. The Company is currently exploring projects with electric utilities in the U.K., Singapore and Thailand. THE OFFERING Common Stock Offered: U.S. Offering (1)............................. 4,000,000 shares International Offering........................ 1,000,000 shares Total Common Stock Offered (1)............ 5,000,000 shares Common Stock to be outstanding after the Offering (1)(2)................................ 40,623,820 shares Use of proceeds................................. For general corporate purposes, including working capital, capital requirements (capital expenditures and negative operating cash flow) in connection with the installation and operation of the Company's networks and research and development expenses. See "Use of Proceeds." Nasdaq National Market Symbol................... CNDS
In addition, NSP, UE and BEn have agreed to acquire $15.0 million, $10.0 million and $3.0 million, respectively, of restricted Common Stock from the Company (the "NSP Purchase", "UE Purchase" and "BEn Purchase", respectively, and together, the "Direct Placements") concurrently with the closing of this Offering. NSP will purchase 882,353 shares of Common Stock at a purchase price of $17.00 per share (the initial public offering price, less a discount of up to 15%, which discount is dependent upon entering into a services agreement with Wisconsin Electric Power Company for at least 750,000 meters (if such services agreement is not entered into, the purchase price per share will be adjusted to 90% of the initial public offering price)). UE and BEn will purchase, respectively, 533,333 shares and 160,000 shares of Common Stock at a purchase price of $18.75 per share (the initial public offering price less the underwriting discounts and commissions). Upon the closing of this Offering and the Direct Placements, NSP, UE and BEn will own approximately 2.17%, 1.31%, and 0.39%, respectively, outstanding of the Common Stock. The closing of this Offering is not conditioned upon the closing of the Direct Placements. See "Direct Placements." - --------- (1) Assumes the U.S. Underwriters' over-allotment option is not exercised. See "Underwriters." (2) Based on the number of shares outstanding as of June 30, 1996, after giving effect to the automatic conversion of all outstanding shares of Preferred Stock into Common Stock and the assumed exercise on a cash basis of warrants to purchase 4,132,970 shares of Common Stock effective upon the closing of this Offering. Also includes the sale of 1,575,686 shares of Common Stock pursuant to the Direct Placements concurrently with the closing of this Offering. See "Direct Placements." Excludes 3,779,136 shares of Common Stock issuable upon exercise of outstanding stock options as of June 30, 1996 granted under the Company's 1992 Stock Option Plan and 1994 Stock Plan with a weighted average exercise price of $0.625 per share. Also excludes 50,150 shares of Common Stock issuable upon exercise of warrants outstanding as of June 30, 1996 with a weighted average exercise price of $7.59 per share. See "Management -- Incentive Stock Plans," "Description of Capital Stock -- Warrants" and Note 7 to Consolidated Financial Statements. ------------------- CELLNET WAS INCORPORATED IN CALIFORNIA IN OCTOBER 1984 AND REINCORPORATED IN DELAWARE IN AUGUST 1996. CELLNET'S SUBSIDIARIES INCLUDE CELLNET DATA SERVICES, INC., CELLNET DATA SERVICES (IS), INC., CELLNET DATA SERVICES (KC), INC., CELLNET DATA SERVICES (MSP), INC., CELLNET DATA SERVICES (SL), INC., CN FREQUENCY (KC), INC., CN FREQUENCY (MSP), INC., CELLNET DATA SERVICES (SF), INC., CN FREQUENCY (SL), INC., CN WAN CORP. AND DAC (UK), LIMITED. THE COMPANY'S PRINCIPAL EXECUTIVE OFFICES ARE LOCATED AT 125 SHOREWAY ROAD, SAN CARLOS, CALIFORNIA 94070. THE TELEPHONE NUMBER AT SUCH ADDRESS IS (415) 508-6000. THE OFFERINGS Common Stock Offered: U.S. Offering (1)............................. 4,000,000 shares International Offering........................ 1,000,000 shares Total Common Stock Offered in the Offering (1)............................. 5,000,000 shares Note Warrant Offering......................... 2,600,000 shares Common Stock to be outstanding after the Offerings (1)(2)............................... 40,623,820 shares Use of proceeds................................. For general corporate purposes, including working capital, capital requirements (capital expenditures and negative operating cash flow) in connection with the installation and operation of the Company's networks and research and development expenses. See "Use of Proceeds." Nasdaq National Market Symbol................... CNDS
In addition, NSP, UE and BEn have agreed to acquire $15.0 million, $10.0 million and $3.0 million, respectively, of restricted Common Stock from the Company (the "NSP Purchase," "UE Purchase" and "BEn Purchase", respectively, and together, the "Direct Placements") concurrently with the closing of the Offering. NSP will purchase 882,353 shares of Common Stock at a purchase price of $17.00 per share (the initial public offering price, less a discount of up to 15%, which discount is dependent upon entering into a services agreement with Wisconsin Electric Power Company for at least 750,000 meters (if such services agreement is not entered into, the purchase price per share will be adjusted to 90% of the initial public offering price)). UE and BEn will purchase, respectively, 533,333 shares and 160,000 shares of Common Stock at a purchase price of $18.75 per share (the initial public offering price less the underwriting discounts and commissions). Upon the closing of the Offering and the Direct Placements, NSP, UE and BEn will own approximately 2.17%, 1.31% and 0.39%, respectively, of the outstanding Common Stock. The closing of the Offering is not conditioned upon the closing of the Direct Placements. See "Direct Placements." - --------- (1) Assumes the underwriters' over-allotment option in the Offering is not exercised. (2) Based on the number of shares outstanding as of June 30, 1996, after giving effect to the automatic conversion of all outstanding shares of Preferred Stock into Common Stock and the assumed exercise on a cash basis of warrants to purchase 4,132,970 shares of Common Stock effective upon the closing of the Offering which includes the assumed exercise of all Note Warrants on a cash basis. Also includes the sale of 1,575,686 shares of Common Stock pursuant to the Direct Placements concurrently with the closing of the Offering. See "Direct Placements." Excludes 3,779,136 shares of Common Stock issuable upon exercise of outstanding stock options as of June 30, 1996 granted under the Company's 1992 Stock Option Plan and 1994 Stock Plan with a weighted average exercise price of $0.625 per share. Also excludes 50,150 shares of Common Stock issuable upon exercise of warrants outstanding as of June 30, 1996 with a weighted average exercise price of $7.59 per share. See "Management -- Incentive Stock Plans," "Description of Capital Stock -- Warrants" and Note 7 to Consolidated Financial Statements. ------------------- CELLNET WAS INCORPORATED IN CALIFORNIA IN OCTOBER 1984 AND REINCORPORATED IN DELAWARE IN AUGUST 1996. CELLNET'S SUBSIDIARIES INCLUDE CELLNET DATA SERVICES, INC., CELLNET DATA SERVICES (IS), INC., CELLNET DATA SERVICES (KC), INC., CELLNET DATA SERVICES (MSP), INC., CELLNET DATA SERVICES (SL), INC., CN FREQUENCY (KC), INC., CN FREQUENCY (MSP), INC., CELLNET DATA SERVICES (SF), INC., CN FREQUENCY (SL), INC., CN WAN CORP. AND DAC (UK), LIMITED. THE COMPANY'S PRINCIPAL EXECUTIVE OFFICES ARE LOCATED AT 125 SHOREWAY ROAD, SAN CARLOS, CALIFORNIA 94070. THE TELEPHONE NUMBER AT SUCH ADDRESS IS (415) 508-6000. SUMMARY CONSOLIDATED FINANCIAL AND OTHER DATA The following table sets forth summary consolidated financial and other data of the Company for each of the three years in the period ended December 31, 1995, for the six months ended June 30, 1995 and 1996 and at June 30, 1996. The financial information data were derived from, and should be read in conjunction with, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Consolidated Financial Statements of the Company and the Notes thereto included elsewhere in this Prospectus. SIX MONTHS YEAR ENDED DECEMBER 31, ENDED JUNE 30, --------------------------------- ---------------------- 1993 1994 1995 1995 1996 --------- ---------- ---------- ---------- ---------- (IN THOUSANDS, EXCEPT PER SHARE DATA) CONSOLIDATED STATEMENT OF OPERATIONS DATA: Revenues............................................. $ 1,757 $ 1,651 $ 2,126 $ 1,291 $ 420 Costs and expenses: Cost of revenues................................. 1,840 1,191 5,129 1,931 3,483 Research and development......................... 5,262 9,693 22,380 6,735 13,009 Marketing and sales.............................. 1,447 3,257 4,201 1,946 2,924 General and administrative....................... 1,450 2,583 6,805 2,874 5,412 --------- ---------- ---------- ---------- ---------- Total costs and expenses....................... 9,999 16,724 38,515 13,486 24,828 --------- ---------- ---------- ---------- ---------- Loss from operations................................. (8,242) (15,073) (36,389) (12,195) (24,408) Other income (expense)............................... (148) 441 (4,564) 75 (7,903) --------- ---------- ---------- ---------- ---------- Loss before income taxes............................. (8,390) (14,632) (40,953) (12,120) (32,311) Provision for income taxes........................... 1 2 3 1 2 --------- ---------- ---------- ---------- ---------- Net loss............................................. $ (8,391) $ (14,634) $ (40,956) $ (12,121) $ (32,313) --------- ---------- ---------- ---------- ---------- --------- ---------- ---------- ---------- ---------- Pro forma net loss per share (1)..................... $ (1.22) $ (0.94) ---------- ---------- ---------- ---------- Shares used in computing pro forma net loss per share (1)................................................. 33,497 34,483 ---------- ---------- ---------- ----------
DECEMBER 31, 1995 JUNE 30, 1996 ----------------- ------------- SELECTED OTHER DATA: Meters under contract (2)..................................................... 1,070,000 1,220,000 Meters in revenue service (2)................................................. 17,559 105,354
JUNE 30, 1996 ------------------------------------------- AS ACTUAL PRO FORMA(3) ADJUSTED(3)(4) ---------- ------------- ---------------- (IN THOUSANDS) CONSOLIDATED BALANCE SHEET DATA: Cash, cash equivalents and short-term investments.................. $ 102,967 $ 106,621 $ 224,131 Total assets....................................................... 162,653 166,307 283,817 Long-term obligations, including current portion................... 195,513 195,513 195,513 Series CC redeemable convertible preferred stock................... 29,486 -- -- Total stockholders' equity (deficit)............................... (70,400) (37,260) 83,050
- --------- (1) For an explanation of the determination of the number of shares used in computing pro forma net loss per share, see Note 1 to Consolidated Financial Statements. (2) "Meters under contract" refers to the aggregate number of meters for which the Company has agreed to provide NMR services under services agreements with utilities and "Meters in revenue service" refers to the aggregate number of meters under contract which have been installed on the Company's networks and for which the Company is receiving NMR service revenues. As of August 31, 1996, the Company had 2,235,000 meters under contract and as of July 31, 1996, the Company had 143,415 meters in revenue service. (3) Reflects the conversion of all outstanding shares of Preferred Stock into Common Stock and the assumed exercise on a cash basis of warrants to purchase 4,132,970 shares of Common Stock at an aggregate exercise price of approximately $3.7 million upon the closing of the Offering. (4) Adjusted to reflect the proceeds of the Offering at an assumed initial public offering price of $20.00 per share and after deducting estimated underwriting discounts and commissions and offering expenses payable by the Company. See "Use of Proceeds." Also reflects the sale of 1,575,686 shares of Common Stock pursuant to the Direct Placements, less estimated issuance costs of approximately $40,000 with respect to such purchases. See "Direct Placements."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000807051_viewstar_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000807051_viewstar_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..7a9f14aadf113f4d649cffdcf0f42ccf688f3a7f
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000807051_viewstar_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and the Financial Statements and Notes thereto appearing elsewhere in this Prospectus. The Common Stock offered hereby involves a high degree of risk. See "Risk Factors." THE COMPANY ViewStar Corporation ("ViewStar" or the "Company") provides client/server document workflow software that enables customers to automate and improve document-intensive business processes across the enterprise. The ViewStar Enterprise Document Workflow System (the "ViewStar System") allows customers to easily define and change work content, work flows, business rules and user roles, facilitating the rapid design, development and deployment of business process applications. The Company's products are used in a wide variety of applications including consumer and mortgage lending, claims processing, underwriting, trust management, contract management, accounts payable and customer service. In today's highly competitive marketplace, companies must continuously improve their core business processes and operations. Having spent considerable resources in recent years for strategic business process reengineering ("BPR"), many organizations now require innovative software solutions to automate and improve their reengineered business processes. Companies worldwide are implementing business process automation solutions to shorten document- intensive processing cycles, increase productivity and deliver superior customer service. In addition, organizations increasingly seek enterprise applications that can integrate structured data, typically stored in databases, with unstructured data such as imaged documents, faxes, electronic documents, mainframe generated reports, digitized voice messages and Web documents. The ViewStar System is an enterprise-class, client/server application framework that is built around Windows NT and utilizes Microsoft's enterprise computing architecture. The ViewStar System is specifically designed for document-intensive business processes that require the integration of structured and unstructured data, moving beyond document management and simple workflow to deliver an integrated document workflow solution. The Company's software supports deployments ranging from small departmental applications to large systems distributed over multiple locations, serving hundreds to thousands of users throughout the enterprise. The first of the Company's @Work Internet products, expected to be available before the end of 1996, is designed to enable users to originate work and track work-in-progress using Web browsers. The Company's objective is to be the leading global provider of enterprise document workflow software solutions. As part of its strategy, the Company intends to expand its market presence by further leveraging its relationships with system integrators, service providers and other information technology leaders. In addition, the Company intends to increase its penetration of the financial services and insurance industries by providing pre-configured vertical applications to these markets. The Company also plans to continue to enhance its product architecture to encompass Internet technologies, adding functionality to take advantage of the Internet infrastructure and Web-based application platforms. The Company sells directly through a field sales organization and indirectly through system integrators and distributors to medium and large-size organizations worldwide. The Company has over 300 installations in a core group of vertical markets including financial services, insurance, healthcare, utilities, energy, telecommunications and government. The Company's customers include Aetna, American Express, Blue Cross/Blue Shield, MCI, Nissan Motor, Norwest Bank, PNC Bank, Texas Commerce Bank, Zurich American and the United States government, as well as numerous international accounts including GAN Insurance Company Ltd., The Halifax Building Society and PPP Healthcare in the U.K., Barclays Bank in Australia, debitel Kommunikation in Germany, Finnish P&T in Finland and SE Banken in Sweden. THE OFFERING Common Stock offered by the Company... 2,000,000 shares Common Stock to be outstanding after the offering......................... 7,296,472 shares (1) Use of proceeds....................... Repayment of approximately $2.0 million of indebtedness and general corporate purposes, including working capital Proposed Nasdaq National Market symbol............................... VSTA
SUMMARY CONSOLIDATED FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) SIX MONTHS ENDED YEARS ENDED DECEMBER 31, JUNE 30, -------------------------------------------- ------------------ 1991 1992 1993 1994 1995 1995 1996 ------- ------- ------- -------- ------- -------- -------- STATEMENTS OF OPERATIONS DATA: Total revenues......... $12,450 $23,131 $28,096 $ 22,812 $25,238 $ 9,644 $ 14,741 Operating income (loss)................ (893) (226) (1,876) (11,122) (7,451) (6,878) 491 Net income (loss)...... (841) (412) (2,315) (11,262) (7,956) (7,071) 403
THREE MONTHS ENDED -------------------------------------------------------- MAR. 31, JUNE 30, SEPT. 30, DEC. 31, MAR. 31, JUNE 30, 1995 1995 1995 1995 1996 1996 -------- -------- --------- -------- -------- -------- Total revenues......... $ 3,836 $ 5,808 $7,511 $8,083 $6,940 $7,801 Operating income (loss)(2)............. (4,325) (2,553) (223) (350) 136 355 Net income (loss)...... (4,372) (2,699) (369) (516) 103 300 Pro forma net income (loss) per share (3).. $ (0.76) $ (0.46) $(0.06) $(0.09) $ 0.02 $ 0.04 Shares used in per share computations (3)................... 5,764 5,813 5,821 5,843 6,456 7,257
JUNE 30, 1996 ------------------------ ACTUAL AS ADJUSTED (4) ------- --------------- BALANCE SHEET DATA: Cash and cash equivalents............................. $ 2,276 Total assets.......................................... 11,298 Long-term debt........................................ 747 Total stockholders' equity (deficit).................. (5,071)
- -------------------- (1) Based on shares outstanding as of June 30, 1996. Excludes 40,459 shares issuable upon the exercise of certain warrants to purchase Common Stock at a weighted average exercise price of $9.30 per share and an aggregate of 857,019 shares of Common Stock issuable upon the exercise of outstanding stock options at a weighted average exercise price of $0.37 per share. See "Management--Stock Plans," and "Description of Capital Stock--Warrants." (2) Excluding nonrecurring charges, operating income would have been $379,000 and $421,000 for the three months ended September 30, 1995 and December 31, 1995, respectively. (3) See Note 1 of Notes to Consolidated Financial Statements for a description of the calculation of pro forma net income (loss) per share. (4) Gives effect to (i) the issuance of 57,792 shares issuable upon net exercise of certain outstanding warrants to purchase Common Stock that terminate immediately prior to the closing of this offering, (ii) the conversion of all outstanding shares of Preferred Stock into Common Stock, which will occur automatically upon the closing of this offering and (iii) the sale of 2,000,000 shares of Common Stock offered by the Company hereby at an assumed initial public offering price of $ per share after deduction of the estimated underwriting discount and offering expenses payable by the Company. See "Use of Proceeds." -------------------- Except as otherwise indicated, the information contained in this Prospectus assumes (i) the 1-for-3.5 reverse stock split of the Company's Common Stock to be effected prior to the closing of this offering, (ii) the reincorporation of the Company in Delaware prior to the effective date of this offering, (iii) no exercise of the Underwriters' over-allotment option, (iv) the conversion of all outstanding shares of Preferred Stock into shares of Common Stock upon the closing of this offering and (v) the issuance of 57,792 shares of Common Stock upon net exercise of the warrants expiring prior to the closing of this offering. See "Description of Capital Stock" and "Underwriting."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000811119_americold_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000811119_americold_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..36f2d6e25f6feffeff75068bf65f20fdb1525219
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000811119_americold_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following prospectus summary is qualified in its entirety by the more detailed information and consolidated financial statements appearing elsewhere in this Prospectus. Prospective investors are urged to read this Prospectus in its entirety. As used herein, the terms "Americold" and the "Company" refer to Americold Corporation, an Oregon corporation, and its subsidiary, unless the context indicates otherwise. See "Risk Factors" for a discussion of certain factors that should be considered in connection with the Offering. THE COMPANY Americold, the nation's largest supplier of public refrigerated warehouse space, provides integrated logistics services for the frozen food industry. These services, consisting of warehousing and transportation management, are provided through the Company's network of 49 refrigerated warehouses in 16 states and through the Company's refrigerated transportation management unit. Americold serves a broad array of customers ranging from small local food producers to most of the large national frozen food companies, including ConAgra, Inc., H. J. Heinz Co., J. R. Simplot Co., Kellogg Company and Ocean Spray Cranberries Inc. The Company's strategy is to use its position as the largest supplier of public refrigerated warehouse space to access both increased volumes of frozen food storage and additional transportation management business. REFRIGERATED WAREHOUSING Since its founding in 1911, the Company has grown to become the largest owner and operator of refrigerated warehouses in the United States. The Company believes it supplies approximately 15% of the total publicly-available freezer storage space in the country. With approximately twice the capacity of its nearest competitor, the Company's network of 49 refrigerated warehouse facilities provides a total storage capacity of approximately 229 million cubic feet. Approximately 94% of the storage space operated by the Company is freezer space (zero degrees Fahrenheit and below), with the remaining space comprised of cooler space (28 degrees Fahrenheit and above) and unrefrigerated dry storage space. Major items stored include potatoes, vegetables, fish, poultry, prepared foods and fruits. The Company believes that its facilities are sufficiently dispersed geographically to allow it to compete in most of the significant markets in the United States. According to 1995 industry statistics, approximately 77% of all commercial freezer space is available through public suppliers, such as the Company, and the remainder is owned or operated by food processors and distributors for their private use. Since 1979, there has been a trend toward the use of public as opposed to private freezer space. The Company believes it is well-positioned to benefit from this growth in public refrigerated warehouse space. Since August 1994, the Company has added approximately 15.1 million cubic feet of new warehouse space, while eliminating approximately 12 million cubic feet of non- strategic warehouse space. Refrigerated warehouse services provided by the Company include storage, handling, blast freezing and facility leasing. In addition to these services, the Company has developed several ancillary services and intends to continue developing and promoting such services as well as adding incremental freezer, cooler or dry space. Ancillary services include product assembly/packaging, palletizing, labeling and SUPERCOLD freezer storage provided at 11 of Americold's facilities for the preservation of products, such as ice cream, which require storage at temperatures as low as 20 degrees below zero (Fahrenheit). TRANSPORTATION MANAGEMENT The Company has recently expanded its focus to provide integrated warehousing and transportation management services to the frozen food industry. To expand its transportation management business, the Company has consolidated its transportation management functions, added staff resources and improved its transportation management information systems capabilities, including integrating these systems with the Company's warehouse information systems. Transportation management services offered by the Company include dispatching, freight rate negotiation, backhaul coordination, freight bill auditing, network flow management, local/store door delivery, order consolidation, truck routing and distribution channel assessment. As part of its expanded transportation management services, the Company has entered into arrangements with three subsidiaries of its largest customer, H.J. Heinz Co. ("Heinz"), pursuant to which it is providing transportation management services from manufacturing plants through distribution channels to the subsidiaries' customers. In addition, for one of these subsidiaries, the Company also manages the in-bound transportation of over 200 non-frozen ingredients to the subsidiary's manufacturing plants. COMPANY STRATEGY The Company's strategy is to use its position as the largest supplier of public refrigerated warehouse space to access both increased volumes of frozen food storage and additional transportation management business. The Company believes its strong industry position, its geographically dispersed network of refrigerated warehouse facilities and its integrated logistics information systems provide it with a competitive advantage in developing and maintaining relationships with large frozen food manufacturers, distributors and retailers that have freezer storage and product distribution requirements in numerous locations throughout the United States. Industry studies suggest that frozen food processors spend approximately twice as much on transportation as on warehousing of frozen food products. The Company's customers, by outsourcing to Americold, may benefit from the transportation efficiencies Americold achieves while being able to reduce redundant staff and avoid individual investments in warehouse facilities and in the computer hardware and software systems necessary for transportation management. The Company's experience in providing a wide range of services in what it believes to be a reliable and cost-effective manner, together with its warehouse network and expanding capabilities in transportation management services, may enable the Company to attract new customers and to offer enhanced services to current customers. The Company believes that the potential cost savings brought to customers in product distribution will strengthen and broaden the Company's relationships with its customers and provide opportunities to expand its operations to meet customer needs. RECENT DEVELOPMENTS On May 9, 1995, the Company filed a prepackaged plan of reorganization (the "Plan") under Chapter 11 of the Bankruptcy Code (the "Prepackaged Bankruptcy"). The principal purpose of the Plan was to reduce the Company's short-term cash requirements with respect to payments due on its senior subordinated indebtedness by extending the maturity of such indebtedness and to adjust certain restrictive financial covenants and other provisions contained in an agreement with one of its principal lenders. The bankruptcy court approved the Plan as filed and it became effective on June 30, 1995. The Plan as approved provided, among other things, that each holder of the Company's then outstanding 11% Senior Subordinated Debentures due 1997 (the "11% Debentures") was entitled to receive a corresponding amount of the Company's new 15% Senior Subordinated Debentures due 2007 (the "15% Debentures"), plus accrued but unpaid interest; that the holders of the Company's Senior Debt, including holders of the 11.45% First Mortgage Bonds, Series A, due 2002 (the "Series A Bonds") and the 11.5% First Mortgage Bonds, Series B, due 2005 (the "Series B Bonds," and together with the Series A Bonds, the "First Mortgage Bonds") were not adversely affected by the Prepackaged Bankruptcy; and that the prior Amended and Restated Investment Agreement dated as of March 2, 1993 (the "Investment Agreement") was superseded by the Second Amended and Restated Investment Agreement dated as of May 5, 1995 (the "Second Investment Agreement") with Metropolitan Life Insurance Company (the "Institutional Investor"). See "Management's Discussion and Analysis of Financial Condition and Results of Operations--Liquidity and Capital Resources--Liquidity--Effect of Prepackaged Bankruptcy" and "Legal Proceedings." The Company believes that the restructuring pursuant to the Prepackaged Bankruptcy has not adversely affected the holders of its Senior Debt or its relationships with its customers, suppliers or shareholders. See "Risk Factors--Conclusion of Prepackaged Bankruptcy." The Company intends to apply the net proceeds of the Offering to redeem at par all of its 15% Debentures. The Company is currently considering the possibility of issuing secured debt to refinance a portion of the Series A Bonds. If such a refinancing is consummated, and if after such refinancing the Institutional Investor holds either (i) less than 25% of the outstanding principal amount of Series A Bonds or (ii) less than $25 million in principal amount of the Series A Bonds, certain covenants, redemption obligations and other provisions of the Second Investment Agreement will terminate. The Second Investment Agreement will terminate completely when neither the Institutional Investor nor any of its affiliates continues to hold any Series A Bonds. See "Debt of the Company--The Second Investment Agreement." The Company will not offer or sell any securities in connection with such refinancing unless such securities are registered under the Securities Act of 1933, as amended (the "Securities Act"), or unless an exemption therefrom is available. There can be no assurance as to the terms of such refinancing or that such refinancing will occur. For certain preliminary unaudited financial data of the Company for its most recently completed fiscal year and for its fourth quarter, both ended February 29, 1996, see "Management's Discussion and Analysis of Financial Condition and Results of Operations--Results of Operations--Preliminary Year-End and Fourth Quarter Results." OWNERSHIP The Company is controlled by Kelso & Company, a private investment firm, and its affiliates ("Kelso"), which together currently hold approximately 53% of the Company's common equity. Management of the Company beneficially owns approximately 11% of the Company's common equity. See "Principal Shareholders." The Company's principal executive offices are located at 7007 S.W. Cardinal Lane, Suite 135, Portland, Oregon 97224. Its telephone number at that address is (503) 624-8585. THE OFFERING $120,000,000 principal amount of % Senior Subordinated Notes due 2008 Maturity Date............. May 1, 2008. Interest.................. % per annum payable semi-annually in arrears on each May 1 and November 1, commencing November 1, 1996; provided that (i) the interest rate on the Notes shall be increased by 1% effective November 1, 1997 if, by such date, the Notes do not achieve the Requisite Rating, (ii) if the Notes do not achieve the Requisite Rating by November 1, 1997 but thereafter the Notes do achieve such Requisite Rating, the interest rate then borne by the Notes shall be decreased by 1% effective on the next interest payment date, and (iii) if, after achieving the Requisite Rating, the Notes are subsequently downgraded below the Requisite Rating, the interest rate then borne by the Notes shall be increased by 1% effective on the next interest payment date. In no event shall the interest rate borne by the Notes be greater than % or less than %. Optional Redemption....... The Notes may not be redeemed at the option of the Company prior to May 1, 2001. Thereafter, the Notes will be redeemable at any time, in whole or in part, at the option of the Company, initially at % of their principal amount declining ratably to 100% of their principal amount on or after May 1, 2003, in each case plus accrued interest. In addition, at any time prior to May 1, 1999 up to 35% of the original principal amount of the Notes will be redeemable, at the option of the Company, from the proceeds of one or more Public Equity Offerings (as defined), at % of their principal amount, plus accrued interest. See "Description of Senior Subordinated Notes--Optional Redemption." Change of Control......... Upon the occurrence of a Change of Control (as defined in the indenture pursuant to which the Notes will be issued, the "Note Indenture"), and after satisfaction by the Company of the requirements described below, each holder of the Notes will have the right to require the Company to repurchase all or any part of such holder's Notes at a price in cash equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of repurchase, subject to the terms of any Senior Debt (as defined in the Note Indenture). The Company's Senior Debt agreements restrict the redemption or repurchase of the Notes so long as Senior Debt remains outstanding. If a Change of Control occurs, there can be no assurance that the Company will have the financial ability to redeem the Notes. See "Description of Senior Subordinated Notes--Change of Control." Ranking and The Notes will be unsecured senior subordinated Subordination............. obligations of the Company, subordinated in right of payment to all existing and future Senior Debt, including, without limitation, the Company's obligations under the credit agreement with its primary bank dated as of June 19, 1995 (the "Bank Credit Agreement") and the indenture governing the First Mortgage Bonds (the "Bond Indenture"), dated as of March 9, 1993 and as amended on June 30, 1995, between the Company and Fleet National Bank of Connecticut, as trustee (the "Bond Trustee"). The Notes will rank pari passu with all other existing and future senior subordinated indebtedness of the Company and senior in right of payment to any future indebtedness of the Company that is expressly subordinated to senior subordinated indebtedness of the Company. See "Debt of the Company--The Bank Credit Agreement" and "--The First Mortgage Bonds," and "Description of Senior Subordinated Notes-- Ranking." As of November 30, 1995, the Company had approximately $349.5 million of Senior Debt outstanding. Covenants................. The Note Indenture will contain certain covenants for the benefit of the holders of the Notes, including among others, covenants limiting (a) the incurrence of additional indebtedness by the Company, (b) the issuance of debt and preferred stock by the Company's subsidiary, (c) the payment of dividends on, and the redemption of, capital stock of the Company and its subsidiary, (d) the making of investments, (e) the sale of assets and subsidiary stock and (f) transactions with affiliates. In addition, the Note Indenture will restrict the ability of the Company to consolidate or merge with or into, or to transfer all or substantially all its assets to, another person. However, these limitations will be subject to a number of important qualifications and exceptions. See "Description of Senior Subordinated Notes-- Certain Covenants" and "--Consolidation, Merger and Sale of Assets." Use of Proceeds........... The net proceeds of the Offering will be used by the Company to retire at par the Company's 15% Debentures. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000814774_firebrand_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000814774_firebrand_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..5a4fb6bc9dd2be8aba0d5ba7f9b69c80e8d5c822
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000814774_firebrand_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by reference to, and should be read in conjunction with, the more detailed information and the financial statements (including the notes thereto) appearing elsewhere in this Prospectus. Certain of the information contained in this summary and elsewhere in this Prospectus, including under "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements. For a discussion of important factors that could cause actual results to differ materially from the forward-looking statements, see "Risk Factors" and "Management's Discussion and Anaylsis of Financial Condition and Results of Operations." Each prospective investor is urged to read this Prospectus in its entirety. THE COMPANY GKN Holding Corp. (the "Company") is primarily engaged in securities brokerage, securities trading and investment banking through GKN Securities Corp. ("GKN"), its principal operating subsidiary. GKN is a full service securities brokerage and investment banking firm which is a registered broker-dealer with the Securities and Exchange Commission ("Commission"), in all 50 states, the District of Columbia and Puerto Rico and a member firm of the National Association of Securities Dealers, Inc. ("NASD"). GKN's principal office is located in New York City, New York and its branch offices are located in Great Neck, New York, Boca Raton, Florida, Miami, Florida, and Stamford, Connecticut. The Company began operations in 1987 following the October stock market decline, at which time the founders perceived an opportunity for the creation of a high quality investment bank serving emerging growth and small capitalization corporate clients and investors. From its inception, the Company's plan has been to develop a high quality firm serving this market niche. Since October 1990, when GKN managed its first underwriting, GKN has acted as managing or co-managing underwriter in a total of 43 public offerings, raising approximately $430 million. GKN also regularly participates as a selling group member or participating underwriter in public offerings managed by other underwriters, including national and regional firms. Thirteen of the offerings managed or co-managed by GKN (raising approximately $170 million) were for Specified Purpose Acquisition Companies(R) ("SPAC(R)"), a new publicly-traded financing vehicle developed and introduced by GKN in 1993. A SPAC combines the characteristics of a traditional acquisition or buyout fund and a more liquid, publicly traded industry-specific investment vehicle. The Company believes that the number and dollar amount of GKN's underwritings and the introduction of SPACs have contributed significantly to increased public and industry awareness of the Company and has resulted in increased demand for GKN's investment banking services, although it should be noted that GKN is not currently involved in any new SPAC offerings and currently does not expect that future SPAC offerings, if any, will represent a material portion of its revenues from investment banking activities in subsequent periods. See "Business-- Investment Banking Activities." The Company has grown significantly over the last five years, primarily through increasing the size of its sales force, but more recently by acquisition and expansion into new areas of business. In March 1995, GKN Fund Management, Inc., a wholly-owned subsidiary of the Company, entered the money management business by becoming the general partner and administrator of Kaleidoscope Partners, L.P., a "fund of funds" with approximately $8.1 million in assets at April 30, 1996. In November 1995, the Company acquired all of the outstanding stock of Shochet Securities, Inc. ("Shochet"), a full-service discount brokerage firm with four branches operating in Southern Florida. In February 1996, GKN Securities AG ("GKN AG"), a wholly-owned subsidiary of the Company, commenced operations in Zurich, Switzerland, distributing securities and providing brokerage services to European institutional money managers. As of April 30, 1996, the Company, through its three brokerage subsidiaries, employed 260 registered representatives, serving primarily retail and, to a lesser extent, institutional customers, representing, in the aggregate, more than 27,000 active accounts. The Company was incorporated under the laws of the State of Delaware on January 30, 1987. GKN was incorporated under the laws of the State of New York on May 31, 1985. The Company and GKN maintain their principal offices at 61 Broadway, New York, New York 10006, and their telephone number is (212) 509-3800. THE OFFERING Common Stock Offered..................................... 2,500,000 Shares Common Stock Outstanding Prior to the Offering........................................ 5,559,125 Shares Common Stock to be Outstanding After the Offering..................................... 8,059,125 Shares Use of Proceeds.......................................... The Company intends to apply the net proceeds of this Offering to expand its existing business by: (i) increasing GKN's equity capital to permit it to underwrite larger offerings and increase its principal trading and market making activities; (ii) expanding GKN's retail and institutional sales forces and Shochet's retail sales force; (iii) enhancing GKN's investment banking and research capabilities; (iv) expanding the Company's money management operations and commencing merchant banking activities; and (v) expanding the Company's international operations. Proposed Nasdaq National Market Symbol................... GKNS
SUMMARY FINANCIAL DATA The summary financial information set forth below is derived from the financial statements appearing elsewhere in this Prospectus. This information should be read in conjunction with such financial statements, including the notes thereto. STATEMENT OF OPERATIONS DATA: YEAR ENDED THREE MONTHS ENDED JANUARY 31, APRIL 30, ------------------------------------------- --------------------------- 1996 1995 1994 1996 1995 ------------- ------------- ------------- ------------- ------------ Total revenues.............................. $43,019,000 $32,410,000 $32,956,000 $18,444,000 $7,157,000 Total expenses.............................. 36,732,000 31,516,000 25,534,000 14,449,000 7,526,000 Income (loss) before provision for income taxes....................................... 6,287,000 894,000 7,422,000 3,995,000 (369,000) Net income (loss)........................... $3,469,000 $381,000 $4,006,000 $2,246,000 $(256,000) Primary earnings (loss) per share(1).............................. $0.61 $0.07 $0.72 $0.40 $(0.04) Primary weighted average number of shares outstanding(1).............................. 5,729,000 5,695,000 5,530,000 5,638,000 5,784,000 OTHER FINANCIAL DATA: Ratio of total assets to stockholders' equity...................................... 1.89 1.37 1.43 1.95 1.35 Pre-tax return on average equity.................................... 47.4% 7.8% 80.3% 25.1% (3.2)% Book value per common share outstanding..... $3.02 $2.30 $2.27 $3.34 $2.25 Registered Representatives(2)............... 224 163 126 260 175
BALANCE SHEET DATA: APRIL 30, 1996 ------------------------------ ACTUAL AS ADJUSTED(3) -------------- -------------- Total assets..................................................................... $ 33,117,000 $ 46,117,000 Total liabilities (excluding subordinated debt).................................. 15,348,000 15,348,000 Subordinated debt................................................................ 868,000 868,000 Total stockholders' equity....................................................... $ 16,901,000 $ 29,901,000
- --------------- (1) Fully diluted earnings per share and fully diluted average number of shares outstanding are not materially different from the primary numbers indicated above. (2) The Registered Representatives data is based upon unaudited personnel records of the Company. (3) Gives effect to the sale of the shares of Common Stock offered hereby ("Shares") at an assumed price of $6.00 per Share and the application of net proceeds therefrom. Unless otherwise indicated, the information in this Prospectus does not give effect to the exercise of the Underwriters' over-allotment option and does not include (i) 5,000,000 shares of Common Stock reserved for issuance under the Company's 1991 Employee Incentive Plan ("1991 Plan"), of which options to purchase 998,506 shares of Common Stock have been granted and are outstanding as of June 30, 1996; (ii) 125,000 shares of Common Stock issuable upon exercise of options and warrants issued outside of the 1991 Plan; or (iii) 1,000,000 shares of Common Stock reserved for issuance under the Company's 1996 Incentive Compensation Plan ("IC Plan").
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000816066_applied_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000816066_applied_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..a3d714d77db58794f944c79184640126206467aa
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000816066_applied_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY This Prospectus contains certain statements of a forward-looking nature re- lating to future events or the future financial performance of the Company. Prospective investors are cautioned that such statements are only predictions and that actual events or results may differ materially. In evaluating such statements, prospective investors should specifically consider the various fac- tors identified in this Prospectus, including the matters set forth under the caption "Risk Factors," which would cause actual results to differ materially from those indicated by such forward-looking statements. The following summary is qualified in its entirety by the more detailed information, including the Consolidated Financial Statements and Notes thereto, appearing elsewhere in this Prospectus. THE COMPANY Applied Imaging designs, develops, manufactures and markets automated clini- cal analysis systems used by laboratories for prenatal and other genetic test- ing. The Company's cytogenetic instrumentation business, which has sold systems to approximately 500 sites in more than 30 countries since its inception, in- cludes systems that enable laboratories to automate aspects of the detection of chromosomal abnormalities associated with conditions such as Down's Syndrome. In addition to the Company's core instrumentation business, the Company is de- veloping a proprietary genetic screening system designed to enable prenatal screening for genetic abnormalities by isolating fetal red blood cells ("fetal blood cells") from a routine maternal blood sample. This new system is designed to improve current prenatal screening techniques by providing an accurate, timely and cost-effective procedure without the risks of miscarriage or fetal damage associated with invasive prenatal testing. Prenatal genetic testing is currently performed either invasively by ex- tracting, culturing and analyzing fetal cells taken from amniotic fluid or pla- cental tissue, or non-invasively by analysis of serum markers derived from a maternal blood sample. The Company estimates approximately 2.3 million pregnant women in the United States undergo some form of prenatal screening each year. Despite the widespread use of prenatal screening, there are significant short- comings associated with existing screening methods. Invasive procedures, which include amniocentesis (extracting fetal cells from the amniotic sac) and chori- onic villus sampling (extracting tissues from the placenta), involve direct ex- traction of fetal cells. These procedures can accurately detect a broad range of chromosomal disorders but pose a risk of fetal loss of between 0.5-1.0%. Due to this risk, these invasive procedures are usually only recommended for women age 35 or older, at which ages, the risk of having a child with a chromosomal disorder is greater than the risk of spontaneous miscarriage associated with these procedures. The Company estimates that these procedures are performed on approximately 300,000 women annually in the United States. The non-invasive screening procedures, which include alpha-fetoprotein ("AFP") and the "triple test," both of which are blood chemistry tests, are currently broadly used for pregnant women including those under the age of 35 with approximately 2 million tests performed annually in the United States. While these tests present no risk to the fetus since they do not directly analyze fetal cells, they are much less accurate with detection rates of approximately 60% for chromosomal disor- ders and false positive rates of approximately 5%. The Company's prenatal screening system under development is intended to pro- vide an accurate, non-invasive test by directly analyzing fetal blood cells isolated from a routine maternal blood sample. The Company's proprietary screening system incorporates (i) a patented blood-based procedure to enrich the concentration of fetal blood cells, (ii) automated image analysis instru- mentation to identify the fetal blood cells and (iii) the use of third-party DNA probes to identify certain chromosomal disorders present in fetal blood cells. This system is expected to be accurate because it evaluates actual fetal cells while posing no risk to the fetus. The Company's prenatal screening sys- tem is currently in preclinical evaluation and application for FDA approval has not yet been submitted. The Company believes that a key aspect of its prenatal screening system is its ability to enrich and identify fetal blood cells so that they can be di- rectly analyzed using available DNA probe technology. As of August 1996, the Company and its collaborators have used the fetal blood cell enrichment proce- dure on a total of 133 maternal blood samples. The Company's system has achieved fetal blood cell identification in 120 of the 133 samples tested, or 90% of cases. In 13 maternal blood samples (10% of the total samples), no fetal blood cells were found. The Company intends to continue preclinical and clini- cal evaluation of this system and anticipates beginning a multi-site interna- tional clinical trial during the first half of 1997. Additionally, the Company intends to file two separate 510(k) applications for the fetal cell enrichment and automated imaging system components of its system before the end of 1996, and an additional application (either a 510(k) tier III or a PMA) for the DNA- probe component of its prenatal screening system. There can be no assurance that the Company will be successful in establishing its prenatal screening sys- tem as a broad-based prenatal screening procedure nor can there be any assur- ance that the prenatal screening system will be approved for marketing by the FDA or, if approved, that clinical acceptance will be achieved. The Company's strategy is to establish its system as a broad-based prenatal screening procedure. The Company anticipates that sales of this system, if ap- proved by the FDA, will include both its proprietary consumable enrichment kits, used to separate fetal blood cells from maternal blood samples and imag- ing instrumentation used to analyze the cells. These new image analysis systems are contemplated to be compatible with the Company's existing installed cytoge- netic instrument base. The Company believes that it can leverage its existing infrastructure, worldwide distribution capabilities and extensive laboratory relationships to support the worldwide introduction of this fetal cell screen- ing system under development. Furthermore, the Company believes that its new cell enrichment and image analysis system could have clinical utility for can- cer applications and the prenatal diagnosis of single gene disorders, and, if the Company obtains additional funding, it intends to pursue the development of these other potential applications. Significant additional research and devel- opment will be necessary to establish the clinical utility of the Company's cell enrichment techniques and image analysis system for these other potential applications. THE OFFERING Common Stock to be offered by the Company....... 1,650,000 shares Common Stock to be outstanding after the Offering(1).................................... 6,757,460 shares Use of proceeds................................. For research and development and clinical trials related to the prenatal screening system; repayment of indebtedness; working capital and general corporate purposes. See "Use of Proceeds." Proposed Nasdaq National Market symbol.......... AICX
SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) SIX MONTHS ENDED YEAR ENDED DECEMBER 31, JUNE 30, ------------------------------------------- ---------------- 1991 1992 1993 1994 1995 1995 1996 ------- ------- ------- ------- ------- ------- ------- (UNAUDITED) STATEMENT OF OPERATIONS DATA: Total revenues.......... $10,781 $11,711 $ 8,681 $ 9,571 $10,798 $ 5,215 $ 5,995 Cost of revenues........ 5,783 6,184 4,965 5,350 5,484 2,611 3,122 ------- ------- ------- ------- ------- ------- ------- Gross profit.......... 4,998 5,527 3,716 4,221 5,314 2,604 2,873 ------- ------- ------- ------- ------- ------- ------- Operating expenses: Research and development........... 1,164 1,316 1,756 2,821 2,919 1,380 1,698 Sales and marketing.... 2,565 3,279 2,543 2,524 2,918 1,335 1,476 General and administrative........ 1,453 1,642 1,229 1,898 2,094 996 949 Restructuring and reorganization costs.. 396 -- -- -- -- -- -- Write-off of research and development in process............... 1,285 -- -- -- -- -- -- ------- ------- ------- ------- ------- ------- ------- Total operating expenses............ 6,863 6,237 5,528 7,243 7,931 3,711 4,123 ------- ------- ------- ------- ------- ------- ------- Operating loss......... $(1,865) $ (710) $(1,812) $(3,022) $(2,617) $(1,107) $(1,250) ======= ======= ======= ======= ======= ======= ======= Net loss............... $ (977) $ (480) $(1,773) $(2,970) $(2,546) $(1,101) $(1,235) ======= ======= ======= ======= ======= ======= ======= Pro forma net loss per common share(2)........ $ (0.45) $ (0.22) ======= ======= Shares used in computing pro forma net loss per common share(2)........ 5,635 5,687
JUNE 30, 1996 ---------------------- ACTUAL AS ADJUSTED(3) ------- -------------- (UNAUDITED) BALANCE SHEET DATA: Cash, cash equivalents and short-term investments....... $ 3,236 $12,581 Working capital......................................... 2,238 12,179 Total assets............................................ 8,089 17,434 Long-term debt.......................................... 223 223 Accumulated deficit..................................... 10,375 10,375 Total stockholders' equity(4)........................... 3,615 13,556
- ------- (1) Based upon shares outstanding as of June 30, 1996. Excludes (i) 497,250 shares issuable upon exercise of options outstanding under the Company's Amended and Restated 1988 Incentive Stock Option Plan (the "1988 Option Plan"), (ii) 508,734 shares issuable upon exercise of outstanding warrants to purchase Common Stock, (iii) 200,000 shares reserved for issuance under the Company's Employee Stock Purchase Plan (the "Purchase Plan"), (iv) 120,000 shares reserved for issuance under the Company's 1994 Director Option Plan (the "Director Plan") and (v) an additional 632,113 shares reserved for issuance under the 1988 Option Plan. See "Management-- Incentive Stock Plans" and "Description of Capital Stock--Warrants." (2) See Note 1 of Notes to Consolidated Financial Statements for information concerning the computation of pro forma net loss per share. (3) As adjusted to reflect the sale of the 1,650,000 shares of Common Stock offered by the Company hereby at an assumed initial public offering price of $7.00 per share and the receipt of the estimated net proceeds therefrom and repayment of short-term debt. See "Use of Proceeds" and "Capitalization." (4) No cash dividends have been declared with respect to the Company's Common and Preferred Stock. --------------- Except as set forth in the Consolidated Financial Statements or as otherwise indicated, all information in this Prospectus assumes (i) the reincorporation of the Company from California to Delaware which occurred on October 8, 1996, (ii) the filing of the Company's Restated Certificate of Incorporation authorizing a class of undesignated Preferred Stock, to be effective upon the closing of this offering, (iii) the conversion of all outstanding shares of Preferred Stock into Common Stock upon the closing of this offering, (iv) the net exercise of certain outstanding warrants to purchase Series F Preferred Stock into 56,783 shares of Common Stock and (v) no exercise of the Underwriters' over-allotment option. See "Description of Capital Stock" and "Underwriting."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000817647_american_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000817647_american_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..b08c06ee5689d802b742be0721a53719511b52b1
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000817647_american_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial data, including the Consolidated Financial Statements and notes thereto included elsewhere in this Prospectus. Unless otherwise stated in this Prospectus, references to (a) the "Company" shall mean American Pad & Paper Company of Delaware, Inc. (formerly known as Williamhouse-Regency of Delaware Inc.) and its consolidated subsidiaries; (b) "APP" shall mean American Pad & Paper Company, the indirect parent of the Company; (c) "Williamhouse" shall mean the operations of the Company prior to its acquisition by APP on October 31, 1995 (the "Acquisition"); and (d) "Ampad" shall mean Ampad Corporation, the former operating subsidiary of APP, prior to Ampad's merger with and into Williamhouse immediately prior to the Acquisition (the "Merger"). See "The Transactions." Although the Company was the surviving corporation in the Merger, Ampad has been treated as the acquiring corporation for accounting purposes. On May 29, 1996, the Company executed a definitive agreement to purchase the Niagara Envelope Company, Inc. ("Niagara"). Financial data presented herein on a pro forma basis for the year ended December 31, 1995 gives effect to the Acquisition, the other transactions related thereto and the acquisition of Niagara as if such transactions occurred on January 1, 1995. See "Unaudited Pro Forma Financial Data." THE COMPANY The Company is one of the largest manufacturers and marketers of paper-based office products (excluding computer forms and copy paper) in the $60 billion to $70 billion North American office products industry. The Company offers a broad product line including nationally branded and private label writing pads, file folders, envelopes and other office products. Through its Ampad division, the Company is among the largest and most important suppliers of pads and other paper-based writing products, filing supplies and envelopes to many of the largest and fastest growing office products distributors. Acquired in October 1995, the Company's Williamhouse division is the leading supplier of mill branded, specialty and commodity envelopes to paper merchants/distributors. The Company's strategy is to grow by focusing on the largest and fastest growing office product distribution channels, making acquisitions, introducing new product lines, broadening product distribution across its channels and maintaining its position among the lowest-cost manufacturers in the industry. As a result of this strategy, the Company's sales have grown at a compound annual rate of approximately 34% from 1992 to 1995. For the year ended December 31, 1995, the Company had net sales of $617.2 million and income from operations of $57.3 million on the pro forma basis described herein. See "Unaudited Pro Forma Financial Data." Since the mid-1980s, the office products industry has experienced significant changes in the channels through which office products are distributed such as the emergence of new channels, including national office products superstores, national contract stationers and mass merchandisers, and consolidation within these and other channels. As a result of these changes, approximately 6,800 office product distributors existed in 1994 compared with approximately 13,300 in 1987. The channels through which office products are distributed from the manufacturer to the end-user include retail channels such as national office products superstores, mass merchandisers and warehouse clubs; commercial channels such as national contract stationers; paper merchants/distributors; and other channels such as regional distributors, school campuses and direct mail. The Company believes that sales of office products through retail channels are approximately $20 billion to $25 billion. The three dominant national superstores (Office Depot, OfficeMax and Staples) have experienced significant growth over the past three years and currently account for approximately 17% of total retail office products sales and approximately 6% of total office products sales. The Company believes that sales of office products through commercial channels are approximately $25 billion to $30 billion. Principally through the acquisition of smaller, regional contract stationers, national contract stationers (including Boise Cascade Office Products, BT Office Products, Corporate Express, U.S. Office Products and the contract stationer divisions of Office Depot and Staples) have grown more rapidly than other commercial channels. These national contract stationers now account for approximately 25% of commercial office products sales and approximately 11% of total office products sales. Certain office products, particularly envelopes, are sold predominantly through paper merchants/distributors or directly to end users. Paper merchants/distributors currently account for approximately 30% of the envelope market. The three largest paper merchants (ResourceNet, Unisource and Zellerbach) have experienced significant growth primarily through consolidation. The Company has targeted and will continue to target those customers driving consolidation in the retail, commercial and paper merchant distribution channels and believes that it is uniquely positioned to meet the special requirements of these customers. These customers seek suppliers, such as the Company, who are able to offer broad product lines, higher value-added innovative products, national distribution capabilities, low costs and reliable service. Furthermore, as these customers continue to grow and as they consolidate their supplier bases, the Company's ability to meet their special requirements becomes an increasingly important competitive advantage. Recognizing Ampad's potential for growth through the changing distribution channels, Bain Capital, Inc. ("Bain Capital") and management formed APP and purchased Ampad from Mead Corporation ("Mead") in 1992. Since that time, management has enhanced the Company's scale, broadened its product line, expanded upon its national presence and strengthened its distribution capabilities through acquisition and innovation while simultaneously delivering higher customer service levels. As a result, the Company's net sales through the most rapidly growing retail and commercial channels increased from $8.8 million in 1992 to $134.8 million ($164.5 million on a pro forma basis) in 1995. The following chart illustrates the Company's principal corporate structure as well as its principal products, customers and brands in its primary business segments. Certain of the operations of the Williamhouse division are conducted through wholly owned subsidiaries of the Company. AMERICAN PAD & PAPER COMPANY | WR ACQUISITION, INC. | THE COMPANY (ISSUER) | _________________________________ | | AMPAD DIVISION WILLIAMHOUSE DIVISION Products: . Pads and Notebooks . Envelopes . Filing Supplies . Invitations . Envelopes . Announcements . Christmas and Holiday Cards Customers: . Retailers . Paper Merchants/Distributors . Contract Stationers . Jobbers . Wholesalers . Personalizing Businesses . Buying Groups Selected Brands: . Ampad(R) . Century(TM) . Embassy(R) . Huxley(TM) . Evidence(R) . Karolton(R) . Globe-Weis(R) . Kent(TM) . Gold Fibre(R) . Peel & Seel(R) . SCM(TM) . Williamhouse(TM) . World Fibre(TM) COMPETITIVE STRENGTHS The combination of the Company's products, customers and national scale distinguishes it as a leading manufacturer and marketer of paper-based office products (excluding computer forms and copy paper) in North America. The Company attributes this position and its continued opportunities for growth and profitability to the following competitive strengths: . Market Leader. The Company has achieved market leadership in core products sold to customers in the largest and fastest growing office products channels by offering one of the broadest assortments of high quality products in the industry. Furthermore, the Company enjoys national brand awareness in many of its product lines, including Ampad, Century, Embassy, Evidence, Gold Fibre, Huxley, Karolton, Kent, Peel & Seel, SCM, Williamhouse and World Fibre. . Well-Positioned and Diversified Customer Base. The Company has substantial opportunities for growth within several distribution channels of the office products industry. The Company has focused on the largest and fastest growing office products channels. Several of the Company's largest customers, such as Boise Cascade Office Products, BT Office Products, Corporate Express, Office Depot, OfficeMax and Staples, are expected by industry analysts to experience annual revenue growth of 15% to 35% over the next five years. The Company's Williamhouse division maintains particularly strong relationships with the largest and fastest growing paper merchants/distributors in the market, including ResourceNet, Unisource and Zellerbach. The Company also maintains strong customer relationships across all of the other office products distribution channels, including mass merchandisers, warehouse clubs, office products wholesalers and independent dealers. . National Scale and Service Capability. The Company's extensive product line, multiple brands and broad price point coverage provide significant advantages and economies of scale in selling to and servicing its customers. The Company has become an increasingly important strategic partner to its customers as they seek higher value-added products, simplify their purchasing organizations and consolidate their relationships among selected national suppliers. The Company's national presence and network of 22 strategically located facilities have enabled it to maintain rapid and efficient order fulfillment standards. In addition, the Company's advanced electronic data interchange ("EDI") capabilities enable it to meet its customers' EDI requirements, executing automated transactions rapidly, efficiently and accurately. . Innovation New Products. The Company has introduced several innovative products as part of its marketing strategy to differentiate itself from other suppliers and enhance profitability. Recent examples include Gold Fibre classic and designer notebooks, Papers with a Purpose, World Fibre ground-wood writing pads and Peel & Seel envelopes. Products introduced since 1992 accounted for over $70 million of the Company's 1995 net sales. The Company's brand recognition and presence with its national customers allows it to more easily introduce new or acquired product lines to those customers. . Low-Cost Manufacturer. The Company believes it is among the lowest-cost manufacturers of paper-based office products in the industry. The Company ensures its low-cost manufacturing position through its paper purchasing and distribution advantages as well as its maintenance of modern and efficient manufacturing technology and a high quality workforce. The Company has been successful in reducing costs with each of its acquisitions in the last three years by continually streamlining its manufacturing processes and overhead structure. From 1992 to 1995, the Company reduced its fixed manufacturing costs from 7.4% to 5.2% of net sales and its selling, general and administrative expenses from 10.5% to 7.2% of net sales. See "Management's Discussion and Analysis of Financial Condition and Results of Operations--Overview." . Purchasing Advantages. The Company has strong relationships with most of the country's largest paper mills, many of which have been conducting business with the Company for more than 30 years. The Company believes it is one of the largest purchasers of the principal paper grades used in its manufacturing operations. In addition, the Company has the largest number of designated mill relationships which involve some of the largest and most recognized paper mill brands such as Hammermill, Hopper, Neenah and Strathmore. These relationships afford the Company certain paper purchasing advantages, including stable supply and favorable pricing arrangements. . Proven Management Team With Successful Track Record. The Company's senior operating management team averages over 25 years each in the paper products industry. Management has succeeded in increasing sales and operating profitability by recognizing and acting on the transition to the fastest growing distribution channels, introducing higher value-added products, acquiring complementary product lines (Karolton in December 1993, SCM Office Supplies, Inc. ("SCM") in July 1994 and certain product lines of Huxley and Globe-Weis in July 1994 and August 1995, respectively), improving manufacturing processes and reducing overhead and administrative costs. GROWTH STRATEGY The Company's strategy is to maintain and strengthen its leadership position by focusing on the following. . Focus on Rapidly Growing Customers. The Company serves many of the largest and best positioned customers in the office products market segment including national office product superstores, mass merchandisers and warehouse clubs, national contract stationers and national paper merchants/distributors. For 1995 on a pro forma basis, approximately 15.3% of the Company's net sales were to national office product superstores, 7.8% to mass merchandisers and warehouse clubs, 9.1% to national contract stationers and 19.7% to the three largest national paper merchants/ distributors. Anticipating further consolidation in the office products industry, the Company expects that its national scope and broad product line will be increasingly important in meeting the need of its customers. The Company will continue to target those customers driving consolidation in the office products industry. . Continue to Introduce New Products. New, higher value-added products give the Company a greater selection to offer its customers and improve product line profitability for both the Company and its customers. The Company plans to differentiate itself from other suppliers and improve profitability through product innovation, differentiation and line extensions. . Pursue Complementary Product Line and Strategic Acquisitions. The office products industry is highly fragmented despite continuing consolidation among its manufacturers. The Company is leading consolidation among manufacturers of writing products, filing supplies and envelopes. The SCM and Williamhouse acquisitions broadened the Company's product line to include filing products and envelopes and enhanced its presence in the growing distribution channels. The Globe-Weis acquisition and the Company's agreement to acquire Niagara demonstrate its commitment to strengthening its competitive and strategic position within its markets. The Company believes that there are significant opportunities to acquire companies in both its existing and complementary product lines. In addition, the Company intends to enter new office products markets through acquisitions of established companies in those markets. . Broaden Product Distribution. The Company's market presence and distribution strengths uniquely position it to sell new or acquired product lines across its distribution channels, including national office product superstores, national contract stationers, office product wholesalers and mass merchandisers. As an important part of its growth strategy, for example, the Company has successfully introduced the envelope product lines acquired in the Acquisition, previously distributed primarily through paper merchants/distributors, to Ampad division's distribution channels under the Ampad and private label names. The Company estimates that this market opportunity is approximately $350 million in annual net sales. . Continue to Reduce Costs. The Company has identified and is in the process of implementing cost reductions in connection with the Acquisition that are expected to result in approximately $7.4 million of annualized cost savings. In addition, management plans to implement further identified cost reductions beyond 1996. THE TRANSACTIONS Acquisition. On October 3, 1995, APP agreed to acquire in a merger transaction all of the outstanding stock of WR Acquisition, Inc. ("WR"), the parent corporation of Williamhouse. In a series of transactions, APP exchanged 100% of the capital stock of its then wholly owned subsidiary, Ampad Corporation, for newly issued shares of WR. WR then effected the Merger of Ampad with and into Williamhouse, with Williamhouse being the surviving legal entity. WR was then merged with a wholly owned subsidiary of APP, pursuant to which WR's stockholders (other than APP and affiliates) received an aggregate of $140.0 million in cash plus reimbursement of certain expenses of $4.0 million. As a result of the transactions, APP now owns all of the issued capital stock of WR, which in turn owns all of the issued capital stock of the Company. APP is owned by the Company's senior management team (Messrs. Hanson, Gard and Benson) and Bain Capital and its related investors. See "Principal Stockholders." In connection with the Acquisition, the Company refinanced approximately $119.1 million of indebtedness, including prepayment penalties of approximately $1.7 million. Concurrently with the closing of the Acquisition on October 31, 1995 (the "Closing"), the Company incurred borrowings under a bank credit agreement (the "Bank Credit Agreement") and the Company entered into a new non-recourse, off-balance sheet accounts receivable securitization program (the "Accounts Receivable Facility"). Bain Capital assisted the Company in analyzing, negotiating and arranging the financing for the Acquisition. Following the Acquisition, the Company's name was changed to American Pad & Paper Company of Delaware, Inc. Tender Offer and Consent Solicitation. On October 23, 1995, an offer (as amended, the "Tender Offer") was commenced to purchase for cash all of the Company's 11 1/2% Senior Subordinated Debentures due 2005 (the "Old Debentures") and a related solicitation (the "Consent Solicitation") of consents to modify certain terms of the indenture under which the Old Debentures were issued. The Company received consents and tenders representing 99.9% in aggregate principal amount of the Old Debentures outstanding at a price of 109% of the aggregate principal amount of the Old Debentures. As of the date hereof, there are no Old Debentures outstanding. Refinancing. Since the Acquisition, the Company has effected the following additional transactions (such transactions, together with the Acquisition, the entering into of the Accounts Receivable Facility and the incurrence of borrowings under the Bank Credit Agreement being referred to collectively as the "Transactions"): (i) the offering of the Notes (the "Offering"); (ii) the Tender Offer and the related Consent Solicitation; (iii) the redemption of $70.6 million of preferred stock and preferred stock equivalents of APP (collectively, the "Preferred Stock"); and (iv) the payment of a $4.5 million cash dividend to pay the liquidation preference, including the return of original costs, on APP's Class P Common Stock (the "Class P Common Stock Dividend"). Certain Arrangements Relating to the Acquisition. Prior to the Acquisition, APP declared a dividend on its common stock and Class P Common Stock (the "Class P Common Stock") of one share of Preferred Stock for each ten shares of common stock and Class P Common Stock. In December 1995, APP redeemed on a pro rata basis a portion of such Preferred Stock with an aggregate liquidation value of approximately $70.6 million from the proceeds of the Offering. At the same time, APP declared a cash dividend of approximately $4.5 million on its Class P Common Stock and, thereafter, converted all outstanding Class P Common Stock on a share-for-share basis into common stock. The Company's senior management team (Messrs. Hanson, Gard and Benson) received an aggregate of 5,400 shares of Preferred Stock as a result of the Preferred Stock Dividend and cash consideration of approximately $9.2 million as a result of the redemption of certain of these shares of Preferred Stock and Preferred Stock equivalents. In connection with the Acquisition, members of Williamhouse's management received substantial payments for their equity interests in Williamhouse. Bain Capital was paid a fee of $5.0 million by Ampad for, among other things, its services in analyzing, negotiating and arranging the financing for the Acquisition. See "Certain Relationships and Related Transactions." Employment Agreements. In June 1996, the Company and Charles G. Hanson, III entered into an employment agreement pursuant to which Mr. Hanson agreed to serve as the Chief Executive Officer of the Company for a period of three years for an annual base salary equal to at least $450,000 plus an annual bonus of up to 100% of his annual base salary (upon the Company achieving certain operating targets) and certain fringe benefits. Russell M. Gard entered into a similar agreement whereby he agreed to serve as the Chief Operating Officer of the Company for an annual base salary equal to at least $400,000 plus an annual bonus of up to 100% of his annual base salary (upon the Company achieving certain operating targets) and certain fringe benefits. Gregory M. Benson has an agreement with the Company pursuant to which he is entitled to an annual base salary of at least $175,000, a bonus of up to 100% of his average annual base salary and certain other payments. See "Management-Management Agreements." SALE OF PERSONALIZING DIVISION The Company's management identified the personalizing division of Williamhouse (the "Personalizing Division") as a nonstrategic asset following the Acquisition and has decided to pursue a sale of the Personalizing Division. As a result, the financial statements of the Company included elsewhere in this Prospectus reflect the Personalizing Division as "Assets for Sale" as of December 31, 1995 and March 31, 1996. On June 6, 1996, the Company signed a definitive agreement with a potential buyer to sell the Personalizing Division. Under the terms of the agreement, the Company will receive gross proceeds of approximately $60 million (subject to certain closing adjustments) from the sale of the Personalizing Division, which it expects to complete by the end of June 1996. The sales agreement is subject to certain conditions, some of which are outside the control of the Company. As a result, no assurance can be given that the sale will be completed or if completed, on the terms set forth in the sales agreement. See "Management's Discussion and Analysis of Financial Condition and Results of Operations - Overview." PENDING ACQUISITION OF NIAGARA On May 29, 1996, the Company executed a definitive agreement to acquire Niagara for an aggregate purchase price of approximately $50 million, plus $5.0 million to be paid under a one-year consulting services agreement (the "Niagara Acquisition"). Niagara supplies mill branded, specialty and commodity envelopes to paper merchants/distributors through four manufacturing facilities located near Buffalo, Chicago, Dallas and Denver. Niagara had 1995 net sales of approximately $106 million and operating income of approximately $8.5 million. The Company expects the Niagara Acquisition to be completed by the middle of July 1996. The Company believes that the Niagara Acquisition will strengthen the Company's distribution capabilities in the Midwest, provide additional manufacturing capacity and provide opportunities to achieve operating improvements through the consolidation of Niagara's operations with those of the Company. The completion of the Niagara Acquisition is subject to certain conditions. Although the Company regularly engages in discussions with companies regarding potential acquisitions, it currently does not have any agreements or understandings relating to acquisitions other than the Niagara Acquisition. USE OF PROCEEDS There will be no cash proceeds to the Company or the Subsidiary Guarantors from the exchange pursuant to the Exchange Offer. The Company received approximately $194 million in net proceeds from the sale of the Notes in the Offering. The net proceeds were used by the Company (i) to repurchase for approximately $109.0 million in cash the Old Debentures in connection with the Tender Offer and Consent Solicitation, together with accrued interest thereon of $5.3 million, (ii) to redeem approximately $70.6 million in aggregate liquidation value of Preferred Stock, (iii) to pay the Class P Common Stock Dividend of $4.5 million, (iv) to provide working capital and (v) to pay related fees and expenses related to the Transactions. See "Use of Proceeds." THE NOTES OFFERING NOTES.......................... The Notes were sold by the Company on December 1, 1995, to BT Securities Corporation and Wasserstein Perella Securities, Inc. (collectively, the "Initial Purchasers") pursuant to a Purchase Agreement, dated November 17, 1995. The Initial Purchasers subsequently resold the Notes to qualified institutional buyers or accredited investors pursuant to Rule 144A under the Securities Act. REGISTRATION RIGHTS.AGREEMENTS.. Pursuant to the Purchase Agreement, the Company, the Subsidiary Guarantors and the Initial Purchasers entered into a Registration Rights Agreement, dated December 1, 1995 (the "Registration Rights Agreement"), which grants the holders of the Notes certain exchange and registration rights. The Exchange Offer is intended to satisfy such exchange rights which terminate upon the consummation of the Exchange Offer. THE EXCHANGE OFFER SECURITIES OFFERED.......... $200,000,000 aggregate principal amount of 13% Senior Subordinated Notes due 2005, Series B (the "Exchange Notes"). THE EXCHANGE OFFER.......... $1,000 principal amount of the Exchange Notes in exchange for each $1,000 principal amount of Notes. As of the date hereof, $200,000,000 aggregate principal amount of Notes are outstanding. The Company will issue the Exchange Notes to holders on or promptly after the Expiration Date. Based on an interpretation by the staff of the Commission set forth in no-action letters issued to third parties, the Company believes that Exchange Notes issued pursuant to the Exchange Offer in exchange for Notes may be offered for resale, resold and otherwise transferred by any holder thereof (other than any such holder which is an "affiliate" of the Company within the meaning of Rule 405 under the Securities Act) without compliance with the registration and prospectus delivery provisions of the Securities Act, provided that such Exchange Notes are acquired in the ordinary course of such holder's business and that such Holder does not intend to participate and has no arrangement or understanding with any person to participate in the distribution of such Exchange Notes. Each Participating Broker-Dealer that receives Exchange Notes for its own account pursuant to the Exchange Offer must acknowledge that it will deliver a prospectus in connection with any resale of such Exchange Notes. The Letter of Transmittal states that by so acknowledging and by delivering a prospectus, a Participating Broker-Dealer will not be deemed to admit that it is an "underwriter" within the meaning of the Securities Act. This Prospectus, as it may be amended or supplemented from time to time, may be used by a Participating Broker-Dealer in connection with resales of Exchange Notes received in exchange for Notes where such Notes were acquired by such Participating Broker-Dealer as a result of market-making activities or other trading activities. The Company has agreed that, for a period of 180 days after the Expiration Date, it will make this Prospectus available to any Participating Broker-Dealer for use in connection with any such resale. See "Plan of Distribution." Any holder who tenders in the Exchange Offer with the intention to participate, or for the purpose of participating, in a distribution of the Exchange Notes could not rely on the position of the staff of the Commission enunciated in no-action letters and, in the absence of an exemption therefrom, must comply with the registration and prospectus delivery requirements of the Securities Act in connection with any resale transaction. Failure to comply with such requirements in such instance may result in such holder incurring liability under the Securities Act for which the holder is not indemnified by the Company. EXPIRATION DATE............. 5:00 p.m., New York City time, on July 22, 1996, unless the Exchange Offer is extended, in which case the term "Expiration Date" means the latest date and time to which the Exchange Offer is extended. ACCRUED INTEREST ON THE EXCHANGE NOTE AND NOTES...................... Each Exchange Note will bear interest from its issuance date. Holders of Notes that are accepted for exchange will receive, in cash, accrued interest thereon to, but not including, the issuance date of the Exchange Notes. Such interest will be paid with the first interest payment on the Exchange Notes. Interest on the Notes accepted for exchange will cease to accrue upon issuance of the Exchange Notes. CONDITIONS TO THE EXCHANGE OFFER............................... The Exchange Offer is subject to certain customary conditions, which may be waived by the Company. See "The Exchange Offer -- Conditions." PROCEDURES FOR TENDERING NOTES........ Each holder of Notes wishing to accept the Exchange Offer must complete, sign and date the accompanying Letter of Transmittal, or a facsimile thereof, in accordance with the instructions contained herein and therein, and mail or otherwise deliver such Letter of Transmittal, or such facsimile, together with the Notes and any other required documentation to the Exchange Agent (as defined) at the address set forth herein. By executing the Letter of Transmittal, each holder will represent to the Company that, among other things, the Exchange Notes acquired pursuant to the Exchange Offer are being obtained in the ordinary course of business of the person receiving such Exchange Notes, whether or not such person is the holder, that neither the holder nor any such other person has any arrangement or understanding with any person to participate in the distribution of such Exchange Notes and that neither the holder nor any such other person is an "affiliate," as defined under Rule 405 of the Securities Act, of the Company. See "The Exchange Offer -- Purpose and Effect of the Exchange Offer" and "-- Procedures for Tendering." UNTENDERED NOTES...................... Following the consummation of the Exchange Offer, holders of Notes eligible to participate but who do not tender their Notes will not have any further registration rights and such Notes will continue to be subject to certain restrictions on transfer. Accordingly, the liquidity of the market for such Notes could be adversely affected upon consummation of the Exchange Offer if such holder does not participate in the Exchange Offer. CONSEQUENCES OF FAILURE TO EXCHANGE......................... The Notes that are not exchanged pursuant to the Exchange Offer will remain restricted securities. Accordingly, such Notes may be resold only (i) to the Company, (ii) pursuant to Rule 144A or Rule 144 under the Securities Act or pursuant to some other exemption under the Securities Act, (iii) outside the United States to a foreign person pursuant to the requirements of Rule 904 under the Securities Act, or (iv) pursuant to an effective registration statement under the Securities Act. See "The Exchange Offer -- Consequences of Failure to Exchange." SHELF REGISTRATION STATEMENT.......................... If any holder of the Notes (other than any such holder which is an "affiliate" of the Company or the Subsidiary Guarantors within the meaning of Rule 405 under the Securities Act) is not eligible under applicable securities laws to participate in the Exchange Offer, and such holder has satisfied certain conditions relating to the provision of information to the Company for use therein, the Company and the Subsidiary Guarantors have agreed to register the Notes on a shelf registration statement (the "Shelf Registration Statement") and use their best efforts to cause it to be declared effective by the Commission as promptly as practical on or after the consummation of the Exchange Offer. The Company and the Subsidiary Guarantors have agreed to maintain the effectiveness of the Shelf Registration Statement for, under certain circumstances, a maximum of three years from the date of issuance of the Notes, to cover resales of the Notes held by any such holders. SPECIAL PROCEDURES FOR BENEFICIAL OWNERS.................. Any beneficial owner whose Notes are registered in the name of a broker, dealer, commercial bank, trust company or other nominee and who wishes to tender should contact such registered holder promptly and instruct such registered holder to tender on such beneficial owner's behalf. If such beneficial owner wishes to tender on such owner's own behalf, such owner must, prior to completing and executing the Letter of Transmittal and delivering its Notes, either make appropriate arrangements to register ownership of the Notes in such owner's name or obtain a properly completed bond power from the registered holder. The transfer or registered ownership may take considerable time. GUARANTEED DELIVERY PROCEDURES......................... Holders of Notes who wish to tender their Notes and whose Notes are not immediately available or who cannot deliver their Notes, the Letter of Transmittal or any other documents required by the Letter of Transmittal to the Exchange Agent (or comply with the procedures for book-entry transfer) on or prior to the Expiration Date must tender their Notes according to the guaranteed delivery procedures set forth in "The Exchange Offer -- Guaranteed Delivery Procedures." WITHDRAWAL RIGHTS.................... Tenders may be withdrawn at any time prior to 5:00 p.m., New York City time, on the Expiration Date. ACCEPTANCE OF NOTES AND DELIVERY OF EXCHANGE NOTES.................. The Company will accept for exchange any and all Notes which are properly tendered in the Exchange Offer prior to 5:00 p.m., New York City time, on the Expiration Date. The Exchange Notes issued pursuant to the Exchange Offer will be delivered promptly following the Expiration Date. See "The Exchange Offer - Terms of the Exchange Offer." MATERIAL FEDERAL INCOME TAX CONSEQUENCES....................... The exchange pursuant to the Exchange Offer should not be a taxable event for Federal income tax purposes. See "Certain Material Federal Income Tax Consequences." EXCHANGE AGENT....................... IBJ Schroder Bank & Trust Company THE EXCHANGE NOTES GENERAL..................... The form and terms of the Exchange Notes are the same as the form and terms of the Notes (which they replace) except that (i) the Exchange Notes bear a Series B designation, (ii) the Exchange Notes have been registered under the Securities Act and, therefore, will not bear legends restricting the transfer thereof, and (iii) the holders of Exchange Notes will not be entitled to certain rights under the Registration Rights Agreement, including the provisions providing for an increase in the interest rate on the Notes in certain circumstances relating to the timing of the Exchange Offer, which rights will terminate when the Exchange Offer is consummated. See "The Exchange Offer--Purpose and Effect of the Exchange Offer." The Exchange Notes will evidence the same debt as the Notes and will be entitled to the benefits of the Indenture. See "Description of Exchange Notes." The Notes and the Exchange Notes are sometimes referred to herein collectively as the "Senior Notes." MATURITY DATE............... November 15, 2005. INTEREST PAYMENT DATES...... Interest on the Exchange Notes will accrue from the date of original issuance (the "Issue Date") and is payable semi-annually on each May 15 and November 15, commencing November 15, 1996. RANKING..................... The Exchange Notes and Guarantees will be general unsecured obligations of the Company and Subsidiary Guarantors and will be subordinated in right of payment to all existing and future Senior Debt of the Company and Guarantor Senior Debt of the Subsidiary Guarantors, respectively. The Senior Notes will rank pari passu with any future senior subordinated indebtedness of the Company and Subsidiary Guarantors and will rank senior to all other subordinated indebtedness of the Company and Subsidiary Guarantors. As of March 31, 1996, the Company had approximately $253.5 million of Senior Debt (excluding $8.6 million of Senior Debt owed by a Subsidiary Guarantor, which is being sold subject to such debt. See "Business--Sale of Personalizing Division"). As of March 31, 1996, the Company had approximately $45.7 million available to be drawn under the revolving credit portion and letter credit facility of the Bank Credit Agreement, which amounts would have been Senior Debt. Under the Indenture (without giving effect to the restrictions in the Bank Credit Agreement), the Company could have incurred approximately $74 million of additional indebtedness, including indebtedness senior in right of payment to the Exchange Notes, at March 31, 1996. OPTIONAL REDEMPTION......... The Exchange Notes are redeemable, in whole or in part, at the option of the Company on or after November 15, 2000, at the redemption prices set forth herein plus accrued interest to the date of redemption. See "Description of Exchange Notes - Redemption." In addition, prior to November 15, 1998, the Company, at its option, may redeem up to 35% of the aggregate principal amount of the Exchange Notes originally issued in the Offering with the net cash proceeds of one or more Public Equity Offerings (as defined), at the redemption prices set forth herein plus accrued interest to the date of redemption. APP has filed a registration statement with the Commission for the purpose of registering the initial public offering (the "Proposed Equity Offering") of its Common Stock, par value $.01 per share (the "Common Stock"). The net proceeds to APP from the Proposed Equity Offering are currently estimated to be approximately $187 million. APP intends to use a portion of such proceeds to allow the Company to redeem approximately $70 million aggregate principal amount of the Notes or Exchange Notes from the holders thereof on a pro rata basis and to allow the Company to pay approximately $8 million in redemption premiums thereon. There can be no assurance that APP will consummate the Proposed Equity Offering, or if it does, that it will use the proceeds therefrom to redeem amounts outstanding under the Notes or the Exchange Notes. See "Proposed Initial Public Offering." CHANGE OF CONTROL........... Upon a Change of Control, each holder will have the right to require the Company to repurchase such holder's Exchange Notes at a price equal to 101% of the principal amount thereof plus accrued interest to the date of repurchase. GUARANTEES.................. The Exchange Notes will be fully and unconditionally guaranteed (the "Guarantees") on a senior subordinated basis by the Subsidiary Guarantors jointly and severally. The Guarantees will be general unsecured obligations of the Subsidiary Guarantors and will be subordinated in right of payment to all existing and future Guarantor Senior Debt. As of March 31, 1996, the Subsidiary Guarantors collectively had approximately $8.6 million of Guarantor Senior Debt (excluding guarantees of Senior Debt). As permitted under the Indenture, the Company expects to merge certain of the Subsidiary Guarantors with and into itself following the sale of the Personalizing Division. CERTAIN COVENANTS........... The Indenture governing the Exchange Notes contains certain covenants that limit the ability of the Company and certain of its subsidiaries to, among other things, incur additional indebtedness, pay dividends or make certain other restricted payments, consummate certain asset sales, enter into certain transactions with affiliates, incur indebtedness that is subordinate in right of payment to any Senior Debt and senior in right of payment to the Exchange Notes, incur liens, impose restrictions on the ability of a subsidiary to pay dividends or make certain payments to the Company and its subsidiaries, merge or consolidate with any other person or sell, assign, transfer, lease, convey or otherwise dispose of all or substantially all of the assets of the Company. In addition, the Indenture requires the Company to use 50% of the net cash proceeds of an Initial Public Offering (as defined) to repay up to $50 million of indebtedness of the Company. For additional information regarding the Notes, see "Description of Exchange Notes."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000818813_bitstream_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000818813_bitstream_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..6e6a7ed806899eaa91a9f6454ddd01c7fe0de332
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000818813_bitstream_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and Consolidated Financial Statements and Notes thereto appearing elsewhere in this Prospectus. Prospective investors should consider carefully the information discussed under "Risk Factors." Except as otherwise indicated, all information in this Prospectus (i) assumes no exercise of the Underwriters' over-allotment option, (ii) reflects the automatic conversion of all shares of Class A Preferred Stock and all shares of Class B Preferred Stock into an equal number of shares of Class A Common Stock and Class B Common Stock, respectively, on the date of this Prospectus, (iii) reflects a two-for-three conversion of shares as part of the reincorporation of the Company in Delaware in May 1996, see "Business -- Delaware Reincorporation," and (iv) reflects a change in the Company's fiscal year, effective December 31, 1995 from a fiscal year end of September 30 to a fiscal year end of December 31. All references to fiscal years ended in 1995 and earlier refer to the fiscal year ended September 30. THE COMPANY Bitstream develops and markets software products and technologies to enhance the creation, transport, viewing and printing of electronic documents. The Company's products and technologies consist of (i) type products, such as libraries of type designs (fonts) and custom type products; (ii) enabling technologies, which deliver typographic capabilities to hardware output devices and software applications; and (iii) TrueDoc, a portable type technology providing for the efficient distribution of text, with fidelity, in a highly compressed format. In addition, beginning in the first half of 1997, the Company expects to market a family of TrueDoc-enhanced portable document products that are based upon Novell, Inc.'s portable document technology, Envoy. The Company has obtained from Novell, Inc. ("Novell") certain rights to market and distribute Envoy. Bitstream primarily licenses its products and technologies to original equipment manufacturers ("OEMs") and independent software vendors ("ISVs") for inclusion in their output devices, embedded systems, applications, Internet authoring tools, World Wide Web browsers and other products. The rapid growth in the use of personal computers, advanced software applications and laser printers has dramatically transformed the document creation, production and distribution process, giving rise to the widespread use of word processing and desktop publishing applications. However, these technologies generally operate as stand-alone systems utilizing unique and often competing standards. The problems presented by such competing standards have been further complicated by the adoption of multi-vendor client/server network architectures and the advent of new distribution media, including the Internet, corporate intranets and new classes of information appliances. Currently, techniques used to present text and graphics are based on existing desktop publishing technologies and, when used in new distribution media, often result in a loss of visual integrity, degraded system performance or both. To efficiently deliver digital information that retains the author's intended visual impression, it is necessary to utilize enabling technologies that reduce file size, minimize bandwidth consumption and operate reliably across heterogeneous computing environments. The Company's enabling technologies and TrueDoc allow text-based digital information to retain its intended appearance without regard to the specific computing platforms, operating systems or resident applications used to create the original document. In addition, with products based upon TrueDoc-enhanced Envoy technology, the Company expects to offer a portable document solution that addresses both text and graphics in a simplified and resource-efficient application. The Company markets its products to OEM and ISV customers worldwide through its direct sales force. Outside North America, the Company distributes software products to corporations and end users through a distributor network. The Company's customers include Accent Software International Ltd., Apple Computer, Inc. ("Apple"), Barco Graphics N.V., Corel Systems Corporation, Interleaf, Inc., Kyocera Corp., Macromedia, Inc., Seiko Epson Corporation, Silicon Graphics, Inc. and Sun Microsystems, Inc. In June 1996, the Company entered into licensing agreements with Oracle Corporation ("Oracle") and Spyglass, Inc. ("Spyglass") to provide them with the Company's TrueDoc technology for incorporation into their World Wide Web browser products or navigation tools. In fiscal year 1993, the Company decided to curtail product distribution through the computer software reseller channel and to concentrate the efforts of the Company on the development and sale of technology and products to OEM and ISV customers. In conjunction with this shift in strategic focus, the Company reorganized its operations, reduced its work force, recapitalized its financial structure, changed senior management and restructured its type design group. This shift in strategic focus took place over a period from approximately July 1993 through September 1994. See "Business -- Shift in Strategic Focus." The Company was incorporated in the Commonwealth of Massachusetts in December 1981 and was reincorporated in the State of Delaware in May 1996. The Company's executive offices are located at 215 First Street, Cambridge, Massachusetts 02142 and its telephone number is (617) 497-6222. - -------------------------------------------------------------------------------- THE OFFERING Class A Common Stock offered hereby.......... 2,100,000 shares Class A and Class B Common Stock to be outstanding after the Offering............. 5,593,247 shares(1) Use of proceeds.............................. Repayment of indebtedness, working capital and other general corporate purposes, including product development and potential acquisitions. Nasdaq National Market symbol................ BITS - --------------- (1) Excludes 1,922,436 shares of Class A Common Stock or Class B Common Stock issuable upon exercise of outstanding options and warrants. See "Management -- Stock Plans" and "Description of Capital Stock."
SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS SIX MONTHS ENDED ENDED YEAR ENDED SEPTEMBER 30, DECEMBER 31,(1) JUNE 30, ---------------------------------------------- -------------------- --------------- 1991 1992 1993 1994 1995 1994 1995 1995 1996 -------- ------- ------- ------ ------ --------- ------ ------ ------ (UNAUDITED) (UNAUDITED) CONSOLIDATED STATEMENTS OF OPERATIONS DATA: Revenues............................... $ 25,093 $20,548 $17,430 $9,832 $8,970 $2,276 $2,355 $4,774 $5,411 Gross profit........................... 17,196 15,115 11,154 7,533 7,391 2,003 1,944 3,980 4,603 Operating income (loss)................ (9,819) (3,339) (4,468) 1,019 1,795 742 250 969 1,002 -------- ------- ------- ------ ------ ------ ------ ------ ------ Net income (loss)...................... $(10,262) $(3,624) $(4,805) $ 846 $1,688 $ 723 $ 738 $ 849 $1,044 ======== ======= ======= ====== ====== ====== ====== ====== ====== Pro forma net income per common and common equivalent share(2)........... $ .38 $ .17 $ .24 ====== ====== ====== Pro forma weighted average common and common equivalent shares outstanding(2)....................... 4,984 4,705 4,745 ====== ====== ====== AS OF JUNE 30, 1996 ------------------------- ACTUAL AS ADJUSTED(3) ------ -------------- (UNAUDITED) CONSOLIDATED BALANCE SHEET DATA: Cash and cash equivalents................................................................. $ 686 $10,381 Working capital........................................................................... 1,729 12,365 Total assets.............................................................................. 5,957 15,511 Long-term obligations..................................................................... 292 23(4) Stockholders' equity...................................................................... 2,852 13,620 - --------------- (1) Effective December 31, 1995, the Company changed its fiscal year end from September 30 to December 31. The information reflected represents results for the three months ended December 31, 1994 and December 31, 1995. The Company's current fiscal year commenced January 1, 1996. (2) Calculated on the basis described in Note 3 of the Notes to the Consolidated Financial Statements. (3) Adjusted to give effect to the sale of 2,100,000 shares of Class A Common Stock offered by the Company hereby at the initial public offering price of $6.00 per share, and the application of the net proceeds therefrom. (4) Does not include $941,000 of short-term indebtedness outstanding as of June 30, 1996 to be repaid by the Company with a portion of the proceeds of this Offering. See "Use of Proceeds" and "Capitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000821616_bentley_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000821616_bentley_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..91294cc2516dc7f12ef12b4a3fe973bf46795893
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000821616_bentley_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the detailed information and consolidated financial statements (including the notes thereto) appearing elsewhere in this Prospectus. Unless otherwise indicated, the information in this Prospectus is based on the assumption that the Underwriter's option to purchase Units from the Company to cover over-allotments is not exercised and that all share and per share information has been adjusted to give retroactive effect to a one-for-ten reverse stock split of the Company's Common Stock effected on July 25, 1995 and an increase in the number of authorized shares of Common Stock from 5,000,000 to 20,000,000 effected on January 1, 1996. As used in this Prospectus, the terms "Company" and "Bentley" refer to Bentley Pharmaceuticals, Inc. unless otherwise indicated by the context. THE COMPANY The Company is an international pharmaceutical and health care company engaged primarily in the manufacturing, marketing and distribution of pharmaceutical products in France and Spain, with limited distribution of health care products and research and development activities in the United States. The Company's operations in France consist of the brokerage of fine chemicals and the marketing of the drug Ceredase, manufactured by Genzyme Corporation and used in the treatment of Gaucher's Disease, under contracts of limited duration with Genzyme Corporation, the most recent of which terminates on March 31, 1996. In Spain, the Company manufactures, packages and distributes both its own and other companies' pharmaceutical products and has recently begun to emphasize the manufacture of pharmaceuticals under contract. In the United States, the Company markets disposable linens to emergency health services which are manufactured under contract. The percentage of the Company's total revenues for the nine months ended September 30, 1995 which are attributable to its operations in France, Spain and the United States are approximately 82%, 17% and 1%, respectively. Limited research and development activities are conducted both in the United States and Europe and the Company has several products under development. The Company's chemical and pharmaceutical operations in France and Spain are a result of its 1991 acquisition of Chimos S.A. and the establishment of a pharmaceutical subsidiary in France, Laboratoires Belmac S.A. (these two entities in France have since been merged into one entity named and referred to herein as Chimos/LBF S.A.) and the 1992 acquisition of Rimafar S.A. (subsequently renamed and referred to herein as Laboratorios Belmac S.A.), respectively. The strategic focus of the Company has shifted in response to the evolution of the global health care environment. The Company has moved from a research and development-oriented pharmaceutical company, developing products from the chemistry laboratory through marketing, to a company seeking to acquire late-stage development compounds that can be marketed within one or two years, and currently marketed products. As a result of this transition, the Company has decreased its research and development expenses dramatically over the past few years as well as implemented cost-cutting measures throughout the Company's operations. The Company emphasizes product distribution in France and Spain, strategic alliances and product acquisitions, which management of the Company expects will move the Company closer to profitability in the near future. Throughout its history, the Company has experienced negative cash flows from operations, which have been reduced in the past three years as a result of the shift in the Company's strategic focus. The Company has funded its operations primarily from financing activities and the sale of rights to certain of its pharmaceutical products. In October 1995 the Company completed private placements of debt and equity securities, of which $1,770,000 of the debt must be repaid from the proceeds of this Offering. A portion of the proceeds of this Offering will be utilized for such payment. The address and telephone number of the Company's principal executive offices are 4830 West Kennedy Boulevard, One Urban Centre, Suite 550, Tampa, Florida 33609, (813) 286-4401. The Company was organized under the laws of the State of Florida in February 1974. CONCURRENT OFFERING Concurrent with the Offering hereby, the Company has registered for concurrent or future sale by certain selling shareholders 593,500 shares of Common Stock pursuant to a separate prospectus. 240,000 of such shares are issuable upon conversion of notes sold in a private placement conducted by the Company in October 1995, to the extent such notes have been converted to Common Stock prior to their repayment upon application of a portion of the proceeds of this Offering. The notes were issued in two private placements in October 1995. In the first placement, the Company received proceeds of $720,000 for the issuance of 120,000 shares of Common Stock and 12% convertible promissory notes in an aggregate principal amount of $720,000 due on the earlier of July 31, 1996 or the closing of this Offering. In the second placement, the Company received proceeds of $1,050,000 for the issuance of 131,250 shares of Common Stock and 12% convertible promissory notes in an aggregate principal amount of $1,050,000 due on the earlier of September 30, 1996 or the closing of this Offering. See "Use of Proceeds," "Management's Discussion and Analysis of Financial Condition and Results of Operations--Liquidity and Capital Resources--Private Placements," and "Underwriting--Private Placements." 102,250 of such shares of Common Stock have been registered upon exercise of various "piggy back" registration rights granted to Baytree Associates, Inc. and Martin E. Janis & Co., Inc. See "Concurrent Offering."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000822084_innerdyne_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000822084_innerdyne_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..978e75d0c76ce60af36abc7eeb28776e0681b7b8
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000822084_innerdyne_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION, INCLUDING "RISK FACTORS," AND FINANCIAL STATEMENTS AND NOTES THERETO, APPEARING ELSEWHERE IN THIS PROSPECTUS. THE DISCUSSION IN THIS PROSPECTUS CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE DISCUSSED HERE. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN THE SECTIONS ENTITLED "RISK FACTORS," "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" AND "BUSINESS," AS WELL AS THOSE DISCUSSED ELSEWHERE IN THIS PROSPECTUS. InnerDyne, Inc. ("InnerDyne" or the "Company") designs, develops, manufactures and commercializes minimally invasive surgical ("M.I.S.") access products incorporating its proprietary radial dilation technology. The Company also has proprietary technology in the areas of thermal ablation and biocompatible coatings, which it intends to continue developing either internally or through strategic alliances. The Company's STEP access products enable a surgeon to perform an M.I.S. procedure without the use of a sharp-bladed trocar to gain access to the patient's abdominal cavity. Access with the Company's STEP product is provided by inserting an expandable sheath into the body cavity through the use of a standard insufflation needle, creating only a small puncture wound. The needle is then removed and the sheath is expanded to an appropriately sized working channel by insertion of a blunt dilator and cannula into the sheath. The blunt dilator is then removed, leaving the cannula in place. The radial dilation of the puncture wound into an appropriately sized working channel holds the cannula in place and obviates the need for an anchoring system that can increase the wound size left following surgery and increase trauma to adjacent tissues. After completion of the procedure, the rigid cannula is removed and the sheath retracts, permitting the opening in the abdominal musculature to recover to a residual wound size that is approximately half the size of that made with a trocar of similar size. The Company believes that the positive attributes of the STEP product could significantly affect health care system costs and patient satisfaction with M.I.S. procedures in which trocars have traditionally been used. The results of a Company-sponsored retrospective comparative outcomes study examining this issue were released during the fourth quarter of 1995. The study included 98 patients and compared an almost equal number of procedures performed using STEP devices and conventional trocars for access. Statistically significant results of that study indicated that STEP reduced device-related complications during surgery by over 90% and resulted in an approximately 22% savings in surgery time. Based upon published operating room costs, this time savings would equate to dollar savings of $345 to $515 per procedure. Management also believes that post-procedure complications, such as infection and incisional hernias at access sites, may be reduced with the use of the STEP device as compared to conventional trocars. It is estimated that in 1994 over 1.0 million procedures traditionally accomplished through open surgery were performed in the United States using M.I.S. techniques. Domestic M.I.S. procedures are expected by industry sources to grow at a rate of almost 11% through 1997, to a level of over 1.4 million procedures. Furthermore, it is estimated that more than 5.3 million domestic surgical procedures performed in 1994 were considered to be potential candidates for minimally invasive approaches. InnerDyne is exploring the potential use of its proprietary radial dilation technology for intra-organ access with its Radially Expanding Dilator ("R.E.D.") product and in other applications such as vascular access, feeding tube placement and orthopedic procedures. The Company has also made significant investments in research and development of its proprietary thermal ablation and biocompatible coatings technology. The Company's ENABL Thermal Ablation System is designed to treat excessive menstrual bleeding by thermally ablating the endometrial lining of the uterus. The Company recently announced the signing of an agreement with Boston Scientific Corporation ("Boston Scientific") covering the potential application and use of InnerDyne's proprietary biocompatible coating technologies with Boston Scientific's stents, grafts, vena cava filters and other implantable medical devices. The Company intends to continue to pursue licensing of its biocompatible coatings technologies to third parties for various applications. THE OFFERING Common Stock offered hereby....... 2,350,000 shares Common Stock to be outstanding after the offering............... 20,939,911 shares (1)(2) Use of Proceeds................... To fund additional development activities and expansion of marketing, sales and manufacturing activities and for general corporate purposes, including working capital. Nasdaq National Market Symbol..... IDYN
SUMMARY FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, --------------------------------- -------------------- 1993 1994 1995 1995 1996 ---------- ---------- --------- --------- --------- STATEMENT OF OPERATIONS DATA: Revenue............................................ $ 43 $ 879 $ 5,275 $ 1,235 $ 1,582 Operating loss..................................... (10,765) (10,061) (5,848) (1,539) (1,601) Net loss........................................... (10,359) (9,904) (5,627) (1,469) (1,584) Net loss per share (3)............................. (0.69) (0.61) (0.32) (0.09) (0.09) Weighted average shares outstanding (3)............ 15,103 16,197 17,561 16,633 18,337
MARCH 31, 1996 ---------------------------- ACTUAL AS ADJUSTED(1)(4) --------- ----------------- BALANCE SHEET DATA: Cash, cash equivalents and marketable investment securities........................ $ 1,820 $ 9,623 Working capital.................................................................... 2,312 10,115 Total assets....................................................................... 4,725 12,528 Long-term debt, excluding current installments..................................... 230 230 Net stockholders' equity........................................................... 3,095 10,898
- ------------------------ (1) Assumes the Underwriters' over-allotment option from the Company is not exercised. See "Underwriting." (2) Based on the number of shares outstanding as of March 31, 1996. Includes 242,952 shares issued upon exercise of warrants on or prior to April 1, 1996. Excludes (i) an aggregate of 1,993,784 shares of Common Stock issuable upon exercise of options outstanding as of March 31, 1996, (ii) 1,881,739 shares of Common Stock reserved for issuance pursuant to the Company's stock option and stock purchase plans, (iii) 235,000 shares of Common Stock issuable upon exercise of the Representative's Warrant and (iv) 166,667 shares of Common Stock to be issued to Boston Scientific Corporation in May 1996. See "Management -- Stock Plans," "Underwriting" and Note 8 of Notes to Financial Statements. (3) For an explanation of the determination of the number of shares used in computing net loss per share, see Note 2 of Notes to Financial Statements. (4) As adjusted to give effect to the sale of 2,350,000 shares of Common Stock offered by the Company at an assumed offering price of $3.875 per share. See "Use of Proceeds" and "Capitalization." ------------------------ EXCEPT AS OTHERWISE NOTED, ALL INFORMATION IN THIS PROSPECTUS ASSUMES NO EXERCISE OF THE UNDERWRITER'S OVER-ALLOTMENT OPTION. SEE "UNDERWRITING."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000822117_norian_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000822117_norian_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..cfbeb1944123d42465758d9e7bd093ce8cecd178
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000822117_norian_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified by the more detailed information and financial statements and notes thereto appearing elsewhere in this Prospectus. THE COMPANY Norian develops, manufactures and markets Norian Skeletal Repair System ("Norian SRS"), a proprietary bone fixation and replacement material designed for use in regions of structurally compromised cancellous bone such as the wrist, hip, knee and spine. Norian SRS is inserted into bone defects as a paste, either through minimally invasive injection or in an open surgical procedure. The material sets within 10 minutes of application and continues to cure over 12 hours to achieve its ultimate strength. The Company believes that Norian SRS provides direct structural support to compromised cancellous bone and can withstand compressive mechanical force soon after a procedure and over time. Additionally, Norian SRS may reduce the need for orthopaedic hardware in weakened cancellous bone. Norian SRS cures into a crystalline structure similar to the mineral phase of natural bone and appears to be replaced by natural bone over time. Fractures in cancellous bone tend to be complex, highly variable and difficult to repair with currently available treatment methods. These problems are compounded when cancellous bone is weakened by osteoporosis. The Company believes that Norian SRS overcomes the shortcomings of currently available treatment methods for cancellous bone fractures. The Company believes that one of the principal benefits of Norian SRS is to provide direct structural support to fractures, thereby reducing the risk of loss of anatomical positioning during the healing process and improving post-operative function and long-term outcome for the patient. In addition, Norian SRS may decrease the overall treatment cost by reducing the extent of rehabilitation required following fracture fixation and immobilization. The orthopaedic trauma market is the second largest segment of the orthopaedic industry, representing approximately 19% of the industry's $2.2 billion estimated 1995 sales in the United States. This market includes over six million fractures in the United States every year. The Company's strategy is to establish Norian SRS as the leading cancellous bone fixation and replacement product to be used independently or in conjunction with conventional fixation devices. Key elements of the Company's strategy include seeking regulatory approvals in the United States and in other selected countries and demonstrating clinical utility and cost-effectiveness by conducting clinical trials of the use of Norian SRS in selected applications. Following receipt of regulatory approvals, the Company intends to focus on providing extensive physician education and training, seeking reimbursement from third-party payors and establishing a direct sales force in the United States and a direct sales force or a network of distributors in foreign markets. However, there can be no assurance that the Company will receive such regulatory approvals or that any such approvals will not contain substantial restrictions limiting the Company's intended uses and applications. The Company intends to seek regulatory approval of Norian SRS as a cancellous bone cement. Under an Investigational Device Exemption ("IDE") approved by the United States Food and Drug Administration ("FDA"), the Company is conducting a randomized, multi-center clinical trial of the use of Norian SRS in the treatment of wrist fractures in up to 324 patients. This study is designed to demonstrate the safety and efficacy of Norian SRS in its ability to maintain the anatomical alignment of cancellous bone fragments and to improve functional outcomes such as grip strength and range of motion. The Company expects to use the data from this trial to support a pre-market approval ("PMA") application to market Norian SRS in the United States and to demonstrate its cost-effectiveness to third-party payors for purposes of reimbursement. As of April 30, 1996, 196 patients had been enrolled in the study. The Company is also seeking to obtain the right to affix to Norian SRS the "CE" mark, an international symbol of adherence to quality assurance standards and compliance with applicable European medical device directives. The CE mark will allow the Company to market the product in all of the member countries of the European Union ("EU"). In addition, the Company has test-marketed Norian SRS in the Netherlands since 1994, where the product is approved for commercial sale. In April 1996, the Company and Mochida Pharmaceutical Co., Ltd. ("Mochida") entered into a collaborative agreement for the exclusive marketing and distribution of Norian SRS in Japan for use in certain applications (the "Mochida Transaction"). The agreement provides for payments by Mochida to Norian of up to a total of $15.0 million, consisting of a $7.0 million equity investment completed in April 1996 and $8.0 million in non-refundable payments based on achievement of time-related, clinical and regulatory milestones, of which $2.0 million was received upon execution of the contract. Mochida will be responsible for performing clinical development in accordance with the Company's protocols and obtaining government approval for Norian SRS in Japan. The Company will be responsible for manufacturing and supplying the product to Mochida. The agreement has an initial term ending on the earlier of 10 years from the date of regulatory approval to commence commercial sales of Norian SRS in Japan or 15 years from the date of the agreement.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000822226_mt_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000822226_mt_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..40658638a2e21d1884d085f2584437a7e78a0037
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000822226_mt_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements, including the related notes, appearing elsewhere in this Prospectus. Unless the context otherwise requires, the 'Issuer' means MT Acquisition Corp. and, after giving effect to the transactions described in 'The Acquisition' (which are referred to herein collectively as the 'Acquisition'), Mettler-Toledo, Inc. The 'Company' or 'Mettler-Toledo' as used in this Prospectus means the Issuer and its subsidiaries, after giving effect on a pro forma basis to the transactions described in 'The Acquisition'. The 'Mettler-Toledo Group' refers to the group of companies being acquired pursuant to the Acquisition. Unless otherwise indicated, industry data contained herein is derived from publicly available industry trade journals, government reports and other publicly available sources, which the Company has not independently verified but which the Company believes to be reliable, and where such sources were not available, from Company estimates, which the Company believes to be reasonable, but which cannot be independently verified. As used in this Prospectus, '$' refers to U.S. dollars and 'SFr' refers to Swiss francs. THE COMPANY GENERAL Mettler-Toledo is the world's largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company focuses on the high value-added segments of the weighing instruments market by providing solutions for specific applications. The Company also manufactures and sells certain related laboratory measurement instruments, with one of the top three market positions worldwide in titrators, thermal analysis systems, pH meters and lab reactors. Mettler-Toledo services a worldwide customer base, with 1995 net sales of $850 million, which were derived 52% in Europe, 37% in North and South America and 11% in Asia and other markets. The Company has a global manufacturing presence, with manufacturing facilities in Europe, the United States and Asia. Weighing is one of the most broadly used measuring techniques, and its results are often used as the basis of commercial transactions. The Company's products are used in the laboratory as an integral part of the research process; in industry for materials preparation, filling, counting and dimensioning; and in food retailing for preparation, portioning and inventory control. Customers include pharmaceutical, biotechnology, chemical, cosmetics, food and beverage, postal, jewelry, metals, logistics, shipping and food retailing businesses, as well as schools, universities and government and private standards labs. MARKET LEADERSHIP Mettler-Toledo is the only company to offer weighing products for laboratory, industrial and food retailing applications throughout the world. The Company believes that in 1995, the global market for weighing instruments for laboratory, industrial and food retailing applications was approximately $4.5 billion and that the Company held a market share more than two times greater than its nearest competitor. The Company believes that, in 1995, it had an approximate 40% market share of the global market for laboratory balances, including the largest market share in each of Europe, the United States and Asia (excluding Japan), and one of the three leading positions in Japan. In the industrial and food retailing market, the Company believes it has the largest market share in Europe and in the United States. In Asia, the Company has a substantial, rapidly growing industrial and food retailing business supported by its established manufacturing presence in China. The Company attributes its worldwide market leadership position to the following competitive strengths: Brand Recognition. The Mettler-Toledo brand name is identified worldwide with accuracy, reliability and innovation. The Company's brand name is so well recognized that laboratory balances are often referred to as 'Mettlers.' Brand recognition is important because weighing applications significantly impact customers' product quality, productivity, cost and regulatory compliance. As a result, customers tend to emphasize accuracy, product reliability, technical innovation, reputation and past experience with a manufacturer's products when making their purchasing decisions for weighing instruments. Technological Innovation. Mettler-Toledo has a long and successful track record of innovation, as demonstrated by the invention of the single-pan analytical balance in 1945 and the introduction of the first fully electronic precision balance in 1973. The Company has continued to be at the forefront of weighing technology with several recent innovations, including its ID 20 terminal and 'Brickstone' weighing sensor technology. The Company has particular expertise in sensor technology, electronics and software, and in the industrial design of measurement instruments. The Company believes it is the global leader in providing sophisticated features, such as data-handling and storage capabilities, integration into management information systems and improved productivity through automation, all of which are increasingly important to users of weighing instruments. The Company devotes substantial resources to research and product development in order to maintain its competitive advantage in technological innovation. Comprehensive Product Range. Mettler-Toledo manufactures a more comprehensive range of weighing instruments than any of its competitors. The Company's broad product line addresses a wide range of weighing applications across many industries and regions. Within an industry, the Company offers multiple products to meet customers' requirements. Its broad range of products allows the Company to leverage its manufacturing and distribution capabilities, sales and service organization and product development activities. Global Sales and Service. The Company has the only global sales and service organization among weighing instruments manufacturers. At June 30, 1996, this organization consisted of 2,700 employees organized into locally based, customer-focused groups that provide prompt service and support to the Company's customers and distributors in virtually all major markets across the globe. The local focus of the Company's sales and service organization enables the Company to adapt marketing and service efforts to different cultural and economic conditions, and provides feedback for manufacturing and product development. Largest Installed Base. The Company believes that it has the largest installed base of weighing instruments in the world. Service revenues from this installed base provide a strong, stable source of recurring revenue, representing approximately 17% of net sales in 1995. The Company believes that its installed base represents a competitive advantage with respect to repeat purchases. Customers tend to remain with an existing supplier who can provide accurate and reliable products and related services. In addition, switching to a new instrument supplier entails additional costs to the customer for training, spare parts, service and system integration requirements. Close relationships and frequent contact with its broad customer base provide the Company with sales leads and new product and application ideas. Diversity of Revenue Base. The Company's revenue base is widely diversified by geographic region, by type of customer and by individual customer. The Company's broad range of product offerings is utilized in many different industries, from chemicals and pharmaceuticals to food processing to food retailing to transportation. The Company supplies customers in over 100 countries, and no one customer accounted for more than 2% of 1995 net sales. The Company's diverse revenue base reduces its exposure to regional or industry- specific economic conditions. INDUSTRY TRENDS The Company believes that the weighing instruments market is being influenced by several industry trends. First, customers are demanding products for industry-specific applications, with significant data management capabilities designed to be integrated into business processes and to improve productivity. Second, quality manufacturing and laboratory requirements are becoming more standardized. For example, ISO 9001 standards require manufacturers to utilize certified measurement instruments, and good laboratory practices require each step in the research process to be recorded with certified instruments so that results can be accurately traced and reproduced. Third, increased harmonization of national weighing standards, particularly in the European Union, has facilitated multinational manufacturers' ability to meet local regulatory requirements and provides broader-based markets for their product lines. Most importantly, there has been significant growth in demand in emerging markets as these economies develop and global manufacturing customers shift production operations to these markets. As a result, customers in these emerging markets require additional and more sophisticated weighing instruments. Global manufacturers operating in emerging markets often utilize the same suppliers that service their needs in other markets. The Company believes that its global operations position it to take advantage of these industry trends. BUSINESS STRATEGY The Company's strategy is to enhance its position as global market leader by providing the most comprehensive, innovative and reliable weighing solutions. The Company plans to actively pursue the following initiatives to increase revenues and profitability: Product Innovation. The Company intends to continue to invest in product innovation in order to provide technologically advanced products to its customers for existing and new applications. Over the last three calendar years, the Company invested $149 million in research and development, which has resulted in a pipeline of new and updated products. A recent example of the Company's extensive product development efforts is the innovative ID 20 terminal for use in the Company's range of industrial scales. ID 20 includes the first personal computer interface to be certified by weights and measures regulators, combined with an ergonomically designed personal computer terminal for industrial applications. Other recent examples include a new moisture analyzer, a dimensioning system for logistics applications that combines volume and weight measurements, a new generation of postal meters and a mid-range food retailing scale. The Company is also focused on innovations that can reduce its production costs. For example, the Company's new 'Brickstone' weighing sensor technology, in addition to providing greater accuracy, reduces from approximately 100 to approximately 50 the number of parts in the sensor, and thus significantly reduces manufacturing costs and the time and expense of design changes. Increased Penetration of Developed Markets. The Company intends to leverage its brand name and existing infrastructure to further penetrate selected geographic regions and product lines in Europe, the United States and Japan. For example, in European food retailing products, the Company plans to further expand from its strong base in German-speaking countries into other countries. In addition, the Company plans to increase penetration with shipping and logistics businesses by introducing a new weighing and dimensioning product. The Company also continues to take advantage of the standardization of weights and measures, both in the European Union and worldwide, which favors a manufacturer with a global presence, such as the Company. Further Expansion in Emerging Markets. The Company believes that global recognition of the Mettler-Toledo brand name and the Company's global sales and service organization position the Company to take advantage of continued growth opportunities in emerging markets. In 1995, the Company had net sales of $69 million in Asia (excluding Japan) and Latin America, representing 8% of net sales. In Asia (excluding Japan), it is the market leader in laboratory weighing instruments and has a substantial and rapidly growing industrial and food retailing business. The Company has been operating in China since 1987 through a 60%-owned joint venture, which owns one manufacturing facility, and the Company plans to complete construction of a new wholly owned manufacturing facility in Shanghai by the end of 1996. The Company believes that this manufacturing infrastructure, as well as its sales and service organization in Asia and its already substantial sales in Asia and Latin America, position it to take advantage of further growth opportunities in emerging markets. Reengineering and Cost Reductions. Over the last three years, the Company has been successful at increasing its margins, despite negative currency effects. These increases have been achieved through, among other things, increased workforce flexibility, a reduction in its overall workforce, a shift in the mix of its workforce toward higher growth, lower cost regions and the introduction of new products with lower manufacturing costs. The Company is currently implementing two projects which are aimed at reducing warehouse capacity, improving inventory turnover and reducing materials handling costs. The Company is restructuring the order and product delivery process in Europe to enable the Company to deliver many of its products to its customers directly from the manufacturing facility within several days. The Company is also streamlining its European spare parts inventory management system. In addition to continuing these cost-cutting efforts, the Company is also evaluating its business strategy as an independent company after the Acquisition and believes that it can support continued sales growth while further reducing its overall cost base. In July 1996, in anticipation of the consummation of the Acquisition, the Company announced the closure of its Westerville, Ohio facility. In addition, the Company will implement a targeted workforce reduction by the end of 1996. The Company expects that these two additional projects will result in annual cost reductions of $8.3 million. Pursue Selected Acquisition Opportunities. The Company has a proven record of acquiring and integrating businesses into existing operations. As an independent company, Mettler-Toledo plans to more actively pursue additional product lines and distribution channels through acquisitions, strategic alliances and joint ventures. The Company believes that by taking advantage of its brand name and global sales and service organization it can expand distribution of acquired product lines and operate acquired businesses more efficiently. The mailing address of the Company's and Holding's principal executive offices is Im Langacher, P.O. Box MT-100, CH-8606, Greifensee, Switzerland. Its telephone number is 41-1-944-22-11.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000823314_advanced_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000823314_advanced_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..930bbfb83d9299d6398bfbf25611f2ef258a862c
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000823314_advanced_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the detailed information and financial statements appearing elsewhere in this Prospectus. The Company Advanced Financial, Inc. (the "Company") is a publicly traded Delaware company formed in June 1988. In July 1990 the principals of the Company recognized an opportunity existed in the mortgage servicing industry due to the collapse of the savings and loan industry. On March 29, 1991 the Company was successful in acquiring Creative Financing, Inc. as a wholly owned subsidiary. In 1992, this subsidiary changed its name to Continental Mortgage, Inc. The name was again changed due to expansion into additional states, to AFI Mortgage, Corp ("AFIM") in November 1994. AFIM is a mortgage banking company servicing approximately $439,000,000 in mortgage loans as of June 30, 1996. The Company's common stock has been traded on the American Stock Exchange since March 29, 1993 under the symbol AVF. On August 7, 1996, the stock had a market price of $1.25. The Company's principal executive offices are located at 5425 Martindale, Shawnee, Kansas 66218. Its telephone number is (913) 441-2466. Summary Financial Data The following summary financial data has been derived from the financial statements of the Company and should be read in conjunction with such financial statements. Three Months Three Months Year Ended Year Ended Ended Ended March 31 March 31 June 30, 1996 June 30, 1995 1996 1995 ------------- ------------- ---- ---- INCOME STATEMENT DATA: Revenues $1,662,485 $1,600,195 $ 6,891,328 $ 5,481,199 Expense 2,224,615 2,287,549 10,026,555 10,295,464 Net Loss ( 562,130) ( 687,354) (3,184,577) (3,963,497) Weighted Average Shares 3,819,000 3,775,000 3,776,000 3,726,000 Earnings (loss) per Share ( .15) ( .19) ( .88) ( 1.11) BALANCE SHEET DATA: June 30, 1996 ----------- Total Assets $19,680,902 Total Liabilities 19,264,703 Stockholders' Equity 416,199
RECENT EVENTS On February 15, 1996, the Company entered into consulting agreements with Ocean Marketing Corporation, a Colorado corporation; and three Delaware corporations, Cored Capital Corporation, Pyramid Holdings, Inc., and Affiliated Services, Inc. Under the terms of each agreement, the Company is to be provided with financial and public relations services, including advice concerning marketing surveys, investor profile information, methods of expanding investor support and increasing investor awareness of the Company and its products and services. The above named consultants are also to provide services to the Company, including broker relations, assisting in the preparation and format of due diligence meetings, and attendance at conventions and trade shows. The term of each consulting agreement is six months, commencing on February 15, 1996. As compensation for each consultant's services, the Company has granted an option to purchase 250,000 shares of common stock to such consultant at an exercise price of $.50 per share. With respect to options granted to Affiliated Services and Pyramid Holdings, such options expire, if not previously exercised, thirty days after a registration statement covering the shares underlying such options has been declared effective by the Securities and Exchange Commission. None of such options have been exercised as of the date of this Prospectus. Any shares issued upon exercise prior to the effectiveness of such registration statement shall be restricted securities as described in Rule 144 promulgated under the Securities Act of 1933. With respect to options granted to Cored Capital Corporation and Ocean Marketing Corporation, such options were to have expired, if not previously exercised ten days after a registration statement which registered the shares for sale underlying such options was filed with the Securities and Exchange Commission. However, prior to their expiration, the parties mutually agreed to extend the expiration date of such options for an indeterminate period of time. Thereafter, Cored Capital Corporation exercised options on 130,000 shares of common stock and Ocean Marketing Corporation exercised options on 250,000 shares of common stock in June of 1996. In January of 1996, the Company defaulted in the payment of its regular quarterly dividend payable on its 10.5% Series B Convertible Preferred Stock. All dividends not paid will accumulate until such time as the Company has determined that its cash flows have improved enough to sufficiently pay the dividend from the cash flow of its operations. The total arrearage is three quarterly payments totaling $117,180 and interest does not accrue on such arrearage.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000825724_mediqual_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000825724_mediqual_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..3a0e47258680d4bc9716a3ffff7f613d1aca4c4b
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000825724_mediqual_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements and notes thereto appearing elsewhere in this Prospectus. THE COMPANY MediQual Systems, Inc. ("MediQual" or the "Company") is a leading supplier of clinical information management ("CIM") systems and services to the health care industry. The Company's systems and services combine proprietary clinical knowledge with raw patient encounter data to create valuable information that providers, payors and suppliers use to monitor and enhance the effectiveness, efficiency and appropriateness of care. Health care industry participants are under continuing pressure to reduce costs without jeopardizing quality of care. Increasingly, cost reductions beyond those achieved through administrative efficiencies are being sought at the clinical level, and must be supported by a measurable, quantifiable relationship between services rendered and patient outcomes. This relationship between services rendered and patient outcomes is imperative to maintaining the confidence and cooperation of clinicians, and can only be established through the analysis of patient encounter data, which resides in individual paper files and is captured, in part, by transaction processing systems. Historically, health care data analysts have depended upon batch reports produced by large mainframe computers that required custom programming and long lead times. To remain competitive, providers, payors and suppliers must develop timely and actionable information either by installing CIM systems in-house, or by engaging third-party consultants and analysts. MediQual has addressed the growing demand for this information by developing its Atlas System, a comprehensive, desktop CIM system. The Atlas System is comprised of five major components: (i) a standardized retrospective data repository; (ii) proprietary benchmarking databases; (iii) embedded clinical knowledge; (iv) comprehensive provider databases and (v) on-line analytical processing. The Atlas System enables users to perform sophisticated, quantitative analyses which may be used for a variety of applications including: benchmarking internal performance, competitively assessing cost and quality positions in local markets, quantifying the impact of managed care and capitated contracts, developing local integrated delivery networks, evaluating the efficacy of new pharmaceuticals and medical devices, credentialing physicians and reporting to third parties for regulatory and contract compliance. The modular design of the Atlas System enables MediQual to integrate additional applications quickly and easily in order to be responsive to evolving customer needs. The Company's CIM systems and services are supported by its proprietary master database which contains complete clinical and administrative detail on more than 20 million patient encounters. This master database is continually expanding as additional patient encounters and new types of data, including pharmaceuticals and outpatient services, are transmitted to the Company by its customers. MediQual has developed for substantially all acute diseases more than 200 statistical regression models which are embedded in the Atlas System and support the Company's analytical services for disease management applications. MediQual serves approximately 400 customers, including leading hospitals, community care networks, medical device manufacturers and pharmaceutical firms. The Company licenses the Atlas System pursuant to annual agreements, and since 1993, has experienced customer renewal rates of 90% or higher. The Company is subject to certain risks, including but not limited to dependence on the Atlas System for a majority of the Company's revenues, dependence on continued access to data, dependence on systems development introduction and enhancements, competition from other service providers and dependence on key personnel. The Company has also experienced a limited history of profitability. THE OFFERING Common Stock offered by the Company..................... 2,200,000 shares Common Stock to be outstanding after the Offering....... 8,264,306 shares(1) Use of proceeds......................................... For redemption of Class A Preferred Stock, redemption of warrants, retirement of debt, working capital and other corporate purposes. See "Use of Proceeds." Proposed American Stock Exchange symbol................. MQV
------------------------------------ SUMMARY FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) SIX MONTHS ENDED YEAR ENDED DECEMBER 31, JUNE 30, ----------------------------------------------- ---------------- 1991 1992 1993 1994 1995 1995 1996 ------- ------- ------- ------- ------- ------- ------ STATEMENT OF OPERATIONS DATA: Revenues: MedisGroups......................................... $14,866 $14,700 $13,097 $ 8,459 $ 4,674 $ 2,173 $ 683 Atlas System........................................ -- -- -- 3,150 5,131 2,614 3,662 CIM Services........................................ -- -- -- 475 1,169 500 1,362 ------- ------- ------- ------- ------- ------ ------ Total revenues.................................. 14,866 14,700 13,097 12,084 10,974 5,287 5,707 Research and development.............................. 2,647 4,204 4,152 3,626 4,013 2,189 1,328 Operating income (loss)............................... (1,199) (225) (233) 132 (1,392) (1,071) 1,440 Net income (loss)..................................... $(1,414) $ (274) $ (186) $ 282 $(1,462) $(1,092) $1,354 Pro forma:(2) Net income (loss) per share......................... $ (.21) $ .20 Weighted average shares outstanding................. 6,632 7,126
JUNE 30, 1996 ------------------------------------------- PRO FORMA ACTUAL PRO FORMA AS ADJUSTED(3) -------- ---------- --------------- BALANCE SHEET DATA: Cash and cash equivalents............................................... $ 1,679 $ 1,679 $ 11,445 Working capital......................................................... 288 288 10,210 Total assets............................................................ 4,185 4,185 13,951 Long-term debt, including current portion............................... 259 259 -- Redeemable preferred stock.............................................. 11,509 3,569 -- Stockholders' equity (deficit).......................................... (10,407) (2,468) 11,327
- --------------- (1) Excludes (i) 1,783,792 shares of Common Stock reserved for issuance under the Company's 1987 Nonqualified Stock Option Plan, as amended, and 1996 Stock Incentive Plan, of which 337,292 shares are subject to options at exercise prices ranging from $1.00 to $7.00 per share, (ii) 26,729 shares of Common Stock subject to warrants with an exercise price of $2.64 per share that will be redeemed upon the closing of the Offering for $103,441 (assuming an initial public offering price of $7.00 per share) and (iii) 156,919 shares of Common Stock issuable upon the exercise of other warrants, at an exercise price of $.80 per share, all outstanding as of June 30, 1996. See "Capitalization," "Management -- Stock Option Plans" and Notes 6 and 9 of Notes to Financial Statements. (2) Computed on the basis described in Note 2 of Notes to Financial Statements. (3) Adjusted to give effect to the sale of the Common Stock offered hereby at an assumed initial public offering price of $7.00 per share and the application of the estimated net proceeds therefrom. See "Use of Proceeds" and "Capitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000825790_packaging_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000825790_packaging_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..0b94d68b7b9fb6d9a6cde576e16030b07c6d1f09
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000825790_packaging_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS APPEARING ELSEWHERE IN THIS PROSPECTUS. AS USED IN THIS PROSPECTUS, UNLESS THE CONTEXT OTHERWISE REQUIRES, EACH OF "PRI" AND THE "COMPANY" REFERS TO PACKAGING RESOURCES INCORPORATED AND ITS PREDECESSORS. THE COMPANY'S FISCAL YEAR ENDS ON THE LAST DAY OF FEBRUARY IN EACH YEAR. ALL REFERENCES IN THIS PROSPECTUS TO FISCAL YEARS REFER TO THE FISCAL YEAR OF THE COMPANY ENDED IN THE YEAR INDICATED. FOR EXAMPLE, "FISCAL 1996" REFERS TO THE FISCAL YEAR OF THE COMPANY ENDED FEBRUARY 29, 1996. THE COMPANY GENERAL The Company is a leading developer, manufacturer and marketer of rigid plastic packaging, serving primarily as a supplier of customized containers for national branded consumer products. The Company is the largest domestic manufacturer of refrigerated yogurt containers, shelf stable, multi-layer (impermeable to air and moisture) containers for nutritional supplements and frosting containers. The Company also believes that it is the largest designer, manufacturer and supplier of promotional beverage cups in the United States, marketing these products primarily to the fast-food and beverage industries. For the fiscal year ended February 29, 1996, the Company generated net sales of $133.8 million. Approximately 82.8% of the Company's net sales in such period were attributable to rigid plastic packaging and 17.2% to promotional beverage cups. In fiscal 1996, the Company produced almost four billion plastic containers, cups and lids. The Company's packaging products are sold to over 450 customers, including manufacturers of national branded food, dairy and pharmaceutical products such as General Mills, Inc. ("General Mills"), including its Yoplait U.S.A. division ("Yoplait"), The Dannon Company, Inc. ("Dannon"), Ross Laboratories ("Ross Labs"), a division of Abbott Laboratories, Inc. ("Abbott Labs"), The Haagen Dazs Company, Inc. ("Haagen Dazs"), Procter & Gamble Company ("Procter & Gamble") and Pillsbury Company ("Pillsbury"). The Company is also a major supplier of promotional beverage cups to over 150 companies in the fast-food and beverage industries, including McDonald's, Burger King, Pizza Hut, Hardee's, Taco Bell, Coca-Cola and Pepsi. The Company's rigid plastic packaging business has benefitted from, and is positioned to continue to participate in, the growth of the markets for its customers' products, particularly refrigerated yogurt and nutritional supplements. According to data compiled by Find/SVP, Inc., a New York-based market research firm ("Find/SVP"), between 1991 and 1994 U.S. retail yogurt sales grew 9.6%, 11.4% and 7.0% from fiscal 1991 to fiscal 1992, from fiscal 1992 to fiscal 1993 and from fiscal 1993 to fiscal 1994, respectively, or at a compound annual rate of 10.6%, reaching approximately $2.0 billion in 1994. The compound annual rate has been presented as an alternative to cumulative or average annual growth rates because it indicates what the rate of growth would be had such rate been constant year to year over the periods discussed; however, the compound annual rate should not be confused with year to year or other measures of growth rates. This expansion of the U.S. yogurt market resulted, in part, from new product innovations such as lower fat and lower calorie product offerings, the introduction of new flavors and consistencies, the increasing recognition of yogurt's nutritional benefits and innovative packaging solutions targeting niche market segments. Despite this growth, the Company believes U.S. yogurt consumption still lags behind that of Europe. During 1991 and 1992, the most recent periods examined by Find/SVP, the per capita consumption of yogurt in Europe was six times that in the U.S. Net sales of Ross Labs' ENSURE-Registered Trademark- ready-to-drink nutritional supplement increased 20% in 1995, reflecting, in part, the aging of the U.S. population and the corresponding growth in the market for such products. Based on these industry and demographic factors, management expects the markets for refrigerated yogurt and nutritional supplements to continue to grow for the foreseeable future. COMPETITIVE STRENGTHS The Company attributes its leading market positions to the following factors: WELL ESTABLISHED CUSTOMER RELATIONSHIPS. The Company has long-standing customer relationships, in many instances as a sole source supplier under multi-year supply agreements. Yoplait, Dannon and Ross Labs, which accounted for over 17.9%, 18.7% and 15.2% of fiscal 1996 sales, respectively, have been customers of PRI since 1979, 1984 and 1991, respectively. In addition, the Company's established position with its largest customers is evidenced by its status as the sole supplier of such customers' most popular sized containers, including the six ounce container for Yoplait, the four, six and eight ounce containers for Dannon and the eight ounce multi-layer container for Ross Labs' ENSURE-REGISTERED TRADEMARK- nutritional supplement. PRI's status as the sole supplier of such containers positions the Company to benefit from future growth in these product markets. In recognition of the Company's performance, Ross Labs recently awarded PRI certified supplier status in Ross Labs' Partners in Excellence Program. CUSTOMER INTEGRATED PRODUCT DEVELOPMENT AND MANUFACTURING. The Company has worked closely with its customers in all phases of product design and production and has invested heavily in customer-driven research and development activities. For example, PRI developed the Autoweld-Registered Trademark- system, a technology that enables Yoplait to assemble, fill and seal its distinctive cone-shaped container. Yoplait leases from the Company the equipment necessary to operate the Autoweld-Registered Trademark- system for use in Yoplait's production facilities. For Dannon, the Company recently designed and developed a four ounce yogurt cup targeted for the food service and children's markets. The Company also worked successfully with Ross Labs to develop the shelf stable, multi-layer packaging applications for its nutritional supplements and infant formula product lines. In promotional cups, the Company has worked closely with several of its promotional beverage cup customers to develop new and distinctive high-definition graphic designs. In 1993, for example, the Company was the winner of the McDonald's Performance Award for the "Jurassic Park" promotional cup. In addition, the Company's facilities are located, in most cases, adjacent to or within close proximity to its largest customers' manufacturing operations, which has created manufacturing and distribution efficiencies. As more of the Company's customers adopt "just- in-time" inventory systems, these efficiencies have become increasingly important. STATE-OF-THE-ART MANUFACTURING TECHNOLOGIES. The Company, through its five manufacturing facilities, has developed production capabilities in injection molding, linear melt phase thermoforming ("thermoforming") and solid phase pressure forming ("pressure forming") and believes it is the only manufacturer in the rigid plastic packaging industry with capabilities in all three such processes. Because each of these processes offers advantages in achieving certain performance features such as structural strength, rigidity and graphics retention, the Company is able to be highly responsive to customer requirements and preferences by offering a broader range of packaging alternatives than its competitors. The Company's three technical facilities feature design, engineering, prototype production, graphics and diagnostic capabilities. Management believes that the Company's in-house capability to design, engineer and build production molds distinguishes the Company from many of its competitors. This capability provides PRI with an important competitive advantage in maintaining product quality as well as in controlling design, development and maintenance costs. To satisfy the rigorous quality control standards of its customers, the Company maintains a comprehensive quality assurance program. During fiscal 1996, based on internal estimates, the return rate for all of the Company's products was less than one quarter of one percent. ADVANCED GRAPHICS TECHNOLOGIES. Management believes that the Company's MasterColor printing system, which produces high definition graphics utilizing a computer controlled nine color press, is the most technologically advanced color processing system in the rigid plastic packaging and promotional beverage cup industries. The MasterColor system enables the Company to create photograph quality images on plastic containers at speeds comparable to conventional high speed printers and thus provides an important competitive advantage. Although the Company employs the MasterColor system primarily in the printing of promotional beverage cups, management believes significant opportunities exist to apply this technology to create more sophisticated and colorful designs for other forms of plastic packaging as manufacturers of branded products seek to enhance and distinguish the image of their products on store shelves. LOW COST PRODUCTION. The Company believes that its manufacturing costs are among the lowest in its industry primarily due to: (i) the economies of scale provided by the Company's high volume production; (ii) the Company's use of state-of-the-art molds and manufacturing techniques that minimize resin requirements, reduce waste and enhance productivity; (iii) the Company's ability to obtain favorable resin pricing based on its substantial purchase requirements; (iv) the low transportation costs resulting from the proximity of the Company's six manufacturing and warehouse facilities to its major customers; and (v) the Company's continual efforts to achieve operating efficiencies and increase productivity. Over the past several years, the Company has significantly upgraded and automated its manufacturing operations, consolidated certain manufacturing facilities and centralized all of its administrative functions to reduce costs and increase efficiency. The Company was founded in 1984 to capitalize on the growth in outsourcing among nationally branded food producers for their packaging needs. Since its formation, the Company has made six strategic acquisitions which have expanded the Company's product mix and enhanced its competitive position. Most recently, during fiscal 1994, the Company acquired Louisiana Plastics, Incorporated ("Louisiana Plastics") and substantially all the assets of Miner Container Printing, Inc. and certain affiliated companies (collectively, "Miner Container"), which established market share leadership in promotional beverage cups, increased injection molding capacity and packaging sales and provided the MasterColor graphics technology. The Company believes that the fundamental benefits of plastic relative to other packaging materials, including (i) design versatility, (ii) light weight and low cost, (iii) strength and durability, (iv) insulating ability and (v) clarity, will promote opportunities for growth in sales and profitability in both the rigid plastic packaging and promotional beverage cup industries. The Company further believes it is well-positioned to capitalize on these opportunities through its advanced, low-cost, customer-oriented operations. STRATEGY The Company's strategy is to enhance its position in the industry by: (i) participating in the growth being experienced by its largest customers by continuing to meet their increasing packaging needs; (ii) strengthening its relationships with these existing customers by continuing to provide new value-added products and services; (iii) expanding into new packaging and promotional cup products and markets; and (iv) continuing to seek opportunities to reduce manufacturing costs and enhance productivity. GROWTH WITH EXISTING CUSTOMERS. The Company will continue to focus on meeting the rigid plastic packaging needs of Yoplait, Dannon and Ross Labs to keep pace with the growth in the markets for their products. Based in part on growth in domestic consumption of refrigerated yogurt, the Company's net sales to Yoplait and Dannon, who rely on the Company to provide substantially all of their single-serving yogurt containers, have increased 13.1%, 14.6%, 34.9% and 15.5% from fiscal 1992 to fiscal 1993, from fiscal 1993 to fiscal 1994, from fiscal 1994 to fiscal 1995 and from fiscal 1995 to fiscal 1996, respectively, or at a compound annual growth rate of over 19% during the last four years. In addition, the Company's net sales as the sole source supplier of multi-layer containers to Ross Labs for its ENSURE-REGISTERED TRADEMARK- nutritional supplement and SIMILAC-REGISTERED TRADEMARK- infant formula grew 75.5%, 11.2%, 24.9% and 11.6% from fiscal 1992 to fiscal 1993, from fiscal 1993 to fiscal 1994, from fiscal 1994 to fiscal 1995 and from fiscal 1995 to fiscal 1996, respectively, or at a compound annual rate in excess of 29% during the last four years. NEW APPLICATIONS FOR EXISTING CUSTOMERS. The Company intends to expand its relationships with existing customers by developing new applications based on its extensive manufacturing capabilities and advanced graphics technologies. For example, the Company applied thin-wall technology, which combines structural strength with reduced cost and weight, to develop Dannon's six and eight ounce containers. In addition, the Company developed the six ounce multi-layer container presently used by Yoplait which features a glossy exterior finish designed to enhance graphics. NEW PRODUCTS AND MARKETS. The Company plans to expand into related product lines serving new markets with several products under development in both rigid plastic packaging and promotional beverage cups. With respect to packaging, management believes there will be significant opportunities to expand the Company's shelf stable, multi-layer packaging to the extent plastic containers are substituted for metal, glass and composites for products requiring extended shelf life, such as condensed soups, vegetables, baby foods and pet foods. In promotional beverage cups, the Company recently entered the professional sports and college stadium cup market and also has under development a number of new products, including a new cup for the gourmet coffee market. In addition, in both packaging and promotional cups, the Company intends to leverage its advanced graphics capabilities by introducing new products which highlight its high definition printing and quality designs. The Company believes these initiatives will reinforce its reputation as an innovative, value-added marketing partner for its customers while adding to future profitability. CONTINUED COST REDUCTION AND PRODUCTIVITY ENHANCEMENTS. The Company continually seeks opportunities to reduce its costs and improve productivity to maintain its competitive position as a low-cost manufacturer. For example, following the acquisition of Miner Container and Louisiana Plastics, the Company selectively consolidated certain manufacturing facilities and centralized administrative functions. During the first quarter of fiscal 1997, the Company completed the consolidation of its Lenexa, Kansas printing operation into the Kansas City, Missouri facility to reduce overhead and transportation costs and increase manufacturing productivity. In fiscal 1997, the Company intends to initiate projects to further reduce costs and enhance productivity, by, among other things, increasing the automation of its packaging and handling systems. STRUCTURE OF THE COMPANY All of the outstanding capital stock of PRI is held by Packaging Resources Group, Inc. ("Group"). All of the outstanding capital stock of Group is held by HPH Industries, Ltd. ("HPH"), which is wholly-owned by Howard P. Hoeper, the Chairman of the Board of Directors, Chief Executive Officer and President of Group and PRI. As of July 24, 1996, assuming the exercise of all outstanding warrants to acquire the capital stock of Group ("Warrants"), HPH, Apollo Packaging Partners, L.P., a Delaware limited partnership and an affiliate of Apollo Advisors, L.P. ("Apollo"), and TCW/Crescent Mezzanine Partners, L.P. together with TCW/ Crescent Mezzanine Trust (collectively, the "TCW Entities") would beneficially own 60%, 29.3% and 10.7% of such stock, respectively. Each of the TCW Entities is an affiliate of Trust Company of the West. The Company's principal executive offices are located at One Conway Park, 100 Field Drive, Suite 300, Lake Forest, Illinois 60045 and its phone number is (847) 295-6100. THE FINANCING PLAN The Old Notes Offering was part of a plan of financing designed to provide the Company with long-term fixed rate financing and increase the Company's revolving credit availability. In connection with such plan of financing, the Company (i) issued $110.0 million aggregate principal amount of Notes, (ii) entered into a credit agreement which provides for a $20.0 million revolving loan facility, subject to certain borrowing conditions and limitations (the "Senior Credit Facility"), (iii) repaid all outstanding borrowings under PRI's existing senior secured credit facility (the "Old Credit Agreement") in the aggregate principal amount of $73.5 million and (iv) funded a dividend to Group in the amount of $31.7 million. Group, in turn, used the dividend from PRI to redeem without penalty or premium a portion of the outstanding 12.5% Senior Subordinated Notes due June 30, 2003 of Group (the "12.5% Notes") at an aggregate redemption price of $31.7 million, leaving $19 million in principal of the 12.5% Notes outstanding as of May 17, 1996. The foregoing transactions by PRI and Group are collectively referred to herein as the "Financing Plan." See "Use of Proceeds" and "Capitalization." The following table illustrates the sources and uses of funds under the Financing Plan: AMOUNT ------------- (IN THOUSANDS) SOURCES OF FUNDS: Notes.......................................................................... $ 110,000 ------------- Total Sources................................................................ $ 110,000 ------------- ------------- USES OF FUNDS: Repayment of indebtedness under Old Credit Agreement........................... $ 73,500 Dividend to Group(a)........................................................... 31,700 Fees and expenses(b)........................................................... 4,150 Working capital................................................................ 650 ------------- Total Uses................................................................... $ 110,000 ------------- -------------
- ------------------------ (a) Dividend proceeds were used by Group to redeem, without penalty or premium, a portion of the 12.5% Notes. (b) Includes the discount paid to the Initial Purchasers (as defined) in connection with the issuance of the Old Notes, bank financing fees and legal and accounting expenses. THE EXCHANGE OFFER The Exchange Offer............ The Company is offering to exchange up to $110,000,000 aggregate principal amount of Exchange Notes for up to $110,000,000 aggregate principal amount of the Old Notes. The Old Notes were initially offered and sold by BT Securities Corporation and Donaldson, Lufkin & Jenrette Securities Corporation as the initial purchasers of the Old Notes (the "Initial Purchasers"), to certain "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) and institutional accredited investors at a price of 100% of the principal amount thereof. The form and terms of the Exchange Notes are substantially identical (including principal amount, interest rate, maturity, security and ranking) to the form and terms of the Old Notes for which they may be exchanged pursuant to the Exchange Offer, except that the Exchange Notes are freely transferable by holders thereof except as provided herein (see "The Exchange Offer--Terms of the Exchange" and "Terms and Conditions of the Letter of Transmittal") and are not entitled to certain registration rights and certain additional interest provisions which are applicable to the Old Notes under a registration rights agreement dated as of May 17, 1996 (the "Registration Rights Agreement") between the Company and the Initial Purchasers. Exchange Notes issued pursuant to the Exchange Offer in exchange for the Old Notes may be offered for resale, resold and otherwise transferred by holders thereof (other than any holder which is (i) an Affiliate of the Company, (ii) a broker-dealer who acquired Old Notes directly from the Company or (iii) a broker-dealer who acquired Old Notes as a result of market-making or other trading activities), without compliance with the registration and prospectus delivery provisions of the Securities Act provided that such Exchange Notes are acquired in the ordinary course of such holders' business and such holders are not engaged in, and do not intend to engage in, and have no arrangement or understanding with any person to participate in, a distribution of such Exchange Notes. Minimum Condition............. The Exchange Offer is not conditioned upon any minimum aggregate principal amount of Old Notes being tendered or accepted for exchange. Expiration Date............... The Exchange Offer will expire at 5:00 p.m., New York City time, on , unless extended. Exchange Date................. The first date of acceptance for exchange for the Old Notes will be the first business day following the Expiration Date. Conditions to the Exchange The obligation of the Company to consummate the Exchange Offer......................... Offer is subject to certain conditions. See "The Exchange Offer -- Conditions to the Exchange Offer." The Company reserves the right to terminate or amend the Exchange Offer at any time prior to the Expiration Date upon the occurrence of any such condition. Withdrawal Rights............. Tenders of Old Notes pursuant to the Exchange Offer may be withdrawn at any time prior to the Expiration Date. Any Old Notes not accepted for any reason will be returned without expense to the tendering holders thereof as promptly as practicable after the expiration or termination of the Exchange Offer.
Procedures for Tendering Old See "The Exchange Offer -- How to Tender." Notes......................... Federal Income Tax The exchange of Old Notes for Exchange Notes by tendering Consequences.................. holders will not be a taxable exchange for federal income tax purposes, and such holders should not recognize any taxable gain or loss as a result of such exchange. Use of Proceeds............... There wil be no cash proceeds to the Company from the exchange pursuant to the Exchange Offer. Effect on Holders of Old As a result of the making of this Exchange Offer, and upon Notes......................... acceptance for exchange of all validly tendered Old Notes pursuant to the terms of this Exchange Offer, the Company will have fulfilled a covenant contained in the terms of the Old Notes and the Registration Rights Agreement, and, accordingly, the holders of the Old Notes will have no further registration or other rights under the Registration Rights Agreement, except under certain limited circumstances. See "Old Notes Registration Rights." Holders of the Old Notes who do not tender their Old Notes in the Exchange Offer will continue to hold such Old Notes and will be entitled to all the rights and limitations applicable thereto under the Indenture. All untendered, and tendered but unaccepted, Old Notes will continue to be subject to the restrictions on transfer provided for in the Old Notes and the Indenture. To the extent that Old Notes are tendered and accepted in the Exchange Offer, the trading market, if any, for the Old Notes not so tendered could be adversely affected. See "Risk Factors -- Consequences of Failure to Exchange Old Notes."
TERMS OF THE EXCHANGE NOTES Securities Offered............ $110,000,000 principal amount of 11 5/8% Senior Secured Notes due 2003. Issuer........................ Packaging Resources Incorporated. Maturity Date................. May 1, 2003. Interest Rate................. The Exchange Notes will bear interest at the rate of 11 5/8% per annum. Interest Payments............. Interest on the Notes will accrue from May 17, 1996 and is payable in cash semi-annually on each May 1 and November 1, commencing November 1, 1996. Optional Redemption........... The Exchange Notes may be redeemed at the option of PRI, in whole or in part, from time to time on or after May 1, 2000, at the redemption prices set forth herein plus accrued and unpaid interest to the redemption date. In addition, at any time on or prior to May 1, 1999, up to 30% of the aggregate principal amount of the Exchange Notes may be redeemed at the option of PRI with the cash proceeds from one or more Public Equity Offerings at 111 5/8% of their principal amount, together with accrued and unpaid interest to the redemption date, if any, provided that after giving effect to such redemption, at least $70.0 million in principal amount of the Exchange Notes remain outstanding immediately after any such redemption. In the case of any Public Equity Offering by Group, PRI is required to apply to a redemption of the Exchange Notes an amount not less than 50% of the aggregate net proceeds of such Public Equity Offering. See "Description of Exchange Notes -- Optional Redemption."
Ranking....................... The Exchange Notes will be senior secured obligations of PRI ranking senior to all subordinated indebtedness of PRI and PARI PASSU in right of payment with all other senior indebtedness of PRI. However, lenders under the Senior Credit Facility have claims with respect to the Company's accounts receivable, raw materials and finished goods in- ventory and the proceeds therefrom constituting collateral for such indebtedness that are effectively senior in right of payment to the claims of holders of the Exchange Notes with respect to such assets. At February 29, 1996, on a pro forma basis, after giving effect to the Financing Plan, PRI would have had outstanding approximately $112.2 million in aggregate principal amount of indebtedness (excluding trade payables and other accrued liabilities), all of which would have constituted senior indebtedness and $0.4 million of which would have been indebtedness under the Senior Credit Facility. In addition, PRI would have had $19.6 million in unused senior secured borrowing capacity under the Senior Credit Facility, subject to certain borrowing conditions and limitations. See "Description of Exchange Notes -- Ranking and Security." Collateral.................... The Collateral securing the Exchange Notes will consist of certain equipment, fixtures and general intangibles, and mortgages on substantially all of the owned and certain of the leased property of the Company, and the proceeds therefrom. The Indenture provides that lenders under an Acquisition Financing Facility will have the right to share on a PARI PASSU basis in any proceeds from the sale of Collateral. See "Description of Exchange Notes -- Security." Sinking Fund.................. None. Change of Control............. Upon a Change of Control, PRI will be required to make an offer to purchase all of the Exchange Notes at 101% of the principal amount thereof, plus accrued and unpaid interest to the date of purchase. There can be no assurance that PRI will have sufficient funds to satisfy its obligation to repurchase the Exchange Notes upon a Change of Control. See "Description of Certain Indebtedness -- The Senior Credit Facility" and "Description of Exchange Notes -- Repurchase at the Option of Holders -- Change of Control." Asset Sales................... Under certain circumstances, PRI will be required to make an offer to purchase all outstanding Exchange Notes at a purchase price in cash equal to 100% of their principal amount, plus accrued and unpaid interest to the date of purchase, with the proceeds of Asset Sales. See "Description of Exchange Notes -- Repurchase at the Option of Holders -- Asset Sales; Collateral Loss Events." Certain Covenants............. The Indenture contains certain covenants that, among other things, limit the Company's ability to make certain restricted payments, incur indebtedness, create certain liens, sell assets, engage in transactions with affiliates, merge or consolidate with other entities or engage in new lines of business. See "Description of Exchange Notes -- Certain Covenants."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000829221_tracor_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000829221_tracor_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..6dfb0a7a12b9751a8bc219d8ad98f68eaabb8d14
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000829221_tracor_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and the financial statements and notes thereto included elsewhere or incorporated by reference in this Prospectus. Unless otherwise indicated, all information in this Prospectus assumes no exercise of the U.S. Underwriters' over-allotment option and no exercise of outstanding options. See "Underwriters." Certain capitalized terms which are used but not defined in this summary are defined elsewhere in this Prospectus. THE COMPANY Tracor, Inc. (collectively with its subsidiaries, "Tracor" or the "Company") provides sophisticated electronic products, systems and services for the U.S. Department of Defense ("DOD"), other U.S. government agencies, foreign governments and commercial customers. The Company's business units operate primarily in the U.S. and foreign defense electronics markets and largely support existing high-priority DOD weapons, platforms and systems. The Company's products and services enable defense customers to enhance the operational performance and readiness of existing weapons as well as extend their useful lives and survivability. As a result, the Company believes it is well positioned to benefit from fundamental changes in national defense strategy precipitated by the end of the Cold War. Since August 1993, the Company has made three substantial acquisitions as part of its strategy to take advantage of a consolidating defense industry. Largely as a result of such acquisitions, Tracor's revenues and net income have increased from $261.8 million and $4.5 million, respectively, in 1992 to $998.1 million and $26.7 million, respectively, on a pro forma basis in 1995. A key component of the Company's strategy has been establishing itself as an industry leader in several high-priority DOD program areas, including: - Navy Systems Engineering and Integration: Tracor is a major provider of systems engineering and integration services to the U.S. Navy and is the principal systems integrator for certain key programs, including both the radio communications suite for cruisers and destroyers equipped with the AEGIS weapon system and the submarine ballistic missile program. The Company has a similar position in other key programs, including shipboard anti-air warfare guided missile systems (including AEGIS) and the Tomahawk cruise missile. - Imagery Exploitation and Mission Planning: Tracor develops enhanced image interpretation and mission planning systems for the DOD and provides these high-priority systems to several critical areas within the defense and intelligence markets. - Countermeasures Dispensers: The Company designed, and currently is the only manufacturer of, the most advanced and widely used countermeasures dispenser systems in the U.S. and is a major supplier of countermeasures expendables in the domestic and international defense markets. These systems provide an important, cost-effective means of protecting combat aircraft and crews. - Drones: Tracor designs, modifies and converts military aircraft into remotely controlled aerial targets ("drones") and produces sub-scale drones, both of which are critical elements of weapons testing and evaluation. To date, the Company has produced more full-scale target drones than any other DOD contractor. - Automatic Test Systems: The Company supplies avionics automatic test equipment to the U.S. Air Force which substantially improves the readiness of advanced military aircraft, including the F-16 fighter. Tracor also is supplying test equipment for the new Japanese F-2 fighter. The Company believes its established positions in high-priority program areas are due, in part, to its longstanding, consistently high-quality performance under existing contracts. Tracor has won substantially all material contract recompetitions in which it has been involved in the last several years and is the recipient of numerous performance awards, including more than 20 Blue Ribbon awards, placing the Company among the approximately top one percent of contractors who received the award based on their individual records for on- schedule deliveries with no quality defects. For the high-priority AEGIS program, Tracor provides primary support for a U.S. Navy unit which won an unprecedented thirteenth AEGIS Excellence Award. All Tracor units emphasize continuous improvement to increase efficiencies and enhance competitiveness. Two operations recently achieved ISO 9001 certification and a third achieved ISO 9002, enabling the Company to reduce costs associated with military specifications and to comply with foreign customer requirements. One of Tracor's major subsidiaries also achieved the Software Engineering Institute ("SEI") Level 3 certification, placing it in the elite class of the 10 percent of software companies which have adopted a standard software process for both management and engineering activities. The Company's competitive performance and cost structure have allowed it to develop strong, long-lasting relationships with its major customers. The Company has been the prime contractor for services and products for many of the U.S. government's key existing programs for periods ranging from 15 to 40 years, and in many cases has been involved in the evolution of a program or weapons class since its inception. The Company currently is performing under approximately 740 contracts with approximately 105 separate agencies of the U.S. government. This existing business base led to a firm backlog of $966 million on April 30, 1996. The two other primary components of Tracor's business strategy are (i) strategic acquisitions of companies with complementary business areas where significant consolidation and cost reduction opportunities exist and (ii) the expansion into new business areas which complement existing technological expertise. The Company's recent acquisitions have broadened and strengthened the Company's position in core business areas and have created significant opportunities for cost savings. The acquisition of Vitro Corporation and its subsidiaries (individually and collectively, "Vitro") in August 1993 established the Company as a major provider of engineering and management support to the U.S. Navy. The acquisition of GDE Holdings, Inc. and its subsidiaries (individually and collectively, "GDE") in November 1994 established Tracor as a major provider of advanced digital imagery and mission planning technology and has made it the largest supplier of avionics automatic test equipment to the U.S. Air Force. The acquisitions of Vitro and GDE also established Tracor as a key supplier to the civilian and defense intelligence organizations of the U.S. government. The acquisition of AEL Industries, Inc. ("AEL") in February 1996 strengthened Tracor's position in long-term electronic warfare production programs and added key capabilities in radio frequency, antenna and microwave technologies. The Company has a large employee base with special high-level security clearances, which are critical for building a presence in the intelligence market. The Company is also actively developing commercial and other nondefense applications for its technology in a number of diverse markets. The largest portion of Tracor's business is in the operations and maintenance segment of the U.S. defense budget. Operations and maintenance now exceeds procurement as the largest segment of the DOD budget. DOD operations and maintenance expenditures emphasize maintaining the readiness of armed forces and are concentrated on upgrading the effectiveness of existing combat systems and on extending their useful lives. Because the Company is a major supplier of systems and services which improve effectiveness, prolong the life of existing weapons platforms and enhance the survivability of combat systems at a relatively low cost, management believes the Company will benefit from these priorities in the DOD budget. A modest increase in the procurement portion is expected, and Tracor is well positioned to benefit from this upturn. Tracor is organized under the laws of Delaware with principal executive offices located at 6500 Tracor Lane, Austin, Texas 78725 (telephone number: (512) 926-2800). MAJOR ACQUISITIONS In recent years the Company has completed three important acquisitions in connection with the implementation of its broader business strategy. In August 1993, Tracor acquired Vitro for approximately $92 million. This acquisition more than doubled Company revenues and made the combined entity a major provider of systems engineering and integration support to the U.S. Navy. In November 1994, the Company purchased GDE for approximately $102 million (the "GDE Acquisition"), which established the Company as a major provider of advanced digital imagery technology to both the DOD and the intelligence community. In February 1996, the Company purchased AEL for approximately $103 million (the "AEL Acquisition") which strengthened Tracor's position in long-term electronic warfare production programs and added key capabilities in radio frequency, antenna and microwave technologies. The acquisitions of Vitro, GDE and AEL have strengthened the Company's core businesses and enhanced the Company's ability to compete in non-traditional business areas. In particular, the Company expects to have an increased ability to bid on contracts in new business areas which draw upon complementary capabilities or customer relationships of any or all of the acquired companies. In addition, since the acquisition of Vitro, significant cost savings have been realized resulting from the consolidation of facilities, staff reductions, process improvements and elimination of other duplicative costs. While a substantial portion of such savings will also result in reductions in sales under cost-reimbursement contracts, the Company's cost competitiveness should be enhanced. The Company has also realized significant net cost savings in connection with the GDE Acquisition and has identified substantial savings in connection with the AEL Acquisition. Management believes the continuing consolidation within the defense industry will result in additional opportunities for the Company to make attractive acquisitions. WESTMARK ACQUISITION On June 13, 1996, the Company consummated the acquisition (the "Westmark Acquisition") of substantially all of the assets of Westmark Systems, Inc. ("Westmark"). The purchase consideration paid by Tracor to Westmark in the Westmark Acquisition included 8,267,435 shares of Common Stock. The principal assets of Westmark acquired by Tracor in the Westmark Acquisition were 978,458 shares of Class A Common Stock, a Series B Warrant to purchase 5,249,428 shares of Common Stock (the "Series B Warrant"), and a Series C Warrant to purchase 5,455,000 shares of Common Stock (the "Series C Warrant" and, together with the Series B Warrant, the "Tracor Warrants"). The shares of the Class A Common Stock and the Tracor Warrants were cancelled and will not be reissued. See "Westmark Acquisition."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000829649_contour_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000829649_contour_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..ddc501dd98113ccb7dbce36790e66c876d5b1154
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000829649_contour_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements appearing elsewhere in this Prospectus. THE COMPANY Contour Medical, Inc. and its Michigan and Florida subsidiaries (the "Company") manufactures a full line of orthopedic care and rehabilitation products in addition to a full line of disposable surgical products. The orthopedic and rehabilitative products include pads and positioning aids for x-rays, CAT scans, mammograms and MRI's; braces for reconstructive rehabilitation after surgery; and finger spreaders, leg spreaders and leg positioning devices to prevent atrophy and speed recovery from surgery. Sterile and non-sterile products such as sponges, swabs, instrument holders, equipment covers and drapes make up the Company's disposable product line. In addition to the standard product lines offered, the Company offers customers the benefit of specialty manufacturing. The Company's staff assists in total product development from concept to completed product manufacturing and distribution. In 1994, the Company began manufacturing and marketing its "REDI NURSE SYSTEM[TM]" product line, which provides custom packaged procedural trays for use in clinics and nursing homes as well as by home health care nurses. The Company also designs and fabricates disposable medical products for sports medicine applications. Beginning in 1995, the Company commenced distribution of medical supply products to nursing home and retirement facilities owned, leased or managed by Retirement Care Associates, Inc., the Company's majority shareholder. The Company has now expanded this activity to other nursing home operators and other health care providers. In March 1996, the Company acquired AmeriDyne Corporation ("AmeriDyne"), a bulk medical supply company based in Jackson, Tennessee. AmeriDyne distributes supplies to hospitals, clinics, physicians, pharmacies, nursing homes and other health care providers in Tennessee, Arkansas, Mississippi, Alabama, Illinois, Texas, Kentucky, Missouri and Virginia. THE OFFERING Common Stock Outstanding 5,214,223 Shares Securities Offered Upon Exercise of Class B Warrants 125,186 Shares of Common Stock Securities Offered Upon Exercise of Class C Warrants 315,000 Shares of Common Stock Securities Offered Upon Conversion of Series A Convertible Preferred Stock 630,000 Shares of Common Stock Securities Offered Upon Exercise of Consultants' Warrants 577,500 Shares of Common Stock Common Stock Outstanding After Offerings by Company 6,861,909 Shares Common Stock Offered by 369,619 Shares Selling Shareholder Nasdaq Small Cap Market Symbol CTMI __________________ As of May 31, 1996. Does not include 415,275 shares of Common Stock issuable upon the exercise of outstanding options. (See "MANAGEMENT.")
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000830260_oregon_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000830260_oregon_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..8089a9d5cd35bec56a6a8b6875ebf2d48df77de4
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000830260_oregon_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements included and incorporated by reference in this Prospectus. Unless otherwise indicated or the context otherwise requires, (i) all information in this Prospectus assumes that the over-allotment option to purchase up to an additional 900,000 shares of Common Stock granted to the underwriters by the Company in the Common Stock Offering is not exercised and (ii) the terms "Company" and "Oregon Steel" refer to Oregon Steel Mills, Inc. and its consolidated subsidiaries. THE COMPANY Oregon Steel operates two steel minimills and four finishing facilities in the western United States and Canada that produce one of the broadest lines of specialty and commodity steel products of any domestic minimill company. The Company emphasizes the cost-efficient production of higher margin specialty steel products targeted at a diverse customer base located primarily in the western United States, western Canada and the Pacific Rim. The Company's manufacturing flexibility allows it to manage actively its product mix in response to changes in customer demand and individual product cycles. Through strategic acquisitions and selective capital additions, the Company has: - increased shipments of steel products from 762,700 tons in 1991 to 1.4 million tons in 1995 - expanded its range of finished products from plate and large diameter welded pipe in 1991 to eight products currently by adding electric resistance welded ("ERW") pipe, rail, rod, bar, wire and seamless oil country tubular goods ("OCTG") - increased its emphasis on higher margin specialty products - expanded its geographic markets from the western United States to national and international markets The Company is organized into two business units: the Oregon Steel Division and the CF&I Steel Division. The Oregon Steel Division is centered on the Company's steel plate minimill in Portland, Oregon (the "Portland Mill"), which is the only steel plate minimill in the 11 western states and one of only two steel plate production facilities operating in that region. The Oregon Steel Division's steel pipe mill in Napa, California (the "Napa Pipe Mill"), one of only four large diameter pipe mills operating in the United States and the only such mill in the 11 western states, produces large diameter pipe that satisfies the demanding specifications of oil and gas transmission companies. The Oregon Steel Division also produces large diameter pipe and ERW pipe at its 60% owned pipe mill in Camrose, Alberta, Canada (the "Camrose Pipe Mill"), which is strategically located in the Alberta natural gas fields to provide transmission pipe to western Canada's gas industry. The CF&I Steel Division consists of steelmaking and finishing facilities in Pueblo, Colorado (the "Pueblo Mill"). Through the Pueblo Mill, the Company is the sole rail manufacturer west of the Mississippi River and is one of only two rail manufacturers in the United States. During 1995 the Company completed the construction and start-up of a combination rod and bar mill that has an annual capacity of approximately 600,000 tons and the capability to produce specialty bar products and high carbon rod in 6,000-pound coils. The Pueblo Mill is also a producer of wire products and OCTG. Oregon Steel seeks to be a cost-efficient producer of specialty and commodity steel products. The Company strives to reduce costs and improve performance by (i) operating manufacturing facilities capable of responding rapidly to changes in customer demand and individual product cycles, (ii) emphasizing the production of higher margin specialty steel products and (iii) investing in efficient and flexible manufacturing technology. CAPITAL IMPROVEMENT PROGRAM As part of its effort to reduce manufacturing costs, upgrade its steelmaking facilities and improve product quality and product mix, the Company initiated a $410 million (excluding capitalized interest) capital improvement program in late 1993, of which approximately $324 million had been expended as of March 31, 1996. The purpose of the program is to (i) expand and improve the steelmaking and casting capability at the Pueblo Mill from 900,000 tons to 1.2 million tons annually, (ii) reduce the cost of producing rail, rod and bar products at the Pueblo Mill while improving product quality and expanding the specialty grades that can be manufactured there, (iii) reduce the cost and improve the yield of plate rolling and other finishing operations at the Portland Mill while increasing plate rolling capacity from 430,000 tons to 1.2 million tons annually and (iv) reduce dependence on scrap steel. Several of these projects have been completed, and construction of various other projects is scheduled to continue through 1996. As part of its strategy in acquiring the CF&I Steel Division in 1993, the Company initiated significant capital additions to the Pueblo Mill. In 1993 work began on a series of capital improvements, principally to the steelmaking facility, rod and bar mills and rail production facilities. These improvements have been substantially completed except for the installation of equipment capable of producing in-line head hardened rail, which is expected to begin operating in the third quarter of 1996. The new rod and bar mill was completed in July 1995 and is expected to reach full production capacity in the fourth quarter of 1996. Major improvements completed to date include expansion of steelmaking and casting capacity from 900,000 tons to 1.2 million tons annually, upgrading from ingot to continuous casting for rail production, enhancement of the ability to produce specialty grades of steel and construction of a new rod and bar mill. These changes are expected to reduce average production costs at the Pueblo Mill, primarily as a result of increased yields and enhanced production efficiencies, and to improve product quality and allow production of a broader range of products. At the Portland Mill, the Company has begun engineering, site preparation and construction work for installation of a new Steckel combination rolling mill (the "Combination Mill"). When fully operational, the Combination Mill is expected to (i) increase capacity of plate rolling operations from 430,000 tons to 1.2 million tons annually, (ii) reduce the cost and improve the yield of plate rolling and other finishing operations, (iii) provide enhanced manufacturing flexibility, (iv) supply substantially all the Company's requirements for plate used in its manufacturing of large diameter line pipe, (v) add coiled plate to the product mix and (vi) be capable of producing wider steel plate than any such mill currently operating in the world. The Combination Mill is currently scheduled to begin start-up operation in the second half of 1996 and is expected to reach full production capacity by the end of 1997. The Company plans to operate the existing rolling mill at the Portland Mill until the Combination Mill is fully operational. The Company believes the improvements described above will significantly reduce production costs at both the CF&I and Oregon Steel Divisions. The Company estimates that the capital improvements at the Pueblo Mill, when fully operational, should reduce the average production costs of making cast steel for use in its finishing operations by approximately $27 per ton and should reduce the average production costs of making rod and bar products from cast steel by approximately $28 per ton (assuming annual production of approximately 1,000,000 tons of cast steel and approximately 500,000 tons of rod and bar products), in each case compared to average costs for the year ended December 31, 1995. In that regard, average manufacturing costs at the CF&I Steel Division during 1995 were higher than anticipated due to start-up difficulties related to the new rod and bar mill. At the Oregon Steel Division, the Company estimates that the Combination Mill and related improvements, when fully operational and assuming production of approximately 775,000 tons of steel plate and coil product annually, should decrease average rolling costs by approximately $45 per ton, including estimated savings of approximately $11 per ton due to the elimination of transportation costs related to the operations at the Company's plate rolling mill in Fontana, California (the "Fontana Plate Mill"), compared to average plate rolling costs for the year ended December 31, 1994. The Company believes 1994 results are more appropriate than 1995 results for calculating the estimated cost savings at the Oregon Steel Division because of the termination of production at the Fontana Plate Mill in the fourth quarter of 1994. Closure of the Fontana Plate Mill, which was an initial step in the Company's plan to consolidate plate rolling operations at the Portland Mill, reduced the Company's effective plate rolling capacity in 1995 and thereafter by approximately 50%. The Company anticipates that plate rolling capacity lost as a result of the Fontana Plate Mill closure will be restored when the Combination Mill is fully operational. There is no assurance that these estimated cost savings will be realized or that capital improvement projects will be fully operational by the dates anticipated, and actual results will vary from the estimates set forth herein. The estimates of cost savings are based on a number of estimates and assumptions, including completion of the capital improvement program and an assumed increase in production, as a result of the capital improvement program, to the production levels set forth above (which in certain cases are at or near the maximum production levels for the respective facilities); average estimated cost savings per ton would be lower, perhaps substantially, at lower rates of production. In addition, these estimates do not take into account, among other things, estimated increased depreciation expenses resulting from the capital improvement program. Due in large part, however, to the assumed increase in production levels as set forth above, depreciation, if taken into account, would not significantly affect the estimated average cost savings for cast steel, but would reduce the estimated average cost savings for rod and bar to $27 per ton and for steel plate to $35 per ton. Furthermore, following completion of capital improvement projects the Company may continue to experience operational difficulties and delays before those projects become fully operational. As a result, there is no assurance that the new rod and bar mill, the Combination Mill or other capital improvement projects will be fully operational by the dates anticipated, which would delay the realization of benefits from those projects. Moreover, completion of the capital improvement program is subject to a number of uncertainties, including the continued availability of borrowings under the Amended Credit Agreement, and there is no assurance that the program will be completed as planned. See "Risk Factors -- Start-Up Difficulties," "-- Funding for the Capital Improvement Program," "-- Potential Delay in Completion of Capital Improvement Program" and "-- Uncertainty of Benefits of Capital Improvement Program; Increase in Interest and Depreciation Expense" and "Business -- Capital Improvement Program." The Company believes the information set forth in the preceding two paragraphs includes "forward-looking statements" within the meaning of Section 27A of the Securities Act and is subject to the safe harbor created by that section. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in those paragraphs and in "Risk Factors" and "Business -- Capital Improvement Program." THE REFINANCING The Notes Offering is part of a refinancing (the "Refinancing") which will include (i) the Common Stock Offering and the Notes Offering, (ii) the amendment of the Company's existing bank credit agreement (the "Old Credit Agreement") to establish a $125 million credit facility (the "Amended Credit Agreement") collateralized by accounts receivable and inventory, none of which is expected to be borrowed as of the completion of the Offerings, and (iii) the repayment in full of all of the outstanding indebtedness under the Old Credit Agreement. See "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Liquidity and Capital Resources" and "Description of Certain Indebtedness." In connection with the proposed Refinancing, Napa Pipe Corporation and Oregon Steel Mills -- Fontana Division, Inc., former subsidiaries of the Company, were merged into the Company in February 1996 (the "Mergers"). The following table sets forth the estimated sources and uses of funds from the Refinancing, assuming a public offering price of $16.00 per share for the Common Stock Offering (in thousands). Sources: Common Stock Offering(1)...................................................... $ 96,000 Notes Offering(1)............................................................. 235,000 Amended Credit Agreement...................................................... -- -------- Total sources......................................................... $331,000 ======== Uses: Repay borrowings under Old Credit Agreement(2)................................ $295,000 Estimated fees and cash expenses(3)........................................... 14,700 Capital expenditures and other general corporate purposes..................... 21,300 -------- Total uses............................................................ $331,000 ========
- --------------- (1) Represents gross proceeds. (2) Estimated outstanding balance upon completion of the Offerings. (3) Includes (i) estimated underwriting discounts and commissions and related expenses of the Offerings and (ii) estimated cash payments in the approximate aggregate amount of $2.6 million to terminate certain interest rate swap agreements related to the Old Credit Agreement. RECENT DEVELOPMENTS On June 7, 1996 the Company announced that a mechanical failure had resulted in the temporary shutdown of the ladle refining furnace (the "LRF") at the Pueblo Mill. The LRF is used to refine the chemistry of the molten steel produced by the electric arc furnaces at the Pueblo Mill. The Company estimates that repairs to the LRF will take approximately 20 days and that, until the LRF is returned to full operation, steel production at the Pueblo Mill will be reduced substantially. There is, however, no assurance that repairs will not take longer. This temporary shutdown of the LRF and the reduction in steel production will increase production costs and adversely affect shipment levels in June and July 1996. The Company estimates that this temporary shutdown will reduce pretax results by approximately $3 million, although the actual effect on results of operations will likely vary from this estimate. The Company has business interruption insurance and is reviewing its coverage under the policy to determine whether it is entitled to any insurance recovery in connection with the LRF shutdown. Although the Company believes there is insurance coverage (subject to a deductible), there is no assurance that the Company will be entitled to any recovery under this policy and, in any event, any recovery would likely occur in a later period. The estimates regarding the length of time it will take to repair the LRF and the effect of the temporary shutdown on results of operations are based on a number of estimates and assumptions and are subject to significant uncertainties. Accordingly, there is no assurance that the LRF will be repaired within the estimated time period set forth above or that the effect of the shutdown on results of operations will not be more adverse than the estimate set forth above. The Company's results of operations for the three months ended March 31, 1996 were favorably affected by strong shipments of rail and OCTG products. Rail sales are expected to decline in the second quarter of 1996, and this decline, together with the need for further adjustment of the product mix at the Pueblo Mill, including rod and bar product mix, is expected to adversely affect results of operations for the second quarter of 1996 compared to the first quarter of 1996. The combined effect of the matters discussed above is expected to have a material adverse effect on the Company's results of operations for the second quarter of 1996 compared to the first quarter of 1996. See "-- Forward-Looking Statements" below.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000831529_connectinc_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000831529_connectinc_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..df11c044fb6a21af692607c558f59fda0305be61
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000831529_connectinc_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information, including Risk Factors and Financial Statements, including Notes thereto, appearing elsewhere in this Prospectus. THE COMPANY CONNECT designs, develops, markets and supports industrial strength, scaleable application software for Internet-based interactive commerce. CONNECT's software and services are designed to reduce the time and overall cost for businesses to implement and maintain a secure sales, marketing and order capture capability on the World Wide Web (the "Web"). The Company's software supports key functions necessary for large-scale interactive commerce, including user registration, multimedia catalog and content management, dynamic merchandising, order capture and management, security, payment processing, enterprise integration and systems administration. In today's competitive global business environment, companies are seeking to streamline their business processes in order to lower costs, forge closer relationships with customers and suppliers and increase market share, revenue and profits. Traditional approaches to sales, marketing and order capture still rely heavily on human involvement, paper-based systems, physical infrastructure and costly advertising and promotion. The Internet is emerging as a powerful new interactive commerce medium that has the potential to address the limitations of these traditional approaches by linking businesses directly with their customers, distributors and suppliers. While the adoption of the Internet as a medium for interactive commerce is in its early stages, Forrester Research, Inc. estimates that the market for all Internet-based packaged applications, including electronic commerce applications (which Forrester Research, Inc. does not separately estimate), will grow from less than $1.0 million in 1995 to over $1.7 billion in 1999. CONNECT's core product, OneServer, which was commercially released in September 1995, is a cross-industry packaged software application for Internet- based interactive commerce, including sales, marketing and order capture. In addition, the Company offers OrderStream, its first preconfigured implementation of OneServer for business-to-business interactive commerce in selected vertical markets. CONNECT's applications are designed to support large numbers of purchasers, products and transactions. The Company's object-oriented software architecture and robust transaction manager tightly integrate OneServer and OrderStream with a relational database to provide increased system performance and transaction capacity. The Company and its Solution Partners offer a broad range of services to implement, support and operate CONNECT's applications. The Company's goal is to be the leading provider of packaged application software for Internet-based interactive commerce. The Company's strategy is to provide comprehensive software and service solutions that can be implemented across a broad range of industries. Additionally, in order to expand market share and establish a leadership position, the Company plans to develop specific implementations of OneServer, such as OrderStream, targeted at specific vertical markets. The Company intends to target corporations planning to deploy large-scale interactive commerce sites on the Web. The Company has licensed OneServer or OrderStream to 11 customers including Ameritech Corporation, Compaq Computer Corporation, ENTEX Information Services, Inc., First Data Corporation, Fruit of the Loom, Inc., PhotoDisc, Inc. and Time Warner Cable (a division of Time Warner Entertainment, L.P.). Three customers are operating OneServer commercially, while the other OneServer licensees are in the process of implementing OneServer applications. Two customers have licensed OrderStream, neither of which is operating the application commercially. During the six months ended June 30, 1996, Fruit of the Loom, Inc. and Time Warner Cable accounted for approximately 25% and 17%, respectively, of the Company's total revenue. No other customer accounted for more than 10% of the Company's total revenue during the first six months of 1996. The Company was incorporated under the laws of the State of California in April 1987 and was reincorporated in Delaware in July 1996. The Company's principal executive offices are located at 515 Ellis Street, Mountain View, California 94043-2242, and its telephone number is (415) 254-4000. CONNECT's World Wide Web site is located at "www.connectinc.com." Information contained on the Company's Web site shall not be deemed to be a part of this Prospectus. As used in this Prospectus, the terms "CONNECT" and the "Company" mean CONNECT, Inc. CONNECT(R) is a registered service mark of the Company. OneServer, OrderStream, CONNECT Online and the CONNECT logo and OneServer logo are trademarks of the Company. This Prospectus also includes trademarks of companies other than CONNECT. THE OFFERING Common Stock offered by the Company..... 2,500,000 shares Common Stock to be outstanding after the offering............................ 18,536,742 shares(1) Nasdaq National Market symbol........... CNKT Use of proceeds......................... Working capital and general corporate purposes. SUMMARY FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) SIX MONTHS YEARS ENDED DECEMBER 31, ENDED JUNE 30, -------------------------------------------- ---------------- 1991 1992 1993 1994 1995 1995 1996 ------- ------- ------- ------- -------- ------- ------- STATEMENT OF OPERATIONS DATA: Revenue: License................ $ 222 $ 212 $ 1,015 $ 1,627 $ 288 $ 89 $ 1,511 Service................ 2,419 2,617 2,847 6,345 8,285 5,464 2,477 ------- ------- ------- ------- -------- ------- ------- Total revenue......... 2,641 2,829 3,862 7,972 8,573 5,553 3,988 Loss from operations(2).......... (2,135) (2,691) (1,648) (1,540) (13,194) (6,733) (9,148) Net loss(2)............. $(2,268) $(2,932) $(1,921) $(1,765) $(14,139) $(7,101) $(9,127) Pro forma net loss per share(3)............... $ (0.79) $ (0.40) $ (0.51) Shares used in computing pro forma net loss per share(3).. 17,814 17,811 17,893
JUNE 30, 1996 ---------------------- ACTUAL AS ADJUSTED(4) ------- -------------- BALANCE SHEET DATA: Cash and cash equivalents................................ $ 5,794 $20,794 Working capital ......................................... 2,787 17,787 Total assets............................................. 11,922 26,922 Long-term debt........................................... 1,214 1,214 Stockholders' equity .................................... 5,196 20,196
- -------- (1) Based on the number of shares outstanding as of June 30, 1996, plus 272,750 shares issued in July 1996 in a private placement to a wholly-owned subsidiary of Fruit of the Loom, Inc., one of the Company's customers. Excludes (i) an aggregate of 3,037,056 shares subject to outstanding options as of June 30, 1996 at a weighted average exercise price of $1.78 per share under the Company's 1989 Stock Option Plan and 1996 Stock Option Plan, (ii) 100,750 shares issuable upon exercise of options granted between July 1, 1996 and August 12, 1996 at a weighted average exercise price of $4.80 per share, and (iii) 219,155 shares issuable upon exercise of warrants outstanding as of June 30, 1996 at a weighted average exercise price of $3.30 per share (of which the Company expects warrants to purchase 200,236 shares will be exercised immediately prior to completion of the offering). See "Capitalization," "Management--Stock Plans" and Notes 8 and 14 of Notes to Financial Statements. (2) Includes a one-time expense of $4.1 million in the first quarter of 1995 from the Company's termination of exclusive distribution rights of its European distributor. See Note 10 of Notes to Financial Statements. (3) See Note 2 of Notes to Financial Statements. (4) As adjusted to give effect to the sale of 2,500,000 shares of Common Stock at an assumed initial public offering price of $7.00 per share. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000832485_mednet_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000832485_mednet_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..010ad2be840212a2ccffae5ffe5aa128b1f3724b
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000832485_mednet_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY RISK FACTORS SECURITIES COVERED BY THIS PROSPECTUS SELLING STOCKHOLDER PLAN OF DISTRIBUTION PRICE RANGE OF COMMON STOCK AND DIVIDEND POLICY SELECTED CONSOLIDATED FINANCIAL DATA MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS BUSINESS DIRECTORS AND EXECUTIVE OFFICERS SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT TRANSACTIONS WITH RELATED PARTIES DESCRIPTION OF SECURITIES LEGAL PROCEEDINGS LEGAL MATTERS EXPERTS CHANGE IN ACCOUNTANTS INDEX TO FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES ------------------- AVAILABLE INFORMATION The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the "Commission"). Reports, proxy statements and other information concerning the Company can be inspected and copied at the public reference facilities maintained by the Commission at its office at Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549, as well as at the Regional Offices of the Commission at Citicorp Center, 300 West Madison Street, Chicago, Illinois 60661; and Seven World Trade Center, New York, New York 10048. Copies of such material can be obtained from the Public Reference Section of the Commission at Room 1024, Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. The Commission also maintains a site on the World Wide Web (hhtp://www.sec.gov) that contains reports, proxy and information statements and other information regarding the Company filed electronically with the Commission. This Prospectus constitutes a part of Registration Statements on Form S-1 filed by the Company with the Commission under the 1933 Act (the "Registration Statement"). This Prospectus omits certain information contained in the Registration Statement, and reference is hereby made to the Registration Statement and related exhibits for further information with respect to the Company and the shares of Common Stock offered hereby. Statements contained herein concerning the provisions of any document disclose all material aspects thereof but are not necessarily complete and, in each instance, reference is made to the copy of such document filed as an exhibit to the Registration Statement or otherwise filed with the Commission. Each such statement is qualified in its entirety by such reference. PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements (including the notes thereto) appearing elsewhere in this Prospectus, including information under "Risk Factors." The Company The Company was incorporated under the laws of the State of Nevada in September, 1985 and changed its name from Medi-Mail, Inc. to Mednet, MPC Corporation in June, 1995. Substantially all of the Company's business is derived from its activities in the managed prescription care industry. The Company, together with its subsidiaries Medi-Mail, Inc. ("Medi-Mail"), Medi-Claim, Inc. ("Medi-Claim"), Medi-Phar, Inc. ("Medi-Phar") and Family Pharmaceuticals of America, Inc. ("FPA"), acts as an integrated, full service prescription drug benefits manager serving individual members of retirement organizations, fraternal organizations, state employee organizations and commercial organizations ("Affinity Groups"), corporations, self insurance trusts, insurance companies and other benefit plan sponsors ("Third-Party Payors" and collectively with the Affinity Groups, "Payors") throughout the United States. The Company's benefit programs (the "Programs") offer prescription drug benefits to approximately two million individuals ("Participants"), most of whom receive funded benefits through Third-Party Payors and/or are members of an Affinity Group. Description of Prescription Benefits Management Business. The Company develops and administers client- specific Programs on behalf of more than 400 Payors throughout the United States. The Company attempts to customize its Programs to meet the Payors' particular benefits strategy combining a number of managed care features to cost effectively manage the Payor's Program. The Programs combine mail-service pharmacy features such as enhanced generic substitution and the convenience of home delivery, with the features of retail network pharmacy such as automated claims adjudication, real time electronic networking of retail pharmacies and card programs. Payors can choose a Program which incorporates on-line electronic claims processing, drug utilization review and an electronic network linking more than 45,000 retail pharmacies in the United States, as well as features of a mail-service pharmacy program. In the alternative, Payors can choose either a mail-service pharmacy program or a network claims processing program to combine with its other existing prescription benefits. Mail-service Pharmacy Operations. The Company's mail-service pharmacy program is conducted from its Las Vegas and Chicago locations. The Company services customers throughout the United States. The Company's mail-service pharmacy program is designed for convenience and to reduce prescription medication and over-the-counter pharmaceutical costs to individuals, corporations, labor unions, retirement systems, health and welfare trusts, insurance companies, federal and state employee plans, health maintenance organizations and third-party administrators. The mail service pharmacy program attracts senior citizens, home-bound persons, sight or hearing impaired persons and users of regularly prescribed medications who are interested in the convenience of direct delivery of medication and/or lowering their medication and pharmaceutical expenses. The Company believes that it delivers prescription medication and over-the-counter pharmaceutical products to the homes of customers at lower costs, on average, than are generally available through retail pharmacies. These medications are typically maintenance medications, which must be taken on an ongoing basis for chronic conditions such as high blood pressure, arthritis and heart and thyroid conditions. The Company believes that these conditions account for a majority of prescription medication expenditures in the United States. Retail Pharmacy Operations. Through Medi-Phar, the Company operates in-clinic retail pharmacies, located in San Diego, California and Las Vegas, Nevada. Operation of the retail pharmacies provided the Company with a working knowledge of the retail pharmacy business which improved the Company's ability to market and develop its service, primarily the pharmacy network and claims processing system of its subsidiary, Medi-Claim. As the Medi-Claim network has developed, this aspect of the retail pharmacies has become less important. The Company has closed four and anticipates closing one more of its retail locations in 1996. Mednet(R) Claims Processing. The Company's prescription claims administration programs ("Claims Programs") are conducted through Medi-Claim. In November 1994, Medi-Claim acquired substantially all of the assets of Medical Services Agency, Inc. ("MSA"), which operated under the registered service mark of Mednet(R), in exchange for 1,600,000 shares of Common Stock. The Claims Programs are sponsor-specific benefit programs through which Medi-Claim processes and adjudicates paper and electronic prescription drug claims generated through a network of participating retail pharmacies. The pharmacy network includes approximately 45,000 retail pharmacies in the United States, each of which contracts with Medi-Claim to provide prescription dispensing at contracted rates. The first quarter of 1996 marked the first time that the Company obtained net income for a fiscal quarter. Management believes that the profitable quarter reflects economies of scale from recent acquisitions, cost-savings from the consolidation of the Home Pharmacy operations and various cost cutrting moves implemented in the fourth quarter of 1995. Operations for the quarter may not be indicative of operations for the entire year. In particular, the small amount of profit for the quarter ($32,000 or $.001 per share on net sales of $25,720,000) means that even small fluctuations in costs or sales could result in future losses. There is no assurance that the Company will be profitable in the future. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business-Recent Developments". As of July 11, 1996, the Company has 32,657,131 shares of Common Stock outstanding (37,647,131 including the Shares). In addition the Company has 267,500 shares of Series A Preferred Stock, 112,500 shares of Series D Preferred, and 125,000 shares of Series E Preferred. Pursuant to the terms of the Stock Purchase Agreement, the Company has also committed to issue 125,000 shares of Series F Preferred, subject to certain conditions precedent. The Company's executive offices are located at 871-C Grier Drive, Las Vegas, Nevada 89119, and its telephone number is (702) 361-3119. The securities offered hereby involve a high degree of risk. See "Risk Factors". The Offering The Common Stock being offered hereby consists of up to 5,000,000 shares issuable on conversion of the Series E Preferred and the Series F Preferred. See "Securities Covered by This Prospectus" and "Plan of Distribution". Summary Financial Data Set forth below are summary consolidated financial data for the Company as of and for the periods indicated. The following information should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations," the Company's Consolidated Financial Statements and Notes thereto, and other financial statements appearing elsewhere in this Prospectus. Three Months Ended March 31, Year Ended December 31, -------------------------- ----------------------------------------------- 1996 1995 1995(1) 1994(2)(3) 1993(4) -------------------------- ------------- ------------- ------------- Statement of Operations Data: Net sales $ 25,720,000 $ 28,329,000 $ 114,297,000 $ 67,863,000 $ 25,224,000 Cost of sales (21,852,000) (24,278,000) (98,253,000) (58,793,000) (19,504,000) Gross profit 3,868,000 4,051,000 16,044,000 9,070,000 5,720,000 Operating Expense (including amortization) (3,414,000) (4,236,000) (26,859,000) (14,794,000) (13,185,000) Net other income (expense) (422,000) (552,000) (2,517,000) 225,000 (761,000) -------------------------- ----------------------------------------------- Net income (loss) $ 32,000 $ (737,000) $ (13,332,000) $ (5,499,000) $ (8,226,000) ========================== =============================================== Net income (loss) per common share $ .00 $ (.03) $ (.53) $ (.26) $ (.49) Weighted average shares outstanding 28,762,000 23,817,000 25,383,000 21,353,000 16,675,000 Balance Sheet Data (end of period)(5): Working capital (deficit) $ (6,533,000) $ 2,749,000 $ (5,138,000) $ 1,420,000 $ 1,310,000 Goodwill and other tangible assets, net 18,034,000 8,882,000 18,582,000 9,308,000 5,406,000 Total assets 44,853,000 22,406,000 41,903,000 22,317,000 13,017,000 Long-term debt less current portion 2,123,000 1,824,000 1,422,000 595,000 952,000 Redeemable Preferred Stock 5,350,000 -- 5,350,000 -- -- Stockholders' equity $ 6,538,000 $ 11,443,000 $ 9,061,000 $ 11,906,000 $ 7,028,000 (1) In September, 1995 the Company acquired substantially all the assets of Home Pharmacy. The acquisition was accounted for as a purchase. The Company has elected to consolidate the operations of Home Pharmacy retroactively to January 1, 1995. (2) In November, 1994 the Company acquired substantially all the assets of Medical Services Agency, Inc. (doing business as Mednet) ("MSA"). The acquisition was accounted for as a purchase. The Company has elected to consolidate the acquisition of MSA retroactively to January 1, 1994 and these amounts include interim results of MSA through September 30, 1994 as determined by management. (3) In June, 1994 the Company acquired all of the issued and outstanding stock of Family Pharmaceuticals of America, Inc. The acquisition was accounted for as a purchase. The Company has elected to consolidate the acquisition of FPA retroactively to January 1, 1994. (4) In April, 1993, the Company acquired substantially all the assets of Mail Rx. The acquisition was accounted for as a purchase. (5) Figures do not include the proceeds to the Company generated by the sale of Series E Preferred to the Selling Stockholder subsequent to March 31, 1996.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000833298_cima-labs_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000833298_cima-labs_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..5dfd6bd8180e817d97a781db6f7a6357047bce04
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000833298_cima-labs_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY AND SHOULD BE READ IN CONJUNCTION WITH THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. FOR A DISCUSSION OF CERTAIN FACTORS TO BE CONSIDERED IN EVALUATING AN INVESTMENT IN THE SHARES OF COMMON STOCK OFFERED HEREBY, SEE "RISK FACTORS." UNLESS OTHERWISE INDICATED, ALL INFORMATION IN THIS PROSPECTUS ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION. SEE "UNDERWRITING." THE COMPANY CIMA is a drug delivery company focused primarily on the development and manufacture of pharmaceutical products based upon its patented OraSolv technology. OraSolv is an oral dosage formulation incorporating microencapsulated active drug ingredients into a tablet which dissolves quickly in the mouth without chewing or water and which effectively masks the taste of the medication being delivered. OraSolv's fast-dissolving capability may enable patients in certain age groups or those with a variety of conditions that limit their ability to swallow conventional tablets to receive medication in a more convenient oral dosage form. The Company believes that OraSolv is more convenient than traditional tablet-based oral dosages as it does not require water to be ingested, thereby enabling immediate medication at the onset of symptoms. In addition, OraSolv can provide more accurate administration of doses than liquid or suspension formulations as no measuring is required. The Company believes OraSolv's ability to be easily ingested by patients will foster greater patient compliance, thereby improving therapeutic outcomes and reducing costs in the healthcare system. CIMA's business focus has evolved over the last several years. From inception until 1992, the Company focused on the development of liquid effervescent products and technologies. In 1993, the U.S. patent covering OraSolv was issued and the Company, perceiving greater commercial opportunity, shifted its focus to the development of OraSolv products. CIMA intends to commercialize the OraSolv technology through collaborations with pharmaceutical and other healthcare companies by developing and manufacturing OraSolv formulations of its collaborators' pharmaceutical products. Since the issuance of the OraSolv patent in 1993, the Company has: - Completed construction of a 75,000 square foot manufacturing facility in Eden Prairie, Minnesota, which has been registered with the FDA and licensed by the State of Minnesota. - Entered into a License and Development Agreement with Glaxo Wellcome plc ("Glaxo") to develop an OraSolv version of Glaxo's Zantac. - Entered into a License Agreement and a Development and License Option Agreement with SmithKline Beecham plc ("SmithKline Beecham") to develop a series of OraSolv versions of SmithKline Beecham products for international and domestic distribution. - Entered into agreements with three other potential partners for the development and manufacture of OraSolv products. - Entered into a License and Supply Agreement with Merck & Co., Inc. ("Merck") to provide an AutoLution (a liquid effervescent) version of Merck's Pepcid AC. - Added key scientific, technical and management personnel. The Company's corporate partnerships enable it to focus on the development and manufacture of OraSolv versions of its partners' products, while allowing its partners to focus on the marketing and distribution of OraSolv formulations. Generally, the Company will be responsible for optimizing the taste-masking and microencapsulation of the active drug ingredient, manufacturing the OraSolv tablets containing the active drug, packaging, labeling and performing quality assurance on the finished product, and shipping the product to its partners. The Company's corporate partners will be responsible for marketing, sale and distribution of the OraSolv product to consumers or healthcare professionals. Generally, corporate partners will also be responsible for the collection and submission of required clinical data, and for the management of required federal or international regulatory approvals of collaborative products. The Company's goal is to have its OraSolv technology incorporated into as many pharmaceutical products as possible with an emphasis on pharmaceutical products which command a large market share or are in large market segments. The Company has developed a strategic plan to accomplish this goal. The Company's primary strategies are to: (i) establish collaborations with pharmaceutical and other healthcare companies; (ii) focus initially on OTC products; (iii) pursue OTC switch and prescription drugs; (iv) expand its intellectual property position; (v) retain the manufacturing rights to the products it develops; and (vi) retain ownership of products developed. THE OFFERING Common Stock offered by: The Company...................................... 1,000,000 shares The Selling Stockholders......................... 1,500,000 shares Common Stock Outstanding after the Offering........ 8,840,099 shares (1) Use of Proceeds.................................... For initiation of commercial production; research and development; and working capital and general corporate purposes Nasdaq National Market Symbol...................... CIMA
SUMMARY FINANCIAL DATA (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, ----------------------------------------------------- -------------------- 1991 1992 1993 1994 1995 1995 1996 --------- --------- --------- --------- --------- --------- --------- STATEMENT OF OPERATIONS DATA: Total revenues: Net sales....................................... $ 2,930 $ 3,251 $ 1,857 $ 1,451 $ 151 $ 11 $ -- Research, development and licensing revenues.... 551 445 368 1,167 684 215 392 Costs and expenses: Cost of goods sold............................ 3,339 3,279 2,844 2,799 240 59 -- Research and product development.............. 843 759 1,857 3,549 6,505 2,292 1,376 Selling, general and administrative........... 1,365 1,306 1,208 2,972 3,658 1,019 784 --------- --------- --------- --------- --------- --------- --------- Operating loss.................................... (2,066) (1,648) (3,684) (6,702) (9,568) (3,144) (1,768) Other income (expense), net....................... (249) (34) 4 490 461 166 34 --------- --------- --------- --------- --------- --------- --------- Net loss.......................................... $ (2,315) $ (1,682) $ (3,680) $ (6,212) $ (9,107) $ (2,978) $ (1,734) --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Net loss per share................................ $ (.90) $ (.53) $ (.78) $ (.95) $ (1.16) $ (.39) $ (.22) --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Weighted average number of shares outstanding..... 2,565 3,198 4,727 6,505 7,822 7,541 7,824 --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
DECEMBER 31, 1995 MARCH 31, 1996 ----------------- ------------------------- ACTUAL ACTUAL AS ADJUSTED(2) ----------------- --------- -------------- BALANCE SHEET DATA: Cash and cash equivalents.......................................... $ 3,559 $ 2,517 $ 10,731 Working capital.................................................... 3,147 1,528 9,742 Total assets....................................................... 15,519 14,364 22,578 Accumulated deficit................................................ (29,259) (30,993) (30,993) Total stockholders' equity......................................... 14,282 12,643 20,857
- ------------ (1) Based on shares outstanding as of March 31, 1996. Excludes 1,915,570 shares of Common Stock reserved for issuance pursuant to the Company's stock option plans, under which options to purchase 1,215,334 shares were outstanding as of March 31, 1996, and 106,467 shares of Common Stock issuable pursuant to warrants. See Note 8 to Financial Statements. (2) As adjusted to reflect receipt of the estimated net proceeds from the sale of 1,000,000 shares of Common Stock by the Company at an assumed public offering price of $9.25 per share. See "Use of Proceeds" and "Capitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000835472_dpd_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000835472_dpd_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..ffe196b6661099c37b9f6741a28373f1d892238d
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000835472_dpd_prospectus_summary.txt
@@ -0,0 +1 @@
+Prospectus Summary This Summary is qualified by the more detailed information (including the financial statements and related notes) set forth elsewhere in this Prospectus which should be read in its entirety. Unless the context indicates, or it is specifically indicated otherwise, all references to (i) "Corning" include Corning Incorporated, a New York corporation, and its consolidated subsidiaries, (ii) "Quest Diagnostics" or the "Company" include Corning Clinical Laboratories Inc. (to be renamed Quest Diagnostics Incorporated prior to the Distributions), a Delaware corporation, and its direct and indirect subsidiaries (other than Covance) and assume that the Distributions have occurred, and (iii) "Covance" include Covance Inc. (formerly Corning Pharmaceutical Services Inc.), a Delaware corporation, and its direct and indirect subsidiaries and assume that the Distributions have occurred. Capitalized terms used but not defined in this Summary are defined elsewhere in this Prospectus. The Company Quest Diagnostics is one of the largest independent clinical laboratory testing companies in the United States. Quest Diagnostics offers a broad range of routine and specialty ("esoteric") testing services used by the medical profession in the diagnosis, monitoring and treatment of disease and other medical conditions. Quest Diagnostics' network, which processes approximately 60 million requisitions for diagnostic tests annually, consists of 17 regional laboratories across the United States and the Corning Nichols Institute ("Nichols") esoteric testing laboratory in San Juan Capistrano, California. In addition, Quest Diagnostics has 14 branch laboratories in the United States as well as one branch laboratory in Mexico City (branch laboratories are smaller than regional laboratories), approximately 200 "STAT" laboratories and approximately 850 patient service centers located throughout the United States. For the year ended December 31, 1995 and the nine months ended September 30, 1996, Quest Diagnostics had net revenues of $1,629 million and $1,231 million, respectively, and Adjusted EBITDA (income (loss) before income taxes plus net interest expense, depreciation and amortization and restructuring and other special charges) of $177 million and $135 million, respectively. Quest Diagnostics operates 24 hours a day, 365 days a year, utilizing a fully integrated collection and processing system. Quest Diagnostics generally performs and reports most routine procedures within 24 hours, employing a variety of sophisticated and computerized laboratory testing instruments. Quest Diagnostics provides daily pickup of specimens from most customers principally through an in-house courier system. The specimens are sent to one of the Company's laboratories where one or more tests are performed. Each patient specimen is accompanied by a test requisition form, which is completed by the customer, that indicates the tests to be performed and provides the necessary billing information. Each specimen and related requisition form is checked for completeness and then given a unique bar-coded identification number. Once the appropriate information is entered into the computer system, the tests are performed and the results are delivered to the doctor, primarily through computer interface or manually. Corning entered the clinical laboratory business in 1982 with the acquisition of MetPath Inc. ("MetPath"), which was founded in 1967 and was one of the first laboratories to expand beyond a regional market. Since January 1993, Quest Diagnostics has acquired over thirty laboratories, including Damon Corporation ("Damon"), Bioran Medical Laboratory ("Bioran") and Maryland Medical Laboratory, Inc. ("MML"). In 1994, Quest Diagnostics enhanced its presence in the esoteric testing market through the acquisition of Nichols, a preeminent clinical laboratory with a leading reputation for esoteric testing and test innovations. While Corning's ownership provided the Company with the capital to grow through acquisitions and to become one of the nation's largest independent clinical laboratory testing companies, the management of both Corning and Quest Diagnostics believe that Quest Diagnostics will be more competitive and operate more successfully in the future as an independent company, with a strong, focused and experienced management team to concentrate on customer needs. Independence will also enable Quest Diagnostics to motivate its employees by offering equity-based incentives tied directly to the performance of the Company and individual performance. Quest Diagnostics' management team has implemented a new business strategy, which focuses the business around three key strategic areas: clinical operations, customer focus and technological leadership and excellence. The Clinical Laboratory Testing Industry Clinical testing is a critical component in the delivery of quality health care service to patients. Currently, clinical laboratory testing is the first step in determining how a significant amount of all health care dollars are spent. Quest Diagnostics believes that in 1995 the entire United States clinical laboratory industry had revenues exceeding $30 billion. The clinical laboratory industry consists primarily of three types of providers: hospital-affiliated laboratories, independent clinical laboratories, such as Quest Diagnostics, and physician-office laboratories. The Company believes that in 1995 approximately 56% of the clinical testing revenues in the United States were attributable to hospital-affiliated laboratories, approximately 36% were attributable to independent clinical laboratories and approximately 8% were attributable to physicians in their offices and laboratories. Quest Diagnostics believes that consolidation will continue in the clinical laboratory testing business. In addition, Quest Diagnostics believes that it and the other large independent clinical laboratory testing companies may have the opportunity to increase their share of the overall clinical laboratories testing market due to a number of external factors, including cost efficiencies afforded by large-scale automated testing, Medicare reimbursement reductions and the growth of managed health care entities which require low-cost testing services and large service networks. In addition, legal restrictions on physician referrals and the ownership of laboratories as well as increased regulation of laboratories are expected to contribute to the continuing consolidation of the industry. Quest Diagnostics believes that a number of factors are likely to positively influence the volume of clinical laboratory testing performed in the United States in the future, including (1) the general aging of the population in the United States; (2) an expanded base of scientific knowledge which has led to the development of more sophisticated specialized tests and an increase in the awareness of physicians of the value of clinical laboratory testing as a cost-effective means of early detection of disease and monitoring of treatment; (3) an increase in the number and types of tests which are, due to advances in technology and increased cost efficiencies, readily available on a more affordable basis to physicians; (4) expanded substance-abuse testing by corporations and governmental agencies; and (5) increased testing for sexually transmitted diseases such as AIDS. The impact of these factors is expected to be offset in part by increased controls over the utilization of clinical laboratory tests by both Medicare and the private sector, particularly managed care organizations. Business Strategy Quest Diagnostics' overall goal is to be recognized by its customers, employees and competitors as the best provider of comprehensive and innovative clinical testing, information and services. To achieve this, Quest Diagnostics' management team has focused the business around three key strategic areas: clinical operations, customer focus and technological leadership and excellence. (bullet) Best Supplier. Quest Diagnostics seeks to be the best supplier of the highest quality and the lowest-cost testing services. Health care providers and patients expect accurate, timely and consistent laboratory test results at a fair price. (bullet) Lowest-cost provider. Quest Diagnostics' average cost per requisition varies significantly among its regional laboratories; there is an approximately $7.00 difference in cost per requisition between the most efficient regional laboratory and the average, and an approximately $13.00 difference in cost per requisition between the most and the least efficient regional laboratories. In many cases, these variations do not relate to testing volumes or mixes, space costs, service requirements or regional labor cost differences. To reduce costs, Quest Diagnostics has begun to replicate the best practices from each region throughout its national network. Management expects to achieve significant cost savings within the next three years as these programs are fully implemented. * (bullet) Highest Quality Provider. Quest Diagnostics is dedicated to providing accurate and timely test results and to being viewed by its customers as the highest quality provider of clinical testing services. Quest Diagnostics believes that implementation of best practices already developed in certain regions will permit the Company to be viewed by its customers as the highest quality provider of clinical testing services. (bullet) Preferred Provider. Quest Diagnostics seeks to be the preferred provider of laboratory testing services to existing and new health care networks on a selective basis determined by profitability of accounts. Quest Diagnostics believes that it will become the preferred provider to these networks as (1) large networks typically prefer to utilize large independent clinical laboratories that can service them on a national or regional basis and (2) the Company continues to pursue its primary strategy of becoming the highest quality, lowest-cost provider. To achieve this, Quest Diagnostics will employ a rigorous national and regional process to both select and pursue customers and allocate resources to support these efforts. *This is a forward looking statement and is based on current expectations. Actual results may vary materially from those projected. See "Business- Important Factors Regarding Forward Looking Statements." In particular, see factors (a), (d) and (j). (bullet) Account Profitability. Quest Diagnostics intends to refocus its sales efforts on pursuing and keeping profitable accounts. Quest Diagnostics is actively reviewing the profitability of its current accounts, including those with managed care organizations, and will either increase pricing or eliminate accounts that cannot be serviced profitably. (bullet) Regional Profitability. Quest Diagnostics presently believes that it has the leading market share among independent clinical laboratories in most routine testing markets of the northeast, mid-Atlantic and midwest regions. Approximately 65% of Quest Diagnostics' revenues and almost all of its EBITDA is generated from markets in which the Company believes that it has the leading market share. In most of these markets, Quest Diagnostics believes that it also is the lowest cost provider. Quest Diagnostics is evaluating its strategic alternatives relative to units whose profitability does not meet its internal goals. These alternatives may include joint ventures, alliances, or dispositions. Quest Diagnostics believes that, while the clinical laboratory industry is becoming national in scope, the Company can subcontract with other clinical laboratories to perform testing for national accounts in any markets in which the Company chooses not to compete. (bullet) Leading Innovator. Quest Diagnostics intends to remain a leading innovator in the clinical laboratory industry by continuing to introduce new tests, technology and services. Through its relationship with the academic community and pharmaceutical and biotechnology firms and a research and development budget exceeding $15 million per year, Quest Diagnostics believes it is one of the leaders in transferring innovation from academic biotechnology laboratories to the market. Recent Developments By a plea agreement and civil agreement and release dated October 9, 1996, between the Department of Justice ("DOJ") and Damon, all federal criminal matters within the scope of the various federal investigations against Damon, and all claims including the civil qui tam cases underlying the civil investigations were settled for an aggregate of $119 million, which sum was reimbursed to Quest Diagnostics by Corning. The Damon settlement does not exclude Quest Diagnostics from future participation in any federal health care programs on account of Damon's practices. Quest Diagnostics' aggregate reserve with respect to all governmental and private claims was $215 million at September 30, 1996 and is estimated to be reduced to $85 million as of the Distribution Date as a result of the payment of settled claims, primarily the Damon settlement of $119 million. Based on information available to management and Quest Diagnostics' experience with past settlements (including the fact that the aggregate amount of the Damon settlement was significantly in excess of established reserves) management has reassessed its reserve levels and believes that its current level of reserves is adequate. However, it is possible that additional information may become available which may cause the final resolution of these matters to be in excess of established reserves by an amount which could be material to Quest Diagnostics' results of operations and, for non-indemnified claims, Quest Diagnostics' cash flows in the period in which such claims are settled. While none of the governmental or nongovernmental investigations or claims is covered by insurance, Quest Diagnostics does not believe that these matters will have a material adverse effect on Quest Diagnostics' overall financial condition. Corning Indemnity In connection with the Distributions, Corning has agreed to indemnify Quest Diagnostics against all monetary penalties, fines or settlements arising out of any governmental claims arising out of alleged violations of applicable federal fraud and health care statutes and relating to billing practices of Quest Diagnostics and its predecessors that have been settled or are pending on the Distribution Date. Corning has also agreed to indemnify Quest Diagnostics for 50% of the aggregate of all judgment or settlement payments made by Quest Diagnostics that are in excess of $42.0 million in respect of claims by private parties (i.e., nongovernmental parties such as private insurers) that relate to indemnified or previously settled governmental claims and that allege overbillings by Quest Diagnostics or any existing subsidiaries of Quest Diagnostics, for services provided prior to the Distribution Date; provided, however, such indemnification for nongovernmental claims will not exceed $25.0 million in the aggregate and all amounts indemnified against by Corning for the benefit of Quest Diagnostics will be calculated on a net after-tax basis. Such indemnification will not cover (i) any governmental claims that arise after the Distribution Date pursuant to service of subpoena or other notice of such investigation after the Distribution Date, (ii) any nongovernmental claims unrelated to the indemnified governmental claims or investigations, (iii) any nongovernmental claims not settled prior to five years after the Distribution Date, (iv) any consequential or incidental damages relating to the billing claims, including losses of revenues and profits as a consequence of exclusion for participation in federal or state health care programs or (v) the fees and expenses of litigation. The Distributions On May 13, 1996, the board of directors of Corning approved a plan to distribute to Corning shareholders the clinical laboratory testing business being conducted by Quest Diagnostics and the contract research business being conducted by Quest Diagnostics' wholly owned subsidiary, Covance (together, the "Distributions"). The Distributions will be effected by distributing all of the outstanding shares of Quest Diagnostics common stock (the "Quest Diagnostics Common Stock") to holders of Corning common stock (the "Corning Common Stock"), followed immediately by the distribution of all of the common stock of Covance (the "Covance Common Stock") to those same holders, as holders of Quest Diagnostics Common Stock. It is expected that the Distributions will be made on December 31, 1996 (the date on which the Distributions are to be made, the "Distribution Date"). Prior to the consummation of the offering of the Notes contemplated hereby (the "Offering"), the Company entered into a $450 million senior, secured credit facility (the "Credit Facility"), among the Company, the lenders listed therein, NationsBank, N.A., as Issuing Bank, Wachovia Bank of Georgia, N.A., as Swingline Bank, and Morgan Guaranty Trust Company of New York, as Administrative Agent. The Credit Facility is comprised of a $300 million six-year amortizing term loan ("Tranche A Loan"), a $50 million seven-year term loan ("Tranche B Loan" and together with the Tranche A Loan, the "Term Loans") and a $100 million six-year revolving working capital facility (the "Working Capital Facility"). Corning currently has approximately $1.2 billion of Quest Diagnostics intercompany debt. Approximately $145 million of net proceeds from the Offering, together with the $350 million of borrowings under the Term Loans, will be paid to Corning in satisfaction of a portion of the outstanding intercompany debt. Corning will contribute the remaining intercompany debt to Quest Diagnostics' capital. Borrowings under the Working Capital Facility, substantially all of which is expected to be available as of the Distribution Date, will provide for future working capital needs and other general corporate purposes. The Offering Securities Offered $150,000,000 aggregate principal amount of % Senior Subordinated Notes due December 15, 2006 (the "Notes"). Maturity Date December 15, 2006. Interest Payment Date June 15 and December 15, commencing June 15, 1997. Optional Redemption by the Company The Notes will be redeemable, in whole or in part, at the option of the Company at any time on or after December 15, 2001, at the redemption prices set forth herein, plus accrued and unpaid interest, if any, to but excluding the date fixed for redemption. In addition, if as a result of an event outside the control of Corning, Quest Diagnostics and Covance, the Distributions do not occur prior to March 31, 1997, the Notes will be subject to redemption, as a whole and not in part, at the option of Quest Diagnostics, prior to June 30, 1997, at a redemption price equal to 101% of the principal amount of the Notes, plus accrued and unpaid interest, if any, to but excluding the date fixed for redemption. See "Description of the Notes--Optional Redemption." Change of Control Offer Upon a Change of Control, the Company has the obligation to offer to purchase all the outstanding Notes at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to but excluding the date of purchase. See "Description of the Notes-- Repurchase at the Option of Holders--Change of Control" for a discussion of the circumstances in which the Company may not be required to make an offer to purchase upon a Change of Control. Offers to Purchase In the event of certain asset sales, the Company will be required to offer to repurchase the Notes at 100% of their principal amount, plus accrued and unpaid interest, if any, to but excluding the date of purchase with the net proceeds of such asset sales. Subordination The Notes will be general unsecured obligations of the Company and will be subordinated in right of payment to all existing and future Senior Debt of the Company, including all indebtedness of the Company under the Credit Facility. The Notes will rank Pari Passu in right of payment with any other senior subordinated indebtedness of the Company. Subsidiary Guarantees The Notes will be guaranteed, jointly and severally, and fully and unconditionally, on a senior subordinated basis by the Guarantors (the "Senior Subordinated Guarantees"). The obligations of any Guarantor with respect to its Senior Subordinated Guarantee will be subordinated in right of payment, to the same extent as the obligations of the Company in respect of the Notes, to all existing and future Senior Guarantees, which will include the guarantees of the Credit Facility. The Senior Subordinated Guarantees would also be subordinated to all existing and future indebtedness of the Guarantors if the Senior Subordinated Guarantees were avoided or subordinated in favor of the Guarantors' other creditors. See "Risk Factors--Fraudulent Conveyance." The obligations of a Guarantor under its Senior Subordinated Guarantee will be released in certain circumstances, including if the Guarantor ceases to guarantee the Credit Facility. See "Description of the Notes--Senior Subordinated Guarantees." Principal Covenants The indenture under which the Notes are issued (the "Indenture") will impose certain limitations on the ability of the Company and its subsidiaries to, among other things, incur additional indebtedness, pay dividends or make certain other restricted payments, consummate certain asset sales, enter into certain transactions with affiliates, incur indebtedness that is subordinate in right of payment to any Senior Debt and senior in right of payment to the Notes, enter into leases, incur liens, merge or consolidate with any other person, or sell, assign, transfer, lease, convey or otherwise dispose of all or substantially all of the assets of the Company. Use of Proceeds The Company intends to use the proceeds from the sale of the Notes, together with the proceeds of borrowings under the Credit Facility, to repay certain intercompany indebtedness owed to Corning. See "Use of Proceeds." The Distributions The Notes are being offered in connection with the Distributions of the Quest Diagnostics Common Stock and the Covance Common Stock to holders of Corning Common Stock. The closing of the offering of the Notes is anticipated to occur prior to the Distributions. Listing The Notes have been approved for listing on the New York Stock Exchange, subject to official notice of issuance. Risk Factors See "Risk Factors" for a discussion of certain factors that should be considered in connection with an investment in the Notes.
Summary Financial Data The following table summarizes certain historical and pro forma financial data of Quest Diagnostics at the dates and for each of the periods indicated. The selected financial data as of and for each of the years ended December 31, 1995, 1994 and 1993 have been derived from the audited combined financial statements of (the "Audited Financial Statements") and the notes thereto included elsewhere herein. The selected financial data as of and for the three and nine months ended September 30, 1996 and 1995 have been derived from the unaudited interim combined financial statements of Quest Diagnostics (the "Interim Financial Statements" and, together with the Audited Financial Statements, the "Financial Statements") and the notes thereto included elsewhere herein. In the opinion of Quest Diagnostics management, the unaudited interim combined financial statements include all adjustments, consisting of only normal recurring adjustments, that are necessary for a fair presentation of the financial position and results of operations for these periods. The unaudited interim results of operations for the three and nine months ended September 30, 1996 are not necessarily indicative of the results for the entire year ending December 31, 1996. The selected pro forma financial data have been derived from the unaudited pro forma combined financial information of Quest Diagnostics for the year ended December 31, 1995 and for the three and nine months ended September 30, 1996 (the "Pro Forma Financial Information") and the notes thereto included elsewhere herein. The pro forma statement of operations data gives effect to the Distributions and the Accounting Policy Change (as defined below) as if they had occurred on January 1, 1995 and the pro forma balance sheet data gives effect to the Distributions and the Accounting Policy Change as if they had occurred on September 30, 1996. The pro forma financial data does not purport to represent what Quest Diagnostics' results of operations would have been if the Distributions and the Accounting Policy Change had in fact occurred on such dates, nor does it purport to indicate the future financial position or results of future operations of Quest Diagnostics. The pro forma adjustments are based upon currently available information and certain assumptions that Quest Diagnostics management believes to be reasonable. The summary historical and pro forma financial data set forth below should be read in conjunction with "Selected Historical Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations," the Financial Statements and the notes thereto and the Pro Forma Financial Information and the notes thereto. Three Months Ended September 30, Nine Months Ended September 30, ------------------------------------------------------------------------------------------------ Pro Forma Historical Pro Forma Historical ------------------------------- ------------------------------- 1996(a) 1996 1995 1996(a) 1996 1995 --------------- --------------- --------------- ---------------- ---------------- -------------- (in thousands, except share, per share and percentage data) Statement of Operations Data: Net revenues $ 405,352 $ 405,352 $ 399,959 $ 1,231,290 $1,231,290 $1,239,474 Costs and expenses: Cost of services 255,390 255,390 240,868 768,809 768,809 735,984 Selling, general and administrative 125,190 125,190 181,346(c) 371,439 371,439 399,635(c) Provision for restructuring and other special charges(d) 155,730 155,730 201,730 201,730 45,885 Interest expense, net 12,189 19,866 20,927 36,938 59,887 61,529 Amortization of intangible assets 7,672 10,328 11,293 23,803 31,772 33,678 Other, net 1,837 1,837 1,930 (198) (198) 4,429 --------------- --------------- --------------- ---------------- ---------------- -------------- Total 558,008 568,341 456,364 1,402,521 1,433,439 1,281,140 --------------- --------------- --------------- ---------------- ---------------- -------------- Income (loss) before taxes (152,656) (162,989) (56,405) (171,231) (202,149) (41,666) Income tax expense (benefit) (40,521) (43,553) (17,810) (34,215) (43,280) (3,642) --------------- --------------- --------------- ---------------- ---------------- -------------- Income (loss) before cumulative effect of change in accounting principle (112,135) (119,436) (38,595) (137,016) (158,869) (38,024) Cumulative effect of change in accounting principle --------------- --------------- --------------- ---------------- ---------------- -------------- Net income (loss) $ (112,135) $ (119,436) $ (38,595) $ (137,016) $ (158,869) $ (38,024) =============== =============== =============== ================ ================ ============== Pro forma shares outstanding(e) 28,901,735 28,901,735 Pro forma net loss per share $ (3.88) $ (4.74) Balance Sheet Data (at end of period): Cash $ 40,000 $ 48,319 $ 46,908 $ 40,000 $ 48,319 $ 46,908 Working capital 306,741 114,718 129,319 306,741 114,718 129,319 Total assets 1,612,459 1,886,378 1,896,058 1,612,459 1,886,378 1,896,058 Long-term debt 515,494 1,219,900 1,114,367 515,494 1,219,900 1,114,367 Total debt 517,379 1,231,785 1,226,211 517,379 1,231,785 1,226,211 Stockholder's equity 604,099 132,670 320,576 604,099 132,670 320,576 Ratio of earnings to fixed charges -- (f) -- (f) -- (f) -- (f) -- (f) -- (f) Supplemental Data: Net cash provided by operating activities $ 25,236 $ 25,236 $ 38,202 $ 41,937 $ 41,937 $ 53,789 Net cash used in investing activities (7,904) (7,904) (17,044) (53,097) (53,097) (77,911) Net cash provided by (used in) financing activities (6,618) (6,618) (18,006) 23,033 23,033 32,311 Bad debt expense $ 30,539 $ 30,539 $ 85,831(c) $ 81,891 $ 81,891 $ 127,297(c) Bad debt expense as a % of net revenues 7.5% 7.5% 21.5% 6.7% 6.7% 10.3% Rent expense $ 12,515 $ 12,515 $ 11,860 $ 37,315 $ 37,315 $ 35,060 Capital expenditures 11,912 11,912 16,441 58,802 58,802 56,062 Depreciation expense $ 14,672 $ 14,672 $ 14,275 $ 43,460 $ 43,460 $ 42,358 EBITDA(g) $ (118,123)(h) $ (118,123)(h) $ (9,910)(c) $ (67,030)(h) $ (67,030)(h) $ 95,899(c) EBITDA as a % of net revenues (29.1%) (29.1%) (2.5%) (5.4%) (5.4%) 7.7% Adjusted EBITDA(i) $ 37,607 $ 37,607 $ (9,910)(c) $ 134,700 $ 134,700 $ 141,784(c) Adjusted EBITDA as a % of net revenues 9.3% 9.3% (2.5%) 10.9% 10.9% 11.4% Supplemental Ratio Data: Adjusted EBITDA/interest expense, net 3.1x 3.6x (Adjusted EBITDA-capital expenditures)/interest expense, net 2.1x 2.1x (Total debt--cash)/annualized adjusted EBITDA 3.2x 2.7x
(Footnotes on page 14) Year Ended December 31, ----------------------------------------------------------- Pro Forma Historical ------------------------------------------- 1995(a) 1995 1994(b) 1993 --------------- --------------- ------------- ------------- (in thousands, except share, per share and percentage data) Statement of Operations Data: Net revenues $ 1,629,388 $1,629,388 $1,633,699 $1,416,338 Costs and expenses: Cost of services 980,232 980,232 969,844 805,729 Selling, general and administrative 523,271(c) 523,271(c) 411,939 363,579 Provision for restructuring and other special charges(d) 50,560 50,560 79,814 99,600 Interest expense, net 50,748 82,016 63,295 41,898 Amortization of intangible assets 34,031 44,656 42,588 28,421 Other, net 6,221 6,221 3,464 6,423 --------------- --------------- ------------- ------------- Total 1,645,063 1,686,956 1,570,944 1,345,650 --------------- --------------- ------------- ------------- Income (loss) before taxes (15,675) (57,568) 62,755 70,688 Income tax expense (benefit) 6,835 (5,516) 34,410 25,929 --------------- --------------- ------------- ------------- Income (loss) before cumulative effect of change in accounting principle (22,510) (52,052) 28,345 44,759 Cumulative effect of change in accounting principle (10,562) --------------- --------------- ------------- ------------- Net income (loss) $ (22,510) $ (52,052) $ 28,345 $ 34,197 =============== =============== ============= ============= Pro forma shares outstanding(e) 28,901,735 Pro forma net loss per share $ (0.78) Balance Sheet Data (at end of period): Cash $ 36,446 $ 38,719 $ 39,410 Working capital 200,740 214,358 139,771 Total assets 1,853,385 1,882,663 1,861,162 Long-term debt 1,195,566 1,153,054 1,025,787 Total debt 1,207,714 1,165,626 1,123,307 Stockholder's equity 295,801 386,812 395,509 Ratio of earnings to fixed charges -- (f) -- (f) 1.77(f) 2.20(f) Supplemental Data: Net cash provided by operating activities $ 85,828 $ 85,828 $ 37,963 $ 99,614 Net cash used in investing activities (93,087) (93,087) (46,186) (473,687) Net cash provided by (used in) financing activities 4,986 4,986 7,532 392,956 Bad debt expense $ 152,590(c) $ 152,590(c) $ 59,480 $ 47,240 Bad debt expense as a % of net revenues 9.4% 9.4% 3.6% 3.3% Rent expense $ 46,900 $ 46,900 $ 49,400 $ 46,900 Capital expenditures 74,045 74,045 93,354 65,317 Depreciation expense $ 56,857 $ 56,857 $ 46,929 $ 38,058 EBITDA(g) $ 125,961(c) $ 125,961(c) $ 215,567 $ 179,065 EBITDA as a % of net revenues 7.7% 7.7% 13.2% 12.6% Adjusted EBITDA(i) $ 176,521(c) $ 176,521(c) $ 295,381 $ 278,665 Adjusted EBITDA as a % of net revenues 10.8% 10.8% 18.1% 19.7% Supplemental Ratio Data: Adjusted EBITDA/interest expense, net 3.5x (Adjusted EBITDA-capital expenditures)/ interest expense, net 2.0x
(Footnotes on page 14) (Footnotes for preceding pages) (a) Adjusted to reflect the pro forma effects of the Distributions and the Accounting Policy Change. See "Selected Historical Financial Data" and "Pro Forma Financial Information."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000837472_boundless_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000837472_boundless_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..209067ed0dc7adc8c1f5ed2e69dc50fdbbb16274
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000837472_boundless_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements and notes thereto appearing elsewhere in this Prospectus. Unless the context otherwise requires, references to the Company in this Prospectus include the Company and its direct and indirect subsidiaries including SunRiver Data Systems, Inc., the Company's principal operating subsidiary. The Company The Company is engaged, through operating subsidiaries, in designing and manufacturing graphics and text computer terminals for business use and in developing Internet software for use by businesses. The Company's general strategy is to be a provider of devices which provide access to corporate network computing environments and software for secure, private communications and electronic commerce over the Internet. The Company has two operating subsidiaries, SunRiver Data Systems, Inc. ("SunRiver Data") and TradeWave Corporation ("TradeWave"). SunRiver Data designs, assembles, sells and supports general purpose desktop computer display terminals, which generally do not have graphics capabilities but some of which have limited graphics capabilities ("General Display Terminals"); high resolution high performance desktop network graphics display terminals ("Network Graphics Displays") (this product was formerly referred to by the Company as "X-Terminals") based on the X-Terminal protocol; and desktop high performance alternatives to personal computer and other terminal products in multi-user, personal computer and minicomputer-based environments ("MultiConsole Terminals"). In addition, a partnership (the "GAI Partnership") formed by SunRiver Data and General Automation, Inc. ("GAI") and managed by GAI designs, integrates, sells and supports multi-user computer systems that can manage large volumes of data running SunRiver Data's and GAI's versions of a data-based system licensed from Pick Systems. These products and services are offered solely to businesses. In October 1995, SunRiver Data acquired assets relating to the General Display Terminal products of Digital Equipment Corporation ("Digital") sold under the "VT(R)" and "Dorio(R)" brands (excluding the VT 400 Series) and, as a result, based on published 1994 industry data, the Company believes that SunRiver Data is the second largest manufacturer of General Display Terminals in the world with an installed user base of more than 5,000,000 units. TradeWave develops and sells Internet software products and value-added network services which enable desktop computer users to conduct commercial transactions by way of the Internet. The Company entered into the General Display Terminal and Network Graphics Displays businesses in December, 1994 when the Company purchased Applied Digital Data Systems, Inc. ("ADDS"), which subsequently changed its name to SunRiver Data Systems, Inc., from NCR Corporation (formerly AT&T Global Information Solutions Company) ("NCR" or "AT&T-GIS"). For more than 25 years, ADDS has been a supplier of General Display Terminals and Network Graphics Displays worldwide under either the customer's or ADDS(R) trademark. Simultaneously with the Company's acquisition of ADDS, the Company acquired all of the assets and business of SunRiver Group, Inc. ("SunRiver Group"). Prior to this acquisition, SunRiver Group had been engaged for more than nine years in the development and manufacture of software and hardware for MultiConsole Terminals. SunRiver Group was a pioneer in the development of high-speed multi-console terminals for open system, multi-user platforms. As a result of the Company's acquisition of ADDS and the assets of SunRiver Group, SunRiver Group owns approximately 60% of the Company's outstanding Common Stock (inclusive of 4,174,704 shares underlying warrants). SunRiver Data offers standard and custom models of its General Display Terminals primarily to retail, financial, telecommunications and wholesale distribution businesses requiring them for data entry and point of sale activities. Standard and custom model Network Graphics Displays are sold by SunRiver Data primarily to telecommunications and financial businesses requiring the ability to provide concurrent information to customers on a variety of topics, such as billing, credit history and other account information. MultiConsole Terminals are typically used by small to medium sized businesses, such as chain stores, requiring predominantly transaction-oriented applications. Sales of systems by the GAI Partnership are primarily to large distribution centers, retail establishments, manufacturers, local governments and data-bases for credit and collection, which require management of large volumes of data. TradeWave develops, markets, licenses and supports software and services that allow businesses to design, build and deploy secure intranet applications and Internet-based electronic commerce systems. Its TradeVPI suite of products and services, introduced in March 1996, provides all the tools necessary for a company to build a "virtual private Internet" for secure business-to-business communications over the public Internet. TradeWave's products have not yet gained widespread commercial acceptance. TradeWave commenced operations in April 1995, when it acquired technology, and the personnel who developed that technology, from the Microelectronics and Computer Technology Corporation ("MCC") and became an associate member of MCC. MCC is a research and development consortium whose members include AT&T, Motorola, Kodak and Digital. The Company was incorporated in Delaware in 1988. Prior to November, 1995, the Company was known as All-Quotes, Inc. The Company's executive offices are located at Echelon IV, Suite 200, 9430 Research Boulevard, Austin, Texas 78759-6543, and its telephone number is (512) 349-5800. Before making an investment in the Common Stock, prospective purchasers should carefully consider certain factors set forth under "Risk Factors." The Offering Common Stock Offered by the Company . . . . . . 2,500,000 shares Offered by Selling Stockholders. . 11,944,210 shares Common Stock Outstanding . . . . . . . . . 47,270,726 shares(1) Common Stock to be Outstanding After the Offering . . . . . . . . 50,545,337 shares(2)(3) Use of Proceeds . . . . . . . . . . . . . The Company will not receive any proceeds from the sale of Common Stock offered by the Selling Stockholders. All or a portion of the shares offered by the Company may either be issued in satisfaction of obligations of TradeWave to MCC and SunRiver Data to NCR or be sold, and the proceeds used, for such purposes. Any remaining shares may be sold by the Company, and the proceeds used, for additional working capital or for other corporate purposes. See "Reorganization-TradeWave Acquisition" and "Recent Developments -Restructuring of Obligations to NCR" and "Use of Proceeds." The Nasdaq SmallCap Market Symbol . . . SRVC - ---------------------------- (1) As of July 3, 1996. Excludes 12,633,679 shares issuable upon exercise of outstanding warrants and options at prices ranging from $1.35 to $8.25 per share (subject to adjustment), and warrants the Company expects to issue to SunRiver Group, with an exercise price of $3.875 per share, in connection with SunRiver Data's acquisition of assets from Digital. See "Reorganization-Financing for the Digital Acquisition," "Management-Executive Compensation" and "Security Ownership of Certain Beneficial Owners and Management." (2) Excludes 12,065,679 shares issuable upon exercise of outstanding warrants and options at prices ranging from $1.35 to $8.25 per share, and includes 568,000 shares offered hereby and issuable upon exercise of warrants at prices ranging from $1.35 to $6.60 per share (subject to adjustment), and the maximum of 206,611 shares issuable to Digital depending on the closing price of the Common Stock on the date of this Prospectus. See "Recent Developments - Purchase of Digital's Assets" and "Selling Stockholders."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000851397_etec_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000851397_etec_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..5c04e90da05dd01abbc360eb831b622cad00469a
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000851397_etec_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information, including "Risk Factors" and the consolidated financial statements and notes thereto, appearing elsewhere in this Prospectus. THE COMPANY Etec Systems, Inc. ("Etec" or the "Company") is the world leader in the production of mask pattern generation equipment for the semiconductor industry. Etec designs, develops, manufactures and markets equipment that produces high precision masks, which are used to print circuit patterns onto semiconductor wafers. Etec sells its MEBES electron beam systems and its CORE and ALTA laser beam systems at prices currently ranging from approximately $2.5 million to $7.5 million each and accessories and upgrades at prices currently ranging from approximately $1.5 million to $5.0 million each. The Company also derives significant revenues from service and support of its installed base of systems. The Company believes that over 230 commercial electron beam and laser beam mask pattern generation systems are currently installed outside the former Eastern Bloc, of which over 155 have been produced by Etec. The Company believes that advanced masks and mask pattern generation tools are becoming strategically important to the advancement of semiconductor technology. During the second half of the 1980s and the beginning of the 1990s, the maskmaking equipment industry experienced an extended period of slow growth, primarily as a result of several advances in semiconductor production methods that sharply reduced the number of mask units required and the precision requirements for masks. The effects of these advances in production methods have largely run their course, which the Company believes will result in mask demand more closely correlating with semiconductor demand. In addition, as semiconductor devices have become more complex, the semiconductor manufacturing process has become very sensitive to mask errors, requiring more complex masks and, as a result, increasingly sophisticated mask pattern generation tools. The Company is the only maskmaking equipment manufacturer currently offering both electron beam and laser beam systems. The Company believes that the different performance and cost characteristics of electron beam and laser beam systems satisfy the broad range of technical requirements and cost sensitivities of its customers. The Company's systems are designed to provide a low cost of ownership through high performance, reliability and ease of maintenance. The Company's goal is to maintain its leadership position in pattern generation for the semiconductor market and leverage its expertise to pursue other opportunities in high performance imaging. To maintain technology leadership, the Company intends to continue to work closely with major customers and seek strategic alliances with other semiconductor industry participants to identify the leading-edge requirements for semiconductor maskmaking. In addition, Etec plans to develop or acquire lithography-related products that serve other markets having technology and market links with its business, such as direct imaging and maskmaking for large-area applications. In furtherance of this strategy, the Company acquired substantially all of the assets of Polyscan, Inc. ("Polyscan"), a developer of laser direct imaging systems for large-area pattern generation applications, in February 1996. The Company also intends to continue to emphasize the compatibility of its new systems with its installed systems and to provide superior technical service and support to its customers. The Company's customers include merchant maskmakers such as Dai Nippon Printing Co. Ltd., DuPont Photomasks, Inc., Photronics, Inc. and Toppan Printing Company, Ltd., and semiconductor manufacturers with captive mask shops, such as International Business Machines Corporation, Intel Corporation ("Intel"), Samsung Electronics Co., Ltd. and Sony Corporation. Concurrently with the completion of this offering, Intel will purchase $10.0 million of the Company's Common Stock and will receive warrants to purchase additional shares of Common Stock. The Company markets and distributes its products directly into North America, Japan, South Korea and Europe through its sales offices in California, Japan, South Korea and France. Customers in Southeast Asia, China and India are currently covered by sales representatives with assistance by the Company's sales and marketing staff in California. THE OFFERING Common Stock offered by the Company............... 500,000 shares Common Stock offered by the Selling Stockholders.. 4,100,000 shares Common Stock to be outstanding after the offering. 18,864,892 shares(1) Use of proceeds................................... For capital expenditures and for general corporate purposes including working capital. Nasdaq National Market symbol..................... ETEC
- -------- (1) Includes 289,855 shares to be sold to Intel pursuant to a private placement concurrently with the consummation of this offering, based on an assumed offering price of $34.50. See "Investment by Intel." Excludes shares of Common Stock issuable upon exercise of stock options of 1,464,233 as of April 30, 1996 and 376,997 shares issuable upon exercise of warrants. Also excludes warrants to purchase 15% of the number of shares of Common Stock purchased by Intel, to be issued to Intel concurrently with such purchase. See "Capitalization" and Note 5 and Note 9 of Notes to Consolidated Financial Statements. SUMMARY CONSOLIDATED FINANCIAL DATA (in thousands, except per share amounts) PRO NINE FORMA MONTHS NINE ENDED MONTHS YEAR ENDED JULY 31, APRIL 30, ENDED ------------------------- ------------------ APRIL 30, 1993 1994 1995(1) 1995 1996(2)(3) 1996(4) -------- ------- ------- ------- ---------- --------- STATEMENT OF OPERATIONS DATA: Revenue................. $ 58,582 $68,710 $82,916 $61,045 $98,035 $98,035 Gross profit............ 16,644 25,481 35,297 25,623 43,635 43,635 Write-off of in-process technology acquired(5). -- -- -- -- 6,269 -- Income (loss) from operations............. (4,439) 9,576 11,403 9,477 10,402 15,540 Income (loss) before income tax provision (benefit), minority interest and extraordinary items.... (9,530) 4,390 7,340 6,011 11,083 16,429 Net income (loss)....... (11,409) 1,612 9,936 4,018 21,846 27,192 Net income (loss) per share.................. $ (0.94) $ 0.12 $ 0.68 $ 0.28 $ 1.23 $ 1.51 Weighted average common shares(6).............. 12,168 14,008 14,594 14,594 17,750 17,996
APRIL 30, 1996 ------------------------------------ PRO FORMA AS ACTUAL PRO FORMA(7) ADJUSTED(7)(8) -------- ------------ -------------- BALANCE SHEET DATA: Cash and investments....................... $ 40,996 $ 50,996 $ 66,983 Working capital............................ 74,052 84,052 100,039 Total assets............................... 157,482 168,082 184,069 Long-term debt, less current portion....... 7,625 7,625 7,625 Total stockholders' equity................. 73,377 83,977 99,964
- -------- (1) Net income (loss) reflects the inclusion of an extraordinary gain of $5.4 million recorded as a result of the early extinguishment of $19.7 million of subordinated notes payable and accrued interest. See Note 3 of Notes to Consolidated Financial Statements. (2) Net income (loss) reflects the inclusion of an extraordinary loss of $300,000 recorded as a result of the early extinguishment of $5.0 million of secured notes payable. (3) Net income (loss) reflects a $15.4 million tax benefit realized as a result of reversing a portion of the Company's valuation allowance associated with certain deferred tax assets. See Note 6 of Notes to Consolidated Financial Statements. (4) Pro forma statement of operations data reflects the consolidated results of the Company after giving effect to the acquisition of substantially all of the assets and certain specified liabilities of Polyscan assuming that the acquisition took place on August 1, 1995. (5) In 1996, the Company wrote off $6.3 million of in-process technology in conjunction with its acquisition of substantially all of the assets and certain specified liabilities of Polyscan. See Note 13 of Notes to Consolidated Financial Statements. (6) Computed on the basis described in Note 1 of Notes to Consolidated Financial Statements. (7) Pro forma balance sheet data reflects the sale of $10.0 million of Common Stock to Intel at an assumed price of $34.50 per share and the issuance of warrants to Intel. See "Investment by Intel." (8) Reflects the event specified in footnote (7) above, and as adjusted to reflect the sale by the Company of the 500,000 shares of Common Stock being offered hereby after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by the Company, and the application of the estimated net proceeds therefrom as set forth under "Use of Proceeds." See "Capitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000852203_cbre_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000852203_cbre_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..3843c97fbff340b2b13006935e7fbe8768770cab
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000852203_cbre_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and consolidated financial statements and related notes appearing elsewhere in this Prospectus. Prospective investors should carefully consider the matters set forth in "Risk Factors." Except as set forth in the consolidated financial statements and notes thereto or otherwise as specified herein, all information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. Effective upon consummation of the Offering, the Company will change its name from CB Commercial Holdings, Inc. to CB Commercial Real Estate Services Group, Inc. Unless the context requires otherwise, the term the "Company" or "CB Commercial" means CB Commercial Real Estate Services Group, Inc. and each of its consolidated subsidiaries. COMPANY OVERVIEW Founded in 1906, the Company believes that it is the largest vertically- integrated commercial real estate services company in the United States with aggregate 1995 revenue of $468.5 million and 231 business unit offices in 107 locations. In addition, the Company has established exclusive alliances with international commercial real estate service firms which have offices in an additional 109 locations in 30 countries. These relationships are reciprocal referral arrangements whereby the Company's clients who require services in a geographic region serviced by its alliance partners must be referred by the Company to its alliance partner operating in that region. Conversely, the Company's alliance partners are obligated to refer their clients with commercial real estate needs in the United States to the Company. These alliances have not generated significant revenues to date. The Company provides a full range of services to commercial real estate tenants, owners, and investors including: (i) brokerage (facilitating sales and leases), investment properties (acquisitions and sales on behalf of investors), corporate services, property management, and real estate market research (collectively, "Property and User Services"), and (ii) mortgage banking (mortgage loan origination and servicing), investment management and advisory services, and valuation and appraisal services (collectively, "Investor Services"). The Company believes that, on the basis of revenues, its brokerage and independent commercial mortgage origination businesses are the largest such businesses in the United States, and that the Company is among the top ten providers of commercial property management, investment management and advisory services and commercial mortgage loan servicing in the United States. The Company's diverse client base includes local, national and multinational corporations, financial institutions, pension funds and other tax exempt entities, local, state and national governmental entities, and individuals. The Company believes that it enjoys a variety of competitive advantages in the commercial real estate services industry, including the Company's-- . Significant deal flow and strong market presence in its core brokerage and property management businesses, both of which are employed for the benefit of all of the Company's business disciplines; . 90-year tradition and history of providing high-quality services and client coverage and internationally recognized "brand" identity which the Company believes is widely respected in the real estate services industry; . Experienced and trained professionals in all business disciplines, including almost 2,000 sales professionals in Property and User Services who have an average tenure of more than eight years with the Company; . Multi-discipline capabilities and extensive multi-market network; . State-of-the-art technology and professional education programs which enable the Company to deliver superior services; . Experienced management team, the members of which have an average tenure of more than 16 years with the Company and will own approximately 15.2% of the Company's Common Stock (including exercisable stock options and shares held through the Company's Deferred Compensation Plan) after the Offering; and . Employees who will own more than 40% of the Company's Common Stock after the Offering. As part of its growth strategy, the Company is continually assessing acquisition opportunities. Management believes that there are significant opportunities in the fragmented and consolidating real estate services industry to acquire additional companies to complement and expand the Company's existing operations. Since the beginning of 1995, the Company has completed three strategic acquisitions. In July 1996, the Company acquired L.J. Melody & Company and L.J. Melody & Company of California (collectively "L.J. Melody"), a nationally-known mortgage banking firm, for $15 million. The L.J. Melody acquisition provides the Company with leadership for its own mortgage banking business, access to loan sources not previously available to the Company and an enhanced ability to access the Company's deal flow in its investment properties and brokerage businesses as a source of mortgage originations. In June 1995, the Company acquired Westmark Realty Advisors L.L.C. ("Westmark"), an investment management and advisory business with approximately $3.0 billion of assets under management, for $37.5 million, plus a supplemental purchase price component of up to $18.0 million based upon Westmark's adjusted operating income. The Westmark acquisition has moved the Company into a business area which the Company believes has the potential for significant growth. In April 1995, the Company acquired Langdon Rieder Corporation ("Langdon Rieder"), a nationally-known tenant representation firm, for $1.5 million in cash and a deferred payment of $1.9 million payable over three years. The deferred payment is subject to forfeiture under certain circumstances. The Langdon Rieder acquisition strengthened the Company's ability to provide sophisticated tenant representation services to its corporate clients. See "Business--Acquisitions." INDUSTRY TRENDS Over the last ten years, the commercial real estate industry has experienced various structural changes and more recently has been experiencing a broad recovery from the real estate "depression" of the early 1990s. The Company believes that these factors and the resulting trends, which are summarized below, create an opportunity for the Company to leverage its experience, multi- discipline integrated services, multi-market presence and brand equity to its competitive advantage-- . CHANGING COMPOSITION AND NEEDS OF INVESTORS AND OWNERS. Investors in and owners of commercial real estate assets have become increasingly institutional (including pension funds, life insurance companies, banks and publicly-held REITs) with geographically diverse portfolios. With respect to institutions other than REITs, this change in the ownership characteristics and management requirements of institutional real estate investors and owners has fueled the demand for, and growth of, sophisticated multi- service, nationally-oriented real estate service providers. As REITs are internally managed and therefore tend to outsource only their brokerage services, their demand for the Company's other real estate services is expected to be less than that of other institutional investors. . CONTINUING OUTSOURCING TREND. The Company believes that the combination of corporate managements' heightened awareness that corporate real estate assets are a major component of corporate net worth and competitive pressures encouraging a greater focus on core businesses has caused corporations to downsize and, as a result, outsource their non-core activities to third-parties. As a consequence, the demand for multi- disciplined, multi-market professional real estate services firms that provide integrated services capable of supplementing a corporate real estate department has increased significantly. . ONGOING INDUSTRY CONSOLIDATION. The Company also believes that the combination of institutional and corporate real estate service needs and demands, together with the real estate "depression" of the early 1990s, has made it necessary for real estate services firms to (i) provide comprehensive, high-quality services, (ii) make significant investments in corporate infrastructure, including information technology and professional education, and (iii) have access to sufficient capital to support these service and investment needs. These factors have fueled the consolidating industry environment, which the Company believes will motivate local and regional real estate service providers to sell to, or form alliances with, major national and international companies. . EXPANDING CMBS MARKET. Wall Street firms and financial institutions have recently been providing a significant amount of third-party commercial mortgage financing and have been accessing the public debt markets by issuing commercial mortgage-backed securities ("CMBS") in order to securitize their portfolios and avoid holding mortgage loans for the long-term, resulting in increasing liquidity in the real estate markets. The Company's access to real estate transaction deal flow and national mortgage origination capabilities enable it to benefit from this expansion of the CMBS market which creates demand for mortgage originations. . RECOVERING MARKETS. Coincident with the long term structural shifts in the commercial real estate industry, commercial real estate markets in the United States have been recovering over the last several years, experiencing increased leasing and sale activity in many product types and geographic market areas. As a result, brokerage and property management fees, which are based upon a percentage of transaction value and total rent collections, respectively, have begun to increase. THE COMPANY'S BUSINESSES PROPERTY AND USER SERVICES Property and User Services include a broad range of services, delivered primarily to users and owners of commercial real estate, including brokerage (facilitating sales and leases), investment properties (acquisitions and sales on behalf of investors), corporate services, property management, and real estate market research. These services are provided with respect to a wide range of commercial real estate properties, including, but not limited to, office space, industrial buildings, retail properties, multifamily residential properties and unimproved land. Brokerage. Brokerage, the Company's original and core business, advises buyers, sellers, landlords and tenants in connection with the leasing and sale of office space, industrial buildings, retail properties, multifamily residential properties and unimproved land. Brokerage employs approximately 1,640 sales professionals nationally generating significant deal flow and real-time market data. This market presence provides the Company with a competitive advantage in developing business opportunities and client contacts and in developing CB Commercial's brand identity for the Company's other business disciplines. The Company believes its commercial brokerage business is the market-leader in the United States based upon both 1995 revenue, which totaled approximately $294.3 million, and the number of completed transactions, which totaled approximately 19,800. Investment Properties. The Company provides sophisticated strategic planning for, and execution of, acquisitions and sales of income-producing commercial properties for its clients through its investment properties sales professionals. In 1995, approximately 1,000 sales transactions were completed with some of the country's largest and most sophisticated investors, including, as examples, Prudential Insurance Co., RREEF and Security Capital. With aggregate estimated sales consideration of more than $4.0 billion in 1995, the Company believes that it is one of the largest providers of investment properties sales services in the United States. Corporate Services. Corporate services, which generally operates through the CBC/Madison Advisory Group, addresses the multiple-market domestic and international real estate needs of corporate America by providing comprehensive, quality services on a cost efficient basis through a single point-of-contact at the Company. Corporate services coordinates the utilization of all the Company's various disciplines to deliver an integrated service to some of the largest and most sophisticated companies in the United States, including, as examples, Eastman Kodak, Ford Motor Company, and Allstate Insurance Company. CBC/Madison Advisory Group directly addresses client demand driven by corporate downsizing, outsourcing, and alliance partnering, expanding a client's real estate department and performing most of the functions involved in corporate real estate administration. CBC/Madison Advisory Group has been one of the Company's fastest growing services, with revenue having increased at a compound annual rate of 50% from 1993 through 1995. Property Management. Property management provides operations, maintenance, marketing and leasing services for income-producing properties owned primarily by institutional investors. The Company provides asset management-oriented services to its clients to implement their specific goals and objectives, focusing on the enhancement of property values through maximization of cash flow. The Company was recently ranked the eighth largest property management firm in the United States by National Real Estate Investor's 1996 Annual Survey based on square footage under management during 1995. As of September 30, 1996, the Company managed 792 properties aggregating approximately 104 million square feet. Real Estate Market Research. The Company provides its research and forecasting services to its other businesses as well as outside corporate and institutional investor clients through CB Commercial/Torto Wheaton Research, the widely-recognized research division of the Company based in Boston, Massachusetts. The Company's research reports and forecasts are utilized by all of the Company's businesses to assist clients with analysis and interpretation of market data in order to provide them with a competitive edge in the rapidly changing real estate marketplace. The Company's publications and products provide real estate data for more than 50 of the largest Metropolitan Statistical Areas ("MSAs") in the United States and are sold on a subscription basis to many of the largest portfolio managers, insurance companies and pension funds in the United States. INVESTOR SERVICES Investor Services includes mortgage banking (mortgage loan origination and servicing), investment management and advisory services, and valuation and appraisal services relating primarily to office space, industrial buildings, retail properties, multifamily residential properties and unimproved land. Mortgage Banking. The Company provides its mortgage origination and servicing through L.J. Melody, a wholly-owned subsidiary of the Company acquired in July 1996 and based in Houston, Texas. On a combined basis including originations by L.J. Melody prior to its acquisition, the Company originated approximately $2.3 billion, $2.0 billion and $1.1 billion of mortgage loans in 1995, 1994 and 1993, respectively. As part of these origination activities, the Company originates mortgages through special conduit arrangements with affiliates of Merrill Lynch, Citicorp, and Lehman Brothers which permit it to service the mortgage loans that it originates and is currently negotiating a similar arrangement with an affiliate of NationsBank. In addition, the Company is a major mortgage originator for insurance companies having originated, on a combined basis, mortgage loans in the names of the insurance companies valued at approximately $1.6 billion in 1995, of which it serviced $891.4 million. As of December 31, 1995, 1994 and 1993, the Company, on a combined basis, serviced mortgage loan portfolios of approximately $7.3 billion, $7.1 billion and $6.3 billion, respectively. Based upon available statistics, the Company believes that, on a combined basis, it is the largest independent commercial mortgage originator in the United States (originating mortgage loans for others, as opposed to originating mortgage loans for its own account). As of December 31, 1995, the Company, on a combined basis, was the eighth largest commercial mortgage loan servicer in the United States. The Company believes it will have a significant competitive advantage in the commercial mortgage loan origination business due to its anticipated integration with the deal flow generated through the Company's brokerage and investment properties sales activities. This integration will not only provide advantages to mortgage banking, but will also facilitate sales transactions enhancing the Company's capability to execute clients' sales assignments. Investment Management and Advisory. The Company provides its investment management and advisory services primarily to large institutions and pension funds through Westmark which employs over 100 professionals and operates nationally from its headquarters in Los Angeles, California. Westmark operates as a separate and independent subsidiary, providing advisory services and managing approximately $3.7 billion in tax-exempt capital invested in more than 220 office, industrial and retail properties located in more than 40 major U.S. markets with an aggregate of more than 40 million square feet. The Company's investment management and advisory activities include creating investment products, raising investor capital, identifying and acquiring specific properties and managing the operations and dispositions of the assets. As of September 30, 1996, the Company represented more than 180 investors in 13 commingled funds and a variety of nondiscretionarily managed separate accounts. Valuation and Appraisal Services. Valuation and appraisal services delivers sophisticated commercial real estate valuations through a variety of products including market value appraisals, portfolio valuations, discounted cash flow analyses, litigation support, feasibility land use studies and fairness opinions. The Company's appraisal staff has more than 80 professionals with approximately 50% of its professionals holding the Member Appraisal Institute ("MAI") professional designation. Valuation and appraisal services operates nationally through 21 regional offices, and its clients are generally portfolio owners, both corporate and institutional. The Company believes it is among the leading commercial real estate appraisal firms in the United States. THE OFFERING Common Stock offered by the Compa- 4,347,000 shares(1) ny................................ Common Stock to be outstanding af- 13,266,171 shares(1)(2) ter the Offering.................. Use of proceeds.................... The net proceeds from the Offering will be used to repay a portion of the Company's senior secured indebtedness and to pay accrued and unpaid interest on the Company's senior subordinated indebtedness. Any remaining net proceeds will be used for general corporate purposes, including to fund acquisitions. See "Use of Proceeds." Listing............................ The Common Stock has been approved for listing on the Nasdaq National Market under the symbol "CBCG."
- -------- (1) Does not include up to 652,050 shares subject to an over-allotment option granted to the Underwriters by the Company. See "Underwriting." (2) Excludes (i) 1,046,890 shares issuable upon exercise of stock options under the Company's stock option plans as of September 30, 1996, (ii) shares of Class C-R and Class J common stock to be repurchased by the Company for an aggregate of $8,000 in connection with the Offering and (iii) 4,000,000 shares of Preferred Stock convertible into a lesser number of shares of Common Stock at the option of the holder after the Offering, which number will not exceed 3,120,000 (assuming there are no dilutive issuances requiring adjustment under the Certificates of Designation for such Preferred Stock). Includes 444,444 shares of Common Stock issuable upon conversion of the 800,000 shares of the Company's Class C-1 common stock (assuming an initial public offering price per share of $22.50). See "Capitalization" and "Description of Capital Stock--Preferred Stock" and "--The Recapitalization." SUMMARY CONSOLIDATED FINANCIAL AND OTHER DATA The following table sets forth summary financial and other data for the Company on a consolidated historical basis and a consolidated pro forma basis for the periods and dates indicated. The summary historical balance sheet data as of December 31, 1995 and 1994 and the statement of operations data for each of the three years in the period ended December 31, 1995 are derived from the financial statements of the Company that have been audited by Arthur Andersen LLP, independent public accountants, included herein. The summary historical balance sheet data as of December 31, 1993, 1992 and 1991 and the statement of operations data for the years ended December 31, 1992 and 1991 are derived from audited financial statements not included herein. The summary historical financial data for each of the nine month periods ended September 30, 1996 and 1995 are derived from unaudited financial statements prepared on the same basis as the audited financial statements and containing, in the opinion of management, all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial position at such dates and the operating results and cash flows for such periods. Period to period comparability in 1995 and 1996 is affected by the Westmark acquisition completed in June 1995 and the L.J. Melody acquisition completed in July 1996. A significant portion of the Company's revenue is transactional in nature and seasonal. Historically, this seasonality has caused the Company's revenue, operating income and net income to be lower in the first two calendar quarters and higher in the third and fourth calendar quarters of each year. The results of operations for the nine months ended September 30, 1996 are not necessarily indicative of results to be expected for the entire year ending December 31, 1996 or for any future period. The summary unaudited pro forma statement of operations data, balance sheet data and other data give effect to the acquisitions of Westmark, L.J. Melody as well as the Offering and Recapitalization as if such transactions had occurred as of January 1, 1995 with respect to operating and other data, and as if the Offering and the Recapitalization had occurred as of September 30, 1996 with respect to the pro forma balance sheet data. The pro forma financial data set forth below is not necessarily indicative of the results that would have been achieved had such transactions been consummated as of the dates indicated or that may be achieved in the future. The information set forth below should be read in conjunction with "Unaudited Pro Forma Financial Statements," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the financial statements for each of the Company, L.J. Melody and Westmark and related notes thereto which are included elsewhere in this Prospectus. NINE MONTHS ENDED SEPTEMBER 30, ------------------------------------------------ 1996 1996 1996 1995 ----------- ----------- ---------- ---------- PRO FORMA ------------------------ ACQUISITION ACQUISITION AND ONLY OFFERING ----------- ----------- (DOLLARS IN THOUSANDS EXCEPT PER SHARE DATA) STATEMENT OF OPERATIONS DATA: Revenue......... $ 394,280 $ 394,280 $ 390,863 $ 324,890 Costs and expenses: Commissions, fees and other incentives..... 198,240 198,240 195,465 167,569 Operating, administrative and other...... 160,741 160,741 159,196 134,839 Depreciation and amortization (1). 10,267 10,267 9,749 8,173 Non-recurring charges........ -- -- -- -- ---------- ---------- ---------- ---------- Operating income (loss)......... 25,032 25,032 26,453 14,309 Interest income. 1,180 1,180 1,035 1,228 Interest expense........ 18,099 13,672 17,883 16,944 ---------- ---------- ---------- ---------- Income (loss) before provision (benefit) for income tax..... 8,113 12,540 9,605 (1,407) Provision for income tax..... 4,323 6,094 4,610 238 Reduction of valuation allowances..... (40,400) (40,400) (40,400) -- ---------- ---------- ---------- ---------- Net provision (benefit) for income tax (2). (36,077) (34,306) (35,790) 238 ---------- ---------- ---------- ---------- Net income (loss)......... $ 44,190 $ 46,846 $ 45,395 $ (1,645) ========== ========== ========== ========== Net income (loss) per common and common equivalent share outstanding.... $ 3.19 $ 3.36 $ 3.28 $ (0.14) Number of shares used in computing per share amounts (3).... 13,858,176 13,049,618 13,858,176 11,908,995 OTHER DATA: EBITDA (4)...... $ 36,202 $ 22,482 Ratio of earnings to fixed charges (5).... 1.42 -- Deficiency of earnings to fixed charges (5)............ -- $ (1,407) Net cash provided by (used in) operating activities..... $ 24,170 $ 551 Net cash (used in) investing activities..... $ (9,517) $ (21,960) Net cash provided by (used in) financing activities..... $ (12,795) $ 3,481 Investments under management at period end (6). $3,730,226 $3,918,825 Loans originated (7)............ $1,715,467 $ 603,097 Loans serviced (7)............ $7,498,905 $3,671,532 Total consideration of properties sold ......... $6,393,389 $4,517,550 Number of sale transactions... 2,758 2,491 Number of lease transactions... 12,521 12,733 ---------- ---------- Total sale and lease transactions... 15,279 15,224 ========== ========== Square feet under management (8). 103,754 95,406 YEAR ENDED DECEMBER 31, ------------------------------------------------------------------------------------ 1995 1995 1995 1994 1993 1992 1991 ------------ ------------ ---------- ---------- ---------- ---------- ---------- PRO FORMA ------------------------- ACQUISITIONS ACQUISITIONS AND ONLY OFFERING ------------ ------------ (DOLLARS IN THOUSANDS EXCEPT PER SHARE DATA) STATEMENT OF OPERATIONS DATA: Revenue......... $ 489,684 $ 489,684 $ 468,460 $ 428,988 $ 392,037 $ 360,223 $ 338,119 Costs and expenses: Commissions, fees and other incentives..... 245,564 245,564 239,018 225,085 206,070 187,582 175,142 Operating, administrative and other...... 200,341 200,341 187,968 170,234 160,073 152,402 159,791 Depreciation and amortization (1). 14,502 14,502 11,631 8,091 49,606 45,855 51,946 Non-recurring charges........ -- -- -- -- -- 4,500 12,030 ---------- ---------- ---------- ---------- ---------- ---------- ---------- Operating income (loss)......... 29,277 29,277 29,843 25,578 (23,712) (30,116) (60,790) Interest income. 1,926 1,926 1,674 1,109 915 1,083 1,349 Interest expense........ 26,080 20,177 23,267 17,362 14,240 15,516 24,805 ---------- ---------- ---------- ---------- ---------- ---------- ---------- Income (loss) before provision (benefit) for income tax..... 5,123 11,026 8,250 9,325 (37,037) (44,549) (84,246) Provision for income tax..... 220 2,581 841 152 112 12 135 Reduction of valuation allowances..... -- -- -- -- -- -- -- ---------- ---------- ---------- ---------- ---------- ---------- ---------- Net provision (benefit) for income tax (2). 220 2,581 841 152 112 12 135 ---------- ---------- ---------- ---------- ---------- ---------- ---------- Net income (loss)......... $ 4,903 $ 8,445 $ 7,409 $ 9,173 $ (37,149) $ (44,561) $ (84,381) ========== ========== ========== ========== ========== ========== ========== Net income (loss) per common and common equivalent share outstanding.... $ 0.36 $ 0.35 $ 0.55 $ 0.69 $ (3.21) $ (3.88) $ (7.39) Number of shares used in computing per share amounts (3).... 13,591,420 12,782,862 13,591,420 13,355,997 11,555,523 11,496,256 11,398,967 OTHER DATA: EBITDA (4)...... $ 41,474 $ 33,669 $ 25,894 $ 15,739 $ (8,844) Ratio of earnings to fixed charges (5).... 1.28 1.40 -- -- -- Deficiency of earnings to fixed charges (5)............ -- -- $ (37,037) $ (44,549) $ (84,246) Net cash provided by (used in) operating activities..... $ 30,632 $ 31,418 $ 19,609 $ 10,911 $ (25,307) Net cash (used in) investing activities..... $ (24,888) $ (3,865) $ (5,629) $ (4,821) $ (3,715) Net cash provided by (used in) financing activities..... $ (11,469) $ (4,923) $ (14,662) $ (2,157) $ 16,012 Investments under management at period end (6). $3,901,727 $ 879,809 $ 760,554 $ 883,761 $ 776,010 Loans originated (7)............ $ 989,872 $ 874,159 $ 613,071 $ 458,792 $ 135,022 Loans serviced (7)............ $3,779,069 $3,578,962 $3,140,635 $3,787,941 $3,830,502 Total consideration of properties sold ......... $6,549,861 $6,521,451 $4,995,234 $4,478,472 $3,986,576 Number of sale transactions... 3,503 3,693 3,249 3,042 2,590 Number of lease transactions... 17,476 17,930 18,338 17,909 17,431 ---------- ---------- ---------- ---------- ---------- Total sale and lease transactions... 20,979 21,623 21,587 20,951 20,021 ========== ========== ========== ========== ========== Square feet under management (8). 105,356 92,311 76,065 70,707 71,156
AS OF SEPTEMBER 30, AS OF DECEMBER 31, ------------------------------- ---------------------------------------------------- 1996 1996 1995 1995 1994 1993 1992 1991 --------- --------- --------- --------- --------- --------- --------- -------- PRO FORMA OFFERING --------- BALANCE SHEET DATA: Cash and cash equiva- lents.................. $ 26,502 $ 24,903 $ 10,842 $ 23,045 $ 28,770 $ 6,140 $ 6,822 $ 2,889 Total assets............ 248,835 232,575 180,038 190,954 150,100 128,914 173,274 212,249 Total long-term debt.... 143,113 231,986 252,468 250,142 233,571 239,853 239,473 240,401 Total liabilities....... 250,596 339,469 344,184 345,642 314,648 303,774 311,630 306,123 Total stockholders' eq- uity (deficit)......... (1,761) (106,894) (164,146) (154,688) (164,548) (174,860) (138,356) (93,874)
(footnotes on following page) - ------- (1) 1993, 1992, and 1991 reflect the amortization of intangibles associated with the acquisition in 1989 of CB Commercial Real Estate Group, Inc. of $42.9 million, $40.7 million and $47.1 million, respectively. (2) Net provision (benefit) for income tax on a consolidated basis for the nine months ended September 30, 1996 was a benefit of ($35.8) million, a change of $36.0 million from a $0.2 million provision for the nine months ended September 30, 1995. During the quarter ended September 30, 1996, the Company projected, on a more likely than not basis, that a portion of its net operating loss carryforwards ("NOLs") would be realized in current and future periods and, accordingly, reduced existing deferred tax asset valuation allowances by $45.7 million, of which $5.3 million has been allocated to the purchase price of L.J. Melody, based on its estimated future potential to generate taxable income, and the remaining $40.4 million has been recorded as a tax benefit (a reduction in income taxes provision). With the recognition of the deferred tax asset, current and future provisions for income tax will be recorded at the full effective tax rate. See "Management's Discussion and Analysis of Financial Condition and Results of Operations--Net Operating Losses." (3) Includes the dilutive effect of 1,046,890 shares issuable upon exercise of stock options outstanding as of September 30, 1996 under the Company's stock option plans. Acquisitions and offering pro forma data excludes shares of Class C-R and Class J common stock to be repurchased by the Company in connection with the Offering and shares of Preferred Stock convertible at the option of the holder into Common Stock after the Offering. Pro forma data includes 444,444 shares of Common Stock issuable upon conversion of the 800,000 shares of the Company's Class C-1 common stock (assuming an initial public offering price per share of $22.50). See "Description of Capital Stock--Preferred Stock" and "--The Recapitalization." (4) EBITDA represents earnings before interest, income taxes, depreciation and amortization, thereby removing the effect of certain non-cash charges on income, consisting of depreciation and the amortization of intangible assets relating to acquisitions. Management believes that the presentation of EBITDA will enhance a reader's understanding of the Company's operating performance and ability to service debt as it provides a measure of cash generated that can be used by the Company to service its debt and for other required or discretionary purposes. Management has used EBITDA as one of the primary measures of operating performance in evaluating its recent acquisitions. Net cash available to the Company for discretionary purposes represents remaining cash, after debt service and other cash requirements, such as capital expenditures are deducted from EBITDA. EBITDA should not be considered as an alternative either (i) to operating income (determined in accordance with generally accepted accounting principles ("GAAP")) or (ii) operating cash flow (determined in accordance with GAAP). (5) The ratio of earnings to fixed charges represents earnings before income taxes and fixed charges divided by fixed charges. Fixed charges include interest expense, one-third of rent expense relating to operating leases, and, for purposes of the pro forma ratios, preferred stock dividends. For purposes of this calculation preferred stock dividends are computed to demonstrate earnings required on a pre-tax basis. Deficiency of earnings to fixed charges is presented for periods when the Company's earnings were not sufficient to cover its fixed charges requirement. Earnings included non- cash depreciation and amortization charges of $9.7 million, $8.2 million, $11.6 million, $8.1 million, $49.6 million, $45.9 million and $51.9 million for the nine month periods ended September 30, 1996 and 1995, and for the years ended December 31, 1995, 1994, 1993, 1992 and 1991, respectively. (6) Investments under management represent the market value of the assets managed as of the end of the period shown. (7) Mortgage loans originated represent the initial principal amount of loans originated during the period and loans serviced represents the outstanding principal balance of loans being serviced as of the end of the period shown. The increase in mortgage loans originated and serviced primarily reflects the acquisition of L.J. Melody on July 1, 1996. (8) Square feet under management represents the total square footage of properties for which the Company provided property management services as of the end of the period shown. THE RECAPITALIZATION Immediately prior to the closing of the Offering, (i) the Company's Certificate of Incorporation will be amended to, among other things, change the name of the Company from CB Commercial Holdings, Inc. to CB Commercial Real Estate Services Group, Inc., effect the conversion of the Class B-1 and Class B-2 common stock of the Company into the Common Stock on a 1-for-1 basis, effect the conversion of the Class C-1 common stock of the Company into a lesser number of shares of Common Stock based upon the initial public offering price per share and provide for the convertibility of the Company's Preferred Stock into Common Stock at the holder's option, and (ii) the Company will repurchase all of the outstanding shares of its Class C-R common stock and Class J common stock for $.01 per share, in each case upon the consummation of the Offering, as part of the proposed recapitalization of the Company's capital structure (the "Recapitalization"). The term Recapitalization as used herein refers to the above-described changes in the Company's capital structure and corporate governance, but does not include the Offering. After the Recapitalization, the holders of the 1,000,000 shares of Series A-1 Preferred Stock and the 2,000,000 shares of Series A-2 Preferred Stock will continue to have two votes and one vote per share, respectively, for such shares on all matters submitted to a vote of stockholders of the Company, and the 1,000,000 shares of Series A-3 Preferred Stock will continue to have no right to vote on matters unless otherwise entitled by statute. The Company is effecting the Recapitalization in order to simplify the Company's capital structure, whereas the Offering is being effected in order to enable the Company to pay down a portion of its outstanding secured debt and help to provide liquidity to the Company's stockholders. See "Description of Capital Stock--Preferred Stock" and "--The Recapitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000854152_actv-inc_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000854152_actv-inc_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..3e52ca69c2bb7687dff0fa755fe179cb2fea8f31
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000854152_actv-inc_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the detailed information and financial statements with notes thereto appearing elsewhere in this Prospectus. THE COMPANY General ACTV, Inc. ("ACTV" or the "Company") has developed proprietary Programming Technologies (the "Programming Technology") that individualize television programming. ACTV's Programming Technology permits the delivery of individualized television, which, in the Company's view, significantly enhances the quality of most genres of television programming. ACTV's Programming Technology provides instant and seamless changes in the live or prerecorded video picture and/or audio and/or graphics in response to the various selections supplied by each viewer. A specially produced ACTV program (the "ACTV Program" or "ACTV Programming") is like a linear TV program, except that it appears to be individualized for each viewer. (Linear programs are standard television programs that can be viewed only as created and do not offer the viewer the option to make choices as to the content of the program or to respond to the contents of the program in an individualized way.) There is no limit to the number of viewers who can interact simultaneously with an ACTV Program. ACTV's individualized programming is designed to work with both single and multiple channels of 6MHz band-width and with different modes of transmission: cable, direct broadcast satellite ("DBS"), multi-microwave distribution systems ("MMDS"), broadcast systems, distance learning networks and closed circuit televisions systems. It is compatible with commonly available one-way analog systems as well as the newer digital systems that have recently begun to be deployed. ACTV's strategy is to generate revenues from the sale of ACTV Programming that it either owns, has licensed or that has been created by a third party under a license from ACTV, including fees paid by subscribers to premium cable networks in which the Company has an ownership interest. The Company's mission is to improve the quality of entertainment and education television programming. The Company also believes that the Programming Technology can enhance the quality of television advertising by enabling the advertiser to customize each commercial for various audience segments. It is the Company's objective to seek advertiser support for its individualized home entertainment networks. The chief markets presently targeted by the Company for the ACTV Programming Technology are in-home entertainment, education (with an emphasis on distance learning), site-based entertainment and internet applications. The Company seeks to exploit these markets, principally in the U.S., through licensing the Programming Technology, by creating joint venture relationships, and by direct sales. 11. Information with Respect to Cover Page; Prospectus Summary; The Company; Registrant Dividend Policy; Certain Market Information; Capitalization; Selected Financial Data; Management's Discussion and Analysis of Financial Condition and Results of Operations; Business; Management; Certain Transactions; Principal Stockholders and Financial Statements. 12. Disclosure of Commission's Not Applicable. Position on Indemnification for Securities Act Liabilities
The Company has eight subsidiaries, which include a national entertainment company, a national education company, a three-dimensional company, and five regional television networks; ACTV Entertainment Inc., a New York corporation ("ACTV Entertainment") incorporated on March 9, 1988, ACTV Interactive, Inc., a Delaware corporation incorporated on July 8, 1992, 3D Virtual, Inc., a Delaware corporation incorporated on July 20, 1995, The Los Angeles Individualized Television Network, Inc., a Delaware corporation incorporated on March 7, 1995, The San Francisco Individualized Television Network, Inc., a Delaware corporation incorporated on December 22, 1995, The Chicago Individualized Television Network, Inc., a Delaware corporation incorporated on December 22, 1995, The New York Individualized Television Network, Inc., a Delaware corporation incorporated on December 22, 1995, and The Atlanta Individualized Television Network, Inc., a Delaware corporation incorporated on December 22, 1995. Unless otherwise indicated, all references in this Prospectus to the Company or ACTV include ACTV and its eight subsidiaries. ACTV was incorporated under the laws of the State of Delaware on July 24, 1989. The Company is the successor, by merger effective November 1, 1989, to ACTV, Inc., a California corporation, organized on July 11, 1983. The Company's executive offices are located at 1270 Avenue of the Americas, New York, New York, 10020, telephone number (212) 262-2570. THE OFFERING Securities Offered Company Shares ................... 2,500,000 shares of Common Stock. See "PLAN OF DISTRIBUTION - Company Shares." Security Holders' Shares .................. 3,850,000 shares of Common Stock. Up to 122,855 of such shares may be issued by the Company upon the exercise of options, warrants or pursuant to SARs that are currently outstanding and are not exercisable for a period of six months. Up to 3,727,145 of such shares may be sold by Selling Security Holders who have acquired or will acquire such shares from the Company (i) upon the exercise of currently exercisable options and warrants, and pursuant to SARs, (ii) upon issuance to consultants pursuant to existing agreements, and (iii) upon issuance in connection with certain financings. The Company will receive the net proceeds of the sale of the Company Shares. It will not receive any proceeds from sales of Security Holders' Shares, but will receive the proceeds of the exercise of any options or warrants exercised by the Selling Security Holders. See "SELLING SECURITY HOLDERS" and "PLAN OF DISTRIBUTION." The exercise prices of the shares of Common Stock issuable upon the exercise of options and warrants, and the number of shares issuable, may be subject to adjustment in the event of a merger, stock split, stock dividend and similar transactions. See "MANAGEMENT - Stock Options and Stock Appreciation Rights" and "DESCRIPTION OF CAPITAL STOCK." Common Stock Outstanding At the Date of this Prospectus(1)................... 11,414,211 Shares After the Offering(1)(2).......... 15,075,784 Shares Common Stock Symbols................ NASDAQ: IATV BSE: IAT Use of Proceeds..................... The net proceeds of the sale of the Company Shares and any proceeds from the exercise of options or warrants underlying Security Holders' Shares being registered hereunder will be applied to working capital, which may include research and development. A portion of the proceeds may be utilized to repurchase shares of Common Stock. The Company will not receive any proceeds from the sales of the Security Holders' Shares. See "USE OF PROCEEDS." Risk Factors........................ An investment in the Company's Common Stock involves a high degree of risk and should be made only after a careful consideration of the significant risk factors that may affect the Company. Such risks include special risks concerning the Company and its business, including among other risks, Operating Losses to Date, Possible Need for Additional Financing and Dilution. See "RISK FACTORS." - ------------ (1) Does not include (a) 80,000 shares of Common Stock issuable pursuant to options being offered pursuant to a separate Prospectus (the "Concurrent Prospectus"). See "CONCURRENT OFFERING." (2) Assumes the issuance of all the 2,500,000 Company Shares and the 1,161,573 unissued Security Holders' Shares being offered hereby, including those underlying options and warrants. See "SELLING SECURITY HOLDERS" and "PLAN OF DISTRIBUTION." SUMMARY FINANCIAL DATA (in dollars, except number of shares) Nine Months Years Ended December 31, Ended September 30, -------------------------------------------------------------------- ------------------------ 1990 1991 1992 1993 1994 1994 1995 ---- ---- ---- ---- ---- ---- ---- Statement of Operations: Revenues $ 615,011 $ 1,018,074 532,596(1) $ 164,602(1) $ 938,416 $ 768,739 $ 1,075,925 Operating Expenses 4,462,771 4,435,322 2,798,847(1) 3,443,513(1) 5,734,132 4,415,721 6,816,816 Equity in Net Loss of ACTV Interactive (2) -- -- 187,781 506,303 143,500 143,500 -- Loss Before Extraordinary Item (3) 3,093,512 3,313,998 2,778,085 4,156,955 5,122,010 3,929,357 5,751,337 Net Loss (3) 3,093,512 3,313,998 2,778,085 4,156,955 4,465,240 3,407,554 5,657,220 Weighted Average Shares Outstanding 3,727,255 4,043,867 4,665,686 5,800,134 7,897,278 7,699,790 9,748,209 Loss Per Common Share Before Extraordinary Item (3) 0.83 0.82 0.59 0.72 0.65 0.51 0.59 Net Loss Per Common Share (3) 0.83 0.82 0.59 0.72 0.57 0.44 0.58 Balance Sheet Data: 12/31/90 12/31/91 12/31/92 12/31/93 12/31/94 9/30/94 9/30/95 -------- -------- -------- -------- -------- ------- ------- Working Capital 2,397,952 128,834 (104,486) 2,263,225 1,503,703 (704,003) 3,458,531 Total Assets 6,211,803 2,828,119 3,146,503 5,920,720 7,733,314 6,129,878 10,454,934 Long Term Obligations 649,796 669,796 1,792,794 2,220,794 2,325,061 2,443,866 222,219 Stockholders' Equity (4) 5,089,036 1,775,038 1,006,314 1,910,603 3,972,543 1,956,892 8,009,212 Total Capitalization 5,738,832 2,444,834 2,799,108 4,131,397 6,297,604 4,400,758 8,231,431
(1) For the period between July 15, 1992, and March 11, 1994, all education sales and expenses were reported separately by the Company's 49% affiliate, ACTV Interactive, and were not consolidated with the Company's statements of operations. For the remainder of 1994, operational results related to education were included with those of the Company, as a result of the Company's March 11, 1994 purchase of the Post Company's 51% interest in ACTV Interactive. (2) The results of ACTV Interactive are accounted for under the equity method of accounting for the years 1992 and 1993 and for the period January 1, 1994 to March 11, 1994. (3) Includes for the year ended 12/31/94 and nine months ended 9/30/94 extraordinary gains of $656,770, ($.08 per share) and $521,803 ($.07 per share), respectively, related to the extinguishment of debt and equipment lease obligations. Includes for the nine months ended 9/30/95 an extraordinary gain of $94,117 ($.01 per share) related to the extinguishment of debt obligations. (4) No cash or non-cash dividends have been paid or granted and the Company does not anticipate the declaration or payment of dividends in the foreseeable future.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000854551_brake_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000854551_brake_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..f2e741f659e0ad6ad6ce3101e20ac100bbc788f1
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000854551_brake_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. THIS PROSPECTUS CONTAINS, IN ADDITION TO HISTORICAL INFORMATION, FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THE RESULTS DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT MIGHT CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN "RISK FACTORS," AS WELL AS THOSE DISCUSSED ELSEWHERE IN THIS PROSPECTUS. THE COMPANY Brake Headquarters U.S.A., Inc. (the "Company") is a specialized distributor in the automotive aftermarket of a complete line of brake system products including brake drums and rotors, brake master cylinders, wheel cylinders, brake pads, brake shoes and brake hoses for virtually all makes and models of domestic and foreign passenger cars and light trucks from model year 1976 to the present. The Company also sells a variety of other "undercar" parts including ride control products, steering/suspension parts, drive shafts, shock absorbers and clutches. The brake line products are sold primarily under the name "Brake Headquarters," as well as under the name "Sanyo Automotive" and other private labels. The Company was incorporated in the State of Delaware on July 13, 1988 as a blind pool which did not conduct business operations until July 1992 when it acquired, in a reverse acquisition (the "Reverse Merger"), all of the outstanding capital stock of Sanyo Automotive Parts, Ltd. ("Sanyo Automotive"). In connection with the Reverse Merger, the Company amended its Certificate of Incorporation to change its name to Sanyo Industries, Inc. On August 8, 1995, the Company changed its name to Brake Headquarters U.S.A., Inc.. The Company is a publicly-owned holding company that conducts substantially all of its current business operations through its wholly-owned subsidiary Sanyo Automotive, a New York corporation formed in 1976, which is currently doing business under the name Brake Headquarters. Common Stock Outstanding as of November 4, 1996 (1)... 3,868,730 Common Stock to be Outstanding Upon Full Exercise of Warrants and Conversion of Promissory Note (2)...... 4,980,030 Warrants Offered...................................... The Warrants are exercisable until August 13, 1999 at an exercise price of $3.80 per share, subject to adjustment and to redemption by the Company in intervals during the period following their registration hereby, as described under "Description of Securities -- Warrants." Use of Proceeds....................................... The Company will not receive any proceeds from the sale of shares of Common Stock offered hereby by the Selling Shareholders but will receive gross proceeds of $3,824,000 from the full exercise of all warrants offered by the Selling Stockholders. Risk Factors.......................................... Prospective investors should carefully consider the matters set forth under the captions "Risk Factors." An investment in the shares of Common Stock offered hereby involves a high degree of risk. Nasdaq Common Stock Symbol............................ BHQU
(1) Excludes an aggregate of 349,000 shares of Common Stock reserved for future issuance upon exercise of options currently outstanding and 131,000 and 120,000 shares reserved for issuance upon options available for issuance under the Company's 1994 and 1995 Employee Stock Option Plans, respectively (the "Plans"), and 100,000 shares of Common Stock reserved for issuance under the Company's Employee Stock Bonus Plan. See "Shares Eligible for Future Sale." (2) Gives effect to the exercise of 900,000 Warrants offered hereby; the Placement Agent's Warrants to purchase up to 120,000 shares of Common Stock and the conversion of a promissory note for 91,300 shares of Common Stock, all of which shares of Common Stock which are issuable are included in this Prospectus. SUMMARY FINANCIAL DATA YEAR ENDED DECEMBER 31, SIX MONTHS ENDED JUNE 30, 1993 1994 1995 1995 1996 STATEMENT OF OPERATIONS DATA: Net sales......................... $17,717,023 $25,094,473 $30,463,730 $15,617,040 $16,614,411 Income (loss) from operations..... 370,009 (1,041,037)(1) 566,874 1,192,111 557,899 Interest expense.................. (314,796) (520,602) (774,762) (305,429) (478,108) Net income (loss)................. 41,187 (1,968,909)(1) (179,072) 546,659 54,791 Net income (loss) per common and common equivalent share (2)..... $ .00 $ (.92) $ (.06) $ .18 $ .02
AS OF DECEMBER 31, AS OF JUNE 30, 1996 1993 1994 1995 ACTUAL AS ADJUSTED(3) BALANCE SHEET DATA: Working capital.................. $ 1,823,459 $ 3,706,239 $ 3,288,863 $ 8,050,180 $ 13,082,180(4) Total assets..................... 10,189,885 11,937,143 15,496,294 17,843,732 22,617,732 Long-term obligations............ 133,927 216,469 630,494 5,230,850 5,230,850 Total stockholders' equity....... 2,176,102 4,124,961 3,855,804 3,966,647 8,998,647(4)
(1) After a non-cash compensatory charge of $2,314,000 resulting from the release of escrow shares, the exercisability of warrants and the conversion of preferred stock, upon the Company's attainment of the specified 1994 pre-tax income level under the Company's July 1992 Reverse Acquisition and certain cumulative levels for the three-year period ended December 31, 1994. See "Certain Relationships and Related Transactions" and Note 4 of Notes to the 1995 Consolidated Financial Statements. (2) Net income (loss) per share is computed on the basis described in Note 1 of Notes to Consolidated Financial Statements including, but not limited to, the adjustment for dividends on preferred stock. (3) As adjusted to reflect the Company's receipt of proceeds of $4,774,000 consisting of (i) $1,000,000 of net proceeds from the Private Placement in August 1996; (ii) $3,420,000 from the exercise of all Warrants; and (iii) $404,000 from full exercise of the Placement Agent's Warrants and after deducting $50,000 of offering expenses (4) Includes $258,000 from the conversion of a Selling Securityholder's promissory note.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000855197_data_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000855197_data_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..79cfffa03d24a8713cd8f692794507f22b44abb7
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000855197_data_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements appearing elsewhere in this Prospectus. References to "Iron Mountain" and the "Company" include Iron Mountain Incorporated (including predecessor entities) and its consolidated subsidiaries, unless the context otherwise requires. THE COMPANY Iron Mountain is the largest records management company in the United States, as measured by revenues. The Company is a full-service provider of records management and related services, enabling customers to outsource records management functions. Pro forma for the Acquisitions (as defined herein), as of June 30, 1996, the Company managed approximately 29.6 million Cartons* in 103 records centers in 33 markets nationwide. The Company has a diversified base of over 19,000 customer accounts, which includes more than half of the Fortune 500 and numerous legal, banking, healthcare, accounting, insurance, entertainment and government organizations. The Company provides storage and related services for all major media, including paper (which is the dominant form of records retention and which has accounted for approximately 85% of the Company's revenues since 1992), computer disks and tapes, microfilm and microfiche, master audio and video tapes, film and optical disks, X-rays and blueprints. The Company's principal services include filing, retrieval and destruction of records, courier pick-up and delivery, database management and customized reporting. The Company also sells storage materials and provides consulting and other records-related services. The Company continues to capitalize on its leading position in the records management industry and the industry trends of increased records retention, outsourcing of records management and vendor consolidation. As a result, the Company has achieved significant increases in revenues and EBITDA (as defined herein). From 1991 to 1995, Iron Mountain's total revenues increased from $62.8 million to $104.4 million primarily from internal growth, representing a compound annual growth rate ("CAGR") of 13.5%. During the same period, storage revenues grew at a 12.9% CAGR while service and storage material sales revenues grew at a 14.6% CAGR. From 1991 to 1995, the Company's EBITDA grew from $15.0 million to $26.1 million, representing a 14.9% CAGR. Revenues and EBITDA for the six months ended June 30, 1996 increased 27.3% (10.2% from internal growth and 17.1% from acquisitions) and 24.8%, respectively, over the same period in 1995. For a discussion of the significance of EBITDA and other measures of the Company's performance determined in accordance with generally accepted accounting principles ("GAAP") and the Company's sources and applications of cash flow, see "Management's Discussion and Analysis of Financial Condition and Results of Operations--Overview" and "--Liquidity and Capital Resources." Industry Overview According to industry sources, organizations in the United States generate an estimated four trillion documents each year, many of which must be retained and remain available for reference for many years. These records may be generally divided into two categories: active and inactive. Inactive records, which are the principal focus of the records management industry, consist of records that are not needed for immediate access but which must be retained for legal or regulatory reasons or for occasional reference to support ongoing business operations. Based on industry studies, the Company believes that inactive records make up approximately 80% of all records. The Company believes that the volume of inactive records is increasing for a number of reasons, including: (i) the rapid growth of inexpensive document producing technologies such as facsimile, desktop printing and computer networking; (ii) increased regulatory requirements; (iii) concerns over possible future litigation and the resulting increases in volume and holding periods of documentation; (iv) the high cost of reviewing records and deciding whether to retain or destroy them; and (v) the failure of many entities to adopt or follow policies on records destruction. Despite the growth of new "paperless" technologies, such as the Internet and e-mail, management believes that stored information remains predominantly paper-based and that such technologies have promoted the creation of hard copies of such electronic information. - ------------- * The term "Carton" is defined as a measurement of volume equal to a single standard storage carton, approximately 1.2 cubic feet. The number of Cartons stored does not include storage volumes in the Company's vital records services and data protection services, which are described under "Business." The Company believes that it benefits from several industry fundamentals, including: (i) the historically non- cyclical nature of the records management industry; (ii) the continued trend towards corporate outsourcing of records management functions; (iii) the ability of larger records management companies to achieve economies of scale with respect to labor, real estate costs and the utilization of management information systems; and (iv) the ongoing consolidation of the records management industry. The Company believes that it is one of only four records management providers with a national operating presence, the balance being regional or, in most instances, single-city operators. According to the Association of Commercial Records Centers (the "ACRC"), a trade group of approximately 500 members, as of January 1994 (the latest date for which such information is available), approximately 2,600 firms offered records storage and management services in the United States. The Company believes that there is a trend toward consolidation in the records management industry and that such trend will continue to accelerate primarily because of: (i) the opportunities to achieve economies of scale; (ii) the industry's capital requirements for growth; (iii) customer demands for more sophisticated technology-based solutions; and (iv) the preference of certain large, national customers to outsource a significant portion of their records management functions to one vendor with a national presence, such as Iron Mountain. Financial Characteristics of Iron Mountain's Business Iron Mountain's records management business has the following financial characteristics: (bullet)Recurring Revenues. Iron Mountain derives a majority of its revenues from fixed periodic (usually monthly) fees charged to customers for storage of records. Storage revenues have grown for 30 consecutive quarters and have represented approximately 60% of the Company's total revenues in each of the last five years. Once a customer places a record in storage with the Company and until that record is destroyed or permanently removed (for which the Company typically receives a service fee), the Company receives recurring payments of fixed periodic fees without incurring additional labor or marketing expenses or significant capital costs. The stable and growing storage base also provides the foundation for increases in revenues and EBITDA from service activities and sales of storage materials. (bullet)Historically Non-Cyclical Business. Iron Mountain has not experienced a reduction of its business as a result of past general economic downturns, although there can be no assurance that this would be the case in the future. Management believes that the outsourcing of records management may accelerate during economic downturns as companies focus on reducing costs through outsourcing non-core operating functions. In addition, management believes that companies that have outsourced records management are less likely during economic downturns to incur the move-out costs and other expenses associated with switching vendors or moving records management in-house. (bullet)Inherent Growth from Existing Customers. The Company's customers have on average generated additional Cartons at a faster rate than stored Cartons have been destroyed or permanently removed. From 1992 to 1995, net Cartons from existing customers grew at an average annual rate of 6.7%. The Company believes the consistent growth of its storage revenues is the result of a number of additional factors, including: (i) the trend toward increased records retention; (ii) customer satisfaction with the Company's services; and (iii) the costs and inconvenience of moving storage operations in-house or to another provider of records management services. (bullet)Diversified and Stable Customer Base. The Company has over 19,000 customer accounts in a variety of industries. The Company currently provides services to more than half of the Fortune 500 and numerous legal, banking, healthcare, accounting, insurance, entertainment and government organizations. Only one of the Company's customers accounted for more than 3% of revenues in 1993, 1994 or 1995. From 1992 to 1995, average annual permanent removals of Cartons represented only approximately 4% of total Cartons stored. (bullet)Capital Expenditures Related Primarily to Growth. The Company's business requires limited annual maintenance capital expenditures. Maintenance capital expenditures were $1.8 million, $1.2 million and $0.9 million in 1993, 1994 and 1995, respectively. From 1992 to 1995, over 90% of the Company's aggregate capital expenditures were growth-related investments, primarily in racking systems, new buildings and leasehold improvements, equipment for new facilities, management information systems and facilities restructuring. These growth-related capital expenditures are primarily discretionary and create additional capacity for increases in revenues and EBITDA. Business Strategy Iron Mountain's business strategy is to increase revenues and EBITDA while maintaining a low-cost operating structure and providing premium service. The Company intends to generate growth by increasing its storage and service revenues from existing customers, adding new customers and making acquisitions. The Company's strategy is based on the following elements: (bullet)Provide Superior Customer Service. The Company believes it has a reputation for providing reliable, quality service based on its more than 45 years of operations, its commitment to providing premium customer service and the continuity and depth of its management team. The Company has successfully implemented a decentralized management structure that enables the Company to respond quickly and flexibly to local customer needs. Iron Mountain's proprietary Safekeeper(R) system enables it to quickly provide customized records management solutions to its customers, enhancing the quality of its services. In addition, Iron Mountain's national operating presence allows it to better service large organizations that require records management functions at multiple, geographically diverse facilities. (bullet)Capitalize on Operating Efficiencies. Iron Mountain pursues a low-cost operating strategy based primarily on achieving economies of scale in the areas of storage, labor and transportation, general and administrative functions and management information systems. Because occupancy costs are a major component of the Company's cost of sales, its real estate management staff aggressively seeks to minimize per Carton storage costs by designing racking systems and operating space to maximize facility storage efficiency, negotiating favorable facility leases, contracting for facilities to be built to its custom specifications, and leasing larger facilities in order to reduce operating costs per Carton. The Company seeks to increase labor efficiency by offering incentive compensation to all full-time employees based upon achieving specific operating targets. Certain operating costs, such as the maintenance of local delivery fleets, general and administrative costs and management information systems, offer economies of scale, providing the Company with operating leverage and the ability to increase its efficiency through further growth. (bullet)Pursue Acquisition Opportunities. The Company believes that it is well positioned to participate in the further consolidation of the records management industry. Iron Mountain's management team has successfully completed 18 acquisitions since the Company embarked on a proactive acquisition strategy in mid-1994, and one additional acquisition is currently pending. The Company intends to continue to make fold-in acquisitions to augment its operations in existing markets and to make strategic acquisitions in new geographic markets, with an emphasis on the 50 largest markets in the United States and potentially in certain markets outside the United States. Following an acquisition in a new market, the Company seeks to increase its business with the acquired customer base and to supplement that growth both with new customers and through appropriate fold-in acquisitions. In addition, the Company has successfully reduced the cost structure of its acquired operations by implementing its efficient operating strategies and leveraging its centralized administrative resources and management information systems. (bullet)Leverage Proprietary Safekeeper System. The Company pioneered the application of advanced information technology to the records management industry. Iron Mountain's proprietary Safekeeper system provides advanced inventory control and information access, enabling the Company to provide faster, higher quality and more flexible solutions to its customers and to lower the costs of its operations. Safekeeper has been designed to easily and effectively integrate newly acquired records management companies and offer improved levels of customer service and records management capabilities to customers acquired through acquisitions. Iron Mountain's Safekeeper system exploits bar-code technology to provide a comprehensive, standardized approach to tracking, accessing and retrieving records. Safekeeper offers state-of-the-art records management capabilities and ease of access to customers while featuring security functions to protect customer information from unauthorized access. Since 1992, the Company has invested $12.5 million to develop and refine its management information systems, including Safekeeper. THE OFFERING Securities Offered $150,000,000 principal amount of % Senior Subordinated Notes due 2006 (the "Notes"). Maturity Date , 2006 Interest Payment Dates and of each year, commencing , 1997. Guarantees The Notes will be fully and unconditionally guaranteed on an unsecured senior subordinated and joint and several basis (the "Subsidiary Guarantees") by substantially all of the Company's present and future Restricted Subsidiaries (collectively, the "Guarantors"). Each of the Guarantors has also guaranteed unconditionally the indebtedness outstanding under the Company's existing bank credit facility (the "Credit Agreement") and will guarantee unconditionally the indebtedness outstanding under the new bank credit facility the Company intends to enter into with its lenders (the "New Credit Facility"). See "Description of the Notes--Subsidiary Guarantees." Subordination The Notes will be general unsecured senior subordinated obligations of the Company ranking junior to all existing and future Senior Debt of the Company, including any indebtedness that may be incurred under the Credit Agreement or the New Credit Facility. The Subsidiary Guarantees will rank junior to all existing and future Senior Debt of the Guarantors. As of June 30, 1996, on a pro forma basis after giving effect to the Transactions, the aggregate outstanding principal amount of Senior Debt of the Company and the Guarantors would have been $24.5 million. See "Description of the Notes--Subordination." Optional Redemption Except as described below, the Notes are not redeemable by the Company prior to , 2001. Thereafter, the Notes are redeemable at the option of the Company, in whole or in part, at any time and from time to time, at the redemption prices set forth herein plus accrued and unpaid interest to, but excluding, the date of redemption. In addition, during the first 36 months after the date of issuance of the Notes, the Company, at its option, may redeem up to 35% of the initial principal amount of the Notes with the net proceeds of one or more Qualified Equity Offerings at a redemption price equal to %, plus accrued and unpaid interest to, but excluding, the date of redemption; provided that at least 65% of the initial principal amount of the Notes remains outstanding after each such redemption. See "Description of the Notes--Optional Redemption." Mandatory Redemption Except with respect to required repurchases upon the occurrence of a Change of Control or in the event of certain Asset Sales, the Company is not required to make sinking fund or redemption payments with respect to the Notes at any time prior to maturity. See "Description of the Notes-- Mandatory Redemption." Change of Control Upon the occurrence of a Change of Control, each Holder of Notes may require the Company to repurchase such Notes at 101% of the principal amount thereof, plus accrued and unpaid interest to, but excluding, the date of repurchase. See "Description of the Notes--Repurchase at the Option of Holders--Change of Control." Certain Covenants The Indenture governing the Notes (the "Indenture") will contain covenants restricting or limiting the ability of the Company and its Restricted Subsidiaries to, among other things: (i) incur additional indebtedness, including indebtedness ranking senior to the Notes and junior to any Senior Debt; (ii) pay dividends or make other restricted payments; (iii) make asset dispositions; (iv) permit liens; (v) enter into sale and leaseback transactions; (vi) enter into certain mergers; (vii) make certain investments; and (viii) enter into transactions with related persons. See "Description of the Notes--Certain Covenants." Use of Proceeds The net proceeds of the Offering will be used to repay outstanding bank debt and certain other indebtedness and to fund a portion of the purchase price of the Pending Acquisition.
RISK FACTORS For a discussion of certain material factors that should be considered in connection with an investment in the Notes offered hereby, see "Risk Factors" on pages 10 to 14.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000860235_team_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000860235_team_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..424e5f439ad6f5503491b22e8791ace0c2051d8e
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000860235_team_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements, including notes thereto, appearing elsewhere in this Prospectus. Unless otherwise indicated, all information presented in this Prospectus assumes no exercise of the Underwriters' over-allotment option and has been adjusted to reflect the 184-to-1 split of the Common Shares prior to the Offering and certain other changes in the Company's capital stock to be effected immediately prior to the issuance and delivery of the Common Shares offered hereby. See "Description of Capital Stock." Unless the context otherwise requires, references in this Prospectus to "TEAM America" and the "Company" refer to TEAM America Corporation and its consolidated subsidiaries. This Prospectus contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from the results anticipated in these forward-looking statements as a result of certain of the factors set forth under "Risk Factors" and elsewhere in this Prospectus.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000861878_stericycle_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000861878_stericycle_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..a90af6daec703ef485337b3779da2f9050cef1f9
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000861878_stericycle_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND THE CONSOLIDATED FINANCIAL STATEMENTS, CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. UNLESS OTHERWISE INDICATED, ALL INFORMATION IN THIS PROSPECTUS (I) REFLECTS A 1-FOR-5.3089 REVERSE STOCK SPLIT EFFECTED IN AUGUST 1996 PURSUANT TO WHICH EACH OUTSTANDING SHARE OF THE COMPANY'S CLASS A AND CLASS B COMMON STOCK BECAME 0.1883629 SHARE OF COMMON STOCK, AND THE UNDERLYING CLASS OF STOCK AND NUMBER OF SHARES ISSUABLE UPON EXERCISE, AND THE EXERCISE PRICE PER SHARE, OF EACH OUTSTANDING OPTION AND WARRANT WERE ADJUSTED ACCORDINGLY, AND (II) ASSUMES THAT THE UNDERWRITERS' OVER-ALLOTMENT OPTION IS NOT EXERCISED. SEE "DESCRIPTION OF CAPITAL STOCK," "CAPITALIZATION" AND "UNDERWRITING." UNLESS THE CONTEXT REQUIRES OTHERWISE, REFERENCES TO "STERICYCLE" AND THE "COMPANY" REFER TO STERICYCLE, INC. AND ITS SUBSIDIARIES. PROSPECTIVE INVESTORS SHOULD CAREFULLY CONSIDER THE INFORMATION UNDER "RISK FACTORS." THE COMPANY Stericycle is a multi-regional integrated company employing proprietary technology to provide environmentally-responsible management of regulated medical waste for the health care industry. Because of the Company's health care orientation, proprietary technology and breadth of service, the Company believes that it is in a unique position to meet the fundamental need of the health care industry to manage regulated medical waste in a safe and cost-effective manner and to capitalize on the current consolidation trend in the regulated medical waste management industry. The Company believes that its exclusive focus on regulated medical waste and the experience of its management in the health care industry distinguish the Company from its chief competitors, most of whom participate in multiple businesses and most of whose management experience is primarily in the solid waste business. The Company believes that its regulated medical waste management system, including its proprietary ELECTRO-THERMAL-DEACTIVATION ("ETD") treatment process, is the only commercially-proven system that provides all of the following benefits: (i) it kills human pathogens in regulated medical waste without generating liquid effluents or regulated air emissions; (ii) it affords certain operating cost advantages over the principal competing technologies; (iii) it reduces the volume of regulated medical waste by up to 85%; (iv) it renders regulated medical waste unrecognizable; (v) it permits the recovery and recycling of usable plastics from regulated medical waste; and (vi) it enables the remaining regulated medical waste to be safely landfilled or used as an alternative fuel in energy production. The Company's full-service program is designed to help to protect its customers and their employees against potential liabilities and injuries in connection with the handling, transportation and disposal of regulated medical waste. The Company's integrated services include regulated medical waste collection, transportation, treatment, disposal, reduction, reuse and recycling services, together with related training and education programs, consulting services and product sales, in four geographic service areas: (i) California; (ii) Washington, Oregon, Idaho and British Columbia; (iii) Wisconsin, Illinois, Indiana and Michigan; and (iv) Massachusetts, Maine, New Hampshire, Vermont, Rhode Island, Connecticut, New York and New Jersey. As of December 31, 1995, the Company served over 13,000 customers, consisting of two principal types of regulated medical waste generators. Approximately 70% of the Company's 1995 revenues were derived from hospitals, blood banks and pharmaceutical manufacturers ("Core" generators), and approximately 30% of its revenues were derived from long-term and subacute care facilities, outpatient clinics, medical and dental offices, industrial clinics, dialysis centers, laboratories, biotechnology and biomedical companies, veterinary offices, municipal health departments, ambulance, fire and police departments, correctional facilities, schools, park districts and funeral homes ("Alternate Care" generators). The Company's current operations are comprised of four treatment centers, one recycling center, five transfer stations and four customer service centers. Regulated medical waste is generally defined as any waste that can cause an infectious disease or that reasonably can be suspected of harboring human pathogenic organisms. Regulated medical waste includes single-use disposable items such as needles, syringes, gloves and laboratory, surgical, emergency room and other supplies which have been in contact with blood or bodily fluids; cultures and stocks of infectious agents; and blood and blood products. Generators of regulated medical waste are responsible for that waste from its origin through its disposal. The Company seeks to offer a single-source solution to a wide spectrum of regulated medical waste management issues confronting generators of regulated medical waste, thereby managing the generators' compliance responsibilities relating to proper packaging, labeling, handling, treatment, disposal, tracking and reporting. In addition, the Company offers programs to assist customers in educating their employees on safety, resource conservation and compliance issues. This full-service approach to regulated medical waste management assists customers in dealing cost-effectively with the increasingly complex regulatory framework in which generators of regulated medical waste operate. An independent study published in 1995 estimated that the size of the regulated medical waste management market in the United States in 1995 was approximately $1 billion. Based upon certain public information and the Company's estimates of its competitors' revenues, the Company believes that it is the second-largest provider of regulated medical waste management services in the United States. The Company believes that the demand for its services will grow as a consequence of certain trends in the health care and regulated medical waste industries: - The handling and disposal of the large quantities of regulated medical waste generated by the health care industry has attracted increasing public awareness and regulatory attention. The Occupational Health and Safety Administration ("OSHA") has issued regulations concerning employee exposure to bloodborne pathogens and other potentially infectious materials that require, among other things, special procedures for handling regulated medical waste and annual training of all personnel who are potentially exposed to blood and bodily fluids. - Alternate Care generators have become an increasingly important source of revenues in the regulated medical waste industry. Individual Alternate Care generators, however, typically do not produce regulated medical waste in sufficient volumes to justify substantial capital expenditures on their own waste treatment facilities or the expense of hiring regulatory compliance personnel. Accordingly, Alternate Care generators often rely on a regulated medical waste management provider for a broad range of regulated medical waste management services. - The health care industry is under increasing pressure to reduce costs and improve efficiency, which the Company believes can be achieved in the case of regulated medical waste by obtaining waste management services from outside sources. - Governmental clean air regulations and public opposition are combining to increase the cost and difficulty of obtaining permits to build and operate incinerators. As a result, many hospitals have shut down their incinerators, and the Company expects that many more will do so, with a corresponding increase in demand for off-site alternative treatment services such as those offered by the Company. - Although the regulated medical waste management industry remains fragmented, the number of competitors is rapidly decreasing as a result of industry consolidation. The Company believes that it has the opportunity to increase its penetration of the geographic service areas in which it currently operates as well as to expand into adjacent service areas and offer additional products and services to its customers. Since August 1993, the Company has acquired eight regulated medical waste management businesses. The Company intends to continue to expand through business acquisitions, in which it will attempt to acquire businesses that can be integrated into the Company's existing operations and businesses in new geographic service areas that can be assembled in a "hub and spoke" configuration using transfer stations and treatment facilities. Through a combination of logistics and marketing efforts and business acquisitions, the Company intends to improve its operating efficiency. Stericycle, Inc. is a Delaware corporation with its principal executive offices located at 1419 Lake Cook Road, Suite 410, Deerfield, Illinois 60015. Its telephone number is (847) 945-6550. THE OFFERING Common Stock offered by the Company............. 3,000,000 shares Common Stock to be outstanding after this 9,218,455 shares (1) Offering........................................ Use of proceeds................................. To repay bank and other debt and for general corporate purposes, including capital expenditures, working capital and potential future acquisitions. See "Use of Proceeds." Proposed Nasdaq National Market symbol.......... SRCL
- ------------------------ (1) Based on the number of shares outstanding as of June 1, 1996, after giving effect to the issuance of 98,001 shares of Common Stock in partial payment of a note to be repaid upon completion of this Offering. Excludes 414,030 shares issuable upon the exercise of outstanding stock options exercisable within 60 days of June 1, 1996, at a weighted average exercise price of $0.69 per share, and 387,468 shares issuable upon the exercise of outstanding warrants all of which were exercisable as of June 1, 1996 at a weighted average exercise price of $5.31 per share. Also excludes 304,413 shares issuable upon the exercise of outstanding stock options, at a weighted average exercise price of $1.35 per share, and 21,778 shares issuable upon the exercise of outstanding warrants at a weighted average exercise price of $34.27 per share, which either were not exercisable within 60 days of June 1, 1996 or were exercisable at prices in excess of $11.00 per share, the mid-point of the price range as set forth on the cover page of this Prospectus. See "Description of Capital Stock -- Options" and "-- Warrants." SUMMARY CONSOLIDATED FINANCIAL DATA (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) SIX MONTHS ENDED YEAR ENDED DECEMBER 31, JUNE 30, ----------------------------------------------------- -------------------- 1991 1992(4) 1993 1994 1995 1995 1996 --------- --------- --------- --------- --------- --------- --------- STATEMENTS OF OPERATIONS DATA: Revenues................................. $ 1,563 $ 5,010 $ 9,141 $ 16,141 $ 21,339 $ 10,756 $ 11,616 Cost of revenues......................... 2,005 5,466 9,137 13,922 17,478 8,872 9,189 Selling, general and administrative expenses................................ 3,377 11,223 5,988 7,927 8,137 4,663 3,315 --------- --------- --------- --------- --------- --------- --------- Loss from operations..................... (3,819) (11,679) (5,984) (5,708) (4,276) (2,779) (888) Interest expense......................... (77) (244) (245) (260) (277) (103) (206) Interest income.......................... 243 283 201 156 9 6 -- --------- --------- --------- --------- --------- --------- --------- Net loss................................. $ (3,653) $ (11,640) $ (6,028) $ (5,812) $ (4,544) $ (2,876) $ (1,094) Less cumulative preferred dividends...... (1,351) (2,737) (3,733) (4,481) --(5) (3,146) -- --------- --------- --------- --------- --------- --------- --------- Loss applicable to common stock.......... $ (5,004) $ (14,377) $ (9,761) $ (10,293) $ (4,544) $ (6,022) $ (1,094) --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Net loss per common share (1)............ $ (2.38) $ (6.64) $ (4.51) $ (4.76) $ (0.65) $ (2.78) $ (0.15) --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Weighted average number of common shares outstanding............................. 2,106,842 2,165,625 2,162,611 2,162,988 7,029,441 2,162,988 7,074,440 --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Pro forma net loss per common share (2)..................................... $ (0.62) $ (0.13) --------- --------- --------- --------- Pro forma weighted average number of common shares outstanding (3)........... 7,237,171 7,492,110 --------- --------- --------- --------- JUNE 30, 1996 -------------------- AS ACTUAL ADJUSTED(6) --------- --------- BALANCE SHEET DATA: Cash and cash equivalents............................................................... $ 40 $ 25,770 Total assets............................................................................ 25,834 51,564 Current portion of long-term debt....................................................... 4,306 816 Long-term debt, net of current maturities............................................... 4,399 2,241 Shareholders' equity.................................................................... 11,911 43,289
- ------------------------------ (1) See Note 2 to the Consolidated Financial Statements for information concerning the computation of net loss per share. (2) Adjusted to give effect to the sale of a sufficient number of shares of Common Stock offered hereby (at an assumed initial public offering price of $11.00 per share, the mid-point of the price range set forth on the cover page of this Prospectus, and after the deduction of estimated underwriting discounts and commissions and a pro rata portion of estimated offering expenses payable by the Company) the net proceeds from the sale of which are used to repay certain indebtedness of the Company, and adjusted to give effect, as of the beginning of the period, to the elimination of the interest expense on the indebtedness repaid ($64,000 for the year ended December 31, 1995 and $86,000 for the six months ended June 30, 1996). The number of such shares would be approximately 207,730 at December 31, 1995 and approximately 417,670 at June 30, 1996. See "Use of Proceeds." (3) Adjusted to include a sufficient number of shares of Common Stock offered hereby (at an assumed initial public offering price of $11.00 per share, the mid-point of the price range set forth of the cover page of this Prospectus, and after the deduction of estimated underwriting discounts and commissions and a pro rata portion of estimated offering expenses payable by the Company) the net proceeds from the sale of which are used to repay certain indebtedness of the Company. The number of such shares would be approximately 207,730 at December 31, 1995 and approximately 417,670 at June 30, 1996. See "Use of Proceeds.". (4) During 1992, the Company approved a restructuring plan which resulted in a nonrecurring charge of $2,747,000, primarily to write-off assets associated with a technology used by the Company prior to the development of the ETD process. (5) In August 1995 and in connection with a recapitalization of the Company, the liquidation preference on the Company's preferred stock was eliminated and the Company's preferred stock was reclassified as Class A common stock. See "Description of Capital Stock -- 1995 Recapitalization." (6) Adjusted to give effect to the sale of 3,000,000 shares of Common Stock offered hereby (at an assumed initial public offering price of $11.00 per share, the mid-point of the price range as set forth on the cover page of this Prospectus, and after the deduction of estimated underwriting discounts and commissions and estimated offering expenses payable by the Company), application of the estimated net proceeds to the Company and the issuance of 98,001 shares of Common Stock in partial payment of a note to be repaid upon completion of this Offering. See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000861885_telesensor_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000861885_telesensor_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..415c958d2139b432fe0a37588ce345db4fa1018c
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000861885_telesensor_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and the Financial Statements and Notes thereto appearing elsewhere in this Prospectus, including information under "Risk Factors." Except as otherwise noted, all information in this Prospectus, including financial information, share and per share data, assumes (i) the issuance of 87,500 shares of Common Stock upon the net exercise of all outstanding warrants, and (ii) no exercise of the Underwriters' over-allotment option. See "Underwriting." This Prospectus contains forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from the results discussed in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, those set forth in the Section entitled "Risk Factors" and elsewhere in this Prospectus. THE COMPANY Telesensory Corporation ("Telesensory" or the "Company"), founded in 1970, develops, manufactures and markets innovative electronic and computer-based products to assist people with severe visual disabilities to achieve greater independence and privacy. The Company is the leading provider of such products in North America, and one of the two leading companies worldwide. The Company makes video magnifiers and other electronic and computer-based assistive devices for people who are severely visually impaired (the "Low Vision Products") and various braille-related and other electronic and computer-based assistive devices for those who are totally blind or without useable light perception (the "Blindness Products"). Severe visual impairment is defined by the National Center for Health Statistics as the inability to read ordinary newspaper print even when wearing glasses or contact lenses. Such people also have difficulty with daily activities such as reading mail and prescription bottles, balancing checkbooks, viewing photographs and working with small objects. The number of people in the United States who are severely visually impaired is estimated at 4.3 million. A much smaller population, estimated at 100,000 in the United States, is either totally blind or lacks useable light perception. Populations in other developed countries are believed to exhibit similar rates of visual impairment. Age- related macular degeneration, which has no known cure, is the leading cause of visual impairment and currently affects 20% of individuals over age 65. Other leading causes of visual impairment and blindness include diabetes and glaucoma. Disabled people, including those who are visually disabled, are increasingly seeking to participate fully in workplace, recreation and other daily activities enjoyed by non-disabled people. There is also a growing awareness of the need to enhance the quality of lives of disabled people. For example, the Americans with Disabilities Act (the "ADA") mandates that public facilities and services be accessible to disabled people, including those with visual impairments. The Company believes that these trends, combined with an aging but active population that desires to preserve its independence, have contributed to a growing demand for devices to assist visually disabled people and the development of a consumer market willing and able to purchase assistive devices without government assistance. The Company believes that only a small percentage of visually impaired people are familiar with or own electronic assistive devices. For example, the Company estimates that annual unit sales of all electronic and computer-based magnification systems in the United States are made to fewer than 0.5% of the 4.3 million people who are severely visually impaired. Low Vision Products accounted for 71% of the Company's net revenue in 1995. Low Vision Products consist of video magnifiers and computer screen magnification systems, which provide adjustable magnification, enhanced contrast and a larger field of view. In 1994, the Company introduced the Aladdin, a highly innovative, advanced video magnifier. In 1995, the Aladdin won the American Society of Aging's Gold Award for outstanding product design for mature consumers. Primarily as a result of the introduction of the Aladdin, unit sales of video magnifiers increased 53% in 1995 over the prior year, to 11,091 units, and increased 18% in the first half of 1996 as compared to the first half of 1995. The Company believes that its sales of video magnifiers, in both units and dollars, represented approximately 55% of the market in the United States in 1995 and significantly exceeded comparable figures for any of its competitors worldwide. Blindness Products accounted for 29% of the Company's net revenue in 1995. The principal product line consists of refreshable computer-controlled braille displays that enable blind persons to operate personal computers. Other Blindness Products include optical character reading systems with synthesized speech or braille output, and braille printers. The Company believes that it is one of the top three manufacturers worldwide for the majority of its Blindness Products. Telesensory believes that it has the largest worldwide distributor and dealer network of any company marketing assistive devices to severely visually impaired people. For distribution of its Low Vision Products, the Company uses a network of approximately 110 United States and 30 international distributors and dealers. For distribution of its Blindness Products, the Company uses approximately 37 United States and generally the same 30 international distributors and dealers that distribute its Low Vision Products, as well as an in-house sales team. International sales represented approximately 35% of total sales in 1995. The Company and its distributors sell to government agencies, institutions, schools, corporations and individuals. The Company estimates that government funded purchases accounted for approximately 40% of domestic sales and a higher percentage of international sales in 1995. Since 1994, the Company has taken a number of steps to enhance net revenue and profitability. These steps included the appointment of Larry Israel as President and Chief Executive Officer in July 1994, the implementation of a cost reduction program, the closure of the Company's manufacturing facility in Ireland, the reorganization of the Company into two operating divisions, the adoption of a continuous flow manufacturing process for its Low Vision Products and the introduction of the Aladdin line of video magnifiers. The Company also strengthened its international operations by acquiring its distributors in the United Kingdom and France in March 1996. Pre-tax earnings have increased from a loss of $1.3 million in 1993 to a profit of $2.3 million in 1995 and a profit of $1.4 million for the first six months of 1996. See "Selected Consolidated Financial Data."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000862148_ev_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000862148_ev_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..b03c70ee345cb1b28a3c92f7982810592b7539e9
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000862148_ev_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY PROSPECTUS SUMMARY The following is intended only to supply certain facts and highlights of the material contained in the body of the Prospectus and is qualified in its entirety by the more detailed information and financial statements and notes thereto appearing elsewhere in this Prospectus and Registration Statement. THE COMPANY The Company is a Delaware corporation with five operating subsidiaries, EV Environmental Systems, Inc., formerly Pollution Control, Inc. ("PCI"), Aer-O-Flo Environmental, Inc. ("Aer-O-Flo"), Pollution Control Engineering, Inc. ("PCE"), EV Engineering, Inc. ("EVE") and EV Contract Management Services, Inc. ("CMS"). PCI, a Kentucky corporation located in Ft. Mitchell, Kentucky (a suburb of Cincinnati, Ohio), is a successor business by merger to a business incorporated in 1985. Aer-O-Flo, an Ontario corporation located in Burlington, Ontario (a suburb of Toronto, Ontario), is a successor business to a business formed in 1963. PCE, a Delaware corporation located in Irvine, California, is the successor to a business formed in 1960. EV Engineering, Inc. and EV Contract Management Services, Inc. (both Delaware corporations) are successors to a business formed in 1969. The Company is engaged in the business of supplying systems and services for the treatment of water and wastewater. The Company markets to its customers its ability to design, supply and operate the total treatment system for the solution of the customer's process discharges. The Company designs the treatment systems, manages the manufacture of the related hardware (through contract manufacturers), manages the installation of the systems, trains customer personnel in their operation, and provides ongoing system management and support. Any combination of these offerings, and in some cases all of them, can be utilized by the Company's customers. The Company believes that its systems provide positive returns on investment for its customers. As freshwater resources are stretched by growth in many regions, the Company believes that reuse of wastewater will become the most economically viable source of additional water. In regions where freshwater use is restricted, it is possible for a customer to expand operations by recycling wastewater or alternatively, to sell water rights to other users. Coupled with reduced operating costs and sewage surcharges, investment in the Company's systems can be economically attractive. The Company does not own or operate a hazardous waste landfill or any other hazardous waste treatment, storage or disposal facility. The Company intends to pursue a business
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000866253_amc_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000866253_amc_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..4bd846941513a09de6f77fee3c4d6da4897cab91
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000866253_amc_prospectus_summary.txt
@@ -0,0 +1 @@
+SUMMARY The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements and notes thereto appearing elsewhere in this Prospectus. This Prospectus contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under "Risk Factors" and elsewhere in this Prospectus. THE COMPANY Cityscape Financial Corp., a Delaware corporation ("Cityscape" or the "Company"), is a consumer finance company engaged in the business of originating, purchasing, selling and servicing mortgage loans secured primarily by one- to four-family residences. The Company originates and purchases loans in the US through its subsidiary Cityscape Corp., a New York corporation ("CSC"), using a network of independent mortgage brokers and loan correspondents, and in the United Kingdom (excluding Northern Ireland, the "UK") through its indirect subsidiary City Mortgage Corporation Limited also using a network of independent mortgage brokers. The majority of the Company's loans are made to owners of single family residences who use the loan proceeds for such purposes as debt consolidation, financing of home improvements and educational expenditures. The Company focuses on lending to individuals who have impaired or unsubstantiated credit histories and/or unverifiable income and require or seek a high degree of personalized service and prompt response to their loan applications. As a result, the Company's customers generally are not averse to paying the higher interest rates that the Company charges for its loan programs as compared to the interest rates charged by conventional mortgage sources. Because its customers generally borrow for reasons other than the purchase of homes, the Company believes that it is not as dependent as traditional mortgage bankers on general levels of home sales and refinancing activity. In the US, the Company originates and purchases loans through three channels: (i) originations through an extensive network of independent mortgage brokers utilizing the Company's New York headquarters and four regional processing offices located in California, Georgia, Illinois and Virginia; (ii) purchases on a flow basis through its Wholesale Loan Acquisition Program from selected financial institutions and mortgage bankers known as loan correspondents; and (iii) purchases of large pools of loans (referred to as "bulk purchases") from other originators. The Company originates loans through a network of independent mortgage brokers in 37 states and the District of Columbia, with its highest producing broker accounting for 2.4% of the total US origination and purchase volume for the six months ended June 30, 1996. The Company strives to process each loan application received from mortgage brokers as quickly as possible in accordance with the Company's loan application approval procedures. Accordingly, most loan applications receive preliminary decisions within 24 hours of receipt and most accepted applications are funded within 15-25 days thereafter. Loans purchased on a flow basis in the Wholesale Loan Acquisition Program are originated by loan correspondents in accordance with the Company's underwriting guidelines and purchased as complete loan packages. The highest producing loan correspondent in the Wholesale Loan Acquisition Program accounted for 3.5% of the total US origination and purchase volume for the six months ended June 30, 1996. In addition, in June 1996, the Company expanded its whole loan purchases to include the purchase of loans which other originators offer in the secondary market on a bulk basis. The Company believes it has the underwriting, servicing and management capabilities in place, as well as the necessary access to capital, to review and purchase bulk loans competitively in this market segment and to benefit from the efficiencies related to the purchase and securitization of such loans. As the Company has expanded the channels through which it originates and purchases loans, it has also broadened the types of loans it offers. The Company offers a wide range of loan products in the US, including traditional residential mortgage loans for refinancing, educational, home improvement and debt consolidation purposes, mortgage loans on small multi-family and mixed-use properties, and more recently, adjustable rate mortgage loans and jumbo loans. The Company also purchases conventional home improvement loans and, to a lesser extent, originates and purchases Title I home improvement loans partially insured by the US Department of Housing and Urban Development. For 1995 and the first six months of 1996, the average principal balances of the Company's loans in the US were $69,551 and $66,940, respectively, the weighted average initial loan-to-value ratios on such loans were 66.4% and 69.9%, respectively, and the weighted average interest rate on such loans were 11.9% and 11.4%, respectively. In May 1995, the Company commenced its UK operations with the formation of City Mortgage Corporation Limited ("CSC-UK"), an English corporation that originates, sells and services loans in England, Scotland and Wales. The UK market for the type of loans the Company produces is highly fragmented and, for a variety of reasons, underserved by conventional lenders as compared to the US market. In the UK, the Company originates loans through a network of independent mortgage brokers. The Company has entered into contracts with several of its highest producing brokers which grant the Company a right of first refusal on all loan applications that meet specified underwriting criteria. To further increase its loan origination volume and market share in the UK, the Company also recently acquired J&J Securities Limited ("J&J") and Heritable Group Limited ("Heritable"), two UK-based mortgage bankers (referred to respectively as the "J&J Acquisition" and the "Heritable Acquisition"). The J&J Acquisition has provided the Company with greater strength in the second lien loan market, additional experienced management personnel and a greater share of the fragmented UK market through additional broker relationships and the expansion of product offerings. J&J's loans are generally second lien mortgage loans with lower loan-to-value ratios, higher interest rates, smaller principal loan balances and higher delinquency experience than the loans traditionally originated by CSC-UK. The Heritable Acquisition represents an expansion of new product types offered to a higher credit quality borrower and that are complementary to the Company's other UK business. Heritable's loans are generally second lien mortgage loans with higher loan-to-value ratios, lower interest rates, smaller principal loan balances and lower delinquency experience than the loans traditionally originated by CSC-UK. For 1995 and the first six months of 1996, the average principal balances of the Company's loans in the UK were $43,120 and $14,940, respectively, the weighted average initial loan-to-value ratios on such loans were 49.0% and 51.6%, respectively, and the weighted average interest rates on such loans were 16.4% and 16.9%, respectively. The Company sells its loans primarily in the secondary market through securitizations in order to maximize profitability and reduce its exposure to fluctuations in interest rates. To a lesser extent, the Company sells its loans through whole loan sales to achieve greater liquidity. Through 1994, the Company sold virtually all of its loan production on a whole loan sale basis in private placements to a variety of institutional purchasers. Since 1995, however, the Company has sold a substantial portion of its loan production in securitizations. The Company completed its first US securitization in March 1995 and its first UK securitization in March 1996. Each of the Company's US securitizations has been credit-enhanced by insurance provided by a monoline insurance company to receive ratings of "Aaa" from Moody's Investor Services, Inc. and "AAA" from Standard & Poor's Ratings Group. The Company funds its originations and purchases through warehouse lines of credit and a standby facility in the US and purchase and sale facilities in the US and the UK into which it sells the loans it originates and purchases prior to their securitization. The Company intends to continue to sell loans primarily through securitizations and, subject to market conditions, through whole loan sales. The Company retains the servicing rights to substantially all loans it originates or purchases. Loan servicing involves the collection of payments due under a loan, the monitoring of the loan, the remitting of payments to the holder of the loan, the furnishing of reports to such holder and the enforcement of the lender's rights, including attempting to recover delinquencies and instituting loan foreclosures. As of June 30, 1996, the Company was servicing an aggregate of $757.9 million of US loans, including $56.2 million of loans as master servicer and $20.1 million as contract servicer, and an aggregate of $332.2 million of UK loans. At December 31, 1995 and June 30, 1996, the Company's ratios of delinquent loans (one or more payments 30 or more days past due) to loans serviced by dollar amount were 3.9% and 5.6%, respectively, on its US loan portfolio and 8.6% and 16.7%, respectively, on its UK loan portfolio. The Company has not experienced material loan losses in part because its loan portfolio has been characterized by relatively low initial loan-to-value ratios. Because the Company only expanded into the business of loan servicing in the US during the last two years and in the UK in May 1995, the Company's loan portfolios are relatively unseasoned. The Company believes that over time its delinquency and loan loss experience will increase as its loan portfolio matures. The Company has reserved for loan losses in amounts which it believes to be adequate to cover potential losses for the credit risks it retains on the loans in its servicing portfolio. Management believes that the business of loan servicing provides an additional and profitable revenue stream and one that is less cyclical than the business of originating and purchasing loans. The Company's business strategy includes (i) geographic expansion throughout the US, (ii) growth through selected acquisitions, (iii) further development and expansion of its UK operations, (iv) expansion of its Wholesale Loan Acquisition Program and bulk purchases, (v) maximization of independent mortgage broker relationships, (vi) maintenance of underwriting standards and infrastructure to continue to service its increasing loan portfolio effectively and (vii) introduction and expansion of new products. USE OF PROCEEDS The Company will not receive any proceeds from the sale of the Securities offered hereby. NASDAQ SYMBOL The Common Stock is traded on Nasdaq under the symbol "CTYS."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000868984_whitehall_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000868984_whitehall_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..f4e3dd8c93c1ce6f5deef521ed1f34eb9e807e84
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000868984_whitehall_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements, including the notes thereto, appearing elsewhere in this Prospectus. Unless otherwise indicated, all information in this Prospectus assumes no exercise of the Underwriters' over-allotment option. The Company's fiscal year ends on January 31. References to fiscal years by date refer to the fiscal year beginning February 1 of that calendar year; for example, "fiscal 1995" began on February 1, 1995 and ended on January 31, 1996. Certain statements in this Prospectus (including this Prospectus Summary) constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Litigation Reform Act"). See "Special Note Regarding Forward-Looking Statements." THE COMPANY Marks Bros. Jewelers, Inc. (the "Company") is a leading, national specialty retailer of fine jewelry, operating 163 stores in 24 states. Founded in 1895, the Company operates stores in regional and super-regional shopping malls under the names Whitehall Co. Jewellers(R) (123 stores), Lundstrom Jewelers(R) (35 stores) and Marks Bros. Jewelers(TM) (5 stores). The Company offers at competitive prices an in-depth selection of fine jewelry in the following key categories: diamond, gold, precious and semi-precious jewelry. The Company's target customers are middle to upper middle income women over 25 years old. Central to the Company's growth in operating profits and its high store productivity are its small but flexible store format, the absence of recourse credit risk, its strong sales culture, and its operating efficiencies at both the store and corporate levels. From fiscal 1991 to fiscal 1995, the Company's net sales grew at a compound annual rate of 14.3%, from $76.7 million to $131.0 million, while income from operations grew at a compound annual rate of 30.2%, from $5.4 million to $15.4 million. The Company's growth during this period is attributable to (i) new store openings, which resulted in an increase in the number of stores from 111 to 146 stores, (ii) higher store productivity, as average annual sales per store increased from $699,000 to $936,000, and (iii) improved operating efficiencies, which resulted in an increase in the Company's operating margin from 7.0% to 11.8%. For the six months ended July 31, 1996, the Company's net sales increased by 23.8% as compared to net sales in the first six months of fiscal 1995, and operating margin improved from 7.0% to 8.5%. The Company believes it has significant opportunities to increase sales and profitability through an increased number of planned store openings, the implementation of several new sales and merchandising programs designed to produce comparable store sales growth, and continued adherence to its strict operating standards regarding performance of sales personnel, store profitability and cost control. The key elements of the Company's multi-faceted operating strategy are as follows: - Small, Flexible Store Format in Regional Malls. The Company believes it has a competitive advantage in obtaining high traffic, "center court" locations in desirable regional and super-regional malls due principally to (i) its small average store size of approximately 790 square feet, which, while considerably smaller than the average store size of most of the Company's competitors, generates comparable sales volumes, (ii) its ability to adapt its store design to various sizes and configurations, and (iii) its high average annual sales per square foot (approximately $1,200 in fiscal 1995). Over two-thirds of the Company's stores are located in high traffic, "center court" locations. The stores' small, flexible format (which lowers the Company's fixed occupancy costs) and high productivity are desirable to mall owners. - Absence of Recourse Credit Risk. The Company operates based upon a "no credit risk" policy. When purchasing on credit, customers must use their personal credit cards, the Company's private label credit card (which is available through a third party and is non-recourse to the Company), or other non-recourse third party credit arrangements. The Company's strict credit policy eliminates its credit risk associated with the customer's failure to pay. This policy also distinguishes the Company from most of its competitors, which not only bear such credit risk, but also rely on finance income in addition to merchandise sales. Photo of Lundstrom Jewelers Store Photo of Whitehall Co. Store - Motivated, Sales-Oriented Store Personnel. The primary responsibility of store sales personnel is selling to customers. Most non-sales activities are largely centralized. Incentive compensation and bonus programs reinforce sales and margin goals on a daily, weekly and monthly basis. The Company continually seeks to enhance the selling skills of its sales associates through recruitment of experienced sales personnel and extensive, ongoing training programs. - Differentiated Merchandising. The Company offers an in-depth selection of merchandise in several key categories of fine jewelry: diamond, gold, precious and semi-precious jewelry. This "key category" focus is oriented to the Company's target customer, the middle to upper middle income woman. Unlike many of its competitors, the Company carries only a limited selection of watches and virtually no costume jewelry or gift merchandise. - Strict Operating Controls. The Company emphasizes high performance standards, backed by strong incentive programs. Adherence to these standards in the areas of store site selection, sales targets, store profitability and cost control is fundamental to the Company's success. RECENT DEVELOPMENTS Strong Operating Performance. The Company's 23.8% increase in net sales for the first six months of fiscal 1996 was driven by a comparable store sales increase of 13.4% and the strong performance of recently opened stores. Operating margin increased 150 basis points to 8.5% for the first six months of fiscal 1996 from 7.0% over the prior year period, and pro forma net income per share increased to $0.18 from $0.05. Store sales productivity continued to increase, as average store sales grew to $972,000 per store ($1,224 per square foot) for the 12 months ended July 31, 1996, from average store sales of $936,000 ($1,187 per square foot) for fiscal 1995. For the first two months of the third quarter of fiscal 1996, comparable store sales increased by 7.8% on top of a 15.9% comparable store sales increase in the corresponding prior year period. Acceleration of Expansion Program. As of October 31, 1996, the Company has opened 18 new stores and plans to open one additional store for a total of 19 new stores by the end of fiscal 1996, compared to the 18 originally planned. As a result of this offering, the Company plans to accelerate its store expansion program to 28 stores scheduled for fiscal 1997 (compared to the 23 originally planned) and already has executed leases for 11 of these locations. The Company intends to open a total of approximately 60 new stores in fiscal 1997 and 1998 combined. Strengthening of Capital Structure. To facilitate its continuing expansion, the Company intends to use proceeds from this offering to strengthen its capital structure, retire $8.0 million of principal amount of its 15% subordinated notes and pay down other outstanding borrowings. THE OFFERING Common Stock Offered by the Company......................... 1,100,000 shares Common Stock Offered by the Selling Stockholders............ 1,205,000 shares Common Stock to be Outstanding Immediately After the Offering.................................................. 9,707,250 shares(1) Use of Proceeds............................................. To reduce indebtedness, accelerate new store openings and for working capital and other general corporate purposes. Nasdaq National Market Symbol............................... MBJI
- ------------------------------ (1) Excludes 1,060,476 shares of Common Stock subject to outstanding stock options at a weighted average exercise price of $10.37 per share, of which 318,760 are currently exercisable at a weighted average exercise price of $0.93 per share. See "Management -- Stock Plans." Photo of Whitehall Co. Store Photo of Whitehall Co. Window display SUMMARY FINANCIAL AND OPERATING DATA (DOLLARS IN THOUSANDS, EXCEPT PER SHARE AND SELECTED OPERATING DATA) YEAR ENDED JANUARY 31, SIX MONTHS ENDED JULY 31, ----------------------------------------------------------- -------------------------- 1992 1993 1994 1995 1996 1995 1996 -------- -------- -------- -------- ----------- ----------- ----------- (UNAUDITED) STATEMENT OF OPERATIONS DATA: Net sales......................... $ 76,749 $ 88,141 $ 91,106 $106,683 $131,022 $52,074 $64,466 Gross profit...................... 31,143 36,035 36,595 42,460 53,300 20,115 25,840 Income from operations............ 5,362 8,064 8,255 11,712 15,413 3,657 5,455 Interest expense.................. 9,397 7,821 8,920 10,594 12,314 6,017 4,557 ESOP compensation expense......... -- 3,800 511 547 -- 295 -- Income (loss) from continuing operations before income tax.... (17,157) (3,557) (1,176) 571 2,048 (2,655) 898 Net income (loss)(1)(2)(3)........ $(24,454) $ (3,557) $ (7,002) $ 571 $ 16,972 $(2,655) $11,712 SUPPLEMENTAL PRO FORMA STATEMENT OF OPERATIONS DATA(4): (UNAUDITED) Net sales......................... $131,022 $52,074 $64,466 Income from operations............ 15,413 3,657 5,455 Interest expense.................. 2,943 1,416 1,503 Net income........................ 7,205 1,345 2,371 Net income per share.............. $ 0.72 $ 0.13 $ 0.23 Weighted average number of common shares and common share equivalents outstanding(5)...... 10,008,222 10,014,617 10,170,053 SELECTED OPERATING DATA: Stores open at end of period...... 111 113 122 131 146 143 155 Average net sales per store(6).... $699,000 $784,000 $791,000 $836,000 $936,000 Average net sales per gross square foot(7)......................... $ 883 $ 1,008 $ 1,013 $ 1,068 $ 1,187 Average merchandise sale.......... $ 192 $ 210 $ 229 $ 245 $ 253 $ 262 Comparable store sales increase (decrease)(8)................... 0.4% 12.5% (0.5)% 7.6% 11.0% 11.8% 13.4%
JULY 31, 1996 ------------------------- ACTUAL AS ADJUSTED(9) ------- -------------- BALANCE SHEET DATA: Working capital......................................................................... $15,030 $ 20,267 Total assets............................................................................ 75,300 75,384 Total debt.............................................................................. 43,532 16,753 Stockholders' equity.................................................................... 4,395 31,258
- ------------------------------ (1) The Company sold its direct marketing division as of January 31, 1992. In connection with this disposition, the Company recorded a $7.3 million loss in the year ended January 31, 1992 on the sale of the discontinued operations and a $2.7 million gain in the year ended January 31, 1994 upon its receipt of the deferred proceeds from the sale. (2) Net loss for the year ended January 31, 1994 reflects a charge for the cumulative effect of the Company's change in accounting in the amount of $8.5 million to adopt AICPA SOP 93-6 for the recognition of compensation expense on shares allocated to the ESOP. See "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Background" and Note 5 of Notes to Financial Statements. (3) Net income for the year ended January 31, 1996 reflects an income tax benefit of $14.9 million, resulting from the reversal of the Company's deferred tax valuation allowance and recognition of a corresponding net deferred tax asset. See "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Background" and Note 6 of Notes to Financial Statements. (4) Supplemental pro forma statement of operations data reflect (i) the Company's initial public offering (the "IPO") and recapitalization in May 1996 (see "The Company"); (ii) the issuance of 1,100,000 shares of Common Stock offered hereby at an assumed public offering price of $27.00 per share (the "Offering") and the anticipated use of the estimated net proceeds therefrom; and (iii) the application of a tax provision (assuming a statutory rate of 40%) to the pro forma net income from continuing operations, as if each such transaction occurred on the first day of the period presented. (5) The pro forma weighted average number of common shares and common share equivalents outstanding for the year ended January 31, 1996, and the six months ended July 31, 1995 and July 31, 1996, respectively, consisted of (i) 9,707,267, 9,713,662 and 9,707,250 shares of Common Stock outstanding (including 3,269,500 shares of Common Stock issued in the IPO and 1,100,000 shares of Common Stock offered hereby); (ii) 3,588, 3,588 and 3,213 common share equivalents relating to Class B Common Stock; (iii) 297,367, 297,367 and 304,098 common share equivalents relating to the Company's 1995 incentive stock option plan and (iv) -0-, -0- and 222,654 common share equivalents relating to the Company's 1996 incentive stock option plan. (6) Average net sales per store represents the total net sales for stores open for a full fiscal year divided by the total number of such stores. (7) Average net sales per gross square foot represents total net sales for stores open for a full fiscal year divided by the total gross square feet of such stores. (8) A store becomes comparable after it has been open for 12 full months. (9) As adjusted to give effect to (i) the Offering; (ii) the receipt of $0.2 million in proceeds to the Company from the exercise of stock options in connection with the Offering; and (iii) the anticipated use of proceeds from the Offering (including a $0.96 million ($0.58 million net of tax) prepayment premium in connection with the redemption of subordinated debt and a non-cash extraordinary charge of $0.5 million ($0.3 million net of tax) relating to the write-off of deferred financing costs). See "Use of Proceeds."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000872548_furrs_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000872548_furrs_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..bb44f803db22aafa327c12a6e0d70c28e4c9bd35
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000872548_furrs_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following is a summary of certain information contained elsewhere in this Prospectus. It is not, and is not intended to be complete. Reference is made to, and this summary is qualified in its entirety by, the more detailed information contained elsewhere in this Prospectus. Unless otherwise defined, capitalized terms used in this Summary have the meanings ascribed to them elsewhere in this Prospectus. Prospective purchasers are encouraged to read carefully all of the information contained in this Prospectus in its entirety. THE COMPANY Furr's/Bishop's, Incorporated, a Delaware corporation (the "Company"), through its subsidiaries, is one of the largest operators of family-style cafeteria restaurants in the United States (based on the number of cafeterias operated). The Company believes that its cafeterias and buffet, which are operated under the "Furr's" and "Bishop's" names, are well recognized in their regional markets for their value, convenience, food quality and friendly service. The Company's 110 cafeterias and one buffet are located in thirteen states in the Southwest, West and Midwest. The Company also operates two specialty restaurants in Lubbock, Texas under the name Zoo-Kini's Soups, Salads and Grill. In addition, the Company operates Dynamic Foods, its food preparation, processing and distribution division in Lubbock, Texas. Dynamic Foods provides approximately 85% of the food and supply requirements of the Company's cafeteria and buffet restaurants. Dynamic Foods also sells pre-cut produce, bakery items, meats and seafood and various prepared foods to the restaurant, food service and retail markets. See "Business." The principal executive offices of the Company are located at 6901 Quaker Avenue, Lubbock, Texas 79413, and the telephone number is (806) 792-7151. Unless the context otherwise requires, all references in this Prospectus to the "Company" include the Company and its subsidiaries. BACKGROUND; THE RESTRUCTURING The Company recently completed a comprehensive restructuring of its and its subsidiaries' financial obligations (the "Restructuring"). As part of the Restructuring, Cafeteria Operators, L.P., a Delaware limited partnership and indirect wholly owned partnership subsidiary of the Company ("Cafeteria Operators"), executed the Amended and Restated Indenture (the "Indenture") dated as of November 15, 1995 between Cafeteria Operators and Fleet National Bank of Massachusetts (f/k/a Shawmut Bank, N.A.), as trustee, pursuant to which, among other things, the terms of $40.0 million aggregate principal amount outstanding under Cafeteria Operators' 11% Senior Secured Notes due June 30, 1998 (the "11% Notes") issued pursuant to the Indenture dated as of March 27, 1992 between the Company and Shawmut Bank, N.A., as collateral agent (the "Old Indenture"), were amended, with the consent of the holders of the 11% Notes at such time (the "Original 11% Noteholders"), to constitute $40.0 million (subject to the issuance of additional notes in payment of the first interest installment) aggregate principal amount of 12% Senior Secured Notes ("12% Notes") issued pursuant to the Indenture. In addition, Cafeteria Operators issued a 12% Note in the original principal amount of $1.7 (plus interest) million to the Trustees of General Electric Pension Trust ("GEPT") in settlement of a $5.4 million judgment against Furr's/Bishop's Cafeterias, L.P., a Delaware limited partnership and indirect wholly owned partnership subsidiary of the Company ("FBLP"). As part of the Restructuring, Wells Fargo Bank, National Association ("Wells Fargo") received an option to purchase 2.5% of the outstanding Common Stock (the "Wells Fargo Option") in satisfaction of approximately $6.1 million principal amount (plus approximately $1.6 million of accrued and unpaid interest) of indebtedness of a subsidiary of the Company. As a result of the Restructuring, indebtedness of Cafeteria Operators in the amount of approximately $153 million aggregate principal amount (plus approximately $46.6 million in accrued and unpaid interest) outstanding under the Old Indenture was exchanged by holders on January 2, 1996 of the 11% Notes (the "Exchanging 11% Noteholders" and together with the Original 11% Noteholders, the "former 11% Noteholders") for an aggregate of 95% of the limited partnership interests of Cafeteria Operators and the right to put to the Company their 95% limited partnership interests in Cafeteria Operators in exchange for 95% of the outstanding Common Stock (the "Put Option"). In addition, outstanding warrants to purchase capital stock of the Company held by certain of the Exchanging 11% Noteholders were cancelled. On March 12, 1996, a majority of the Exchanging 11% Noteholders exercised the Put Option and, accordingly, all Exchanging 11% Noteholders put their aggregate 95% limited partnership interests to the Company in exchange for 95% of the outstanding Common Stock. On March 15, 1996, Wells Fargo exercised the Wells Fargo Option thereby becoming the beneficial owner of 2.5% of the outstanding Common Stock. As of the date of this Prospectus, the Exchanging 11% Noteholders no longer own any limited partnership interests of Cafeteria Operators; however, they and their successors and assigns own an aggregate of 95.0% of the outstanding Common Stock. See "Background; The Restructuring" and "Risk Factors -- Ownership of the Company."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000873269_pharmavene_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000873269_pharmavene_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..a92713abbf971fb6c6e340036d5c138c7fb35118
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000873269_pharmavene_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND THE FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. INVESTORS SHOULD CAREFULLY CONSIDER THE INFORMATION SET FORTH UNDER THE HEADING "RISK FACTORS." EXCEPT AS OTHERWISE NOTED, ALL INFORMATION IN THIS PROSPECTUS ASSUMES NO EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION AND REFLECTS (I) THE ONE-FOR-SIX REVERSE SPLIT OF THE COMMON STOCK EFFECTIVE IN MARCH 1996 AND (II) THE AUTOMATIC CONVERSION OF ALL OUTSTANDING SHARES OF MANDATORILY REDEEMABLE SERIES A CONVERTIBLE PREFERRED STOCK, $.01 PAR VALUE (THE "PREFERRED STOCK"), INTO SHARES OF COMMON STOCK AND CERTAIN RELATED TRANSACTIONS UPON THE CLOSING OF THIS OFFERING. THE COMPANY Pharmavene, Inc. (the "Company") develops pharmaceutical products utilizing advanced drug delivery systems. The Company has developed a portfolio of drug delivery and screening technologies designed to produce optimal delivery of a particular pharmaceutical product for a given indication. These technologies include its proprietary Peptitrol systems for the oral delivery of hard-to-deliver compounds, oral controlled-release and sustained-release delivery, transmucosal delivery through tissues in the oral cavity and transdermal delivery. Instead of emphasizing a specific drug delivery system, the Company selects the drug delivery system that it believes is most effective for delivery of a specific compound and that can result in such advantages as convenient dosing, reduced side effects, improved bioavailability or easier administration. The Company has also developed various screening technologies, including its proprietary Peptiscreen system, to systematically and rapidly test a large number of formulations. The Company's strategy in selecting its current product candidates has been to generally select pharmaceutical products for reformulation that the Company believes have a significant commercial market, that are off-patent or for which patent protection will no longer be available at the time the Company's product is introduced and where enhancement of the method of delivery is expected to have measurable clinical value as compared to the existing delivery method. The Company generally selects products for reformulation that treat indications that have relatively simple, clear-cut clinical end-points. Most of the Company's product candidates are reformulations of existing compounds approved by the U.S. Food and Drug Administration (the "FDA") and the Company's delivery systems usually contain inactive ingredients that are generally recognized as safe (GRAS) for food use as determined by the FDA or are inactive ingredients that the Company believes are safe for such use. Therefore, the Company believes that the development process for its products may be expedited and some of the regulatory approval risks may be reduced. In addition to reformulating existing compounds, the Company also intends to seek arrangements with other companies developing pharmaceutical products based on new molecular entities to use the Company's drug delivery systems to formulate these products. The Company's initial product is expected to be Carbatrol, a sustained-release, patented formulation of carbamazepine for the treatment of epilepsy. In 1994, U.S. sales of carbamazepine were approximately $148 million. A major cause of seizures in epileptic patients is patient noncompliance with the treatment regimen, which can be caused by frequent dosing and an adverse side effect profile. Carbatrol would provide convenient twice-a-day dosing and could be administered orally as a capsule or sprinkled on food. On June 1, 1996, the Company's New Drug Application ("NDA") under Section 505(b)(2) (a "505(b)(2) NDA") of the Federal Food, Drug and Cosmetic Act, as amended, relating to Carbatrol was accepted for filing by the FDA. If approved for marketing, Carbatrol, which has been licensed to Athena Neurosciences, Inc. ("Athena"), a wholly-owned subsidiary of Elan Corporation plc ("Elan"), will compete directly with CIBA-Geigy's twice-a-day, extended-release formulation of carbamazepine. The Company has 11 other product candidates, including oral controlled-release formulations of Selegiline SR for treatment of cocaine craving and for the treatment of Parkinson's Disease, Acyclovir CD for the treatment of viral infections, Nifedipine SR (a generic version of Procardia XL) for the treatment of cardiovascular disorders and Insulin CD for diabetes. The Company is also developing a transmucosal formulation of dihydroergotamine (DHE) for the treatment of migraine headache, an injectable formulation of butyrylcholinesterase (BChE) for the treatment of cocaine overdose and for the treatment of post- surgical apnea, as well as three transdermal sustained-release products, Alprazolam TD and Lorazepam TD for the treatment of anxiety and PI 181.2 TD for the treatment of emesis. A number of these product candidates are in the early stages of development. The Company has developed its proprietary Peptitrol drug delivery technologies for the enhanced oral delivery of pharmaceutical compounds that are hard to deliver or have poor oral bioavailability, such as peptides and other large molecules. The Peptitrol drug delivery systems use one or more hydrophobic or hydrophilic materials to protect the pharmaceutical compound from degradation and to increase absorption of the compound from the gastrointestinal tract. The Company then uses its proprietary Peptiscreen cell culture screens to rapidly test the formulations developed using Peptitrol technologies. The Company is currently in the process of developing Acyclovir CD, Insulin CD and DHE IR using its Peptitrol and Peptiscreen technologies. The Company generally intends to develop its products and commence clinical testing in humans and then to seek collaborators to undertake further testing, obtain regulatory approval, manufacture and market such products. In August 1994, the Company entered into its first license agreement with Rhone-Poulenc Rorer, Inc. and its Armour Pharmaceutical Company subsidiary, which subsequently merged with Behringwerke to form the Centeon joint venture (together, "Rhone-Poulenc Rorer") to develop, manufacture and market its BChE Injectable products for the treatment of cocaine overdose and reversal of post-surgical apnea. The Company's BChE Injectable products have been designated as Orphan Drugs by the FDA for each of these indications. As a result, the Company may be entitled to marketing exclusivity for these indications for a seven-year period, subject to certain limitations, if it is the first sponsor to receive FDA approval for such indications. See "Business -- Government Regulation." On July 1, 1996, the Company entered into an exclusive license agreement with Athena for the worldwide marketing, sale and distribution of Carbatrol. Carbatrol will be marketed in the United States by Athena and by its affiliates or sublicensees in the rest of the world. Under the agreement, Athena (i) will make a $2.0 million payment within ten days of the execution of the agreement, (ii) will fund all future development costs associated with Carbatrol which are approved by a steering committee, (iii) will make a milestone payment of up to $8.0 million upon FDA approval of the Company's Carbatrol NDA, of which $5.0 million is creditable against future royalty payments which may be earned on product sales, and (iv) will make future royalty payments to the Company based on net sales of Carbatrol. The milestone payment is conditioned upon the absence of any finding of exclusivity for CIBA-Geigy's Tegretol XR or any actual or threatened proceeding seeking such a finding. Athena has been granted the right to purchase 220,000 shares of Common Stock in this offering. The Company was incorporated in Delaware on December 22, 1989, as Substance Abuse Sciences, Inc. In February 1990, the Company changed its name to Pharmavene, Inc. The Company's executive offices are located at 1550 East Gude Drive, Rockville, Maryland 20850 and its telephone number is (301) 838-2500. THE OFFERING Common Stock offered.......................... 2,200,000 shares Common Stock to be outstanding after the offering..................................... 8,672,332 shares (1) Use of proceeds............................... To fund research and development activities, including the continued development of Carbatrol, and for general corporate purposes. See "Use of Proceeds." Proposed Nasdaq National Market symbol........ "PHVN"
- ------------------ (1) Includes an aggregate of 6,182,818 shares of Common Stock that will be issued upon consummation of this offering, or that have been issued subsequent to March 31, 1996, in connection with the conversion of Preferred Stock and certain convertible notes and the exercise of options under the Stock Option Plan. See "Capitalization." Excludes as of July 1, 1996: (i) 1,827,759 shares of Common Stock reserved for issuance upon exercise of options granted, to be granted or available for grant under the Company's 1991 Stock Option Plan (the "Stock Option Plan"); and (ii) 665,084 shares of Common Stock reserved for issuance upon exercise of warrants that are outstanding or that the Company has agreed to issue. See "Capitalization," "Management -- Stock Options," "Certain Transactions" and "Description of Capital Stock." SUMMARY FINANCIAL DATA FOR THE PERIOD FOR THE THREE MONTHS FEBRUARY 16, FOR THE YEARS ENDED DECEMBER 31, 1990 (DATE OF ENDED MARCH 31, INCEPTION) TO --------------------------------- ---------------------- MARCH 31, 1993 1994 1995 1995 1996 1996 ----------- --------- --------- --------- ----------- ------------- (IN THOUSANDS, EXCEPT PER SHARE DATA) STATEMENT OF OPERATIONS DATA: Revenues: Licensing revenue........................ $ -- $ 2,000 $ -- $ -- $ -- $ 2,000 Research and development revenue......... -- -- 111 95 19 130 Research and development grants.......... 269 194 -- -- -- 513 Interest income.......................... 19 46 35 5 10 201 ----------- --------- --------- --------- ----------- ------------- Total revenues............................. 288 2,240 146 100 29 2,844 ----------- --------- --------- --------- ----------- ------------- Expenses: Research and development................. 3,932 4,936 4,987 1,230 1,266 20,397 General and administrative............... 1,413 1,317 1,392 369 478 6,777 Interest expense......................... 426 (1) 132 446 58 3,572 (1) 5,166 ----------- --------- --------- --------- ----------- ------------- Total expenses............................. 5,771 6,385 6,825 1,657 5,316 32,340 ----------- --------- --------- --------- ----------- ------------- Net loss................................... $ (5,483) $ (4,145) $ (6,679) $ (1,557) $ (5,287 ) $ (29,496 ) ----------- --------- --------- --------- ----------- ------------- ----------- --------- --------- --------- ----------- ------------- Net loss per common and common equivalent share..................................... $ (1.59 ) $ (1.20) $ (1.91) $ (0.45) $ (1.51 ) $ (8.76 ) ----------- --------- --------- --------- ----------- ------------- ----------- --------- --------- --------- ----------- ------------- Weighted average common and common equivalent shares outstanding............. 3,455 3,458 3,495 3,466 3,508 3,366 ----------- --------- --------- --------- ----------- ------------- ----------- --------- --------- --------- ----------- -------------
MARCH 31, 1996 ------------------------------------------- PRO FORMA ACTUAL PRO FORMA (2) AS ADJUSTED(2)(3) --------- ------------- ----------------- (IN THOUSANDS) BALANCE SHEET DATA: Cash and cash equivalents........................................... $ 586 $ 2,590 $ 24,288 Working capital (deficit)........................................... (225) 1,067 22,766 Total assets........................................................ 3,802 4,901 26,600 Convertible notes................................................... 938 -- -- Capital lease obligations, less current portion..................... 784 784 784 Mandatorily Redeemable Series A Convertible Preferred Stock......... 24,697 -- -- Deficit accumulated during the development stage.................... (29,496) (32,694) (32,694) Total stockholders' equity (deficit)................................ (24,293) 2,442 24,142
- ------------------ (1) Includes non-cash charges of $292,000 during the year ended December 31, 1993, relating to the issuance of warrants to purchase Common Stock at an exercise price below the fair market value per share of the Common Stock and $3,325,000 during the period ended March 31, 1996 in connection with the conversion of an aggregate of $8,000,000 principal amount of convertible notes (the "Convertible Notes") into Preferred Stock at a conversion price below the originally agreed upon conversion price. See "Management's Discussion and Analysis," "Certain Transactions" and Notes 5 and 11 of Notes to Financial Statements. (2) Gives effect to the following events subsequent to March 31, 1996: (i) the borrowing on April 25, 1996 and June 11, 1996 of an aggregate of $2,000,000 principal amount under a credit agreement with certain stockholders entered into in 1996 (the "1996 Credit Agreement"); (ii) the conversion of all of the shares of Preferred Stock outstanding into an aggregate of 5,636,452 shares of Common Stock upon the consummation of this offering; (iii) the conversion of all borrowings under the 1996 Credit Agreement into 545,455 shares of Common Stock upon consummation of this offering ($3,000,000 of such borrowings were outstanding on July 1, 1996 and the foregoing assumes no additional borrowings under the 1996 Credit Agreement and an initial public offering price of $11.00 per share); and (iv) the issuance on June 17, 1996 of 911 shares of Common Stock upon the exercise of options under the Stock Option Plan. See "Capitalization," "Certain Transactions," "Description of Capital Stock" and the Notes to the Financial Statements. (3) Adjusted to give effect to the sale of 2,200,000 shares of Common Stock offered hereby at an assumed initial public offering price of $11.00 per share. See "Capitalization."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000877929_anergen_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000877929_anergen_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..26e60881979ffc5f6089e5576474a965a5b48217
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000877929_anergen_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information, including "Risk Factors," and the Financial Statements and Notes thereto, appearing elsewhere in this Prospectus. This Prospectus contains forward-looking statements that involve risks and uncertainties. The Company's actual results may differ materially from the results discussed in the forward- looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business" as well as elsewhere in this Prospectus. THE COMPANY Anergen, Inc. ("Anergen" or "the Company") is focused on the treatment of autoimmune diseases through the discovery and development of proprietary therapeutics that selectively interrupt the disease process. Anergen's current research and development efforts are focused on two distinct core technologies, AnergiX(TM) and AnervaX(TM), that the Company believes may be used to treat a broad range of autoimmune diseases without generally suppressing the immune system. Patient selection has begun for a Phase I clinical trial of the Company's AnergiX compound for the treatment of multiple sclerosis ("MS") and the Company has initiated a Phase II clinical trial of its AnervaX compound for the treatment of rheumatoid arthritis ("RA"). Since 1993, the Company has collaborated with Novo Nordisk A/S ("Novo Nordisk") in the development of AnergiX treatments for MS, insulin dependent diabetes mellitus ("IDDM") and myasthenia gravis ("MG"). In June 1996, the Company announced a collaborative agreement with N.V. Organon ("Organon") to develop an AnergiX treatment for RA. In the body's immune system, T cells normally regulate the identification and destruction of foreign substances and malignant cells. Autoimmune diseases are caused by abnormal destruction of healthy body tissues by disease-specific T cells. Anergen's results to date suggest that treatments based on its core technologies may interrupt the chain of events fundamental to the onset and continuation of certain autoimmune diseases. The Company's AnergiX technology selectively destroys or inactivates (anergizes) the T cells implicated in the disease process. Its second core technology, AnervaX, stimulates the immune system to produce antibodies that block the presentation of self-antigens to destructive T cells. The Company believes that, because its potential therapeutics target only disease-specific T cells, the normal function of the immune system should remain unaffected. In contrast, currently available therapies for autoimmune diseases treat only the symptoms of the disease or broadly suppress the immune system, which can compromise the ability of the immune system to protect against foreign substances. Anergen received investigational new drug application ("IND") clearance in December 1995 with the United States Food and Drug Administration ("FDA") to begin Phase I clinical testing of its AnergiX compound for the treatment of MS. In preclinical studies, the administration of an AnergiX compound prevented or reduced disease symptoms caused by the T cell initiated autoimmune response in animal models. The Company has also demonstrated in vitro that its AnergiX compound can inactivate human T cells associated with MS. The Company is collaborating with Novo Nordisk on the development of this compound. In April 1996, the Company initiated a multicenter, double-blind, placebo-controlled Phase II clinical trial of its AnervaX compound for the treatment of RA. The results of a Phase I clinical trial completed in October 1995 indicated that AnervaX is well tolerated and can stimulate an immune response in RA patients. Preclinical results have also demonstrated that the Company's AnervaX approach may prevent the onset or reduce the severity of autoimmune disease in animal models. The Company entered into a collaborative agreement with Novo Nordisk in August 1993 under which Novo Nordisk, in exchange for certain marketing rights, will support research and development of the Company's MS, MG and IDDM programs, make milestone payments, and pay royalties on product sales, if any. The Company has the right to co-promote any resultant products for MS and MG in North America. In addition, at the time of the agreement, Novo Nordisk made an $8 million equity investment in the Company. In March 1996, the development program with Novo Nordisk was extended through August 1998, increasing total funds expected to be received by the Company under the collaboration from $25 million to $35 million. These amounts do not include the cost of clinical trials that will be borne directly by Novo Nordisk. In June 1996, the Company entered into a collaborative agreement with Organon under which Organon, in exchange for certain marketing rights, will support research and development of an AnergiX compound to treat RA that incorporates a proprietary peptide discovered by Organon. Under the arrangement, Organon will also pay the Company a one-time license fee, make milestone payments and pay royalties on product sales, if any. The license fee, research and development support and milestone payments that the Company may receive under this agreement are estimated to exceed $15 million. These amounts do not include the cost of clinical trials that will be borne directly by Organon. The Company was incorporated in California in April 1988 as Biospan Corporation and changed its name to Anergen, Inc. in July 1991. The Company's principal executive offices are located at 301 Penobscot Drive, Redwood City, California 94063, and its telephone number at that location is (415) 361-8901. THE OFFERING Common Stock Offered by the Company....... 3,500,000 shares(1) Common Stock to be Outstanding after the Offering................................ 18,529,430 shares(2) Use of Proceeds........................... Research and product development, clinical trials, additional personnel, capital equipment, manufacturing expansion and other working capital and general corporate purposes. See "Use of Proceeds." Nasdaq National Market Symbol............. ANRG
- --------------- (1) Assumes no exercise of the Underwriters' over-allotment option to purchase up to 525,000 additional shares of Common Stock. (2) Based upon the number of shares outstanding as of March 31, 1996. Excludes 825,815 shares issuable upon exercise of options outstanding under the Company's 1988 Stock Option Plan, 20,000 shares issuable upon exercise of options outstanding under the Company's 1995 Director Option Plan and 459,015 shares of Common Stock issuable upon exercise of outstanding warrants. See "Capitalization," "Management -- Incentive Stock Plans" and Note 6 to Financial Statements. SUMMARY FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, ----------------------------------------------- ----------------- 1991 1992 1993 1994 1995 1995 1996 ------- ------- ------- ------- ------- ------- ------- STATEMENTS OF OPERATIONS DATA: Revenues: Contract revenues -- related party...... $ -- $ -- $ 339 $ 2,325 $ 3,001 $ 551 $ 783 Interest income......................... 163 544 312 207 533 17 139 ------- ------- ------- ------- ------- ------- ------- Total revenues................... 163 544 651 2,532 3,534 568 922 ------- ------- ------- ------- ------- ------- ------- Expenses: Research and development................ 2,696 4,525 5,553 7,423 8,322 1,898 1,895 General and administrative.............. 1,218 1,494 1,716 1,831 1,976 462 503 Interest expense........................ 142 78 226 238 322 71 55 ------- ------- ------- ------- ------- ------- ------- Total expenses................... 4,056 6,097 7,495 9,492 10,620 2,431 2,453 ------- ------- ------- ------- ------- ------- ------- Net loss.................................. $(3,893) $(5,553) $(6,844) $(6,960) $(7,086) $(1,863) $(1,531) ======= ======= ======= ======= ======= ======= ======= Net loss per share(1)..................... $ (0.96) $ (0.99) $ (1.12) $ (0.97) $ (0.55) $ (0.25) $ (0.10) ======= ======= ======= ======= ======= ======= ======= Shares used in calculating per share data(1)................................. 4,059 5,599 6,118 7,202 12,859 7,527 14,984 ======= ======= ======= ======= ======= ======= =======
MARCH 31, 1996 -------------------------- ACTUAL AS ADJUSTED(2) ------- -------------- BALANCE SHEET DATA: Cash, equivalents and short-term investments...................... $ 9,653 $ 19,144 Total assets...................................................... 12,461 21,952 Long-term portion of capital lease obligations and debt........... 636 636 Total shareholders' equity........................................ 10,190 19,681
- --------------- (1) See Note 1 to Financial Statements for the method used to determine shares used in calculating per share data. (2) Adjusted to reflect the sale by the Company of the 3,500,000 shares of Common Stock offered hereby at an assumed public offering price of $3.00 per share.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000878760_physician_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000878760_physician_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..4ab2ee04d4d0afb93dc5b50080e7bd7881977808
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000878760_physician_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and the Consolidated Financial Statements and Notes thereto appearing elsewhere in this Prospectus. Prospective investors should consider carefully the information discussed under 'Risk Factors.' Except as otherwise indicated, all information in this Prospectus (i) has been adjusted to give effect to an increase in the number of authorized shares of common stock from 5,000 to 100,000,000 and a change in the par value of common stock from $.01 to $.001 per share (the 'Common Stock'), to be effective prior to the completion of the Offering, (ii) has been adjusted to reflect the 1,400-for-one stock split with respect to the Common Stock that will occur prior to completion of the Offering and (iii) assumes no exercise of the Underwriters' over-allotment option. THE COMPANY Based on its discussions with others in the industry and data available to the Company, the Company believes that it is a leading provider of business management services to hospital-affiliated physicians in an array of practice settings, including solo and group practices, independent practice associations ('IPAs'), specialty networks and other affiliated-physician groups (such physicians and groups being referred to in this Prospectus as 'Physicians'). The Company offers its clients a broad variety of business management services, ranging from accounts receivable management to financial, administrative and strategic support, data management and information systems support. In addition, the Company employs its proprietary technology and extensive financial and patient encounter databases to provide a comprehensive range of managed care services to its clients, including contract review and negotiation, implementation and administration, thereby enhancing their ability to profitably participate in managed care systems. The Company's services enable Physicians to maintain their independence and clinical autonomy while maximizing their reimbursement and cashflow. The Company believes that it is one of the largest providers of business management services to Physicians. Physicians continue to experience increasing pressure on fees coupled with a growing complexity in obtaining reimbursement from third party payors. In addition, the growth of managed care has fostered the need by Physicians for reliable health care resource utilization data, which is critical in every phase of the physician-payor relationship. Given these and other market forces, the Company believes that there is an increasing need among Physicians for sophisticated business management services and information systems provided on an outsourced basis. The Company believes that the business management services industry is highly fragmented, with services often provided to physicians by smaller accounts receivable management companies with annual revenues of less than $2 million. These organizations are unable to provide the broad range of services provided by the Company due to their limited capital and management resources and to their less comprehensive patient encounter databases, which restrict their ability to provide data that assists Physicians in managing their practices more effectively, including in the evaluation of managed care proposals. The Company believes that, as managed care becomes more prevalent, and as physicians continue to demand greater sophistication, broader product lines and higher service levels, these smaller service providers will find it increasingly difficult to compete. The Company currently provides service to over 2,000 physicians, including radiologists, anesthesiologists, pathologists and emergency room physicians, as well as other specialists, many of whom are affiliated with some form of group practice, IPA or other specialty network. The Company intends to continue utilizing its experience in working with Physicians in a number of different practice settings by acquiring and managing various types of specialty networks. For example, the Company manages what it believes is the oldest and largest IPA in the United States, with over 340 physicians. In addition, with its acquisition of a Cleveland-based company, planned to occur simultaneously with the Offering, the Company believes, based on the Acquired Business' expertise, reputation and experience in the industry with respect to management service organizations ('MSOs'), that it will become a leader in the formation, development and management of MSOs. For its services, the Company generally is compensated with a management fee based upon a percentage of its clients' net collections, which percentage is determined after considering a broad range of factors, including the medical specialty of the client and the nature of the services to be provided. In most cases, the Company enters into written contracts with its clients, which range in duration from month-to-month to five years and renew automatically unless notice to the contrary is given. The agreements describe in general the nature of the services to be provided and the management fee to be charged by the Company. As of December 31, 1995, the Company experienced client retention (as measured by the continuation of written contracts in existence at the end of 1994) of approximately 95% of those clients to which it provided services at the end of 1994. The Company estimates that for the 12 months ended December 31, 1995, its subsidiary, Spring Anesthesia Group, Inc., retained approximately 83% of its clients, substantially all of which are individual physicians that do not have written agreements with Spring. The Company's strategy is to build upon its reputation and expertise in providing a broad range of cost-effective, value-added business management services to Physicians through internal growth and by acquisition. The specific elements of the Company's strategy include (i) providing a high level of customer service on a local level while utilizing cost-effective centralized processing centers, (ii) offering an increasingly broad array of value-added services, such as IPA and MSO services, that address the changing health care environment, (iii) continuing to focus on technological means of increasing Physician revenue by expanding and developing proprietary software systems, patient encounter databases, statistical reporting systems and electronic data interfaces, (iv) expanding geographically through acquisition opportunities in the consolidating physician business management services industry and (v) cross-selling its services to other medical specialties. The Company has entered into agreements to acquire (the 'Acquisitions') simultaneously with the Offering, three businesses, one of which consists of three affiliated companies (all of such businesses being referred to collectively as the 'Acquired Businesses'), currently providing business management services to Physicians. The Offering is contingent on the Acquisitions being completed simultaneously with the Offering. After giving effect to the Acquisitions, the total number of physicians served by the Company will increase to over 2,500. PSS believes that each of the Acquired Businesses operates in a manner consistent with the Company's core business strategy and gives it the opportunity to provide its services to Physicians in other regions of the United States. THE OFFERING Common Stock offered by the Company................ 3,500,000 shares(1) Common Stock to be outstanding after the Offering......................................... 5,740,000 shares(1)(2) Use of proceeds.................................... Pending and future acquisitions; repayment of debt; redemption of preferred stock; working capital and other general corporate purposes. Proposed Nasdaq National Market symbol............. PHSS
- ------------ (1) Does not include up to an aggregate of 525,000 shares of Common Stock that may be sold by the Company pursuant to the Underwriters' over-allotment option. See 'Underwriting.' (2) Excludes 939,750 shares of Common Stock reserved for future issuance under the Company's proposed stock option plan. It is anticipated that options to purchase up to 95,000 shares of Common Stock will be granted as of the completion of the Offering. See 'Management -- Stock Option Plan.' SUMMARY CONSOLIDATED FINANCIAL AND PRO FORMA INFORMATION (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) NINE MONTHS ENDED YEAR ENDED DECEMBER 31, SEPTEMBER 30, ----------------------------------------------- --------------------------------- PRO FORMA PRO FORMA 1992 1993(1) 1994 1994(2) 1994 1995 1995(2) --------- --------- --------- ----------- --------- --------- --------- INCOME STATEMENT DATA: Revenue............................... $ 8,123 $ 13,080 $ 18,773 $ 26,897 $ 14,789 $ 14,631 $ 20,841 Operating expenses: Salaries and wages............... 3,101 5,898 8,866 12,214 6,552 7,234 10,076 General and administrative....... 2,021 4,291 6,723 9,349 5,121 5,020 6,748 Depreciation and amortization.... 1,781 2,566 3,349 4,124 2,522 2,549 3,119 --------- --------- --------- ----------- --------- --------- --------- Total operating expenses.... 6,903 12,755 18,938 25,687 14,196 14,802 19,943 --------- --------- --------- ----------- --------- --------- --------- Income (loss) from operations......... 1,221 325 (165) 1,210 593 (171) 898 Net income (loss)..................... $ 16 $ (672) $ (1,067) $ (363) $ (942) --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Net (loss) per share.................. $ (0.08) $ (0.40) $ (0.58) $ (0.24) $ (0.51) --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Weighted average shares outstanding(3)...................... 2,240,000 2,240,000 2,240,000 2,240,000 2,240,000 --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Pro forma net income.................. $ 326 $ 53 ----------- --------- ----------- --------- Pro forma net income per share........ $ .06 $ .01 ----------- --------- ----------- --------- Pro forma weighted average shares outstanding(3)...................... 5,740,000 5,740,000 ----------- --------- ----------- ---------
SEPTEMBER 30, 1995 ----------------------- ACTUAL PRO FORMA(2) ------- ------------ (UNAUDITED) BALANCE SHEET DATA: Working capital (deficiency).................................................................. $(1,351) $ 9,034 Total assets.................................................................................. 21,618 42,966 Long-term liabilities, net of current portion................................................. 15,463 6,749 Redeemable preferred stock.................................................................... 2,382 -- Stockholders' equity (deficiency)............................................................. (3,429) 28,321
- ------------ (1) The results for the year ended December 31, 1993 include the results of Spring Anesthesia Group, Inc. from the date of acquisition, August 1, 1993, through December 31, 1993. (2) The pro forma data gives effect to: (a) the acquisition of the Acquired Businesses (NCHC Group, MM Support and DPS) and (b) the sale of the shares of Common Stock offered hereby and the application of the net proceeds thereof as described in 'Use of Proceeds' as if each had occurred at the beginning of the periods presented. In addition, the pro forma information is based on available information and certain assumptions and adjustments. See Notes 1 and 2 to the Pro Forma Financial Information. (3) Weighted average shares outstanding includes 2,240,000 shares outstanding prior to the Offering after adjustment to reflect the 1,400-for-one stock split which will occur prior to completion of the Offering. In addition, pro forma weighted average shares outstanding includes 3,500,000 shares being sold in connection with the Offering. Weighted average shares outstanding and pro forma weighted average shares outstanding do not include any shares reserved for future issuance under the Company's proposed stock option plan.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000878901_koo-koo_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000878901_koo-koo_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..3626411344de34e557df3d3c2b6c5cebc17705a1
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000878901_koo-koo_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements appearing elsewhere in this Prospectus. Without limiting the generality of the foregoing, prospective investors should carefully consider the factors set forth under the caption "Risk Factors." THE COMPANY Koo Koo Roo, Inc. (the "Company") operates restaurants in the emerging food service category of fresh, convenient meals. The restaurants feature the Company's proprietary Original Skinless Flame-Broiled Chicken/TM/, fresh oven- roasted hand-carved turkey, country herb rotisserie chicken, made to order tossed salads, specialty sandwiches on fresh baked rolls, a signature vegetable soup and more than 23 side dishes including hand-mashed potatoes, stuffing, steamed green beans and other vegetables, rices and grains, all prepared fresh in small batches on-site throughout the day. As of March 31, 1996, the Company operated 18 Koo Koo Roo restaurants. The Company's restaurants are designed to appeal to consumers who look for good tasting, freshly prepared food, and who also appreciate menu items that are wholesome and healthy. The products are easy to understand, high in quality and generally low in fat, calories and cholesterol, without the negative connotation or taste of "health food." The sights and smells of fresh food preparation, such as turkey carving and salad tossing, are displayed in glass enclosed stations featuring "chefs" in restaurant whites and toques. Over the past several years, executive management, together with the Company's corporate chef and professional designers, developed the layout, menu and appearance of the current prototype store, referred to as the Koo Koo Roo California Kitchen/TM/ concept. The performance and continuing improvement of this concept led management to plan for a rapid expansion starting in 1995 and to focus on Company ownership or joint venture relationships rather than franchising. The Company is presently emphasizing growth through the development of additional Koo Koo Roo California Kitchen/TM/ stores which will be either owned and operated by the Company or owned in partnership with its existing domestic joint venture partner and operated by the Company. It intends to act opportunistically to establish additional joint venture arrangements and make restaurant acquisitions and may also grow through the acquisition of complementary businesses. Although the focus in 1996 will be on Company-owned restaurants, the Company may pursue additional joint ventures or franchising in certain markets. The Company's principal executive offices are located at 11075 Santa Monica Boulevard, Suite 225, Los Angeles, California 90025 and its telephone number is (310) 479-2080. RECENT DEVELOPMENTS The Company announced several significant transactions in March 1996, including a letter of intent related to the establishment of a joint venture in Canada, the acquisition of 90% of the outstanding capital stock of Color Me Mine, Inc. ("Color Me Mine"), an operator of a small chain of paint-your-own ceramics studios, and the closing of two private placements. In the private placements, the Company received gross proceeds aggregating $33.2 million relating to the issuance of (i) 450,000 shares of Common Stock for $7.245 per share (subject to adjustment) and (ii) 1,200,000 shares of a newly-designated class of 5% Convertible Preferred Stock for $25.00 per share, as well as related warrants. The number of shares of Common Stock issuable in connection with such transactions and offered hereby is subject to adjustment and will depend upon factors which cannot be predicted by the Company at this time including, among others, the future market price of the Common Stock. See "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations--Recent Private Placements," "Description of Capital Stock" and Note 14 to the Consolidated Financial Statements. THE OFFERING Common Stock Offered by the Selling Stockholders (estimate) ............ 5,250,000 shares (1) Shares of Common Stock Outstanding Prior to the Offering....................... 14,766,999 shares (2) Use of Proceeds.............................. The proceeds from the sale of the shares of Common Stock offered hereby are solely for the account of the Selling Stockholders. Accordingly, the Company will receive none of the proceeds from sales thereof. See "Use of Proceeds." Nasdaq National Market Common Stock Symbol... KKRO
- -------------------- (1) As set forth in the text on the cover of this Prospectus, this offering includes the resale of such presently indeterminate number of shares of Common Stock as shall be issued in respect of: (i) 450,000 shares of Common Stock (subject to adjustment) issued in a private placement in March 1996, (ii) all shares of Common Stock issuable upon conversion of or otherwise in respect of 1,200,000 shares of the Registrant's 5% Convertible Preferred Stock issued in a private placement in March 1996, (iii) 40,500 shares of Common Stock (subject to adjustment) issuable upon the exercise of warrants issued in connection with the foregoing private placements, (iv) all shares of Common Stock upon conversion of or otherwise in respect of 108,000 shares of the Registrant's 5% Convertible Preferred Stock issuable upon the exercise of warrants issued in connection with the foregoing private placements and (v) 84,409 shares of Common Stock originally issued in other private placements. The number of shares of Common Stock indicated to be offered hereby on the cover of this Prospectus and above is an estimate based upon the market price of the Common Stock set forth on the cover page of this Prospectus assuming that all shares of Convertible Preferred Stock are converted on the first date permitted. The number of shares of Common Stock issuable in connection with such transactions and offered for resale hereby is subject to adjustment and could be materially less or more than such amount depending upon factors which cannot be predicted by the Company at this time, including, among others, the future market price of the Common Stock. This presentation is not intended to constitute a prediction as to the future market price of the Common Stock. See "Risk Factors--Effect of Conversion of Convertible Preferred Stock; Potential Common Stock Adjustment" and "Description of Capital Stock."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000879313_sygnet_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000879313_sygnet_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..43d3a807aa2fb25e0461b0b9fea7fcda49104a7d
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000879313_sygnet_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information (including the Company's combined financial statements and notes thereto) contained elsewhere in this Prospectus. Unless the context otherwise requires, references to the "Company" are to Sygnet Wireless, Inc., an Ohio corporation, its wholly-owned subsidiary, Sygnet Communications, Inc., and their respective predecessors prior to the corporate restructuring described elsewhere in this Prospectus and include the operations to be acquired in part with the proceeds of the Offering. The term "Horizon Acquisition" refers to the acquisition under the agreement to purchase five RSAs in western Pennsylvania and New York (PA-1, PA-2, PA-6, PA-7 and NY-3) from three Horizon Cellular Telephone Company affiliates, as described more fully below under "Business -- The Horizon Acquisition." THE COMPANY Upon consummation of the Horizon Acquisition, the Company will own and operate cellular telephone systems serving one large cluster with approximately 2.4 million Pops in northeastern Ohio, western Pennsylvania and western New York. The Horizon Acquisition will add five RSAs (the "Horizon Systems") to the three MSAs and one RSA currently operated by the Company (the "Existing Systems"), providing the Company with over 89,000 subscribers. The Company's cellular systems are located in Youngstown, Ohio and Erie, Pennsylvania and in primarily suburban and rural areas between the Cleveland, Akron-Canton, Pittsburgh, Buffalo and Rochester metropolitan areas. The Company believes that its mix of suburban and rural locations provides it with advantages over cellular operators in predominately urban areas, including greater roaming revenue opportunities, lower distribution costs and higher costs of entry for new competitors. The Company has converted all of its Existing Systems to TDMA digital technology and will selectively convert the more densely populated portions of the Horizon Systems to digital technology in early 1997. For a general description of the cellular telephone industry and the regulation thereof, see "Business -- Overview of the Cellular Telephone Industry" and "Business -- Regulatory Overview." The Company began operating cellular systems in 1985 in Youngstown, Ohio and has expanded to cover nine contiguous markets through a series of acquisitions. The Company is owned and controlled by the Williamson family, which has owned and operated broadcast and other communications companies in northeastern Ohio and western Pennsylvania since 1926. The following table summarizes the Existing Systems and the Horizon Systems. DATE OF TOTAL POPS OWNERSHIP NET POPS ACQUISITION EXISTING SYSTEMS(1) Youngstown, OH MSA............................... 491,900 100% 491,900 1985 Sharon, PA MSA................................... 122,100 100% 122,100 1987 Erie, PA MSA..................................... 280,600 100% 280,600 1995 Columbiana, OH, OH-11 RSA........................ 111,700 100% 111,700 1991 HORIZON SYSTEMS(1)(2) Chautauqua, NY, NY-3 RSA......................... 485,200 100% 485,200 1996 Crawford, PA, PA-1 RSA........................... 197,200 100% 197,200 1996 Lawrence, PA, PA-6 RSA........................... 376,400 100% 376,400 1996 Indiana, PA, PA-7 RSA............................ 217,100 100% 217,100 1996 McKean, PA, PA-2 RSA(3).......................... 89,400 100% 89,400 1996 ---------- --------- Total.................................... 2,371,600 2,371,600
- ----------------------------- (1) All of the Existing Systems and Horizon Systems licenses are non-wireline licenses. (2) To be acquired as described under "Business -- The Horizon Acquisition." (3) The Horizon Acquisition includes the Pops in the PA-2 RSA where the Company has IOA pending the FCC's final determination of the qualifications of the initial lottery winner to hold the permanent license for the PA-2 RSA. The Company will not be issued the permanent license to provide cellular service in this RSA (unless the Company were to reach an agreement to purchase the license from the eventual recipient of the license) and the Company's IOA from the FCC will expire upon selection of the new licensee and the commencement of operations by that licensee. Until the expiration of the IOA, however, the Company is entitled to all revenue and income generated by the PA-2 RSA. The Company believes that the expiration of such authority will not have a material adverse effect on its results of operations, financial position or cash flows. CERTAIN TERMS For regulatory purposes, the Federal Communications Commission ("FCC") has designated regions of the United States as either a Metropolitan Statistical Area ("MSA") or Rural Service Area ("RSA"). Interests in cellular markets are commonly measured on the basis of the population of the MSA or RSA served, with each person in the market area referred to as a "Pop." The number of Pops (or "Net Pops") owned is not the same as the number of subscribers, or even potential subscribers. As used in this Prospectus, unless otherwise indicated, the term "Pops" means the estimate of the population of an MSA or RSA, as derived from the Rand McNally Commercial Atlas and Marketing Guide population estimates. The term "Net Pops" means the estimated population with respect to a given service area multiplied by the percentage interest that the Company owns in the entity licensed in such service area (except in the case of the PA-2 RSA which the Company does not own, but operates under an FCC grant of Interim Operating Authority ("IOA")). Because the Company owns 100% of the interest in each of its MSAs and RSAs, at this point in time, Net Pops equal Pops. Except for historical financial information and unless otherwise indicated, all references herein to Pops, Net Pops and the Company's systems give effect to consummation of the Horizon Acquisition, which will occur simultaneously with the closing of the Offering. The term "non-wireline" license refers to the license for any market that was initially awarded to a company, individual or group, not affiliated with any landline carrier providing service in the market. The term "wireline" license refers to the license for any market that was initially awarded to a company, individual or group, affiliated with a landline carrier providing service in the market. There is, however, no technical distinction between a wireline and a non-wireline license. The term "system" means an FCC-licensed cellular telephone system. The term "cell" refers to the service area of an individual transmitter location in a cellular system. The term "footprint" refers to the total system coverage area represented by an MSA or RSA served under FCC license by a given licensee. The term "TDMA" means a digital technology that uses time division multiple access. The term "PCS" means personal communications services. The term "churn" refers to the ratio of disconnected monthly subscribers to average monthly subscribers. The term "CTIA" means the Cellular Telecommunications Industry Association. The term "NACN" means the North American Cellular Network. ADDITIONAL INFORMATION The Company has filed with the Securities and Exchange Commission (the "SEC") a Registration Statement on Form S-1 (the "Registration Statement") under the Securities Act with respect to the Notes offered hereby. This Prospectus, which constitutes a part of the Registration Statement, does not contain all of the information set forth in the Registration Statement, certain items of which are contained in schedules and exhibits to the Registration Statement as permitted by the rules and regulations of the SEC. Any statements contained herein concerning the provisions of any document filed as an Exhibit to the Registration Statement or otherwise filed with the SEC are not necessarily complete and, in each instance, reference is made to the copy of such document so filed. Each such statement is qualified in its entirety by such reference. The Company intends to furnish holders of the Notes annual reports containing audited financial statements and quarterly reports for the first three quarters of the fiscal year containing unaudited financial statements. IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE NOTES AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH TRANSACTIONS MAY BE EFFECTED IN THE OPEN MARKET OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. BUSINESS STRATEGY The Company's goal is to become the leading full service provider of mobile telecommunications services in its cluster by offering technically advanced cellular service, superior coverage and a high level of customer service at competitive prices. Specifically, the Company's business objectives are to increase penetration and improve profitability in both the Horizon Systems and its Existing Systems by taking advantage of its ability to operate in a much larger regional footprint. In addition, the Company may in the future acquire additional systems that provide the Company with the ability to further its strategic objectives. - Developing the Horizon Systems. The Company believes that the Horizon Systems are underdeveloped and underpenetrated compared to its Existing Systems and represent a substantial growth opportunity for the Company. By taking advantage of marketing, operating and engineering synergies arising from the Horizon Acquisition, the Company believes that it will be able to decrease overall per subscriber operating costs and rapidly increase penetration in the Horizon Systems to levels comparable to those achieved in its Existing Systems. Immediately upon consummation of the Horizon Acquisition, the Company will apply its business strategy to the Horizon Systems, which strategy has generated significant subscriber and revenue growth in its Existing Systems, including the Erie, PA MSA acquired in September 1995 (the "Erie Acquisition"). - Aggressive Marketing and Promotion of Cellular Services. The Company plans to implement the aggressive marketing programs that it has been using in its Existing Systems to increase subscriber activations in the Horizon Systems. These include competitive rate plans which provide low priced regional roaming rates tailored for individual markets and attractive equipment prices. In addition, the Company will use a mix of advertising media such as television, radio and outdoor advertising to reach potential new subscribers. - Local Retail Outlets and Superior Customer Service. The Company strives to provide a high level of customer service and the Company's use of local retail stores is a key element of this local subscriber service strategy. The Company's stores are staffed with sales and customer service representatives who provide a more direct, specifically targeted level of customer service than is ordinarily offered by larger competitors relying on centralized customer service operations. By having a permanent local retail presence, the sales staff can cultivate local market knowledge that allows them to focus their efforts on the specific demands of the market or markets in which they operate. This improves their ability to establish relationships with customers, to understand the customer's needs and to reduce churn. The sales team's ability to promote the Company's services both inside and outside of its cluster is enhanced by its license to market under the CELLULAR ONE(R) brand name and its continuing participation in the NACN, a national cellular network comprised principally of non-wireline carriers whose goal is to make cellular service "seamless" throughout North America by facilitating automatic roaming to and from member systems. - Advanced Systems Design. The Company's system design and the TDMA digital technology it employs provide the foundation for technically superior cellular service. The Company has deployed a large number of cell sites in each service area. Consequently, subscribers in the Existing Systems enjoy a high level of local and regional coverage, resulting in high quality hand-held coverage throughout most of its population centers, minimal call blocking, seamless call delivery through NACN and the availability of digital voice and data services. All of the Company's existing cells have already been upgraded to offer TDMA digital services and the Company intends to selectively improve the technology being used in the Horizon Systems to match this high quality level. The Company believes it is well positioned to address new technologies that might become available in its markets. - Decentralized Marketing Management. The Company has assembled management, sales and operating staff with extensive experience and relationships within each market. The decentralized market management structure adopted by the Company allows it to tailor its service to meet the needs of each market. This local approach to marketing is coordinated with senior management of the Company and allows each market to benefit from shared corporate resources. - Acquisition Strategy. The Company's primary external growth strategy has been to develop its cellular system by pursuing acquisitions that expand its regional footprint, can be operated efficiently, enhance its reciprocal relationships with other cellular telephone carriers and provide an opportunity to gain significant competitive advantages. As it has done successfully in the past, the Company intends to pursue acquisition opportunities which permit the Company to achieve these strategic objectives either with respect to its current cluster or elsewhere. - Future Competition. The Company is preparing for what is expected to be an increasingly competitive telecommunications environment by aggressively working to attract new subscribers. The Company believes it is prepared for this competition because it is not dependent on high roaming or local rates. In addition, the Company believes that it can effectively face this competition from its position as an incumbent in the cellular field with a high quality network that is not capacity constrained. The Company also has an extensive footprint, strong distribution channels, superior customer service capabilities and an experienced management team. Because the Company operates in medium to small markets, the new PCS licensees may be unable or unwilling to offer commercially viable wireless service in much of the Company's area in the near term. The Company believes the extensive capital expenditures required to deploy the infrastructure for PCS is more readily justifiable from an economic standpoint in larger, more densely populated urban areas. This constraint of PCS may position the Company to offer roaming services to PCS customers, as well as to provide bulk lines of service for resale to certain PCS companies. For example, the Company's existing Youngstown and Erie systems are equipped to provide TDMA digital roaming to AT&T Wireless PCS subscribers when AT&T Wireless introduces dual band TDMA phones in the adjacent Cleveland and Buffalo-Rochester MTAs. THE HORIZON ACQUISITION On July 11, 1996, the Company signed an agreement with Horizon Cellular Telephone Company of Chautauqua, L.P., Horizon Cellular Telephone Company of Crawford, L.P. and Horizon Cellular Telephone Company of Indiana, L.P. (the "Horizon Companies") to purchase for $250.0 million in cash (subject to net working capital adjustment) the Horizon Systems, which consist of the PA-1, PA-2, PA-6, PA-7 and NY-3 RSAs. Under the agreement, the Company is to become the cellular licensee serving contiguous markets representing approximately 1.3 million Pops and covering over 16,125 square miles in western Pennsylvania and New York. The PA-2 RSA, which represents 89,400 Pops, currently operates under IOA pending the FCC's final determination of the qualifications of the initial lottery winner to hold the permanent license for the PA-2 RSA. While the Company is not acquiring a permanent license for the PA-2 RSA, it is entitled to all revenue and income generated by the cellular system until the FCC resolves the dispute. The Company is unable to predict when or how the FCC will resolve this matter. Simultaneously with the closing of the Horizon Acquisition, the Subsidiary will obtain secured financing from a number of commercial lenders (the "Lenders") under a $300.0 million revolving line of credit (the "Bank Credit Facility"), the agents for which will be Toronto Dominion (Texas), Inc. and PNC Bank, National Association. In addition, the Company will issue (the "Preferred Stock Investment") $20.0 million liquidation amount of Cumulative Preferred Stock (the "Preferred Stock") to Toronto Dominion Investments, Inc. or one or more other affiliates of Toronto Dominion (Texas), Inc. Dividends on the Preferred Stock will accrue at a rate of 15% per annum for the first four quarters and will increase by 2% for each four quarter period thereafter until reaching a maximum rate of 21% per year, and such dividends will be payable solely through the issuance of additional Preferred Stock. If any event of default under the terms of the Preferred Stock occurs and is continuing or if the Company's Annualized Operating Cash Flow Ratio (using substantially the same definition as that used in the Indenture) exceeds 12.0-to-1.0, then the otherwise applicable dividend rate for the Preferred Stock will be increased by 5% per annum. In addition, Toronto Dominion Investments, Inc. is entitled to warrants to purchase Class A Common Stock (as defined) of the Company unless the Preferred Stock is redeemed with the proceeds of an initial public offering of Class A Common Stock or from other permitted sources within nine months of the date of the Preferred Stock Investment. See "Description of Capital Stock -- Preferred Stock." Proceeds of the Offering, the Preferred Stock Investment and borrowings under the Bank Credit Facility will be used to pay the purchase price in the Horizon Acquisition and the related fees and expenses. See "Use of Proceeds." If the proceeds of the Offering have not been so applied within 120 days of the closing of the sale of the Notes, the Company will offer to purchase the Notes at 101% of the principal amount thereof, plus accrued interest to the purchase date. See "Description of Notes -- Limitation on Use of Proceeds; Proceeds Purchase Offer." The remainder of availability under the Bank Credit Facility will be used for working capital purposes, to refinance $71.5 million in existing debt (unless repaid earlier using proceeds of the Offering) and for system expansion. See "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Liquidity and Capital Resources" and "Description of Bank Credit Facility." THE OFFERING The following summary description of the Notes is qualified in its entirety by the more detailed information set forth under the caption "Description of Notes" contained elsewhere in this Prospectus. Notes Offered...................... $110,000,000 aggregate principal amount of % Senior Notes due 2006. Maturity Date...................... October 1, 2006. Interest Payment Dates............. April 1 and October 1 of each year, commencing April 1, 1997. Mandatory Redemption............... None. Optional Redemption................ The Notes will be redeemable, in whole or in part, at the option of the Company at any time on or after October 1, 2001 at the redemption prices set forth herein, plus accrued and unpaid interest, if any, to the date of redemption. In addition, at any time during the first 36 months after the date of the original issuance of Notes, the Company may redeem up to an aggregate of $38.5 million in principal amount of Notes at a redemption price of % of the principal amount thereof, plus accrued and unpaid interest thereon, with the net proceeds of an offering of Qualified Capital Stock (as defined) of the Company; provided that at least $71.5 million in aggregate principal amount of Notes remain outstanding immediately after the occurrence of such redemption. See "Description of Notes -- Optional Redemption." Limitations on Use of Proceeds; Proceeds Purchase Offer............ All net proceeds received by the Company from the sale of the Notes shall be applied to the purchase of assets in the Horizon Acquisition or, as set forth below, to repay indebtedness under the Subsidiary's existing bank credit facility pending such acquisition; provided, however, that no such proceeds may be applied to the purchase of assets in Horizon Acquisition until the Company has received at least $19.0 million in proceeds from the Preferred Stock Investment and the Trustee has received certain opinions and certificates regarding the Horizon Acquisition. Pending the consummation of the Horizon Acquisition, all such proceeds shall be held by the Company in a separate bank account, except that up to $71.5 million of the net proceeds from the sale of the Notes may be contributed to the Subsidiary to repay indebtedness under the Subsidiary's existing bank credit facility, but only to the extent that the banks thereunder consent to allow the amounts repaid to be reborrowed and paid as a dividend to the Company for the sole purpose of funding a repurchase of the Notes in the event that the Horizon Acquisition does not occur within 120 days following the closing of the sale of the Notes. In the event that all of the net proceeds of the sale of the Notes have not been so applied, directly or indirectly, to the purchase of assets in the Horizon Acquisition within 120 days of the closing of the sale of the Notes, the Company will make an offer (a "Proceeds Purchase Offer") to all holders of Notes to purchase on a pro rata basis, at a price of 101% of the principal amount thereof plus accrued interest to the purchase date, all Notes that may be purchased at such price with such unapplied net proceeds. Ranking............................ The Notes will be general unsecured obligations of the Company and will rank pari passu with all senior indebtedness of the Company, if any, and senior in right of payment to all subordinated indebtedness of the Company, if any. The Company is a holding company with no direct operations and assets other than the stock of the Subsidiary. The Notes will not be guaranteed by the Subsidiary, therefore the Notes will be structurally subordinated to all liabilities of the Subsidiary. After giving effect to the Horizon Acquisition and the other transactions described under "Unaudited Pro Forma Condensed Consolidated Financial Data" (the "Related Transactions") as if such transactions had occurred on June 30, 1996, the Subsidiary would have had $211.8 million of total outstanding indebtedness (including $204.4 million of secured borrowings under the Bank Credit Facility), all of which is structurally senior in right of payment to the Notes. The indenture governing the Notes (the "Indenture") will allow the Company and the Subsidiary to incur additional indebtedness. See "Description of Notes -- Certain Covenants." Certain Covenants.................. The Indenture imposes certain limitations on the ability of the Company and its Restricted Subsidiaries (as defined) to, among other things, incur Indebtedness (as defined), make Restricted Payments (as defined), effect certain Asset Sales (as defined), enter into certain transactions with Related Persons (as defined), merge or consolidate with any other person or transfer all or substantially all of their properties and assets. See "Description of Notes -- Certain Covenants." Change of Control.................. Upon the occurrence of a Change of Control (as defined in the Indenture), each holder of Notes will have the right to require the Company to repurchase such holder's Notes at 101% of the principal amount thereof plus accrued and unpaid interest thereon, if any, to the repurchase date. In addition, a Change in Control (as defined in the Bank Credit Facility) will result both in an event of default under the Bank Credit Facility permitting the Lenders to accelerate such indebtedness and in a Mandatory Redemption Event under the terms of the Preferred Stock (as defined in the Preferred Stock Investment). Under such circumstances, the Company may be obligated to redeem, repurchase or otherwise satisfy up to as much as $110.0 million in principal under the Notes, $300.0 million in principal under the Bank Credit Facility, and $20.0 mil- lion face amount of the Preferred Stock (plus, as applicable, associated accrued interest, dividends, penalties, premiums and expenses). The Bank Credit Facility may restrict the ability of the Company to obtain the funds necessary to repurchase the Notes in the event of a Change of Control, and the Company may not have sufficient funds or financing available to satisfy its obligations to repurchase the Notes. See "Description of Notes -- Certain Covenants -- Change of Control" and "Description of Bank Facility" and "Description of Capital Stock -- Preferred Stock." Events of Default.................. Events of Default under the Indenture include failure to pay principal or interest on the Notes, failure to make payments on other indebtedness, breach of certain covenants, certain events of bankruptcy and insolvency and other customary events. See "Description of Notes -- Events of Default and Remedies." Use of Proceeds.................... The Company intends to use the net proceeds of the Offering to finance a portion of the Horizon Acquisition. See "Use of Proceeds" and "Business -- The Horizon Acquisition."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000879969_carematrix_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000879969_carematrix_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..961fa6ec7092a91f05f684e5abd04ff978f38cb4
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000879969_carematrix_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and financial statements, including the notes thereto, appearing elsewhere in this Prospectus. Prospective investors should consider carefully the information set forth under "Risk Factors." Unless otherwise indicated, information in this Prospectus assumes (i) no exercise of the Underwriters' option to purchase from the Selling Stockholders up to 937,500 additional shares of Common Stock to cover over-allotments, if any, and (ii) a one-for-five reverse stock split of the Company's Common Stock effective October 14, 1996 (the "Reverse Split"). The Company CareMatrix Corporation (the "Company") (formerly known as The Standish Care Company) is a provider of assisted living services, operating 20 facilities in eight states with a capacity of approximately 1,580 residents. Of these facilities, two are owned, nine are leased and nine are managed. The Company's three year growth objective is to develop at least 60 new facilities, with a capacity of approximately 7,200 residents, and to acquire additional assisted living facilities or operations. Currently, the Company is developing 28 facilities, of which four facilities are now under construction. The Company's strategy is to provide a full range of assisted living and related services across a range of pricing options. The Company believes that it can effectively and efficiently respond to a variety of the needs of seniors as they age and require additional care. The Company expects its assisted living facilities to serve as the foundation from which it will provide a continuum of care for its residents. When its assisted living facilities are integrated with supportive independent living facilities, skilled nursing/rehabilitation facilities and Alzheimer's care programs, the Company believes that it will have the ability to provide a less stressful transition for those of its residents who need a higher degree of care to more supportive environments either within the same facility, in a campus setting or in a nearby facility. The Company believes that by offering such a continuum of care to its residents, it will be better able to respond to resident needs than free-standing assisted living facilities that do not provide the flexibility for their residents to age in place. The Company intends to provide at all of its assisted living facilities a full range of quality senior residential services that are designed to permit residents to age in place by meeting their evolving personal and health care needs. To accomplish this objective, the Company is developing comprehensive service packages and integrated campuses that the Company believes will enable it to become a leading provider of assisted living services to seniors within a fully integrated matrix of social and healthcare service models. The Company believes that the popularity of assisted living and other senior care alternatives will increase the demand for quality facilities that provide such services across upper, moderate and lower income markets. The Company is developing four such models to meet this anticipated demand: (bullet) Chancellor Park--These facilities will provide supportive independent and assisted living services and are designed to serve primarily upper income residents. The capacity of this model ranges from 100 to 160 residents. The average monthly service fee paid by residents will range from approximately $2,300 to $4,900. (bullet) Chancellor Gardens--These facilities, which target a broader population base, will provide similiar services to moderate and upper income residents. This model typically accommodates 80 to 140 residents. The average monthly service fee paid by residents will range from approximately $1,400 to $3,000. (bullet) Chancellor Village--These facilities, which further broaden the Company's service market, are designed to accommodate lower income residents and Medicaid-eligible residents. This model typically accommodates 80 to 100 residents. The average monthly service fee for residents will range from approximately $900 to $2,000. (bullet) Chancellor Place--These facilities, which will be free-standing or integrated within other Company facilities to provide a continuum of care, are specially designed to meet the programmatic needs of residents with early or intermediate Alzheimer's disease and other forms of dementia. This model, which targets upper income seniors, accommodates 40 to 80 residents. The average monthly service fee paid by residents will range from approximately $3,200 to $3,600. Upon the completion of the Offering, the Company will implement an aggressive development and acquisition program designed to enhance the Company's ability to achieve its growth strategy. The Company will seek to cluster its facilities within selected geographic regions to achieve marketing, cost and service advantages. The Company believes that by combining different levels of care in a single, integrated campus or facility or through a network of facilities within a distinct market, it will be able to respond to the varied needs of seniors as they age, meet the cost containment objectives of private and governmental payor sources and create significant competitive advantages. The Company's senior management team has extensive experience in developing, operating and managing senior residence facilities. The Company expects that the facilities it plans to develop and subsequently manage or lease over the next three years will be developed for both related and unrelated parties. See "Risk Factors-- Dependence by the Company on Related Party Agreements" and "Business--Development and Acquisition." On October 4, 1996, twelve wholly owned subsidiaries of The Standish Care Company ("Standish") were merged into twelve corporations controlled by Abraham D. Gosman, members of his family and certain members of senior management (collectively, "Pre-Merger CareMatrix"), with the stockholders of Pre-Merger CareMatrix receiving approximately 92% of the then outstanding shares of Standish common stock (the "Merger"). Following the Merger, The Standish Care Company changed its name to CareMatrix Corporation. The Merger was accounted for as a reverse acquisition, whereby Pre-Merger CareMatrix is treated as the acquiror for accounting purposes. The Offering Common Stock Offered 6,250,000 shares Common Stock to be Outstanding After the Offering 17,116,000 shares (1) (2) Use of Proceeds To finance future acquisitions and development, to repay outstanding debt to, and redeem the Series B Preferred Stock held by, the Company's principal stockholder, to pay dividends in arrears on the Series A Preferred Stock and for working capital purposes. See "Use of Proceeds." American Stock Exchange symbol CMD
- ------------- (1) Does not include (i) an aggregate of 323,151 shares of Common Stock issuable following the completion of the Offering upon exercise or conversion of outstanding warrants and convertible securities of the Company and (ii) an aggregate of 1,600,000 shares of Common Stock reserved for issuance under the Company's stock option/equity incentive plans, of which approximately 680,000 have been granted at an average exercise price of approximately $14.50 per share. See "Capitalization," "Management" and "Shares Eligible for Future Sale." (2) Includes 108,000 shares of Common Stock to be issued as a fee in connection with the Merger and 19,140 shares of Common Stock issuable upon the expected conversion of the Series A Preferred Stock. See Note 3 to Unaudited Pro Forma Combined Balance Sheet and "Underwriting." Summary Combined Financial Data The following table sets forth the historical combined financial information of the Company and pro forma financial information to give effect to the Merger, the purchase in July 1996 of certain assets from an entity controlled by the Company's principal stockholder (the "Asset Purchase"), the Reverse Split and the sale of the Common Stock offered hereby. The Merger was accounted for as a reverse acquisition, whereby Pre-Merger CareMatrix is deemed the acquiror for accounting purposes. Accordingly, the financial history presented is that of Pre-Merger CareMatrix. Pro Forma Pro Forma (2) As Adjusted (3) ------------------------ -------------------------- June 24, 1994 Six Six (Inception) Year Ended Months Year Ended Months Year Ended Six Months to December Ended December Ended December Ended December 31, 31, June 30, 31, June 30, 31, June 30, 1994 (1) 1995 (1) 1996 (1) 1995 1996 1995 1996 ------------ ----------- --------- ----------- --------- ----------- ----------- (in thousands, except per share data) Statement of Operations Data: Net revenues $ 366 $ 2,485 $ 2,389 $ 10,921 $ 7,059 $ 10,921 $ 7,059 Operating costs and expenses 2,865 9,147 5,591 20,113 11,128 20,113 11,128 ------------ ----------- --------- ----------- --------- ----------- ----------- Loss from operations (2,499) (6,662) (3,202) (9,192) (4,069) (9,192) (4,069) Interest income -- -- (24) (153) (53) (153) (53) Interest expense 56 544 559 2,044 1,382 1,500 823 Other -- -- -- (558) (743) (558) (743) ------------ ----------- --------- ----------- --------- ----------- ----------- Loss (4) $(2,555) $(7,206) $(3,737) $(10,525) $(4,655) $ (9,981) $(4,096) ============ =========== ========= =========== ========= =========== =========== Pro forma loss per share $ (0.97) $ (0.43) $ (0.58) $ (0.24) Shares outstanding 10,866 10,866 17,116 17,116
June 30, 1996 ------------------------------------------- Pro Forma Historical Pro Forma As Adjusted (1) (5) (6) ----------- ---------- -------------- (in thousands) Balance Sheet Data: Cash and cash equivalents $ 2,028 $ 3,284 $104,064 Working capital (deficit) 1,286 (3,038) 98,900 Total assets 6,022 44,464 145,244 Long-term debt, less current maturities (7) 16,992 30,753 10,461 Stockholders' equity (deficit) (13,498) 3,326 125,556
- ------------- (1) The historical combined financial data represents the combined financial position and results of operations for the Company for the periods presented. (2) Gives effect to the Merger, the Asset Purchase and the Reverse Split as if such transactions had occurred as of January 1, 1995. See "Unaudited Pro Forma Financial Information." (3) Gives effect to (i) the Merger, the Asset Purchase and the Reverse Split and (ii) the sale of Common Stock offered hereby (assuming a public offering price of $21.25 per share) and the application of the net proceeds therefrom, as if such transactions had occurred as of January 1, 1995. See "Use of Proceeds" and "Unaudited Pro Forma Financial Information." (4) Provisions for income taxes have not been reflected in these combined financial statements since there is no taxable income on a combined basis. See Note 2 of the CareMatrix Combined Financial Statements. (5) Adjusted to give effect to the Merger and the Asset Purchase as if such transactions had occurred on June 30, 1996. See "Unaudited Pro Forma Financial Information." (6) Adjusted to give effect to (i) the Merger and the Asset Purchase and (ii) the sale of the Common Stock offered hereby (assuming a public offering price of $21.25 per share) and the application of the net proceeds therefrom as if such transactions had occurred on June 30, 1996. See "Use of Proceeds" and "Unaudited Pro Forma Financial Information."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000880238_core-inc_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000880238_core-inc_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..169e98ad36b3d2d158e908b93d515c9c5a21f541
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000880238_core-inc_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following information is qualified in its entirety by the more detailed information and financial statements (including the notes thereto) appearing elsewhere in this Prospectus. See "Risk Factors" for a discussion of certain factors to be considered by prospective investors. THE COMPANY CORE, INC. is a national provider of managed disability and health care benefits management services to Fortune 500 companies and other self-insured employers, third-party administrators and insurance carriers. The Company's services include managed disability services using CORE's proprietary WorkAbility(R) disability management software, specialty physician and behavioral health review services and health care benefits utilization review and case management services. The Company's services are designed to assist its clients monitor and control disability and health care benefits costs without compromising the quality of health care services provided to the patient. CORE's managed disability services include monitoring the appropriateness of disability durations under short and long-term disability plans and workers' compensation programs in order to reduce unnecessary absenteeism and its related costs of wage replacement, hiring and training replacement personnel and lost productivity. These services are based on CORE's WorkAbility program, a proprietary software program developed over a ten-year period through the statistical analysis of disability utilization data. CORE's WorkAbility managed disability program provides an objective, medically based method for recommending and monitoring employee's return-to-work dates. The WorkAbility program is designed to obtain and analyze relevant medical and work-related information with the initial onset of the employee's absence and thus assure that the employee, attending physician and employer all have reasonable and consistent expectations as to the projected return-to-work date. CORE's independent physician review programs provide pre-certification, concurrent and appellate physician review services for use with utilization management programs of the Company's insurance company and self-insured corporate clients. The Company believes its more than 230 Board certified physician reviewers comprise the largest independent physician review service in the country. CORE's behavioral health review program provides comparable review services by psychiatric specialists in sub-specialties such as adult and child psychiatry, alcoholism and chemical dependency. The Company also provides utilization review services designed to evaluate the medical necessity and appropriateness of health care services prescribed for participants in health care and medical plans. In cases of high cost injuries or illness, CORE also renders case management services for individual cases to assure that cost- effective treatment alternatives are utilized. In recent years, large corporations have begun to recognize the magnitude of the annual cost of occupational and non-occupational injuries and illnesses, which according to a 1991 publication exceeded $2,200 per employee, or 8% of total payroll costs. These expenses present a significant challenge to corporate productivity. The Company estimates that total U.S. costs due to injury and illness-related workplace absence are approximately $260 billion per year. According to an industry source, workers' compensation expenditures grew at an average annual rate of over 10% from 1982 through 1991, and the Company believes this growth is continuing. The Company estimates that workers' compensation costs were approximately $60 billion in 1994. Despite the general awareness of this high level of workers' compensation costs, expenditures for group disability (including short-term disability and long-term disability plans), sick pay and family leave represent a far larger share of total expenditures at approximately $200 billion in 1994. Two driving factors behind the increase in group disability and workers' compensation expenditures are workplace and legislative changes. Work-related changes that have contributed to rising benefits costs include the aging of the active workforce, increased volatility in hiring and layoffs (which often results in increased benefits utilization) and increased diagnoses of repetitive stress-related injuries. Also contributing to rising disability benefit costs and awareness are legislative changes such as the Family Medical Leave Act and the Americans with Disabilities Act, which mandate accommodation for family circumstances and disabled workers, which both have a growing impact on accommodation and lost time issues. Until recently, recognition and management of these productivity costs have been impaired by their difficulty in measurement, the fragmentation of responsibilities for disability programs within human resources and risk management departments of most corporations and the historical focus on group health managed care. While a small group of companies is emerging that are applying managed care principles to the workers' compensation industry, historically there have been few, if any, companies focusing on the provision of managed care techniques to the broader disabilities market. With the support of its analytic and physician services, CORE's products provide employers with an integrated and comprehensive approach to disability benefits management. CORE intends to expand its position as a leading provider of managed disability benefits services by utilizing its proprietary WorkAbility program and related services to assist its clients in reducing the direct costs of short and long-term disability and workers' compensation benefits and improving employee productivity. The Company believes that the combination of its health care and disability management tools and its strong information technology foundation provide an effective management platform that can be tailored to meet the needs of self-insured employers and third-party payors. The principal elements of the Company's strategy for achieving its objectives are (i) to market aggressively its WorkAbility program in order to achieve greater penetration into the managed disability market; (ii) to pursue disability management outsourcing contracts with large employers; (iii) to make selective acquisitions of businesses that can provide service line extensions and cross- selling synergies in the managed disability market; (iv) to utilize its WorkAbility program as a technology platform in developing managed disability networks in certain geographical markets; and (v) to establish through the WorkAbility program the capability to enter into capitated or other "at risk" arrangements with payors in the managed disability market. On May 10, 1996, CORE entered into an Asset Purchase Agreement (the "AmHealth Agreement") to acquire substantially all of the assets and operations of AmHealth, Inc. (excluding its accounts receivable). AmHealth, Inc. is a management services organization that manages occupational health clinics and on-site industrial facilities in California. On July 24, 1996, the Company terminated the AmHealth Agreement. See "Risk Factors--Termination of AmHealth Acquisition Agreement," "Recent Developments" and "Management's Discussion and Analysis of Financial Condition and Results of Operations--Overview." THE OFFERING Common Stock being offered......... 2,000,000 shares(1) Common Stock outstanding after the offering.......................... 6,842,271 shares(1)(2) Use of Proceeds.................... To expand operating capacity and for other working capital and general corporate purposes Nasdaq National Market Symbol...... CORE
- -------- (1) Excludes up to 300,000 shares of Common Stock that may be sold by the Company pursuant to the Underwriters' over-allotment option. See "Underwriting." (2) Based on the number of shares of Common Stock outstanding as of May 31, 1996. Excludes 1,535,979 shares of Common Stock issuable upon exercise of stock options and warrants outstanding at such date. See "Management." SUMMARY FINANCIAL INFORMATION (IN THOUSANDS, EXCEPT PER SHARE DATA) THREE MONTHS YEAR ENDED DECEMBER 31, ENDED MARCH 31, --------------------------------------- ------------------ 1993 1994 1995 1995 1996 ------- ------- --------------------- -------- -------- ACTUAL PRO FORMA(2) ------- ------------ STATEMENT OF OPERATIONS DATA: Revenues................ $16,316 $16,746 $20,769 $24,847 $ 4,729 $6,584 Cost of services........ 10,714 11,305 12,839 14,352 3,117 3,939 ------- ------- ------- ------- -------- ------- Gross profit.......... 5,602 5,441 7,930 10,495 1,612 2,645 Total operating ex- penses................. 9,295 10,151 8,185 10,171 2,791 2,151 ------- ------- ------- ------- -------- ------- Income (loss) from operations(1).......... (3,693) (4,710) (255) 324 (1,179) 494 Other income, net....... 317 11 176 14 27 41 ------- ------- ------- ------- -------- ------- Net income (loss)....... $(3,376) $(4,699) $ (79) $ 338 $(1,152) $ 535 ======= ======= ======= ======= ======== ======= Net income (loss) per common share........... $ (0.73) $ (1.01) $ (0.02) $ 0.07 $ (.24) $ .10 ======= ======= ======= ======= ======== ======= Weighted average number of common shares outstanding............ 4,611 4,668 4,755 5,069 4,740 5,532 ======= ======= ======= ======= ======== =======
MARCH 31, 1996 ------------------------ ACTUAL AS ADJUSTED(3) -------- -------------- BALANCE SHEET DATA: Working capital........................................ $ 2,850 $ 20,249 Total assets........................................... 12,866 30,264 Long-term obligations.................................. 427 427 Accumulated deficit.................................... (10,329) (10,329) Stockholders' equity................................... 8,213 25,612
- -------- (1) Includes the write-off of goodwill in the amount of $2,294,000 and merger related costs and expenses of $1,114,000 in 1994 and merger related costs and expenses of $994,000 in 1995. See "Management's Discussion and Analysis of Financial Condition and Results of Operations." (2) Gives effect to the CRS Acquisition (as defined herein) as if such transaction had been completed as of January 1, 1995. See "Pro Forma Combined Condensed Statement of Operations (Unaudited)." (3) Gives effect to the sale of the shares of Common Stock offered hereby (based on an assumed public offering price of $9.625 per share) and the receipt of the estimated net proceeds therefrom as if such transaction had occurred as of March 31, 1996. See "Use of Proceeds." ---------------- Except as otherwise indicated herein, information in this Prospectus assumes no exercise of the Underwriters' option to purchase from the Company up to an aggregate of 300,000 shares of Common Stock to cover over-allotments, if any. See "Underwriting."
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000880259_biotranspl_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000880259_biotranspl_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..54b4fd5cb30f503e815321fc11b1bef080a22466
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000880259_biotranspl_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY The following summary is qualified in its entirety by the more detailed information and the Consolidated Financial Statements and Notes thereto appearing elsewhere in this Prospectus, including the information under "Risk Factors." This Prospectus contains forward-looking statements which involve risks and uncertainties. The Company's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed under "Risk Factors." Certain technical and medical terms are defined or explained under "Business -- The Company," "-- Overview of Organ Transplantation" and elsewhere in this Prospectus.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000880414_ambar-inc_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000880414_ambar-inc_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..48970bdc63dd61fdf7ab471855518263ce3c7948
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000880414_ambar-inc_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY This summary is qualified in its entirety by the more detailed information and the consolidated financial statements and notes thereto appearing elsewhere in this Prospectus. Unless otherwise indicated, all information in this Prospectus assumes (i) that the Underwriters' over- allotment option will not be exercised and (ii) that a reorganization pursuant to which the Company will reincorporate in Louisiana will have been consummated. Immediately prior to consummation of this Offering, the Company will also increase its authorized shares of Common Stock from 7 million to 25 million, $.01 par value per share, will authorize 10 million shares of Preferred Stock, $.01 par value per share and will amend certain other provisions of its Articles of Incorporation. See "Description of Capital Stock." The Company General AMBAR is principally engaged in the custom blending, distribution and sale of clear brine fluids ("CBFs"), drilling fluids (or "muds") and other chemicals used in the drilling, completion and workover (repair and maintenance) of oil and gas wells. The principal consumers of AMBAR's products are oil and gas operators, particularly those with operations offshore in the United States Gulf of Mexico and onshore along the Gulf Coast. Oil and gas operators use muds during the well drilling stage to control formation pressures, lubricate and cool drill bits, and carry cuttings out of the hole. CBFs, which generally are significantly more expensive than muds, are used primarily in the completion and workover stages, when well operators seek to maintain or restore well productivity. To diversify its business and to achieve partial vertical integration of its oilfield business, AMBAR has recently secured access to a brine stream and acquired a plant in Manistee, Michigan (the "Manistee facility") that it is presently retrofitting to produce liquid and dry calcium chloride, important raw materials used in the production of the Company's CBFs and which also have a number of other commercial and industrial applications. AMBAR also provides certain environmental products and services relating to oil spill response, control and remediation, environmental contingency planning and the control and treatment of both hazardous and non-hazardous oilfield waste. Strategy Diversify into Non-Oilfield Markets. The Company intends to diversify its business through the sale of the liquid and dry calcium chloride produced at the Manistee facility into several larger non-oilfield markets. The most significant commercial applications of calcium chloride are to de-ice roads, control road dust and stabilize roadbeds. The Company also intends to add a bromine extraction process to the Manistee facility. The primary commercial applications of bromine are in pharmaceuticals, specialty chemicals and fire retardants. Bromine is also a raw material used in certain important components of many of the Company's higher density, higher cost CBFs. Increase Revenues and Profitability of Oilfield Fluids Business. AMBAR believes that the product costs relating to its CBFs will be favorably affected through its production of calcium chloride at the Manistee facility. Although the Company believes that it will continue to procure calcium chloride from third parties that are geographically convenient, it also believes that its introduction of a substantial volume of low cost calcium chloride into the market will allow it to moderate its product costs. In addition, once AMBAR adds a bromine extraction process, it expects to realize significant cost savings in the production of its higher margin CBFs. The Company also intends to expand its share of the CBF and drilling mud markets by increasing the sales force dedicated to these product lines. Expand and Develop Environmental Products and Services Business. A portion of the net proceeds of the Offering will be used by AMBAR to expand its oil spill response capabilities in the Texas Gulf Coast region and to continue development of new applications for its environmental products. AMBAR is also currently in the process of using and testing AmBaSol, a proprietary chemical designed to rapidly dissolve hazardous oilfield waste (found in barium sulfate scale), in applications such as well stimulation, vessel cleaning and the remediation of hazardous oilfield waste. AMBAR intends to continue development of applications for, and increase its marketing of, this product. The Offering Common Stock offered by the Company......................... 3,000,000 shares Common Stock offered by the Selling Shareholders............ 500,000 shares Common Stock to be outstanding after this Offering...... 6,811,505 shares Use of Proceeds............................................. To repay the outstanding balance of the Company's revolving credit facility; to retire long-term indebtedness and to fund the completion of the retrofitting of the Manistee facility; to fund expansion and development of the Company's Environmental Products and Services Division; and for working capital and general corporate purposes. The Company will not receive any of the proceeds from the sale of Common Stock by the Selling Shareholders. See "Business," "Use of Proceeds" and "Principal and Selling Shareholders." Nasdaq National Market Symbol.............................. AMBR
____________________ [FN] Includes 110,000 shares issuable upon the exercise of warrants held by a Selling Shareholder, all of which will be sold in the Offering. Summary Consolidated Financial Data (in thousands, except per share amounts) Nine Months Ended Fiscal Year Ended June 30, March 31, ------------------------------------- ----------------------- 1993 1994 1995 1995 1996 ----------- ---------- --------- --------- ----------- Statement of Operations Data: Revenues: Oilfield products and services . . . . . . . . . $ 20,973 $ 37,546 $ 31,661 $ 24,842 $ 27,883 Environmental products and services . . . . . . . . . 3,946 5,762 6,416 4,539 7,725 ----------- ---------- --------- ---------- ---------- Total revenues . . . . . . $ 24,919 $ 43,308 $ 38,077 $ 29,381 $ 35,608 Gross profit . . . . . . . . . . . 2,323 6,942 4,841 4,311 3,891 Operating income (loss) . . . . . . (1,816) 2,375 371 1,009 473 Net income (loss) . . . . . . . . . $ (1,200) $ 1,277 $ (236) $ 294 $ (129) Net income (loss) per share . . . . $ (.33) $ .35 $ (.06) $ .08 $ (.03) Weighted average common shares outstanding . . . . . . . 3,628 3,632 3,667 3,663 3,732 Cash dividends . . . . . . . . . . -- -- -- -- -- At March 31, 1996 ----------------- As Actual Adjusted --------- ------------ Balance Sheet Data: Working capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 6,167 $ 38,901 Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39,077 62,443 Long-term liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,611 3,739 Stockholders' equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,865 50,471
____________________ [FN] Adjusted to reflect the sale of 3,000,000 shares of Common Stock by the Company, the exercise of warrants to purchase 110,000 shares of Common Stock by a Selling Shareholder and the application of the estimated net proceeds therefrom.
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000882100_corvas_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000882100_corvas_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..838f49163a57fca6fe0c1d8d32d6b31e0f487f76
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000882100_corvas_prospectus_summary.txt
@@ -0,0 +1 @@
+PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION, INCLUDING RISK FACTORS AND CONSOLIDATED FINANCIAL STATEMENTS AND NOTES THERETO, APPEARING ELSEWHERE IN THIS PROSPECTUS. THIS PROSPECTUS CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD- LOOKING STATEMENTS. FACTORS THAT MIGHT CAUSE SUCH A DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN "RISK FACTORS", AS WELL AS THOSE DISCUSSED ELSEWHERE IN THIS PROSPECTUS. THE COMPANY Corvas International, Inc. ("Corvas" or the "Company") is a biopharmaceutical firm engaged in the design and development of a new generation of therapeutic agents in the fields of thrombosis and inflammation. The Company seeks to develop and to commercialize novel drugs for the improved treatment and prevention of major cardiovascular diseases, such as heart attack, stroke, deep vein thrombosis, pulmonary embolism, and acute inflammation associated with trauma, shock and reperfusion injury in stroke. In contrast to currently available therapies, the Company's candidate drugs are designed to intervene more specifically in the disease process. Corvas intends to develop both parenteral and oral drugs to treat patients who cannot be optimally treated with current therapeutics. The Company believes that its antithrombotic drug discovery and development program is among the most comprehensive in the industry and that, together with its alliance partner, it is well positioned to develop and commercialize orally-active antithrombotic agents. Corvas has discovered its portfolio of drug candidates by integrating the Company's in-depth knowledge of the biology of thrombosis and, more generally, vascular biology, with advanced and proprietary drug discovery and design technology. The Company believes that such technology has broad potential application outside the antithrombotic field and will provide the basis for expanding its product portfolio. Corvas' scientists are experienced in a wide range of disciplines which are integrated in a systematic discovery approach. Current programs employ medicinal chemistry, peptide chemistry, computer-aided drug design, structural biology, molecular biology, biochemistry, physiology, and pharmacology competencies. The Company's programs are based on three technology platforms: structure-based drug design, biological discovery, and molecular pharmacology. The first two platforms generate drug leads, while the third technology platform enables the selection of drug candidates. The Company's structure-based drug design programs are the source of small molecule drugs, including those demonstrating oral activity. Biological discovery methods, including novel gene discovery, cloning, expression, and mutagenesis methods are used to identify novel biologicals as drug candidates and discovery tools. Molecular pharmacology techniques, including IN VITRO biochemical analysis and IN VIVO biological testing, are used to rigorously characterize the many drug leads derived from the two other platforms in order to select specific drug candidates for preclinical and clinical development. The Company has several antithrombotic compounds in clinical and preclinical development, including orally-active thrombin inhibitors, which are being developed in collaboration with Schering Corporation ("Schering-Plough"). Corvas has developed a portfolio of orally-active, potent and selective thrombin inhibitors upon which this alliance is based. In the second half of 1995, Corvas conducted an initial human safety study of CVS-1123, a lead orally-active thrombin inhibitor. In this Phase Ia study, CVS-1123 demonstrated oral activity and was well tolerated. Corvas and Schering-Plough are actively evaluating a series of follow-on compounds in the same chemical class in order to select a candidate for development by Schering-Plough. This selection is expected to be made by the end of 1996. Corvas is also conducting active discovery programs for inhibitors of coagulation Factor Xa and Factor VIIa, with its co-factor tissue factor ("Factor VIIa/TF"). The primary goal of these programs is the development of safe and effective orally-active drugs. A secondary goal has been the development of parenteral agents targeting these factors. In 1994, Schering- Plough acquired an option to expand its alliance with Corvas to include Factor Xa 2. inhibitors. In January 1996, Schering-Plough made a $1,000,000 payment to extend its option rights until December 1996. In 1995, Company scientists presented initial scientific data on a newly discovered class of natural anticoagulant peptides known as the NAP family. Specific members of this family inhibit either Factor Xa or Factor VIIa/TF. The Company has selected and commenced preclinical development of a Factor VIIa/TF inhibitor as a parenteral agent for acute care indications, such as treatment of venous thrombosis and prevention of pulmonary embolism. In its anti-inflammatory program, the Company has discovered a promising novel protein, neutrophil inhibitory factor ("NIF"), which blocks certain white blood cell functions associated with inflammation. In 1995, initial studies demonstrating the potential of NIF as a therapy for stroke victims were presented at a scientific conference by Corvas collaborators and published in a leading journal. Based on these early results, the Company entered into an agreement with Pfizer Inc. ("Pfizer") to collaborate on the development of NIF. A Phase Ia clinical trial has been completed for the Company's first drug candidate, CORSEVIN M, an antibody-based antithrombotic which has been licensed to, and is being further developed by, Centocor, Inc. ("Centocor"). In 1992, Corvas entered into an alliance with Ortho Diagnostic Systems, Inc. ("Ortho"), a Johnson & Johnson company, to develop and commercialize a laboratory test for blood clotting function based on Corvas' proprietary technology. Corvas supplies a critical raw material, recombinant human tissue factor, to Ortho and has licensed rights to Ortho. Ortho currently produces and markets prothrombin time reagents based on such technology. The Company's principal executive offices are located at 3030 Science Park Road, San Diego, California 92121 and its telephone number is (619) 455-9800. Unless the context otherwise requires, "Corvas" and the "Company" refer to Corvas International, Inc., and its subsidiaries, if any. CORVAS-Registered Trademark- is a registered trademark, and the Corvas logo, CORTHROMBIN-TM-, CORDECIN AS-TM-, CORSEVIN AS-TM- and CORSEVIN M-TM- are trademarks, of the Company. The Prospectus also includes names and marks of companies other than the Company. 3. THE OFFERING Common Stock offered hereby. . . . . . . . . . . . . . . . . . . . . . . . . 1,000,000 shares Common Stock to be outstanding after the offering. . . . . . . . . . . . . . 13,682,471 (1) Use of proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Research, development, preclinical and clinical testing, and working capital and general corporate purposes. See "Use of Proceeds." Nasdaq National Market symbol. . . . . . . . . . . . . . . . . . . . . . . . CVAS
SUMMARY CONSOLIDATED FINANCIAL DATA (In thousands, except per share amounts) CONSOLIDATED STATEMENTS OF OPERATIONS DATA: THREE MONTHS YEARS ENDED DECEMBER 31, ENDED MARCH 31, ----------------------------------------------- ------------------- 1991 1992 1993 1994 1995 1995 1996 ---- ---- ---- ---- ---- ---- ---- (UNAUDITED) Revenues . . . . . . . . . . . . . . . . . $ 1,268 $ 886 $ 845 $ 1,130 $ 5,402 $ 1,080 $ 2,187 Research and development costs . . . . . . 6,252 8,894 12,115 11,378 9,723 2,259 2,299 Total costs and expenses . . . . . . . . . 12,208 12,044 15,287 16,730 12,516 2,946 3,116 Net loss . . . . . . . . . . . . . . . . . (10,098) (9,467) (13,369) (14,903) (6,293) (1,649) (631) Net loss per share (2) . . . . . . . . . . (2.14) (1.08) (1.44) (1.60) (0.67) (0.18) (0.05) Shares used in calculation of net loss per share (2) . . . . . . . 4,724 8,747 9,295 9,336 9,374 9,359 11,507
CONSOLIDATED BALANCE SHEETS DATA: December 31, March 31, 1996 --------------------------- 1995 Actual As Adjusted (3) ------------- --------- ---------------- (UNAUDITED) Cash, cash equivalents and short-term debt securities. . . . . . . . . . . . .$12,451 $24,908 $29,782 Working capital. . . . . . . . . . . . . . 7,372 21,570 26,444 4. Total assets . . . . . . . . . . . . . . . 14,462 27,370 32,244 Accumulated deficit. . . . . . . . . . . .(60,588) (61,219) (61,219) Total stockholders' equity. . . . . . . . 8,768 23,118 27,992
- -------------------- (1) Excludes, as of May 24, 1996, 1,701,903 shares of Common Stock issuable upon exercise of outstanding options at a weighted average price of $3.47 per share and 3,008,715 shares of Common Stock issuable upon the exercise of outstanding warrants at a weighted average price of $6.00 per share. (2) See Note 2 of Notes to Consolidated Financial Statements. (3) As adjusted to give effect to the issuance of 1,000,000 shares of Common Stock offered hereby at an assumed offering price of $4.87 per share net of estimated offering expenses. See "Use of Proceeds" and "Capitalization." 5. RISK FACTORS THIS PROSPECTUS CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF CERTAIN FACTORS SET FORTH BELOW, AS WELL AS THOSE DISCUSSED ELSEWHERE IN THIS PROSPECTUS. THE FOLLOWING RISK FACTORS SHOULD BE CONSIDERED CAREFULLY IN ADDITION TO THE OTHER INFORMATION CONTAINED IN THIS PROSPECTUS BEFORE PURCHASING THE COMMON STOCK OFFERED HEREBY: EARLY STAGE OF DEVELOPMENT The Company is at an early stage of development. Corvas has only three products from which it derives revenue: recombinant human tissue factor used in a diagnostic test to determine the blood clotting ability of patients, and recombinant human tissue factor and a group of tissue factor-specific monoclonal antibodies used in the research market. The revenue generated from such products has not been substantial in any given year. In addition, Corvas has conducted human clinical trials for only two product candidates, CVS-1123 and CORSEVIN M. The Company's product candidates will require significant additional development, laboratory and clinical trials, regulatory approval and additional investment prior to their commercialization. The Company does not expect to be able to market any of these product candidates for a number of years. There can be no assurance that the Company's product development efforts will progress any further or be successfully completed. In addition, there can be no assurance that the Company's potential products will be capable of being produced in commercial quantities at reasonable costs, that required regulatory approvals can be obtained or that any potential products, if introduced, will be successfully marketed or achieve customer acceptance. CONTINUING OPERATING LOSSES; ACCUMULATED DEFICIT The Company has experienced significant operating losses since its inception in 1987. At March 31, 1996, the Company had an accumulated deficit of approximately $61,219,000. The Company expects to incur substantial additional operating losses over the next several years as the Company attempts to sustain, and possibly expand, its research and development and clinical trial efforts. Substantially all of the Company's revenues to date have consisted of revenue from collaborative agreements, research grants and interest income. To achieve profitable operations, the Company, alone or with others, must successfully identify, develop, manufacture and market additional proprietary products. See "Management's Discussion and Analysis of Financial Condition and Results of Operations." FUTURE CAPITAL NEEDS; UNCERTAINTY OF ADDITIONAL FUNDING The Company will require substantial funds to conduct the research and development and preclinical and clinical testing of its products, to establish commercial scale manufacturing facilities and to market its products. The Company's future capital requirements will depend on many factors, including, but not limited to, the following factors: continued scientific progress in its drug discovery programs; the magnitude of these programs; progress of preclinical testing and clinical trials; the time and costs involved in obtaining regulatory approvals; the costs involved in filing, prosecuting, maintaining and enforcing patent claims; competing technological and market developments; changes in its existing research relationships; the ability of the Company to establish and maintain collaborative or licensing arrangements; the cost of manufacturing scale-up; and effective commercialization activities and arrangements. The Company intends to seek such additional funding either through collaborative arrangements or through public or private financings. There can be no assurance that additional financing will be available, or, if available, that it will be available on acceptable terms. If additional funds are raised by issuing securities, further dilution to existing stockholders may result. If adequate funds are not available, the Company may be required to delay, scale back or eliminate one or more of its drug discovery programs or obtain funds through arrangements with collaborative partners or others that may require the Company to relinquish rights to certain of its technologies, product candidates or products that the Company would not otherwise relinquish. 6. UNPREDICTABILITY OF, AND LIMITED EXPERIENCE IN, CONDUCTING PRECLINICAL AND CLINICAL TRIALS Although certain of the Company's officers and employees have prior experience in conducting clinical trials, the Company itself has conducted only two early-stage clinical trials to date; Phase Ia clinical trials of CVS-1123 and Phase Ia clinical trials of CORSEVIN M. At present, the Company intends to commence Phase I clinical trials in 1997 of a NAP compound. There can be no assurance that the Company will be able to commence any or all of the clinical trials as currently planned for 1997, or that the Company will meet its development schedule for any of its products in development. If the Company or its collaborators were unable to commence clinical trials as planned, complete the clinical trials or demonstrate the safety and efficacy of its products, the Company's business, financial condition and results of operations would be materially and adversely affected. There can be no assurance that if a product from the Company's research and development programs or any other therapeutic product is successfully developed according to plans, it will be approved by the U.S. Food and Drug Administration ("FDA") on a timely basis or at all. In addition, because the Company will, in a number of cases, rely on its contractual rights to access data collected by others in phases of its clinical trials, the Company is dependent on the continued satisfaction by such parties of their contractual obligations to provide such access and to cooperate with the Company in the execution of successful filings with the FDA. There can be no assurance that the FDA will permit such reliance. If the Company were unable to rely on clinical data collected by others, the Company may be required to repeat clinical trials, which could significantly delay commercialization and require significantly greater capital. Before obtaining regulatory approvals for the commercial sale of any of its products under development, the Company must demonstrate through preclinical studies and clinical trials that the product is safe and efficacious for use in the target indication for which approval is sought. The results from preclinical studies and early clinical trials may not be predictive of results that will be obtained in later-stage testing, and there can be no assurance that future clinical trials conducted by the Company or its collaborators will demonstrate the safety and efficacy of any products or will result in approval to market products. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials, even after promising results in earlier trials. The rate of completion of the Company's clinical trials is dependent upon, among other factors, the rate of patient enrollment. Patient enrollment is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the study. Delays in planned patient enrollment may result in increased costs and delays, which could have a material adverse effect on the Company. UNCERTAINTIES OF REGULATORY APPROVAL; GOVERNMENT REGULATION The production and marketing of the Company's products and its ongoing research and development activities are subject to regulation by numerous governmental authorities in the U.S. and other countries. Any drug developed by the Company must undergo rigorous preclinical and clinical testing and an extensive regulatory approval process mandated by the FDA and equivalent foreign authorities before it can be marketed. These processes can take a number of years and require the expenditure of substantial resources. The time required for completing such testing and obtaining such approvals is uncertain and approval itself may not be obtained. The Company has conducted human clinical testing of two product candidates, CVS-1123 and CORSEVIN M. No additional human tests of CVS-1123 are currently planned. Further testing of CORSEVIN M, by Centocor, and the Company's other product candidates in research and development may reveal undesirable and unintended side effects or other characteristics that may prevent or limit their commercial use. The FDA or the Company and its collaborators may decide to discontinue or to suspend clinical trials at any time if the subjects or patients who are participating in such trials are being exposed to unacceptable health risks. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the FDA or the Company to delay or to suspend clinical trials. Furthermore, there can be no assurance that any of the Company's products will be approved by the FDA for any indication. Products, if any, resulting from the Company's research and development programs are not expected to be commercially available for a number of years. Even if regulatory 7. approval of a product is granted, such approval may entail limitations on the indicated uses for which the product may be marketed. In addition, a marketed product, its manufacturer and the facilities in which the product is manufactured are subject to continual review and periodic inspections. Later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions on such product or manufacturer, including withdrawal of the product from the market. See "Business - Government Regulation." RELIANCE ON COLLABORATIVE PARTNERS Corvas has relied and will continue to rely on certain established pharmaceutical companies interested in its technology to fund a portion of its research and development expenses. The Company has entered into collaborative research agreements with these collaborative partners whereby the partners provide capital in exchange for certain technology, product, manufacturing and marketing rights related to the collaborative research. In November 1991, the Company entered into an agreement with Centocor pursuant to which Corvas granted rights to Centocor to license and to commercialize certain monoclonal antibody products developed by Corvas. For one such monoclonal antibody product, CORSEVIN M, Corvas completed a Phase Ia clinical trial in 1993. Centocor has informed the Company that it intends to continue the development of CORSEVIN M. In 1994, Centocor terminated its option rights to future monoclonal antibody products discovered or acquired by the Company. Corvas will depend on Centocor for the continued development of CORSEVIN M and resulting product sales. The Company may receive a future milestone payment upon receipt of certain regulatory approvals and royalties on any product sales. To date, Corvas has entered into collaborative agreements with Pfizer for the development of NIF, with Schering-Plough for the discovery and commercialization of oral thrombin inhibitor drugs for the prevention and treatment of chronic cardiovascular disorders, with Ortho for the manufacture and worldwide marketing by Ortho of diagnostic tests containing recombinant human tissue factor produced by Corvas and with Centocor pursuant to which Corvas granted rights to Centocor to license and commercialize certain monoclonal antibody products developed by Corvas. As a result, the Company is dependent on Pfizer, Schering-Plough and Centocor with respect to the regulatory filings relating to, and the clinical testing of, certain of the Company's product candidates developed under the collaborations described above. Any of Pfizer, Schering-Plough or Centocor may, based on data obtained in these trials or otherwise, elect to halt or repeat these trials or conduct clinical trials using different formulations of these product candidates. Any of these actions could result in delays in the clinical development of compounds covered by these collaborations. Furthermore, the amount and timing of resources dedicated by these strategic partners to the collaborations is not within the Company's control. In addition, Corvas is dependent on the efforts of Ortho in order to receive revenue from the recombinant human tissue factor produced by the Company. There can be no assurance that the interests of the Company will continue to coincide with those of its collaborators or that the collaborators will not develop independently or with third parties, products that could compete with the Company's products, or that disagreements over rights, technology or other proprietary interests will not occur. Further, there can be no assurance that the collaborative agreements will be extended at the end of their respective terms. If any of the Company's collaborators breaches or terminates its agreement with the Company, or fails to conduct its collaborative activities in a timely manner, the research program under the applicable collaborative agreement, or the development and commercialization of product candidates subject to such collaboration, may be adversely affected. There can be no assurance that the Company's existing strategic alliances will be successful, that the Company will receive any further payments pursuant to the collaborative agreements or that the collaborations will continue. If the strategic alliances are not continued or successful, the Company's business could be materially and adversely affected. Corvas has also established collaborations with scientists at a number of leading U.S. and European academic and clinical research centers to further its technology and product development objectives. These collaborations are generally conducted pursuant to agreements which give the Company a license, or the option to license, certain technology, patent rights or materials which may be valuable to the Company. These agreements may require the Company to fund research or to pay license fees or milestone payments and, upon commercial sale of certain products, royalties. 8. Corvas also expects to rely on additional collaborative arrangements to develop and commercialize some of its products in the future. There can be no assurance that the Company will be able to negotiate acceptable collaborative arrangements, in the future, or that such collaborative arrangements or its existing collaborative arrangements, will be successful. In addition, collaborative partners may pursue alternative technologies or develop alternative compounds either on their own or in collaboration with others, including the Company's competitors, as a means of developing treatments for the diseases targeted by any collaborative programs. See "Business - Strategic Alliances." TECHNOLOGICAL CHANGE AND COMPETITION The Company is engaged in a rapidly evolving field. Competition from other biotechnology companies, pharmaceutical companies and research and academic institutions is intense and expected to increase. There can be no assurance that the Company's competitors will not succeed in developing products based on the Company's technology or other technologies which are more effective than technologies being developed by the Company or which would render the Company's technology and products obsolete and noncompetitive. Many of the Company's competitors may have substantially greater financial, technical and human resources than the Company. In addition, many of these competitors may have significantly greater experience than the Company in undertaking preclinical testing and clinical trials of new pharmaceutical products and obtaining regulatory approvals of human therapeutic products. Accordingly, the Company's competitors may succeed in obtaining FDA approval for products more rapidly than the Company. Furthermore, if the FDA permits the Company to commence commercial sales of products, the Company will compete with respect to manufacturing efficiency and marketing capabilities, areas in which it has limited or no experience. Products under development by the Company address an array of markets. The Company's competition will be determined in part by the potential indications for which the Company's compounds are developed and ultimately are approved by regulatory authorities. For certain of the Company's potential products, an important factor in competition may be the timing of market introduction of its, or competitive, products. Accordingly, the relative speed with which Corvas can develop products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market is expected to be an important competitive factor. The Company expects that competition among products approved for sale will be based on, among other things, product efficacy, safety, reliability, availability, price and patent position. See "Business - Competition." MANUFACTURING LIMITATIONS In order for the Company's products to be successful, the products must be manufactured in sufficient commercial quantities, in compliance with regulatory requirements, and at an acceptable cost. The Company has limited experience in pilot scale manufacturing. For larger scale production, as will be required for Phase I and later phases of clinical testing, the Company must rely on third parties to manufacture its product candidates. If the Company is unable to develop or contract for large scale manufacturing capabilities on acceptable terms, the Company's ability to conduct clinical trials may be adversely affected, resulting in the delay of submission of products for regulatory approval, which in turn could adversely affect the Company's competitive position and its chances of achieving profitability. See "Business - Properties and Manufacturing." PATENTS AND PROPRIETARY RIGHTS The Company's success will depend in part on its ability to obtain patent protection for its products, both in the U.S. and other countries. The patent position of biotechnology and pharmaceutical companies is highly uncertain and involves complex legal and factual questions. There is no consistent policy regarding the breadth of claims allowed in biotechnology patents. The Company intends to file applications as appropriate for patents covering both its products and processes. As of the date of this Prospectus, Corvas holds rights in nine U.S. patents and has been notified of four allowed patent applications in the U.S. Of the issued patents, seven are owned by the Company and two are licensed by the Company. Corvas has filed or holds licenses to 55 additional patent applications that currently are pending in the U.S. Patent and Trademark Office. Approximately one-third of 9. these pending patent applications are duplicate applications the Company filed in anticipation of changes to U.S. patent law that became effective in June 1995 and that may affect the term of U.S. patents. Foreign counterparts of certain of the U.S. applications have been filed in many countries. In addition, Corvas holds rights in four foreign-issued patents; Corvas owns one such patent and is the exclusive licensee, in a defined field of use, of the remaining three foreign patents. There can be no assurance that patents will issue from any of the patent applications owned or licensed by the Company or that claims allowed under any issued patents will be sufficiently broad to protect the Company's technology. In addition, there can be no assurance that any patents issued or licensed to the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder will provide proprietary protection to the Company. As is typical in the biotechnology industry, the commercial success of the Company will depend in part on the Company neither being found infringing on patents issued to competitors nor breaching the technology licenses upon which the Company's products might be based. While the Company is aware of third party patent applications and issued patents in the Company's field, it is uncertain whether these will require the Company to alter products or processes, obtain licenses or cease certain activities. If the Company is required to obtain such licenses, there can be no assurance the Company will be able to obtain any necessary licenses at a reasonable cost. Failure by the Company to obtain a license to any technology that it requires to commercialize its products and obtain FDA approval within an acceptable period of time, if required to do so, would have a material adverse effect on the Company. Litigation, which could result in substantial costs to the Company, may also be necessary to enforce any patents issued to the Company or to determine the scope and validity of others' proprietary rights. In 1993, the U.S. Patent and Trademark Office declared an interference and is currently in the process of determining the priority of invention between a patent for which some rights are licensed to the Company and a patent application for which rights are licensed to another party. The subject matter of these licenses is recombinant tissue factor which is used by Ortho to determine the blood clotting ability of patients. There can be no assurance that the U.S. Patent and Trademark Office will rule in a manner favorable to the Company on this matter. In addition to patents, the Company relies on trade secrets and proprietary know-how, which it seeks to protect, in part, through appropriate confidentiality and proprietary information and inventions agreements with its current and prospective collaborative partners, employees, scientific advisors and consultants. There can be no assurance that these agreements will not be breached, that the Company will have adequate remedies for any breach, or that the Company's trade secrets will not otherwise become known or be independently discovered by competitors. Certain of the Company's research has been funded in part by the Federal Small Business Innovation Research ("SBIR") program. As a result of such funding, the U.S. Government will have certain rights ("Government Rights") in any technology, including inventions, developed with the funding. These rights include the grant of a non-exclusive, paid-up, worldwide license to such inventions for any governmental purpose. In addition, the government has the right to require the Company to grant an exclusive license to any of such inventions to a third party if the government determines that (i) adequate steps have not been taken to commercialize such inventions, (ii) such action is necessary to meet public health or safety needs or (iii) such action is necessary to meet requirements for public use under federal regulations. Federal law requires any licensor of an invention that was partially funded by federal grants to obtain a covenant from its exclusive licensee to substantially manufacture products using the invention in the U.S. In addition, the Company's licenses may also relate to technology developed with federal funding and, therefore, may also be subject to Government Rights. See "Business - Patents and Proprietary Rights." ABSENCE OF SALES AND MARKETING EXPERIENCE The Company has no experience in sales, marketing or distribution. To market any of its products directly, the Company must develop a substantial marketing and sales force with technical expertise and supporting distribution capability. Alternatively, the Company may obtain the assistance of a pharmaceutical company with a large distribution system and a large direct sales force. Other than its agreements with Ortho, Centocor, Schering-Plough and Pfizer, the Company does not have any existing distribution arrangements with any pharmaceutical company 10. for its products. There can be no assurance that the Company will be able to establish sales and distribution capabilities or be successful in gaining market acceptance for its products. DEPENDENCE ON REIMBURSEMENT Corvas' ability to commercialize its products successfully may depend in part on the extent to which reimbursement for the cost of such products and related treatment will be available from government health administration authorities, private health insurers and other organizations. Third-party payors are increasingly challenging the price of medical products and services. Significant uncertainty exists as to the reimbursement status of newly approved health care products, and there can be no assurance that adequate third-party coverage will be available to enable Corvas to maintain price levels sufficient to realize an appropriate return on its investment in product development. PRODUCT LIABILITY AND INSURANCE The Company's business exposes it to potential product liability risks which are inherent in the testing, manufacturing and marketing of human diagnostic and therapeutic products. While it has been the Company's practice to obtain clinical trials liability insurance when appropriate, there can be no assurance that it will be able to obtain or to maintain such insurance on acceptable terms or that insurance will provide adequate coverage against potential liabilities. HAZARDOUS MATERIALS The Company's research and development involves the controlled use of hazardous materials, chemicals and radioactive compounds. Although the Company believes that its safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any damages that result, which liability could exceed the resources of the Company. VOLATILITY OF COMMON STOCK PRICE The market prices for securities of biotechnology companies, including Corvas, have historically been highly volatile, and the market from time to time has experienced significant price and volume fluctuations that are unrelated to the operating performance of such companies. Factors such as announcements of technological innovations or new commercial therapeutic products by the Company or others, governmental regulations, developments in patent or other proprietary rights, developments in the Company's relationships with its collaborative partners, public concern as to the safety of drugs developed by the Company or others and general market conditions may have a significant effect on the market price of the Company's Common Stock. Fluctuations in financial performance from period to period also may have a significant impact on the market price of the Common Stock. See "Price Range of Common Stock." 11. USE OF PROCEEDS The net proceeds to the Company from the sale of the 1,000,000 shares of Common Stock offered by the Company hereby at an assumed offering price of $5.00 are estimated to be approximately $4,874,000, after deducting estimated offering expenses. The Company expects to use the net proceeds of this offering to continue research and development activities and preclinical and clinical testing, and for working capital and general corporate purposes. The Company may also use a portion of such net proceeds and existing cash and investment balances to acquire or to invest in businesses, products or technologies that are complementary to those of the Company, although no such material acquisitions are planned or being negotiated as of the date of this Prospectus, and no portion of the net proceeds has been allocated for any specific material acquisition. Pending such uses, the net proceeds will be invested in interest bearing, investment grade securities. The amounts actually expended for such purposes may vary significantly depending upon numerous factors, including progress of the Company's drug programs, the number and breadth of these programs, achievement of milestones under strategic alliance arrangements, the ability of the Company to establish and maintain additional strategic alliances and licensing arrangements, the progress of the development and commercialization efforts of the Company's strategic alliance partners, competing technological and market developments, the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other intellectual property rights, the regulatory process and other factors. DIVIDEND POLICY The Company has never declared or paid any cash dividends on its capital stock. The Company currently intends to retain any future earnings to finance the growth and development of its business and therefore does not anticipate paying any cash dividends in the foreseeable future. 12. PRICE RANGE OF COMMON STOCK The Company's Common Stock began trading on the Nasdaq National Market on January 30, 1992 under the symbol "CVAS." Prior to January 30, 1992, there was no public market for the Company's Common Stock. The following table sets forth for the periods indicated the high and low sale prices of Common Stock as reported by the Nasdaq National Market. HIGH LOW ------- ------- YEAR ENDING DECEMBER 31, 1996 Second Quarter (through June 21, 1996) . . . . . . $7.00 $4 3/4 First Quarter . . . . . . . . . . . . . . . . . . 6 1/8 3 5/8 YEAR ENDED DECEMBER 31, 1995 . . . . . . . . . . . Fourth Quarter . . . . . . . . . . . . . . . . . . 7 3/8 2 1/8 Third Quarter. . . . . . . . . . . . . . . . . . . 4 5/8 2 3/8 Second Quarter . . . . . . . . . . . . . . . . . . 2 7/8 1 5/8 First Quarter. . . . . . . . . . . . . . . . . . . 2 5/8 1 7/8 YEAR ENDING DECEMBER 31, 1994 Fourth Quarter . . . . . . . . . . . . . . . . . . 3 1 5/8 Third Quarter. . . . . . . . . . . . . . . . . . . 3 1/4 2 1/8 Second Quarter . . . . . . . . . . . . . . . . . . 4 1/2 2 7/8 First Quarter. . . . . . . . . . . . . . . . . . . 5 1/4 3 3/4
On June 21, 1996, the last reported sale price of the Common Stock was $5.25 per share. As of June 21, 1996, there were approximately 1,214 holders of record of the Common Stock. 13. CAPITALIZATION The following table sets forth the capitalization of the Company (i) as of March 31, 1996 and (ii) as adjusted to give effect to the issuance of 1,000,000 shares of Common Stock offered hereby at an assumed offering price of $5.00 per share after deducting estimated offering expenses. MARCH 31, 1996 (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) ------------------------------- Actual As Adjusted -------------- ---------------- Long-term debt, net of current portion $ 7 $ 7 Stockholders' equity: Series A convertible preferred stock, $.001 par value, authorized 10,000,000 shares, issued and outstanding 1,000,000 shares actual and as adjusted 1 1 Common stock, $.001 par value, authorized 50,000,000 shares, issued and outstanding 12,522,000 shares actual and 13,522,000 shares outstanding as adjusted (1) 13 14 Additional paid-in capital 84,323 89,196 Accumulated deficit (61,219) (61,219) ------------ ------------ Total stockholders' equity 23,118 27,992 ------------ ------------ Total capitalization $ 23,125 $ 27,999 ------------ ------------ ------------ ------------ - ----------------------
(1) Excludes(i) 1,499,917 shares of Common Stock issuable upon exercise of options outstanding as of March 31, 1996 at a weighted average exercise price of $3.06 per share and (ii) 3,008,715 shares of Common Stock as of March 31, 1996 issuable upon exercise of warrants outstanding as of March 31, 1996 at a weighted average exercise price of $6.00 per share. Subsequent to March 31, 1996, options to purchase 85,619 of these shares were exercised and options to purchase an additional 287,605 shares of Common Stock (net of cancellations) were granted. See "Description of Capital Stock" and Note 13 14. of Notes to Consolidated Financial Statements. Also excludes 75,000 shares of Common Stock issued in May 1996 in connection with the settlement of a lawsuit. See "Business - Legal Proceedings." 15. SELECTED CONSOLIDATED FINANCIAL DATA The selected data presented below under the captions "Consolidated Statements of Operations Data" and "Consolidated Balance Sheets Data" for, and as of the end of, each of the years in the five-year periods ended December 31, 1995, are derived from the consolidated financial statements of Corvas International, Inc. and Subsidiary, which financial statements have been audited by KPMG Peat Marwick LLP, independent certified public accountants. The consolidated financial statements as of December 31, 1994 and 1995, and for each of the years in the three-year period ended December 31, 1995, and the report thereon, are included elsewhere in this Prospectus. The selected data presented below for the three-month periods ended March 31, 1995 and 1996 are derived from the unaudited consolidated financial statements included elsewhere in this Prospectus and, in the opinion of management, includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of operations for such interim periods. Operating results for the three months ended March 31, 1996 are not necessarily indicative of results for the full year or for any future period. The data set forth below should be read in conjunction with the consolidated financial statements and related notes included elsewhere in this Prospectus. Three Months Ended Years Ended December 31, March 31, ----------------------------------------------- ------------------ 1991 1992 1993 1994 1995 1995 1996 -------- -------- -------- -------- -------- -------- -------- Consolidated Statements of Operations Data (In thousands, except per share amounts): REVENUES: Net product sales. . . . . . . . . . . . . . $ 121 $ 263 $ 323 $ 280 $ 406 $ 46 $ 21 Research grants. . . . . . . . . . . . . . . 397 513 192 667 -- -- -- Revenue from collaborative agreements (primarily from related party). . . . . . . . . . . . -- -- -- -- 4,354 1,000 2,085 License fees . . . . . . . . . . . . . . . . 750 100 100 -- 500 -- -- Royalties. . . . . . . . . . . . . . . . . . -- 10 230 183 142 34 81 -------- -------- -------- -------- -------- -------- -------- Total revenues . . . . . . . . . . . . . . . 1,268 886 845 1,130 5,402 1,080 2,187 -------- -------- -------- -------- -------- -------- -------- COSTS AND EXPENSES: Cost of products sold. . . . . . . . . . . . 17 106 105 83 211 5 24 Research and development . . . . . . . . . . 6,252 8,894 12,115 11,378 9,723 2,259 2,299 Purchased research and development. . . . . . . . . . . . . . . . 4,060 -- -- -- -- -- -- General and administrative . . . . . . . . . 1,879 3,044 3,067 3,159 2,582 682 793 Litigation settlement and related expenses . . . . . . . . . . . . . -- -- -- 535 -- -- -- Restructuring charge . . . . . . . . . . . . -- -- -- 1,575 -- -- -- -------- -------- -------- -------- -------- -------- -------- 16. Total costs and expenses . . . . . . . . . . 12,208 12,044 15,287 16,730 12,516 2,946 3,116 -------- -------- -------- -------- -------- -------- -------- Loss from operations . . . . . . . . . . . . (10,940) (11,158) (14,442) (15,600) (7,114) (1,866) (929) Other income, net. . . . . . . . . . . . . . 842 1,691 1,073 697 821 217 298 -------- -------- -------- -------- -------- -------- -------- Net loss . . . . . . . . . . . . . . . . . . $(10,098) $(9,467) $(13,369) $(14,903) $(6,293) $(1,649) $ (631) -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- Net loss per share (1) . . . . . . . . . . . $ (2.14) $ (1.08) $ (1.44) $ (1.60) $ (0.67) $ (0.18) $ (0.05) -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- Shares used in calculation of net loss per share (1) . . . . . . . . . . . . . 4,724 8,747 9,295 9,336 9,374 9,359 11,507 -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
17. Years Ended December 31, ------------------------------------------------ March 31, 1991 1992 1993 1994 1995 1996 --------- -------- -------- -------- -------- -------------- (UNAUDITED) Consolidated Balance Sheets Data (In thousands): Cash, cash equivalents and short-term debt securities . . . . . . . . . $13,853 $ 36,398 $ 23,180 $ 19,867 $ 12,451 $24,908 Working capital. . . . . . . . . . . . . . . 13,764 20,987 22,477 13,902 7,372 21,570 Total assets . . . . . . . . . . . . . . . . 16,153 38,925 26,522 22,509 14,462 27,370 Accumulated deficit. . . . . . . . . . . . . (16,556) (26,023) (39,392) (54,295) (60,588) (61,219) Total stockholders' equity . . . . . . . . . 14,260 37,592 24,474 14,647 8,768 23,118
(1) See Note 2 of Notes to Consolidated Financial Statements. 18. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE FOLLOWING DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN THIS SECTION, AS WELL AS THOSE DISCUSSED ELSEWHERE IN THIS PROSPECTUS. OVERVIEW Formed in 1987, Corvas is a biopharmaceutical firm engaged in the design and development of a new generation of therapeutic agents for the prevention and treatment of major cardiovascular and inflammatory diseases. To date, the Company has not generated significant revenues from product sales. The Company has not been profitable since inception and expects to incur substantial additional operating losses on an annual basis over the next several years as the Company attempts to sustain, and possibly expand, its research and development and clinical trial efforts. No assurance can be given that the Company can generate sufficient revenues to become profitable at all or on a sustained basis. At March 31, 1996, the Company had an accumulated deficit of $61,219,000. In December 1994, the Company ceased operation of its Belgian subsidiary and, accordingly, recorded a one-time restructuring charge for severance and other expenses. The Belgian operation accounted for 20% of the consolidated operating expenses in 1994 (including the restructuring charge of $1,575,000) and 20% in 1993. RESULTS OF OPERATIONS THREE MONTHS ENDED MARCH 31, 1996 AND 1995 Operating revenues increased from $1,080,000 in the quarter ended March 31, 1995 to $2,187,000 in the first quarter of 1996. This increase is mainly attributable to a $1,000,000 option extension fee received from Schering-Plough pursuant to a strategic alliance agreement for the prevention and treatment of chronic cardiovascular disorders. Accounting for $85,000 of this increase is revenue recognized pursuant to the research and option agreement initiated in October 1995 with Pfizer to collaborate on the development of neutrophil inhibitory factor, an anti-inflammatory agent. First quarter total costs and expenses increased from $2,946,000 in 1995 to $3,116,000 in 1996. Research and development expenditures remained relatively constant comparing these periods, increasing by $40,000. General and administrative expenses increased by $111,000 in the first quarter of 1996 over the same quarter of 1995 due to increased personnel costs and investor relations activities. Comparing the first quarters of 1995 to 1996, total other income increased from $217,000 to $298,000. The majority of this increase resulted from the sale of material to Pfizer in conjunction with the above-mentioned collaboration. Differences in the timing and composition of revenues earned and expenses incurred may contribute to quarter-to-quarter variations in operating results. 19. YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 Operating revenues increased to $5,402,000 in 1995, from $1,130,000 in 1994 and $845,000 in 1993. The major factor contributing to this increase in 1995 was the recognition of $4,354,000 of revenue from collaborative agreements. Of this revenue, $4,000,000 is attributable to the Company's strategic alliance agreement with Schering-Plough to collaborate on the discovery and commercialization of oral thrombin inhibitor drugs for the prevention and treatment of chronic cardiovascular disorders. The remaining $354,000 of revenue from collaborative agreements, and an additional $500,000 in license fees, is attributable to the Company's research and option agreement initiated in October 1995 with Pfizer to collaborate on the development of neutrophil inhibitory factor, an anti-inflammatory agent with therapeutic potential for stroke and other indications. Revenue from product sales increased to $406,000 in 1995, compared to $280,000 and $323,000 in 1994 and 1993, respectively. The majority of product sales were made under agreements with Ortho, whereby Ortho acquired worldwide rights to produce and distribute a Corvas product for diagnostic use in determining the blood clotting ability of patients. In order to maintain its rights pursuant to these agreements, Ortho is required to make minimum annual purchases of materials, royalty payments, and one additional milestone payment. These revenue increases were partially offset by a decrease in research grants revenue. No revenue from research grants was recorded in 1995, compared to $667,000 in 1994 and $192,000 in 1993. This decrease results from closing the Belgian subsidiary, which received the majority of the grant revenue. Research and development expenses decreased to $9,723,000 in 1995, from $11,378,000 in 1994 and $12,115,000 in 1993. Research and development expenses accounted for 78% of the total costs and expenses in 1995, 68% in 1994 and 79% in 1993. This decrease in 1995, primarily due to the closure of the Belgian subsidiary, was partially offset by an increase in clinical trial, preclinical development and medicinal chemistry costs. The decrease in 1994 was caused by the recording of two one-time charges in 1994: a restructuring charge of $1,575,000 pursuant to closing the Belgian subsidiary, and a charge of $535,000 for settlement of stockholder litigation. General and administrative expenses decreased to $2,582,000 in 1995, from $3,159,000 in 1994 and $3,067,000 in 1993. Major factors contributing to the decrease in 1995 include decreased administrative headcount and the final charges for deferred compensation expense related to certain options granted prior to the Company's initial public offering. Total other income was $821,000 in 1995, $697,000 in 1994 and $1,073,000 in 1993. The increase from 1994 to 1995 was primarily attributable to higher investment balances available as a result of the equity and research funding received from Schering-Plough in December 1994. Subject to the availability of additional capital, the Company expects that all expenses will increase over the next several years as the Company's research and development programs progress. However, due to revenue expected to be recognized pursuant to the Company's collaborative agreements, operating losses are not expected to increase significantly, if at all, in 1996 beyond the 1995 amount. In October 1995, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123"), effective for fiscal years beginning after December 15, 1995. SFAS 123 establishes the fair value based method of accounting for stock-based compensation arrangements, under which compensation cost is determined using the fair value of the stock option at the grant date and the number of options vested, and is recognized over the periods in which the related services are rendered. The Company will adopt SFAS 123 using the pro forma disclosure method. 20. LIQUIDITY AND CAPITAL RESOURCES Since inception, the Company has financed its operations primarily through private placements of convertible preferred stock, the initial public offering of common stock, a private placement of equity securities, interest income earned on cash and investment balances, and revenues from collaborative agreements, research grants and license agreements. On February 2, 1996, the Company completed a private placement of equity securities consisting of 3,000,000 units, resulting in proceeds of $14,835,000, net of estimated issuance costs. Each unit consisted of one share of common stock and one callable warrant to purchase one additional share of common stock. The Company's principal sources of liquidity are its cash and cash equivalents, time deposits and debt securities which, net of a restricted time deposit of $60,000, totaled $24,848,000 as of March 31, 1996. Working capital at March 31, 1996 was $21,570,000. Available cash is invested in accordance with an investment policy set by the Board of Directors, which has the objective to maximize income with preservation of principal and maintenance of adequate liquidity. The policy provides guidelines concerning the quality, term and liquidity of investments. The Company presently invests its excess cash in U.S. government securities. The Company expects to incur substantial additional costs in the foreseeable future, including costs related to sustaining and possibly expanding research and development activities and preclinical and clinical testing, and that such costs will continue to increase. As a result, the Company expects it will experience substantial additional operating losses over the next several years. With the cash infusion from the recent private placement, the Company believes its existing capital resources and interest earned thereon will be adequate to satisfy its capital requirements into 1998. In addition, the Company may also receive milestone payments and royalties on sales of products resulting from its alliances. However, there can be no assurance that products will be successfully developed and commercialized or that the Company will receive any such amounts under these alliances. The Company's future capital requirements will depend on many factors, including, but not limited to, the following factors: continued scientific progress in its drug discovery programs; the magnitude of these programs; progress of preclinical testing and clinical trials; the time and costs involved in obtaining regulatory approvals; the costs involved in filing, prosecuting, maintaining and enforcing patent claims; competing technological and market developments; changes in its existing research relationships; the ability of the Company to establish and maintain collaborative or licensing arrangements; the cost of manufacturing scale-up; and effective commercialization activities and arrangements. The Company leases its laboratory and office facilities and certain equipment under operating and capital leases. It is expected that the Company will need to acquire additional property and equipment as research and development activities progress. The Company anticipates the need for expansion of its laboratory and office facilities over the next several years. The Company's business is subject to significant risks, including but not limited to the risks associated with its research and development efforts, obtaining and enforcing patents, the lengthy and expensive regulatory approval process, product reimbursement levels, competition from other products, dependence on collaborative partners and other third parties, and the availability of capital. Even if the Company's products appear promising at an early 21. stage of development, they may not reach the market for a number of reasons. Such reasons include the possibilities that the potential products: will be ineffective or found to be unsafe during clinical trials, will fail to receive necessary regulatory approvals, will be difficult to manufacture on a large scale, will be uneconomical to market or will be precluded from commercialization by proprietary rights of third parties. Uncertainties associated with the duration and expense of preclinical and clinical testing of any of the Company's products make it difficult to predict the Company's capital requirements, and unexpected developments and/or regulatory requirements could greatly increase the cost of development of such products and affect the timing of anticipated revenues from product sales. Failure by the Company to obtain regulatory approval for any product will preclude its commercialization. In addition, failure by the Company to obtain patent protection may make certain of its products commercially unattractive. To continue its product development efforts, the Company will be required to raise substantial additional funds through public or private sales of its securities and through collaborative arrangements. The Company's ability to raise additional funds through such sales of securities depends in part on investors' perceptions of the biotechnology industry in general and of the Company in particular. The market for biotechnology company stocks has historically been highly volatile and, accordingly, there can be no assurance that additional funding will be available, or, if available, that it will be available on acceptable terms. The Company is seeking to enter into additional collaborative relationships to support development and commercialization under which rights to certain of its technologies or products will be granted. There can be no assurance that the Company will be able to conclude such relationships on satisfactory terms, if at all, or that agreements with its collaborators will successfully reduce its funding requirements. In addition, the Company has no established bank financing arrangements, and there can be no assurance that it will be able to establish such arrangements on satisfactory terms, if at all. If adequate funds are not available, the Company may be required to significantly delay, scale back or eliminate one or more of its drug discovery programs or obtain funds through arrangements with collaborative partners or others that may require the Company to relinquish rights to certain of its technologies, product candidates or products that the Company would not otherwise relinquish. At December 31, 1995, the Company had available net operating loss carryforwards of approximately $37,368,000 for federal income tax reporting purposes which begin to expire in 2002. The net operating loss carryforwards for state purposes, which began to expire in 1995 and fully expire in 2000, are approximately 50% of the federal tax amounts. The Company has unused research and development tax credits for federal income tax reporting purposes of $2,314,000 at December 31, 1995. In accordance with Internal Revenue Code Section 382, the annual utilization of net operating loss carryforwards and credits existing prior to a change in control may be limited. The Company, several of its current and former directors, and Centocor, Inc. were parties to a legal proceeding filed February 18, 1993 in the U.S. District Court for the Southern District of California. The complaint was filed by a stockholder of the Company who represented a class of persons who purchased Corvas stock from January 30, 1992 through April 14, 1992. A settlement was agreed upon and judgment of the Court entered on August 28, 1995. Upon final determination of allocations of stock to approved claimants, the remaining Corvas settlement amounts were distributed in May 1996. The Company continues to deny all claims of wrongdoing and maintains this denial as part of the settlement agreement. Of the $535,000 charge recorded in 1994 related to this settlement, $193,000 remains accrued at March 31, 1996. See "Business - Legal Proceedings." In 1993, the U.S. Patent and Trademark Office declared an interference and is currently in the process of determining the priority of invention between a patent for which some rights are licensed to the Company and a patent application for which rights are licensed to another party. The subject matter of these licenses is recombinant tissue factor which is used by Ortho to determine the blood clotting abilities of patients. The Company believes that its licensed patent should be upheld and is contesting the other party's claims of prior invention. However, there can be no assurance that such patent will be upheld. See "Business - Legal Proceedings." 22. BUSINESS EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE FOLLOWING DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE DISCUSSED HEREIN. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN THIS SECTION, AS WELL AS THOSE DISCUSSED ELSEWHERE IN THIS PROSPECTUS. OVERVIEW Corvas is a biopharmaceutical firm engaged in the design and development of a new generation of therapeutic agents in the fields of thrombosis and inflammation. The Company seeks to develop and commercialize novel drugs for the improved treatment and prevention of major cardiovascular diseases, such as heart attack, stroke, deep vein thrombosis, pulmonary embolism, and acute inflammation associated with trauma, shock and reperfusion injury in stroke. In contrast to currently available therapies, the Company's candidate drugs are designed to intervene more specifically in the disease process. Corvas intends to develop both parenteral and oral drugs to treat patients who cannot be optimally treated with current therapeutics. The Company believes that its antithrombotic drug discovery and development program is among the most comprehensive in the industry and that, together with its alliance partner, it is well positioned to develop and commercialize orally-active antithrombotic agents. Corvas has discovered its portfolio of drug candidates by integrating the Company's in-depth knowledge of the biology of thrombosis and, more generally, vascular biology, with advanced and proprietary drug discovery and design technology. The Company believes that such technology has broad potential application outside the antithrombotic field and will provide the basis for expanding its product portfolio. Corvas' scientists are experienced in a wide range of disciplines which are all integrated in a systematic discovery approach. Current programs employ medicinal chemistry, peptide chemistry, computer-aided drug design, structural biology, molecular biology, biochemistry, physiology, and pharmacology competencies. The Company's programs are based on three technology platforms: structure-based drug design, biological discovery, and molecular pharmacology. The first two platforms generate drug leads, while the third technology platform enables the selection of drug candidates. The Company's structure-based drug design programs are the source of small molecule drugs, including those demonstrating oral activity. Biological discovery methods, including novel gene discovery, cloning, expression, and mutagenesis methods are used to identify novel biologicals as drug candidates and discovery tools. Molecular pharmacology techniques, including IN VITRO biochemical analysis and IN VIVO biological testing, are used to rigorously characterize the many drug leads derived from the two other platforms in order to select specific drug candidates for preclinical and clinical development. The Company has several antithrombotic compounds in clinical and preclinical development, including orally-active thrombin inhibitors, which are being developed in collaboration with Schering-Plough. Corvas has developed a portfolio of orally-active, potent and selective thrombin inhibitors upon which this alliance is based. In the second half of 1995, Corvas conducted an initial human safety study of CVS-1123, a lead orally-active thrombin inhibitor. In this Phase Ia study, CVS-1123 demonstrated oral activity and was well tolerated. Corvas and Schering-Plough are actively evaluating a series of follow-on compounds in the same chemical class in order to select a candidate for development by Schering-Plough. This selection is expected to be made by the end of 1996. See "Business - Strategic Alliances - Relationship with Schering- Plough." 23. Corvas is also conducting active discovery programs for inhibitors of coagulation Factor Xa and Factor VIIa/TF. The primary goal of these programs is the development of safe and effective orally-active drugs. A secondary goal has been the development of parenteral agents targeting these factors. In 1994, Schering-Plough acquired an option to expand its alliance with Corvas to include Factor Xa inhibitors. In January 1996, Schering-Plough made a $1,000,000 payment to extend its option rights until December 1996. See "Business - Strategic Alliances - Relationship with Schering-Plough." In 1995, Company scientists presented initial scientific data on a newly discovered class of natural anticoagulant peptides known as the NAP family. Specific members of this family inhibit either Factor Xa or Factor VIIa/TF. The Company has selected and commenced preclinical development of a Factor VIIa/TF inhibitor as a parenteral agent for acute care indications, such as treatment of venous thrombosis and prevention of pulmonary embolism. In its anti-inflammatory program, the Company has discovered a promising novel protein, NIF, which blocks certain white blood cell functions associated with inflammation. In 1995, initial studies demonstrating the potential of NIF as a therapy for stroke victims were presented at a scientific conference by Corvas collaborators and published in a leading journal. Based on these early results, the Company entered into an agreement with Pfizer to collaborate on the development of NIF. See "Business - Strategic Alliances - Relationship with Pfizer." A Phase Ia clinical trial has been completed for the Company's first drug candidate, CORSEVIN M, an antibody-based antithrombotic which has been licensed to, and is being further developed by, Centocor. See "Business - Strategic Alliances - Relationship with Centocor." In 1992, Corvas entered into an alliance with Ortho to develop and commercialize a laboratory test for blood clotting function based on Corvas' proprietary technology. Corvas supplies a critical raw material, recombinant human tissue factor, to Ortho and has licensed rights to Ortho. Ortho currently produces and markets prothrombin time reagents based on such technology. See "Business - Strategic Alliances - Relationship with Ortho Diagnostic Systems." With regard to the foregoing discussion of the Company's research and development programs, there can be no assurance that either the underlying science or the related research and development being conducted will successfully yield approved clinical products. Such research and development efforts are subject to failure at any time. BUSINESS STRATEGY Corvas was formed to discover and develop novel pharmaceutical products for the improved treatment and prevention of acute and chronic cardiovascular diseases, inflammatory diseases, and related vascular disorders, including deep vein thrombosis, pulmonary embolism, heart attack, unstable angina, atrial fibrillation, and stroke. The Company believes that it has established a leadership position in the discovery and development of antithrombotic agents - drugs which prevent the formation of blood clots - and particularly in the design of oral drugs which have significant clinical and commercial potential. The Company is also pursuing the development of new parenteral antithrombotic agents based on recent discoveries. Key elements of the Company's strategy include the following: * FOCUS ON ANTITHROMBOTIC DRUGS, A HIGH GROWTH SECTOR IN THE LARGE CARDIOVASCULAR MARKETPLACE. Corvas is developing a portfolio of antithrombotic drug candidates, directed at three molecular targets, for multiple clinical indications and routes of administration. The Company believes that its program to develop blockers of blood coagulation enzymes is among the most comprehensive in the industry. 24. * EXPAND ITS LEADERSHIP POSITION IN INHIBITION OF SPECIFIC PROTEASES AND RECEPTORS INVOLVED IN THROMBOSIS AND RELATED DISEASE MECHANISMS. Corvas has focused on antithrombotic drugs to exploit the potential that has been created by advances in understanding the biology of the disease and new molecular discovery technologies. The blood coagulation enzymes are members of a structurally-related class of serine proteases. Corvas believes it has achieved a leading position in the development of orally-active inhibitors of thrombin (CORTHROMBIN compounds). Advances made in this specific program, and other proprietary technologies, are being leveraged by application to other targets in the same family, including Factor Xa and Factor VIIa/TF. * INTEGRATE DRUG DISCOVERY METHODOLOGIES WITH BIOLOGICAL EVALUATION FOR RAPID ITERATION OF DEVELOPMENT CANDIDATES. Company scientists are experienced in a wide range of disciplines which are all integrated in a systematic discovery approach. Active programs exploit medicinal chemistry, peptide chemistry, computer- aided drug design, structural biology, molecular biology, biochemistry, physiology, and pharmacology competencies. The Company's programs are based on three technology platforms: structure- based drug design, biological discovery, and molecular pharmacology. Structure-based drug design programs are the source of small molecule drugs, including those possessing oral activity. Biological discovery methods, including novel gene discovery, cloning, expression, and mutagenesis methods are used to identify novel biologicals as drug candidates and discovery tools. Molecular pharmacology techniques, including IN VITRO biochemical analysis and IN VIVO biological testing, are used to rigorously characterize the many drug leads in order to select specific drug candidates for preclinical and clinical development. * ESTABLISH A STRONG PORTFOLIO OF PATENTS AND PROPRIETARY TECHNOLOGY. Corvas has adopted a proactive policy of filing and prosecuting patent applications claiming a range of inventions, including uses and methods of synthesis of new molecules, discovery methods, novel genes and gene products, and novel analytical reagents. Corvas has entered into selected agreements to license enabling technology from third parties and intends to seek rights to additional external technology on an ongoing basis to complement internal discovery efforts. See "Business - Patents and Proprietary Rights." * ENTER INTO STRATEGIC ALLIANCES WITH ESTABLISHED PHARMACEUTICAL FIRMS FOR PRODUCTS TARGETED AT CHRONIC INDICATIONS. Corvas has established an initial alliance for chronic care products based on oral thrombin inhibitors (CORTHROMBIN compounds) with Schering-Plough. This relationship may be expanded, at Schering- Plough's option, to include Factor Xa inhibitors (CORDECIN compounds). See "Business - Strategic Alliances - Relationship with Schering- Plough." The Company intends to establish additional alliances to access resources to support the development and commercialization of other chronic care products. * RETAIN/EXPLOIT U.S. RIGHTS TO SELECTED ACUTE CARE PRODUCTS WHEN CONSISTENT WITH THE FIRM'S FINANCIAL RESOURCES AND EXPECTED RETURN ON STOCKHOLDER INVESTMENT. Corvas plans to seek to retain exclusive rights, joint commercialization rights, or co-promotion rights to selected acute care products for the U.S. market when exploiting such rights is feasible and is expected to provide an appropriate economic return, balancing the resources required and risks involved. Based on this strategy, the Company formed an alliance with Pfizer to develop and commercialize NIF as a therapy for stroke. See "Business - Strategic Alliances - Relationship with Pfizer." More recently, the Company has commenced the development of a product candidate from the NAP family. Corvas plans to seek one or more partners to aid in the development of this product and plans to participate in the development and commercialization of such product in the U.S. 25. * EXPAND PRODUCT PORTFOLIO BY APPLICATION OF TECHNOLOGY TO DISEASE TARGETS OUTSIDE THE ANTITHROMBOTIC DRUG FIELD. The Company's technology platforms may be broadly applied to the discovery and development of inhibitors of new serine proteases. In the course of conducting its antithrombotic program, proprietary chemical methods for inhibiting such enzymes have been discovered. The Company is currently adapting these chemical methods to combinatorial chemistry formats to increase the speed and economy of new lead discovery and to strengthen its ability to expand the number of target enzymes in its portfolio. The computational chemistry and drug design technology resident at Corvas also permits the expansion and leveraging of the firm's existing portfolio. Expansion areas being targeted include inflammation and oncology, in which specific proteases play key roles in physiology. The Company also plans to explore the application of its tissue factor technology beyond the current use as a laboratory diagnostic reagent. BACKGROUND Thrombosis and inflammation are closely linked pathologic processes employed by the body to protect itself against injury. When these processes are excessively or inappropriately activated, the processes themselves can result in significant tissue injury, disease and death. THROMBOSIS The formation of a blood clot, or thrombus, in the body results from a complex cascade of biochemical events involving the blood coagulation proteins and blood platelets. Although blood clot formation is a normal vascular repair mechanism, when this mechanism is activated within a blood vessel, local thrombosis may result and occlude the blood vessel. Vascular diseases associated with thrombosis afflict more than 3,000,000 individuals annually in the U.S. and are the causes of significant mortality and morbidity associated with cardiovascular diseases. Thrombosis causes several significant diseases characterized by the location of the blood vessel where the thrombus is lodged. For example, acute myocardial infarction ("MI") results from obstruction of blood flow due to a thrombus in a coronary artery which supplies blood to the heart muscle; stroke or transient ischemic attacks ("TIA") may result from a thrombus in an artery which supplies blood to a part of the brain. Similarly, a clot in the deep veins of the legs, called deep vein thrombosis ("DVT"), causes local inflammation, pain and other complications, including the dislodgment of part of the thrombus which can travel to the lungs and result in life-threatening pulmonary embolism ("PE"). Thrombosis can also be generalized, with microthrombus formation occurring throughout the vascular system. This condition, known as disseminated intravascular coagulation ("DIC"), is a consequence of cancer and various infectious diseases, including sepsis, and may result in depletion of blood coagulation factors, multiple organ failure, hemorrhage and death. Activation of the thrombotic mechanisms contributes to unstable angina ("UA") or serious chest pain and atrial fibrillation ("AF") or rapid, uncontrolled heart muscle contractions. Patients with UA are at significant risk of Ml, and patients with AF are at significant risk of Ml and stroke due to enhanced risk of thrombosis. Patients with TIA are also at risk of stroke. Finally, DVT and PE can arise from complications of vascular surgery such as major orthopedic surgery. Two classes of antithrombotics are presently in clinical use: anticoagulants and antiplatelet agents. In the U.S., heparins and warfarin are the only drugs currently approved for use as anticoagulants. Aspirin is the most commonly used antiplatelet agent, although the first in a new class of antiplatelet agents, GPIIb/IIIa antagonists, has been recently introduced to the market. Although these drugs are widely prescribed, they have significant limitations. Heparins, which act by an indirect mechanism, can cause excessive bleeding and decreased platelet count (thrombocytopenia) and can be administered only by injection. Recently, low molecular weight heparins have been introduced in the U.S. These agents may be injected subcutaneously and routine monitoring of coagulation function is no longer required. These advantages have led to adoption for certain indications, yet low molecular 26. weight heparins still suffer from many of the limitations of traditional heparins. Warfarin lacks specificity of action, may cause bleeding, must be carefully monitored and, due to its slow onset of action, is unsuitable for use as an acute antithrombotic drug. Aspirin also has a slow onset of action and its effect is reversed by the natural production of new blood platelets, a process that takes seven to eleven days. In addition, chronic administration of aspirin carries the risk of gastrointestinal bleeding and hemorrhagic stroke. Currently, GPIIb/IIIa antagonists can be administered acutely by intravenous routes and must be used with an anticoagulant such as heparin. These and other factors limit the use of the currently available antithrombotic drugs, especially on a chronic basis. As there are no selective orally-active thrombin, Factor Xa or Factor VIIa inhibitors presently available, the compounds under development at Corvas aim to address unmet needs in antithrombotic therapy. The worldwide market for antithrombotic agents is estimated to be greater than $2,000,000,000, based on 1994 market audits. Approximately half of the sales are in each of the antiplatelet and anticoagulant categories. According to these market audits, 1994 U.S. sales of anticoagulants were greater than $440,000,000. Of this total, approximately $300,000,000 was contributed by the sales of COUMADIN-Registered Trademark-, the DuPont-Merck brand of warfarin. Sales of COUMADIN have been growing in recent years due to adoption by many physicians for two newly approved indications: treatment of patients with AF for prevention of stroke and prevention of recurrent MI. Treatment guidelines issued by the American College of Chest Physicians ("ACCP") in October 1995 recommend the use of oral anticoagulation to decrease the risk of stroke. Yet federal government agency estimates are that only 25% of AF patients are currently treated with oral anticoagulants. Based on interviews with clinicians, the Company believes that this is primarily because physicians fear the bleeding complications of COUMADIN. Approximately $140,000,000 of the U.S. anticoagulant sales reported in 1994 are in the parenteral category and comprise the traditional heparins and new low molecular weight heparin. In 1994, sales of LOVENOX-Registered Trademark-, the first low molecular weight heparin introduced in the U.S. by Rhone-Poulenc Rorer ("RPR"), reached $38,000,000. RPR has reported that sales of LOVENOX and related brands exceeded $300,000,000 worldwide in 1995. LOVENOX is primarily indicated for prophylaxis of venous thrombosis in major orthopedic surgery, such as hip and knee replacement. In October 1995, treatment guidelines for use of anticoagulation as prophylaxis to prevent deep vein thrombosis were also issued by the ACCP. PE resulting from DVT is estimated to be the most frequent cause of preventable in-hospital deaths. It is estimated that increased prophylaxis with low molecular weight heparins will reduce the risk of fatal pulmonary embolism in major orthopedic procedures. A second low molecular weight heparin, FRAGMIN-TM-, was recently approved in the U.S. for use as therapy in major abdominal surgery. The Company believes the large number of patients affected by thrombotic and associated vascular diseases, together with the limited efficacy of, and adverse side effects associated with, existing surgical procedures and drug therapies, provides significant market opportunities for new drugs. The recent growth in sales in the antithrombotic drug category supports the view that physicians are adopting new agents in search of better therapeutic outcomes and economics. Corvas is building on recent scientific advances in the understanding of the mechanisms of blood clot formation and is developing new therapeutics designed to intervene more specifically in the disease process to result in drugs which the Company believes will offer important economic and therapeutic advantages over existing therapy. INFLAMMATION Inflammation is a response by the body to injury and infection. The diverse inflammatory responses are mediated by a series of molecular events, known as the inflammatory cascades, by which the body attempts to limit or destroy the injurious agents, heal wounds and maintain health. However, inflammatory responses can result in significant tissue injury and disease. A primary event in a major class of inflammatory response is the attachment, or adhesion, of neutrophils, a specific type of white blood cell, to endothelial cells which line the blood vessel walls. Adhesion is caused by the interaction of specific receptors on the neutrophils with target adhesion molecules on the endothelial cells. After adhesion occurs, the neutrophils migrate across the lining of the blood vessel and into the tissue where they release toxic substances, which contribute to tissue damage. These events occur in both acute and chronic inflammatory conditions. Acute disorders which are often accompanied by this inflammatory response 27. include stroke, traumatic shock and many forms of reperfusion injury which can occur following certain surgical procedures such as aortic aneurysm repair, artery bypass grafting and major abdominal surgery. Current anti-inflammatory drugs generally seek to alleviate symptoms rather than intervene in the underlying disease processes. Blocking the activation and adhesion of white blood cells to endothelial cells, and thereby preventing their accumulation in tissue, is an alternate approach which could more effectively intervene early in the inflammatory process. Using advanced understanding of the underlying mechanisms of inflammation and tissue injury, Corvas is seeking to develop new anti-inflammatory agents designed to intervene early in the disease process and provide improved efficacy and safety. The Company is focusing its NIF program on the development of a protein drug that will inhibit neutrophil activation, adhesion and transmigration into brain tissue to attenuate and prevent injury following stroke and head trauma. The Company believes this approach may lead to a new drug for the treatment of stroke victims, for whom no effective therapy exists. INTEGRATED TECHNOLOGY PLATFORMS In its drug discovery programs, Corvas applies a highly integrated, multidisciplinary approach to produce novel molecules as both drug discovery tools and drug candidates. The Company's medicinal chemistry expertise is essential to the development of synthetic pharmaceuticals and is supported by its capabilities in protein engineering, biochemistry, immunology, monoclonal antibody technology, analytical chemistry, animal pharmacology, molecular modeling and IN VITRO and IN VIVO biological testing. In addition, the Company has developed combinatorial chemistry approaches which have yielded lead compounds for its antithrombotic program. The Company believes these technologies have potential application to the discovery of drug candidates in other therapeutic fields. STRUCTURE-BASED DRUG DESIGN Corvas scientists have extensive knowledge and experience in computer-aided drug design and have developed novel, proprietary software to expedite the protein-based design of synthetic drugs. Using computer-aided molecular modeling techniques, Company scientists have developed models of the active sites of serine proteases and have gained valuable insights regarding the unique features of specific targets. Corvas has also used computer modeling to study the interaction of candidate drugs with target enzymes. In addition, through collaboration with university-based scientists, Corvas has obtained X-ray crystal structures of candidate drugs bound to the active site of the target enzyme thrombin. Crystal structures of Corvas inhibitors bound to Factor Xa and Factor VIIa/TF are also being determined. By systematic iterative synthesis, biological evaluation and modeling, Company scientists have developed a comprehensive database correlating biological activity of candidate drugs with their structures. The Company has developed several proprietary chemical strategies for inhibiting serine protease enzymes using a concept known as "transition state analog inhibition." In this approach, an inhibitor is synthesized which mimics the "transition state" structure that is intermediate between that of the enzyme's substrate and its product. By exploiting this principle, Company scientists have produced inhibitors of three enzymes in the coagulation cascade and several other targets outside of thrombosis. The resulting inhibitors bind reversibly, but tightly, to the target enzyme and have been shown to exhibit excellent pharmacologic properties. Company scientists are currently combining certain Corvas proprietary inhibitor chemistry with recently developed methods of combinatorial chemistry to create methods of producing large libraries of candidate inhibitors. It is expected that such methods, if successfully developed, will improve the speed of lead identification efforts and enable the Company to more rapidly expand its portfolio to new target enzymes. BIOLOGICAL DISCOVERY Natural products have been a source of new drugs for many years. Advances in molecular biology permit the search for, and identification of, new biological activities in a variety of sources if appropriate analytical assays exist. A secondary discovery strategy used by Corvas scientists has been to examine blood-feeding parasites which infect mammals as a source of biologically-active agents which can serve as mechanistic probes and potential drug 28. candidates. Using specialized assays of coagulation enzyme and white blood cell activity, Corvas scientists have discovered natural molecules which inhibit certain blood coagulation enzymes and certain white blood cell functions. These molecules, from the NAP and NIF families, are further described below. Techniques used to discover these molecules include classical protein fractionation and activity purification as well as gene cloning techniques, including specialized expression cloning methods developed by Corvas scientists. The study of the structure and function of molecules evolved by nature to perform specialized biochemical functions often yields novel insights into molecular mechanisms. Such studies have provided competitive advantages to Company scientists which are being applied in its small molecule drug discovery programs. The Company anticipates using its biological discovery competence to identify molecules that act on new drug discovery targets and to identify novel targets for future discovery programs as well. MOLECULAR PHARMACOLOGY Using the two platform technologies described earlier, Company scientists seek to generate many lead molecules which must be rigorously evaluated to determine their suitability as drug candidates for further preclinical and clinical development. This evaluation process relies on Corvas' expertise in molecular pharmacology. Corvas has evolved a highly specialized capability to evaluate leads for selection as candidate antithrombotic and related drugs. Such expertise depends on a unique blend of IN VITRO biochemical and IN VIVO biological techniques, with testing in both small and large laboratory animal models of disease processes. Selection of candidates from leads depends on the specific intended use and route of administration of a drug. Company scientists are highly experienced in evaluating molecules for bioavailability by various routes of administration, including the oral, intravenous and subcutaneous routes. To complement its internal resources in physiology and pharmacology, the Company has conducted numerous animal studies in collaboration with outside investigators, primarily in academic settings, who provide specialized models and comparative data bases which are critical to the drug selection process. PRODUCT DEVELOPMENT PROGRAMS The following table describes the Company's primary drug development programs and their potential therapeutic indications and development status. There can be no assurance that the Company's product development efforts will progress any further or be successfully completed. In addition, there can be no assurance that the Company's potential products will be capable of being produced in commercial quantities at reasonable costs, that required regulatory approvals can be obtained or that any potential products, if introduced, will be successfully marketed or achieve market acceptance. 29. PROGRAM/MOLECULAR TARGET THERAPEUTIC INDICATIONS(1) DEVELOPMENT STATUS(2) - ------------------------ -------------------------- --------------------- ANTITHROMBOTIC CORTHROMBIN COMPOUNDS/THROMBIN Oral(3) DVT, PE, UA, stroke, AF Phase Ia trial completed in 1995; Schering-Plough expected to start Phase I trial in 1997 CORDECIN AS COMPOUNDS(4)/FACTOR Xa Parenteral (NAP-5) MI, UA, DVT, PE Preclinical development Oral Post-MI, UA, stroke, AF, DVT Lead evaluation/Preclinical development CORSEVIN AS COMPOUNDS/FACTOR VIIa/TF Parenteral (NAPc2) DVT, PE, UA Preclinical development Oral Post-MI, prevention of Lead discovery cardiovascular disease, UA, stroke, AF CORSEVIN M(5)/FACTOR VIIa Antithrombotic Phase Ib clinical trials ANTI-INFLAMMATORY NIF(6) Stroke, reperfusion injury Preclinical development with Pfizer
________________ (1) The following abbreviations are used in the table: AF=atrial fibrillation; MI=myocardial infarction; DVT=deep vein thrombosis; PE=pulmonary embolism; UA=unstable angina. (2) The following definitions apply to the table: "Lead discovery"=Identification of lead compounds with activity in appropriate IN VITRO assay systems. These lead compounds may require additional chemical manipulation and more extensive evaluation prior to selection of candidates, if any, for preclinical development. "Lead evaluation"=Extensive evaluation of lead compounds in multiple IN VITRO assay systems and preliminary animal pharmacology studies. "Preclinical development"=Conduct of specific studies to support clinical testing. See "Business - Government Regulation" for a description of the clinical trial process. (3) Oral CORTHROMBIN has been licensed to Schering-Plough. See "Business - Strategic Alliances - Relationship with Schering-Plough." (4) Schering-Plough has an exclusive option until December 1996 for CORDECIN AS compounds. See "Business - Strategic Alliances - Relationship with Schering-Plough." (5) CORSEVIN M has been licensed to Centocor. See "Business - Strategic Alliances - Relationship with Centocor." 30. (6) NIF is subject to an option by Pfizer to take an exclusive license to the product and related technology. See "Business - Strategic Alliances - Relationship with Pfizer." ANTITHROMBOTIC PROGRAM Currently available antithrombotic agents, despite their limitations, are used in a diverse range of clinical indications. In clinical practice, multiple antithrombotic drugs are often administered concurrently, and it is expected that drugs under development by Corvas may also be used in multidrug regimens. The Company has therefore adopted a broad approach in its antithrombotic program, targeting intervention at three key biochemical steps, in order to develop agents for multiple clinical indications. Corvas is developing compounds which inhibit Factor VIIa/TF, Factor Xa and thrombin, and believes that these drugs may have advantages over currently available antithrombotic drugs and over certain other antithrombotic drugs under development. As additional preclinical and clinical data are obtained, the Company expects to select optimal compounds for further development in specific clinical indications, either as parenteral or oral drugs. The Company believes that its program targeting the inhibition of the key coagulation enzymes is among the most comprehensive in the industry and that it has achieved a leading position in the design and development of orally-active antithrombotic agents. CORTHROMBIN COMPOUNDS. Corvas has developed highly potent and selective small molecule inhibitors of thrombin, a key blood enzyme that produces fibrin and causes platelet aggregation. Fibrin and platelets are the two major components of a blood clot. In December 1994, Corvas entered into a strategic alliance with Schering-Plough to develop and commercialize oral thrombin inhibitor drugs. See "Business - Strategic Alliances - Relationship with Schering-Plough." Corvas has developed a strong portfolio of orally-active thrombin inhibitors upon which this alliance is based. Lead compounds in several classes have been identified for further development and are being actively studied in animals and in early human testing. In the second half of 1995, Corvas conducted an initial human safety study of CVS-1123, a lead orally- active thrombin inhibitor. In this Phase Ia study, CVS-1123 demonstrated oral activity and was well tolerated. The Company presented the first results of the Phase Ia clinical trial at a scientific meeting in April 1996. Corvas and Schering-Plough are actively evaluating a series of follow-on compounds in the same chemical class as CVS-1123 in order to select a drug candidate for development by Schering-Plough. This selection is expected to be made by the end of 1996, upon which Schering-Plough will make a $3,000,000 milestone payment. Corvas has filed a series of patent applications covering novel thrombin inhibitor structures, chemical strategies for inhibiting thrombin and related enzymes, and methods of treating thrombosis with such inhibitors. The Company believes that it has and will continue to establish a strong patent position in the field of thrombin inhibitors. See "Business - Patents and Proprietary Rights." CORDECIN AS COMPOUNDS. Corvas is developing synthetic inhibitors of Factor Xa. Progress has been made in the identification of potent and specific Factor Xa inhibitors in IN VITRO assay systems and in IN VIVO animal models, including compounds which exhibit oral activity in rodent models of thrombosis and oral bioavailability in conscious dogs. Research activities are focused on continued refinement of these molecules to identify suitable preclinical candidates. As part of the strategic alliance with Schering-Plough to develop and commercialize oral antithrombotic drugs, Schering-Plough has obtained an exclusive option for CORDECIN through December 1996. See "Business - Strategic Alliances - Relationship with Schering-Plough." CORSEVIN AS COMPOUNDS. Corvas has designed, synthesized and evaluated a large number of proprietary synthetic compounds which inhibit the activity of Factor VIIa/TF. Additional medicinal chemistry research and pharmacology testing is ongoing to refine these molecules and further improve their potency and selectivity. The Company intends to seek a strategic alliance to support the development of Factor VIIa/TF inhibitors for chronic therapy. NAP FAMILY. In addition to the chemistry-based approach described above, Corvas scientists have recently discovered a unique family of small protein inhibitors of Factors Xa and VIIa/TF. These NAP proteins were discovered from blood-feeding hookworms, parasites which have evolved efficient anticoagulation mechanisms. 31. Based on comparative data developed both in the Company's laboratories and with collaborators, the Company believes that these agents exhibit unprecedented antithrombotic potency in animal models. In addition, animal studies demonstrate that NAP proteins may be administered by the subcutaneous route, and assuming that similar properties are demonstrated in humans, this is expected to be an attractive competitive feature of these agents. The discovery and characterization of a specific Factor Xa inhibitor, NAP-5, was reported at scientific meetings in 1995, including the American Heart Association, and was discussed in a full paper in the PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES ("PNAS"). The cloning and characterization of a novel Factor VIIa/TF inhibitor, NAPc2, is described in a second paper, published on March 5, 1996 in PNAS. The Company plans to present additional scientific results at meetings throughout 1996. Based on the preclinical studies conducted to date, the Company has selected NAPc2 as a development candidate and has commenced the necessary preclinical studies to bring NAPc2 to the clinic for initial human testing in early 1997. Initial clinical trials and early Phase II efficacy studies are currently being designed. The Company has engaged a contract manufacturer to produce the necessary clinical supplies. CORSEVIN M. Corvas has developed CORSEVIN M, a potent and specific monoclonal antibody fragment. CORSEVIN M acts at the initial step of the coagulation cascade by binding to coagulation Factor Vlla and neutralizing its clot-forming activity. In 1993, the Company completed a Phase I clinical trial of CORSEVIN M which it believes is the first specific inhibitor of the initiation of the coagulation cascade to have been tested in humans. In Phase Ia clinical trials, this compound showed potential as a safe, fast-acting, potent and reversible anticoagulant. Because the Company is focusing its resources on non-antibody based pharmaceuticals, it licensed this product to Centocor. The Company has been advised that Centocor intends to continue the development of CORSEVIN M and that Centocor is currently evaluating its future development strategy for the agent in the light of the recent clinical trial results with its antiplatelet agent REOPRO-TM-. The Company expects that Centocor will conduct all future trials, if any, of CORSEVIN M. See "Business - Strategic Alliances - Relationship with Centocor." ANTI-INFLAMMATORY PROGRAM NIF. Corvas is developing NIF, a protein which inhibits neutrophil activation, adhesion and transmigration into tissue. Corvas scientists have demonstrated that NIF interacts specifically with a cell adhesion receptor (integrin) on the surface of neutrophils known as CD11b/CD18 (Mac-1). The interaction of NIF with CD11b/CD18 blocks the adhesion of neutrophils to the endothelial cells which line blood vessels, and thereby inhibits the first step in the development of an inflammatory response. Corvas has produced multiple recombinant forms of NIF, selected one form for preclinical development, and demonstrated activity of the molecule in several animal pharmacology models of acute inflammation. The Company believes that NIF is the first identified, naturally-occurring inhibitor of CD11b/CD18, and that this novel molecule may have application as an acute anti-inflammatory drug with safety and efficacy advantages over current clinical therapy and other investigational agents. NIF represents a potential parenteral acute-care anti-inflammatory product. The Company has continued animal pharmacology studies of NIF, focusing on stroke and reperfusion injury, in which earlier studies have shown NIF to be highly effective. In 1995, initial studies demonstrating the potential of NIF as a therapy for stroke victims were presented at a scientific conference by Corvas collaborators and published in the ANNALS OF NEUROLOGY. Based on these early results, the Company entered into a strategic alliance with Pfizer in October 1995 to collaborate on the development of NIF as a therapy for stroke and head injury. In collaboration with Pfizer and an academic laboratory, studies to evaluate the efficacy of NIF in animal models of stroke are continuing. Additionally the Corvas-Pfizer collaboration is currently focusing on the manufacture of additional supplies of NIF for toxicology studies and early human studies. If the project proceeds on schedule, initial human studies are planned for 1997. See "Business - Strategic Alliances - Relationship with Pfizer." DRUG DESIGN In its drug discovery programs, Corvas applies a highly integrated, multidisciplinary approach to produce novel molecules as both drug discovery tools and drug candidates. The Company's medicinal chemistry expertise is essential to the development of synthetic pharmaceuticals and is supported by its capabilities in protein engineering, biochemistry, immunology, monoclonal antibody technology, analytical chemistry, animal pharmacology, 32. molecular modeling and IN VITRO and IN VIVO biological testing. In addition, the Company has developed combinatorial chemistry approaches which have yielded lead compounds for its antithrombotic program. The Company believes these technologies have potential application for the discovery of drug candidates for other therapeutic indications. Corvas scientists also have extensive knowledge and experience in computer- aided drug design and have developed novel, proprietary software to expedite the protein-based design of synthetic drugs. Using computer-aided molecular modeling techniques, Company scientists have developed models of the active sites of serine proteases and have gained valuable insights regarding the unique features of specific targets. Corvas has also used computer modeling to study the interaction of candidate drugs with target enzymes. By systematic synthesis, biological evaluation and modeling, Company scientists have developed a comprehensive database correlating biological activity of candidate drugs with their structures. COMMERCIAL PRODUCTS The Company has entered into two agreements with Ortho for manufacturing and worldwide marketing by Ortho of diagnostic tests containing recombinant human tissue factor produced by Corvas. See "Business - Strategic Alliances - Relationship with Ortho Diagnostic Systems." Corvas also supplies recombinant human tissue factor and a group of tissue factor-specific monoclonal antibodies to a distributor for use in the research market. Sales of these products have not been significant to date and are not expected to be significant in the future. STRATEGIC ALLIANCES As part of the Company's strategy for the research, development and commercialization of its products, the Company may enter into various arrangements with corporate partners, licensors, licensees and others. Such arrangements may include the grant of manufacturing, marketing or other rights. There can be no assurance that any additional arrangements beyond those detailed below will be established or that new products will be successfully developed and commercialized under any existing alliances. If the Company is not able to establish additional arrangements, it could encounter delays in developing its products or find that the development, manufacture or sale of its products in such markets is adversely affected. While Corvas believes that parties to any such arrangements will have an economic motivation to succeed in performing their contractual responsibilities, the amount and timing of resources they devote to these activities will not be within the Company's control. RELATIONSHIP WITH SCHERING-PLOUGH In December 1994, the Company entered into a strategic alliance agreement with Schering-Plough to collaborate on the discovery and commercialization of oral thrombin inhibitor drugs for the prevention and treatment of chronic cardiovascular disorders. The initial collaboration covers development of inhibitors of thrombin, a key blood clotting enzyme. In addition, Schering- Plough acquired an exclusive option (which was extended to December 1996 upon payment of $1,000,000) to expand the program to include inhibitors of a second significant blood coagulation enzyme, Factor Xa. Under the terms of the agreement, Schering-Plough will compensate the Company for the costs of research and preclinical development of thrombin inhibitors over two years. Schering-Plough, which is responsible for certain preclinical development, all clinical trials and regulatory activities, received exclusive worldwide manufacturing and marketing rights for any resulting thrombin inhibitors. The Company may also receive milestone payments and royalties on sales of therapeutics resulting from this alliance. However, there can be no assurance that products will be successfully developed and commercialized under this alliance. In connection with this alliance, Schering-Plough paid certain fees and purchased 1,000,000 shares of Series A Convertible Preferred Stock of the Company in 1994 resulting in net proceeds of $4,864,000. Revenue of $4,000,000 was recognized under this agreement in 1995. If the option for Factor Xa is exercised, Schering-Plough 33. has agreed to make an additional equity investment, as well as payments for certain fees, research and development expenses, and regulatory milestones. To date, Corvas has received a total of $14,000,000 from Schering-Plough under the alliance. Schering-Plough beneficially owns approximately 9.0% of the outstanding securities of the Company on an as-converted basis. RELATIONSHIP WITH PFIZER In October 1995, the Company entered into a research and option agreement with Pfizer to collaborate on the development of NIF. During the option period, which concludes in October 1996 but may be extended by Pfizer until April 1997, Pfizer will fund its own further development of NIF, including costs associated with clinical trials. If Pfizer exercises its option by April 1997, pursuant to a license and development agreement, Corvas will conduct certain development activities for an additional two-year period and Pfizer will receive an exclusive, worldwide license to further develop, manufacture and market NIF as a therapeutic agent. If the option to enter into the license and development agreement is exercised, Pfizer will pay the Company an additional license fee of $1,000,000 and will compensate the Company for certain costs of research and preclinical development of NIF over a two-year period. If products are successfully commercialized from this agreement, the Company will also receive milestone payments and royalty payments on product sales. However, there can be no assurance that products will be successfully developed and commercialized under this alliance. RELATIONSHIP WITH ORTHO DIAGNOSTIC SYSTEMS In June 1992, the Company entered into two agreements with Ortho for manufacturing and worldwide marketing by Ortho of diagnostic tests containing recombinant human tissue factor produced by Corvas. These tests are used to determine the blood clotting ability of patients. European sales of this product commenced in 1992 and sales in the U.S. commenced in 1993. In order to maintain its rights pursuant to these agreements, Ortho is required to make minimum annual purchases of materials, royalty payments, and one additional milestone payment. RELATIONSHIP WITH CENTOCOR In November 1991, the Company entered into an agreement with Centocor in which Corvas granted rights to Centocor to license and commercialize certain monoclonal antibody products developed by Corvas. For one such monoclonal antibody product, CORSEVIN M, Corvas completed a Phase Ia clinical trial in 1993. Centocor has informed the Company that it intends to continue the development of CORSEVIN M. Corvas will depend on Centocor for the continued development of CORSEVIN M and product sales. In 1994, Centocor terminated its option rights to future monoclonal antibody products discovered or acquired by the Company. The Company may receive a future milestone payment upon receipt of certain regulatory approvals and royalties on product sales. In connection with this alliance, Centocor purchased preferred stock (subsequently converted to common stock) of the Company for an aggregate purchase price of $9,250,000. In connection with a lawsuit brought against Corvas, several of its directors and Centocor, Centocor transferred 600,000 of its Corvas shares towards the settlement during 1995. See "Business - Legal Proceedings." On an as-converted basis, Centocor presently beneficially owns approximately 4.9% of the outstanding securities of the Company. RESEARCH COLLABORATIONS AND LICENSES Corvas has also established collaborations with scientists at a number of leading U.S. and European academic and clinical research centers to further its technology and product development objectives. These collaborations are generally conducted pursuant to agreements which give the Company a license, or the option to license, certain technology, patent rights or materials which may be valuable to the Company. These agreements may require the Company to fund research or to pay license fees or milestone payments and, upon commercial sale of certain products, royalties. The Company also has several contractual arrangements with scientific advisors and collaborators for which the Company compensates these individuals or an affiliated entity. 34. PATENTS AND PROPRIETARY RIGHTS The Company's success will depend in part on its ability to obtain patent protection for its products, both in the U.S. and other countries. The patent position of biotechnology and pharmaceutical companies is highly uncertain and involves complex legal and factual questions. There is no consistent policy regarding the breadth of claims allowed in biotechnology patents. The Company intends to file applications as appropriate for patents covering both its products and processes. As of the date of this Prospectus, Corvas holds rights in nine U.S. patents and has been notified of four allowed patent applications in the U.S. Of the issued patents, seven are owned by the Company and two are licensed by the Company. Corvas has filed or holds licenses to 55 additional patent applications that currently are pending in the U.S. Patent and Trademark Office. Approximately one-third of these pending patent applications are duplicate applications the Company filed in anticipation of changes to U.S. patent law that became effective in June 1995 and that may affect the term of U.S. patents. Foreign counterparts of certain of the U.S. applications have been filed in many countries. In addition, Corvas holds rights in four foreign-issued patents; Corvas owns one such patent and is the exclusive licensee, in a defined field of use, of the remaining three foreign patents. There can be no assurance that patents will issue from any of the patent applications owned or licensed by the Company or that claims allowed under any issued patents will be sufficiently broad to protect the Company's technology. In addition, there can be no assurance that any patents issued or licensed to the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder will provide proprietary protection to the Company. As is typical in the biotechnology industry, the commercial success of the Company will depend in part on the Company neither being found infringing on patents issued to competitors nor breaching the technology licenses upon which the Company's products might be based. While the Company is aware of third party patent applications and issued patents in the Company's field, it is uncertain whether these will require the Company to alter products or processes, obtain licenses or cease certain activities. If the Company is required to obtain such licenses, there can be no assurance the Company will be able to obtain any necessary licenses at a reasonable cost. Failure by the Company to obtain a license to any technology that it requires to commercialize its products and obtain FDA approval within an acceptable period of time, if required to do so, would have a material adverse effect on the Company. Litigation, which could result in substantial costs to the Company, may also be necessary to enforce any patents issued to the Company or to determine the scope and validity of others' proprietary rights. In 1993, the U.S. Patent and Trademark Office declared an interference and is currently in the process of determining the priority of invention between a patent for which some rights are licensed to the Company and a patent application for which rights are licensed to another party. The subject matter of these licenses is recombinant tissue factor which is used by Ortho to determine the blood clotting ability of patients. There can be no assurance that the U.S. Patent and Trademark Office will rule in a manner favorable to the Company on this matter. See "Business - Legal Proceedings." In addition to patents, the Company relies on trade secrets and proprietary know-how, which it seeks to protect, in part, through appropriate confidentiality and proprietary information and inventions agreements with its current and prospective collaborative partners, employees, scientific advisors and consultants. There can be no assurance that these agreements will not be breached, that the Company will have adequate remedies for any breach, or that the Company's trade secrets will not otherwise become known or be independently discovered by competitors. Certain of the Company's research has been funded in part by the SBIR program. As a result of such funding, Government Rights will exist in any technology, including inventions, developed with the funding. These rights include the grant of a non-exclusive, paid-up, worldwide license to such inventions for any governmental purpose. In addition, the government has the right to require the Company to grant an exclusive license to any of such inventions to a third party if the government determines that (i) adequate steps have not been taken to commercialize such inventions, (ii) such action is necessary to meet public health or safety needs or (iii) such action is necessary to meet requirements for public use under federal regulations. Federal law requires any licensor of an invention that was partially funded by federal grants to obtain a covenant from its exclusive licensee to substantially manufacture products using the invention in the U.S. In addition, the Company's licenses may also relate to technology developed with federal funding and, therefore, may also be subject to Government Rights. 35. GOVERNMENT REGULATION The production and marketing of the Company's products and its ongoing research and development activities are subject to regulation by numerous governmental authorities in the U.S. and other countries. Any drug developed by the Company must undergo rigorous preclinical and clinical testing and an extensive regulatory approval process mandated by FDA and equivalent foreign authorities before it can be marketed. Various federal and, in some cases, state statutes and regulations also govern or influence the manufacturing, safety, labeling, storage, recordkeeping and marketing of such products. These processes can take a number of years and require the expenditure of substantial resources. Any failure by the Company or its collaborators or licensees to obtain, or any delay in obtaining, regulatory approvals could adversely affect the marketing of any products developed by the Company and its ability to receive product or royalty revenue. The activities required before a pharmaceutical agent may be marketed in the U.S. begin with preclinical testing. Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the potential safety and efficacy of the product and its formulations. The results of these studies must be submitted to the FDA as part of an Investigational New Drug Application ("IND"), which must be reviewed and become effective pursuant to FDA regulations before proposed clinical testing can begin. Typically, clinical testing involves a three-phase process. In Phase I, clinical trials are conducted with a small number of subjects to determine the early safety profile and the pattern of drug distribution and metabolism. In Phase II, clinical trials are conducted with groups of patients afflicted with a specified disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety. In Phase III, large scale, multicenter, comparative clinical trials are conducted with patients afflicted with a target disease in order to provide enough data for the statistical proof of efficacy and safety required by the FDA and others. The results of the preclinical and clinical testing are then submitted to the FDA for a pharmaceutical product in the form of a New Drug Application ("NDA"), or for a biological product in the form of a Product License Application ("PLA"), for approval to commence commercial sales. In responding to an NDA or PLA, the FDA may grant marketing approval, request additional information or deny the application if it determines that the application does not demonstrate to the satisfaction of the FDA that the product is safe and effective for its labeled indications. With respect to biological products, an Establishment License Application ("ELA") must also be filed, and the FDA must approve the manufacturing facilities for the products. There can be no assurance that approvals will be granted on a timely basis, if at all. Among the conditions for NDA or PLA approval is the requirement that the prospective manufacturer's quality control and manufacturing procedures conform on an ongoing basis with Good Manufacturing Practices ("GMP"). In complying with GMP, manufacturers must continue to expend time, money and effort in the area of production and quality control to ensure full technical compliance. Manufacturing facilities are subject to periodic inspections by the FDA, and noncompliance may result in the withdrawal of previously granted approvals and/or the imposition of other regulatory enforcement sanctions. The Company is also subject to regulation by the Food and Drug Branch of the California Department of Health Services ("FDB") and, prior to the marketing of any of its products manufactured in California, the Company will be required to secure a drug manufacturing license from the FDB. Such licenses are issued after an FDB inspection of manufacturing facilities, and are reissued on an annual basis after reinspection by the FDB. The Company is also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with the Company's research. The extent of government regulation which might result from any legislation or administrative action cannot be accurately predicted. 36. COMPETITION Due to the high incidence of cardiovascular and inflammatory diseases, most of the major pharmaceutical companies have significant research and product development programs in these areas. The Company expects to encounter significant competition as to each of the products it seeks to develop. Several existing products have well-established market positions and there are a number of new antithrombotic products in advanced clinical development. The Company's competitors include fully-integrated pharmaceutical and biotechnology companies which have expertise in research and development, manufacturing processes, testing, obtaining regulatory approvals and marketing, and may have financial and other resources greater than those of the Company. Smaller companies also may prove to be significant competitors. Furthermore, academic institutions, government agencies and other public and private research organizations conduct research relating to cardiovascular and inflammatory diseases and may seek patent protection for, and establish collaborative arrangements for the development and marketing of, products for the treatment of cardiovascular and inflammatory diseases. Products developed by these and other entities may compete directly with those being developed by the Company. These companies and institutions may also compete with the Company in recruiting and retaining highly qualified scientific personnel. The Company's competition will be determined in part by the potential indications for which the Company's products are developed and ultimately approved by regulatory authorities, by the timing of such approvals and market introduction and by whether any currently available drugs, or drugs under development by others, are effective in the same indications. Accordingly, the relative speed with which the Company can develop products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market is expected to be important competitive factors. The Company expects that competition among products approved for sale will be based, among other things, on product efficacy, safety, reliability, availability, price and patent position. PROPERTIES AND MANUFACTURING The Company presently occupies approximately 30,200 square feet of laboratory and office space in San Diego pursuant to a lease that expires in September 1997 and has two one-year renewal options remaining. The Company does not have manufacturing facilities for pilot scale or commercial production of compounds under development as therapeutic products. The Company must presently rely on third parties to manufacture its candidate products for clinical testing. For its diagnostic product, the Company has established a quality control and quality assurance program, including a set of standard operating procedures. The Company relies on outside manufacturers for production of raw materials for this product. For therapeutic products, however, the Company will need to establish further manufacturing, quality control and quality assurance programs. The Company will continue to be dependent on contract manufacturers or strategic partners. There can be no assurance that these manufacturers will be available or will meet the Company's requirements for quality, quantity and timeliness, or that the Company would be able to find substitute manufacturers, if necessary. HUMAN RESOURCES As of May 24, 1996, Corvas employed 70 individuals on a full-time basis, 19 of whom hold Ph.D. degrees. A significant number of the Company's management and professional employees have had prior experience with pharmaceutical, biotechnology or medical product companies. Corvas believes that it has been highly successful in attracting skilled and experienced scientific personnel; however, competition for such personnel is intense. None of the Company's employees is covered by a collective bargaining agreement. All of the Company's employees are covered by confidentiality and arbitration agreements, and certain of its officers have employment contracts. 37. LEGAL PROCEEDINGS The Company, several of its current and former directors, and Centocor were parties to a legal proceeding filed February 18, 1993 in the U.S. District Court for the Southern District of California. The complaint was filed by a stockholder of the Company who represented a class of persons who purchased Corvas stock from January 30, 1992 through April 14, 1992. A settlement was agreed upon and judgment of the Court entered on August 28, 1995. Upon final determination of allocations of stock to approved claimants, the remaining Corvas settlement amounts were distributed in May 1996. The Company continues to deny all claims of wrongdoing and maintains this denial as part of the settlement agreement. In 1993, the U.S. Patent and Trademark Office declared an interference and is currently in the process of determining the priority of invention between a patent for which some rights are licensed to the Company and a patent application for which rights are licensed to another party. The subject matter of these licenses is recombinant tissue factor which is used by Ortho to determine the blood clotting abilities of patients (See "Commercial Products"). The Company believes that its licensed patent should be upheld and is contesting the other party's claims of prior invention. However, there can be no assurance that such patent will be upheld. MANAGEMENT EXECUTIVE OFFICERS AND DIRECTORS The executive officers and directors of the Company, and their ages as of May 24, 1996, are as follows: NAME AGE POSITION ---- --- --------- Randall E. Woods. . . . . . . . . . . . . . . . . 44 President and Chief Executive Officer John E. Crawford. . . . . . . . . . . . . . . . . 41 Executive Vice President, Chief Financial Officer and Secretary Donald H. Picker, Ph.D. . . . . . . . . . . . . . 50 Executive Vice President and Chief Operating Officer William C. Ripka, Ph.D. . . . . . . . . . . . . . 56 Senior Vice President, Chemical Research Howard R. Soule, Ph.D.. . . . . . . . . . . . . . 45 Vice President, Product Development George P. Vlasuk, Ph.D. . . . . . . . . . . . . . 40 Vice President, Biological Research David S. Kabakoff, Ph.D.(1) . . . . . . . . . . . 48 Chairman of the Bboard of Directors Thomas S. Edgington, M.D.(1). . . . . . . . . . . 64 Director John H. Fried, Ph.D.(3) . . . . . . . . . . . . . 66 Director Theodor H. Heinrichs(3) . . . . . . . . . . . . . 69 Director M. Blake Ingle, Ph.D.(1)(2) . . . . . . . . . . . 54 Director Michael Sorell, M.D.(2) . . . . . . . . . . . . . 48 Director W. Leigh Thompson, Jr., M.D., Ph.D. . . . . . . . 57 Director Gerard Van Acker(2) . . . . . . . . . . . . . . . 52 Director Nicole Vitullo (3). . . . . . . . . . . . . . . . 39 Director
__________________ (1) Member of Executive Committee (2) Member of Audit Committee (3) Member of Compensation and Stock Option Committee RANDALL E. WOODS has been President and Chief Executive Officer since 38. May 1996. Prior to that, he served as President of the U.S. Operations, Boehringer Mannheim Pharmaceuticals Corporation from March 1994 to March 1996 and was Vice President of Marketing and Sales from December 1993 to March 1994. Prior to that, he served in various capacities at Eli Lilly & Company from 1973 to December 1993. Mr. Woods received an M.B.A. degree from Western Michigan University. JOHN E. CRAWFORD, a founder of Corvas, has been Chief Financial Officer since the Company's organization in May 1987, Executive Vice President since April 1989 and Secretary since March 1991. Mr. Crawford also served as President from May 1987 to April 1989, Chief Operating Officer from April 1989 to February 1991, Secretary from May 1987 to June 1989 and as a director from May 1987 to March 1991. Mr. Crawford received an M.B.A. from the University of Chicago Graduate School of Business. DONALD H. PICKER, Ph.D. joined Corvas in February 1996 as Executive Vice President and Chief Operating Officer. Prior to joining Corvas, Dr. Picker was employed by Genta, Inc. for four years, most recently as Senior Vice President, Research and Development. From 1987 to 1991, he was employed at Johnson Matthey, Inc., most recently as Worldwide Vice President, Biomedical Research and Development. Dr. Picker received his Ph.D. in organic chemistry from the State University of New York in Albany. WILLIAM C. RIPKA, Ph.D. joined Corvas in May 1990 as Vice President, Pharmaceutical Research. In January 1995, Dr. Ripka was promoted to Senior Vice President, Chemical Research. Prior to joining Corvas, he was employed for twenty-four years by E.I. duPont de Nemours & Co. in various research positions, most recently as Research Fellow and Supervisor of Drug Design and Molecular Modeling. Dr. Ripka received his Ph.D. in physical organic chemistry from the University of Illinois. HOWARD R. SOULE, Ph.D. has served as Vice President, Product Development since February 1989. From May 1988 to February 1989, he served as Director, Product Development. Dr. Soule was Program Manager of Infectious Disease Research and Development at Kallestad Diagnostics from 1984 to 1988 and previously worked as a Senior Research Chemist at Mallinckrodt, Inc. Dr. Soule received his Ph.D. in virology from Baylor College of Medicine and has four years of post-doctoral experience at The Scripps Research Institute. GEORGE P. VLASUK, Ph.D. joined Corvas in August 1991 as Director, Molecular Pharmacology. He served as Executive Director, Molecular Pharmacology from July 1993 to January 1995, when he was promoted to Vice President, Biological Research. Previously, he was employed for six years at Merck Sharp & Dohme Research Laboratories, most recently as Associate Director of Hematology Research. Dr. Vlasuk received his Ph.D. in biochemistry from Kent State University. DAVID S. KABAKOFF, Ph.D. was named Chairman of the Board in January 1996 and has been a director since June 1989. He also served as President from April 1989 to May 1996, Chief Executive Officer from April 1989 to February 1991 and from November 1991 to May 1996, and Chief Operating Officer from February 1991 to November 1991. Dr. Kabakoff is Executive Vice President and a director of Dura Pharmaceuticals, Inc. and President of an affiliated development company, Spiros Corporation. THOMAS S. EDGINGTON, M.D., a founder of Corvas, has been a director since May 1987 and served as Chairman of the Board from that time until February 1991. He is a Member of The Scripps Research Institute ("Scripps"), with which he has been affiliated since 1965. Since 1968, Dr. Edgington has also been adjunct Professor of Pathology at the University of California, San Diego, and, from 1968 to 1974, he was head of the Department of Pathology and Laboratory Medicine which he founded at Scripps. He has been Vice President for Research, Chairman of the National Research Committee and a member of the Board of Directors of the American Heart Association. He was a member of the Board of Directors and the Past-President of the Federation of American Societies for Experimental Biology. 39. JOHN H. FRIED, Ph.D. was elected a director in May 1992. Dr. Fried served in various executive capacities at Syntex Corporation ("Syntex") from April 1964 to March 1992. He served as President of Syntex Research from 1976 to March 1992, Senior Vice President of Syntex from 1981 to 1985, and Vice Chairman from 1985 to January 1993. Dr. Fried is Chairman of the Board of Alexion Pharmaceuticals and President of Fried and Company, Inc. THEODOR H. HEINRICHS joined the Board of Directors in February 1988. He also served as Chief Executive Officer and Chairman of the Board from February 1991 through November 1991 and January 1996, respectively. Mr. Heinrichs is a general partner with Hambrecht & Quist Life Science Venture Partners ("H&Q LSV"), with whom he has been affiliated since 1985. Mr. Heinrichs served as Chairman of the Board of Directors of Telios Pharmaceuticals, Inc. ("Telios") from January until June 1994. Telios filed for protection under Chapter 11 in the Federal Bankruptcy Court in January 1995 and was subsequently acquired by INTEGRA, L.S. Mr. Heinrichs also served as Chief Executive Officer of Canji, Inc. ("Canji") from its inception through March 1993 and was Chairman of the Board until March 1995. Canji was acquired by Schering-Plough in 1996. M. BLAKE INGLE, Ph.D. was elected a director in January 1994. Dr. Ingle was the President and Chief Executive Officer of Canji from March 1993 to February 1996, when it was acquired by Schering-Plough. Prior to that, he was employed in a variety of capacities with the IMCERA Group, Inc., consisting of Mallinckrodt Medical, Mallinckrodt Specialty Chemicals and Pitman Moore from 1980 to 1993, most recently serving as President/Chief Executive Officer. Dr. Ingle was a director of Telios and was its Chief Executive Officer from December 1994 to January 1995. He currently serves as a director for Synbiotics Corporation and as a member of the Board of Trustees at La Jolla Cancer Research Foundation. MICHAEL SORELL, M.D. was appointed a director in April 1996. He, with several partners, is currently forming an investment bank based in New York. He was associated with Morgan Stanley & Co. in various capacities, the last being Principal, from July 1986 to February 1992. He left the firm to become a partner in a joint venture with Essex Investment Management of Boston. In August 1994, he rejoined Morgan Stanley as the emerging growth analyst and principal where he served until February 1996. Prior to that, he was on staff at Memorial Sloan-Kettering Cancer Center and worked in Clinical Development at Schering-Plough Corporation. W. LEIGH THOMPSON, JR., M.D., Ph.D. was appointed as a director in January 1996. Dr. Thompson retired as Chief Scientific Officer of Eli Lilly and Company in 1995, where he had served in various capacities since 1982. He is the President and Chief Executive Officer of Profound Quality Resources, Ltd., a consulting company, and serves on the Board of Directors for GENEMEDICINE, INC., DNX Corporation, Guilford Pharmaceuticals and Orphan Medical, Inc. GERARD VAN ACKER has been a director since March 1991. Mr. Van Acker has been President and Chief Executive Officer of Gewestelijke Investeringsmaatschappij voor Vlaanderen, N.V. (The Investment Company for Flanders) ("GIMV"), based in Antwerp, Belgium, since founding it in 1980. He was a co-founder and the first President of PGS and currently serves as its Vice-Chairman. Mr. Van Acker is also a director of BARCO, N.V. NICOLE VITULLO was appointed a director in April 1996. She has been a Vice President since November 1992 with Rothschild Asset Management, Inc., which manages two publicly traded funds, International Biotechnology Trust ("IBT") and Biotechnology Investments, Limited. She served as Director of Corporate Communications at Cephalon, Inc. from July 1991 to November 1992. Prior to that, she was Manager, Healthcare Investments at Eastman Kodak Company. Ms. Vitullo serves on the boards of directors of Cytel Corporation, Anergen, Incorporated, and LocalMed, Inc. Mr. Van Acker was nominated for election as a director in accordance with an agreement among the Company, GIMV and PGS, entered into in March 1991 under which the Company issued shares of preferred stock (subsequently converted into common stock) to GIMV and PGS. Pursuant to such agreement, the Company has agreed that, for as long as the holders of such shares of stock hold not less than 10% of the voting power of the 40. Company, it will nominate for election to the Board of Directors the number of persons designated by such holders that they would be entitled to elect under cumulative voting. Each officer serves at the discretion of the Board of Directors subject to existing employment agreements in the case of Mr. Woods, Mr. Crawford and Dr. Picker. See "Management - Employment Agreements." The Company's Bylaws permit the Board of Directors to establish by resolution the authorized number of directors, and the Company currently has ten directors authorized. The Company's Restated Certificate of Incorporation and Bylaws provide that the Board of Directors shall be divided into three classes, each class consisting, as nearly as possible, of one-third of the total number of directors, with each class having a three-year term. Each director holds office until the annual meeting of stockholders of the Company which coincides with the end of such director's three-year term and until such director's successors have been elected and duly qualified. There are no family relationships among any of the directors or officers of the Company. BOARD COMMITTEES The Executive Committee presently consists of Drs. Kabakoff, Edgington and Ingle. This committee is authorized to exercise the full authority of the Board of Directors except with respect to (i) those matters not permitted by the Delaware General Corporation Law to be delegated to any committee, (ii) approval of obligations of the Company in amounts greater than $100,000, (iii) approval of annual operating plans, business plans and major strategic decisions and (iv) approval of other major transactions such as corporate partnerships or financing plans. The Audit Committee consists of Mr. Van Acker and Drs. Ingle and Sorell. The Audit Committee, which meets periodically with management and the Company's independent auditors, reviews the results and scope of the audit and other services provided by the Company's independent auditors and reviews internal accounting procedures and the adequacy of internal controls. The Compensation and Stock Option Committee consists of Mr. Heinrichs, Dr. Fried and Ms. Vitullo. This committee reviews and recommends to the Board salaries, incentives and other forms of compensation for officers and other employees, administers the Company's various incentive compensation and benefit plans, including the Company's 1991 Incentive and Compensation Plan, and recommends policies relating to such plans. DIRECTOR COMPENSATION Members of the Board of Directors generally do not receive compensation for service as directors or for service as members of any committee of the Board, except as noted. Mr. Heinrichs and Dr. Edgington each received compensation of $36,000 for service as non-employee members of the Executive Committee in 1995. Dr. Edgington is currently receiving $36,000 for these services in 1996. Drs. Fried, Ingle, Sorell and Thompson currently receive compensation at the rate of $12,000 per year for service as outside directors unaffiliated with any principal stockholder. The members of the Board are also eligible for reimbursement for their expenses incurred in connection with Company business in accordance with Company policy. In addition, directors have received, and are anticipated to receive in the future, stock options under the Company's equity incentive plans or otherwise. Each non-employee director of the Company receives a non-discretionary stock option grant annually under the Company's 1991 Incentive and Compensation Plan ("1991 Plan"). Options granted to the non-employee directors under the 1991 Plan are not intended by the Company to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended (the "Code"), nor do they disqualify the members of the Compensation and Stock Option Committee as "disinterested directors." Pursuant to an agreement executed in 1988, Dr. Edgington presently receives $36,000 annually for consulting services rendered to the Company. 41. Pursuant to an agreement executed in June 1992, Dr. Fried presently receives $12,000 annually for consulting services rendered to the Company. Pursuant to an agreement executed in May 1996, Mr. Heinrichs presently receives $12,000 annually for consulting services rendered to the Company. Pursuant to an agreement executed in May 1996, Dr. Kabakoff will receive $8,500 for consulting services rendered to the Company in May 1996. COMPENSATION AND STOCK OPTION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION Mr. Heinrichs, who currently serves on the Compensation and Stock Option Committee of the Board, also served as Chief Executive Officer of the Company from February 1991 to November 1991. Dr. Fried, who currently serves on the Compensation and Stock Option Committee of the Board, entered into an agreement with the Company in June 1992 pursuant to which Dr. Fried presently receives fees of $12,000 annually for consulting services rendered to the Company. EXECUTIVE COMPENSATION SUMMARY COMPENSATION TABLE The following table sets forth for the years ended December 31, 1995, 1994 and 1993, compensation awarded, or paid to and earned by, the Company's Chief Executive Officer and the four other most highly compensated executive officers whose salary and bonus were in excess of $100,000 for services rendered to the Company during the fiscal year ended December 31, 1995 (collectively, the "Named Executive Officers"): Long-Term Compensation Annual Compensation Awards --------------------------------- ------------- All Other Fiscal Compensation Year Salary($)(1) Bonus($) Shares ($)(3) Name and Principal -------- ----------- ------------ Underlying ------------- Position Options (#)(2) - --------------------------- -------------- David S. Kabakoff, Ph.D(4).... 1995 212,000 -- 164,285 3,971 Chairman, President & 1994 205,000 24,000 65,000 3,974 Chief Executive Officer 1993 205,000 -- -- 3,748 John E. Crawford.............. 1995 129,000 -- 85,000 2,725 Executive Vice President 1994 125,000 12,000 35,000 2,637 & Chief Financial Officer 1993 125,000 -- 15,000 2,507 William C. Ripka, Ph.D........ 1995 165,000 -- 68,000 4,694 Senior Vice President, 1994 160,000 12,000 25,000 4,732 Chemical Research 1993 160,000 -- -- 4,468 Howard R. Soule, Ph.D......... 1995 127,500 -- 40,000 2,406 Vice President, 1994 121,500 12,000 35,000 2,365 Product Development 1993 118,000 -- -- 2,215 George P. Vlasuk, Ph.D........ 1995 130,160 -- 63,257 843 Vice President, Biological Research (5)
42. - ------------------ (1) Includes amounts earned but deferred into the Company's 401(k) Compensation Deferral and Savings Plan ("401(k) Plan") at the election of the executive. (2) The Company has not issued any restricted stock awards or stock appreciation rights ("SARs") to date. These numbers include options regranted by the Company in an exchange that took place on January 16, 1995. See "Option Grants in Last Fiscal Year." (3) Includes amounts paid on behalf of executives for long-term disability insurance premiums and life insurance premiums. (4) Effective May 10, 1996, Dr. Kabakoff resigned as President and Chief Executive Officer of the Company, but will continue as Chairman of the Board. He was also a Consultant to the Company through May 31, 1996. (5) Dr. Vlasuk became an executive officer in January 1995. OPTION GRANTS IN LAST FISCAL YEAR The following table sets forth, for the fiscal year ended December 31, 1995, certain information regarding options granted or repriced to each of the Named Executive Officers: Individual Grants ----------------------------------------------------------- Potential Realizable Value at Assumed Number of Percentage Annual Rates of Stock Shares of Total Price Appreciation for Underlying Options Exercise Option Terms ($)(6)(7) Options Granted in Price Expiration --------------------------- Name Granted Fiscal ($/Sh)(5) Date 5% 10% - --------------------------- (#)(1)(3) Year(4) ----------- ----------- ----------- ----------- -------------- ------------- David S. Kabakoff, Ph.D.(8).... 164,285(1) 21.8% 2.1875 01/15/05 226,008 572,749 John E. Crawford............... 75,000(1) 9.9% 2.1875 01/15/05 103,178 261,473 10,000(2) 1.3% 3.8125 10/12/05 23,977 60,761 William C. Ripka, Ph.D......... 68,000(1) 9.0% 2.1875 01/15/05 93,548 237,069 Howard R. Soule, Ph.D.......... 30,000(1) 4.0% 2.1875 01/15/05 41,271 104,589 10,000(2) 1.3% 3.8125 10/12/05 23,977 60,761 George P. Vlasuk, Ph.D......... 63,257(1) 8.4% 2.1875 01/15/05 87,023 220,534
_______________ (1) On January 16, 1995, the Compensation and Stock Option Committee of the Board of Directors approved an offer for all employees, including officers, to exchange outstanding options with exercise prices greater than $2.44 per share for an equivalent number of options issued under the 1991 Plan at the fair market value on January 16, 1995. The new options did not vest for six months from the date of grant (12 months for executive officers), at which time the options vested in the equivalent percentage as the canceled options at the 43. time such options were canceled. After the initial vesting of at least 25%, the remainder of the options vest 6.25% per quarter. The options remain exercisable for 10 years from the new grant date. For each employee, the receipt of the replacement grant was subject to the employee's consent to the cancellation of the original grants. (2) Options granted on October 13, 1995 vest over a four year period, 25% on the first anniversary of the grant date and 6.25% each quarter thereafter until fully vested. Upon certain corporate events resulting in a change in control, at the discretion of the Board of Directors, (i) the outstanding options will be assumed or replaced by substitute options granted by any surviving corporation, or (ii) the outstanding options will become exercisable for a minimum of 30 days prior to such event. (3) Options have a maximum term of 10 years measured from the grant date, subject to earlier termination upon the optionee's cessation of service with the Company. (4) Based on an aggregate of 754,727 shares subject to options granted to employees in fiscal 1995, including grants to Named Executive Officers and shares subject to replacement options granted. (5) The exercise price is equal to 100% of the fair market value of the Common Stock on the date of grant, as determined by the Compensation and Stock Option Committee of the Board of Directors. (6) The 5% and 10% assumed rates of appreciation are suggested by the rules of the Securities and Exchange Commission ("Commission") and do not represent the Company's estimate or projection of the future Common Stock price. There can be no assurance that any of the values reflected in the table will be achieved. Actual gains, if any, on stock option exercises and Common Stock holdings are dependent upon a number of factors, including the future performance of the Common Stock, overall market conditions and the timing of option exercises, if any. (7) The potential realizable value is calculated based on the term of the option at its time of grant (10 years in all cases above). It is calculated by assuming that the stock price on the date of grant appreciates at the indicated annual rate, compounded annually for the entire term of the option and that the option is exercised and sold on the last day of its term for the appreciated stock price. No gain to the optionee is possible unless the stock price increases over the option term, which will benefit all stockholders. For example, a stockholder who purchased one share of stock on January 16, 1995 at $2.1875, held the stock for 10 years and sold it on January 15, 2005 while the stock appreciated at 5% and 10% would have profits of $1.38 and $3.49, respectively, on his $2.1875 investment. (8) Effective May 10, 1996, Dr. Kabakoff resigned as President and Chief Executive Officer of the Company, but will continue as Chairman of the Board. He was also a consultant to the Company through May 31, 1996. AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION VALUES The following table sets forth information with respect to the exercise of stock options by the Named Executive Officers, during the fiscal year ended December 31, 1995 and the number and value of securities underlying unexercised options held by the Named Executive Officers as of December 31, 1995: NUMBER OF SHARES UNDERLYING VALUE OF UNEXERCISED IN- UNEXERCISED OPTIONS AT THE-MONEY OPTIONS AT DECEMBER 31, 1995(#)(1) DECEMBER 31, 1995($)(1)(2) ---------------------------- ----------------------------- SHARES VALUE ACQUIRED ON REALIZED NAME EXERCISE (#) ($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE - ---------------------------------- ------------ -------- ----------- ------------- ----------- ------------- David S. Kabakoff, Ph.D(3) . . . . -- -- 53,743 164,285 257,966 544,194 John E. Crawford . . . . . . . . . -- -- -- 85,000 -- 265,312
44. William C. Ripka, Ph.D.. . . . . . 10,000 29,375 21,428 68,000 99,104 225,250 11,428 59,283 Howard R. Soule, Ph.D. . . . . . . -- -- 33,320 66,250 140,936 191,250 George P. Vlasuk, Ph.D.. . . . . . 5,143 26,679 20,611 42,646 68,273 141,264
- -------------------------- (1) Includes options granted under the 1987 Stock Option Plan ("1987 Plan"), the 1989 Stock Option Plan ("1989 Plan") and the 1991 Plan. Options granted under the 1987 Plan and the 1989 Plan generally vest at the rate of 25% per year over four years and have a term of 10 years. In December 1991, the Board of Directors voted to terminate the 1987 Plan and the 1989 Plan, and no additional grants of options have been made under either of such plans since they were terminated. Options granted under the 1991 Plan generally have the vesting schedule reflected in Footnotes 1 and 2 of "Stock Option Grants and Exercises." (2) Amounts reflected are based on the fair market value of the Company's Common Stock at December 31, 1995 ($5.375) minus the exercise price of the options. (3) Effective May 10, 1996, Dr. Kabakoff resigned as President and Chief Executive Officer of the Company, but will continue as Chairman of the Board. He was also a consultant to the Company through May 31, 1996. EQUITY INCENTIVE PLANS 1987 AND 1989 STOCK OPTION PLANS The Company has a 1987 Plan under which options were granted to key employees and directors of, and consultants to, the Company. As of May 24, 1996, there are 102,529 shares of Common Stock reserved for issuance upon exercise of currently outstanding options under the 1987 Plan, and no options to purchase additional shares of Common Stock are available for future grant. In addition, the Company has a 1989 Plan under which options were granted to key employees and directors of, and consultants to, the Company. As of May 24, 1996, there are 23,743 shares of Common Stock reserved for issuance upon exercise of currently outstanding options under the 1989 Plan and no shares remain available for future grants. Both plans provide for the grant of incentive stock options, intended to qualify as such under Section 422A of the Code, and nonstatutory stock options. The Board of Directors administers the 1987 Plan and the 1989 Plan (collectively, "Stock Option Plans"). The maximum term of each option granted under the Stock Option Plans is ten years. The aggregate fair market value of the Common Stock with respect to which incentive stock options are first exercisable by an optionee in any calendar year may not exceed $100,000. Options granted under the Stock Option Plans generally are nontransferable and expire 30 days after the termination of an optionee's service to the Company. In general, if an optionee is permanently disabled or dies during his or her service to the Company, such person's options may be exercised up to the earlier of the options' expiration date or one year following such disability or death. In December 1991, the Board of Directors voted to terminate the 1987 Plan and the 1989 Plan, effective as of January 30, 1992. The Company has not made any additional grants of options under either the 1987 Plan or the 1989 Plan since the Board of Directors voted to terminate such plans. However, previously granted options continue to be governed by the terms of the 1987 Plan or the 1989 Plan (and the option agreements executed thereunder), as applicable. As of May 24, 1996, the Company had outstanding options under the Stock Option Plans to purchase an aggregate of 126,272 shares held by 20 persons at the weighted average per share exercise price of $1.06. The exercise price of all options granted under the Stock Option Plans has equaled or exceeded the fair market value of the Common Stock on the date of grant as determined in good faith by the Compensation and Stock Option Committee of the Board of Directors. As of May 24, 1996, options 45. to purchase 242,068 shares of Common Stock granted pursuant to the Stock Option Plans have been exercised. As of May 24, 1996, there were no shares available for future grant under the Stock Option Plans. 1991 INCENTIVE AND COMPENSATION PLAN In December 1991, the Board of Directors adopted the 1991 Plan, under which the Company may grant or issue incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, dividend equivalents, performance awards and stock payments to key employees, officers and directors of, and consultants to, the Company. The 1991 Plan provides for the issuance of 1,275,000 shares of Common Stock. The number of shares issuable under the 1991 Plan will automatically increase each year such that the number of shares issuable at the beginning of any fiscal year will equal 10% of the number of outstanding shares of Common Stock, less the number of shares issued, and as to which options or other awards have been granted and are outstanding under the 1991 Plan (other than annual grants of nonstatutory options to non-employee directors) and the Stock Option Plans. The 1991 Plan provides for appropriate adjustments in the numbers and kind of shares subject to the 1991 Plan and to outstanding grants thereunder in the event of stock splits, stock dividends and certain other types of recapitalizations or restructurings. In January 1996 and April 1996, the Board of Directors amended the 1991 Plan, subject to stockholder approval, to increase the aggregate number of shares of Common Stock authorized for issuance under the 1991 Plan from 1,275,000 shares to 2,225,000 shares and to automatically increase the number of shares issuable under the 1991 Plan each quarter such that the number of shares issuable at the beginning of any fiscal quarter will equal 18% of the number of outstanding shares of Common Stock, less the number of shares issued or subject to outstanding options or other awards under the 1991 Plan (other than annual grants of nonstatutory options to non-employee directors) and the Stock Option Plans. A Compensation and Stock Option Committee duly appointed by the Board of Directors has authority to select the key employees, officers and directors of, and consultants to, the Company to whom grants are to be made (provided that incentive stock options may only be granted to employees of the Company), to designate the type of grant or award to be issued, to designate the number of shares covered by each grant or award, to impose a vesting schedule or other restrictions on the grants or awards, to specify the amount and type of consideration to be paid upon the exercise or receipt of a grant or award under the 1991 Plan (provided that the exercise price of incentive stock options may not be less than the fair market value of the underlying stock on the date of grant), to interpret and adopt rules for the operation of the 1991 Plan and to specify other terms of the grant or award, all subject to the terms of the 1991 Plan. The Compensation and Stock Option Committee may in its discretion delegate to the Chief Executive Officer or the Secretary of the Company, or both, all of its powers, other than the authority to make grants or awards under the 1991 Plan. To the extent that the aggregate fair market value of stock with respect to which incentive stock options are first exercisable by an optionee during any calendar year (under the 1991 Plan and/or under the Stock Option Plans) exceeds $100,000, such options shall be taxed as nonstatutory stock options. Under the 1991 Plan, on the date of the first meeting of the Board of Directors (but in no event later than the 30th day of each fiscal year), each director of the Company who is not an employee of the Company or a parent or a subsidiary of the Company, will automatically receive an award of a nonstatutory stock option exercisable for 5,000 shares of Common Stock. The exercise price of such option will be 85% of the fair market value of such shares of Common Stock on the date the option is granted, and the option shall become exercisable as to 25% of the underlying shares on the first through fourth anniversaries of the grant date. As of May 24, 1996, the Company had outstanding options under the 1991 Plan to purchase an aggregate of 1,567,060 shares held by 82 persons at the weighted average per share exercise price of $3.68. The exercise price of all options granted under the 1991 Plan has equaled or exceeded the fair market value of the Common Stock on the date of grant as determined in good faith by the Compensation and Stock Option 46. Committee of the Board of Directors. As of May 24, 1996, options to purchase 79,061 shares of Common Stock granted pursuant to the 1991 Plan have been exercised. In addition, the Board of Directors has granted, other than under the Stock Option Plans and the 1991 Plan, nonstatutory options to purchase an aggregate of 47,142 shares of Common Stock at a weighted average exercise price of $3.02 per share. The fair market value of the Common Stock on the grant dates, as determined in good faith by the Board of Directors, was $0.88 per share and $3.50 per share. In each case, the Board of Directors established the exercise price of the option at a level it determined to be in the best interests of the Company and necessary to achieve the compensatory purpose of the option. As of May 24, 1996, the Company had outstanding nonstatutory options to purchase an aggregate of 8,571 shares held by 2 persons at the weighted average per share exercise price of $0.88. As of May 24, 1996, nonstatutory options to purchase 28,928 shares of Common Stock have been exercised. 47. EMPLOYEE STOCK PURCHASE PLAN In December 1991, the Company adopted the Employee Stock Purchase Plan ("Purchase Plan") covering an aggregate of 150,000 shares of Common Stock. The Purchase Plan is intended to qualify as an employee stock purchase plan within the meaning of Section 423 of the Code. Under the Purchase Plan, the Board of Directors may authorize participation by eligible employees, including officers, in periodic offerings following the commencement of the Purchase Plan. The Board of Directors may delegate administration of the Purchase Plan to a committee selected by the Board of Directors. Employees are eligible to participate in the Purchase Plan if they are employed by the Company, or a subsidiary of the Company designated by the Board of Directors, for at least 20 hours per week and are employed by the Company or a subsidiary of the Company designated by the Board of Directors for at least five months per calendar year. Employees who participate in an offering have up to 10% of their earnings withheld pursuant to the Purchase Plan. The amount withheld is then used to purchase shares of the Common Stock issued by the Company on specified dates determined by the Board of Directors. The price of Common Stock purchased under the Purchase Plan will be equal to 85% of the lower of the fair market value of the Common Stock on the commencement date of each offering period or on the relevant purchase date. Employees may end their participation in the offering at any time during the offering period, and participation ends automatically on termination of employment with the Company. 401(K) PLAN In 1988, the Company adopted a 401(k) Plan covering all of the Company's employees. Pursuant to the 401(k) Plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit ($9,500 in 1996) and have the amount of such reduction contributed to the 401(k) Plan. The 401(k) Plan is intended to qualify under section 401 of the Code so that contributions by employees or by the Company to the 401(k) Plan, and income earned on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan and so that contributions by the Company, if any, will be deductible by the Company when made. The Trustee of the 401(k) Plan, at the discretion of each participant, invests the assets of the 401(k) Plan in any of the five investment options. The 401(k) Plan permits, but does not require, qualified nonelective contributions and company profit sharing contributions by the Company on behalf of all participants in the plan. The Company has not made any such contributions to date, but does pay the transaction costs associated with investment options under the 401(k) Plan. EMPLOYMENT AGREEMENTS Pursuant to an executive employment agreement between the Company and John E. Crawford entered into in April 1989, Mr. Crawford receives a base salary, bonuses and equity compensation as determined by the compensation and Stock Option Committee of the Board of Directors. His current annual base salary is $137,000. If Mr. Crawford's employment is terminated without cause (or if he resigns under certain specified conditions, including a change of control of the Company), he will receive as severance his then-current salary and continued health insurance benefits over the 180-day period following the date of termination. If Mr. Crawford's employment is terminated with cause or he resigns, his compensation and benefits will cease immediately and he will not be entitled to severance benefits. Upon his death or total disability, he or his estate or personal representative shall be entitled to receive his then-current salary and benefits 48. over the 180-day period following the date of such event. Pursuant to an executive employment agreement between the Company and Donald H. Picker, Ph.D. entered into in February 1996, Dr. Picker receives a base salary, bonuses and equity compensation as determined by the Compensation and Stock Option Committee of the Board of Directors. His current annual base salary is $250,000. If Dr. Picker's employment is terminated without cause, he will receive as severance his then-current salary and continued health insurance benefits over the 180-day period following the date of termination. If Dr. Picker's employment is terminated with cause or he resigns, his compensation and benefits will cease immediately and he will not be entitled to severance benefits. Upon his death or total disability, he or his estate or personal representative shall be entitled to receive his then-current salary and benefits over the 90-day period following the date of such event. Pursuant to an executive employment agreement between the Company and Randall E. Woods entered into in May 1996, Mr. Woods receives a base salary, bonuses and equity compensation as determined by the Compensation and Stock Option Committee of the Board of Directors. His current annual base salary is $300,000. If Mr. Woods' employment is terminated without cause within one year of his hire date, he will receive as severance (i) his then-current salary and continued health insurance benefits over the 12-month period following the date of termination, and (ii) one-fourth of the stock options granted to Mr. Woods upon his employment with the Company will immediately vest and become exercisable. If such termination occurs after the first year of his employment with the Company, Mr. Woods will receive as severance his then-current salary, continued health insurance benefits and continued stock option vesting over the 180-day period following the date of termination. If Mr. Woods' employment is terminated with cause or he resigns, his compensation and benefits will cease immediately and he will not be entitled to severance benefits. Upon his death or total disability, he or his estate or personal representative shall be entitled to receive his then-current salary and benefits over the 90-day period following the date of such event. LIMITATIONS OF LIABILITY AND INDEMNIFICATION MATTERS The Registrant's Amended and Restated Certificate of Incorporation and Bylaws include provisions to (i) eliminate the personal liability of its directors for monetary damages resulting from breaches of their fiduciary duty to the extent permitted by Section 102(b)(7) of the Delaware General Corporation Law ("Delaware Law") and (ii) require the Registrant to indemnify its directors and officers to the fullest extent permitted by Section 145 of the Delaware Law, including circumstances in which indemnification is otherwise discretionary. The Registrant believes that these provisions are necessary to attract and retain qualified persons as directors and officers. These provisions do not eliminate the directors' duty of care and, in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware Law. In addition, each director will continue to be subject to liability for breach of the director's duty of loyalty to the Registrant, for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for acts or omissions that the director believes to be contrary to the best interests of the Registrant or its stockholders, for any transaction from which the director derived an improper personal benefit, for acts or omissions involving a reckless disregard for the director's duty to the Registrant or its stockholders when the director was aware or should have been aware of a risk of serious injury to the Registrant or its stockholders, for acts or omissions that constitute an unexcused pattern of inattention that amounts to an abdication of the director's duty to the Registrant or its stockholders, for improper transactions between the director and the Registrant and for improper distributions to stockholders and loans to directors and officers. The provision also does not affect a director's responsibilities under any other law, such as federal securities laws or state or federal environmental laws. The Registrant has entered into indemnity agreements with each of its directors and executive officers that require the Registrant to indemnify such persons against expenses, judgments, fines, settlements and other amounts incurred (including expenses of a derivative action) in connection with any proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director or an executive officer of the Registrant or any of its affiliated enterprises, provided such person acted in good faith 49. and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe his conduct was unlawful. The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. At present, there is no pending litigation or proceeding involving a director or officer of the Registrant as to which indemnification is being sought nor is the Registrant aware of any threatened litigation that may result in claims for indemnification by any officer or director. The Registrant has an insurance policy covering the officers and directors of the Registrant with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise. CERTAIN TRANSACTIONS In December 1994, the Company entered into a strategic alliance agreement with Schering-Plough to collaborate on the discovery and commercialization of oral thrombin inhibitor drugs for the prevention and treatment of chronic cardiovascular disorders. The initial collaboration covers development of inhibitors of thrombin, a key blood-clotting enzyme. In addition, Schering- Plough acquired an exclusive option (which was extended to December 1996 upon payment of $1,000,000) to expand the program to include inhibitors of a second significant blood coagulation enzyme, Factor Xa. Under the terms of the agreement, Schering-Plough will compensate the Company for the costs of research and preclinical development of thrombin inhibitors over two years. Schering-Plough, which is responsible for certain preclinical development, all clinical trials and regulatory activities, received exclusive worldwide manufacturing and marketing rights for resulting thrombin inhibitors. The Company may also receive milestone payments and royalties on sales of therapeutics resulting from this alliance. However, there can be no assurance that products will be successfully developed and commercialized under this alliance. In connection with this alliance, Schering-Plough paid certain fees and purchased 1,000,000 shares of Series A Convertible Preferred Stock of the Company in 1994 resulting in net proceeds of $4,864,000. Revenue of $4,000,000 was recognized under this agreement in 1995. If the option for Factor Xa is exercised, Schering-Plough has agreed to make an additional equity investment, as well as payments for certain fees, research and development expenses, and regulatory milestones. To date, Corvas has received a total of $14,000,000 from Schering-Plough under the alliance. Schering-Plough beneficially owns approximately 9.0% of the outstanding securities of the Company on an as- converted basis. In February 1996, the Company completed a private placement of equity securities consisting of 3,000,000 units (the "Units"). Each Unit consisted of one share of common stock and one callable warrant to purchase one additional share of common stock. In connection with such private placement, International Biotechnology Trust and AKKAD, both beneficial owners of more than 5% of the outstanding securities of the Company, purchased 1,400,000 and 800,000 Units, respectively. In February 1996, the Company loaned $300,000 to Dr. Picker in connection with his employment with the Company. The loans were evidenced by two promissory notes, one in the amount of $180,000 (the "$180,000 Note"), secured by his primary residence in San Diego County, California, at an interest rate of 6% per annum, and one in the amount of $120,000 (the "$120,000 Note"), unsecured and bearing no interest. The entire outstanding principal balance of the $180,000 Note is due and payable in full upon the earlier of (i) five years from the loan date or (ii) upon Dr. Picker's termination for cause. In April 1996, Dr. Picker repaid $60,000 of the principal balance of the $120,000 Note. The remaining $60,000 of the outstanding principal balance of the $120,000 Note is due and payable in full thirty days after the earlier of (i) one year from the loan date or (ii) Dr. Picker's termination for cause. The Company will forgive the remaining $60,000 of the outstanding principal balance of the $120,000 Note (i) one year from the date of the note provided Dr. Picker has been continuously employed by the Company for one year or (ii) upon Dr. Picker's termination without cause. In February 1996, Dr. Picker entered into an employment agreement with the Company. In May 1996, Mr. Woods entered into an employment agreement with the Company. See "Management - Employment Agreements." 50. In May 1996, the Company granted Mr. Woods stock options under the 1991 Plan to purchase up to 325,000 shares of Common Stock at an exercise price of $5.06 per share in connection with his employment with the Company. Such options vest over four years: (i) one-fourth of the shares vest after twelve continuous months of service with the Company, and (ii) the remaining three- fourths of the shares vest at a rate of 6.25% for each subsequent quarter of completed service. 51. PRINCIPAL STOCKHOLDERS 5% STOCKHOLDERS The following table sets forth certain information regarding beneficial ownership of the Company's stock as of May 24, 1996 and as adjusted to reflect the sale of the Common Stock being offered hereby by each stockholder known by the Company to be the beneficial owner of more than 5% of a class of the Registrant's voting securities. Unless otherwise indicated in the footnotes to this table, each of the stockholders named in this table has sole voting power and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 13,682,471 shares of Common Stock outstanding on an as-converted basis on May 24, 1996 and 14,682,471 shares of Common Stock outstanding on an as-converted basis after completion of this Offering, adjusted as required by rules promulgated by the Commission. Ownership information is based upon information furnished by the respective entities, including any Schedule 13D or 13G. PERCENTAGE BENEFICIALLY OWNED SHARES ----------------------- BENEFICIALLY BEFORE AFTER BENEFICIAL OWNER OWNED OFFERING OFFERING - ---------------- ----- -------- -------- Rothschild Asset Management Ltd. International Biotechnology Trust plc(1) . . 2,800,000 18.6% 17.4% Five Arrows House St. Swithin's Lane London EC4N 8NR England Wanger Asset Management, L.P. 227 West Monroe, Suite 3000 Chicago, IL 60606-5016 AKKAD (Acorn Fund)(2). . . . . . . . . . . . 1,600,000 11.0% 10.3% c/o State Street Bank & Trust 225 Franklin Street Boston, Massachusetts 02110 PGS International N.V.(3). . . . . . . . . . 1,334,793 9.8% 9.1% Prins Hendriklaan 20 1075 BC Amsterdam, The Netherlands GIMV, N.V.(4). . . . . . . . . . . . . . . . 1,142,857 8.4% 7.8% Karel Oomsstraat 37 2018 Antwerp, Belgium
52. Schering Corporation(5). . . . . . . . . . . 1,250,000(5) 9.0% 8.4% 2000 Galloping Hill Road Kenilworth, New Jersey 07033
- ---------------------- (1) Includes 1,400,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of May 24, 1996. (2) Includes 800,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of May 24, 1996. (3) PGS International Netherlands has sole voting and dispository rights to all 1,334,793 shares. PGS International Belgium, a subsidiary of PGS International Netherlands, holds 300,000 of those shares in its name and 1,034,793 shares are held in the name of Chelsea, N.V., a subsidiary of Plant Genetic Systems which is a subsidiary of PGS International Belgium. Mr. Van Acker is Vice Chairman of Plant Genetic Systems and disclaims beneficial ownership of these shares. (4) Held by a subsidiary, Take Off Fonds, N.V. Excludes shares of Common Stock held by PGS, of which GIMV owns 22% of the equity securities. GIMV disclaims beneficial ownership of such shares. Mr. Van Acker is the President and Chief Executive Officer of GIMV and disclaims beneficial ownership of these shares. (5) Includes 1,000,000 shares of Series A Convertible Preferred Stock on an as- converted basis and 250,000 shares of Convertible Preferred Stock issuable upon exercise of an option exercisable within 60 days of May 24, 1996. DIRECTORS AND EXECUTIVE OFFICERS The following table sets forth certain information regarding the ownership of the Company's Common Stock as of May 24, 1996 and as adjusted to reflect the sale of the Common Stock offered hereby by (i) each director and nominee for director, (ii) each of the Named Executive Officers, and (iii) all directors and executive officers as a group. Except as otherwise indicated, the Company believes that the beneficial owners of the Common Stock listed below, based on information furnished by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where applicable. Applicable percentages are based on 13,682,471 shares of Common Stock outstanding on an as-converted basis on May 24, 1996 and 14,682,471 shares of Common Stock outstanding on an as-converted basis after completion of this Offering, adjusted as required by rules promulgated by the Commission. Ownership information is based upon information furnished by the respective individuals, including any Section 16 filings. PERCENTAGE BENEFICIALLY OWNED SHARES ----------------------- BENEFICIALLY BEFORE AFTER DIRECTORS: OWNED OFFERING OFFERING - ---------- ----- -------- -------- Nicole Vitullo(1). . . . . . . . . . . . . . 2,800,000 18.6% 17.4% Gerard Van Acker(2). . . . . . . . . . . . . 2,490,864 18.2% 17.0%
53. Theodor H. Heinrichs(3). . . . . . . . . . . 688,624 5.0% 4.7% Thomas S. Edgington, M.D.(4) . . . . . . . . 285,490 2.1% 1.9% David S. Kabakoff, Ph.D.(5). . . . . . . . . 234,167 1.7% 1.6% John H. Fried, Ph.D.(6). . . . . . . . . . . 39,750 * * M. Blake Ingle, Ph.D.(7) . . . . . . . . . . 14,750 * * Michael Sorell, M.D. . . . . . . . . . . . . -- -- -- W. Leigh Thompson, Jr., M.D., Ph.D.. . . . . -- -- -- Randall E. Woods . . . . . . . . . . . . . . -- -- --
54. PERCENTAGE BENEFICIALLY OWNED SHARES ----------------------- BENEFICIALLY BEFORE AFTER EXECUTIVE OFFICERS: OWNED OFFERING OFFERING - ------------------- ----- -------- -------- John E. Crawford(8). . . . . . . . . . . . . . . . . . . . . 198,172 1.4% 1.3% William C. Ripka, Ph.D.(9) . . . . . . . . . . . . . . . . . 56,490 * * Howard R. Soule, Ph.D.(10) . . . . . . . . . . . . . . . . . 62,943 * * George P. Vlasuk, Ph.D.(11). . . . . . . . . . . . . . . . . 39,437 * * All officers and directors as group (15 persons)(12) . . . . 6,910,687 44.6% 41.9%
- ----------------------- * Less than 1%. (1) Includes 1,400,000 shares of Common Stock and 1,400,000 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of May 24, 1996 owned by IBT. Ms. Vitullo is a vice president of Rothschild Asset Management, Inc., which manages the IBT fund. Ms. Vitullo disclaims beneficial ownership of such shares owned by IBT. (2) Includes 13,214 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996, 1,334,793 shares beneficially owned by PGS, of which Mr. Van Acker is the Vice Chairman, and 1,142,857 shares beneficially owned by GIMV, of which Mr. Van Acker is the Chief Executive Officer. Mr. Van Acker disclaims beneficial ownership of such shares beneficially owned by PGS and GIMV. (3) Includes 18,928 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996 and 669,696 shares owned by H&Q LSV and its affiliates. Mr. Heinrichs is a general partner of H&Q LSV. Mr. Heinrichs disclaims beneficial ownership of such shares owned by H&Q LSV and its affiliates. (4) Includes 39,776 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996. Also includes 245,714 shares held in a trust for which Dr. Edgington is both a trustee and a beneficiary. (5) Includes 116,196 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996. Also includes 4,000 shares held by Dr. Kabakoff's wife as custodian for his minor children. (6) Includes 34,750 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996. (7) Includes 3,750 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996. (8) Includes 159,928 shares of Common Stock held in a trust for which Mr. Crawford is both a trustee and a beneficiary and 38,124 shares issuable upon exercise of options exercisable within 60 days of May 24, 1996. (9) Includes 56,490 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996. (10) Includes 62,382 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996. 55. (11) Includes 37,294 shares of Common Stock issuable upon exercise of options exercisable within 60 days of May 24, 1996. (12) Includes 1,820,904 shares of Common Stock issuable upon exercise of options exercisable within 60 days. See notes (1) through (11) above. DESCRIPTION OF CAPITAL STOCK GENERAL The Company is authorized to issue 50,000,000 shares of Common Stock, $.001 par value per share, and 10,000,000 shares of undesignated Preferred Stock, $.001 par value per share. COMMON STOCK As of May 24, 1996, there were 12,682,471 outstanding shares of the Company's Common Stock. Holders of Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Subject to preferences that may be applicable to any outstanding shares of Convertible Preferred Stock, holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available for the payment of dividends. See "Dividend Policy." In the event of a liquidation, dissolution or winding up of the Company, holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of Convertible Preferred Stock. Holders of Common Stock have no preemptive rights or rights to convert their Common Stock into any other securities. There are no redemption or sinking fund provisions applicable to the Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable. All shares of Common Stock issuable upon conversion of the outstanding shares of Convertible Preferred Stock will be validly issued, fully paid and nonassessable upon such conversion. CONVERTIBLE PREFERRED STOCK As of May 24, 1996, there were 1,000,000 outstanding shares of the Company's Series A Convertible Preferred Stock and an option to purchase an additional 250,000 shares of the Company's Convertible Preferred Stock. All such outstanding shares of the Company's Series A Convertible Preferred Stock is convertible into one share of the Company's Common Stock and will automatically convert if the market price of the Company's Common Stock for 10 consecutive trading days exceeds $7.50 per share. Pursuant to the Company's Certificate of Incorporation, the Board of Directors has the authority, without further action by the stockholders, to issue shares of Preferred Stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, option or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the Common Stock. The Board of Directors, without stockholder approval, can issue Preferred Stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of Common Stock. Preferred Stock could thus be issued quickly with terms calculated to delay or prevent a change in control of the Company or make removal of management more difficult. Additionally, the issuance of Preferred Stock may decrease the market price of the Common Stock, and may adversely affect the voting and other rights of the holders of Common Stock. WARRANTS As of May 24, 1996, there were outstanding warrants to purchase an aggregate of 3,008,715 shares of Common Stock at a weighted average exercise price of $6.00 per share. REGISTRATION RIGHTS The holders of approximately 3,845,973 shares of Common Stock and their permitted transferees (the "Holders") are entitled to certain rights with respect to the registration of such shares under the Securities Act. 56. Under the terms of an agreement between the Company and the Holders, if the Company proposes to register any of its securities under the Securities Act, either for its own account or for the account of other security holders exercising registration rights, the Holders are entitled to notice of such registration and are entitled to include shares of such Common Stock therein. The Holders also have the right to request that the Company file a registration statement under the Securities Act at the Company's expense with respect to their shares of Common Stock, and the Company is required to use its best efforts to effect such registration. In addition, such Holders may require the Company to file registration statements on Form S-3 when such registration form becomes available to the Company. All such registration rights are subject to certain conditions and limitations, including the right of the underwriters of an offering to limit the number of shares to be included in such registration. Generally, the Company is required to bear the expense of all "piggy-back" and demand registrations (but not registrations on Form S-3 requested by the Holders), except for stock transfer fees and underwriters' fees, discounts or commissions relating to the sale of securities by holders. Schering-Plough, which holds 1,000,000 shares of Series A Convertible Preferred Stock, and its permitted transferees are entitled to certain rights with respect to the registration of such shares under the Securities Act. Under the terms of an agreement between the Company and Schering-Plough, if the Company proposes to register any of its securities under the Securities Act, either for its own account or for the account of other security holders exercising registration rights, Schering-Plough is entitled to notice of such registration and is entitled to include its converted shares therein. In addition, Schering-Plough may require the Company to file registration statements on Form S-3 when such registration form becomes available to the Company. All such registration rights are subject to certain conditions and limitations, including the right of the underwriters of an offering to limit the number of shares to be included in such registration. Generally, the Company is required to bear the expense of all "piggy-back" registrations (but not registrations on Form S-3 requested by Schering-Plough), except for stock transfer fees and underwriters' fees, discounts or commissions relating to the sale of securities by holders. TRANSFER AGENT AND REGISTRAR American Stock Transfer & Trust Company is the transfer agent and registrar for the Company's Common Stock. 57. SHARES ELIGIBLE FOR FUTURE SALE Upon completion of this offering, the Company will have 13,682,471 shares of Common Stock outstanding, assuming no exercise of outstanding options and warrants. Of these shares, the 1,000,000 shares of Common Stock sold in this offering, the 3,000,000 shares sold in the Company's initial public offering, the 3,000,000 shares sold in the Company's private placement and registered on a Form S-3 Registration Statement and the 650,000 shares previously sold and registered under the same Form S-3 Registration Statement will be freely transferable without restriction under the Securities Act and the regulations promulgated thereunder. The remaining 6,032,471 shares of Common Stock held by officers, directors, employees, consultants and other stockholders of the Company were sold by the Company in reliance on exemptions from the registration requirements of the Securities Act and are "restricted securities" within the meaning of Rule 144 under the Securities Act. These shares are freely tradable, subject in certain instances to compliance with the provisions of Rules 144 and 701. In addition, an aggregate of approximately 3,008,715 shares of Common Stock issuable upon exercise of outstanding warrants is eligible for immediate sale under Rule 144 upon exercise of such warrants. Under all Stock Option Plans, and for grants outside the Stock Option Plans, there are currently 564,567 shares of Common Stock issuable upon exercise of outstanding options exercisable within 60 days. The Company also has 1,000,000 shares of Series A Convertible Preferred Stock outstanding and an option to purchase an additional 250,000 shares of Convertible Preferred Stock. In general, under Rule 144 as currently in effect, a person (or persons whose shares are aggregated), including an affiliate, who has beneficially owned shares for at least two years is entitled to sell, within any three-month period, a number of shares that does not exceed the greater of (i) one percent of the then outstanding Common Stock (approximately 136,825 shares immediately after this offering) or (ii) the average weekly trading volume in the Common Stock during the four calendar weeks preceding such sale, subject to the filing of a Form 144 with respect to such sale and certain other limitations and restrictions. In addition, a person who is not deemed to have been an affiliate of the Company at any time during the three months preceding a sale, and who has beneficially owned the shares proposed to be sold for at least three years, would be entitled to sell such shares under Rule 144(k) without regard to the volume limitations described above or certain other restrictions of Rule 144. Under Rule 701, an employee, officer or director of, or consultant to, the Company who purchased shares pursuant to a written compensatory plan or contract including the 1991 Plan, and who is not an affiliate of the Company, is entitled to sell such shares without having to comply with the public information, holding period, volume limitation or notice provisions of Rule 144 and permits affiliates to sell such shares without having to comply with the Rule 144 holding period restrictions. The holders of approximately 3,845,973 shares of Common Stock and 1,000,000 shares of Series A Convertible Preferred Stock and their permitted transferees are entitled to certain rights with respect to the registration of such shares under the Securities Act. See "Description of Capital Stock - Registration Rights." Sales of a substantial number of shares of Common Stock by existing or by stockholders purchasing in this offering could have a negative impact on the market price of the Common Stock. PLAN OF DISTRIBUTION The Common Stock is being offered to a limited number of investors directly by the Company. The price of the Common Stock offered hereby will be determined through negotiations between the Company and the purchasers. 58. In order to comply with the securities laws of certain states, if applicable, the Common Stock will be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the Common Stock may not be sold unless it has been registered or qualified for sale. The Company will pay all of the expenses incident to the offering and sale of the Common Stock. LEGAL MATTERS The validity of the issuance of the Common Stock offered hereby will be passed upon for the Company by Cooley Godward Castro Huddleson & Tatum, San Diego, California. Certain members of Cooley Godward Castro Huddleson & Tatum beneficially own an aggregate of 23,941 shares of the Company's Common Stock. EXPERTS The consolidated financial statements of Corvas International, Inc. and Subsidiary as of December 31, 1994 and 1995, and for each of the years in the three-year period ended December 31, 1995, have been included herein and in the Registration Statement in reliance upon the report of KPMG Peat Marwick LLP, independent certified public accountants, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. AVAILABLE INFORMATION The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and in accordance therewith files reports, proxy statements and other information with the Commission. Such reports, proxy statements and other information filed by the Company may be inspected and copied at the public reference facilities maintained by the Commission at Room 1024, 450 Fifth Street, N.W., Judiciary Plaza, Washington, D.C. 20549, and at the SEC's following Regional Offices: Chicago Regional Office, Suite 1400, 500 West Madison Street, Chicago, Illinois 60661; and New York Regional Office, Seven World Trade Center, Suite 1300, New York, New York 10048. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission at 450 Fifth Street, N.W., Judiciary Plaza, Washington, D.C. 20549. ADDITIONAL INFORMATION The Company has filed with the Securities and Exchange Commission, Washington, D.C., a Registration Statement on Form S-1 under the Securities Act, with respect to the shares of Common Stock offered hereby. This Prospectus does not contain all of the information set forth in the Registration Statement and the exhibits and schedules thereto. Statements contained in this Prospectus as to the contents of any contract or any other document referred to are not necessarily complete and, in each instance, reference is made to the copy of such contract or other document filed as an exhibit to the Registration Statement, each such statement being qualified in all respects by such reference. For further information with respect to the Company and the Common Stock offered hereby, reference is made to such Registration Statement, exhibits and schedules. A copy of the Registration Statement and the exhibits and schedules thereto may be inspected by anyone without charge at the public reference facilities maintained by the Commission at 450 Fifth Street, N.W., Judiciary Plaza, Washington, D.C. 20549, and copies of all or any part of the Registration Statement may be obtained from the Public Reference Section of the Commission upon the payment of certain fees prescribed by the Commission. 59 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS PAGE Independent Auditors' Report . . . . . . . . . . . . . . . . . . . . . . . F-1 Consolidated Balance Sheets as of December 31, 1994 and 1995 and March 31, 1996 (Unaudited) . . . . . . . . . . . . . . . F-2 Consolidated Statements of Operations for the three years ended December 31, 1995 and for the three months ended March 31, 1995 and 1996 (unaudited). . . . . . . . . . . . . . . . . F-3 Consolidated Statements of Stockholders' Equity (Deficit) for the three years ended December 31, 1995 and for the three months ended March 31, 1996 (unaudited). . . . . . . . . . . . . . . F-4 Consolidated Statements of Cash Flows for the three years ended December 31, 1995 and for the three months ended March 31, 1995 and 1996 (unaudited). . . . . . . . . . . . . . . . . F-5 Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . F-6 INDEPENDENT AUDITORS' REPORT The Board of Directors Corvas International, Inc.: We have audited the accompanying consolidated balance sheets of Corvas International, Inc. and subsidiary as of December 31, 1994 and 1995, and the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 1995. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted out audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Corvas International, Inc. and subsidiary as of December 31, 1994 and 1995, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 1995, in conformity with generally accepted accounting principles. KPMG PEAT MARWICK LLP San Diego, California January 29, 1996, except for Note 13 to the consolidated financial statements, as to which date is February 2, 1996. F-1 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) December 31, March 31, ---------------------------- ------------ ASSETS 1994 1995 1996 ---- ---- ---- (unaudited) Current assets: Cash and cash equivalents $ 3,687 $ 1,427 $ 1,114 Short-term debt securities held to maturity and time deposits, partially restricted (notes 2 and 7) 16,180 11,024 23,794 Receivables 306 338 301 Note receivable from related party (note 3) --- --- 120 Other current assets 242 250 486 ----------- ----------- ----------- Total current assets 20,415 13,039 25,815 Property and equipment, net (notes 4 and 7) 2,094 1,423 1,375 Note receivable from related party (note 3) --- --- 180 ----------- ----------- ----------- $ 22,509 $ 14,462 $ 27,370 ----------- ----------- ----------- ----------- ----------- ----------- LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 253 $ 272 $ 155 Accrued expenses 840 461 377 Accrued benefits 645 --- --- Accrued vacation 169 205 228 Accrued litigation settlement expenses (note 13) 535 313 193 Current portion of capital lease obligation (note 7) 71 77 79 Deferred rent (note 7) --- 34 23 Deferred revenue (note 8) 4,000 4,305 3,190 ----------- ----------- ----------- Total current liabilities 6,513 5,667 4,245 ----------- ----------- ----------- ----------- ----------- ----------- Long-term capital lease obligation (note 7) 104 27 7 Deferred rent (note 7) 245 --- --- Deferred revenue (note 8) 1,000 --- --- Stockholders' equity (note 5): Series A convertible preferred stock, $.001 par value, authorized 10,000,000 shares, issued and outstanding 1,000,000 shares at December 31, 1994 and 1995 and March 31, 1996 (liquidating preference $5 per share) 1 1 1 Common stock, $.001 par value, authorized 50,000,000 shares, issued and outstanding 9,352,000 shares at December 31, 1994, 9,448,000 shares at December 31, 9 9 13 1995 and 12,522,000 shares at March 31,1996 Additional paid-in capital 69,149 69,346 84,323 Accumulated deficit (54,295) (60,588) (61,219) Deferred compensation (83) --- --- Foreign currency translation adjustment (134) --- --- ----------- ----------- ----------- Total stockholders' equity 14,647 8,768 23,118 Commitments and contingencies (notes 7 and 13) ----------- ----------- ----------- $ 22,509 $ 14,462 $ 27,370 ----------- ----------- ----------- ----------- ----------- -----------
See accompanying notes to consolidated financial statements. F-2 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Years Ended December 31, Three Months Ended March 31, ------------------------------------ ---------------------------- 1993 1994 1995 1995 1996 ---- ---- ---- ---- ---- (unaudited) REVENUES: Net product sales $ 323 $ 280 $ 406 $ 46 $ 21 Research grants (note 11) 192 667 --- --- --- Revenue from collaborative agreements (primarily from related party) (note 8) --- --- 4,354 1,000 2,085 License fees (note 8) 100 --- 500 --- --- Royalties (note 8) 230 183 142 34 81 ------- ------- ------- ------- ------- Total revenues 845 1,130 5,402 1,080 2,187 ------- ------- ------- ------- ------- COSTS AND EXPENSES: Cost of products sold 105 83 211 5 24 Research and development (note 11) 12,115 11,378 9,723 2,259 2,299 General and administrative 3,067 3,159 2,582 682 793 Litigation settlement and related expenses (note 13) --- 535 --- --- --- Restructuring charge (note 9) --- 1,575 --- --- --- ------- ------- ------- ------- ------- Total costs and expenses 15,287 16,730 12,516 2,946 3,116 ------- ------- ------- ------- ------- Loss from operations (14,442) (15,600) (7,114) (1,866) (929) ------- ------- ------- ------- ------- OTHER INCOME: Interest income, net 1,073 686 835 249 268 Other income --- 11 (14) (32) 30 ------- ------- ------- ------- ------- 1,073 697 821 217 298 ------- ------- ------- ------- ------- Net loss $(13,369) $(14,903) $ (6,293) $ (1,649) $ (631) ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- Net loss per share $ (1.44) $ (1.60) $ (0.67) $ (0.18) $ (0.05) ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- Shares used in calculation of net loss per share 9,295 9,336 9,374 9,359 11,507 ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
See accompanying notes to consolidated financial statements. F-3 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Consolidated Statements of Stockholders' Equity (Deficit) (In thousands) Series A Convertible Preferred Stock Common Stock Additional ------------------------------ ------------------------- Paid-In Shares Amount Shares Amount Capital ------------- -------------- ----------- ----------- ------------ Balance as of December 31, 1992 --- $ --- 9,282 9 $ 64,306 Common stock issued upon exercise of stock options --- --- 33 --- 32 Common stock issued pursuant to employee stock purchase plan --- --- 11 --- 53 Amortization of deferred compensation --- --- --- --- (37) Foreign currency translation adjustment --- --- --- --- --- Net loss --- --- --- --- --- ------------- -------------- ----------- ----------- ------------ Balance as of December 31, 1993 --- --- 9,326 9 64,354 Common stock issued upon exercise of stock options --- --- 14 --- 11 Common stock issued pursuant to employee stock purchase plan --- --- 12 --- 30 Series A preferred stock issued for cash, net of issuance costs 1,000 1 --- --- 4,863 Amortization of deferred compensation --- --- --- --- (109) Foreign currency translation adjustment --- --- --- --- --- Net loss --- --- --- --- --- ------------- -------------- ----------- ----------- ------------ Balance as of December 31, 1994 1,000 1 9,352 9 69,149 Common stock issued upon exercise of stock options --- --- 74 --- 150 Common stock issued pursuant to employee stock purchase plan --- --- 16 --- 35 Common stock issued pursuant to employee performance stock award --- --- 6 --- 12 Amortization of deferred compensation --- --- --- --- --- Foreign currency translation adjustment --- --- --- --- --- Net loss --- --- --- --- --- ------------- -------------- ----------- ----------- ------------ Balance as of December 31, 1995 1,000 1 9,448 9 69,346 Common stock issued upon exercise of stock options --- --- 24 --- 27 Common stock and warrants issued for cash in private placement, net of issuance costs --- --- 3,000 3 14,832 Common stock issued in settlement of lawsuit --- --- 50 1 118 Net loss --- --- --- --- --- ------------- -------------- ----------- ----------- ------------ Balance as of March 31, 1996 (unaudited) 1,000 $ 1 12,522 $ 13 $ 84,323 ------------- -------------- ----------- ----------- ------------ ------------- -------------- ----------- ----------- ------------ Foreign Total Currency Stockholders' Accumulated Deferred Translation Equity Deficit Compensation Adjustment (Deficit) ------------- -------------- ----------- ----------- Balance as of December 31, 1992 $ (26,023) $ (644) $ (56) $ 37,592 Common stock issued upon exercise of stock options --- --- --- 32 Common stock issued pursuant to employee stock purchase plan --- --- --- 53 Amortization of deferred compensatio --- 265 --- 228 Foreign currency translation adjustme --- --- (62) (62) Net loss (13,369) --- --- (13,369) ------------- -------------- ----------- ----------- Balance as of December 31, 1993 (39,392) (379) (118) 24,474 Common stock issued upon exercise of stock options --- --- --- 11 Common stock issued pursuant to employee stock purchase plan --- --- --- 30 Series A preferred stock issued for cash, net of issuance costs --- --- --- 4,864 Amortization of deferred compensation --- 296 --- 187 Foreign currency translation adjustment --- --- (16) (16) Net loss (14,903) --- --- (14,903) ------------- -------------- ----------- ----------- Balance as of December 31, 1994 (54,295) (83) (134) 14,647 Common stock issued upon exercise of stock options --- --- --- 150 Common stock issued pursuant to employee stock purchase plan --- --- --- 35 Common stock issued pursuant to employee performance stock award --- --- --- 12 Amortization of deferred compensation --- 83 --- 83 Foreign currency translation adjustment --- --- 134 134 Net loss (6,293) --- --- (6,293) ------------- -------------- ----------- ----------- Balance as of December 31, 1995 (60,588) --- --- 8,768 Common stock issued upon exercise of stock options --- --- --- 27 Common stock and warrants issued for cash in private placement, net of issuance costs --- --- --- 14,835 Common stock issued in settlement of lawsuit --- --- --- 119 Net loss (631) --- --- (631) ------------- -------------- ----------- ----------- Balance as of March 31, 1996 (unaudited) $ (61,219) $ --- $ --- $ 23,118 ------------- -------------- ----------- ----------- ------------- -------------- ----------- -----------
See accompanying notes to consolidated financial statements. F-4 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS IN THOUSANDS Three Months Ended Years Ended December 31, March 31, ------------------------------------------- --------------------------- 1993 1994 1995 1995 1996 ------------------------------------------- --------------------------- (unaudited) Cash flows from operating activities: Net loss $ (13,369) $ (14,903) $ (6,293) $ (1,649) $ (631) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 737 814 834 192 211 Amortization of premiums and discounts on investments 145 (26) (377) 21 (41) Amortization of deferred compensation 228 187 83 21 --- Stock compensation expense --- --- 12 12 --- Translation loss --- --- 92 --- --- Common stock issued in settlement of lawsuit --- --- --- --- 119 Loss on disposal of property and equipment --- --- 154 --- --- Change in assets and liabilities: (Increase) decrease in receivables (260) 346 (32) 45 37 (Increase) decrease in other current assets (2) 107 (8) (218) (236) Increase (decrease) in accounts payable, accrued expenses, accrued benefits, accrued vacation and accrued litigation settlement expenses 745 738 (1,191) (1,323) (298) Increase (decrease) in deferred revenue --- 5,000 (695) (1,000) (1,115) Decrease in deferred rent (30) (99) (211) (36) (11) ------------ ------------ ----------- ----------- ---------- Net cash used in operating activities (11,806) (7,836) (7,632) (3,935) (1,965) ------------ ------------ ----------- ----------- ---------- Cash flows from investing activities: Purchases of investments held to maturity (6,356) (23,587) (14,927) (5,111) (15,927) Proceeds from maturity of investments held to maturity 20,788 28,728 20,460 6,200 3,200 Purchases of property and equipment (1,099) (443) (577) (103) (164) Proceeds from sale of property and equipment --- --- 256 278 --- Repayments from (loans to) employees (150) 150 --- --- (300) ------------ ------------ ----------- ----------- ---------- Net cash provided by (used in) investing activities 13,183 4,848 5,212 1,264 (13,191) ------------ ------------ ----------- ----------- ---------- Cash flows from financing activities: Principal payments under capital lease obligation --- (46) (71) (17) (19) Net proceeds from issuance of preferred stock --- 4,864 --- --- --- Net proceeds from issuance of common stock 77 41 185 5 14,862 ------------ ------------ ----------- ----------- ---------- Net cash provided by (used in) financing activities 77 4,859 114 (12) 14,843 Effect of exchange rate changes on cash (95) (69) 46 (157) --- ------------ ------------ ----------- ----------- ---------- Net increase (decrease) in cash and cash equivalents 1,359 1,802 (2,260) (2,840) (313) Cash and cash equivalents at beginning of period 526 1,885 3,687 3,687 1,427 ------------ ------------ ----------- ----------- ---------- Cash and cash equivalents at end of period $ 1,885 $ 3,687 $ 1,427 $ 847 $ 1,114 ------------ ------------ ----------- ----------- ---------- ------------ ------------ ----------- ----------- ---------- Supplemental disclosures: Interest paid $ --- $ 9 $ 11 $ 3 $ 2 Noncash financing activities- Equipment acquisitions under capital lease $ --- $ 221 $ --- $ --- $ ---
See accompanying notes to consolidated financial statements. F-5 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements December 31, 1994 and 1995 and March 31, 1996 (unaudited) (l) THE COMPANY Corvas International, Inc. (the "Company") was incorporated on March 27, 1987 under the laws of the State of California. In July 1993, the Company reincorporated in the state of Delaware. The Company is engaged in the design and development of a new generation of therapeutic agents for the prevention and treatment of major cardiovascular and inflammatory diseases. Prior to December 1994, the Company was considered to be in the development stage for financial reporting purposes. For years prior to 1995, financial statements of the Company were consolidated to include the accounts of Corvas International, Inc. in San Diego and its Belgian subsidiary, Corvas International, N.V. All material intercompany balances and transactions have been eliminated in consolidation. Operating activities at the Belgian subsidiary ceased in December 1994 and the subsidiary was liquidated in December 1995. (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) CASH EQUIVALENTS: Cash equivalents consist of an investment in a short-term government fund and are stated at cost, which approximates market value. (b) SHORT-TERM DEBT SECURITIES HELD TO MATURITY AND TIME DEPOSITS: Short-term debt securities consist of government-backed debt instruments. Short-term debt securities are carried at amortized cost which approximates market value and mature at various dates through November 1, 1996. At March 31, 1996 and December 31, 1994 and 1995, $60,000 of time deposits were restricted related to the facility lease. See Note 7. In May 1993, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 115, "Accounting for Certain Investments in Debt and Equity Securities" ("SFAS 115"). SFAS 115 requires that investments be classified as "held to maturity", "available for sale" or "trading securities". The Company records its investments held to maturity at amortized cost, which approximates fair value. Other investments in debt and equity securities are recorded at fair market value. The cost of securities sold, if any, is based on the specific identification method. The Company adopted SFAS 115 effective January 1, 1994. The adoption of SFAS 115 did not have a material impact on the Company's financial position or results of operations. (c) DEPRECIATION AND AMORTIZATION: Depreciation for financial reporting purposes is provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. Assets held under capital lease are amortized over the life of the lease. (d) RESEARCH AND DEVELOPMENT COSTS: Research and development costs are expensed in the period incurred. (e) PATENTS: Costs to obtain and maintain patents are expensed as incurred. F-6 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued (f) NET LOSS PER SHARE: Net loss per share is computed using the weighted average number of common and common share equivalents outstanding. Common equivalent shares from convertible preferred stock, stock options and warrants are excluded from the computation as their effect is antidilutive. (g) FOREIGN CURRENCY TRANSLATION: Assets and liabilities of subsidiary operations denominated in foreign currencies are translated at rates in effect at the end of the year. Revenues and expenses are translated at average rates throughout the year. The local currency is considered to be the functional currency, and adjustments resulting from such translation are included in foreign currency translation adjustment, a separate component of stockholders' equity. To date, no sales have been generated by the Company's foreign subsidiary, which was liquidated in 1995. See Note 9. (h) REVENUE RECOGNITION: Revenue on product sales is recorded at the time of shipment. Research grant revenue is recognized as research and development activities are performed under the terms of the research contracts. Revenue from collaborative agreements is generally recognized over the term of the agreement or upon achievement of certain milestones. Advance payments received in excess of amounts earned are classified as deferred revenue. (i) RECLASSIFICATIONS: Certain amounts in the 1993 and 1994 financial statements were reclassified to conform with the 1995 presentation. (j) USE OF ESTIMATES: Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities to prepare these financial statements in conformity with generally accepted accounting principles. Actual results could differ from those estimates. (k) FAIR VALUE OF FINANCIAL INSTRUMENTS: Statement of Financial Accounting Standards No. 107, "Disclosures about Fair Value of Financial Instruments" ("SFAS 107"), defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The carrying amount of cash and cash equivalents, short-term debt securities held to maturity, time deposits, receivables, notes receivable, other current assets, accounts payable, accrued expenses, accrued benefits, accrued vacation, accrued litigation settlement expenses, capital lease obligations, deferred rent and deferred revenue, included in the accompanying consolidated balance sheets, approximate the estimated fair value of those instruments because of their short maturities. (l) BASIS OF PRESENTATION: The interim financial information contained herein is unaudited but, in management's opinion, includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation. Results for the interim periods are not necessarily indicative of results for other interim periods or for the full year. F-7 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued (3) NOTES RECEIVABLE (UNAUDITED) The notes receivable as of March 31, 1996 consist of loans to an officer of the Company issued in February 1996 in connection with his employment with the Company. The $120,000 loan, which is unsecured and bears no interest, is due and payable in full on the earlier of one year from the loan date or the officer's termination for cause. The $180,000 loan bears interest at 6% per annum and is secured by his primary residence. This loan is due and payable in full on the earlier of five years from the loan date or the officer's termination for cause. (4) PROPERTY AND EQUIPMENT Property and equipment are recorded at cost and are summarized as follows (in thousands). December 31, March 31, --------------- --------- 1994 1995 1996 ---- ---- ---- (unaudited) Machinery and equipment $ 3,233 $ 2,906 $ 3,066 Furniture and fixtures 139 135 135 Leasehold improvements 670 732 735 ------- ------- -------- Total property and equipment 4,042 3,773 3,936 Less accumulated depreciation and amortization (1,948) (2,350) (2,561) ------- ------- -------- $ 2,094 $ 1,423 $ 1,375 ------- ------- -------- ------- ------- --------
(5) STOCKHOLDERS' EQUITY (a) CONVERTIBLE PREFERRED STOCK: In December 1994, in conjunction with a strategic alliance with Schering-Plough Corporation (See Note 8), the Company issued 1,000,000 shares of Series A Convertible Preferred Stock, resulting in net proceeds of $4,864,000. Each share of Series A preferred stock is convertible into one share of the Company's common stock, and will automatically convert if the market price of the Company's common stock for 10 consecutive trading days exceeds $7.50 per share. As a result, 1,000,000 shares of common stock have been reserved for the potential conversion of Series A preferred stock. Each share of Series A preferred stock is entitled to a fixed, cumulative dividend of $.40 per share per annum, when and if declared by the Board of Directors. No such dividends have been declared. In addition, each share is entitled to one vote and has a liquidating preference of $5.00 plus any declared and unpaid dividends. The Company has a total of 10,000,000 shares of authorized preferred stock. (b) COMMON STOCK: On February 2, 1996, the Company completed a private placement of equity securities consisting of 3,000,000 units, resulting in proceeds of $14,835,000, net of estimated issuance costs. Each unit consisted of one share of common stock and one callable warrant to purchase one additional share of common stock. In February 1992, the Company completed its initial public offering of 3,000,000 shares of common stock, resulting in net proceeds of $32,470,000. The Company filed Restated Articles of Incorporation in February 1992 which increased to 50,000,000 the number of authorized common shares. F-8 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued (c) STOCK OPTIONS: The Company has several plans and arrangements under which incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, dividend equivalents, performance awards and stock payments can be granted to key personnel, including officers, directors, and outside consultants. The terms are determined by the Compensation and Stock Option Committee of the Board of Directors. Options have a term of 10 years and generally become exercisable over a four-year period beginning one year from the date of grant at a price per share not less than the fair market value on the date of grant. All employee options granted after December 1, 1994 vest 25% at the end of the first year and 6.25% per quarter each quarter thereafter. Activity under these plans and arrangements from 1993 through 1995 is as follows (in thousands except per share amounts). Options Exercise Price ------- -------------- Outstanding, December 31, 1992 761 $ 0.70 - $ 8.50 Granted 167 $ 4.00 - $ 7.88 Exercised (33) $ 0.70 - $ 3.50 Cancelled (55) $ 0.88 - $ 7.75 ----- Outstanding, December 31, 1993 840 $ 0.70 - $ 8.50 Granted 305 $ 2.44 - $ 4.94 Exercised (14) $ 0.70 - $ 0.88 Cancelled (43) $ 0.88 - $ 8.06 ----- Outstanding, December 31, 1994 1,088 $ 0.70 - $ 8.50 Granted 755 $ 1.75 - $ 4.31 Exercised (74) $ 0.70 - $ 3.50 Cancelled (711) $ 0.88 - $ 8.50 ----- Outstanding, December 31, 1995 1,058 $ 0.70 - $ 7.06 Granted 468 $ 3.72 - $ 4.94 Exercised (24) $ 0.70 - $ 2.19 Cancelled (2) $ 2.13 - $ 3.75 ----- Outstanding, March 31, 1996 (unaudited) 1,500 $ 0.70 - $ 7.06 ----- -----
As of March 31, 1996, net options for 1,765,000 shares have been granted since inception of the plan, 504,000 shares were vested and exercisable, 265,000 shares were vested and had been exercised and 996,000 shares remain unvested. A total of 1,500,000 shares are reserved for issuance pursuant to outstanding options, and no shares are available for future grant. In January 1995, the Company offered certain holders of stock options, excluding outside directors of the Company, the opportunity to exchange an issued option for a new stock option on a one-for-one basis at the market value on January 16, 1995. After a waiting period of 6 months (12 months for officers), vesting of the exchanged options was restored to the level existing prior to the exchange. A total of 608,000 options at an average exercise price of $4.83 were exchanged for options with an exercise price of $2.19 per share. These options are included as grants and cancellations in the preceding table. For certain options granted prior to the Company's initial public offering, deferred compensation expense was recognized for the excess of the deemed fair value over the exercise price at the date of grant. This deferred compensation was amortized to expense ratably over the vesting period of each option. As of December 31, 1995, all such deferred compensation expense has been amortized. F-9 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued (d) PERFORMANCE AWARDS: In January 1995, the Company granted a total of 6,000 shares of common stock as a performance award to all employees, excluding senior management of the Company. These shares were fully vested and non- restrictive. (e) WARRANTS: In conjunction with the private placement of equity securities completed in February 1996, the Company issued callable warrants to purchase 3,000,000 shares of common stock. The warrants are exercisable at $6.00 per share over a period of six years unless called earlier by the Company. In conjunction with the negotiation of equipment leases entered into in 1990, the Company issued warrants to purchase approximately 9,000 shares of preferred stock (subsequently converted to common stock) to the lessors in lieu of security deposits. The warrants are exercisable at $6.13 or $7.00 per share over a period of ten years from the inception of the leases. The lease agreements are described in Note 7. As of March 31, 1996, none of the outstanding warrants have been exercised. (f) STOCK PURCHASE PLAN: In December 1991, the Company adopted an employee stock purchase plan that provides for the issuance of up to 150,000 shares of common stock. The plan is intended to qualify under Section 423 of the Internal Revenue Code and is for the benefit of qualifying employees, as designated by the Compensation and Stock Option Committee of the Board of Directors. Under the terms of the plan, participating employees are eligible to have a maximum of 10% of their compensation withheld through payroll deductions to purchase shares of common stock at the lower of 85% of the fair market value at the beginning of each offering period or of the fair market value on predetermined dates. As of March 31, 1996, 47,000 shares of common stock have been issued pursuant to this plan. (6) INCOME TAXES The Company accounts for income taxes in accordance with Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes' ("SFAS 109"). Under the asset and liability method of SFAS 109, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Under SFAS 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company adopted SFAS 109 effective January 1, 1993. The adoption did not have a material effect on the consolidated balance sheets or statements of operations. The Company has no net, taxable temporary differences which would require recognition of deferred tax liabilities and, due to the uncertainty of future realizability, has recorded a valuation allowance against any deferred tax assets for deductible temporary differences and tax operating loss carryforwards. The Company increased its valuation allowance by approximately $2,400,000 and $2,200,000 for the years ended December 31, 1995 and 1994, respectively, primarily as a result of the increase in tax operating loss carryforwards. F-10 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued At December 31, 1995, the Company had available net operating loss carryforwards of approximately $37,368,000 for federal income tax reporting purposes which begin to expire in 2002. The net operating loss carry- forwards for state purposes, which began to expire in 1995 and fully expire in 2000, are approximately 50% of the federal tax amounts. The Company has unused research and development tax credits for federal income tax purposes of $2,314,000 at December 31, 1995. In accordance with Internal Revenue Code Section 382, the annual utilization of net operating loss carryforwards and credits existing prior to a change in control may be limited. (7) COMMITMENTS (a) LEASE COMMITMENTS: The Company currently leases its principal facility under an operating lease and certain equipment under a capital lease. The facility lease expires in September 1997 and has two one-year renewal options remaining. Terms of the lease provide for escalating rent payments during the lease term. For financial reporting purposes, rent expense is recognized on a straight-line basis over the term of the lease. Accordingly, rent expense recognized in excess of cash rent paid is reflected as deferred rent. Total rent expense under this lease for the years ended December 31, 1995, 1994 and 1993 was $733,000, $722,000 and $710,000, respectively. Through December 31, 1994, the Company had a lease commitment, which commenced in 1993, with a related party for its Belgian operation. See Notes 9 and 12. Rent expense for this operation for the years ended December 31, 1994 and 1993 was $74,000 and $40,000, respectively. In 1990, the Company entered into equipment leases for a total of $485,000 to be paid over 48 and 61 months. In 1991, the Company entered into additional equipment leases for $243,000 in aggregate to be paid over 37 and 42 months. As of December 31, 1995, these leases have all expired. Lease expense on these operating leases for the years ended December 31, 1995, 1994 and 1993 was $58,000, $247,000 and $361,000, respectively. In 1994, the Company entered into a capital equipment lease for $221,000 to be paid over 36 months. The amortization expense on this lease for the years ended December 31, 1995 and 1994 was $44,000 and $30,000, respectively. Annual future minimum commitments under these leases for years ending December 31 are as follows (in thousands). Operating Capital Lease Lease ----- ----- 1996 $ 652 $ 82 1997 --- 28 -------- ------- Total minimum lease payments $ 652 110 -------- -------- Less amount representing interest (6) ------- Present value of capital lease payments 104 Less current portion (77) ------- Long-term capital lease obligation $ 27 ------- -------
F-11 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued (b) LETTER OF CREDIT: The Company has an unused standby letter of credit of $60,000 that bears interest at the prime rate plus 1% and expires on September 30, 1996 with provisions for annual renewal. This letter of credit, collateralized by a $60,000 time deposit, is pledged in lieu of a security deposit against the principal facility lease discussed above. (8) COLLABORATIVE AGREEMENTS In October 1995, the Company entered into a research and option agreement with Pfizer Inc. ("Pfizer") to collaborate on the development of neutrophil inhibitory factor ("NIF"), an anti-inflammatory agent with therapeutic potential for stroke and other indications. Of the $1,159,000 payment received from Pfizer, license fees of $500,000 and revenue from collaborative agreements of $354,000 were recorded in 1995 on the accompanying statements of operations. The balance of $305,000 is included in deferred revenue on the accompanying balance sheets. During the option period, which concludes in October 1996 but may be extended by Pfizer until April 1997, Pfizer will fund its own further development of NIF including costs associated with clinical trials. If Pfizer exercises its option by April 1997, pursuant to a license and development agreement, Corvas will conduct certain development activities for an additional two-year period and Pfizer will receive an exclusive, worldwide license to further develop, manufacture and market NIF as a therapeutic agent. If the option to enter into the license and development agreement is exercised, Pfizer will pay the Company an additional license fee and will compensate the Company for certain costs of research and preclinical development of NIF over a two- year period. If products are successfully commercialized from this agreement, the Company will also receive milestone payments and royalty payments on product sales. In December 1994, the Company entered into a strategic alliance agreement with Schering Corporation ("Schering-Plough") to collaborate on the discovery and commercialization of oral thrombin inhibitor drugs for the prevention and treatment of chronic cardiovascular disorders. In January 1996, Schering-Plough extended to December 1996 its exclusive option to expand the program to include a second blood clotting enzyme with a $1,000,000 payment which is included as revenue during the three months ended March 31, 1996 in the consolidated statements of operations. Under the terms of the agreement, Schering-Plough will compensate the Company for the costs of research and preclinical development of thrombin inhibitors over two years. A $5,000,000 payment received in 1994 was recorded as deferred revenue as of December 31, 1994. Of this amount, revenue of $4,000,000 was recognized in 1995 and an additional $4,000,000 received through December 31, 1995 has been recorded as deferred revenue on the accompanying balance sheets. This additional $4,000,000 will be recognized as revenue in 1996. The Company may also receive milestone payments and royalties on sales of therapeutics resulting from this alliance. Schering-Plough, which is responsible for certain preclinical development and all future clinical trials and regulatory activities, received exclusive worldwide manufacturing and marketing rights for any resulting thrombin inhibitors. Under a separate agreement also completed in December 1994, Schering-Plough purchased 1,000,000 shares of Series A convertible preferred stock of the Company resulting in net proceeds of $4,864,000. If the option described above is exercised, Schering-Plough has agreed to an additional equity investment. F-12 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued In June 1992, the Company entered into two agreements with Ortho Diagnostic Systems, Inc. ("Ortho"), a Johnson & Johnson company, granting Ortho exclusive worldwide rights to market certain diagnostic reagents. Ortho is obligated to order stipulated minimum amounts each year, or must pay the Company the deficiency between the minimum and the amount actually ordered. Net product sales for the years ended December 31, 1995, 1994 and 1993 were $282,000, $169,000 and $166,000, respectively. These agreements provide that Ortho pay royalties based on unit sales of this product, as well as two milestone payments, the first of which was received in 1992. For the years ended December 31, 1995, 1994 and 1993, royalties under this agreement amounted to $142,000, $183,000 and $230,000, respectively. In November 1991, Centocor, Inc. acquired an exclusive option pursuant to which it licensed certain monoclonal antibody products under development by the Company, as well as future monoclonal antibody products discovered or acquired by the Company. In November 1991, Centocor exercised its option to license a product which was undergoing clinical trials (designated by the Company as CORSEVIN M) for which the Company received a cash license payment of $750,000 in 1991. Centocor paid the Company $100,000 in each of 1993 and 1992 for rights to future monoclonal antibody products, and terminated these option rights in 1994. The Company may also receive a future milestone payment and royalties on product sales; however there is no assurance that the product will be successfully developed. The Company has also entered into research and licensing agreements with scientific consultants, universities and other research institutions which have required the Company to make royalty payments for the years ended December 31, 1995, 1994 and 1993 of $15,000, $14,000 and 16,000, respectively. (9) RESTRUCTURING CHARGE AND LIQUIDATION OF SUBSIDIARY In December 1994, the Company ceased operation of its research and development subsidiary, Corvas International, N.V. in Gent, Belgium. The Belgian operation accounted for 20% of the consolidated operating expenses in 1994 (including a restructuring charge) and 20% in 1993. In connection with this restructuring, the accompanying consolidated statements of operations reflect a one-time charge to earnings of $1,575,000 in 1994 for severance and other expenses. Included in accrued expenses as of December 31, 1994 was $164,000, which was paid in 1995. Corvas International, N.V. was liquidated on December 19, 1995. Substantially all of the assets have been liquidated and any remaining or future liabilities have been assumed by the Company. (10)EMPLOYEE BENEFITS PLAN Effective January 1, 1988, the Board of Directors approved the Corvas 401(k) Compensation Deferral Savings Plan ("The Plan"), adopting provisions of the Internal Revenue Code Section 401(k). The Plan was approved by the IRS in 1989, and was amended and restated in 1994. The Plan is for the benefit of all qualifying employees, and permits employee voluntary contributions, qualified nonelective contributions and company profit sharing contributions. No employer contributions have been approved by the Board of Directors through March 31, 1996. (11)RESEARCH GRANTS For the years ended December 31, 1994 and 1993, research grant revenue of $667,000 and $192,000, respectively, was recorded related to Small Business Innovation Research (SBIR) and other grants. No such revenue was recorded in 1995. The related expenses, which equal research grant revenues, are recorded as research and development expenses in the accompanying consolidated statements of operations. F-13 CORVAS INTERNATIONAL, INC. AND SUBSIDIARY Notes to Consolidated Financial Statements, Continued (12)RELATED PARTY TRANSACTIONS Pursuant to the acquisition of the Belgian subsidiary, the Company entered into a facility and equipment services agreement with a principal shareholder of the Company in 1991. Under the terms of the agreement, the Company acquired certain services in advance and committed to pay for other services at the principal shareholder's determined cost. The Company amortized $74,000 of prepaid services in 1993 and was charged $410,000 and $361,000 in 1994 and 1993, respectively, pursuant to this agreement. See Notes 7 and 9. (13)LEGAL MATTERS The Company, several of its current and former directors, and Centocor, Inc. were parties to a legal proceeding filed February 18, 1993, in the U.S. District Court for the Southern District of California. The complaint was filed by a shareholder of the Company who represented a class of persons who purchased Corvas stock from January 30, 1992 through April 14, 1992. A settlement was agreed upon and judgment of the Court entered on August 28, 1995. The Company continues to deny all claims of wrongdoing and maintains this denial as part of the settlement agreement. Of the $535,000 charge related to this settlement recorded at December 31, 1994, $193,000 and $313,000 remain accrued at March 31, 1996 and December 31, 1995, respectively. In 1993, the U.S. Patent and Trademark Office declared an interference and is currently in the process of determining the priority of invention between a patent for which some rights are licensed to the Company and a patent application for which rights are licensed to another party. The subject matter of these licenses is recombinant tissue factor which is used by Ortho to determine the blood clotting abilities of patients. The Company believes that its licensed patent should be upheld and is contesting the other party's claims of prior invention. However, there is no assurance that such patent will be upheld. F-14 NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS IN CONNECTION WITH THE OFFERING OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH OTHER INFORMATION AND REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF OR THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO ITS DATE. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF OFFER TO BUY ANY SECURITIES OTHER THAN THE REGISTERED SECURITIES TO WHICH IT RELATES. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SUCH SECURITIES IN ANY CIRCUMSTANCES IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. - -------------------------------------------------------------------------------- TABLE OF CONTENTS Page ---- Prospectus Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 Use of Proceeds. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Dividend Policy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Price Range of Common Stock. . . . . . . . . . . . . . . . . . . . . . . . 12 Capitalization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Selected Consolidated Financial Data . . . . . . . . . . . . . . . . . . . 14 Management's Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . . . . 16 Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Certain Transactions . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Principal Stockholders . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Description of Capital Stock . . . . . . . . . . . . . . . . . . . . . . . 50 Shares Eligible for Future Sale. . . . . . . . . . . . . . . . . . . . . . 52 Plan of Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Legal Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 Experts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 Available Information. . . . . . . . . . . . . . . . . . . . . . . . . . . 53 Additional Information . . . . . . . . . . . . . . . . . . . . . . . . . . 53 - -------------------------------------------------------------------------------- PART II INFORMATION NOT REQUIRED IN PROSPECTUS ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION The following table sets forth all expenses payable by the Registrant in connection with the sale of the Common Stock being registered. All of the amounts shown are estimates, except for the registration fee and the Nasdaq fee. Registration fee . . . . . . . . . $ 1,814 Nasdaq fee . . . . . . . . . . . . 17,500 Legal fees and expenses. . . . . . 75,000 Accounting fees and expenses . . . 30,000 Miscellaneous. . . . . . . . . . . 1,686 -------- Total . . . . . . . . . . . . $126,000 -------- --------
ITEM 14. INDEMNIFICATION OF OFFICERS AND DIRECTORS Under Section 145 of the Delaware General Corporation Law (the "Delaware Law"), the Registrant has broad powers to indemnify its directors and officers against liabilities they may incur in such capacities, including liabilities under the Securities Act. The Registrant's Amended and Restated Certificate of Incorporation and Bylaws include provisions to (i) eliminate the personal liability of its directors for monetary damages resulting from breaches of their fiduciary duty to the extent permitted by Section 102(b)(7) of the Delaware Law and (ii) require the Registrant to indemnify its directors and officers to the fullest extent permitted by Section 145 of the Delaware Law, including circumstances in which indemnification is otherwise discretionary. Pursuant to Section 145 of the Delaware Law, a corporation generally has the power to indemnify its present and former directors, officers, employees and agents against expenses incurred by them in connection with any suit to which they are, or are threatened to be made, a party by reason of their serving in such positions so long as they acted in good faith and in a manner they reasonably believed to be in, or not opposed to, the best interests of the corporation, and with respect to any criminal action, they had no reasonable cause to believe their conduct was unlawful. The Registrant believes that these provisions are necessary to attract and retain qualified persons as directors and officers. These provisions do not eliminate the directors' duty of care and, in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware Law. In addition, each director will continue to be subject to liability for breach of the director's duty of loyalty to the Registrant, for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for acts or omissions that the director believes to be contrary to the best interests of the Registrant or its stockholders, for any transaction from which the director derived an improper personal benefit, for acts or omissions involving a reckless disregard for the director's duty to the Registrant or its stockholders when the director was aware or should have been aware of a risk of serious injury to the Registrant or its stockholders, for acts or omission that constitute an unexcused pattern of inattention that amounts to an abdication of the director's duty to the Registrant or its stockholders, for improper transactions between the director and the Registrant and for improper distributions to stockholders and loans to directors and officers. The provision also does not affect a director's responsibilities under any other law, such as federal securities laws or state or federal environmental laws. The Registrant has entered into indemnity agreements with each of its directors and executive officers that require the Registrant to indemnify such persons against expenses, judgments, fines, settlements and other amounts incurred (including expenses of a derivative action) in connection with any proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director or an executive officer of the Registrant or any of its affiliated enterprises, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe his conduct was unlawful. The II-1 indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. At present, there is no pending litigation or proceeding involving a director or officer of the Registrant as to which indemnification is being sought nor is the Registrant aware of any threatened litigation that may result in claims for indemnification by any officer or director. The Registrant has an insurance policy covering the officers and directors of the Registrant with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise. ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES Since March 1993, the Registrant has sold and issued the following unregistered securities: 1. In December 1994, the Registrant issued 1,000,000 shares of Series A Convertible Preferred Stock to Schering-Plough at a price of $5.00 per share and an option to purchase an additional 250,000 shares of Convertible Preferred Stock. 2. In January 1996, the Registrant issued 50,000 shares of Common Stock to Agricultural Excess Surplus Insurance Company, in consideration for services rendered in connection with the settlement of a lawsuit. 3. In February 1996, the Registrant issued 3,000,000 shares of Common Stock in a unit financing to certain investors at a price of $5.00 per unit. Each unit consists of one share of Common Stock and one callable warrant to purchase one additional share of Common Stock. The sales and issuances of securities in the transactions described above were deemed to be exempt from registration under the Securities Act by virtue of Section 4(2) and/or Regulation D promulgated under the Securities Act. The purchasers in each case represented their intention to acquire the securities for investment only and not with a view to the distribution thereof. Appropriate legends are affixed to the stock certificates issued in such transactions. Similar legends were imposed in connection with any subsequent sales of any such securities. All recipients either received adequate information about the Registrant or had access, through employment or other relationships, to such information. II-2 ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES EXHIBIT NUMBER DESCRIPTION OF DOCUMENT - ------ ----------------------- 3.1 Amended and Restated Certificate of Incorporation.(8) 3.2 Bylaws.(8) 4.1 Reference is made to exhibits 3.1, 3.2, 10.20, 10.25, 10.26, 10.43 and 10.45. 4.2 Specimen stock certificate.(1) 5.1 Opinion of Cooley Godward Castro Huddleson & Tatum.(17) 10.1 Form of Indemnification Agreement between the Company and each director and executive officer.(1) 10.2 Stock Option Plan of the Company, as amended.(1) 10.3 Form of Incentive Stock Option Agreement under the Stock Option Plan.(1) 10.4 Form of Non-Incentive Stock Option Agreement under the Stock Option Plan.(1) 10.5 Second Stock Option Plan of the Company.(1) 10.6 Incentive Stock Option Agreement between the Company and David S. Kabakoff, dated as of October 2, 1989.(1) 10.7 Non-Statutory Stock Option Agreement of Theodor H. Heinrichs, dated October 17, 1991.(2) 10.8 Non-Statutory Stock Option Agreement of Pieter C. Bax, dated November 20, 1991.(2) 10.9 Form of Employee Stock Purchase Plan.(1) 10.10 1991 Incentive and Compensation Plan of the Company.(1) 10.11 Form of Incentive Stock Option Agreement under the 1991 Incentive and Compensation Plan of the Company.(2) 10.12 Form of Non-Qualified Stock Option Agreement under the 1991 Incentive and Compensation Plan of the Company.(2) 10.13 Form of Restricted Stock Purchase Agreement between the Company and certain individuals or entities, and attached schedule.(1) 10.14 Second Amended and Restated Stock Registration Rights Agreement between the Company and certain investors and warrantholders named therein, dated as of February 14, 1991, as amended on March 19, 1991, November 13, 1991 and December 4, 1991, and supplemental letter agreement dated December 12, 1991.(1) 10.15 Employment Agreement between the Company and David S. Kabakoff, dated as of March 6, 1989.(1) 10.16 Employment Agreement between the Company and John E. Crawford, dated as of April 17, 1989.(1) 10.17 Consulting Agreement between the Company and Thomas S. Edgington, dated as of May 21, 1987, with attachments and addenda, as extended and assigned pursuant to the Consulting Agreement Extension, dated as of May 21, 1991.(1) 10.18 Consulting Agreement between the Company and John H. Fried, dated as of June 3, 1992.(6) 10.19 Antibody Option Agreement between the Company and Centocor, Inc., dated as of November 7, 1991, with exhibit.(1)(4) II-3 EXHIBIT NUMBER DESCRIPTION OF DOCUMENT - ------ ----------------------- 10.20 Voting Agreement between Centocor Delaware, Inc. and certain equity security holders of the Company dated November 20, 1991.(1) 10.21 Standstill Letter Agreement between the Company and Centocor, Inc., dated November 20, 1991.(1) 10.22 Research and License Agreement for Human Tissue Factor for Diagnostic Purposes between the Company and Scripps Clinic and Research Foundation, dated May 19, 1988, as amended, including exhibits.(1)(4) 10.23 Agreement for International Business Combination (Series C and D Preferred Stock) between the Company and Plant Genetic Systems, N.V. and Take Off Fonds, N.V., dated as of March 6, 1991.(1) 10.24 Series E, F and G Preferred Stock Purchase Agreement between the Company and Centocor Delaware, Inc., dated as of November 20, 1991.(1) 10.25 Warrant to purchase Series B Preferred Stock of the Company issued to Comdisco, Inc. on June 19, 1990, as amended on January 2, 1992.(1) 10.26 Warrant to purchase Series B Preferred Stock of the Company issued to Praktikerfinans AB on November 30, 1990, as amended on January 15, 1992.(1) 10.27 Master Lease Agreement dated as of June 19, 1990 between the Company and Comdisco, Inc., with exhibit, as amended on January 2, 1992.(1) 10.28 Ventana Leaseline Agreement dated as of March 30, 1990 between the Company and Ventana Leasing, Inc., with exhibit.(1) 10.29 Ventana Leaseline Agreement dated as of September 15, 1991 between the Company and Ventana Leasing, Inc., with exhibits.(1) 10.30 Master Lease Agreement between the Company and Lease Management Services, dated as of August 29, 1991, with addendum and related Equipment Financing Agreement Number 10729 between the Company and Lease Management Services, dated as of August 29, 1991.(1) 10.31 Lease Agreement for 3030 Science Park Road, San Diego, California between the Company and Hartford Accident and Indemnity Company, dated as of March 28, 1989, as amended on March 23, 1990, May 18, 1990 and May 16, 1991.(1) 10.32 Fourth Lease Amendment to Lease Agreement for 3030 Science Park Road, San Diego, California between the Company and Hartford Accident and Indemnity Company, dated as of January 21, 1992.(1) 10.33 Waiver of Conversion Price Adjustment Agreement between the Company and Centocor Delaware, Inc., dated as of January 10, 1992.(1) 10.34 Supply Agreement and License Agreement between the Company and Ortho Diagnostic Systems, Inc., dated June 8, 1992, amended as to confidential treatment pursuant to a Form 8 filed March 18, 1993.(3)(5) 10.35 Fifth Lease Amendment to Lease Agreement for 3030 Science Park Road, San Diego, California between the Company and Hartford Accident and Indemnity Company, dated as of April 15, 1992, Sixth Lease Amendment dated as of July 16, 1992, Seventh Lease Amendment dated as of January 18, 1993.(6) 10.36 Permanent Waiver of Right of Centocor, Inc. to nominate second director under Series E, F and G Preferred Stock Purchase Agreement filed as Exhibit 10.24 herein.(8) II-4 EXHIBIT NUMBER DESCRIPTION OF DOCUMENT - ------ ----------------------- 10.37 Assignment of Lease Agreement for 3030 Science Park Road, San Diego, California from Corvas International, Inc., a California corporation, to Corvas International, Inc., a Delaware corporation, dated September 14, 1993.(8) 10.38 Corvas International, Inc. 401(k) Compensation Deferral Savings Plan and Trust Agreement (Amended and Restated as of January 1, 1989) (Revised to incorporate amendments to plan).(10) 10.39 Research and License Agreement for Oral Thrombin Inhibitor Drugs between the Company and Schering Corporation and Schering-Plough LTD., dated as of December 14, 1994.(10)(11) 10.40 Series A Preferred Stock Purchase Agreement between the Company and Schering Corporation, dated as of December 14, 1994.(10)(11) 10.41 Eighth Lease Amendment to Lease Agreement for 3030 Science Park Road, San Diego, California between the Company and Hartford Accident and Indemnity Company, dated as of July 7, 1995.(12) 10.42 Extension of Consulting Agreement between the Company and Thomas S. Edgington and Molecular Biology Consultants, dated as of May 21, 1995. (13) 10.43 Form of Warrant Agreement to purchase Common Stock of the Company issued to certain individuals affiliated with Ventana Leasing, Inc. on June 16, 1995.(13) 10.44 Collaborative Research and Option Agreement between the Company and Pfizer Inc. and Pfizer Limited, dated as of October 14, 1995.(13)(14) 10.45 Common Stock and Warrant Purchase Agreement between the Company and certain purchasers, dated as of February 2, 1996, with exhibits.(13) 10.46 Employment Agreement between the Company and Donald H. Picker, dated as of February 2, 1996, with certain exhibits thereto.(13) 10.47 Loan Agreement between the Company and Donald H. Picker, dated February 23, 1996, and the Promissory Notes and letter agreement related thereto.(15) 10.48 Ninth Lease Amendment to Lease Agreement for 3030 Science Park Road, San Diego, California between the Company and Hartford Accident and Indemnity Company, dated as of March 15, 1996.(15) 10.49 Permanent Waiver of Right of Centocor, Inc. to nominate director under Series E, F and G Preferred Stock Purchase Agreement (see Exhibit 10.24).(15) 10.50 Consulting Agreement between the Company and David S. Kabakoff, dated as of May 1, 1996.(16) 10.51 Consulting Agreement between the Company and Theodor H. Heinrichs, dated as of May 1, 1996.(17) 10.52 Employment Agreement by and between the Company and Randall E. Woods, dated as of May 10, 1996, with certain exhibits thereto.(17) 21.1 Subsidiary of the Company.(1) 23.1** Independent Auditors' Consent. Reference is made to page II-8. 23.2 Consent of Cooley Godward Castro Huddleson & Tatum. Reference is made to Exhibit 5.1. 24.1 Power of Attorney. (15) - ------------------------ II-5 ** Filed herewith. (1) Incorporated by reference to Registration Statement on Form S-1 (No. 33- 44555), as amended, filed December 13, 1991. (2) Incorporated by reference to Registration Statement on Form S-8 (No. 33- 45607), as amended, filed February 10, 1992. (3) Incorporated by reference to Quarterly Report on Form 10-Q, filed August 14, 1992. (4) Portions of this exhibit have been granted confidential treatment pursuant to an order granted by the Securities and Exchange Commission on January 30, 1992. (5) Portions of this exhibit have been granted confidential treatment pursuant to an order granted by the Securities and Exchange Commission on December 10, 1992. (6) Incorporated by reference to Annual Report on Form 10-K, filed March 30, 1993. (7) Incorporated by reference to Quarterly Report on Form 10-Q, filed May 14, 1993. (8) Incorporated by reference to Annual Report on Form 10-K, filed February 23, 1994. (9) Incorporated by reference to Quarterly Report on Form 10-Q, filed November 14, 1994. (10) Incorporated by reference to Annual Report on Form 10-K, filed March 30, 1995. (11) Portions of this exhibit have been granted confidential treatment pursuant to an order granted by the Securities and Exchange Commission on May 11, 1995. (12) Incorporated by reference to Quarterly Report on Form 10-Q, filed November 13, 1995. (13) Incorporated by reference to Annual Report on Form 10-K, filed February 28, 1996. (14) Portions of this exhibit have been granted confidential treatment pursuant to an order granted by the Securities and Exchange Commission on April 26, 1996. (15) Incorporated by reference to Registration Statement on Form S-1 (No. 333-2644), filed March 25, 1996. (16) Incorporated by reference to Quarterly Report on Form 10-Q, filed May 13, 1996. (17) Incorporated by reference to Amendment No. 1 to Registration Statement on Form S-1 (No. 333-2644), filed May 31, 1996. ITEM 17. UNDERTAKINGS Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to provisions described in Item 15 or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. The undersigned Registrant undertakes that: (1) for the purpose of determining any liability under the Securities Act, the information omitted from and form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it was declared effective; and (2) for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. II-6 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Amendment No. 2 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on June 24, 1996. CORVAS INTERNATIONAL, INC. By: /s/ RANDALL E. WOODS ------------------------------------- Randall E. Woods President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this Amendment No. 2 to Registration Statement has been signed below by the following persons in the capacities and on the dates indicated. Signature Title Date - --------- ----- ---- /s/ RANDALL E. WOODS President and Chief Executive Officer June 24, 1996 - ------------------------------------- (Principal Executive Officer) Randall E. Woods /s/ JOHN E. CRAWFORD Executive Vice President, Chief June 24, 1996 - ------------------------------------- Financial Officer and Secretary John E. Crawford (Principal Financial and Accounting Officer) /s/ DAVID S. KABAKOFF, PH.D.* Chairman of the Board of Directors June 24, 1996 - ------------------------------------- David S. Kabakoff, Ph.D. /s/ THOMAS S. EDGINGTON, M.D.* Director June 24, 1996 - ------------------------------------- Thomas S. Edgington, M.D. /s/ JOHN H. FRIED, PH.D.* Director June 24, 1996 - ------------------------------------- John H. Fried, Ph.D. /s/ THEODOR H. HEINRICHS* Director June 24, 1996 - ------------------------------------- Theodor H. Heinrichs /s/ M. BLAKE INGLE, PH.D.* Director June 24, 1996 - ------------------------------------- M. Blake Ingle, Ph.D. Director June 24, 1996 - ------------------------------------- Michael Sorell, M.D. /s/ W. LEIGH THOMPSON, JR. M.D.,PH.D* Director June 24, 1996 - ------------------------------------- W. Leigh Thompson, Jr., M.D., Ph.D. /s/ GERALD VAN ACKER* Director June 24, 1996 - ------------------------------------- Gerard Van Acker Director June 24, 1996 - ------------------------------------- Nicole Vitullo * By: /s/ JOHN E. CRAWFORD June 24, 1996 - ------------------------------------- John E. Crawford ATTORNEY-IN-FACT
II-7 INDEPENDENT AUDITORS' CONSENT We consent to the use of our report included herein and to the references to our firm under the headings "Selected Consolidated Financial Data" and "Experts" in the Prospectus. San Diego, California June 24, 1996 II-8 -----END PRIVACY-ENHANCED MESSAGE-----
\ No newline at end of file
diff --git a/parsed_sections/prospectus_summary/1996/CIK0000883232_c-m-life_prospectus_summary.txt b/parsed_sections/prospectus_summary/1996/CIK0000883232_c-m-life_prospectus_summary.txt
new file mode 100644
index 0000000000000000000000000000000000000000..c84cb3a58f02bb89866d4a04b004acf4a932f212
--- /dev/null
+++ b/parsed_sections/prospectus_summary/1996/CIK0000883232_c-m-life_prospectus_summary.txt
@@ -0,0 +1 @@
+SUMMARY THE CONTRACT The Panorama Plus Annuity is an individual and group flexible premium deferred annuity which can be purchased on a non-tax-qualified basis ("Non-qualified Contract") or with the proceeds from certain plans qualifying for favorable federal income tax treatment ("Qualified Contract"). The Contract Owner allocates Purchase Payments among two Investment Accounts of C.M. Life: the Panorama Plus Separate Account (the "Separate Account") and the General Account. PURCHASE PAYMENTS A Contract may be purchased with a minimum initial Purchase Payment of at least $500. From time to time, this minimum initial Purchase Payment may be changed. The Contract Owner may make additional Purchase Payments of at least $50 each at any time before the Annuity Income Date. Subsequent Purchase Payments allocated to the General Account are limited in amount, based in part on prior Purchase Payment allocations to that Account. (See "Purchase Payments," page ). THE PANORAMA PLUS INVESTMENT ACCOUNTS On the Contract Issue Date, the initial Net Purchase Payment is allocated among the Investment Accounts (that is, among the General Account and/or the Sub-Accounts of the Separate Account) in accordance with the allocation percentages specified by the Contract Owner in the Application. Allocation changes for subsequent Purchase Payments may be made by sending a Written Request to the Annuity Service Center. Allocation changes will be effective when the Annuity Service Center receives a Written Request. THE SEPARATE ACCOUNT. The Separate Account, a separate account of C.M. Life, invests in shares of various investment Portfolios of two mutual funds ("Funds"): the Panorama Series Fund, Inc. ("the Panorama Fund") and the Oppenheimer Variable Account Funds ("OVAF"). In addition to the Money Portfolio and the Bond Portfolio of OVAF, three (3) Portfolios of the Panorama Fund are currently available under the Contract: the Total Return Portfolio, the Growth Portfolio, and the International Equity Portfolio. Each of the five Sub-Accounts of the Separate Account invests solely in a corresponding Portfolio of a Fund. Because the Separate Account Balance will increase or decrease depending on the investment experience of the selected Sub-Accounts, the Contract Owner bears the entire investment risk with respect to Purchase Payments allocated to, and amounts transferred to, the Separate Account. (See "The Separate Account," page ). THE GENERAL ACCOUNT. The General Account provides for fixed accumulations and a specified interest rate on Purchase Payments allocated to, and amounts transferred to, the General Account. The interest rate will be reset periodically, currently quarterly, at the sole discretion of C.M. Life. The General Account Balance may be subject to an Interest Rate Factor Adjustment upon Surrender and on the Annuity Income Date. (See "Interest Rate Adjustment Factor," page ). The Interest Rate Factor Adjustment does not apply to Contracts issued to Pennsylvania residents. Because of this adjustment and for other reasons, the amount payable upon Surrender, or applied to Annuity Income payments, may be more or less than the General Account Balance at that time, and more or less than the total Purchase Payments allocated to and amounts transferred to the General Account. Thus, the Contract Owner bears certain investment risk with respect to the General Account Balance. (See "The General Account," page ). TRANSFERS The Contract Owner may transfer amounts from one Investment Account or Sub-Account to another Investment Account or Sub-Account, with certain limitations, during the Accumulation Period (I.E., prior to the Annuity Income Date). The Beneficiary may exercise this right if a Death Benefit has become payable. The minimum transfer amount is $100. In addition, the total of all transfers to or from the General Account during any Contract Year is limited to the greater of (a) 30% of the General Account Balance as of the end of the immediately preceding Contract Year, or (b) $25,000. Additional limitations apply to transfers to or from the General Account and the Money Sub-Account. (See "Transfers," page ). 7 During the Annuity Period (I.E., after the Annuity Income Date), a portion of the Separate Account Balance may be transferred from one Sub-Account to any other Sub-Account once during any Contract Year. Transfers to or from the General Account are not permitted during the Annuity Period. (See "Transfers," page ). DOLLAR COST AVERAGING There are three Dollar Cost Averaging options available to the Contract Owner. First, the Contract Owner may elect to transfer fixed dollar amounts at regular intervals from one Sub-Account to another Sub-Account, and to change the fixed dollar amount and the Sub-Accounts selected. As a second option, the Contract Owner may elect to transfer fixed dollar amounts from the General Account to Sub-Accounts (other than the Money Sub-Account). Total transfers from the General Account are limited in the Contract Year of the initial Purchase Payment to the greater of: (i) 30% of the initial Purchase Payment; or (ii) $25,000. In subsequent Contract Years, total transfers from the General Account are limited to the greater of: (i) 30% of the General Account Balance as of the end of the immediately preceding Contract Year; or (ii) $25,000. The timing of the election of this option is restricted. As a third option, the Contract Owner may elect to transfer the credited interest of the General Account at specified intervals to one or more of the Sub-Accounts (other than the Money Sub-Account). A General Account Balance of at least $5,000 must be available at the time of each transfer. Only one Dollar Cost Averaging option may be in effect at any one time. There currently is no charge for Dollar Cost Averaging. However, the Company reserves the right to charge for Dollar Cost Averaging in the future. The Contract Owner may not simultaneously participate in both Dollar Cost Averaging and Systematic Withdrawals. Changes in the Dollar Cost Averaging option may only be made by Written Request from the Contract Owner to terminate the existing Dollar Cost Averaging option, accompanied by a Written Request identifying the new Dollar Cost Averaging option selected. For more details on "Dollar Cost Averaging," see page . SURRENDERS The Contract Owner may elect to Surrender all or a portion ($100 minimum per partial surrender) of the Contract Balance in exchange for a cash payment from C.M. Life at any time during the Accumulation Period and prior to payment of the Death Benefit. Following any partial Surrender, the Contract Balance must be at least $250. Partial Surrenders may be withdrawn from both the General Account Balance and the Separate Account Balance. Partial and full Surrenders are subject to any applicable Surrender Charge, Interest Rate Factor Adjustment, and Contract Maintenance Fee. There is currently no limit on the frequency or timing of Surrenders. (See "Surrenders," page .). Please note, federal income taxes and a tax penalty may be applicable. (See "CERTAIN FEDERAL INCOME TAX CONSEQUENCES," page .) THERE IS NO GUARANTEED OR MINIMUM SURRENDER VALUE, SO REGARDLESS OF THE EXTENT TO WHICH PURCHASE PAYMENTS ARE ALLOCATED TO THE SEPARATE ACCOUNT OR TO THE GENERAL ACCOUNT, THE PROCEEDS OF A FULL SURRENDER (THAT IS, THE SURRENDER VALUE) COULD BE LESS THAN THE TOTAL PURCHASE PAYMENTS. SYSTEMATIC WITHDRAWALS Upon Written Request, the Contract Owner may elect Systematic Withdrawals ($100 minimum per withdrawal) to begin on or after the first anniversary of the Contract Issue Date during the Accumulation Period. There is currently no charge for Systematic Withdrawals. However, the Company reserves the right to charge for Systematic Withdrawals in the future. The Contract Owner may not simultaneously participate in both Systematic Withdrawals and Dollar Cost Averaging. Systematic Withdrawals changes may only be made by Written Request from the Contract Owner to terminate the existing Systematic Withdrawals program accompanied by a Written Request identifying the new Systematic Withdrawals election. (See page .) Systematic Withdrawals may result in tax liabilities. See "Certain Federal Income Tax Consequences," page . 8 TERMINAL ILLNESS BENEFIT In the event that a Contract Owner becomes terminally ill during the Accumulation Period and prior to age 75, the Contract Owner may elect, unless prohibited by law, by submission of a Written Request, a Terminal Illness Benefit equal to the greater of (a) the Purchase Payments less any prior withdrawals and charges; or (b) the Contract Balance. (See "Terminal Illness Benefit," page .) DEATH BENEFIT In the event that the Contract Owner or Annuitant dies prior to the Annuity Income Date, a Death Benefit is payable upon receipt of satisfactory proof of death of the Contract Owner or the Annuitant, an election of the Death Benefit Option and return of the Contract. The Death Benefit will at least equal the Contract Balance at the time of payment. No Surrender Charge, Interest Rate Factor Adjustment, or Contract Maintenance Fee is imposed upon amounts received as a Death Benefit. (If the Annuitant dies before the Contract Owner and there is a Contingent Annuitant who is less than 85 years of age on the Annuitant's date of death, and such Contract Owner is a natural person, no Death Benefit is payable, and the Contract continues in force, with the Contingent Annuitant becoming the Annuitant.) (See "Death Benefit," page .) CHARGES AND DEDUCTIONS SURRENDER CHARGE. To help defray sales expenses a 5% Surrender Charge will be deducted from the Contract Balance in the event of any partial or full Surrender during the first five (5) Contract Years. However, beginning in the second Contract Year, a Free Surrender Amount, equal to 10% of the Contract Balance as of the end of the immediately preceding Contract Year, will be exempt from any Surrender Charge (and any Interest Rate Factor Adjustment see below). In addition, no Surrender Charge or Interest Rate Factor Adjustment is imposed on partial or full Surrenders during the Window Period, which is the last thirty (30) days of each Five-Year Period. C.M. LIFE GUARANTEES THAT THE AGGREGATE SURRENDER CHARGE WILL NEVER EXCEED 8.5% OF THE TOTAL PURCHASE PAYMENTS MADE UNDER THE CONTRACT. (See "Surrender Charge," page .) INTEREST RATE FACTOR ADJUSTMENT. An Interest Rate Factor Adjustment may be applied in the event of any partial or full Surrender of the General Account Balance during the Accumulation Period, and on the Annuity Income Date (if the General Account Balance is applied to a Variable Annuity Option). The Interest Rate Factor Adjustment does not apply to amounts invested in the Separate Account or to Contracts issued to Pennsylvania residents. The Interest Rate Factor Adjustment may be positive or negative. It is based on interest rates payable on U.S. Treasury securities. In general, if rates on U.S. Treasury securities are higher when you Surrender than when you made the applicable Purchase Payments (or up to .30% lower), a negative Interest Rate Factor Adjustment may be applied, and on a full Surrender of your General Account Balance, you could receive an amount lower than the amount of Purchase Payments made (even for Purchase Payments allocated to the General Account). However, if rates on U.S. Treasury securities are more than .30% lower when you Surrender than when you made the applicable Purchase Payments, a positive Interest Rate Factor Adjustment may be applied, and on a full Surrender of your General Account Balance, you could receive an amount higher than the amount of Purchase Payments made, plus interest. (For partial Surrenders of the General Account Balance, the Interest Rate Factor Adjustment will be added to or subtracted from the remaining General Account Balance.) No Interest Rate Factor Adjustment will be applied during the Window Period; in addition, no Interest Rate Factor Adjustment will be applied to the General Account Free Surrender Amount. (See "Interest Rate Factor Adjustment," page .) SEPARATE ACCOUNT CHARGES. C.M. Life deducts a daily charge equal to a percentage of the net assets in the Separate Account for the mortality and expense risks assumed by C.M. Life under the Contracts. The effective annual rate of this charge currently is 1.07%. It may increase but it will not exceed an effective annual rate of 1.25% of the average daily value of the Separate Account's net assets. (See "Mortality and Expense Risk Charge," page .) C.M. Life also deducts a daily Administrative Expense Charge from the net assets of each of the Sub-Accounts of the Separate Account to partially cover expenses incurred by C.M. Life in connection with the administration of the Separate Account and the Contract. This charge is currently at an effective annual 9 rate of 0.07% and it may increase, but the annual charges for mortality and expense risks and administrative expenses are guaranteed not to exceed an effective annual rate of 1.50% of the daily value of the Separate Account's net assets. (See "Administrative Expense Charge," page .) CONTRACT CHARGES. There is also an annual Contract Maintenance Fee imposed each year for Contract maintenance and related administrative expenses. This charge is currently $30 per Contract. It will be calculated as a pro rata portion of the balance of each Sub-Account and the General Account, and deducted from the Contract Balance on the last day of each Contract Year during the Accumulation Period, and upon Full Surrender of the Contract. For Contracts issued to Pennsylvania residents, the Fee will be calculated as a pro rata portion of the balance of each Sub-Account. The Contract Maintenance Fee may increase but it will not exceed $60 per Contract Year. (See "Contract Maintenance Fee," page .) TAXES. C.M. Life may incur Premium Taxes relating to the Contracts. Depending upon applicable state law, C.M. Life will deduct any Premium Taxes related to a particular Contract from Purchase Payments, from the Contract Balance upon Surrender, or on the Annuity Income Date. (See "Premium Taxes," page .) No charges are currently made against the Sub-Accounts for federal, state, or local taxes other than Premium Taxes. However, C.M. Life may deduct charges for such taxes in the future. (See "Federal, State and Local Taxes," page .) CHARGES AGAINST THE FUNDS. The value of the net assets of the Sub-Accounts of the Separate Account will reflect the investment advisory fee and other expenses incurred by the Portfolios of the Funds. EXPENSE DATA. The charges and deductions explained above are summarized in the following table. This tabular information regarding expenses assumes that the entire Contract Balance is in the Separate Account. MONEY TOTAL INTERNATIONAL MARKET(2) INCOME(3) RETURN GROWTH EQUITY ----------- ----------- --------- ----------- --------------- CONTRACT OWNER TRANSACTION EXPENSES(1) Sales Load On Purchase Payments.......... 0 0 0 0 0 Maximum Surrender (as a % of Contract Balance Surrendered)(4)........................ 5% 5% 5% 5% 5% ------------------------------------------------ Annual Contract Maintenance Fee.......... $30 Per Contract Transfer Fee............................. Currently No Fee ------------------------------------------------ SEPARATE ACCOUNT ANNUAL EXPENSES (AS A PERCENTAGE OF ACCOUNT VALUE) Mortgage and Expense Risk Charge......... 1.07% 1.07% 1.07% 1.07% 1.07% Administrative Expense Charge............ 0.07% 0.07% 0.07% 0.07% 0.07% ----------- ----------- --------- ----------- ------ Total Separate Account Annual Expenses... 1.14% 1.14% 1.14% 1.14% 1.14% ----------- ----------- --------- ----------- ------ PORTFOLIO ANNUAL EXPENSES(5) (AS A PERCENTAGE OF AVERAGE NET ASSETS) Management Fees.......................... 0.45% 0.75% 0.553% 0.613% 0.98% Other Expenses........................... 0.06% 0.05% 0.037% 0.047% 0.28% ----------- ----------- --------- ----------- ------ Total Portfolio Annual Expenses.......... 0.51% 0.80% 0.59% 0.66% 1.26% ----------- ----------- --------- ----------- ------ ----------- ----------- --------- ----------- ------
(1) In addition to the Contract Owner transaction expenses reflected in the table, an Interest Rate Factor Adjustment is applied to the amount of General Account Balance under the Contract subject to full or partial Surrender during the Accumulation Period, and on the Annuity Income Date (if the General Account Balance is applied to a Variable Annuity Option), unless the amount surrendered is a Free Surrender Amount, or the Surrender is made during a Window Period (the Adjustment does not apply to Contracts issued to Pennsylvania residents). The Interest Rate Factor Adjustment may increase or decrease the General Account Balance Surrender proceeds. 10 (2) Prior to May 1, 1996, the Money Market Sub-Account was invested in the Money Market Portfolio of the Panorama Fund. The management fee, other expenses and total portfolio annual expenses for the Money Market Portfolio for the fiscal year ended December 31, 1995 were 0.50%, 0.07% and .0.57%, respectively. On May 1, 1996, after receiving an order from the SEC approving the transaction C.M. Life redeemed the shares of the Money Market Portfolio of the Panorama Fund and purchased shares of the Money Fund of OVAF with the proceeds. (3) Prior to May 1, 1996, the Government Securities and Income Sub-Accounts of the Separate Account were invested in the corresponding Portfolios of the Panorama Fund. The management fee, other expenses and total portfolio annual expenses for the fiscal year ended December 31, 1995 for the Government Securities Portfolio were 0.554%, 0.156% and 0.71%, respectively and for the Income Portfolio were 0.59%, 0.06%, and 0.65%, respectively. On May 1, 1996, after receiving an order from the SEC approving the transaction, C.M. Life redeemed the shares of the Government Securities and Income Portfolios of the Panorama Fund and purchased shares of the Bond Portfolio of OVAF with the proceeds. Immediately following the substitution, the assets of the Government Securities Sub-Account were transferred to the Income Sub-Account, thereby consolidating the Government Securities Sub-Account into the Income Sub-Account. (4) The Surrender Charge is not applicable after the fifth anniversary of the Contract Issue Date. (5) The Portfolio expenses are actual expenses for each Portfolio for the fiscal year ended December 31, 1995. 11 EXAMPLES The Contract Owner would pay the following expenses on a $1,000 investment, assuming a 5% annual return on assets (and assuming the entire Contract Balance is allocated to the Separate Account). 1. If the Contract is surrendered at the end of the applicable time period: 1 YEAR 3 YEARS 5 YEARS 10 YEARS ------ ------- ------- -------- Money Market Sub-Account.................... $69.84 $106.03 $ 97.03 $210.49 Income Sub-Account.......................... $72.73 $114.80 $112.55 $242.24 Total Return Sub-Account.................... $70.64 $108.46 $101.33 $219.34 Growth Sub-Account.......................... $71.34 $110.57 $105.08 $227.03 International Equity Sub-Account............ $77.32 $128.60 $136.78 $290.72
2. If the Contract is not surrendered or annuitized: 1 YEAR 3 YEARS 5 YEARS 10 YEARS ------ ------- ------- -------- Money Market Sub-Account.................... $18.21 $ 56.39 $ 97.03 $210.49 Income Sub-Account.......................... $21.25 $ 65.61 $112.55 $242.24 Total Return Sub-Account.................... $19.05 $ 58.94 $101.33 $219.34 Growth Sub-Account.......................... $19.78 $ 61.16 $105.08 $227.03 International Equity Sub-Account............ $26.08 $ 80.12 $136.78 $290.72
The above table and examples are intended to assist the Contract Owner in understanding the costs and expenses that will be borne, directly or indirectly, by Purchase Payments allocated to the Separate Account. The table and examples reflect the charges and expenses anticipated for the Separate Account and reflect the actual expenses for each Portfolio for the 1995 fiscal year. For a more complete description of the various charges and expenses described in the table and examples, see "Charges and Deductions," page , and the prospectus for each Fund. In addition to the expenses listed above, Premium Taxes may be applicable. THE EXAMPLES SHOULD NOT BE CONSIDERED A REPRESENTATION OF PAST OR FUTURE EXPENSES, AND ACTUAL EXPENSES MAY BE GREATER OR LESSER THAN THOSE SHOWN. 12 PANORAMA PLUS SEPARATE ACCOUNT OF C.M. LIFE INSURANCE COMPANY CONDENSED FINANCIAL INFORMATION The audited financial statements for the year ended December 31, 1995 and the period from inception (May 13, 1992) to December 31, 1995 are included in the Statement of Additional Information, which is incorporated by reference in this Prospectus. ACCUMULATION UNIT VALUES DEC. 31, DEC. 31, DEC. 31, DEC. 31, 1992(A) 1992 1993 1994 1995 --------- --------- --------- ---------- ---------- SUB-ACCOUNT Money Market $1.000000 $1.012022 $1.027456 $1.054570 $1.100599 Government Securities(b) $1.000000 $1.061901 $1.158653 $1.095471 $1.281804 Income $1.000000 $1.060916 $1.174260 $1.114759 $1.306525 Total Return $1.000000 $1.058946 $1.217379 $1.186187 $1.460595 Growth $1.000000 $1.064372 $1.276534 $1.258146 $1.711382 International Equity $1.000000 $0.950887 $1.146031 $1.145014 $1.251930 ACCUMULATION UNITS OUTSTANDING Money Market 681,553 3,136,932 13,603,045 16,949,501 Government Securities(b) 2,152,739 8,444,505 11,994,574 13,726,057 Income 2,564,029 12,281,025 16,488,930 20,617,764 Total Return 12,316,597 71,182,538 147,324,713 194,679,349 Growth 2,798,378 19,370,204 49,636,052 83,371,008 International Equity 742,623 5,578,969 22,419,639 31,322,974
(a) Commencement of operations for the Sub-Accounts occurred on May 13, 1992. (b) Prior to May 1, 1996, the Government Securities Sub-Account was offered as part of the Separate Account and, accordingly, is included in the Condensed Financial Information and financial statements. However, the Government Securities Sub-Account is no longer available for investment. RIGHT TO RETURN THE CONTRACT No Surrender Charge will be applied if the Contract Owner returns the Contract to the Annuity Service Center for cancellation during the first fifteen (15) calendar days following the Contract Issue Date (or a longer period, if required by law). Upon return of the Contract during this period, C.M. Life will refund the Separate Account Balance and any Purchase Payments made to the General Account. If required by state law, C.M. Life will refund all Purchase Payments received upon cancellation of the Contract. FEDERAL INCOME TAX CONSEQUENCES OF INVESTMENT IN THE CONTRACT With respect to Contract Owners who are natural persons, there should be no federal income tax on increases in the Contract Balance (if any) until a distribution under the Contract occurs (E.G., a Surrender or Annuity Income payment) or is deemed to occur (E.G., a pledge or assignment of a Contract). Generally, a portion of any distribution or deemed distribution will be taxable as ordinary income. The taxable portion of certain distributions will be subject to withholding unless the recipient elects otherwise. In addition, a penalty tax may apply to certain distributions or deemed distributions under the Contract. (See "CERTAIN FEDERAL INCOME TAX CONSEQUENCES," page .) 13 INQUIRIES AND WRITTEN NOTICES AND REQUESTS Any questions about procedures or the Contract, or any Written Request required to be directed to C.M. Life, should be sent to Annuity Service Center, 140 Garden Street, Mail Station 305, Hartford, CT 06154. Telephone requests and inquiries may be made by calling 1-800-234-5606. All inquiries and Written Requests should include the Contract number, the Contract Owner's name and the Annuitant's name. VARIATIONS IN CONTRACT PROVISIONS Certain provisions of the Contracts may vary from the descriptions in this Prospectus in order to comply with different state laws. Any such variations will be included in the Contract itself or in riders or endorsements. Note: The foregoing summary is qualified in its entirety by the detailed information in the remainder of this Prospectus, in the Statement of Additional Information, in the prospectus for each Fund, and in the Contract, all of which should be referred to for more detailed information. This Prospectus generally describes only the Contract, the Separate Account and the General Account. A separate prospectus attached hereto describes each Fund. C.M. LIFE INSURANCE COMPANY C.M. Life, 140 Garden Street, Hartford, Connecticut 06154, is a stock life insurance company. It was chartered by a special Act of the Connecticut General Assembly on April 25, 1980. It is principally engaged in the sale of life insurance and annuities, and is licensed in all states except New York. C.M. Life is a wholly-owned subsidiary of Massachusetts Mutual Life Insurance Company ("MassMutual"). MassMutual is a mutual life insurance company specially chartered by the Commonwealth of Massachusetts on May 14, 1851. It is currently licensed to transact life (including variable life), accident, and health insurance business in all states, the District of Columbia and certain provinces of Canada. As of March 1, 1996, MassMutual had total assets of $50 billion. Prior to February 29, 1996, C.M. Life was a wholly-owned subsidiary of Connecticut Mutual Life Insurance Company ("Connecticut Mutual"). On February 29, 1996, Connecticut Mutual merged with and into MassMutual. Connecticut Mutual was a mutual life insurance company originally chartered by a special act of the Connecticut General Assembly in 1846. Upon the merger, Connecticut Mutual's existence ceased and MassMutual became the surviving company under the name Massachusetts Mutual Life Insurance Company. In approving the merger, the boards of directors of MassMutual and Connecticut Mutual determined that the merger would result in a combined company that would be stronger and more efficient and therefore more competitive than either MassMutual or Connecticut Mutual alone. On January 26, 1996, 95.76% of the policyholders of MassMutual and 95.75% of the insured of MassMutual, each voting as a separate class, voted to approve the merger. On January 27, 1996, 94.0% of the policyholders of Connecticut Mutual and 94.27% of the members of Connecticut Mutual, each voting as a separate class, voted to approved the merger. In addition, the Connecticut Insurance Department and the Massachusetts Division of Insurance approved the merger. The merger did not affect any provisions of, or rights or obligations under, the Contracts issued by C.M. Life. For more information about C.M. Life, see "ADDITIONAL INFORMATION ABOUT C.M. LIFE," page . 14 THE PANORAMA PLUS ANNUITY CONTRACT The Panorama Plus Annuity Contract is an individual and group Flexible Premium Deferred Annuity Contract. In certain states the Contract is only available as a group contract. In these states, a Certificate (also referred to herein as a "Contract"), which summarizes the provisions of the group contract under which the Certificate is issued, is issued to individuals. The rights and benefits under the Contract are summarized below. However, the description of the Contract contained in this Prospectus is qualified in its entirety by the Contract itself, a copy of which is available upon request from C.M. Life. The Contract may be purchased on a non-tax-qualified basis ("Non-qualified Contract"). The Contract may also be purchased and used in connection with retirement plans or individual retirement accounts that qualify for favorable federal income tax treatment ("Qualified Contract"). Group contracts may be issued to any employer, entity, or other group acceptable to C.M. Life. An eligible member of a group to which a group contract has been issued may become a participant by completing an Application and forwarding an initial Purchase Payment to C.M. Life. The rights and benefits of a participant under a group contract are summarized in a certificate issued to the participant. Provisions of the group contract are controlling. All rights and benefits may be exercised by the participant without the consent of the group contract owner. Unless otherwise stated, the rights and benefits of an owner of an Individual Panorama Plus Annuity and an owner of a certificate under a group Panorama Plus Annuity are the same. Accordingly, as used herein, the term "Contract" means either an individual annuity or a certificate under a group annuity, depending on the state where it is issued. THERE IS NO GUARANTEED OR MINIMUM SURRENDER VALUE UNDER THE CONTRACT, SO THE AMOUNT RECEIVED ON SURRENDER COULD BE LESS THAN THE AMOUNT OF PURCHASE PAYMENTS. CONTRACT APPLICATION AND ISSUANCE OF CONTRACTS Before it will issue a Contract, C.M. Life must receive a completed Application and an initial Purchase Payment of at least $500. From time to time, this initial Purchase Payment may be reduced. C.M. Life reserves the right to reject any Application or Purchase Payment. If the Application is properly completed and can be accepted in the form received, any initial Net Purchase Payment will be credited to the Contract Balance within two (2) business days after the later of receipt of the Application or receipt of the initial Purchase Payment at the Annuity Service Center. (The Net Purchase Payment is the total Purchase Payment less any applicable Premium Tax.) If the initial Net Purchase Payment allocated to the Separate Account cannot be credited because the Application or other issuing requirements are incomplete, the applicant will be contacted within five (5) business days and given an explanation for the delay, and the initial Purchase Payment will be returned at that time unless the applicant consents to C.M. Life's retaining the initial Purchase Payment and crediting it as soon as the necessary requirements are fulfilled. The date on which the initial Net Purchase Payment is credited to the Contract Balance is the Contract Issue Date. The Contract Issue Date is the date used to determine Contract Years and Contract anniversaries. The Contract Owner may return the Contract for cancellation during the first fifteen (15) calendar days following the Contract Issue Date (or a longer period, if required by law). Upon return of the Contract, C.M. Life will refund the Separate Account Balance (as of the date the returned Contract and cancellation request are received in good order at the Annuity Service Center) and any Purchase Payments allocated to the General Account. For Contracts issued in the States of North Carolina, South Carolina or Washington, C.M. Life will refund all Purchase Payments received upon cancellation of the Contract during this period. ELECTRONIC DATA TRANSMISSION OF APPLICATION INFORMATION. C.M. Life will accept, by agreement with certain broker-dealers, electronic data transmissions of Application information, along with wire transmittals of 15 initial Purchase Payments, from these broker-dealers to the Annuity Service Center for purchase of the Contract. Please contact the Annuity Service Center to receive more information about electronic data transmission of Application information. PURCHASE PAYMENTS All Purchase Payment checks or drafts should be made payable to C.M. Life Insurance Company and sent to the Annuity Service Center. INITIAL PURCHASE PAYMENT. The minimum initial Purchase Payment that C.M. Life currently will accept under a Contract is $500. C.M. Life reserves the right to increase or decrease this amount for Contracts issued after some future date. The initial Purchase Payment is the only Purchase Payment required to be paid under a Contract. However, this initial Purchase Payment may be waived in the case of certain salary reduction/employer contribution arrangements or Automatic Investment Plans, in which case the minimum contribution will be $40 per month per participant. ADDITIONAL PURCHASE PAYMENTS. Before a Death Benefit has become payable and prior to the Annuity Income Date, the Contract Owner may make additional Purchase Payments at any time, and in any frequency. The minimum additional Purchase Payment is $50. If the Annuitant is age 76 or older as of the Contract Issue Date, cumulative Purchase Payments under the Contract may not exceed $500,000. If the Annuitant is younger than age 76 as of the Contract Issue Date, cumulative Purchase Payments may not exceed $1,000,000 without the prior consent of C.M. Life. ALLOCATION OF PURCHASE PAYMENTS. The Contract Owner must allocate Purchase Payments to one or more of the Sub-Accounts or to the General Account, or some combination thereof. The Contract Owner must specify the initial allocation in the Application. This allocation will be used for additional Purchase Payments unless the Contract Owner requests a change of allocation. If the Contract Owner fails to specify how Purchase Payments are to be allocated, the Purchase Payment(s) cannot be accepted. Additional Purchase Payments allocated to the Separate Account will be credited to the Contract and added to the Contract Balance as of the Valuation Period when they are received. Purchase Payments allocated to the General Account will be credited with interest from the day after deposit. After the first Contract Year, the Purchase Payments allocated to the General Account during any Contract Year may not exceed the greater of: (i) 125% of the average annual Purchase Payments allocated to the General Account during the last five (5) full Contract Years (or all years, if less than five (5)); or (ii) $25,000. This restriction does not apply during the Window Period. The Contract Owner may change the allocation instructions for future Purchase Payments by sending a Written Request, signed by such Contract Owner, to the Annuity Service Center. The allocation change will apply to Purchase Payments received with the Written Request and after the Valuation Period in which the Written Request is received. PAYMENT NOT HONORED BY BANK. Any payment due under the Contract which is derived, all or in part, from any amount paid to C.M. Life by check or draft may be postponed until such time as C.M. Life determines that such check or draft has been honored. CONTRACT BALANCE On the Contract Issue Date, the accepted Contract Balance equals the initial Net Purchase Payment. Thereafter, the Contract Balance equals the sum of the Separate Account Balance and the General Account Balance. The Contract Balance will increase by (1) any additional Purchase Payments accepted by C.M. Life, and (2) any increases in the Contract Balance due to investment results of the selected Investment Account or Sub-Account. The Contract Balance will decrease by (1) any Surrenders, including applicable charges, 16 (2) any decreases in the Contract Balance due to investment results of the selected Sub-Accounts, and (3) charges imposed by C.M. Life. The Interest Rate Factor Adjustment imposed upon partial Surrenders may also increase or decrease the remaining Contract Balance. The Contract Balance is expected to change from Valuation Period to Valuation Period, reflecting the investment experience of the selected Sub-Account(s), as well as deductions for charges. A Valuation Period is the period between successive Valuation Dates. It begins at the close of business on each Valuation Date and ends at the close of business on the next succeeding Valuation Date. Holidays are generally not Valuation Dates. THE SEPARATE ACCOUNT BALANCE. When a Net Purchase Payment is allocated to, or an amount is transferred to, a Sub-Account of the Separate Account, it is credited to the Contract in the form of Accumulation Units. Each Sub-Account of the Separate Account has a distinct Accumulation Unit value. The number of Accumulation Units credited is determined by dividing the Net Purchase Payment, or amount transferred, by the dollar value of one Accumulation Unit of the Sub-Account as of the end of the Valuation Period during which the allocation is made. When amounts are transferred out of, or Surrendered from, a Sub-Account, Accumulation Units are cancelled or redeemed in a similar manner. For each Sub-Account, the Accumulation Unit value for a given Valuation Period is based on the net asset value of a share of the corresponding Portfolio of Series Fund I. Therefore, the Accumulation Units will fluctuate in value from day to day based on the investment experience of the corresponding Portfolio, and the Separate Account Balance will decrease or increase to reflect the investment performance of the corresponding Portfolio. The Separate Account Balance also reflects expenses borne by the Portfolio(s) and the deduction of certain charges. The determination of Sub-Account Accumulation Unit values is described in detail in the Statement of Additional Information. THE GENERAL ACCOUNT BALANCE. When a Net Purchase Payment is allocated or an amount is transferred to the General Account, it is credited to the General Account Balance. In addition, interest at a specified interest rate is credited to the General Account Balance. When amounts are transferred out of, or Surrendered from, the General Account, the General Account Balance is reduced accordingly. Unlike the Separate Account, there are no Accumulation Units in the General Account. (See "The General Account," page .) MINIMUM CONTRACT BALANCE. A minimum Contract Balance of $250 must be maintained during the Accumulation Period. If the Contract Owner fails to maintain the minimum Contract Balance, then C.M. Life may, upon sixty (60) days notice, terminate the Contract, and return the Contract Balance, minus any applicable fees or charges, to the Contract Owner. If the Contract Owner makes sufficient Purchase Payments to restore the Contract Balance to the minimum Contract Balance within sixty (60) days of the date of notice, the Contract will continue in force. PANORAMA PLUS INVESTMENT ACCOUNTS Purchase Payments paid under a Contract may be allocated to one or more of the five Sub-Accounts of the Separate Account, to the General Account, or to a combination of these Investment Accounts. There is no guaranteed or minimum Surrender Value for any Purchase Payments, or with respect to amounts allocated to any Investment Account. THE SEPARATE ACCOUNT PANORAMA PLUS SEPARATE ACCOUNT. The Panorama Plus Separate Account of C.M. Life Insurance Company (the "Separate Account") was established as a separate account under the laws of the State of Connecticut, on September 25, 1991. The Separate Account will receive and invest the Net Purchase Payments under the Contracts that are allocated to it as well as amounts transferred to it in shares of two 17 mutual funds ("Funds"): the Panorama Series Fund, Inc. (the "Panorama Fund") (formerly known as Connecticut Mutual Financial Services Series Fund I, Inc.) and the Oppenheimer Variable Account Funds ("OVAF"). The Separate Account currently is divided into five (5) Sub-Accounts. Additional Sub-Accounts may be established in the future at the discretion of C.M. Life. Each Sub-Account invests exclusively in shares of a corresponding Portfolio of the Funds. Prior to May 1, 1996, the Money Market Sub-Account, the Government Securities Sub-Account and the Income Sub-Account were invested in shares of the corresponding Portfolios of the Panorama Fund. On May 1, 1996, after receiving an order from the SEC approving the transaction, C.M. Life redeemed the shares of the Money Market Portfolio held by the Money Market Sub- Account and purchased shares of the Money Portfolio with the proceeds. On that date, C.M. Life also redeemed shares of the Government Securities Portfolio and the Income Portfolio held by the Government Securities and Income Sub-Accounts and purchased shares of the Bond Portfolio with the proceeds. Immediately following the substitution of shares, the assets of the Government Securities Sub-Account were transferred to the Income Sub-Account, thereby consolidating the Government Securities Sub-Account into the Income Sub-Account. The portfolio substitutions and sub-account consolidation took place at net asset value with no change in the amount of any Contract Owner's death benefit or dollar value of his or her investment in the Separate Account. C.M. Life and its affiliates did not receive any compensation or remuneration as a result of this transaction. Under Connecticut law, the assets of the Separate Account are owned by C.M. Life, but they are held separately from the other assets of C.M. Life, and are not chargeable with liabilities incurred in any other business operation of C.M. Life (except to the extent that assets in the Separate Account exceed the reserves and other liabilities of the Separate Account). Income, gains, and losses incurred on the assets in the Sub-Accounts of the Separate Account, whether or not realized, are credited to or charged against that Sub-Account, without regard to other income, gains or losses of any other Investment Account or Sub-Account of C.M. Life. Therefore, the investment performance of any Sub-Account is entirely independent of the investment performance of C.M. Life's general account assets or any other separate account maintained by C.M. Life. The Contract Owner bears the entire investment risk with respect to the Contract Balance allocated to the Separate Account, and the Separate Account Balance will be more or less than the total of the Net Purchase Payments allocated to, and transfers into, the Separate Account. The Separate Account is registered with the Securities and Exchange Commission (the "SEC") under the Investment Company Act of 1940, as amended, (the "1940 Act") as a unit investment trust. It meets the definition of a "separate account" under the federal securities laws. However, the SEC does not supervise the management or the investment practices or policies of the Separate Account or of C.M. Life. THE FUNDS. The Separate Account will invest exclusively in shares of the Panorama Fund and OVAF ("Funds"), each of which is a series-type mutual fund registered with the SEC under the "1940 Act" as an open-end, diversified management investment company. In addition to the Money Portfolio and Bond Portfolio of OVAF, three (3) Portfolios of the Panorama Fund are currently available under the Contract: the Total Return Portfolio, the Growth Portfolio, and the International Equity Portfolio. The assets of each Portfolio are held separately from the assets of the other Portfolios, and each Portfolio has its own distinct investment objective and policies. Each Portfolio operates as a separate investment fund, and the income or losses of one Portfolio have no effect on the investment performance of any other Portfolio. 18 The investment objective of each of the available Portfolios is stated as follows: Money Seeks the maximum current income from investments in "money market" Portfolio securities consistent with low capital risk and the maintenance of liquidity. There can be no assurance that the Money Portfolio will maintain a stable net asset value per share of $1, and the Money Portfolio is not insured or guaranteed by the U.S. Government. Bond Seeks a high level of current income from investments in high-yield, Portfolio fixed-income securities rated "Baa" or better by Moody's or "BBB" or better by Standard & Poor's. As a secondary investment objective, the Bond Fund seeks capital growth when consistent with its primary objective. Total Return Seeks to maximize the total investment return (including capital Portfolio appreciation and income) by allocating its assets among stocks, corporate bonds, securities issued by the U.S. Government and its instrumentalities, and money market instruments according to changing market conditions. Growth Seeks long-term growth of capital by investing primarily in common stocks Portfolio with low price-earnings ratios and better than anticipated earnings. Realization of income is a secondary consideration. International Seeks to provide long-term growth of capital by investing, under normal Equity market conditions, at least 90% of its assets in equity securities (such as Portfolio common stocks) of companies whose primary stock market is outside the U.S.
OppenheimerFunds, Inc. ("OFI"), an investment adviser registered with the SEC under the Investment Advisers Act of 1940, as amended, ("Investment Advisers Act") is the investment adviser to the Funds. OFI has operated as an investment adviser since 1959 and, including a subsidiary, manages investment companies with more than $50 billion in assets and nearly 3 million shareholder accounts. OFI is owned by Oppenheimer Acquisition Corp., a holding company that is owned in part by senior officers of OFI and controlled by MassMutual. The address of OFI is Two World Trade Center, New York, NY 10048-0203. Babson-Stewart Ivory International ("Babson-Stewart") provides sub-advisory services to the International Equity Portfolio pursuant to a sub-advisory agreement between Babson-Stewart and OFI. Babson-Stewart is located at One Memorial Drive, Cambridge, MA 02142, and is a parntership formed in 1987 between David L. Babson & Co., Inc., a subsidiary of MassMutual, and Stewart Ivory & Co., Ltd., located in Edinburgh, Scotland. THERE IS NO ASSURANCE THAT ANY PORTFOLIO WILL ACHIEVE ITS STATED OBJECTIVE. MORE DETAILED INFORMATION, INCLUDING A DESCRIPTION OF EACH PORTFOLIO'S INVESTMENT OBJECTIVE AND POLICIES AND A DESCRIPTION OF RISKS INVOLVED IN INVESTING IN EACH OF THE PORTFOLIOS AND OF EACH PORTFOLIO'S FEES AND EXPENSES IS CONTAINED IN THE PROSPECTUS FOR THE FUNDS, A CURRENT COPY OF WHICH IS ATTACHED TO THIS PROSPECTUS. INFORMATION CONTAINED IN THE PROSPECTUSES FOR THE FUNDS SHOULD BE READ CAREFULLY BEFORE MAKING ALLOCATIONS TO A SUB-ACCOUNT OF THE SEPARATE ACCOUNT. THE GENERAL ACCOUNT The General Account is made up of all of the assets of C.M. Life other than those allocated to any separate account. Purchase Payments will be allocated to the General Account to the extent elected by the Contract Owner at the time of the initial Purchase Payment or as subsequently elected. In addition, all or part of the Separate Account Balance may be transferred to the General Account as described under "Transfers." Assets supporting amounts allocated to the General Account become part of C.M. Life's general account assets and are available to fund the claims of all classes of customers, policy owners and other creditors of C.M. Life. Interests under the Contract relating to the General Account are registered under the Securities Act of 1933, as amended, ("1933 Act") but the General Account is not registered under the 1940 Act. 19 Contract Balances in the General Account will not share in the investment performance of the General Account or any portion thereof. Instead, C.M. Life will pay a specified rate of interest on such balance. The interest rate credited to General Account Balances will vary at the sole discretion of C.M. Life. The Contract Owner should check with his or her agent or the Annuity Service Center for current availability. However, C.M. Life will credit interest at an effective annual rate of not less than 3% per year, compounded annually, to amounts allocated to the General Account under the Contract. C.M. Life is not obligated to credit any interest in excess of 3%. There is no specific formula for the determination of the interest rate. Some of the factors that C.M. Life may consider in determining the interest rate are: general economic trends; rates of return currently available and anticipated on C.M. Life's investments; expected investment yields; regulatory and tax requirements; and competitive factors. C.M. Life may, with respect to investments and average terms of investments, use dedication (cash flow matching), and/or duration matching, or other methods to minimize C.M. Life's risk in volatile interest rate environments of not achieving the rates it is crediting. ANY INTEREST CREDITED TO AMOUNTS ALLOCATED TO THE GENERAL ACCOUNT IN EXCESS OF 3% PER YEAR WILL BE DETERMINED AT THE SOLE DISCRETION OF C.M. LIFE. THE CONTRACT OWNER ASSUMES THE RISK THAT INTEREST CREDITED ON AMOUNTS ALLOCATED TO THE GENERAL ACCOUNT MAY NOT EXCEED 3% PER YEAR. C.M. Life resets this rate periodically. It currently resets the rate quarterly, but in the future the rate may be reset more or less frequently. The Contract Owner also assumes the risk that the Surrender Value of amounts allocated to the General Account will be less than the General Account Balance, and less than the Net Purchase Payments allocated to the General Account. C.M. Life is aware of no statutory limitations on the maximum amount of interest it may credit, and the Board of Directors has set no limitations. However, inherent in C.M. Life's exercise of discretion in this regard is the equitable allocation of distributable earnings and surplus among its various policyholders and Contract Owners and to its sole stockholder. Surrenders of General Account Balances may be subject to an Interest Rate Factor Adjustment (as well as a Surrender Charge), so Surrender proceeds may be less than Purchase Payments. The Interest Rate Factor Adjustment may also apply to any General Account Balance applied to Variable Annuity Income payments. The Adjustment does not apply to Contracts issued to Pennsylvania residents. For more information, see "Surrender Charge," page , and "Interest Rate Factor Adjustment," page . C.M. Life will invest the assets of the General Account in those assets chosen by C.M. Life and allowed by applicable state laws regarding the nature and quality of investments that may be made by life insurance companies, and the percentage of their assets that may be committed to any particular type of investment. In general, these laws permit investments, within specified limits and subject to certain qualifications, in federal, state and municipal obligations, corporate bonds, preferred and common stocks, real estate mortgages, real estate and certain other investments. C.M. Life intends to invest assets of the General Account primarily in debt instruments as follows: (1) securities issued by the United States Government or its agencies or instrumentalities, which issues may or may not be guaranteed by the United States Government; (2) debt securities which have an investment grade, at the time of purchase, within the four highest grades assigned by Moody's Investors Services, Inc. ("Moody's") (Aaa, Aa, A or Baa), Standard & Poor's Corporation ("Standard & Poor's) (AAA, AA, A or BBB) or any other nationally recognized rating service; and (3) other debt instruments, including, but not limited to, issues of or guaranteed by banks or bank holding companies and corporations, which obligations, although not rated by Moody's or Standard & Poor's, are deemed by C.M. Life's management to have an investment quality comparable to securities which may be purchased as stated above. General Account assess may also be invested in: (4) other evidences of indebtedness secured by mortgages or deeds of trust representing liens upon real estate; and (5) private placements (I.E., securities not registered with the SEC, and for which there may not be a liquid market). Notwithstanding the foregoing, C.M. Life may also invest a portion of the General Account assets in (6) below investment grade debt instruments. Instruments rated "Baa" and/or "BBB" or lower normally involve a higher risk of default and are less liquid than higher rated instruments. If the rating of an investment grade debt security held by C.M. Life is subsequently downgraded 20 to below investment grade, the decision to retain or dispose of the security will be made based upon an individual evaluation of the circumstances surrounding the downgrading, and the prospects for continued deterioration, stabilization and/or improvement. C.M. Life is not obligated to invest amounts allocated to the General Account according to any particular strategy, except as may be required by applicable state insurance laws. Investments not indicated herein may also be made. C.M. Life may utilize a "segregated account" within its general asset account in connection with the General Account Contract Balances. Nevertheless, Contract Owners who allocate amounts to the General Account do not share in the investment performance of that segregated account or any other portion of the assets of C.M. Life. Accordingly, in contrast to the Panorama Plus Separate Account discussed above, there are no "units" or calculation of "unit values" to measure the investment performance of the General Account. (This type of segregated account is sometimes referred to as a "non-unitized separate account.") TRANSFERS The Contract Owner may transfer Contract Balance amounts to or from the General Account and/or any Sub-Account of the Separate Account, within certain limits, as described below. Although no fee is currently imposed on transfers, C.M. Life reserves the right to charge such a fee in the future, and to otherwise restrict the transfer privilege in any way, or to eliminate it entirely. DURING THE ACCUMULATION PERIOD, the Contract Owner (or the Beneficiary, if a Death Benefit has become payable) may transfer Contract Balance amounts, subject to the following provisions. - The Contract Owner signs and submits a Written Request for a transfer which is received by the Annuity Service Center. - The minimum transfer amount is $100. - The total amount of all transfers to or from the General Account during each Contract Year is limited to the greater of: (i) 30% of the General Account Balance as of the end of the immediately preceding Contract Year; or (ii) $25,000. - Transfers between the General Account and the Money Sub-Account (together, the "Competing Accounts") are only permitted during a Window Period. In addition, for a period of ninety (90) days following a transfer out of one Competing Account, no transfers (i.e., from any Account) may be made into the other Competing Account. - Similarly, for a period of ninety (90) days following a transfer into either Competing Account, no transfers (i.e., to any Account) may be made out of the other Competing Account. DURING THE ANNUITY PERIOD, the Contract Owner (who may or may not be the Annuitant) may transfer Separate Account Balance amounts, subject to the following provisions. - The Contract Owner signs and submits a Written Request for a transfer which is received by the Annuity Service Center. - Transfers to or from the General Account are not permitted during the Annuity Period. - Transfers during the Annuity Period may be made only once during any Contract Year. - Transfers between Sub-Accounts during the Annuity Period will be processed based on the formula outlined in the Statement of Additional Information. Contract Owners may elect to make transfers by telephone. To do so, the Contract Owner must submit a completed Written Request electing the telephone transfer privilege. Telephone requests must be received at the Annuity Service Center no later than 3:30 Eastern Standard Time to assure same day pricing. Telephone requests will not be accepted after that time. C.M. Life will use reasonable procedures to confirm that instructions communicated by telephone are genuine. If it does not, C.M. Life may be liable for any losses due to unauthorized or fraudulent instructions. C.M. Life may tape record all telephone instructions. 21 C.M. Life will not be liable for any loss, liability, cost or expense incurred by the Contract Owner for acting in accordance with such telephone instructions believed to be genuine. The telephone transfer privilege may be discontinued by C.M. Life at any time. DOLLAR COST AVERAGING To the extent provided below, amounts from Sub-Accounts and the General Account may be transferred at regular intervals. This election is called "Dollar Cost Averaging." Upon Written Request, a Contract Owner may elect Dollar Cost Averaging ("DCA") to begin at any time during the Accumulation Period, except as otherwise provided in DCA Option 2 -- Fixed Dollar Amount Transfers described below. There is currently no charge for DCA. However, the Company reserves the right to charge for DCA in the future. The Contract Owner may not simultaneously participate in both DCA and Systematic Withdrawals. (See "Systematic Withdrawals" at page .) DCA will begin when a properly completed Written Request from the Contract Owner is received by the Company at least five (5) business days prior to the transfer start date selected by the Contract Owner. If the DCA start date is less than five (5) days after the date the Written Request is received by the Company, the Company may defer the DCA start date for one (1) month. If no start date has been selected, the Company will automatically start DCA within five (5) business days after the Written Request is received. If DCA is elected, the Contract Owner may direct the transfer of amounts at regular intervals under one of the following options: DCA OPTION 1 FROM THE SUB-ACCOUNTS -- This option provides for the transfer of fixed dollar amounts at regular intervals from any one Sub-Account to one or more other Sub-Account(s), as elected by the Contract Owner. Transfers must be at least $100 per transferee Sub- Account. Transfers to the General Account are not permitted. DCA OPTIONS 2 & 3 FROM THE GENERAL ACCOUNT -- These options provide for the transfer of amounts at regular intervals from the General Account to one or more of the Sub-Accounts (other than the Money Market Sub-Account). Except during the Window Period, additional transfers from the General Account are not permitted while a DCA option 2 or 3 is in effect. DCA Options 2 and 3 are described below. DCA OPTION 2 -- FIXED DOLLAR AMOUNT TRANSFERS --This option provides for the transfer of fixed dollar amounts at regular intervals from the General Account to one or more of the Sub-Accounts (other than the Money Market Sub-Account). Transfers must be for at least $100 per transferee Sub-Account. Total transfers from the General Account are limited in the Contract Year of the initial Purchase Payment to the greater of: (i) 30% of the initial Purchase Payment; or (ii) $25,000. In subsequent Contract Years total transfers from the General Account are limited to the greater of: (i) 30% of the General Account Balance as of the end of the immediately preceding Contract Year; or (ii) $25,000. Election into this option may only be made during the Accumulation Period as follows: at the time of the initial Purchase Payment into the General Account; or, in subsequent years, on the Contract Year anniversary, provided that the Company receives the Written Request for this election at least five (5) business days in advance of such anniversary. DCA OPTION 3 -- INTEREST-ONLY TRANSFERS -- This option provides for the transfer of the credited interest of the General Account at regular intervals to one or more of the Sub-Accounts (other than the Money Market Sub-Account). The transferred amount is comprised of the credited interest for the selected interval (E.G., monthly, quarterly). The $100 minimum transfer amount does not apply to this option. To participate in this option, there is a $5,000 minimum General Account Balance required at the time of each transfer. 22 Changes in the terms of any option elected (such as amount transferred or Sub-Account designation) may be made by Written Request to terminate the existing DCA, along with a Written Request providing new DCA elections. DCA will terminate when any of the following occurs: (1) the number of designated transfers has been completed; (2) the value of the General Account or Sub-Account is insufficient to complete the next transfer; (3) a Written Request from the Contract Owner is received at least five (5) business days prior to the next transfer date; (4) for Option 3, where the General Account balance falls below $5,000; (5) the Annuity Income Date arrives; or (6) the Contract is terminated. Except as otherwise provided, Dollar Cost Averaging is subject to the transfer provisions of the Contract. (See "Transfers" page .) Dollar Cost Averaging is not currently available in all states. DISTRIBUTIONS UNDER THE CONTRACT SURRENDERS The Contract Owner may surrender all or a portion of the Contract Balance in exchange for a cash payment from C.M. Life. The proceeds payable upon a full Surrender are the Contract Balance less any applicable Surrender Charge, Contract Maintenance Fee, any applicable premium taxes, and plus or minus any applicable Interest Rate Factor Adjustment. The net proceeds payable upon full Surrender are the "Surrender Value." THERE IS NO MINIMUM OR GUARANTEED SURRENDER VALUE. The proceeds payable upon a partial Surrender are the Surrender amount requested; any applicable Surrender Charge is subtracted from, and any applicable Interest Rate Factor Adjustment is added to, or subtracted from, the remaining Contract Balance. There is no Surrender Charge or Interest Rate Factor Adjustment on Surrenders during a Window Period. Any Surrender Charge or Contract Maintenance Fee imposed on Surrender will be allocated among the General Account and the Sub-Accounts in the same manner (pro rata) as the Contract Balance subject to Surrender is allocated among the General Account and the Sub-Accounts. For Contracts issued to Pennsylvania residents, the Contract Maintenance Fee will be allocated pro rata among the Sub-Accounts. Any applicable Interest Rate Factor Adjustment imposed on a Surrender will be imposed only on the amount of General Account Balance subject to Surrender. For partial Surrenders, the Contract Owner must specify the Investment Account or Sub-Account from which surrendered amounts should be taken. The minimum amount that can be withdrawn from any Sub-Account or the General Account is $100. In addition, following any partial Surrender, the remaining Contract Balance must be at least $250. If the processing of a partial Surrender request would result in a remaining Contract Balance of less than $250, C.M. Life will treat the partial Surrender request as a full Surrender of the Contract, and the Surrender Value will be paid. Following payment of the Surrender Value, the Contract will be canceled. The Contract Owner may request the Contract Balance at any time during the life of the Annuitant and Contract Owner and prior to the Annuity Income Date, by sending a Written Request to the Annuity Service Center. Surrenders are permitted any time dU ring the Accumulation Period. (See "Annuity Options," page .) C.M. Life will process all partial Surrender and full Surrender requests within seven (7) calendar days (unless a shorter period is required under applicable law) following receipt by the Annuity Service Center of the Contract Owner's Written Request, except in the following situations for the following Accounts. 23 GENERAL ACCOUNT -- C.M. Life reserves the right to defer payment of any Surrender from the General Account for up to six (6) months. SEPARATE ACCOUNT -- C.M. Life reserves the right to defer the payment of any Surrender from the Separate Account as permitted by the 1940 Act. Such delay may occur because: (i) the New York Stock Exchange is closed for trading; (ii) the SEC determines that a state of emergency exists; or (iii) an order or pronouncement of the SEC permits a delay for the protection of Contract Owners. In addition, a Purchase Payment amount is not available to satisfy a Written Request for Surrender until the check, or other instrument by which such Purchase Payment was made, has been honored. Beginning in the second Contract Year, the Contract Owner is entitled to an annual Free Surrender Amount, which is exempt from a Surrender Charge and from any Interest Rate Factor Adjustment. The Free Surrender Amount equals 10% of the Contract Balance as of the end of the immediately preceding Contract Year, and is allocated among the General Account and Sub-Accounts in the same proportion as the partial Surrender or full Surrender requested. The Free Surrender amount may be taken in multiple installments in each Contract Year. Any amount subject to Surrender in excess of the Free Surrender Amount is subject to the Surrender Charge and the Interest Rate Factor Adjustment, as applicable. (See "Interest Rate Factor Adjustment," page and "Surrender Charge," page .) Any unused Free Surrender Amount cannot be accumulated and carried from one year to the next. (Surrenders may result in tax liabilities. See "CERTAIN FEDERAL INCOME TAX CONSEQUENCES," page .) Until April 30, 1997, no sales charges will be imposed upon redemption of a Contract where the proceeds of such redemption are applied to the purchase of a new MassMutual group annuity contract. This waiver does not eliminate applicable charges under the particular group contract, and upon surrender of the group contract, charges may apply. Since the Contract Owner assumes the entire investment risk with respect to Purchase Payments and transfers allocated to the Separate Account, and certain risks with respect to amounts allocated to the General Account, and because Surrenders are subject to a Surrender Charge, an Interest Rate Factor Adjustment, a Contract Maintenance Fee, and possibly Premium Taxes, THE TOTAL AMOUNT PAID UPON FULL SURRENDER MAY BE MORE OR LESS THAN THE TOTAL PURCHASE PAYMENTS MADE (taking any prior partial Surrenders into account). Following a Surrender of the total Contract Balance, or at any time the Contract Balance is zero, all rights of the Contract Owner and Annuitant will terminate. SYSTEMATIC WITHDRAWALS Upon Written Request, a Contract Owner may elect Systematic Withdrawals ($100 minimum per withdrawal) to begin on or after the first anniversary of the Contract Issue Date during the Accumulation Period. There is currently no charge for Systematic Withdrawals. However, the Company reserves the right to charge for Systematic Withdrawals in the future. The Contract Owner may not simultaneously participate in both Systematic Withdrawals and Dollar Cost Averaging. If Systematic Withdrawals are elected, the Contract Owner may withdraw fixed dollar amounts at regular intervals from the Contract Balance. Systematic Withdrawals will begin when a properly completed Written Request from the Contract Owner is received by the Company, at least five (5) business days prior to the Systematic Withdrawals start date selected by the Contract Own. If the Systematic Withdrawals start date is less than five (5) days after the date the Written Request is received by the Company, the Company may defer the Systematic Withdrawals start date for one (1) month. If no start date has been selected, the Company will automatically start Systematic Withdrawals within five (5) business days after the Written Request is received. 24 Changes in Systematic Withdrawals may only be made by Written Request from the Contract Owner to terminate the existing Systematic Withdrawals election along with a Written Request designating a new Systematic Withdrawals election. Systematic Withdrawals will terminate when any of the following occurs: (1) the number of designated Systematic Withdrawals has been completed; (2) the value of the General Account or Sub-Account is insufficient to complete the next withdrawal; (3) Written Request from the Contract Owner is received at least five (5) business days prior to the next withdrawal date; (4) the Annuity Income Date arrives; or (5) the Contract is terminated. Withdrawals in excess of the Free Surrender Amount may be subject to any applicable Surrender Charge and Interest Rate Factor Adjustment. (See "Surrenders," page .) Further, withdrawals may result in tax liabilities. See "CERTAIN FEDERAL INCOME TAX CONSEQUENCES," page . The Systematic Withdrawals plan is not currently available in all states. ANNUITY INCOME PAYMENTS C.M. Life will pay an Annuity Income beginning on the Annuity Income Date, provided no Death Benefit has become payable, and the Contract Owner has selected an available Annuity Option and payment schedule by Written Request. The Annuity Option and frequency of Annuity Income payments may not be changed after Annuity Income payments begin. Unless the Contract Owner specifies otherwise, the payee of the Annuity Income is the applicable Annuitant. After the death of the Annuitant, any remaining payments will be made to the Beneficiary. The dollar amount and frequency of the payments will depend on numerous factors, such as the Contract Balance, the type of Annuity and Annuity Option elected, possibly age and sex, and any applicable Interest Rate Factor Adjustment. ANNUAL INCOME DATE. Initially, the Annuity Income Date is selected by the Contract Owner at the time the Application is completed. The Annuity Income Date may be changed from time to time by the Contract Owner by Written Request to C.M. Life, provided that notice of each change is received by C.M. Life at its Annuity Service Center at least thirty (30) days prior to the then-current Annuity Income Date. Except as otherwise permitted by C.M. Life, an Annuity Income Date must be a date which is no earlier than the fifth anniversary of the Contract Issue Date. The latest Annuity Income Date which may be elected is the Annuitant's 90th birthday (unless a longer period is required under applicable state law). ELECTION OF ANNUITY OPTION. The Contract Owner will choose an Annuity Option in the Application. During the lifetime of the Annuitant and Contract Owner and prior to the Annuity Income Date, the Contract Owner may change the election, but a Written Request specifying a change of election must be received by C.M. Life at its Annuity Service Center at least thirty (30) days prior to the Annuity Income Date. If no election is made at least thirty (30) days prior to the Annuity Income Date, Annuity Income will be paid under Option B, life income with 120 monthly payments guaranteed. (See "Annuity Options," page .) If the Annuitant or Contract Owner dies prior to the Annuity Income Date, the Beneficiary may receive a Death Benefit. (See "Death Benefit," page .) 25 PREMIUM TAX. C.M. Life may be required by state law to pay a Premium Tax on the amount applied to an Annuity Option (or upon Surrender). If so, C.M. Life will deduct the Premium Tax before applying (or paying) the proceeds. ANNUITY OPTIONS The Contract provides six (6) Annuity Options which are described below. Five (5) of these are offered as EITHER a Fixed Annuity or a Variable Annuity (Option E is only available as a Fixed Annuity). Contract Owners may elect a Fixed Annuity, a Variable Annuity, or a combination of both. If the Contract Owner elects a combination, he must specify what part of the Contract Balance is to be applied to the Fixed and Variable Options. Unless specified otherwise, the General Account Balance will be used to provide a Fixed Annuity, and the Separate Account Balance will be used to provide a Variable Annuity. (If the General Account Balance is used to provide Variable Annuity Income payments, then the Interest Rate Factor Adjustment will be applied at that time.) Variable Annuity income payments will be based on the Sub-Account(s) selected by the Contract Owner, or on the allocation of the Separate Account Balance among the Sub-Accounts. If the amount of the Annuity Income will depend on the age or sex of the Annuitant, C.M. Life reserves the right to ask for satisfactory proof of the Annuitant's (and Joint Annuitant's) age and sex. C.M. Life may delay Annuity Income payments until satisfactory proof is received. On the Annuity Income Date, the sum of: (i) the General Account Balance (adjusted by the Interest Rate Factor Adjustment to the extent that the General Account Balance is applied to a Variable Annuity Option); and (ii) the Separate Account Balance; minus (iii) any Premium Tax, will be applied to provide for Annuity Income payments under the selected Annuity Option. A FIXED ANNUITY provides for Annuity Income payments which will remain constant pursuant to the terms of the Annuity Option elected. The effect of choosing a Fixed Annuity is that the amount of each payment will be set on the Annuity Income Date and will not change. If a Fixed Annuity is selected, the Separate Account Balance used to provide the Fixed Annuity will be transferred to the general assets of C.M. Life, and the Annuity Income payments will be fixed in amount by the Fixed Annuity provisions selected, and, for some options, the age and sex (if consideration of sex is allowed) of the Annuitant. The Fixed Annuity payment amounts are determined by applying the Annuity Purchase Rate specified in the Contract to the portion of the Contract Balance allocated to the Fixed Annuity Option selected by the Contract Owner. A VARIABLE ANNUITY provides for payments that fluctuate or vary in dollar amount, based on the investment performance of a Separate Account Sub-Account. The Variable Annuity purchase rate tables in the Contract reflect an assumed interest rate of 4%, so if the actual net investment performance of the Sub- Account is less than this rate, then the dollar amount of the actual Annuity Income payments will decrease. If the actual net investment performance of the Sub-Account is higher than this rate, then the dollar amount of the actual Annuity Income payments will increase. If the net investment performance exactly equals the 4% rate, then the dollar amount of the actual Annuity Income payments will remain constant. ANNUITY UNITS AND PAYMENTS. The dollar amount of each Variable Annuity payment depends on the number of "Annuity Units" credited to that Annuity Option and the value of those units. The number of Annuity Units is determined as follows. 1. The number of Annuity Units credited in each Sub-Account will be determined by dividing the product of the portion of the Contract Balance to be applied to the Sub-Account and the Annuity Purchase Rate specified in the Contract by the value of one Annuity Unit in that Sub-Account on the Annuity Income Date. 26 2. The amount of each Annuity Income payment equals the product of the Annuitant's number of Annuity Units and the Annuity Unit Values on the payment date. The amount of each payment may vary from prior Annuity Income payments. ANNUITY UNIT VALUE. The value of an Annuity Unit in a Sub-Account on a ny Valuation Date is determined as follows. 1. The Net Investment Factor for the Valuation Period (for the appropriate Annuity Income payment frequency) just ended is multiplied by the value of the Annuity Unit for the Sub-Account on the preceding Valuation Date. 2. The result in (1) is then divided by an interest factor. The interest factor equals 1.00 plus the interest rate for the number of days since the preceding Valuation Date. Interest is based on an effective annual rate of 4%. This compensates for the interest assumption built into the Annuity Purchase Rates. The Contract Owner may choose to receive Annuity Income payments under any one of the Annuity Options described below. The Company may consent to other plans of payment before the Annuity Income Date. NOTE CAREFULLY: UNDER ANNUITY OPTIONS A AND C, IT WOULD BE POSSIBLE FOR ONLY ONE (1) ANNUITY INCOME PAYMENT TO BE MADE IF THE ANNUITANT WERE TO DIE BEFORE THE DUE DATE OF THE SECOND ANNUITY PAYMENT; ONLY TWO (2) ANNUITY INCOME PAYMENTS IF THE ANNUITANT WERE TO DIE BEFORE THE DUE DATE OF THE THIRD ANNUITY PAYMENT; AND SO FORTH. The following Annuity Options are available. ANNUITY OPTION A -- Life Income -- Periodic payments will be made as long as the Annuitant lives. ANNUITY OPTION B -- Life Income with Period Certain -- Periodic payments will be made for a guaranteed period, or as long as the Annuitant lives, whichever is longer. The guaranteed period, which is selected by the Contract Owner, may be five (5), ten (10), or twenty (20) years. ANNUITY OPTION C -- Joint and Last Survivor Payments -- Periodic payments will be made during the joint lifetime of two (2) Annuitants, continuing in the same amount during the lifetime of the surviving Annuitant. ANNUITY OPTION D -- Joint and 2/3 Survivor Annuity -- Periodic payments will be made during the joint lifetime of two (2) Annuitants. Payments will continue during the lifetime of the surviving Annuitant, and will be computed on the basis of two-thirds of the annuity payment (or units) in effect during the joint lifetime. ANNUITY OPTION E -- PERIOD CERTAIN -- (Available as a Fixed Annuity only)-Periodic payments will be made for a specified period. The specified period must be at least five (5) years and cannot be more than thirty (30) years. ANNUITY OPTION F -- Special Income Settlement Agreement -- C.M. Life will pay the proceeds in accordance with terms agreed upon in writing by the Contract Owner and C.M. Life. This option may be elected only at the Annuity Income Date. * * * * * Annuity Income Payments. Except as otherwise agreed to by the Contract Owner and C.M. Life, Annuity Income payments will be payable monthly. The minimum amount that may be applied under any Annuity Option, and the minimum periodic Annuity Income payment allowed, are the most recently 27 published minimums designated by C.M. Life for this purpose. A portion or the entire amount of the Annuity Payments may be taxable as ordinary income. If, at the time the Annuity Payments begin, C.M. Life has not received a proper written election not to have federal income taxes withheld, C.M. Life must by law withhold such taxes from the taxable portion of such annuity payments and remit that amount to the federal government. (See "CERTAIN FEDERAL INCOME TAX CONSEQUENCES," page .) TERMINAL ILLNESS BENEFIT In the event that a Contract Owner becomes terminally ill during the Accumulation Period and prior to age 75, the Contract Owner may elect, unless prohibited by law, by submission of a Written Request, a Terminal Illness. Benefit equal to the greater of: (a) the Purchase Payments less any prior withdrawals and charges; or (b) the Contract Balance. The Company will require proof that the Contract Owner is terminally ill and not expected to live more than twelve (12) months. This proof will include, but is not limited to, certification by a licensed medical practitioner performing within the scope of his/her license. The licensed medical practitioner must not be the Contract Owner, Annuitant or the Contingent Annuitant, or the parent, spouse or child of the Contract Owner, Annuitant or Contingent Annuitant. Payment of the Terminal Illness Benefit is determined on the date the Company receives the Written Request. No Contract Maintenance Fee for the current year, Surrender Charge or Interest Rate Factor Adjustment shall apply with respect to any Terminal Illness Benefit. Payment of the Terminal Illness Benefit will be in full settlement of the Company's liability under the Contract. The Terminal Illness Benefit is not available for Contracts issued in Kansas, Mississippi, Texas, or Pennsylvania. DEATH BENEFIT If the Annuitant or Contract Owner dies prior to the Annuity Income Date, a Death Benefit will be paid to the Beneficiary upon receipt at the Annuity Service Center of proof of death. If, however, the Annuitant dies before such Contract Owner and there is a Contingent Annuitant who is less than 85 years of age on the Annuitant's date of death (and such Contract Owner is a natural person), then no Death Benefit is payable, and the Contract will continue in force, with the Contingent Annuitant as the Annuitant. For purposes of the Death Benefit, the Annuitant is the Annuitant named in the Application. The Death Benefit is payable upon receipt of proof of death, as well as proof that the death occurred during the Accumulation Period. Upon receipt of this proof and an election of a Death Benefit Option, and return of the Contract, the Death Benefit generally will be payable after C.M. Life has sufficient information to make the payment(s). Payments under a Death Benefit Option are determined at the time of payment, and, if the deceased Annuitant or Contract Owner was a natural person less than age 75 at death, are based on the greater of (a) the Contract Balance or (b) the Purchase Payments less any prior withdrawals and charges. Otherwise, the payments are based on the Contract Balance at the time of payment. No Surrender Charge, Interest Rate Factor Adjustment, or Contract Maintenance Fee shall apply with respect to any Death Benefit Option. Payment of the Death Benefit will be in full settlement of the Company's liability under this Contract. The available Death Benefit Options depend on whether the Contract Owner and Annuitant are the same person. 28 DEATH OF CONTRACT OWNER. If the Contract Owner is not the Annuitant, and the Contract Owner dies before the Annuitant and prior to the Annuity Income Date, one of the following provisions will apply. 1. If the Contract Owner's spouse is the Beneficiary and survives the Contract Owner, the spouse may select only Death Benefit Option A, B, or C within one (1) year after the Contract Owners death. (See page ). If the surviving spouse does not make a selection within one (1) year after the Contract Owner's death, the surviving spouse will become the Contract Owner. 2. If the Beneficiary is a natural person other than the Contract Owner's spouse, the Beneficiary may select only Death Benefit Option B or C within one (1) year after the Contract Owner's death. (See page ). If no selection is made within one (1) year after the Contract Owner's death, the Death Benefit will be paid to the Beneficiary in a single sum at that time. 3. If the Beneficiary is not a natural person, it may select only Death Benefit Option B or D within one (1) year after the Contract Owner's death. 4. If no Beneficiary survives the Contract Owner, the Annuitant shall be deemed to be the Beneficiary and provision 1 or 2 above shall apply. If no selection is made within one (1) year after the Contract Owner's death, the Death Benefit will be paid in a single sum at that time. DEATH OF CONTRACT OWNER/ANNUITANT. If the Contract Owner and Annuitant are the same person, and the Contract Owner/Annuitant dies before the Annuity Income Date, one of the following provisions applies. 1. If the Contract Owner/Annuitant's spouse is the Beneficiary, the surviving spouse may only select Death Benefit Option B, C, or G within (1) one year after the Contract Owner/Annuitant's death. (See below.) If no selection is made within one (1) year after the Contract Owner/Annuitant's death, the surviving spouse will become the Contract Owner and Annuitant of the Contract. 2. If the Beneficiary is a natural person other than the Contract Owner/Annuitant's spouse, the Beneficiary may select only Death Benefit Option B or C within (1) one year of the Contract Owner/ Annuitant's death. If no selection is made within one (1) year after the Contract Owner/Annuitant's death, the Death Benefit will be paid in a single sum at that time. 3. If the Beneficiary is not a natural person, it may select only Death Benefit Option B or D within one (1) year after the Contract Owner/Annuitant's death. See below. 4. If no Beneficiary survives the Contract Owner/Annuitant, the Death Benefit will be paid in a single sum to the Contract Owner/Annuitant's estate within five (5) years of the date of death. If no selection is made within one (1) year after the Contract Owner/Annuitant's death, the Death Benefit will be paid in a single sum at that time. DEATH OF ANNUITANT. If the Contract Owner and Annuitant are not the same person, and the Annuitant dies before the Contract Owner and prior to the Annuity Income Date, and there is no Contingent Annuitant younger than age 85 (or if the Contract Owner is not a natural person), one of the following provisions applies. 1. The Beneficiary, if a natural person, may only select Death Benefit Option E or F within one (1) year after the Annuitant's death. (See page .) 29 If no selection is made within one (1) year after the Annuitant's death, the Death Benefit will be paid in a single sum to the Beneficiary at that time. 2. If the Beneficiary is not a natural person, it may only select Death Benefit Option D or E within one (1) year after the Annuitant's death. (See page ). If no selection is made within one (1) year after the Annuitant's death, the Death Benefit will be paid in a single sum at that time. 3. If no Beneficiary survives the Annuitant, the Contract Owner shall be deemed the Beneficiary and provision 1 or 2 immediately above shall apply. DEATH BENEFIT OPTIONS. Life expectancy for purposes of these Death Benefit Options will be determined from the tables in the Regulations, under Section 72 of the Code. The following Death Benefit Options are available: DEATH BENEFIT OPTION A -- To become the Contract Owner; DEATH BENEFIT OPTION B -- To receive the Death Benefit as a single sum within one (1) year after the Contract Owner's death; DEATH BENEFIT OPTION C -- To receive the Death Benefit under any Annuity Option offered in the Contract, provided the entire Death Benefit is distributed: 1. Within five (5) years of the date of death; or 2. Over a period not extending beyond the life expectancy of the Beneficiary; or 3. Over the life of the Beneficiary. If the Death Benefit is to be paid under provision (2) or (3), the first installment payment must be made within one (1) year after the Contract Owner's death. DEATH BENEFIT OPTION D -- To receive the Death Benefit under any Annuity Option offered in the Contract, provided the entire Death Benefit is distributed within five (5) years of the date of death; DEATH BENEFIT OPTION E -- To receive the Death Benefit as a single sum within one (1) year after the Annuitant's death; DEATH BENEFIT OPTION F -- To receive the Death Benefit under any Annuity Option offered in the Contract, provided the Death Benefit is distributed: 1. Over a period not extending beyond the life expectancy of the Beneficiary; or 2. Over the life of the Beneficiary. The first installment payment must be made within one (1) year after the Annuitant's death. DEATH BENEFIT OPTION G -- To become the Contract Owner and Annuitant of the Contract, just as if the Beneficiary had always been the Contract Owner and Annuitant. DEATH OF ANNUITANT ON OR AFTER ANNUITY INCOME DATE. The Death Benefit payable if the Annuitant dies on or after the Annuity Income Date, if any, depends on the Annuity Option in effect on the date of death of the Annuitant. Any remaining payments will be distributed at least as rapidly as under the method of distribution being used as of the date of the Annuitant's death. If a Beneficiary dies while receiving such benefits, the 30 balance of the benefits, if any, will be paid in a single sum to the estate of the Beneficiary. If no Beneficiary survives the Annuitant, the benefits, if any, will be paid in a single sum to the estate of the last Annuitant to die. BENEFICIARY. One or more Beneficiaries may be designated to receive benefits concurrently, contingently or successively upon the death of the Contract Owner and/or the Annuitant. The Beneficiary designation in the Application will remain in effect until changed. The Contract Owner may, upon Written Request, change the designated Beneficiary before a Death Benefit has become payable. The Beneficiary's consent to such change is not required unless the Beneficiary was irrevocably designated or consent is required by law. (If an irrevocable Beneficiary dies, the Contract Owner may then designate a new Beneficiary.) The change will take effect as of the date the Contract Owner signs the Written Request. However, the change is subject to any payments made or actions taken by C.M. Life before receipt of the Written Request. On or after receipt of proof of death at the Annuity Service Center, the Beneficiary shall have the exclusive right to (i) appoint a contingent Beneficiary to succeed to the interest of the Beneficiary in the event of the Beneficiary's death; and (ii) make transfers under the Contract. (See "Transfers," page 19.) IRS REQUIRED DISTRIBUTION Federal tax law requires that if the Contract Owner dies before the Annuity Income Date, then the entire value of the Contract must generally be distributed within five (5) years of the date of death of the Contract Owner. Special rules may apply to the spouse of the deceased Contract Owner. (See "Federal Tax Matters," page B-11 of the Statement of Additional Information, for a detailed description of these rules.) RESTRICTIONS UNDER THE TEXAS OPTIONAL RETIREMENT PROGRAM Section 36.105 of the Texas Educational Code permits participants in the Texas Optional Retirement Program ("ORP") to withdraw their interests in a variable annuity contract issued under the ORP only upon: (1) termination of employment in the Texas public institutions of higher education; (2) retirement; or (3) death. Accordingly, a participant in the ORP (or the participant's estate if the participant has died) will be required to obtain a certificate of termination from the employer, or a certificate of death, before the Contract can be surrendered. RESTRICTIONS UNDER SECTION 403(B) PLANS Section 403(b) of the Code provides for tax-deferred retirement savings plans for employees of certain non-profit and educational organizations. In accordance with the requirements of Section 403(b), any Contract used for a 403(b) plan will prohibit distributions of elective contributions, and earnings on elective contributions, except upon death of the employee, attainment of age 59 1/2, separation from service, disability, or financial hardship. In addition, income attributable to elective contributions may not be distributed in the case of hardship. CHARGES AND DEDUCTIONS C.M. Life will make certain charges and deductions under the Contract in order to compensate it for incurring expenses in distributing the Contract, bearing mortality and expense risks under the Contract, and administering the Investment Accounts and the Contract. Charges may also be made for Premium Taxes, and other federal, state or local taxes. Charges and expenses are also deducted from the assets of the Portfolios. SURRENDER CHARGE C.M. Life will incur expenses relating to the sale of Contracts, including commissions to registered representatives and other promotional expenses. In connection with a full Surrender or partial Surrender 31 during the first five (5) Contract Years, C.M. Life may deduct from the Contract Balance a Surrender Charge equal to 5% of any Contract Balance surrendered in order to help cover distribution expenses. The Surrender Charge will be deducted as of the date of the receipt at the Annuity Service Center of the Written Request for the Surrender. Any Surrender Charge assessed will be allocated among the General Account and the Sub-Accounts in the same manner (pro rata) as the Contract Balance subject to Surrender is allocated among the General Account and the Sub-Accounts. The Surrender Charge will not be applied under the following circumstances: 1. Cancellation of the Contract during the 15-day examination period; 2. Full Surrender of the Contract on the Annuity Income Date; 3. Partial Surrenders or full Surrenders during the Window Period or after the first five (5) Contract Years, (the Window Period is the last thirty (30) days of each Five-Year Period under the Contract); 4. Upon payment of the Death Benefit; 5. On any Free Surrender Amount. Beginning in the second Contract Year, the Contract Owner is entitled to an annual Free Surrender Amount, which is exempt from a Surrender Charge and any applicable Interest Rate Factor Adjustment. See "Interest Rate Factor Adjustment" below. The Free Surrender Amount will be allocated among the General Account and/or Sub-Accounts in the same proportions as the partial Surrender or full Surrender amount. The Free Surrender Amount equals 10% of the Contract Balance as of the end of the immediately preceding Contract Year. Contract Owners may elect to receive 10% of the Contract Balance in multiple installments each contract year. Any amount redeemed during the year in excess of this 10% amount will be subject to a Surrender Charge (and any applicable Interest Rate Factor Adjustment); and 6. Partial Surrenders or full Surrenders of Contracts issued in exchange for Variable Annuity Contracts issued by Connecticut Mutual through its Panorama Separate Account which are beyond any applicable Surrender Charge period. More information about how the Surrender Charge is calculated for partial Surrenders and full Surrenders is contained in Appendices I and III attached hereto. In the case of a partial Surrender, the Surrender Charge will be deducted from the Contract Balance remaining after payment of the requested Surrender amount, or from the amount paid if sufficient balances do not remain in the Sub-Account or General Account to which the Surrender is allocated. Until April 30, 1997, no sales charges will be imposed upon redemption of a Contract where the proceeds of such redemption are applied to the purchase of a new MassMutual group annuity contract. This waiver does not eliminate applicable charges under the particular group contract, and upon surrender of the group contract, charges may apply. C.M. Life anticipates that the Surrender Charge will not generate sufficient funds to pay the cost of distributing the Contracts. If this charge is insufficient to cover distribution expenses, the deficiency will be met from C.M. Life's general funds, which will include amounts derived from the charge for mortality and expense risks. C.M. LIFE GUARANTEES THAT THE AGGREGATE SURRENDER CHARGE WILL NEVER EXCEED 8.5% OF THE TOTAL PURCHASE PAYMENTS MADE UNDER THE CONTRACT. 32 INTEREST RATE FACTOR ADJUSTMENT An Interest Rate Factor Adjustment will be applied in the event of any partial Surrender or full Surrender of the General Account Balance during the Accumulation Period, and on the Annuity Income Date (to the extent, if any, that the General Account Balance is applied to a Variable Annuity Option), but not during a Window Period. The Interest Rate Factor Adjustment is not applicable to the Separate Account or to Contracts issued to Pennsylvania residents. The Interest Rate Factor Adjustment is based on interest rates payable on U.S. Treasury securities. In general, if rates on U.S. Treasury securities are higher (or up to .30% lower) when you Surrender than when you made the applicable Purchase Payments, a negative Interest Rate Factor Adjustment will be applied, and in the event of a full Surrender, YOU COULD RECEIVE AN AMOUNT LOWER THAN THE GENERAL ACCOUNT BALANCE AT THE TIME OF SURRENDER AND EVEN LOWER THAN THE AMOUNT OF PURCHASE PAYMENTS MADE. If rates on U.S. Treasury secur-ities are more than .30% lower when you Surrender than when you made the applicable Purchase Payments, a positive Interest Rate Factor Adjustment will be applied, and in the event of a full Surrender, you could receive an amount higher than the General Account Balance. No Interest Rate Factor Adjustment will be applied during a Window Period; in addition, no Interest Rate Factor Adjustment will be applied to the General Account Free Surrender Amount. (For partial Surrenders of General Account Balance, the Interest Rate Factor Adjustment will be added to or subtracted from the remaining General Account Balance.) (See "Surrender Charge," page .) The Interest Rate Factor Adjustment will reflect the relationship between: (i) the weighted average of U.S. Treasury Index Rates corresponding to Purchase Payments and Transfers into the General Account during the current Five-Year Period (as adjusted for partial Surrenders or Transfers out of the General Account); (ii) the U.S. Treasury Index Rate which would be applicable during the time remaining in the current Five-Year Period on the date of the surrender; and (iii) the time remaining in the current Five-Year Period. The Interest Rate Factor Adjustment formula includes a set percentage factor (.30%) designed to compensate C.M. Life for certain expenses and losses that might be incurred as a direct or indirect result or consequence of Surrenders. In general, if the weighted average of U.S. Treasury Index Rates corresponding to Purchase Payments and Transfers during the current Five-Year Period is lower than the U.S. Treasury Index Rate which would be applicable during the time remaining in the current Five-Year Period (or exceeds such rate by less than .30%), then the application of the Interest Rate Factor Adjustment will result in a lower payment upon Surrender. Therefore, in order for there to be a positive Interest Rate Factor Adjustment, the U.S. Treasury Index Rate must have decreased sufficiently to offset this percentage factor; otherwise, the Interest Rate Factor Adjustment will be negative. In the event of a partial Surrender, there is no Interest Rate Factor Adjustment if the General Account Free Surrender Amount exceeds the General Account portion of such partial Surrender. There is no limit on the Interest Rate Factor Adjustment (except as required by state law with respect to a negative Interest Rate Factor Adjustment and as disclosed in Contracts issued in Oregon and Washington with respect to a positive Interest Rate Factor Adjustment). Additional information regarding the Interest Rate Factor Adjustment is included in Appendices II and III. MORTALITY AND EXPENSE RISK CHARGE C.M. Life imposes a daily charge as compensation for bearing certain mortality and expense risks in connection with the Contracts. This charge currently is 1.07% annually (equal to a daily rate of 0.002932%). It may increase, but it will not exceed an effective annual rate of 1.25% of the average daily value of net assets in the Separate Account. (The approximate portion of this charge estimated to be attributable to mortality risks is 0.42%; the approximate portion of this charge estimated to be attributable to expense risks is 0.65%.) The Mortality and Expense Risk Charge is reflected in the Accumulation Unit value or Annuity Unit value for the Contract for each Sub-Account. 33 Contract Balances and Annuity Income payments are not affected by changes in actual mortality experience nor by actual expenses incurred by C.M. Life. The mortality risks assumed by C.M. Life arise from its contractual obligations to make Annuity Income payments (determined in accordance with the annuity tables and other provisions contained in the Contract), and to pay Death Benefits prior to the Annuity Income Date. Thus, Contract Owners are assured that neither the Annuitant's own longevity, nor an unanticipated improvement in general life expectancy, will adversely affect the Annuity Income payments that the Annuitant will receive under the Contract. C.M. Life also bears substantial risk in connection with the Death Benefit. During the Accumulation Period C.M. Life will, if the deceased Annuitant or Contract Owner was a natural person less than age 75 at death, pay a Death Benefit equal to the greater of (a) the Contract Balance, or (b) the Purchase Payments less any prior partial surrenders and charges. Otherwise, the Death Benefit is based on the Contract Balance. The Death Benefit is paid without imposition of a Surrender Charge or the Interest Rate Factor Adjustment. The expense risk assumed by C.M. Life is the risk that C.M. Life's actual expenses in administering the Contract and the Separate Account will exceed the amount recovered through Administrative Charges. If the Mortality and Expense Risk Charge is insufficient to cover C.M. Life's actual costs, C.M. Life will bear the loss. Conversely, if the charge is more than sufficient to cover costs, the excess will be profit to C.M. Life. C.M. Life expects a profit from this charge. To the extent that the Surrender Charge is insufficient to cover the actual cost of Contract distribution, the deficiency will be met from C.M. Life's general corporate assets, which may include amounts derived from the Mortality and Expense Risk Charge. ADMINISTRATIVE CHARGES In order to cover the costs of administering the Contracts and the Separate Account, C.M. Life deducts a Contract Maintenance Fee from the Contract Balance of each Contract, and also deducts a daily Administrative Expense Charge from the assets of each Sub-Account of the Separate Account. CONTRACT MAINTENANCE FEE. A Contract Maintenance Fee is deducted from the Contract Balance of each Contract on the last day of each Contract Year during the Accumulation Period, and upon full Surrender of the Contract. The charge is not deducted after the Annuity Income Date. This Contract Maintenance Fee currently is $30 per Contract per Contract Year. It may be increased, but will not exceed $60. C.M. Life does not anticipate realizing any profit from this charge. The Contract Maintenance Fee will be deducted pro rata from the Sub-Accounts in the Separate Account and the General Account, in the same proportion that the amount of Contract Balance in each Sub-Account and the General Account bears to the total Contract Balance. For Contracts issued to Pennsylvania residents, the Fee will be calculated as a pro rata portion of the balance of each Sub-Account. ADMINISTRATIVE EXPENSE CHARGE. C.M. Life also deducts a daily Administrative Expense Charge from the assets of each Sub-Account of the Separate Account. This charge is currently at an effective annual rate of 0.07% (equal to a daily rate of 0.000192%). C.M. Life does not anticipate realizing any profit from this charge. The Administrative Expense Charge may be increased in the future, but the combined total of the Administrative Expense Charge and the Mortality and Expense Risk Charge will never exceed an effective annual rate of 1.50% of the average daily value of net assets in the Separate Account. PREMIUM TAXES C.M. Life may pay Premium Taxes in connection with Purchase Payments under the Contracts. Depending upon applicable state law, C.M. Life will deduct the Premium Taxes paid with respect to a particular Contract from the Purchase Payments, from the Contract Balance on the Annuity Income Date (thus reducing the Contract Balance), or upon the full Surrender of a Contract. Premium Taxes currently range from 0% to 4.28% of Purchase Payments. 34 FEDERAL, STATE AND LOCAL TAXES No charges are currently made for federal, state, or local taxes other than Premium Taxes. However, C.M. Life reserves the right to deduct charges in the future for such taxes, or other economic burden resulting from the application of any tax laws that C.M. Life determines to be attributable to the Contracts. OTHER EXPENSES INCLUDING INVESTMENT ADVISORY FEES Each Portfolio of the Funds is responsible for all of its expenses. In addition, charges will be made against each Portfolio of the Funds for investment advisory services provided to the Funds or the Portfolio. The net assets of each Portfolio of the Funds will reflect deductions in connection with investment advisory fees and other expenses. For more information concerning investment advisory fees and other charges against the Portfolios, see the prospectuses for the Funds, a current copy of which accompanies this Prospectus. DISTRIBUTOR OF THE CONTRACTS Effective May 1, 1996, MML Distributors, LLC ("MML Distributors") (formerly known as Connecticut Mutual Financial Services, LLC), 1414 Main Street, Springfield, MA 01144-1013, an affiliate of C.M. Life, is the principal underwriter of the Contracts pursuant to an Underwriting and Servicing Agreement to which MML Distributors and C.M. Life on behalf of the Separate Account are parties. Since March 1, 1996, MML Investors Services, Inc. ("MMLISI"), also located at 1414 Main Street, Springfield, MA 01144-1013, has served as the co-underwriter of the Contracts. Both MML Distributors and MMLISI are registered with the Securities and Exchange Commission ("SEC") as broker-dealers under the Securities Exchange Act of 1934 and are members of the National Association of Securities Dealers, Inc. ("NASD"). MML Distributors may enter into selling agreements with respect to the Contracts with other broker-dealers that are registered with the SEC and are members of the NASD ("selling brokers"). Contracts are sold through agents who are licensed under applicable insurance law to sell the Contracts. These agents are also registered representatives of selling brokers or of MMLISI. MML Distributors does business as MML Distributors, L.L.C. in the states of Illinois, Michigan, Oklahoma, South Dakota and Washington, and as MML Distributors, Limited Liability Company in the states of Maine, Ohio and West Virginia. Commissions of up to 6.0% of Purchase Payments are paid on Contract sales. GENERAL PROVISIONS ASSIGNMENT OF THE CONTRACT A Written Request specifying the terms of an assignment of the Contract must be provided to the Annuity Service Center. Until the Written Request is received at the Annuity Service Center, C.M. Life will not be required to take notice of, or be responsible for, any transfer of interest in the Contract by assignment, agreement, or otherwise. C.M. Life will not be responsible for the validity of tax consequences of any assignment. Any assignment made after the Death Benefit has become payable will be valid only with C.M. Life's consent. If the Contract is assigned, the Contract Owner's rights may only be exercised with the consent of the assignee of record. 35 CONTRACT CHANGES BY C.M. LIFE C.M. Life reserves the right to amend the Contract to meet the requirements of any applicable federal or state laws or regulations, or to make other changes permitted by the Contract. C.M. Life will notify the Contract Owner in writing of any such amendments. Any changes to the Contract by C.M. Life must be signed by an authorized officer of C.M. Life. Agents of C.M. Life have no authority to alter or modify any of the terms, conditions, agreements of the Contract, or to waive any of its provisions. CONTRACT TERMINATION The Contract will terminate upon the occurrence of any of the following events: 1. The date of the last Annuity Income payment; 2. The date payment is made of the Contract Balance; 3. The date of the last Death Benefit payment to the last Beneficiary; 4. The date the Contract is returned under the "Right to Examine Contract" provision, see page ; or 5. Failure to maintain the required Minimum Contract Balance. INCONTESTABILITY The Contract is incontestable. MISSTATEMENT OF AGE OR SEX If the Annuitant's age or sex has been incorrectly stated, the Annuity Income payable will be that which the Contract Balance, reduced by any applicable Premium Tax, would have purchased at the correct age and sex. After correction, the Annuitant will receive the sum of any underpayments made by C.M. Life within thirty (30) calendar days. The amounts of any overpayments made by C.M. Life will be charged against the payment(s) following the correction. NONPARTICIPATING The Contract is nonparticipating and will not share in any surplus earnings of C.M. Life. No dividends are payable on the Contract. NON-BUSINESS DAYS If the due date for any activity required by the Contract falls on a non-business day for C.M. Life, performance will be rendered on the first business day following the due date. REGULATORY REQUIREMENTS All interest guarantees, surrender benefits, and amounts payable at death will not be less than the minimum benefits approved under the laws and regulations of the state in which the Contract is delivered. C.M. Life will administer the Contract in accordance with the U.S. tax laws and regulations in order to retain its status as an annuity contract. 36 RIGHT TO EXAMINE CONTRACT No Surrender Charge will be applied if the Contract Owner returns the Contract for cancellation during the first fifteen (15) calendar days following the Contract Issue Date (or a longer period, if required by law). In addition, no Interest Rate Factor Adjustment, or Contract Maintenance Fee or premium tax will be applied upon such a cancellation. C.M. Life will refund the Separate Account Balance and/or any Purchase Payments made to the General Account upon return of the Contract. If required by state law, C.M. Life will refund any Purchase Payment regardless of whether they were allocated to one or more Sub-Account or to the General Account. CERTAIN FEDERAL INCOME TAX CONSEQUENCES THE FOLLOWING DISCUSSION IS A GENERAL DESCRIPTION OF FEDERAL TAX CONSIDERATIONS RELATING TO THE CONTRACT AND IS NOT INTENDED AS TAX ADVICE. THIS DISCUSSION IS NOT INTENDED TO ADDRESS THE TAX CONSEQUENCES RESULTING FROM ALL OF THE SITUATIONS IN WHICH A PERSON MAY BE ENTITLED TO OR MAY RECEIVE A DISTRIBUTION UNDER THE CONTRACT. ANY PERSON CONCERNED ABOUT THESE TAX IMPLICATIONS SHOULD CONSULT A COMPETENT TAX ADVISOR BEFORE INITIATING ANY TRANSACTION. THIS DISCUSSION IS BASED UPON C.M. LIFE'S UNDERSTANDING OF THE PRESENT FEDERAL INCOME TAX LAWS AS THEY ARE CURRENTLY INTERPRETED BY THE INTERNAL REVENUE SERVICE. NO REPRESENTATION IS MADE AS TO THE LIKELIHOOD OF THE CONTINUATION OF THE PRESENT FEDERAL INCOME TAX LAWS, OR OF THE CURRENT INTERPRETATION BY THE INTERNAL REVENUE SERVICE. MOREOVER, NO ATTEMPT HAS BEEN MADE TO CONSIDER ANY APPLICABLE STATE OR OTHER TAX LAWS. The Contract may be purchased on a non-tax-qualified basis ("Non-qualified Contract"), or purchased and used in connection with plans qualifying for favorable tax treatment ("Qualified Contract"). Qualified Contracts are designed for use by individuals whose premium payments are comprised solely of proceeds from and/or contributions under retirement plans which are intended to qualify as plans entitled to special income tax treatment under Sections 401(a), 403(b), 408, or 457 of the Internal Revenue Code of 1986, as amended (the "Code"). The ultimate effect of federal income taxes on the amounts held under a Contract, Annuity Income payments, the economic benefit to the Contract Owner, the Annuitant, or the Beneficiary depends on the type of retirement plan, on the tax and employment status of the individual concerned, and on the employer's tax status. In addition, certain requirements must be satisfied in purchasing a Qualified Contract with proceeds from a tax-qualified plan and receiving distributions from a Qualified Contract in order to continue receiving favorable tax treatment. Therefore, purchasers of Qualified Contracts should seek competent legal and tax advice regarding the suitability of the Contract for their situation, the applicable requirements, and the tax treatment of the rights and benefits of the Contract. The following discussion assumes that a Qualified Contract is purchased with proceeds from and/or contributions under retirement plans that qualify for the intended special federal income tax treatment. The following discussion is based on the assumption that the Contract qualifies as an annuity contract for federal income tax purposes. The Statement of Additional Information discusses the requirements for qualifying as an annuity. TAXATION OF ANNUITIES IN GENERAL. Section 72 of the Code governs taxation of annuities in general. C.M. Life believes that the Contract Owner who is a natural person generally is not taxed on increases in the value of a Contract until distribution occurs by withdrawing all or part of the Contract Balance (e.g., Surrenders or Annuity Income payments under the Annuity Option elected). For this purpose, the assignment, pledge, or agreement to assign or pledge any portion of the Contract Balance (and in the case of a Qualified Contract, any portion of an interest in the qualified plan) generally will be treated as a distribution. The taxable portion of a distribution (in the form of a single sum payment or an annuity) is taxable as ordinary income. 37 The Contract Owner of any annuity contract that is not a natural person generally must include in income any increase in the excess of the Contract's Contract Balance over the "investment in the contract" (discussed below) during the taxable year. There are some exceptions to this rule, and a prospective Contract Owner that is not a natural person may wish to discuss these with a competent tax adviser. The following discussion generally applies to a Contract owned by a natural person. SURRENDERS. In the case of a Surrender under a Qualified Contract, under section 72(e) of the Code, a ratable portion of the amount received is taxable, generally based on the ratio of the "investment in the contract" to the individual's total accrued benefit for balance under the retirement plan. The "investment in the contract" generally equals the amount of any premium payments paid by or on behalf of any individual for a Qualified Contract. (The investment in the Contract does not include amounts contributed by or on behalf of an individual by an employer.). For a Contract issued in connection with Qualified Plans, the "investment in the contract" can be zero. Special tax rules may be available for certain distributions from a Qualified Contract. With respect to Non-qualified Contracts, partial Surrenders are generally treated as taxable income to the extent that the Contract Balance immediately before the Surrender exceeds the "investment in the contract" at that time. The Contract Balance immediately before a partial Surrender may have to be increased by any positive Interest Rate Factor Adjustment which results from such a Surrender. There is, however, no definitive guidance on the proper tax treatment of Interest Rate Factor Adjustments, and the Contract Owner should contact a competent tax adviser with respect to the potential tax consequences of an Interest Rate Factor Adjustment. Full Surrenders are treated as taxable income to the extent that the amount received exceeds the "investment in the contract." ANNUITY INCOME PAYMENTS. Although tax consequences may vary depending on the annuity option elected under the Contract, under Code section 72(b), gross income generally does not include that part of any amount received as an annuity under an annuity contract that bears the same ratio to such amount as the "investment in the contract" bears to the expected return at the Annuity Income Date. In this respect (prior to recovery of the investment in the contract), there is generally no tax on the amount of each payment which represents the same ratio that the "investment in the contract" bears to the total expected value of the annuity payments for the term of the payments. However, the remainder of each income payment is taxable. In all cases, after the "investment in the contract" is recovered, the full amount of any additional annuity payments is taxable. PENALTY TAX. In the case of a distribution pursuant to a Non-qualified Contract, there may be imposed a federal penalty tax equal to 10% of the amount treated as taxable income. In general, however, there is no penalty tax on distributions: (1) made on or after the date on which the Contract Owner attains age 59 1/2; (2) made as a result of death or disability of the Contract Owner; (3) received in substantially equal periodic payments as a life annuity, or a joint and survivor annuity, for the lives or life expectancies of the Contract Owner and a "designated beneficiary"; (4) from a Qualified Plan where other rules apply; (5) allocable to investment in the Contract before August 14, 1982; (6) under a qualified funding asset (as defined in Code section 130(d)); (7) under an immediate annuity (as defined in Code section 72(u)(4)); or (8) which are purchased by an employer on termination of certain types of Qualified Plans, and which are held by the employer until the employee separates from service. Other similar tax penalties may apply to certain distributions under a Qualified Contract. TRANSFERS, ASSIGNMENTS, OR EXCHANGES OF THE POLICY. A transfer of ownership of a Contract, the designation of the Annuitant or other Beneficiary who is not also the Contract Owner, the designation of certain annuity dates, or the exchange of a Contract, may result in certain tax consequences to the Contract Owner that are not discussed here. The Contract Owner contemplating any such transfer, assignment, designation, or exchange of a Contract, should contact a competent tax adviser with respect to the potential tax effects of such a transaction. 38 MULTIPLE CONTRACTS. All Non-qualified Annuity Contracts that are issued by C.M. Life (or its affiliates) to the same Contract Owner during any calendar year are required by law to be are treated as one Annuity Contract for purposes of determining the amount includable in gross income under section 72(e) of the Code. In addition, the Treasury Department has specific authority to issue regulations that prevent the avoidance of section 72(e) through the serial purchase of annuity contracts or otherwise. Congress has also indicated that the Treasury Department may have authority to treat the combination purchase of an immediate annuity contract and separate deferred annuity contract as a single annuity contract under its general authority to prescribe rules as may be necessary to enforce the income tax laws. WITHHOLDING. The Unemployment Compensation Amendment Act of 1992 made significant changes under the Code for the treatment of distributions of Qualified Plans and Section 403(b) annuities. The Act amended Section 402 of the Code and expanded the types of distributions that can be rolled over tax-free to an Individual Retirement Account, another Qualified Plan, or a Section 403(b) annuity. Under the law, all taxable distributions from Qualified Plans and Section 403(b) annuities are eligible for rollover except 1) annuities paid over life or life expectancy; 2) installments for periods spanning ten (10) years or more; and 3) required minimum distributions under Section 401(a)(9). The Act also amended Section 3405 to impose mandatory 20% income tax withholding on any eligible rollover distribution that an employee receives personally and does not elect to have paid in a direct rollover. The law is effective for payments made after December 31, 1992. Payments that are not eligible for rollover remain subject to the existing pension annuity distribution rules, which are subject to withholding at the rate of 10% for lump sum distributions. Recipients of these types of distributions are generally provided with an opportunity to elect not to have tax withheld from the distributions. POSSIBLE CHANGES IN TAXATION. In past years, legislation has been proposed that would have adversely modified the federal taxation of certain annuities. For example, one such proposal would have changed the tax treatment of non-qualified annuities that did not have "substantial life contingencies" by taxing income as it is credited to the annuity. Although as of the date of this prospectus Congress is not actively considering any legislation regarding the taxation of annuities, there is always the possibility that the tax treatment of annuities could change by legislation or other means (such as IRS regulations, revenue rulings, judicial decisions, etc.). Moreover, it is also possible that any change could be retroactive (that is, effective prior to the date of the change). OTHER TAX CONSEQUENCES. As noted above, the foregoing discussion of the federal income tax consequences under the Contract is not exhaustive, and special rules are provided with respect to other tax situations not discussed in this Prospectus. Further, the federal income tax consequences discussed herein reflect C.M. Life's understanding of current law and the law may change. Federal estate, and state and local estate, inheritance, and other tax consequences of ownership, or receipt of distributions under the Contract, depend on the individual circumstances of each Contract Owner or recipient of the distribution. A competent tax adviser should be consulted for further information. QUALIFIED PLANS The Contract is designed for use with several types of Qualified Plans. The tax rules applicable to Contract Owners in Qualified Plans, including restrictions on contributions and benefits, taxation of distributions, and any tax penalties, vary according to the type of plan and the terms and conditions of the plan itself. Various tax penalties may apply to contributions in excess of specified limits, aggregate distributions in excess of $150,000 annually, distributions that do not satisfy specified requirements, and certain other 39 transactions with respect to Qualified Plans. Therefore, no attempt is made to provide more than general information about the use of the Contract with the various types of Qualified Plans. Contract Owners, Annuitants and Beneficiaries are cautioned that the rights of any person to any benefits under Qualified Plans may be subject to the terms and conditions of the plans themselves, regardless of the terms and conditions of the Contract. Some retirement plans are subject to distribution and other requirements that are not incorporated in the administration of the Contracts. Contract Owners are responsible for determining that contributions, distributions and other transactions with respect to the Contracts satisfy applicable law. Purchasers of Contracts for use with any retirement plan should consult their legal counsel and tax adviser regarding the suitability of the Contract. Following are brief descriptions of the various types of Qualified Plans in connection with which C.M. Life will issue the Contract. Contracts for all types of Qualified Plans may not be available in all states. When issued in connection with a Qualified Plan, the Contract will generally be subject to endorsement. QUALIFIED PENSION AND PROFIT SHARING PLANS. Section 401(a) of the Code permits corporate employers to establish various types of retirement plans for employees. Such retirement plans may permit the purchase of the Contract in order to provide benefits under the plans. Adverse tax consequences to the plan, to the participant or to both may result if this Contract is assigned or transferred to any individual as a means to provide benefit payments. The Self-Employed Individuals' Tax Retirement Act of 1962, as amended, commonly referred to as "H.R. 10," permits self-employed individuals to establish Qualified Plans for themselves and their employees. Purchasers of a Contract for use with such plans should seek competent advice regarding the suitability of the proposed plan documents and the Contract to their specific needs. INDIVIDUAL RETIREMENT ANNUITIES AND INDIVIDUAL RETIREMENT ACCOUNTS. Section 408 of the Code permits eligible individuals to contribute to an individual retirement program known as an Individual Retirement Annuity, or Individual Retirement Account (each hereinafter referred to as "IRA"). Individual Retirement Annuities are subject to limitations on the amount that may be contributed and deducted and the time when distributions may commence. Also, distributions from certain other types of Qualified Plans may be "rolled over" on a tax-deferred basis into an IRA. The sale of a Contract for use with an IRA may be subject to special disclosure requirements of the Internal Revenue Service. Purchasers of the Contract for use with IRAs will be provided with supplemental information required by the Internal Revenue Service or other appropriate agency. Such purchasers will have the right to revoke their purchase within seven (7) days of the earlier of the establishment of the IRA, or their purchase. Purchasers should seek competent advice as to the suitability of the Contract for use with IRAs. Additional information regarding IRAs is provided in Appendix IV, beginning on page . TAX-SHELTERED ANNUITIES. Section 403(b) of the Code permits public school employees, and employees of certain types of religious, charitable, educational, and scientific organizations, specified in Section 501(c)(3) of the Code, to purchase annuity contracts and, subject to certain limitations, exclude the amount of premiums from gross income for tax purposes. However, these payments may be subject to FICA (Social Security) taxes. These annuity contracts are commonly referred to as "Tax-Sheltered Annuities." Subject to certain exceptions, withdrawals under Tax-Sheltered Annuities which are attributable to contributions made pursuant to salary reduction agreements are prohibited unless made after the Contract Owner attains age 59 1/2, upon the Contract Owner's separation from service, upon the Contract Owner's death or disability, or for an amount not greater than the total of such contributions in the case of hardship. SECTION 457 DEFERRED COMPENSATION ("SECTION 457") PLANS. Under Section 457 of the Code, employees of (and independent contractors who perform services for) certain state and local governmental units, or certain tax-exempt employers, may participate in a Section 457 plan of their employer, allowing them to defer part of their salary or other compensation. The amount deferred, and any income on such amount, will not be taxable until paid or otherwise made available to the employee. Depending on the terms of the particular plan, the employer may be entitled to draw on deferred amounts for purposes unrelated to its section 457 plan obligations. In general, all amounts received under a section 457 plan are taxable. 40 The maximum amount that can be deferred under a Section 457 plan in any tax year is ordinarily one-third of the employee's includable compensation, up to $7,500. Includable compensation means earnings for services rendered to the employer which is includable in the employee's gross income, but excluding any contributions under the Section 457 plan, or a Tax-Sheltered Annuity. During the last three (3) years before an individual attains normal retirement age, additional "catch-up" deferrals are permitted. The deferred amounts will be used by the employer to purchase the Contract. The Contract will be issued to the employer, and all Contract Balances will be subject to the claims of the employer's creditors. The employee has no rights or vested interest in the Contract, and is only entitled to payment in accordance with the Section 457 plan provisions. Present federal income tax law does not allow tax-free transfers or rollovers for amounts accumulated in a Section 457 plan, except for transfers to other Section 457 plans in certain limited cases. RESTRICTIONS UNDER QUALIFIED CONTRACTS. Other restrictions with respect to the election, commencement, or distribution of benefits may apply under Qualified Contracts or under the terms of the plans in respect of which Qualified Contracts are issued. GENERAL At the time the initial Purchase Payment is paid, a prospective purchaser must specify whether he or she is purchasing a Non-qualified Contract or a Qualified Contract. If the initial Purchase Payment is derived from an exchange or surrender of another annuity contract, C.M. Life may require that the prospective purchaser provide information with regard to the federal income tax status of the previous annuity contract. C.M. Life will require that persons purchase separate Contracts if they desire to invest monies qualifying for different annuity tax treatment under the Code. Each such separate Contract would require the minimum initial Purchase Payment stated above. Additional Purchase Payments under a Contract must qualify for the same federal income tax treatment as the initial Purchase Payment under the Contract. C.M. Life will not accept an additional Purchase Payment under a Contract if the federal income tax treatment of such Purchase Payment would be different from that of the initial Purchase Payment. ADDITIONAL INFORMATION ABOUT C.M. LIFE THE BUSINESS OF C.M. LIFE C.M. Life, 140 Garden Street, Hartford, Connecticut, 06154, is a stock life insurance company. It was chartered by a Special Act of the Connecticut General Assembly on April 25, 1980. It is principally engaged in the sale of life insurance and annuities, and is licensed to sell insurance in all states except New York. As of December 31, 1995, C.M. Life is licensed to sell annuities in a majority of states and is seeking to be licensed in all states except New York. As of December 31, 1995, C.M. Life was a wholly owned subsidiary of Connecticut Mutual Life Insurance Company ("Connecticut Mutual"), the sixth oldest life insurance company in the United States, and the first life insurance company formed in Connecticut. Connecticut Mutual was chartered by a Special Act of the Connecticut General Assembly on 1846 and has continuously engaged in the insurance business since that time. On September 8, 1995, the Board of Directors of Connecticut Mutual approved the merger of Connecticut Mutual and Massachusetts Mutual Life Insurance Company ("MassMutual"). Thereafter, a definitive agreement was signed by both companies. On January 27, 1996. Connecticut Mutual and insurance subsidiary policyholders and other insureds and annuitants approved the merger. The merger was reviewed by the insurance regulatory authorities in Massachusetts and Connecticut, and approved. The merger was effective March 1, 1996. 41 MassMutual is a mutual life insurance company specially chartered by the Commonwealth of Massachusetts on May 14, 1851. It is currently licensed to transact life (including variable life), and accident and health insurance business in all states, the District of Columbia and certain provinces of Canada. The surviving company is the fifth largest mutual life insurance company, and the eighth largest life insurance company, in the United States, in each case based on the combined statutory total assets of MassMutual and Connecticut Mutual at December 31, 1994. Further references to Connecticut Mutual contained herein should be read to refer to MassMutual. SELECTED FINANCIAL DATA THE FOLLOWING SELECTED FINANCIAL DATA FOR THE COMPANY SHOULD BE READ IN CONJUNCTION WITH THE FINANCIAL STATEMENTS AND NOTES THERETO INCLUDED IN THIS PROSPECTUS AND THE RELATED MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. C.M. LIFE INSURANCE COMPANY SELECTED FINANCIAL DATA FOR THE YEARS ENDED DECEMBER 31, ($ IN THOUSANDS) RESERVES: 1995 1994 1993 1992 1991 - --------------------------------------- --------- --------- --------- --------- --------- Premiums, annuity considerations and other income.......................... $ 135,949 $ 112,222 $ 108,460 $ 117,805 $ 125,763 Less: reinsurance ceded (50,732) (54,032) (56,905) (60,830) (15,846) --------- --------- --------- --------- --------- Net premiums, annuity considerations and other income...................... 85,217 58,190 51,555 56,975 109,917 Net investment income and realized gains and losses...................... 67,675 57,354 57,919 56,286 53,187 --------- --------- --------- --------- --------- Total Revenue........................ 152,892 115,544 109,474 113,261 163,104 BENEFITS, LOSSES AND EXPENSES: Benefits, claims and settlement expenses.............................. 132,067 101,243 98,700 111,843 129,797 Other operating expenses............... 50,837 28,829 28,440 35,369 47,199 Less: reinsurance benefits and expenses ceded..................... (52,538) (45,804) (50,001) (54,537) (25,156) --------- --------- --------- --------- --------- Total Benefits, Losses and Expenses........................... 130,366 84,268 77,139 92,675 151,840 --------- --------- --------- --------- --------- Income Before Federal Income Tax Expense............................... 22,526 31,276 32,335 20,586 11,264 Federal Income Tax Expense............. 8,776 13,488 11,241 9,055 6,429 --------- --------- --------- --------- --------- Net Income............................. $ 13,750 $ 17,788 $ 21,094 $ 11,531 $ 4,835 --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- Total Assets........................... $1,533,748 $1,208,291 $ 970,010 $ 768,333 $ 664,755 --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
42 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS RESULTS OF OPERATIONS (DOLLAR AMOUNTS IN THOUSANDS) 1995 COMPARED WITH 1994 For the year ended December 31, 1995, C.M. Life had net income of $13,750, as compared with net income of $17,788 in 1994. The decrease in net income of $4,038 is attributable to increased benefit, claims and settlement expenses and increased acquisition and insurance expenses which exceeded the increase in net premiums and net investment income. Premiums before reinsurance ceded increased $23,040 to $134,278 in 1995 from $111,238 in 1994. Premiums for CM Windows, a single premium deferred annuity, increased $9,412 to $18,894 in 1995 from $9,482 in 1994. The increase is attributable to higher interest rates and increased promotional efforts, which increased demand for single premium deferred annuity products. Premiums for life insurance products increased $13,628 to $115,384 in 1995 from $101,756 in 1994 due to higher sales of universal life policies, primarily the Enterprise Plus product, as well as by increased renewal premiums. Reinsurance premiums ceded decreased by $3,300 in 1995. The decrease is attributable to the decrease in reinsured business as well as increased retention limits. The Enterprise Plus Universal Life product is not included in the C.M. Life/Connecticut Mutual reinsurance treaty. Net investment income increased by $8,928 over 1994. This increase is attributable to increased invested assets and policy loans. Net realized capital losses were $1,140 in 1995 as compared to net realized capital losses of $2,533 in 1994. This loss is due to realized net losses of $1,962, with $822 being transferred to the IMR (Interest Maintenance Reserve) in 1995 as compared to realized net losses of $7,332 in 1994, with $4,799 being transferred to the IMR. Benefits, claims and settlement expenses, before reinsurance benefit reimbursements, increased by $30,824 from 1994. Surrender benefits before reinsurance increased by $2,443, to $33,494 in 1995 from $31,051 in 1994 and reserves ceded increased $6,173. Contributing to the increase was an increase in death claims of $12,853, increased change in reserves of $8,300, increased reserves ceded of $6,173 and increased surrenders and other benefits of $3,498. Acquisition expenses increased $21,190 over 1994. This increase is attributable to increased sales, especially of the new Enterprise Plus Universal Life product. Income tax expense decreased by $4,712 over 1994. This decrease is attributable to lower taxable income in 1995 versus 1994. Taxable income was $27,726, $38,660 and $33,080 in 1995, 1994 and 1993, respectively. C.M. Life's Federal income tax expense is based on income which is currently taxable. The differences between pre-tax book income and taxable income are primarily for lower tax basis reserves for future policy benefits and other book/tax differences associated with gross investment income. RESULTS OF OPERATIONS (DOLLAR AMOUNTS IN THOUSANDS) 1994 COMPARED WITH 1993 For the year ended December 31, 1994, C.M. Life had net income of $17,788, as compared with net income of $21,094 in 1993. The decrease in net income of $3,306 is attributable to increased benefit, claims and settlement expenses as well as an increase in net realized capital losses and increased federal tax expense, partially offset by increased net premiums, net investment income and decreased reinsurance ceded and acquisition and insurance expenses. 43 Premiums before reinsurance ceded increased $3,141 to $111,238 in 1994 from $108,097 in 1993. Premiums for CM Windows, a single premium deferred annuity, increased $7,343 to $9,482 in 1994 from $2,139 in 1993. The increase is attributable to higher interest rates, which increased demand for single premium deferred annuity products. Premiums for life insurance products decreased $4,202 to $101,756 in 1994 from $105,958 in 1993 due to lower sales of new universal life policies and Executive Benefit Life policies offset by higher term policy sales. Reinsurance premiums ceded decreased by $2,873 in 1994. The decrease is attributable to the decrease in reinsured business as well as increased retention limits. Net investment income increased by $2,427 over 1993; this increase is attributable to increased invested assets. Net realized capital losses were $2,533 in 1994 as compared to a net realized gain of $459 in 1993. This loss is due to realized net losses of $7,332, with $4,799 being transferred to the IMR in 1994 as compared to realized net gains of $4,906 in 1993, with $4,447 of those being transferred to the IMR. The $7,332 loss included realized losses of $2,093 related to the bulk sale of a number of mortgages during 1994 and losses of $2,158 resulted from the sale of two real estate properties. There were no real estate sales in 1993. Benefits, claims and settlement expenses, before reinsurance benefit reimbursements increased by $2,543 from 1993. Surrender benefits before reinsurance increased by $2,116, to $31,051 in 1994 from $28,935 in 1993 and reserves ceded increased $4,928. This increase was partially offset by decreased death claims of $3,217 and decreased change in reserves of $1,580. Income tax expense increased by $2,247 over 1993. This increase is attributable to higher taxable income in 1994 versus 1993. Taxable income was $38,660, $33,080 and $27,414 in 1994, 1993 and 1992, respectively. C.M. Life's Federal income tax expense is based on income which is currently taxable. The differences between pre-tax book income and taxable income are primarily lower tax basis reserves for future policy benefits and other book/tax differences associated with gross investment income. LIQUIDITY AND CAPITAL RESOURCES C.M. Life's operations have historically provided substantial cash flow. The majority of the Company's cash is invested in investment-grade securities to provide ample protection for policyholders. The liabilities of the Company are predominantly long-term in nature and, therefore, the Company invests in long-term fixed maturity investments such as bonds. C.M. Life's liquidity requirements were met by funds provided from operations and investment activity. The primary uses of funds were to purchase investments and to pay commissions, insurance operating expenses and policy benefits. There is not expected to be any material change to C.M. Life's liquidity as a result of the merger of Connecticut Mutual and MassMutual. SEGMENT INFORMATION During 1995, 1994 and 1993, C.M. Life's operations consisted of one business segment which was principally the sale of universal life insurance and annuity products. C.M. Life is not dependent upon any single customer and no single customer accounted for more than 10% of revenues in 1995, 1994 or 1993. 44 RESERVES In accordance with the life insurance laws and regulations under which C.M. Life operates, it is obligated to carry on its books, as liabilities, actuarially determined reserves to meet its obligations on outstanding contracts. Reserves are based on mortality tables in general use in the United States and are computed to equal amounts that, with additions from premiums to be received, and with interest on such reserves computed annually at certain assumed rates, will be sufficient to meet C.M. Life's policy obligations at their maturities or in the event of an insured's death. In the accompanying financial statements, these reserves are determined in accordance with statutory regulations which is a generally accepted accounting principle for wholly owned stock life insurance subsidiaries of mutual life insurance companies. INVESTMENTS At December 31, 1995, the composition of C.M. Life's $976,511 of invested assets was 75.5% fixed maturities, 7.4% equity securities, 2.7% mortgage loans, 12.9% policy loans, and 1.5% cash and cash equivalents. FIXED MATURITIES C.M. Life invests in fixed maturities with the objective of balancing reasonable returns with liquidity, interest rate and credit risks. As a result, C.M. Life's fixed maturity portfolio consists primarily of government securities and high-quality marketable corporate securities. At December 31, 1995, the fixed maturity securities portfolio consisted of $675,850 of investment grade bonds, which represented 91.8% of the fixed maturity portfolio. Below investment grade bonds (those rated below "Baa") were $60,249, which represented 8.2% of the fixed maturity portfolio. Ratings are obtained from external rating agencies, and if not externally rated, are rated by C.M. Life internally using similar methods. The interest rates available on below-investment-grade securities are generally significantly higher than available on other corporate debt securities. Also the risk of loss due to default by the borrower is significantly greater with respect to such below-investment-grade securities for any of a number of reasons including: those securities are unsecured or subordinated to other creditors of the issuer, or are issued by companies that usually have high levels of indebtedness. C.M. Life attempts to minimize the exposure to any one issuer and by closely monitoring the credit worthiness of such issuers. C.M. Life's fixed maturity securities portfolio included $150,694 and $167,641 of mortgage-backed securities at December 31, 1995 and 1994, respectively. The mortgage-backed securities are subject to risks associated with variable prepayments of the underlying mortgages. Prepayments of the underlying mortgages cause those securities to have different actual maturities than scheduled at the time of purchase. The Company limits its investment risk by purchasing fixed maturities either guaranteed by U.S. government-sponsored entities or securities supported in the securitization structure by junior securities enabling the assets to achieve investment grade status. EQUITY SECURITIES In 1995, C.M. Life invested in common stock with the objective of securing long-term asset appreciation. MORTGAGE LOANS ON REAL ESTATE C.M. Life is not currently originating any mortgages. At December 31, 1995 and 1994, C.M. Life's mortgage loans were $26,705 and $42,038, respectively. Mortgage loans, as a percentage of invested assets, have decreased to 2.7% as of December 31, 1995, from 4.8% as of December 31, 1994. Management closely monitors the ongoing performance of the mortgage loan portfolio. Loans are reviewed individually to determine if other than temporary impairments exist. For non-performing loans, 45 reserves are established considering the value of the underlying collateral. Mortgage loans in the amount of $2,774, or 10.4% of the mortgage loan portfolio, were delinquent 90 days or more as of December 31, 1995. This compares with $2,774, or 6.6% of the mortgage loan portfolio at December 31, 1994. Restructured loans are loans whose terms such as interest rate, amortization, or maturity have been modified and are currently performing pursuant to such modified terms. C.M. Life restructures loans to protect its investment and only when it is anticipated that the borrower will be able to meet the modified terms. As of December 31, 1995 and 1994, $17,128 and $24,034 of mortgage loans have been restructured. POLICY LOANS As of December 31, 1995 and 1994, C.M. Life's policy loans were $126,014 and $109,720, respectively. Policy loans, as a percentage of invested assets, have increased from 12.5% in 1994 to 12.9% in 1995. Variable interest rate policy loans were 98.6% and 98.5% of total policy loans at December 31, 1995 and 1994, respectively. For loans with variable interest rates, the rates are adjusted annually based upon changes in a corporate bond index. COMPETITION C.M. Life is engaged in a business that is highly competitive because of the large number of stock and mutual life insurance companies and other entities marketing insurance products comparable to those of C.M. Life. MassMutual is the eighth largest life insurance company in the country with over $52 billion in life insurance assets and $103 billion in total assets. Best's Insurance Reports, Life-Health Edition, upgraded C.M. Life's rating on March 4, 1996 to the highest possible rating of A++ as a result of the merger. MassMutual's ratings were the highest possible from A.M. Best (A++), Duff & Phelps (AAA) and Standard & Poors (AAA), and the second-highest rating from Moody's Investors Service (Aa1). In management's view, independent ratings are significant factors in the competitiveness of insurance companies. TRANSACTIONS WITH CONNECTICUT MUTUAL Connecticut Mutual allocates certain expenses to C.M. Life for providing operating facilities, human resources, computer software development and managerial services. Total expenses allocated to C.M. Life were approximately $34,008, $16,412, and $18,831 in 1995, 1994 and 1993, respectively. The increase is attributable to increased sales for C.M. Life and decreased sales for the parent, Connecticut Mutual, resulting in a larger portion of certain expenses being allocated to C.M. Life. In the future, the parent company (MassMutual) will continue to allocate certain expenses to C.M. Life. REGULATION Currently, the Federal government does not directly regulate the business of insurance. However, Federal legislative, regulatory and judicial decisions and initiatives often have significant effects on C.M. Life's business. Types of changes that are most likely to affect C.M. Life's business include changes to: (a) the taxation of life insurance companies; (b) the tax treatment of insurance products; (c) the securities laws, particularly as they relate to insurance and annuity products; (d) the "business of insurance" exemption from any of the provisions of the anti-trust laws; and (e) declining barriers which prevent most banks from selling or underwriting insurance. C.M. Life could also be affected by federal initiatives that have impact on the ownership of or investment in United States companies by foreign companies or investors. NEW ACCOUNTING PRONOUNCEMENTS The Financial Accounting Standards Board (FASB) has issued an interpretation declaring that financial statements of mutual life insurance companies, and their wholly owned subsidiaries, which are prepared on 46 the basis of statutory accounting principles, will no longer be considered to be in conformity with Generally Accepted Accounting Principles (GAAP). This interpretation applies to financial statements issued for fiscal years beginning after December 15, 1995. Certain accounting principles for mutual life insurance companies, which will be required to be in compliance with GAAP, were also issued by the FASB and the American Institute of Certified Public Accountants in January 1995. The financial statement impact of adopting these accounting principles has not been determined by the Company. The effect of initially adopting the FASB interpretation will be reported retroactively through restatement of all previously issued financial statements presented for comparative purposes for fiscal years beginning after December 15, 1992. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Financial statements, in the form required by Regulation S-X, are set forth in this Prospectus. The Registrant is not required to file supplementary financial data specified by Item 302 of Regulation S-K. C.M. LIFE'S DIRECTORS AND EXECUTIVE OFFICERS POSITION WITH C.M. LIFE; NAME (AGE AT 5/01/96) YEAR COMMENCED OTHER POSITIONS DURING THE PAST FIVE (5) YEARS - ----------------------------- ----------------------- ---------------------------------------------------------- David E. Sams, Jr. (53) Director and President, President and Chief Financial Officer of MassMutaul since July 1993 (Principal March 1, 1996; President and Chief Executive Officer of Executive Officer) Connecticut Mutual from July 1993 until February 29, 1996; previously President and Chief Executive Officer of Capital Holding Corp. (now Providian Corporation) -- Agency Group; and Chairman, Commonwealth Life Insurance Company; Director, Compdent Dental Benefit Plans. J. Brinke Marcuccilli (41) Director, June 1995; Chief Executive Officer of MML Investors Services, Inc. Chief Financial Officer since March 1, 1996; Chief Financial Officer, Connecticut August 1994 Mutual from May 1994 until February 29, 1996; Vice President/Chief Financial Officer of Providian Corporation, Agency Group from January 1983 until May 1994. John A. Hubbard (42) Actuary, May 1987 Actuary, Connecticut Mutual from December 1991 until February 29, 1996; Associate Actuary, Connecticut Mutual, March 1990 until December 1991. Ann F. Lomeli (40) Secretary, December Vice President, Associate Corporate Secretary and 1988 Associate General Counsel of MassMutual since March 1, 1996; Corporate Secretary and Counsel of Connecticut Mutual from December 1988 until February 29, 1996. Emelia M. Bruno (47) Controller, August 1994 Corporate Comptroller of MassMutual since March 1, 1996; Controller of Connecticut Mutual from May 1994 until February 29, 1996, and Assistant Vice President of Connecticut Mutual from 1988 until February 29, 1996. Scott C. Peters (38) Treasurer, February Vice President and Treasurer from February 1994 until 1994 February 29, 1996; Associate Treasurer from August 1992 until February 1994; Assistant Vice President and Director of Treasury Operations from September 1990 until August 1992.
47 Effective June 9, 1995, Donald H. Pond, Jr., Director of C.M. Life since February 1990, Vice President and Chief Operating Officer of C.M. Life since August 1988, and Executive Vice President of Connecticut Mutual since November 1988, resigned from his positions at Connecticut Mutual and C.M. Life. Effective May 1995, Rodney O. Martin, Director of C.M. Life since May 1994, and Vice President and Chief Agency Officer of Connecticut Mutual since March 1990, resigned from his positions at Connecticut Mutual and C.M. Life Effective September 1, 1995, David J. Beed, Vice President of C.M. Life since March 1991 and Senior Vice President of Connecticut Mutual for Strategic Planning and Total Quality since June 1992, resigned from his positions at Connecticut Mutual and C.M. Life. Effective September 1995, Donald A. Skokan, Actuary for C.M. Life since February 1991 and Actuary for Connecticut Mutual since December 1989, resigned from his positions at Connecticut Mutual and C.M. Life. Effective May 17, 1995, John D. Loewenberg was elected Executive Vice President of C.M. Life, and a Director on June 9, 1995. He resigned from both of those positions on March 5, 1996. COMPENSATION OF C.M. LIFE'S DIRECTORS AND EXECUTIVE OFFICERS Until February 29, 1996, the officers and directors of C.M. Life were employees of Connecticut Mutual, and performed their duties for C.M. Life as part of their employment with Connecticut Mutual. As of March 1, 1996, C.M. Life became a wholly owned subsidiary of MassMutual. Many of the directors and officers of C.M. Life also serve as directors and officers of other companies that are also wholly-owned by MassMutual. Although applicable expense allocation agreements between and among MassMutual and its subsidiaries (such as C.M. Life) do not specifically allocate to the subsidiaries portions of the salaries paid by MassMutual, the amount of compensation received by any one director or officer of C.M. Life from MassMutual for services performed for C.M. Life would not exceed $100,000. The directors of C.M. Life do not receive fees (or expenses) for serving as directors of C.M. Life, or for attending directors' meetings. None of the officers or directors of C.M. Life owns shares of capital stock of C.M. Life, which is wholly-owned by MassMutual. The officers and directors of C.M. Life, individually and as a group, hold (by virtue of their ownership of insurance policies issued by MassMutual) interests in MassMutual of less than one (1) percent. ADDITIONAL INFORMATION ABOUT THE SEPARATE ACCOUNT ADDITION, DELETION OR SUBSTITUTION OF INVESTMENTS C.M. Life cannot and does not guarantee that any of the Sub-Accounts of the Separate Account, or Portfolios of the Funds, will always be available for Purchase Payments, allocations, or transfers. C.M. Life retains the right to make changes in the Separate Account and its investments. C.M. Life reserves the right to eliminate the shares of any Portfolio held by a Sub-Account, and to substitute shares of another Portfolio of the Funds, or of another registered open-end management investment company, for the shares of any Portfolio, if the shares of the Portfolio are no longer available for investment, or if, in C.M. Life's judgment, investment in any Portfolio would be inappropriate in view of the purposes of the Separate Account. To the extent required by the 1940 Act, substitutions of shares attributable to the Contract Owner's interest in a Sub-Account will not be made without prior notice to the Contract Owner and the prior approval of the SEC. Nothing contained herein shall prevent the Separate Account from purchasing other securities for other series or classes of variable annuity policies, or from effecting an exchange between series or classes of variable annuity policies on the basis of requests made by Contract Owners. 48 New Sub-Accounts may be established when, at the sole discretion of C.M. Life, marketing, tax, investment or other conditions warrant. Any new Sub-Accounts may be made available to existing Contract Owners on a basis to be determined by C.M. Life. Each additional Sub-Account will purchase shares in a Portfolio of the Funds, or in another mutual fund or investment vehicle. C.M. Life may also eliminate one or more Sub-Accounts if, at its sole discretion, marketing, tax, investment or other conditions warrant such change. In the event any Sub-Account is eliminated, C.M. Life will notify Contract Owners and request a reallocation of the amounts invested in the eliminated Sub-Account. In the event of any such substitution or change, C.M. Life may, by appropriate endorsement, make such changes in the Contracts as may be necessary or appropriate to reflect such substitution or change. Furthermore, if deemed to be in the best interests of persons having voting rights under the Contracts, the Separate Account may be (i) operated as a management company under the 1940 Act or any other form permitted by law, (ii) deregistered under the 1940 Act in the event such registration is no longer required, or (iii) combined with one or more other separate accounts. To the extent permitted by applicable law, C.M. Life also may transfer the assets of the Separate Account associated with the Contracts to another account or accounts. PERFORMANCE DATA From time to time the yield of the Money Market Sub-Account may be advertised. In addition, total returns for all of the Sub-Accounts may be advertised. These figures will be based on historical performance for the Portfolios and are not intended to and do not indicate future performance. The yield of the Money Market Sub-Account refers to the annualized income generated by an investment in that Sub-Account over a specified seven-day period. The yield is "annualized" by assuming that the income generated for that seven-day period is generated each seven-day period over a 52-week period, and is shown as a percentage of that investment. The effective yield is calculated similarly, but, when annualized, the income earned by an investment in that Sub-Account is assumed to be reinvested. The effective yield will be slightly higher than the yield because of the compounding effect of this assumed reinvestment. Total returns for the Money Market Sub-Account, the Income Sub-Account, the Total Return Sub-Account, the Growth Sub-Account, and the International Equity Sub-Account, may be calculated pursuant to a standardized formula or in non-standardized manners. The standardized total return of the Sub-Accounts refers to return quotations assuming an investment has been held in the Sub-Account for various periods of time including, but not limited to, one (1) year, five (5) years, and ten (10) years (if the Sub-Account has been in operation for those periods), and a period measured from the date the Sub-Account commenced operations. The total return quotations will represent the average annual compounded rates of return that would equate an initial investment of $1,000 to the redemption value of that investment as of the last day of each of the periods for which total return quotations are provided. Accordingly, the total return quotations will reflect not only income but also changes in principal value (that is, changes in the accumulation unit values), whereas the yield figures will only reflect income. In addition, the standardized total return quotations will reflect the Surrender Charge imposed on Surrenders, but the standardized yield figures will not. In addition, the Separate Account may from time to time also disclose total return in non-standard formats and cumulative total return for the Sub-Accounts. The non-standard average annual total return and cumulative total return would not reflect the Surrender Charge, which if reflected would lower the performance figures for periods of less than five (5) years. The Funds may from time to time also disclose standard total returns and non-standard total returns for the Sub-Accounts based on or covering periods of time other than those indicated above. All non-standard performance data will only be disclosed if the standard total return is also disclosed. For additional information regarding the calculation of performance data, please refer to the Statement of Additional Information. 49 Also from time to time, in advertisements, sales literature, or in reports to Contract Owners, the Separate Account may compare the performance of the Sub-Accounts to that of other variable accounts or investment vehicles with similar investment objectives, or to relevant indices published by recognized mutual fund or variable annuity statistical rating services, or publications of general variable annuity statistical rating services, or publications of general interest, such as Forbes or Money magazines. For example, a Sub-Account's performance might be compared to that of other accounts or investments with a similar investment objective as compiled by Lipper Analytical Services, Inc., VARDs, Morningstar, Inc., or by others. In addition, a Sub-Account's performance might be compared to that of recognized stock market indicators, including, but not limited to, the Standard & Poor's 500 Stock Index (which is a group of unmanaged securities widely regarded by investors as representative of the stock market in general), and the Dow Jones Industrial Average (which is a price-weighted average of 30 large, well-known industrial stocks that are generally the leaders in their industry). Performance comparisons should not be considered representative of the future performance of a Sub-Account. Performance data may also be calculated for shorter or longer base periods. The Separate Account may use various base periods as may be deemed necessary or appropriate to provide investors with the most informative performance data information, depending on the then-current market conditions. Performance will vary from time to time and historical results will not be representative of future performance. Performance information may not provide a basis for comparison with other investments or other investment companies using a different method of calculating performance. Current yield is not fixed and varies with changes in investment income and accumulation unit values. The Money Market Sub-Account's yield will be affected if it experiences a net inflow of new money which is invested at interest rates different from those being earned on its then-current investments. An investor's principal in a Sub-Account and a Sub-Account's return are not guaranteed and will fluctuate according to market conditions. And, as noted above, advertised performance data figures will be historical figures for a Contract during the Accumulation Period. The Separate Account may also from time to time, in advertisements, sales literature or in reports to shareholders, discuss the Separate Account's fees and compare those fees to industry averages and to other variable accounts. The Separate Account may also discuss the total amount of money invested in variable annuities. VOTING RIGHTS There are no voting rights associated with the General Account Balance. With respect to the Separate Account Balance, C.M. Life will be the "shareholder" of the Funds, and as such, C.M. Life will have certain voting rights. However, to the extent required by law, C.M. Life will vote the Funds shares held by the Separate Account at regular and special shareholder meetings of the Funds in accordance with instructions received from persons having voting interests in the Portfolios. If, however, the 1940 Act or any regulation thereunder should be amended, or if the present interpretation thereof should change, and as a result C.M. Life determines that it is permitted to vote the Funds' shares in its own right, it may elect to do so. Before the Annuity Income Date, the Contract Owner holds the voting interest in the selected Portfolios. The number of votes that the Contract Owner has the right to instruct will be calculated separately for each Sub-Account. The number of votes that the Contract Owner has the right to instruct for a particular Sub-Account will be determined by dividing his or her Contract Balance in the Sub-Account by the net asset value per share of the corresponding Portfolio in which the Sub-Account invests. Fractional shares will be counted. After the Annuity Income Date, the person receiving Annuity Payments has the voting interest, and the number of votes decreases as Annuity Payments are made and as the reserves for the Contract decrease. The 50 person's number of votes will be determined by dividing the reserve for the Contract allocated to the applicable Sub-Account by the net asset value per share of the corresponding Portfolio of the Funds. Fractional shares will be counted. The number of votes that the Contract Owner, or person receiving income payments, has the right to instruct will be determined as of the date established by the Funds for determining shareholders eligible to vote at the meeting of the Funds. C.M. Life will solicit voting instructions by sending Contract Owners, or other persons entitled to vote, written requests for instructions prior to that meeting, in accordance with procedures established by the Funds. Portfolio shares for which no timely instructions are received may be voted in proportion to the voting instructions that are received with respect to all Contracts participating in the same Sub-Account. Shares held by C.M. Life or its affiliates, in which Contract Owners or other persons entitled to vote have no beneficial interest, may be voted by the shareholder thereof (C.M. Life or its affiliates) at its sole discretion. Each person having a voting interest in a Sub-Account will receive proxy material, reports, and other materials relating to the appropriate Portfolio. It should be noted that the Funds are not required to, and do not intend to, hold annual or other regular meetings of shareholders. REGULATION C.M. Life is organized as a Connecticut stock life insurance company, and is subject to Connecticut law governing insurance companies. C.M. Life is regulated and supervised by the Connecticut Commissioner of Insurance. By March 1 of each year, C.M. Life must prepare and file an annual statement, in a form prescribed by the Connecticut Insurance Department, which covers C.M. Life's operations for the preceding calendar year, and must prepare and file a statement of financial condition as of December 31 of such year. The Commissioner and his or her agents have the right at all times to review or examine C.M. Life's books and assets. A full examination of C.M. Life's operations will be conducted periodically according to the rules end practices of the National Association of Insurance Commissioners ("NAIC"). C.M. Life is also subject to the insurance laws of the states in which it is authorized to do business, to various federal and state securities laws and regulations, and to regulatory agencies which administer those laws and regulations. C.M. Life can be assessed up to prescribed limits for policyholder losses incurred by insolvent insurers under the insurance guaranty fund laws of most states. C.M. Life cannot predict or estimate the amount any such future assessments it may have to pay. However, the insurance guaranty laws of most states provide for deferring payment, or exempting a company from paying such an assessment, if it would threaten such insurer's financial strength. Several states, including Connecticut, also regulate insurers and their affiliates, such as C.M. Life and its affiliates, under insurance holding company laws and regulations. Under such laws, inter-company transactions such as dividend payments to parent companies and transfers of assets, may be subject to prior notice and approval, depending on factors such as the size of the transaction in relation to the financial position of the companies. Currently, the Federal government does not directly regulate the business of insurance. However, federal legislative, regulatory and judicial decisions and initiatives often have significant effects on C.M. Life's business. Types of changes that are most likely to affect C.M. Life's business include changes to: (a) the taxation of life insurance companies; (b) the tax treatment of insurance products; (c) the securities laws, particularly as they relate to insurance and annuity products; (d) the "business of insurance" exemption from many of the provisions of the anti-trust laws; and (e) the barriers preventing most banks from selling or underwriting insurance. C.M. Life could also be affected by federal initiatives that have impact on the 51 ownership of or investment in United States companies by foreign companies or investors. C.M. Life alone, and not the federal Government, or any of its agencies or instrumentalities, backs the guarantees associated with the Contracts. LEGAL PROCEEDINGS C.M. Life is not involved in any litigation that is of material importance in relation to its General Account assets. In addition, there are no legal proceedings to which the Separate Account is a party. AVAILABLE INFORMATION C.M. Life is subject to the informational requirements of the Securities Exchange Act of 1934, and, in accordance therewith, files reports and other information with the SEC. Such reports and other information can be inspected and copied at the public reference facilities of the SEC, at Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549. Copies of such materials also can be obtained from the Public Reference Section of the Commission, at 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. C.M. Life has filed registration statements (the "Registration Statements") with the SEC under the Securities Act of 1933 relating to the Contracts offered by this Prospectus. This Prospectus has been filed as part of the Registration Statements, and does not contain all of the information set forth in the Registration Statements. Reference is hereby made to such Registration Statements for further information relating to C.M. Life and the Contracts. The Registration Statements may be inspected and copied, and copies can be obtained at prescribed rates in the manner set forth in the preceding paragraph. 52 STATEMENT OF ADDITIONAL INFORMATION TABLE OF CONTENTS A Statement of Additional Information is available (at no cost) which contains more details concerning the subjects discussed in this Prospectus. The following is the Table of Contents for that Statement. TABLE OF CONTENTS Page ---- More Information About the Contract. . . . . . . . . . . . . . . . . . . . . B-3 Determination of Sub-Account Accumulation Unit Values . . . . . . . . . B-3 Annuity Period Transfer Formulas. . . . . . . . . . . . . . . . . . . . B-5 Records, Reports and Services. . . . . . . . . . . . . . . . . . . . . . . . B-6 Performance Data and Calculations. . . . . . . . . . . . . . . . . . . . . . B-7 Money Market Sub-Account Yield. . . . . . . . . . . . . . . . . . . . . B-7 Sub-Account Total Return Calculations: Standardized . . . . . . . . . . B-8 Other Performance Data: Non-Standardized. . . . . . . . . . . . . . . . B-9 Federal Tax Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-9 Other Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .B-14 Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . .B-15 Panorama Plus Separate Account . . . . . . . . . . . . . . . . . . . . . . .B-16 53 FINANCIAL STATEMENTS The financial statements for C.M. Life and the related report of independent public accountants are contained in this Prospectus. The Statement of Additional Information contains financial statements for the Separate Account. Arthur Andersen LLP, Hartford, Connecticut 06103, serves as independent auditors for the Separate Account. The financial statements included (incorporated by reference) in this Prospectus and elsewhere in this Registration Statement have been audited by Arthur Andersen LLP, as indicated in their reports with respect thereto, and are included here in reliance upon the authority of said firm as experts in accounting and auditing in giving said reports. 54 REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS To C.M. Life Insurance Company: We have audited the accompanying balance sheets of C.M. Life Insurance Company (a Connecticut corporation and a wholly owned subsidiary of Connecticut Mutual Life Insurance Company) as of December 31, 1995 and 1994, and the related statements of operations, stockholder's equity and cash flows for each of the three years in the period ended December 31, 1995. These financial statements and the schedules referred to below are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedules based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of C.M. Life Insurance Company as of December 31, 1995 and 1994, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 1995 in conformity with generally accepted accounting principles. Our audits were made for the purpose of forming an opinion on the basic financial statements taken as a whole. Schedules I and VI are presented for purposes of complying with the Securities and Exchange Commission's rules and are not part of the basic financial statements. These schedules have been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, fairly state in all material respects the financial data required to be set forth therein in relation to the basic financial statements taken as a whole. Arthur Andersen LLP Hartford, Connecticut February 15, 1996 (Except with respect to the matter discussed in Note 13, as to which the date is March 4, 1996.) -55- INDEX TO FINANCIAL STATEMENTS AND SCHEDULES C.M. LIFE INSURANCE COMPANY BALANCE SHEETS AS OF DECEMBER 31, 1995 AND 1994 . . . . . . . . . . . . . . . . . . . . . . . . C.M. LIFE INSURANCE COMPANY STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 . . . . . . . . . . . . . . C.M. LIFE INSURANCE COMPANY STATEMENTS OF STOCKHOLDER'S EQUITY FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 . . . . . . . . . . . . . . C.M. LIFE INSURANCE COMPANY STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 . . . . . . . . . . . . . . C.M. LIFE INSURANCE COMPANY NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1995, 1994 AND 1993 . . . . . . . . . . . . . . . . . . . . . . . . -56- C.M. LIFE INSURANCE COMPANY BALANCE SHEETS AS OF DECEMBER 31, 1995 AND 1994 ($ IN THOUSANDS EXCEPT PER SHARE AMOUNTS) 1995 1994 ---- ---- ASSETS: Investments: Fixed maturities at cost (fair value: $767,888 in 1995 and $684,213 in 1994) $ 736,099 $ 717,291 Preferred stock at cost (fair value: $210 in 1995 and $2,065 in 1994) 263 1,815 Common stock at market value (cost: $64,225 in 1995) 72,361 -- Mortgage loans on real estate net realizable value 26,705 42,038 Real estate at cost -- 1,897 Policy loans at outstanding balance 126,014 109,720 Cash and cash equivalents 15,069 3,025 ---------- ---------- Total investments 976,511 875,786 Accrued investment income 14,781 14,023 Premiums due and deferred 6,831 5,330 Amounts due from reinsurers 902 1,162 Other assets 3,291 2,318 Assets of Separate Account 531,432 309,672 ---------- ---------- TOTAL ASSETS $1,533,748 $1,208,291 ---------- ---------- ---------- ---------- LIABILITIES AND STOCKHOLDER'S EQUITY: LIABILITIES: Future policy benefits $ 813,188 $ 751,808 Policy claims and benefits currently payable 2,026 1,722 Indebtedness to related parties 12,624 6,965 Federal income tax payable 2,820 2,446 Asset valuation reserve 15,868 6,640 Other liabilities 10,622 7,906 Other deposits 54,269 31,690 Transfers due from Separate Account (22,300) (14,445) Liabilities of Separate Account 531,432 309,672 ---------- ---------- TOTAL LIABILITIES $1,420,549 $1,104,454 ---------- ---------- COMMITMENTS AND CONTINGENCIES -- SEE NOTE 12 STOCKHOLDER'S EQUITY: Common stock, $200 par value - 50,000 shares authorized, 2,500 2,500 12,500 shares issued and outstanding Additional paid-in capital 43,759 43,759 Retained earnings 66,940 57,578 ---------- ---------- TOTAL STOCKHOLDER'S EQUITY 113,199 103,837 ---------- ---------- TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY $1,533,748 $1,208,291 ---------- ---------- ---------- ----------
The accompanying notes are an integral part of these financial statements. -57- C.M. LIFE INSURANCE COMPANY STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 ($ IN THOUSANDS) 1995 1994 1993 ---- ---- ---- REVENUES: Premiums and annuity considerations $134,278 $111,238 $108,097 Less: reinsurance ceded (50,732) (54,032) (56,905) -------- -------- -------- Net premiums and annuity considerations 83,546 57,206 51,192 Net investment income 68,815 59,887 57,460 Net realized capital (losses) gains on investments (1,140) (2,533) 459 Other income 1,671 984 363 -------- -------- -------- TOTAL REVENUES 152,892 115,544 109,474 -------- -------- -------- BENEFITS, LOSSES AND EXPENSES: Benefits, claims and settlement expenses 132,067 101,243 98,700 Acquisition and insurance expenses 45,820 24,630 25,436 Other expenses 5,017 4,199 3,004 Less: reinsurance benefits and expenses ceded (52,538) (45,804) (50,001) -------- -------- -------- TOTAL BENEFITS, LOSSES AND EXPENSES 130,366 84,268 77,139 -------- -------- -------- INCOME BEFORE FEDERAL INCOME TAX EXPENSE 22,526 31,276 32,335 FEDERAL INCOME TAX EXPENSE 8,776 13,488 11,241 -------- -------- -------- NET INCOME $13,750 $17,788 $21,094 -------- -------- -------- -------- -------- --------
The accompanying notes are an integral part of these financial statements. -58- C.M. LIFE INSURANCE COMPANY STATEMENTS OF STOCKHOLDER'S EQUITY FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 ($ IN THOUSANDS) 1995 1994 1993 ---- ---- ---- Common Stock $ 2,500 $ 2,500 $ 2,500 Additional Paid-in Capital 43,759 43,759 43,759 -------- -------- ------- 46,259 46,259 46,259 Retained Earnings Balance, beginning of year 57,578 41,639 21,163 Net income 13,750 17,788 21,094 Change in asset valuation reserve (9,228) (106) (1,313) Change in nonadmitted assets (1,157) (1,761) 675 Net unrealized capital gain 5,997 18 84 Other -- -- (64) -------- -------- ------- Balance, end of year 66,940 57,578 41,639 -------- -------- ------- TOTAL STOCKHOLDER'S EQUITY $113,199 $103,837 $87,898 -------- -------- ------- -------- -------- -------
The accompanying notes are an integral part of these financial statements. -59- C.M. LIFE INSURANCE COMPANY STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 ($ IN THOUSANDS) 1995 1994 1993 ---- ---- ---- CASH PROVIDED: Premiums and annuity considerations, net of reinsurance $ 82,207 $ 56,346 $ 49,530 Other deposits 177,301 193,970 129,030 Net investment income 69,306 60,886 58,728 Commission and expense allowance and reserve adjustment 13,904 22,484 29,576 on reinsurance ceded Other 9,196 -- 2,106 --------- --------- --------- 351,914 333,686 268,970 --------- --------- --------- Benefits and interest to policyholders and beneficiaries, net (58,415) (43,808) (28,973) of reinsurance Acquisition and insurance expenses, net of reinsurance (49,690) (25,934) (28,619) Transfers to Separate Account (135,757) (168,913) (114,917) Federal income taxes paid (8,445) (10,076) (11,579) Other payments, net (17,838) (15,132) (17,903) --------- --------- --------- (270,145) (263,863) (201,991) --------- --------- --------- Net cash provided by operations 81,769 69,823 66,979 Proceeds from the disposition of: Fixed maturities 382,105 224,884 334,801 Equity securities 11,191 -- 2,629 Mortgage loans on real estate 12,725 24,154 10,833 Other cash provided -- -- 855 --------- --------- --------- Total cash provided 487,790 318,861 416,097 --------- --------- --------- CASH APPLIED: Purchases of fixed maturities 401,658 320,272 408,017 Purchases of equity securities 72,911 -- 296 Other applications 1,177 1,153 3,974 --------- --------- --------- Total cash applied 475,746 321,425 412,287 --------- --------- --------- Net increase (decrease) in cash and cash equivalents 12,044 (2,564) 3,810 CASH AND CASH EQUIVALENTS: Beginning of year 3,025 5,589 1,779 --------- --------- --------- End of year $ 15,069 $ 3,025 $ 5,589 --------- --------- ---------
The accompanying notes are an integral part of these financial statements. -60- C.M. Life Insurance Company Notes to Financial Statements December 31, 1995, 1994 and 1993 ($ In Thousands) 1. ORGANIZATION: C.M. Life Insurance Company (C.M. Life) is a wholly owned stock life insurance subsidiary of Connecticut Mutual Life Insurance Company (Connecticut Mutual). C.M. Life is primarily engaged in the sale of individual life insurance and annuity products. C.M. Life is licensed to transact business in all states except New York. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: C.M. Life's financial statements have been prepared in conformity with accounting practices and procedures of the National Association of Insurance Commissioners (NAIC) as prescribed or permitted by the Insurance Department of the State of Connecticut, which are considered to be generally accepted accounting principles (GAAP) for wholly owned stock life insurance subsidiaries of mutual life insurance companies. (see Note 2.h.). The principal accounting practices currently followed by C.M. Life are as follows: a. Assets -- Assets are stated at amounts reported to state regulatory authorities. Certain assets, such as prepaid agent commissions and other prepaid expenses, are excluded from the balance sheet and amounted to $3,839 and $2,684 as of December 31, 1995 and 1994. b. Investments -- Investments are valued in accordance with procedures prescribed by the NAIC. Fixed maturities eligible for amortization are reported at amortized cost. Eligible preferred stocks are reported at cost and common stocks are reported at market value. Mortgage loans on real estate are reported at the unpaid principal balance unless delinquent, at which time they are reported at the lower of the unpaid principal balance or fair value. Investments in real estate which have been identified for possible sale within the next twelve months are reported at the lower of cost, less accumulated depreciation or market value. The Company calculates depreciation for its real estate investments using principally the straight line method. Policy loans are reported at the aggregate amount of the unpaid balances. The Company maintains an Interest Maintenance Reserve (IMR), prescribed by the NAIC, for all fixed income investments and defers all interest rate related losses, net of taxes, as they occur. The deferral is subsequently amortized to net investment income over the period remaining to maturity of the assets sold. All other realized gains and losses are reported in the Statements of Operations upon sale. Unrealized capital gains and losses are reported as additions to or reductions from retained earnings. The Asset Valuation Reserve (AVR), prescribed by the NAIC, provides a general reserve for possible decline in the value of bonds, stocks, mortgage loans, real estate and other invested assets. The reserve is computed based on prescribed factors, each designed to address specific asset risks. Changes in the AVR are charged or credited directly to retained earnings. The AVR increased by $9,228 and $106 in 1995 and 1994, respectively. There were no investments which exceeded 10% of total stockholder's equity as of December 31, 1995 and 1994. Loans overdue more than 12 months were as follows: -61- 1995 1994 ---- ---- Defaults on mortgages: (non-income producing for 12 months) $2,774 $2,774
c. Disclosure of the Fair Value of Financial Instruments -- Fair value is defined as "the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale." See Note 8. d. Reserves for Payment of Future Benefits: Reserves for payment of future benefits on life insurance, developed using accepted actuarial methods, are established and maintained primarily on the Commissioners' Reserve Valuation Method utilizing the 1980 Commissioners' Standard Ordinary Mortality Table with interest rates of 4%-4 1/2%. Reserves for single premium deferred annuities are calculated based on the Commissioners' Annuity Reserve Valuation Method utilizing the change in fund method and assuming interest on changes in funds of 8.0%, 7.0% and 7.5% in 1995, 1994 and 1993, respectively. Additional reserves are maintained for contracts where the cash surrender value exceeds the actuarially determined reserve. e. Separate Accounts: Separate accounts include the assets and liabilities of certain annuity contracts that must be segregated from C.M. Life's general assets under the terms of the contracts. The assets consist primarily of marketable securities reported at market value. Reserves for these annuity contracts have been established using assumed interest rates and valuation methods that will provide reserves at least as great as those required by law and contract provisions. Transfers due from Separate Account, a contra-liability, represents Separate Account liabilities in excess of Separate Account reserves. f. Premiums and Insurance Operating Expenses: Premiums are reported as income when due. Commissions and other costs relating to the solicitation, underwriting and issuance of new contracts are reported as acquisition and insurance expenses in the year incurred. g. Cash Equivalents: For purposes of the Statements of Cash Flows, C.M. Life considers all highly liquid short-term investments with a maturity of twelve months or less from the date of purchase to be cash equivalents. The carrying amounts reported approximate those assets' fair value. h. New Accounting Pronouncements: The Financial Accounting Standards Board (FASB) has issued an interpretation stating that financial statements of mutual life insurance companies, and their wholly owned subsidiaries, which are prepared on the basis of statutory accounting principles, will no longer be considered to be in conformity with GAAP. This interpretation applies to financial statements issued for fiscal years beginning after December 15, 1995. Certain accounting principles for mutual life insurance companies, which will be required to be in compliance with GAAP, were also issued by the FASB and the American Institute of Certified Public Accountants in January 1995. The financial statement impact of adopting these accounting principles has not been determined by the Company. The effect of initially adopting the FASB interpretation shall be reported retroactively through restatement of all previously issued financial statements presented for comparative purposes for fiscal years beginning after December 15, 1992. i. Reclassifications: The 1994 and 1993 financial statements and Notes to Financial Statements reflect certain reclassifications to conform with the 1995 presentation. j. Certain Risks and Uncertainties: The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as well as disclosures of contingent assets and liabilities, both at the date of the financial statements. Management must also make estimates and assumptions that affect amounts of revenues and expenses for the reporting period. Actual results could differ from these estimates. -62- Future events, which could impact the estimates used in these financial statements, include changes in the levels of mortality and interest rates. 3. FEDERAL INCOME TAXES: C.M. Life is included in Connecticut Mutual's consolidated Federal income tax return and, in accordance with a written tax-sharing agreement, makes a provision for payment to Connecticut Mutual based on its income included in Connecticut Mutual's consolidated taxable income. This provision is based on income which is currently taxable. 4. STOCKHOLDER'S EQUITY: The Board of Directors of Connecticut Mutual has authorized the contribution of funds to C.M. Life sufficient to meet the capital requirements of all states in which C.M. Life is licensed to do business. Substantially all of the statutory stockholder's equity is subject to dividend restrictions relating to various state regulations which limit the payment of dividends without prior approval. 5. REINSURANCE: C.M. Life reinsures (cedes) a portion of its life insurance business to Connecticut Mutual and other insurers, in order to reduce insurance risk. C.M. Life's retention limit per individual insured is $4 million; the portion of the risk exceeding the retention limit is reinsured with other insurers. The reinsurance contract with Connecticut Mutual is a modified coinsurance quota-share treaty. Under the treaty C.M. Life cedes 50% of the premiums on universal life policies issued in 1985 and 75% of the premiums with issue dates on or after January 1, 1986. In return Connecticut Mutual pays C.M. Life a stipulated expense allowance, death and surrender benefits, and a modified coinsurance adjustment. Reserves for payment of future benefits for the ceded policies are retained by C.M. Life. C.M. Life also has a stop-loss agreement with Connecticut Mutual under which C.M. Life cedes claims which, in aggregate, exceed $24,245 in 1995, $18,348 in 1994, and $16,431 in 1993. In 1995, 1994, and 1993, the limit was not exceeded. The agreement was amended and renewed in 1994 for a duration of three years. The amended maximum coverage is $25,000. C.M. Life paid approximately $602, $435, and $446 in premiums under the agreement in 1995, 1994 and 1993, respectively. C.M. Life is contingently liable with respect to ceded reinsurance in the event any reinsurer is unable to fulfill its contractual obligations. 6. INVESTMENTS: FIXED MATURITIES: The carrying value and estimated fair value of investments in fixed maturities as of December 31, 1995 and 1994 are as follows: -63- Gross Gross Estimated Carrying Unrealized Unrealized Fair 1995 Value Gains Losses Value - ---- -------- ---------- ---------- --------- U.S. Government $ 24,102 $ 1,764 $ 2 $ 25,864 Special Revenue and Special Assessment Obligations and all Non-guaranteed Obli- gations of Government Agencies, Authorities, and Subdivisions 3,715 -- 6 3,709 Foreign Government, Province & Municipal 11,186 483 295 11,374 Public Utility 45,150 2,303 16 47,437 Mortgage Backed Obligations 150,694 7,144 347 157,491 Industrial and Miscellaneous 501,252 21,472 711 522,013 -------- ------- --------- -------- Total Fixed Maturities $736,099 $33,166 $ 1,377 $767,888 -------- ------- --------- -------- -------- ------- --------- -------- Gross Gross Estimated Carrying Unrealized Unrealized Fair 1994 Value Gains Losses Value - ---- -------- ---------- ---------- --------- U.S. Government $ 62,501 $ -- $ 1,874 $ 60,627 Special Revenue and Special Assessment Obligations and all Non-guaranteed Obli- gations of Government Agencies, Authorities, and Subdivisions 4,373 -- 375 3,998 Foreign Government, Province & Municipal 16,175 117 904 15,388 Public Utility 38,773 227 1,605 37,395 Mortgage Backed Obligations 167,641 533 12,184 155,990 Industrial and Miscellaneous 427,828 967 17,980 410,815 -------- ------- --------- -------- Total Fixed Maturities $717,291 $ 1,844 $ 34,922 $684,213 -------- ------- --------- -------- -------- ------- --------- --------
The carrying value and estimated fair value of C.M. Life's fixed maturities at December 31, 1995, by contractual maturity, are shown below. Actual maturities may differ from contractual maturities because borrowers may have the right to prepay obligations with or without prepayment penalties. Estimated Carrying Fair Value Value -------- --------- Due in one year or less $ 17,729 $ 17,781 Due after one year through five years 306,539 313,886
-64- Due after five years through ten years 225,283 240,231 Due after ten years 35,854 38,499 Mortgage-backed securities 150,694 157,491 ------- ------- Total $736,099 $767,888 -------- -------- -------- --------
Proceeds from sales of fixed maturities were $380,567, $224,884, and $334,801 for 1995, 1994 and 1993, respectively. Gross gains of $3,598, $1,358, and $5,931 and gross losses of $4,658, $4,439, and $1,016 were realized on those sales for 1995, 1994 and 1993, respectively. MORTGAGE LOANS ON REAL ESTATE: The following table provides a breakdown of the carrying value of mortgage loans on real estate by geographical location: 1995 1994 ------- -------- United States Northeast $15,241 $22,111 South Atlantic 8,187 13,090 South Central -- 3,462 West 3,277 3,375 ------- -------- Total $26,705 $42,038 ------- -------- ------- --------
Outstanding mortgages whose terms have been modified aggregated $17,128 and $24,034 which represents 64.1% and 57.2% of the total portfolio as of December 31, 1995 and 1994, respectively. Income recognized during 1995, 1994 and 1993 on these restructured loans was $1,317, $1,379 and $1,495, respectively. Income that would have been recognized during 1995, 1994 and 1993 on these loans, if such loans had been current in accordance with their original terms and had been outstanding throughout the year, was $1,799, $2,296 and $2,568, respectively. Commitments to loan additional funds to mortgage loan borrowers, on loans whose terms have been modified, are not significant. Loans either overdue more than three months or in the process of foreclosure were $2,774 at December 31, 1995 and 1994. Additionally, C.M. Life had properties which it acquired in satisfaction of debt of $1,897 at December 31, 1994. 7. DERIVATIVES: C.M. Life makes only limited use of derivative instruments (as defined in Statement of Financial Accounting Standards No. 119 "DISCLOSURE ABOUT DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS") which include swaps, options and futures, to hedge equity exposure and to hedge reinvestment of proceeds from major anticipated transactions. Derivatives are not used for trading purposes. C.M. Life held one swap investment totaling $12,000 notional amount as of December 31, 1995. During 1995 options (protective puts) were utilized to hedge equity exposures and were accounted for on a mark to market basis. The net 1995 realized losses from this activity were $140. The notional amount of such options totaled $35,900 as of December 31, 1995. During 1994 interest rate futures were acquired to hedge the reinvestment of anticipated proceeds from a bulk mortgage sale. The actual gain of $95 was amortized over the expected term of the assets acquired with the mortgage sale proceeds. No interest rate futures were held as of December 31, 1995 and 1994. -65- 8. FAIR VALUE DISCLOSURE OF OTHER FINANCIAL INSTRUMENTS: The Company has identified certain assets and liabilities as financial instruments that require fair value disclosure. Fair value is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced liquidation sale. If quoted market prices are not available, the values are estimated using discounted cash flow analysis or other valuation techniques. These various techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. The following methods and assumptions were used to estimate the fair value of each class of these instruments for which it is practicable to estimate the value. The estimated fair value for the public bonds is based on the quoted market price from various external bond pricing services. Private bonds are assigned an internal quality rating which parallels independent rating agency criteria and is consistent with NAIC ratings. The fair value of these bonds is estimated by discounting the expected future cash flows using a current discount rate based on the quality rating and maturity of the specific instruments. The estimated fair value for the equity securities is based on quoted market prices from national securities exchanges and over-the-counter markets. The fair value for performing mortgages is determined by discounting the expected future cash flows using the current interest rates at which similar loans would be made to borrowers with similar credit ratings and remaining maturities. Non-performing mortgages are valued based on a discounted cash flow analysis on the underlying collateral using the current market rate for similar collateral. Policy loans are issued with either fixed or variable interest rates, depending upon the terms of the policies. For those loans with fixed interest rates, the interest rates range from 5% to 8%. Since policy loans do not have defined maturities, management believes it is impractical to estimate the fair value of fixed rate policy loans. For loans with variable interest rates, the rates are adjusted annually based upon changes in a corporate bond index and are stated at fair value. Separate Account assets and liabilities are valued at market. A portion of annuity reserves, which represent contracts in their accumulation phase, are considered to be financial instruments. The Company determines fair value to be equal to the cash surrender value of these contracts (including market value adjustments, if any), which represents the amount payable to policyholders on demand. Since supplementary contracts may be perceived as deposit liabilities with defined maturities, the Company has determined fair value based on the discounted value of amounts payable at maturity of the contract. Discount rates used to determine fair value range from 6.5% to 7.9%. All other deposit liabilities are not considered to have defined maturities. The Company has determined fair value for these contracts to be equal to the cash surrender value, which is that amount which is payable to policyholders on demand. -66- The estimated fair values for assets and liabilities, which the Company has identified as investment contracts and borrowed funds, are as follows: 1995 1994 ---- ---- Carrying Estimated Carrying Estimated Value Fair Value Value Fair Value -------- ---------- -------- ---------- ASSETS Bonds $736,099 $767,888 $717,291 $684,213 Common and Preferred Stock 72,624 72,571 1,815 2,065 Mortgages 26,705 26,783 42,038 40,241 Policy Loans 126,014 126,014 109,720 109,720 Cash and Cash Equivalents 15,069 15,069 3,025 3,025 Assets of Separate Account 531,432 531,432 309,672 309,672 LIABILITIES Future Policy Benefits Annuity Reserves -- Accumulation Phase 49,078 49,683 30,239 28,868 Other Deposits 54,269 54,918 31,690 29,484 Other Liabilities Funds Deposited Under Income Settlements-- Supplementary Contracts Without Life Contingencies 215 208 270 260 Liabilities of Separate 531,432 531,432 309,672 309,672
9. RELATED PARTY TRANSACTIONS: Connecticut Mutual allocates certain expenses to C.M. Life for providing operating facilities, human resources, computer software development and managerial services. Total expenses allocated to C.M. Life were approximately $34,008, $16,412 and $18,831 in 1995, 1994 and 1993, respectively. 10. NET INVESTMENT INCOME: Net Investment Income is comprised of the following: 1995 1994 1993 ---- ---- ---- Fixed maturities $54,625 $47,658 $43,983 Mortgage loans on real estate 2,709 4,383 5,813 Policy loans 9,905 7,925 7,448 Amortization of IMR (60) 309 251 Other 3,091 1,449 1,844 ------- ------- ------- Total investment income 70,270 61,724 59,339 Less: Applicable investment expenses 1,455 1,837 1,879 ------- ------- ------- Net investment income $68,815 $59,887 $57,460 ------- ------- ------- ------- ------- -------
Net investment income and realized gains and losses applicable to the Separate Account are not included in C.M. Life's net investment income and realized gains and losses reported in the Statements of Operations. -67- 11. REALIZED AND UNREALIZED GAINS AND LOSSES: The cost of investments sold is determined by the specific identification method. Realized gains and losses and the change in the difference between market value and cost for fixed maturities and equity securities are summarized as follows: 1995 1994 1993 ---- ---- ---- Realized Gains and Losses: Fixed Maturities: Realized gains $ 3,598 $ 1,358 $ 5,931 Realized losses (4,658) (4,439) (1,016) --------- --------- ------- (1,060) (3,081) 4,915 --------- --------- ------- Equity Securities and Options: Realized gains 1,518 -- 4 Realized losses (758) -- -- --------- --------- ------- 760 -- 4 --------- --------- ------- Real Estate: Realized gains -- -- -- Realized losses (310) (2,158) -- --------- --------- (310) (2,158) -- --------- --------- ------- Mortgage Loans: Realized gains 52 -- -- Realized losses (1,404) (2,093) (13) --------- --------- ------- (1,352) (2,093) (13) --------- --------- ------- (Gains)/Losses Transferred to IMR 822 4,799 (4,447) --------- --------- ------- Net Realized Capital Gains/(Losses) $ (1,140) $ (2,533) $ 459 --------- --------- ------- --------- --------- ------- Unrealized Gains and Losses: Fixed Maturities: Net unrealized gains(losses),end of year $ 31,789 $ (33,077) $20,870 Net unrealized gains, beginning of year (33,077) 20,870 16,497 --------- --------- ------- Change in unrealized gains or losses on fixed maturities $ 64,866 $ (53,947) $ 4,373 --------- --------- ------- --------- --------- -------
The change in unrealized gains and (losses) for equity securities were $7,422, $(30), and $50 as of December 31, 1995, 1994 and 1993, respectively. 12. CONTINGENCIES: C.M. Life is involved in regulatory proceedings and various litigation in the ordinary course of business. In the opinion of management, the ultimate resolution of such proceedings and litigation will not result in fines or judgements which, in the aggregate, would materially affect C.M. Life's financial position. -68- 13. MERGER OF CONNECTICUT MUTUAL: On September 8, 1995, the Board of Directors of Connecticut Mutual approved the merger of Connecticut Mutual and Massachusetts Mutual Life Insurance Company. Thereafter, a definitive agreement was signed by both companies. On January 27, 1996, Connecticut Mutual and insurance subsidiary policyholders' and other insureds and annuitants approved the merger. The merger was reviewed by the insurance regulatory authorities in Massachusetts and Connecticut, and approved. The merger was effective March 1, 1996. -69- SCHEDULE I C.M. LIFE INSURANCE COMPANY SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES AS OF DECEMBER 31, 1995 ($ IN THOUSANDS) Fair Balance Cost or Value Sheet Type of Investment Other Basis (see note) Amount ----------- ---------- ------- Fixed Maturities: U.S. Government $ 24,102 $ 25,864 $ 24,102 Special Revenue and Special Assessment Obligations and all Non-guaranteed Obligations of Government Agencies Authorities, and Subdivisions 3,715 3,709 3,715 Foreign Government, Province and Municipal 11,186 11,374 11,186 Public Utility 45,150 47,437 45,150 Mortgage Backed Obligations 150,694 157,491 150,694 Industrial and Miscellaneous 501,252 522,013 501,252 -------- -------- -------- Total Fixed Maturities 736,099 767,888 736,099 -------- -------- -------- Equity Securities: Nonredeemable Preferred Stocks 263 210 263 Common Stocks 64,225 72,361 72,361 -------- -------- -------- Total Equity Securities 64,488 72,571 72,624 -------- -------- -------- Total Fixed Maturities and Equity Securities 800,587 840,459 808,723 -------- -------- -------- -------- Other Investments: Mortgage Loans on Real Estate 33,611 26,783 26,705 Real Estate -- (see note) -- Policy Loans 126,014 (see note) 126,014 Cash and Cash Equivalents 15,069 15,069 15,069 -------- -------- Total Other Investments 174,694 167,788 -------- -------- Total Investments $975,281 $976,511 -------- -------- -------- --------
Note: Fair values for equity securities and fixed maturities approximate those quotations published by applicable stock exchanges or are received from other reliable sources. Fair values for real estate are not -70- readily available. Approximately 98% of policy loans are comprised of variable interest rate loans whose carrying value approximate fair value. -71- SCHEDULE VI C.M. LIFE INSURANCE COMPANY REINSURANCE FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993 ($ IN THOUSANDS) Ceded Gross To Other Net Amount Companies Amount ------ --------- ------ DECEMBER 31, 1995 Life insurance in force $19,132,954 $7,323,441 $11,809,513 ----------- ---------- ----------- ----------- ---------- ----------- Premiums: Life Insurance $134,278 $50,732 $83,546 -------- ------- ------- -------- ------- ------- DECEMBER 31, 1994 Life insurance in force $15,800,300 $7,310,290 $8,490,010 ----------- ---------- ---------- ----------- ---------- ---------- Premiums: Life Insurance $111,238 $54,032 $57,206 -------- ------- ------- -------- ------- ------- DECEMBER 31, 1993 Life insurance in force $14,521,452 $7,382,223 $7,139,229 ----------- ---------- ---------- ----------- ---------- ---------- Premiums: Life insurance $108,097 $56,905 $51,192 -------- ------- ------- -------- ------- -------
-72- APPENDIX I SURRENDER CHARGE CALCULATION A Surrender Charge is deducted from the Contract Balance upon partial or full Surrender of the Contract, unless certain conditions apply. (See "Surrender Charge," page _.) The PARTIAL SURRENDER CHARGE formula is calculated as follows: (PS - FREE) x 5%(95%) = PSC, but not less than zero. The FULL SURRENDER CHARGE formula is calculated as follows: (FS - FREE) x 5% = FSC. Where: (PS) is the Partial Surrender Amount. (FS) is the Full Surrender Amount. (FREE) is the Free Surrender Amount. (PSC) is the Partial Surrender Charge Amount. (FSC) is the Full Surrender Charge Amount. EXAMPLE Assume a Separate Account Balance of $50,000 at the beginning of the second Contract Year. 1) If there is a Full Surrender at the beginning of the second Contract Year: Surrender Charge = ($50,000 - $5,000) x .05 = $2,250.00. Thus, the Surrender proceeds would be = $50,000 - $30 - $2,250.00 = $47,720.00 NOTE: THE CONTRACT MAINTENANCE FEE ($30) APPLIES TO FULL SURRENDERS. 2) If there is a Partial Surrender of $10,000 at the beginning of the second Contract Year: Surrender Charge = ($10,000 - $5000) x .05/.95 = $263.16. Thus, the Separate Account Balance would be reduced by $10,000 + $263.16 = $10,263.16. 73 APPENDIX II INTEREST RATE FACTOR ADJUSTMENT CALCULATION The amount of General Account Balance partially or fully Surrendered during the Accumulation Period, and the total General Account Balance on the Annuity Income Date (if and to the extent that the General Account Balance is applied to a Variable Annuity Option), will be subject to an Interest Rate Factor Adjustment. The Interest Rate Factor Adjustment is based on interest rates payable on U.S. Treasury securities. In general, if rates on U.S. Treasury securities are higher when you Surrender than when you made the applicable Purchase Payments, a negative Interest Rate Factor Adjustment will generally be applied to the amount Surrendered, and you could receive an amount lower than the amount of Purchase Payments made. If rates on U.S. Treasury securities are lower when you Surrender than when you made the applicable Purchase Payments, a positive Interest Rate Factor Adjustment will generally be applied to the amount Surrendered, and you could receive an amount higher than the amount of Purchase Payments made. No Interest Rate Factor Adjustment will be applied during the Window Period. In addition, no Interest Rate Factor Adjustment will be applied to the General Account Free Surrender Amount or to Contracts issued to Pennsylvania residents. The Interest Rate Factor Adjustment will reflect the relationship between (i) the weighted average of U.S. Treasury Index Rates corresponding to Purchase Payments and Transfers into the General Account during the current Five-Year Period (as adjusted for partial Surrenders or Transfers out of the General Account), (ii) the U.S. Treasury Index Rate which would be applicable during the time remaining in the current Five-Year Period on the date of the Surrender, and (iii) the time remaining in the current Five-Year Period. In general, if the weighted average of U.S. Treasury Index Rates corresponding to Purchase Payments and Transfers during the current Five-Year Period is lower than the U.S. Treasury Index Rate which would be applicable during the time remaining in the current Five-Year Period, then the application of the Interest Rate Factor Adjustment will result in a lower payment upon Surrender. The PARTIAL SURRENDER Interest Rate Factor Adjustment Formula is: (1 - 1/IRF) x (GAPS - GAF + GAPSC) = IRFA. In the event of a Partial Surrender, there is no Interest Rate Factor Adjustment if the General Account Free Surrender Amount exceeds the General Account portion of such Partial Surrender. The FULL SURRENDER Interest Rate Factor Adjustment Formula is: (IRF - 1) x (GAFS - GAF) = IRFA. Where: (GAPS) is the General Account Partial Surrender Amount. (GAFS) is the General Account Full Surrender Amount. (GAF) is the General Account Free Surrender Amount. (GAPSC) is the General Account portion of the Partial Surrender Charge Amount determined as follows: GAPSC = (GAPS - GAF) x 5%/95%, but not less than zero. (IRF) is the Interest Rate Factor. (IRFA) is the Interest Rate Factor Adjustment. 74 The Interest Rate Factor is determined by the following formula: (N - 12) (1+Ta) - --------------- =IRF (N - 12) (1.003+Tb) Where: (Ta) is the weighted average of the U.S. Treasury Index Rates which correspond to the Purchase Payments and/or Transfers allocated to the General Account during the current Five-Year Period. The U.S. Treasury Index Rate corresponding to each such allocation is determined by the number of full years and fractions thereof (but not less than one (1) year) remaining from the date of the allocation until the end of the current Five-Year Period. For purposes of determining the average of these rates, each U.S. Treasury Index Rate is weighted by the amount of the corresponding allocation (as adjusted to reflect any partial Surrenders and/or transfers from the General Account subsequent to such allocation). The General Account Balance at the beginning of any Five-Year Period will be treated as a new allocation for purposes of this calculation. Each allocation made prior to a Partial Surrender and/or transfer from the General Account (other than the current Surrender) shall be adjusted by multiplying such allocation by the following fraction: 1 - PS/GAB Where: (PS) is the amount of the Partial Surrender and/or transfer from the General Account made subsequent to the allocation, (GAB) is the beginning General Account Balance on the date of such Partial Surrender and/or transfer from the General Account, A separate adjustment shall be calculated for each prior Partial Surrender and/or transfer from the General Account. (Tb) is the U.S. Treasury Index Rate with a maturity equal to the number of full years and fractions thereof (but not less than one (1) year) remaining in the current Five-Year Period on the date of the Partial or Full Surrender, (N) is the number of whole months remaining in the current Five-Year Period as of the date of the Partial or Full Surrender (rounded down), 1.003 builds into the formula a factor representing direct and indirect costs to C.M. Life associated with liquidating General Account assets in order to satisfy Surrender requests or to begin making Annuity Income payments (to the extent the General Account Balance is applied to purchase a Variable Annuity). This adjustment of .30% has been added to the denominator of the formula because it is anticipated that a substantial portion (more than half) of applicable General Account portfolio assets will be in relatively illiquid private placement securities. Thus, in addition to direct transaction costs, if such securities must be sold (e.g., because of Surrenders), the market price may be lower because they are not registered securities. Accordingly, even if interest rates decline, there will not be a positive adjustment until this factor is overcome, and then any adjustment will be lower than otherwise, to compensate for this factor. Similarly, if interest rates rise, any negative adjustment will be greater than otherwise, to compensate for this factor. If interest rates stay the same, this factor will result in a small but negative Interest Rate Factor Adjustment. (IRF) is the Interest Rate Factor. EXAMPLES. The following examples illustrate the calculation of the Interest Rate Factor and the Interest Rate Factor Adjustment. 75 In the following examples, the Interest Rate Factor Adjustment formula is applied so as to produce only positive numbers, which are then added to, or subtracted from, the Surrender proceeds (for Full General Account Balance Surrenders) or the remaining General Account Balance (for Partial General Account Balance Surrenders). For example, if the Interest Rate Factor is .7, then the Interest Rate Factor Adjustment calculation illustrated below will show 1-.7, rather than .7-1, to result in a positive number. For examples 1 and 2, assume no change in interest rates. 1) Assume a $50,000 General Account Balance at the beginning of the second Five-Year Period, and a Full Surrender at that time. Also, assume the U.S. Treasury Index Rate at that time is 7%. (5) (1.07) THEN:IRF= ------- =.9861 (1.073) Interest Rate Factor Adjustment [deducted from proceeds] = (1 - .9861) x ($50,000 - $5,000) = $625.50. 2) Assume a $50,000 General Account Balance at the beginning of the tenth Contract Year with a Full Surrender at that time. Also, assume the U.S. Treasury Index Rate remains at 7% for all maturities: 1.07 THEN:IRF= ----- =.9972 1.073 Interest Rate Factor Adjustment [deducted from proceeds] = (1-.9972) x ($50,000 - $5,000) = $126.00. For examples 3 and 4, assume a General Account Balance of $50,000 at the beginning of the seventh Contract Year. 3) Assume a Full Surrender at the beginning of the seventh Contract Year: a) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 5.40%. (This is a decrease in rates of 1.60%). Then the IRF = 1.05. Interest Rate Factor Adjustment = (1.05 - 1) x ($50,000 - $5,000) = $2,250. Thus, the actual amount of Surrender proceeds paid = $50,000 + $2,250 - $30 = $52,220. b) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 8.08%. (This is an INCREASE in rates of 1.08%). Then the IRF = .95. Interest Rate Factor Adjustment = (1 - .95) x ($50,000 - $5,000) = $2,250. Thus, the actual amount of Surrender proceeds paid = $50,000 - $2,250 - $30 = $47,720. NOTE: THE CONTRACT MAINTENANCE FEE ($30) APPLIES TO FULL SURRENDERS. 4) Assume a partial Surrender of $10,000 at the beginning of the seventh Contract Year: a) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 5.40%. (This is a decrease in rates of 1.60%). Then the IRF = 1.05. ( 1 ) (1- ------)x($10,000-$5,000)=$238.10. ( .1.05) Interest Rate Factor Adjustment =
Thus, the General Account Balance would be reduced by $10,000 - $238.10 = $9,761.90. 76 b) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 8.08%. (This is an INCREASE in rates of 1.08%). Then the IRF = .95. ( 1 ) (--- -1)x($10,000-$5,000)=$263.16. (.95 ) Interest Rate Factor Adjustment =
Thus, the General Account Balance would be reduced by $10,000- $236.16=$10,263.16. 77 APPENDIX III EXAMPLES The following examples illustrate the impact of the Interest Rate Factor Adjustment together with the Surrender Charge (See Appendix I.) on Surrender proceeds. For examples 1 and 2, assume a General Account Balance of $50,000 at the beginning of the second Contract Year. 1) Assume a Full Surrender at the beginning of the second Contract Year. a) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 4.18%. (This is a DECREASE in rates of 2.82%). Then the IRF = 1.10. Surrender Charge = ( $50,000 - $5,000 ) x .05 = $2,250.00. Interest Rate Factor Adjustment = ( 1.10 - 1 ) x ( $50,000 - $5,000 ) = $4,500.00. Thus, the actual amount of Surrender proceeds paid = $50,000 - $2,250 + $4,500 - $30 = $52,220.00. b) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 9.56%. (This is an INCREASE in rates of 2.56%). Then the IRF = .9. Surrender Charge = ( $50,000 - $5,000 ) x .05 = $2,250.00. Interest Rate Factor Adjustment = ( 1 - .9 ) x ( $50,000 - $5,000) = $4,500.00. Thus, the actual amount of Surrender proceeds paid = $50,000 - $2,250 - $4,500 - $30 = $43,220.00. NOTE: THE CONTRACT MAINTENANCE FEE ($30) APPLIES TO FULL SURRENDERS. 2) Assume a partial Surrender of $10,000 at the beginning of the second Contract Year. a) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 4.18%. (This is a DECREASE in rates of 2.82%.) Then the IRF = 1.10. Surrender Charge = ( $10,000 - $5,000 ) x .05/.95 = $263.16. Interest Rate Factor Adjustment = ( 1 ) (1- ------)x($10,000-$5,000+$263.16)=$478.47 ( 1.10)
Thus, the General Account Balance will be reduced by $10,000 + $263.16 - $478.47 = $9,784.69. b) Assume that the beginning U.S. Treasury Index Rate was 7%, and the current U.S. Treasury Index Rate is 9.56%. (This is an increase in rates of 2.56%.) Then the IRF = .9. Surrender Charge = ( $10,000 - $5,000 ) x .05/.95 = $263.16. Interest Rate Factor Adjustment = ( 1 - 1.9 ) x ( $10,000 - $5,000 + $263.16 ) = $584.80. Thus, the General Account Balance will be reduced by $10,000 + $263.16 + $584.80 = $10,847.96. 78 APPENDIX IV INDIVIDUAL RETIREMENT ANNUITY DISCLOSURE This statement is designed to assist you in understanding the requirements of federal tax law which apply to your Individual Retirement Annuity ("IRA"), Spousal IRA or your Simplified Employee Pension IRA ("SEP-IRA") for employer contributions. If you should desire further information regarding your IRA, it may be obtained either from your G. R. Phelps & Co., Inc. ("G.R. Phelps") representative, from any district office of the Internal Revenue Service, or from a competent tax adviser. The growth in the value of the annuity is neither guaranteed nor projected. SEVEN-DAY REVIEW PERIOD You have seven (7) days after you sign your application to review this statement and the Prospectus without obligation. If you notify G. R. Phelps or your representative, either orally or in writing, within this seven-day period that you do not wish to keep your Contract, your entire Purchase Payment will be refunded to you. Registered Representative: Address: c/o G. R. Phelps & Co., Inc. 140 Garden Street Hartford, Connecticut 06154 Telephone: 1 (800) 234-5606 ELIGIBILITY REQUIREMENTS All persons with earned compensation are eligible for IRAs. Additionally, if you have a spouse who has earned no compensation (and you file a joint tax return), you may establish an IRA on behalf of your spouse. Of course, if you have a working spouse who has earned compensation, that spouse may establish his or her own IRA. Lastly, a divorced or legally separated spouse may treat taxable alimony or separate maintenance payments as compensation for purposes of establishing an IRA. THE ANNUITY AS AN IRA When this Annuity is issued as an IRA, the Contract is amended to provide that the Contract is both nontransferable and nonforfeitable. CONTRIBUTIONS AND DEDUCTIONS As a result of significant changes made by the Tax Reform Act of 1986, contributions to your IRA are limited at two levels. First, there are limits on the amount of contributions which may be deducted for income tax purposes. Second, there is a limit with respect to the amount of nondeductible contributions which can be made. If neither you nor your spouse (if you file a joint return) is an active participant in an employer-maintained retirement plan, then you are eligible to make deductible contributions to an IRA equal to the lesser of 100% of compensation or $2,000 ($2,250 in the case of a Spousal IRA). (See page 75.) However, if you or your spouse (if you file a joint return) is an active participant in an employer-maintained retirement plan, your deduction limit for contributions to an IRA is reduced. Specifically, individuals with adjusted gross income over $35,000, married taxpayers filing jointly with adjusted gross income over $50,000, and a married taxpayer filing separately with adjusted gross income over $10,000, are no longer allowed any IRA deductions if they participate in an employer-maintained retirement plan. In the case of a married couple filing jointly, the restrictions apply where either spouse so participates. For single individuals with adjusted gross income between $25,000 and $35,000, married taxpayers filing 79 jointly with adjusted gross income between $40,000 and $50,000, and a married taxpayer filing separately with adjusted gross income between $0 and $10,000, the IRA deduction will be phased out ratably as income rises above the threshold limits. Nevertheless, you may still make designated nondeductible IRA contributions to the extent of the excess of (1) the lesser of $2,000 ($2,250 in the case of a Spousal IRA), or 100% of compensation annually, over (2) the applicable IRA deduction limit. You may also choose to make a contribution nondeductible even if you could have deducted part or all of the contribution. Interest or other earnings on your IRA contribution, whether from deductible or nondeductible contributions, will not be taxed until distributed to you. For purposes of the above discussion, you are an "active participant" in an employer-maintained retirement plan, if you are covered by such plan, even if you are not yet vested in your retirement benefit. However, an individual who is a participant in only an eligible state deferred compensation plan, as defined in Internal Revenue Code section 457(b), is not considered to be an "active participant." In order to qualify for a particular tax year, IRA contributions must be made during such tax year, or by the deadline for filing your income tax return for that year (not including extensions). For calendar year taxpayers the deadline is generally April 15. If you make contributions in excess of the combined deductible and nondeductible limits, you may be liable for a nondeductible excise tax of 6% of the amount of the excess. You may withdraw an excess contribution together with the net income attributable to the excess, on or before the due date (including extensions of time) for filing your federal income tax return, and the excess amount will be treated as if you never contributed it, regardless of the size of the contribution. The accompanying distribution of the net income, however, is includable in income for the year in which the excess contribution is made. Excess amounts which are not withdrawn by this method are subject to the 6% excise tax in the year of contribution, and are carried over and taxed each year until the year the excess is reduced. No contribution may be made by you to your IRA during or after the tax year in which you attain age 70 1/2. SPOUSAL IRAS If your spouse has no compensation for the year and you file a joint return, you may set up and make contributions to an IRA for your spouse, as well as for yourself. Subject to the active participant rules discussed above, the maximum amount that you can deduct for contributions to both IRAs is the lesser of $2,250, or 100% of compensation. You may not contribute, however, more than $2,000 to either IRA for any year. SEP-IRAS Under a SEP-IRA agreement, your employer may contribute 15% of your compensation, up to $30,000 each year to your IRA. The contribution and interest earned is excludable from your income until such time as it is distributed to you. You must withdraw any excess contribution made to your SEP-IRA by your employer before the date for filing your return. If you do not, you are liable for the 6% excise tax discussed.above. SEP-IRAs are also generally subject to the other requirements applicable to IRAs. ROLLOVER CONTRIBUTIONS AND TRANSFERS You are permitted to withdraw any portion of the value of your IRA and reinvest it in another IRA account, but not more frequently than once in any twelve-month period. Such withdrawals may also be made from other IRAs and contributed to this contract. The amount of the withdrawal reinvested in another IRA within sixty (60) days after the date it is received is called a "rollover contribution" and is not subject to tax. Of course, you will not be allowed a tax deduction for the amount of any rollover contribution. You may not roll over IRA distributions required because you have reached age 70 1/2, or an IRA you inherited as a beneficiary (unless you are the surviving spouse). A similar type of rollover contribution can be made with the proceeds of an eligible rollover distribution or a lump-sum distribution from a qualified retirement plan. Such a distribution must also be invested in the IRA within sixty (60) days of receipt. A lump sum distribution is one made from a Qualified Plan (1) because of your death; (2) because you reached age 80 59 1/2; (3) because you left your job (unless you are self-employed); or (4) because you become permanently disabled (but only if you are self-employed). To be considered a lump sum, the distribution must also be made entirely in a single tax year, and must represent the entire value of your account in the retirement plan (and in all plans of a similar type sponsored by the same employer). Properly made, such a distribution will not be taxable until you receive payments from the IRA created with it. Eligible rollover distributions are generally all taxable distributions from Qualified Plans and Section 403(b) annuities except for: (1) amounts paid over your life or life expectancy; or (2) installments for periods spanning ten (10) years or more; and (3) required minimum distributions. Also, if you receive a distribution upon a plan termination, you may make a rollover contribution to an IRA. In addition to rollover contributions, you may have the assets of one IRA directly transferred (without any distribution to you) to another IRA. Direct IRA to IRA transfers are not subject to the one-year waiting period applicable to IRA rollover contributions. WITHDRAWALS In general, IRA withdrawals are taxable in full. If you have made both deductible and nondeductible IRA contributions, the part of the withdrawal that is from nondeductible contributions (not including interest) is excludable from income. The amount excludable from income for the tax year is the portion of the amount withdrawn that has the same ratio to the amount withdrawn as your total nondeductible IRA contributions (of all your IRAs) have to the total balance of all your IRAs, including rollover IRAs. The remaining portion of the amount withdrawn for the tax year is includible in income. For purposes of this calculation, all your IRAs are treated as one (1) contract, and all withdrawals you make during a tax year are treated as one (1) distribution, and the value of the contract (after adding back distributions made during the year), income on the contract and investment in the contract are computed at the end of the year. The special tax rules for lump sum distributions from pension plans do not apply to IRAs. PREMATURE DISTRIBUTIONS Premature distributions are amounts you withdraw from your IRA before you are age 59 1/2. Premature distributions which are not rolled over are subject to a penalty tax equal to 10% of the amount of the distribution includible in gross income in the tax year, unless you are totally disabled, or receive the distributions in substantially equal payments (at least annually) for your life or life expectancy, or the joint lives or life expectancies of you and your beneficiary, or unless the distributions are made to your beneficiary upon your death. The penalty tax is also applicable to income taxable distributions deemed to have been made upon disqualification of your IRA as a result of a prohibited transaction (including, in general, the sale or assignment of your interest in your IRA to anyone), or as a result of borrowing on your IRA, or using your IRA as security for a loan. INADEQUATE DISTRIBUTION OR UNDERDISTRIBUTION---50% TAX Your IRA is intended to provide retirement benefits over your lifetime. Thus, federal law requires that you either (1) receive a lump sum distribution from your IRA not later than April 1st of the year after the year in which you attain age 70 1/2 or (2) start to receive periodic payments by that date. If you elect to receive periodic payments, those payments must be sufficient to pay out the entire value of your IRA during your life or life expectancy or over the life or life expectancies of you and your beneficiary. If the payments are not sufficient to meet these annual requirements, an excise tax of 50% will be imposed on the amount of any underpayment. EXCESS DISTRIBUTIONS---15% TAX Certain persons, particularly those who participate in more than one (1) tax-qualified retirement plan, may be subject to an excise tax of 15% on certain excess aggregate distributions from those plans. In general, excess distributions are taxable 81 distributions from all tax-qualified plans in excess of a specified annual limit for payments made in the form of an annuity (generally, $150,000 for 1993, indexed for inflation), or five (5) times the annual limit for lump sum distributions. DEATH BENEFITS If you should die before receiving any benefits from your IRA, your beneficiary must elect to either (1) receive the balance of your account in a lump sum within five (5) years of your death, or (2) have the balance applied to purchase an immediate annuity payable over the life or life expectancy of the beneficiary. Such annuity must commence within one (1) year of your death. If your spouse is your beneficiary, however, distributions are not required to be distributed until the date you would have attained age 70 1/2, and if your spouse dies before any distribution to him or her commences, your spouse is treated as the owner of your IRA for purposes of any required distributions. If you should die after benefits have commenced to you, the remaining portion of your account must be distributed to your beneficiary as rapidly as under the method of distribution in effect on the date of your death. If you engage in certain prohibited transactions with your IRA, the IRA will lose its exemption from taxation. Depending on the type of prohibited transaction, you must include in income all or a portion of the fair market value of the IRA account. Examples of prohibited transactions are: (1) any borrowing from the account; (2) use of the account as security for a loan; (3) receipt by you or certain family members of unreasonable compensation for managing the IRA. PROTOTYPE STATUS C.M. Life anticipates requesting an opinion letter from the Internal Revenue Service stating that your prototype IRA qualifies as a prototype IRA. An opinion letter would only be a determination as to the form of the IRA, and would not represent a determination as to its merits. REPORTING TO THE IRS If you make a designated nondeductible contribution to an IRA for a taxable year, or receive a distribution from an IRA during a taxable year, you are required to provide such information as the IRS may prescribe on your tax return for the taxable year and, to the extent required, for succeeding taxable years. The information that may be required includes, but is not limited to: (1) the amount of designated nondeductible contributions for the taxable year; (2) the total amount of designated nondeductible contributions for all preceding taxable years that have not previously been withdrawn; (3) the total balance of all your IRAs as of the close of the calendar year with or within which the taxable year ends; and (4) the amount of distributions from your IRAs during the taxable year. If the required information is not shown on your return, all IRA contributions are presumed to have been deductible. Therefore, they will be taxable upon withdrawal from the IRA, unless it can be shown, with satisfactory evidence, that the contributions were nondeductible when they were made. Whenever you are liable for one of the penalty taxes discussed above (6% for excess contributions, 10% for premature distributions, 50% for underpayments, or 15% for excess distributions), you must file Form 5329 with the Internal Revenue Service. The form is to be attached to your income tax return (Form 1040) for the tax year in which the penalty applies. FINANCIAL DISCLOSURE The charges which may be made against a contribution to your IRA include the Mortality and Expense Risk Charge, and other fees for the Investment Accounts set forth in the Prospectus. The charges which may be made against a withdrawal are also described in the Prospectus, and you should read the Prospectus carefully and retain it for your future reference. Growth in the value of your IRA is neither projected nor guaranteed. Capital gains in excess of net realized short-term capital losses of a Portfolio are declared and paid annually in additional full and fractional shares. 82 PART II. INFORMATION NOT REQUIRED IN A PROSPECTUS Item 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION Not applicable ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS The following provisions regarding the Indemnification of Directors and Officers of the Registrant are applicable: CONNECTICUT LAW. Except where an applicable insurance policy is procured, Connecticut General Statutes ("C.G.S.") Section 33-320a is the sole source of indemnification rights for directors and officers of Connecticut corporations and for persons who may be deemed to be controlling persons by reason of their status as a shareholder, director, officer, employee or agent of a Connecticut corporation. Under C.G.S. Section 33-320a, a corporation shall indemnify any director or officer who was or is a party, or was threatened to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter referred to as "proceeding") by virtue of the fact that he or the person whose legal representative he is: (i) is or was a director or officer of the corporation; (ii) while a director or an officer of the corporation, is or was serving at the request of the corporation as a director, officer, partner, trustee, employee or agent of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise (hereinafter referred to as "enterprise"), other than an employee benefit plan or trust; or (iii) while a director or an officer of the corporation, is or was a director or officer serving at the request of the corporation as a fiduciary or an employee benefit plan or trust maintained for the benefit of employees of the corporation or any other enterprise, against "covered expenditures" if (and only if) his conduct met the applicable statutory eligibility standard. The types of expenditures which are covered and the statutory eligibility standard vary according to the type of proceeding to which the director or officer is or was a party or was threatened to be made a party. According to C.G.S. Section 33-320a, in non-derivative proceedings other than ones brought in connection with an alleged claim based upon the purchase or sale by a director or officer of securities of the corporation or of another enterprise, which the director or officer serves or served at the request of the corporation, the corporation shall indemnify a director or officer against judgments, fines, penalties, amounts paid in settlement and reasonable expenses, including attorneys' fees, actually incurred by him in connection with the proceeding, or any appeal therein, IF AND ONLY IF he acted (i) in good faith and (ii) in a manner he reasonably believed to be in the best interests of the corporation or, in the case of a person serving as a fiduciary of any employee benefit plan or trust, in a manner he reasonably believed to be in the best interests of the corporation or in the best interest of the participants and beneficiaries of such employee benefit plan or trust and consistent with the provisions of such employee benefit plan or trust. However, where the proceeding brought is criminal in nature, C.G.S. Section 33-320a requires that the director or officer must satisfy the additional condition that he had no reasonable cause to believe that his conduct was unlawful in order to be indemnified. A director or officer also will be entitled to indemnification as described above if (i) he is successful on the merits in the defense of any non-derivative proceeding brought against him or (ii) a court shall have determined that in view of all the circumstances he is fairly and reasonably entitled to be indemnified. The decision about whether the director or officer qualifies for indemnification under C.G.S. Section 33-320a may be made (i) in writing by a majority of those members of the board of directors who were not parties to the proceeding in question, (ii) in writing by independent legal counsel selected by a consent in writing signed by a majority of those directors who were not parties to the proceeding, or (iii) by the shareholders of the corporation at a special or annual meeting by an affirmative vote of at least a majority of the voting power of shares not owned by parties to the proceeding. A director or officer also may apply to a court of competent jurisdiction for indemnification even though he previously applied to the board, independent legal counsel or the shareholders and his application for indemnification was rejected. For purposes of C.G.S. Section 33-320a, the termination of any proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not create, of itself, a presumption that the director or officer did not act in good faith or in a manner which that director or officer did not believe B-1 reasonably to be in the best interests of the corporation or of the participants and beneficiaries of an employee benefit plan or trust and consistent with the provisions of such plan or trust. Likewise, the termination of a criminal act or proceeding shall not create, of itself, a presumption that the director or officer had reasonable cause to believe that his conduct was unlawful. In non-derivative proceedings based on the purchase or sale of securities of the corporation or of another enterprise, which the director or officer serves or served at the request of the corporation, C.G.S Section 33-320a provides that the corporation shall indemnify the director or officer only after a court shall have determined upon application that, in view of all the circumstances, the director or officer is fairly and reasonably entitled to be indemnified. Furthermore, the expenditures for which the director or officer shall be indemnified shall be only such amount as the court determines to be appropriate. Pursuant to C.G.S. Section 33-320a, where a director or officer was or is a party or was threatened to be made a party to a derivative proceeding, the corporation shall indemnify him against expenses, including attorneys' fees, actually and reasonably incurred by him in connection with the proceeding or any appeal therein, in relation to matters as to which he is finally adjudged not to have breached his duty to the corporation. The corporation also shall indemnify a director or officer where the court determines that, in view of all the circumstances, such person is fairly and reasonably entitled to be indemnified; however, in such a situation, the individual shall be indemnified only for such amount as the court determines to be appropriate. Furthermore, the statute provides that the corporation shall not indemnify a director or officer for amounts paid to the corporation, to a plaintiff or to counsel for a plaintiff in settling or otherwise disposing of a threatened or pending action, with or without court approval, or for expenses incurred in defending a threatened action or a pending action which is settled or otherwise disposed of without court approval. C.G.S. Section 33-320a also provides that expenses incurred in defending a proceeding may be paid by the corporation in advance of the final disposition of such proceeding upon authorization of the board of directors, provided said expenses are indemnifiable under the statute and the director or officer agrees to repay such amount if he is later found not entitled to indemnification by the corporation. Lastly, C.G.S. Section 33-320a is intended to be an exclusive statute. A corporation established under Connecticut statute cannot indemnify a director or officer (other than a director or officer who is or was serving at the request of the corporation as a director, officer, partner, trustee, employee or agent of another enterprise), to an extent either greater or less than that authorized by the statute, and any provision in the certificate of incorporation, the by-laws, a shareholder or director resolution, or agreement or otherwise that is inconsistent with the statute is invalid. C.M. Life Insurance Company was not established under Connecticut statute but was instead created by special act of the Connecticut General Assembly. Currently, its charter does not have provisions dealing with indemnification of its directors or officers, therefore the provisions of C.G.S. Section 33-320a currently apply to such indemnification. However, in the event C.M. Life Insurance Company's charter is amended by the Connecticut General Assembly in such a manner which is inconsistent with the statute, the charter would take precedence over C.G.S. Section 33-320a. Notwithstanding the above, C.G.S. Section 33-320a specifically authorizes a corporation to procure insurance providing greater indemnification rights than those set out in the statute the premium cost of which may be shared with the director or officer on such basis as may be agreed upon. The directors and officers may be covered by an errors and omissions insurance policy or other insurance policy. Insofar as indemnification for liability arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being B-2 registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. Item 15. RECENT SALES OF UNREGISTERED SECURITIES Not applicable. Item 16. EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES (a) Exhibits (1) (a) Principal Underwriting Agreement by and between C.M. Life Insurance Company and G.R. Phelps & Company, Inc.** (b) Underwriting and Servicing Agreement between MML Investors Services, Inc. and C.M. Life Insurance Company.*** (3) (a) Charter of C.M. Life Insurance Company* (b) By Laws of C.M. Life Insurance Company* (4) (a) Form of Individual Contract for the Panorama Plus Annuity.** (i) Form of IRA Endorsement for the Panorama Plus Annuity Individual Contract.** (ii) Form of Terminal Illness Endorsement for the Panorama Plus Annuity Individual Contract.** (iii) Form of Tax-Sheltered Annuity Endorsement for the Panorama Plus Annuity Individual Contract.** (iv) Form of Qualified Plan Endorsement for the Panorama Plus Annuity Individual Contract.** (v) Form of Unisex Endorsement for the Panorama Plus Annuity Individual Contract.** (vi) Form of Systematic Withdrawal Endorsement for the Panorama Plus Annuity Individual Contract.** (vii) Form of Dollar Cost Averaging Endorsement for the Panorama Plus Annuity Individual Contract.** (b) Form of Group Contract for the Panorama Plus Annuity.** (i) Form of IRA Endorsement for the Panorama Plus Annuity Group Contract.** (ii) Form of Terminal Illness Endorsement for the Panorama Plus Annuity Group Contract.** (iii) Form of Tax-Sheltered Annuity Endorsement for the Panorama Plus Annuity Group Contract.** (iv) Form of Qualified Plan Endorsement for the Panorama Plus Annuity Group Contract.** (v) Form of Unisex Endorsement for the Panorama Plus Annuity Group Contract.** (vi) Form of Systematic Withdrawal Endorsement for the Panorama Plus Annuity Group Contract.** (vii) Form of Dollar Cost Averaging Endorsement for the Panorama Plus Annuity Group Contract.** B-3 (c) Form of Individual Certificate for the Panorama Plus Annuity.** (i) Form of IRA Endorsement for the Panorama Plus Annuity Individual Certificate.** (ii) Form of Terminal Illness Endorsement for the Panorama Plus Annuity Individual Certificate.** (iii) Form of Tax-Sheltered Annuity Endorsement for the Panorama Plus Annuity Individual Certificate.** (iv) Form of Qualified Plan Endorsement for the Panorama Plus Annuity Individual Certificate.** (v) Form of Unisex Endorsement for the Panorama Plus Annuity Individual Certificate.** (vi) Form of Systematic Withdrawal Endorsement for the Panorama Plus Annuity Individual Certificate.** (vii) Form of Dollar Cost Averaging Endorsement for the Panorama Plus Annuity Individual Certificate.** (d) Form of Application for the Panorama Plus Annuity Individual Contract.** (e) Form of Application Supplement for Panorama Plus Tax Sheltered Annuity.** (f) Form of Application for the Panorama Plus Annuity Group Contract.** (g) Form of Application for Panorama Plus Annuity Group Contract (NC).** (h) Form of Application for the Panorama Plus Annuity Individual Certificate.** (i) Form of Certificate Application Supplement for Panorama Plus Tax Sheltered Annuity.** (5) Opinion Regarding Legality*** (10) (a) Agreement to Purchase Shares by and between C.M. Life Insurance Company and Connecticut Mutual Financial Services Series Fund I, Inc.** (b) Participation Agreement among Oppenheimer Variable Account Funds, OppenheimerFunds, Inc. and C.M. Life Insurance Company*** (21) Subsidiaries of Registrant** (23) (a) Consent of Independent Auditors*** (b) Consent of Counsel*** (24) (a) Powers of Attorney*** (b) Certified Board of Directors Resolution*** (b) Financial Data Schedule*** * Incorporated by reference to the initial registration statement on Form N-4 for the Panorama Plus Separate Account (File No. 33-45122) as filed with the Securities and Exchange Commission on January 16, 1992. B-4 ** Incorporated by reference to Pre-Effective Amendment No. 1 to the registration statement on Form N-4 for the Panorama Plus Separate Account (File No. 33-45122) as filed with the Securities and Exchange Commission on April 13, 1992. *** Filed herewith. Item 17. UNDERTAKINGS The undersigned registrant hereby undertakes: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represents a fundamental change in the information set forth in the registration statement; and (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. (4) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (5) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. B-5 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this initial registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hartford, State of Connecticut, on this 8th day of April, 1996. C. M. LIFE INSURANCE COMPANY *BY */s/ Ann F. Lomeli --------------------- David E. Sams, Jr. Director and President Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. Signatures Title Date - ---------- ----- ---- */s/ Ann F. Lomeli Director and President April 8,1996 - --------------------- (Principal Executive Officer) David E. Sams, Jr. */s/ Ann F. Lomeli - --------------------- J. Brinke Marcuccilli Chief Financial Officer April 8, 1996 */s/ Ann F. Lomeli Controller April 8, 1996 - --------------------- (Principal Accounting Emelia M. Bruno Officer) */s/ Ann F. Lomeli *Attorney in fact pursuant April 8, 1996 - --------------------- to the Powers of Attorney Ann F. Lomeli filed herewith. FORM S-1 INDEX TO EXHIBITS EXHIBIT (1)(b) Underwriting and Servicing Agreement between MML Investors Services, Inc. and C.M. Life Insurance Company (5) Opinion Regarding Legality (10)(b) Participation Agreement among Oppenheimer Variable Account Funds, OppenheimerFunds, Inc. and C.M. Life Insurance Company (23(a) Consent of Independent Auditors (23)(b) Consent of Counsel (24)(a) Powers of Attorney (24)(b) Certified Board of Directors Resolution (27) Financial Data Schedule EX-1.(B) 2 EXHIBIT 1(B) UNDERWRITING AND SERVICING AGREEMENT EXHIBIT 1(b) UNDERWRITING AND SERVICING AGREEMENT This UNDERWRITING AND SERVICING AGREEMENT is made this 1st day of March, 1996, by and between MML Investors Services, Inc. ("MMLISI") and C. M. Life Insurance Company ("C. M. Life"), on its own behalf and on behalf of Panorama Plus Separate Account (the "Separate Account"), a separate account of C. M. Life, as follows: WHEREAS, the Separate Account was established on September 25, 1991 pursuant to authority of C. M. Life's Board of Directors in order to set aside and invest assets attributable to certain variable annuity contracts (the "Contracts") issued by C. M. Life; and WHEREAS, C. M. Life has registered the Separate Account under the Investment Company Act of 1940, as amended, (the "1940 Act") and has registered the Contracts under the Securities Act of 1933, as amended, (the "1933 Act"); and WHEREAS, C. M. Life will continue the effectiveness of the registrations of the Separate Account under the 1940 Act and the Contracts under the 1933 Act; and WHEREAS, C. M. Life intends for the Contracts to be sold by its agents and brokers who are required to be registered representatives of a broker-dealer that is registered with the Securities and Exchange Commission (the "SEC") under the Securities Exchange Act of 1934 ("1934 Act") and a member of the National Association of Securities Dealers, Inc. (the "NASD"); and WHEREAS, C. M. Life desires to engage MMLISI, a broker-dealer registered with the SEC under the 1934 Act and a member of the NASD, to act as a co-underwriter ("Co-underwriter") in connection with the distribution of the Contracts by the full-time career contracted agents of C. M. Life ("Agents") and certain other brokers, and in connection therewith, to provide certain services and supervision to such Agents and brokers who are also registered representatives of MMLISI and who sell the Contracts, and to otherwise perform certain duties and functions that are necessary and proper for the distribution of the Contracts as required under applicable federal and state securities laws and NASD regulations, and MMLISI desires to act as Co-underwriter for the sale of the Contracts and to assume such responsibilities; NOW, THEREFORE, the parties hereto agree as follows: 1. UNDERWRITER. C. M. Life hereby appoints MMLISI as, and MMLISI agrees to serve as, Co-underwriter of the Contracts during the term of this Agreement for purposes of federal and state securities laws. C. M. Life reserves the right, however, to refuse at any time or times to sell any Contracts hereunder for any reason, and C.M. Life maintains ultimate responsibility for the sales of the Contracts. 2. SERVICES. MMLISI agrees, on behalf of C. M. Life and in its capacity as Co-underwriter, to undertake at its own expense except as otherwise provided herein, to provide certain sales, administrative and supervisory services relative to the Contracts as described below, and otherwise to perform all duties that are necessary and proper for the distribution of the Contracts as required under applicable federal and state securities laws and NASD regulations. 3. BEST EFFORTS. MMLISI shall use reasonable efforts to sell the Contracts but does not agree hereby to sell any specific number of Contracts and shall be free to act as underwriter of other securities. MMLISI agrees to offer the Contracts for sale in accordance with the prospectus then in effect for the Contracts. 4. COMPLIANCE AND SUPERVISION. All persons who are engaged directly or indirectly in the operations of MMLISI and C. M. Life in connection with the offer or sale of the Contracts shall be considered a "person associated" with MMLISI as defined in Section 3(a)(18) of the 1934 Act. MMLISI shall have full responsibility for the securities activities of each such person as contemplated by Section 15 of the 1934 Act. MMLISI shall be fully responsible for carrying out all compliance, supervisory and other obligations hereunder with respect to the activities of its registered representatives as required by the NASD Rules of Fair Practice (the "Rules") and applicable federal and state securities laws. Without limiting the generality of the foregoing, MMLISI agrees that it shall be fully responsible for: (a) ensuring that no representative of MMLISI shall offer or sell the Contracts until such person is appropriately licensed, registered, or otherwise qualified to offer and sell such Contracts under the federal securities laws and any applicable securities laws of each state or other jurisdiction in which such Contracts may be lawfully sold, in which C. M. Life is licensed to sell the Contracts, and in which such person shall offer or sell the Contracts; and (b) training and supervising C. M. Life's Agents and brokers who are also registered representatives of MMLISI for purposes of complying on a continuous basis with the Rules and with federal and state securities laws applicable in connection with the offering and sale of the Contracts. In this connection, MMLISI shall: (i) jointly conduct with C. M. Life such training (including the preparation and utilization of training materials) as in the opinion of MMLISI and C. M. Life is necessary to accomplish the purposes of this Agreement; - 2 - (ii) establish and implement reasonable written procedures for supervision of sales practices of registered representatives of MMLISI who sell the Contracts; (iii) provide a sufficient number of registered principals and an adequately staffed compliance department to carry out the responsibilities as set forth herein; (iv) take reasonable steps to ensure that C. M. Life Agents and brokers who are also registered representatives of MMLISI recommend the purchase of the Contracts only upon reasonable grounds to believe that the purchase of the Contracts is suitable for such applicant; and (v) impose disciplinary measures on agents of C. M. Life who are also registered representatives of MMLISI as required. The parties hereto recognize that any registered representative of MMLISI selling the Contracts as contemplated by this Agreement shall also be acting as an insurance agent of C. M. Life or as an insurance broker, and that the rights of MMLISI to supervise such persons shall be limited to the extent specifically described herein or required under applicable federal or state securities laws or NASD regulations. Such persons shall not be considered employees of MMLISI and shall be considered agents of MMLISI only as and to the extent required by such laws and regulations. Further, it is intended by the parties hereto that such persons are and shall continue to be considered to have a common law independent contractor relationship with C. M. Life and not to be common law employees of C. M. Life. 5. REGISTRATION AND QUALIFICATION OF CONTRACTS. C. M. Life has prepared or caused to be prepared a registration statement describing the Contracts, together with exhibits thereto (hereinafter referred to as the "Registration Statement"). The Registration Statement includes a prospectus (the "Prospectus") for the Contracts. C. M. Life agrees to execute such papers and to do such acts and things as shall from time-to-time be reasonably requested by MMLISI for the purpose of qualifying and maintaining qualification of the Contracts for sale under applicable state law and for maintaining the registration of the Separate Account and interests therein under the 1933 Act and the 1940 Act, to the end that there will be available for sale from time-to-time such amounts of the Contracts as MMLISI may reasonably be expected to sell. C. M. Life shall advise MMLISI promptly of any action of the SEC or any authorities of any state or territory, of which it is aware, affecting registration or qualification of the Separate Account, or rights to offer the Contracts for sale. If any event shall occur as a result of which it is necessary to amend or supplement the Registration Statement in order to make the statements therein, in light of the circumstances under which they were or are made, true, complete or not misleading, C. M. Life will forthwith prepare and furnish to MMLISI, without charge, - 3 - amendments or supplements to the Registration Statement sufficient to make the statements made in the Registration Statement as so amended or supplemented true, complete and not misleading in light of the circumstances under which they were made. 6. REPRESENTATIONS OF C. M. LIFE. C. M. Life represents and warrants to MMLISI as follows: (a) C. M. Life is an insurance company duly organized under the laws of the State of Connecticut and is in good standing and is authorized to conduct business under the laws of each state in which the Contracts are sold, that the Separate Account was legally and validly established as a segregated asset account under the Insurance Code of Connecticut, and that the Separate Account has been properly registered as a unit investment trust in accordance with the provisions of the 1940 Act to serve as a segregated investment account for the Contracts. (b) All persons that will be engaging in the offer or sale of the Contracts will be authorized insurance agents of C. M. Life. (c) The Registration Statement does not and will not contain any misstatements of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were or are made, not materially misleading. (d) C. M. Life shall make available to MMLISI copies of all financial statements that MMLISI reasonably requests for use in connection with the offer and sale of the Contracts. (e) No federal or state agency or bureau has issued an order preventing or suspending the offer of the Contracts or the use of the Registration Statement, or of any part thereof, with respect to the sale of the Contracts. (f) The offer and sale of the Contracts is not subject to registration, or if necessary, is registered, under the Blue Sky laws of the states in which the Contracts will be offered and sold. (g) The Contracts are qualified for offer and sale under the applicable state insurance laws in those states in which the Contracts shall be offered for sale. In each state where such qualification is effected, C. M. Life shall file and make such statements or reports as are or may be required by the laws of such state. (h) This Agreement has been duly authorized, executed and delivered by C. M. Life and constitutes the valid and legally binding obligation of C. M. Life. Neither the execution and delivery of this Agreement by C. M. Life nor the consummation of the transactions contemplated herein will result in a breach or violation of any provision of - 4 - the state insurance laws applicable to C. M. Life, any judicial or administrative orders in which it is named or any material agreement or instrument to which it is a party or by which it is bound. 7. REPRESENTATIONS OF MMLISI. MMLISI represents and warrants to C. M. Life as follows: (a) MMLISI is duly registered as a broker-dealer under the 1934 Act and is a member in good standing of the NASD and, to the extent necessary to perform the activities contemplated hereunder, is duly registered, or otherwise qualified, under the applicable securities laws of every state or other jurisdiction in which the Contracts are available for sale. (b) This Agreement has been duly authorized, executed and delivered by MMLISI and constitutes the valid and legally binding obligation of MMLISI. Neither the execution and delivery of this Agreement by MMLISI nor the consummation of the transactions contemplated herein will result in a breach or violation of any provision of the federal or state securities laws or the Rules, applicable to MMLISI, or any judicial or administrative orders in which it is named or any material agreement or instrument to which it is a party or by which it is bound. (c) MMLISI shall comply with the Rules and the securities laws of any jurisdiction in which it sells, directly or indirectly, any Contracts. 8. EXPENSES. MMLISI shall be responsible for all expenses incurred in connection with its provision of services and the performance of its obligations hereunder, except as otherwise provided herein. C. M. Life shall be responsible for all expenses of printing and distributing the Prospectuses, and all other expenses of preparing, printing and distributing all other sales literature or material for use in connection with offering the Contracts for sale. 9. SALES LITERATURE AND ADVERTISING. MMLISI agrees to ensure that its registered representatives use only the Prospectus, statements of additional information, or other applicable and authorized sales literature then in effect in selling the Contracts. MMLISI is not authorized to give any information or to make any representations concerning the Contracts other than those contained in the current Registration Statement filed with the SEC or in such sales literature as may be authorized by C. M. Life. MMLISI agrees to make timely filings with the SEC, the NASD, and such other regulatory authorities as may be required of any sales literature or advertising materials relating to the Contracts and intended for distribution to prospective investors. C. M. Life shall review and approve all advertising and sales literature concerning the Contracts - 5 - utilized by MMLISI. MMLISI also agrees to furnish to C. M. Life copies of all agreements and plans it intends to use in connection with any sales of the Contracts. 10. APPLICATIONS. All applications for Contracts shall be made on application forms supplied by C. M. Life, and shall be remitted by MMLISI promptly, together with such forms and any other required documentation, directly to C. M. Life at the address indicated on such application or to such other address as C. M. Life may, from time to time, designate in writing. All applications are subject to acceptance or rejection by C. M. Life at its sole discretion. 11. PAYMENTS. All money payable in connection with any of the Contracts, whether as premiums, purchase payments or otherwise, and whether paid by, or on behalf of any applicant or Contract owner, is the property of C. M. Life and shall be transmitted immediately in accordance with the administrative procedures of C. M. Life without any deduction or offset for any reason, including by example but not limitation, any deduction or offset for compensation claimed by MMLISI. Checks or money orders as payment on any Contract shall be drawn to the order of "C. M. Life Insurance Company." No cash payments shall be accepted by MMLISI in connection with the Contracts. Unless otherwise agreed to by C. M. Life in writing, neither MMLISI nor any of C. M. Life's Agents nor any broker shall have an interest in any surrender charges, deductions or other fees payable to C. M. Life as set forth herein. 12. INSURANCE LICENSES. C. M. Life shall apply for and maintain the proper insurance licenses and appointments for each of the Agents and brokers selling the Contracts in all states or jurisdictions in which the Contracts are offered for sale by such person. C. M. Life reserves the right to refuse to appoint any proposed Agent or broker, and to terminate an Agent or broker once appointed. C. M. Life agrees to be responsible for all licensing or other fees required under pertinent state insurance laws to properly authorize Agents or brokers for the sale of the Contracts; however, the foregoing shall not limit C. M. Life's right to collect such amount from any person or entity other than MMLISI. 13. AGENT/BROKER COMPENSATION. Commissions or other fees due all brokers and Agents in connection with the sale of Contracts shall be paid by C. M. Life, on behalf of MMLISI, to the persons entitled thereto in accordance with the applicable agreement between each such broker or Agent and C. M. Life or a general agent thereof. MMLISI shall assist C. M. Life in the payment of such amounts as C. M. Life shall reasonably request, provided that MMLISI shall not be required to perform any acts that would subject it to registration under the insurance laws of any state. The responsibility of MMLISI shall include the performance of all activities by MMLISI necessary in order that the payment of such amounts fully complies with all applicable federal and state securities laws. Unless applicable federal or state securities law shall require, C. M. Life retains the ultimate right to determine the commission rate paid to its Agents. - 6 - 14. MMLISI COMPENSATION. As payment for its services hereunder, MMLISI shall receive an annual fee that has the following components: (1) a fixed fee in the amount of $64,000 per year, and (2) a variable fee in the amount of 2 basis points (.0002) per year of new sales of the Contracts. Payments shall commence and be made no later than December 31 of the year in which a Contract is issued. The variable component of the fee shall be paid to MMLISI's wholly-owned subsidiary, MML Insurance Agency, Inc. ("MMLIAI"). The fixed component shall be renegotiated annually commencing in 1997. The last agreed-to amounts for each of these fees shall remain in effect until the new fees are mutually agreed upon and are set forth in schedules attached hereto. 15. BOOKS AND RECORDS. MMLISI and C. M. Life shall each cause to be maintained and preserved for the period prescribed such accounts, books, and other documents as are required of it by the 1934 Act and any other applicable laws and regulations. In particular, without limiting the foregoing, MMLISI shall cause all the books and records in connection with the offer and sale of the Contracts by its registered representatives to be maintained and preserved in conformity with the requirements of Rules 17a-3 and 17a-4 under the 1934 Act, to the extent that such requirements are applicable to the Contracts. The books, accounts, and records of MMLISI and C. M. Life as to all transactions hereunder shall be maintained so as to disclose clearly and accurately the nature and details of the transactions. The payment of premiums, purchase payments, commissions and other fees and payments in connection with the Contracts by its registered representatives shall be reflected on the books and records of MMLISI as required under applicable NASD regulations and federal and state securities laws requirements. MMLISI and C. M. Life, from time to time during the term of this Agreement, shall divide the administrative responsibility for maintaining and preserving the books, records and accounts kept in connection with the Contracts; provided, however, in the case of books, records and accounts kept pursuant to a requirement of applicable law or regulation, the ultimate and legal responsibility for maintaining and preserving such books, records and accounts shall be that of the party which is required to maintain or preserve such books, records and accounts under the applicable law or regulation, and such books, records and accounts shall be maintained and preserved under the supervision of that party. MMLISI and C. M. Life shall each cause the other to be furnished with such reports as it may reasonably request for the purpose of meeting its reporting and recordkeeping requirements under such regulations and laws, and under the insurance laws of the Commonwealth of Massachusetts and any other applicable states or jurisdictions. MMLISI and C. M. Life each agree and understand that all documents, reports, records, books, files and other materials required under applicable Rules and federal and state securities laws shall be the property of MMLISI, unless such documents, reports, records, books, files and other materials are required by applicable regulation or law to - 7 - be also maintained by C. M. Life, in which case such material shall be the joint property of MMLISI and C. M. Life. All other documents, reports, records, books, files and other materials maintained relative to this Agreement shall be the property of C. M. Life. Upon termination of this Agreement, all said material shall be returned to the applicable party. MMLISI and C. M. Life shall establish and maintain facilities and procedures for the safekeeping of all books, accounts, records, files, and other materials related to this Agreement. Such books, accounts, records, files, and other materials shall remain confidential and shall not be voluntarily disclosed to any other person or entity except as described below in section 16. 16. AVAILABILITY OF RECORDS. MMLISI and C. M. Life shall each submit to all regulatory and administrative bodies having jurisdiction over the sales of the Contracts, present or future, any information, reports, or other material that any such body by reason of this Agreement may request or require pursuant to applicable laws or regulations. In particular, without limiting the foregoing, C. M. Life agrees that any books and records it maintains pursuant to paragraph 15 of this Agreement which are required to be maintained under Rule 17a-3 or 17a-4 of the 1934 Act shall be subject to inspection by the SEC in accordance with Section 17(a) of the 1934 Act and Sections 30 and 31 of the 1940 Act. 17. CONFIRMATIONS. C. M. Life agrees to prepare and mail a confirmation for each transaction in connection with the Contracts at or before the completion thereof as required by the 1934 Act and applicable interpretations thereof, including Rule 10b-10 thereunder. Each such confirmation shall reflect the facts of the transaction, and the form thereof will show that it is being sent on behalf of MMLISI acting in the capacity of agent for C. M. Life. 18. INDEMNIFICATION. C. M. Life shall indemnify MMLISI, its registered representatives, officers, directors, employees, agents and controlling persons and hold such persons harmless, from and against any and all losses, damages, liabilities, claims, demands, judgments, settlements, costs and expenses of any nature whatsoever (including reasonable attorneys' fees and disbursements) resulting or arising out of or based upon an allegation or finding that: (i) the Registration Statement or any application or other document or written information provided by or on behalf of C. M. Life includes any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein, in light of the circumstances under which they are made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, written information furnished to C. M. Life by MMLISI or its registered representatives specifically for use in the preparation thereof, or (ii) there is a misrepresentation, breach of warranty or failure to fulfill any covenant or warranty made or undertaken by C. M. Life hereunder. - 8 - MMLISI will indemnify C. M. Life, its officers, directors, employees, agents and controlling persons and hold such persons harmless, from and against any and all losses, damages, liabilities, claims, demands, judgments, settlements, costs and expenses of any nature whatsoever (including reasonable attorneys' fees and disbursements) resulting or arising out of or based upon an allegation or finding that: (i) MMLISI or its registered representatives offered or sold or engaged in any activity relating to the offer and sale of the Contracts which was in violation of any provision of the federal securities laws or, (ii) there is a material misrepresentation, material breach of warranty or material failure to fulfill any covenant or warranty made or undertaken by MMLISI hereunder. Promptly after receipt by an indemnified party under this paragraph 18 of notice of the commencement of any action by a third party, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this paragraph 18, notify the indemnifying party of the commencement thereof; but the omission to notify the indemnifying party will not relieve the indemnifying party from liability which the indemnifying party may have to any indemnified party otherwise than under this paragraph. In case any such action is brought against any indemnified party, and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, to assume the defense thereof, with counsel satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of its election to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this paragraph for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation. 19. INDEPENDENT CONTRACTOR. MMLISI shall be an independent contractor. MMLISI is responsible for its own conduct and the employment, control and conduct of its agents and employees and for injury to such agents or employees or to others through its agents or employees. MMLISI assumes full responsibility for its agents and employees under applicable statutes and agrees to pay all employer taxes thereunder. 20. TERMINATION. Subject to termination as hereinafter provided, this Agreement shall remain in full force and effect for the initial term of the Agreement, which shall be for a two year period commencing on the date first above written, and this Agreement shall continue in full force and effect from year to year thereafter, until terminated as herein provided. This Agreement may be terminated by either party hereto upon 30 days written notice to the other party, or at any time upon the mutual written consent of the parties hereto. This Agreement shall automatically be terminated in the event of its assignment. Subject to C. M. Life's approval, however, MMLISI may delegate any duty or function assigned to it in this agreement provided that such delegation is permissible under applicable law. Upon termination of this Agreement, all authorizations, rights and obligations shall cease except the the obligations to settle accounts hereunder, including - 9 - the settlement of monies due in connection with the Contracts in effect at the time of termination or issued pursuant to applications received by C. M. Life prior to termination. 21. INTERPRETATION. This Agreement shall be subject to the provisions of the 1934 Act and the rules, regulations, and rulings thereunder and of the NASD, from time to time in effect, and the terms hereof shall be interpreted and construed in accordance therewith. If any provision of this Agreement shall be held or made invalid by a court decision, statute, rule, or otherwise, the remainder of this Agreement shall not be affected thereby. This Agreement shall be interpreted in accordance with the laws of the Commonwealth of Massachusetts. 22. NON-EXCLUSIVITY. The services of MMLISI and C. M. Life to the Separate Account hereunder are not to be deemed exclusive and MMLISI and C. M. Life shall be free to render similar services to others so long as their services hereunder are not impaired or interfered with hereby. 23. AMENDMENT. This Agreement constitutes the entire Agreement between the parties hereto and may not be modified except in a written instrument executed by all parties hereto. 24. INTERESTS IN AND OF MMLISI. It is understood that any of the policyholders, directors, officers, employees and agents of C. M. Life may be a shareholder, director, officer, employee, or agent of, or be otherwise interested in, MMLISI, any affiliated person of MMLISI, any organization in which MMLISI may have an interest, or any organization which may have an interest in MMLISI; that MMLISI, any such affiliated person or any such organization may have an interest in C. M. Life; and that the existence of any such dual interest shall not affect the validity hereof or of any transaction hereunder except as otherwise provided in the Charter, Articles of Incorporation, or By-Laws of C. M. Life and MMLISI, respectively, or by specific provision of applicable law. IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed by their respective officials thereunto duly authorized and seals to be affixed, as of the day and year first above written. ATTEST: C. M. LIFE INSURANCE COMPANY, on its behalf and on behalf of PANORAMA PLUS SEPARATE ACCOUNT By: ------------------------------ - 10 - ATTEST: MML INVESTORS SERVICES, INC. By: ----------------------------- - 11 - EX-5 3 EXHIBIT 5 OPINION 2 EXHIBIT 5 [LETTERHEAD OF C.M. LIFE] April 5, 1996 Board of Directors C.M. Life Insurance Company 140 Garden Street Hartford, CT 06154 Gentlemen: With reference to the registration statement on Form S-1 under the Securities Act of 1933 filed by C.M. Life Insurance Company (the "Company") with the Securities and Exchange Commission for the general account option under the Panorama Plus group and individual flexible premium deferred variable annuity ("Contracts"), I have examined such documents and such law as I have considered necessary and appropriate, and on the basis of such examination, it is my opinion that: 1. The Company is duly organized and validly existing under the laws of the State of Connecticut and is duly to issue the Contracts; and 2. The Contracts, when issued in accordance with the prospectus contained in the above-mentioned registration statement, will be legally issued and valid, legal and binding obligations of the Company in accordance with their terms. I hereby consent to the filing of this opinion as an exhibit to the above-mentioned Registration Statement. Very truly yours, /s/ Michael A. Chong --------------------------- Michael A. Chong Counsel EX-10.(B) 4 EXHIBIT 10(B) EXHIBIT 10(b) PARTICIPATION AGREEMENT Among OPPENHEIMER VARIABLE ACCOUNT FUNDS, OPPENHEIMERFUNDS, INC. and CM LIFE INSURANCE COMPANY THIS AGREEMENT (the "Agreement"), made and entered into as of the 12th day of January, 1996 by and among CM Life Insurance Company (hereinafter the "Company"), on its own behalf and on behalf of C.M. Multi-Account A (hereinafter collectively the "Accounts"), Oppenheimer Variable Account Funds (hereinafter the "Fund") and OppenheimerFunds, Inc. (hereinafter the "Adviser"). WHEREAS, the Fund is an open-end management investment company and is available to act as the investment vehicle for separate accounts now in existence or to be established at any date hereafter for variable life insurance policies and variable annuity contracts (collectively, the "Variable Insurance Products") offered by insurance companies (hereinafter "Participating Insurance Company"); WHEREAS, the beneficial interest in the Fund is divided into several series of shares, each designated a "Portfolio", and each representing the interests in a particular managed pool of securities and other assets; WHEREAS, the Fund has obtained an order from the Securities and Exchange Commission, dated July 16, 1986 (File No. 812-6324) granting Participating Insurance Company and variable annuity and variable life insurance separate accounts exemptions from the provisions of sections 9(a), 13(a), 15(a), and 15(b) of the Investment Company Act of 1940, as amended, (hereinafter the "1940 Act") and Rules 6e-2(b)(15) and 6e-3(T)(b)(15) thereunder, to the extent necessary to permit shares of the Fund to be sold to and held by variable annuity and variable life insurance separate accounts of both affiliated and unaffiliated life insurance companies (hereinafter the "Shared Funding Exemptive Order") WHEREAS, the Fund is registered as an open-end management investment company under the 1940 Act and its shares are registered under the Securities Act of 1933, as amended (hereinafter the "1933 Act"); WHEREAS, the Adviser is duly registered as an investment adviser under the federal Investment Advisers Act of 1940; WHEREAS, the Company has registered or will register certain variable annuity and/or life insurance contracts under the 1933 Act (hereinafter "Contracts"); WHEREAS, the Accounts are or will be duly organized, validly existing segregated asset accounts, established by resolution of the Board of Directors of the Company, to set aside and invest assets attributable to the aforesaid variable contracts (the Contract(s) and the Account(s) covered by the Agreement are specified in Schedule B attached hereto, as may be modified by mutual consent from time to time); WHEREAS, the Company have registered or will register the Accounts as unit investment trusts under the 1940 Act; WHEREAS, to the extent permitted by applicable insurance laws and regulations, the Company intend to purchase shares in the Portfolios (the Portfolios covered by this Agreement are specified in Schedule A attached hereto as may be modified by mutual consent from time to time), on behalf of the Accounts (which are also described on Schedule A, as may be modified by mutual consent from time to time) to fund the Contracts and the Fund is authorized to sell such shares to unit investment trusts such as the Accounts at net asset value; and NOW, THEREFORE, in consideration of their mutual promises, the Fund, the Adviser and the Company agree as follows: ARTICLE I. SALE OF FUND SHARES 1.1 The Fund agrees that shares of the Fund will be sold only to Variable Insurance Products. - 2 - 1.2. The Company shall not permit any person other than a Contract Holder or such Contract Holder's duly authorized representative to give instructions to the Company which would require the Company to redeem or exchange shares of the Fund. ARTICLE II. SALES MATERIAL, PROSPECTUSES AND OTHER REPORTS 2.1. The Company shall furnish, or shall cause to be furnished, to the Fund or its designee, each piece of sales literature or other promotional material in which the Fund or the Adviser is named, at least ten Business Days prior to its use. No such material shall be used if the Fund or its designee reasonably object to such use within ten Business Days after receipt of such material. "Business Day" shall mean any day in which the New York Stock Exchange is open for trading and in which the Fund calculates its net asset value pursuant to the rules of the Securities and Exchange Commission. 2.2. The Company shall not give any information or make any representations or statements on behalf of the Fund or concerning the Fund in connection with the sale of the Contracts other than the information or representations contained in the registration statement or prospectus for the Fund shares, as such registration statement and prospectus may be amended or supplemented from time to time, or in reports or proxy statements for the Fund, or in sale literature or other promotional material approved by the Fund or its designee, except with the permission of the Fund. 2.3. For purposes of this Article II, the phrase "sales literature or other promotional material" means advertisements (such as material published, or designed for use in, a newspaper, magazine, or other periodical, radio, television, telephone or tape recording, videotape display, signs or billboard or electronic media), and sales literature (such as brochures, circulars, market letters and form letters), distributed or made generally available to customers or the public. 2.4. The Fund shall provide a copy of its current prospectus within a reasonable period of its filing date, and provide other assistance as is reasonably necessary in order for the Company once each year (or more frequently if the prospectus for the Fund is supplemented or amended) to have - 3 - the prospectus for the Contracts and the Fund's prospectus printed together in one document (such printing to be at the Company's expense). The Adviser shall be permitted to review and approve the typeset form of the Fund's Prospectus prior to such printing. 2.5. The Fund or the Adviser shall provide the Company with either: (i) a copy of the Fund's proxy material, reports to shareholders, other information relating to the Fund necessary to prepare financial reports, and other communications to shareholders for printing and distribution to Contract owners at the Company's expense, or (ii) camera ready and/or printed copies, if appropriate, of such material for distribution to Contract owners at the Company' expense, within a reasonable period of the filing date for definitive copies of such material. The Adviser shall be permitted to review and approve the typeset form of such proxy material and shareholder reports prior to such printing provided such materials have been provided within a reasonable period. ARTICLE III. FEES AND EXPENSES 3.1. The Fund and Adviser shall pay no fee or other compensation to the Company under this agreement, and the Company shall pay no fee or other compensation to the Fund or Adviser, except as provided herein. 3.2. All expenses incident to performance by each party of its respective duties under this Agreement shall be paid by that party. The Fund shall see to it that all its shares are registered and authorized for issuance in accordance with applicable federal law and, if and to the extent advisable by the Fund, in accordance with applicable state laws prior to their sale. The Fund shall bear the expenses for the cost of registration and qualification of the Fund's shares, preparation and filing of the Fund's prospectus and registration statement, proxy materials and reports, and the preparation of all statements and notices required by any federal or state law. 3.3. The Company shall bear the expenses of typesetting, printing and distributing the Fund's prospectus, proxy materials and reports to owners of Contracts issued by the Company. 3.4. In the event the Fund adds one or more additional Portfolios and the parties - 4 - desire to make such Portfolios available to the respective Contract owners as an underlying investment medium, a new Schedule A or an amendment to this Agreement shall be executed by the parties authorizing the issuance of shares of the new Portfolios to the particular Account. The amendment may also provide for the sharing of expenses for the establishment of new Portfolios among Participating Insurance Company desiring to invest in such Portfolios and the provision of funds as the initial investment in the new Portfolios. ARTICLE IV. POTENTIAL CONFLICTS 4.1. The Board of Trustees of the Fund (the "Board") will monitor the Fund for the existence of any material irreconcilable conflict between the interests of the Contract owners of all separate accounts investing in the Fund. An irreconcilable material conflict may arise for a variety of reasons, including: (a) an action by any state insurance regulatory authority; (b) a change in applicable federal or state insurance, tax, or securities laws or regulations, or a public ruling, private letter ruling, no-action or interpretative letter, or any similar action by insurance, tax, or securities regulatory authorities; (c) an administrative or judicial decision in any relevant proceeding; (d) the manner in which the investments of any Portfolio are being managed; (e) a difference in voting instructions given by variable annuity contract and variable life insurance contract owners; or (f) a decision by an insurer to disregard the voting instructions of Contract owners. The Board shall promptly inform the Company if it determines that an irreconcilable material conflict exists and the implications thereof. 4.2. The Company will each report any potential or existing conflicts of which it is aware to the Board. The Company will assist the Board in carrying out its responsibilities in monitoring such conflicts by providing the Board in a timely manner with all information reasonably necessary for the Board to consider any issues raised. This includes, but is not limited to, an obligation by the Company to inform the Board whenever Contract owner voting instructions are disregarded and by confirming in writing, at the Fund's request, that the Company are unaware of any such potential or existing material irreconcilable conflicts. - 5 - 4.3. If it is determined by a majority of the Board, or a majority of its disinterested Trustees, that a material irreconcilable conflict exists, the Company shall, at their expense and to the extent reasonably practicable (as determined by a majority of the disinterested trustees), take whatever steps are necessary to remedy or eliminate the irreconcilable material conflict, up to an including: (1) withdrawing the assets allocable to some or all of the separate accounts from the Fund or any Portfolio and reinvesting such assets in a different investment medium, including (but not limited to) another Portfolio of the Fund, or submitting the question whether such segregation should be implemented to a vote of all affected Contract owners and, as appropriate, segregating the assets of any appropriate group (I.E., annuity contract owners, life insurance contract owners, or variable contract owners of one or more Participating Insurance Company) that votes in favor of such segregation, or offering to the affected Contract owners the option of making such a change; and (2) establishing a new registered management investment company or managed separate account. 4.4. If a material irreconcilable conflict arises because of a decision by the Company to disregard Contract owner voting instructions and that decision represents a minority position or would preclude a majority vote, the Company may be required, at the Fund's election, to withdraw the Account's investment in the Fund and terminate this Agreement; provided, however, that such withdrawal and termination shall be limited to the extent required by the foregoing material irreconcilable conflict as determined by a majority of the disinterested members of the Board. Any such withdrawal and termination must take place within six (6) months after the Fund gives written notice that this provision is being implemented, and until the end of the six month period the Fund shall continue to accept and implement orders by the Company for the purchase and redemption of shares of the Fund. 4.5. If a material irreconcilable conflict arises because a particular state insurance regulator's decision applicable to the Company conflicts with the majority of other state regulators, then the Company will withdraw the Account's investment in the Fund and terminate this Agreement within - 6 - six months after the Board informs the Company in writing that it has determined that such decision has created an irreconcilable material conflict; provided, however, that such withdrawal and termination shall be limited to the extent required by the foregoing material irreconcilable conflict as determined by a majority of the disinterested members of the Board. Until the end of the foregoing six month period, the Fund shall continue to accept and implement orders by the Company for the purchase and redemption of shares of the Fund, subject to applicable regulatory limitation. 4.6. For purposes of Sections 4.3 through 4.6 of this Agreement, a majority of the disinterested members of the Board shall determine whether any proposed action adequately remedies any irreconcilable material conflict, but in no event will the Fund be required to establish a new funding medium for the Contracts. The Company shall not be required by Section 4.3 to establish a new funding medium for Contracts if an offer to do so has been declined by vote of a majority of Contract owners materially adversely affected by the irreconcilable material conflict. In the event that the Board determines that any proposed action does not adequately remedy any irreconcilable material conflict, then the Company will withdraw the particular Account's investment in the Fund and terminate this Agreement within six (6) months after the Board informs the Company in writing of the foregoing determination, provided, however, that such withdrawal and termination shall be limited to the extent required by any such material irreconcilable conflict as determined by a majority of the disinterested members of the Board. ARTICLE V. APPLICABLE LAW 5.1. This Agreement shall be construed and the provisions hereof interpreted under and in accordance with the laws of New York. 5.2. This Agreement shall be subject to the provisions of the 1933, 1934 and 1940 Acts, and the rules and regulations and rulings thereunder, including such exemptions from those statutes, rules and regulations as the Securities and Exchange Commission may grant (including, but not - 7 - limited to, the Shared Funding Exemptive Order) and the terms hereof shall be interpreted and construed in accordance therewith. ARTICLE VI. TERMINATION 6.1 This Agreement shall terminate with respect to some or all Portfolios: (a) at the option of any party upon six month's advance written notice to the other parties; (b) at the option of the Company to the extent that shares of Portfolios are not reasonably available to meet the requirements of its Contracts or are not appropriate funding vehicles for the Contracts, as determined by the Company reasonably and in good faith. Prompt notice of the election to terminate for such cause and an explanation of such cause shall be furnished by the Company; or (c) as provided in Article IV 6.2. It is understood and agreed that the right of any party hereto to terminate this Agreement pursuant to Section 6.1(a) may be exercised for cause or for no cause. ARTICLE VII. NOTICES Any notice shall be sufficiently given when sent by registered or certified mail to the other party at the address of such party set forth below or at such other address as such party may from time to time specify to the other party. If to the Fund: Oppenheimer Variable Account Funds c/o OppenheimerFunds, Inc. 2 World Trade Center New York, NY 10048-0203 Attn: Legal Department - 8 - If to the Adviser: OppenheimerFunds, Inc. 2 World Trade Center New York, NY 10048-0203 Attn: General Counsel If to the Company: CM Life Insurance Company 140 Garden Street Hartford, CT 06154 Attn: Legal Department ARTICLE VIII. MISCELLANEOUS 8.1. Subject to the requirements of legal process and regulatory authority, each party hereto shall treat as confidential the names and addresses of the owners of the Contracts and all information reasonably identified as confidential in writing by any other party hereto and, except as permitted by this Agreement, shall not disclose, disseminate or utilize such names and addresses and other confidential information without the express written consent of the affected party until such time as it may come into the public domain. 8.2. The captions in this Agreement are included for convenience of reference only and in no way define or delineate any of the provisions hereof or otherwise affect their construction or effect. 8.3. This Agreement may be executed simultaneously in two or more counterparts, each of which taken together shall constitute one and the same instrument. 8.4. If any provision of this Agreement shall be held or made invalid by a court decision, statute, rule or otherwise, the remainder of the Agreement shall not be affected thereby. 8.5. Each party hereto shall cooperate with, and promptly notify each other party and all appropriate governmental authorities (including without limitation the Securities and Exchange Commission, the NASD and state insurance regulators) and shall permit such authorities reasonable - 9 - access to its books and records in connection with any investigation or inquiry relating to this Agreement or the transactions contemplated hereby. 8.6. The rights, remedies and obligations contained in this Agreement are cumulative and are in addition to any and all rights, remedies and obligations, at law or in equity, which the parties hereto are entitled to under state and federal laws. 8.7. It is understood by the parties that this Agreement is not an exclusive arrangement in any respect. 8.8. The Company and the Adviser each understand and agree that the obligations of the Fund under this Agreement are not binding upon any shareholder of the Fund personally, but bind only the Fund and the Fund's property; the Company and the Adviser each represent that it has notice of the provisions of the Declaration of Trust of the Fund disclaiming shareholder liability for acts or obligations of the Fund. 8.9. The parties agree that the Company may, on behalf of their respective Accounts and Contracts listed in Exhibits A and B, elect to make additional Portfolios available to Accounts upon the approval of the Adviser and the provision of reasonable notice to the Adviser. Any Portfolio so added will be subject to all of the terms and conditions of this Agreement. IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed in its name and on its behalf by its duly authorized representative and its seal to be hereunder affixed as of the date specified below. CM LIFE INSURANCE COMPANY By its authorized officer, By: -------------------------------- Title: -------------------------------- Date: -------------------------------- - 10 - OPPENHEIMER VARIABLE ACCOUNT FUNDS By its authorized officer, By: -------------------------------- Robert G. Zack Title: Assistant Secretary -------------------------------- Date: -------------------------------- OPPENHEIMERFUNDS, INC. By its authorized officer, By: -------------------------------- Mitchell J. Lindauer Title: Vice President -------------------------------- Date: -------------------------------- - 11 - SCHEDULE A Portfolios of Oppenheimer Variable Account Funds: Oppenheimer Money Fund Oppenheimer Bond Fund - 12 - SCHEDULE B C.M. Multi-Account A (Panorama Premier Contract) Panorama Plus Separate Account (Panorama Plus Contract) legag\999CM - 13 - EX-23.(A) 5 EXHIBIT 23(A) EXHIBIT 23(a) CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS As independent public accountants, we hereby consent to the use of our report (and to all references to our Firm) included in or made a part of this Registration Statement for C.M. Life Insurance Company. /s/ ARTHUR ANDERSEN LLP Hartford, Connecticut April 4, 1996 EX-23.(B) 6 EXHIBIT 23(B) EXHIBIT 23(b) [LETTERHEAD OF C.M. LIFE] April 5, 1996 Board of Directors C.M. Life Insurance Company 140 Garden Street Hartford, CT 06154 Gentlemen: With reference to the registration statement on Form S-1 under the Securities Act of 1933 filed by C.M. Life Insurance Company (the "Company") with the Securities and Exchange Commission for the general account option under the Panorama Plus group and individual flexible premium deferred variable annuity ("Contracts"), I have examined such documents and such law as I have considered necessary and appropriate, and on the basis of such examination, it is my opinion that: 1. The Company is duly organized and validly existing under the laws of the State of Connecticut and is duly to issue the Contracts; and 2. The Contracts, when issued in accordance with the prospectus contained in the above-mentioned registration statement, will be legally issued and valid, legal and binding obligations of the Company in accordance with their terms. I hereby consent to the filing of this opinion as an exhibit to the above-mentioned Registration Statement. Very truly yours, /s/ Michael A. Chong --------------------------- Michael A. Chong Counsel EX-24.(A) 7 EXHIBIT 24(A) POWER OF ATTORNEY EXHIBIT 24(a) POWER OF ATTORNEY C.M. LIFE SEPARATE INVESTMENT ACCOUNTS The undersigned, David E. Sams, Jr., a member of the Board of Directors and President of C.M. Life Insurance Company ("C.M. Life"), does hereby constitute and appoint Lawrence V. Burkett, Thomas F. English, Richard M. Howe, Michael Berenson, and Ann F. Lomeli, and each of them individually, as his true and lawful attorneys and agents. The attorneys and agents shall have full power of substitution and power to take any and all actions and execute any and all instruments on the undersigned's behalf as a member of the Board of Directors and President of C.M. Life that said attorneys and agents may deem necessary or advisable to enable C.M. Life to comply with the Securities Act of 1933, as amended (the "1933 Act"), the Investment Company Act of 1940, as amended (the "1940 Act"), and any rules, regulations, orders or other requirements of the Securities and Exchange Commission (the "Commission") thereunder. This power of attorney applies to the registration, under the 1933 Act and the 1940 Act, of shares of beneficial interest of C.M. Life's separate investment accounts (the "C.M. Life Separate Accounts"), as well as interests of C.M. Life's General Account. This power of attorney authorizes such attorneys and agents to sign the undersigned's name on his behalf as a member of the Board of Directors and President of C.M. Life to the Registration Statements and to any instruments or documents filed or to be filed with the Commission under the 1933 Act and the 1940 Act in connection with such Registration Statements, including any and all amendments to such statements, documents or instruments of any C.M. Life Separate Account, or C.M. Life's General Account, including but not limited to those listed below. C.M. Multi-Account A SEI Variable Annuity Panorama Premier Variable Annuity OFFITBANK Variable Annuity Panorama Plus Separate Account C.M. Life Variable Life Separate Account I The undersigned hereby ratifies and confirms all that said attorneys and agents shall do or cause to be done by virtue hereof. IN WITNESS WHEREOF, the undersigned has set his hand this 21st of March, 1996. /s/ David E. Sams, Jr. ----------------------------------- David E. Sams, Jr. Director and President Attest: Ann F. Lomeli ------------- EXHIBIT 24(a) POWER OF ATTORNEY C.M. LIFE SEPARATE INVESTMENT ACCOUNTS The undersigned, J. Brinke Marcuccilli, a member of the Board of Directors and Chief Financial Officer of C.M. Life Insurance Company ("C.M. Life"), does hereby constitute and appoint Lawrence V. Burkett, Thomas F. English, Richard M. Howe, Michael Berenson, and Ann F. Lomeli, and each of them individually, as his true and lawful attorneys and agents. The attorneys and agents shall have full power of substitution and power to take any and all actions and execute any and all instruments on the undersigned's behalf as a member of the Board of Directors and Chief Financial Officer of C.M. Life that said attorneys and agents may deem necessary or advisable to enable C.M. Life to comply with the Securities Act of 1933, as amended (the "1933 Act"), the Investment Company Act of 1940, as amended (the "1940 Act"), and any rules, regulations, orders or other requirements of the Securities and Exchange Commission (the "Commission") thereunder. This power of attorney applies to the registration, under the 1933 Act and the 1940 Act, of shares of beneficial interest of C.M. Life's separate investment accounts (the "C.M. Life Separate Accounts"), as well as interests of C.M. Life's General Account. This power of attorney authorizes such attorneys and agents to sign the undersigned's name on his behalf as a member of the Board of Directors and Chief Financial Officer of C.M. Life to the Registration Statements and to any instruments or documents filed or to be filed with the Commission under the 1933 Act and the 1940 Act in connection with such Registration Statements, including any and all amendments to such statements, documents or instruments of any C.M. Life Separate Account, or C.M. Life's General Account, including but not limited to those listed below. C.M. Multi-Account A SEI Variable Annuity Panorama Premier Variable Annuity OFFITBANK Variable Annuity Panorama Plus Separate Account C.M. Life Variable Life Separate Account I The undersigned hereby ratifies and confirms all that said attorneys and agents shall do or cause to be done by virtue hereof. IN WITNESS WHEREOF, the undersigned has set his hand this 22nd day of March, 1996. /s/ J. Brinke Marcuccilli -------------------------- J. Brinke Marcuccilli Director and Chief Financial Officer Attest: Ann F. Lomeli ------------- EXHIBIT 24(a) POWER OF ATTORNEY C.M. LIFE SEPARATE INVESTMENT ACCOUNTS The undersigned, Emelia M. Bruno, Controller of C.M. Life Insurance Company ("C.M. Life"), does hereby constitute and appoint Lawrence V. Burkett, Thomas F. English, Richard M. Howe, Michael Berenson, and Ann F. Lomeli, and each of them individually, as her true and lawful attorneys and agents. The attorneys and agents shall have full power of substitution and power to take any and all actions and execute any and all instruments on the undersigned's behalf as a member of the Board of Directors and Controller of C.M. Life that said attorneys and agents may deem necessary or advisable to enable C.M. Life to comply with the Securities Act of 1933, as amended (the "1933 Act"), the Investment Company Act of 1940, as amended (the "1940 Act"), and any rules, regulations, orders or other requirements of the Securities and Exchange Commission (the "Commission") thereunder. This power of attorney applies to the registration, under the 1933 Act and the 1940 Act, of shares of beneficial interest of C.M. Life's separate investment accounts (the "C.M. Life Separate Accounts"), as well as interests of C.M. Life's General Account. This power of attorney authorizes such attorneys and agents to sign the undersigned's name on her behalf as a member of the Board of Directors and Controller of C.M. Life to the Registration Statements and to any instruments or documents filed or to be filed with the Commission under the 1933 Act and the 1940 Act in connection with such Registration Statements, including any and all amendments to such statements, documents or instruments of any C.M. Life Separate Account, or C.M. Life's General Account, including but not limited to those listed below. C.M. Multi-Account A SEI Variable Annuity Panorama Premier Variable Annuity OFFITBANK Variable Annuity Panorama Plus Separate Account C.M. Life Variable Life Separate Account I The undersigned hereby ratifies and confirms all that said attorneys and agents shall do or cause to be done by virtue hereof. IN WITNESS WHEREOF, the undersigned has set her hand this 22nd day of March, 1996. /s/ Emelia M. Bruno ------------------------ Emelia M. Bruno Director and Controller Attest: Ann F. Lomeli ------------- EX-24.(B) 8 EXHIBIT 24(B) EXHIBIT 24(b) C.M. LIFE INSURANCE COMPANY I, ANN F. LOMELI, Secretary of C.M. Life Insurance Company, do hereby certify that the following is a true and accurate copy of a Resolution adopted by unanimous consent of the Board of Directors of C.M. Life Insurance Company on the 22nd day of March 1996; RESOLVED, that it is desirable and in the best interest of the Company that interests in its general account option under the Panorama Plus combination fixed and variable annuity be registered under the Securities Act of 1933 in appropriate amounts to facilitate sales of the annuity; and that Lawrence V. Burkett, Thomas F. English, Richard M. Howe, Michael Berenson, and Ann F. Lomeli are each individually authorized, acting alone or in conjunction with the other, to perform on behalf of the Company any and all such acts as each may deem necessary or advisable in order to allow the Company to continuously offer interests in its fixed account option to the general public, and in connection therewith to execute and file all requisite papers and documents on behalf of the Directors and Officers of the Company, including, but not limited to, registration statements, exemptive requests, no-action letter requests, reports, and any amendments thereto under the Securities Act of 1933, the Securities Exchange Act of 1934, and/or the Investment Company Act of 1940, and the execution by any one of them of any such paper or document or the doing of any such act in connection with the foregoing matters shall conclusively establish their authority therefor from the Company and the approval and ratification by the Company of the papers and documents so executed and the action so taken. IN WITNESS WHEREOF, I hereunto set my hand as Secretary and have affixed the corporate seal of said Company, this 22nd day of March 1996. /s/ Ann F. Lomeli ------------------------------- Ann F. Lomeli, Secretary EX-27 9 EXHIBIT 27 (FDS) 7 0000883232 C.M. LIFE INSURANCE COMPANY 1000 12-MOS DEC-31-1995 DEC-31-1995 736099 0 0 72624 26705 0 976511 15069 902 0 1533748 813188 0 2026 531432 0 2500 0 0 110699 1533748 83546 68815 (1140) 1671 132067